[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fzgKzwuvLevJc31blqmxeUeTe-8F6osnjIkldmp4vMv8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"Pfizer",[6,4],"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",3075,true,204,661,55146158,245,228,[15,18,21,24,27,30,33,36],{"name":16,"count":17},"Healthy",347,{"name":19,"count":20},"Healthy Volunteers",85,{"name":22,"count":23},"Rheumatoid Arthritis",62,{"name":25,"count":26},"Breast Neoplasms",50,{"name":28,"count":29},"Healthy Participants",44,{"name":31,"count":32},"Breast Cancer",43,{"name":34,"count":35},"Pain",40,{"name":37,"count":35},"Diabetes Mellitus, Type 2",[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03052608","A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","2020-03-20","Lorlatinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04649359","MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb","2022-06-17","Elranatamab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03395197","Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC","2022-10-03","Talazoparib with enzalutamide",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03861273","A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B","2022-11-16","PF-06838435\u002F fidanacogene elaparvovec",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT02319837","Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)","2023-01-31","Enzalutamide",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05463952","A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+\u002FHER2- Locally Advanced or Metastatic Breast Cancer (BC)","2023-05-04","vepdegestrant",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04721977","A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","2023-07-17","Tucatinib",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04281485","Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy","2024-05-15","PF-06939926",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04370054","Study to Evaluate the Efficacy and Safety of PF-07055480 \u002F Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults","2024-06-17","PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2\u002F6 Human Factor VIII Gene Therapy",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT03709680","Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent\u002FRefractory Solid Tumors","2024-08-26","Palbociclib",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,313,503,768,796,814,832,850,868,1047,1226,1473,1624,1746,1861,1958,2061,2158,2381,2493,2617,2700,2746,2807,2869,2923,2980,3049,3091,3141,3186,3293,3376,3472,3498,3524,3567,3657,3739,3825,3878,3933,3965,3996,4022,4044,4066,4088,4110,4132,4154,4187,4387,4573,4706,4798,4869,4903,4988,5050,5080,5118,5160,5202,5236,5254,5282,5300,5326,5350,5375,5393,5411,5432,5460,5478,5496,5514,5532,5550,5568,5586,5608,5633,5654,5672,5698,5716,5734,5752,5866,5998,6043,6073,6095,6326,6361,6391,6421,6469,6516,6538,6560,6597,6615,6633,6651,6669,6687,6705,6729,6747,6774,6792,6810,6828,6851,6880,6898,6916,6934,6952,6970,6988,7013,7031,7049,7067,7091,7109,7135,7153,7171,7198,7216,7234,7252,7270,7288,7306,7331,7349,7477,7499,7639,7684,7800,7863,7893,7927,8090,8188,8264,8343,8421,8488,8518,8548,8566,8584,8602,8625,8643,8661,8679,8697,8715,8738,8760,8778,8796,8814,8840,8862,8894,8912,8930,8948,8966,8984,9002,9020,9038,9067,9090,9119,9137,9155,9179,9202,9220,9247,9265,9283,9301,9319,9337,9355,9373,9451,9493,9533,9709,9775,9817,9850,9917,9982,10030,10056,10095,10117,10147,10179,10209,10244,10262,10285,10308,10326,10351,10374,10398,10420,10444,10467,10485,10508,10532,10555,10579,10603,10638,10656,10674,10692,10710,10728,10746,10764,10786,10810,10833,10855,10879,10902,11075,11198,11272,11431,11537,11654,11752,11834,11884,11969,12046,12115,12192,12261,12341,12401,12460,12519,12568,12620,12675,12732,12780,12823,12869,12916,12956,13007,13046,13087,13137,13163,13200,13235,13264,13300,13343,13382,13432,13468,13502,13531,13558,13586,13615,13643,13675,13697,13725,13756,13778,13815,13844,13877,13908,13941,13970,13992,14014,14043,14069,14095,14123,14144,14169,14187,14205,14223,14245,14267,14291,14309,14327,14345,14369,14387,14409,14427,14451,14473,14496,14514,14537,14555,14579,14601,14619,14642,14660,14684,14702,14720,14742,14767,14785,14807,14831,14849,14873,14894,14916,14934,14955,14973,14995,15019,15044,15062,15080,15103,15126,15147,15169,15195,15213,15231,15253,15271,15293,15317,15335,15358,15376,15398,15416,15439,15457,15479,15505,15526,15551,15569,15587,15608,15632,15653,15681,15699,15721,15743,15761,15785,15809,15827,15845,15866,15890,15908,15932,15950,15972,15994,16012,16035,16053,16076,16103,16121,16139,16157,16180,16203,16221,16244,16262,16286,16304,16327,16352,16370,16388,16406,16428,16446,16471,16489,16507,16525,16543,16561,16584,16606,16624,16647,16665,16687,16710,16733,16756,16774,16792,16810,16831,16849,16867,16891,16909,17010,17130,17259,17363,17443,17549,17628,17710,17780,17842,17900,17944,18016,18067,18116,18169,18207,18257,18307,18364,18414,18476,18510,18558,18604,18676,18710,18746,18785,18823,18878,18926,18962,18992,19035,19076,19120,19158,19197,19237,19282,19318,19352,19385,19421,19450,19479,19522,19559,19590,19618,19644,19677,19711,19757,19783,19813,19845,19879,19907,19949,19986,20017,20043,20078,20117,20139,20172,20194,20224,20246,20281,20303,20335,20357,20384,20416,20447,20469,20498,20522,20550,20581,20616,20638,20660,20686,20708,20730,20752,20774,20796,20818,20845,20875,20897,20926,20952,20986,21017,21039,21069,21106,21133,21157,21179,21205,21230,21252,21275,21297,21315,21338,21356,21374,21392,21413,21434,21456,21477,21495,21518,21540,21558,21576,21594,21612,21630,21651,21669,21687,21705,21728,21751,21769,21790,21808,21826,21848,21866,21891,21909,21927,21945,21963,21986,22004,22026,22044,22062,22086,22104,22126,22147,22165,22183,22201,22222,22240,22263,22284,22309,22330,22356,22374,22392,22415,22436,22459,22484,22502,22529,22547,22571,22589,22612,22630,22651,22674,22692,22715,22738,22756,22779,22797,22821,22839,22864,22882,22904,22928,22946,22971,22995,23013,23038,23056,23083,23101,23119,23137,23159,23177,23195,23213,23231,23249,23267,23285,23307,23330,23348,23366,23384,23407,23425,23443,23461,23479,23501,23523,23551,23569,23593,23611,23629,23654,23675,23693,23711,23729,23754,23772,23796,23814,23832,23850,23873,23894,23918,23936,23954,23972,23993,24015,24033,24051,24069,24092,24115,24133,24159,24177,24195,24222,24240,24258,24282,24306,24324,24345,24363,24381,24403,24424,24449,24471,24494,24512,24535,24553,24571,24589,24610,24628,24646,24664,24685,24711,24729,24751,24769,24794,24812,24830,24854,24879,24897,24915,24933,24955,24978,24996,25022,25040,25058,25076,25097,25118,25142,25160,25178,25196,25218,25236,25254,25272,25295,25316,25339,25357,25375,25393,25411,25429,25447,25465,25483,25501,25524,25542,25563,25581,25599,25617,25635,25653,25671,25689,25707,25725,25743,25761,25785,25803,25821,25842,25866,25884,25902,25925,25943,25961,25979,26000,26018,26040,26062,26087,26105,26123,26145,26168,26193,26211,26229,26247,26265,26291,26309,26327,26345,26363,26385,26410,26428,26446,26464,26488,26506,26528,26546,26569,26587,26614,26632,26650,26668,26689,26713,26735,26753,26858,26949,27054,27146,27214,27303,27374,27456,27521,27573,27625,27676,27730,27783,27832,27877,27918,27973,28024,28069,28108,28157,28211,28253,28301,28344,28380,28425,28475,28511,28559,28599,28641,28673,28716,28755,28790,28832,28865,28893,28932,28970,29001,29027,29064,29097,29131,29157,29202,29242,29270,29305,29353,29396,29425,29461,29501,29532,29567,29599,29634,29656,29682,29710,29737,29765,29787,29813,29835,29857,29886,29911,29933,29964,29986,30016,30045,30075,30102,30129,30160,30193,30220,30247,30277,30299,30327,30358,30392,30419,30446,30479,30501,30523,30545,30569,30598,30622,30647,30677,30709,30733,30758,30786,30817,30848,30870,30892,30914,30948,30972,30997,31024,31052,31080,31119,31147,31174,31201,31234,31256,31274,31292,31310,31328,31346,31369,31391,31409,31427,31445,31463,31486,31504,31525,31547,31570,31588,31606,31627,31652,31670,31694,31712,31730,31748,31770,31802,31820,31838,31856,31874,31892,31910,31928,31949,31970,31992,32010,32035,32053,32071,32095,32113,32131,32149,32167,32189,32207,32228,32250,32273,32291,32312,32330,32351,32372,32397,32415,32433,32451,32478,32496,32514,32532,32550,32568,32586,32604,32625,32650,32668,32686,32710,32728,32746,32764,32782,32800,32821,32839,32863,32881,32899,32917,32943,32961,32984,33002,33027,33045,33063,33081,33099,33117,33135,33161,33179,33197,33215,33233,33251,33269,33290,33311,33329,33350,33371,33393,33411,33429,33447,33465,33490,33508,33526,33550,33572,33590,33617,33635,33653,33676,33694,33715,33738,33756,33774,33792,33816,33834,33852,33870,33888,33910,33928,33946,33964,33986,34004,34022,34040,34058,34076,34099,34123,34141,34159,34177,34201,34223,34241,34264,34282,34300,34322,34344,34362,34384,34402,34424,34442,34464,34482,34500,34521,34539,34562,34580,34598,34619,34637,34658,34683,34701,34719,34737,34755,34776,34798,34820,34838,34856,34877,34898,34922,34940,34962,34985,35007,35032,35050,35068,35089,35107,35128,35146,35164,35182,35206,35232,35250,35268,35286,35308,35326,35348,35366,35384,35405,35423,35445,35466,35490,35508,35526,35547,35565,35583,35601,35619,35637,35655,35673,35691,35715,35733,35751,35769,35790,35812,35835,35853,35871,35892,35910,35933,35956,35978,35996,36020,36038,36056,36078,36096,36121,36139,36157,36175,36193,36211,36229,36247,36270,36288,36306,36324,36342,36371,36389,36407,36425,36443,36461,36479,36497,36526,36544,36562,36580,36598,36616,36634,36652,36670,36688,36706,36724,36742,36760,36778,36796,36814,36832,36850,36868,36889,36907,36933,36951,36969,36987,37011,37029,37051,37069,37087,37105,37128,37146,37164,37182,37200,37218,37236,37254,37276,37294,37316,37334,37352,37375,37396,37414,37435,37459,37477,37495,37513,37536,37554,37576,37594,37616,37638,37656,37674,37692,37718,37736,37754,37772,37793,37818,37839,37857,37875,37893,37911,37935,37953,37971,37989,38012,38030,38053,38071,38089,38118,38136,38154,38172,38231,38292,38334,38390,38428,38480,38514,38558,38604,38643,38685,38728,38774,38814,38855,38890,38920,38953,38991,39019,39052,39089,39127,39155,39187,39216,39246,39282,39308,39360,39391,39426,39463,39489,39515,39541,39567,39600,39633,39674,39711,39745,39779,39814,39844,39878,39913,39938,39967,39989,40017,40039,40069,40107,40129,40156,40184,40209,40236,40265,40287,40319,40341,40363,40393,40421,40443,40473,40511,40533,40555,40577,40609,40639,40661,40691,40723,40745,40767,40792,40814,40843,40875,40908,40938,40967,40994,41025,41047,41069,41091,41115,41143,41165,41189,41219,41241,41263,41285,41313,41345,41363,41385,41403,41426,41444,41465,41486,41507,41528,41552,41570,41588,41613,41631,41649,41667,41688,41711,41735,41753,41771,41789,41807,41825,41843,41861,41879,41897,41915,41939,41957,41975,41997,42018,42039,42060,42081,42099,42123,42141,42159,42177,42195,42218,42236,42254,42275,42293,42311,42329,42347,42371,42389,42407,42425,42443,42467,42488,42511,42529,42547,42569,42593,42611,42629,42652,42670,42694,42712,42730,42748,42766,42784,42810,42828,42846,42867,42889,42911,42938,42956,42974,42992,43016,43034,43056,43077,43102,43120,43138,43156,43174,43192,43216,43234,43256,43274,43295,43321,43339,43357,43375,43396,43419,43437,43458,43476,43499,43517,43535,43553,43578,43596,43614,43632,43650,43671,43695,43713,43731,43749,43770,43791,43809,43827,43845,43863,43885,43903,43921,43939,43962,43980,43998,44020,44038,44059,44077,44095,44117,44135,44159,44177,44195,44213,44231,44249,44267,44285,44303,44321,44339,44360,44381,44404,44422,44445,44463,44481,44505,44523,44545,44563,44585,44607,44629,44655,44673,44691,44709,44727,44748,44766,44788,44806,44824,44842,44864,44882,44904,44925,44947,44965,44991,45009,45027,45045,45063,45084,45108,45126,45144,45162,45180,45206,45224,45242,45266,45284,45308,45326,45344,45362,45383,45404,45427,45445,45467,45485,45506,45529,45547,45565,45583,45605,45623,45644,45667,45689,45707,45725,45743,45764,45786,45808,45826,45844,45866,45884,45906,45927,45945,45966,45990,46008,46029,46051,46069,46090,46114,46132,46150,46171,46196,46214,46239,46257,46275,46298,46322,46340,46366,46384,46402,46420,46438,46456,46478,46496,46518,46536,46559,46577,46595,46617,46635,46656,46679,46697,46720,46738,46756,46777,46801,46819,46837,46855,46873,46891,46909,46927,46945,46963,46981,46999,47024,47042,47060,47078,47096,47118,47136,47161,47179,47201,47223,47241,47262,47280,47298,47319,47342,47367,47385,47403,47424,47448,47466,47484,47502,47523,47547,47568,47586,47611,47629,47647,47665,47686,47704,47722,47743,47764,47782,47800,47818,47836,47854,47872,47890,47913,47931,47949,47967,47985,48007,48030,48048,48066,48090,48108,48126,48153,48171,48189,48207,48225,48243,48261,48290,48308,48326,48347,48365,48389,48407,48425,48443,48466,48484,48502,48524,48542,48560,48578,48596,48617,48639,48657,48679,48702,48720,48738,48759,48780,48802,48825,48843,48861,48883,48901,48919,48937,48965,48983,49001,49019,49037,49055,49077,49095,49124,49142,49160,49178,49196,49214,49236,49257,49279,49297,49315,49336,49359,49377,49395,49413,49431,49453,49471,49492,49513,49538,49556,49574,49592,49610,49632,49650,49671,49689,49712,49730,49753,49775,49799,49817,49835,49853,49876,49894,49912,49933,49957,49975,49993,50017,50040,50058,50080,50105,50123,50141,50159,50177,50208,50226,50244,50262,50280,50298,50316,50334,50352,50375,50393,50414,50438,50456,50474,50492,50516,50534,50552,50570,50588,50606,50628,50646,50664,50682,50700,50718,50742,50760,50778,50803,50821,50839,50857,50875,50898,50916,50939,50962,50980,50998,51019,51037,51058,51080,51098,51122,51145,51168,51186,51204,51222,51244,51265,51288,51306,51328,51346,51368,51389,51413,51431,51449,51467,51492,51510,51528,51546,51567,51587,51608,51626,51644,51666,51684,51702,51720,51738,51760,51778,51799,51822,51840,51861,51879,51900,51925,51943,51961,51982,52000,52018,52036,52054,52072,52090,52117,52135,52153,52171,52189,52207,52225,52243,52261,52279,52297,52315,52333,52354,52376,52394,52412,52430,52448,52466,52488,52506,52530,52548,52569,52590,52613,52636,52654,52672,52696,52714,52732,52750,52771,52792,52814,52835,52857,52878,52896,52914,52932,52954,52978,52996,53014,53032,53053,53071,53092,53110,53128,53151,53169,53187,53205,53223,53241,53259,53277,53300,53326,53344,53362,53384,53402,53424,53442,53460,53482,53500,53522,53540,53558,53585,53603,53621,53639,53657,53680,53702,53727,53745,53763,53781,53799,53817,53839,53857,53879,53901,53919,53942,53960,53978,54001,54023,54044,54070,54091,54109,54127,54145,54163,54184,54202,54220,54256,54274,54292,54310,54328,54346,54364,54382,54400,54418,54436,54454,54472,54490,54508,54526,54544,54562,54580,54598,54621,54642,54665,54683,54701,54719,54737,54759,54777,54798,54822,54840,54858,54879,54905,54923,54941,54959,54977,54999,55017,55039,55064,55082,55100,55118,55142,55164,55185,55203,55227,55245,55263,55285,55303,55324,55346,55364,55385,55407,55425,55451,55469,55487,55512,55530,55548,55566,55591,55609,55627,55645,55663,55681,55699,55717,55739,55762,55780,55802,55820,55845,55863,55881,55899,55922,55940,55962,55980,55998,56021,56039,56057,56082,56100,56118,56136,56157,56180,56198,56216,56234,56252,56275,56293,56311,56333,56355,56377,56395,56416,56434,56452,56473,56491,56513,56531,56549,56567,56589,56607,56629,56655,56673,56691,56709,56727,56748,56766,56790,56808,56826,56844,56862,56880,56898,56919,56942,56960,56985,57003,57021,57042,57060,57082,57107,57125,57143,57161,57183,57201,57219,57819,58046,58236,58450,58641,58852,59052,59218,59374,59500,59642,59789,59919,60056,60167,60285,60386,60474,60580,60666,60756,60814,60900,60954,61004,61060,61125,61190,61242,61299,61359,61413,61465,61522,61567,61621,61659,61693,61727,61764,61802,61841,61877,61915,61952,61990,62029,62077,62114,62140,62166,62201,62231,62267,62301,62337,62373,62408,62442,62478,62508,62545,62577,62609,62636,62669,62697,62719,62752,62774,62796,62826,62848,62879,62909,62936,62958,62988,63013,63043,63065,63097,63128,63150,63171,63194,63212,63238,63256,63274,63292,63313,63336,63357,63379,63402,63425,63443,63461,63479,63497,63515,63533,63551,63569,63587,63605,63623,63641,63659,63677,63695,63713,63731,63749,63772,63794,63816,63837,63859,63883,63901,63924,63947,63971,63994,64015,64036,64057,64078,64103,64127,64148,64171,64192,64217,64239,64261,64282,64304,64322,64340,64358,64376,64397,64415,64437,64459,64477,64495,64517,64543,64565,64589,64615,64633,64654,64675,64693,64715,64740,64763,64785,64807,64829,64851,64869,64891,64914,64935,64956,64977,64998,65016,65038,65060,65078,65102,65120,65138,65156,65174,65192,65215,65238,65262,65280,65298,65319,65343,65368,65391,65409,65427,65448,65466,65487,65509,65527,65545,65566,65588,65606,65630,65652,65673,65691,65713,65738,65756,65778,65796,65818,65843,65861,65879,65901,65923,65941,65959,65977],{"intervention":98,"totalTrials":99,"cells":100},"Rimegepant",19,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":121,"PHASE4":258,"NA":303},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":103},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},"NCT01430442","Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine","COMPLETED",[92],"2012-05","2011-10",1026,[117,118],"Migraine","Acute Treatment of Migraine",[98,120],"Sumatriptan",{"trials":122,"activeCount":257,"soonestReadout":159},[123,133,145,155,165,176,187,197,207,217,227,238,248],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT04743141","Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine","RECRUITING",[93],"2030-07-31","2021-04-28",600,[118],[98],{"nctId":134,"briefTitle":135,"status":126,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT06641466","A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine",[93],"2026-11-29","2027-03-30","2025-03-11",723,[142],"Menstrual Migraine",[98,144,98],"Standard of Care",{"nctId":146,"briefTitle":147,"status":111,"phases":148,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":154},"NCT03732638","Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults",[92,93],"2019-12-10","2021-02-02","2018-11-14",1590,[117],[98],{"nctId":156,"briefTitle":157,"status":126,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":164},"NCT06616194","A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine",[93],"2026-10-08","2027-12-02","2024-11-15",200,[117],[98],{"nctId":166,"briefTitle":167,"status":168,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT05262517","Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders","TERMINATED",[93],"2023-05-18","2022-05-05",126,[174],"Temporomandibular Disorders (TMD)",[98],{"nctId":177,"briefTitle":178,"status":111,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT03461757","Trial in Adult Subjects With Acute Migraines",[93],"2018-10-08","2018-10-15","2018-02-27",1811,[185],"Migraine, With or Without Aura",[98],{"nctId":188,"briefTitle":189,"status":126,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":196},"NCT05156398","Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects",[93],"2031-11-29","2032-11-27","2022-02-28",640,[117],[98],{"nctId":198,"briefTitle":199,"status":111,"phases":200,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":206},"NCT05399485","Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)",[93],"2024-01-18","2024-11-07","2022-08-09",496,[117],[98],{"nctId":208,"briefTitle":209,"status":111,"phases":210,"primaryCompletion":211,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":216},"NCT05810038","A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.",[93],"2025-08-25","2025-12-10","2023-05-15",787,[117],[98],{"nctId":218,"briefTitle":219,"status":111,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT03237845","Safety and Efficacy in Adult Subjects With Acute Migraines",[93],"2018-01-25","2018-01-31","2017-07-27",1499,[185],[98],{"nctId":228,"briefTitle":229,"status":111,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT04574362","Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine",[93],"2021-11-24","2021-12-16","2020-10-22",1648,[236],"Acute Migraine",[98],{"nctId":239,"briefTitle":240,"status":111,"phases":241,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":247},"NCT03235479","Safety and Efficacy Study in Adult Subjects With Acute Migraines",[93],"2018-01-21","2018-01-26","2017-07-18",1485,[185],[98],{"nctId":249,"briefTitle":250,"status":111,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT03266588","Open Label Safety Study in Acute Treatment of Migraine",[92,93],"2019-07-15","2017-08-30",3019,[185],[98],4,{"trials":259,"activeCount":302,"soonestReadout":265},[260,270,282,292],{"nctId":261,"briefTitle":262,"status":263,"phases":264,"primaryCompletion":265,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},"NCT07609914","A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine","NOT_YET_RECRUITING",[94],"2028-05-14","2026-05-27",400,[118],[98],{"nctId":271,"briefTitle":272,"status":111,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":281},"NCT05207865","Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention",[94],"2024-07-02","2022-03-15",441,[117,278,279,280],"Episodic Migraine","Phonophobia","Photophobia",[98],{"nctId":283,"briefTitle":284,"status":111,"phases":285,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":291},"NCT05518123","Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications",[94],"2025-03-31","2025-07-08","2022-11-07",962,[117],[98],{"nctId":293,"briefTitle":294,"status":111,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT05509400","Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use",[94],"2025-03-10","2025-06-10","2022-10-18",813,[117],[98,98],1,{"trials":304,"activeCount":103},[305],{"nctId":306,"briefTitle":307,"status":308,"phases":309,"conditions":310,"interventions":311},"NCT03934086","An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine","NO_LONGER_AVAILABLE",[],[117],[312],"rimegepant",{"intervention":43,"totalTrials":314,"cells":315},16,{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":365,"PHASE3":378,"PHASE4":389,"NA":412},{"trials":317,"activeCount":103},[],{"trials":319,"activeCount":103},[320,330,344,354],{"nctId":321,"briefTitle":322,"status":168,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":302,"conditions":326,"interventions":328},"NCT03726333","Hepatic Impairment Study for Lorlatinib in Cancer Patients",[91],"2021-07-08","2020-01-14",[327],"Advanced Cancers",[329,329,329,329,329],"lorlatinib",{"nctId":331,"briefTitle":332,"status":168,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT04800822","PF-07284892 in Participants With Advanced Solid Tumors",[91],"2024-06-19","2021-03-17",53,[338],"Solid Tumor",[340,329,341,342,343],"PF-07284892","binimetinib","cetuximab","encorafenib",{"nctId":345,"briefTitle":346,"status":111,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":353},"NCT03542305","Lorlatinib Renal Impairment Study",[91],"2020-02-20","2018-08-23",29,[352],"Renal Impairment",[43],{"nctId":355,"briefTitle":356,"status":111,"phases":357,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":364},"NCT05224609","A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction",[91],"2024-08-13","2022-04-28",21,[362,363,19],"Moderate Hepatic Impairment","Severe Hepatic Impairment",[43],{"trials":366,"activeCount":103},[367],{"nctId":368,"briefTitle":369,"status":111,"phases":370,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":377},"NCT03909971","A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China",[92],"2020-08-10","2024-10-21","2019-04-28",109,[376],"Carcinoma, Non-Small-Cell Lung",[43],{"trials":379,"activeCount":302,"soonestReadout":42},[380],{"nctId":40,"briefTitle":41,"status":381,"phases":382,"primaryCompletion":42,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":387},"ACTIVE_NOT_RECRUITING",[93],"2028-12-31","2017-04-27",296,[376],[43,388],"Crizotinib",{"trials":390,"activeCount":302,"soonestReadout":405},[391,401],{"nctId":392,"briefTitle":393,"status":111,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":400},"NCT04541706","Lorlatinib in ALK Inhibitor Treated Unresectable Advanced\u002FRecurrent ALK-Positive Non Small Cell Lung Cancer Patients in India",[94],"2022-07-20","2020-08-27",100,[399],"Advanced Non-Small Cell Lung Cancer",[43],{"nctId":402,"briefTitle":403,"status":381,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":411},"NCT05144997","Lorlatinib Continuation Study",[94],"2026-12-28","2021-12-28",76,[409,410],"Non-Small-Cell Lung Cancer","NSCLC",[43],{"trials":413,"activeCount":502,"soonestReadout":445},[414,441,450,457,467,475,485,492],{"nctId":415,"briefTitle":416,"status":111,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":423},"NCT05834348","A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.",[],"2024-01-23","2023-06-23",5279,[422],"Non-Small Cell Lung Cancer",[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],"crizotinib","brigatinib","ceritinib","alectinib","atezolizumab","bevacizumab","paclitaxel","carboplatin","docetaxel","erlotinib","gefitinib","afatinib","dacomitinib","osimertinib","pembrolizumab","nivolumab","entrectinib",{"nctId":442,"briefTitle":443,"status":381,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":26,"conditions":447,"interventions":449},"NCT07556549","A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a\u002FmNSCLC",[],"2026-06-30","2026-05-18",[448],"Non-Small Cell Lung Cancer ALK-positive",[43],{"nctId":451,"briefTitle":452,"status":453,"phases":454,"conditions":455,"interventions":456},"NCT03127618","Lorlatinib - PF-06463922","APPROVED_FOR_MARKETING",[],[],[43],{"nctId":458,"briefTitle":459,"status":111,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":466},"NCT06282991","A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled",[],"2021-01-18","2020-07-22",73,[465],"Non-Small Cell Lung Carcinoma",[43],{"nctId":468,"briefTitle":469,"status":381,"phases":470,"primaryCompletion":445,"completion":445,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT06678555","A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.",[],"2025-07-04",35,[376],[43],{"nctId":476,"briefTitle":477,"status":126,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT06487078","Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context",[95],"2028-11-30","2025-01-20",90,[483],"ALK+ Non-Small-Cell Lung Carcinoma",[43],{"nctId":486,"briefTitle":487,"status":308,"phases":488,"conditions":489,"interventions":491},"NCT03178071","Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive",[],[490],"Non Small Cell Lung Cancer ALK Positive or ROS1 Positive",[43],{"nctId":493,"briefTitle":494,"status":168,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT04753658","Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib",[],"2022-09-30","2021-03-19",15,[500],"Neuroblastoma",[329],3,{"intervention":424,"totalTrials":504,"cells":505},27,{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":632,"PHASE3":676,"PHASE4":695,"NA":717},{"trials":507,"activeCount":103},[],{"trials":509,"activeCount":103},[510,519,528,535,545,556,565,573,581,590,601,614,621],{"nctId":511,"briefTitle":512,"status":168,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":29,"conditions":516,"interventions":518},"NCT01121588","Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)",[91],"2023-09-07","2011-03-22",[517],"Neoplasms Malignant",[388],{"nctId":520,"briefTitle":521,"status":111,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":527},"NCT01297595","Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule",[91],"2011-04","2011-03",22,[16],[424],{"nctId":529,"briefTitle":530,"status":111,"phases":531,"primaryCompletion":113,"completion":113,"start":113,"enrollment":314,"conditions":532,"interventions":533},"NCT01549574","Drug Drug Interaction Study Of Crizotinib With Esomeprazole.",[91],[16],[424,534],"esomeprazole",{"nctId":536,"briefTitle":537,"status":111,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},"NCT01576406","Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients",[91],"2016-06","2012-07",88,[543],"Advanced Cancer",[424,424,424,424,424],{"nctId":546,"briefTitle":547,"status":111,"phases":548,"primaryCompletion":549,"completion":550,"start":551,"enrollment":26,"conditions":552,"interventions":554},"NCT01999972","A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors",[91],"2017-02-22","2019-09-05","2014-02-26",[553],"Advanced Solid Tumors",[555,424,555,424,555,424],"axitinib",{"nctId":557,"briefTitle":558,"status":111,"phases":559,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":563,"interventions":564},"NCT01168934","A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers",[91],"2010-09","2010-08",14,[16],[424,424],{"nctId":566,"briefTitle":567,"status":111,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":314,"conditions":571,"interventions":572},"NCT01419041","A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function",[91],"2012-08","2011-11",[352],[424,424],{"nctId":574,"briefTitle":575,"status":111,"phases":576,"primaryCompletion":577,"completion":577,"start":577,"enrollment":578,"conditions":579,"interventions":580},"NCT01125904","A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers",[91],"2010-06",5,[16],[424],{"nctId":582,"briefTitle":583,"status":111,"phases":584,"primaryCompletion":585,"completion":585,"start":586,"enrollment":498,"conditions":587,"interventions":588},"NCT01147055","Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers",[91],"2010-10","2010-07",[16],[424,589,424],"rifampin",{"nctId":591,"briefTitle":592,"status":111,"phases":593,"primaryCompletion":594,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":599},"NCT03137134","A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.",[91],"2017-09-19","2017-10-17","2017-06-20",18,[16],[388,600],"Esomeprazole",{"nctId":602,"briefTitle":603,"status":111,"phases":604,"primaryCompletion":605,"completion":605,"start":606,"enrollment":360,"conditions":607,"interventions":608},"NCT02006277","A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation",[91],"2014-03","2013-12",[16],[609,610,611,612,613,610,611,424,612],"Crizotinib prototype microsphere 0.529 mg\u002Fmg","crizotinib prototype microsphere 0.470 mg\u002Fmg","crizotinib prototype microsphere 0.420 mg\u002Fmg","crizotinib oral solution","crizotinib prototype microsphere 0.529 mg\u002Fmg",{"nctId":615,"briefTitle":616,"status":111,"phases":617,"primaryCompletion":560,"completion":560,"start":586,"enrollment":498,"conditions":618,"interventions":619},"NCT01149785","Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers",[91],[16],[424,620,424],"ketoconazole",{"nctId":622,"briefTitle":623,"status":168,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT02511184","Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients",[91],"2017-12","2015-10",9,[629],"ALK-positive Advanced NSCLC",[388,631],"Pembrolizumab",{"trials":633,"activeCount":103},[634,646,655,665],{"nctId":635,"briefTitle":636,"status":111,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":645},"NCT01945021","Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC",[92],"2015-07-31","2020-01-22","2013-09-30",129,[643,644,388],"Non Small Cell Lung Cancer","ROS1 Proto Oncogene",[388],{"nctId":647,"briefTitle":648,"status":649,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":103,"conditions":653,"interventions":654},"NCT01500824","A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer","WITHDRAWN",[92],"2016-05","2014-05",[422],[388],{"nctId":656,"briefTitle":657,"status":168,"phases":658,"primaryCompletion":150,"completion":659,"start":660,"enrollment":32,"conditions":661,"interventions":662},"NCT02584634","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",[91,92],"2022-07-13","2015-12-18",[422],[663,664,388],"Avelumab","PF-06463922",{"nctId":666,"briefTitle":667,"status":111,"phases":668,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT01970865","A Study Of PF-06463922 An ALK\u002FROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations",[91,92],"2017-03-15","2023-05-24","2014-01-08",364,[674],"ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC",[664,388],{"trials":677,"activeCount":302,"soonestReadout":42},[678,691],{"nctId":679,"briefTitle":680,"status":111,"phases":681,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":688},"NCT01639001","A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients",[93],"2015-06-30","2020-01-08","2012-09-29",207,[687],"NSCLC (Non-small Cell Lung Cancer)",[388,689,690],"Pemetrexed\u002FCisplatin","Pemetrexed\u002FCarboplatin",{"nctId":40,"briefTitle":41,"status":381,"phases":692,"primaryCompletion":42,"completion":383,"start":384,"enrollment":385,"conditions":693,"interventions":694},[93],[376],[43,388],{"trials":696,"activeCount":302,"soonestReadout":701},[697,707],{"nctId":698,"briefTitle":699,"status":381,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":504,"conditions":703,"interventions":706},"NCT05160922","Crizotinib Continuation Clinical Study",[94],"2028-03-21","2021-12-27",[410,704,705],"ALCL","IMT",[424],{"nctId":708,"briefTitle":709,"status":168,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":714,"interventions":716},"NCT03672643","Long Term Safety Observation of Crizotinib in Chinese NSCLC Population",[94],"2023-09-28","2019-01-28",41,[715],"ALK or ROS1-positive NSCLC",[388],{"trials":718,"activeCount":302,"soonestReadout":723},[719,729,738,742,752,761],{"nctId":720,"briefTitle":721,"status":381,"phases":722,"primaryCompletion":723,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":728},"NCT03375242","Safety and Efficacy of Xalkori ROS1",[],"2026-11-06","2017-10-25",97,[727],"Non-small Cell Lung Cancer",[424],{"nctId":730,"briefTitle":731,"status":111,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":737},"NCT01597258","Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)",[],"2018-03-16","2012-05-29",2029,[727],[388],{"nctId":415,"briefTitle":416,"status":111,"phases":739,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":740,"interventions":741},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"nctId":743,"briefTitle":744,"status":111,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":751},"NCT00828919","Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials",[95],"2023-08-14","2003-03-07",52,[750],"Solid Tumors",[555,424],{"nctId":753,"briefTitle":754,"status":111,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":760},"NCT02679170","Study to IDEntify Patients With Advanced\u002FMetastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)",[],"2022-05-04","2016-06-29",692,[422],[388],{"nctId":762,"briefTitle":763,"status":308,"phases":764,"conditions":765,"interventions":767},"NCT02473497","Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients",[],[766],"Neoplasm",[388],{"intervention":769,"totalTrials":302,"cells":770},"Binimetinib only treatment",{"EARLY_PHASE1":771,"PHASE1":773,"PHASE2":775,"PHASE3":777,"PHASE4":779,"NA":794},{"trials":772,"activeCount":103},[],{"trials":774,"activeCount":103},[],{"trials":776,"activeCount":103},[],{"trials":778,"activeCount":103},[],{"trials":780,"activeCount":302,"soonestReadout":785},[781],{"nctId":782,"briefTitle":783,"status":126,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":789},"NCT05203172","The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials",[94],"2029-07-31","2022-07-05",46,[750],[769,790,791,792,793],"Encorafenib only Treatment","Encorafenib & Binimetinib Treatment","Treatment of Encorafenib & Binimetinib & Ribociclib","Treatment of Encorafenib & Binimetinib & Cetuximab",{"trials":795,"activeCount":103},[],{"intervention":790,"totalTrials":302,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":804,"PHASE4":806,"NA":812},{"trials":799,"activeCount":103},[],{"trials":801,"activeCount":103},[],{"trials":803,"activeCount":103},[],{"trials":805,"activeCount":103},[],{"trials":807,"activeCount":302,"soonestReadout":785},[808],{"nctId":782,"briefTitle":783,"status":126,"phases":809,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":810,"interventions":811},[94],[750],[769,790,791,792,793],{"trials":813,"activeCount":103},[],{"intervention":791,"totalTrials":302,"cells":815},{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":822,"PHASE4":824,"NA":830},{"trials":817,"activeCount":103},[],{"trials":819,"activeCount":103},[],{"trials":821,"activeCount":103},[],{"trials":823,"activeCount":103},[],{"trials":825,"activeCount":302,"soonestReadout":785},[826],{"nctId":782,"briefTitle":783,"status":126,"phases":827,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":828,"interventions":829},[94],[750],[769,790,791,792,793],{"trials":831,"activeCount":103},[],{"intervention":792,"totalTrials":302,"cells":833},{"EARLY_PHASE1":834,"PHASE1":836,"PHASE2":838,"PHASE3":840,"PHASE4":842,"NA":848},{"trials":835,"activeCount":103},[],{"trials":837,"activeCount":103},[],{"trials":839,"activeCount":103},[],{"trials":841,"activeCount":103},[],{"trials":843,"activeCount":302,"soonestReadout":785},[844],{"nctId":782,"briefTitle":783,"status":126,"phases":845,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":846,"interventions":847},[94],[750],[769,790,791,792,793],{"trials":849,"activeCount":103},[],{"intervention":793,"totalTrials":302,"cells":851},{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":866},{"trials":853,"activeCount":103},[],{"trials":855,"activeCount":103},[],{"trials":857,"activeCount":103},[],{"trials":859,"activeCount":103},[],{"trials":861,"activeCount":302,"soonestReadout":785},[862],{"nctId":782,"briefTitle":783,"status":126,"phases":863,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":864,"interventions":865},[94],[750],[769,790,791,792,793],{"trials":867,"activeCount":103},[],{"intervention":869,"totalTrials":870,"cells":871},"PF-08634404",10,{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":969,"PHASE4":1043,"NA":1045},{"trials":873,"activeCount":103},[],{"trials":875,"activeCount":103},[],{"trials":877,"activeCount":578,"soonestReadout":882},[878,896,910,934,954],{"nctId":879,"briefTitle":880,"status":126,"phases":881,"primaryCompletion":882,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":894},"NCT07227012","Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.",[91,92],"2027-10-18","2028-10-17","2025-12-01",138,[887,888,889,890,891,892,893],"Carcinoma, Hepatocellular","Hepatocellular Cancer","Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma","Liver Neoplasms","Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma",[869,895],"Ipilimumab",{"nctId":897,"briefTitle":898,"status":126,"phases":899,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":908},"NCT07421700","Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer",[91,92],"2027-12-06","2028-09-05","2026-03-11",132,[905,906,907],"Urothelial Cancer","Advanced\u002FMetastatic Urothelial Cancer","Urothelial Carcinoma",[869,909],"Enfortumab Vedotin",{"nctId":911,"briefTitle":912,"status":126,"phases":913,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":932},"NCT07227415","Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",[91,92],"2027-11-02","2028-11-01","2026-02-10",224,[919,920,921,922,923,924,925,926,927,928,929,930,931],"Carcinoma, Renal Cell","Advanced Renal Cell Carcinoma","Renal Cancer","Renal Neoplasm","Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Clear-cell Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell Metastasis","Advanced or Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell, Advanced","Metastatic Renal Cell Cancer","Metastatic Renal Cell Carcinoma ( mRCC)","Metastatic\u002FAdvanced Renal Cell Carcinoma",[869,895,933],"Axitinib",{"nctId":935,"briefTitle":936,"status":263,"phases":937,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":951},"NCT07489066","Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC",[92],"2028-08-04","2031-08-05","2026-04-01",120,[943,944,945,946,947,948,422,949,950],"Carcinoma","Non-Small-Cell Lung","Lung Cancer (NSCLC)","Lung Neoplasms","Carcinoma, Non-Small-Cell Lung (NSCLC)","Lung Disease","Non-small Cell Lung Cancer, Non-squamous","Non-small Cell Lung Cancer, Squamous",[869,952,953],"Chemotherapy Regimen 1","Chemotherapy Regimen 2",{"nctId":955,"briefTitle":956,"status":126,"phases":957,"primaryCompletion":958,"completion":959,"start":960,"enrollment":35,"conditions":961,"interventions":967},"NCT07476287","Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer",[92],"2028-03-19","2031-03-19","2026-05-15",[962,963,964,946,965,966],"Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","Transformed Small Cell Lung Cancer","Carcinoma, Small Cell Lung","Small Cell Cancer Of The Lung",[869,968],"Chemotherapy",{"trials":970,"activeCount":578,"soonestReadout":975},[971,983,998,1010,1031],{"nctId":972,"briefTitle":973,"status":126,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":982},"NCT07222566","Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[93],"2029-02-27","2032-08-26","2026-01-06",1410,[399,422,376,947,980,981],"Metastatic Non Small Cell Lung Cancer","Lung Cancer",[869,631,952,953],{"nctId":984,"briefTitle":985,"status":126,"phases":986,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":996},"NCT07392892","A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer",[92,93],"2031-07-22","2032-07-21","2026-04-28",840,[992,993,994,995],"Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma","Metastatic Gastric Cancer","Gastroesophageal Junction Cancer","Esophageal Adenocarcinoma",[869,968,997],"Nivolumab",{"nctId":999,"briefTitle":1000,"status":263,"phases":1001,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":130,"conditions":1005,"interventions":1008},"NCT07578649","Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer",[93],"2029-06-01","2031-01-30","2026-10-09",[1006,1007],"Endometrial Neoplasms","Endometrial Cancer",[869,631,1009],"Standard of Care Chemotherapy",{"nctId":1011,"briefTitle":1012,"status":126,"phases":1013,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1029},"NCT07222800","Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer",[93],"2030-03-29","2031-08-01","2025-12-11",800,[1019,1020,1021,1022,1023,1024,1025,1026,1027,1028],"Intestinal Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms","Neoplasms by Site","Digestive System Diseases","Gastrointestinal Diseases","Colonic Diseases","Intestinal Diseases","Rectal Diseases","Colorectal Neoplasms",[869,1030,968],"Bevacizumab",{"nctId":1032,"briefTitle":1033,"status":126,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT07226999","Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer",[92,93],"2030-06-14","2034-03-11","2025-12-09",550,[1040],"Small Cell Lung Cancer (SCLC)",[869,1042,968],"Atezolizumab",{"trials":1044,"activeCount":103},[],{"trials":1046,"activeCount":103},[],{"intervention":48,"totalTrials":314,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1088,"PHASE3":1125,"PHASE4":1173,"NA":1175},{"trials":1050,"activeCount":103},[],{"trials":1052,"activeCount":1087,"soonestReadout":1057},[1053,1066,1076],{"nctId":1054,"briefTitle":1055,"status":381,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1063},"NCT05675449","A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma",[91],"2025-07-07","2028-02-29","2022-12-14",59,[1062],"Multiple Myeloma",[48,1064,1065],"Carfilzomib","Maplirpacept",{"nctId":1067,"briefTitle":1068,"status":111,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":257,"conditions":1073,"interventions":1075},"NCT04798586","MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma",[91],"2022-05-27","2023-05-17","2021-03-22",[1074],"Relapsed or Refractory Multiple Myeloma",[48],{"nctId":1077,"briefTitle":1078,"status":126,"phases":1079,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":1084,"interventions":1085},"NCT06215118","A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",[91],"2027-04-10","2028-03-09","2024-02-20",87,[1062],[48,1086],"Iberdomide",2,{"trials":1089,"activeCount":302,"soonestReadout":47},[1090,1109,1115],{"nctId":1091,"briefTitle":1092,"status":111,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1108},"NCT05228470","A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.",[92],"2023-08-06","2025-09-11","2021-12-21",39,[48,1099,1062,1100,1101,1102,1103,1104,1105,1106,1107],"Myeloma","Relapsed Multiple Myeloma","Refractory Multiple Myeloma","PF-06863135","BCMA","Bispecific","Bispecific Antibody","BCMA-CD3 Bispecific","MagnetisMM-8",[48],{"nctId":45,"briefTitle":46,"status":381,"phases":1110,"primaryCompletion":47,"completion":1111,"start":150,"enrollment":1112,"conditions":1113,"interventions":1114},[92],"2026-12-31",187,[1062],[48],{"nctId":1116,"briefTitle":1117,"status":111,"phases":1118,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1124},"NCT05014412","A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment",[92],"2023-06-15","2025-12-12","2021-10-07",86,[1062],[48],{"trials":1126,"activeCount":257,"soonestReadout":1131},[1127,1140,1151,1163],{"nctId":1128,"briefTitle":1129,"status":126,"phases":1130,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1136},"NCT05020236","A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments",[93],"2026-04-27","2027-05-31","2021-10-04",944,[1062],[48,1137,1138,1139],"Daratumumab","Pomalidomide","Dexamethasone",{"nctId":1141,"briefTitle":1142,"status":381,"phases":1143,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1149},"NCT05317416","Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant",[93],"2027-08-04","2029-10-31","2022-03-25",854,[1062],[48,1150,1150,48],"Lenalidomide",{"nctId":1152,"briefTitle":1153,"status":126,"phases":1154,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1160},"NCT06152575","MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)",[93],"2026-08-30","2027-12-30","2024-02-08",492,[1062],[48,1161,1138,1139,1162,1064],"Elotuzumab","Bortezomib",{"nctId":1164,"briefTitle":1165,"status":126,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1172},"NCT05623020","A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant",[93],"2030-10-18","2033-10-03","2022-11-10",1116,[1062],[48,1137,1150,1139,1162],{"trials":1174,"activeCount":103},[],{"trials":1176,"activeCount":302,"soonestReadout":1208},[1177,1186,1195,1204,1213,1219],{"nctId":1178,"briefTitle":1179,"status":111,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1185},"NCT06504524","A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US",[],"2024-05-31","2023-09-01",633,[1062],[48,144],{"nctId":1187,"briefTitle":1188,"status":111,"phases":1189,"primaryCompletion":1190,"completion":1190,"start":52,"enrollment":1191,"conditions":1192,"interventions":1193},"NCT05565391","A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma",[],"2022-11-04",508,[1062],[48,1194],"Standard of care",{"nctId":1196,"briefTitle":1197,"status":111,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1203},"NCT05932290","A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma",[],"2023-07-12","2023-06-01",514,[1062],[48,1194],{"nctId":1205,"briefTitle":1206,"status":381,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1212},"NCT06581848","Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).",[],"2030-01-31","2025-06-05",150,[1062],[48],{"nctId":1214,"briefTitle":1215,"status":308,"phases":1216,"conditions":1217,"interventions":1218},"NCT05238311","Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)",[],[1062],[48],{"nctId":1220,"briefTitle":1221,"status":111,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":87,"enrollment":257,"conditions":1224,"interventions":1225},"NCT06592222","A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies",[],"2025-03-03",[1062],[48,1194],{"intervention":88,"totalTrials":525,"cells":1227},{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1294,"PHASE3":1349,"PHASE4":1394,"NA":1405},{"trials":1229,"activeCount":103},[],{"trials":1231,"activeCount":103},[1232,1244,1253,1261,1273,1284],{"nctId":1233,"briefTitle":1234,"status":111,"phases":1235,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":1239,"conditions":1240,"interventions":1242},"NCT02499146","Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer",[91],"2018-07-31","2024-12-24","2015-09-11",26,[1241],"Advanced Breast Cancer",[88,1243],"Letrozole",{"nctId":1245,"briefTitle":1246,"status":111,"phases":1247,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":498,"conditions":1250,"interventions":1251},"NCT01953731","A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)",[91],"2014-01","2013-10",[16],[88,1252],"Rifampin",{"nctId":1254,"briefTitle":1255,"status":111,"phases":1256,"primaryCompletion":651,"completion":651,"start":652,"enrollment":1257,"conditions":1258,"interventions":1259},"NCT02085538","Study Of Palbociclib (PD-0332991) In Renal Impairment",[91],31,[352],[1260,1260,1260,1260],"palbociclib",{"nctId":1262,"briefTitle":1263,"status":111,"phases":1264,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1271},"NCT03220191","Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib",[91],"2017-09-03","2017-09-26","2017-07-21",12,[1270],"Healthy Volunteer",[88,1272],"Rabeprazole",{"nctId":1274,"briefTitle":1275,"status":111,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":407,"conditions":1280,"interventions":1282},"NCT02501902","Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC",[91],"2018-10-10","2018-12-27","2015-11-23",[1281],"Metastatic Pancreatic Ductal Adenocarcinoma",[88,1283],"Nab-Paclitaxel",{"nctId":1285,"briefTitle":1286,"status":111,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":605,"enrollment":504,"conditions":1289,"interventions":1290},"NCT02059330","A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects",[91],"2014-06",[16],[1291,1292,1293,88,1292],"Palbociclib 75mg","Palbociclib 125mg","Palbociclib 100mg",{"trials":1295,"activeCount":502,"soonestReadout":87},[1296,1306,1322,1338],{"nctId":1297,"briefTitle":1298,"status":381,"phases":1299,"primaryCompletion":1111,"completion":1111,"start":1300,"enrollment":472,"conditions":1301,"interventions":1303},"NCT05226871","Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies",[92],"2022-07-07",[31,1302],"Head and Neck Cancer",[88,1304,1305,1243],"Cetuximab","Fulvestrant",{"nctId":1307,"briefTitle":1308,"status":126,"phases":1309,"primaryCompletion":1310,"completion":1311,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1318},"NCT04606446","Study of PF-07248144 in Advanced or Metastatic Solid Tumors",[92],"2029-07-13","2029-08-10","2020-11-16",320,[1315,1316,1317],"Locally Advanced or Metastatic ER+ HER2- Breast Cancer","Locally Advanced or Metastatic Castration-resistant Prostate Cancer","Locally Advanced or Metastatic Non-small Cell Lung Cancer",[1319,1305,1243,88,1320,1321],"PF-07248144","PF-07220060","PF-07850327, ARV-471, vepdegestrant",{"nctId":85,"briefTitle":86,"status":381,"phases":1323,"primaryCompletion":87,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1333},[92],"2025-10-18","2019-05-24",128,[1328,750,1329,1330,500,1331,1332],"Ewing Sarcoma","Rhabdoid Tumor","Rhabdomyosarcoma","Medulloblastoma","Diffuse Intrinsic Pontine Glioma",[88,1334,1335,1336,1337],"Temozolomide","Irinotecan","Topotecan","Cyclophosphamide",{"nctId":1339,"briefTitle":1340,"status":111,"phases":1341,"primaryCompletion":1342,"completion":1343,"start":1344,"enrollment":1345,"conditions":1346,"interventions":1348},"NCT02499120","Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer",[92],"2018-07-19","2022-09-07","2015-09-10",125,[1347],"Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[1260,1304],{"trials":1350,"activeCount":1087,"soonestReadout":1355},[1351,1360,1371,1384],{"nctId":1352,"briefTitle":1353,"status":381,"phases":1354,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1060,"conditions":1357,"interventions":1358},"NCT05909397","Vepdegestrant (ARV-471\u002FPF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)\u002FHER2(-) Advanced Breast Cancer",[93],"2026-12-30","2023-08-09",[31],[1359,88,1243,88],"Vepdegestrant",{"nctId":1361,"briefTitle":1362,"status":111,"phases":1363,"primaryCompletion":1364,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1370},"NCT01942135","Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)",[93],"2014-12-05","2022-09-28","2013-09-26",521,[1369],"Metastatic Breast Cancer",[88,1305,1305],{"nctId":1372,"briefTitle":1373,"status":381,"phases":1374,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1380},"NCT06760637","Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced\u002FMetastatic Disease",[93],"2029-01-02","2037-12-29","2025-01-06",1035,[31],[1320,1381,1382,1260,1383],"letrozole","abemaciclib","ribociclib",{"nctId":1385,"briefTitle":1386,"status":111,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1393},"NCT02600923","Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate",[93],"2019-05-28","2016-04-15",131,[1392],"Advanced Breast Cancer Female",[88,1243],{"trials":1395,"activeCount":103},[1396],{"nctId":1397,"briefTitle":1398,"status":111,"phases":1399,"primaryCompletion":1400,"completion":1400,"start":1401,"enrollment":1402,"conditions":1403,"interventions":1404},"NCT02679755","Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",[94],"2019-07-25","2016-03-09",252,[31],[88,1243],{"trials":1406,"activeCount":1087,"soonestReadout":1440},[1407,1417,1427,1436,1446,1453,1463],{"nctId":1408,"briefTitle":1409,"status":111,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":1413,"conditions":1414,"interventions":1416},"NCT03921866","UK Ibrance Patient Program (IPP) Study",[],"2021-03-04","2019-03-01",191,[1415],"HR+\u002FHER2- Locally Advanced, Metastatic Breast Cancer",[88],{"nctId":1418,"briefTitle":1419,"status":111,"phases":1420,"primaryCompletion":1421,"completion":1421,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1425},"NCT05399329","Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line\u002FSecond-line Treatment for HR+\u002FHER2- Advanced Breast Cancer in Japan",[],"2025-06-27","2022-04-20",693,[31],[88,1426],"Endocrine therapy",{"nctId":1428,"briefTitle":1429,"status":111,"phases":1430,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":1433,"conditions":1434,"interventions":1435},"NCT04671615","A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.",[],"2022-11-30","2020-12-06",559,[1369],[1260],{"nctId":1437,"briefTitle":1438,"status":126,"phases":1439,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":1442,"conditions":1443,"interventions":1445},"NCT04654208","Swedish Ibrance Registries Insights (SIRI)",[],"2026-05-31","2020-12-15",1500,[1444],"Malignant Neoplasm of Breast",[1260],{"nctId":1447,"briefTitle":1448,"status":308,"phases":1449,"conditions":1450,"interventions":1452},"NCT02142868","Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",[],[1451],"Advanced Breast Cancer (Female)",[88,1243],{"nctId":1454,"briefTitle":1455,"status":381,"phases":1456,"primaryCompletion":1355,"completion":1355,"start":1457,"enrollment":302,"conditions":1458,"interventions":1459},"NCT06495164","A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer",[],"2024-06-24",[31,1444],[88,1460,1461,1462],"Aromatase inhibitor","Ribociclib","Abemaciclib",{"nctId":1464,"briefTitle":1465,"status":111,"phases":1466,"primaryCompletion":1467,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1471},"NCT06086340","Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.",[],"2024-01-24","2023-09-29",779,[31],[88,1472],"Aromatase Inhibitor",{"intervention":1474,"totalTrials":562,"cells":1475},"Etrasimod",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1491,"PHASE3":1551,"PHASE4":1595,"NA":1597},{"trials":1477,"activeCount":103},[],{"trials":1479,"activeCount":302,"soonestReadout":1484},[1480],{"nctId":1481,"briefTitle":1482,"status":126,"phases":1483,"primaryCompletion":1484,"completion":1485,"start":1486,"enrollment":1487,"conditions":1488,"interventions":1490},"NCT07153159","A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women",[91],"2026-09-12","2026-10-12","2025-08-07",8,[1489],"Healthy Participant",[1474],{"trials":1492,"activeCount":1087,"soonestReadout":1527},[1493,1502,1513,1523,1534,1542],{"nctId":1494,"briefTitle":1495,"status":111,"phases":1496,"primaryCompletion":496,"completion":1497,"start":1441,"enrollment":1498,"conditions":1499,"interventions":1501},"NCT04682639","A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis",[92],"2023-06-30",108,[1500],"Eosinophilic Esophagitis",[1474,1474],{"nctId":1503,"briefTitle":1504,"status":126,"phases":1505,"primaryCompletion":1506,"completion":1507,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1512},"NCT07470879","A Study of How the Medicine Called \"Etrasimod\" Works in Children With the Gut Disease Called Ulcerative Colitis",[92],"2030-09-10","2034-08-20","2026-05-30",24,[1511],"Colitis, Ulcerative",[1474],{"nctId":1514,"briefTitle":1515,"status":111,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT04556734","Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata",[92],"2023-06-07","2020-07-29",80,[1521],"Alopecia Areata",[1474,1474],{"nctId":1524,"briefTitle":1525,"status":126,"phases":1526,"primaryCompletion":1527,"completion":1528,"start":1529,"enrollment":1530,"conditions":1531,"interventions":1533},"NCT05287126","A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis",[92],"2029-06-16","2033-07-10","2022-12-16",36,[1532],"Ulcerative Colitis",[1474],{"nctId":1535,"briefTitle":1536,"status":111,"phases":1537,"primaryCompletion":334,"completion":334,"start":1538,"enrollment":1539,"conditions":1540,"interventions":1541},"NCT04607837","Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis",[92],"2021-04-12",234,[1532],[1474],{"nctId":1543,"briefTitle":1544,"status":111,"phases":1545,"primaryCompletion":1546,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1550},"NCT05061446","Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis",[92],"2023-10-06","2021-09-10",54,[1532],[1474,1474],{"trials":1552,"activeCount":302,"soonestReadout":1557},[1553,1561,1572,1581],{"nctId":1554,"briefTitle":1555,"status":381,"phases":1556,"primaryCompletion":1557,"completion":1557,"start":550,"enrollment":1558,"conditions":1559,"interventions":1560},"NCT03950232","An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis",[93],"2029-06-19",896,[1532],[1474],{"nctId":1562,"briefTitle":1563,"status":168,"phases":1564,"primaryCompletion":1565,"completion":1566,"start":1567,"enrollment":1568,"conditions":1569,"interventions":1571},"NCT04173273","A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease",[93],"2025-04-23","2025-06-09","2020-01-06",375,[1570],"Crohn's Disease",[1474,1474],{"nctId":1573,"briefTitle":1574,"status":111,"phases":1575,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1580},"NCT04706793","Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)",[93],"2022-08-03","2020-12-25",42,[1532],[1474],{"nctId":1582,"briefTitle":1583,"status":168,"phases":1584,"primaryCompletion":1585,"completion":1585,"start":1586,"enrollment":1587,"conditions":1588,"interventions":1593},"NCT05732454","A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection",[92,93],"2024-04-29","2023-01-18",58,[1589,1590,1591,1592],"Atopic Dermatitis","Atopic Dermatitis, Unspecified","Eczema","Eczema, Atopic",[1594],"etrasimod",{"trials":1596,"activeCount":103},[],{"trials":1598,"activeCount":1087,"soonestReadout":445},[1599,1606,1616],{"nctId":1600,"briefTitle":1601,"status":1602,"phases":1603,"conditions":1604,"interventions":1605},"NCT06025227","Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.","AVAILABLE",[],[1511],[1474],{"nctId":1607,"briefTitle":1608,"status":126,"phases":1609,"primaryCompletion":1610,"completion":1611,"start":1612,"enrollment":1613,"conditions":1614,"interventions":1615},"NCT06398626","An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis",[],"2027-10-01","2028-07-07","2024-09-17",300,[1511],[1474],{"nctId":1617,"briefTitle":1618,"status":126,"phases":1619,"primaryCompletion":445,"completion":445,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1623},"NCT06294925","A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis",[],"2024-05-08",360,[1511],[1474],{"intervention":1305,"totalTrials":1625,"cells":1626},11,{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1659,"PHASE3":1706,"PHASE4":1732,"NA":1734},{"trials":1628,"activeCount":103},[],{"trials":1630,"activeCount":103},[1631,1645],{"nctId":1632,"briefTitle":1633,"status":111,"phases":1634,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1640},"NCT01597193","Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer",[91],"2015-12-15","2018-01-22","2012-04-30",101,[31],[1641,1642,1643,1644,1641,1643],"enzalutamide","anastrozole","exemestane","fulvestrant",{"nctId":1646,"briefTitle":1647,"status":649,"phases":1648,"primaryCompletion":1649,"completion":1650,"start":1651,"enrollment":103,"conditions":1652,"interventions":1657},"NCT05905341","Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.",[91],"2026-04-14","2028-04-13","2024-01-15",[31,1653,1654,1655,1656,750],"Ovarian Cancer","Liposarcoma","Non-small Cell Lung Cancer (NSCLC)","Endometrial",[1658,1305,1658,1305,1658,1305,1658,1305,1658,1305,1658,1305,1658,1305],"PF-07224826",{"trials":1660,"activeCount":257,"soonestReadout":1665},[1661,1675,1688,1692,1696],{"nctId":1662,"briefTitle":1663,"status":381,"phases":1664,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1671},"NCT06105632","A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment",[92],"2026-01-12","2028-01-21","2024-01-09",333,[1670],"Advanced or Metastatic Breast Cancer",[1672,1305,1673,1674],"PF-07220060 CDK4 inhibitor","Everolimus","Exemestane",{"nctId":1676,"briefTitle":1677,"status":381,"phases":1678,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":1683,"interventions":1686},"NCT04557449","Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors",[92],"2026-09-23","2027-11-23","2020-09-23",362,[1654,1684,25,1685],"Prostate Cancer","Adenocarcinoma of Lung",[1320,1243,1305,1687,63],"Midazolam",{"nctId":1297,"briefTitle":1298,"status":381,"phases":1689,"primaryCompletion":1111,"completion":1111,"start":1300,"enrollment":472,"conditions":1690,"interventions":1691},[92],[31,1302],[88,1304,1305,1243],{"nctId":1307,"briefTitle":1308,"status":126,"phases":1693,"primaryCompletion":1310,"completion":1311,"start":1312,"enrollment":1313,"conditions":1694,"interventions":1695},[92],[1315,1316,1317],[1319,1305,1243,88,1320,1321],{"nctId":1697,"briefTitle":1698,"status":168,"phases":1699,"primaryCompletion":1700,"completion":1288,"start":1701,"enrollment":1702,"conditions":1703,"interventions":1704},"NCT00372996","Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer",[92],"2012-09","2007-02",219,[25],[1705,1643,1643,1305],"CP-751,871",{"trials":1707,"activeCount":1087,"soonestReadout":1712},[1708,1719,1723],{"nctId":1709,"briefTitle":1710,"status":381,"phases":1711,"primaryCompletion":1712,"completion":1713,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1717},"NCT05654623","A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer",[93],"2025-01-31","2028-05-15","2023-03-03",624,[1241],[1718,1305],"ARV-471",{"nctId":1361,"briefTitle":1362,"status":111,"phases":1720,"primaryCompletion":1364,"completion":1365,"start":1366,"enrollment":1367,"conditions":1721,"interventions":1722},[93],[1369],[88,1305,1305],{"nctId":1724,"briefTitle":1725,"status":126,"phases":1726,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":267,"conditions":1730,"interventions":1731},"NCT07062965","A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.",[93],"2027-07-22","2030-11-04","2025-08-05",[31],[1319,1305,1673,1674],{"trials":1733,"activeCount":103},[],{"trials":1735,"activeCount":103},[1736],{"nctId":1737,"briefTitle":1738,"status":111,"phases":1739,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":1742,"conditions":1743,"interventions":1744},"NCT07096024","A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market",[],"2025-02-07","2025-01-21",1772,[25],[1745,1644],"palbociclib plus fulvestrant",{"intervention":631,"totalTrials":1625,"cells":1747},{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1788,"PHASE3":1813,"PHASE4":1843,"NA":1845},{"trials":1749,"activeCount":103},[],{"trials":1751,"activeCount":302,"soonestReadout":1756},[1752,1774,1784],{"nctId":1753,"briefTitle":1754,"status":126,"phases":1755,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1762},"NCT06447662","A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",[91],"2028-01-19","2029-01-18","2024-06-27",330,[1761,1028,376],"Carcinoma, Pancreatic Ductal",[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],"PF-07934040","Gemcitabine","Nab-paclitaxel","Fluorouracil","Oxaliplatin","Leucovorin","pemetrexed","Cisplatin","Paclitaxel","Carboplatin","Sasanlimab",{"nctId":1775,"briefTitle":1776,"status":168,"phases":1777,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":1781,"interventions":1782},"NCT06704724","A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",[91],"2026-05-12","2024-12-10",30,[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],"PF-07985045",{"nctId":622,"briefTitle":623,"status":168,"phases":1785,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":1786,"interventions":1787},[91],[629],[388,631],{"trials":1789,"activeCount":302,"soonestReadout":1805},[1790,1801],{"nctId":1791,"briefTitle":1792,"status":168,"phases":1793,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1799},"NCT05926960","A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma",[92],"2026-02-02","2023-06-13",38,[1798],"Melanoma",[343,341,438,1800,439],"ipilimumab",{"nctId":1802,"briefTitle":1803,"status":381,"phases":1804,"primaryCompletion":1805,"completion":1806,"start":1807,"enrollment":1808,"conditions":1809,"interventions":1811},"NCT05217446","A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer",[92],"2026-06-01","2027-01-26","2022-07-11",107,[1810],"Metastatic Colorectal Cancer",[1812,1304,631],"Encorafenib",{"trials":1814,"activeCount":257,"soonestReadout":1665},[1815,1819,1823,1833],{"nctId":972,"briefTitle":973,"status":126,"phases":1816,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":1817,"interventions":1818},[93],[399,422,376,947,980,981],[869,631,952,953],{"nctId":999,"briefTitle":1000,"status":263,"phases":1820,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":130,"conditions":1821,"interventions":1822},[93],[1006,1007],[869,631,1009],{"nctId":1824,"briefTitle":1825,"status":381,"phases":1826,"primaryCompletion":1665,"completion":1827,"start":1828,"enrollment":1829,"conditions":1830,"interventions":1831},"NCT04657991","A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",[93],"2026-08-31","2021-01-15",257,[1798],[1812,1832,631],"Binimetinib",{"nctId":1834,"briefTitle":1835,"status":126,"phases":1836,"primaryCompletion":901,"completion":1837,"start":1838,"enrollment":1839,"conditions":1840,"interventions":1841},"NCT06758401","This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.",[93],"2029-03-01","2025-07-23",714,[422,376,947],[1842,631],"Sigvotatug Vedotin",{"trials":1844,"activeCount":103},[],{"trials":1846,"activeCount":103},[1847,1851],{"nctId":415,"briefTitle":416,"status":111,"phases":1848,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":1849,"interventions":1850},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"nctId":1852,"briefTitle":1853,"status":111,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1860},"NCT04682587","To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma",[],"2021-04-05","2021-02-24",481,[1859],"Renal Cell Carcinoma",[933,663,631],{"intervention":1862,"totalTrials":627,"cells":1863},"Abrocitinib",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1883,"PHASE3":1885,"PHASE4":1904,"NA":1906},{"trials":1865,"activeCount":103},[],{"trials":1867,"activeCount":103},[1868],{"nctId":1869,"briefTitle":1870,"status":111,"phases":1871,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":1874,"interventions":1875},"NCT04903093","A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.",[91],"2021-10-26","2021-06-04",[19],[1862,1876,1877,1878,1879,1880,1881,1882],"Abrocitinib Suspension F1","Abrocitinib Suspension F2","Abrocitinib Suspension F3","Abrocitinib Suspension F4","Abrocitinib Suspension F5","Abrocitinib Suspension F6","Famotidine",{"trials":1884,"activeCount":103},[],{"trials":1886,"activeCount":1087,"soonestReadout":1900},[1887,1896],{"nctId":1888,"briefTitle":1889,"status":126,"phases":1890,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1895},"NCT06807281","A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema",[93],"2032-02-22","2025-12-02",500,[1589],[1862],{"nctId":1897,"briefTitle":1898,"status":126,"phases":1899,"primaryCompletion":1900,"completion":1900,"start":1901,"enrollment":1210,"conditions":1902,"interventions":1903},"NCT06807268","A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema",[93],"2027-05-02","2025-07-24",[1591],[1862],{"trials":1905,"activeCount":103},[],{"trials":1907,"activeCount":257,"soonestReadout":1912},[1908,1918,1925,1935,1944,1951],{"nctId":1909,"briefTitle":1910,"status":126,"phases":1911,"primaryCompletion":1912,"completion":1913,"start":1914,"enrollment":1915,"conditions":1916,"interventions":1917},"NCT05689151","A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.",[],"2026-06-05","2027-12-31","2023-03-09",183,[1589,1591],[1862],{"nctId":1919,"briefTitle":1920,"status":308,"phases":1921,"conditions":1922,"interventions":1923},"NCT04564755","Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis",[],[1589],[1924],"abrocitinib",{"nctId":1926,"briefTitle":1927,"status":126,"phases":1928,"primaryCompletion":1929,"completion":1930,"start":1931,"enrollment":1210,"conditions":1932,"interventions":1934},"NCT06899204","Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.",[],"2026-07-01","2027-02-15","2026-01-13",[1589,1590,1933],"Dermatitis, Atopic",[1862],{"nctId":1936,"briefTitle":1937,"status":126,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1941,"conditions":1942,"interventions":1943},"NCT05391061","A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis",[],"2027-11-22","2023-01-07",1100,[1933],[1862],{"nctId":1945,"briefTitle":1946,"status":1602,"phases":1947,"conditions":1948,"interventions":1950},"NCT05466578","Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)",[],[1949],"Severe Uncontrolled Atopic Dermatitis",[1924],{"nctId":1952,"briefTitle":1953,"status":126,"phases":1954,"primaryCompletion":1913,"completion":1913,"start":1955,"enrollment":267,"conditions":1956,"interventions":1957},"NCT05721937","A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring",[],"2023-07-25",[1589],[1862],{"intervention":1304,"totalTrials":1625,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1993,"PHASE3":2030,"PHASE4":2057,"NA":2059},{"trials":1961,"activeCount":103},[],{"trials":1963,"activeCount":1087,"soonestReadout":1756},[1964,1968,1972,1976],{"nctId":1753,"briefTitle":1754,"status":126,"phases":1965,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":1966,"interventions":1967},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":331,"briefTitle":332,"status":168,"phases":1969,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":1970,"interventions":1971},[91],[338],[340,329,341,342,343],{"nctId":1775,"briefTitle":1776,"status":168,"phases":1973,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":1974,"interventions":1975},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"nctId":1977,"briefTitle":1978,"status":126,"phases":1979,"primaryCompletion":1980,"completion":1981,"start":786,"enrollment":1982,"conditions":1983,"interventions":1987},"NCT05355701","A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.",[91],"2029-02-02","2030-08-06",267,[1798,409,1984,1985,1986],"Thyroid Cancer","Glioma","Advanced Colorectal Cancer (Part 1)",[1988,341,342,1989,1990,1991,1992],"PF-07799933","midazolam","fluorouracil","leucovorin","oxaliplatin",{"trials":1994,"activeCount":1087,"soonestReadout":1805},[1995,2005,2009,2013,2026],{"nctId":1996,"briefTitle":1997,"status":168,"phases":1998,"primaryCompletion":1999,"completion":1999,"start":2000,"enrollment":99,"conditions":2001,"interventions":2002},"NCT01925274","A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer",[92],"2016-04-06","2013-11-15",[1810],[2003,2004,1304,1335],"PF-05212384","irinotecan",{"nctId":1297,"briefTitle":1298,"status":381,"phases":2006,"primaryCompletion":1111,"completion":1111,"start":1300,"enrollment":472,"conditions":2007,"interventions":2008},[92],[31,1302],[88,1304,1305,1243],{"nctId":1802,"briefTitle":1803,"status":381,"phases":2010,"primaryCompletion":1805,"completion":1806,"start":1807,"enrollment":1808,"conditions":2011,"interventions":2012},[92],[1810],[1812,1304,631],{"nctId":2014,"briefTitle":2015,"status":111,"phases":2016,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":2020,"conditions":2021,"interventions":2023},"NCT01719380","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",[92],"2015-10-31","2019-02-12","2012-11-23",156,[2022],"Colorectal Cancer",[2024,1304,2025],"LGX818","BYL719",{"nctId":1339,"briefTitle":1340,"status":111,"phases":2027,"primaryCompletion":1342,"completion":1343,"start":1344,"enrollment":1345,"conditions":2028,"interventions":2029},[92],[1347],[1260,1304],{"trials":2031,"activeCount":302,"soonestReadout":2048},[2032,2044],{"nctId":2033,"briefTitle":2034,"status":111,"phases":2035,"primaryCompletion":2036,"completion":1169,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2041},"NCT02928224","Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan\u002FCetuximab or Infusional 5-Fluorouracil (5-FU)\u002FFolinic Acid (FA)\u002FIrinotecan (FOLFIRI)\u002FCetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer",[93],"2019-02-11","2016-10-13",702,[2040],"BRAF V600E-mutant Metastatic Colorectal Cancer",[1812,1832,1304,1335,2042,2043],"Folinic Acid","5-Fluorouracil",{"nctId":2045,"briefTitle":2046,"status":381,"phases":2047,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2054},"NCT04607421","A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer",[93],"2025-12-08","2027-12-28","2020-12-21",831,[2053],"Neoplasms",[1812,1304,1767,1335,1768,2055,2056,1030],"5-FU","Capecitabine",{"trials":2058,"activeCount":103},[],{"trials":2060,"activeCount":103},[],{"intervention":68,"totalTrials":870,"cells":2062},{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2128,"PHASE3":2148,"PHASE4":2154,"NA":2156},{"trials":2064,"activeCount":103},[],{"trials":2066,"activeCount":1087,"soonestReadout":67},[2067,2073,2083,2092,2101,2109,2118],{"nctId":65,"briefTitle":66,"status":381,"phases":2068,"primaryCompletion":67,"completion":286,"start":2069,"enrollment":2070,"conditions":2071,"interventions":2072},[91],"2022-08-16",6,[25],[68],{"nctId":2074,"briefTitle":2075,"status":111,"phases":2076,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":1268,"conditions":2080,"interventions":2081},"NCT05538312","A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults",[91],"2023-04-24","2023-05-22","2023-02-23",[16],[68,2082],"Itraconazole",{"nctId":2084,"briefTitle":2085,"status":111,"phases":2086,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":870,"conditions":2090,"interventions":2091},"NCT06911788","A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults",[91],"2025-05-23","2025-06-13","2025-04-03",[28],[1359,1359],{"nctId":2093,"briefTitle":2094,"status":126,"phases":2095,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":1509,"conditions":2099,"interventions":2100},"NCT07231991","A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function",[91],"2026-12-04","2026-12-23","2025-11-18",[28],[68],{"nctId":2102,"briefTitle":2103,"status":111,"phases":2104,"primaryCompletion":2105,"completion":2106,"start":1157,"enrollment":498,"conditions":2107,"interventions":2108},"NCT06256510","A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam",[91],"2024-04-16","2024-05-13",[28],[1687,1359],{"nctId":2110,"briefTitle":2111,"status":111,"phases":2112,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":1268,"conditions":2116,"interventions":2117},"NCT06275841","A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant",[91],"2024-05-03","2024-05-24","2024-02-23",[16],[68,534],{"nctId":2119,"briefTitle":2120,"status":111,"phases":2121,"primaryCompletion":2122,"completion":2123,"start":2124,"enrollment":1268,"conditions":2125,"interventions":2126},"NCT06005688","A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants",[91],"2023-10-11","2023-11-21","2023-08-18",[28],[1359,2127],"Carbamazepine",{"trials":2129,"activeCount":1087,"soonestReadout":2134},[2130,2140],{"nctId":2131,"briefTitle":2132,"status":381,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":2136,"enrollment":2137,"conditions":2138,"interventions":2139},"NCT06206837","A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.",[91,92],"2025-09-05","2026-09-07","2024-02-19",71,[31],[68,1320],{"nctId":2141,"briefTitle":2142,"status":381,"phases":2143,"primaryCompletion":1111,"completion":1111,"start":2144,"enrollment":1625,"conditions":2145,"interventions":2146},"NCT06125522","TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)",[91,92],"2024-01-10",[31],[68,2147],"Samuraciclib",{"trials":2149,"activeCount":302,"soonestReadout":1355},[2150],{"nctId":1352,"briefTitle":1353,"status":381,"phases":2151,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1060,"conditions":2152,"interventions":2153},[93],[31],[1359,88,1243,88],{"trials":2155,"activeCount":103},[],{"trials":2157,"activeCount":103},[],{"intervention":63,"totalTrials":2159,"cells":2160},20,{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2196,"PHASE3":2254,"PHASE4":2328,"NA":2342},{"trials":2162,"activeCount":103},[],{"trials":2164,"activeCount":302,"soonestReadout":2187},[2165,2169,2183],{"nctId":1632,"briefTitle":1633,"status":111,"phases":2166,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":2167,"interventions":2168},[91],[31],[1641,1642,1643,1644,1641,1643],{"nctId":2170,"briefTitle":2171,"status":168,"phases":2172,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":2175,"conditions":2176,"interventions":2181},"NCT03685591","PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors",[91],"2022-03-30","2018-10-04",49,[25,2177,2178,1798,2179,2180,1028,919,891],"Prostate Neoplasms","Neoplasms, Squamous Cell","Mesothelioma","Pancreatic Neoplasms",[2182,63],"PF-06952229",{"nctId":2184,"briefTitle":2185,"status":126,"phases":2186,"primaryCompletion":2187,"completion":2188,"start":2189,"enrollment":2190,"conditions":2191,"interventions":2194},"NCT03460977","A Study of Mevrometostat for Treatment of Relapsed\u002FRefractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",[91],"2028-04-20","2029-07-07","2018-04-17",453,[2192,1040,2193],"Metastatic Castration Resistant Prostate Cancer (mCRPC)","Follicular Lymphoma (FL)",[2195,63,2082],"Mervometostat",{"trials":2197,"activeCount":302,"soonestReadout":1679},[2198,2208,2212,2223,2233,2244],{"nctId":2199,"briefTitle":2200,"status":111,"phases":2201,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":748,"conditions":2204,"interventions":2205},"NCT01547299","Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer",[92],"2013-11-30","2012-03-31",[1684],[63,2206,2207],"Leuprolide","Dutasteride",{"nctId":1676,"briefTitle":1677,"status":381,"phases":2209,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":2210,"interventions":2211},[92],[1654,1684,25,1685],[1320,1243,1305,1687,63],{"nctId":2213,"briefTitle":2214,"status":111,"phases":2215,"primaryCompletion":2216,"completion":2216,"start":2217,"enrollment":2218,"conditions":2219,"interventions":2222},"NCT02384382","A Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)",[92],"2019-05-03","2015-11-30",23,[2220,2221],"Prostate Carcinoma Metastatic to the Bone","Castration Resistant Prostate Cancer",[63],{"nctId":2224,"briefTitle":2225,"status":111,"phases":2226,"primaryCompletion":2227,"completion":2228,"start":569,"enrollment":2229,"conditions":2230,"interventions":2231},"NCT01664923","Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer",[92],"2015-02","2018-01",396,[1684],[63,2232],"Bicalutamide",{"nctId":2234,"briefTitle":2235,"status":111,"phases":2236,"primaryCompletion":2237,"completion":2238,"start":2239,"enrollment":2240,"conditions":2241,"interventions":2243},"NCT01091103","Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide",[92],"2012-02-29","2013-08-31","2010-02-18",60,[2242],"Metastatic Progressive Castration-resistant Prostate Cancer",[63],{"nctId":2245,"briefTitle":2246,"status":111,"phases":2247,"primaryCompletion":2248,"completion":2144,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2253},"NCT01889238","Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer",[92],"2015-03-01","2013-06-12",118,[2252],"Advanced, Androgen Receptor Positive Triple Negative Breast Cancer",[63],{"trials":2255,"activeCount":502,"soonestReadout":62},[2256,2267,2277,2286,2297,2308,2316],{"nctId":2257,"briefTitle":2258,"status":111,"phases":2259,"primaryCompletion":2260,"completion":2261,"start":2262,"enrollment":2263,"conditions":2264,"interventions":2266},"NCT00974311","Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy",[93],"2011-09-15","2017-11-02","2009-09-30",1199,[2265],"Castration-Resistant Prostate Cancer",[63],{"nctId":60,"briefTitle":61,"status":381,"phases":2268,"primaryCompletion":62,"completion":2269,"start":2270,"enrollment":2271,"conditions":2272,"interventions":2275},[93],"2026-09-19","2014-12-17",1068,[2273,1684,2274],"Hormone Sensitive Prostate Cancer","Cancer of the Prostate",[63,2276],"Leuprolide Open Label",{"nctId":2278,"briefTitle":2279,"status":111,"phases":2280,"primaryCompletion":640,"completion":2281,"start":2282,"enrollment":2283,"conditions":2284,"interventions":2285},"NCT01212991","A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer",[93],"2019-02-14","2010-09-16",1717,[1684],[63],{"nctId":2287,"briefTitle":2288,"status":111,"phases":2289,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":2293,"conditions":2294,"interventions":2296},"NCT02003924","Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer",[93],"2017-06-28","2025-11-28","2013-10-31",1401,[2295,1684,2274],"Nonmetastatic Castration-Resistant Prostate Cancer",[63],{"nctId":2298,"briefTitle":2299,"status":126,"phases":2300,"primaryCompletion":2301,"completion":479,"start":2302,"enrollment":2303,"conditions":2304,"interventions":2306},"NCT06629779","A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.",[93],"2026-12-02","2024-10-22",900,[2305],"Metastatic Castration-Resistant Prostate Cancer",[2307,63],"PF-06821497",{"nctId":2309,"briefTitle":2310,"status":649,"phases":2311,"primaryCompletion":2312,"start":2313,"enrollment":103,"conditions":2314,"interventions":2315},"NCT02929576","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer",[93],"2019-04","2016-09",[31],[63,1771],{"nctId":2317,"briefTitle":2318,"status":126,"phases":2319,"primaryCompletion":2320,"completion":2321,"start":2322,"enrollment":2323,"conditions":2324,"interventions":2326},"NCT07028853","This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.",[93],"2028-09-12","2034-12-08","2025-09-28",1000,[2325,2273,1684,2274],"Metastatic Castration Sensitive Prostate Cancer (mCSPC)",[2327,63],"Mevrometostat",{"trials":2329,"activeCount":103},[2330],{"nctId":2331,"briefTitle":2332,"status":111,"phases":2333,"primaryCompletion":2334,"completion":2335,"start":2336,"enrollment":2337,"conditions":2338,"interventions":2339},"NCT01995513","Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients",[94],"2016-11-15","2022-08-31","2013-10-22",509,[1684],[63,2340,2341],"Abiraterone","Prednisone",{"trials":2343,"activeCount":103},[2344,2354,2372],{"nctId":2345,"briefTitle":2346,"status":111,"phases":2347,"primaryCompletion":1497,"completion":1497,"start":2348,"enrollment":2349,"conditions":2350,"interventions":2352},"NCT05520138","Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)",[],"2022-08-29",5506,[2351],"Prostatic Neoplasms, Castration-Resistant",[63,2353],"Abiraterone acetate",{"nctId":2355,"briefTitle":2356,"status":111,"phases":2357,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":2361,"interventions":2362},"NCT05701007","Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland",[],"2024-04-10","2023-02-13",1083,[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],"abiraterone","apalutamide","cabazitaxel","Radium-223","Lutetium-177","degarelix","goserelin","leuprorelin","triptorelin",{"nctId":2373,"briefTitle":2374,"status":111,"phases":2375,"primaryCompletion":2376,"completion":2376,"start":2377,"enrollment":2378,"conditions":2379,"interventions":2380},"NCT05968599","A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer",[],"2025-02-14","2023-07-24",2731,[2351],[63,2353],{"intervention":1243,"totalTrials":498,"cells":2382},{"EARLY_PHASE1":2383,"PHASE1":2385,"PHASE2":2391,"PHASE3":2457,"PHASE4":2481,"NA":2487},{"trials":2384,"activeCount":103},[],{"trials":2386,"activeCount":103},[2387],{"nctId":1233,"briefTitle":1234,"status":111,"phases":2388,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":1239,"conditions":2389,"interventions":2390},[91],[1241],[88,1243],{"trials":2392,"activeCount":502,"soonestReadout":1679},[2393,2404,2408,2412,2416,2427,2436,2445],{"nctId":2394,"briefTitle":2395,"status":111,"phases":2396,"primaryCompletion":2397,"completion":2398,"start":2399,"enrollment":2400,"conditions":2401,"interventions":2402},"NCT01684215","A Study Of Oral Palbociclib (PD-0332991), A CDK4\u002F6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer",[92],"2016-03-04","2018-10-25","2012-10-19",61,[2053,25],[2403,2403,1381,2403,1381],"PD-0332991",{"nctId":1676,"briefTitle":1677,"status":381,"phases":2405,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":2406,"interventions":2407},[92],[1654,1684,25,1685],[1320,1243,1305,1687,63],{"nctId":1297,"briefTitle":1298,"status":381,"phases":2409,"primaryCompletion":1111,"completion":1111,"start":1300,"enrollment":472,"conditions":2410,"interventions":2411},[92],[31,1302],[88,1304,1305,1243],{"nctId":1307,"briefTitle":1308,"status":126,"phases":2413,"primaryCompletion":1310,"completion":1311,"start":1312,"enrollment":1313,"conditions":2414,"interventions":2415},[92],[1315,1316,1317],[1319,1305,1243,88,1320,1321],{"nctId":2417,"briefTitle":2418,"status":111,"phases":2419,"primaryCompletion":2420,"completion":2421,"start":2422,"enrollment":2423,"conditions":2424,"interventions":2425},"NCT00721409","Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer",[92],"2013-11-29","2017-12-20","2008-09-15",177,[31],[2426,1381,1381],"PD 0332991",{"nctId":2428,"briefTitle":2429,"status":168,"phases":2430,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":314,"conditions":2433,"interventions":2434},"NCT00880009","Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer",[92],"2010-05-31","2009-07-30",[31],[2435,1243,1243],"Bosutinib",{"nctId":2437,"briefTitle":2438,"status":111,"phases":2439,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":2443,"interventions":2444},"NCT06465368","A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause",[92],"2025-07-10","2024-07-11",121,[31],[1320,1381],{"nctId":2446,"briefTitle":2447,"status":168,"phases":2448,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":562,"conditions":2451,"interventions":2454},"NCT01430585","Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer",[92],"2012-12","2012-03",[2452,2453],"Early Breast Cancer (Phase 2)","Advanced Breast Cancer (Phase 1b)",[2455,2456,1243],"PF-04691502","PF-04691502 in combination with Letrozole",{"trials":2458,"activeCount":1087,"soonestReadout":1355},[2459,2463,2473,2477],{"nctId":1352,"briefTitle":1353,"status":381,"phases":2460,"primaryCompletion":1355,"completion":1355,"start":1356,"enrollment":1060,"conditions":2461,"interventions":2462},[93],[31],[1359,88,1243,88],{"nctId":2464,"briefTitle":2465,"status":111,"phases":2466,"primaryCompletion":2467,"completion":2468,"start":2469,"enrollment":2470,"conditions":2471,"interventions":2472},"NCT01740427","A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+\u002FHER2- Advanced Breast Cancer (PALOMA-2)",[93],"2016-02-26","2023-11-09","2013-02-22",666,[25],[2403,1243,1243],{"nctId":1372,"briefTitle":1373,"status":381,"phases":2474,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":2475,"interventions":2476},[93],[31],[1320,1381,1382,1260,1383],{"nctId":1385,"briefTitle":1386,"status":111,"phases":2478,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":1390,"conditions":2479,"interventions":2480},[93],[1392],[88,1243],{"trials":2482,"activeCount":103},[2483],{"nctId":1397,"briefTitle":1398,"status":111,"phases":2484,"primaryCompletion":1400,"completion":1400,"start":1401,"enrollment":1402,"conditions":2485,"interventions":2486},[94],[31],[88,1243],{"trials":2488,"activeCount":103},[2489],{"nctId":1447,"briefTitle":1448,"status":308,"phases":2490,"conditions":2491,"interventions":2492},[],[1451],[88,1243],{"intervention":2494,"totalTrials":870,"cells":2495},"20-valent pneumococcal conjugate vaccine",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2516,"PHASE3":2544,"PHASE4":2613,"NA":2615},{"trials":2497,"activeCount":103},[],{"trials":2499,"activeCount":302,"soonestReadout":2504},[2500],{"nctId":2501,"briefTitle":2502,"status":381,"phases":2503,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":2507,"interventions":2509},"NCT07086677","A Study to Learn About How a New Pneumococcal Vaccine Works in Adults",[91],"2027-10-21","2025-07-22",380,[2508],"Streptococcus Pneumoniae",[2510,2511,2512,2513,2514,2494,2515],"PG4 vaccine in Buffer 1 with low dose PA-001","PG4 in Buffer 1 with low dose PA-002","PG4 in Buffer 1 with high dose PA-001","PG4 vaccine in Buffer 1 with high dose PA-002","PG4 vaccine in Buffer 2","Saline",{"trials":2517,"activeCount":1087,"soonestReadout":2522},[2518,2533],{"nctId":2519,"briefTitle":2520,"status":381,"phases":2521,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":2525,"interventions":2527},"NCT06182124","A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults",[91,92],"2026-05-23","2023-12-20",558,[2526],"Pneumococcal Disease",[2528,2529,2494,2530,2531,2532],"Multivalent Pneumococcal Vaccine - Formulation 1","Multivalent Pneumococcal Vaccine - Formulation 2","Licensed pneumococcal comparator vaccine","Multivalent Pneumococcal Vaccine - Formulation 3","Multivalent Pneumococcal Vaccine - Formulation 4",{"nctId":2534,"briefTitle":2535,"status":381,"phases":2536,"primaryCompletion":2537,"completion":2537,"start":2538,"enrollment":2539,"conditions":2540,"interventions":2541},"NCT06524414","A Study to Learn About How a New Pneumococcal Vaccine Works in Infants",[92],"2027-05-01","2024-07-25",605,[2526],[2542,2494,2543],"PG4","15-valent pneumococcal conjugate vaccine",{"trials":2545,"activeCount":302,"soonestReadout":2570},[2546,2556,2566,2575,2584,2596,2604],{"nctId":2547,"briefTitle":2548,"status":111,"phases":2549,"primaryCompletion":2550,"completion":2550,"start":2551,"enrollment":2552,"conditions":2553,"interventions":2554},"NCT04530838","20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants",[93],"2022-04-02","2020-09-16",668,[2526],[2494,2555],"13-valent pneumococcal conjugate vaccine",{"nctId":2557,"briefTitle":2558,"status":111,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT04546425","20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants",[93],"2022-04-22","2023-02-18","2020-09-09",1258,[2526],[2494,2555],{"nctId":2567,"briefTitle":2568,"status":126,"phases":2569,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":2573,"interventions":2574},"NCT07573462","A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants",[93],"2028-12-30","2026-05-04",2400,[2526],[2542,2494],{"nctId":2576,"briefTitle":2577,"status":111,"phases":2578,"primaryCompletion":2579,"completion":2579,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2583},"NCT04382326","20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants",[93],"2022-09-02","2020-05-20",1997,[2526],[2494,2555],{"nctId":2585,"briefTitle":2586,"status":111,"phases":2587,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":2590,"conditions":2591,"interventions":2594},"NCT04887948","Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2",[93],"2021-12-08","2021-05-20",570,[2526,2592,2593],"COVID-19","SARS-CoV-2 Infection",[2494,2595],"BNT162b2",{"nctId":2597,"briefTitle":2598,"status":111,"phases":2599,"primaryCompletion":1200,"completion":1200,"start":2600,"enrollment":2601,"conditions":2602,"interventions":2603},"NCT05408429","Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13",[93],"2022-06-24",356,[2526],[2494,2555],{"nctId":2605,"briefTitle":2606,"status":111,"phases":2607,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":2611,"interventions":2612},"NCT05512819","A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan",[93],"2025-09-20","2022-09-16",541,[2526],[2494,2555],{"trials":2614,"activeCount":103},[],{"trials":2616,"activeCount":103},[],{"intervention":968,"totalTrials":627,"cells":2618},{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2623,"PHASE3":2682,"PHASE4":2696,"NA":2698},{"trials":2620,"activeCount":103},[],{"trials":2622,"activeCount":103},[],{"trials":2624,"activeCount":302,"soonestReadout":958},[2625,2637,2648,2656,2667,2678],{"nctId":2626,"briefTitle":2627,"status":111,"phases":2628,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":2632,"interventions":2634},"NCT00003673","CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse",[92],"1999-03","1998-03",55,[2633],"Leukemia",[2635,2636],"chemotherapy","gemtuzumab ozogamicin",{"nctId":2638,"briefTitle":2639,"status":111,"phases":2640,"completion":2641,"start":2642,"enrollment":2643,"conditions":2644,"interventions":2646},"NCT00070629","CPG 7909 Injection in Non-Small Cell Lung Cancer",[92],"2007-07","2003-05",116,[2645],"Carcinoma, Non-Small Cell Lung",[2647,968,968],"CPG 7909",{"nctId":2649,"briefTitle":2650,"status":111,"phases":2651,"primaryCompletion":2652,"completion":2652,"start":2653,"enrollment":2631,"conditions":2654,"interventions":2655},"NCT00003131","CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse",[92],"2002-02","1997-02",[2633],[2635,2636],{"nctId":2657,"briefTitle":2658,"status":111,"phases":2659,"primaryCompletion":2660,"completion":2661,"start":2662,"enrollment":2663,"conditions":2664,"interventions":2665},"NCT00246571","Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer",[92],"2010-05","2011-06","2006-01",217,[25],[2666,968],"SU011248",{"nctId":2668,"briefTitle":2669,"status":111,"phases":2670,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":2673,"conditions":2674,"interventions":2676},"NCT00070642","CPG 7909 Injection in Melanoma",[92],"2005-12","2003-12",184,[2675],"Carcinoma, Melanoma",[2647,2677,968,2647,2647],"dacarbazine",{"nctId":955,"briefTitle":956,"status":126,"phases":2679,"primaryCompletion":958,"completion":959,"start":960,"enrollment":35,"conditions":2680,"interventions":2681},[92],[962,963,964,946,965,966],[869,968],{"trials":2683,"activeCount":502,"soonestReadout":1014},[2684,2688,2692],{"nctId":984,"briefTitle":985,"status":126,"phases":2685,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":2686,"interventions":2687},[92,93],[992,993,994,995],[869,968,997],{"nctId":1011,"briefTitle":1012,"status":126,"phases":2689,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":2690,"interventions":2691},[93],[1019,1020,1021,1022,1023,1024,1025,1026,1027,1028],[869,1030,968],{"nctId":1032,"briefTitle":1033,"status":126,"phases":2693,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":2694,"interventions":2695},[92,93],[1040],[869,1042,968],{"trials":2697,"activeCount":103},[],{"trials":2699,"activeCount":103},[],{"intervention":1320,"totalTrials":2070,"cells":2701},{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2718,"PHASE3":2736,"PHASE4":2742,"NA":2744},{"trials":2703,"activeCount":103},[],{"trials":2705,"activeCount":103},[2706],{"nctId":2707,"briefTitle":2708,"status":111,"phases":2709,"primaryCompletion":2710,"completion":2711,"start":2712,"enrollment":2713,"conditions":2714,"interventions":2716},"NCT07160738","A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060",[91],"2025-11-24","2025-12-22","2025-09-22",25,[2715],"Healthy Adults",[1320,2082,2717],"Probenecid",{"trials":2719,"activeCount":502,"soonestReadout":2134},[2720,2724,2728,2732],{"nctId":1676,"briefTitle":1677,"status":381,"phases":2721,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":2722,"interventions":2723},[92],[1654,1684,25,1685],[1320,1243,1305,1687,63],{"nctId":2131,"briefTitle":2132,"status":381,"phases":2725,"primaryCompletion":2134,"completion":2135,"start":2136,"enrollment":2137,"conditions":2726,"interventions":2727},[91,92],[31],[68,1320],{"nctId":1307,"briefTitle":1308,"status":126,"phases":2729,"primaryCompletion":1310,"completion":1311,"start":1312,"enrollment":1313,"conditions":2730,"interventions":2731},[92],[1315,1316,1317],[1319,1305,1243,88,1320,1321],{"nctId":2437,"briefTitle":2438,"status":111,"phases":2733,"primaryCompletion":2440,"completion":2440,"start":2441,"enrollment":2442,"conditions":2734,"interventions":2735},[92],[31],[1320,1381],{"trials":2737,"activeCount":302,"soonestReadout":1375},[2738],{"nctId":1372,"briefTitle":1373,"status":381,"phases":2739,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":2740,"interventions":2741},[93],[31],[1320,1381,1382,1260,1383],{"trials":2743,"activeCount":103},[],{"trials":2745,"activeCount":103},[],{"intervention":2747,"totalTrials":257,"cells":2748},"PF-08653944",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2771,"PHASE3":2789,"PHASE4":2803,"NA":2805},{"trials":2750,"activeCount":103},[],{"trials":2752,"activeCount":1087,"soonestReadout":2757},[2753,2763],{"nctId":2754,"briefTitle":2755,"status":381,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":1548,"conditions":2759,"interventions":2762},"NCT07400679","A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity",[91],"2026-09-18","2026-02-04",[2760,2761,16],"Overweight","Obesity",[2747],{"nctId":2764,"briefTitle":2765,"status":126,"phases":2766,"primaryCompletion":2767,"completion":2767,"start":2768,"enrollment":1239,"conditions":2769,"interventions":2770},"NCT07519135","A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function",[91],"2027-07-09","2026-04-15",[16],[2747],{"trials":2772,"activeCount":302,"soonestReadout":1144},[2773],{"nctId":2774,"briefTitle":2775,"status":263,"phases":2776,"primaryCompletion":1144,"completion":2777,"start":2778,"enrollment":2779,"conditions":2780,"interventions":2787},"NCT07575932","A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)",[92],"2028-01-05","2026-05-11",872,[2760,2761,2781,2782,2783,2784,2785,2786],"Overweight and\u002For Obesity","Overweight or Obesity","Overnutrition","Nutrition Disorders","Nutritional and Metabolic Diseases","Body Weight",[2788,2747],"PF-08653945",{"trials":2790,"activeCount":302,"soonestReadout":2795},[2791],{"nctId":2792,"briefTitle":2793,"status":126,"phases":2794,"primaryCompletion":2795,"completion":2796,"start":2797,"enrollment":2798,"conditions":2799,"interventions":2802},"NCT07400653","A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)",[93],"2027-10-12","2028-05-16","2026-02-24",999,[2761,2781,2760,2800,2801],"Diabetes, Type 2","Type 2 Diabetes",[2747],{"trials":2804,"activeCount":103},[],{"trials":2806,"activeCount":103},[],{"intervention":1718,"totalTrials":2070,"cells":2808},{"EARLY_PHASE1":2809,"PHASE1":2811,"PHASE2":2842,"PHASE3":2859,"PHASE4":2865,"NA":2867},{"trials":2810,"activeCount":103},[],{"trials":2812,"activeCount":103},[2813,2823,2832],{"nctId":2814,"briefTitle":2815,"status":111,"phases":2816,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":1509,"conditions":2820,"interventions":2821},"NCT05673889","A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults",[91],"2023-03-15","2023-04-19","2023-01-27",[16],[1718,2822],"Dabigatran etexilate",{"nctId":2824,"briefTitle":2825,"status":111,"phases":2826,"primaryCompletion":2827,"completion":2828,"start":2829,"enrollment":627,"conditions":2830,"interventions":2831},"NCT05732428","A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+\u002FHER2- Advanced Breast Cancer in China",[91],"2024-03-29","2024-11-01","2023-02-20",[31],[1718],{"nctId":2833,"briefTitle":2834,"status":111,"phases":2835,"primaryCompletion":2836,"completion":2837,"start":2838,"enrollment":1268,"conditions":2839,"interventions":2840},"NCT05652660","A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults",[91],"2023-02-09","2023-03-06","2022-12-09",[16],[1718,2841],"Rosuvastatin",{"trials":2843,"activeCount":1087,"soonestReadout":2848},[2844,2852],{"nctId":2845,"briefTitle":2846,"status":381,"phases":2847,"primaryCompletion":2848,"completion":2848,"start":2079,"enrollment":2849,"conditions":2850,"interventions":2851},"NCT05548127","TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)",[91,92],"2026-09-01",37,[31],[1718,1462],{"nctId":2853,"briefTitle":2854,"status":381,"phases":2855,"primaryCompletion":1355,"completion":1355,"start":2856,"enrollment":2159,"conditions":2857,"interventions":2858},"NCT05573555","TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)",[91,92],"2023-03-01",[31],[1718,1461],{"trials":2860,"activeCount":302,"soonestReadout":1712},[2861],{"nctId":1709,"briefTitle":1710,"status":381,"phases":2862,"primaryCompletion":1712,"completion":1713,"start":1714,"enrollment":1715,"conditions":2863,"interventions":2864},[93],[1241],[1718,1305],{"trials":2866,"activeCount":103},[],{"trials":2868,"activeCount":103},[],{"intervention":1767,"totalTrials":2070,"cells":2870},{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2899,"PHASE3":2901,"PHASE4":2919,"NA":2921},{"trials":2872,"activeCount":103},[],{"trials":2874,"activeCount":1087,"soonestReadout":1756},[2875,2879,2891,2895],{"nctId":1753,"briefTitle":1754,"status":126,"phases":2876,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":2877,"interventions":2878},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":2880,"briefTitle":2881,"status":111,"phases":2882,"primaryCompletion":561,"completion":2883,"start":2884,"enrollment":407,"conditions":2885,"interventions":2887},"NCT00555620","Study Of Sunitinib In Combination With Cisplatin\u002FCapecitabine Or Oxaliplatin\u002FCapecitabine In Patients With Advanced Gastric Cancer",[91],"2011-12","2008-05",[2886],"Stomach Neoplasms",[2888,1992,2889,2888,2890,2889],"capecitabine","sunitinib malate","cisplatin",{"nctId":1775,"briefTitle":1776,"status":168,"phases":2892,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":2893,"interventions":2894},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"nctId":1977,"briefTitle":1978,"status":126,"phases":2896,"primaryCompletion":1980,"completion":1981,"start":786,"enrollment":1982,"conditions":2897,"interventions":2898},[91],[1798,409,1984,1985,1986],[1988,341,342,1989,1990,1991,1992],{"trials":2900,"activeCount":103},[],{"trials":2902,"activeCount":302,"soonestReadout":2048},[2903,2907],{"nctId":2045,"briefTitle":2046,"status":381,"phases":2904,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":2905,"interventions":2906},[93],[2053],[1812,1304,1767,1335,1768,2055,2056,1030],{"nctId":2908,"briefTitle":2909,"status":168,"phases":2910,"primaryCompletion":2911,"completion":2911,"start":2912,"enrollment":350,"conditions":2913,"interventions":2915},"NCT02951156","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and\u002For Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R\u002FR DLBCL)",[93],"2019-12-02","2016-12-16",[2914],"Diffuse Large B-Cell Lymphoma",[663,2916,2917,2918,1764,1767],"Utomilumab","Rituximab","Bendamustine",{"trials":2920,"activeCount":103},[],{"trials":2922,"activeCount":103},[],{"intervention":1139,"totalTrials":578,"cells":2924},{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2944,"PHASE3":2946,"PHASE4":2976,"NA":2978},{"trials":2926,"activeCount":103},[],{"trials":2928,"activeCount":103},[2929],{"nctId":2930,"briefTitle":2931,"status":168,"phases":2932,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":2935,"conditions":2936,"interventions":2939},"NCT03530683","A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma",[91],"2024-07-18","2018-05-14",189,[2937,1062,2938,2914],"Lymphoma","Acute Myeloid Leukemia",[1065,2940,2941,1064,1139,2942,2943],"Azacitidine","Venetoclax","Anti-CD20 Targeting agent","Isatuximab",{"trials":2945,"activeCount":103},[],{"trials":2947,"activeCount":502,"soonestReadout":1131},[2948,2952,2956,2960],{"nctId":1128,"briefTitle":1129,"status":126,"phases":2949,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":2950,"interventions":2951},[93],[1062],[48,1137,1138,1139],{"nctId":1152,"briefTitle":1153,"status":126,"phases":2953,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":2954,"interventions":2955},[93],[1062],[48,1161,1138,1139,1162,1064],{"nctId":1164,"briefTitle":1165,"status":126,"phases":2957,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":2958,"interventions":2959},[93],[1062],[48,1137,1150,1139,1162],{"nctId":2961,"briefTitle":2962,"status":168,"phases":2963,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":2965,"interventions":2967},"NCT00562965","Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)",[93],"2007-11",[2966],"Lymphoma, Follicular",[2968,2969,2969,2970,2971,2972,2973,2974,2975],"inotuzumab ozogamicin","rituximab","cyclophosphamide","vincristine","prednisone\u002Fprednisolone","mitoxantrone","fludarabine","dexamethasone",{"trials":2977,"activeCount":103},[],{"trials":2979,"activeCount":103},[],{"intervention":2981,"totalTrials":578,"cells":2982},"MET097",{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":3032,"PHASE4":3045,"NA":3047},{"trials":2984,"activeCount":103},[],{"trials":2986,"activeCount":103},[],{"trials":2988,"activeCount":1087,"soonestReadout":2993},[2989,2999,3010,3022],{"nctId":2990,"briefTitle":2991,"status":381,"phases":2992,"primaryCompletion":2993,"completion":2994,"start":2995,"enrollment":2996,"conditions":2997,"interventions":2998},"NCT06973720","A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight",[92],"2025-12-16","2026-10-16","2025-04-07",268,[2761,2782],[2981],{"nctId":3000,"briefTitle":3001,"status":126,"phases":3002,"primaryCompletion":3003,"completion":3003,"start":3004,"enrollment":3005,"conditions":3006,"interventions":3008},"NCT06924320","A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes",[91,92],"2026-09-15","2025-03-06",381,[3007],"Obesity and Obesity-related Medical Conditions",[3009,2981],"MET233 and MET097",{"nctId":3011,"briefTitle":3012,"status":111,"phases":3013,"primaryCompletion":3014,"completion":3015,"start":3016,"enrollment":3017,"conditions":3018,"interventions":3021},"NCT06897202","A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM",[92],"2025-12-29","2026-03-18","2025-03-14",133,[3019,3020],"Obesity in Diabetes","Type 2 Diabetes Mellitus (T2DM)",[2981],{"nctId":3023,"briefTitle":3024,"status":111,"phases":3025,"primaryCompletion":3026,"completion":3027,"start":3028,"enrollment":3029,"conditions":3030,"interventions":3031},"NCT06712836","A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight",[92],"2025-07-03","2026-04-30","2024-10-09",239,[2761,2782],[2981],{"trials":3033,"activeCount":302,"soonestReadout":3038},[3034],{"nctId":3035,"briefTitle":3036,"status":126,"phases":3037,"primaryCompletion":3038,"completion":3039,"start":3040,"enrollment":3041,"conditions":3042,"interventions":3044},"NCT07311850","Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity",[93],"2027-09-21","2028-04-25","2025-12-19",3501,[3043],"Obesity and Overweight",[2981],{"trials":3046,"activeCount":103},[],{"trials":3048,"activeCount":103},[],{"intervention":1768,"totalTrials":578,"cells":3050},{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3067,"PHASE3":3081,"PHASE4":3087,"NA":3089},{"trials":3052,"activeCount":103},[],{"trials":3054,"activeCount":1087,"soonestReadout":1756},[3055,3059,3063],{"nctId":1753,"briefTitle":1754,"status":126,"phases":3056,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":3057,"interventions":3058},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":1775,"briefTitle":1776,"status":168,"phases":3060,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":3061,"interventions":3062},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"nctId":1977,"briefTitle":1978,"status":126,"phases":3064,"primaryCompletion":1980,"completion":1981,"start":786,"enrollment":1982,"conditions":3065,"interventions":3066},[91],[1798,409,1984,1985,1986],[1988,341,342,1989,1990,1991,1992],{"trials":3068,"activeCount":103},[3069],{"nctId":3070,"briefTitle":3071,"status":168,"phases":3072,"completion":3073,"start":3074,"enrollment":3075,"conditions":3076,"interventions":3078},"NCT00037180","For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy",[92],"2003-01","2002-04",212,[3077,1028],"Neoplasm Metastasis",[3079,1335,3080,1768],"Celecoxib","5-fluorouracil",{"trials":3082,"activeCount":302,"soonestReadout":2048},[3083],{"nctId":2045,"briefTitle":2046,"status":381,"phases":3084,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":3085,"interventions":3086},[93],[2053],[1812,1304,1767,1335,1768,2055,2056,1030],{"trials":3088,"activeCount":103},[],{"trials":3090,"activeCount":103},[],{"intervention":1319,"totalTrials":578,"cells":3092},{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3125,"PHASE3":3131,"PHASE4":3137,"NA":3139},{"trials":3094,"activeCount":103},[],{"trials":3096,"activeCount":302,"soonestReadout":3101},[3097,3107,3116],{"nctId":3098,"briefTitle":3099,"status":381,"phases":3100,"primaryCompletion":3101,"completion":3102,"start":3103,"enrollment":1268,"conditions":3104,"interventions":3106},"NCT07335419","A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)",[91],"2026-02-22","2026-03-21","2026-01-02",[3105],"Healthy Adult Participants",[1319,2082],{"nctId":3108,"briefTitle":3109,"status":111,"phases":3110,"primaryCompletion":3111,"completion":3112,"start":3113,"enrollment":1268,"conditions":3114,"interventions":3115},"NCT07198035","A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144",[91],"2025-12-17","2026-01-15","2025-09-18",[2715],[1319,2127],{"nctId":3117,"briefTitle":3118,"status":111,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":1509,"conditions":3123,"interventions":3124},"NCT07117799","A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy Adults",[91],"2025-06-18","2025-07-11","2025-02-04",[2715],[1319,1319,1319],{"trials":3126,"activeCount":302,"soonestReadout":1310},[3127],{"nctId":1307,"briefTitle":1308,"status":126,"phases":3128,"primaryCompletion":1310,"completion":1311,"start":1312,"enrollment":1313,"conditions":3129,"interventions":3130},[92],[1315,1316,1317],[1319,1305,1243,88,1320,1321],{"trials":3132,"activeCount":302,"soonestReadout":1727},[3133],{"nctId":1724,"briefTitle":1725,"status":126,"phases":3134,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":267,"conditions":3135,"interventions":3136},[93],[31],[1319,1305,1673,1674],{"trials":3138,"activeCount":103},[],{"trials":3140,"activeCount":103},[],{"intervention":3142,"totalTrials":502,"cells":3143},"Ritlecitinib 100 mg",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3161,"PHASE4":3182,"NA":3184},{"trials":3145,"activeCount":103},[],{"trials":3147,"activeCount":103},[],{"trials":3149,"activeCount":302,"soonestReadout":3154},[3150],{"nctId":3151,"briefTitle":3152,"status":126,"phases":3153,"primaryCompletion":3154,"completion":3155,"start":3156,"enrollment":162,"conditions":3157,"interventions":3159},"NCT07219615","A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.",[92],"2026-12-25","2027-04-23","2025-10-30",[3158],"Chronic Spontaneous Urticaria",[3160,3142],"Ritlecitinib 50 mg",{"trials":3162,"activeCount":1087,"soonestReadout":3178},[3163,3174],{"nctId":3164,"briefTitle":3165,"status":381,"phases":3166,"primaryCompletion":3167,"completion":3167,"start":3168,"enrollment":3169,"conditions":3170,"interventions":3172},"NCT06163326","A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo",[93],"2027-03-31","2024-01-19",394,[3171],"Vitiligo",[3173,3142],"Ritlecitinib",{"nctId":3175,"briefTitle":3176,"status":381,"phases":3177,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":1038,"conditions":3180,"interventions":3181},"NCT06873945","A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata",[93],"2026-12-21","2025-04-01",[1521],[3142,3160],{"trials":3183,"activeCount":103},[],{"trials":3185,"activeCount":103},[],{"intervention":1812,"totalTrials":1268,"cells":3187},{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3221,"PHASE3":3262,"PHASE4":3276,"NA":3278},{"trials":3189,"activeCount":103},[],{"trials":3191,"activeCount":103},[3192,3196,3213],{"nctId":331,"briefTitle":332,"status":168,"phases":3193,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":3194,"interventions":3195},[91],[338],[340,329,341,342,343],{"nctId":3197,"briefTitle":3198,"status":111,"phases":3199,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":3203,"interventions":3205},"NCT03864042","Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",[91],"2023-05-29","2018-01-02",56,[553,3204],"Metastatic Melanoma",[3206,3207,3208,3209,1989,3210,3211,343,341,3212],"losartan","dextromethorphan","caffeine","omeprazole","rosuvastatin","bupropion immediate release","modafinil",{"nctId":3214,"briefTitle":3215,"status":168,"phases":3216,"primaryCompletion":3217,"completion":3217,"start":3218,"enrollment":302,"conditions":3219,"interventions":3220},"NCT03878719","Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma",[91],"2022-08-19","2020-08-03",[1798],[341,343],{"trials":3222,"activeCount":302,"soonestReadout":1805},[3223,3234,3244,3248,3258],{"nctId":3224,"briefTitle":3225,"status":168,"phases":3226,"primaryCompletion":1071,"completion":3227,"start":3228,"enrollment":3229,"conditions":3230,"interventions":3231},"NCT04585815","Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)",[91,92],"2024-10-29","2020-11-10",34,[376],[3232,1812,1832,1773,933,3233],"Sasanlimab Prefilled syringe","SEA-TGT",{"nctId":3235,"briefTitle":3236,"status":111,"phases":3237,"primaryCompletion":3238,"completion":3239,"start":3240,"enrollment":3241,"conditions":3242,"interventions":3243},"NCT03915951","An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer",[92],"2022-09-22","2025-10-03","2019-06-04",98,[727],[343,341],{"nctId":1791,"briefTitle":1792,"status":168,"phases":3245,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":3246,"interventions":3247},[92],[1798],[343,341,438,1800,439],{"nctId":3249,"briefTitle":3250,"status":168,"phases":3251,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":3254,"conditions":3255,"interventions":3257},"NCT03911869","An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis",[92],"2022-01-27","2019-04-30",13,[3256],"Brain Metastases",[343,341],{"nctId":1802,"briefTitle":1803,"status":381,"phases":3259,"primaryCompletion":1805,"completion":1806,"start":1807,"enrollment":1808,"conditions":3260,"interventions":3261},[92],[1810],[1812,1304,631],{"trials":3263,"activeCount":1087,"soonestReadout":2048},[3264,3268,3272],{"nctId":1824,"briefTitle":1825,"status":381,"phases":3265,"primaryCompletion":1665,"completion":1827,"start":1828,"enrollment":1829,"conditions":3266,"interventions":3267},[93],[1798],[1812,1832,631],{"nctId":2033,"briefTitle":2034,"status":111,"phases":3269,"primaryCompletion":2036,"completion":1169,"start":2037,"enrollment":2038,"conditions":3270,"interventions":3271},[93],[2040],[1812,1832,1304,1335,2042,2043],{"nctId":2045,"briefTitle":2046,"status":381,"phases":3273,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":3274,"interventions":3275},[93],[2053],[1812,1304,1767,1335,1768,2055,2056,1030],{"trials":3277,"activeCount":103},[],{"trials":3279,"activeCount":103},[3280],{"nctId":3281,"briefTitle":3282,"status":111,"phases":3283,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":3286,"conditions":3287,"interventions":3288},"NCT05260684","Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US",[],"2023-12-31","2022-01-17",716,[1798],[1812,1832,3289,3290,3291,3292],"Vemurafenib","Cobimetinib","Dabrafenib","Trametinib",{"intervention":1030,"totalTrials":870,"cells":3294},{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3307,"PHASE3":3358,"PHASE4":3368,"NA":3370},{"trials":3296,"activeCount":103},[],{"trials":3298,"activeCount":302,"soonestReadout":1756},[3299,3303],{"nctId":1753,"briefTitle":1754,"status":126,"phases":3300,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":3301,"interventions":3302},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":1775,"briefTitle":1776,"status":168,"phases":3304,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":3305,"interventions":3306},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":3308,"activeCount":103},[3309,3319,3330,3341,3349],{"nctId":3310,"briefTitle":3311,"status":168,"phases":3312,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":1413,"conditions":3315,"interventions":3316},"NCT00609622","Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer",[92],"2011-07","2008-04",[1028],[3317,3318,429,3318],"sunitinib","mFOLFOX6",{"nctId":3320,"briefTitle":3321,"status":168,"phases":3322,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":597,"conditions":3325,"interventions":3327},"NCT01937715","A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer",[91,92],"2015-08","2014-02",[3326],"Metastatic Colorectal Carcinoma",[2003,3328,1030,3329],"FOLFIRI regimen","FOLFIRI",{"nctId":3331,"briefTitle":3332,"status":111,"phases":3333,"primaryCompletion":524,"completion":3334,"start":3335,"enrollment":3336,"conditions":3337,"interventions":3338},"NCT00615056","A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen",[92],"2012-04","2008-03",171,[1028],[1030,3329,3339,3340,3339,3329,1030,3340],"AG-013736","FOLFOX",{"nctId":3342,"briefTitle":3343,"status":111,"phases":3344,"primaryCompletion":3334,"completion":3345,"start":2662,"enrollment":1112,"conditions":3346,"interventions":3347},"NCT00460603","Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer",[91,92],"2012-11",[1028],[429,3348,3339],"AG-013726",{"nctId":3350,"briefTitle":3351,"status":111,"phases":3352,"primaryCompletion":523,"completion":3353,"start":3314,"enrollment":2250,"conditions":3354,"interventions":3357},"NCT00600821","A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.",[92],"2012-10",[3355,3356],"Non-Small-Cell Lung Carcinoma","Adenocarcinoma",[1030,1772,1771,3339,1772,1771],{"trials":3359,"activeCount":1087,"soonestReadout":2048},[3360,3364],{"nctId":1011,"briefTitle":1012,"status":126,"phases":3361,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":3362,"interventions":3363},[93],[1019,1020,1021,1022,1023,1024,1025,1026,1027,1028],[869,1030,968],{"nctId":2045,"briefTitle":2046,"status":381,"phases":3365,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":3366,"interventions":3367},[93],[2053],[1812,1304,1767,1335,1768,2055,2056,1030],{"trials":3369,"activeCount":103},[],{"trials":3371,"activeCount":103},[3372],{"nctId":415,"briefTitle":416,"status":111,"phases":3373,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":3374,"interventions":3375},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":3173,"totalTrials":870,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3415,"PHASE3":3417,"PHASE4":3443,"NA":3445},{"trials":3379,"activeCount":103},[],{"trials":3381,"activeCount":103},[3382,3389,3398,3407],{"nctId":3383,"briefTitle":3384,"status":111,"phases":3385,"primaryCompletion":3386,"completion":3386,"start":2113,"enrollment":1268,"conditions":3387,"interventions":3388},"NCT06369454","A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food",[91],"2024-07-31",[19],[3173],{"nctId":3390,"briefTitle":3391,"status":111,"phases":3392,"primaryCompletion":1119,"completion":2377,"start":3393,"enrollment":1268,"conditions":3394,"interventions":3397},"NCT05852340","A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants",[91],"2023-05-09",[19,3395,3396],"Adult","Pharmacokinetics",[3173],{"nctId":3399,"briefTitle":3400,"status":111,"phases":3401,"primaryCompletion":3402,"completion":3402,"start":3403,"enrollment":1268,"conditions":3404,"interventions":3405},"NCT05097716","Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide",[91],"2022-01-10","2021-11-02",[19],[3173,3406],"Tolbutamide",{"nctId":3408,"briefTitle":3409,"status":111,"phases":3410,"primaryCompletion":3411,"completion":3411,"start":1547,"enrollment":1268,"conditions":3412,"interventions":3413},"NCT05040295","A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults",[91],"2021-11-19",[28],[3414,3414,3414],"ritlecitinib",{"trials":3416,"activeCount":103},[],{"trials":3418,"activeCount":1087,"soonestReadout":3167},[3419,3430,3434],{"nctId":3420,"briefTitle":3421,"status":111,"phases":3422,"primaryCompletion":3423,"completion":3423,"start":3424,"enrollment":3425,"conditions":3426,"interventions":3429},"NCT05583526","A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo",[93],"2026-02-05","2022-12-01",607,[3427,3428],"Stable Nonsegmental Vitiligo","Active Nonsegmental Vitiligo",[3173],{"nctId":3164,"briefTitle":3165,"status":381,"phases":3431,"primaryCompletion":3167,"completion":3167,"start":3168,"enrollment":3169,"conditions":3432,"interventions":3433},[93],[3171],[3173,3142],{"nctId":3435,"briefTitle":3436,"status":381,"phases":3437,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":3440,"conditions":3441,"interventions":3442},"NCT06072183","A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2",[93],"2027-07-30","2023-11-08",1571,[3427,3428],[3173,3173],{"trials":3444,"activeCount":103},[],{"trials":3446,"activeCount":302,"soonestReadout":3451},[3447,3456,3466],{"nctId":3448,"briefTitle":3449,"status":126,"phases":3450,"primaryCompletion":3451,"completion":3451,"start":3452,"enrollment":3453,"conditions":3454,"interventions":3455},"NCT06531109","Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib",[],"2028-03-31","2024-08-07",850,[1521],[3173],{"nctId":3457,"briefTitle":3458,"status":111,"phases":3459,"primaryCompletion":3460,"completion":3460,"start":3461,"enrollment":3462,"conditions":3463,"interventions":3465},"NCT07200128","A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings",[],"2025-05-30","2025-02-03",123,[3464],"Severe Alopecia Areata",[3173],{"nctId":3467,"briefTitle":3468,"status":1602,"phases":3469,"conditions":3470,"interventions":3471},"NCT05522556","Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)",[],[1521],[3173],{"intervention":1462,"totalTrials":502,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3484,"PHASE4":3490,"NA":3492},{"trials":3475,"activeCount":103},[],{"trials":3477,"activeCount":103},[],{"trials":3479,"activeCount":302,"soonestReadout":2848},[3480],{"nctId":2845,"briefTitle":2846,"status":381,"phases":3481,"primaryCompletion":2848,"completion":2848,"start":2079,"enrollment":2849,"conditions":3482,"interventions":3483},[91,92],[31],[1718,1462],{"trials":3485,"activeCount":302,"soonestReadout":1375},[3486],{"nctId":1372,"briefTitle":1373,"status":381,"phases":3487,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":3488,"interventions":3489},[93],[31],[1320,1381,1382,1260,1383],{"trials":3491,"activeCount":103},[],{"trials":3493,"activeCount":302,"soonestReadout":1355},[3494],{"nctId":1454,"briefTitle":1455,"status":381,"phases":3495,"primaryCompletion":1355,"completion":1355,"start":1457,"enrollment":302,"conditions":3496,"interventions":3497},[],[31,1444],[88,1460,1461,1462],{"intervention":1461,"totalTrials":502,"cells":3499},{"EARLY_PHASE1":3500,"PHASE1":3502,"PHASE2":3504,"PHASE3":3510,"PHASE4":3516,"NA":3518},{"trials":3501,"activeCount":103},[],{"trials":3503,"activeCount":103},[],{"trials":3505,"activeCount":302,"soonestReadout":1355},[3506],{"nctId":2853,"briefTitle":2854,"status":381,"phases":3507,"primaryCompletion":1355,"completion":1355,"start":2856,"enrollment":2159,"conditions":3508,"interventions":3509},[91,92],[31],[1718,1461],{"trials":3511,"activeCount":302,"soonestReadout":1375},[3512],{"nctId":1372,"briefTitle":1373,"status":381,"phases":3513,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":3514,"interventions":3515},[93],[31],[1320,1381,1382,1260,1383],{"trials":3517,"activeCount":103},[],{"trials":3519,"activeCount":302,"soonestReadout":1355},[3520],{"nctId":1454,"briefTitle":1455,"status":381,"phases":3521,"primaryCompletion":1355,"completion":1355,"start":1457,"enrollment":302,"conditions":3522,"interventions":3523},[],[31,1444],[88,1460,1461,1462],{"intervention":3525,"totalTrials":502,"cells":3526},"marstacimab",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3541,"PHASE3":3543,"PHASE4":3554,"NA":3556},{"trials":3528,"activeCount":103},[],{"trials":3530,"activeCount":302,"soonestReadout":3535},[3531],{"nctId":3532,"briefTitle":3533,"status":126,"phases":3534,"primaryCompletion":3535,"completion":3535,"start":3536,"enrollment":498,"conditions":3537,"interventions":3539},"NCT06703606","A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.",[91],"2027-05-05","2025-05-13",[3538],"Severe Hemophilia A",[3540],"MARSTACIMAB",{"trials":3542,"activeCount":103},[],{"trials":3544,"activeCount":302,"soonestReadout":3549},[3545],{"nctId":3546,"briefTitle":3547,"status":126,"phases":3548,"primaryCompletion":3549,"completion":3549,"start":2838,"enrollment":397,"conditions":3550,"interventions":3553},"NCT05611801","A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B",[93],"2028-09-10",[3551,3552],"Hemophilia A","Hemophilia B",[3525],{"trials":3555,"activeCount":103},[],{"trials":3557,"activeCount":302,"soonestReadout":3562},[3558],{"nctId":3559,"briefTitle":3560,"status":381,"phases":3561,"primaryCompletion":3562,"completion":3562,"start":3156,"enrollment":26,"conditions":3563,"interventions":3565},"NCT07161687","A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.",[],"2030-04-11",[3564],"Hemophilia A or B",[3566],"Marstacimab",{"intervention":1335,"totalTrials":1625,"cells":3568},{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3591,"PHASE3":3632,"PHASE4":3653,"NA":3655},{"trials":3570,"activeCount":103},[],{"trials":3572,"activeCount":103},[3573,3582],{"nctId":3574,"briefTitle":3575,"status":111,"phases":3576,"conditions":3577,"interventions":3581},"NCT00037804","Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction",[91],[3578,968,3579,3580],"Unspecified Adult Solid Tumor","Liver Dysfunction","Neoplasms, Solid Tumor",[1335],{"nctId":3583,"briefTitle":3584,"status":168,"phases":3585,"primaryCompletion":3586,"completion":3586,"start":114,"enrollment":3587,"conditions":3588,"interventions":3589},"NCT01347866","Clinical Study Of PI3K\u002FmTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer",[91],"2015-12",105,[543],[2003,3590,2003,2004],"PD-0325901",{"trials":3592,"activeCount":302,"soonestReadout":87},[3593,3597,3606,3615,3619,3623],{"nctId":1996,"briefTitle":1997,"status":168,"phases":3594,"primaryCompletion":1999,"completion":1999,"start":2000,"enrollment":99,"conditions":3595,"interventions":3596},[92],[1810],[2003,2004,1304,1335],{"nctId":3598,"briefTitle":3599,"status":111,"phases":3600,"primaryCompletion":3601,"completion":2883,"start":3602,"enrollment":3603,"conditions":3604,"interventions":3605},"NCT00404495","Combination of Irinotecan and Temozolomide in Children With Brain Tumors.",[92],"2011-01","2007-04",83,[1985,1331],[1335,1334],{"nctId":3607,"briefTitle":3608,"status":111,"phases":3609,"primaryCompletion":3610,"completion":3610,"start":3611,"enrollment":3612,"conditions":3613,"interventions":3614},"NCT00072852","Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine",[92],"2007-05","2003-11",134,[25],[1335],{"nctId":85,"briefTitle":86,"status":381,"phases":3616,"primaryCompletion":87,"completion":1324,"start":1325,"enrollment":1326,"conditions":3617,"interventions":3618},[92],[1328,750,1329,1330,500,1331,1332],[88,1334,1335,1336,1337],{"nctId":3070,"briefTitle":3071,"status":168,"phases":3620,"completion":3073,"start":3074,"enrollment":3075,"conditions":3621,"interventions":3622},[92],[3077,1028],[3079,1335,3080,1768],{"nctId":3624,"briefTitle":3625,"status":111,"phases":3626,"completion":3627,"start":3628,"enrollment":885,"conditions":3629,"interventions":3630},"NCT00139711","Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer",[92],"2006-06","2003-03",[376],[1335,3631],"Docetaxel",{"trials":3633,"activeCount":302,"soonestReadout":2048},[3634,3638,3649],{"nctId":2033,"briefTitle":2034,"status":111,"phases":3635,"primaryCompletion":2036,"completion":1169,"start":2037,"enrollment":2038,"conditions":3636,"interventions":3637},[93],[2040],[1812,1832,1304,1335,2042,2043],{"nctId":3639,"briefTitle":3640,"status":111,"phases":3641,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":3645,"interventions":3646},"NCT00457691","Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer",[93],"2010-03","2007-06",768,[1810],[3647,2004,3648,3317,3647,2004,3648],"5 fluorouracil","levo- leucovorin",{"nctId":2045,"briefTitle":2046,"status":381,"phases":3650,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":3651,"interventions":3652},[93],[2053],[1812,1304,1767,1335,1768,2055,2056,1030],{"trials":3654,"activeCount":103},[],{"trials":3656,"activeCount":103},[],{"intervention":3658,"totalTrials":3659,"cells":3660},"VLA15",7,{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3665,"PHASE3":3697,"PHASE4":3735,"NA":3737},{"trials":3662,"activeCount":103},[],{"trials":3664,"activeCount":103},[],{"trials":3666,"activeCount":103},[3667,3678,3688],{"nctId":3668,"briefTitle":3669,"status":111,"phases":3670,"primaryCompletion":3671,"completion":3672,"start":3673,"enrollment":3674,"conditions":3675,"interventions":3677},"NCT03769194","Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.",[92],"2019-12-18","2020-10-02","2018-12-17",572,[3676],"Lyme Borreliosis",[3658],{"nctId":3679,"briefTitle":3680,"status":111,"phases":3681,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":3686,"interventions":3687},"NCT03970733","Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis",[92],"2020-04-07","2022-03-28","2019-07-01",246,[3676],[3658],{"nctId":3689,"briefTitle":3690,"status":111,"phases":3691,"primaryCompletion":1146,"completion":3692,"start":3693,"enrollment":3694,"conditions":3695,"interventions":3696},"NCT04801420","Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population",[92],"2025-07-02","2021-03-08",625,[3676],[3658],{"trials":3698,"activeCount":1087,"soonestReadout":2096},[3699,3707,3718,3727],{"nctId":3700,"briefTitle":3701,"status":381,"phases":3702,"primaryCompletion":3703,"completion":3703,"start":3704,"enrollment":685,"conditions":3705,"interventions":3706},"NCT07226882","A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults",[93],"2028-01-27","2025-11-19",[3676],[3658],{"nctId":3708,"briefTitle":3709,"status":111,"phases":3710,"primaryCompletion":3711,"completion":3712,"start":3713,"enrollment":3714,"conditions":3715,"interventions":3717},"NCT05477524","An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)",[93],"2026-01-07","2026-02-06","2022-08-04",12546,[3716],"Lyme Disease",[3658],{"nctId":3719,"briefTitle":3720,"status":111,"phases":3721,"primaryCompletion":3722,"completion":3722,"start":3723,"enrollment":3724,"conditions":3725,"interventions":3726},"NCT05634811","Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children",[93],"2025-07-21","2022-12-12",3547,[3716],[3658],{"nctId":3728,"briefTitle":3729,"status":126,"phases":3730,"primaryCompletion":2096,"completion":2096,"start":3731,"enrollment":3732,"conditions":3733,"interventions":3734},"NCT07500506","A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine",[93],"2026-04-08",1712,[3716],[3658],{"trials":3736,"activeCount":103},[],{"trials":3738,"activeCount":103},[],{"intervention":3740,"totalTrials":3659,"cells":3741},"RSVpreF",{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3757,"PHASE3":3772,"PHASE4":3821,"NA":3823},{"trials":3743,"activeCount":103},[],{"trials":3745,"activeCount":103},[3746],{"nctId":3747,"briefTitle":3748,"status":111,"phases":3749,"primaryCompletion":3750,"completion":3750,"start":1914,"enrollment":1191,"conditions":3751,"interventions":3752},"NCT05788237","A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults",[91],"2023-09-27",[16],[3753,3754,3740,3755,3756],"RSVpreF+qIRV","qIRV","RSVpreF + qIRV 1.0 mL formulation","RSVpreF + qIRV 0.5 mL formulation",{"trials":3758,"activeCount":103},[3759],{"nctId":3760,"briefTitle":3761,"status":111,"phases":3762,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":3766,"interventions":3767},"NCT05886777","A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).",[92],"2024-01-01","2023-06-05",1142,[28],[3768,3769,3740,3770,3771],"Combination [RSVpreF+BNTb162b2]","Bivalent BNT162b2","QIV","Normal Saline Placebo",{"trials":3773,"activeCount":1087,"soonestReadout":1827},[3774,3783,3793,3803,3811],{"nctId":3775,"briefTitle":3776,"status":126,"phases":3777,"primaryCompletion":3778,"completion":3778,"start":3779,"enrollment":1038,"conditions":3780,"interventions":3782},"NCT06866405","A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose",[93],"2028-02-24","2025-04-16",[3781],"RSV Infection",[3740],{"nctId":3784,"briefTitle":3785,"status":111,"phases":3786,"primaryCompletion":3787,"completion":3787,"start":3788,"enrollment":3789,"conditions":3790,"interventions":3792},"NCT05842967","A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease",[93],"2024-03-18","2023-05-11",885,[3791],"RESPIRATORY SYNCYTIAL VIRUS (RSV)",[3740],{"nctId":3794,"briefTitle":3795,"status":111,"phases":3796,"primaryCompletion":3797,"completion":3797,"start":3798,"enrollment":3799,"conditions":3800,"interventions":3802},"NCT04424316","A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.",[93],"2023-10-27","2020-06-17",14727,[3801],"Respiratory Tract Infection",[3740],{"nctId":3804,"briefTitle":3805,"status":126,"phases":3806,"primaryCompletion":1827,"completion":1827,"start":2778,"enrollment":3807,"conditions":3808,"interventions":3810},"NCT07543380","A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.",[93],130,[3809],"Respiratory Syncytial Virus (RSV)",[3740],{"nctId":3812,"briefTitle":3813,"status":111,"phases":3814,"primaryCompletion":3815,"completion":3815,"start":3816,"enrollment":3817,"conditions":3818,"interventions":3820},"NCT05096208","Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age",[93],"2022-04-04","2021-10-21",1028,[3819],"RSV",[3740,3740,3740],{"trials":3822,"activeCount":103},[],{"trials":3824,"activeCount":103},[],{"intervention":1769,"totalTrials":578,"cells":3826},{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3847,"PHASE3":3858,"PHASE4":3874,"NA":3876},{"trials":3828,"activeCount":103},[],{"trials":3830,"activeCount":302,"soonestReadout":1756},[3831,3835,3843],{"nctId":1753,"briefTitle":1754,"status":126,"phases":3832,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":3833,"interventions":3834},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":3836,"briefTitle":3837,"status":111,"phases":3838,"primaryCompletion":3839,"completion":3642,"start":2964,"enrollment":787,"conditions":3840,"interventions":3841},"NCT00560573","Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer",[91],"2008-06",[376],[1705,1770,1764,3842],"Pemetrexed",{"nctId":1775,"briefTitle":1776,"status":168,"phases":3844,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":3845,"interventions":3846},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":3848,"activeCount":103},[3849],{"nctId":3850,"briefTitle":3851,"status":168,"phases":3852,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":1530,"conditions":3855,"interventions":3856},"NCT00321308","Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer",[92],"2008-01","2006-09",[2645],[1769,3857],"pemetrexed + PF-3512676",{"trials":3859,"activeCount":302,"soonestReadout":3864},[3860],{"nctId":3861,"briefTitle":3862,"status":381,"phases":3863,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":3867,"interventions":3869},"NCT05059522","Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing",[93],"2026-09-30","2021-09-29",68,[3868,410,1653,905,750],"Advanced Malignancies",[663,3870,3871,3842,933,3872,2916,3873],"Lorlatanib","Talazoparib","CMP 001","PF04518600",{"trials":3875,"activeCount":103},[],{"trials":3877,"activeCount":103},[],{"intervention":3879,"totalTrials":257,"cells":3880},"ibuzatrelvir",{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3903,"PHASE3":3905,"PHASE4":3929,"NA":3931},{"trials":3882,"activeCount":103},[],{"trials":3884,"activeCount":103},[3885,3894],{"nctId":3886,"briefTitle":3887,"status":111,"phases":3888,"primaryCompletion":3889,"completion":3889,"start":3890,"enrollment":1268,"conditions":3891,"interventions":3892},"NCT07235137","A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults",[91],"2025-11-21","2025-10-16",[1489],[3893],"Ibuzatrelvir",{"nctId":3895,"briefTitle":3896,"status":111,"phases":3897,"primaryCompletion":3898,"completion":3898,"start":3899,"enrollment":1268,"conditions":3900,"interventions":3901},"NCT06646042","A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults",[91],"2025-01-17","2024-10-28",[16],[3879,3902],"carbamazepine ER",{"trials":3904,"activeCount":103},[],{"trials":3906,"activeCount":1087,"soonestReadout":3922},[3907,3918],{"nctId":3908,"briefTitle":3909,"status":126,"phases":3910,"primaryCompletion":3911,"completion":3912,"start":3913,"enrollment":3914,"conditions":3915,"interventions":3917},"NCT06679140","A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease",[93],"2027-10-03","2028-03-02","2024-12-08",2330,[3916],"COVID-19 SARS-CoV-2 Infection",[3879],{"nctId":3919,"briefTitle":3920,"status":126,"phases":3921,"primaryCompletion":3922,"completion":3923,"start":3924,"enrollment":1613,"conditions":3925,"interventions":3927},"NCT07013474","A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised",[93],"2027-09-27","2028-02-25","2025-07-14",[3926],"COVID-19 Infection",[3879,3928],"remdesivir",{"trials":3930,"activeCount":103},[],{"trials":3932,"activeCount":103},[],{"intervention":1150,"totalTrials":502,"cells":3934},{"EARLY_PHASE1":3935,"PHASE1":3937,"PHASE2":3939,"PHASE3":3951,"PHASE4":3961,"NA":3963},{"trials":3936,"activeCount":103},[],{"trials":3938,"activeCount":103},[],{"trials":3940,"activeCount":103},[3941],{"nctId":3942,"briefTitle":3943,"status":168,"phases":3944,"primaryCompletion":3945,"completion":3946,"start":3947,"enrollment":2070,"conditions":3948,"interventions":3949},"NCT05626322","Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma",[91,92],"2024-08-12","2025-05-01","2023-08-04",[2914],[1065,3950,1150],"Tafasitamab",{"trials":3952,"activeCount":1087,"soonestReadout":1144},[3953,3957],{"nctId":1141,"briefTitle":1142,"status":381,"phases":3954,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":1147,"conditions":3955,"interventions":3956},[93],[1062],[48,1150,1150,48],{"nctId":1164,"briefTitle":1165,"status":126,"phases":3958,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":3959,"interventions":3960},[93],[1062],[48,1137,1150,1139,1162],{"trials":3962,"activeCount":103},[],{"trials":3964,"activeCount":103},[],{"intervention":3160,"totalTrials":502,"cells":3966},{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3980,"PHASE3":3986,"PHASE4":3992,"NA":3994},{"trials":3968,"activeCount":103},[],{"trials":3970,"activeCount":103},[3971],{"nctId":3972,"briefTitle":3973,"status":111,"phases":3974,"primaryCompletion":3975,"completion":3975,"start":3976,"enrollment":314,"conditions":3977,"interventions":3978},"NCT05128058","A Target Occupancy Study With Ritlecitinib.",[91],"2022-01-14","2021-10-22",[16],[3160,3979],"Ritlecitinib 200 mg",{"trials":3981,"activeCount":302,"soonestReadout":3154},[3982],{"nctId":3151,"briefTitle":3152,"status":126,"phases":3983,"primaryCompletion":3154,"completion":3155,"start":3156,"enrollment":162,"conditions":3984,"interventions":3985},[92],[3158],[3160,3142],{"trials":3987,"activeCount":302,"soonestReadout":3178},[3988],{"nctId":3175,"briefTitle":3176,"status":381,"phases":3989,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":1038,"conditions":3990,"interventions":3991},[93],[1521],[3142,3160],{"trials":3993,"activeCount":103},[],{"trials":3995,"activeCount":103},[],{"intervention":1064,"totalTrials":502,"cells":3997},{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4010,"PHASE3":4012,"PHASE4":4018,"NA":4020},{"trials":3999,"activeCount":103},[],{"trials":4001,"activeCount":302,"soonestReadout":1057},[4002,4006],{"nctId":2930,"briefTitle":2931,"status":168,"phases":4003,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":2935,"conditions":4004,"interventions":4005},[91],[2937,1062,2938,2914],[1065,2940,2941,1064,1139,2942,2943],{"nctId":1054,"briefTitle":1055,"status":381,"phases":4007,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":1060,"conditions":4008,"interventions":4009},[91],[1062],[48,1064,1065],{"trials":4011,"activeCount":103},[],{"trials":4013,"activeCount":302,"soonestReadout":1155},[4014],{"nctId":1152,"briefTitle":1153,"status":126,"phases":4015,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":4016,"interventions":4017},[93],[1062],[48,1161,1138,1139,1162,1064],{"trials":4019,"activeCount":103},[],{"trials":4021,"activeCount":103},[],{"intervention":952,"totalTrials":1087,"cells":4023},{"EARLY_PHASE1":4024,"PHASE1":4026,"PHASE2":4028,"PHASE3":4034,"PHASE4":4040,"NA":4042},{"trials":4025,"activeCount":103},[],{"trials":4027,"activeCount":103},[],{"trials":4029,"activeCount":302,"soonestReadout":938},[4030],{"nctId":935,"briefTitle":936,"status":263,"phases":4031,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":4032,"interventions":4033},[92],[943,944,945,946,947,948,422,949,950],[869,952,953],{"trials":4035,"activeCount":302,"soonestReadout":975},[4036],{"nctId":972,"briefTitle":973,"status":126,"phases":4037,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":4038,"interventions":4039},[93],[399,422,376,947,980,981],[869,631,952,953],{"trials":4041,"activeCount":103},[],{"trials":4043,"activeCount":103},[],{"intervention":953,"totalTrials":1087,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4048,"PHASE2":4050,"PHASE3":4056,"PHASE4":4062,"NA":4064},{"trials":4047,"activeCount":103},[],{"trials":4049,"activeCount":103},[],{"trials":4051,"activeCount":302,"soonestReadout":938},[4052],{"nctId":935,"briefTitle":936,"status":263,"phases":4053,"primaryCompletion":938,"completion":939,"start":940,"enrollment":941,"conditions":4054,"interventions":4055},[92],[943,944,945,946,947,948,422,949,950],[869,952,953],{"trials":4057,"activeCount":302,"soonestReadout":975},[4058],{"nctId":972,"briefTitle":973,"status":126,"phases":4059,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":4060,"interventions":4061},[93],[399,422,376,947,980,981],[869,631,952,953],{"trials":4063,"activeCount":103},[],{"trials":4065,"activeCount":103},[],{"intervention":1137,"totalTrials":1087,"cells":4067},{"EARLY_PHASE1":4068,"PHASE1":4070,"PHASE2":4072,"PHASE3":4074,"PHASE4":4084,"NA":4086},{"trials":4069,"activeCount":103},[],{"trials":4071,"activeCount":103},[],{"trials":4073,"activeCount":103},[],{"trials":4075,"activeCount":1087,"soonestReadout":1131},[4076,4080],{"nctId":1128,"briefTitle":1129,"status":126,"phases":4077,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":4078,"interventions":4079},[93],[1062],[48,1137,1138,1139],{"nctId":1164,"briefTitle":1165,"status":126,"phases":4081,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":4082,"interventions":4083},[93],[1062],[48,1137,1150,1139,1162],{"trials":4085,"activeCount":103},[],{"trials":4087,"activeCount":103},[],{"intervention":1138,"totalTrials":1087,"cells":4089},{"EARLY_PHASE1":4090,"PHASE1":4092,"PHASE2":4094,"PHASE3":4096,"PHASE4":4106,"NA":4108},{"trials":4091,"activeCount":103},[],{"trials":4093,"activeCount":103},[],{"trials":4095,"activeCount":103},[],{"trials":4097,"activeCount":1087,"soonestReadout":1131},[4098,4102],{"nctId":1128,"briefTitle":1129,"status":126,"phases":4099,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":4100,"interventions":4101},[93],[1062],[48,1137,1138,1139],{"nctId":1152,"briefTitle":1153,"status":126,"phases":4103,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":4104,"interventions":4105},[93],[1062],[48,1161,1138,1139,1162,1064],{"trials":4107,"activeCount":103},[],{"trials":4109,"activeCount":103},[],{"intervention":2542,"totalTrials":1087,"cells":4111},{"EARLY_PHASE1":4112,"PHASE1":4114,"PHASE2":4116,"PHASE3":4122,"PHASE4":4128,"NA":4130},{"trials":4113,"activeCount":103},[],{"trials":4115,"activeCount":103},[],{"trials":4117,"activeCount":302,"soonestReadout":2537},[4118],{"nctId":2534,"briefTitle":2535,"status":381,"phases":4119,"primaryCompletion":2537,"completion":2537,"start":2538,"enrollment":2539,"conditions":4120,"interventions":4121},[92],[2526],[2542,2494,2543],{"trials":4123,"activeCount":302,"soonestReadout":2570},[4124],{"nctId":2567,"briefTitle":2568,"status":126,"phases":4125,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":4126,"interventions":4127},[93],[2526],[2542,2494],{"trials":4129,"activeCount":103},[],{"trials":4131,"activeCount":103},[],{"intervention":1162,"totalTrials":1087,"cells":4133},{"EARLY_PHASE1":4134,"PHASE1":4136,"PHASE2":4138,"PHASE3":4140,"PHASE4":4150,"NA":4152},{"trials":4135,"activeCount":103},[],{"trials":4137,"activeCount":103},[],{"trials":4139,"activeCount":103},[],{"trials":4141,"activeCount":1087,"soonestReadout":1155},[4142,4146],{"nctId":1152,"briefTitle":1153,"status":126,"phases":4143,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":4144,"interventions":4145},[93],[1062],[48,1161,1138,1139,1162,1064],{"nctId":1164,"briefTitle":1165,"status":126,"phases":4147,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":4148,"interventions":4149},[93],[1062],[48,1137,1150,1139,1162],{"trials":4151,"activeCount":103},[],{"trials":4153,"activeCount":103},[],{"intervention":4155,"totalTrials":1087,"cells":4156},"Osivelotor",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4169,"PHASE3":4171,"PHASE4":4183,"NA":4185},{"trials":4158,"activeCount":103},[],{"trials":4160,"activeCount":302,"soonestReadout":4165},[4161],{"nctId":4162,"briefTitle":4163,"status":263,"phases":4164,"primaryCompletion":4165,"completion":4166,"start":3003,"enrollment":748,"conditions":4167,"interventions":4168},"NCT06507904","A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults",[91],"2027-02-12","2027-05-03",[16],[4155],{"trials":4170,"activeCount":103},[],{"trials":4172,"activeCount":302,"soonestReadout":4177},[4173],{"nctId":4174,"briefTitle":4175,"status":126,"phases":4176,"primaryCompletion":4177,"completion":4178,"start":3238,"enrollment":4179,"conditions":4180,"interventions":4182},"NCT05431088","A Phase 2\u002F3 Study in Adult and Adolescent Participants With SCD",[92,93],"2030-12-30","2032-12-31",389,[4181],"Sickle Cell Disease",[4155],{"trials":4184,"activeCount":103},[],{"trials":4186,"activeCount":103},[],{"intervention":933,"totalTrials":1509,"cells":4188},{"EARLY_PHASE1":4189,"PHASE1":4191,"PHASE2":4248,"PHASE3":4300,"PHASE4":4328,"NA":4330},{"trials":4190,"activeCount":103},[],{"trials":4192,"activeCount":103},[4193,4202,4210,4217,4226,4230,4238],{"nctId":4194,"briefTitle":4195,"status":111,"phases":4196,"primaryCompletion":4197,"completion":1411,"start":4198,"enrollment":2631,"conditions":4199,"interventions":4201},"NCT02493751","A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)",[91],"2018-04-03","2015-10-26",[4200],"Renal Cell Cancer",[663,933],{"nctId":4203,"briefTitle":4204,"status":111,"phases":4205,"primaryCompletion":4206,"completion":4206,"start":4207,"enrollment":2070,"conditions":4208,"interventions":4209},"NCT00726752","A Study In Patients With Advanced Solid Tumor",[91],"2010-04","2008-07",[2053],[933],{"nctId":4211,"briefTitle":4212,"status":111,"phases":4213,"primaryCompletion":4214,"completion":4214,"start":1701,"enrollment":1268,"conditions":4215,"interventions":4216},"NCT00447005","Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors",[91],"2009-08",[943],[933],{"nctId":4218,"briefTitle":4219,"status":111,"phases":4220,"primaryCompletion":4221,"completion":3353,"start":4222,"enrollment":525,"conditions":4223,"interventions":4225},"NCT00842244","Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer",[91],"2009-12","2009-04",[2886,4224],"Advanced Gastric Cancer",[555,2888,2890],{"nctId":546,"briefTitle":547,"status":111,"phases":4227,"primaryCompletion":549,"completion":550,"start":551,"enrollment":26,"conditions":4228,"interventions":4229},[91],[553],[555,424,555,424,555,424],{"nctId":4231,"briefTitle":4232,"status":168,"phases":4233,"primaryCompletion":161,"completion":161,"start":4234,"enrollment":541,"conditions":4235,"interventions":4236},"NCT04458259","Study of PF-07265807 in Participants With Metastatic Solid Tumors.",[91],"2020-09-24",[3077],[4237,1773,933],"PF-07265807",{"nctId":4239,"briefTitle":4240,"status":111,"phases":4241,"primaryCompletion":4242,"completion":4243,"start":4244,"enrollment":748,"conditions":4245,"interventions":4246},"NCT02133742","A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",[91],"2017-03-31","2019-07-03","2014-09-16",[1859],[933,4247],"MK-3475",{"trials":4249,"activeCount":302,"soonestReadout":914},[4250,4254,4263,4272,4276,4284,4293],{"nctId":3224,"briefTitle":3225,"status":168,"phases":4251,"primaryCompletion":1071,"completion":3227,"start":3228,"enrollment":3229,"conditions":4252,"interventions":4253},[91,92],[376],[3232,1812,1832,1773,933,3233],{"nctId":4255,"briefTitle":4256,"status":111,"phases":4257,"primaryCompletion":2641,"completion":2641,"start":4258,"enrollment":4259,"conditions":4260,"interventions":4262},"NCT00094094","Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer",[92],"2005-02",32,[946,4261],"Carcinoma, Non-small Cell Lung",[555],{"nctId":4264,"briefTitle":4265,"status":111,"phases":4266,"primaryCompletion":4267,"completion":4268,"start":4269,"enrollment":917,"conditions":4270,"interventions":4271},"NCT01210495","Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma",[92],"2014-03-03","2016-12-20","2010-12-06",[889],[933],{"nctId":911,"briefTitle":912,"status":126,"phases":4273,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":4274,"interventions":4275},[91,92],[919,920,921,922,923,924,925,926,927,928,929,930,931],[869,895,933],{"nctId":4277,"briefTitle":4278,"status":111,"phases":4279,"primaryCompletion":3353,"completion":4280,"start":4214,"enrollment":4281,"conditions":4282,"interventions":4283},"NCT00835978","Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer",[92],"2016-02",213,[919],[555,555,555],{"nctId":4285,"briefTitle":4286,"status":168,"phases":4287,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":597,"conditions":4290,"interventions":4291},"NCT01441414","PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma",[92],"2014-03-27","2011-11-21",[924],[4292,933,933],"PF-04856884",{"nctId":4294,"briefTitle":4295,"status":168,"phases":4296,"primaryCompletion":2836,"completion":2836,"start":4297,"enrollment":2400,"conditions":4298,"interventions":4299},"NCT03472560","A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)",[92],"2018-05-02",[422,905],[663,933],{"trials":4301,"activeCount":302,"soonestReadout":3864},[4302,4313,4317],{"nctId":4303,"briefTitle":4304,"status":111,"phases":4305,"primaryCompletion":4306,"completion":4307,"start":4308,"enrollment":1158,"conditions":4309,"interventions":4311},"NCT00920816","Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer",[93],"2012-07-27","2021-04-29","2009-08-25",[4310],"Kidney Neoplasms",[933,4312],"Sorafenib",{"nctId":3861,"briefTitle":3862,"status":381,"phases":4314,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":4315,"interventions":4316},[93],[3868,410,1653,905,750],[663,3870,3871,3842,933,3872,2916,3873],{"nctId":4318,"briefTitle":4319,"status":111,"phases":4320,"primaryCompletion":4321,"completion":4322,"start":4323,"enrollment":4324,"conditions":4325,"interventions":4326},"NCT02684006","A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)",[93],"2023-08-31","2024-06-26","2016-03-23",886,[4200],[663,933,4327],"Sunitinib",{"trials":4329,"activeCount":103},[],{"trials":4331,"activeCount":103},[4332,4336,4342,4353,4363,4373,4377],{"nctId":743,"briefTitle":744,"status":111,"phases":4333,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":4334,"interventions":4335},[95],[750],[555,424],{"nctId":4337,"briefTitle":4338,"status":308,"phases":4339,"primaryCompletion":605,"completion":605,"start":2450,"conditions":4340,"interventions":4341},"NCT01473043","Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment",[],[1859],[933],{"nctId":4343,"briefTitle":4344,"status":111,"phases":4345,"primaryCompletion":406,"completion":406,"start":4346,"enrollment":4347,"conditions":4348,"interventions":4351},"NCT00700258","Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]",[],"2008-02-13",1520,[928,4349,4350],"Lymphoma, Mantle-Cell","Gastrointestinal Stroma Tumors",[4352,4352,4327,4327,933],"Temsirolimus",{"nctId":4354,"briefTitle":4355,"status":111,"phases":4356,"primaryCompletion":4357,"completion":4358,"start":4359,"enrollment":4360,"conditions":4361,"interventions":4362},"NCT02156895","Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea",[],"2021-04-21","2021-08-06","2018-07-17",111,[920],[933],{"nctId":4364,"briefTitle":4365,"status":111,"phases":4366,"primaryCompletion":4367,"completion":4367,"start":4368,"enrollment":4369,"conditions":4370,"interventions":4371},"NCT05012865","Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)",[],"2022-01-31","2021-09-14",48,[1859],[4372,555],"avelumab",{"nctId":1852,"briefTitle":1853,"status":111,"phases":4374,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":4375,"interventions":4376},[],[1859],[933,663,631],{"nctId":4378,"briefTitle":4379,"status":111,"phases":4380,"primaryCompletion":4381,"completion":4381,"start":4382,"enrollment":4383,"conditions":4384,"interventions":4386},"NCT04033991","Study of Patients With Metastatic and\u002For Advanced Renal Cell Carcinoma, Treated With Sunitinib\u002FAxitinib.",[],"2020-12-18","2019-09-27",684,[943,4385],"Renal Cell",[4327,933],{"intervention":4388,"totalTrials":99,"cells":4389},"Tofacitinib",{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4414,"PHASE3":4452,"PHASE4":4505,"NA":4518},{"trials":4391,"activeCount":103},[],{"trials":4393,"activeCount":103},[4394,4405],{"nctId":4395,"briefTitle":4396,"status":111,"phases":4397,"primaryCompletion":4398,"completion":4398,"start":4399,"enrollment":1060,"conditions":4400,"interventions":4403},"NCT01736696","Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis",[91],"2004-04","2002-11",[4401,4402],"Psoriasis","Immunomodulation",[4404,4404,4404,4404,4404,4404],"tofacitinib",{"nctId":4406,"briefTitle":4407,"status":111,"phases":4408,"primaryCompletion":4409,"completion":4409,"start":4410,"enrollment":1268,"conditions":4411,"interventions":4412},"NCT04111614","A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.",[91],"2019-12-12","2019-10-11",[16],[4388,4413],"Tofacitinib Oral Solution",{"trials":4415,"activeCount":103},[4416,4426,4434,4443],{"nctId":4417,"briefTitle":4418,"status":111,"phases":4419,"primaryCompletion":4420,"completion":4420,"start":1518,"enrollment":4421,"conditions":4422,"interventions":4423},"NCT04413617","TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE",[92],"2022-02-07",460,[22],[4424,4425,4388],"PF-06650833","PF-06651600",{"nctId":4427,"briefTitle":4428,"status":649,"phases":4429,"primaryCompletion":2551,"completion":4430,"start":4431,"enrollment":103,"conditions":4432,"interventions":4433},"NCT04412252","Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy",[92],"2020-10-18","2020-07-06",[2592],[4388],{"nctId":4435,"briefTitle":4436,"status":111,"phases":4437,"primaryCompletion":4438,"completion":4439,"start":1288,"enrollment":4440,"conditions":4441,"interventions":4442},"NCT02147587","A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate",[92],"2015-06","2015-07",112,[22],[4388],{"nctId":4444,"briefTitle":4445,"status":111,"phases":4446,"primaryCompletion":4447,"completion":4447,"start":4448,"enrollment":4449,"conditions":4450,"interventions":4451},"NCT02996500","Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate",[92],"2018-08-15","2016-11-10",269,[22],[4424,4388],{"trials":4453,"activeCount":302,"soonestReadout":4500},[4454,4463,4471,4479,4486,4496],{"nctId":4455,"briefTitle":4456,"status":111,"phases":4457,"primaryCompletion":4458,"completion":4438,"start":4459,"enrollment":4460,"conditions":4461,"interventions":4462},"NCT01458951","A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis",[93],"2015-05","2012-06",547,[1532],[4404],{"nctId":4464,"briefTitle":4465,"status":111,"phases":4466,"primaryCompletion":129,"completion":129,"start":4467,"enrollment":9,"conditions":4468,"interventions":4470},"NCT03486457","Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis",[93],"2018-08-10",[4469],"Psoriatic Arthritis",[4388,4388],{"nctId":4472,"briefTitle":4473,"status":111,"phases":4474,"primaryCompletion":669,"completion":669,"start":4475,"enrollment":4476,"conditions":4477,"interventions":4478},"NCT02281552","A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis",[93],"2014-11-18",209,[22],[4388,4388],{"nctId":4480,"briefTitle":4481,"status":111,"phases":4482,"primaryCompletion":4458,"completion":4458,"start":3334,"enrollment":4483,"conditions":4484,"interventions":4485},"NCT01465763","A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis",[93],614,[1532],[4404],{"nctId":4487,"briefTitle":4488,"status":111,"phases":4489,"primaryCompletion":4490,"completion":4490,"start":4491,"enrollment":4492,"conditions":4493,"interventions":4495},"NCT01500551","Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis",[92,93],"2025-02-12","2013-03-18",302,[4494],"Juvenile Idiopathic Arthritis",[4388,4388],{"nctId":4497,"briefTitle":4498,"status":381,"phases":4499,"primaryCompletion":4500,"completion":4501,"start":4502,"enrollment":2250,"conditions":4503,"interventions":4504},"NCT04624230","Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis",[93],"2027-04-14","2029-07-04","2021-08-12",[1532],[4404],{"trials":4506,"activeCount":103},[4507],{"nctId":4508,"briefTitle":4509,"status":111,"phases":4510,"primaryCompletion":462,"completion":462,"start":4511,"enrollment":4512,"conditions":4513,"interventions":4515},"NCT02092467","Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis",[94],"2014-03-14",4372,[4514],"Arthritis, Rheumatoid",[4404,4404,4516,4517],"adalimumab","etanercept",{"trials":4519,"activeCount":302,"soonestReadout":4539},[4520,4527,4535,4543,4552,4562],{"nctId":4521,"briefTitle":4522,"status":111,"phases":4523,"primaryCompletion":72,"completion":72,"start":2261,"enrollment":4524,"conditions":4525,"interventions":4526},"NCT03387423","Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis",[],1459,[4514],[4388],{"nctId":4528,"briefTitle":4529,"status":111,"phases":4530,"primaryCompletion":540,"completion":540,"start":4531,"enrollment":3603,"conditions":4532,"interventions":4534},"NCT01375127","Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients",[],"2011-08",[4533],"Kidney Transplantation",[4388,4388],{"nctId":4536,"briefTitle":4537,"status":126,"phases":4538,"primaryCompletion":4539,"completion":4539,"start":4540,"enrollment":941,"conditions":4541,"interventions":4542},"NCT04338204","Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden",[],"2026-03-30","2020-09-14",[1532],[4404],{"nctId":4544,"briefTitle":4545,"status":111,"phases":4546,"primaryCompletion":4547,"completion":4547,"start":4548,"enrollment":4549,"conditions":4550,"interventions":4551},"NCT03981900","IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis",[],"2023-02-06","2019-01-04",314,[4514],[4388,4388],{"nctId":4553,"briefTitle":4554,"status":111,"phases":4555,"primaryCompletion":4556,"completion":4556,"start":4557,"enrollment":4558,"conditions":4559,"interventions":4561},"NCT04721821","Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.",[],"2021-11-29","2021-01-22",7807,[4560],"Arthritis Rheumatoid",[4388],{"nctId":4563,"briefTitle":4564,"status":111,"phases":4565,"primaryCompletion":4566,"completion":4566,"start":77,"enrollment":4567,"conditions":4568,"interventions":4569},"NCT06418529","A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis",[],"2024-07-19",21340,[22],[4404,4570,4571,4572],"tumor necrosis factor inhibitors","abatacept","tocilizumab or sarilumab",{"intervention":1643,"totalTrials":314,"cells":4574},{"EARLY_PHASE1":4575,"PHASE1":4577,"PHASE2":4583,"PHASE3":4630,"PHASE4":4686,"NA":4696},{"trials":4576,"activeCount":103},[],{"trials":4578,"activeCount":103},[4579],{"nctId":1632,"briefTitle":1633,"status":111,"phases":4580,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":4581,"interventions":4582},[91],[31],[1641,1642,1643,1644,1641,1643],{"trials":4584,"activeCount":302,"soonestReadout":1665},[4585,4593,4597,4604,4611,4619,4623],{"nctId":4586,"briefTitle":4587,"status":649,"phases":4588,"primaryCompletion":4589,"completion":4589,"start":4590,"enrollment":103,"conditions":4591,"interventions":4592},"NCT01658176","Study Of PF-04691502 (PI3K\u002FmTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer",[92],"2015-04","2013-01",[25],[2455,1674,1674],{"nctId":1662,"briefTitle":1663,"status":381,"phases":4594,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":4595,"interventions":4596},[92],[1670],[1672,1305,1673,1674],{"nctId":4598,"briefTitle":4599,"status":111,"phases":4600,"completion":3854,"start":4601,"enrollment":787,"conditions":4602,"interventions":4603},"NCT00174343","Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients",[92],"2001-11",[25],[1643],{"nctId":4605,"briefTitle":4606,"status":168,"phases":4607,"primaryCompletion":577,"completion":577,"start":4608,"enrollment":1578,"conditions":4609,"interventions":4610},"NCT00793546","Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer",[92],"2009-02",[1241],[2435,1643,1674],{"nctId":4612,"briefTitle":4613,"status":168,"phases":4614,"primaryCompletion":4615,"completion":4615,"start":4616,"enrollment":397,"conditions":4617,"interventions":4618},"NCT00040014","Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women",[92],"2006-12","2002-06",[25],[1643],{"nctId":1697,"briefTitle":1698,"status":168,"phases":4620,"primaryCompletion":1700,"completion":1288,"start":1701,"enrollment":1702,"conditions":4621,"interventions":4622},[92],[25],[1705,1643,1643,1305],{"nctId":4624,"briefTitle":4625,"status":168,"phases":4626,"primaryCompletion":4627,"completion":4627,"start":3643,"enrollment":2070,"conditions":4628,"interventions":4629},"NCT00417885","A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and\u002For PgR [Progesterone Receptor] + Breast Cancer",[91,92],"2009-07",[25],[1643,2889],{"trials":4631,"activeCount":302,"soonestReadout":1727},[4632,4641,4652,4661,4671,4675],{"nctId":4633,"briefTitle":4634,"status":111,"phases":4635,"primaryCompletion":4636,"completion":4221,"start":4601,"enrollment":4637,"conditions":4638,"interventions":4639},"NCT01237327","Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer",[93],"2007-12",84,[1369],[4640,1643],"Megestrol acetate",{"nctId":4642,"briefTitle":4643,"status":111,"phases":4644,"primaryCompletion":4645,"completion":4646,"start":4647,"enrollment":4648,"conditions":4649,"interventions":4650},"NCT00279448","Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer",[93],"2008-11","2009-06","2002-01",9779,[25],[1643,4651],"tamoxifen",{"nctId":4653,"briefTitle":4654,"status":111,"phases":4655,"primaryCompletion":4656,"completion":4656,"start":4657,"enrollment":4658,"conditions":4659,"interventions":4660},"NCT00143390","Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced\u002FRecurrent Breast Cancer",[93],"2010-12","2005-04",298,[25],[1643,1642],{"nctId":4662,"briefTitle":4663,"status":111,"phases":4664,"primaryCompletion":4665,"completion":4666,"start":4667,"enrollment":4648,"conditions":4668,"interventions":4669},"NCT00036270","Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane",[93],"2008-10","2011-02","2001-08",[25],[1643,4670],"tamoxifen + exemestane",{"nctId":1724,"briefTitle":1725,"status":126,"phases":4672,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":267,"conditions":4673,"interventions":4674},[93],[31],[1319,1305,1673,1674],{"nctId":4676,"briefTitle":4677,"status":111,"phases":4678,"primaryCompletion":4679,"completion":4680,"start":4681,"enrollment":4682,"conditions":4683,"interventions":4684},"NCT00038467","Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer",[93],"2003-06","2013-03","1998-02",4740,[25],[4685,1674],"Tamoxifen",{"trials":4687,"activeCount":103},[4688],{"nctId":4689,"briefTitle":4690,"status":111,"phases":4691,"primaryCompletion":3602,"completion":3602,"start":4692,"enrollment":4693,"conditions":4694,"interventions":4695},"NCT00649090","A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer",[94],"2005-03",1549,[25],[1643],{"trials":4697,"activeCount":103},[4698],{"nctId":4699,"briefTitle":4700,"status":111,"phases":4701,"primaryCompletion":4645,"completion":4645,"start":4702,"enrollment":4703,"conditions":4704,"interventions":4705},"NCT00932165","Special Investigation For Patients With Renal And\u002FOr Hepatic Disorders On Aromasin",[],"2004-12",451,[25],[1674],{"intervention":341,"totalTrials":562,"cells":4707},{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4742,"PHASE3":4780,"PHASE4":4790,"NA":4792},{"trials":4709,"activeCount":103},[],{"trials":4711,"activeCount":302,"soonestReadout":1980},[4712,4716,4720,4734,4738],{"nctId":331,"briefTitle":332,"status":168,"phases":4713,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":4714,"interventions":4715},[91],[338],[340,329,341,342,343],{"nctId":3197,"briefTitle":3198,"status":111,"phases":4717,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":4718,"interventions":4719},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"nctId":4721,"briefTitle":4722,"status":168,"phases":4723,"primaryCompletion":4724,"completion":4724,"start":4725,"enrollment":4726,"conditions":4727,"interventions":4732},"NCT04543188","A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement",[91],"2024-03-20","2021-01-08",65,[4728,376,4729,4730,4731],"Malignant Melanoma","Brain Neoplasms, Primary","Brain Neoplasms","Malignant Neoplasms",[4733,1832,1687],"PF-07284890",{"nctId":3214,"briefTitle":3215,"status":168,"phases":4735,"primaryCompletion":3217,"completion":3217,"start":3218,"enrollment":302,"conditions":4736,"interventions":4737},[91],[1798],[341,343],{"nctId":1977,"briefTitle":1978,"status":126,"phases":4739,"primaryCompletion":1980,"completion":1981,"start":786,"enrollment":1982,"conditions":4740,"interventions":4741},[91],[1798,409,1984,1985,1986],[1988,341,342,1989,1990,1991,1992],{"trials":4743,"activeCount":103},[4744,4748,4760,4764,4768,4772],{"nctId":3224,"briefTitle":3225,"status":168,"phases":4745,"primaryCompletion":1071,"completion":3227,"start":3228,"enrollment":3229,"conditions":4746,"interventions":4747},[91,92],[376],[3232,1812,1832,1773,933,3233],{"nctId":4749,"briefTitle":4750,"status":111,"phases":4751,"primaryCompletion":4752,"completion":4753,"start":4754,"enrollment":4755,"conditions":4756,"interventions":4759},"NCT03271047","Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation",[92],"2020-10-13","2021-02-25","2017-10-18",75,[4757,4758],"MSS","RAS-mutant Colorectal Cancer",[341,439,1800],{"nctId":3235,"briefTitle":3236,"status":111,"phases":4761,"primaryCompletion":3238,"completion":3239,"start":3240,"enrollment":3241,"conditions":4762,"interventions":4763},[92],[727],[343,341],{"nctId":1791,"briefTitle":1792,"status":168,"phases":4765,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":4766,"interventions":4767},[92],[1798],[343,341,438,1800,439],{"nctId":3249,"briefTitle":3250,"status":168,"phases":4769,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":3254,"conditions":4770,"interventions":4771},[92],[3256],[343,341],{"nctId":4773,"briefTitle":4774,"status":168,"phases":4775,"primaryCompletion":4776,"completion":150,"start":4447,"enrollment":1530,"conditions":4777,"interventions":4779},"NCT03637491","A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors",[91,92],"2020-12-03",[4778],"Pancreatic Cancer",[663,1832,3871],{"trials":4781,"activeCount":302,"soonestReadout":1665},[4782,4786],{"nctId":1824,"briefTitle":1825,"status":381,"phases":4783,"primaryCompletion":1665,"completion":1827,"start":1828,"enrollment":1829,"conditions":4784,"interventions":4785},[93],[1798],[1812,1832,631],{"nctId":2033,"briefTitle":2034,"status":111,"phases":4787,"primaryCompletion":2036,"completion":1169,"start":2037,"enrollment":2038,"conditions":4788,"interventions":4789},[93],[2040],[1812,1832,1304,1335,2042,2043],{"trials":4791,"activeCount":103},[],{"trials":4793,"activeCount":103},[4794],{"nctId":3281,"briefTitle":3282,"status":111,"phases":4795,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":3286,"conditions":4796,"interventions":4797},[],[1798],[1812,1832,3289,3290,3291,3292],{"intervention":2056,"totalTrials":1487,"cells":4799},{"EARLY_PHASE1":4800,"PHASE1":4802,"PHASE2":4812,"PHASE3":4840,"PHASE4":4856,"NA":4858},{"trials":4801,"activeCount":103},[],{"trials":4803,"activeCount":103},[4804,4808],{"nctId":4218,"briefTitle":4219,"status":111,"phases":4805,"primaryCompletion":4221,"completion":3353,"start":4222,"enrollment":525,"conditions":4806,"interventions":4807},[91],[2886,4224],[555,2888,2890],{"nctId":2880,"briefTitle":2881,"status":111,"phases":4809,"primaryCompletion":561,"completion":2883,"start":2884,"enrollment":407,"conditions":4810,"interventions":4811},[91],[2886],[2888,1992,2889,2888,2890,2889],{"trials":4813,"activeCount":302,"soonestReadout":72},[4814,4822,4829],{"nctId":4815,"briefTitle":4816,"status":111,"phases":4817,"primaryCompletion":4221,"completion":113,"start":3314,"enrollment":4818,"conditions":4819,"interventions":4821},"NCT00662025","Study Of Sunitinib With Capecitabine In Breast Cancer",[92],63,[4820],"Advanced\u002FMetastatic Breast Cancer",[2056,4327],{"nctId":70,"briefTitle":71,"status":381,"phases":4823,"primaryCompletion":72,"completion":445,"start":4824,"enrollment":4825,"conditions":4826,"interventions":4827},[92],"2021-04-08",66,[31],[73,4828,2056],"Trastuzumab",{"nctId":4830,"briefTitle":4831,"status":168,"phases":4832,"primaryCompletion":524,"completion":524,"start":4833,"enrollment":4259,"conditions":4834,"interventions":4839},"NCT00959946","Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer",[91,92],"2009-09",[4835,4836,1986,4837,4838],"Advanced Breast Cancer (Parts 1 and 2)","Advanced Pancreatic Cancer (Part 1)","Advanced Cholangiocarcinoma (Part 1)","Advanced Glioblastoma Multiforme (Part 1)",[2435,2056],{"trials":4841,"activeCount":302,"soonestReadout":2048},[4842,4852],{"nctId":4843,"briefTitle":4844,"status":168,"phases":4845,"primaryCompletion":4846,"completion":2661,"start":4847,"enrollment":4848,"conditions":4849,"interventions":4850},"NCT00373113","A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine",[93],"2009-10","2006-11",482,[25],[2056,4851],"Sunitinib malate",{"nctId":2045,"briefTitle":2046,"status":381,"phases":4853,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":4854,"interventions":4855},[93],[2053],[1812,1304,1767,1335,1768,2055,2056,1030],{"trials":4857,"activeCount":103},[],{"trials":4859,"activeCount":103},[4860],{"nctId":4861,"briefTitle":4862,"status":111,"phases":4863,"primaryCompletion":4864,"completion":4864,"start":4865,"enrollment":1122,"conditions":4866,"interventions":4868},"NCT06961331","Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.",[],"2025-09-25","2025-05-07",[4867],"Metastatic HER2+ Advanced Breast Cancer",[73,4828,2056],{"intervention":1673,"totalTrials":502,"cells":4870},{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4875,"PHASE3":4881,"PHASE4":4887,"NA":4889},{"trials":4872,"activeCount":103},[],{"trials":4874,"activeCount":103},[],{"trials":4876,"activeCount":302,"soonestReadout":1665},[4877],{"nctId":1662,"briefTitle":1663,"status":381,"phases":4878,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":4879,"interventions":4880},[92],[1670],[1672,1305,1673,1674],{"trials":4882,"activeCount":302,"soonestReadout":1727},[4883],{"nctId":1724,"briefTitle":1725,"status":126,"phases":4884,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":267,"conditions":4885,"interventions":4886},[93],[31],[1319,1305,1673,1674],{"trials":4888,"activeCount":103},[],{"trials":4890,"activeCount":103},[4891],{"nctId":4892,"briefTitle":4893,"status":111,"phases":4894,"primaryCompletion":4895,"completion":4895,"start":4896,"enrollment":4897,"conditions":4898,"interventions":4900},"NCT02264665","OPALINE : A Study Of Morbidity And Mortality At 2 Years",[],"2019-11-18","2015-05-12",144,[4899],"Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive",[3317,4901,4902],"everolimus","chemotherapies recommended in france",{"intervention":4904,"totalTrials":3659,"cells":4905},"Ritonavir",{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4946,"PHASE3":4963,"PHASE4":4984,"NA":4986},{"trials":4907,"activeCount":103},[],{"trials":4909,"activeCount":103},[4910,4919,4928,4937],{"nctId":4911,"briefTitle":4912,"status":111,"phases":4913,"primaryCompletion":4914,"completion":4914,"start":3723,"enrollment":1487,"conditions":4915,"interventions":4916},"NCT05441215","A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir\u002FRitonavir) in Healthy Lactating Women",[91],"2023-12-15",[28],[4917,4918],"nirmatrelvir","ritonavir",{"nctId":4920,"briefTitle":4921,"status":168,"phases":4922,"primaryCompletion":4923,"completion":4924,"start":4925,"enrollment":2713,"conditions":4926,"interventions":4927},"NCT05386472","A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19",[91],"2025-03-26","2025-05-12","2022-06-22",[2592],[4917,4918],{"nctId":4929,"briefTitle":4930,"status":111,"phases":4931,"primaryCompletion":4932,"completion":4932,"start":4933,"enrollment":1268,"conditions":4934,"interventions":4935},"NCT05129475","Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants",[91],"2022-01-12","2021-11-12",[28],[4936,4904],"PF-07321332\u002Fritonavir",{"nctId":4938,"briefTitle":4939,"status":649,"phases":4940,"primaryCompletion":4666,"completion":4666,"start":3601,"enrollment":103,"conditions":4941,"interventions":4943},"NCT01251848","Drug Interaction Between Ritonavir And Sitaxsentan",[91],[4942],"Pulmonary Arterial Hypertension",[4944,4904,4945,4904],"Sitaxentan","Sitaxsentan",{"trials":4947,"activeCount":103},[4948],{"nctId":4949,"briefTitle":4950,"status":649,"phases":4951,"primaryCompletion":4952,"completion":4953,"start":4954,"enrollment":103,"conditions":4955,"interventions":4961},"NCT05545319","A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19",[92],"2023-09-21","2024-01-06","2022-12-13",[4956,4957,4958,4959,4960],"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","Coronavirus Disease 2019 (COVID-19)","Immunocompromised","Hospitalization","Child, Hospitalized",[4962,4904],"Nirmatrelvir",{"trials":4964,"activeCount":302,"soonestReadout":4979},[4965,4975],{"nctId":4966,"briefTitle":4967,"status":111,"phases":4968,"primaryCompletion":4969,"completion":4969,"start":4970,"enrollment":4971,"conditions":4972,"interventions":4973},"NCT05047601","A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection",[92,93],"2022-04-12","2021-09-09",2954,[2592],[4974,4904],"PF-07321332",{"nctId":4976,"briefTitle":4977,"status":126,"phases":4978,"primaryCompletion":4979,"completion":4979,"start":4980,"enrollment":4981,"conditions":4982,"interventions":4983},"NCT05261139","EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)\u002FRitonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease",[93],"2026-07-30","2022-03-07",160,[2592],[4917,4918],{"trials":4985,"activeCount":103},[],{"trials":4987,"activeCount":103},[],{"intervention":4989,"totalTrials":2070,"cells":4990},"PF-06741086",{"EARLY_PHASE1":4991,"PHASE1":4993,"PHASE2":5011,"PHASE3":5029,"PHASE4":5046,"NA":5048},{"trials":4992,"activeCount":103},[],{"trials":4994,"activeCount":103},[4995,5004],{"nctId":4996,"briefTitle":4997,"status":111,"phases":4998,"primaryCompletion":4999,"completion":4999,"start":5000,"enrollment":2070,"conditions":5001,"interventions":5003},"NCT04878731","Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia",[91],"2021-08-10","2021-04-16",[5002],"Severe Hemophilia",[4989],{"nctId":5005,"briefTitle":5006,"status":111,"phases":5007,"primaryCompletion":5008,"completion":5008,"start":3323,"enrollment":713,"conditions":5009,"interventions":5010},"NCT02531815","Dose Escalation Study of PF-06741086 In Healthy Subjects",[91],"2016-07",[16],[4989],{"trials":5012,"activeCount":103},[5013,5021],{"nctId":5014,"briefTitle":5015,"status":111,"phases":5016,"primaryCompletion":5017,"completion":5017,"start":5018,"enrollment":504,"conditions":5019,"interventions":5020},"NCT02974855","PF-06741086 Multiple Dose Study in Severe Hemophilia",[92],"2018-12-03","2017-03-08",[3564],[4989,4989,4989,4989],{"nctId":5022,"briefTitle":5023,"status":111,"phases":5024,"primaryCompletion":5025,"completion":5025,"start":5026,"enrollment":2159,"conditions":5027,"interventions":5028},"NCT03363321","PF-06741086 Long-term Treatment in Severe Hemophilia",[92],"2020-08-05","2018-05-30",[3564],[4989],{"trials":5030,"activeCount":302,"soonestReadout":128},[5031,5038],{"nctId":5032,"briefTitle":5033,"status":126,"phases":5034,"primaryCompletion":128,"completion":128,"start":5035,"enrollment":12,"conditions":5036,"interventions":5037},"NCT05145127","Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors",[93],"2021-11-17",[3551,3552],[4989],{"nctId":5039,"briefTitle":5040,"status":111,"phases":5041,"primaryCompletion":5042,"completion":5042,"start":5043,"enrollment":2935,"conditions":5044,"interventions":5045},"NCT03938792","Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B",[93],"2025-04-29","2020-03-09",[3551,3552],[4989],{"trials":5047,"activeCount":103},[],{"trials":5049,"activeCount":103},[],{"intervention":4917,"totalTrials":257,"cells":5051},{"EARLY_PHASE1":5052,"PHASE1":5054,"PHASE2":5064,"PHASE3":5070,"PHASE4":5076,"NA":5078},{"trials":5053,"activeCount":103},[],{"trials":5055,"activeCount":103},[5056,5060],{"nctId":4911,"briefTitle":4912,"status":111,"phases":5057,"primaryCompletion":4914,"completion":4914,"start":3723,"enrollment":1487,"conditions":5058,"interventions":5059},[91],[28],[4917,4918],{"nctId":4920,"briefTitle":4921,"status":168,"phases":5061,"primaryCompletion":4923,"completion":4924,"start":4925,"enrollment":2713,"conditions":5062,"interventions":5063},[91],[2592],[4917,4918],{"trials":5065,"activeCount":103},[5066],{"nctId":4949,"briefTitle":4950,"status":649,"phases":5067,"primaryCompletion":4952,"completion":4953,"start":4954,"enrollment":103,"conditions":5068,"interventions":5069},[92],[4956,4957,4958,4959,4960],[4962,4904],{"trials":5071,"activeCount":302,"soonestReadout":4979},[5072],{"nctId":4976,"briefTitle":4977,"status":126,"phases":5073,"primaryCompletion":4979,"completion":4979,"start":4980,"enrollment":4981,"conditions":5074,"interventions":5075},[93],[2592],[4917,4918],{"trials":5077,"activeCount":103},[],{"trials":5079,"activeCount":103},[],{"intervention":78,"totalTrials":502,"cells":5081},{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5095,"PHASE3":5105,"PHASE4":5114,"NA":5116},{"trials":5083,"activeCount":103},[],{"trials":5085,"activeCount":103},[5086],{"nctId":5087,"briefTitle":5088,"status":168,"phases":5089,"primaryCompletion":3683,"completion":5090,"start":5091,"enrollment":2218,"conditions":5092,"interventions":5094},"NCT03362502","A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy",[91],"2025-07-28","2018-01-23",[5093],"Duchenne Muscular Dystrophy",[78],{"trials":5096,"activeCount":103},[5097],{"nctId":5098,"briefTitle":5099,"status":168,"phases":5100,"primaryCompletion":3239,"completion":3239,"start":5101,"enrollment":870,"conditions":5102,"interventions":5104},"NCT05429372","Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy",[92],"2022-08-08",[5103],"Muscular Dystrophy, Duchenne",[78],{"trials":5106,"activeCount":302,"soonestReadout":77},[5107],{"nctId":75,"briefTitle":76,"status":381,"phases":5108,"primaryCompletion":77,"completion":5109,"start":5110,"enrollment":5111,"conditions":5112,"interventions":5113},[93],"2039-04-15","2020-11-05",114,[5093],[78,78],{"trials":5115,"activeCount":103},[],{"trials":5117,"activeCount":103},[],{"intervention":5119,"totalTrials":502,"cells":5120},"PF-06823859",{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5133,"PHASE3":5144,"PHASE4":5156,"NA":5158},{"trials":5122,"activeCount":103},[],{"trials":5124,"activeCount":103},[5125],{"nctId":5126,"briefTitle":5127,"status":111,"phases":5128,"primaryCompletion":5129,"completion":5129,"start":5130,"enrollment":3254,"conditions":5131,"interventions":5132},"NCT05037409","Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants",[91],"2022-03-27","2021-09-28",[16],[5119],{"trials":5134,"activeCount":103},[5135],{"nctId":5136,"briefTitle":5137,"status":168,"phases":5138,"primaryCompletion":1209,"completion":2098,"start":5139,"enrollment":1487,"conditions":5140,"interventions":5143},"NCT05879718","A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.",[92],"2023-07-07",[5141,5142],"Lupus Erythematosus, Systemic","Lupus Erythematosus, Cutaneous",[5119],{"trials":5145,"activeCount":302,"soonestReadout":5150},[5146],{"nctId":5147,"briefTitle":5148,"status":126,"phases":5149,"primaryCompletion":5150,"completion":5150,"start":5151,"enrollment":5152,"conditions":5153,"interventions":5155},"NCT05895786","A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]",[93],"2027-07-28","2023-05-20",318,[5154],"Myositis",[5119],{"trials":5157,"activeCount":103},[],{"trials":5159,"activeCount":103},[],{"intervention":5161,"totalTrials":502,"cells":5162},"ponsegromab",{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5174,"PHASE3":5187,"PHASE4":5198,"NA":5200},{"trials":5164,"activeCount":103},[],{"trials":5166,"activeCount":103},[5167],{"nctId":5168,"briefTitle":5169,"status":111,"phases":5170,"primaryCompletion":5139,"completion":5139,"start":1586,"enrollment":597,"conditions":5171,"interventions":5172},"NCT05685264","A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults",[91],[16],[5173,5173],"Ponsegromab",{"trials":5175,"activeCount":103},[5176],{"nctId":5177,"briefTitle":5178,"status":111,"phases":5179,"primaryCompletion":5180,"completion":1565,"start":5181,"enrollment":1112,"conditions":5182,"interventions":5186},"NCT05546476","Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15",[92],"2024-03-13","2022-11-21",[727,4778,2022,5183,5184,5185],"Loss of Appetite","Fatigue","Cachexia",[5161],{"trials":5188,"activeCount":302,"soonestReadout":5193},[5189],{"nctId":5190,"briefTitle":5191,"status":126,"phases":5192,"primaryCompletion":5193,"completion":5194,"start":3239,"enrollment":5195,"conditions":5196,"interventions":5197},"NCT06989437","A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue",[92,93],"2028-01-17","2029-12-10",982,[5185,1281],[5161],{"trials":5199,"activeCount":103},[],{"trials":5201,"activeCount":103},[],{"intervention":2916,"totalTrials":502,"cells":5203},{"EARLY_PHASE1":5204,"PHASE1":5206,"PHASE2":5208,"PHASE3":5222,"PHASE4":5232,"NA":5234},{"trials":5205,"activeCount":103},[],{"trials":5207,"activeCount":103},[],{"trials":5209,"activeCount":103},[5210],{"nctId":5211,"briefTitle":5212,"status":168,"phases":5213,"primaryCompletion":5214,"completion":5214,"start":5215,"enrollment":5216,"conditions":5217,"interventions":5218},"NCT02554812","A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)",[91,92],"2023-03-23","2015-11-09",409,[543],[663,2916,5219,5220,5221],"PF-04518600","PD 0360324","CMP-001",{"trials":5223,"activeCount":302,"soonestReadout":3864},[5224,5228],{"nctId":3861,"briefTitle":3862,"status":381,"phases":5225,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":5226,"interventions":5227},[93],[3868,410,1653,905,750],[663,3870,3871,3842,933,3872,2916,3873],{"nctId":2908,"briefTitle":2909,"status":168,"phases":5229,"primaryCompletion":2911,"completion":2911,"start":2912,"enrollment":350,"conditions":5230,"interventions":5231},[93],[2914],[663,2916,2917,2918,1764,1767],{"trials":5233,"activeCount":103},[],{"trials":5235,"activeCount":103},[],{"intervention":2276,"totalTrials":302,"cells":5237},{"EARLY_PHASE1":5238,"PHASE1":5240,"PHASE2":5242,"PHASE3":5244,"PHASE4":5250,"NA":5252},{"trials":5239,"activeCount":103},[],{"trials":5241,"activeCount":103},[],{"trials":5243,"activeCount":103},[],{"trials":5245,"activeCount":302,"soonestReadout":62},[5246],{"nctId":60,"briefTitle":61,"status":381,"phases":5247,"primaryCompletion":62,"completion":2269,"start":2270,"enrollment":2271,"conditions":5248,"interventions":5249},[93],[2273,1684,2274],[63,2276],{"trials":5251,"activeCount":103},[],{"trials":5253,"activeCount":103},[],{"intervention":5255,"totalTrials":302,"cells":5256},"PF-08046054",{"EARLY_PHASE1":5257,"PHASE1":5259,"PHASE2":5261,"PHASE3":5263,"PHASE4":5278,"NA":5280},{"trials":5258,"activeCount":103},[],{"trials":5260,"activeCount":103},[],{"trials":5262,"activeCount":103},[],{"trials":5264,"activeCount":302,"soonestReadout":5269},[5265],{"nctId":5266,"briefTitle":5267,"status":126,"phases":5268,"primaryCompletion":5269,"completion":5270,"start":5271,"enrollment":5272,"conditions":5273,"interventions":5276},"NCT07144280","A Study to Learn About the Study Medicine Called PF-08046054\u002FSGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)",[93],"2028-03-10","2032-03-10","2025-09-29",680,[5274,5275,465],"Non-small Cell Carcinoma","Non-Small Cell Lung Cancer Metastatic",[5255,5277],"Docetaxel monotherapy",{"trials":5279,"activeCount":103},[],{"trials":5281,"activeCount":103},[],{"intervention":5277,"totalTrials":302,"cells":5283},{"EARLY_PHASE1":5284,"PHASE1":5286,"PHASE2":5288,"PHASE3":5290,"PHASE4":5296,"NA":5298},{"trials":5285,"activeCount":103},[],{"trials":5287,"activeCount":103},[],{"trials":5289,"activeCount":103},[],{"trials":5291,"activeCount":302,"soonestReadout":5269},[5292],{"nctId":5266,"briefTitle":5267,"status":126,"phases":5293,"primaryCompletion":5269,"completion":5270,"start":5271,"enrollment":5272,"conditions":5294,"interventions":5295},[93],[5274,5275,465],[5255,5277],{"trials":5297,"activeCount":103},[],{"trials":5299,"activeCount":103},[],{"intervention":5301,"totalTrials":302,"cells":5302},"Dazukibart",{"EARLY_PHASE1":5303,"PHASE1":5305,"PHASE2":5307,"PHASE3":5309,"PHASE4":5322,"NA":5324},{"trials":5304,"activeCount":103},[],{"trials":5306,"activeCount":103},[],{"trials":5308,"activeCount":103},[],{"trials":5310,"activeCount":302,"soonestReadout":5315},[5311],{"nctId":5312,"briefTitle":5313,"status":126,"phases":5314,"primaryCompletion":5315,"completion":5315,"start":5316,"enrollment":5317,"conditions":5318,"interventions":5321},"NCT06698796","A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies",[93],"2027-11-25","2025-01-22",211,[5319,5320],"Dermatomyositis","Polymyositis",[5301],{"trials":5323,"activeCount":103},[],{"trials":5325,"activeCount":103},[],{"intervention":5327,"totalTrials":302,"cells":5328},"Rimegepant\u002FBHV3000",{"EARLY_PHASE1":5329,"PHASE1":5331,"PHASE2":5333,"PHASE3":5335,"PHASE4":5346,"NA":5348},{"trials":5330,"activeCount":103},[],{"trials":5332,"activeCount":103},[],{"trials":5334,"activeCount":103},[],{"trials":5336,"activeCount":302,"soonestReadout":5341},[5337],{"nctId":5338,"briefTitle":5339,"status":126,"phases":5340,"primaryCompletion":5341,"completion":5341,"start":1828,"enrollment":5342,"conditions":5343,"interventions":5345},"NCT04649242","Randomized Study in Children and Adolescents With Migraine: Acute Treatment",[93],"2029-01-09",2100,[5344],"Pediatric Migraine",[5327],{"trials":5347,"activeCount":103},[],{"trials":5349,"activeCount":103},[],{"intervention":5351,"totalTrials":302,"cells":5352},"C.difficile vaccine",{"EARLY_PHASE1":5353,"PHASE1":5355,"PHASE2":5357,"PHASE3":5359,"PHASE4":5371,"NA":5373},{"trials":5354,"activeCount":103},[],{"trials":5356,"activeCount":103},[],{"trials":5358,"activeCount":103},[],{"trials":5360,"activeCount":302,"soonestReadout":5365},[5361],{"nctId":5362,"briefTitle":5363,"status":126,"phases":5364,"primaryCompletion":5365,"completion":5366,"start":212,"enrollment":5367,"conditions":5368,"interventions":5370},"NCT07282665","A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older",[93],"2028-12-11","2029-06-07",32000,[5369],"Clostridioides Difficile Associated Disease",[5351],{"trials":5372,"activeCount":103},[],{"trials":5374,"activeCount":103},[],{"intervention":1009,"totalTrials":302,"cells":5376},{"EARLY_PHASE1":5377,"PHASE1":5379,"PHASE2":5381,"PHASE3":5383,"PHASE4":5389,"NA":5391},{"trials":5378,"activeCount":103},[],{"trials":5380,"activeCount":103},[],{"trials":5382,"activeCount":103},[],{"trials":5384,"activeCount":302,"soonestReadout":1002},[5385],{"nctId":999,"briefTitle":1000,"status":263,"phases":5386,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":130,"conditions":5387,"interventions":5388},[93],[1006,1007],[869,631,1009],{"trials":5390,"activeCount":103},[],{"trials":5392,"activeCount":103},[],{"intervention":1161,"totalTrials":302,"cells":5394},{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5399,"PHASE3":5401,"PHASE4":5407,"NA":5409},{"trials":5396,"activeCount":103},[],{"trials":5398,"activeCount":103},[],{"trials":5400,"activeCount":103},[],{"trials":5402,"activeCount":302,"soonestReadout":1155},[5403],{"nctId":1152,"briefTitle":1153,"status":126,"phases":5404,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":5405,"interventions":5406},[93],[1062],[48,1161,1138,1139,1162,1064],{"trials":5408,"activeCount":103},[],{"trials":5410,"activeCount":103},[],{"intervention":58,"totalTrials":302,"cells":5412},{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5419,"PHASE4":5428,"NA":5430},{"trials":5414,"activeCount":103},[],{"trials":5416,"activeCount":103},[],{"trials":5418,"activeCount":103},[],{"trials":5420,"activeCount":302,"soonestReadout":57},[5421],{"nctId":55,"briefTitle":56,"status":381,"phases":5422,"primaryCompletion":57,"completion":5423,"start":5424,"enrollment":5425,"conditions":5426,"interventions":5427},[93],"2031-02-25","2019-07-29",51,[3552],[58],{"trials":5429,"activeCount":103},[],{"trials":5431,"activeCount":103},[],{"intervention":5433,"totalTrials":302,"cells":5434},"PF-07275315 dose 1",{"EARLY_PHASE1":5435,"PHASE1":5437,"PHASE2":5439,"PHASE3":5441,"PHASE4":5456,"NA":5458},{"trials":5436,"activeCount":103},[],{"trials":5438,"activeCount":103},[],{"trials":5440,"activeCount":103},[],{"trials":5442,"activeCount":302,"soonestReadout":5447},[5443],{"nctId":5444,"briefTitle":5445,"status":126,"phases":5446,"primaryCompletion":5447,"completion":5448,"start":5449,"enrollment":5450,"conditions":5451,"interventions":5453},"NCT07363694","A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease",[92,93],"2030-10-24","2031-01-16","2026-02-11",1156,[5452],"Moderate to Severe Chronic Obstructive Pulmonary Disease",[5433,5454,5455],"PF-07275315-dose 2","PF-07275315-dose 3",{"trials":5457,"activeCount":103},[],{"trials":5459,"activeCount":103},[],{"intervention":5454,"totalTrials":302,"cells":5461},{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5468,"PHASE4":5474,"NA":5476},{"trials":5463,"activeCount":103},[],{"trials":5465,"activeCount":103},[],{"trials":5467,"activeCount":103},[],{"trials":5469,"activeCount":302,"soonestReadout":5447},[5470],{"nctId":5444,"briefTitle":5445,"status":126,"phases":5471,"primaryCompletion":5447,"completion":5448,"start":5449,"enrollment":5450,"conditions":5472,"interventions":5473},[92,93],[5452],[5433,5454,5455],{"trials":5475,"activeCount":103},[],{"trials":5477,"activeCount":103},[],{"intervention":5455,"totalTrials":302,"cells":5479},{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5486,"PHASE4":5492,"NA":5494},{"trials":5481,"activeCount":103},[],{"trials":5483,"activeCount":103},[],{"trials":5485,"activeCount":103},[],{"trials":5487,"activeCount":302,"soonestReadout":5447},[5488],{"nctId":5444,"briefTitle":5445,"status":126,"phases":5489,"primaryCompletion":5447,"completion":5448,"start":5449,"enrollment":5450,"conditions":5490,"interventions":5491},[92,93],[5452],[5433,5454,5455],{"trials":5493,"activeCount":103},[],{"trials":5495,"activeCount":103},[],{"intervention":3870,"totalTrials":302,"cells":5497},{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5502,"PHASE3":5504,"PHASE4":5510,"NA":5512},{"trials":5499,"activeCount":103},[],{"trials":5501,"activeCount":103},[],{"trials":5503,"activeCount":103},[],{"trials":5505,"activeCount":302,"soonestReadout":3864},[5506],{"nctId":3861,"briefTitle":3862,"status":381,"phases":5507,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":5508,"interventions":5509},[93],[3868,410,1653,905,750],[663,3870,3871,3842,933,3872,2916,3873],{"trials":5511,"activeCount":103},[],{"trials":5513,"activeCount":103},[],{"intervention":3872,"totalTrials":302,"cells":5515},{"EARLY_PHASE1":5516,"PHASE1":5518,"PHASE2":5520,"PHASE3":5522,"PHASE4":5528,"NA":5530},{"trials":5517,"activeCount":103},[],{"trials":5519,"activeCount":103},[],{"trials":5521,"activeCount":103},[],{"trials":5523,"activeCount":302,"soonestReadout":3864},[5524],{"nctId":3861,"briefTitle":3862,"status":381,"phases":5525,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":5526,"interventions":5527},[93],[3868,410,1653,905,750],[663,3870,3871,3842,933,3872,2916,3873],{"trials":5529,"activeCount":103},[],{"trials":5531,"activeCount":103},[],{"intervention":3873,"totalTrials":302,"cells":5533},{"EARLY_PHASE1":5534,"PHASE1":5536,"PHASE2":5538,"PHASE3":5540,"PHASE4":5546,"NA":5548},{"trials":5535,"activeCount":103},[],{"trials":5537,"activeCount":103},[],{"trials":5539,"activeCount":103},[],{"trials":5541,"activeCount":302,"soonestReadout":3864},[5542],{"nctId":3861,"briefTitle":3862,"status":381,"phases":5543,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":5544,"interventions":5545},[93],[3868,410,1653,905,750],[663,3870,3871,3842,933,3872,2916,3873],{"trials":5547,"activeCount":103},[],{"trials":5549,"activeCount":103},[],{"intervention":3928,"totalTrials":302,"cells":5551},{"EARLY_PHASE1":5552,"PHASE1":5554,"PHASE2":5556,"PHASE3":5558,"PHASE4":5564,"NA":5566},{"trials":5553,"activeCount":103},[],{"trials":5555,"activeCount":103},[],{"trials":5557,"activeCount":103},[],{"trials":5559,"activeCount":302,"soonestReadout":3922},[5560],{"nctId":3919,"briefTitle":3920,"status":126,"phases":5561,"primaryCompletion":3922,"completion":3923,"start":3924,"enrollment":1613,"conditions":5562,"interventions":5563},[93],[3926],[3879,3928],{"trials":5565,"activeCount":103},[],{"trials":5567,"activeCount":103},[],{"intervention":2055,"totalTrials":302,"cells":5569},{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5574,"PHASE3":5576,"PHASE4":5582,"NA":5584},{"trials":5571,"activeCount":103},[],{"trials":5573,"activeCount":103},[],{"trials":5575,"activeCount":103},[],{"trials":5577,"activeCount":302,"soonestReadout":2048},[5578],{"nctId":2045,"briefTitle":2046,"status":381,"phases":5579,"primaryCompletion":2048,"completion":2049,"start":2050,"enrollment":2051,"conditions":5580,"interventions":5581},[93],[2053],[1812,1304,1767,1335,1768,2055,2056,1030],{"trials":5583,"activeCount":103},[],{"trials":5585,"activeCount":103},[],{"intervention":53,"totalTrials":302,"cells":5587},{"EARLY_PHASE1":5588,"PHASE1":5590,"PHASE2":5592,"PHASE3":5594,"PHASE4":5604,"NA":5606},{"trials":5589,"activeCount":103},[],{"trials":5591,"activeCount":103},[],{"trials":5593,"activeCount":103},[],{"trials":5595,"activeCount":302,"soonestReadout":52},[5596],{"nctId":50,"briefTitle":51,"status":381,"phases":5597,"primaryCompletion":52,"completion":5598,"start":5599,"enrollment":5600,"conditions":5601,"interventions":5603},[93],"2027-06-30","2017-12-18",1054,[5602],"mCRPC",[53],{"trials":5605,"activeCount":103},[],{"trials":5607,"activeCount":103},[],{"intervention":5609,"totalTrials":302,"cells":5610},"talazoparib plus enzalutamide",{"EARLY_PHASE1":5611,"PHASE1":5613,"PHASE2":5615,"PHASE3":5617,"PHASE4":5629,"NA":5631},{"trials":5612,"activeCount":103},[],{"trials":5614,"activeCount":103},[],{"trials":5616,"activeCount":103},[],{"trials":5618,"activeCount":302,"soonestReadout":5623},[5619],{"nctId":5620,"briefTitle":5621,"status":381,"phases":5622,"primaryCompletion":5623,"completion":5624,"start":5625,"enrollment":5626,"conditions":5627,"interventions":5628},"NCT04821622","Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC",[93],"2026-02-18","2027-08-28","2021-05-12",599,[1684],[5609],{"trials":5630,"activeCount":103},[],{"trials":5632,"activeCount":103},[],{"intervention":83,"totalTrials":302,"cells":5634},{"EARLY_PHASE1":5635,"PHASE1":5637,"PHASE2":5639,"PHASE3":5641,"PHASE4":5650,"NA":5652},{"trials":5636,"activeCount":103},[],{"trials":5638,"activeCount":103},[],{"trials":5640,"activeCount":103},[],{"trials":5642,"activeCount":302,"soonestReadout":82},[5643],{"nctId":80,"briefTitle":81,"status":381,"phases":5644,"primaryCompletion":82,"completion":5645,"start":5646,"enrollment":5647,"conditions":5648,"interventions":5649},[93],"2026-10-25","2020-08-18",77,[3551],[83],{"trials":5651,"activeCount":103},[],{"trials":5653,"activeCount":103},[],{"intervention":2307,"totalTrials":302,"cells":5655},{"EARLY_PHASE1":5656,"PHASE1":5658,"PHASE2":5660,"PHASE3":5662,"PHASE4":5668,"NA":5670},{"trials":5657,"activeCount":103},[],{"trials":5659,"activeCount":103},[],{"trials":5661,"activeCount":103},[],{"trials":5663,"activeCount":302,"soonestReadout":2301},[5664],{"nctId":2298,"briefTitle":2299,"status":126,"phases":5665,"primaryCompletion":2301,"completion":479,"start":2302,"enrollment":2303,"conditions":5666,"interventions":5667},[93],[2305],[2307,63],{"trials":5669,"activeCount":103},[],{"trials":5671,"activeCount":103},[],{"intervention":5673,"totalTrials":302,"cells":5674},"Ritlecitinib higher dose",{"EARLY_PHASE1":5675,"PHASE1":5677,"PHASE2":5679,"PHASE3":5681,"PHASE4":5694,"NA":5696},{"trials":5676,"activeCount":103},[],{"trials":5678,"activeCount":103},[],{"trials":5680,"activeCount":103},[],{"trials":5682,"activeCount":302,"soonestReadout":5687},[5683],{"nctId":5684,"briefTitle":5685,"status":126,"phases":5686,"primaryCompletion":5687,"completion":5688,"start":5689,"enrollment":5690,"conditions":5691,"interventions":5692},"NCT07029711","A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata",[93],"2027-04-20","2027-05-18","2025-07-31",225,[3464],[5673,5693],"Ritlecitinib lower dose",{"trials":5695,"activeCount":103},[],{"trials":5697,"activeCount":103},[],{"intervention":5693,"totalTrials":302,"cells":5699},{"EARLY_PHASE1":5700,"PHASE1":5702,"PHASE2":5704,"PHASE3":5706,"PHASE4":5712,"NA":5714},{"trials":5701,"activeCount":103},[],{"trials":5703,"activeCount":103},[],{"trials":5705,"activeCount":103},[],{"trials":5707,"activeCount":302,"soonestReadout":5687},[5708],{"nctId":5684,"briefTitle":5685,"status":126,"phases":5709,"primaryCompletion":5687,"completion":5688,"start":5689,"enrollment":5690,"conditions":5710,"interventions":5711},[93],[3464],[5673,5693],{"trials":5713,"activeCount":103},[],{"trials":5715,"activeCount":103},[],{"intervention":1842,"totalTrials":302,"cells":5717},{"EARLY_PHASE1":5718,"PHASE1":5720,"PHASE2":5722,"PHASE3":5724,"PHASE4":5730,"NA":5732},{"trials":5719,"activeCount":103},[],{"trials":5721,"activeCount":103},[],{"trials":5723,"activeCount":103},[],{"trials":5725,"activeCount":302,"soonestReadout":901},[5726],{"nctId":1834,"briefTitle":1835,"status":126,"phases":5727,"primaryCompletion":901,"completion":1837,"start":1838,"enrollment":1839,"conditions":5728,"interventions":5729},[93],[422,376,947],[1842,631],{"trials":5731,"activeCount":103},[],{"trials":5733,"activeCount":103},[],{"intervention":2327,"totalTrials":302,"cells":5735},{"EARLY_PHASE1":5736,"PHASE1":5738,"PHASE2":5740,"PHASE3":5742,"PHASE4":5748,"NA":5750},{"trials":5737,"activeCount":103},[],{"trials":5739,"activeCount":103},[],{"trials":5741,"activeCount":103},[],{"trials":5743,"activeCount":302,"soonestReadout":2320},[5744],{"nctId":2317,"briefTitle":2318,"status":126,"phases":5745,"primaryCompletion":2320,"completion":2321,"start":2322,"enrollment":2323,"conditions":5746,"interventions":5747},[93],[2325,2273,1684,2274],[2327,63],{"trials":5749,"activeCount":103},[],{"trials":5751,"activeCount":103},[],{"intervention":663,"totalTrials":314,"cells":5753},{"EARLY_PHASE1":5754,"PHASE1":5756,"PHASE2":5772,"PHASE3":5801,"PHASE4":5837,"NA":5839},{"trials":5755,"activeCount":103},[],{"trials":5757,"activeCount":103},[5758,5762],{"nctId":4194,"briefTitle":4195,"status":111,"phases":5759,"primaryCompletion":4197,"completion":1411,"start":4198,"enrollment":2631,"conditions":5760,"interventions":5761},[91],[4200],[663,933],{"nctId":5763,"briefTitle":5764,"status":168,"phases":5765,"primaryCompletion":5766,"completion":5767,"start":5768,"enrollment":3229,"conditions":5769,"interventions":5771},"NCT02603419","Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)",[91],"2018-12-01","2019-04-11","2016-03-10",[5770],"Hodgkins Lymphoma",[663,663,663,663,663,663],{"trials":5773,"activeCount":103},[5774,5778,5789,5793,5797],{"nctId":656,"briefTitle":657,"status":168,"phases":5775,"primaryCompletion":150,"completion":659,"start":660,"enrollment":32,"conditions":5776,"interventions":5777},[91,92],[422],[663,664,388],{"nctId":5779,"briefTitle":5780,"status":168,"phases":5781,"primaryCompletion":3683,"completion":5782,"start":5783,"enrollment":5784,"conditions":5785,"interventions":5788},"NCT03565991","Javelin BRCA\u002FATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors",[92],"2023-02-03","2018-06-18",202,[5786,5787],"Locally Advanced or Metastatic Solid Tumors","Genes, BRCA 1",[663,3871],{"nctId":4773,"briefTitle":4774,"status":168,"phases":5790,"primaryCompletion":4776,"completion":150,"start":4447,"enrollment":1530,"conditions":5791,"interventions":5792},[91,92],[4778],[663,1832,3871],{"nctId":5211,"briefTitle":5212,"status":168,"phases":5794,"primaryCompletion":5214,"completion":5214,"start":5215,"enrollment":5216,"conditions":5795,"interventions":5796},[91,92],[543],[663,2916,5219,5220,5221],{"nctId":4294,"briefTitle":4295,"status":168,"phases":5798,"primaryCompletion":2836,"completion":2836,"start":4297,"enrollment":2400,"conditions":5799,"interventions":5800},[92],[422,905],[663,933],{"trials":5802,"activeCount":302,"soonestReadout":3864},[5803,5814,5825,5829,5833],{"nctId":5804,"briefTitle":5805,"status":111,"phases":5806,"primaryCompletion":5807,"completion":5808,"start":5809,"enrollment":5810,"conditions":5811,"interventions":5812},"NCT02580058","A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant\u002FRefractory Ovarian Cancer (JAVELIN Ovarian 200)",[93],"2018-09-19","2022-07-12","2015-12-21",566,[1653],[4372,5813],"PLD",{"nctId":5815,"briefTitle":5816,"status":168,"phases":5817,"primaryCompletion":5818,"completion":5819,"start":5820,"enrollment":5821,"conditions":5822,"interventions":5824},"NCT02952586","Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)",[93],"2019-12-23","2020-08-25","2016-11-28",697,[5823],"Squamous Cell Carcinoma of the Head and Neck",[663],{"nctId":3861,"briefTitle":3862,"status":381,"phases":5826,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":5827,"interventions":5828},[93],[3868,410,1653,905,750],[663,3870,3871,3842,933,3872,2916,3873],{"nctId":2908,"briefTitle":2909,"status":168,"phases":5830,"primaryCompletion":2911,"completion":2911,"start":2912,"enrollment":350,"conditions":5831,"interventions":5832},[93],[2914],[663,2916,2917,2918,1764,1767],{"nctId":4318,"briefTitle":4319,"status":111,"phases":5834,"primaryCompletion":4321,"completion":4322,"start":4323,"enrollment":4324,"conditions":5835,"interventions":5836},[93],[4200],[663,933,4327],{"trials":5838,"activeCount":103},[],{"trials":5840,"activeCount":103},[5841,5849,5858,5862],{"nctId":5842,"briefTitle":5843,"status":168,"phases":5844,"primaryCompletion":5845,"completion":5845,"start":1586,"enrollment":99,"conditions":5846,"interventions":5848},"NCT05568407","A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer",[],"2023-06-16",[5847],"Bladder Cancer",[663],{"nctId":5850,"briefTitle":5851,"status":111,"phases":5852,"primaryCompletion":5853,"completion":5853,"start":5854,"enrollment":5855,"conditions":5856,"interventions":5857},"NCT04822350","A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA",[],"2024-04-25","2021-07-13",596,[907],[663],{"nctId":4364,"briefTitle":4365,"status":111,"phases":5859,"primaryCompletion":4367,"completion":4367,"start":4368,"enrollment":4369,"conditions":5860,"interventions":5861},[],[1859],[4372,555],{"nctId":1852,"briefTitle":1853,"status":111,"phases":5863,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":1857,"conditions":5864,"interventions":5865},[],[1859],[933,663,631],{"intervention":3871,"totalTrials":498,"cells":5867},{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5913,"PHASE3":5960,"PHASE4":5977,"NA":5979},{"trials":5869,"activeCount":103},[],{"trials":5871,"activeCount":103},[5872,5880,5888,5895,5903],{"nctId":5873,"briefTitle":5874,"status":111,"phases":5875,"primaryCompletion":5876,"completion":5876,"start":5877,"enrollment":3229,"conditions":5878,"interventions":5879},"NCT02997163","An Open-Label Pharmacokinetics and Safety Study of Talazoparib",[91],"2019-01-30","2017-02-21",[553],[3871],{"nctId":5881,"briefTitle":5882,"status":111,"phases":5883,"primaryCompletion":5884,"completion":5885,"start":2037,"enrollment":1796,"conditions":5886,"interventions":5887},"NCT03042910","A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors",[91],"2017-05-30","2017-06-22",[338],[3871],{"nctId":5889,"briefTitle":5890,"status":111,"phases":5891,"primaryCompletion":5892,"completion":5892,"start":2313,"enrollment":2070,"conditions":5893,"interventions":5894},"NCT03070548","A Study of Talazoparib in Patients With Advanced Solid Tumors",[91],"2017-06",[553],[3871],{"nctId":5896,"briefTitle":5897,"status":111,"phases":5898,"primaryCompletion":5899,"completion":5899,"start":5900,"enrollment":1796,"conditions":5901,"interventions":5902},"NCT02997176","An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)",[91],"2020-02-12","2016-09-30",[553],[3871],{"nctId":5904,"briefTitle":5905,"status":111,"phases":5906,"primaryCompletion":5907,"completion":2933,"start":5908,"enrollment":5909,"conditions":5910,"interventions":5911},"NCT03343054","A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors",[91],"2021-01-11","2017-11-30",28,[2053,25],[5912],"talazoparib",{"trials":5914,"activeCount":103},[5915,5924,5935,5939,5943,5952],{"nctId":5916,"briefTitle":5917,"status":168,"phases":5918,"primaryCompletion":1681,"completion":1681,"start":5919,"enrollment":2400,"conditions":5920,"interventions":5922},"NCT03499353","Talazoparib For Neoadjuvant Treatment Of Germline BRCA1\u002F2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer",[92],"2018-08-27",[5921],"Early Breast Cancer",[5923],"TALAZOPARIB",{"nctId":5925,"briefTitle":5926,"status":168,"phases":5927,"primaryCompletion":5928,"completion":5929,"start":5930,"enrollment":4637,"conditions":5931,"interventions":5934},"NCT02034916","A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and\u002For Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)",[92],"2016-09-01","2018-10-31","2013-12-13",[25,5932,5933],"BRCA 1 Gene Mutation","BRCA 2 Gene Mutation",[5912],{"nctId":5779,"briefTitle":5780,"status":168,"phases":5936,"primaryCompletion":3683,"completion":5782,"start":5783,"enrollment":5784,"conditions":5937,"interventions":5938},[92],[5786,5787],[663,3871],{"nctId":4773,"briefTitle":4774,"status":168,"phases":5940,"primaryCompletion":4776,"completion":150,"start":4447,"enrollment":1530,"conditions":5941,"interventions":5942},[91,92],[4778],[663,1832,3871],{"nctId":5944,"briefTitle":5945,"status":111,"phases":5946,"primaryCompletion":5947,"completion":5947,"start":5948,"enrollment":941,"conditions":5949,"interventions":5951},"NCT02921919","Open-Label Extension and Safety Study of Talazoparib",[92],"2021-07-20","2016-11-08",[5950],"Cancer",[3871],{"nctId":5953,"briefTitle":5954,"status":649,"phases":5955,"primaryCompletion":5956,"start":5957,"enrollment":103,"conditions":5958,"interventions":5959},"NCT02836028","A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer",[92],"2020-06","2016-10",[1653],[3871,1334],{"trials":5961,"activeCount":302,"soonestReadout":3864},[5962,5966],{"nctId":3861,"briefTitle":3862,"status":381,"phases":5963,"primaryCompletion":3864,"completion":3864,"start":3865,"enrollment":3866,"conditions":5964,"interventions":5965},[93],[3868,410,1653,905,750],[663,3870,3871,3842,933,3872,2916,3873],{"nctId":5967,"briefTitle":5968,"status":111,"phases":5969,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":5973,"conditions":5974,"interventions":5975},"NCT01945775","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and\u002For Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",[93],"2017-09-15","2021-03-05","2013-10-14",431,[25,5932,5933],[5912,5976],"Physician's-Choice",{"trials":5978,"activeCount":103},[],{"trials":5980,"activeCount":103},[5981,5990],{"nctId":5982,"briefTitle":5983,"status":111,"phases":5984,"primaryCompletion":5985,"completion":5985,"start":5986,"enrollment":5987,"conditions":5988,"interventions":5989},"NCT05141708","Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1\u002F2m",[],"2022-06-30","2021-12-17",33,[1369,25],[3871],{"nctId":5991,"briefTitle":5992,"status":111,"phases":5993,"primaryCompletion":5994,"completion":5994,"start":5995,"enrollment":4637,"conditions":5996,"interventions":5997},"NCT04987931","Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer",[],"2021-10-11","2021-08-20",[31],[3871],{"intervention":144,"totalTrials":2070,"cells":5999},{"EARLY_PHASE1":6000,"PHASE1":6002,"PHASE2":6004,"PHASE3":6006,"PHASE4":6023,"NA":6025},{"trials":6001,"activeCount":103},[],{"trials":6003,"activeCount":103},[],{"trials":6005,"activeCount":103},[],{"trials":6007,"activeCount":302,"soonestReadout":137},[6008,6012],{"nctId":134,"briefTitle":135,"status":126,"phases":6009,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":6010,"interventions":6011},[93],[142],[98,144,98],{"nctId":6013,"briefTitle":6014,"status":111,"phases":6015,"primaryCompletion":6016,"completion":3313,"start":6017,"enrollment":6018,"conditions":6019,"interventions":6021},"NCT00605280","A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.",[92,93],"2009-11","2005-09",317,[6020],"Macular Edema Associated With Diabetes Mellitus",[144,6022],"Macugen",{"trials":6024,"activeCount":103},[],{"trials":6026,"activeCount":103},[6027,6031,6035,6039],{"nctId":1178,"briefTitle":1179,"status":111,"phases":6028,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":1183,"conditions":6029,"interventions":6030},[],[1062],[48,144],{"nctId":1187,"briefTitle":1188,"status":111,"phases":6032,"primaryCompletion":1190,"completion":1190,"start":52,"enrollment":1191,"conditions":6033,"interventions":6034},[],[1062],[48,1194],{"nctId":1196,"briefTitle":1197,"status":111,"phases":6036,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":6037,"interventions":6038},[],[1062],[48,1194],{"nctId":1220,"briefTitle":1221,"status":111,"phases":6040,"primaryCompletion":1223,"completion":1223,"start":87,"enrollment":257,"conditions":6041,"interventions":6042},[],[1062],[48,1194],{"intervention":439,"totalTrials":257,"cells":6044},{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6049,"PHASE3":6059,"PHASE4":6065,"NA":6067},{"trials":6046,"activeCount":103},[],{"trials":6048,"activeCount":103},[],{"trials":6050,"activeCount":103},[6051,6055],{"nctId":4749,"briefTitle":4750,"status":111,"phases":6052,"primaryCompletion":4752,"completion":4753,"start":4754,"enrollment":4755,"conditions":6053,"interventions":6054},[92],[4757,4758],[341,439,1800],{"nctId":1791,"briefTitle":1792,"status":168,"phases":6056,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":6057,"interventions":6058},[92],[1798],[343,341,438,1800,439],{"trials":6060,"activeCount":302,"soonestReadout":987},[6061],{"nctId":984,"briefTitle":985,"status":126,"phases":6062,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":6063,"interventions":6064},[92,93],[992,993,994,995],[869,968,997],{"trials":6066,"activeCount":103},[],{"trials":6068,"activeCount":103},[6069],{"nctId":415,"briefTitle":416,"status":111,"phases":6070,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":6071,"interventions":6072},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":428,"totalTrials":1087,"cells":6074},{"EARLY_PHASE1":6075,"PHASE1":6077,"PHASE2":6079,"PHASE3":6081,"PHASE4":6087,"NA":6089},{"trials":6076,"activeCount":103},[],{"trials":6078,"activeCount":103},[],{"trials":6080,"activeCount":103},[],{"trials":6082,"activeCount":302,"soonestReadout":1035},[6083],{"nctId":1032,"briefTitle":1033,"status":126,"phases":6084,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":6085,"interventions":6086},[92,93],[1040],[869,1042,968],{"trials":6088,"activeCount":103},[],{"trials":6090,"activeCount":103},[6091],{"nctId":415,"briefTitle":416,"status":111,"phases":6092,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":6093,"interventions":6094},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":1687,"totalTrials":1239,"cells":6096},{"EARLY_PHASE1":6097,"PHASE1":6099,"PHASE2":6306,"PHASE3":6312,"PHASE4":6314,"NA":6324},{"trials":6098,"activeCount":103},[],{"trials":6100,"activeCount":502,"soonestReadout":6233},[6101,6112,6121,6130,6139,6148,6157,6172,6176,6185,6194,6203,6213,6217,6225,6229,6239,6251,6259,6266,6275,6284,6292,6296],{"nctId":6102,"briefTitle":6103,"status":111,"phases":6104,"primaryCompletion":6105,"completion":6105,"start":6106,"enrollment":6107,"conditions":6108,"interventions":6109},"NCT05580003","A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People",[91],"2023-09-15","2022-10-17",94,[16],[6110,1687,6111],"PF-07817883","Moxifloxacin",{"nctId":6113,"briefTitle":6114,"status":111,"phases":6115,"primaryCompletion":3345,"completion":3345,"start":3353,"enrollment":1268,"conditions":6116,"interventions":6119},"NCT01757756","Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects",[91],[6117,37,6118],"Diabetes Mellitus","Glucose Metabolism Disorders",[6120,1989],"Pf-05175157",{"nctId":6122,"briefTitle":6123,"status":111,"phases":6124,"primaryCompletion":6125,"completion":6125,"start":6126,"enrollment":1268,"conditions":6127,"interventions":6128},"NCT03126721","The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults",[91],"2017-07-11","2017-04-18",[16],[1989,6129],"PF-06751979",{"nctId":6131,"briefTitle":6132,"status":111,"phases":6133,"primaryCompletion":6134,"completion":6134,"start":6135,"enrollment":870,"conditions":6136,"interventions":6137},"NCT03916406","THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS",[91],"2019-06-25","2019-04-18",[1270],[6138,1687],"PF 06835919",{"nctId":6140,"briefTitle":6141,"status":126,"phases":6142,"primaryCompletion":6143,"completion":6144,"start":960,"enrollment":941,"conditions":6145,"interventions":6146},"NCT07426757","An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers",[91],"2029-07-10","2030-07-10",[3868,543],[6147,1687],"PF-07994525",{"nctId":6149,"briefTitle":6150,"status":111,"phases":6151,"primaryCompletion":5957,"completion":5957,"start":4458,"enrollment":6152,"conditions":6153,"interventions":6155},"NCT02440100","A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects",[91],92,[6154],"Healthy Adult Subjects and Healthy Elderly Subjects",[6156,1687],"PF-06648671",{"nctId":6158,"briefTitle":6159,"status":111,"phases":6160,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":6163,"interventions":6164},"NCT05981365","Voxelotor CYP and Transporter Cocktail Interaction Study",[91],"2023-10-04","2023-04-17",[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],"Voxelotor","Bupropion","Repaglinide","Flurbiprofen","Omeprazole","Metformin","Furosemide",{"nctId":2102,"briefTitle":2103,"status":111,"phases":6173,"primaryCompletion":2105,"completion":2106,"start":1157,"enrollment":498,"conditions":6174,"interventions":6175},[91],[28],[1687,1359],{"nctId":6177,"briefTitle":6178,"status":111,"phases":6179,"primaryCompletion":6180,"completion":6180,"start":6181,"enrollment":941,"conditions":6182,"interventions":6183},"NCT05113940","A Study of PF-07258669 In Healthy Adult Participants",[91],"2023-07-27","2021-11-08",[28],[6184,1687],"PF-07258669",{"nctId":6186,"briefTitle":6187,"status":111,"phases":6188,"primaryCompletion":6189,"completion":6189,"start":4933,"enrollment":26,"conditions":6190,"interventions":6192},"NCT06033612","Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults",[91],"2022-07-27",[6191],"Respiratory Syncytial Virus Infections",[6193,1687],"RV299",{"nctId":6195,"briefTitle":6196,"status":111,"phases":6197,"primaryCompletion":6198,"completion":6198,"start":3353,"enrollment":6199,"conditions":6200,"interventions":6201},"NCT01707082","A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults",[91],"2013-05",69,[16],[6202,6202,6202,6202,6202,1989,6202,1989,6202],"PF-06282999",{"nctId":6204,"briefTitle":6205,"status":111,"phases":6206,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":498,"conditions":6209,"interventions":6211},"NCT01807377","Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects",[91],"2013-08","2013-04",[6210],"Diabetes Mellitus Type 2",[6212,1687,1687],"PF-05175157",{"nctId":3197,"briefTitle":3198,"status":111,"phases":6214,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":6215,"interventions":6216},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"nctId":6218,"briefTitle":6219,"status":111,"phases":6220,"primaryCompletion":6221,"completion":6221,"start":1441,"enrollment":314,"conditions":6222,"interventions":6223},"NCT04621227","Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity",[91],"2021-05-13",[2761],[6224,2841,1687],"PF-06882961",{"nctId":4721,"briefTitle":4722,"status":168,"phases":6226,"primaryCompletion":4724,"completion":4724,"start":4725,"enrollment":4726,"conditions":6227,"interventions":6228},[91],[4728,376,4729,4730,4731],[4733,1832,1687],{"nctId":6230,"briefTitle":6231,"status":381,"phases":6232,"primaryCompletion":6233,"completion":6233,"start":3239,"enrollment":314,"conditions":6234,"interventions":6235},"NCT07190430","A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants",[91],"2025-12-15",[1589],[6236,1687,6237,6238],"PF-08049820","Dabigatran Etexilate","Portia (EE and LN) or equivalent oral",{"nctId":6240,"briefTitle":6241,"status":111,"phases":6242,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":6245,"conditions":6246,"interventions":6247},"NCT03782662","A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants",[91],"2019-03-17","2018-11-07",82,[6191],[2082,6248,6249,1687,6250],"Verapamil","Rifampicin","RV521",{"nctId":6252,"briefTitle":6253,"status":111,"phases":6254,"primaryCompletion":6255,"completion":6255,"start":1082,"enrollment":26,"conditions":6256,"interventions":6257},"NCT06279234","A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus",[91],"2025-04-11",[3020,2761],[2841,1687,6169,6258],"PF-06954522",{"nctId":6260,"briefTitle":6261,"status":111,"phases":6262,"primaryCompletion":6263,"completion":6263,"start":6198,"enrollment":1239,"conditions":6264,"interventions":6265},"NCT01756781","A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.",[91],"2013-07",[16],[1687,2403,1687,2403],{"nctId":6267,"briefTitle":6268,"status":111,"phases":6269,"primaryCompletion":6270,"completion":6270,"start":6271,"enrollment":2713,"conditions":6272,"interventions":6273},"NCT06920498","A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.",[91],"2025-06-19","2024-12-03",[28],[6274,1687],"PF-07941944",{"nctId":6276,"briefTitle":6277,"status":111,"phases":6278,"primaryCompletion":6279,"completion":6279,"start":3797,"enrollment":6280,"conditions":6281,"interventions":6282},"NCT06106009","A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults",[91],"2024-08-19",117,[16],[6283,1687],"PF-07976016",{"nctId":6285,"briefTitle":6286,"status":111,"phases":6287,"primaryCompletion":6288,"completion":6288,"start":2523,"enrollment":541,"conditions":6289,"interventions":6290},"NCT06177457","A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants",[91],"2024-12-02",[28],[6291,1687],"PF-07293893",{"nctId":1977,"briefTitle":1978,"status":126,"phases":6293,"primaryCompletion":1980,"completion":1981,"start":786,"enrollment":1982,"conditions":6294,"interventions":6295},[91],[1798,409,1984,1985,1986],[1988,341,342,1989,1990,1991,1992],{"nctId":6297,"briefTitle":6298,"status":111,"phases":6299,"primaryCompletion":6300,"completion":6300,"start":6301,"enrollment":2713,"conditions":6302,"interventions":6304},"NCT03647670","A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers",[91],"2018-10-16","2018-07-03",[6303],"Phase 1",[6305,1687],"PF-04965842",{"trials":6307,"activeCount":302,"soonestReadout":1679},[6308],{"nctId":1676,"briefTitle":1677,"status":381,"phases":6309,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":6310,"interventions":6311},[92],[1654,1684,25,1685],[1320,1243,1305,1687,63],{"trials":6313,"activeCount":103},[],{"trials":6315,"activeCount":103},[6316],{"nctId":6317,"briefTitle":6318,"status":111,"phases":6319,"primaryCompletion":561,"completion":561,"start":577,"enrollment":5909,"conditions":6320,"interventions":6322},"NCT00952653","Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam",[94],[6321],"Major Depressive Disorder",[6323,1687],"Desvenlafaxine Succinate Sustained Release",{"trials":6325,"activeCount":103},[],{"intervention":6236,"totalTrials":502,"cells":6327},{"EARLY_PHASE1":6328,"PHASE1":6330,"PHASE2":6344,"PHASE3":6355,"PHASE4":6357,"NA":6359},{"trials":6329,"activeCount":103},[],{"trials":6331,"activeCount":1087,"soonestReadout":6233},[6332,6340],{"nctId":6333,"briefTitle":6334,"status":381,"phases":6335,"primaryCompletion":6336,"completion":6336,"start":6337,"enrollment":2137,"conditions":6338,"interventions":6339},"NCT06686797","A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults",[91],"2026-02-23","2024-11-27",[16],[6236],{"nctId":6230,"briefTitle":6231,"status":381,"phases":6341,"primaryCompletion":6233,"completion":6233,"start":3239,"enrollment":314,"conditions":6342,"interventions":6343},[91],[1589],[6236,1687,6237,6238],{"trials":6345,"activeCount":302,"soonestReadout":6350},[6346],{"nctId":6347,"briefTitle":6348,"status":126,"phases":6349,"primaryCompletion":6350,"completion":6350,"start":6351,"enrollment":6352,"conditions":6353,"interventions":6354},"NCT07216027","A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema",[92],"2028-02-02","2025-11-20",165,[1589,1592],[6236],{"trials":6356,"activeCount":103},[],{"trials":6358,"activeCount":103},[],{"trials":6360,"activeCount":103},[],{"intervention":895,"totalTrials":257,"cells":6362},{"EARLY_PHASE1":6363,"PHASE1":6365,"PHASE2":6367,"PHASE3":6385,"PHASE4":6387,"NA":6389},{"trials":6364,"activeCount":103},[],{"trials":6366,"activeCount":103},[],{"trials":6368,"activeCount":1087,"soonestReadout":882},[6369,6373,6377,6381],{"nctId":879,"briefTitle":880,"status":126,"phases":6370,"primaryCompletion":882,"completion":883,"start":884,"enrollment":885,"conditions":6371,"interventions":6372},[91,92],[887,888,889,890,891,892,893],[869,895],{"nctId":4749,"briefTitle":4750,"status":111,"phases":6374,"primaryCompletion":4752,"completion":4753,"start":4754,"enrollment":4755,"conditions":6375,"interventions":6376},[92],[4757,4758],[341,439,1800],{"nctId":1791,"briefTitle":1792,"status":168,"phases":6378,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":6379,"interventions":6380},[92],[1798],[343,341,438,1800,439],{"nctId":911,"briefTitle":912,"status":126,"phases":6382,"primaryCompletion":914,"completion":915,"start":916,"enrollment":917,"conditions":6383,"interventions":6384},[91,92],[919,920,921,922,923,924,925,926,927,928,929,930,931],[869,895,933],{"trials":6386,"activeCount":103},[],{"trials":6388,"activeCount":103},[],{"trials":6390,"activeCount":103},[],{"intervention":73,"totalTrials":502,"cells":6392},{"EARLY_PHASE1":6393,"PHASE1":6395,"PHASE2":6405,"PHASE3":6411,"PHASE4":6413,"NA":6415},{"trials":6394,"activeCount":103},[],{"trials":6396,"activeCount":302,"soonestReadout":1111},[6397],{"nctId":6398,"briefTitle":6399,"status":381,"phases":6400,"primaryCompletion":1111,"completion":1111,"start":6401,"enrollment":2713,"conditions":6402,"interventions":6404},"NCT05382364","Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)",[91],"2022-06-29",[4867,25,6403,2022],"Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)",[73],{"trials":6406,"activeCount":302,"soonestReadout":72},[6407],{"nctId":70,"briefTitle":71,"status":381,"phases":6408,"primaryCompletion":72,"completion":445,"start":4824,"enrollment":4825,"conditions":6409,"interventions":6410},[92],[31],[73,4828,2056],{"trials":6412,"activeCount":103},[],{"trials":6414,"activeCount":103},[],{"trials":6416,"activeCount":103},[6417],{"nctId":4861,"briefTitle":4862,"status":111,"phases":6418,"primaryCompletion":4864,"completion":4864,"start":4865,"enrollment":1122,"conditions":6419,"interventions":6420},[],[4867],[73,4828,2056],{"intervention":1334,"totalTrials":578,"cells":6422},{"EARLY_PHASE1":6423,"PHASE1":6425,"PHASE2":6427,"PHASE3":6451,"PHASE4":6465,"NA":6467},{"trials":6424,"activeCount":103},[],{"trials":6426,"activeCount":103},[],{"trials":6428,"activeCount":302,"soonestReadout":87},[6429,6433,6443,6447],{"nctId":3598,"briefTitle":3599,"status":111,"phases":6430,"primaryCompletion":3601,"completion":2883,"start":3602,"enrollment":3603,"conditions":6431,"interventions":6432},[92],[1985,1331],[1335,1334],{"nctId":6434,"briefTitle":6435,"status":111,"phases":6436,"primaryCompletion":4647,"start":6437,"conditions":6438,"interventions":6440},"NCT00004200","Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",[92],"1999-10",[6439],"Brain and Central Nervous System Tumors",[6441,6442],"prinomastat","temozolomide",{"nctId":85,"briefTitle":86,"status":381,"phases":6444,"primaryCompletion":87,"completion":1324,"start":1325,"enrollment":1326,"conditions":6445,"interventions":6446},[92],[1328,750,1329,1330,500,1331,1332],[88,1334,1335,1336,1337],{"nctId":5953,"briefTitle":5954,"status":649,"phases":6448,"primaryCompletion":5956,"start":5957,"enrollment":103,"conditions":6449,"interventions":6450},[92],[1653],[3871,1334],{"trials":6452,"activeCount":103},[6453],{"nctId":6454,"briefTitle":6455,"status":111,"phases":6456,"completion":6457,"start":6458,"enrollment":2250,"conditions":6459,"interventions":6461},"NCT00068952","Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme",[93],"2006-03","2003-08",[6460],"Glioblastoma",[6462,1334,6463,6464],"Edotecarin","Carmustine","Lomustine",{"trials":6466,"activeCount":103},[],{"trials":6468,"activeCount":103},[],{"intervention":6470,"totalTrials":502,"cells":6471},"ATM-AVI",{"EARLY_PHASE1":6472,"PHASE1":6474,"PHASE2":6476,"PHASE3":6488,"PHASE4":6512,"NA":6514},{"trials":6473,"activeCount":103},[],{"trials":6475,"activeCount":103},[],{"trials":6477,"activeCount":302,"soonestReadout":6482},[6478],{"nctId":6479,"briefTitle":6480,"status":126,"phases":6481,"primaryCompletion":6482,"completion":6482,"start":6483,"enrollment":4369,"conditions":6484,"interventions":6486},"NCT05639647","Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections",[92],"2026-08-17","2023-04-18",[6485],"Gram-negative Bacterial Infections",[6470,6487],"BAT",{"trials":6489,"activeCount":103},[6490,6498],{"nctId":6491,"briefTitle":6492,"status":168,"phases":6493,"primaryCompletion":6494,"completion":6494,"start":1577,"enrollment":498,"conditions":6495,"interventions":6497},"NCT03580044","Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria",[93],"2023-01-23",[6496],"Serious Bacterial Infection",[6470,6487],{"nctId":6499,"briefTitle":6500,"status":111,"phases":6501,"primaryCompletion":2079,"completion":2079,"start":6502,"enrollment":6503,"conditions":6504,"interventions":6508},"NCT03329092","A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.",[93],"2018-04-05",422,[6505,6506,6507],"Complicated Intra-abdominal Infection","Hosptial Acquired Pneumonia","Ventilator Associated Pneumonia",[6470,6509,6510,6511],"MTZ","MER","COL",{"trials":6513,"activeCount":103},[],{"trials":6515,"activeCount":103},[],{"intervention":6487,"totalTrials":1087,"cells":6517},{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6528,"PHASE4":6534,"NA":6536},{"trials":6519,"activeCount":103},[],{"trials":6521,"activeCount":103},[],{"trials":6523,"activeCount":302,"soonestReadout":6482},[6524],{"nctId":6479,"briefTitle":6480,"status":126,"phases":6525,"primaryCompletion":6482,"completion":6482,"start":6483,"enrollment":4369,"conditions":6526,"interventions":6527},[92],[6485],[6470,6487],{"trials":6529,"activeCount":103},[6530],{"nctId":6491,"briefTitle":6492,"status":168,"phases":6531,"primaryCompletion":6494,"completion":6494,"start":1577,"enrollment":498,"conditions":6532,"interventions":6533},[93],[6496],[6470,6487],{"trials":6535,"activeCount":103},[],{"trials":6537,"activeCount":103},[],{"intervention":1337,"totalTrials":1087,"cells":6539},{"EARLY_PHASE1":6540,"PHASE1":6542,"PHASE2":6544,"PHASE3":6550,"PHASE4":6556,"NA":6558},{"trials":6541,"activeCount":103},[],{"trials":6543,"activeCount":103},[],{"trials":6545,"activeCount":302,"soonestReadout":87},[6546],{"nctId":85,"briefTitle":86,"status":381,"phases":6547,"primaryCompletion":87,"completion":1324,"start":1325,"enrollment":1326,"conditions":6548,"interventions":6549},[92],[1328,750,1329,1330,500,1331,1332],[88,1334,1335,1336,1337],{"trials":6551,"activeCount":103},[6552],{"nctId":2961,"briefTitle":2962,"status":168,"phases":6553,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":6554,"interventions":6555},[93],[2966],[2968,2969,2969,2970,2971,2972,2973,2974,2975],{"trials":6557,"activeCount":103},[],{"trials":6559,"activeCount":103},[],{"intervention":6561,"totalTrials":502,"cells":6562},"PF-07275315",{"EARLY_PHASE1":6563,"PHASE1":6565,"PHASE2":6580,"PHASE3":6591,"PHASE4":6593,"NA":6595},{"trials":6564,"activeCount":103},[],{"trials":6566,"activeCount":103},[6567,6574],{"nctId":6568,"briefTitle":6569,"status":111,"phases":6570,"primaryCompletion":2106,"completion":2106,"start":6571,"enrollment":4726,"conditions":6572,"interventions":6573},"NCT05411588","A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People",[91],"2022-06-09",[19],[6561],{"nctId":6575,"briefTitle":6576,"status":111,"phases":6577,"primaryCompletion":3924,"completion":3924,"start":1377,"enrollment":3254,"conditions":6578,"interventions":6579},"NCT06675188","A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants",[91],[16],[6561],{"trials":6581,"activeCount":302,"soonestReadout":6586},[6582],{"nctId":6583,"briefTitle":6584,"status":126,"phases":6585,"primaryCompletion":6586,"completion":1132,"start":6587,"enrollment":1402,"conditions":6588,"interventions":6590},"NCT06977581","A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma",[92],"2027-03-08","2025-05-20",[6589],"Asthma",[6561],{"trials":6592,"activeCount":103},[],{"trials":6594,"activeCount":103},[],{"trials":6596,"activeCount":103},[],{"intervention":1672,"totalTrials":302,"cells":6598},{"EARLY_PHASE1":6599,"PHASE1":6601,"PHASE2":6603,"PHASE3":6609,"PHASE4":6611,"NA":6613},{"trials":6600,"activeCount":103},[],{"trials":6602,"activeCount":103},[],{"trials":6604,"activeCount":302,"soonestReadout":1665},[6605],{"nctId":1662,"briefTitle":1663,"status":381,"phases":6606,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":6607,"interventions":6608},[92],[1670],[1672,1305,1673,1674],{"trials":6610,"activeCount":103},[],{"trials":6612,"activeCount":103},[],{"trials":6614,"activeCount":103},[],{"intervention":2528,"totalTrials":302,"cells":6616},{"EARLY_PHASE1":6617,"PHASE1":6619,"PHASE2":6621,"PHASE3":6627,"PHASE4":6629,"NA":6631},{"trials":6618,"activeCount":103},[],{"trials":6620,"activeCount":103},[],{"trials":6622,"activeCount":302,"soonestReadout":2522},[6623],{"nctId":2519,"briefTitle":2520,"status":381,"phases":6624,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":6625,"interventions":6626},[91,92],[2526],[2528,2529,2494,2530,2531,2532],{"trials":6628,"activeCount":103},[],{"trials":6630,"activeCount":103},[],{"trials":6632,"activeCount":103},[],{"intervention":2529,"totalTrials":302,"cells":6634},{"EARLY_PHASE1":6635,"PHASE1":6637,"PHASE2":6639,"PHASE3":6645,"PHASE4":6647,"NA":6649},{"trials":6636,"activeCount":103},[],{"trials":6638,"activeCount":103},[],{"trials":6640,"activeCount":302,"soonestReadout":2522},[6641],{"nctId":2519,"briefTitle":2520,"status":381,"phases":6642,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":6643,"interventions":6644},[91,92],[2526],[2528,2529,2494,2530,2531,2532],{"trials":6646,"activeCount":103},[],{"trials":6648,"activeCount":103},[],{"trials":6650,"activeCount":103},[],{"intervention":2530,"totalTrials":302,"cells":6652},{"EARLY_PHASE1":6653,"PHASE1":6655,"PHASE2":6657,"PHASE3":6663,"PHASE4":6665,"NA":6667},{"trials":6654,"activeCount":103},[],{"trials":6656,"activeCount":103},[],{"trials":6658,"activeCount":302,"soonestReadout":2522},[6659],{"nctId":2519,"briefTitle":2520,"status":381,"phases":6660,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":6661,"interventions":6662},[91,92],[2526],[2528,2529,2494,2530,2531,2532],{"trials":6664,"activeCount":103},[],{"trials":6666,"activeCount":103},[],{"trials":6668,"activeCount":103},[],{"intervention":2531,"totalTrials":302,"cells":6670},{"EARLY_PHASE1":6671,"PHASE1":6673,"PHASE2":6675,"PHASE3":6681,"PHASE4":6683,"NA":6685},{"trials":6672,"activeCount":103},[],{"trials":6674,"activeCount":103},[],{"trials":6676,"activeCount":302,"soonestReadout":2522},[6677],{"nctId":2519,"briefTitle":2520,"status":381,"phases":6678,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":6679,"interventions":6680},[91,92],[2526],[2528,2529,2494,2530,2531,2532],{"trials":6682,"activeCount":103},[],{"trials":6684,"activeCount":103},[],{"trials":6686,"activeCount":103},[],{"intervention":2532,"totalTrials":302,"cells":6688},{"EARLY_PHASE1":6689,"PHASE1":6691,"PHASE2":6693,"PHASE3":6699,"PHASE4":6701,"NA":6703},{"trials":6690,"activeCount":103},[],{"trials":6692,"activeCount":103},[],{"trials":6694,"activeCount":302,"soonestReadout":2522},[6695],{"nctId":2519,"briefTitle":2520,"status":381,"phases":6696,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":6697,"interventions":6698},[91,92],[2526],[2528,2529,2494,2530,2531,2532],{"trials":6700,"activeCount":103},[],{"trials":6702,"activeCount":103},[],{"trials":6704,"activeCount":103},[],{"intervention":6706,"totalTrials":302,"cells":6707},"Disitamab vedotin",{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6712,"PHASE3":6723,"PHASE4":6725,"NA":6727},{"trials":6709,"activeCount":103},[],{"trials":6711,"activeCount":103},[],{"trials":6713,"activeCount":302,"soonestReadout":6718},[6714],{"nctId":6715,"briefTitle":6716,"status":126,"phases":6717,"primaryCompletion":6718,"completion":6719,"start":6720,"enrollment":397,"conditions":6721,"interventions":6722},"NCT06966453","A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer",[91,92],"2027-10-25","2030-01-27","2025-06-30",[31,25],[6706],{"trials":6724,"activeCount":103},[],{"trials":6726,"activeCount":103},[],{"trials":6728,"activeCount":103},[],{"intervention":909,"totalTrials":302,"cells":6730},{"EARLY_PHASE1":6731,"PHASE1":6733,"PHASE2":6735,"PHASE3":6741,"PHASE4":6743,"NA":6745},{"trials":6732,"activeCount":103},[],{"trials":6734,"activeCount":103},[],{"trials":6736,"activeCount":302,"soonestReadout":900},[6737],{"nctId":897,"briefTitle":898,"status":126,"phases":6738,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":6739,"interventions":6740},[91,92],[905,906,907],[869,909],{"trials":6742,"activeCount":103},[],{"trials":6744,"activeCount":103},[],{"trials":6746,"activeCount":103},[],{"intervention":6748,"totalTrials":302,"cells":6749},"Low Dose PF-07328948",{"EARLY_PHASE1":6750,"PHASE1":6752,"PHASE2":6754,"PHASE3":6768,"PHASE4":6770,"NA":6772},{"trials":6751,"activeCount":103},[],{"trials":6753,"activeCount":103},[],{"trials":6755,"activeCount":302,"soonestReadout":6760},[6756],{"nctId":6757,"briefTitle":6758,"status":126,"phases":6759,"primaryCompletion":6760,"completion":6761,"start":6270,"enrollment":6762,"conditions":6763,"interventions":6765},"NCT06991257","A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)",[92],"2027-11-16","2027-12-14",620,[6764],"Heart Failure",[6748,6766,6767],"Medium Dose PF-07328948","High Dose PF-07328948",{"trials":6769,"activeCount":103},[],{"trials":6771,"activeCount":103},[],{"trials":6773,"activeCount":103},[],{"intervention":6766,"totalTrials":302,"cells":6775},{"EARLY_PHASE1":6776,"PHASE1":6778,"PHASE2":6780,"PHASE3":6786,"PHASE4":6788,"NA":6790},{"trials":6777,"activeCount":103},[],{"trials":6779,"activeCount":103},[],{"trials":6781,"activeCount":302,"soonestReadout":6760},[6782],{"nctId":6757,"briefTitle":6758,"status":126,"phases":6783,"primaryCompletion":6760,"completion":6761,"start":6270,"enrollment":6762,"conditions":6784,"interventions":6785},[92],[6764],[6748,6766,6767],{"trials":6787,"activeCount":103},[],{"trials":6789,"activeCount":103},[],{"trials":6791,"activeCount":103},[],{"intervention":6767,"totalTrials":302,"cells":6793},{"EARLY_PHASE1":6794,"PHASE1":6796,"PHASE2":6798,"PHASE3":6804,"PHASE4":6806,"NA":6808},{"trials":6795,"activeCount":103},[],{"trials":6797,"activeCount":103},[],{"trials":6799,"activeCount":302,"soonestReadout":6760},[6800],{"nctId":6757,"briefTitle":6758,"status":126,"phases":6801,"primaryCompletion":6760,"completion":6761,"start":6270,"enrollment":6762,"conditions":6802,"interventions":6803},[92],[6764],[6748,6766,6767],{"trials":6805,"activeCount":103},[],{"trials":6807,"activeCount":103},[],{"trials":6809,"activeCount":103},[],{"intervention":2543,"totalTrials":302,"cells":6811},{"EARLY_PHASE1":6812,"PHASE1":6814,"PHASE2":6816,"PHASE3":6822,"PHASE4":6824,"NA":6826},{"trials":6813,"activeCount":103},[],{"trials":6815,"activeCount":103},[],{"trials":6817,"activeCount":302,"soonestReadout":2537},[6818],{"nctId":2534,"briefTitle":2535,"status":381,"phases":6819,"primaryCompletion":2537,"completion":2537,"start":2538,"enrollment":2539,"conditions":6820,"interventions":6821},[92],[2526],[2542,2494,2543],{"trials":6823,"activeCount":103},[],{"trials":6825,"activeCount":103},[],{"trials":6827,"activeCount":103},[],{"intervention":6829,"totalTrials":302,"cells":6830},"PF-06838435",{"EARLY_PHASE1":6831,"PHASE1":6833,"PHASE2":6835,"PHASE3":6845,"PHASE4":6847,"NA":6849},{"trials":6832,"activeCount":103},[],{"trials":6834,"activeCount":103},[],{"trials":6836,"activeCount":302,"soonestReadout":6841},[6837],{"nctId":6838,"briefTitle":6839,"status":381,"phases":6840,"primaryCompletion":6841,"completion":6842,"start":5885,"enrollment":360,"conditions":6843,"interventions":6844},"NCT03307980","Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B",[92],"2029-05-29","2029-10-25",[3552],[6829],{"trials":6846,"activeCount":103},[],{"trials":6848,"activeCount":103},[],{"trials":6850,"activeCount":103},[],{"intervention":6852,"totalTrials":302,"cells":6853},"Vaccine Candidate #1",{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6858,"PHASE3":6874,"PHASE4":6876,"NA":6878},{"trials":6855,"activeCount":103},[],{"trials":6857,"activeCount":103},[],{"trials":6859,"activeCount":302,"soonestReadout":6864},[6860],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6863,"primaryCompletion":6864,"completion":6864,"start":6336,"enrollment":6865,"conditions":6866,"interventions":6867},"NCT07431853","A Study to Learn About mRNA Vaccines Against Influenza in Adults",[92],"2027-06-22",770,[2715],[6852,6868,6869,6870,6871,6872,6873],"Vaccine Candidate #2","Vaccine Candidate #3","Vaccine Candidate #4","Vaccine Candidate #5","Vaccine Candidate #6","TIV1 or TIV2",{"trials":6875,"activeCount":103},[],{"trials":6877,"activeCount":103},[],{"trials":6879,"activeCount":103},[],{"intervention":6868,"totalTrials":302,"cells":6881},{"EARLY_PHASE1":6882,"PHASE1":6884,"PHASE2":6886,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6883,"activeCount":103},[],{"trials":6885,"activeCount":103},[],{"trials":6887,"activeCount":302,"soonestReadout":6864},[6888],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6889,"primaryCompletion":6864,"completion":6864,"start":6336,"enrollment":6865,"conditions":6890,"interventions":6891},[92],[2715],[6852,6868,6869,6870,6871,6872,6873],{"trials":6893,"activeCount":103},[],{"trials":6895,"activeCount":103},[],{"trials":6897,"activeCount":103},[],{"intervention":6869,"totalTrials":302,"cells":6899},{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6901,"activeCount":103},[],{"trials":6903,"activeCount":103},[],{"trials":6905,"activeCount":302,"soonestReadout":6864},[6906],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6907,"primaryCompletion":6864,"completion":6864,"start":6336,"enrollment":6865,"conditions":6908,"interventions":6909},[92],[2715],[6852,6868,6869,6870,6871,6872,6873],{"trials":6911,"activeCount":103},[],{"trials":6913,"activeCount":103},[],{"trials":6915,"activeCount":103},[],{"intervention":6870,"totalTrials":302,"cells":6917},{"EARLY_PHASE1":6918,"PHASE1":6920,"PHASE2":6922,"PHASE3":6928,"PHASE4":6930,"NA":6932},{"trials":6919,"activeCount":103},[],{"trials":6921,"activeCount":103},[],{"trials":6923,"activeCount":302,"soonestReadout":6864},[6924],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6925,"primaryCompletion":6864,"completion":6864,"start":6336,"enrollment":6865,"conditions":6926,"interventions":6927},[92],[2715],[6852,6868,6869,6870,6871,6872,6873],{"trials":6929,"activeCount":103},[],{"trials":6931,"activeCount":103},[],{"trials":6933,"activeCount":103},[],{"intervention":6871,"totalTrials":302,"cells":6935},{"EARLY_PHASE1":6936,"PHASE1":6938,"PHASE2":6940,"PHASE3":6946,"PHASE4":6948,"NA":6950},{"trials":6937,"activeCount":103},[],{"trials":6939,"activeCount":103},[],{"trials":6941,"activeCount":302,"soonestReadout":6864},[6942],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6943,"primaryCompletion":6864,"completion":6864,"start":6336,"enrollment":6865,"conditions":6944,"interventions":6945},[92],[2715],[6852,6868,6869,6870,6871,6872,6873],{"trials":6947,"activeCount":103},[],{"trials":6949,"activeCount":103},[],{"trials":6951,"activeCount":103},[],{"intervention":6872,"totalTrials":302,"cells":6953},{"EARLY_PHASE1":6954,"PHASE1":6956,"PHASE2":6958,"PHASE3":6964,"PHASE4":6966,"NA":6968},{"trials":6955,"activeCount":103},[],{"trials":6957,"activeCount":103},[],{"trials":6959,"activeCount":302,"soonestReadout":6864},[6960],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6961,"primaryCompletion":6864,"completion":6864,"start":6336,"enrollment":6865,"conditions":6962,"interventions":6963},[92],[2715],[6852,6868,6869,6870,6871,6872,6873],{"trials":6965,"activeCount":103},[],{"trials":6967,"activeCount":103},[],{"trials":6969,"activeCount":103},[],{"intervention":6873,"totalTrials":302,"cells":6971},{"EARLY_PHASE1":6972,"PHASE1":6974,"PHASE2":6976,"PHASE3":6982,"PHASE4":6984,"NA":6986},{"trials":6973,"activeCount":103},[],{"trials":6975,"activeCount":103},[],{"trials":6977,"activeCount":302,"soonestReadout":6864},[6978],{"nctId":6861,"briefTitle":6862,"status":126,"phases":6979,"primaryCompletion":6864,"completion":6864,"start":6336,"enrollment":6865,"conditions":6980,"interventions":6981},[92],[2715],[6852,6868,6869,6870,6871,6872,6873],{"trials":6983,"activeCount":103},[],{"trials":6985,"activeCount":103},[],{"trials":6987,"activeCount":103},[],{"intervention":6989,"totalTrials":302,"cells":6990},"ALLR3",{"EARLY_PHASE1":6991,"PHASE1":6993,"PHASE2":6995,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":6992,"activeCount":103},[],{"trials":6994,"activeCount":103},[],{"trials":6996,"activeCount":302,"soonestReadout":7001},[6997],{"nctId":6998,"briefTitle":6999,"status":126,"phases":7000,"primaryCompletion":7001,"completion":7002,"start":1071,"enrollment":397,"conditions":7003,"interventions":7005},"NCT05748171","A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to \u003C18 Years) With First Relapse ALL",[92],"2033-10-31","2036-11-04",[7004],"ACUTE LYMPHOBLASTIC LEUKEMIA",[7006,6989],"Inotuzumab ozogamicin",{"trials":7008,"activeCount":103},[],{"trials":7010,"activeCount":103},[],{"trials":7012,"activeCount":103},[],{"intervention":3009,"totalTrials":302,"cells":7014},{"EARLY_PHASE1":7015,"PHASE1":7017,"PHASE2":7019,"PHASE3":7025,"PHASE4":7027,"NA":7029},{"trials":7016,"activeCount":103},[],{"trials":7018,"activeCount":103},[],{"trials":7020,"activeCount":302,"soonestReadout":3003},[7021],{"nctId":3000,"briefTitle":3001,"status":126,"phases":7022,"primaryCompletion":3003,"completion":3003,"start":3004,"enrollment":3005,"conditions":7023,"interventions":7024},[91,92],[3007],[3009,2981],{"trials":7026,"activeCount":103},[],{"trials":7028,"activeCount":103},[],{"trials":7030,"activeCount":103},[],{"intervention":1321,"totalTrials":302,"cells":7032},{"EARLY_PHASE1":7033,"PHASE1":7035,"PHASE2":7037,"PHASE3":7043,"PHASE4":7045,"NA":7047},{"trials":7034,"activeCount":103},[],{"trials":7036,"activeCount":103},[],{"trials":7038,"activeCount":302,"soonestReadout":1310},[7039],{"nctId":1307,"briefTitle":1308,"status":126,"phases":7040,"primaryCompletion":1310,"completion":1311,"start":1312,"enrollment":1313,"conditions":7041,"interventions":7042},[92],[1315,1316,1317],[1319,1305,1243,88,1320,1321],{"trials":7044,"activeCount":103},[],{"trials":7046,"activeCount":103},[],{"trials":7048,"activeCount":103},[],{"intervention":2147,"totalTrials":302,"cells":7050},{"EARLY_PHASE1":7051,"PHASE1":7053,"PHASE2":7055,"PHASE3":7061,"PHASE4":7063,"NA":7065},{"trials":7052,"activeCount":103},[],{"trials":7054,"activeCount":103},[],{"trials":7056,"activeCount":302,"soonestReadout":1111},[7057],{"nctId":2141,"briefTitle":2142,"status":381,"phases":7058,"primaryCompletion":1111,"completion":1111,"start":2144,"enrollment":1625,"conditions":7059,"interventions":7060},[91,92],[31],[68,2147],{"trials":7062,"activeCount":103},[],{"trials":7064,"activeCount":103},[],{"trials":7066,"activeCount":103},[],{"intervention":7068,"totalTrials":302,"cells":7069},"PF-07868489",{"EARLY_PHASE1":7070,"PHASE1":7072,"PHASE2":7074,"PHASE3":7085,"PHASE4":7087,"NA":7089},{"trials":7071,"activeCount":103},[],{"trials":7073,"activeCount":103},[],{"trials":7075,"activeCount":302,"soonestReadout":7080},[7076],{"nctId":7077,"briefTitle":7078,"status":126,"phases":7079,"primaryCompletion":7080,"completion":7080,"start":7081,"enrollment":1530,"conditions":7082,"interventions":7084},"NCT07073820","A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489",[92],"2028-07-18","2025-11-10",[7083],"Pulmonary Hypertension",[7068],{"trials":7086,"activeCount":103},[],{"trials":7088,"activeCount":103},[],{"trials":7090,"activeCount":103},[],{"intervention":1336,"totalTrials":302,"cells":7092},{"EARLY_PHASE1":7093,"PHASE1":7095,"PHASE2":7097,"PHASE3":7103,"PHASE4":7105,"NA":7107},{"trials":7094,"activeCount":103},[],{"trials":7096,"activeCount":103},[],{"trials":7098,"activeCount":302,"soonestReadout":87},[7099],{"nctId":85,"briefTitle":86,"status":381,"phases":7100,"primaryCompletion":87,"completion":1324,"start":1325,"enrollment":1326,"conditions":7101,"interventions":7102},[92],[1328,750,1329,1330,500,1331,1332],[88,1334,1335,1336,1337],{"trials":7104,"activeCount":103},[],{"trials":7106,"activeCount":103},[],{"trials":7108,"activeCount":103},[],{"intervention":7110,"totalTrials":302,"cells":7111},"PF-07220060 + PF-07104091 combination dose escalation",{"EARLY_PHASE1":7112,"PHASE1":7114,"PHASE2":7116,"PHASE3":7129,"PHASE4":7131,"NA":7133},{"trials":7113,"activeCount":103},[],{"trials":7115,"activeCount":103},[],{"trials":7117,"activeCount":302,"soonestReadout":7122},[7118],{"nctId":7119,"briefTitle":7120,"status":381,"phases":7121,"primaryCompletion":7122,"completion":7122,"start":7123,"enrollment":7124,"conditions":7125,"interventions":7126},"NCT05262400","A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors",[91,92],"2026-08-23","2022-03-14",192,[31,750],[7110,7110,7110,7110,7110,7127,7127,7128,7110,7110,7110],"PF-07104091 + PF-07220060 + fulvestrant dose expansion","PF-07104091 + PF-07220060 + letrozole dose expansion",{"trials":7130,"activeCount":103},[],{"trials":7132,"activeCount":103},[],{"trials":7134,"activeCount":103},[],{"intervention":7127,"totalTrials":302,"cells":7136},{"EARLY_PHASE1":7137,"PHASE1":7139,"PHASE2":7141,"PHASE3":7147,"PHASE4":7149,"NA":7151},{"trials":7138,"activeCount":103},[],{"trials":7140,"activeCount":103},[],{"trials":7142,"activeCount":302,"soonestReadout":7122},[7143],{"nctId":7119,"briefTitle":7120,"status":381,"phases":7144,"primaryCompletion":7122,"completion":7122,"start":7123,"enrollment":7124,"conditions":7145,"interventions":7146},[91,92],[31,750],[7110,7110,7110,7110,7110,7127,7127,7128,7110,7110,7110],{"trials":7148,"activeCount":103},[],{"trials":7150,"activeCount":103},[],{"trials":7152,"activeCount":103},[],{"intervention":7128,"totalTrials":302,"cells":7154},{"EARLY_PHASE1":7155,"PHASE1":7157,"PHASE2":7159,"PHASE3":7165,"PHASE4":7167,"NA":7169},{"trials":7156,"activeCount":103},[],{"trials":7158,"activeCount":103},[],{"trials":7160,"activeCount":302,"soonestReadout":7122},[7161],{"nctId":7119,"briefTitle":7120,"status":381,"phases":7162,"primaryCompletion":7122,"completion":7122,"start":7123,"enrollment":7124,"conditions":7163,"interventions":7164},[91,92],[31,750],[7110,7110,7110,7110,7110,7127,7127,7128,7110,7110,7110],{"trials":7166,"activeCount":103},[],{"trials":7168,"activeCount":103},[],{"trials":7170,"activeCount":103},[],{"intervention":7172,"totalTrials":302,"cells":7173},"PF-07104091 monotherapy dose escalation",{"EARLY_PHASE1":7174,"PHASE1":7176,"PHASE2":7178,"PHASE3":7192,"PHASE4":7194,"NA":7196},{"trials":7175,"activeCount":103},[],{"trials":7177,"activeCount":103},[],{"trials":7179,"activeCount":302,"soonestReadout":1111},[7180],{"nctId":7181,"briefTitle":7182,"status":381,"phases":7183,"primaryCompletion":1111,"completion":1111,"start":2551,"enrollment":7184,"conditions":7185,"interventions":7186},"NCT04553133","PF-07104091 as a Single Agent and in Combination Therapy",[92],157,[962,1653,31],[7172,7187,7188,7189,7189,7190,7191],"PF-07104091 + palbociclib + fulvestrant","PF-07104091 + palbociclib + letrozole","PF-07104091 monotherapy dose expansion","PF-07104091 + Fulvestrant","PF-0704091 + Fulvestrant",{"trials":7193,"activeCount":103},[],{"trials":7195,"activeCount":103},[],{"trials":7197,"activeCount":103},[],{"intervention":7187,"totalTrials":302,"cells":7199},{"EARLY_PHASE1":7200,"PHASE1":7202,"PHASE2":7204,"PHASE3":7210,"PHASE4":7212,"NA":7214},{"trials":7201,"activeCount":103},[],{"trials":7203,"activeCount":103},[],{"trials":7205,"activeCount":302,"soonestReadout":1111},[7206],{"nctId":7181,"briefTitle":7182,"status":381,"phases":7207,"primaryCompletion":1111,"completion":1111,"start":2551,"enrollment":7184,"conditions":7208,"interventions":7209},[92],[962,1653,31],[7172,7187,7188,7189,7189,7190,7191],{"trials":7211,"activeCount":103},[],{"trials":7213,"activeCount":103},[],{"trials":7215,"activeCount":103},[],{"intervention":7188,"totalTrials":302,"cells":7217},{"EARLY_PHASE1":7218,"PHASE1":7220,"PHASE2":7222,"PHASE3":7228,"PHASE4":7230,"NA":7232},{"trials":7219,"activeCount":103},[],{"trials":7221,"activeCount":103},[],{"trials":7223,"activeCount":302,"soonestReadout":1111},[7224],{"nctId":7181,"briefTitle":7182,"status":381,"phases":7225,"primaryCompletion":1111,"completion":1111,"start":2551,"enrollment":7184,"conditions":7226,"interventions":7227},[92],[962,1653,31],[7172,7187,7188,7189,7189,7190,7191],{"trials":7229,"activeCount":103},[],{"trials":7231,"activeCount":103},[],{"trials":7233,"activeCount":103},[],{"intervention":7189,"totalTrials":302,"cells":7235},{"EARLY_PHASE1":7236,"PHASE1":7238,"PHASE2":7240,"PHASE3":7246,"PHASE4":7248,"NA":7250},{"trials":7237,"activeCount":103},[],{"trials":7239,"activeCount":103},[],{"trials":7241,"activeCount":302,"soonestReadout":1111},[7242],{"nctId":7181,"briefTitle":7182,"status":381,"phases":7243,"primaryCompletion":1111,"completion":1111,"start":2551,"enrollment":7184,"conditions":7244,"interventions":7245},[92],[962,1653,31],[7172,7187,7188,7189,7189,7190,7191],{"trials":7247,"activeCount":103},[],{"trials":7249,"activeCount":103},[],{"trials":7251,"activeCount":103},[],{"intervention":7190,"totalTrials":302,"cells":7253},{"EARLY_PHASE1":7254,"PHASE1":7256,"PHASE2":7258,"PHASE3":7264,"PHASE4":7266,"NA":7268},{"trials":7255,"activeCount":103},[],{"trials":7257,"activeCount":103},[],{"trials":7259,"activeCount":302,"soonestReadout":1111},[7260],{"nctId":7181,"briefTitle":7182,"status":381,"phases":7261,"primaryCompletion":1111,"completion":1111,"start":2551,"enrollment":7184,"conditions":7262,"interventions":7263},[92],[962,1653,31],[7172,7187,7188,7189,7189,7190,7191],{"trials":7265,"activeCount":103},[],{"trials":7267,"activeCount":103},[],{"trials":7269,"activeCount":103},[],{"intervention":7191,"totalTrials":302,"cells":7271},{"EARLY_PHASE1":7272,"PHASE1":7274,"PHASE2":7276,"PHASE3":7282,"PHASE4":7284,"NA":7286},{"trials":7273,"activeCount":103},[],{"trials":7275,"activeCount":103},[],{"trials":7277,"activeCount":302,"soonestReadout":1111},[7278],{"nctId":7181,"briefTitle":7182,"status":381,"phases":7279,"primaryCompletion":1111,"completion":1111,"start":2551,"enrollment":7184,"conditions":7280,"interventions":7281},[92],[962,1653,31],[7172,7187,7188,7189,7189,7190,7191],{"trials":7283,"activeCount":103},[],{"trials":7285,"activeCount":103},[],{"trials":7287,"activeCount":103},[],{"intervention":2788,"totalTrials":302,"cells":7289},{"EARLY_PHASE1":7290,"PHASE1":7292,"PHASE2":7294,"PHASE3":7300,"PHASE4":7302,"NA":7304},{"trials":7291,"activeCount":103},[],{"trials":7293,"activeCount":103},[],{"trials":7295,"activeCount":302,"soonestReadout":1144},[7296],{"nctId":2774,"briefTitle":2775,"status":263,"phases":7297,"primaryCompletion":1144,"completion":2777,"start":2778,"enrollment":2779,"conditions":7298,"interventions":7299},[92],[2760,2761,2781,2782,2783,2784,2785,2786],[2788,2747],{"trials":7301,"activeCount":103},[],{"trials":7303,"activeCount":103},[],{"trials":7305,"activeCount":103},[],{"intervention":7307,"totalTrials":302,"cells":7308},"Part A: ATM-AVI Single Dose, Cohorts 1-4",{"EARLY_PHASE1":7309,"PHASE1":7311,"PHASE2":7313,"PHASE3":7325,"PHASE4":7327,"NA":7329},{"trials":7310,"activeCount":103},[],{"trials":7312,"activeCount":103},[],{"trials":7314,"activeCount":302,"soonestReadout":7319},[7315],{"nctId":7316,"briefTitle":7317,"status":126,"phases":7318,"primaryCompletion":7319,"completion":7319,"start":7320,"enrollment":4369,"conditions":7321,"interventions":7323},"NCT06462235","A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)",[92],"2027-04-25","2024-09-25",[7322],"Gram-negative Bacterial Infection",[7307,7324],"Part B: Multiple-dose ATM-AVI, Cohorts 1-4",{"trials":7326,"activeCount":103},[],{"trials":7328,"activeCount":103},[],{"trials":7330,"activeCount":103},[],{"intervention":7324,"totalTrials":302,"cells":7332},{"EARLY_PHASE1":7333,"PHASE1":7335,"PHASE2":7337,"PHASE3":7343,"PHASE4":7345,"NA":7347},{"trials":7334,"activeCount":103},[],{"trials":7336,"activeCount":103},[],{"trials":7338,"activeCount":302,"soonestReadout":7319},[7339],{"nctId":7316,"briefTitle":7317,"status":126,"phases":7340,"primaryCompletion":7319,"completion":7319,"start":7320,"enrollment":4369,"conditions":7341,"interventions":7342},[92],[7322],[7307,7324],{"trials":7344,"activeCount":103},[],{"trials":7346,"activeCount":103},[],{"trials":7348,"activeCount":103},[],{"intervention":2968,"totalTrials":3254,"cells":7350},{"EARLY_PHASE1":7351,"PHASE1":7353,"PHASE2":7355,"PHASE3":7402,"PHASE4":7434,"NA":7444},{"trials":7352,"activeCount":103},[],{"trials":7354,"activeCount":103},[],{"trials":7356,"activeCount":302,"soonestReadout":7001},[7357,7367,7371,7382,7393],{"nctId":7358,"briefTitle":7359,"status":111,"phases":7360,"primaryCompletion":7361,"completion":7361,"start":7362,"enrollment":7363,"conditions":7364,"interventions":7366},"NCT00867087","Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma",[92],"2012-10-31","2009-06-08",64,[7365],"Lymphoma, B-Cell",[2968,2969],{"nctId":6998,"briefTitle":6999,"status":126,"phases":7368,"primaryCompletion":7001,"completion":7002,"start":1071,"enrollment":397,"conditions":7369,"interventions":7370},[92],[7004],[7006,6989],{"nctId":7372,"briefTitle":7373,"status":111,"phases":7374,"primaryCompletion":7375,"completion":7376,"start":7377,"enrollment":7378,"conditions":7379,"interventions":7381},"NCT00299494","Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)",[91,92],"2014-05-19","2014-06-02","2006-05-04",119,[7380],"B-Cell Lymphoma",[2968,2968,2968,2917],{"nctId":7383,"briefTitle":7384,"status":111,"phases":7385,"primaryCompletion":7386,"completion":7387,"start":4531,"enrollment":7388,"conditions":7389,"interventions":7391},"NCT01363297","Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia",[92],"2014-08","2016-01",72,[7390],"Acute Lymphocytic Leukemia",[7392],"Inotuzumab Ozogamicin",{"nctId":7394,"briefTitle":7395,"status":111,"phases":7396,"primaryCompletion":7397,"completion":7398,"start":2432,"enrollment":7399,"conditions":7400,"interventions":7401},"NCT00868608","Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma",[92],"2012-01-10","2013-06-27",81,[2937],[7392],{"trials":7403,"activeCount":103},[7404,7418,7430],{"nctId":7405,"briefTitle":7406,"status":111,"phases":7407,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":7411,"conditions":7412,"interventions":7414},"NCT01564784","A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia",[93],"2016-03-08","2017-01-04","2012-08-02",326,[7413],"Acute Lymphoblastic Leukemia",[2968,7415,7416,7417],"FLAG","HIDAC","cytarabine and mitoxantrone",{"nctId":7419,"briefTitle":7420,"status":168,"phases":7421,"primaryCompletion":7422,"completion":7422,"start":7423,"enrollment":7424,"conditions":7425,"interventions":7427},"NCT01232556","A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed\u002FRefractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy",[93],"2014-03-28","2011-04-04",338,[7426],"Lymphoma, Non-Hodgkin",[7006,2917,7428,7429],"rituximab + gemcitabine","rituximab +bendamustine",{"nctId":2961,"briefTitle":2962,"status":168,"phases":7431,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":7432,"interventions":7433},[93],[2966],[2968,2969,2969,2970,2971,2972,2973,2974,2975],{"trials":7435,"activeCount":103},[7436],{"nctId":7437,"briefTitle":7438,"status":111,"phases":7439,"primaryCompletion":3452,"completion":7440,"start":7441,"enrollment":29,"conditions":7442,"interventions":7443},"NCT05687032","A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia",[94],"2025-11-06","2023-02-24",[7413],[2968],{"trials":7445,"activeCount":103},[7446,7452,7460,7468],{"nctId":7447,"briefTitle":7448,"status":453,"phases":7449,"conditions":7450,"interventions":7451},"NCT03127605","Inotuzumab Ozogamicin - PF-05208773",[],[],[7392],{"nctId":7453,"briefTitle":7454,"status":111,"phases":7455,"primaryCompletion":7456,"completion":7456,"start":1567,"enrollment":5909,"conditions":7457,"interventions":7459},"NCT04456959","InO - A Retrospective Study of UK Patients With Leukaemia",[],"2021-01-27",[7458],"Precursor Cell Lymphoblastic Leukemia-Lymphoma",[7392],{"nctId":7461,"briefTitle":7462,"status":111,"phases":7463,"primaryCompletion":1237,"completion":1237,"start":7464,"enrollment":1498,"conditions":7465,"interventions":7467},"NCT04307134","Besponsa Post Marketing Surveillance Study",[],"2020-07-09",[7466],"Hematologic Malignancy",[7006],{"nctId":7469,"briefTitle":7470,"status":111,"phases":7471,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":4259,"conditions":7474,"interventions":7476},"NCT05597085","A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment",[],"2023-07-10","2023-03-08",[7475],"Adult Relapsed\u002FRefractory B Cell Acute Lymphoblastic Leukemia",[7392],{"intervention":4828,"totalTrials":1087,"cells":7478},{"EARLY_PHASE1":7479,"PHASE1":7481,"PHASE2":7483,"PHASE3":7489,"PHASE4":7491,"NA":7493},{"trials":7480,"activeCount":103},[],{"trials":7482,"activeCount":103},[],{"trials":7484,"activeCount":302,"soonestReadout":72},[7485],{"nctId":70,"briefTitle":71,"status":381,"phases":7486,"primaryCompletion":72,"completion":445,"start":4824,"enrollment":4825,"conditions":7487,"interventions":7488},[92],[31],[73,4828,2056],{"trials":7490,"activeCount":103},[],{"trials":7492,"activeCount":103},[],{"trials":7494,"activeCount":103},[7495],{"nctId":4861,"briefTitle":4862,"status":111,"phases":7496,"primaryCompletion":4864,"completion":4864,"start":4865,"enrollment":1122,"conditions":7497,"interventions":7498},[],[4867],[73,4828,2056],{"intervention":2082,"totalTrials":7500,"cells":7501},17,{"EARLY_PHASE1":7502,"PHASE1":7504,"PHASE2":7622,"PHASE3":7624,"PHASE4":7635,"NA":7637},{"trials":7503,"activeCount":103},[],{"trials":7505,"activeCount":502,"soonestReadout":3101},[7506,7510,7524,7532,7539,7543,7551,7560,7567,7574,7582,7586,7596,7604,7608,7612],{"nctId":2074,"briefTitle":2075,"status":111,"phases":7507,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":1268,"conditions":7508,"interventions":7509},[91],[16],[68,2082],{"nctId":7511,"briefTitle":7512,"status":111,"phases":7513,"primaryCompletion":7514,"completion":7515,"start":7516,"enrollment":5855,"conditions":7517,"interventions":7522},"NCT00585195","A Study Of Oral PF-02341066, A C-Met\u002FHepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",[91],"2020-07-30","2022-01-19","2006-04-19",[448,7518,7519,7520,7521],"Non-Small Cell Lung Cancer c-Met Dependent","Non-Small Cell Lung Cancer ROS Marker Positive","Systemic Anaplastic Large-Cell Lymphoma","Advanced Malignancies Except Leukemia",[7523,1252,2082],"PF-02341066",{"nctId":7525,"briefTitle":7526,"status":111,"phases":7527,"primaryCompletion":3200,"completion":3200,"start":7528,"enrollment":314,"conditions":7529,"interventions":7530},"NCT05745701","A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults",[91],"2023-02-22",[16],[7531,2082],"PF-07081532",{"nctId":7533,"briefTitle":7534,"status":111,"phases":7535,"primaryCompletion":7536,"completion":7536,"start":5947,"enrollment":1268,"conditions":7537,"interventions":7538},"NCT04962022","Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332\u002FRitonavir in Healthy Participants",[91],"2021-09-30",[1489],[4936,2082,4936],{"nctId":3098,"briefTitle":3099,"status":381,"phases":7540,"primaryCompletion":3101,"completion":3102,"start":3103,"enrollment":1268,"conditions":7541,"interventions":7542},[91],[3105],[1319,2082],{"nctId":7544,"briefTitle":7545,"status":111,"phases":7546,"primaryCompletion":4242,"completion":7547,"start":7548,"enrollment":314,"conditions":7549,"interventions":7550},"NCT02838264","A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers",[91],"2017-05-03","2016-08-16",[16],[664,664,664,664,2082],{"nctId":7552,"briefTitle":7553,"status":111,"phases":7554,"primaryCompletion":296,"completion":296,"start":7555,"enrollment":314,"conditions":7556,"interventions":7557},"NCT06541678","A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.",[91],"2024-12-23",[16],[7558,7559,2082],"Danuglipron","Cyclosporine",{"nctId":7561,"briefTitle":7562,"status":111,"phases":7563,"primaryCompletion":7472,"completion":7472,"start":7564,"enrollment":1268,"conditions":7565,"interventions":7566},"NCT05822440","A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.",[91],"2023-04-13",[16],[6110,2082],{"nctId":7568,"briefTitle":7569,"status":111,"phases":7570,"primaryCompletion":7571,"completion":7571,"start":2313,"enrollment":1268,"conditions":7572,"interventions":7573},"NCT02883114","An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.",[91],"2016-11",[16],[6156,2082],{"nctId":7575,"briefTitle":7576,"status":111,"phases":7577,"primaryCompletion":1288,"completion":1288,"start":7578,"enrollment":1509,"conditions":7579,"interventions":7580},"NCT02100553","Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens\u002FBazedoxifene in Non-Obese and Obese Postmenopausal Women",[91],"2014-04",[16],[7581,2082,7581,7581,2082,7581],"CE\u002FBZA",{"nctId":2707,"briefTitle":2708,"status":111,"phases":7583,"primaryCompletion":2710,"completion":2711,"start":2712,"enrollment":2713,"conditions":7584,"interventions":7585},[91],[2715],[1320,2082,2717],{"nctId":7587,"briefTitle":7588,"status":111,"phases":7589,"primaryCompletion":7590,"completion":7590,"start":7591,"enrollment":1268,"conditions":7592,"interventions":7594},"NCT04090047","A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants",[91],"2019-12-19","2019-09-24",[7593],"Heathy Participants",[7595,2082],"PF-06700841",{"nctId":7597,"briefTitle":7598,"status":111,"phases":7599,"primaryCompletion":7600,"completion":7600,"start":7601,"enrollment":1239,"conditions":7602,"interventions":7603},"NCT06706869","A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults",[91],"2025-02-20","2024-12-11",[16],[6184,2082],{"nctId":6240,"briefTitle":6241,"status":111,"phases":7605,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":6245,"conditions":7606,"interventions":7607},[91],[6191],[2082,6248,6249,1687,6250],{"nctId":2184,"briefTitle":2185,"status":126,"phases":7609,"primaryCompletion":2187,"completion":2188,"start":2189,"enrollment":2190,"conditions":7610,"interventions":7611},[91],[2192,1040,2193],[2195,63,2082],{"nctId":7613,"briefTitle":7614,"status":263,"phases":7615,"primaryCompletion":7616,"completion":7617,"start":7618,"enrollment":562,"conditions":7619,"interventions":7620},"NCT07575945","A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.",[91],"2026-06-26","2026-07-23","2026-05-05",[1489],[7621,2082],"PF-08642534",{"trials":7623,"activeCount":103},[],{"trials":7625,"activeCount":103},[7626],{"nctId":7627,"briefTitle":7628,"status":111,"phases":7629,"primaryCompletion":4608,"completion":4608,"start":6457,"enrollment":7630,"conditions":7631,"interventions":7633},"NCT00289991","Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)",[93],489,[7632],"Antifungal Prophylaxis of Invasive Fungal Infections",[2082,7634],"Vfend - voriconazole",{"trials":7636,"activeCount":103},[],{"trials":7638,"activeCount":103},[],{"intervention":1990,"totalTrials":578,"cells":7640},{"EARLY_PHASE1":7641,"PHASE1":7643,"PHASE2":7657,"PHASE3":7659,"PHASE4":7680,"NA":7682},{"trials":7642,"activeCount":103},[],{"trials":7644,"activeCount":1087,"soonestReadout":1756},[7645,7649,7653],{"nctId":1753,"briefTitle":1754,"status":126,"phases":7646,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":7647,"interventions":7648},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":1775,"briefTitle":1776,"status":168,"phases":7650,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":7651,"interventions":7652},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"nctId":1977,"briefTitle":1978,"status":126,"phases":7654,"primaryCompletion":1980,"completion":1981,"start":786,"enrollment":1982,"conditions":7655,"interventions":7656},[91],[1798,409,1984,1985,1986],[1988,341,342,1989,1990,1991,1992],{"trials":7658,"activeCount":103},[],{"trials":7660,"activeCount":103},[7661,7671],{"nctId":7662,"briefTitle":7663,"status":111,"phases":7664,"primaryCompletion":7665,"completion":7665,"start":7666,"conditions":7667,"interventions":7668},"NCT00004252","Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer",[93],"2007-09","1999-11",[2022],[1990,7669,7670],"leucovorin calcium","semaxanib",{"nctId":7672,"briefTitle":7673,"status":111,"phases":7674,"primaryCompletion":7675,"start":7676,"conditions":7677,"interventions":7678},"NCT00026273","Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer",[93],"2004-09","2001-01",[2022],[3328,1990,7679,7669],"irinotecan hydrochloride",{"trials":7681,"activeCount":103},[],{"trials":7683,"activeCount":103},[],{"intervention":1773,"totalTrials":1268,"cells":7685},{"EARLY_PHASE1":7686,"PHASE1":7688,"PHASE2":7788,"PHASE3":7794,"PHASE4":7796,"NA":7798},{"trials":7687,"activeCount":103},[],{"trials":7689,"activeCount":1087,"soonestReadout":1756},[7690,7703,7716,7720,7732,7736,7744,7753,7764,7773,7784],{"nctId":7691,"briefTitle":7692,"status":126,"phases":7693,"primaryCompletion":7694,"completion":7695,"start":7440,"enrollment":7696,"conditions":7697,"interventions":7699},"NCT07206225","A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer",[91],"2030-01-29","2033-01-28",294,[7698],"Non-muscle Invasive Bladder Cancer",[7700,1773,7701,7702],"PF-08052667","BCG","PF-02921367",{"nctId":7704,"briefTitle":7705,"status":168,"phases":7706,"primaryCompletion":7707,"completion":7707,"start":7708,"enrollment":2070,"conditions":7709,"interventions":7714},"NCT06870487","A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers",[91],"2026-04-23","2025-05-08",[7710,7711,7712,7713,1798,422],"Peripheral T Cell Lymphoma","Diffuse Large B-cell Lymphoma","Classical Hodgkin Lymphoma","Head and Neck Squamous Cell Carcinoma",[7715,1773],"PF-08046032",{"nctId":1753,"briefTitle":1754,"status":126,"phases":7717,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":7718,"interventions":7719},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":7721,"briefTitle":7722,"status":168,"phases":7723,"primaryCompletion":3239,"completion":3239,"start":7724,"enrollment":870,"conditions":7725,"interventions":7729},"NCT06546553","A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",[91],"2024-09-06",[2053,7726,5823,1859,7727,7728],"Non-small-cell Lung Cancer","Colorectal Carcinoma","Ovarian Carcinoma",[7730,7731],"PF-07826390","sasanlimab",{"nctId":4231,"briefTitle":4232,"status":168,"phases":7733,"primaryCompletion":161,"completion":161,"start":4234,"enrollment":541,"conditions":7734,"interventions":7735},[91],[3077],[4237,1773,933],{"nctId":7737,"briefTitle":7738,"status":168,"phases":7739,"primaryCompletion":3924,"completion":3924,"start":7740,"enrollment":257,"conditions":7741,"interventions":7742},"NCT06580938","A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer",[91],"2024-11-11",[643,5847,1859,1798,1302,2022],[7743,1773],"PF-07921585",{"nctId":7745,"briefTitle":7746,"status":168,"phases":7747,"primaryCompletion":7748,"completion":7749,"start":1157,"enrollment":627,"conditions":7750,"interventions":7751},"NCT06285097","A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",[91],"2025-01-03","2025-02-13",[2053,7726,1798,5823,1859,907,7727,7728],[7752,1773],"PF-07820435",{"nctId":7754,"briefTitle":7755,"status":168,"phases":7756,"primaryCompletion":7757,"completion":7758,"start":7759,"enrollment":1487,"conditions":7760,"interventions":7762},"NCT06974734","A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies",[91],"2026-03-20","2026-03-31","2025-05-06",[7761,1761,4728,1347],"Carcinoma, Non Small Cell Lung",[7763,7731],"PF-08046037",{"nctId":7765,"briefTitle":7766,"status":649,"phases":7767,"primaryCompletion":7768,"completion":7768,"start":7769,"enrollment":103,"conditions":7770,"interventions":7771},"NCT05259397","PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)",[91],"2022-09-19","2022-03-24",[5847],[7772,7731],"PF-07225570",{"nctId":7774,"briefTitle":7775,"status":168,"phases":7776,"primaryCompletion":7777,"completion":7777,"start":7778,"enrollment":360,"conditions":7779,"interventions":7782},"NCT05233436","PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors",[91],"2023-10-16","2022-02-24",[553,7780,994,905,643,7781],"Gastric Cancer","Head and Neck Squamous Cell Carcinomas",[7783,1773],"PF-07265028",{"nctId":1775,"briefTitle":1776,"status":168,"phases":7785,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":7786,"interventions":7787},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":7789,"activeCount":103},[7790],{"nctId":3224,"briefTitle":3225,"status":168,"phases":7791,"primaryCompletion":1071,"completion":3227,"start":3228,"enrollment":3229,"conditions":7792,"interventions":7793},[91,92],[376],[3232,1812,1832,1773,933,3233],{"trials":7795,"activeCount":103},[],{"trials":7797,"activeCount":103},[],{"trials":7799,"activeCount":103},[],{"intervention":7801,"totalTrials":2070,"cells":7802},"PF-07328948",{"EARLY_PHASE1":7803,"PHASE1":7805,"PHASE2":7855,"PHASE3":7857,"PHASE4":7859,"NA":7861},{"trials":7804,"activeCount":103},[],{"trials":7806,"activeCount":1087,"soonestReadout":7851},[7807,7815,7822,7832,7840,7847],{"nctId":7808,"briefTitle":7809,"status":126,"phases":7810,"primaryCompletion":7811,"completion":7811,"start":7812,"enrollment":5909,"conditions":7813,"interventions":7814},"NCT07315360","A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function",[91],"2027-03-13","2026-01-28",[352,16],[7801],{"nctId":7816,"briefTitle":7817,"status":111,"phases":7818,"primaryCompletion":2768,"completion":2768,"start":7819,"enrollment":870,"conditions":7820,"interventions":7821},"NCT07455240","A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults",[91],"2026-03-02",[1489],[7801],{"nctId":7823,"briefTitle":7824,"status":111,"phases":7825,"primaryCompletion":7826,"completion":7826,"start":7827,"enrollment":1239,"conditions":7828,"interventions":7829},"NCT06837259","A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults",[91],"2025-06-11","2025-03-19",[2715],[7801,7830,7831],"cyclosporine","clarithromycin",{"nctId":7833,"briefTitle":7834,"status":111,"phases":7835,"primaryCompletion":7836,"completion":7836,"start":7837,"enrollment":1122,"conditions":7838,"interventions":7839},"NCT05807490","A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults",[91],"2024-07-10","2023-04-05",[16],[7801,7801,7801,7801,7801,7801,7801,7801,7801,7801,7801,7801],{"nctId":7841,"briefTitle":7842,"status":111,"phases":7843,"primaryCompletion":7844,"completion":7844,"start":6106,"enrollment":2159,"conditions":7845,"interventions":7846},"NCT05654181","A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants",[91],"2023-05-03",[16],[7801],{"nctId":7848,"briefTitle":7849,"status":126,"phases":7850,"primaryCompletion":7851,"completion":7851,"start":2711,"enrollment":1239,"conditions":7852,"interventions":7854},"NCT07269301","A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function",[91],"2027-02-23",[7853,16],"Hepatic Impairment",[7801],{"trials":7856,"activeCount":103},[],{"trials":7858,"activeCount":103},[],{"trials":7860,"activeCount":103},[],{"trials":7862,"activeCount":103},[],{"intervention":7864,"totalTrials":1087,"cells":7865},"PF-07985631",{"EARLY_PHASE1":7866,"PHASE1":7868,"PHASE2":7885,"PHASE3":7887,"PHASE4":7889,"NA":7891},{"trials":7867,"activeCount":103},[],{"trials":7869,"activeCount":1087,"soonestReadout":7882},[7870,7878],{"nctId":7871,"briefTitle":7872,"status":126,"phases":7873,"primaryCompletion":7874,"completion":7874,"start":7875,"enrollment":6152,"conditions":7876,"interventions":7877},"NCT06994897","A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults",[91],"2027-12-08","2025-08-13",[16],[7864],{"nctId":7879,"briefTitle":7880,"status":126,"phases":7881,"primaryCompletion":7882,"completion":7882,"start":1016,"enrollment":407,"conditions":7883,"interventions":7884},"NCT07235150","A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults",[91],"2027-08-24",[16],[7864],{"trials":7886,"activeCount":103},[],{"trials":7888,"activeCount":103},[],{"trials":7890,"activeCount":103},[],{"trials":7892,"activeCount":103},[],{"intervention":1988,"totalTrials":1087,"cells":7894},{"EARLY_PHASE1":7895,"PHASE1":7897,"PHASE2":7919,"PHASE3":7921,"PHASE4":7923,"NA":7925},{"trials":7896,"activeCount":103},[],{"trials":7898,"activeCount":1087,"soonestReadout":7903},[7899,7915],{"nctId":7900,"briefTitle":7901,"status":126,"phases":7902,"primaryCompletion":7903,"completion":7904,"start":1431,"enrollment":7905,"conditions":7906,"interventions":7913},"NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors",[91],"2027-08-09","2029-02-07",124,[1798,1985,1984,422,4731,4730,7907,7908,7909,7910,7911,7912,687],"Advanced or Metastatic Solid Tumors","HGG","LGG","Low Grade Glioma","High Grade Glioma","Differentiated Thyroid Cancer",[7914,1988],"PF-07799544",{"nctId":1977,"briefTitle":1978,"status":126,"phases":7916,"primaryCompletion":1980,"completion":1981,"start":786,"enrollment":1982,"conditions":7917,"interventions":7918},[91],[1798,409,1984,1985,1986],[1988,341,342,1989,1990,1991,1992],{"trials":7920,"activeCount":103},[],{"trials":7922,"activeCount":103},[],{"trials":7924,"activeCount":103},[],{"trials":7926,"activeCount":103},[],{"intervention":7928,"totalTrials":597,"cells":7929},"Tafamidis",{"EARLY_PHASE1":7930,"PHASE1":7932,"PHASE2":8003,"PHASE3":8005,"PHASE4":8043,"NA":8053},{"trials":7931,"activeCount":103},[],{"trials":7933,"activeCount":1087,"soonestReadout":7978},[7934,7943,7952,7959,7967,7974,7982,7988,7995],{"nctId":7935,"briefTitle":7936,"status":111,"phases":7937,"primaryCompletion":7938,"completion":7938,"start":7939,"enrollment":597,"conditions":7940,"interventions":7941},"NCT03280173","A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood",[91],"2018-02-23","2017-09-29",[16],[7942],"tafamidis",{"nctId":7944,"briefTitle":7945,"status":111,"phases":7946,"primaryCompletion":7947,"completion":7948,"start":7949,"enrollment":1780,"conditions":7950,"interventions":7951},"NCT03266705","A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood",[91],"2018-02-15","2018-03-01","2017-09-20",[16],[7942],{"nctId":7953,"briefTitle":7954,"status":111,"phases":7955,"primaryCompletion":1700,"completion":1700,"start":540,"enrollment":627,"conditions":7956,"interventions":7958},"NCT01655511","Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers",[91],[7957],"TTR Cardiomyopathy",[7928,7928,7928],{"nctId":7960,"briefTitle":7961,"status":111,"phases":7962,"primaryCompletion":7963,"completion":7963,"start":7964,"enrollment":627,"conditions":7965,"interventions":7966},"NCT03662191","Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)",[91],"2019-01-10","2018-09-28",[19],[7928],{"nctId":7968,"briefTitle":7969,"status":111,"phases":7970,"primaryCompletion":7971,"completion":7971,"start":652,"enrollment":1509,"conditions":7972,"interventions":7973},"NCT02189330","A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples",[91],"2014-07",[19],[7928,7928,7928,7928,7928],{"nctId":7975,"briefTitle":7976,"status":126,"phases":7977,"primaryCompletion":7978,"completion":7978,"start":7979,"enrollment":1509,"conditions":7980,"interventions":7981},"NCT07470866","A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions",[91],"2026-06-02","2026-03-23",[16],[7928,7928],{"nctId":7983,"briefTitle":7984,"status":111,"phases":7985,"primaryCompletion":4438,"completion":4438,"start":4589,"enrollment":1268,"conditions":7986,"interventions":7987},"NCT02406560","A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food",[91],[19],[7942,7942,7942],{"nctId":7989,"briefTitle":7990,"status":126,"phases":7991,"primaryCompletion":7992,"completion":7992,"start":2778,"enrollment":1780,"conditions":7993,"interventions":7994},"NCT07587697","A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions",[91],"2026-08-03",[2715],[7928,7928,7928],{"nctId":7996,"briefTitle":7997,"status":111,"phases":7998,"primaryCompletion":7999,"completion":7999,"start":8000,"enrollment":1268,"conditions":8001,"interventions":8002},"NCT02746926","A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers",[91],"2016-07-15","2016-04-29",[16],[7942],{"trials":8004,"activeCount":103},[],{"trials":8006,"activeCount":103},[8007,8017,8026,8033],{"nctId":8008,"briefTitle":8009,"status":111,"phases":8010,"primaryCompletion":8011,"completion":8011,"start":8012,"enrollment":8013,"conditions":8014,"interventions":8016},"NCT00925002","Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis",[93],"2020-07-08","2009-08-05",93,[8015],"ATTR-PN",[7928],{"nctId":8018,"briefTitle":8019,"status":111,"phases":8020,"primaryCompletion":8021,"completion":8021,"start":8022,"enrollment":276,"conditions":8023,"interventions":8025},"NCT01994889","Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy",[93],"2018-02-07","2013-12-09",[8024],"Transthyretin (TTR) Amyloid Cardiomyopathy",[7928,7928],{"nctId":8027,"briefTitle":8028,"status":111,"phases":8029,"primaryCompletion":3324,"completion":3324,"start":570,"enrollment":870,"conditions":8030,"interventions":8032},"NCT01435655","The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin",[93],[8031],"Transthyretin Familial Amyloid Polyneuropathy",[7942],{"nctId":8034,"briefTitle":8035,"status":111,"phases":8036,"primaryCompletion":8037,"completion":8038,"start":8039,"enrollment":8040,"conditions":8041,"interventions":8042},"NCT02791230","Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy",[93],"2023-10-26","2023-11-02","2016-06-13",1733,[8024],[7928],{"trials":8044,"activeCount":103},[8045],{"nctId":8046,"briefTitle":8047,"status":111,"phases":8048,"primaryCompletion":7777,"completion":7777,"start":8049,"enrollment":336,"conditions":8050,"interventions":8052},"NCT04814186","A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",[94],"2021-07-22",[8051],"Transthyretin Amyloid Cardiomyopathy",[7928],{"trials":8054,"activeCount":103},[8055,8063,8072,8082],{"nctId":8056,"briefTitle":8057,"status":111,"phases":8058,"primaryCompletion":8059,"completion":8059,"start":7473,"enrollment":870,"conditions":8060,"interventions":8062},"NCT05139680","A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis",[],"2023-05-19",[8061],"Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype",[7942],{"nctId":8064,"briefTitle":8065,"status":111,"phases":8066,"primaryCompletion":8067,"completion":8067,"start":8068,"enrollment":26,"conditions":8069,"interventions":8071},"NCT06393465","Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy",[],"2026-04-07","2024-06-15",[8070],"Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)",[7928],{"nctId":8073,"briefTitle":8074,"status":111,"phases":8075,"primaryCompletion":8076,"completion":8076,"start":8077,"enrollment":578,"conditions":8078,"interventions":8081},"NCT05560555","Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.",[],"2022-11-15","2022-10-24",[8079,8080],"Hereditary Transthyretin Amyloidosis (ATTRv)","Polyneuropathy",[7928],{"nctId":8083,"briefTitle":8084,"status":111,"phases":8085,"primaryCompletion":8086,"completion":8086,"start":8087,"enrollment":2070,"conditions":8088,"interventions":8089},"NCT06086353","A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India",[],"2025-06-06","2024-03-25",[8051],[7928],{"intervention":1770,"totalTrials":3254,"cells":8091},{"EARLY_PHASE1":8092,"PHASE1":8094,"PHASE2":8139,"PHASE3":8158,"PHASE4":8184,"NA":8186},{"trials":8093,"activeCount":103},[],{"trials":8095,"activeCount":302,"soonestReadout":1756},[8096,8103,8107,8111,8118,8127,8131,8135],{"nctId":8097,"briefTitle":8098,"status":111,"phases":8099,"primaryCompletion":4627,"completion":605,"start":2964,"enrollment":504,"conditions":8100,"interventions":8101},"NCT00553696","Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer",[91],[2886],[1770,8102,4327],"S-1",{"nctId":1753,"briefTitle":1754,"status":126,"phases":8104,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":8105,"interventions":8106},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":4218,"briefTitle":4219,"status":111,"phases":8108,"primaryCompletion":4221,"completion":3353,"start":4222,"enrollment":525,"conditions":8109,"interventions":8110},[91],[2886,4224],[555,2888,2890],{"nctId":8112,"briefTitle":8113,"status":111,"phases":8114,"primaryCompletion":4221,"completion":561,"start":8115,"enrollment":3229,"conditions":8116,"interventions":8117},"NCT00555672","Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer",[91],"2008-08",[2886],[3080,2890,2889],{"nctId":8119,"briefTitle":8120,"status":111,"phases":8121,"primaryCompletion":683,"completion":683,"start":8122,"enrollment":8123,"conditions":8124,"interventions":8125},"NCT01920061","A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)",[91],"2013-09-10",110,[766],[2003,3631,1770,8126],"Dacomitinib",{"nctId":2880,"briefTitle":2881,"status":111,"phases":8128,"primaryCompletion":561,"completion":2883,"start":2884,"enrollment":407,"conditions":8129,"interventions":8130},[91],[2886],[2888,1992,2889,2888,2890,2889],{"nctId":3836,"briefTitle":3837,"status":111,"phases":8132,"primaryCompletion":3839,"completion":3642,"start":2964,"enrollment":787,"conditions":8133,"interventions":8134},[91],[376],[1705,1770,1764,3842],{"nctId":1775,"briefTitle":1776,"status":168,"phases":8136,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":8137,"interventions":8138},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":8140,"activeCount":103},[8141,8150],{"nctId":8142,"briefTitle":8143,"status":168,"phases":8144,"primaryCompletion":114,"completion":114,"start":4206,"enrollment":627,"conditions":8145,"interventions":8147},"NCT00977561","A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer",[92],[8146],"Small Cell Lung Carcinoma",[8148,1770,8149,1770,8149],"figitumumab","Etoposide",{"nctId":8151,"briefTitle":8152,"status":111,"phases":8153,"primaryCompletion":570,"completion":570,"start":8154,"enrollment":1796,"conditions":8155,"interventions":8156},"NCT00735904","Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer",[92],"2008-12",[947],[3339,8157,2890],"gemcitabine",{"trials":8159,"activeCount":103},[8160,8166,8176],{"nctId":8161,"briefTitle":8162,"status":649,"phases":8163,"primaryCompletion":652,"completion":652,"start":586,"enrollment":103,"conditions":8164,"interventions":8165},"NCT00907504","Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer",[93],[376],[1705,1770,1764,1770,1764],{"nctId":8167,"briefTitle":8168,"status":168,"phases":8169,"primaryCompletion":3839,"completion":3839,"start":8170,"enrollment":8171,"conditions":8172,"interventions":8173},"NCT00254904","Randomized Trial of Gemcitabine\u002FCisplatin + PF-3512676 vs Gemcitabine\u002FCisplatin Alone in Patients With Advanced NSCLC",[93],"2005-11",839,[376],[1770,1764,8174,1770,8175],"PF-3512676","Gemcitabine + Cisplatin",{"nctId":8177,"briefTitle":8178,"status":111,"phases":8179,"primaryCompletion":8180,"start":2629,"conditions":8181,"interventions":8182},"NCT00004199","Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer",[93],"2001-07",[981],[2890,8183,6441],"gemcitabine hydrochloride",{"trials":8185,"activeCount":103},[],{"trials":8187,"activeCount":103},[],{"intervention":1764,"totalTrials":1625,"cells":8189},{"EARLY_PHASE1":8190,"PHASE1":8192,"PHASE2":8213,"PHASE3":8237,"PHASE4":8260,"NA":8262},{"trials":8191,"activeCount":103},[],{"trials":8193,"activeCount":302,"soonestReadout":1756},[8194,8198,8205,8209],{"nctId":1753,"briefTitle":1754,"status":126,"phases":8195,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":8196,"interventions":8197},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":8199,"briefTitle":8200,"status":168,"phases":8201,"primaryCompletion":523,"completion":523,"start":4615,"enrollment":32,"conditions":8202,"interventions":8203},"NCT00437203","PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine",[91],[2053],[8204,8157],"PF-00477736",{"nctId":3836,"briefTitle":3837,"status":111,"phases":8206,"primaryCompletion":3839,"completion":3642,"start":2964,"enrollment":787,"conditions":8207,"interventions":8208},[91],[376],[1705,1770,1764,3842],{"nctId":1775,"briefTitle":1776,"status":168,"phases":8210,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":8211,"interventions":8212},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":8214,"activeCount":103},[8215,8223,8233],{"nctId":8216,"briefTitle":8217,"status":111,"phases":8218,"primaryCompletion":8219,"completion":8219,"start":8220,"enrollment":4360,"conditions":8221,"interventions":8222},"NCT00219557","AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer",[92],"2008-03-14","2005-07-05",[2180],[1764,3339,1764],{"nctId":8224,"briefTitle":8225,"status":168,"phases":8226,"primaryCompletion":8227,"completion":8227,"start":8228,"enrollment":502,"conditions":8229,"interventions":8231},"NCT02109445","Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies",[92],"2014-11-06","2014-09-03",[8230],"Metastatic Cancer Pancreas",[8232,1764,1765,8232,1764,1765,1764,1765],"PF-03084014",{"nctId":8151,"briefTitle":8152,"status":111,"phases":8234,"primaryCompletion":570,"completion":570,"start":8154,"enrollment":1796,"conditions":8235,"interventions":8236},[92],[947],[3339,8157,2890],{"trials":8238,"activeCount":103},[8239,8243,8247,8256],{"nctId":8161,"briefTitle":8162,"status":649,"phases":8240,"primaryCompletion":652,"completion":652,"start":586,"enrollment":103,"conditions":8241,"interventions":8242},[93],[376],[1705,1770,1764,1770,1764],{"nctId":2908,"briefTitle":2909,"status":168,"phases":8244,"primaryCompletion":2911,"completion":2911,"start":2912,"enrollment":350,"conditions":8245,"interventions":8246},[93],[2914],[663,2916,2917,2918,1764,1767],{"nctId":8248,"briefTitle":8249,"status":111,"phases":8250,"primaryCompletion":8251,"completion":8252,"start":2641,"enrollment":8253,"conditions":8254,"interventions":8255},"NCT00471146","Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.",[93],"2009-01","2010-11",630,[1761],[3339,1764,1764],{"nctId":8167,"briefTitle":8168,"status":168,"phases":8257,"primaryCompletion":3839,"completion":3839,"start":8170,"enrollment":8171,"conditions":8258,"interventions":8259},[93],[376],[1770,1764,8174,1770,8175],{"trials":8261,"activeCount":103},[],{"trials":8263,"activeCount":103},[],{"intervention":2515,"totalTrials":3659,"cells":8265},{"EARLY_PHASE1":8266,"PHASE1":8268,"PHASE2":8284,"PHASE3":8310,"PHASE4":8339,"NA":8341},{"trials":8267,"activeCount":103},[],{"trials":8269,"activeCount":302,"soonestReadout":2504},[8270,8274],{"nctId":2501,"briefTitle":2502,"status":381,"phases":8271,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":8272,"interventions":8273},[91],[2508],[2510,2511,2512,2513,2514,2494,2515],{"nctId":8275,"briefTitle":8276,"status":111,"phases":8277,"primaryCompletion":4438,"completion":4438,"start":2449,"enrollment":8278,"conditions":8279,"interventions":8281},"NCT01723254","A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis",[91],190,[8280],"Allergic Rhinitis",[8282,8283,2515],"IGE-1","IGE-2",{"trials":8285,"activeCount":103},[8286,8301],{"nctId":8287,"briefTitle":8288,"status":111,"phases":8289,"primaryCompletion":8290,"completion":8291,"start":8292,"enrollment":8293,"conditions":8294,"interventions":8300},"NCT01323270","A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to \u003C19 Years.",[92],"2012-10-08","2013-02-19","2011-03-18",753,[8295,8296,8297,8298,8299],"Meningococcal Vaccine","rLP2086","Repevax","N Meningitidis Serogroup B","Meningitis",[8296,8297,2515,8297],{"nctId":8302,"briefTitle":8303,"status":111,"phases":8304,"primaryCompletion":8305,"completion":8305,"start":3798,"enrollment":8306,"conditions":8307,"interventions":8308},"NCT04440176","A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules",[92],"2024-01-05",309,[8295],[8309,2515],"MenABCWY",{"trials":8311,"activeCount":103},[8312,8322,8330],{"nctId":8313,"briefTitle":8314,"status":111,"phases":8315,"primaryCompletion":8316,"completion":8316,"start":3798,"enrollment":8317,"conditions":8318,"interventions":8319},"NCT04440163","MenABCWY Noninferiority Study in Healthy Participants ≥10 to \u003C26 Years of Age",[93],"2022-07-24",2431,[8295],[8309,2515,8320,8321],"Trumenba","MenACWY-CRM",{"nctId":8323,"briefTitle":8324,"status":111,"phases":8325,"primaryCompletion":4589,"completion":4589,"start":6208,"enrollment":8326,"conditions":8327,"interventions":8328},"NCT01830855","A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to \u003C19 Years",[93],3596,[8295],[8296,8296,8296,8329,2515],"Havrix",{"nctId":8331,"briefTitle":8332,"status":111,"phases":8333,"primaryCompletion":8334,"completion":8334,"start":8335,"enrollment":8336,"conditions":8337,"interventions":8338},"NCT03135834","A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to \u003C26 Years of Age.",[93],"2022-10-25","2017-04-24",1610,[8295],[8309,2515,8296,8321],{"trials":8340,"activeCount":103},[],{"trials":8342,"activeCount":103},[],{"intervention":8344,"totalTrials":3659,"cells":8345},"Zavegepant",{"EARLY_PHASE1":8346,"PHASE1":8348,"PHASE2":8376,"PHASE3":8378,"PHASE4":8417,"NA":8419},{"trials":8347,"activeCount":103},[],{"trials":8349,"activeCount":302,"soonestReadout":8362},[8350,8358,8366],{"nctId":8351,"briefTitle":8352,"status":111,"phases":8353,"primaryCompletion":8354,"completion":8354,"start":8355,"enrollment":3254,"conditions":8356,"interventions":8357},"NCT05960032","A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants",[91],"2023-12-12","2023-10-23",[16],[8344],{"nctId":8359,"briefTitle":8360,"status":126,"phases":8361,"primaryCompletion":8362,"completion":8362,"start":8363,"enrollment":314,"conditions":8364,"interventions":8365},"NCT06995729","A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine",[91],"2027-08-12","2025-05-16",[118],[8344],{"nctId":8367,"briefTitle":8368,"status":168,"phases":8369,"primaryCompletion":8370,"completion":8371,"start":8372,"enrollment":8373,"conditions":8374,"interventions":8375},"NCT04987944","Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma",[91],"2023-03-29","2023-04-04","2021-10-18",45,[6589],[8344],{"trials":8377,"activeCount":103},[],{"trials":8379,"activeCount":103},[8380,8390,8400,8408],{"nctId":8381,"briefTitle":8382,"status":111,"phases":8383,"primaryCompletion":8384,"completion":8385,"start":8386,"enrollment":8387,"conditions":8388,"interventions":8389},"NCT03872453","Acute Treatment Trial in Adult Subjects With Migraines",[92,93],"2019-10-31","2019-11-11","2019-03-25",2154,[117],[8344],{"nctId":8391,"briefTitle":8392,"status":111,"phases":8393,"primaryCompletion":8394,"completion":8395,"start":8396,"enrollment":8397,"conditions":8398,"interventions":8399},"NCT04408794","Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine",[92,93],"2021-12-09","2021-12-23","2020-06-29",974,[236],[8344],{"nctId":8401,"briefTitle":8402,"status":111,"phases":8403,"primaryCompletion":3460,"completion":3460,"start":8404,"enrollment":8405,"conditions":8406,"interventions":8407},"NCT05989048","A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults",[93],"2023-11-29",1414,[117],[8344],{"nctId":8409,"briefTitle":8410,"status":168,"phases":8411,"primaryCompletion":8412,"completion":8412,"start":8413,"enrollment":8414,"conditions":8415,"interventions":8416},"NCT04346615","Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",[92,93],"2022-04-29","2020-04-25",47,[3926],[8344],{"trials":8418,"activeCount":103},[],{"trials":8420,"activeCount":103},[],{"intervention":1065,"totalTrials":3659,"cells":8422},{"EARLY_PHASE1":8423,"PHASE1":8425,"PHASE2":8453,"PHASE3":8482,"PHASE4":8484,"NA":8486},{"trials":8424,"activeCount":103},[],{"trials":8426,"activeCount":302,"soonestReadout":1057},[8427,8436,8440,8444],{"nctId":8428,"briefTitle":8429,"status":111,"phases":8430,"primaryCompletion":8431,"completion":8431,"start":8432,"enrollment":3659,"conditions":8433,"interventions":8434},"NCT05567887","A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies",[91],"2024-10-02","2022-11-02",[2937,1062],[8435],"maplirpacept",{"nctId":2930,"briefTitle":2931,"status":168,"phases":8437,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":2935,"conditions":8438,"interventions":8439},[91],[2937,1062,2938,2914],[1065,2940,2941,1064,1139,2942,2943],{"nctId":1054,"briefTitle":1055,"status":381,"phases":8441,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":1060,"conditions":8442,"interventions":8443},[91],[1062],[48,1064,1065],{"nctId":8445,"briefTitle":8446,"status":111,"phases":8447,"primaryCompletion":8448,"completion":8448,"start":8449,"enrollment":870,"conditions":8450,"interventions":8452},"NCT05896774","A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China",[91],"2024-11-06","2023-06-28",[8451,1062],"Non-Hodgkin Lymphoma",[1065],{"trials":8454,"activeCount":103},[8455,8459,8469],{"nctId":3942,"briefTitle":3943,"status":168,"phases":8456,"primaryCompletion":3945,"completion":3946,"start":3947,"enrollment":2070,"conditions":8457,"interventions":8458},[91,92],[2914],[1065,3950,1150],{"nctId":8460,"briefTitle":8461,"status":168,"phases":8462,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":35,"conditions":8465,"interventions":8466},"NCT05896163","A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.",[91,92],"2026-04-09","2023-08-30",[2914],[8435,8467,8468],"Glofitamab","Obinutuzumab",{"nctId":8470,"briefTitle":8471,"status":168,"phases":8472,"primaryCompletion":2122,"completion":8473,"start":8474,"enrollment":870,"conditions":8475,"interventions":8480},"NCT05261490","Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer",[91,92],"2024-02-15","2022-08-01",[1653,8476,7728,8477,8478,8479],"Ovarian Neoplasms","Fallopian Tube Cancer","Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma",[8435,8481],"Pegylated Liposomal Doxorubicin",{"trials":8483,"activeCount":103},[],{"trials":8485,"activeCount":103},[],{"trials":8487,"activeCount":103},[],{"intervention":1765,"totalTrials":257,"cells":8489},{"EARLY_PHASE1":8490,"PHASE1":8492,"PHASE2":8506,"PHASE3":8512,"PHASE4":8514,"NA":8516},{"trials":8491,"activeCount":103},[],{"trials":8493,"activeCount":302,"soonestReadout":1756},[8494,8498,8502],{"nctId":1753,"briefTitle":1754,"status":126,"phases":8495,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":8496,"interventions":8497},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":1775,"briefTitle":1776,"status":168,"phases":8499,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":8500,"interventions":8501},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"nctId":1274,"briefTitle":1275,"status":111,"phases":8503,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":407,"conditions":8504,"interventions":8505},[91],[1281],[88,1283],{"trials":8507,"activeCount":103},[8508],{"nctId":8224,"briefTitle":8225,"status":168,"phases":8509,"primaryCompletion":8227,"completion":8227,"start":8228,"enrollment":502,"conditions":8510,"interventions":8511},[92],[8230],[8232,1764,1765,8232,1764,1765,1764,1765],{"trials":8513,"activeCount":103},[],{"trials":8515,"activeCount":103},[],{"trials":8517,"activeCount":103},[],{"intervention":2822,"totalTrials":502,"cells":8519},{"EARLY_PHASE1":8520,"PHASE1":8522,"PHASE2":8540,"PHASE3":8542,"PHASE4":8544,"NA":8546},{"trials":8521,"activeCount":103},[],{"trials":8523,"activeCount":302,"soonestReadout":6233},[8524,8532,8536],{"nctId":8525,"briefTitle":8526,"status":168,"phases":8527,"primaryCompletion":8528,"completion":8528,"start":8529,"enrollment":314,"conditions":8530,"interventions":8531},"NCT05788328","A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants",[91],"2023-09-11","2023-03-27",[16],[2822,2841,7531],{"nctId":2814,"briefTitle":2815,"status":111,"phases":8533,"primaryCompletion":2817,"completion":2818,"start":2819,"enrollment":1509,"conditions":8534,"interventions":8535},[91],[16],[1718,2822],{"nctId":6230,"briefTitle":6231,"status":381,"phases":8537,"primaryCompletion":6233,"completion":6233,"start":3239,"enrollment":314,"conditions":8538,"interventions":8539},[91],[1589],[6236,1687,6237,6238],{"trials":8541,"activeCount":103},[],{"trials":8543,"activeCount":103},[],{"trials":8545,"activeCount":103},[],{"trials":8547,"activeCount":103},[],{"intervention":7700,"totalTrials":302,"cells":8549},{"EARLY_PHASE1":8550,"PHASE1":8552,"PHASE2":8558,"PHASE3":8560,"PHASE4":8562,"NA":8564},{"trials":8551,"activeCount":103},[],{"trials":8553,"activeCount":302,"soonestReadout":7694},[8554],{"nctId":7691,"briefTitle":7692,"status":126,"phases":8555,"primaryCompletion":7694,"completion":7695,"start":7440,"enrollment":7696,"conditions":8556,"interventions":8557},[91],[7698],[7700,1773,7701,7702],{"trials":8559,"activeCount":103},[],{"trials":8561,"activeCount":103},[],{"trials":8563,"activeCount":103},[],{"trials":8565,"activeCount":103},[],{"intervention":7701,"totalTrials":302,"cells":8567},{"EARLY_PHASE1":8568,"PHASE1":8570,"PHASE2":8576,"PHASE3":8578,"PHASE4":8580,"NA":8582},{"trials":8569,"activeCount":103},[],{"trials":8571,"activeCount":302,"soonestReadout":7694},[8572],{"nctId":7691,"briefTitle":7692,"status":126,"phases":8573,"primaryCompletion":7694,"completion":7695,"start":7440,"enrollment":7696,"conditions":8574,"interventions":8575},[91],[7698],[7700,1773,7701,7702],{"trials":8577,"activeCount":103},[],{"trials":8579,"activeCount":103},[],{"trials":8581,"activeCount":103},[],{"trials":8583,"activeCount":103},[],{"intervention":7702,"totalTrials":302,"cells":8585},{"EARLY_PHASE1":8586,"PHASE1":8588,"PHASE2":8594,"PHASE3":8596,"PHASE4":8598,"NA":8600},{"trials":8587,"activeCount":103},[],{"trials":8589,"activeCount":302,"soonestReadout":7694},[8590],{"nctId":7691,"briefTitle":7692,"status":126,"phases":8591,"primaryCompletion":7694,"completion":7695,"start":7440,"enrollment":7696,"conditions":8592,"interventions":8593},[91],[7698],[7700,1773,7701,7702],{"trials":8595,"activeCount":103},[],{"trials":8597,"activeCount":103},[],{"trials":8599,"activeCount":103},[],{"trials":8601,"activeCount":103},[],{"intervention":8603,"totalTrials":302,"cells":8604},"PF-07832837",{"EARLY_PHASE1":8605,"PHASE1":8607,"PHASE2":8617,"PHASE3":8619,"PHASE4":8621,"NA":8623},{"trials":8606,"activeCount":103},[],{"trials":8608,"activeCount":302,"soonestReadout":8613},[8609],{"nctId":8610,"briefTitle":8611,"status":126,"phases":8612,"primaryCompletion":8613,"completion":8613,"start":8614,"enrollment":7378,"conditions":8615,"interventions":8616},"NCT06564389","FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients",[91],"2027-06-02","2024-11-05",[28,1589],[8603],{"trials":8618,"activeCount":103},[],{"trials":8620,"activeCount":103},[],{"trials":8622,"activeCount":103},[],{"trials":8624,"activeCount":103},[],{"intervention":2510,"totalTrials":302,"cells":8626},{"EARLY_PHASE1":8627,"PHASE1":8629,"PHASE2":8635,"PHASE3":8637,"PHASE4":8639,"NA":8641},{"trials":8628,"activeCount":103},[],{"trials":8630,"activeCount":302,"soonestReadout":2504},[8631],{"nctId":2501,"briefTitle":2502,"status":381,"phases":8632,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":8633,"interventions":8634},[91],[2508],[2510,2511,2512,2513,2514,2494,2515],{"trials":8636,"activeCount":103},[],{"trials":8638,"activeCount":103},[],{"trials":8640,"activeCount":103},[],{"trials":8642,"activeCount":103},[],{"intervention":2511,"totalTrials":302,"cells":8644},{"EARLY_PHASE1":8645,"PHASE1":8647,"PHASE2":8653,"PHASE3":8655,"PHASE4":8657,"NA":8659},{"trials":8646,"activeCount":103},[],{"trials":8648,"activeCount":302,"soonestReadout":2504},[8649],{"nctId":2501,"briefTitle":2502,"status":381,"phases":8650,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":8651,"interventions":8652},[91],[2508],[2510,2511,2512,2513,2514,2494,2515],{"trials":8654,"activeCount":103},[],{"trials":8656,"activeCount":103},[],{"trials":8658,"activeCount":103},[],{"trials":8660,"activeCount":103},[],{"intervention":2512,"totalTrials":302,"cells":8662},{"EARLY_PHASE1":8663,"PHASE1":8665,"PHASE2":8671,"PHASE3":8673,"PHASE4":8675,"NA":8677},{"trials":8664,"activeCount":103},[],{"trials":8666,"activeCount":302,"soonestReadout":2504},[8667],{"nctId":2501,"briefTitle":2502,"status":381,"phases":8668,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":8669,"interventions":8670},[91],[2508],[2510,2511,2512,2513,2514,2494,2515],{"trials":8672,"activeCount":103},[],{"trials":8674,"activeCount":103},[],{"trials":8676,"activeCount":103},[],{"trials":8678,"activeCount":103},[],{"intervention":2513,"totalTrials":302,"cells":8680},{"EARLY_PHASE1":8681,"PHASE1":8683,"PHASE2":8689,"PHASE3":8691,"PHASE4":8693,"NA":8695},{"trials":8682,"activeCount":103},[],{"trials":8684,"activeCount":302,"soonestReadout":2504},[8685],{"nctId":2501,"briefTitle":2502,"status":381,"phases":8686,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":8687,"interventions":8688},[91],[2508],[2510,2511,2512,2513,2514,2494,2515],{"trials":8690,"activeCount":103},[],{"trials":8692,"activeCount":103},[],{"trials":8694,"activeCount":103},[],{"trials":8696,"activeCount":103},[],{"intervention":2514,"totalTrials":302,"cells":8698},{"EARLY_PHASE1":8699,"PHASE1":8701,"PHASE2":8707,"PHASE3":8709,"PHASE4":8711,"NA":8713},{"trials":8700,"activeCount":103},[],{"trials":8702,"activeCount":302,"soonestReadout":2504},[8703],{"nctId":2501,"briefTitle":2502,"status":381,"phases":8704,"primaryCompletion":2504,"completion":2504,"start":2505,"enrollment":2506,"conditions":8705,"interventions":8706},[91],[2508],[2510,2511,2512,2513,2514,2494,2515],{"trials":8708,"activeCount":103},[],{"trials":8710,"activeCount":103},[],{"trials":8712,"activeCount":103},[],{"trials":8714,"activeCount":103},[],{"intervention":8716,"totalTrials":302,"cells":8717},"PF-08065010",{"EARLY_PHASE1":8718,"PHASE1":8720,"PHASE2":8730,"PHASE3":8732,"PHASE4":8734,"NA":8736},{"trials":8719,"activeCount":103},[],{"trials":8721,"activeCount":302,"soonestReadout":8726},[8722],{"nctId":8723,"briefTitle":8724,"status":263,"phases":8725,"primaryCompletion":8726,"completion":8726,"start":8727,"enrollment":397,"conditions":8728,"interventions":8729},"NCT07235163","A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults",[91],"2027-07-16","2026-04-13",[16],[8716],{"trials":8731,"activeCount":103},[],{"trials":8733,"activeCount":103},[],{"trials":8735,"activeCount":103},[],{"trials":8737,"activeCount":103},[],{"intervention":8739,"totalTrials":302,"cells":8740},"ODT2 Test formulation",{"EARLY_PHASE1":8741,"PHASE1":8743,"PHASE2":8752,"PHASE3":8754,"PHASE4":8756,"NA":8758},{"trials":8742,"activeCount":103},[],{"trials":8744,"activeCount":302,"soonestReadout":2135},[8745],{"nctId":8746,"briefTitle":8747,"status":263,"phases":8748,"primaryCompletion":2135,"completion":2135,"start":446,"enrollment":1530,"conditions":8749,"interventions":8750},"NCT07594769","A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults",[91],[117],[8739,8751],"ODT Reference formulation",{"trials":8753,"activeCount":103},[],{"trials":8755,"activeCount":103},[],{"trials":8757,"activeCount":103},[],{"trials":8759,"activeCount":103},[],{"intervention":8751,"totalTrials":302,"cells":8761},{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8770,"PHASE3":8772,"PHASE4":8774,"NA":8776},{"trials":8763,"activeCount":103},[],{"trials":8765,"activeCount":302,"soonestReadout":2135},[8766],{"nctId":8746,"briefTitle":8747,"status":263,"phases":8767,"primaryCompletion":2135,"completion":2135,"start":446,"enrollment":1530,"conditions":8768,"interventions":8769},[91],[117],[8739,8751],{"trials":8771,"activeCount":103},[],{"trials":8773,"activeCount":103},[],{"trials":8775,"activeCount":103},[],{"trials":8777,"activeCount":103},[],{"intervention":1763,"totalTrials":302,"cells":8779},{"EARLY_PHASE1":8780,"PHASE1":8782,"PHASE2":8788,"PHASE3":8790,"PHASE4":8792,"NA":8794},{"trials":8781,"activeCount":103},[],{"trials":8783,"activeCount":302,"soonestReadout":1756},[8784],{"nctId":1753,"briefTitle":1754,"status":126,"phases":8785,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":8786,"interventions":8787},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"trials":8789,"activeCount":103},[],{"trials":8791,"activeCount":103},[],{"trials":8793,"activeCount":103},[],{"trials":8795,"activeCount":103},[],{"intervention":6147,"totalTrials":302,"cells":8797},{"EARLY_PHASE1":8798,"PHASE1":8800,"PHASE2":8806,"PHASE3":8808,"PHASE4":8810,"NA":8812},{"trials":8799,"activeCount":103},[],{"trials":8801,"activeCount":302,"soonestReadout":6143},[8802],{"nctId":6140,"briefTitle":6141,"status":126,"phases":8803,"primaryCompletion":6143,"completion":6144,"start":960,"enrollment":941,"conditions":8804,"interventions":8805},[91],[3868,543],[6147,1687],{"trials":8807,"activeCount":103},[],{"trials":8809,"activeCount":103},[],{"trials":8811,"activeCount":103},[],{"trials":8813,"activeCount":103},[],{"intervention":8815,"totalTrials":302,"cells":8816},"PF-08046033",{"EARLY_PHASE1":8817,"PHASE1":8819,"PHASE2":8832,"PHASE3":8834,"PHASE4":8836,"NA":8838},{"trials":8818,"activeCount":103},[],{"trials":8820,"activeCount":302,"soonestReadout":8825},[8821],{"nctId":8822,"briefTitle":8823,"status":126,"phases":8824,"primaryCompletion":8825,"completion":8826,"start":3731,"enrollment":8827,"conditions":8828,"interventions":8831},"NCT07519655","Phase 1 Study of PF-08046033 in Advanced Solid Tumors",[91],"2028-07-14","2029-07-14",250,[944,8829,8830],"Esophageal Cancer","Cutaneous Melanoma",[8815],{"trials":8833,"activeCount":103},[],{"trials":8835,"activeCount":103},[],{"trials":8837,"activeCount":103},[],{"trials":8839,"activeCount":103},[],{"intervention":8841,"totalTrials":302,"cells":8842},"PF-08057418",{"EARLY_PHASE1":8843,"PHASE1":8845,"PHASE2":8854,"PHASE3":8856,"PHASE4":8858,"NA":8860},{"trials":8844,"activeCount":103},[],{"trials":8846,"activeCount":302,"soonestReadout":7617},[8847],{"nctId":8848,"briefTitle":8849,"status":126,"phases":8850,"primaryCompletion":7617,"completion":7617,"start":8851,"enrollment":1487,"conditions":8852,"interventions":8853},"NCT07575906","A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.",[91],"2026-05-08",[16],[8841],{"trials":8855,"activeCount":103},[],{"trials":8857,"activeCount":103},[],{"trials":8859,"activeCount":103},[],{"trials":8861,"activeCount":103},[],{"intervention":8863,"totalTrials":302,"cells":8864},"E coli vaccine 1 Dose A",{"EARLY_PHASE1":8865,"PHASE1":8867,"PHASE2":8886,"PHASE3":8888,"PHASE4":8890,"NA":8892},{"trials":8866,"activeCount":103},[],{"trials":8868,"activeCount":302,"soonestReadout":8873},[8869],{"nctId":8870,"briefTitle":8871,"status":126,"phases":8872,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":8876,"interventions":8877},"NCT07122986","A Study to Learn About a Vaccine Against E Coli in Healthy Adults",[91],"2028-05-26","2025-08-11",310,[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],"E coli vaccine 1 Dose B","E coli vaccine 2","E coli vaccine 3","E coli Vaccine 4 Dose A","E coli Vaccine 4 Dose B","E coli Vaccine 4 Dose C","E coli Vaccine 5 Dose A","E coli Vaccine 5 Dose B",{"trials":8887,"activeCount":103},[],{"trials":8889,"activeCount":103},[],{"trials":8891,"activeCount":103},[],{"trials":8893,"activeCount":103},[],{"intervention":8878,"totalTrials":302,"cells":8895},{"EARLY_PHASE1":8896,"PHASE1":8898,"PHASE2":8904,"PHASE3":8906,"PHASE4":8908,"NA":8910},{"trials":8897,"activeCount":103},[],{"trials":8899,"activeCount":302,"soonestReadout":8873},[8900],{"nctId":8870,"briefTitle":8871,"status":126,"phases":8901,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":8902,"interventions":8903},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":8905,"activeCount":103},[],{"trials":8907,"activeCount":103},[],{"trials":8909,"activeCount":103},[],{"trials":8911,"activeCount":103},[],{"intervention":8879,"totalTrials":302,"cells":8913},{"EARLY_PHASE1":8914,"PHASE1":8916,"PHASE2":8922,"PHASE3":8924,"PHASE4":8926,"NA":8928},{"trials":8915,"activeCount":103},[],{"trials":8917,"activeCount":302,"soonestReadout":8873},[8918],{"nctId":8870,"briefTitle":8871,"status":126,"phases":8919,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":8920,"interventions":8921},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":8923,"activeCount":103},[],{"trials":8925,"activeCount":103},[],{"trials":8927,"activeCount":103},[],{"trials":8929,"activeCount":103},[],{"intervention":8880,"totalTrials":302,"cells":8931},{"EARLY_PHASE1":8932,"PHASE1":8934,"PHASE2":8940,"PHASE3":8942,"PHASE4":8944,"NA":8946},{"trials":8933,"activeCount":103},[],{"trials":8935,"activeCount":302,"soonestReadout":8873},[8936],{"nctId":8870,"briefTitle":8871,"status":126,"phases":8937,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":8938,"interventions":8939},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":8941,"activeCount":103},[],{"trials":8943,"activeCount":103},[],{"trials":8945,"activeCount":103},[],{"trials":8947,"activeCount":103},[],{"intervention":8881,"totalTrials":302,"cells":8949},{"EARLY_PHASE1":8950,"PHASE1":8952,"PHASE2":8958,"PHASE3":8960,"PHASE4":8962,"NA":8964},{"trials":8951,"activeCount":103},[],{"trials":8953,"activeCount":302,"soonestReadout":8873},[8954],{"nctId":8870,"briefTitle":8871,"status":126,"phases":8955,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":8956,"interventions":8957},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":8959,"activeCount":103},[],{"trials":8961,"activeCount":103},[],{"trials":8963,"activeCount":103},[],{"trials":8965,"activeCount":103},[],{"intervention":8882,"totalTrials":302,"cells":8967},{"EARLY_PHASE1":8968,"PHASE1":8970,"PHASE2":8976,"PHASE3":8978,"PHASE4":8980,"NA":8982},{"trials":8969,"activeCount":103},[],{"trials":8971,"activeCount":302,"soonestReadout":8873},[8972],{"nctId":8870,"briefTitle":8871,"status":126,"phases":8973,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":8974,"interventions":8975},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":8977,"activeCount":103},[],{"trials":8979,"activeCount":103},[],{"trials":8981,"activeCount":103},[],{"trials":8983,"activeCount":103},[],{"intervention":8883,"totalTrials":302,"cells":8985},{"EARLY_PHASE1":8986,"PHASE1":8988,"PHASE2":8994,"PHASE3":8996,"PHASE4":8998,"NA":9000},{"trials":8987,"activeCount":103},[],{"trials":8989,"activeCount":302,"soonestReadout":8873},[8990],{"nctId":8870,"briefTitle":8871,"status":126,"phases":8991,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":8992,"interventions":8993},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":8995,"activeCount":103},[],{"trials":8997,"activeCount":103},[],{"trials":8999,"activeCount":103},[],{"trials":9001,"activeCount":103},[],{"intervention":8884,"totalTrials":302,"cells":9003},{"EARLY_PHASE1":9004,"PHASE1":9006,"PHASE2":9012,"PHASE3":9014,"PHASE4":9016,"NA":9018},{"trials":9005,"activeCount":103},[],{"trials":9007,"activeCount":302,"soonestReadout":8873},[9008],{"nctId":8870,"briefTitle":8871,"status":126,"phases":9009,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":9010,"interventions":9011},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":9013,"activeCount":103},[],{"trials":9015,"activeCount":103},[],{"trials":9017,"activeCount":103},[],{"trials":9019,"activeCount":103},[],{"intervention":8885,"totalTrials":302,"cells":9021},{"EARLY_PHASE1":9022,"PHASE1":9024,"PHASE2":9030,"PHASE3":9032,"PHASE4":9034,"NA":9036},{"trials":9023,"activeCount":103},[],{"trials":9025,"activeCount":302,"soonestReadout":8873},[9026],{"nctId":8870,"briefTitle":8871,"status":126,"phases":9027,"primaryCompletion":8873,"completion":8873,"start":8874,"enrollment":8875,"conditions":9028,"interventions":9029},[91],[28],[8863,8878,8879,8880,8881,8882,8883,8884,8885],{"trials":9031,"activeCount":103},[],{"trials":9033,"activeCount":103},[],{"trials":9035,"activeCount":103},[],{"trials":9037,"activeCount":103},[],{"intervention":9039,"totalTrials":302,"cells":9040},"PF-08046876",{"EARLY_PHASE1":9041,"PHASE1":9043,"PHASE2":9059,"PHASE3":9061,"PHASE4":9063,"NA":9065},{"trials":9042,"activeCount":103},[],{"trials":9044,"activeCount":302,"soonestReadout":9049},[9045],{"nctId":9046,"briefTitle":9047,"status":126,"phases":9048,"primaryCompletion":9049,"completion":9050,"start":9051,"enrollment":8875,"conditions":9052,"interventions":9058},"NCT07090499","A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors",[91],"2028-07-08","2029-07-08","2025-08-20",[9053,5847,907,399,7761,9054,1302,8829,9055,9056,995,9057,4778],"Advanced\u002FMetastatic Solid Tumors","Carcinoma, Squamous Cell of Head and Neck","Gastroesophageal Junction Adenocarcinoma","Esophageal Squamous Cell Carcinoma","Pancreatic Adenocarcinoma",[9039],{"trials":9060,"activeCount":103},[],{"trials":9062,"activeCount":103},[],{"trials":9064,"activeCount":103},[],{"trials":9066,"activeCount":103},[],{"intervention":9068,"totalTrials":302,"cells":9069},"atirmociclib",{"EARLY_PHASE1":9070,"PHASE1":9072,"PHASE2":9082,"PHASE3":9084,"PHASE4":9086,"NA":9088},{"trials":9071,"activeCount":103},[],{"trials":9073,"activeCount":302,"soonestReadout":9078},[9074],{"nctId":9075,"briefTitle":9076,"status":126,"phases":9077,"primaryCompletion":9078,"completion":7616,"start":9079,"enrollment":7388,"conditions":9080,"interventions":9081},"NCT07215078","Study About Whether Atirmociclib\u002FPF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants",[91],"2026-06-03","2025-10-08",[1270],[9068],{"trials":9083,"activeCount":103},[],{"trials":9085,"activeCount":103},[],{"trials":9087,"activeCount":103},[],{"trials":9089,"activeCount":103},[],{"intervention":9091,"totalTrials":302,"cells":9092},"Ibuzatrelvir co-process API film coated",{"EARLY_PHASE1":9093,"PHASE1":9095,"PHASE2":9111,"PHASE3":9113,"PHASE4":9115,"NA":9117},{"trials":9094,"activeCount":103},[],{"trials":9096,"activeCount":302,"soonestReadout":9078},[9097],{"nctId":9098,"briefTitle":9099,"status":126,"phases":9100,"primaryCompletion":9078,"completion":9101,"start":8727,"enrollment":597,"conditions":9102,"interventions":9109},"NCT07552779","A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir",[91],"2026-07-06",[9103,4957,9104,9105,3801,9106,2592,3926,3916,9107,9108],"Coronavirus Disease 2019","COVID-19 (Coronavirus Disease 2019)","Upper Respiratory Tract Infections","Respiratory Tract Diseases","Pneumonia","Lung Diseases",[9091,9110],"Ibuzatrelvir filmcoated",{"trials":9112,"activeCount":103},[],{"trials":9114,"activeCount":103},[],{"trials":9116,"activeCount":103},[],{"trials":9118,"activeCount":103},[],{"intervention":9110,"totalTrials":302,"cells":9120},{"EARLY_PHASE1":9121,"PHASE1":9123,"PHASE2":9129,"PHASE3":9131,"PHASE4":9133,"NA":9135},{"trials":9122,"activeCount":103},[],{"trials":9124,"activeCount":302,"soonestReadout":9078},[9125],{"nctId":9098,"briefTitle":9099,"status":126,"phases":9126,"primaryCompletion":9078,"completion":9101,"start":8727,"enrollment":597,"conditions":9127,"interventions":9128},[91],[9103,4957,9104,9105,3801,9106,2592,3926,3916,9107,9108],[9091,9110],{"trials":9130,"activeCount":103},[],{"trials":9132,"activeCount":103},[],{"trials":9134,"activeCount":103},[],{"trials":9136,"activeCount":103},[],{"intervention":7914,"totalTrials":302,"cells":9138},{"EARLY_PHASE1":9139,"PHASE1":9141,"PHASE2":9147,"PHASE3":9149,"PHASE4":9151,"NA":9153},{"trials":9140,"activeCount":103},[],{"trials":9142,"activeCount":302,"soonestReadout":7903},[9143],{"nctId":7900,"briefTitle":7901,"status":126,"phases":9144,"primaryCompletion":7903,"completion":7904,"start":1431,"enrollment":7905,"conditions":9145,"interventions":9146},[91],[1798,1985,1984,422,4731,4730,7907,7908,7909,7910,7911,7912,687],[7914,1988],{"trials":9148,"activeCount":103},[],{"trials":9150,"activeCount":103},[],{"trials":9152,"activeCount":103},[],{"trials":9154,"activeCount":103},[],{"intervention":9156,"totalTrials":302,"cells":9157},"Genotropin 4mg",{"EARLY_PHASE1":9158,"PHASE1":9160,"PHASE2":9171,"PHASE3":9173,"PHASE4":9175,"NA":9177},{"trials":9159,"activeCount":103},[],{"trials":9161,"activeCount":302,"soonestReadout":9166},[9162],{"nctId":9163,"briefTitle":9164,"status":126,"phases":9165,"primaryCompletion":9166,"completion":9167,"start":9168,"enrollment":1239,"conditions":9169,"interventions":9170},"NCT07542886","A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults",[91],"2026-06-25","2026-07-22","2026-04-22",[16],[9156],{"trials":9172,"activeCount":103},[],{"trials":9174,"activeCount":103},[],{"trials":9176,"activeCount":103},[],{"trials":9178,"activeCount":103},[],{"intervention":9180,"totalTrials":302,"cells":9181},"PF-07999415",{"EARLY_PHASE1":9182,"PHASE1":9184,"PHASE2":9194,"PHASE3":9196,"PHASE4":9198,"NA":9200},{"trials":9183,"activeCount":103},[],{"trials":9185,"activeCount":302,"soonestReadout":9190},[9186],{"nctId":9187,"briefTitle":9188,"status":381,"phases":9189,"primaryCompletion":9190,"completion":9190,"start":9191,"enrollment":4259,"conditions":9192,"interventions":9193},"NCT06965465","A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults",[91],"2026-08-22","2025-06-20",[16],[9180],{"trials":9195,"activeCount":103},[],{"trials":9197,"activeCount":103},[],{"trials":9199,"activeCount":103},[],{"trials":9201,"activeCount":103},[],{"intervention":6238,"totalTrials":302,"cells":9203},{"EARLY_PHASE1":9204,"PHASE1":9206,"PHASE2":9212,"PHASE3":9214,"PHASE4":9216,"NA":9218},{"trials":9205,"activeCount":103},[],{"trials":9207,"activeCount":302,"soonestReadout":6233},[9208],{"nctId":6230,"briefTitle":6231,"status":381,"phases":9209,"primaryCompletion":6233,"completion":6233,"start":3239,"enrollment":314,"conditions":9210,"interventions":9211},[91],[1589],[6236,1687,6237,6238],{"trials":9213,"activeCount":103},[],{"trials":9215,"activeCount":103},[],{"trials":9217,"activeCount":103},[],{"trials":9219,"activeCount":103},[],{"intervention":9221,"totalTrials":302,"cells":9222},"PF-07799933 tablets with PF-07799544 fasted",{"EARLY_PHASE1":9223,"PHASE1":9225,"PHASE2":9239,"PHASE3":9241,"PHASE4":9243,"NA":9245},{"trials":9224,"activeCount":103},[],{"trials":9226,"activeCount":302,"soonestReadout":9231},[9227],{"nctId":9228,"briefTitle":9229,"status":126,"phases":9230,"primaryCompletion":9231,"completion":9231,"start":9232,"enrollment":314,"conditions":9233,"interventions":9234},"NCT07563894","Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544",[91],"2026-06-24","2026-04-10",[16],[9221,9235,9236,9237,9238],"PF-07799933 film-coated tablets with PF-07799544 fasted","PF-07799933 film-coated tablets with PF-07799544 fed","PF-07799933 film-coated tablets fasted","PF-07799933 film-coated tablets following rabeprazole pretreatment fasted",{"trials":9240,"activeCount":103},[],{"trials":9242,"activeCount":103},[],{"trials":9244,"activeCount":103},[],{"trials":9246,"activeCount":103},[],{"intervention":9235,"totalTrials":302,"cells":9248},{"EARLY_PHASE1":9249,"PHASE1":9251,"PHASE2":9257,"PHASE3":9259,"PHASE4":9261,"NA":9263},{"trials":9250,"activeCount":103},[],{"trials":9252,"activeCount":302,"soonestReadout":9231},[9253],{"nctId":9228,"briefTitle":9229,"status":126,"phases":9254,"primaryCompletion":9231,"completion":9231,"start":9232,"enrollment":314,"conditions":9255,"interventions":9256},[91],[16],[9221,9235,9236,9237,9238],{"trials":9258,"activeCount":103},[],{"trials":9260,"activeCount":103},[],{"trials":9262,"activeCount":103},[],{"trials":9264,"activeCount":103},[],{"intervention":9236,"totalTrials":302,"cells":9266},{"EARLY_PHASE1":9267,"PHASE1":9269,"PHASE2":9275,"PHASE3":9277,"PHASE4":9279,"NA":9281},{"trials":9268,"activeCount":103},[],{"trials":9270,"activeCount":302,"soonestReadout":9231},[9271],{"nctId":9228,"briefTitle":9229,"status":126,"phases":9272,"primaryCompletion":9231,"completion":9231,"start":9232,"enrollment":314,"conditions":9273,"interventions":9274},[91],[16],[9221,9235,9236,9237,9238],{"trials":9276,"activeCount":103},[],{"trials":9278,"activeCount":103},[],{"trials":9280,"activeCount":103},[],{"trials":9282,"activeCount":103},[],{"intervention":9237,"totalTrials":302,"cells":9284},{"EARLY_PHASE1":9285,"PHASE1":9287,"PHASE2":9293,"PHASE3":9295,"PHASE4":9297,"NA":9299},{"trials":9286,"activeCount":103},[],{"trials":9288,"activeCount":302,"soonestReadout":9231},[9289],{"nctId":9228,"briefTitle":9229,"status":126,"phases":9290,"primaryCompletion":9231,"completion":9231,"start":9232,"enrollment":314,"conditions":9291,"interventions":9292},[91],[16],[9221,9235,9236,9237,9238],{"trials":9294,"activeCount":103},[],{"trials":9296,"activeCount":103},[],{"trials":9298,"activeCount":103},[],{"trials":9300,"activeCount":103},[],{"intervention":9238,"totalTrials":302,"cells":9302},{"EARLY_PHASE1":9303,"PHASE1":9305,"PHASE2":9311,"PHASE3":9313,"PHASE4":9315,"NA":9317},{"trials":9304,"activeCount":103},[],{"trials":9306,"activeCount":302,"soonestReadout":9231},[9307],{"nctId":9228,"briefTitle":9229,"status":126,"phases":9308,"primaryCompletion":9231,"completion":9231,"start":9232,"enrollment":314,"conditions":9309,"interventions":9310},[91],[16],[9221,9235,9236,9237,9238],{"trials":9312,"activeCount":103},[],{"trials":9314,"activeCount":103},[],{"trials":9316,"activeCount":103},[],{"trials":9318,"activeCount":103},[],{"intervention":1086,"totalTrials":302,"cells":9320},{"EARLY_PHASE1":9321,"PHASE1":9323,"PHASE2":9329,"PHASE3":9331,"PHASE4":9333,"NA":9335},{"trials":9322,"activeCount":103},[],{"trials":9324,"activeCount":302,"soonestReadout":1080},[9325],{"nctId":1077,"briefTitle":1078,"status":126,"phases":9326,"primaryCompletion":1080,"completion":1081,"start":1082,"enrollment":1083,"conditions":9327,"interventions":9328},[91],[1062],[48,1086],{"trials":9330,"activeCount":103},[],{"trials":9332,"activeCount":103},[],{"trials":9334,"activeCount":103},[],{"trials":9336,"activeCount":103},[],{"intervention":2195,"totalTrials":302,"cells":9338},{"EARLY_PHASE1":9339,"PHASE1":9341,"PHASE2":9347,"PHASE3":9349,"PHASE4":9351,"NA":9353},{"trials":9340,"activeCount":103},[],{"trials":9342,"activeCount":302,"soonestReadout":2187},[9343],{"nctId":2184,"briefTitle":2185,"status":126,"phases":9344,"primaryCompletion":2187,"completion":2188,"start":2189,"enrollment":2190,"conditions":9345,"interventions":9346},[91],[2192,1040,2193],[2195,63,2082],{"trials":9348,"activeCount":103},[],{"trials":9350,"activeCount":103},[],{"trials":9352,"activeCount":103},[],{"trials":9354,"activeCount":103},[],{"intervention":7621,"totalTrials":302,"cells":9356},{"EARLY_PHASE1":9357,"PHASE1":9359,"PHASE2":9365,"PHASE3":9367,"PHASE4":9369,"NA":9371},{"trials":9358,"activeCount":103},[],{"trials":9360,"activeCount":302,"soonestReadout":7616},[9361],{"nctId":7613,"briefTitle":7614,"status":263,"phases":9362,"primaryCompletion":7616,"completion":7617,"start":7618,"enrollment":562,"conditions":9363,"interventions":9364},[91],[1489],[7621,2082],{"trials":9366,"activeCount":103},[],{"trials":9368,"activeCount":103},[],{"trials":9370,"activeCount":103},[],{"trials":9372,"activeCount":103},[],{"intervention":1771,"totalTrials":627,"cells":9374},{"EARLY_PHASE1":9375,"PHASE1":9377,"PHASE2":9398,"PHASE3":9404,"PHASE4":9443,"NA":9445},{"trials":9376,"activeCount":103},[],{"trials":9378,"activeCount":302,"soonestReadout":1756},[9379,9383,9394],{"nctId":1753,"briefTitle":1754,"status":126,"phases":9380,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":9381,"interventions":9382},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":9384,"briefTitle":9385,"status":111,"phases":9386,"completion":9387,"start":9388,"enrollment":1097,"conditions":9389,"interventions":9390},"NCT00174356","PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel\u002F Carboplatin As 1st Line Chemotherapy In NSCLC Patients",[91],"2005-10","2002-12",[2645],[9391,9392,9393],"CI 1033","PACLITAXEL","CARBOPLATIN",{"nctId":1775,"briefTitle":1776,"status":168,"phases":9395,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":9396,"interventions":9397},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":9399,"activeCount":103},[9400],{"nctId":3350,"briefTitle":3351,"status":111,"phases":9401,"primaryCompletion":523,"completion":3353,"start":3314,"enrollment":2250,"conditions":9402,"interventions":9403},[92],[3355,3356],[1030,1772,1771,3339,1772,1771],{"trials":9405,"activeCount":103},[9406,9418,9429,9439],{"nctId":9407,"briefTitle":9408,"status":111,"phases":9409,"primaryCompletion":9410,"completion":9411,"start":9412,"enrollment":9413,"conditions":9414,"interventions":9415},"NCT01989676","A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)",[93],"2016-08-24","2020-06-27","2014-02-24",707,[1369],[9416,1771,9417,1771],"PF-05280014","Herceptin®",{"nctId":9419,"briefTitle":9420,"status":168,"phases":9421,"primaryCompletion":9422,"completion":9422,"start":9423,"enrollment":1487,"conditions":9424,"interventions":9426},"NCT04325698","A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC",[93],"2021-05-10","2020-06-11",[9425],"Advanced Non-squamous NSCLC",[9427,9428,1771,1772],"PF-06439535","Bevacizumab-EU",{"nctId":9430,"briefTitle":9431,"status":168,"phases":9432,"primaryCompletion":524,"completion":1700,"start":3314,"enrollment":9433,"conditions":9434,"interventions":9438},"NCT00596830","Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology",[93],681,[9435,9436,9437,376],"Carcinoma, Squamous Cell","Carcinoma, Adenosquamous","Carcinoma, Large Cell",[1705,1772,1771,1772,1771],{"nctId":2309,"briefTitle":2310,"status":649,"phases":9440,"primaryCompletion":2312,"start":2313,"enrollment":103,"conditions":9441,"interventions":9442},[93],[31],[63,1771],{"trials":9444,"activeCount":103},[],{"trials":9446,"activeCount":103},[9447],{"nctId":415,"briefTitle":416,"status":111,"phases":9448,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":9449,"interventions":9450},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":1772,"totalTrials":3659,"cells":9452},{"EARLY_PHASE1":9453,"PHASE1":9455,"PHASE2":9469,"PHASE3":9475,"PHASE4":9485,"NA":9487},{"trials":9454,"activeCount":103},[],{"trials":9456,"activeCount":302,"soonestReadout":1756},[9457,9461,9465],{"nctId":1753,"briefTitle":1754,"status":126,"phases":9458,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":1759,"conditions":9459,"interventions":9460},[91],[1761,1028,376],[1763,1764,1765,1304,1766,1767,1768,1030,631,1769,1770,1771,1772,1773],{"nctId":9384,"briefTitle":9385,"status":111,"phases":9462,"completion":9387,"start":9388,"enrollment":1097,"conditions":9463,"interventions":9464},[91],[2645],[9391,9392,9393],{"nctId":1775,"briefTitle":1776,"status":168,"phases":9466,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":9467,"interventions":9468},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":9470,"activeCount":103},[9471],{"nctId":3350,"briefTitle":3351,"status":111,"phases":9472,"primaryCompletion":523,"completion":3353,"start":3314,"enrollment":2250,"conditions":9473,"interventions":9474},[92],[3355,3356],[1030,1772,1771,3339,1772,1771],{"trials":9476,"activeCount":103},[9477,9481],{"nctId":9419,"briefTitle":9420,"status":168,"phases":9478,"primaryCompletion":9422,"completion":9422,"start":9423,"enrollment":1487,"conditions":9479,"interventions":9480},[93],[9425],[9427,9428,1771,1772],{"nctId":9430,"briefTitle":9431,"status":168,"phases":9482,"primaryCompletion":524,"completion":1700,"start":3314,"enrollment":9433,"conditions":9483,"interventions":9484},[93],[9435,9436,9437,376],[1705,1772,1771,1772,1771],{"trials":9486,"activeCount":103},[],{"trials":9488,"activeCount":103},[9489],{"nctId":415,"briefTitle":416,"status":111,"phases":9490,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":9491,"interventions":9492},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":9494,"totalTrials":502,"cells":9495},"ABRYSVO",{"EARLY_PHASE1":9496,"PHASE1":9498,"PHASE2":9500,"PHASE3":9502,"PHASE4":9504,"NA":9506},{"trials":9497,"activeCount":103},[],{"trials":9499,"activeCount":103},[],{"trials":9501,"activeCount":103},[],{"trials":9503,"activeCount":103},[],{"trials":9505,"activeCount":103},[],{"trials":9507,"activeCount":502,"soonestReadout":9512},[9508,9515,9523],{"nctId":9509,"briefTitle":9510,"status":263,"phases":9511,"primaryCompletion":9512,"completion":9512,"start":960,"enrollment":302,"conditions":9513,"interventions":9514},"NCT07235397","Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset",[],"2026-11-13",[6191],[9494],{"nctId":9516,"briefTitle":9517,"status":381,"phases":9518,"primaryCompletion":9519,"completion":9519,"start":884,"enrollment":9520,"conditions":9521,"interventions":9522},"NCT07249320","Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants",[],"2027-09-30",39456,[3809],[9494],{"nctId":9524,"briefTitle":9525,"status":381,"phases":9526,"primaryCompletion":9527,"completion":9527,"start":8874,"enrollment":302,"conditions":9528,"interventions":9532},"NCT07122661","STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)",[],"2027-04-30",[3809,9529,9530,9106,9531],"Respiratory Syncytial Virus","Lower Respiratory Tract Disease","Acute Respiratory Illness (ARI)",[9494],{"intervention":9534,"totalTrials":7500,"cells":9535},"Apixaban",{"EARLY_PHASE1":9536,"PHASE1":9538,"PHASE2":9547,"PHASE3":9566,"PHASE4":9579,"NA":9590},{"trials":9537,"activeCount":103},[],{"trials":9539,"activeCount":103},[9540],{"nctId":9541,"briefTitle":9542,"status":111,"phases":9543,"primaryCompletion":114,"completion":114,"start":9544,"enrollment":525,"conditions":9545,"interventions":9546},"NCT01437839","Food Effect Study For Apixaban Commercial Image Tablets",[91],"2011-09",[16],[9534,9534],{"trials":9548,"activeCount":103},[9549,9558],{"nctId":9550,"briefTitle":9551,"status":111,"phases":9552,"primaryCompletion":4833,"completion":4833,"start":3839,"enrollment":9553,"conditions":9554,"interventions":9556},"NCT00787150","A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation",[92],222,[9555],"Atrial Fibrillation",[9534,9534,9557],"Warfarin sodium",{"nctId":9559,"briefTitle":9560,"status":168,"phases":9561,"primaryCompletion":4656,"completion":4656,"start":4222,"enrollment":9562,"conditions":9563,"interventions":9565},"NCT00852397","A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients",[92],151,[9564],"Acute Coronary Syndrome",[9534,9534],{"trials":9567,"activeCount":103},[9568],{"nctId":9569,"briefTitle":9570,"status":111,"phases":9571,"primaryCompletion":9572,"completion":9572,"start":4590,"enrollment":1519,"conditions":9573,"interventions":9576},"NCT01780987","AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients",[93],"2014-09",[9574,9575],"Deep Vein Thrombosis","Pulmonary Embolism",[9534,9577,9578],"Unfractionated Heparin","Warfarin",{"trials":9580,"activeCount":103},[9581],{"nctId":9582,"briefTitle":9583,"status":111,"phases":9584,"primaryCompletion":9585,"completion":9585,"start":9586,"enrollment":1442,"conditions":9587,"interventions":9588},"NCT02100228","Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)",[94],"2017-02-08","2014-07-14",[9555],[9534,9589],"Parenteral heparin and\u002For oral Vitamin K antagonist",{"trials":9591,"activeCount":1087,"soonestReadout":9596},[9592,9602,9613,9623,9633,9641,9651,9659,9669,9678,9692,9701],{"nctId":9593,"briefTitle":9594,"status":381,"phases":9595,"primaryCompletion":9596,"completion":9596,"start":8474,"enrollment":302,"conditions":9597,"interventions":9598},"NCT05038228","High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France",[],"2026-05-29",[9555],[9534,9599,9600,9601],"Rivaroxaban","Dabigatran","Vitamin K antagonist",{"nctId":9603,"briefTitle":9604,"status":381,"phases":9605,"primaryCompletion":445,"completion":445,"start":9606,"enrollment":302,"conditions":9607,"interventions":9609},"NCT04618913","Anticoagulation in Patients With Venous Thromboembolism and Cancer",[],"2020-12-14",[2053,9608],"Embolism",[9534,9599,9610,9600,9611,9612],"Edoxaban","VKA","LMWH",{"nctId":9614,"briefTitle":9615,"status":111,"phases":9616,"primaryCompletion":9617,"completion":9617,"start":222,"enrollment":9618,"conditions":9619,"interventions":9620},"NCT03572972","Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea",[],"2018-12-20",64684,[9555],[9534,9600,9599,9621,9622],"warfarin","Antiplatelets",{"nctId":9624,"briefTitle":9625,"status":111,"phases":9626,"primaryCompletion":9627,"completion":9627,"start":9628,"enrollment":9629,"conditions":9630,"interventions":9632},"NCT05438888","Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data",[],"2022-10-19","2022-07-01",77814,[9631],"Non-valvular Atrial Fibrillation",[9578,9534],{"nctId":9634,"briefTitle":9635,"status":649,"phases":9636,"primaryCompletion":9637,"completion":9637,"start":4895,"enrollment":103,"conditions":9638,"interventions":9639},"NCT04198844","The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and\u002For Fracture: A Nation-wide Population Based Study",[],"2020-03-31",[9555],[9621,9640],"apixaban",{"nctId":9642,"briefTitle":9643,"status":111,"phases":9644,"primaryCompletion":9645,"completion":9645,"start":9646,"enrollment":9647,"conditions":9648,"interventions":9650},"NCT04681482","Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare",[],"2020-11-03","2020-11-02",107383,[9555,2761,9649],"Anticoagulants",[9534],{"nctId":9652,"briefTitle":9653,"status":111,"phases":9654,"primaryCompletion":9655,"completion":9655,"start":9655,"enrollment":9656,"conditions":9657,"interventions":9658},"NCT05321810","Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation",[],"2022-04-15",193565,[9631],[9534,9578],{"nctId":9660,"briefTitle":9661,"status":111,"phases":9662,"primaryCompletion":9663,"completion":9663,"start":9664,"enrollment":9665,"conditions":9666,"interventions":9668},"NCT05795062","Treatment Patterns Among Patients With Venous Thromboembolism in the United States",[],"2023-09-30","2023-03-10",13945,[9667],"Venous Thromboembolism",[9640,9621],{"nctId":9670,"briefTitle":9671,"status":111,"phases":9672,"primaryCompletion":7536,"completion":7536,"start":9673,"enrollment":9674,"conditions":9675,"interventions":9676},"NCT05022563","Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea",[],"2021-08-31",55759,[9667],[9677,9578,9534,9599,9600,9610],"Parenteral anticoagulant",{"nctId":9679,"briefTitle":9680,"status":649,"phases":9681,"primaryCompletion":9682,"completion":9682,"start":9683,"enrollment":103,"conditions":9684,"interventions":9688},"NCT04808934","NOAC Portuguese Real World Study",[],"2020-12-01","2020-06-01",[9685,9686,9687],"Stroke","Systemic Embolism","Major Bleeding",[9534,9689,9690,9691],"dabigatran","rivaroxaban","VKAs",{"nctId":9693,"briefTitle":9694,"status":111,"phases":9695,"primaryCompletion":9696,"completion":9696,"start":5139,"enrollment":9697,"conditions":9698,"interventions":9699},"NCT05838664","A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France",[],"2024-09-30",2140403,[9555],[9700,9611,9640,9690,9689],"No OAC",{"nctId":9702,"briefTitle":9703,"status":111,"phases":9704,"primaryCompletion":5018,"completion":5018,"start":9705,"enrollment":9706,"conditions":9707,"interventions":9708},"NCT03441633","Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)",[],"2016-02-18",51690,[9555],[9640,9689,9611,9690],{"intervention":9600,"totalTrials":870,"cells":9710},{"EARLY_PHASE1":9711,"PHASE1":9713,"PHASE2":9739,"PHASE3":9741,"PHASE4":9743,"NA":9745},{"trials":9712,"activeCount":103},[],{"trials":9714,"activeCount":103},[9715,9723,9733],{"nctId":9716,"briefTitle":9717,"status":111,"phases":9718,"primaryCompletion":9719,"completion":9719,"start":9720,"enrollment":2159,"conditions":9721,"interventions":9722},"NCT03742336","Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants",[91],"2019-02-18","2018-11-21",[16],[6305,9600],{"nctId":9724,"briefTitle":9725,"status":111,"phases":9726,"primaryCompletion":9727,"completion":9727,"start":9728,"enrollment":1509,"conditions":9729,"interventions":9730},"NCT05064800","PF-07321332\u002FRitonavir and Ritonavir on Dabigatran Study in Healthy Participants",[91],"2021-12-06","2021-09-21",[28],[9600,9731,9732],"PF-07321332\u002Fritonavir + Dabigatran","Ritonavir + Dabigatran",{"nctId":9734,"briefTitle":9735,"status":111,"phases":9736,"primaryCompletion":1288,"completion":1288,"start":652,"enrollment":504,"conditions":9737,"interventions":9738},"NCT02102633","Drug Interaction Study Between Bosutinib And Dabigatran",[91],[16],[9600,2435,9600],{"trials":9740,"activeCount":103},[],{"trials":9742,"activeCount":103},[],{"trials":9744,"activeCount":103},[],{"trials":9746,"activeCount":1087,"soonestReadout":9596},[9747,9751,9755,9759,9763,9767,9771],{"nctId":9593,"briefTitle":9594,"status":381,"phases":9748,"primaryCompletion":9596,"completion":9596,"start":8474,"enrollment":302,"conditions":9749,"interventions":9750},[],[9555],[9534,9599,9600,9601],{"nctId":9603,"briefTitle":9604,"status":381,"phases":9752,"primaryCompletion":445,"completion":445,"start":9606,"enrollment":302,"conditions":9753,"interventions":9754},[],[2053,9608],[9534,9599,9610,9600,9611,9612],{"nctId":9614,"briefTitle":9615,"status":111,"phases":9756,"primaryCompletion":9617,"completion":9617,"start":222,"enrollment":9618,"conditions":9757,"interventions":9758},[],[9555],[9534,9600,9599,9621,9622],{"nctId":9670,"briefTitle":9671,"status":111,"phases":9760,"primaryCompletion":7536,"completion":7536,"start":9673,"enrollment":9674,"conditions":9761,"interventions":9762},[],[9667],[9677,9578,9534,9599,9600,9610],{"nctId":9679,"briefTitle":9680,"status":649,"phases":9764,"primaryCompletion":9682,"completion":9682,"start":9683,"enrollment":103,"conditions":9765,"interventions":9766},[],[9685,9686,9687],[9534,9689,9690,9691],{"nctId":9693,"briefTitle":9694,"status":111,"phases":9768,"primaryCompletion":9696,"completion":9696,"start":5139,"enrollment":9697,"conditions":9769,"interventions":9770},[],[9555],[9700,9611,9640,9690,9689],{"nctId":9702,"briefTitle":9703,"status":111,"phases":9772,"primaryCompletion":5018,"completion":5018,"start":9705,"enrollment":9706,"conditions":9773,"interventions":9774},[],[9555],[9640,9689,9611,9690],{"intervention":9599,"totalTrials":3659,"cells":9776},{"EARLY_PHASE1":9777,"PHASE1":9779,"PHASE2":9781,"PHASE3":9783,"PHASE4":9785,"NA":9787},{"trials":9778,"activeCount":103},[],{"trials":9780,"activeCount":103},[],{"trials":9782,"activeCount":103},[],{"trials":9784,"activeCount":103},[],{"trials":9786,"activeCount":103},[],{"trials":9788,"activeCount":1087,"soonestReadout":9596},[9789,9793,9797,9801,9805,9809,9813],{"nctId":9593,"briefTitle":9594,"status":381,"phases":9790,"primaryCompletion":9596,"completion":9596,"start":8474,"enrollment":302,"conditions":9791,"interventions":9792},[],[9555],[9534,9599,9600,9601],{"nctId":9603,"briefTitle":9604,"status":381,"phases":9794,"primaryCompletion":445,"completion":445,"start":9606,"enrollment":302,"conditions":9795,"interventions":9796},[],[2053,9608],[9534,9599,9610,9600,9611,9612],{"nctId":9614,"briefTitle":9615,"status":111,"phases":9798,"primaryCompletion":9617,"completion":9617,"start":222,"enrollment":9618,"conditions":9799,"interventions":9800},[],[9555],[9534,9600,9599,9621,9622],{"nctId":9670,"briefTitle":9671,"status":111,"phases":9802,"primaryCompletion":7536,"completion":7536,"start":9673,"enrollment":9674,"conditions":9803,"interventions":9804},[],[9667],[9677,9578,9534,9599,9600,9610],{"nctId":9679,"briefTitle":9680,"status":649,"phases":9806,"primaryCompletion":9682,"completion":9682,"start":9683,"enrollment":103,"conditions":9807,"interventions":9808},[],[9685,9686,9687],[9534,9689,9690,9691],{"nctId":9693,"briefTitle":9694,"status":111,"phases":9810,"primaryCompletion":9696,"completion":9696,"start":5139,"enrollment":9697,"conditions":9811,"interventions":9812},[],[9555],[9700,9611,9640,9690,9689],{"nctId":9702,"briefTitle":9703,"status":111,"phases":9814,"primaryCompletion":5018,"completion":5018,"start":9705,"enrollment":9706,"conditions":9815,"interventions":9816},[],[9555],[9640,9689,9611,9690],{"intervention":9818,"totalTrials":1087,"cells":9819},"NGENLA",{"EARLY_PHASE1":9820,"PHASE1":9822,"PHASE2":9824,"PHASE3":9826,"PHASE4":9828,"NA":9830},{"trials":9821,"activeCount":103},[],{"trials":9823,"activeCount":103},[],{"trials":9825,"activeCount":103},[],{"trials":9827,"activeCount":103},[],{"trials":9829,"activeCount":103},[],{"trials":9831,"activeCount":1087,"soonestReadout":1679},[9832,9840],{"nctId":9833,"briefTitle":9834,"status":381,"phases":9835,"primaryCompletion":9836,"completion":9836,"start":4547,"enrollment":302,"conditions":9837,"interventions":9839},"NCT05602766","Ngenla Subcutaneous Injection Special Investigation",[],"2029-04-06",[9838],"Growth Hormone Deficiency Without Epiphyseal Closure",[9818],{"nctId":9841,"briefTitle":9842,"status":381,"phases":9843,"primaryCompletion":1679,"completion":1679,"start":9844,"enrollment":9845,"conditions":9846,"interventions":9848},"NCT05509894","Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone",[],"2024-06-20",565,[9847],"Pediatric Growth Hormone Deficiency",[9849],"Ngenla",{"intervention":2595,"totalTrials":2070,"cells":9851},{"EARLY_PHASE1":9852,"PHASE1":9854,"PHASE2":9856,"PHASE3":9858,"PHASE4":9864,"NA":9866},{"trials":9853,"activeCount":103},[],{"trials":9855,"activeCount":103},[],{"trials":9857,"activeCount":103},[],{"trials":9859,"activeCount":103},[9860],{"nctId":2585,"briefTitle":2586,"status":111,"phases":9861,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":2590,"conditions":9862,"interventions":9863},[93],[2526,2592,2593],[2494,2595],{"trials":9865,"activeCount":103},[],{"trials":9867,"activeCount":302,"soonestReadout":9872},[9868,9879,9892,9901,9909],{"nctId":9869,"briefTitle":9870,"status":381,"phases":9871,"primaryCompletion":9872,"completion":9872,"start":3779,"enrollment":302,"conditions":9873,"interventions":9878},"NCT06923137","A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19",[],"2030-10-31",[3916,2592,3926,4957,9104,9874,9875,9876,9877],"COVID-19 Vaccination","COVID-19 Vaccines","SARS-CoV-2 Infection, COVID19","SARS-CoV-2 Infection, COVID-19",[2595],{"nctId":9880,"briefTitle":9881,"status":111,"phases":9882,"primaryCompletion":5986,"completion":5986,"start":9883,"enrollment":9884,"conditions":9885,"interventions":9891},"NCT05020145","COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States",[],"2021-08-25",1277747,[4958,9886,9887,9888,9889,9890],"Immunosuppressed","Covid-19","SARS-COV-2","SARS-COV-2 Infection","Breakthrough Infection",[2595],{"nctId":9893,"briefTitle":9894,"status":111,"phases":9895,"primaryCompletion":9896,"completion":9896,"start":9897,"enrollment":9898,"conditions":9899,"interventions":9900},"NCT04880447","Special Investigation of COMIRNATY in the Population With Underlying Diseases",[],"2022-04-14","2021-05-26",1075,[2592],[2595],{"nctId":9902,"briefTitle":9903,"status":111,"phases":9904,"primaryCompletion":2819,"completion":2819,"start":9905,"enrollment":9906,"conditions":9907,"interventions":9908},"NCT04815031","Drug Use Investigation of COMIRNATY Intramuscular Injection",[],"2021-03-20",14570,[2592],[2595],{"nctId":9910,"briefTitle":9911,"status":111,"phases":9912,"primaryCompletion":9913,"completion":9913,"start":2817,"enrollment":9914,"conditions":9915,"interventions":9916},"NCT05621239","A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People",[],"2023-04-03",260,[2592],[2595],{"intervention":9918,"totalTrials":2070,"cells":9919},"Nirmatrelvir\u002FRitonavir",{"EARLY_PHASE1":9920,"PHASE1":9922,"PHASE2":9956,"PHASE3":9958,"PHASE4":9960,"NA":9962},{"trials":9921,"activeCount":103},[],{"trials":9923,"activeCount":103},[9924,9934,9942,9948],{"nctId":9925,"briefTitle":9926,"status":111,"phases":9927,"primaryCompletion":9928,"completion":9928,"start":1365,"enrollment":1268,"conditions":9929,"interventions":9931},"NCT05544786","Relative Bioavailability Study of Nirmatrelvir\u002FRitonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir\u002FRitonavir Oral Powder in Healthy Participants.",[91],"2022-11-29",[9930],"Biological Availability",[9932,9918,9918,9933,9933],"Nirmatrelvir\u002F ritonavir","Nirmatrelvir\u002Fritonavir",{"nctId":9935,"briefTitle":9936,"status":111,"phases":9937,"primaryCompletion":9938,"completion":9938,"start":9939,"enrollment":1268,"conditions":9940,"interventions":9941},"NCT05898672","A Study to Learn About the Study Medicine Called Nirmatrelvir\u002FRitonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin",[91],"2023-08-10","2023-06-09",[3396,19],[2841,9933],{"nctId":9943,"briefTitle":9944,"status":111,"phases":9945,"primaryCompletion":288,"completion":288,"start":2335,"enrollment":498,"conditions":9946,"interventions":9947},"NCT05525910","Relative Bioavailability Study of Nirmatrelvir\u002FRitonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants",[91],[9930,28],[9932,9933,9933,9932,9932],{"nctId":9949,"briefTitle":9950,"status":649,"phases":9951,"primaryCompletion":1037,"completion":1037,"start":9952,"enrollment":103,"conditions":9953,"interventions":9954},"NCT06397144","A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants",[91],"2025-08-15",[9930,28],[9955,9955,9933,9933],"Paxlovid",{"trials":9957,"activeCount":103},[],{"trials":9959,"activeCount":103},[],{"trials":9961,"activeCount":103},[],{"trials":9963,"activeCount":302,"soonestReadout":9968},[9964,9973],{"nctId":9965,"briefTitle":9966,"status":263,"phases":9967,"primaryCompletion":9968,"completion":9968,"start":9969,"enrollment":9970,"conditions":9971,"interventions":9972},"NCT07089680","A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19",[],"2025-11-30","2025-08-18",1200,[4957],[9918],{"nctId":9974,"briefTitle":9975,"status":649,"phases":9976,"primaryCompletion":9977,"completion":9977,"start":9978,"enrollment":103,"conditions":9979,"interventions":9981},"NCT05997485","A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco",[],"2024-06-30","2024-03-30",[9980],"COVID-19 Drug Treatment",[9918],{"intervention":1460,"totalTrials":578,"cells":9983},{"EARLY_PHASE1":9984,"PHASE1":9986,"PHASE2":9988,"PHASE3":9990,"PHASE4":9992,"NA":9994},{"trials":9985,"activeCount":103},[],{"trials":9987,"activeCount":103},[],{"trials":9989,"activeCount":103},[],{"trials":9991,"activeCount":103},[],{"trials":9993,"activeCount":103},[],{"trials":9995,"activeCount":302,"soonestReadout":1355},[9996,10005,10014,10022,10026],{"nctId":9997,"briefTitle":9998,"status":111,"phases":9999,"primaryCompletion":10000,"completion":10000,"start":10000,"enrollment":10001,"conditions":10002,"interventions":10003},"NCT05361655","Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor",[],"2021-09-01",2888,[1369],[10004,1460],"Palbociclib + an aromatase inhibitor",{"nctId":10006,"briefTitle":10007,"status":111,"phases":10008,"primaryCompletion":8394,"completion":8394,"start":10009,"enrollment":10010,"conditions":10011,"interventions":10012},"NCT05012644","Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone",[],"2021-07-16",197,[1369],[10013,1460],"Palbociclib + aromatase inhibitor",{"nctId":10015,"briefTitle":10016,"status":111,"phases":10017,"primaryCompletion":8038,"completion":8038,"start":10018,"enrollment":10019,"conditions":10020,"interventions":10021},"NCT05043506","European Treatment Patterns and Outcomes Associated With First-Line CDK4\u002F6 Inhibition and Hormonal Therapies",[],"2022-02-08",1939,[1369],[10013,1460],{"nctId":1454,"briefTitle":1455,"status":381,"phases":10023,"primaryCompletion":1355,"completion":1355,"start":1457,"enrollment":302,"conditions":10024,"interventions":10025},[],[31,1444],[88,1460,1461,1462],{"nctId":1464,"briefTitle":1465,"status":111,"phases":10027,"primaryCompletion":1467,"completion":1467,"start":1468,"enrollment":1469,"conditions":10028,"interventions":10029},[],[31],[88,1472],{"intervention":9611,"totalTrials":502,"cells":10031},{"EARLY_PHASE1":10032,"PHASE1":10034,"PHASE2":10036,"PHASE3":10038,"PHASE4":10040,"NA":10042},{"trials":10033,"activeCount":103},[],{"trials":10035,"activeCount":103},[],{"trials":10037,"activeCount":103},[],{"trials":10039,"activeCount":103},[],{"trials":10041,"activeCount":103},[],{"trials":10043,"activeCount":302,"soonestReadout":445},[10044,10048,10052],{"nctId":9603,"briefTitle":9604,"status":381,"phases":10045,"primaryCompletion":445,"completion":445,"start":9606,"enrollment":302,"conditions":10046,"interventions":10047},[],[2053,9608],[9534,9599,9610,9600,9611,9612],{"nctId":9693,"briefTitle":9694,"status":111,"phases":10049,"primaryCompletion":9696,"completion":9696,"start":5139,"enrollment":9697,"conditions":10050,"interventions":10051},[],[9555],[9700,9611,9640,9690,9689],{"nctId":9702,"briefTitle":9703,"status":111,"phases":10053,"primaryCompletion":5018,"completion":5018,"start":9705,"enrollment":9706,"conditions":10054,"interventions":10055},[],[9555],[9640,9689,9611,9690],{"intervention":10057,"totalTrials":502,"cells":10058},"nirmatrelvir-ritonavir",{"EARLY_PHASE1":10059,"PHASE1":10061,"PHASE2":10063,"PHASE3":10065,"PHASE4":10067,"NA":10069},{"trials":10060,"activeCount":103},[],{"trials":10062,"activeCount":103},[],{"trials":10064,"activeCount":103},[],{"trials":10066,"activeCount":103},[],{"trials":10068,"activeCount":103},[],{"trials":10070,"activeCount":302,"soonestReadout":4539},[10071,10079,10087],{"nctId":10072,"briefTitle":10073,"status":111,"phases":10074,"primaryCompletion":10075,"completion":10075,"start":10075,"enrollment":10076,"conditions":10077,"interventions":10078},"NCT07090486","A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.",[],"2025-04-15",14000,[2592],[10057],{"nctId":10080,"briefTitle":10081,"status":111,"phases":10082,"primaryCompletion":161,"completion":161,"start":10083,"enrollment":10084,"conditions":10085,"interventions":10086},"NCT07072793","A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe",[],"2024-10-31",131005,[9104],[10057],{"nctId":10088,"briefTitle":10089,"status":381,"phases":10090,"primaryCompletion":4539,"completion":4539,"start":10091,"enrollment":10092,"conditions":10093,"interventions":10094},"NCT07261085","A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir\u002FPF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.",[],"2025-10-27",99000,[2592],[10057],{"intervention":9610,"totalTrials":1087,"cells":10096},{"EARLY_PHASE1":10097,"PHASE1":10099,"PHASE2":10101,"PHASE3":10103,"PHASE4":10105,"NA":10107},{"trials":10098,"activeCount":103},[],{"trials":10100,"activeCount":103},[],{"trials":10102,"activeCount":103},[],{"trials":10104,"activeCount":103},[],{"trials":10106,"activeCount":103},[],{"trials":10108,"activeCount":302,"soonestReadout":445},[10109,10113],{"nctId":9603,"briefTitle":9604,"status":381,"phases":10110,"primaryCompletion":445,"completion":445,"start":9606,"enrollment":302,"conditions":10111,"interventions":10112},[],[2053,9608],[9534,9599,9610,9600,9611,9612],{"nctId":9670,"briefTitle":9671,"status":111,"phases":10114,"primaryCompletion":7536,"completion":7536,"start":9673,"enrollment":9674,"conditions":10115,"interventions":10116},[],[9667],[9677,9578,9534,9599,9600,9610],{"intervention":10118,"totalTrials":1087,"cells":10119},"COVID-19 Vaccine",{"EARLY_PHASE1":10120,"PHASE1":10122,"PHASE2":10124,"PHASE3":10126,"PHASE4":10128,"NA":10130},{"trials":10121,"activeCount":103},[],{"trials":10123,"activeCount":103},[],{"trials":10125,"activeCount":103},[],{"trials":10127,"activeCount":103},[],{"trials":10129,"activeCount":103},[],{"trials":10131,"activeCount":302,"soonestReadout":10136},[10132,10140],{"nctId":10133,"briefTitle":10134,"status":381,"phases":10135,"primaryCompletion":10136,"completion":10136,"start":4367,"enrollment":2798,"conditions":10137,"interventions":10139},"NCT05160636","A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza",[],"2027-01-31",[2592,9103,10138],"Influenza",[10118],{"nctId":10141,"briefTitle":10142,"status":649,"phases":10143,"primaryCompletion":10144,"completion":10144,"start":10144,"enrollment":103,"conditions":10145,"interventions":10146},"NCT06163677","A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.",[],"2024-01-17",[2592,9103,10138],[10118],{"intervention":10148,"totalTrials":1087,"cells":10149},"TALZENNA",{"EARLY_PHASE1":10150,"PHASE1":10152,"PHASE2":10163,"PHASE3":10165,"PHASE4":10167,"NA":10169},{"trials":10151,"activeCount":103},[],{"trials":10153,"activeCount":103},[10154],{"nctId":10155,"briefTitle":10156,"status":111,"phases":10157,"primaryCompletion":10158,"completion":10159,"start":2050,"enrollment":463,"conditions":10160,"interventions":10161},"NCT04672460","A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors",[91],"2022-02-04","2022-07-22",[553,750,1653,31,1684,410,4778,2022],[10148,10162,10162],"Talazoparib soft gel",{"trials":10164,"activeCount":103},[],{"trials":10166,"activeCount":103},[],{"trials":10168,"activeCount":103},[],{"trials":10170,"activeCount":302,"soonestReadout":915},[10171],{"nctId":10172,"briefTitle":10173,"status":263,"phases":10174,"primaryCompletion":915,"completion":915,"start":10175,"enrollment":130,"conditions":10176,"interventions":10177},"NCT04982848","Korea Post Marketing Surveillance (PMS) Study of Talzenna®",[],"2027-06-01",[25],[10178],"Talzenna",{"intervention":10180,"totalTrials":1087,"cells":10181},"Avastin",{"EARLY_PHASE1":10182,"PHASE1":10184,"PHASE2":10193,"PHASE3":10195,"PHASE4":10197,"NA":10199},{"trials":10183,"activeCount":103},[],{"trials":10185,"activeCount":103},[10186],{"nctId":10187,"briefTitle":10188,"status":111,"phases":10189,"primaryCompletion":7386,"completion":7386,"start":1248,"enrollment":10190,"conditions":10191,"interventions":10192},"NCT02031991","A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)",[91],102,[16],[9427,10180,10180],{"trials":10194,"activeCount":103},[],{"trials":10196,"activeCount":103},[],{"trials":10198,"activeCount":103},[],{"trials":10200,"activeCount":302,"soonestReadout":1440},[10201],{"nctId":10202,"briefTitle":10203,"status":381,"phases":10204,"primaryCompletion":1440,"completion":1440,"start":10205,"enrollment":2323,"conditions":10206,"interventions":10207},"NCT07527832","An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.",[],"2026-04-20",[2022],[10208,10180],"Bevacizumab-Pfizer Biosimilar",{"intervention":10210,"totalTrials":1087,"cells":10211},"Somatrogon",{"EARLY_PHASE1":10212,"PHASE1":10214,"PHASE2":10216,"PHASE3":10218,"PHASE4":10231,"NA":10233},{"trials":10213,"activeCount":103},[],{"trials":10215,"activeCount":103},[],{"trials":10217,"activeCount":103},[],{"trials":10219,"activeCount":103},[10220],{"nctId":10221,"briefTitle":10222,"status":111,"phases":10223,"primaryCompletion":10224,"completion":10224,"start":10225,"enrollment":1083,"conditions":10226,"interventions":10228},"NCT03831880","Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD",[93],"2020-08-28","2019-02-07",[10227],"Growth Hormone Deficiency",[10229,10230],"Genotropin","somatrogon",{"trials":10232,"activeCount":103},[],{"trials":10234,"activeCount":302,"soonestReadout":10239},[10235],{"nctId":10236,"briefTitle":10237,"status":126,"phases":10238,"primaryCompletion":10239,"completion":901,"start":10240,"enrollment":26,"conditions":10241,"interventions":10243},"NCT06587035","A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.",[],"2026-09-21","2025-01-30",[10242],"Dwarfism, Pituitary",[10210],{"intervention":9601,"totalTrials":302,"cells":10245},{"EARLY_PHASE1":10246,"PHASE1":10248,"PHASE2":10250,"PHASE3":10252,"PHASE4":10254,"NA":10256},{"trials":10247,"activeCount":103},[],{"trials":10249,"activeCount":103},[],{"trials":10251,"activeCount":103},[],{"trials":10253,"activeCount":103},[],{"trials":10255,"activeCount":103},[],{"trials":10257,"activeCount":302,"soonestReadout":9596},[10258],{"nctId":9593,"briefTitle":9594,"status":381,"phases":10259,"primaryCompletion":9596,"completion":9596,"start":8474,"enrollment":302,"conditions":10260,"interventions":10261},[],[9555],[9534,9599,9600,9601],{"intervention":10263,"totalTrials":302,"cells":10264},"Non intervention",{"EARLY_PHASE1":10265,"PHASE1":10267,"PHASE2":10269,"PHASE3":10271,"PHASE4":10273,"NA":10275},{"trials":10266,"activeCount":103},[],{"trials":10268,"activeCount":103},[],{"trials":10270,"activeCount":103},[],{"trials":10272,"activeCount":103},[],{"trials":10274,"activeCount":103},[],{"trials":10276,"activeCount":302,"soonestReadout":10281},[10277],{"nctId":10278,"briefTitle":10279,"status":263,"phases":10280,"primaryCompletion":10281,"completion":10281,"start":3027,"enrollment":1780,"conditions":10282,"interventions":10284},"NCT07391761","A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan",[],"2028-01-31",[10283],"Refractory Multiple Myeloma (RRMM)",[10263],{"intervention":10286,"totalTrials":302,"cells":10287},"Avibactam sodium\u002FCeftazidime hydrate",{"EARLY_PHASE1":10288,"PHASE1":10290,"PHASE2":10292,"PHASE3":10294,"PHASE4":10296,"NA":10298},{"trials":10289,"activeCount":103},[],{"trials":10291,"activeCount":103},[],{"trials":10293,"activeCount":103},[],{"trials":10295,"activeCount":103},[],{"trials":10297,"activeCount":103},[],{"trials":10299,"activeCount":302,"soonestReadout":10304},[10300],{"nctId":10301,"briefTitle":10302,"status":263,"phases":10303,"primaryCompletion":10304,"completion":10304,"start":3003,"enrollment":1060,"conditions":10305,"interventions":10307},"NCT06864585","A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan",[],"2029-03-30",[10306],"Infectious Diseases",[10286],{"intervention":9612,"totalTrials":302,"cells":10309},{"EARLY_PHASE1":10310,"PHASE1":10312,"PHASE2":10314,"PHASE3":10316,"PHASE4":10318,"NA":10320},{"trials":10311,"activeCount":103},[],{"trials":10313,"activeCount":103},[],{"trials":10315,"activeCount":103},[],{"trials":10317,"activeCount":103},[],{"trials":10319,"activeCount":103},[],{"trials":10321,"activeCount":302,"soonestReadout":445},[10322],{"nctId":9603,"briefTitle":9604,"status":381,"phases":10323,"primaryCompletion":445,"completion":445,"start":9606,"enrollment":302,"conditions":10324,"interventions":10325},[],[2053,9608],[9534,9599,9610,9600,9611,9612],{"intervention":10327,"totalTrials":302,"cells":10328},"Palbociclib + endocrine therapy",{"EARLY_PHASE1":10329,"PHASE1":10331,"PHASE2":10333,"PHASE3":10335,"PHASE4":10337,"NA":10339},{"trials":10330,"activeCount":103},[],{"trials":10332,"activeCount":103},[],{"trials":10334,"activeCount":103},[],{"trials":10336,"activeCount":103},[],{"trials":10338,"activeCount":103},[],{"trials":10340,"activeCount":302,"soonestReadout":10345},[10341],{"nctId":10342,"briefTitle":10343,"status":381,"phases":10344,"primaryCompletion":10345,"completion":10346,"start":10347,"enrollment":10348,"conditions":10349,"interventions":10350},"NCT04767594","First-line Palbociclib and Endocrine Therapy for Patients With HR+\u002FHER2- Advanced Breast Cancer in the Real-world Setting.",[],"2028-04-03","2028-04-30","2020-10-27",1407,[25],[10327],{"intervention":10352,"totalTrials":302,"cells":10353},"Non-Interventional Study",{"EARLY_PHASE1":10354,"PHASE1":10356,"PHASE2":10358,"PHASE3":10360,"PHASE4":10362,"NA":10364},{"trials":10355,"activeCount":103},[],{"trials":10357,"activeCount":103},[],{"trials":10359,"activeCount":103},[],{"trials":10361,"activeCount":103},[],{"trials":10363,"activeCount":103},[],{"trials":10365,"activeCount":302,"soonestReadout":10370},[10366],{"nctId":10367,"briefTitle":10368,"status":381,"phases":10369,"primaryCompletion":10370,"completion":10370,"start":940,"enrollment":10371,"conditions":10372,"interventions":10373},"NCT07177209","Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population",[],"2026-07-31",4000,[1532],[10352],{"intervention":10375,"totalTrials":302,"cells":10376},"Litfulo",{"EARLY_PHASE1":10377,"PHASE1":10379,"PHASE2":10381,"PHASE3":10383,"PHASE4":10385,"NA":10387},{"trials":10378,"activeCount":103},[],{"trials":10380,"activeCount":103},[],{"trials":10382,"activeCount":103},[],{"trials":10384,"activeCount":103},[],{"trials":10386,"activeCount":103},[],{"trials":10388,"activeCount":302,"soonestReadout":10393},[10389],{"nctId":10390,"briefTitle":10391,"status":126,"phases":10392,"primaryCompletion":10393,"completion":10393,"start":10394,"enrollment":10395,"conditions":10396,"interventions":10397},"NCT07152119","A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.",[],"2030-03-23","2025-08-27",3000,[3464],[10375],{"intervention":10399,"totalTrials":302,"cells":10400},"Rimegepant for acute migraine treatment",{"EARLY_PHASE1":10401,"PHASE1":10403,"PHASE2":10405,"PHASE3":10407,"PHASE4":10409,"NA":10411},{"trials":10402,"activeCount":103},[],{"trials":10404,"activeCount":103},[],{"trials":10406,"activeCount":103},[],{"trials":10408,"activeCount":103},[],{"trials":10410,"activeCount":103},[],{"trials":10412,"activeCount":302,"soonestReadout":10370},[10413],{"nctId":10414,"briefTitle":10415,"status":381,"phases":10416,"primaryCompletion":10370,"completion":10370,"start":10417,"enrollment":8827,"conditions":10418,"interventions":10419},"NCT06898047","Consistency of Response With Rimegepant in Acute Treatment of Migraine",[],"2025-11-15",[117],[10399],{"intervention":10421,"totalTrials":302,"cells":10422},"Xeljanz",{"EARLY_PHASE1":10423,"PHASE1":10425,"PHASE2":10427,"PHASE3":10429,"PHASE4":10431,"NA":10433},{"trials":10424,"activeCount":103},[],{"trials":10426,"activeCount":103},[],{"trials":10428,"activeCount":103},[],{"trials":10430,"activeCount":103},[],{"trials":10432,"activeCount":103},[],{"trials":10434,"activeCount":302,"soonestReadout":3864},[10435],{"nctId":10436,"briefTitle":10437,"status":126,"phases":10438,"primaryCompletion":3864,"completion":3864,"start":10439,"enrollment":870,"conditions":10440,"interventions":10443},"NCT05754710","Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis",[],"2024-04-12",[10441,10442],"Psoriatic Arthritis, Juvenile","Polyarticular Juvenile Idiopathic Arthritis",[10421],{"intervention":10445,"totalTrials":302,"cells":10446},"Bretovameran",{"EARLY_PHASE1":10447,"PHASE1":10449,"PHASE2":10451,"PHASE3":10453,"PHASE4":10455,"NA":10457},{"trials":10448,"activeCount":103},[],{"trials":10450,"activeCount":103},[],{"trials":10452,"activeCount":103},[],{"trials":10454,"activeCount":103},[],{"trials":10456,"activeCount":103},[],{"trials":10458,"activeCount":302,"soonestReadout":1355},[10459],{"nctId":10460,"briefTitle":10461,"status":381,"phases":10462,"primaryCompletion":1355,"completion":1355,"start":10463,"enrollment":10464,"conditions":10465,"interventions":10466},"NCT06613984","Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)",[],"2024-10-11",660,[9874],[10445],{"intervention":10208,"totalTrials":302,"cells":10468},{"EARLY_PHASE1":10469,"PHASE1":10471,"PHASE2":10473,"PHASE3":10475,"PHASE4":10477,"NA":10479},{"trials":10470,"activeCount":103},[],{"trials":10472,"activeCount":103},[],{"trials":10474,"activeCount":103},[],{"trials":10476,"activeCount":103},[],{"trials":10478,"activeCount":103},[],{"trials":10480,"activeCount":302,"soonestReadout":1440},[10481],{"nctId":10202,"briefTitle":10203,"status":381,"phases":10482,"primaryCompletion":1440,"completion":1440,"start":10205,"enrollment":2323,"conditions":10483,"interventions":10484},[],[2022],[10208,10180],{"intervention":10486,"totalTrials":302,"cells":10487},"Receipt of PCV20",{"EARLY_PHASE1":10488,"PHASE1":10490,"PHASE2":10492,"PHASE3":10494,"PHASE4":10496,"NA":10498},{"trials":10489,"activeCount":103},[],{"trials":10491,"activeCount":103},[],{"trials":10493,"activeCount":103},[],{"trials":10495,"activeCount":103},[],{"trials":10497,"activeCount":103},[],{"trials":10499,"activeCount":302,"soonestReadout":1440},[10500],{"nctId":10501,"briefTitle":10502,"status":381,"phases":10503,"primaryCompletion":1440,"completion":1440,"start":10504,"enrollment":10505,"conditions":10506,"interventions":10507},"NCT07251465","A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia",[],"2026-01-21",846279,[9107],[10486],{"intervention":10509,"totalTrials":302,"cells":10510},"ABRYSVO Vaccination",{"EARLY_PHASE1":10511,"PHASE1":10513,"PHASE2":10515,"PHASE3":10517,"PHASE4":10519,"NA":10521},{"trials":10512,"activeCount":103},[],{"trials":10514,"activeCount":103},[],{"trials":10516,"activeCount":103},[],{"trials":10518,"activeCount":103},[],{"trials":10520,"activeCount":103},[],{"trials":10522,"activeCount":302,"soonestReadout":10527},[10523],{"nctId":10524,"briefTitle":10525,"status":381,"phases":10526,"primaryCompletion":10527,"completion":10527,"start":10528,"enrollment":302,"conditions":10529,"interventions":10531},"NCT06813872","Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania",[],"2027-07-31","2025-02-24",[10530],"Respiratory Syncytial Viruses",[10509],{"intervention":10533,"totalTrials":302,"cells":10534},"Prior standard of care receipt of Pfizer's ABRYSVO vaccine",{"EARLY_PHASE1":10535,"PHASE1":10537,"PHASE2":10539,"PHASE3":10541,"PHASE4":10543,"NA":10545},{"trials":10536,"activeCount":103},[],{"trials":10538,"activeCount":103},[],{"trials":10540,"activeCount":103},[],{"trials":10542,"activeCount":103},[],{"trials":10544,"activeCount":103},[],{"trials":10546,"activeCount":302,"soonestReadout":10551},[10547],{"nctId":10548,"briefTitle":10549,"status":381,"phases":10550,"primaryCompletion":10551,"completion":10551,"start":10552,"enrollment":302,"conditions":10553,"interventions":10554},"NCT06077968","A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease",[],"2029-05-01","2023-11-01",[10530],[10533],{"intervention":10556,"totalTrials":302,"cells":10557},"Rimegepant sulfate",{"EARLY_PHASE1":10558,"PHASE1":10560,"PHASE2":10562,"PHASE3":10564,"PHASE4":10566,"NA":10568},{"trials":10559,"activeCount":103},[],{"trials":10561,"activeCount":103},[],{"trials":10563,"activeCount":103},[],{"trials":10565,"activeCount":103},[],{"trials":10567,"activeCount":103},[],{"trials":10569,"activeCount":302,"soonestReadout":128},[10570],{"nctId":10571,"briefTitle":10572,"status":263,"phases":10573,"primaryCompletion":128,"completion":10574,"start":10575,"enrollment":10395,"conditions":10576,"interventions":10578},"NCT07497854","A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea",[],"2030-08-01","2026-10-01",[10577],"Migraine With or Without Aura",[10556],{"intervention":10580,"totalTrials":302,"cells":10581},"Anti-human thymocyte immunoglobulin, equine",{"EARLY_PHASE1":10582,"PHASE1":10584,"PHASE2":10586,"PHASE3":10588,"PHASE4":10590,"NA":10592},{"trials":10583,"activeCount":103},[],{"trials":10585,"activeCount":103},[],{"trials":10587,"activeCount":103},[],{"trials":10589,"activeCount":103},[],{"trials":10591,"activeCount":103},[],{"trials":10593,"activeCount":302,"soonestReadout":10598},[10594],{"nctId":10595,"briefTitle":10596,"status":381,"phases":10597,"primaryCompletion":10598,"completion":10598,"start":10599,"enrollment":302,"conditions":10600,"interventions":10602},"NCT06039020","ATGAM General Investigation",[],"2027-01-22","2024-02-21",[10601],"Aplastic Anemia",[10580],{"intervention":10604,"totalTrials":302,"cells":10605},"Tozinameran 12 Years of age and older",{"EARLY_PHASE1":10606,"PHASE1":10608,"PHASE2":10610,"PHASE3":10612,"PHASE4":10614,"NA":10616},{"trials":10607,"activeCount":103},[],{"trials":10609,"activeCount":103},[],{"trials":10611,"activeCount":103},[],{"trials":10613,"activeCount":103},[],{"trials":10615,"activeCount":103},[],{"trials":10617,"activeCount":302,"soonestReadout":10622},[10618],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10621,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10625,"interventions":10630},"NCT05032976","Korea Comirnaty Post-marketing Surveillance",[],"2027-01-24","2022-03-18",12000,[2592,10626,10627,10628,10629],"Vaccines","Adverse Effects","SARS-CoV-2","Safety",[10604,10631,10632,10633,10634,10635,10636,10637],"Tozinameran 5 to 11 Years of age","Tozinameran 6 months to 4 years of age","Riltozinameran 12 Years of age and older","Famtozinameran 12 Years of age and older","Famtozinameran 5 to 11 Years of age","Raxtozinameran 12 years of age and older","Raxtozinameran 6 months to 4 years of age",{"intervention":10631,"totalTrials":302,"cells":10639},{"EARLY_PHASE1":10640,"PHASE1":10642,"PHASE2":10644,"PHASE3":10646,"PHASE4":10648,"NA":10650},{"trials":10641,"activeCount":103},[],{"trials":10643,"activeCount":103},[],{"trials":10645,"activeCount":103},[],{"trials":10647,"activeCount":103},[],{"trials":10649,"activeCount":103},[],{"trials":10651,"activeCount":302,"soonestReadout":10622},[10652],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10653,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10654,"interventions":10655},[],[2592,10626,10627,10628,10629],[10604,10631,10632,10633,10634,10635,10636,10637],{"intervention":10632,"totalTrials":302,"cells":10657},{"EARLY_PHASE1":10658,"PHASE1":10660,"PHASE2":10662,"PHASE3":10664,"PHASE4":10666,"NA":10668},{"trials":10659,"activeCount":103},[],{"trials":10661,"activeCount":103},[],{"trials":10663,"activeCount":103},[],{"trials":10665,"activeCount":103},[],{"trials":10667,"activeCount":103},[],{"trials":10669,"activeCount":302,"soonestReadout":10622},[10670],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10671,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10672,"interventions":10673},[],[2592,10626,10627,10628,10629],[10604,10631,10632,10633,10634,10635,10636,10637],{"intervention":10633,"totalTrials":302,"cells":10675},{"EARLY_PHASE1":10676,"PHASE1":10678,"PHASE2":10680,"PHASE3":10682,"PHASE4":10684,"NA":10686},{"trials":10677,"activeCount":103},[],{"trials":10679,"activeCount":103},[],{"trials":10681,"activeCount":103},[],{"trials":10683,"activeCount":103},[],{"trials":10685,"activeCount":103},[],{"trials":10687,"activeCount":302,"soonestReadout":10622},[10688],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10689,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10690,"interventions":10691},[],[2592,10626,10627,10628,10629],[10604,10631,10632,10633,10634,10635,10636,10637],{"intervention":10634,"totalTrials":302,"cells":10693},{"EARLY_PHASE1":10694,"PHASE1":10696,"PHASE2":10698,"PHASE3":10700,"PHASE4":10702,"NA":10704},{"trials":10695,"activeCount":103},[],{"trials":10697,"activeCount":103},[],{"trials":10699,"activeCount":103},[],{"trials":10701,"activeCount":103},[],{"trials":10703,"activeCount":103},[],{"trials":10705,"activeCount":302,"soonestReadout":10622},[10706],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10707,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10708,"interventions":10709},[],[2592,10626,10627,10628,10629],[10604,10631,10632,10633,10634,10635,10636,10637],{"intervention":10635,"totalTrials":302,"cells":10711},{"EARLY_PHASE1":10712,"PHASE1":10714,"PHASE2":10716,"PHASE3":10718,"PHASE4":10720,"NA":10722},{"trials":10713,"activeCount":103},[],{"trials":10715,"activeCount":103},[],{"trials":10717,"activeCount":103},[],{"trials":10719,"activeCount":103},[],{"trials":10721,"activeCount":103},[],{"trials":10723,"activeCount":302,"soonestReadout":10622},[10724],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10725,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10726,"interventions":10727},[],[2592,10626,10627,10628,10629],[10604,10631,10632,10633,10634,10635,10636,10637],{"intervention":10636,"totalTrials":302,"cells":10729},{"EARLY_PHASE1":10730,"PHASE1":10732,"PHASE2":10734,"PHASE3":10736,"PHASE4":10738,"NA":10740},{"trials":10731,"activeCount":103},[],{"trials":10733,"activeCount":103},[],{"trials":10735,"activeCount":103},[],{"trials":10737,"activeCount":103},[],{"trials":10739,"activeCount":103},[],{"trials":10741,"activeCount":302,"soonestReadout":10622},[10742],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10743,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10744,"interventions":10745},[],[2592,10626,10627,10628,10629],[10604,10631,10632,10633,10634,10635,10636,10637],{"intervention":10637,"totalTrials":302,"cells":10747},{"EARLY_PHASE1":10748,"PHASE1":10750,"PHASE2":10752,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10749,"activeCount":103},[],{"trials":10751,"activeCount":103},[],{"trials":10753,"activeCount":103},[],{"trials":10755,"activeCount":103},[],{"trials":10757,"activeCount":103},[],{"trials":10759,"activeCount":302,"soonestReadout":10622},[10760],{"nctId":10619,"briefTitle":10620,"status":381,"phases":10761,"primaryCompletion":10622,"completion":10622,"start":10623,"enrollment":10624,"conditions":10762,"interventions":10763},[],[2592,10626,10627,10628,10629],[10604,10631,10632,10633,10634,10635,10636,10637],{"intervention":10765,"totalTrials":302,"cells":10766},"Lorviqua",{"EARLY_PHASE1":10767,"PHASE1":10769,"PHASE2":10771,"PHASE3":10773,"PHASE4":10775,"NA":10777},{"trials":10768,"activeCount":103},[],{"trials":10770,"activeCount":103},[],{"trials":10772,"activeCount":103},[],{"trials":10774,"activeCount":103},[],{"trials":10776,"activeCount":103},[],{"trials":10778,"activeCount":302,"soonestReadout":10281},[10779],{"nctId":10780,"briefTitle":10781,"status":126,"phases":10782,"primaryCompletion":10281,"completion":10281,"start":2078,"enrollment":130,"conditions":10783,"interventions":10785},"NCT05599412","Post Marketing Surveillance(PMS) Study of Lorviqua in Korea",[],[10784],"Metastatic ALK+ Non Small Cell Lung Cancer",[10765],{"intervention":10787,"totalTrials":302,"cells":10788},"Pneumococcal 20-valent conjugate vaccine",{"EARLY_PHASE1":10789,"PHASE1":10791,"PHASE2":10793,"PHASE3":10795,"PHASE4":10797,"NA":10799},{"trials":10790,"activeCount":103},[],{"trials":10792,"activeCount":103},[],{"trials":10794,"activeCount":103},[],{"trials":10796,"activeCount":103},[],{"trials":10798,"activeCount":103},[],{"trials":10800,"activeCount":302,"soonestReadout":10805},[10801],{"nctId":10802,"briefTitle":10803,"status":126,"phases":10804,"primaryCompletion":10805,"completion":10805,"start":10806,"enrollment":10464,"conditions":10807,"interventions":10809},"NCT06760208","A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market",[],"2027-03-01","2025-11-13",[10808,10629],"Pneumococcal Immunization",[10787],{"intervention":10811,"totalTrials":302,"cells":10812},"Vyndamax",{"EARLY_PHASE1":10813,"PHASE1":10815,"PHASE2":10817,"PHASE3":10819,"PHASE4":10821,"NA":10823},{"trials":10814,"activeCount":103},[],{"trials":10816,"activeCount":103},[],{"trials":10818,"activeCount":103},[],{"trials":10820,"activeCount":103},[],{"trials":10822,"activeCount":103},[],{"trials":10824,"activeCount":302,"soonestReadout":1111},[10825],{"nctId":10826,"briefTitle":10827,"status":381,"phases":10828,"primaryCompletion":1111,"completion":1111,"start":10829,"enrollment":8123,"conditions":10830,"interventions":10832},"NCT04801329","Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy",[],"2021-06-29",[10831],"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)",[10811],{"intervention":10834,"totalTrials":302,"cells":10835},"Pfizer-BioNTech COVID-19 mRNA vaccine",{"EARLY_PHASE1":10836,"PHASE1":10838,"PHASE2":10840,"PHASE3":10842,"PHASE4":10844,"NA":10846},{"trials":10837,"activeCount":103},[],{"trials":10839,"activeCount":103},[],{"trials":10841,"activeCount":103},[],{"trials":10843,"activeCount":103},[],{"trials":10845,"activeCount":103},[],{"trials":10847,"activeCount":302,"soonestReadout":1440},[10848],{"nctId":10849,"briefTitle":10850,"status":381,"phases":10851,"primaryCompletion":1440,"completion":3864,"start":8355,"enrollment":302,"conditions":10852,"interventions":10854},"NCT05876377","Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data",[],[10628,2592,10853],"Post-Acute COVID-19 Syndrome",[10834],{"intervention":10856,"totalTrials":302,"cells":10857},"Velsipity",{"EARLY_PHASE1":10858,"PHASE1":10860,"PHASE2":10862,"PHASE3":10864,"PHASE4":10866,"NA":10868},{"trials":10859,"activeCount":103},[],{"trials":10861,"activeCount":103},[],{"trials":10863,"activeCount":103},[],{"trials":10865,"activeCount":103},[],{"trials":10867,"activeCount":103},[],{"trials":10869,"activeCount":302,"soonestReadout":10874},[10870],{"nctId":10871,"briefTitle":10872,"status":126,"phases":10873,"primaryCompletion":10874,"completion":10874,"start":1131,"enrollment":10875,"conditions":10876,"interventions":10878},"NCT07459686","An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis",[],"2029-01-29",553,[10877],"Ulcerative Colitis (UC)",[10856],{"intervention":10880,"totalTrials":302,"cells":10881},"Bosulif",{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10888,"PHASE4":10890,"NA":10892},{"trials":10883,"activeCount":103},[],{"trials":10885,"activeCount":103},[],{"trials":10887,"activeCount":103},[],{"trials":10889,"activeCount":103},[],{"trials":10891,"activeCount":103},[],{"trials":10893,"activeCount":302,"soonestReadout":10898},[10894],{"nctId":10895,"briefTitle":10896,"status":126,"phases":10897,"primaryCompletion":10898,"completion":10898,"start":480,"enrollment":130,"conditions":10899,"interventions":10901},"NCT06297161","A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).",[],"2028-06-01",[10900],"Chronic Leukemia Myelogenous",[10880],{"intervention":2555,"totalTrials":360,"cells":10903},{"EARLY_PHASE1":10904,"PHASE1":10906,"PHASE2":10917,"PHASE3":10927,"PHASE4":11037,"NA":11073},{"trials":10905,"activeCount":103},[],{"trials":10907,"activeCount":103},[10908],{"nctId":10909,"briefTitle":10910,"status":111,"phases":10911,"primaryCompletion":10912,"completion":10912,"start":114,"enrollment":7388,"conditions":10913,"interventions":10915},"NCT01531322","A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects",[91],"2012-01",[10914],"Pneumococcal Infection",[10916,10916,10916],"13-valent Pneumococcal Conjugate Vaccine",{"trials":10918,"activeCount":103},[10919],{"nctId":10920,"briefTitle":10921,"status":111,"phases":10922,"primaryCompletion":560,"completion":560,"start":10923,"enrollment":4755,"conditions":10924,"interventions":10926},"NCT00824850","Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort",[92],"2010-01",[10925],"Pneumococcal Conjugate Vaccine",[10916,10916],{"trials":10928,"activeCount":103},[10929,10933,10943,10953,10957,10964,10968,10977,10990,10997,11001,11010,11018,11022,11029],{"nctId":2547,"briefTitle":2548,"status":111,"phases":10930,"primaryCompletion":2550,"completion":2550,"start":2551,"enrollment":2552,"conditions":10931,"interventions":10932},[93],[2526],[2494,2555],{"nctId":10934,"briefTitle":10935,"status":111,"phases":10936,"primaryCompletion":10937,"completion":10937,"start":7665,"enrollment":10938,"conditions":10939,"interventions":10941},"NCT00492557","Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults",[93],"2008-02",1185,[10940],"Pneumococcal Infections",[2555,10942],"13vPnC + TIV",{"nctId":10944,"briefTitle":10945,"status":111,"phases":10946,"primaryCompletion":8252,"completion":8252,"start":4206,"enrollment":10947,"conditions":10948,"interventions":10952},"NCT01026038","Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.",[93],263,[10949,10950,10629,10951],"13-valent Pneumococcal Vaccine","Immunization","Antibody Response",[2555],{"nctId":2557,"briefTitle":2558,"status":111,"phases":10954,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":10955,"interventions":10956},[93],[2526],[2494,2555],{"nctId":10958,"briefTitle":10959,"status":111,"phases":10960,"primaryCompletion":560,"completion":560,"start":8251,"enrollment":10961,"conditions":10962,"interventions":10963},"NCT00743652","Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.",[93],373,[2526,10949],[10916,10916,10916,10916,10916],{"nctId":2576,"briefTitle":2577,"status":111,"phases":10965,"primaryCompletion":2579,"completion":2579,"start":2580,"enrollment":2581,"conditions":10966,"interventions":10967},[93],[2526],[2494,2555],{"nctId":10969,"briefTitle":10970,"status":111,"phases":10971,"primaryCompletion":6208,"completion":6208,"start":3642,"enrollment":10972,"conditions":10973,"interventions":10975},"NCT00962780","Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine",[93],303,[10974,10940],"HIV Infections",[10916,10976],"23-valent Pneumococcal Polysaccharide Vaccine",{"nctId":10978,"briefTitle":10979,"status":111,"phases":10980,"primaryCompletion":10981,"completion":10981,"start":10982,"enrollment":10983,"conditions":10984,"interventions":10986},"NCT01200368","Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants",[93],"2011-11-30","2010-09-24",551,[10985],"Healthy Subjects",[2555,10987,10988,10989,10989],"diphtheria, tetanus, and acellular pertussis vaccine","7-valent pneumococcal conjugate vaccine","DTaP",{"nctId":10991,"briefTitle":10992,"status":111,"phases":10993,"primaryCompletion":113,"completion":113,"start":6016,"enrollment":10994,"conditions":10995,"interventions":10996},"NCT00963235","Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS",[93],331,[10974,10940],[2555],{"nctId":2597,"briefTitle":2598,"status":111,"phases":10998,"primaryCompletion":1200,"completion":1200,"start":2600,"enrollment":2601,"conditions":10999,"interventions":11000},[93],[2526],[2494,2555],{"nctId":11002,"briefTitle":11003,"status":111,"phases":11004,"primaryCompletion":11005,"completion":11005,"start":11006,"enrollment":11007,"conditions":11008,"interventions":11009},"NCT03571607","A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.",[93],"2018-11-16","2018-07-12",206,[10940],[2555],{"nctId":11011,"briefTitle":11012,"status":111,"phases":11013,"primaryCompletion":4222,"completion":11014,"start":2884,"enrollment":11015,"conditions":11016,"interventions":11017},"NCT00500266","Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects",[93],"2009-05",1053,[10940],[10916],{"nctId":2605,"briefTitle":2606,"status":111,"phases":11019,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":11020,"interventions":11021},[93],[2526],[2494,2555],{"nctId":11023,"briefTitle":11024,"status":111,"phases":11025,"primaryCompletion":9572,"completion":9572,"start":1248,"enrollment":1893,"conditions":11026,"interventions":11028},"NCT01964716","13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.",[93],[11027],"Pneumococcal Vaccines",[2555,2555],{"nctId":11030,"briefTitle":11031,"status":111,"phases":11032,"primaryCompletion":4531,"completion":4531,"start":4636,"enrollment":11033,"conditions":11034,"interventions":11035},"NCT00508742","Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization",[93],1866,[10940],[10916,11036],"7 valent pneumococcal conjugate vaccine",{"trials":11038,"activeCount":103},[11039,11048,11056,11063],{"nctId":11040,"briefTitle":11041,"status":111,"phases":11042,"primaryCompletion":4458,"completion":4458,"start":9572,"enrollment":11043,"conditions":11044,"interventions":11046},"NCT02124161","Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.",[94],882,[11045],"PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE",[2555,11047,11047,2555],"Seasonal Inactivated Influenza Vaccine",{"nctId":11049,"briefTitle":11050,"status":111,"phases":11051,"primaryCompletion":4439,"completion":4439,"start":7386,"enrollment":9970,"conditions":11052,"interventions":11054},"NCT02034877","13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India",[94],[11053],"Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC",[11055],"13-valent Pneumococcal conjugate vaccine",{"nctId":11057,"briefTitle":11058,"status":111,"phases":11059,"primaryCompletion":1431,"completion":1431,"start":11060,"enrollment":162,"conditions":11061,"interventions":11062},"NCT05329259","A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India",[94],"2022-10-06",[2526],[2555],{"nctId":11064,"briefTitle":11065,"status":111,"phases":11066,"primaryCompletion":4590,"completion":4590,"start":4531,"enrollment":11067,"conditions":11068,"interventions":11069},"NCT01392378","Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®",[94],908,[11027],[2555,11070,11071,2555,11070,11072,2555,11070,11071,2555,11070,11072,2555,11070],"INFANRIX hexa","Paracetamol","Ibuprofen",{"trials":11074,"activeCount":103},[],{"intervention":11076,"totalTrials":498,"cells":11077},"Treatment A",{"EARLY_PHASE1":11078,"PHASE1":11080,"PHASE2":11182,"PHASE3":11184,"PHASE4":11186,"NA":11196},{"trials":11079,"activeCount":103},[],{"trials":11081,"activeCount":103},[11082,11089,11100,11109,11115,11121,11130,11136,11142,11148,11154,11160,11166,11173],{"nctId":11083,"briefTitle":11084,"status":111,"phases":11085,"primaryCompletion":560,"completion":560,"start":560,"enrollment":314,"conditions":11086,"interventions":11087},"NCT01184001","A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects",[91],[22],[11076,11088,11088,11076],"Treatment B",{"nctId":11090,"briefTitle":11091,"status":649,"phases":11092,"primaryCompletion":11093,"completion":11094,"start":11095,"enrollment":103,"conditions":11096,"interventions":11097},"NCT06661694","A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults",[91],"2025-09-08","2025-09-09","2025-04-28",[16],[11076,11088,11098,11099],"Treatment C","Treatment D",{"nctId":11101,"briefTitle":11102,"status":111,"phases":11103,"primaryCompletion":11104,"completion":11104,"start":11105,"enrollment":2159,"conditions":11106,"interventions":11108},"NCT06693518","A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults",[91],"2025-01-15","2024-11-22",[11107],"SARS-CoV-2 Infections",[11088,11076],{"nctId":11110,"briefTitle":11111,"status":111,"phases":11112,"primaryCompletion":4627,"completion":4627,"start":4646,"enrollment":1530,"conditions":11113,"interventions":11114},"NCT00867282","A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers",[91],[3396],[11076,11088],{"nctId":11116,"briefTitle":11117,"status":111,"phases":11118,"primaryCompletion":560,"completion":560,"start":561,"enrollment":1509,"conditions":11119,"interventions":11120},"NCT01184092","A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)",[91],[22],[11076,11088,11098,11076,11098,11088,11088,11098,11076,11088,11076,11098,11098,11076,11088,11098,11088,11076],{"nctId":11122,"briefTitle":11123,"status":111,"phases":11124,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":1578,"conditions":11125,"interventions":11126},"NCT01181700","A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers",[91],[3396],[11076,11088,11098,11099,11127,11128,11129],"Treatment E","Treatment F","Treatment G",{"nctId":11131,"briefTitle":11132,"status":111,"phases":11133,"primaryCompletion":4531,"completion":4531,"start":3313,"enrollment":870,"conditions":11134,"interventions":11135},"NCT01388829","Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532",[91],[16],[11076,11088],{"nctId":11137,"briefTitle":11138,"status":111,"phases":11139,"primaryCompletion":524,"completion":524,"start":4666,"enrollment":1780,"conditions":11140,"interventions":11141},"NCT01277991","A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550",[91],[4514],[11076,11088,11088,11076],{"nctId":11143,"briefTitle":11144,"status":111,"phases":11145,"primaryCompletion":4206,"completion":4206,"start":10923,"enrollment":2159,"conditions":11146,"interventions":11147},"NCT01043276","A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355",[91],[6589],[11076,11088,11098,11099,11127],{"nctId":11149,"briefTitle":11150,"status":111,"phases":11151,"primaryCompletion":4846,"completion":4846,"start":4627,"enrollment":1530,"conditions":11152,"interventions":11153},"NCT00928278","A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers",[91],[16],[11076,11088,11098,11099],{"nctId":11155,"briefTitle":11156,"status":111,"phases":11157,"primaryCompletion":6016,"completion":6016,"start":4833,"enrollment":1530,"conditions":11158,"interventions":11159},"NCT00977015","Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers",[91],[16],[11076,11088],{"nctId":11161,"briefTitle":11162,"status":111,"phases":11163,"primaryCompletion":4646,"completion":4646,"start":11014,"enrollment":1530,"conditions":11164,"interventions":11165},"NCT00862667","A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.",[91],[16],[11076,11088,11098],{"nctId":11167,"briefTitle":11168,"status":111,"phases":11169,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":11171,"interventions":11172},"NCT01272375","This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers",[91],"2011-05",[16],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11174,"briefTitle":11175,"status":111,"phases":11176,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":11179,"interventions":11180},"NCT03978143","Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants",[91],"2019-10-17","2019-06-12",[19],[11076,11088,11098,11099,11127,11128,11129,11181],"Treatment H",{"trials":11183,"activeCount":103},[],{"trials":11185,"activeCount":103},[],{"trials":11187,"activeCount":103},[11188],{"nctId":11189,"briefTitle":11190,"status":111,"phases":11191,"primaryCompletion":4222,"completion":4222,"start":4222,"enrollment":1780,"conditions":11192,"interventions":11194},"NCT00902512","Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations",[94],[11193],"Healthy Males",[11076,11195,11088,11098],"Blood samples for the analysis of sildenafil in plasma",{"trials":11197,"activeCount":103},[],{"intervention":11088,"totalTrials":498,"cells":11199},{"EARLY_PHASE1":11200,"PHASE1":11202,"PHASE2":11260,"PHASE3":11262,"PHASE4":11264,"NA":11270},{"trials":11201,"activeCount":103},[],{"trials":11203,"activeCount":103},[11204,11208,11212,11216,11220,11224,11228,11232,11236,11240,11244,11248,11252,11256],{"nctId":11083,"briefTitle":11084,"status":111,"phases":11205,"primaryCompletion":560,"completion":560,"start":560,"enrollment":314,"conditions":11206,"interventions":11207},[91],[22],[11076,11088,11088,11076],{"nctId":11090,"briefTitle":11091,"status":649,"phases":11209,"primaryCompletion":11093,"completion":11094,"start":11095,"enrollment":103,"conditions":11210,"interventions":11211},[91],[16],[11076,11088,11098,11099],{"nctId":11101,"briefTitle":11102,"status":111,"phases":11213,"primaryCompletion":11104,"completion":11104,"start":11105,"enrollment":2159,"conditions":11214,"interventions":11215},[91],[11107],[11088,11076],{"nctId":11110,"briefTitle":11111,"status":111,"phases":11217,"primaryCompletion":4627,"completion":4627,"start":4646,"enrollment":1530,"conditions":11218,"interventions":11219},[91],[3396],[11076,11088],{"nctId":11116,"briefTitle":11117,"status":111,"phases":11221,"primaryCompletion":560,"completion":560,"start":561,"enrollment":1509,"conditions":11222,"interventions":11223},[91],[22],[11076,11088,11098,11076,11098,11088,11088,11098,11076,11088,11076,11098,11098,11076,11088,11098,11088,11076],{"nctId":11122,"briefTitle":11123,"status":111,"phases":11225,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":1578,"conditions":11226,"interventions":11227},[91],[3396],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11131,"briefTitle":11132,"status":111,"phases":11229,"primaryCompletion":4531,"completion":4531,"start":3313,"enrollment":870,"conditions":11230,"interventions":11231},[91],[16],[11076,11088],{"nctId":11137,"briefTitle":11138,"status":111,"phases":11233,"primaryCompletion":524,"completion":524,"start":4666,"enrollment":1780,"conditions":11234,"interventions":11235},[91],[4514],[11076,11088,11088,11076],{"nctId":11143,"briefTitle":11144,"status":111,"phases":11237,"primaryCompletion":4206,"completion":4206,"start":10923,"enrollment":2159,"conditions":11238,"interventions":11239},[91],[6589],[11076,11088,11098,11099,11127],{"nctId":11149,"briefTitle":11150,"status":111,"phases":11241,"primaryCompletion":4846,"completion":4846,"start":4627,"enrollment":1530,"conditions":11242,"interventions":11243},[91],[16],[11076,11088,11098,11099],{"nctId":11155,"briefTitle":11156,"status":111,"phases":11245,"primaryCompletion":6016,"completion":6016,"start":4833,"enrollment":1530,"conditions":11246,"interventions":11247},[91],[16],[11076,11088],{"nctId":11161,"briefTitle":11162,"status":111,"phases":11249,"primaryCompletion":4646,"completion":4646,"start":11014,"enrollment":1530,"conditions":11250,"interventions":11251},[91],[16],[11076,11088,11098],{"nctId":11167,"briefTitle":11168,"status":111,"phases":11253,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":11254,"interventions":11255},[91],[16],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11174,"briefTitle":11175,"status":111,"phases":11257,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":11258,"interventions":11259},[91],[19],[11076,11088,11098,11099,11127,11128,11129,11181],{"trials":11261,"activeCount":103},[],{"trials":11263,"activeCount":103},[],{"trials":11265,"activeCount":103},[11266],{"nctId":11189,"briefTitle":11190,"status":111,"phases":11267,"primaryCompletion":4222,"completion":4222,"start":4222,"enrollment":1780,"conditions":11268,"interventions":11269},[94],[11193],[11076,11195,11088,11098],{"trials":11271,"activeCount":103},[],{"intervention":11273,"totalTrials":498,"cells":11274},"Naproxen",{"EARLY_PHASE1":11275,"PHASE1":11284,"PHASE2":11297,"PHASE3":11361,"PHASE4":11411,"NA":11429},{"trials":11276,"activeCount":103},[11277],{"nctId":11278,"briefTitle":11279,"status":111,"phases":11280,"primaryCompletion":4656,"completion":4656,"start":586,"enrollment":1509,"conditions":11281,"interventions":11283},"NCT00830050","Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients",[90],[11282],"Osteoarthritis",[11273],{"trials":11285,"activeCount":103},[11286],{"nctId":11287,"briefTitle":11288,"status":111,"phases":11289,"primaryCompletion":11290,"completion":11290,"start":11291,"enrollment":1530,"conditions":11292,"interventions":11294},"NCT00743587","A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb",[91],"2009-03","2008-09",[11293],"Osteoarthritis Thumbs",[11295,11296,11273],"Oxycodone","Tramadol",{"trials":11298,"activeCount":103},[11299,11310,11319,11328,11342,11352],{"nctId":11300,"briefTitle":11301,"status":111,"phases":11302,"primaryCompletion":11303,"completion":8012,"start":11304,"enrollment":11305,"conditions":11306,"interventions":11307},"NCT00913627","Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain",[92],"2009-08-01","2009-05-07",196,[34],[11308,11308,11309],"ibuprofen","naproxen",{"nctId":11311,"briefTitle":11312,"status":168,"phases":11313,"completion":11314,"start":11315,"enrollment":3075,"conditions":11316,"interventions":11317},"NCT00418782","A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain",[92],"2007-08","2007-01",[11282],[11309,11318],"CE-224535",{"nctId":11320,"briefTitle":11321,"status":111,"phases":11322,"primaryCompletion":4666,"completion":524,"start":2660,"enrollment":11323,"conditions":11324,"interventions":11325},"NCT01102660","Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee",[92],172,[11282],[11326,11326,11273,11327,11327,11273],"PH-797804","Naproxen + PH-797804",{"nctId":11329,"briefTitle":11330,"status":111,"phases":11331,"primaryCompletion":11332,"completion":11333,"start":11334,"enrollment":11335,"conditions":11336,"interventions":11338},"NCT00876187","A Study of Tanezumab in Adults With Chronic Low Back Pain",[92],"2010-06-16","2011-02-01","2009-06-15",1359,[11337],"Low Back Pain",[11339,11340,11341,11273],"Tanezumab 20 mg IV","Tanezumab 10 mg IV","Tanezumab 5 mg IV",{"nctId":11343,"briefTitle":11344,"status":168,"phases":11345,"primaryCompletion":4666,"completion":4666,"start":586,"enrollment":8278,"conditions":11346,"interventions":11348},"NCT01147458","A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee",[92],[11347],"Osteoarthritis, Knee",[11349,11350,11351,11350,11349,11351,11349,11273,11350,11273,11350,11349],"PF-04191834","PF-04191834 placebo","Naproxen placebo",{"nctId":11353,"briefTitle":11354,"status":111,"phases":11355,"primaryCompletion":3323,"completion":3323,"start":11356,"enrollment":4492,"conditions":11357,"interventions":11359},"NCT02262754","PF-06372865 In Subjects With Chronic Low Back Pain",[92],"2014-10",[11358],"Chronic Low Back Pain",[11360,11273],"PF-06372865",{"trials":11362,"activeCount":103},[11363,11375,11383,11391,11400],{"nctId":11364,"briefTitle":11365,"status":111,"phases":11366,"primaryCompletion":11367,"completion":11368,"start":11369,"enrollment":11370,"conditions":11371,"interventions":11372},"NCT00863304","Tanezumab in Osteoarthritis of the Hip or Knee (2)",[93],"2010-04-27","2010-08-16","2009-06-09",849,[11282],[11373,11374,11309],"tanezumab 10 mg","tanezumab 5 mg",{"nctId":11376,"briefTitle":11377,"status":111,"phases":11378,"primaryCompletion":4398,"completion":4657,"start":11379,"enrollment":5690,"conditions":11380,"interventions":11382},"NCT00652925","A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA",[93],"2002-10",[11381],"Arthritis, Juvenile Rheumatoid",[3079,3079,11273],{"nctId":11384,"briefTitle":11385,"status":111,"phases":11386,"completion":4398,"start":11387,"enrollment":3807,"conditions":11388,"interventions":11389},"NCT00648258","A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan",[93],"2003-07",[11282],[11390,11309],"valdecoxib",{"nctId":11392,"briefTitle":11393,"status":111,"phases":11394,"completion":7675,"start":11395,"enrollment":11396,"conditions":11397,"interventions":11399},"NCT00652808","Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee",[93],"2004-05",265,[11282,11398],"Knee",[11390,11309],{"nctId":11401,"briefTitle":11402,"status":111,"phases":11403,"primaryCompletion":11404,"completion":11405,"start":11406,"enrollment":11407,"conditions":11408,"interventions":11410},"NCT00830063","Tanezumab In Osteoarthritis Of The Knee (2)",[93],"2010-05-17","2010-08-31","2009-05-05",832,[11409,11282],"Arthritis",[11373,11374,11309],{"trials":11412,"activeCount":103},[11413,11422],{"nctId":11414,"briefTitle":11415,"status":111,"phases":11416,"completion":11417,"start":7675,"enrollment":2539,"conditions":11418,"interventions":11420},"NCT00137033","Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population",[94],"2005-07",[11419],"Peptic Ulcers",[3079,11273,11421],"ASA",{"nctId":11423,"briefTitle":11424,"status":111,"phases":11425,"primaryCompletion":2449,"completion":2449,"start":4833,"enrollment":11426,"conditions":11427,"interventions":11428},"NCT00807846","A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects",[94],201,[11381],[3079,11273],{"trials":11430,"activeCount":103},[],{"intervention":11072,"totalTrials":1268,"cells":11432},{"EARLY_PHASE1":11433,"PHASE1":11435,"PHASE2":11453,"PHASE3":11487,"PHASE4":11506,"NA":11535},{"trials":11434,"activeCount":103},[],{"trials":11436,"activeCount":103},[11437,11444],{"nctId":11438,"briefTitle":11439,"status":111,"phases":11440,"primaryCompletion":4206,"completion":4206,"start":4846,"enrollment":597,"conditions":11441,"interventions":11442},"NCT01064726","A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.",[91],[8280],[11072,11443],"Fluticasone propionate",{"nctId":11445,"briefTitle":11446,"status":111,"phases":11447,"primaryCompletion":11448,"completion":11448,"start":11356,"enrollment":2159,"conditions":11449,"interventions":11450},"NCT02260947","Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints",[91],"2014-12",[16],[11451,11451,11452,11072],"PF-06273340","Pregabalin",{"trials":11454,"activeCount":103},[11455,11459,11468,11476],{"nctId":11300,"briefTitle":11301,"status":111,"phases":11456,"primaryCompletion":11303,"completion":8012,"start":11304,"enrollment":11305,"conditions":11457,"interventions":11458},[92],[34],[11308,11308,11309],{"nctId":11460,"briefTitle":11461,"status":111,"phases":11462,"primaryCompletion":11463,"completion":11463,"start":11464,"enrollment":3169,"conditions":11465,"interventions":11466},"NCT01559259","Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain",[92],"2012-09-13","2012-04-10",[34],[11467,11467,11467,11072],"Ibuprofen\u002Facetaminophen",{"nctId":11469,"briefTitle":11470,"status":168,"phases":11471,"primaryCompletion":2450,"completion":113,"start":114,"enrollment":481,"conditions":11472,"interventions":11474},"NCT01512160","Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain",[92],[11473],"Post-surgical Dental Pain",[11475,11475,11072],"PF-04531083",{"nctId":11477,"briefTitle":11478,"status":111,"phases":11479,"primaryCompletion":11480,"completion":11480,"start":11481,"enrollment":11482,"conditions":11483,"interventions":11485},"NCT01529346","Efficacy Of PF-05089771 In Treating Postoperative Dental Pain",[92],"2012-06-25","2011-12-12",235,[11484],"Postoperative Dental Pain",[11486,11486,11486,11072],"PF-05089771",{"trials":11488,"activeCount":103},[11489,11496],{"nctId":11490,"briefTitle":11491,"status":168,"phases":11492,"primaryCompletion":11170,"completion":11170,"start":10923,"enrollment":314,"conditions":11493,"interventions":11495},"NCT01035346","Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection",[93],[11494],"Infection",[11072],{"nctId":11497,"briefTitle":11498,"status":111,"phases":11499,"primaryCompletion":11500,"completion":11500,"start":11501,"enrollment":11502,"conditions":11503,"interventions":11504},"NCT02863575","A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen\u002FCaffeine",[93],"2018-04-06","2017-10-24",374,[34],[11505,11072],"Ibuprofen\u002FCaffeine",{"trials":11507,"activeCount":103},[11508,11516,11524,11528],{"nctId":11509,"briefTitle":11510,"status":111,"phases":11511,"completion":11512,"start":3073,"enrollment":11513,"conditions":11514,"interventions":11515},"NCT00630929","Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)",[94],"2004-02",388,[11347],[11072,3079],{"nctId":11517,"briefTitle":11518,"status":111,"phases":11519,"primaryCompletion":3628,"completion":3628,"start":11379,"enrollment":11520,"conditions":11521,"interventions":11522},"NCT00620867","Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)",[94],393,[11347],[11072,11523],"celecoxib",{"nctId":11064,"briefTitle":11065,"status":111,"phases":11525,"primaryCompletion":4590,"completion":4590,"start":4531,"enrollment":11067,"conditions":11526,"interventions":11527},[94],[11027],[2555,11070,11071,2555,11070,11072,2555,11070,11071,2555,11070,11072,2555,11070],{"nctId":11529,"briefTitle":11530,"status":111,"phases":11531,"primaryCompletion":11170,"completion":11170,"start":11170,"enrollment":1509,"conditions":11532,"interventions":11533},"NCT01350596","A Bioequivalence Study Of Ibuprofen 50mg\u002Fml (laboratórios Pfizer Ltda) In The Oral Suspension Form.",[94],[16],[11534,11072],"Alivium®",{"trials":11536,"activeCount":103},[],{"intervention":11538,"totalTrials":1268,"cells":11539},"13vPnC",{"EARLY_PHASE1":11540,"PHASE1":11542,"PHASE2":11561,"PHASE3":11572,"PHASE4":11633,"NA":11652},{"trials":11541,"activeCount":103},[],{"trials":11543,"activeCount":103},[11544,11552],{"nctId":11545,"briefTitle":11546,"status":111,"phases":11547,"primaryCompletion":7812,"completion":7812,"start":11548,"enrollment":267,"conditions":11549,"interventions":11550},"NCT07019909","A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults",[91],"2025-07-06",[2526],[11551,11538],"20vPnC",{"nctId":11553,"briefTitle":11554,"status":111,"phases":11555,"primaryCompletion":11556,"completion":11556,"start":11557,"enrollment":3169,"conditions":11558,"interventions":11559},"NCT05489328","Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age",[91],"2022-10-07","2022-08-15",[2526],[11538,11560],"PCV15",{"trials":11562,"activeCount":103},[11563],{"nctId":11564,"briefTitle":11565,"status":111,"phases":11566,"primaryCompletion":11567,"completion":11567,"start":11568,"enrollment":4421,"conditions":11569,"interventions":11570},"NCT03512288","Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants",[92],"2020-02-11","2018-04-16",[10940],[11571,11538],"Multivalent",{"trials":11573,"activeCount":103},[11574,11584,11591,11599,11605,11613,11622],{"nctId":11575,"briefTitle":11576,"status":111,"phases":11577,"primaryCompletion":11578,"completion":11578,"start":11579,"enrollment":11580,"conditions":11581,"interventions":11582},"NCT03760146","Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults",[93],"2019-12-16","2018-12-12",3902,[2526],[11551,11538,11583],"PPSV23",{"nctId":11585,"briefTitle":11586,"status":111,"phases":11587,"primaryCompletion":5899,"completion":5899,"start":2018,"enrollment":11588,"conditions":11589,"interventions":11590},"NCT03835975","Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination",[93],875,[2526],[11538,11583,11551],{"nctId":11592,"briefTitle":11593,"status":111,"phases":11594,"primaryCompletion":11595,"completion":11595,"start":2281,"enrollment":11596,"conditions":11597,"interventions":11598},"NCT03828617","Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults",[93],"2019-10-09",1710,[2526],[11551,11551,11551,11538],{"nctId":11600,"briefTitle":11601,"status":111,"phases":11602,"primaryCompletion":577,"completion":577,"start":11290,"enrollment":1539,"conditions":11603,"interventions":11604},"NCT00824655","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children",[93],[11027],[11538,11538],{"nctId":11606,"briefTitle":11607,"status":111,"phases":11608,"primaryCompletion":4636,"completion":4636,"start":11609,"enrollment":11610,"conditions":11611,"interventions":11612},"NCT00562354","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years",[93],"2007-10",271,[16],[11538],{"nctId":11614,"briefTitle":11615,"status":111,"phases":11616,"primaryCompletion":11617,"completion":11617,"start":11618,"enrollment":11619,"conditions":11620,"interventions":11621},"NCT04875533","20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan",[93],"2022-05-13","2021-06-14",1425,[2526],[11551,11538,11583],{"nctId":11623,"briefTitle":11624,"status":111,"phases":11625,"primaryCompletion":11626,"completion":11627,"start":11628,"enrollment":11629,"conditions":11630,"interventions":11631},"NCT03574389","A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children",[93],"2021-08-23","2023-10-13","2018-06-23",936,[10940,10925],[11538,11632],"Hib",{"trials":11634,"activeCount":103},[11635,11644],{"nctId":11636,"briefTitle":11637,"status":111,"phases":11638,"primaryCompletion":11639,"completion":11639,"start":11640,"enrollment":11641,"conditions":11642,"interventions":11643},"NCT03548337","Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India",[94],"2019-12-20","2018-05-31",301,[10626],[11538],{"nctId":11645,"briefTitle":11646,"status":111,"phases":11647,"primaryCompletion":11648,"completion":11648,"start":11649,"enrollment":397,"conditions":11650,"interventions":11651},"NCT03777865","Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India",[94],"2019-04-17","2018-12-14",[10626],[11538],{"trials":11653,"activeCount":103},[],{"intervention":11390,"totalTrials":1625,"cells":11655},{"EARLY_PHASE1":11656,"PHASE1":11658,"PHASE2":11660,"PHASE3":11670,"PHASE4":11713,"NA":11750},{"trials":11657,"activeCount":103},[],{"trials":11659,"activeCount":103},[],{"trials":11661,"activeCount":103},[11662],{"nctId":11663,"briefTitle":11664,"status":111,"phases":11665,"completion":11666,"start":4679,"enrollment":11667,"conditions":11668,"interventions":11669},"NCT00650624","A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)",[92],"2004-01",416,[11347],[11390,11390,11390],{"trials":11671,"activeCount":103},[11672,11682,11690,11697,11701,11705],{"nctId":11673,"briefTitle":11674,"status":111,"phases":11675,"completion":11676,"start":11379,"enrollment":11677,"conditions":11678,"interventions":11680},"NCT00683137","Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery",[93],"2003-02",450,[34,11679],"Hallux Valgus",[11390,11390,11681],"valdecoxib\u002Fplacebo",{"nctId":11683,"briefTitle":11684,"status":111,"phases":11685,"completion":4258,"start":11686,"enrollment":11687,"conditions":11688,"interventions":11689},"NCT00650039","Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction",[93],"2004-03",488,[34],[11390,11390],{"nctId":11691,"briefTitle":11692,"status":111,"phases":11693,"completion":3628,"start":9388,"enrollment":1621,"conditions":11694,"interventions":11696},"NCT00653354","Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery",[93],[11695],"Pain, Post-surgical",[11390,11681],{"nctId":11384,"briefTitle":11385,"status":111,"phases":11698,"completion":4398,"start":11387,"enrollment":3807,"conditions":11699,"interventions":11700},[93],[11282],[11390,11309],{"nctId":11392,"briefTitle":11393,"status":111,"phases":11702,"completion":7675,"start":11395,"enrollment":11396,"conditions":11703,"interventions":11704},[93],[11282,11398],[11390,11309],{"nctId":11706,"briefTitle":11707,"status":111,"phases":11708,"completion":11387,"start":4399,"enrollment":11709,"conditions":11710,"interventions":11712},"NCT00661635","A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain",[93],490,[11711,34],"Laparoscopic Cholecystectomy",[11390,11390],{"trials":11714,"activeCount":103},[11715,11723,11732,11741],{"nctId":11716,"briefTitle":11717,"status":111,"phases":11718,"completion":2642,"start":4399,"enrollment":11719,"conditions":11720,"interventions":11721},"NCT00649610","Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain",[94],340,[11337],[11390,11722],"diclofenac",{"nctId":11724,"briefTitle":11725,"status":111,"phases":11726,"primaryCompletion":11727,"completion":11727,"start":11686,"enrollment":11728,"conditions":11729,"interventions":11731},"NCT00650598","A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction",[94],"2004-08",328,[11730],"Pain, Postoperative",[11390,11722],{"nctId":11733,"briefTitle":11734,"status":111,"phases":11735,"completion":11736,"start":9388,"enrollment":5784,"conditions":11737,"interventions":11740},"NCT00671320","A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle",[94],"2003-10",[34,11738,11739],"Sprains and Strains","Sprain",[11390,11722],{"nctId":11742,"briefTitle":11743,"status":111,"phases":11744,"completion":11387,"start":3073,"enrollment":11745,"conditions":11746,"interventions":11748},"NCT00649415","A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea",[94],154,[11747],"Dysmenorrhea",[11749,11390],"piroxicam",{"trials":11751,"activeCount":103},[],{"intervention":11753,"totalTrials":627,"cells":11754},"Tick-Borne Encephalitis",{"EARLY_PHASE1":11755,"PHASE1":11757,"PHASE2":11759,"PHASE3":11776,"PHASE4":11811,"NA":11832},{"trials":11756,"activeCount":103},[],{"trials":11758,"activeCount":103},[],{"trials":11760,"activeCount":103},[11761,11770],{"nctId":11762,"briefTitle":11763,"status":111,"phases":11764,"completion":11765,"start":2652,"enrollment":11766,"conditions":11767,"interventions":11769},"NCT00161850","FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years",[92],"2002-08",615,[11768],"Encephalitis, Tick-borne",[11753],{"nctId":11771,"briefTitle":11772,"status":111,"phases":11773,"completion":11765,"start":2652,"enrollment":11766,"conditions":11774,"interventions":11775},"NCT00161889","FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years",[92],[11768],[11753],{"trials":11777,"activeCount":103},[11778,11786,11794,11803],{"nctId":11779,"briefTitle":11780,"status":111,"phases":11781,"completion":4647,"start":11782,"enrollment":11783,"conditions":11784,"interventions":11785},"NCT00161824","Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR",[93],"2001-10",3800,[11768],[11753],{"nctId":11787,"briefTitle":11788,"status":111,"phases":11789,"completion":11790,"start":11791,"conditions":11792,"interventions":11793},"NCT00161746","Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years",[92,93],"1999-06","1998-04",[11768],[11753],{"nctId":11795,"briefTitle":11796,"status":111,"phases":11797,"primaryCompletion":11798,"completion":11798,"start":11799,"enrollment":4492,"conditions":11800,"interventions":11802},"NCT00840801","Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children",[93],"2010-05-20","2009-02-06",[11801],"Encephalitis, Tick-Borne",[11753,11753],{"nctId":11804,"briefTitle":11805,"status":111,"phases":11806,"completion":11765,"start":11807,"enrollment":11808,"conditions":11809,"interventions":11810},"NCT00161876","FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years",[93],"2002-05",3973,[11768],[11753],{"trials":11812,"activeCount":103},[11813,11819,11825],{"nctId":11814,"briefTitle":11815,"status":111,"phases":11816,"completion":11395,"start":11686,"conditions":11817,"interventions":11818},"NCT00161954","Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years",[94],[11768],[11753],{"nctId":11820,"briefTitle":11821,"status":111,"phases":11822,"primaryCompletion":586,"completion":560,"start":2641,"enrollment":4549,"conditions":11823,"interventions":11824},"NCT00503529","TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)",[94],[11801],[11753],{"nctId":11826,"briefTitle":11827,"status":111,"phases":11828,"primaryCompletion":4207,"completion":4645,"start":11829,"enrollment":1568,"conditions":11830,"interventions":11831},"NCT00161967","TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)",[94],"2005-05",[11801],[11753],{"trials":11833,"activeCount":103},[],{"intervention":11098,"totalTrials":627,"cells":11835},{"EARLY_PHASE1":11836,"PHASE1":11838,"PHASE2":11872,"PHASE3":11874,"PHASE4":11876,"NA":11882},{"trials":11837,"activeCount":103},[],{"trials":11839,"activeCount":103},[11840,11844,11848,11852,11856,11860,11864,11868],{"nctId":11090,"briefTitle":11091,"status":649,"phases":11841,"primaryCompletion":11093,"completion":11094,"start":11095,"enrollment":103,"conditions":11842,"interventions":11843},[91],[16],[11076,11088,11098,11099],{"nctId":11116,"briefTitle":11117,"status":111,"phases":11845,"primaryCompletion":560,"completion":560,"start":561,"enrollment":1509,"conditions":11846,"interventions":11847},[91],[22],[11076,11088,11098,11076,11098,11088,11088,11098,11076,11088,11076,11098,11098,11076,11088,11098,11088,11076],{"nctId":11122,"briefTitle":11123,"status":111,"phases":11849,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":1578,"conditions":11850,"interventions":11851},[91],[3396],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11143,"briefTitle":11144,"status":111,"phases":11853,"primaryCompletion":4206,"completion":4206,"start":10923,"enrollment":2159,"conditions":11854,"interventions":11855},[91],[6589],[11076,11088,11098,11099,11127],{"nctId":11149,"briefTitle":11150,"status":111,"phases":11857,"primaryCompletion":4846,"completion":4846,"start":4627,"enrollment":1530,"conditions":11858,"interventions":11859},[91],[16],[11076,11088,11098,11099],{"nctId":11161,"briefTitle":11162,"status":111,"phases":11861,"primaryCompletion":4646,"completion":4646,"start":11014,"enrollment":1530,"conditions":11862,"interventions":11863},[91],[16],[11076,11088,11098],{"nctId":11167,"briefTitle":11168,"status":111,"phases":11865,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":11866,"interventions":11867},[91],[16],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11174,"briefTitle":11175,"status":111,"phases":11869,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":11870,"interventions":11871},[91],[19],[11076,11088,11098,11099,11127,11128,11129,11181],{"trials":11873,"activeCount":103},[],{"trials":11875,"activeCount":103},[],{"trials":11877,"activeCount":103},[11878],{"nctId":11189,"briefTitle":11190,"status":111,"phases":11879,"primaryCompletion":4222,"completion":4222,"start":4222,"enrollment":1780,"conditions":11880,"interventions":11881},[94],[11193],[11076,11195,11088,11098],{"trials":11883,"activeCount":103},[],{"intervention":11885,"totalTrials":627,"cells":11886},"varenicline tartrate",{"EARLY_PHASE1":11887,"PHASE1":11889,"PHASE2":11914,"PHASE3":11916,"PHASE4":11926,"NA":11967},{"trials":11888,"activeCount":103},[],{"trials":11890,"activeCount":103},[11891,11899,11907],{"nctId":11892,"briefTitle":11893,"status":111,"phases":11894,"completion":11895,"start":11895,"enrollment":562,"conditions":11896,"interventions":11898},"NCT00452894","Phase 1 Clinical Trial of Varenicline in Chinese Healthy Smoking Volunteers",[91],"2007-03",[11897],"Smoking",[11885],{"nctId":11900,"briefTitle":11901,"status":111,"phases":11902,"primaryCompletion":10937,"completion":10937,"start":11609,"enrollment":4369,"conditions":11903,"interventions":11905},"NCT00527150","Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers",[91],[11904],"Smoking Cessation",[11906,11906,11906,11906,11906],"Varenicline Tartrate",{"nctId":11908,"briefTitle":11909,"status":111,"phases":11910,"primaryCompletion":3839,"completion":3839,"start":3314,"enrollment":597,"conditions":11911,"interventions":11912},"NCT00661765","A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.",[91],[11904],[11885,11913],"varenicline free base",{"trials":11915,"activeCount":103},[],{"trials":11917,"activeCount":103},[11918],{"nctId":11919,"briefTitle":11920,"status":111,"phases":11921,"completion":3643,"start":3854,"enrollment":11922,"conditions":11923,"interventions":11924},"NCT00371813","An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking",[93],334,[11904],[11925],"Varenicline tartrate",{"trials":11927,"activeCount":103},[11928,11935,11943,11952,11960],{"nctId":11929,"briefTitle":11930,"status":111,"phases":11931,"primaryCompletion":4646,"completion":4214,"start":3314,"enrollment":11932,"conditions":11933,"interventions":11934},"NCT00594204","Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking",[94],593,[11904],[11885],{"nctId":11936,"briefTitle":11937,"status":111,"phases":11938,"primaryCompletion":4222,"completion":4627,"start":8115,"enrollment":11939,"conditions":11940,"interventions":11942},"NCT00717093","Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use",[94],432,[11941],"Tobacco Use Cessation",[11906],{"nctId":11944,"briefTitle":11945,"status":111,"phases":11946,"primaryCompletion":4439,"completion":4439,"start":113,"enrollment":11947,"conditions":11948,"interventions":11949},"NCT01574703","Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.",[94],4595,[11904],[11885,11950,11951],"bupropion hydrochloride","Nicotine Replacement Therapy Patch",{"nctId":11953,"briefTitle":11954,"status":111,"phases":11955,"primaryCompletion":11956,"completion":11956,"start":570,"enrollment":11957,"conditions":11958,"interventions":11959},"NCT01456936","Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders",[94],"2015-01",8144,[11904],[11885,11950,11951],{"nctId":11961,"briefTitle":11962,"status":111,"phases":11963,"primaryCompletion":6263,"completion":6263,"start":3313,"enrollment":11964,"conditions":11965,"interventions":11966},"NCT01370356","A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction",[94],1510,[11904],[11906],{"trials":11968,"activeCount":103},[],{"intervention":2341,"totalTrials":1487,"cells":11970},{"EARLY_PHASE1":11971,"PHASE1":11973,"PHASE2":11982,"PHASE3":12008,"PHASE4":12038,"NA":12044},{"trials":11972,"activeCount":103},[],{"trials":11974,"activeCount":103},[11975],{"nctId":11976,"briefTitle":11977,"status":111,"phases":11978,"primaryCompletion":560,"completion":560,"start":561,"enrollment":597,"conditions":11979,"interventions":11980},"NCT01199900","Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism",[91],[16],[11981,11981,2341,11981,11981,2341,2341],"PF-04171327",{"trials":11983,"activeCount":103},[11984,11993,12000],{"nctId":11985,"briefTitle":11986,"status":168,"phases":11987,"primaryCompletion":11988,"completion":3353,"start":3335,"enrollment":9553,"conditions":11989,"interventions":11990},"NCT00634933","Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis",[92],"2010-02",[4514],[11991,11992,2341,11991,11992,2341,11991,11992,2341],"TRU-015","Methylprednisolone",{"nctId":11994,"briefTitle":11995,"status":111,"phases":11996,"primaryCompletion":2884,"completion":3642,"start":9387,"enrollment":8013,"conditions":11997,"interventions":11999},"NCT00137436","Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer",[91,92],[11998],"Prostatic Neoplasms",[3631,2341,2666],{"nctId":12001,"briefTitle":12002,"status":111,"phases":12003,"primaryCompletion":523,"completion":2883,"start":12004,"enrollment":9,"conditions":12005,"interventions":12006},"NCT00313781","Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)",[92],"2006-05",[11998],[1705,432,12007,432,12007],"prednisone",{"trials":12009,"activeCount":103},[12010,12017,12026],{"nctId":12011,"briefTitle":12012,"status":168,"phases":12013,"primaryCompletion":2883,"completion":2883,"start":4207,"enrollment":12014,"conditions":12015,"interventions":12016},"NCT00676650","Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy",[93],873,[11998],[2341,3317,2341],{"nctId":12018,"briefTitle":12019,"status":111,"phases":12020,"primaryCompletion":7665,"completion":7665,"start":12021,"conditions":12022,"interventions":12023},"NCT00004071","Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer",[92,93],"1999-08",[1684],[12024,12025,12007],"leflunomide","mitoxantrone hydrochloride",{"nctId":12027,"briefTitle":12028,"status":168,"phases":12029,"primaryCompletion":4656,"completion":10912,"start":12030,"enrollment":7388,"conditions":12031,"interventions":12034},"NCT00311311","Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients",[93],"2006-04",[12032,12033],"Atherosclerosis","Kidney Failure",[12035,12036,12007,12037,12035,12036,12007],"tacrolimus","mycophenolate mofetil","sirolimus",{"trials":12039,"activeCount":103},[12040],{"nctId":2331,"briefTitle":2332,"status":111,"phases":12041,"primaryCompletion":2334,"completion":2335,"start":2336,"enrollment":2337,"conditions":12042,"interventions":12043},[94],[1684],[63,2340,2341],{"trials":12045,"activeCount":103},[],{"intervention":12047,"totalTrials":1487,"cells":12048},"Diclofenac",{"EARLY_PHASE1":12049,"PHASE1":12051,"PHASE2":12053,"PHASE3":12055,"PHASE4":12084,"NA":12113},{"trials":12050,"activeCount":103},[],{"trials":12052,"activeCount":103},[],{"trials":12054,"activeCount":103},[],{"trials":12056,"activeCount":103},[12057,12065,12074],{"nctId":12058,"briefTitle":12059,"status":168,"phases":12060,"completion":4398,"start":3074,"enrollment":26,"conditions":12061,"interventions":12063},"NCT00139646","Parecoxib in Renal Colic",[93],[12062],"Colic",[12064,12047],"Parecoxib",{"nctId":12066,"briefTitle":12067,"status":111,"phases":12068,"completion":12069,"start":3073,"enrollment":12070,"conditions":12071,"interventions":12073},"NCT00648141","Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis",[93],"2005-01",458,[12072],"Spondylitis, Ankylosing",[3079,3079,12047],{"nctId":12075,"briefTitle":12076,"status":168,"phases":12077,"primaryCompletion":12078,"completion":12079,"start":12080,"enrollment":3425,"conditions":12081,"interventions":12082},"NCT00864097","Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip",[93],"2010-11-16","2010-11-24","2009-08-11",[11282],[12083,11722,12083,11722,12083,11722,11722],"tanezumab",{"trials":12085,"activeCount":103},[12086,12090,12094,12101,12105],{"nctId":11716,"briefTitle":11717,"status":111,"phases":12087,"completion":2642,"start":4399,"enrollment":11719,"conditions":12088,"interventions":12089},[94],[11337],[11390,11722],{"nctId":11724,"briefTitle":11725,"status":111,"phases":12091,"primaryCompletion":11727,"completion":11727,"start":11686,"enrollment":11728,"conditions":12092,"interventions":12093},[94],[11730],[11390,11722],{"nctId":12095,"briefTitle":12096,"status":111,"phases":12097,"completion":4258,"start":6458,"enrollment":8827,"conditions":12098,"interventions":12100},"NCT00174317","Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip",[94],[12099],"Osteoarthritis, Hip",[3079,12047],{"nctId":11733,"briefTitle":11734,"status":111,"phases":12102,"completion":11736,"start":9388,"enrollment":5784,"conditions":12103,"interventions":12104},[94],[34,11738,11739],[11390,11722],{"nctId":12106,"briefTitle":12107,"status":111,"phases":12108,"completion":12109,"start":11736,"enrollment":12110,"conditions":12111,"interventions":12112},"NCT00640432","Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain",[94],"2004-10",244,[11337],[12047,3079],{"trials":12114,"activeCount":103},[],{"intervention":12116,"totalTrials":1487,"cells":12117},"Inhaled Insulin",{"EARLY_PHASE1":12118,"PHASE1":12120,"PHASE2":12122,"PHASE3":12133,"PHASE4":12180,"NA":12190},{"trials":12119,"activeCount":103},[],{"trials":12121,"activeCount":103},[],{"trials":12123,"activeCount":103},[12124],{"nctId":12125,"briefTitle":12126,"status":111,"phases":12127,"completion":12128,"start":4702,"enrollment":2159,"conditions":12129,"interventions":12131},"NCT00143104","To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.",[92],"2006-10",[12130],"Diabetes Mellitus, Type 1",[12132],"Inhaled insulin",{"trials":12134,"activeCount":103},[12135,12144,12152,12159,12166,12174],{"nctId":12136,"briefTitle":12137,"status":168,"phases":12138,"primaryCompletion":12139,"completion":12139,"start":12140,"enrollment":12141,"conditions":12142,"interventions":12143},"NCT00282971","A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus",[93],"2008-02-19","2006-03-06",354,[6210],[12116],{"nctId":12145,"briefTitle":12146,"status":168,"phases":12147,"primaryCompletion":8154,"completion":8154,"start":11807,"enrollment":12148,"conditions":12149,"interventions":12150},"NCT00137046","Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes",[93],582,[12130],[12151,12116],"Subcutaneous Insulin",{"nctId":12153,"briefTitle":12154,"status":111,"phases":12155,"completion":3643,"start":3073,"enrollment":12156,"conditions":12157,"interventions":12158},"NCT00150410","Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose",[93],626,[6117],[12132],{"nctId":12160,"briefTitle":12161,"status":111,"phases":12162,"primaryCompletion":4665,"completion":4665,"start":3073,"enrollment":12163,"conditions":12164,"interventions":12165},"NCT00139659","A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma",[93],288,[6589,6117],[12116,12151],{"nctId":12167,"briefTitle":12168,"status":168,"phases":12169,"primaryCompletion":8154,"completion":8154,"start":4616,"enrollment":12170,"conditions":12171,"interventions":12172},"NCT00136916","Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes",[93],635,[6117],[12116,12173],"Subcutaneous insulin",{"nctId":12175,"briefTitle":12176,"status":168,"phases":12177,"primaryCompletion":11609,"completion":11609,"start":11609,"enrollment":1087,"conditions":12178,"interventions":12179},"NCT00479258","Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents",[93],[12130],[12132,12151],{"trials":12181,"activeCount":103},[12182],{"nctId":12183,"briefTitle":12184,"status":111,"phases":12185,"primaryCompletion":8115,"completion":8115,"start":11895,"enrollment":12186,"conditions":12187,"interventions":12188},"NCT00418522","This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus",[94],413,[37],[12189,12116],"Insulin glargine",{"trials":12191,"activeCount":103},[],{"intervention":12193,"totalTrials":3659,"cells":12194},"Alprazolam",{"EARLY_PHASE1":12195,"PHASE1":12197,"PHASE2":12239,"PHASE3":12248,"PHASE4":12250,"NA":12259},{"trials":12196,"activeCount":103},[],{"trials":12198,"activeCount":103},[12199,12207,12215,12223,12231],{"nctId":12200,"briefTitle":12201,"status":111,"phases":12202,"primaryCompletion":4846,"completion":4846,"start":4214,"enrollment":2218,"conditions":12203,"interventions":12204},"NCT00860119","Bioequivalence of Alprazolam Sublingual vs Oral Tablets",[91],[16],[12205,12206],"alprazolam sublingual","alprazolam oral",{"nctId":12208,"briefTitle":12209,"status":168,"phases":12210,"completion":10937,"start":7665,"enrollment":8414,"conditions":12211,"interventions":12212},"NCT00580190","Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects",[91],[16],[12213,12214],"alprazolam","PF-00572778",{"nctId":12216,"briefTitle":12217,"status":649,"phases":12218,"primaryCompletion":12219,"completion":12219,"start":12220,"enrollment":103,"conditions":12221,"interventions":12222},"NCT01046162","A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions",[91],"2010-07-22","2010-07-15",[16],[12193,12193],{"nctId":12224,"briefTitle":12225,"status":111,"phases":12226,"primaryCompletion":4645,"completion":4645,"start":4665,"enrollment":1509,"conditions":12227,"interventions":12228},"NCT00810316","Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population",[91],[3396],[12193,12229,12230],"Alprazolam XR","Clonazepam",{"nctId":12232,"briefTitle":12233,"status":111,"phases":12234,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":5909,"conditions":12235,"interventions":12237},"NCT01256151","Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet",[91],[12236],"Anxiety Disorder",[12193,12238],"Alprazolam sublingual",{"trials":12240,"activeCount":103},[12241],{"nctId":12242,"briefTitle":12243,"status":111,"phases":12244,"completion":12128,"start":2662,"enrollment":481,"conditions":12245,"interventions":12247},"NCT00245609","Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure",[92],[12246],"Dental Anxiety",[11452,12193],{"trials":12249,"activeCount":103},[],{"trials":12251,"activeCount":103},[12252],{"nctId":12253,"briefTitle":12254,"status":111,"phases":12255,"primaryCompletion":9544,"completion":9544,"start":11170,"enrollment":1780,"conditions":12256,"interventions":12257},"NCT01322867","A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets",[94],[16],[12213,12258],"alprazolam oral solution",{"trials":12260,"activeCount":103},[],{"intervention":12262,"totalTrials":3659,"cells":12263},"Meropenem",{"EARLY_PHASE1":12264,"PHASE1":12266,"PHASE2":12268,"PHASE3":12292,"PHASE4":12323,"NA":12339},{"trials":12265,"activeCount":103},[],{"trials":12267,"activeCount":103},[],{"trials":12269,"activeCount":103},[12270,12282],{"nctId":12271,"briefTitle":12272,"status":111,"phases":12273,"primaryCompletion":12274,"completion":12275,"start":12276,"enrollment":9,"conditions":12277,"interventions":12279},"NCT00752219","Prospective Multicenter Doubleblind Randomized Study of NXL104\u002FCeftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections",[92],"2009-11-30","2009-12-31","2009-03-31",[12278],"Complicated Intra-abdominal Infections",[12280,12281],"ceftazidime\u002FNXL104 + metronidazole","meropenem",{"nctId":12283,"briefTitle":12284,"status":111,"phases":12285,"primaryCompletion":12286,"completion":12286,"start":12287,"enrollment":3603,"conditions":12288,"interventions":12289},"NCT02475733","Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).",[92],"2017-06-01","2015-08-01",[12278],[12290,12262,12291],"Ceftazidime -avibactam","Metronidazole",{"trials":12293,"activeCount":103},[12294,12303,12313],{"nctId":12295,"briefTitle":12296,"status":111,"phases":12297,"primaryCompletion":7578,"completion":7578,"start":2450,"enrollment":12298,"conditions":12299,"interventions":12301},"NCT01499290","Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections",[93],493,[12300],"Complicated Intra-Abdominal Infection",[12302,12291,12262],"CAZ-AVI",{"nctId":12304,"briefTitle":12305,"status":111,"phases":12306,"primaryCompletion":12307,"completion":12307,"start":4590,"enrollment":12308,"conditions":12309,"interventions":12310},"NCT01726023","Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections",[93],"2015-03",486,[6505],[12311,12312,12262],"Ceftazidime-avibactam","metronidazole",{"nctId":12314,"briefTitle":12315,"status":111,"phases":12316,"primaryCompletion":7387,"completion":7387,"start":6208,"enrollment":12317,"conditions":12318,"interventions":12321},"NCT01808092","A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia",[93],969,[12319,12320],"Nosocomial Pneumonia (NP)","Ventilator-associated Pneumonia (VAP)",[12322,12281],"ceftazidim-avibactam",{"trials":12324,"activeCount":103},[12325,12332],{"nctId":12326,"briefTitle":12327,"status":111,"phases":12328,"primaryCompletion":6017,"completion":3610,"start":2652,"enrollment":2070,"conditions":12329,"interventions":12331},"NCT00318994","Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis",[94],[12330],"Pancreatitis",[12262],{"nctId":12333,"briefTitle":12334,"status":111,"phases":12335,"primaryCompletion":3627,"completion":3627,"start":4647,"enrollment":4981,"conditions":12336,"interventions":12338},"NCT00318552","Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.",[94],[12337],"Sepsis",[12262],{"trials":12340,"activeCount":103},[],{"intervention":12342,"totalTrials":2070,"cells":12343},"Viagra",{"EARLY_PHASE1":12344,"PHASE1":12346,"PHASE2":12363,"PHASE3":12365,"PHASE4":12367,"NA":12399},{"trials":12345,"activeCount":103},[],{"trials":12347,"activeCount":103},[12348,12356],{"nctId":12349,"briefTitle":12350,"status":649,"phases":12351,"primaryCompletion":129,"completion":129,"start":12352,"enrollment":103,"conditions":12353,"interventions":12354},"NCT04391868","A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form",[91],"2021-01-30",[16],[12342,12355,12355],"Sildenafil Citrate ODF",{"nctId":12357,"briefTitle":12358,"status":111,"phases":12359,"primaryCompletion":1700,"completion":1700,"start":569,"enrollment":336,"conditions":12360,"interventions":12361},"NCT01737203","Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil",[91],[16],[12342,12362,12362],"sildenafil ODT",{"trials":12364,"activeCount":103},[],{"trials":12366,"activeCount":103},[],{"trials":12368,"activeCount":103},[12369,12378,12385,12391],{"nctId":12370,"briefTitle":12371,"status":111,"phases":12372,"completion":11727,"start":11686,"enrollment":12373,"conditions":12374,"interventions":12377},"NCT00159809","Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction",[94],140,[12375,12376],"Impotence","Depression",[12342],{"nctId":12379,"briefTitle":12380,"status":111,"phases":12381,"completion":11829,"start":11686,"enrollment":12382,"conditions":12383,"interventions":12384},"NCT00143221","Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)",[94],350,[12375],[12342],{"nctId":12386,"briefTitle":12387,"status":111,"phases":12388,"primaryCompletion":7665,"completion":7665,"start":8170,"enrollment":1915,"conditions":12389,"interventions":12390},"NCT00301262","Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied",[94],[12375],[12342],{"nctId":12392,"briefTitle":12393,"status":111,"phases":12394,"completion":7665,"start":12395,"enrollment":12396,"conditions":12397,"interventions":12398},"NCT00343200","A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.",[94],"2006-07",371,[12375],[12342],{"trials":12400,"activeCount":103},[],{"intervention":12402,"totalTrials":2070,"cells":12403},"Inhaled Human Insulin",{"EARLY_PHASE1":12404,"PHASE1":12406,"PHASE2":12408,"PHASE3":12410,"PHASE4":12429,"NA":12458},{"trials":12405,"activeCount":103},[],{"trials":12407,"activeCount":103},[],{"trials":12409,"activeCount":103},[],{"trials":12411,"activeCount":103},[12412,12420],{"nctId":12413,"briefTitle":12414,"status":168,"phases":12415,"completion":11895,"start":12416,"enrollment":525,"conditions":12417,"interventions":12418},"NCT00287066","A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition",[93],"2006-02",[6117],[12402,12419],"Regular Human Insulin",{"nctId":12421,"briefTitle":12422,"status":111,"phases":12423,"completion":12424,"start":12425,"enrollment":1613,"conditions":12426,"interventions":12427},"NCT00424411","Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes",[93],"2000-12","1999-09",[37],[12428],"Inhaled human insulin",{"trials":12430,"activeCount":103},[12431,12438,12445,12451],{"nctId":12432,"briefTitle":12433,"status":111,"phases":12434,"completion":1701,"start":3854,"enrollment":1780,"conditions":12435,"interventions":12436},"NCT00367445","A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus",[94],[37],[12402,12437],"Insulin Glargine",{"nctId":12439,"briefTitle":12440,"status":111,"phases":12441,"primaryCompletion":8115,"completion":8115,"start":4615,"enrollment":12442,"conditions":12443,"interventions":12444},"NCT00391027","A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®",[94],261,[37],[12437,12402],{"nctId":12446,"briefTitle":12447,"status":168,"phases":12448,"primaryCompletion":4636,"completion":4636,"start":3643,"enrollment":2175,"conditions":12449,"interventions":12450},"NCT00437489","A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.",[94],[37],[12402,12402],{"nctId":12452,"briefTitle":12453,"status":168,"phases":12454,"primaryCompletion":3839,"completion":3839,"start":4847,"enrollment":1587,"conditions":12455,"interventions":12456},"NCT00356421","A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®",[94],[12130],[12402,12457],"Insulin lispro",{"trials":12459,"activeCount":103},[],{"intervention":12461,"totalTrials":2070,"cells":12462},"fesoterodine fumarate",{"EARLY_PHASE1":12463,"PHASE1":12465,"PHASE2":12481,"PHASE3":12491,"PHASE4":12507,"NA":12517},{"trials":12464,"activeCount":103},[],{"trials":12466,"activeCount":103},[12467,12474],{"nctId":12468,"briefTitle":12469,"status":111,"phases":12470,"primaryCompletion":540,"completion":540,"start":113,"enrollment":1509,"conditions":12471,"interventions":12473},"NCT01566760","A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers",[91],[12472],"Urinary Bladder, Overactive",[12461,12461,12461,12461,12461],{"nctId":12475,"briefTitle":12476,"status":168,"phases":12477,"primaryCompletion":4221,"completion":4221,"start":4222,"enrollment":2240,"conditions":12478,"interventions":12479},"NCT00832650","Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit",[91],[16],[12461,12480],"solifenacin",{"trials":12482,"activeCount":103},[12483],{"nctId":12484,"briefTitle":12485,"status":111,"phases":12486,"primaryCompletion":8251,"completion":8251,"start":2964,"enrollment":12487,"conditions":12488,"interventions":12490},"NCT00561951","Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.",[92],951,[12489],"Overactive Bladder",[12461,12461],{"trials":12492,"activeCount":103},[12493,12500],{"nctId":12494,"briefTitle":12495,"status":111,"phases":12496,"primaryCompletion":4214,"completion":4214,"start":10937,"enrollment":12497,"conditions":12498,"interventions":12499},"NCT00658684","Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.",[93],153,[12489],[12461],{"nctId":12501,"briefTitle":12502,"status":111,"phases":12503,"primaryCompletion":4207,"completion":4207,"start":3602,"enrollment":3732,"conditions":12504,"interventions":12505},"NCT00444925","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)",[93],[12489],[12461,12506],"tolterodine tartrate",{"trials":12508,"activeCount":103},[12509],{"nctId":12510,"briefTitle":12511,"status":111,"phases":12512,"primaryCompletion":560,"completion":560,"start":3839,"enrollment":12513,"conditions":12514,"interventions":12515},"NCT00798434","A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.",[94],794,[12472],[12516],"Fesoterodine fumarate",{"trials":12518,"activeCount":103},[],{"intervention":12520,"totalTrials":578,"cells":12521},"desvenlafaxine succinate sustained release",{"EARLY_PHASE1":12522,"PHASE1":12524,"PHASE2":12533,"PHASE3":12535,"PHASE4":12560,"NA":12566},{"trials":12523,"activeCount":103},[],{"trials":12525,"activeCount":103},[12526],{"nctId":12527,"briefTitle":12528,"status":111,"phases":12529,"primaryCompletion":8252,"completion":8252,"start":560,"enrollment":713,"conditions":12530,"interventions":12532},"NCT01190514","Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast\u002FFed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)",[91],[12531],"Depression - Major Depressive Disorder",[12520,12520,12520,12520],{"trials":12534,"activeCount":103},[],{"trials":12536,"activeCount":103},[12537,12546,12553],{"nctId":12538,"briefTitle":12539,"status":111,"phases":12540,"primaryCompletion":12541,"completion":12541,"start":12542,"enrollment":11719,"conditions":12543,"interventions":12544},"NCT01372150","A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD",[93],"2015-03-20","2011-11-17",[6321],[12520,12545],"fluoxetine",{"nctId":12547,"briefTitle":12548,"status":111,"phases":12549,"primaryCompletion":524,"completion":524,"start":11290,"enrollment":12550,"conditions":12551,"interventions":12552},"NCT00831415","Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)",[93],304,[6321],[12520],{"nctId":12554,"briefTitle":12555,"status":111,"phases":12556,"primaryCompletion":3853,"completion":3853,"start":4615,"enrollment":1893,"conditions":12557,"interventions":12559},"NCT00401245","The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms",[93],[12558],"Vasomotor Symptoms",[12520,12520,12520,12520,12520,12520,12520],{"trials":12561,"activeCount":103},[12562],{"nctId":6317,"briefTitle":6318,"status":111,"phases":12563,"primaryCompletion":561,"completion":561,"start":577,"enrollment":5909,"conditions":12564,"interventions":12565},[94],[6321],[6323,1687],{"trials":12567,"activeCount":103},[],{"intervention":12569,"totalTrials":578,"cells":12570},"Pegvisomant",{"EARLY_PHASE1":12571,"PHASE1":12573,"PHASE2":12590,"PHASE3":12592,"PHASE4":12601,"NA":12618},{"trials":12572,"activeCount":103},[],{"trials":12574,"activeCount":103},[12575,12583],{"nctId":12576,"briefTitle":12577,"status":111,"phases":12578,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":562,"conditions":12579,"interventions":12581},"NCT01181973","Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects",[91],[12580],"Bioavailability",[12582,12582,12582,12582],"pegvisomant",{"nctId":12584,"briefTitle":12585,"status":168,"phases":12586,"primaryCompletion":9544,"completion":3353,"start":6016,"enrollment":1509,"conditions":12587,"interventions":12589},"NCT00976508","Figitumumab Combined With Pegvisomant For Advanced Solid Tumors",[91],[1028,946,25,11998,12588],"Sarcoma",[8148,12582],{"trials":12591,"activeCount":103},[],{"trials":12593,"activeCount":103},[12594],{"nctId":12595,"briefTitle":12596,"status":111,"phases":12597,"completion":2641,"start":4398,"enrollment":314,"conditions":12598,"interventions":12600},"NCT00143416","Long Term Study With B2036-PEG",[93],[12599],"Acromegaly",[12569],{"trials":12602,"activeCount":103},[12603,12611],{"nctId":12604,"briefTitle":12605,"status":111,"phases":12606,"completion":12004,"start":12607,"enrollment":397,"conditions":12608,"interventions":12609},"NCT00068042","A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly",[94],"2003-04",[12599],[12569,12610],"Sandostatin LAR",{"nctId":12612,"briefTitle":12613,"status":111,"phases":12614,"completion":12004,"start":11736,"enrollment":4755,"conditions":12615,"interventions":12616},"NCT00068029","Pegvisomant And Sandostatin LAR Combination Study",[94],[12599],[12617,12610,12569],"Pegvisomant\u002F Sandostatin LAR",{"trials":12619,"activeCount":103},[],{"intervention":12621,"totalTrials":578,"cells":12622},"Olanzapine",{"EARLY_PHASE1":12623,"PHASE1":12625,"PHASE2":12635,"PHASE3":12637,"PHASE4":12648,"NA":12673},{"trials":12624,"activeCount":103},[],{"trials":12626,"activeCount":103},[12627],{"nctId":12628,"briefTitle":12629,"status":111,"phases":12630,"completion":9387,"start":11417,"enrollment":597,"conditions":12631,"interventions":12633},"NCT00150215","A First In Human Study Of PF-00184562 In Healthy Volunteers",[91],[12632],"Schizophrenia",[12634,12621],"PF-00184562",{"trials":12636,"activeCount":103},[],{"trials":12638,"activeCount":103},[12639],{"nctId":12640,"briefTitle":12641,"status":111,"phases":12642,"completion":8170,"start":3628,"enrollment":397,"conditions":12643,"interventions":12645},"NCT00145444","Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study",[93],[12632,12644],"Psychotic Disorders",[12646,12647],"olanzapine","ziprasidone",{"trials":12649,"activeCount":103},[12650,12659,12667],{"nctId":12651,"briefTitle":12652,"status":168,"phases":12653,"primaryCompletion":2641,"completion":3853,"start":4847,"enrollment":350,"conditions":12654,"interventions":12657},"NCT00329108","Ziprasidone And Olanzapine's Outcomes In Mania",[94],[12655,12656],"Acute Mania","Bipolar Disorder, Manic",[12658,12646],"ziprasidone hydrochloride",{"nctId":12660,"briefTitle":12661,"status":111,"phases":12662,"completion":3602,"start":2652,"enrollment":12663,"conditions":12664,"interventions":12665},"NCT00418171","Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)",[94],18239,[12632],[12666,12621],"Ziprasidone",{"nctId":12668,"briefTitle":12669,"status":111,"phases":12670,"completion":1701,"start":12607,"enrollment":4440,"conditions":12671,"interventions":12672},"NCT00239109","Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.",[94],[12632],[12666,12621],{"trials":12674,"activeCount":103},[],{"intervention":12676,"totalTrials":578,"cells":12677},"Adalimumab",{"EARLY_PHASE1":12678,"PHASE1":12680,"PHASE2":12682,"PHASE3":12693,"PHASE4":12724,"NA":12730},{"trials":12679,"activeCount":103},[],{"trials":12681,"activeCount":103},[],{"trials":12683,"activeCount":103},[12684],{"nctId":12685,"briefTitle":12686,"status":111,"phases":12687,"primaryCompletion":8251,"completion":8251,"start":7665,"enrollment":12688,"conditions":12689,"interventions":12690},"NCT00550446","A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis",[92],386,[4514],[12676,12691,12691,12691,12692,12692],"CP-690-550","CP-690,550",{"trials":12694,"activeCount":103},[12695,12705,12714],{"nctId":12696,"briefTitle":12697,"status":111,"phases":12698,"primaryCompletion":12699,"completion":12699,"start":12700,"enrollment":12701,"conditions":12702,"interventions":12703},"NCT04230213","A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis",[93],"2021-06-22","2020-01-13",455,[22],[12704,4516],"PF-06410293",{"nctId":12706,"briefTitle":12707,"status":111,"phases":12708,"primaryCompletion":660,"completion":660,"start":12709,"enrollment":6503,"conditions":12710,"interventions":12711},"NCT01877668","Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study",[93],"2014-01-20",[4469],[12712,12713,12676],"Tofacitinib 5 mg BID","Tofacitinib 10 mg BID",{"nctId":12715,"briefTitle":12716,"status":111,"phases":12717,"primaryCompletion":12718,"completion":12719,"start":12720,"enrollment":12721,"conditions":12722,"interventions":12723},"NCT02480153","A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).",[93],"2016-08-31","2017-12-06","2015-06-25",597,[22],[12704,12676],{"trials":12725,"activeCount":103},[12726],{"nctId":4508,"briefTitle":4509,"status":111,"phases":12727,"primaryCompletion":462,"completion":462,"start":4511,"enrollment":4512,"conditions":12728,"interventions":12729},[94],[4514],[4404,4404,4516,4517],{"trials":12731,"activeCount":103},[],{"intervention":12733,"totalTrials":257,"cells":12734},"Tolterodine ER",{"EARLY_PHASE1":12735,"PHASE1":12737,"PHASE2":12739,"PHASE3":12741,"PHASE4":12751,"NA":12778},{"trials":12736,"activeCount":103},[],{"trials":12738,"activeCount":103},[],{"trials":12740,"activeCount":103},[],{"trials":12742,"activeCount":103},[12743],{"nctId":12744,"briefTitle":12745,"status":111,"phases":12746,"primaryCompletion":4846,"completion":4846,"start":10937,"enrollment":12747,"conditions":12748,"interventions":12749},"NCT00611026","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.",[93],2417,[12489],[12733,12750],"Fesoterodine",{"trials":12752,"activeCount":103},[12753,12759,12769],{"nctId":12754,"briefTitle":12755,"status":168,"phases":12756,"primaryCompletion":569,"completion":569,"start":524,"enrollment":597,"conditions":12757,"interventions":12758},"NCT01302938","Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder",[94],[12489],[12733],{"nctId":12760,"briefTitle":12761,"status":111,"phases":12762,"primaryCompletion":3643,"completion":3643,"start":4615,"enrollment":12763,"conditions":12764,"interventions":12767},"NCT00411437","Effects Of Detrol LA On Memory And Cognition In Elderly Population",[94],220,[12765,12766],"Memory","Cognition",[12733,12768],"Oxybutynin ER",{"nctId":12770,"briefTitle":12771,"status":111,"phases":12772,"completion":12773,"start":12774,"enrollment":1519,"conditions":12775,"interventions":12777},"NCT00137397","A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder",[94],"2006-08","2004-11",[12776],"Urinary Incontinence",[12733],{"trials":12779,"activeCount":103},[],{"intervention":12781,"totalTrials":257,"cells":12782},"moroctocog alfa",{"EARLY_PHASE1":12783,"PHASE1":12785,"PHASE2":12793,"PHASE3":12795,"PHASE4":12797,"NA":12821},{"trials":12784,"activeCount":103},[],{"trials":12786,"activeCount":103},[12787],{"nctId":12788,"briefTitle":12789,"status":111,"phases":12790,"primaryCompletion":4590,"completion":4590,"start":569,"enrollment":314,"conditions":12791,"interventions":12792},"NCT01579903","Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)",[91],[3551],[12781,12781],{"trials":12794,"activeCount":103},[],{"trials":12796,"activeCount":103},[],{"trials":12798,"activeCount":103},[12799,12806,12815],{"nctId":12800,"briefTitle":12801,"status":168,"phases":12802,"primaryCompletion":4680,"completion":4680,"start":11014,"enrollment":12803,"conditions":12804,"interventions":12805},"NCT00884390","Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings",[94],208,[3551],[12781],{"nctId":12807,"briefTitle":12808,"status":111,"phases":12809,"primaryCompletion":12810,"completion":12811,"start":4221,"enrollment":2849,"conditions":12812,"interventions":12813},"NCT00914459","Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients",[94],"2016-03","2016-04",[3551],[12814],"Moroctocog alfa",{"nctId":12816,"briefTitle":12817,"status":168,"phases":12818,"primaryCompletion":3313,"completion":4531,"start":4608,"enrollment":1268,"conditions":12819,"interventions":12820},"NCT00765726","Study Evaluating The Safety Of Xyntha In Usual Care Settings",[94],[3551],[12814],{"trials":12822,"activeCount":103},[],{"intervention":12824,"totalTrials":257,"cells":12825},"Desvenlafaxine Succinate Sustained-Release",{"EARLY_PHASE1":12826,"PHASE1":12828,"PHASE2":12830,"PHASE3":12832,"PHASE4":12857,"NA":12867},{"trials":12827,"activeCount":103},[],{"trials":12829,"activeCount":103},[],{"trials":12831,"activeCount":103},[],{"trials":12833,"activeCount":103},[12834,12841,12850],{"nctId":12835,"briefTitle":12836,"status":111,"phases":12837,"primaryCompletion":4206,"completion":4206,"start":8154,"enrollment":12838,"conditions":12839,"interventions":12840},"NCT00798707","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder",[93],709,[6321],[12824,12824],{"nctId":12842,"briefTitle":12843,"status":111,"phases":12844,"primaryCompletion":7665,"completion":7665,"start":3854,"enrollment":12845,"conditions":12846,"interventions":12848},"NCT00384033","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder",[93],638,[12847],"Depressive Disorder, Major",[12824,12824,12849],"Duloxetine 60 mg\u002Fday",{"nctId":12851,"briefTitle":12539,"status":111,"phases":12852,"primaryCompletion":12853,"completion":12853,"start":4531,"enrollment":12854,"conditions":12855,"interventions":12856},"NCT01371734",[93],"2015-09",363,[6321],[12824,12824],{"trials":12858,"activeCount":103},[12859],{"nctId":12860,"briefTitle":12861,"status":111,"phases":12862,"primaryCompletion":2661,"completion":2661,"start":577,"enrollment":12863,"conditions":12864,"interventions":12865},"NCT01121484","Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)",[94],439,[6321],[12866],"desvenlafaxine succinate sustained-release",{"trials":12868,"activeCount":103},[],{"intervention":12870,"totalTrials":257,"cells":12871},"latanoprost",{"EARLY_PHASE1":12872,"PHASE1":12874,"PHASE2":12884,"PHASE3":12895,"PHASE4":12905,"NA":12914},{"trials":12873,"activeCount":103},[],{"trials":12875,"activeCount":103},[12876],{"nctId":12877,"briefTitle":12878,"status":111,"phases":12879,"primaryCompletion":11290,"completion":11290,"start":2884,"enrollment":8414,"conditions":12880,"interventions":12883},"NCT00638742","A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.",[91],[12881,12882],"Glaucoma","Ocular Hypertension",[12870],{"trials":12885,"activeCount":103},[12886],{"nctId":12887,"briefTitle":12888,"status":111,"phases":12889,"primaryCompletion":577,"completion":577,"start":10923,"enrollment":1257,"conditions":12890,"interventions":12892},"NCT00934089","A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329",[92],[12891,12882],"Glaucoma, Open-Angle",[12893,12894,12893,12870],"PF-04217329","latanoprost vehicle",{"trials":12896,"activeCount":103},[12897],{"nctId":12898,"briefTitle":12899,"status":111,"phases":12900,"primaryCompletion":6016,"completion":6016,"start":4207,"enrollment":12901,"conditions":12902,"interventions":12903},"NCT00716859","A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.",[93],139,[12881],[12904,12870],"Timolol",{"trials":12906,"activeCount":103},[12907],{"nctId":12908,"briefTitle":12909,"status":111,"phases":12910,"completion":4258,"start":2672,"enrollment":130,"conditions":12911,"interventions":12912},"NCT00647101","A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma",[94],[12891,12882],[12913],"Latanoprost",{"trials":12915,"activeCount":103},[],{"intervention":12917,"totalTrials":257,"cells":12918},"Taliglucerase alfa",{"EARLY_PHASE1":12919,"PHASE1":12921,"PHASE2":12923,"PHASE3":12925,"PHASE4":12946,"NA":12954},{"trials":12920,"activeCount":103},[],{"trials":12922,"activeCount":103},[],{"trials":12924,"activeCount":103},[],{"trials":12926,"activeCount":103},[12927,12934,12940],{"nctId":12928,"briefTitle":12929,"status":111,"phases":12930,"primaryCompletion":6208,"completion":6198,"start":8154,"enrollment":1257,"conditions":12931,"interventions":12933},"NCT00712348","Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase",[93],[12932],"Gaucher Disease",[12917],{"nctId":12935,"briefTitle":12936,"status":111,"phases":12937,"primaryCompletion":652,"completion":9572,"start":4531,"enrollment":99,"conditions":12938,"interventions":12939},"NCT01422187","A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease",[93],[12932],[12917],{"nctId":12941,"briefTitle":12942,"status":111,"phases":12943,"primaryCompletion":7971,"completion":7386,"start":9544,"enrollment":498,"conditions":12944,"interventions":12945},"NCT01411228","A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease",[93],[12932],[12917],{"trials":12947,"activeCount":103},[12948],{"nctId":12949,"briefTitle":12950,"status":111,"phases":12951,"primaryCompletion":113,"completion":540,"start":561,"enrollment":1625,"conditions":12952,"interventions":12953},"NCT01132690","A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease",[94],[12932],[12917],{"trials":12955,"activeCount":103},[],{"intervention":12957,"totalTrials":257,"cells":12958},"Simvastatin",{"EARLY_PHASE1":12959,"PHASE1":12961,"PHASE2":12970,"PHASE3":12972,"PHASE4":12985,"NA":13005},{"trials":12960,"activeCount":103},[],{"trials":12962,"activeCount":103},[12963],{"nctId":12964,"briefTitle":12965,"status":111,"phases":12966,"primaryCompletion":2883,"completion":2883,"start":570,"enrollment":562,"conditions":12967,"interventions":12969},"NCT01469468","A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects",[91],[12968],"Type 2 Diabetes Mellitus",[12957,6212],{"trials":12971,"activeCount":103},[],{"trials":12973,"activeCount":103},[12974],{"nctId":12975,"briefTitle":12976,"status":111,"phases":12977,"completion":12773,"start":2662,"enrollment":194,"conditions":12978,"interventions":12982},"NCT00267254","A Clinical Trial Comparing Torcetrapib\u002FAtorvastatin To Simvastatin In Subjects With High Cholesterol.",[93],[12979,12980,12981],"Hyperlipidemia","Dyslipidemia","Hypercholesterolemia",[12983,12984],"torcetrapib\u002Fatorvastatin","simvastatin",{"trials":12986,"activeCount":103},[12987,12997],{"nctId":12988,"briefTitle":12989,"status":111,"phases":12990,"completion":4692,"start":12991,"enrollment":12992,"conditions":12993,"interventions":12995},"NCT00159835","Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD",[94],"1999-02",8600,[12994],"Cardiovascular Diseases",[12996,12984],"atorvastatin",{"nctId":12998,"briefTitle":12999,"status":111,"phases":13000,"completion":3602,"start":11666,"enrollment":13001,"conditions":13002,"interventions":13003},"NCT00141141","Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia",[94],383,[12981],[13004,12957],"Atorvastatin",{"trials":13006,"activeCount":103},[],{"intervention":13008,"totalTrials":257,"cells":13009},"alprazolam XR",{"EARLY_PHASE1":13010,"PHASE1":13012,"PHASE2":13018,"PHASE3":13020,"PHASE4":13022,"NA":13044},{"trials":13011,"activeCount":103},[],{"trials":13013,"activeCount":103},[13014],{"nctId":12224,"briefTitle":12225,"status":111,"phases":13015,"primaryCompletion":4645,"completion":4645,"start":4665,"enrollment":1509,"conditions":13016,"interventions":13017},[91],[3396],[12193,12229,12230],{"trials":13019,"activeCount":103},[],{"trials":13021,"activeCount":103},[],{"trials":13023,"activeCount":103},[13024,13031,13038],{"nctId":13025,"briefTitle":13026,"status":168,"phases":13027,"completion":12109,"start":11395,"enrollment":2175,"conditions":13028,"interventions":13030},"NCT00634790","A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks",[94],[13029],"Panic Disorder",[13008],{"nctId":13032,"briefTitle":13033,"status":168,"phases":13034,"completion":7675,"start":13035,"enrollment":502,"conditions":13036,"interventions":13037},"NCT00635076","A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder",[94],"2004-07",[13029],[13008],{"nctId":13039,"briefTitle":13040,"status":168,"phases":13041,"completion":7675,"start":4398,"enrollment":314,"conditions":13042,"interventions":13043},"NCT00635531","A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder",[94],[13029],[13008],{"trials":13045,"activeCount":103},[],{"intervention":10229,"totalTrials":257,"cells":13047},{"EARLY_PHASE1":13048,"PHASE1":13050,"PHASE2":13052,"PHASE3":13054,"PHASE4":13076,"NA":13085},{"trials":13049,"activeCount":103},[],{"trials":13051,"activeCount":103},[],{"trials":13053,"activeCount":103},[],{"trials":13055,"activeCount":103},[13056,13064,13068],{"nctId":13057,"briefTitle":13058,"status":111,"phases":13059,"primaryCompletion":569,"completion":569,"start":4615,"enrollment":13060,"conditions":13061,"interventions":13063},"NCT00396097","Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature",[93],316,[13062],"Idiopathic Short Stature",[10229,10229],{"nctId":10221,"briefTitle":10222,"status":111,"phases":13065,"primaryCompletion":10224,"completion":10224,"start":10225,"enrollment":1083,"conditions":13066,"interventions":13067},[93],[10227],[10229,10230],{"nctId":13069,"briefTitle":13070,"status":111,"phases":13071,"completion":4258,"start":13072,"enrollment":8123,"conditions":13073,"interventions":13075},"NCT00174408","Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age",[93],"1990-03",[13074],"Growth Disorders",[10229],{"trials":13077,"activeCount":103},[13078],{"nctId":13079,"briefTitle":13080,"status":168,"phases":13081,"primaryCompletion":8251,"completion":8251,"start":3335,"enrollment":870,"conditions":13082,"interventions":13084},"NCT00555009","Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury",[94],[13083,10227],"Brain Injuries",[10229],{"trials":13086,"activeCount":103},[],{"intervention":13088,"totalTrials":257,"cells":13089},"ALO-02",{"EARLY_PHASE1":13090,"PHASE1":13092,"PHASE2":13109,"PHASE3":13111,"PHASE4":13123,"NA":13135},{"trials":13091,"activeCount":103},[],{"trials":13093,"activeCount":103},[13094,13103],{"nctId":13095,"briefTitle":13096,"status":111,"phases":13097,"primaryCompletion":113,"completion":113,"start":2450,"enrollment":3254,"conditions":13098,"interventions":13100},"NCT01557257","Pharmacokinetics Study of ALO-02 and OxyContin",[91],[13099],"Management of Moderate to Severe Pain",[13088,13101,13088,13101,13102,13101],"Naltrexone block","OxyContin",{"nctId":13104,"briefTitle":13105,"status":111,"phases":13106,"primaryCompletion":10912,"completion":10912,"start":114,"enrollment":1509,"conditions":13107,"interventions":13108},"NCT01456507","Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone\u002F6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone",[91],[16],[13088,13088,13088],{"trials":13110,"activeCount":103},[],{"trials":13112,"activeCount":103},[13113],{"nctId":13114,"briefTitle":13115,"status":111,"phases":13116,"primaryCompletion":13117,"completion":13117,"start":4459,"enrollment":13118,"conditions":13119,"interventions":13122},"NCT01571362","A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain",[93],"2013-06",410,[13120,11337,13121],"Chronic Pain","Analgesia",[13088],{"trials":13124,"activeCount":103},[13125],{"nctId":13126,"briefTitle":13127,"status":168,"phases":13128,"primaryCompletion":13129,"completion":13130,"start":13131,"enrollment":4259,"conditions":13132,"interventions":13134},"NCT02680847","Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain",[94],"2018-01-10","2018-01-24","2016-01-21",[13133],"Moderate-severe Pain",[13088],{"trials":13136,"activeCount":103},[],{"intervention":12437,"totalTrials":502,"cells":13138},{"EARLY_PHASE1":13139,"PHASE1":13141,"PHASE2":13143,"PHASE3":13145,"PHASE4":13147,"NA":13161},{"trials":13140,"activeCount":103},[],{"trials":13142,"activeCount":103},[],{"trials":13144,"activeCount":103},[],{"trials":13146,"activeCount":103},[],{"trials":13148,"activeCount":103},[13149,13153,13157],{"nctId":12432,"briefTitle":12433,"status":111,"phases":13150,"completion":1701,"start":3854,"enrollment":1780,"conditions":13151,"interventions":13152},[94],[37],[12402,12437],{"nctId":12439,"briefTitle":12440,"status":111,"phases":13154,"primaryCompletion":8115,"completion":8115,"start":4615,"enrollment":12442,"conditions":13155,"interventions":13156},[94],[37],[12437,12402],{"nctId":12183,"briefTitle":12184,"status":111,"phases":13158,"primaryCompletion":8115,"completion":8115,"start":11895,"enrollment":12186,"conditions":13159,"interventions":13160},[94],[37],[12189,12116],{"trials":13162,"activeCount":103},[],{"intervention":12035,"totalTrials":502,"cells":13164},{"EARLY_PHASE1":13165,"PHASE1":13167,"PHASE2":13169,"PHASE3":13177,"PHASE4":13183,"NA":13198},{"trials":13166,"activeCount":103},[],{"trials":13168,"activeCount":103},[],{"trials":13170,"activeCount":103},[13171],{"nctId":13172,"briefTitle":13173,"status":111,"phases":13174,"primaryCompletion":12395,"completion":12395,"start":11829,"enrollment":2400,"conditions":13175,"interventions":13176},"NCT00106639","A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients",[92],[4533],[12692,12692,12035],{"trials":13178,"activeCount":103},[13179],{"nctId":12027,"briefTitle":12028,"status":168,"phases":13180,"primaryCompletion":4656,"completion":10912,"start":12030,"enrollment":7388,"conditions":13181,"interventions":13182},[93],[12032,12033],[12035,12036,12007,12037,12035,12036,12007],{"trials":13184,"activeCount":103},[13185],{"nctId":13186,"briefTitle":13187,"status":111,"phases":13188,"primaryCompletion":6207,"completion":6207,"start":4646,"enrollment":13189,"conditions":13190,"interventions":13195},"NCT00895583","Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients",[94],254,[13191,13192,13193,13194],"Graft Rejection","Kidney Transplant","Renal Allograft Recipients","Renal Transplant",[13196,13197,13196],"Tacrolimus","Sirolimus",{"trials":13199,"activeCount":103},[],{"intervention":11295,"totalTrials":502,"cells":13201},{"EARLY_PHASE1":13202,"PHASE1":13204,"PHASE2":13219,"PHASE3":13221,"PHASE4":13223,"NA":13233},{"trials":13203,"activeCount":103},[],{"trials":13205,"activeCount":103},[13206,13210],{"nctId":11287,"briefTitle":11288,"status":111,"phases":13207,"primaryCompletion":11290,"completion":11290,"start":11291,"enrollment":1530,"conditions":13208,"interventions":13209},[91],[11293],[11295,11296,11273],{"nctId":13211,"briefTitle":13212,"status":111,"phases":13213,"primaryCompletion":13214,"completion":13214,"start":6263,"enrollment":13215,"conditions":13216,"interventions":13217},"NCT01825447","A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users",[91],"2013-09",89,[16],[13218,11295],"Oxycodone + Naltrexone",{"trials":13220,"activeCount":103},[],{"trials":13222,"activeCount":103},[],{"trials":13224,"activeCount":103},[13225],{"nctId":13226,"briefTitle":13227,"status":168,"phases":13228,"primaryCompletion":13229,"completion":13229,"start":13230,"enrollment":2070,"conditions":13231,"interventions":13232},"NCT00484718","Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo\u002FOxycodone\u002FCelecoxib.",[94],"2009-06-10","2008-01-17",[11282],[11523,11295],{"trials":13234,"activeCount":103},[],{"intervention":4685,"totalTrials":502,"cells":13236},{"EARLY_PHASE1":13237,"PHASE1":13239,"PHASE2":13241,"PHASE3":13243,"PHASE4":13253,"NA":13262},{"trials":13238,"activeCount":103},[],{"trials":13240,"activeCount":103},[],{"trials":13242,"activeCount":103},[],{"trials":13244,"activeCount":103},[13245,13249],{"nctId":4642,"briefTitle":4643,"status":111,"phases":13246,"primaryCompletion":4645,"completion":4646,"start":4647,"enrollment":4648,"conditions":13247,"interventions":13248},[93],[25],[1643,4651],{"nctId":4676,"briefTitle":4677,"status":111,"phases":13250,"primaryCompletion":4679,"completion":4680,"start":4681,"enrollment":4682,"conditions":13251,"interventions":13252},[93],[25],[4685,1674],{"trials":13254,"activeCount":103},[13255],{"nctId":13256,"briefTitle":13257,"status":111,"phases":13258,"primaryCompletion":585,"completion":585,"start":561,"enrollment":1780,"conditions":13259,"interventions":13260},"NCT01189500","Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects",[94],[3396],[4685,13261],"Tamoxifen and Desvenlafaxine Succinate Sustained Release",{"trials":13263,"activeCount":103},[],{"intervention":13265,"totalTrials":502,"cells":13266},"ramipril",{"EARLY_PHASE1":13267,"PHASE1":13269,"PHASE2":13271,"PHASE3":13273,"PHASE4":13282,"NA":13298},{"trials":13268,"activeCount":103},[],{"trials":13270,"activeCount":103},[],{"trials":13272,"activeCount":103},[],{"trials":13274,"activeCount":103},[13275],{"nctId":13276,"briefTitle":13277,"status":168,"phases":13278,"primaryCompletion":2964,"completion":2964,"start":12128,"enrollment":6503,"conditions":13279,"interventions":13281},"NCT00389519","A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents",[93],[13280],"Hypertension",[13265],{"trials":13283,"activeCount":103},[13284,13291],{"nctId":13285,"briefTitle":13286,"status":111,"phases":13287,"primaryCompletion":13214,"completion":13214,"start":4636,"enrollment":13288,"conditions":13289,"interventions":13290},"NCT00502242","Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus",[94],229,[13192],[13265,13265],{"nctId":13292,"briefTitle":13293,"status":111,"phases":13294,"completion":12774,"start":13295,"enrollment":8875,"conditions":13296,"interventions":13297},"NCT00044265","Treatment of Pediatric Hypertension With Altace Trial",[94],"2002-07",[13280],[13265],{"trials":13299,"activeCount":103},[],{"intervention":13301,"totalTrials":502,"cells":13302},"Imipenem\u002Fcilastatin",{"EARLY_PHASE1":13303,"PHASE1":13305,"PHASE2":13307,"PHASE3":13328,"PHASE4":13330,"NA":13341},{"trials":13304,"activeCount":103},[],{"trials":13306,"activeCount":103},[],{"trials":13308,"activeCount":103},[13309,13319],{"nctId":13310,"briefTitle":13311,"status":111,"phases":13312,"primaryCompletion":577,"completion":586,"start":4645,"enrollment":13313,"conditions":13314,"interventions":13316},"NCT00690378","Comparative Study of NXL104\u002FCeftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections",[92],137,[13315],"Complicated Urinary Tract Infection",[13317,13318],"NXL104\u002Fceftazidime","Imipenem\u002FCilastatin",{"nctId":13320,"briefTitle":13321,"status":168,"phases":13322,"primaryCompletion":2661,"completion":2661,"start":8154,"enrollment":1498,"conditions":13323,"interventions":13325},"NCT00707239","Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem\u002FCilastatin Subjects With Hospital-Acquired Pneumonia",[92],[13324],"Pneumonia, Bacterial",[13326,13326,13327],"tigecycline","imipenem\u002Fcilastatin",{"trials":13329,"activeCount":103},[],{"trials":13331,"activeCount":103},[13332],{"nctId":13333,"briefTitle":13334,"status":111,"phases":13335,"primaryCompletion":626,"completion":626,"start":3345,"enrollment":13336,"conditions":13337,"interventions":13339},"NCT01721408","A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem\u002FCliastatin to Treat Complicated Intra-Abdominal Infection",[94],470,[13338],"Intra-abdominal Infection",[13340,13301],"Tigecycline",{"trials":13342,"activeCount":103},[],{"intervention":13344,"totalTrials":502,"cells":13345},"Aripiprazole",{"EARLY_PHASE1":13346,"PHASE1":13348,"PHASE2":13350,"PHASE3":13360,"PHASE4":13362,"NA":13380},{"trials":13347,"activeCount":103},[],{"trials":13349,"activeCount":103},[],{"trials":13351,"activeCount":103},[13352],{"nctId":13353,"briefTitle":13354,"status":111,"phases":13355,"primaryCompletion":11291,"completion":11291,"start":2964,"enrollment":13356,"conditions":13357,"interventions":13358},"NCT00580125","Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia",[92],164,[12632],[13359,13344,13359,13359],"PF-00217830",{"trials":13361,"activeCount":103},[],{"trials":13363,"activeCount":103},[13364,13373],{"nctId":13365,"briefTitle":13366,"status":111,"phases":13367,"primaryCompletion":585,"completion":585,"start":561,"enrollment":1796,"conditions":13368,"interventions":13371},"NCT01188668","Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects",[94],[3396,13369,13370],"Cytochrome P-450 CYP2D6","CYP3A4 Protein, Human",[13344,13372],"Aripiprazole + desvenlafaxine succinate sustained release",{"nctId":13374,"briefTitle":13375,"status":111,"phases":13376,"completion":4692,"start":4398,"enrollment":13377,"conditions":13378,"interventions":13379},"NCT00634348","A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients",[94],256,[12632],[13344,12666],{"trials":13381,"activeCount":103},[],{"intervention":13383,"totalTrials":502,"cells":13384},"latanoprost 0.005%",{"EARLY_PHASE1":13385,"PHASE1":13387,"PHASE2":13389,"PHASE3":13409,"PHASE4":13421,"NA":13430},{"trials":13386,"activeCount":103},[],{"trials":13388,"activeCount":103},[],{"trials":13390,"activeCount":103},[13391],{"nctId":13392,"briefTitle":13393,"status":111,"phases":13394,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":13397,"interventions":13399},"NCT00572455","Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.",[92],"2009-06-26","2007-12-11",[13398,12882],"Primary Open-Angle Glaucoma",[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],"PF-04217329 - Lowest Dose","PF-04217329 - Low Dose","PF-04217329 - Middle Dose","PF-04217329 - High Middle Dose","PF-04217329 - High Dose","PF-4217329 - Highest Dose","PF-04217329 - Vehicle","Latanoprost Vehicle","Latanoprost 0.005%",{"trials":13410,"activeCount":103},[13411],{"nctId":13412,"briefTitle":13413,"status":111,"phases":13414,"primaryCompletion":11790,"completion":11790,"start":13415,"enrollment":13416,"conditions":13417,"interventions":13418},"NCT00800267","A Study of Glaucoma or Ocular Hypertension in Patients Within the United States",[93],"1997-07",418,[12882,12881],[13383,13419,13420],"fixed combination latanoprost-timolol","timolol 0.5%",{"trials":13422,"activeCount":103},[13423],{"nctId":13424,"briefTitle":13425,"status":111,"phases":13426,"completion":12030,"start":2652,"enrollment":13427,"conditions":13428,"interventions":13429},"NCT00140062","Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.",[94],329,[12882,12891],[13383],{"trials":13431,"activeCount":103},[],{"intervention":13433,"totalTrials":502,"cells":13434},"Dextromethorphan",{"EARLY_PHASE1":13435,"PHASE1":13437,"PHASE2":13452,"PHASE3":13454,"PHASE4":13456,"NA":13466},{"trials":13436,"activeCount":103},[],{"trials":13438,"activeCount":103},[13439,13448],{"nctId":13440,"briefTitle":13441,"status":111,"phases":13442,"primaryCompletion":8251,"completion":8251,"start":4645,"enrollment":562,"conditions":13443,"interventions":13446},"NCT00788047","A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan",[91],[13444,13445],"Huntington Disease","Alzheimer Disease",[13433,13447],"Dimebon + Dextromethorphan",{"nctId":3197,"briefTitle":3198,"status":111,"phases":13449,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":13450,"interventions":13451},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"trials":13453,"activeCount":103},[],{"trials":13455,"activeCount":103},[],{"trials":13457,"activeCount":103},[13458],{"nctId":13459,"briefTitle":13460,"status":168,"phases":13461,"primaryCompletion":524,"completion":524,"start":4656,"enrollment":12373,"conditions":13462,"interventions":13465},"NCT01257542","Acute Cough Study In Children",[94],[13463,13464],"Common Cold","Infections, Upper Respiratory Tract",[13433],{"trials":13467,"activeCount":103},[],{"intervention":13469,"totalTrials":1087,"cells":13470},"Tafamidis meglumine",{"EARLY_PHASE1":13471,"PHASE1":13473,"PHASE2":13485,"PHASE3":13487,"PHASE4":13489,"NA":13500},{"trials":13472,"activeCount":103},[],{"trials":13474,"activeCount":103},[13475],{"nctId":13476,"briefTitle":13477,"status":111,"phases":13478,"primaryCompletion":13479,"completion":13480,"start":13481,"enrollment":525,"conditions":13482,"interventions":13483},"NCT05498701","A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food",[91],"2022-12-18","2022-12-19","2022-09-29",[16],[13484,13469],"Tafamidis free acid",{"trials":13486,"activeCount":103},[],{"trials":13488,"activeCount":103},[],{"trials":13490,"activeCount":103},[13491],{"nctId":13492,"briefTitle":13493,"status":111,"phases":13494,"primaryCompletion":13495,"completion":13495,"start":129,"enrollment":498,"conditions":13496,"interventions":13498},"NCT04828993","The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients",[94],"2023-02-12",[13497],"Transthyretin Amyloid Polyneuropathy (ATTR-PN)",[13499],"tafamidis meglumine",{"trials":13501,"activeCount":103},[],{"intervention":13503,"totalTrials":1087,"cells":13504},"Eletriptan",{"EARLY_PHASE1":13505,"PHASE1":13507,"PHASE2":13509,"PHASE3":13511,"PHASE4":13513,"NA":13529},{"trials":13506,"activeCount":103},[],{"trials":13508,"activeCount":103},[],{"trials":13510,"activeCount":103},[],{"trials":13512,"activeCount":103},[],{"trials":13514,"activeCount":103},[13515,13522],{"nctId":13516,"briefTitle":13517,"status":111,"phases":13518,"completion":6458,"start":3073,"enrollment":13519,"conditions":13520,"interventions":13521},"NCT00632385","Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy",[94],127,[117],[13503],{"nctId":13523,"briefTitle":13524,"status":111,"phases":13525,"completion":2672,"start":4399,"enrollment":941,"conditions":13526,"interventions":13527},"NCT00634985","Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs",[94],[117],[13528],"eletriptan",{"trials":13530,"activeCount":103},[],{"intervention":13532,"totalTrials":1087,"cells":13533},"tolterodine extended release",{"EARLY_PHASE1":13534,"PHASE1":13536,"PHASE2":13538,"PHASE3":13540,"PHASE4":13548,"NA":13556},{"trials":13535,"activeCount":103},[],{"trials":13537,"activeCount":103},[],{"trials":13539,"activeCount":103},[],{"trials":13541,"activeCount":103},[13542],{"nctId":13543,"briefTitle":13544,"status":111,"phases":13545,"primaryCompletion":12128,"completion":12128,"start":11829,"enrollment":9914,"conditions":13546,"interventions":13547},"NCT00139724","Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet",[93],[12776],[13532],{"trials":13549,"activeCount":103},[13550],{"nctId":13551,"briefTitle":13552,"status":111,"phases":13553,"completion":12069,"start":11686,"enrollment":1558,"conditions":13554,"interventions":13555},"NCT00645281","A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.",[94],[12472],[13532],{"trials":13557,"activeCount":103},[],{"intervention":13559,"totalTrials":1087,"cells":13560},"Intravenous infusions of Xyntha",{"EARLY_PHASE1":13561,"PHASE1":13563,"PHASE2":13571,"PHASE3":13573,"PHASE4":13575,"NA":13584},{"trials":13562,"activeCount":103},[],{"trials":13564,"activeCount":103},[13565],{"nctId":13566,"briefTitle":13567,"status":111,"phases":13568,"primaryCompletion":3323,"completion":3323,"start":4439,"enrollment":3254,"conditions":13569,"interventions":13570},"NCT02461992","Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A",[91],[3551],[13559],{"trials":13572,"activeCount":103},[],{"trials":13574,"activeCount":103},[],{"trials":13576,"activeCount":103},[13577],{"nctId":13578,"briefTitle":13579,"status":111,"phases":13580,"primaryCompletion":5008,"completion":13581,"start":4589,"enrollment":20,"conditions":13582,"interventions":13583},"NCT02492984","PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A",[94],"2016-08",[3551],[13559],{"trials":13585,"activeCount":103},[],{"intervention":13587,"totalTrials":1087,"cells":13588},"Lipitor",{"EARLY_PHASE1":13589,"PHASE1":13591,"PHASE2":13600,"PHASE3":13602,"PHASE4":13604,"NA":13613},{"trials":13590,"activeCount":103},[],{"trials":13592,"activeCount":103},[13593],{"nctId":13594,"briefTitle":13595,"status":111,"phases":13596,"primaryCompletion":4608,"completion":4608,"start":4645,"enrollment":407,"conditions":13597,"interventions":13598},"NCT00777517","Bioequivalence Study On Pediatric Appropriate Formulation",[91],[12981],[13587,13599],"Atorvastatin pediatric formulation",{"trials":13601,"activeCount":103},[],{"trials":13603,"activeCount":103},[],{"trials":13605,"activeCount":103},[13606],{"nctId":13607,"briefTitle":13608,"status":111,"phases":13609,"primaryCompletion":3335,"completion":3335,"start":10937,"enrollment":1268,"conditions":13610,"interventions":13611},"NCT00844376","Bioavailability Study for New Atorvastatin Formulation",[94],[12981],[13612,13587],"Atorvastatin suspension",{"trials":13614,"activeCount":103},[],{"intervention":11047,"totalTrials":1087,"cells":13616},{"EARLY_PHASE1":13617,"PHASE1":13619,"PHASE2":13621,"PHASE3":13623,"PHASE4":13635,"NA":13641},{"trials":13618,"activeCount":103},[],{"trials":13620,"activeCount":103},[],{"trials":13622,"activeCount":103},[],{"trials":13624,"activeCount":103},[13625],{"nctId":13626,"briefTitle":13627,"status":111,"phases":13628,"primaryCompletion":13629,"completion":13629,"start":13630,"enrollment":13631,"conditions":13632,"interventions":13633},"NCT05301322","Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age",[93],"2022-10-12","2022-04-13",1471,[9529],[13634,11047],"RSVpreF Vaccine",{"trials":13636,"activeCount":103},[13637],{"nctId":11040,"briefTitle":11041,"status":111,"phases":13638,"primaryCompletion":4458,"completion":4458,"start":9572,"enrollment":11043,"conditions":13639,"interventions":13640},[94],[11045],[2555,11047,11047,2555],{"trials":13642,"activeCount":103},[],{"intervention":13644,"totalTrials":1087,"cells":13645},"Cymbalta",{"EARLY_PHASE1":13646,"PHASE1":13648,"PHASE2":13650,"PHASE3":13652,"PHASE4":13654,"NA":13673},{"trials":13647,"activeCount":103},[],{"trials":13649,"activeCount":103},[],{"trials":13651,"activeCount":103},[],{"trials":13653,"activeCount":103},[],{"trials":13655,"activeCount":103},[13656,13665],{"nctId":13657,"briefTitle":13658,"status":649,"phases":13659,"primaryCompletion":13660,"completion":13660,"start":13661,"enrollment":103,"conditions":13662,"interventions":13663},"NCT03729284","A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta",[94],"2020-06-07","2020-03-30",[16],[13644,13664],"Duloxetine Hydrochloride",{"nctId":13666,"briefTitle":13667,"status":649,"phases":13668,"primaryCompletion":13669,"completion":13669,"start":13661,"enrollment":103,"conditions":13670,"interventions":13671},"NCT03794154","A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions",[94],"2020-06-05",[16],[13644,13672],"Duloxetine hydrochloride",{"trials":13674,"activeCount":103},[],{"intervention":13664,"totalTrials":1087,"cells":13676},{"EARLY_PHASE1":13677,"PHASE1":13679,"PHASE2":13681,"PHASE3":13683,"PHASE4":13685,"NA":13695},{"trials":13678,"activeCount":103},[],{"trials":13680,"activeCount":103},[],{"trials":13682,"activeCount":103},[],{"trials":13684,"activeCount":103},[],{"trials":13686,"activeCount":103},[13687,13691],{"nctId":13657,"briefTitle":13658,"status":649,"phases":13688,"primaryCompletion":13660,"completion":13660,"start":13661,"enrollment":103,"conditions":13689,"interventions":13690},[94],[16],[13644,13664],{"nctId":13666,"briefTitle":13667,"status":649,"phases":13692,"primaryCompletion":13669,"completion":13669,"start":13661,"enrollment":103,"conditions":13693,"interventions":13694},[94],[16],[13644,13672],{"trials":13696,"activeCount":103},[],{"intervention":13698,"totalTrials":1087,"cells":13699},"Loxoprofen",{"EARLY_PHASE1":13700,"PHASE1":13702,"PHASE2":13704,"PHASE3":13706,"PHASE4":13715,"NA":13723},{"trials":13701,"activeCount":103},[],{"trials":13703,"activeCount":103},[],{"trials":13705,"activeCount":103},[],{"trials":13707,"activeCount":103},[13708],{"nctId":13709,"briefTitle":13710,"status":111,"phases":13711,"start":12109,"enrollment":13712,"conditions":13713,"interventions":13714},"NCT00141154","Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan",[93],1234,[11337],[3079,13698],{"trials":13716,"activeCount":103},[13717],{"nctId":13718,"briefTitle":13719,"status":111,"phases":13720,"primaryCompletion":4206,"completion":4206,"start":6016,"enrollment":8278,"conditions":13721,"interventions":13722},"NCT00994461","Study Of Celecoxib In Healthy Subjects",[94],[19],[3079,13698],{"trials":13724,"activeCount":103},[],{"intervention":13726,"totalTrials":1087,"cells":13727},"Cabergoline",{"EARLY_PHASE1":13728,"PHASE1":13730,"PHASE2":13732,"PHASE3":13734,"PHASE4":13743,"NA":13754},{"trials":13729,"activeCount":103},[],{"trials":13731,"activeCount":103},[],{"trials":13733,"activeCount":103},[],{"trials":13735,"activeCount":103},[13736],{"nctId":13737,"briefTitle":13738,"status":111,"phases":13739,"completion":2642,"start":4399,"enrollment":32,"conditions":13740,"interventions":13742},"NCT00627003","A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS",[93],[13741],"Restless Legs Syndrome",[13726],{"trials":13744,"activeCount":103},[13745],{"nctId":13746,"briefTitle":13747,"status":168,"phases":13748,"completion":6017,"start":13035,"enrollment":12763,"conditions":13749,"interventions":13751},"NCT00174239","Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.",[94],[13750],"Parkinson Disease",[13752,13753],"cabergoline","controlled-release levodopa \u002F carbidopa",{"trials":13755,"activeCount":103},[],{"intervention":12610,"totalTrials":1087,"cells":13757},{"EARLY_PHASE1":13758,"PHASE1":13760,"PHASE2":13762,"PHASE3":13764,"PHASE4":13766,"NA":13776},{"trials":13759,"activeCount":103},[],{"trials":13761,"activeCount":103},[],{"trials":13763,"activeCount":103},[],{"trials":13765,"activeCount":103},[],{"trials":13767,"activeCount":103},[13768,13772],{"nctId":12604,"briefTitle":12605,"status":111,"phases":13769,"completion":12004,"start":12607,"enrollment":397,"conditions":13770,"interventions":13771},[94],[12599],[12569,12610],{"nctId":12612,"briefTitle":12613,"status":111,"phases":13773,"completion":12004,"start":11736,"enrollment":4755,"conditions":13774,"interventions":13775},[94],[12599],[12617,12610,12569],{"trials":13777,"activeCount":103},[],{"intervention":13779,"totalTrials":1087,"cells":13780},"Ceftriaxone",{"EARLY_PHASE1":13781,"PHASE1":13783,"PHASE2":13785,"PHASE3":13787,"PHASE4":13799,"NA":13813},{"trials":13782,"activeCount":103},[],{"trials":13784,"activeCount":103},[],{"trials":13786,"activeCount":103},[],{"trials":13788,"activeCount":103},[13789],{"nctId":13790,"briefTitle":13791,"status":111,"phases":13792,"primaryCompletion":6198,"completion":6198,"start":2883,"enrollment":13793,"conditions":13794,"interventions":13797},"NCT01371838","A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia",[93],848,[13795,13796],"Community-Acquired Bacterial Pneumonia","Lung Infection of Individual Not Recently Hospitalized",[13798,13779],"Ceftaroline",{"trials":13800,"activeCount":103},[13801],{"nctId":13802,"briefTitle":13803,"status":111,"phases":13804,"completion":4616,"start":7676,"enrollment":1702,"conditions":13805,"interventions":13807},"NCT00035347","Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia",[94],[13806],"Community-Acquired Pneumonia (CAP)",[13808,13809,13810,13811,13812],"IV azithromycin","ceftriaxone","oral azithromycin","IV levofloxacin","oral levofloxacin",{"trials":13814,"activeCount":103},[],{"intervention":13816,"totalTrials":1087,"cells":13817},"Amlodipine besylate\u002Fatorvastatin calcium single pill combination",{"EARLY_PHASE1":13818,"PHASE1":13820,"PHASE2":13822,"PHASE3":13824,"PHASE4":13826,"NA":13842},{"trials":13819,"activeCount":103},[],{"trials":13821,"activeCount":103},[],{"trials":13823,"activeCount":103},[],{"trials":13825,"activeCount":103},[],{"trials":13827,"activeCount":103},[13828,13835],{"nctId":13829,"briefTitle":13830,"status":111,"phases":13831,"primaryCompletion":4846,"completion":4846,"start":11895,"enrollment":13832,"conditions":13833,"interventions":13834},"NCT00407537","Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors",[94],1531,[13280,12981],[13816],{"nctId":13836,"briefTitle":13837,"status":111,"phases":13838,"primaryCompletion":3314,"completion":3314,"start":11315,"enrollment":12,"conditions":13839,"interventions":13840},"NCT00412113","A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk",[94],[12980,13280],[13841,13816,13841,13816],"Amlodipine besylate",{"trials":13843,"activeCount":103},[],{"intervention":13845,"totalTrials":1087,"cells":13846},"Nelfinavir",{"EARLY_PHASE1":13847,"PHASE1":13849,"PHASE2":13851,"PHASE3":13853,"PHASE4":13867,"NA":13875},{"trials":13848,"activeCount":103},[],{"trials":13850,"activeCount":103},[],{"trials":13852,"activeCount":103},[],{"trials":13854,"activeCount":103},[13855],{"nctId":13856,"briefTitle":13857,"status":168,"phases":13858,"primaryCompletion":6458,"completion":6458,"start":3073,"enrollment":7500,"conditions":13859,"interventions":13861},"NCT00650637","A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea",[93],[13860],"Diarrhea",[13862,13863,13864,13865,13863,13866],"Calcium Carbonate","nelfinavir","lamivudine","loperamide","lamivudine + zidovudine",{"trials":13868,"activeCount":103},[13869],{"nctId":13870,"briefTitle":13871,"status":111,"phases":13872,"completion":3627,"start":6457,"enrollment":3866,"conditions":13873,"interventions":13874},"NCT00312182","Thorough QT Study of Nelfinavir",[94],[19],[13845],{"trials":13876,"activeCount":103},[],{"intervention":13878,"totalTrials":1087,"cells":13879},"parecoxib\u002Fvaldecoxib",{"EARLY_PHASE1":13880,"PHASE1":13882,"PHASE2":13884,"PHASE3":13886,"PHASE4":13896,"NA":13906},{"trials":13881,"activeCount":103},[],{"trials":13883,"activeCount":103},[],{"trials":13885,"activeCount":103},[],{"trials":13887,"activeCount":103},[13888],{"nctId":13889,"briefTitle":13890,"status":168,"phases":13891,"completion":11686,"start":12607,"enrollment":13892,"conditions":13893,"interventions":13894},"NCT00651300","A Study of the Recovery Benefits After Treatment With Parecoxib\u002FValdecoxib in Patients Undergoing Abdominal Surgery",[93],91,[34],[13895],"Parecoxib\u002FValdecoxib",{"trials":13897,"activeCount":103},[13898],{"nctId":13899,"briefTitle":13900,"status":168,"phases":13901,"completion":13035,"start":13902,"enrollment":257,"conditions":13903,"interventions":13905},"NCT00660855","A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib\u002FValdecoxib 40 Mg\u002FDay For Treatment Of Post-Laparoscopic Surgery Pain",[94],"2004-06",[13904],"Pain, Post Surgical",[13878],{"trials":13907,"activeCount":103},[],{"intervention":13909,"totalTrials":1087,"cells":13910},"Sayana Press",{"EARLY_PHASE1":13911,"PHASE1":13913,"PHASE2":13923,"PHASE3":13925,"PHASE4":13927,"NA":13939},{"trials":13912,"activeCount":103},[],{"trials":13914,"activeCount":103},[13915],{"nctId":13916,"briefTitle":13917,"status":111,"phases":13918,"primaryCompletion":1901,"completion":1901,"start":13919,"enrollment":13920,"conditions":13921,"interventions":13922},"NCT04893798","A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and Abdomen",[91],"2021-09-16",67,[16],[13909],{"trials":13924,"activeCount":103},[],{"trials":13926,"activeCount":103},[],{"trials":13928,"activeCount":103},[13929],{"nctId":13930,"briefTitle":13931,"status":111,"phases":13932,"primaryCompletion":13933,"completion":13933,"start":13934,"enrollment":13935,"conditions":13936,"interventions":13938},"NCT03034057","Sayana Press UK Self-Injection Study",[94],"2018-12-07","2017-08-23",169,[13937],"Contraception",[13909],{"trials":13940,"activeCount":103},[],{"intervention":13942,"totalTrials":1087,"cells":13943},"Amlodipine\u002Fatorvastatin single pill",{"EARLY_PHASE1":13944,"PHASE1":13946,"PHASE2":13948,"PHASE3":13950,"PHASE4":13959,"NA":13968},{"trials":13945,"activeCount":103},[],{"trials":13947,"activeCount":103},[],{"trials":13949,"activeCount":103},[],{"trials":13951,"activeCount":103},[13952],{"nctId":13953,"briefTitle":13954,"status":111,"phases":13955,"completion":11417,"start":11395,"enrollment":13956,"conditions":13957,"interventions":13958},"NCT00143234","Amlodipine\u002FAtorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels",[93],1825,[13280,12979],[13942],{"trials":13960,"activeCount":103},[13961],{"nctId":13962,"briefTitle":13963,"status":111,"phases":13964,"completion":3854,"start":12109,"enrollment":13965,"conditions":13966,"interventions":13967},"NCT00174304","Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.",[94],1120,[13280,12979],[13942],{"trials":13969,"activeCount":103},[],{"intervention":11950,"totalTrials":1087,"cells":13971},{"EARLY_PHASE1":13972,"PHASE1":13974,"PHASE2":13976,"PHASE3":13978,"PHASE4":13980,"NA":13990},{"trials":13973,"activeCount":103},[],{"trials":13975,"activeCount":103},[],{"trials":13977,"activeCount":103},[],{"trials":13979,"activeCount":103},[],{"trials":13981,"activeCount":103},[13982,13986],{"nctId":11944,"briefTitle":11945,"status":111,"phases":13983,"primaryCompletion":4439,"completion":4439,"start":113,"enrollment":11947,"conditions":13984,"interventions":13985},[94],[11904],[11885,11950,11951],{"nctId":11953,"briefTitle":11954,"status":111,"phases":13987,"primaryCompletion":11956,"completion":11956,"start":570,"enrollment":11957,"conditions":13988,"interventions":13989},[94],[11904],[11885,11950,11951],{"trials":13991,"activeCount":103},[],{"intervention":11951,"totalTrials":1087,"cells":13993},{"EARLY_PHASE1":13994,"PHASE1":13996,"PHASE2":13998,"PHASE3":14000,"PHASE4":14002,"NA":14012},{"trials":13995,"activeCount":103},[],{"trials":13997,"activeCount":103},[],{"trials":13999,"activeCount":103},[],{"trials":14001,"activeCount":103},[],{"trials":14003,"activeCount":103},[14004,14008],{"nctId":11944,"briefTitle":11945,"status":111,"phases":14005,"primaryCompletion":4439,"completion":4439,"start":113,"enrollment":11947,"conditions":14006,"interventions":14007},[94],[11904],[11885,11950,11951],{"nctId":11953,"briefTitle":11954,"status":111,"phases":14009,"primaryCompletion":11956,"completion":11956,"start":570,"enrollment":11957,"conditions":14010,"interventions":14011},[94],[11904],[11885,11950,11951],{"trials":14013,"activeCount":103},[],{"intervention":14015,"totalTrials":1087,"cells":14016},"Unfractionated heparin",{"EARLY_PHASE1":14017,"PHASE1":14019,"PHASE2":14021,"PHASE3":14023,"PHASE4":14029,"NA":14041},{"trials":14018,"activeCount":103},[],{"trials":14020,"activeCount":103},[],{"trials":14022,"activeCount":103},[],{"trials":14024,"activeCount":103},[14025],{"nctId":9569,"briefTitle":9570,"status":111,"phases":14026,"primaryCompletion":9572,"completion":9572,"start":4590,"enrollment":1519,"conditions":14027,"interventions":14028},[93],[9574,9575],[9534,9577,9578],{"trials":14030,"activeCount":103},[14031],{"nctId":14032,"briefTitle":14033,"status":168,"phases":14034,"primaryCompletion":8154,"completion":8154,"start":3643,"enrollment":14035,"conditions":14036,"interventions":14039},"NCT00435487","Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome",[94],173,[14037,14038],"Angina, Unstable","Myocardial Infarction",[14040,14015],"Dalteparin",{"trials":14042,"activeCount":103},[],{"intervention":12457,"totalTrials":1087,"cells":14044},{"EARLY_PHASE1":14045,"PHASE1":14047,"PHASE2":14049,"PHASE3":14051,"PHASE4":14061,"NA":14067},{"trials":14046,"activeCount":103},[],{"trials":14048,"activeCount":103},[],{"trials":14050,"activeCount":103},[],{"trials":14052,"activeCount":103},[14053],{"nctId":14054,"briefTitle":14055,"status":111,"phases":14056,"primaryCompletion":8115,"completion":8115,"start":3627,"enrollment":1413,"conditions":14057,"interventions":14058},"NCT00348374","Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes",[93],[6117],[14059,14060],"Insulin Lispro","Exubera",{"trials":14062,"activeCount":103},[14063],{"nctId":12452,"briefTitle":12453,"status":168,"phases":14064,"primaryCompletion":3839,"completion":3839,"start":4847,"enrollment":1587,"conditions":14065,"interventions":14066},[94],[12130],[12402,12457],{"trials":14068,"activeCount":103},[],{"intervention":11071,"totalTrials":1087,"cells":14070},{"EARLY_PHASE1":14071,"PHASE1":14073,"PHASE2":14075,"PHASE3":14077,"PHASE4":14087,"NA":14093},{"trials":14072,"activeCount":103},[],{"trials":14074,"activeCount":103},[],{"trials":14076,"activeCount":103},[],{"trials":14078,"activeCount":103},[14079],{"nctId":14080,"briefTitle":14081,"status":649,"phases":14082,"primaryCompletion":7571,"completion":7571,"start":12811,"enrollment":103,"conditions":14083,"interventions":14084},"NCT01938144","Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America",[93],[13463],[14085,14086,11071],"Advil Congestion Relief","Advil Allergy and Congestion Relief",{"trials":14088,"activeCount":103},[14089],{"nctId":11064,"briefTitle":11065,"status":111,"phases":14090,"primaryCompletion":4590,"completion":4590,"start":4531,"enrollment":11067,"conditions":14091,"interventions":14092},[94],[11027],[2555,11070,11071,2555,11070,11072,2555,11070,11071,2555,11070,11072,2555,11070],{"trials":14094,"activeCount":103},[],{"intervention":14096,"totalTrials":1087,"cells":14097},"Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl",{"EARLY_PHASE1":14098,"PHASE1":14100,"PHASE2":14102,"PHASE3":14104,"PHASE4":14112,"NA":14121},{"trials":14099,"activeCount":103},[],{"trials":14101,"activeCount":103},[],{"trials":14103,"activeCount":103},[],{"trials":14105,"activeCount":103},[14106],{"nctId":14107,"briefTitle":14108,"status":111,"phases":14109,"primaryCompletion":2964,"start":3854,"enrollment":1759,"conditions":14110,"interventions":14111},"NCT00460486","Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule",[93],[11801],[14096],{"trials":14113,"activeCount":103},[14114],{"nctId":14115,"briefTitle":14116,"status":111,"phases":14117,"completion":14118,"start":11829,"conditions":14119,"interventions":14120},"NCT00163540","Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)",[94],"2005-06",[11768],[14096],{"trials":14122,"activeCount":103},[],{"intervention":14124,"totalTrials":302,"cells":14125},"Pegvisomant treatment",{"EARLY_PHASE1":14126,"PHASE1":14128,"PHASE2":14130,"PHASE3":14132,"PHASE4":14134,"NA":14142},{"trials":14127,"activeCount":103},[],{"trials":14129,"activeCount":103},[],{"trials":14131,"activeCount":103},[],{"trials":14133,"activeCount":103},[],{"trials":14135,"activeCount":103},[14136],{"nctId":14137,"briefTitle":14138,"status":111,"phases":14139,"completion":3602,"start":12774,"enrollment":1780,"conditions":14140,"interventions":14141},"NCT00151437","Canadian Pegvisomant Compassionate Study In Acromegalic Patients",[94],[12599],[14124],{"trials":14143,"activeCount":103},[],{"intervention":14145,"totalTrials":302,"cells":14146},"Phase 1: Etanercept",{"EARLY_PHASE1":14147,"PHASE1":14149,"PHASE2":14151,"PHASE3":14153,"PHASE4":14155,"NA":14167},{"trials":14148,"activeCount":103},[],{"trials":14150,"activeCount":103},[],{"trials":14152,"activeCount":103},[],{"trials":14154,"activeCount":103},[],{"trials":14156,"activeCount":103},[14157],{"nctId":14158,"briefTitle":14159,"status":111,"phases":14160,"primaryCompletion":6208,"completion":6208,"start":4646,"enrollment":14161,"conditions":14162,"interventions":14163},"NCT00848354","Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy",[94],429,[22],[14145,14164,14165,14164,14166],"Phase 1: Methotrexate","Phase 2: Optional ETN, SSZ, HCQ, MTX","Phase 1: Conventiaonal DMARD",{"trials":14168,"activeCount":103},[],{"intervention":14164,"totalTrials":302,"cells":14170},{"EARLY_PHASE1":14171,"PHASE1":14173,"PHASE2":14175,"PHASE3":14177,"PHASE4":14179,"NA":14185},{"trials":14172,"activeCount":103},[],{"trials":14174,"activeCount":103},[],{"trials":14176,"activeCount":103},[],{"trials":14178,"activeCount":103},[],{"trials":14180,"activeCount":103},[14181],{"nctId":14158,"briefTitle":14159,"status":111,"phases":14182,"primaryCompletion":6208,"completion":6208,"start":4646,"enrollment":14161,"conditions":14183,"interventions":14184},[94],[22],[14145,14164,14165,14164,14166],{"trials":14186,"activeCount":103},[],{"intervention":14165,"totalTrials":302,"cells":14188},{"EARLY_PHASE1":14189,"PHASE1":14191,"PHASE2":14193,"PHASE3":14195,"PHASE4":14197,"NA":14203},{"trials":14190,"activeCount":103},[],{"trials":14192,"activeCount":103},[],{"trials":14194,"activeCount":103},[],{"trials":14196,"activeCount":103},[],{"trials":14198,"activeCount":103},[14199],{"nctId":14158,"briefTitle":14159,"status":111,"phases":14200,"primaryCompletion":6208,"completion":6208,"start":4646,"enrollment":14161,"conditions":14201,"interventions":14202},[94],[22],[14145,14164,14165,14164,14166],{"trials":14204,"activeCount":103},[],{"intervention":14166,"totalTrials":302,"cells":14206},{"EARLY_PHASE1":14207,"PHASE1":14209,"PHASE2":14211,"PHASE3":14213,"PHASE4":14215,"NA":14221},{"trials":14208,"activeCount":103},[],{"trials":14210,"activeCount":103},[],{"trials":14212,"activeCount":103},[],{"trials":14214,"activeCount":103},[],{"trials":14216,"activeCount":103},[14217],{"nctId":14158,"briefTitle":14159,"status":111,"phases":14218,"primaryCompletion":6208,"completion":6208,"start":4646,"enrollment":14161,"conditions":14219,"interventions":14220},[94],[22],[14145,14164,14165,14164,14166],{"trials":14222,"activeCount":103},[],{"intervention":14224,"totalTrials":302,"cells":14225},"Bosentan",{"EARLY_PHASE1":14226,"PHASE1":14228,"PHASE2":14230,"PHASE3":14232,"PHASE4":14234,"NA":14243},{"trials":14227,"activeCount":103},[],{"trials":14229,"activeCount":103},[],{"trials":14231,"activeCount":103},[],{"trials":14233,"activeCount":103},[],{"trials":14235,"activeCount":103},[14236],{"nctId":14237,"briefTitle":14238,"status":111,"phases":14239,"primaryCompletion":6207,"completion":6207,"start":3854,"enrollment":3587,"conditions":14240,"interventions":14241},"NCT00323297","Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension",[94],[4942],[14224,14224,14242],"Sildenafil Citrate",{"trials":14244,"activeCount":103},[],{"intervention":14246,"totalTrials":302,"cells":14247},"Flavoquine®, Camoquin® Suspension",{"EARLY_PHASE1":14248,"PHASE1":14250,"PHASE2":14252,"PHASE3":14254,"PHASE4":14256,"NA":14265},{"trials":14249,"activeCount":103},[],{"trials":14251,"activeCount":103},[],{"trials":14253,"activeCount":103},[],{"trials":14255,"activeCount":103},[],{"trials":14257,"activeCount":103},[14258],{"nctId":14259,"briefTitle":14260,"status":111,"phases":14261,"primaryCompletion":4646,"completion":4646,"start":11014,"enrollment":1796,"conditions":14262,"interventions":14264},"NCT00859807","A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects",[94],[14263],"Falciparum Malaria",[14246,14246],{"trials":14266,"activeCount":103},[],{"intervention":14268,"totalTrials":302,"cells":14269},"VACCINE: placebo",{"EARLY_PHASE1":14270,"PHASE1":14272,"PHASE2":14274,"PHASE3":14276,"PHASE4":14278,"NA":14289},{"trials":14271,"activeCount":103},[],{"trials":14273,"activeCount":103},[],{"trials":14275,"activeCount":103},[],{"trials":14277,"activeCount":103},[],{"trials":14279,"activeCount":103},[14280],{"nctId":14281,"briefTitle":14282,"status":111,"phases":14283,"primaryCompletion":1249,"completion":1249,"start":11291,"enrollment":14284,"conditions":14285,"interventions":14287},"NCT00744263","Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults",[94],84496,[14286,10940,10949],"Pneumonia, Pneumococcal",[14268,14288],"VACCINE: 13-valent pneumococcal conjugate vaccine",{"trials":14290,"activeCount":103},[],{"intervention":14288,"totalTrials":302,"cells":14292},{"EARLY_PHASE1":14293,"PHASE1":14295,"PHASE2":14297,"PHASE3":14299,"PHASE4":14301,"NA":14307},{"trials":14294,"activeCount":103},[],{"trials":14296,"activeCount":103},[],{"trials":14298,"activeCount":103},[],{"trials":14300,"activeCount":103},[],{"trials":14302,"activeCount":103},[14303],{"nctId":14281,"briefTitle":14282,"status":111,"phases":14304,"primaryCompletion":1249,"completion":1249,"start":11291,"enrollment":14284,"conditions":14305,"interventions":14306},[94],[14286,10940,10949],[14268,14288],{"trials":14308,"activeCount":103},[],{"intervention":12768,"totalTrials":302,"cells":14310},{"EARLY_PHASE1":14311,"PHASE1":14313,"PHASE2":14315,"PHASE3":14317,"PHASE4":14319,"NA":14325},{"trials":14312,"activeCount":103},[],{"trials":14314,"activeCount":103},[],{"trials":14316,"activeCount":103},[],{"trials":14318,"activeCount":103},[],{"trials":14320,"activeCount":103},[14321],{"nctId":12760,"briefTitle":12761,"status":111,"phases":14322,"primaryCompletion":3643,"completion":3643,"start":4615,"enrollment":12763,"conditions":14323,"interventions":14324},[94],[12765,12766],[12733,12768],{"trials":14326,"activeCount":103},[],{"intervention":13612,"totalTrials":302,"cells":14328},{"EARLY_PHASE1":14329,"PHASE1":14331,"PHASE2":14333,"PHASE3":14335,"PHASE4":14337,"NA":14343},{"trials":14330,"activeCount":103},[],{"trials":14332,"activeCount":103},[],{"trials":14334,"activeCount":103},[],{"trials":14336,"activeCount":103},[],{"trials":14338,"activeCount":103},[14339],{"nctId":13607,"briefTitle":13608,"status":111,"phases":14340,"primaryCompletion":3335,"completion":3335,"start":10937,"enrollment":1268,"conditions":14341,"interventions":14342},[94],[12981],[13612,13587],{"trials":14344,"activeCount":103},[],{"intervention":14346,"totalTrials":302,"cells":14347},"Azithromycin Extended Release",{"EARLY_PHASE1":14348,"PHASE1":14350,"PHASE2":14352,"PHASE3":14354,"PHASE4":14356,"NA":14367},{"trials":14349,"activeCount":103},[],{"trials":14351,"activeCount":103},[],{"trials":14353,"activeCount":103},[],{"trials":14355,"activeCount":103},[],{"trials":14357,"activeCount":103},[14358],{"nctId":14359,"briefTitle":14360,"status":111,"phases":14361,"completion":1701,"start":3627,"enrollment":14362,"conditions":14363,"interventions":14365},"NCT00367120","Zmax Compared to Augmentin in Sinusitis",[94],762,[14364],"Sinusitis",[14346,14366],"Amoxicillin\u002FClavulanate",{"trials":14368,"activeCount":103},[],{"intervention":14366,"totalTrials":302,"cells":14370},{"EARLY_PHASE1":14371,"PHASE1":14373,"PHASE2":14375,"PHASE3":14377,"PHASE4":14379,"NA":14385},{"trials":14372,"activeCount":103},[],{"trials":14374,"activeCount":103},[],{"trials":14376,"activeCount":103},[],{"trials":14378,"activeCount":103},[],{"trials":14380,"activeCount":103},[14381],{"nctId":14359,"briefTitle":14360,"status":111,"phases":14382,"completion":1701,"start":3627,"enrollment":14362,"conditions":14383,"interventions":14384},[94],[14364],[14346,14366],{"trials":14386,"activeCount":103},[],{"intervention":14388,"totalTrials":302,"cells":14389},"Fesoterodine 8 mg",{"EARLY_PHASE1":14390,"PHASE1":14392,"PHASE2":14394,"PHASE3":14396,"PHASE4":14398,"NA":14407},{"trials":14391,"activeCount":103},[],{"trials":14393,"activeCount":103},[],{"trials":14395,"activeCount":103},[],{"trials":14397,"activeCount":103},[],{"trials":14399,"activeCount":103},[14400],{"nctId":14401,"briefTitle":14402,"status":111,"phases":14403,"primaryCompletion":113,"completion":113,"start":11170,"enrollment":14404,"conditions":14405,"interventions":14406},"NCT01302054","A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.",[94],990,[12472],[14388],{"trials":14408,"activeCount":103},[],{"intervention":11195,"totalTrials":302,"cells":14410},{"EARLY_PHASE1":14411,"PHASE1":14413,"PHASE2":14415,"PHASE3":14417,"PHASE4":14419,"NA":14425},{"trials":14412,"activeCount":103},[],{"trials":14414,"activeCount":103},[],{"trials":14416,"activeCount":103},[],{"trials":14418,"activeCount":103},[],{"trials":14420,"activeCount":103},[14421],{"nctId":11189,"briefTitle":11190,"status":111,"phases":14422,"primaryCompletion":4222,"completion":4222,"start":4222,"enrollment":1780,"conditions":14423,"interventions":14424},[94],[11193],[11076,11195,11088,11098],{"trials":14426,"activeCount":103},[],{"intervention":14428,"totalTrials":302,"cells":14429},"IV pantoprazole",{"EARLY_PHASE1":14430,"PHASE1":14432,"PHASE2":14434,"PHASE3":14436,"PHASE4":14438,"NA":14449},{"trials":14431,"activeCount":103},[],{"trials":14433,"activeCount":103},[],{"trials":14435,"activeCount":103},[],{"trials":14437,"activeCount":103},[],{"trials":14439,"activeCount":103},[14440],{"nctId":14441,"briefTitle":14442,"status":168,"phases":14443,"primaryCompletion":14444,"completion":14444,"start":14445,"enrollment":99,"conditions":14446,"interventions":14448},"NCT02401035","PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects",[94],"2021-06-18","2017-05-09",[14447],"Gastroesophageal Reflux Disease",[14428],{"trials":14450,"activeCount":103},[],{"intervention":14452,"totalTrials":302,"cells":14453},"Nelfinavir mesylate, 625 mg",{"EARLY_PHASE1":14454,"PHASE1":14456,"PHASE2":14458,"PHASE3":14460,"PHASE4":14462,"NA":14471},{"trials":14455,"activeCount":103},[],{"trials":14457,"activeCount":103},[],{"trials":14459,"activeCount":103},[],{"trials":14461,"activeCount":103},[],{"trials":14463,"activeCount":103},[14464],{"nctId":14465,"briefTitle":14466,"status":111,"phases":14467,"primaryCompletion":2964,"completion":2964,"start":6457,"enrollment":314,"conditions":14468,"interventions":14470},"NCT00246610","Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy",[94],[14469],"HIV Infection",[14452],{"trials":14472,"activeCount":103},[],{"intervention":14474,"totalTrials":302,"cells":14475},"Tolterodine ER 4 mg QD",{"EARLY_PHASE1":14476,"PHASE1":14478,"PHASE2":14480,"PHASE3":14482,"PHASE4":14484,"NA":14494},{"trials":14477,"activeCount":103},[],{"trials":14479,"activeCount":103},[],{"trials":14481,"activeCount":103},[],{"trials":14483,"activeCount":103},[],{"trials":14485,"activeCount":103},[14486],{"nctId":14487,"briefTitle":14488,"status":111,"phases":14489,"completion":12004,"start":12774,"enrollment":14490,"conditions":14491,"interventions":14492},"NCT00147654","Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction",[94],830,[12776],[14474,14493],"Tamsulosin 0.4 mg QD",{"trials":14495,"activeCount":103},[],{"intervention":14493,"totalTrials":302,"cells":14497},{"EARLY_PHASE1":14498,"PHASE1":14500,"PHASE2":14502,"PHASE3":14504,"PHASE4":14506,"NA":14512},{"trials":14499,"activeCount":103},[],{"trials":14501,"activeCount":103},[],{"trials":14503,"activeCount":103},[],{"trials":14505,"activeCount":103},[],{"trials":14507,"activeCount":103},[14508],{"nctId":14487,"briefTitle":14488,"status":111,"phases":14509,"completion":12004,"start":12774,"enrollment":14490,"conditions":14510,"interventions":14511},[94],[12776],[14474,14493],{"trials":14513,"activeCount":103},[],{"intervention":14515,"totalTrials":302,"cells":14516},"CsA+Rapamune+CS",{"EARLY_PHASE1":14517,"PHASE1":14519,"PHASE2":14521,"PHASE3":14523,"PHASE4":14525,"NA":14535},{"trials":14518,"activeCount":103},[],{"trials":14520,"activeCount":103},[],{"trials":14522,"activeCount":103},[],{"trials":14524,"activeCount":103},[],{"trials":14526,"activeCount":103},[14527],{"nctId":14528,"briefTitle":14529,"status":111,"phases":14530,"primaryCompletion":3335,"completion":3335,"start":12030,"enrollment":12,"conditions":14531,"interventions":14533},"NCT01601821","Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids",[94],[14532],"Inflammation",[14515,14534],"CsA+MMF+CS",{"trials":14536,"activeCount":103},[],{"intervention":14534,"totalTrials":302,"cells":14538},{"EARLY_PHASE1":14539,"PHASE1":14541,"PHASE2":14543,"PHASE3":14545,"PHASE4":14547,"NA":14553},{"trials":14540,"activeCount":103},[],{"trials":14542,"activeCount":103},[],{"trials":14544,"activeCount":103},[],{"trials":14546,"activeCount":103},[],{"trials":14548,"activeCount":103},[14549],{"nctId":14528,"briefTitle":14529,"status":111,"phases":14550,"primaryCompletion":3335,"completion":3335,"start":12030,"enrollment":12,"conditions":14551,"interventions":14552},[94],[14532],[14515,14534],{"trials":14554,"activeCount":103},[],{"intervention":14556,"totalTrials":302,"cells":14557},"FSME-IMMUN 0.25 mL Junior",{"EARLY_PHASE1":14558,"PHASE1":14560,"PHASE2":14562,"PHASE3":14564,"PHASE4":14566,"NA":14577},{"trials":14559,"activeCount":103},[],{"trials":14561,"activeCount":103},[],{"trials":14563,"activeCount":103},[],{"trials":14565,"activeCount":103},[],{"trials":14567,"activeCount":103},[14568],{"nctId":14569,"briefTitle":14570,"status":111,"phases":14571,"primaryCompletion":14572,"completion":14572,"start":14573,"enrollment":14574,"conditions":14575,"interventions":14576},"NCT00894686","Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)",[94],"2017-05-10","2009-04-26",179,[11801],[14556],{"trials":14578,"activeCount":103},[],{"intervention":14580,"totalTrials":302,"cells":14581},"Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care",{"EARLY_PHASE1":14582,"PHASE1":14584,"PHASE2":14586,"PHASE3":14588,"PHASE4":14590,"NA":14599},{"trials":14583,"activeCount":103},[],{"trials":14585,"activeCount":103},[],{"trials":14587,"activeCount":103},[],{"trials":14589,"activeCount":103},[],{"trials":14591,"activeCount":103},[14592],{"nctId":14593,"briefTitle":14594,"status":111,"phases":14595,"primaryCompletion":8154,"completion":4222,"start":12395,"enrollment":14596,"conditions":14597,"interventions":14598},"NCT00359801","Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety",[94],1976,[6117],[14580,14580],{"trials":14600,"activeCount":103},[],{"intervention":12258,"totalTrials":302,"cells":14602},{"EARLY_PHASE1":14603,"PHASE1":14605,"PHASE2":14607,"PHASE3":14609,"PHASE4":14611,"NA":14617},{"trials":14604,"activeCount":103},[],{"trials":14606,"activeCount":103},[],{"trials":14608,"activeCount":103},[],{"trials":14610,"activeCount":103},[],{"trials":14612,"activeCount":103},[14613],{"nctId":12253,"briefTitle":12254,"status":111,"phases":14614,"primaryCompletion":9544,"completion":9544,"start":11170,"enrollment":1780,"conditions":14615,"interventions":14616},[94],[16],[12213,12258],{"trials":14618,"activeCount":103},[],{"intervention":14620,"totalTrials":302,"cells":14621},"Varenicline 1mg BID",{"EARLY_PHASE1":14622,"PHASE1":14624,"PHASE2":14626,"PHASE3":14628,"PHASE4":14630,"NA":14640},{"trials":14623,"activeCount":103},[],{"trials":14625,"activeCount":103},[],{"trials":14627,"activeCount":103},[],{"trials":14629,"activeCount":103},[],{"trials":14631,"activeCount":103},[14632],{"nctId":14633,"briefTitle":14634,"status":111,"phases":14635,"primaryCompletion":2228,"completion":2228,"start":523,"enrollment":14636,"conditions":14637,"interventions":14638},"NCT01312909","Smoking Cessation Study In Healthy Adolescent Smokers",[94],312,[11904],[14620,14639],"Varenicline 0.5mg BID",{"trials":14641,"activeCount":103},[],{"intervention":14639,"totalTrials":302,"cells":14643},{"EARLY_PHASE1":14644,"PHASE1":14646,"PHASE2":14648,"PHASE3":14650,"PHASE4":14652,"NA":14658},{"trials":14645,"activeCount":103},[],{"trials":14647,"activeCount":103},[],{"trials":14649,"activeCount":103},[],{"trials":14651,"activeCount":103},[],{"trials":14653,"activeCount":103},[14654],{"nctId":14633,"briefTitle":14634,"status":111,"phases":14655,"primaryCompletion":2228,"completion":2228,"start":523,"enrollment":14636,"conditions":14656,"interventions":14657},[94],[11904],[14620,14639],{"trials":14659,"activeCount":103},[],{"intervention":14661,"totalTrials":302,"cells":14662},"Etanercept + Acitretin",{"EARLY_PHASE1":14663,"PHASE1":14665,"PHASE2":14667,"PHASE3":14669,"PHASE4":14671,"NA":14682},{"trials":14664,"activeCount":103},[],{"trials":14666,"activeCount":103},[],{"trials":14668,"activeCount":103},[],{"trials":14670,"activeCount":103},[],{"trials":14672,"activeCount":103},[14673],{"nctId":14674,"briefTitle":14675,"status":111,"phases":14676,"primaryCompletion":523,"completion":523,"start":4627,"enrollment":2240,"conditions":14677,"interventions":14679},"NCT00936065","Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis",[94],[14678],"Moderate to Severe Psoriasis",[14680,14661,14681],"Etanercept","Acitretin",{"trials":14683,"activeCount":103},[],{"intervention":14681,"totalTrials":302,"cells":14685},{"EARLY_PHASE1":14686,"PHASE1":14688,"PHASE2":14690,"PHASE3":14692,"PHASE4":14694,"NA":14700},{"trials":14687,"activeCount":103},[],{"trials":14689,"activeCount":103},[],{"trials":14691,"activeCount":103},[],{"trials":14693,"activeCount":103},[],{"trials":14695,"activeCount":103},[14696],{"nctId":14674,"briefTitle":14675,"status":111,"phases":14697,"primaryCompletion":523,"completion":523,"start":4627,"enrollment":2240,"conditions":14698,"interventions":14699},[94],[14678],[14680,14661,14681],{"trials":14701,"activeCount":103},[],{"intervention":9589,"totalTrials":302,"cells":14703},{"EARLY_PHASE1":14704,"PHASE1":14706,"PHASE2":14708,"PHASE3":14710,"PHASE4":14712,"NA":14718},{"trials":14705,"activeCount":103},[],{"trials":14707,"activeCount":103},[],{"trials":14709,"activeCount":103},[],{"trials":14711,"activeCount":103},[],{"trials":14713,"activeCount":103},[14714],{"nctId":9582,"briefTitle":9583,"status":111,"phases":14715,"primaryCompletion":9585,"completion":9585,"start":9586,"enrollment":1442,"conditions":14716,"interventions":14717},[94],[9555],[9534,9589],{"trials":14719,"activeCount":103},[],{"intervention":14721,"totalTrials":302,"cells":14722},"morphine sulfate extended release",{"EARLY_PHASE1":14723,"PHASE1":14725,"PHASE2":14727,"PHASE3":14729,"PHASE4":14731,"NA":14740},{"trials":14724,"activeCount":103},[],{"trials":14726,"activeCount":103},[],{"trials":14728,"activeCount":103},[],{"trials":14730,"activeCount":103},[],{"trials":14732,"activeCount":103},[14733],{"nctId":14734,"briefTitle":14735,"status":111,"phases":14736,"primaryCompletion":4645,"completion":8154,"start":3335,"enrollment":14737,"conditions":14738,"interventions":14739},"NCT00640042","Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza",[94],1570,[34],[14721],{"trials":14741,"activeCount":103},[],{"intervention":14743,"totalTrials":302,"cells":14744},"inotuzumab ozogamicin-dose level 2",{"EARLY_PHASE1":14745,"PHASE1":14747,"PHASE2":14749,"PHASE3":14751,"PHASE4":14753,"NA":14765},{"trials":14746,"activeCount":103},[],{"trials":14748,"activeCount":103},[],{"trials":14750,"activeCount":103},[],{"trials":14752,"activeCount":103},[],{"trials":14754,"activeCount":103},[14755],{"nctId":14756,"briefTitle":14757,"status":111,"phases":14758,"primaryCompletion":14759,"completion":14760,"start":3684,"enrollment":10190,"conditions":14761,"interventions":14763},"NCT03677596","A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed\u002F Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",[94],"2022-09-21","2023-05-26",[2633,14762,7004],"Precursor b-Cell Lymphoblastic Leukemia-Lymphoma",[14743,14764],"Inotuzumab ozogamicin-dose level 1",{"trials":14766,"activeCount":103},[],{"intervention":14764,"totalTrials":302,"cells":14768},{"EARLY_PHASE1":14769,"PHASE1":14771,"PHASE2":14773,"PHASE3":14775,"PHASE4":14777,"NA":14783},{"trials":14770,"activeCount":103},[],{"trials":14772,"activeCount":103},[],{"trials":14774,"activeCount":103},[],{"trials":14776,"activeCount":103},[],{"trials":14778,"activeCount":103},[14779],{"nctId":14756,"briefTitle":14757,"status":111,"phases":14780,"primaryCompletion":14759,"completion":14760,"start":3684,"enrollment":10190,"conditions":14781,"interventions":14782},[94],[2633,14762,7004],[14743,14764],{"trials":14784,"activeCount":103},[],{"intervention":14786,"totalTrials":302,"cells":14787},"Any commercially available NSAID with the indication for osteoarthritis",{"EARLY_PHASE1":14788,"PHASE1":14790,"PHASE2":14792,"PHASE3":14794,"PHASE4":14796,"NA":14805},{"trials":14789,"activeCount":103},[],{"trials":14791,"activeCount":103},[],{"trials":14793,"activeCount":103},[],{"trials":14795,"activeCount":103},[],{"trials":14797,"activeCount":103},[14798],{"nctId":14799,"briefTitle":14800,"status":111,"phases":14801,"primaryCompletion":8252,"completion":8252,"start":12128,"enrollment":14802,"conditions":14803,"interventions":14804},"NCT00373685","GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)",[94],8067,[11282],[3079,14786],{"trials":14806,"activeCount":103},[],{"intervention":14808,"totalTrials":302,"cells":14809},"iso- 5 - mononitrate",{"EARLY_PHASE1":14810,"PHASE1":14812,"PHASE2":14814,"PHASE3":14816,"PHASE4":14818,"NA":14829},{"trials":14811,"activeCount":103},[],{"trials":14813,"activeCount":103},[],{"trials":14815,"activeCount":103},[],{"trials":14817,"activeCount":103},[],{"trials":14819,"activeCount":103},[14820],{"nctId":14821,"briefTitle":14822,"status":111,"phases":14823,"completion":12069,"start":14824,"enrollment":162,"conditions":14825,"interventions":14827},"NCT00143195","Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina",[94],"2001-04",[14826],"Myocardial Ischemia",[14828,14808],"Amlodipine",{"trials":14830,"activeCount":103},[],{"intervention":11421,"totalTrials":302,"cells":14832},{"EARLY_PHASE1":14833,"PHASE1":14835,"PHASE2":14837,"PHASE3":14839,"PHASE4":14841,"NA":14847},{"trials":14834,"activeCount":103},[],{"trials":14836,"activeCount":103},[],{"trials":14838,"activeCount":103},[],{"trials":14840,"activeCount":103},[],{"trials":14842,"activeCount":103},[14843],{"nctId":11414,"briefTitle":11415,"status":111,"phases":14844,"completion":11417,"start":7675,"enrollment":2539,"conditions":14845,"interventions":14846},[94],[11419],[3079,11273,11421],{"trials":14848,"activeCount":103},[],{"intervention":14850,"totalTrials":302,"cells":14851},"Elelyso 60 units\u002Fkg",{"EARLY_PHASE1":14852,"PHASE1":14854,"PHASE2":14856,"PHASE3":14858,"PHASE4":14860,"NA":14871},{"trials":14853,"activeCount":103},[],{"trials":14855,"activeCount":103},[],{"trials":14857,"activeCount":103},[],{"trials":14859,"activeCount":103},[],{"trials":14861,"activeCount":103},[14862],{"nctId":14863,"briefTitle":14864,"status":649,"phases":14865,"primaryCompletion":14866,"completion":14866,"start":14867,"enrollment":103,"conditions":14868,"interventions":14870},"NCT03021941","Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease",[94],"2020-06-30","2019-07-31",[14869],"Type 1 Gaucher Disease",[14850],{"trials":14872,"activeCount":103},[],{"intervention":14874,"totalTrials":302,"cells":14875},"ziprazidone",{"EARLY_PHASE1":14876,"PHASE1":14878,"PHASE2":14880,"PHASE3":14882,"PHASE4":14884,"NA":14892},{"trials":14877,"activeCount":103},[],{"trials":14879,"activeCount":103},[],{"trials":14881,"activeCount":103},[],{"trials":14883,"activeCount":103},[],{"trials":14885,"activeCount":103},[14886],{"nctId":14887,"briefTitle":14888,"status":168,"phases":14889,"completion":4258,"start":3611,"enrollment":1210,"conditions":14890,"interventions":14891},"NCT00159757","12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients",[94],[12632],[14874],{"trials":14893,"activeCount":103},[],{"intervention":14895,"totalTrials":302,"cells":14896},"artesunate sachets",{"EARLY_PHASE1":14897,"PHASE1":14899,"PHASE2":14901,"PHASE3":14903,"PHASE4":14905,"NA":14914},{"trials":14898,"activeCount":103},[],{"trials":14900,"activeCount":103},[],{"trials":14902,"activeCount":103},[],{"trials":14904,"activeCount":103},[],{"trials":14906,"activeCount":103},[14907],{"nctId":14908,"briefTitle":14909,"status":111,"phases":14910,"primaryCompletion":4646,"completion":4646,"start":4646,"enrollment":35,"conditions":14911,"interventions":14912},"NCT00875030","A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects",[94],[19],[14895,14913],"Arsuamoon",{"trials":14915,"activeCount":103},[],{"intervention":14913,"totalTrials":302,"cells":14917},{"EARLY_PHASE1":14918,"PHASE1":14920,"PHASE2":14922,"PHASE3":14924,"PHASE4":14926,"NA":14932},{"trials":14919,"activeCount":103},[],{"trials":14921,"activeCount":103},[],{"trials":14923,"activeCount":103},[],{"trials":14925,"activeCount":103},[],{"trials":14927,"activeCount":103},[14928],{"nctId":14908,"briefTitle":14909,"status":111,"phases":14929,"primaryCompletion":4646,"completion":4646,"start":4646,"enrollment":35,"conditions":14930,"interventions":14931},[94],[19],[14895,14913],{"trials":14933,"activeCount":103},[],{"intervention":14935,"totalTrials":302,"cells":14936},"Tolterodine ER 4mg QD",{"EARLY_PHASE1":14937,"PHASE1":14939,"PHASE2":14941,"PHASE3":14943,"PHASE4":14945,"NA":14953},{"trials":14938,"activeCount":103},[],{"trials":14940,"activeCount":103},[],{"trials":14942,"activeCount":103},[],{"trials":14944,"activeCount":103},[],{"trials":14946,"activeCount":103},[14947],{"nctId":14948,"briefTitle":14949,"status":111,"phases":14950,"primaryCompletion":3627,"start":4692,"enrollment":267,"conditions":14951,"interventions":14952},"NCT00143481","Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women",[94],[12776],[14935],{"trials":14954,"activeCount":103},[],{"intervention":13841,"totalTrials":302,"cells":14956},{"EARLY_PHASE1":14957,"PHASE1":14959,"PHASE2":14961,"PHASE3":14963,"PHASE4":14965,"NA":14971},{"trials":14958,"activeCount":103},[],{"trials":14960,"activeCount":103},[],{"trials":14962,"activeCount":103},[],{"trials":14964,"activeCount":103},[],{"trials":14966,"activeCount":103},[14967],{"nctId":13836,"briefTitle":13837,"status":111,"phases":14968,"primaryCompletion":3314,"completion":3314,"start":11315,"enrollment":12,"conditions":14969,"interventions":14970},[94],[12980,13280],[13841,13816,13841,13816],{"trials":14972,"activeCount":103},[],{"intervention":14974,"totalTrials":302,"cells":14975},"FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%",{"EARLY_PHASE1":14976,"PHASE1":14978,"PHASE2":14980,"PHASE3":14982,"PHASE4":14984,"NA":14993},{"trials":14977,"activeCount":103},[],{"trials":14979,"activeCount":103},[],{"trials":14981,"activeCount":103},[],{"trials":14983,"activeCount":103},[],{"trials":14985,"activeCount":103},[14986],{"nctId":14987,"briefTitle":14988,"status":111,"phases":14989,"primaryCompletion":3642,"completion":3642,"start":10923,"enrollment":3462,"conditions":14990,"interventions":14992},"NCT01054820","Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain",[94],[14991],"Acute Back Strain",[14974],{"trials":14994,"activeCount":103},[],{"intervention":14996,"totalTrials":302,"cells":14997},"Pegaptanib Sodium 0.3 mg",{"EARLY_PHASE1":14998,"PHASE1":15000,"PHASE2":15002,"PHASE3":15004,"PHASE4":15006,"NA":15017},{"trials":14999,"activeCount":103},[],{"trials":15001,"activeCount":103},[],{"trials":15003,"activeCount":103},[],{"trials":15005,"activeCount":103},[],{"trials":15007,"activeCount":103},[15008],{"nctId":15009,"briefTitle":15010,"status":168,"phases":15011,"primaryCompletion":4214,"completion":4214,"start":12395,"enrollment":12163,"conditions":15012,"interventions":15016},"NCT00327470","An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD",[94],[15013,15014,15015],"Age Related Macular Degeneration (AMD)","Macular Degeneration","Choroidal Neovascularization (CNV)",[14996],{"trials":15018,"activeCount":103},[],{"intervention":15020,"totalTrials":302,"cells":15021},"Celecoxib 200 milligrams",{"EARLY_PHASE1":15022,"PHASE1":15024,"PHASE2":15026,"PHASE3":15028,"PHASE4":15030,"NA":15042},{"trials":15023,"activeCount":103},[],{"trials":15025,"activeCount":103},[],{"trials":15027,"activeCount":103},[],{"trials":15029,"activeCount":103},[],{"trials":15031,"activeCount":103},[15032],{"nctId":15033,"briefTitle":15034,"status":111,"phases":15035,"primaryCompletion":12774,"completion":12774,"start":15036,"enrollment":1759,"conditions":15037,"interventions":15039},"NCT02528201","A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis",[94],"2002-09",[15038],"Ankylosing Spondylitis",[15020,15040,15041],"Celecoxib 400 milligrams","diclofenac 50 milligrams",{"trials":15043,"activeCount":103},[],{"intervention":15040,"totalTrials":302,"cells":15045},{"EARLY_PHASE1":15046,"PHASE1":15048,"PHASE2":15050,"PHASE3":15052,"PHASE4":15054,"NA":15060},{"trials":15047,"activeCount":103},[],{"trials":15049,"activeCount":103},[],{"trials":15051,"activeCount":103},[],{"trials":15053,"activeCount":103},[],{"trials":15055,"activeCount":103},[15056],{"nctId":15033,"briefTitle":15034,"status":111,"phases":15057,"primaryCompletion":12774,"completion":12774,"start":15036,"enrollment":1759,"conditions":15058,"interventions":15059},[94],[15038],[15020,15040,15041],{"trials":15061,"activeCount":103},[],{"intervention":15041,"totalTrials":302,"cells":15063},{"EARLY_PHASE1":15064,"PHASE1":15066,"PHASE2":15068,"PHASE3":15070,"PHASE4":15072,"NA":15078},{"trials":15065,"activeCount":103},[],{"trials":15067,"activeCount":103},[],{"trials":15069,"activeCount":103},[],{"trials":15071,"activeCount":103},[],{"trials":15073,"activeCount":103},[15074],{"nctId":15033,"briefTitle":15034,"status":111,"phases":15075,"primaryCompletion":12774,"completion":12774,"start":15036,"enrollment":1759,"conditions":15076,"interventions":15077},[94],[15038],[15020,15040,15041],{"trials":15079,"activeCount":103},[],{"intervention":15081,"totalTrials":302,"cells":15082},"Methylphenidate Hydrochloride",{"EARLY_PHASE1":15083,"PHASE1":15085,"PHASE2":15087,"PHASE3":15089,"PHASE4":15091,"NA":15101},{"trials":15084,"activeCount":103},[],{"trials":15086,"activeCount":103},[],{"trials":15088,"activeCount":103},[],{"trials":15090,"activeCount":103},[],{"trials":15092,"activeCount":103},[15093],{"nctId":15094,"briefTitle":15095,"status":649,"phases":15096,"primaryCompletion":15097,"completion":15097,"start":5807,"enrollment":103,"conditions":15098,"interventions":15100},"NCT03536390","A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD",[94],"2021-04-22",[15099],"Attention Deficit Hyperactivity Disorder",[15081],{"trials":15102,"activeCount":103},[],{"intervention":15104,"totalTrials":302,"cells":15105},"Atorvastatin 80mg",{"EARLY_PHASE1":15106,"PHASE1":15108,"PHASE2":15110,"PHASE3":15112,"PHASE4":15114,"NA":15124},{"trials":15107,"activeCount":103},[],{"trials":15109,"activeCount":103},[],{"trials":15111,"activeCount":103},[],{"trials":15113,"activeCount":103},[],{"trials":15115,"activeCount":103},[15116],{"nctId":15117,"briefTitle":15118,"status":111,"phases":15119,"completion":7675,"start":15120,"enrollment":12763,"conditions":15121,"interventions":15123},"NCT00457340","Atorvastatin For The Reduction Of Ventricular Arrhythmias",[94],"2000-02",[15122],"Arrhythmia",[15104],{"trials":15125,"activeCount":103},[],{"intervention":15127,"totalTrials":302,"cells":15128},"PARECOXIB SODIUM",{"EARLY_PHASE1":15129,"PHASE1":15131,"PHASE2":15133,"PHASE3":15135,"PHASE4":15137,"NA":15145},{"trials":15130,"activeCount":103},[],{"trials":15132,"activeCount":103},[],{"trials":15134,"activeCount":103},[],{"trials":15136,"activeCount":103},[],{"trials":15138,"activeCount":103},[15139],{"nctId":15140,"briefTitle":15141,"status":649,"phases":15142,"enrollment":103,"conditions":15143,"interventions":15144},"NCT00435747","Efficacy And Safety Of Parecoxib IV\u002FIM 40 Mg Vs Placebo Following Sub Muscular Breast Augmentation",[94],[11730],[15127],{"trials":15146,"activeCount":103},[],{"intervention":15148,"totalTrials":302,"cells":15149},"FSME-IMMUN 0.5ml",{"EARLY_PHASE1":15150,"PHASE1":15152,"PHASE2":15154,"PHASE3":15156,"PHASE4":15158,"NA":15167},{"trials":15151,"activeCount":103},[],{"trials":15153,"activeCount":103},[],{"trials":15155,"activeCount":103},[],{"trials":15157,"activeCount":103},[],{"trials":15159,"activeCount":103},[15160],{"nctId":15161,"briefTitle":15162,"status":111,"phases":15163,"completion":11417,"start":13902,"enrollment":11719,"conditions":15164,"interventions":15166},"NCT00161785","Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years",[94],[15165],"Tick-borne Encephalitis",[15148],{"trials":15168,"activeCount":103},[],{"intervention":15170,"totalTrials":302,"cells":15171},"Tofacitinib with methotrexate",{"EARLY_PHASE1":15172,"PHASE1":15174,"PHASE2":15176,"PHASE3":15178,"PHASE4":15180,"NA":15193},{"trials":15173,"activeCount":103},[],{"trials":15175,"activeCount":103},[],{"trials":15177,"activeCount":103},[],{"trials":15179,"activeCount":103},[],{"trials":15181,"activeCount":103},[15182],{"nctId":15183,"briefTitle":15184,"status":111,"phases":15185,"primaryCompletion":15186,"completion":15186,"start":7386,"enrollment":15187,"conditions":15188,"interventions":15190},"NCT02187055","An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate",[94],"2016-12",1152,[15189],"Rhematoid Arthritis",[15170,15191,15192],"Tofacitinib without methotrexate","Adalimumab with methotrexate",{"trials":15194,"activeCount":103},[],{"intervention":15191,"totalTrials":302,"cells":15196},{"EARLY_PHASE1":15197,"PHASE1":15199,"PHASE2":15201,"PHASE3":15203,"PHASE4":15205,"NA":15211},{"trials":15198,"activeCount":103},[],{"trials":15200,"activeCount":103},[],{"trials":15202,"activeCount":103},[],{"trials":15204,"activeCount":103},[],{"trials":15206,"activeCount":103},[15207],{"nctId":15183,"briefTitle":15184,"status":111,"phases":15208,"primaryCompletion":15186,"completion":15186,"start":7386,"enrollment":15187,"conditions":15209,"interventions":15210},[94],[15189],[15170,15191,15192],{"trials":15212,"activeCount":103},[],{"intervention":15192,"totalTrials":302,"cells":15214},{"EARLY_PHASE1":15215,"PHASE1":15217,"PHASE2":15219,"PHASE3":15221,"PHASE4":15223,"NA":15229},{"trials":15216,"activeCount":103},[],{"trials":15218,"activeCount":103},[],{"trials":15220,"activeCount":103},[],{"trials":15222,"activeCount":103},[],{"trials":15224,"activeCount":103},[15225],{"nctId":15183,"briefTitle":15184,"status":111,"phases":15226,"primaryCompletion":15186,"completion":15186,"start":7386,"enrollment":15187,"conditions":15227,"interventions":15228},[94],[15189],[15170,15191,15192],{"trials":15230,"activeCount":103},[],{"intervention":15232,"totalTrials":302,"cells":15233},"Ampicillin\u002Fsulbactam",{"EARLY_PHASE1":15234,"PHASE1":15236,"PHASE2":15238,"PHASE3":15240,"PHASE4":15242,"NA":15251},{"trials":15235,"activeCount":103},[],{"trials":15237,"activeCount":103},[],{"trials":15239,"activeCount":103},[],{"trials":15241,"activeCount":103},[],{"trials":15243,"activeCount":103},[15244],{"nctId":15245,"briefTitle":15246,"status":111,"phases":15247,"completion":6017,"start":3611,"enrollment":9562,"conditions":15248,"interventions":15249},"NCT00137007","Zithromax EV in Community-Acquired Pneumonia (CAP)",[94],[9107],[15250,15232],"Azithromycin",{"trials":15252,"activeCount":103},[],{"intervention":13372,"totalTrials":302,"cells":15254},{"EARLY_PHASE1":15255,"PHASE1":15257,"PHASE2":15259,"PHASE3":15261,"PHASE4":15263,"NA":15269},{"trials":15256,"activeCount":103},[],{"trials":15258,"activeCount":103},[],{"trials":15260,"activeCount":103},[],{"trials":15262,"activeCount":103},[],{"trials":15264,"activeCount":103},[15265],{"nctId":13365,"briefTitle":13366,"status":111,"phases":15266,"primaryCompletion":585,"completion":585,"start":561,"enrollment":1796,"conditions":15267,"interventions":15268},[94],[3396,13369,13370],[13344,13372],{"trials":15270,"activeCount":103},[],{"intervention":15272,"totalTrials":302,"cells":15273},"Depo-Provera Contraceptive Injection - DP150CI",{"EARLY_PHASE1":15274,"PHASE1":15276,"PHASE2":15278,"PHASE3":15280,"PHASE4":15282,"NA":15291},{"trials":15275,"activeCount":103},[],{"trials":15277,"activeCount":103},[],{"trials":15279,"activeCount":103},[],{"trials":15281,"activeCount":103},[],{"trials":15283,"activeCount":103},[15284],{"nctId":15285,"briefTitle":15286,"status":111,"phases":15287,"primaryCompletion":12773,"completion":2641,"start":11791,"enrollment":12382,"conditions":15288,"interventions":15290},"NCT00139685","Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception",[94],[13937,15289],"Bone Density",[15272],{"trials":15292,"activeCount":103},[],{"intervention":15294,"totalTrials":302,"cells":15295},"Cosopt",{"EARLY_PHASE1":15296,"PHASE1":15298,"PHASE2":15300,"PHASE3":15302,"PHASE4":15304,"NA":15315},{"trials":15297,"activeCount":103},[],{"trials":15299,"activeCount":103},[],{"trials":15301,"activeCount":103},[],{"trials":15303,"activeCount":103},[],{"trials":15305,"activeCount":103},[15306],{"nctId":15307,"briefTitle":15308,"status":111,"phases":15309,"completion":12395,"start":11417,"enrollment":15310,"conditions":15311,"interventions":15313},"NCT00140049","A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W\u002F Glaucoma",[94],238,[15312,12882],"Glaucoma, Open Angle",[15314,15294],"Xalacom",{"trials":15316,"activeCount":103},[],{"intervention":12658,"totalTrials":302,"cells":15318},{"EARLY_PHASE1":15319,"PHASE1":15321,"PHASE2":15323,"PHASE3":15325,"PHASE4":15327,"NA":15333},{"trials":15320,"activeCount":103},[],{"trials":15322,"activeCount":103},[],{"trials":15324,"activeCount":103},[],{"trials":15326,"activeCount":103},[],{"trials":15328,"activeCount":103},[15329],{"nctId":12651,"briefTitle":12652,"status":168,"phases":15330,"primaryCompletion":2641,"completion":3853,"start":4847,"enrollment":350,"conditions":15331,"interventions":15332},[94],[12655,12656],[12658,12646],{"trials":15334,"activeCount":103},[],{"intervention":15336,"totalTrials":302,"cells":15337},"clindamycin",{"EARLY_PHASE1":15338,"PHASE1":15340,"PHASE2":15342,"PHASE3":15344,"PHASE4":15346,"NA":15356},{"trials":15339,"activeCount":103},[],{"trials":15341,"activeCount":103},[],{"trials":15343,"activeCount":103},[],{"trials":15345,"activeCount":103},[],{"trials":15347,"activeCount":103},[15348],{"nctId":15349,"briefTitle":15350,"status":111,"phases":15351,"completion":14118,"start":12069,"enrollment":3612,"conditions":15352,"interventions":15354},"NCT00219570","Dalacin-T Gel Post Approval Study",[94],[15353],"Acne Vulgaris",[15336,15355],"nadifloxacin",{"trials":15357,"activeCount":103},[],{"intervention":15355,"totalTrials":302,"cells":15359},{"EARLY_PHASE1":15360,"PHASE1":15362,"PHASE2":15364,"PHASE3":15366,"PHASE4":15368,"NA":15374},{"trials":15361,"activeCount":103},[],{"trials":15363,"activeCount":103},[],{"trials":15365,"activeCount":103},[],{"trials":15367,"activeCount":103},[],{"trials":15369,"activeCount":103},[15370],{"nctId":15349,"briefTitle":15350,"status":111,"phases":15371,"completion":14118,"start":12069,"enrollment":3612,"conditions":15372,"interventions":15373},[94],[15353],[15336,15355],{"trials":15375,"activeCount":103},[],{"intervention":15377,"totalTrials":302,"cells":15378},"Doxazosin mysylate GITS",{"EARLY_PHASE1":15379,"PHASE1":15381,"PHASE2":15383,"PHASE3":15385,"PHASE4":15387,"NA":15396},{"trials":15380,"activeCount":103},[],{"trials":15382,"activeCount":103},[],{"trials":15384,"activeCount":103},[],{"trials":15386,"activeCount":103},[],{"trials":15388,"activeCount":103},[15389],{"nctId":15390,"briefTitle":15391,"status":111,"phases":15392,"completion":12069,"start":3611,"enrollment":1519,"conditions":15393,"interventions":15395},"NCT00648323","Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement",[94],[15394],"Prostate",[15377],{"trials":15397,"activeCount":103},[],{"intervention":13753,"totalTrials":302,"cells":15399},{"EARLY_PHASE1":15400,"PHASE1":15402,"PHASE2":15404,"PHASE3":15406,"PHASE4":15408,"NA":15414},{"trials":15401,"activeCount":103},[],{"trials":15403,"activeCount":103},[],{"trials":15405,"activeCount":103},[],{"trials":15407,"activeCount":103},[],{"trials":15409,"activeCount":103},[15410],{"nctId":13746,"briefTitle":13747,"status":168,"phases":15411,"completion":6017,"start":13035,"enrollment":12763,"conditions":15412,"interventions":15413},[94],[13750],[13752,13753],{"trials":15415,"activeCount":103},[],{"intervention":15417,"totalTrials":302,"cells":15418},"doxycycline monohydrate",{"EARLY_PHASE1":15419,"PHASE1":15421,"PHASE2":15423,"PHASE3":15425,"PHASE4":15427,"NA":15437},{"trials":15420,"activeCount":103},[],{"trials":15422,"activeCount":103},[],{"trials":15424,"activeCount":103},[],{"trials":15426,"activeCount":103},[],{"trials":15428,"activeCount":103},[15429],{"nctId":15430,"briefTitle":15431,"status":111,"phases":15432,"primaryCompletion":8154,"completion":8154,"start":4645,"enrollment":1509,"conditions":15433,"interventions":15435},"NCT00939562","Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate",[94],[15434],"Bacterial Infection",[15417,15436],"doxycycline carragenate",{"trials":15438,"activeCount":103},[],{"intervention":15436,"totalTrials":302,"cells":15440},{"EARLY_PHASE1":15441,"PHASE1":15443,"PHASE2":15445,"PHASE3":15447,"PHASE4":15449,"NA":15455},{"trials":15442,"activeCount":103},[],{"trials":15444,"activeCount":103},[],{"trials":15446,"activeCount":103},[],{"trials":15448,"activeCount":103},[],{"trials":15450,"activeCount":103},[15451],{"nctId":15430,"briefTitle":15431,"status":111,"phases":15452,"primaryCompletion":8154,"completion":8154,"start":4645,"enrollment":1509,"conditions":15453,"interventions":15454},[94],[15434],[15417,15436],{"trials":15456,"activeCount":103},[],{"intervention":15458,"totalTrials":302,"cells":15459},"Dalteparin sodium",{"EARLY_PHASE1":15460,"PHASE1":15462,"PHASE2":15464,"PHASE3":15466,"PHASE4":15468,"NA":15477},{"trials":15461,"activeCount":103},[],{"trials":15463,"activeCount":103},[],{"trials":15465,"activeCount":103},[],{"trials":15467,"activeCount":103},[],{"trials":15469,"activeCount":103},[15470],{"nctId":15471,"briefTitle":15472,"status":168,"phases":15473,"completion":2672,"start":12607,"enrollment":1487,"conditions":15474,"interventions":15476},"NCT00655122","Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study",[94],[15475,9574,14040],"Thromboembolism",[15458],{"trials":15478,"activeCount":103},[],{"intervention":15480,"totalTrials":302,"cells":15481},"Tranexamic acid + Standard of Care",{"EARLY_PHASE1":15482,"PHASE1":15484,"PHASE2":15486,"PHASE3":15488,"PHASE4":15490,"NA":15503},{"trials":15483,"activeCount":103},[],{"trials":15485,"activeCount":103},[],{"trials":15487,"activeCount":103},[],{"trials":15489,"activeCount":103},[],{"trials":15491,"activeCount":103},[15492],{"nctId":15493,"briefTitle":15494,"status":111,"phases":15495,"primaryCompletion":523,"completion":11170,"start":4833,"enrollment":6107,"conditions":15496,"interventions":15502},"NCT00827931","Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery",[94],[15497,15498,15499,15500,15501],"Biliary Tract Surgical Procedures","Pancreaticoduodenectomy","Esophagectomy","Colectomy","Gastrectomy",[15480],{"trials":15504,"activeCount":103},[],{"intervention":15506,"totalTrials":302,"cells":15507},"oral Diclofenac",{"EARLY_PHASE1":15508,"PHASE1":15510,"PHASE2":15512,"PHASE3":15514,"PHASE4":15516,"NA":15524},{"trials":15509,"activeCount":103},[],{"trials":15511,"activeCount":103},[],{"trials":15513,"activeCount":103},[],{"trials":15515,"activeCount":103},[],{"trials":15517,"activeCount":103},[15518],{"nctId":15519,"briefTitle":15520,"status":168,"phases":15521,"primaryCompletion":10923,"completion":10923,"start":6016,"enrollment":1487,"conditions":15522,"interventions":15523},"NCT00894790","Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident",[94],[34],[3079,15506],{"trials":15525,"activeCount":103},[],{"intervention":15527,"totalTrials":302,"cells":15528},"Eraxis",{"EARLY_PHASE1":15529,"PHASE1":15531,"PHASE2":15533,"PHASE3":15535,"PHASE4":15537,"NA":15549},{"trials":15530,"activeCount":103},[],{"trials":15532,"activeCount":103},[],{"trials":15534,"activeCount":103},[],{"trials":15536,"activeCount":103},[],{"trials":15538,"activeCount":103},[15539],{"nctId":15540,"briefTitle":15541,"status":111,"phases":15542,"primaryCompletion":577,"completion":577,"start":2641,"enrollment":15543,"conditions":15544,"interventions":15546},"NCT00496197","Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis",[94],282,[15545],"Candidiasis",[15527,15547,15548],"Diflucan","Vfend",{"trials":15550,"activeCount":103},[],{"intervention":15547,"totalTrials":302,"cells":15552},{"EARLY_PHASE1":15553,"PHASE1":15555,"PHASE2":15557,"PHASE3":15559,"PHASE4":15561,"NA":15567},{"trials":15554,"activeCount":103},[],{"trials":15556,"activeCount":103},[],{"trials":15558,"activeCount":103},[],{"trials":15560,"activeCount":103},[],{"trials":15562,"activeCount":103},[15563],{"nctId":15540,"briefTitle":15541,"status":111,"phases":15564,"primaryCompletion":577,"completion":577,"start":2641,"enrollment":15543,"conditions":15565,"interventions":15566},[94],[15545],[15527,15547,15548],{"trials":15568,"activeCount":103},[],{"intervention":15548,"totalTrials":302,"cells":15570},{"EARLY_PHASE1":15571,"PHASE1":15573,"PHASE2":15575,"PHASE3":15577,"PHASE4":15579,"NA":15585},{"trials":15572,"activeCount":103},[],{"trials":15574,"activeCount":103},[],{"trials":15576,"activeCount":103},[],{"trials":15578,"activeCount":103},[],{"trials":15580,"activeCount":103},[15581],{"nctId":15540,"briefTitle":15541,"status":111,"phases":15582,"primaryCompletion":577,"completion":577,"start":2641,"enrollment":15543,"conditions":15583,"interventions":15584},[94],[15545],[15527,15547,15548],{"trials":15586,"activeCount":103},[],{"intervention":15588,"totalTrials":302,"cells":15589},"tolterodine SR, overactive bladder",{"EARLY_PHASE1":15590,"PHASE1":15592,"PHASE2":15594,"PHASE3":15596,"PHASE4":15598,"NA":15606},{"trials":15591,"activeCount":103},[],{"trials":15593,"activeCount":103},[],{"trials":15595,"activeCount":103},[],{"trials":15597,"activeCount":103},[],{"trials":15599,"activeCount":103},[15600],{"nctId":15601,"briefTitle":15602,"status":111,"phases":15603,"completion":9387,"start":7675,"enrollment":130,"conditions":15604,"interventions":15605},"NCT00143377","Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB",[94],[12776],[15588],{"trials":15607,"activeCount":103},[],{"intervention":15609,"totalTrials":302,"cells":15610},"Dextromethorphan Hydrobromide",{"EARLY_PHASE1":15611,"PHASE1":15613,"PHASE2":15615,"PHASE3":15617,"PHASE4":15619,"NA":15630},{"trials":15612,"activeCount":103},[],{"trials":15614,"activeCount":103},[],{"trials":15616,"activeCount":103},[],{"trials":15618,"activeCount":103},[],{"trials":15620,"activeCount":103},[15621],{"nctId":15622,"briefTitle":15623,"status":168,"phases":15624,"primaryCompletion":15625,"completion":15625,"start":15626,"enrollment":1390,"conditions":15627,"interventions":15629},"NCT02651116","Dextromethorphan Pediatric Acute Cough Study",[94],"2020-03-19","2016-02-25",[15628],"Cough",[15609],{"trials":15631,"activeCount":103},[],{"intervention":15633,"totalTrials":302,"cells":15634},"Sulfasalazine",{"EARLY_PHASE1":15635,"PHASE1":15637,"PHASE2":15639,"PHASE3":15641,"PHASE4":15643,"NA":15651},{"trials":15636,"activeCount":103},[],{"trials":15638,"activeCount":103},[],{"trials":15640,"activeCount":103},[],{"trials":15642,"activeCount":103},[],{"trials":15644,"activeCount":103},[15645],{"nctId":15646,"briefTitle":15647,"status":168,"phases":15648,"primaryCompletion":1248,"completion":1248,"start":577,"enrollment":1087,"conditions":15649,"interventions":15650},"NCT00637780","Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis",[94],[11381],[15633],{"trials":15652,"activeCount":103},[],{"intervention":15654,"totalTrials":302,"cells":15655},"Zavicefta, Ceftazidime-Avibactam",{"EARLY_PHASE1":15656,"PHASE1":15658,"PHASE2":15660,"PHASE3":15662,"PHASE4":15664,"NA":15679},{"trials":15657,"activeCount":103},[],{"trials":15659,"activeCount":103},[],{"trials":15661,"activeCount":103},[],{"trials":15663,"activeCount":103},[],{"trials":15665,"activeCount":103},[15666],{"nctId":15667,"briefTitle":15668,"status":111,"phases":15669,"primaryCompletion":4321,"completion":4321,"start":15670,"enrollment":2240,"conditions":15671,"interventions":15677},"NCT04882085","Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults",[94],"2021-08-26",[15672,15673,15674,15675,15676,13338],"Urinary Tract Infection","Acute Pyelonephritis","Hospital Acquired Pneumonia","Ventilator-associated Pneumonia","Bacteremia",[15654,15678],"Best Available Treatment",{"trials":15680,"activeCount":103},[],{"intervention":15678,"totalTrials":302,"cells":15682},{"EARLY_PHASE1":15683,"PHASE1":15685,"PHASE2":15687,"PHASE3":15689,"PHASE4":15691,"NA":15697},{"trials":15684,"activeCount":103},[],{"trials":15686,"activeCount":103},[],{"trials":15688,"activeCount":103},[],{"trials":15690,"activeCount":103},[],{"trials":15692,"activeCount":103},[15693],{"nctId":15667,"briefTitle":15668,"status":111,"phases":15694,"primaryCompletion":4321,"completion":4321,"start":15670,"enrollment":2240,"conditions":15695,"interventions":15696},[94],[15672,15673,15674,15675,15676,13338],[15654,15678],{"trials":15698,"activeCount":103},[],{"intervention":15700,"totalTrials":302,"cells":15701},"Viagra (Sildenafil Citrate) 100 mg",{"EARLY_PHASE1":15702,"PHASE1":15704,"PHASE2":15706,"PHASE3":15708,"PHASE4":15710,"NA":15719},{"trials":15703,"activeCount":103},[],{"trials":15705,"activeCount":103},[],{"trials":15707,"activeCount":103},[],{"trials":15709,"activeCount":103},[],{"trials":15711,"activeCount":103},[15712],{"nctId":15713,"briefTitle":15714,"status":111,"phases":15715,"primaryCompletion":12004,"completion":12004,"start":15716,"enrollment":8827,"conditions":15717,"interventions":15718},"NCT00143260","Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose",[94],"2005-08",[12375],[15700],{"trials":15720,"activeCount":103},[],{"intervention":15722,"totalTrials":302,"cells":15723},"Tranexamic Acid plus standard of care",{"EARLY_PHASE1":15724,"PHASE1":15726,"PHASE2":15728,"PHASE3":15730,"PHASE4":15732,"NA":15741},{"trials":15725,"activeCount":103},[],{"trials":15727,"activeCount":103},[],{"trials":15729,"activeCount":103},[],{"trials":15731,"activeCount":103},[],{"trials":15733,"activeCount":103},[15734],{"nctId":15735,"briefTitle":15736,"status":111,"phases":15737,"primaryCompletion":577,"completion":577,"start":4222,"enrollment":6245,"conditions":15738,"interventions":15740},"NCT00824564","Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture",[94],[15739],"Femoral Fractures",[15722],{"trials":15742,"activeCount":103},[],{"intervention":12617,"totalTrials":302,"cells":15744},{"EARLY_PHASE1":15745,"PHASE1":15747,"PHASE2":15749,"PHASE3":15751,"PHASE4":15753,"NA":15759},{"trials":15746,"activeCount":103},[],{"trials":15748,"activeCount":103},[],{"trials":15750,"activeCount":103},[],{"trials":15752,"activeCount":103},[],{"trials":15754,"activeCount":103},[15755],{"nctId":12612,"briefTitle":12613,"status":111,"phases":15756,"completion":12004,"start":11736,"enrollment":4755,"conditions":15757,"interventions":15758},[94],[12599],[12617,12610,12569],{"trials":15760,"activeCount":103},[],{"intervention":15762,"totalTrials":302,"cells":15763},"Detrol LA",{"EARLY_PHASE1":15764,"PHASE1":15766,"PHASE2":15768,"PHASE3":15770,"PHASE4":15772,"NA":15783},{"trials":15765,"activeCount":103},[],{"trials":15767,"activeCount":103},[],{"trials":15769,"activeCount":103},[],{"trials":15771,"activeCount":103},[],{"trials":15773,"activeCount":103},[15774],{"nctId":15775,"briefTitle":15776,"status":111,"phases":15777,"primaryCompletion":15778,"completion":15779,"start":2662,"enrollment":130,"conditions":15780,"interventions":15782},"NCT00282932","Detrol LA In Men With Overactive Bladder.",[94],"2007-05-01","2007-05-14",[15781],"Overactive Bladder (OAB)",[15762],{"trials":15784,"activeCount":103},[],{"intervention":15786,"totalTrials":302,"cells":15787},"nelfinavir 1,250 mg twice daily",{"EARLY_PHASE1":15788,"PHASE1":15790,"PHASE2":15792,"PHASE3":15794,"PHASE4":15796,"NA":15807},{"trials":15789,"activeCount":103},[],{"trials":15791,"activeCount":103},[],{"trials":15793,"activeCount":103},[],{"trials":15795,"activeCount":103},[],{"trials":15797,"activeCount":103},[15798],{"nctId":15799,"briefTitle":15800,"status":111,"phases":15801,"primaryCompletion":4615,"completion":4615,"start":9387,"enrollment":1268,"conditions":15802,"interventions":15804},"NCT00141284","An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C",[94],[14469,15803],"Hepatitis C",[15786,15805,15806],"Zidovudine 300 mg twice daily","Lamivudine 150 mg twice daily",{"trials":15808,"activeCount":103},[],{"intervention":15805,"totalTrials":302,"cells":15810},{"EARLY_PHASE1":15811,"PHASE1":15813,"PHASE2":15815,"PHASE3":15817,"PHASE4":15819,"NA":15825},{"trials":15812,"activeCount":103},[],{"trials":15814,"activeCount":103},[],{"trials":15816,"activeCount":103},[],{"trials":15818,"activeCount":103},[],{"trials":15820,"activeCount":103},[15821],{"nctId":15799,"briefTitle":15800,"status":111,"phases":15822,"primaryCompletion":4615,"completion":4615,"start":9387,"enrollment":1268,"conditions":15823,"interventions":15824},[94],[14469,15803],[15786,15805,15806],{"trials":15826,"activeCount":103},[],{"intervention":15806,"totalTrials":302,"cells":15828},{"EARLY_PHASE1":15829,"PHASE1":15831,"PHASE2":15833,"PHASE3":15835,"PHASE4":15837,"NA":15843},{"trials":15830,"activeCount":103},[],{"trials":15832,"activeCount":103},[],{"trials":15834,"activeCount":103},[],{"trials":15836,"activeCount":103},[],{"trials":15838,"activeCount":103},[15839],{"nctId":15799,"briefTitle":15800,"status":111,"phases":15840,"primaryCompletion":4615,"completion":4615,"start":9387,"enrollment":1268,"conditions":15841,"interventions":15842},[94],[14469,15803],[15786,15805,15806],{"trials":15844,"activeCount":103},[],{"intervention":15846,"totalTrials":302,"cells":15847},"Nelfinavir and Omeprazole",{"EARLY_PHASE1":15848,"PHASE1":15850,"PHASE2":15852,"PHASE3":15854,"PHASE4":15856,"NA":15864},{"trials":15849,"activeCount":103},[],{"trials":15851,"activeCount":103},[],{"trials":15853,"activeCount":103},[],{"trials":15855,"activeCount":103},[],{"trials":15857,"activeCount":103},[15858],{"nctId":15859,"briefTitle":15860,"status":111,"phases":15861,"completion":2662,"start":8170,"enrollment":2159,"conditions":15862,"interventions":15863},"NCT00251030","A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects",[94],[19],[15846],{"trials":15865,"activeCount":103},[],{"intervention":15867,"totalTrials":302,"cells":15868},"Tramadol Hydrochloride 50mg",{"EARLY_PHASE1":15869,"PHASE1":15871,"PHASE2":15873,"PHASE3":15875,"PHASE4":15877,"NA":15888},{"trials":15870,"activeCount":103},[],{"trials":15872,"activeCount":103},[],{"trials":15874,"activeCount":103},[],{"trials":15876,"activeCount":103},[],{"trials":15878,"activeCount":103},[15879],{"nctId":15880,"briefTitle":15881,"status":111,"phases":15882,"primaryCompletion":4615,"start":6457,"enrollment":15883,"conditions":15884,"interventions":15886},"NCT00290901","Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.",[94],754,[15885],"Back Pain",[15867,15887],"Celebrex 200mg",{"trials":15889,"activeCount":103},[],{"intervention":15887,"totalTrials":302,"cells":15891},{"EARLY_PHASE1":15892,"PHASE1":15894,"PHASE2":15896,"PHASE3":15898,"PHASE4":15900,"NA":15906},{"trials":15893,"activeCount":103},[],{"trials":15895,"activeCount":103},[],{"trials":15897,"activeCount":103},[],{"trials":15899,"activeCount":103},[],{"trials":15901,"activeCount":103},[15902],{"nctId":15880,"briefTitle":15881,"status":111,"phases":15903,"primaryCompletion":4615,"start":6457,"enrollment":15883,"conditions":15904,"interventions":15905},[94],[15885],[15867,15887],{"trials":15907,"activeCount":103},[],{"intervention":15909,"totalTrials":302,"cells":15910},"CP-690,500 5 mg",{"EARLY_PHASE1":15911,"PHASE1":15913,"PHASE2":15915,"PHASE3":15917,"PHASE4":15919,"NA":15930},{"trials":15912,"activeCount":103},[],{"trials":15914,"activeCount":103},[],{"trials":15916,"activeCount":103},[],{"trials":15918,"activeCount":103},[],{"trials":15920,"activeCount":103},[15921],{"nctId":15922,"briefTitle":15923,"status":168,"phases":15924,"primaryCompletion":15925,"completion":10623,"start":15926,"enrollment":12373,"conditions":15927,"interventions":15928},"NCT03281304","A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission",[94],"2020-02-14","2017-11-16",[1532],[15909,15929],"CP-690,550 10 mg",{"trials":15931,"activeCount":103},[],{"intervention":15929,"totalTrials":302,"cells":15933},{"EARLY_PHASE1":15934,"PHASE1":15936,"PHASE2":15938,"PHASE3":15940,"PHASE4":15942,"NA":15948},{"trials":15935,"activeCount":103},[],{"trials":15937,"activeCount":103},[],{"trials":15939,"activeCount":103},[],{"trials":15941,"activeCount":103},[],{"trials":15943,"activeCount":103},[15944],{"nctId":15922,"briefTitle":15923,"status":168,"phases":15945,"primaryCompletion":15925,"completion":10623,"start":15926,"enrollment":12373,"conditions":15946,"interventions":15947},[94],[1532],[15909,15929],{"trials":15949,"activeCount":103},[],{"intervention":15951,"totalTrials":302,"cells":15952},"Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide",{"EARLY_PHASE1":15953,"PHASE1":15955,"PHASE2":15957,"PHASE3":15959,"PHASE4":15961,"NA":15970},{"trials":15954,"activeCount":103},[],{"trials":15956,"activeCount":103},[],{"trials":15958,"activeCount":103},[],{"trials":15960,"activeCount":103},[],{"trials":15962,"activeCount":103},[15963],{"nctId":15964,"briefTitle":15965,"status":111,"phases":15966,"primaryCompletion":4646,"completion":4646,"start":3610,"enrollment":4360,"conditions":15967,"interventions":15969},"NCT00855738","A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice",[94],[15968],"Focal Epilepsy",[15951],{"trials":15971,"activeCount":103},[],{"intervention":15973,"totalTrials":302,"cells":15974},"EMBEDA™ (morphine sulfate\u002Fnaltrexone hydrochloride) crush",{"EARLY_PHASE1":15975,"PHASE1":15977,"PHASE2":15979,"PHASE3":15981,"PHASE4":15983,"NA":15992},{"trials":15976,"activeCount":103},[],{"trials":15978,"activeCount":103},[],{"trials":15980,"activeCount":103},[],{"trials":15982,"activeCount":103},[],{"trials":15984,"activeCount":103},[15985],{"nctId":15986,"briefTitle":15987,"status":168,"phases":15988,"primaryCompletion":524,"completion":524,"start":4206,"enrollment":562,"conditions":15989,"interventions":15990},"NCT01100437","Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients",[94],[13120],[15973,15991],"EMBEDA™ (morphine sulfate\u002Fnaltrexone hydrochloride) whole",{"trials":15993,"activeCount":103},[],{"intervention":15991,"totalTrials":302,"cells":15995},{"EARLY_PHASE1":15996,"PHASE1":15998,"PHASE2":16000,"PHASE3":16002,"PHASE4":16004,"NA":16010},{"trials":15997,"activeCount":103},[],{"trials":15999,"activeCount":103},[],{"trials":16001,"activeCount":103},[],{"trials":16003,"activeCount":103},[],{"trials":16005,"activeCount":103},[16006],{"nctId":15986,"briefTitle":15987,"status":168,"phases":16007,"primaryCompletion":524,"completion":524,"start":4206,"enrollment":562,"conditions":16008,"interventions":16009},[94],[13120],[15973,15991],{"trials":16011,"activeCount":103},[],{"intervention":16013,"totalTrials":302,"cells":16014},"Zithromax",{"EARLY_PHASE1":16015,"PHASE1":16017,"PHASE2":16019,"PHASE3":16021,"PHASE4":16023,"NA":16033},{"trials":16016,"activeCount":103},[],{"trials":16018,"activeCount":103},[],{"trials":16020,"activeCount":103},[],{"trials":16022,"activeCount":103},[],{"trials":16024,"activeCount":103},[16025],{"nctId":16026,"briefTitle":16027,"status":111,"phases":16028,"completion":11387,"start":9388,"enrollment":1621,"conditions":16029,"interventions":16031},"NCT00643539","Multicenter, Open, Randomized Comparative Trial To Compare The Efficacy Of Azithromycin Versus Amoxicillin In Children With Strep Throat",[94],[16030],"Tonsillitis",[16013,16032],"Clamoxyl",{"trials":16034,"activeCount":103},[],{"intervention":16032,"totalTrials":302,"cells":16036},{"EARLY_PHASE1":16037,"PHASE1":16039,"PHASE2":16041,"PHASE3":16043,"PHASE4":16045,"NA":16051},{"trials":16038,"activeCount":103},[],{"trials":16040,"activeCount":103},[],{"trials":16042,"activeCount":103},[],{"trials":16044,"activeCount":103},[],{"trials":16046,"activeCount":103},[16047],{"nctId":16026,"briefTitle":16027,"status":111,"phases":16048,"completion":11387,"start":9388,"enrollment":1621,"conditions":16049,"interventions":16050},[94],[16030],[16013,16032],{"trials":16052,"activeCount":103},[],{"intervention":16054,"totalTrials":302,"cells":16055},"Pravastatin",{"EARLY_PHASE1":16056,"PHASE1":16058,"PHASE2":16060,"PHASE3":16062,"PHASE4":16064,"NA":16074},{"trials":16057,"activeCount":103},[],{"trials":16059,"activeCount":103},[],{"trials":16061,"activeCount":103},[],{"trials":16063,"activeCount":103},[],{"trials":16065,"activeCount":103},[16066],{"nctId":16067,"briefTitle":16068,"status":111,"phases":16069,"completion":12424,"start":16070,"enrollment":130,"conditions":16071,"interventions":16073},"NCT00380939","This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.",[94],"1999-04",[16072],"Coronary Arteriosclerosis",[13004,16054],{"trials":16075,"activeCount":103},[],{"intervention":16077,"totalTrials":302,"cells":16078},"Crisaborole ointment, 2%",{"EARLY_PHASE1":16079,"PHASE1":16081,"PHASE2":16083,"PHASE3":16085,"PHASE4":16087,"NA":16101},{"trials":16080,"activeCount":103},[],{"trials":16082,"activeCount":103},[],{"trials":16084,"activeCount":103},[],{"trials":16086,"activeCount":103},[],{"trials":16088,"activeCount":103},[16089],{"nctId":16090,"briefTitle":16091,"status":168,"phases":16092,"primaryCompletion":16093,"completion":16093,"start":16094,"enrollment":16095,"conditions":16096,"interventions":16097},"NCT03539601","A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD",[94],"2020-12-11","2018-04-27",237,[1589],[16077,16098,16099,16100],"Hydrocortisone butyrate cream, 0.1%","Pimecrolimus cream, 1%","Crisaborole Vehicle",{"trials":16102,"activeCount":103},[],{"intervention":16098,"totalTrials":302,"cells":16104},{"EARLY_PHASE1":16105,"PHASE1":16107,"PHASE2":16109,"PHASE3":16111,"PHASE4":16113,"NA":16119},{"trials":16106,"activeCount":103},[],{"trials":16108,"activeCount":103},[],{"trials":16110,"activeCount":103},[],{"trials":16112,"activeCount":103},[],{"trials":16114,"activeCount":103},[16115],{"nctId":16090,"briefTitle":16091,"status":168,"phases":16116,"primaryCompletion":16093,"completion":16093,"start":16094,"enrollment":16095,"conditions":16117,"interventions":16118},[94],[1589],[16077,16098,16099,16100],{"trials":16120,"activeCount":103},[],{"intervention":16099,"totalTrials":302,"cells":16122},{"EARLY_PHASE1":16123,"PHASE1":16125,"PHASE2":16127,"PHASE3":16129,"PHASE4":16131,"NA":16137},{"trials":16124,"activeCount":103},[],{"trials":16126,"activeCount":103},[],{"trials":16128,"activeCount":103},[],{"trials":16130,"activeCount":103},[],{"trials":16132,"activeCount":103},[16133],{"nctId":16090,"briefTitle":16091,"status":168,"phases":16134,"primaryCompletion":16093,"completion":16093,"start":16094,"enrollment":16095,"conditions":16135,"interventions":16136},[94],[1589],[16077,16098,16099,16100],{"trials":16138,"activeCount":103},[],{"intervention":16100,"totalTrials":302,"cells":16140},{"EARLY_PHASE1":16141,"PHASE1":16143,"PHASE2":16145,"PHASE3":16147,"PHASE4":16149,"NA":16155},{"trials":16142,"activeCount":103},[],{"trials":16144,"activeCount":103},[],{"trials":16146,"activeCount":103},[],{"trials":16148,"activeCount":103},[],{"trials":16150,"activeCount":103},[16151],{"nctId":16090,"briefTitle":16091,"status":168,"phases":16152,"primaryCompletion":16093,"completion":16093,"start":16094,"enrollment":16095,"conditions":16153,"interventions":16154},[94],[1589],[16077,16098,16099,16100],{"trials":16156,"activeCount":103},[],{"intervention":16158,"totalTrials":302,"cells":16159},"FSME-IMMUN 0.5 ml",{"EARLY_PHASE1":16160,"PHASE1":16162,"PHASE2":16164,"PHASE3":16166,"PHASE4":16168,"NA":16178},{"trials":16161,"activeCount":103},[],{"trials":16163,"activeCount":103},[],{"trials":16165,"activeCount":103},[],{"trials":16167,"activeCount":103},[],{"trials":16169,"activeCount":103},[16170],{"nctId":16171,"briefTitle":16172,"status":111,"phases":16173,"primaryCompletion":4438,"completion":4438,"start":3334,"enrollment":16174,"conditions":16175,"interventions":16177},"NCT01582698","TBE Seropersistence up to 10 Years After First Booster in Adults",[94],243,[16176],"Tick-borne Encephalitis (TBE)",[16158],{"trials":16179,"activeCount":103},[],{"intervention":16181,"totalTrials":302,"cells":16182},"Fesoterodine 8mg",{"EARLY_PHASE1":16183,"PHASE1":16185,"PHASE2":16187,"PHASE3":16189,"PHASE4":16191,"NA":16201},{"trials":16184,"activeCount":103},[],{"trials":16186,"activeCount":103},[],{"trials":16188,"activeCount":103},[],{"trials":16190,"activeCount":103},[],{"trials":16192,"activeCount":103},[16193],{"nctId":16194,"briefTitle":16195,"status":111,"phases":16196,"primaryCompletion":3345,"completion":3345,"start":11170,"enrollment":16197,"conditions":16198,"interventions":16199},"NCT01302067","A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine",[94],2012,[12489],[16181,16200],"Fesoterodine 4mg",{"trials":16202,"activeCount":103},[],{"intervention":16200,"totalTrials":302,"cells":16204},{"EARLY_PHASE1":16205,"PHASE1":16207,"PHASE2":16209,"PHASE3":16211,"PHASE4":16213,"NA":16219},{"trials":16206,"activeCount":103},[],{"trials":16208,"activeCount":103},[],{"trials":16210,"activeCount":103},[],{"trials":16212,"activeCount":103},[],{"trials":16214,"activeCount":103},[16215],{"nctId":16194,"briefTitle":16195,"status":111,"phases":16216,"primaryCompletion":3345,"completion":3345,"start":11170,"enrollment":16197,"conditions":16217,"interventions":16218},[94],[12489],[16181,16200],{"trials":16220,"activeCount":103},[],{"intervention":16222,"totalTrials":302,"cells":16223},"Desvenlafaxine Succinate Sustained-Release Formulation 50 mg",{"EARLY_PHASE1":16224,"PHASE1":16226,"PHASE2":16228,"PHASE3":16230,"PHASE4":16232,"NA":16242},{"trials":16225,"activeCount":103},[],{"trials":16227,"activeCount":103},[],{"trials":16229,"activeCount":103},[],{"trials":16231,"activeCount":103},[],{"trials":16233,"activeCount":103},[16234],{"nctId":16235,"briefTitle":16236,"status":111,"phases":16237,"primaryCompletion":4666,"completion":4666,"start":3642,"enrollment":16238,"conditions":16239,"interventions":16240},"NCT01056289","Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)",[94],480,[6321],[16222,16241],"Desvenlafaxine Succinate Sustained-Release Formulation 25 mg",{"trials":16243,"activeCount":103},[],{"intervention":16241,"totalTrials":302,"cells":16245},{"EARLY_PHASE1":16246,"PHASE1":16248,"PHASE2":16250,"PHASE3":16252,"PHASE4":16254,"NA":16260},{"trials":16247,"activeCount":103},[],{"trials":16249,"activeCount":103},[],{"trials":16251,"activeCount":103},[],{"trials":16253,"activeCount":103},[],{"trials":16255,"activeCount":103},[16256],{"nctId":16235,"briefTitle":16236,"status":111,"phases":16257,"primaryCompletion":4666,"completion":4666,"start":3642,"enrollment":16238,"conditions":16258,"interventions":16259},[94],[6321],[16222,16241],{"trials":16261,"activeCount":103},[],{"intervention":16263,"totalTrials":302,"cells":16264},"Ultracet",{"EARLY_PHASE1":16265,"PHASE1":16267,"PHASE2":16269,"PHASE3":16271,"PHASE4":16273,"NA":16284},{"trials":16266,"activeCount":103},[],{"trials":16268,"activeCount":103},[],{"trials":16270,"activeCount":103},[],{"trials":16272,"activeCount":103},[],{"trials":16274,"activeCount":103},[16275],{"nctId":16276,"briefTitle":16277,"status":111,"phases":16278,"primaryCompletion":16279,"completion":16279,"start":16280,"enrollment":2240,"conditions":16281,"interventions":16282},"NCT03803371","Bioequivalence Study of Tramadol Hydrochloride \u002FParacetamol Tablets Versus Ultracet Tablets",[94],"2019-06-28","2019-03-26",[16],[16263,16283],"Tramadol hydrochloride 37.5 mg\u002FParacetamol 325 mg tablets -",{"trials":16285,"activeCount":103},[],{"intervention":16283,"totalTrials":302,"cells":16287},{"EARLY_PHASE1":16288,"PHASE1":16290,"PHASE2":16292,"PHASE3":16294,"PHASE4":16296,"NA":16302},{"trials":16289,"activeCount":103},[],{"trials":16291,"activeCount":103},[],{"trials":16293,"activeCount":103},[],{"trials":16295,"activeCount":103},[],{"trials":16297,"activeCount":103},[16298],{"nctId":16276,"briefTitle":16277,"status":111,"phases":16299,"primaryCompletion":16279,"completion":16279,"start":16280,"enrollment":2240,"conditions":16300,"interventions":16301},[94],[16],[16263,16283],{"trials":16303,"activeCount":103},[],{"intervention":16305,"totalTrials":302,"cells":16306},"Non-selective NSAIDS",{"EARLY_PHASE1":16307,"PHASE1":16309,"PHASE2":16311,"PHASE3":16313,"PHASE4":16315,"NA":16325},{"trials":16308,"activeCount":103},[],{"trials":16310,"activeCount":103},[],{"trials":16312,"activeCount":103},[],{"trials":16314,"activeCount":103},[],{"trials":16316,"activeCount":103},[16317],{"nctId":16318,"briefTitle":16319,"status":111,"phases":16320,"primaryCompletion":3314,"completion":3314,"start":3610,"enrollment":16321,"conditions":16322,"interventions":16324},"NCT00446797","Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain",[94],278,[16323],"Ankle Sprain",[16305,3079],{"trials":16326,"activeCount":103},[],{"intervention":16328,"totalTrials":302,"cells":16329},"Magnex (Sulbactam Sodium\u002FCefoperazone Sodium 1:1) Pfizer Ltd.",{"EARLY_PHASE1":16330,"PHASE1":16332,"PHASE2":16334,"PHASE3":16336,"PHASE4":16338,"NA":16350},{"trials":16331,"activeCount":103},[],{"trials":16333,"activeCount":103},[],{"trials":16335,"activeCount":103},[],{"trials":16337,"activeCount":103},[],{"trials":16339,"activeCount":103},[16340],{"nctId":16341,"briefTitle":16342,"status":111,"phases":16343,"completion":4657,"start":13035,"enrollment":16344,"conditions":16345,"interventions":16346},"NCT00360607","A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections",[94],307,[11494],[16328,16347,16348,16349],"Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited","Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.","Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.",{"trials":16351,"activeCount":103},[],{"intervention":16347,"totalTrials":302,"cells":16353},{"EARLY_PHASE1":16354,"PHASE1":16356,"PHASE2":16358,"PHASE3":16360,"PHASE4":16362,"NA":16368},{"trials":16355,"activeCount":103},[],{"trials":16357,"activeCount":103},[],{"trials":16359,"activeCount":103},[],{"trials":16361,"activeCount":103},[],{"trials":16363,"activeCount":103},[16364],{"nctId":16341,"briefTitle":16342,"status":111,"phases":16365,"completion":4657,"start":13035,"enrollment":16344,"conditions":16366,"interventions":16367},[94],[11494],[16328,16347,16348,16349],{"trials":16369,"activeCount":103},[],{"intervention":16348,"totalTrials":302,"cells":16371},{"EARLY_PHASE1":16372,"PHASE1":16374,"PHASE2":16376,"PHASE3":16378,"PHASE4":16380,"NA":16386},{"trials":16373,"activeCount":103},[],{"trials":16375,"activeCount":103},[],{"trials":16377,"activeCount":103},[],{"trials":16379,"activeCount":103},[],{"trials":16381,"activeCount":103},[16382],{"nctId":16341,"briefTitle":16342,"status":111,"phases":16383,"completion":4657,"start":13035,"enrollment":16344,"conditions":16384,"interventions":16385},[94],[11494],[16328,16347,16348,16349],{"trials":16387,"activeCount":103},[],{"intervention":16349,"totalTrials":302,"cells":16389},{"EARLY_PHASE1":16390,"PHASE1":16392,"PHASE2":16394,"PHASE3":16396,"PHASE4":16398,"NA":16404},{"trials":16391,"activeCount":103},[],{"trials":16393,"activeCount":103},[],{"trials":16395,"activeCount":103},[],{"trials":16397,"activeCount":103},[],{"trials":16399,"activeCount":103},[16400],{"nctId":16341,"briefTitle":16342,"status":111,"phases":16401,"completion":4657,"start":13035,"enrollment":16344,"conditions":16402,"interventions":16403},[94],[11494],[16328,16347,16348,16349],{"trials":16405,"activeCount":103},[],{"intervention":16407,"totalTrials":302,"cells":16408},"Ketoprofen 100mg",{"EARLY_PHASE1":16409,"PHASE1":16411,"PHASE2":16413,"PHASE3":16415,"PHASE4":16417,"NA":16426},{"trials":16410,"activeCount":103},[],{"trials":16412,"activeCount":103},[],{"trials":16414,"activeCount":103},[],{"trials":16416,"activeCount":103},[],{"trials":16418,"activeCount":103},[16419],{"nctId":16420,"briefTitle":16421,"status":111,"phases":16422,"primaryCompletion":4646,"completion":4646,"start":3643,"enrollment":11719,"conditions":16423,"interventions":16424},"NCT00553605","Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic",[94],[34],[16407,16425],"Parecoxib 40mg",{"trials":16427,"activeCount":103},[],{"intervention":16425,"totalTrials":302,"cells":16429},{"EARLY_PHASE1":16430,"PHASE1":16432,"PHASE2":16434,"PHASE3":16436,"PHASE4":16438,"NA":16444},{"trials":16431,"activeCount":103},[],{"trials":16433,"activeCount":103},[],{"trials":16435,"activeCount":103},[],{"trials":16437,"activeCount":103},[],{"trials":16439,"activeCount":103},[16440],{"nctId":16420,"briefTitle":16421,"status":111,"phases":16441,"primaryCompletion":4646,"completion":4646,"start":3643,"enrollment":11719,"conditions":16442,"interventions":16443},[94],[34],[16407,16425],{"trials":16445,"activeCount":103},[],{"intervention":16447,"totalTrials":302,"cells":16448},"dexmedetomidine",{"EARLY_PHASE1":16449,"PHASE1":16451,"PHASE2":16453,"PHASE3":16455,"PHASE4":16457,"NA":16469},{"trials":16450,"activeCount":103},[],{"trials":16452,"activeCount":103},[],{"trials":16454,"activeCount":103},[],{"trials":16456,"activeCount":103},[],{"trials":16458,"activeCount":103},[16459],{"nctId":16460,"briefTitle":16461,"status":111,"phases":16462,"primaryCompletion":3403,"completion":16463,"start":16464,"enrollment":1326,"conditions":16465,"interventions":16467},"NCT04237792","Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to \u003C17 Years Undergoing MRI Scans",[94],"2021-11-30","2020-02-18",[16466],"MRI Sedation",[16447,16468],"propofol",{"trials":16470,"activeCount":103},[],{"intervention":16468,"totalTrials":302,"cells":16472},{"EARLY_PHASE1":16473,"PHASE1":16475,"PHASE2":16477,"PHASE3":16479,"PHASE4":16481,"NA":16487},{"trials":16474,"activeCount":103},[],{"trials":16476,"activeCount":103},[],{"trials":16478,"activeCount":103},[],{"trials":16480,"activeCount":103},[],{"trials":16482,"activeCount":103},[16483],{"nctId":16460,"briefTitle":16461,"status":111,"phases":16484,"primaryCompletion":3403,"completion":16463,"start":16464,"enrollment":1326,"conditions":16485,"interventions":16486},[94],[16466],[16447,16468],{"trials":16488,"activeCount":103},[],{"intervention":13808,"totalTrials":302,"cells":16490},{"EARLY_PHASE1":16491,"PHASE1":16493,"PHASE2":16495,"PHASE3":16497,"PHASE4":16499,"NA":16505},{"trials":16492,"activeCount":103},[],{"trials":16494,"activeCount":103},[],{"trials":16496,"activeCount":103},[],{"trials":16498,"activeCount":103},[],{"trials":16500,"activeCount":103},[16501],{"nctId":13802,"briefTitle":13803,"status":111,"phases":16502,"completion":4616,"start":7676,"enrollment":1702,"conditions":16503,"interventions":16504},[94],[13806],[13808,13809,13810,13811,13812],{"trials":16506,"activeCount":103},[],{"intervention":13810,"totalTrials":302,"cells":16508},{"EARLY_PHASE1":16509,"PHASE1":16511,"PHASE2":16513,"PHASE3":16515,"PHASE4":16517,"NA":16523},{"trials":16510,"activeCount":103},[],{"trials":16512,"activeCount":103},[],{"trials":16514,"activeCount":103},[],{"trials":16516,"activeCount":103},[],{"trials":16518,"activeCount":103},[16519],{"nctId":13802,"briefTitle":13803,"status":111,"phases":16520,"completion":4616,"start":7676,"enrollment":1702,"conditions":16521,"interventions":16522},[94],[13806],[13808,13809,13810,13811,13812],{"trials":16524,"activeCount":103},[],{"intervention":13811,"totalTrials":302,"cells":16526},{"EARLY_PHASE1":16527,"PHASE1":16529,"PHASE2":16531,"PHASE3":16533,"PHASE4":16535,"NA":16541},{"trials":16528,"activeCount":103},[],{"trials":16530,"activeCount":103},[],{"trials":16532,"activeCount":103},[],{"trials":16534,"activeCount":103},[],{"trials":16536,"activeCount":103},[16537],{"nctId":13802,"briefTitle":13803,"status":111,"phases":16538,"completion":4616,"start":7676,"enrollment":1702,"conditions":16539,"interventions":16540},[94],[13806],[13808,13809,13810,13811,13812],{"trials":16542,"activeCount":103},[],{"intervention":13812,"totalTrials":302,"cells":16544},{"EARLY_PHASE1":16545,"PHASE1":16547,"PHASE2":16549,"PHASE3":16551,"PHASE4":16553,"NA":16559},{"trials":16546,"activeCount":103},[],{"trials":16548,"activeCount":103},[],{"trials":16550,"activeCount":103},[],{"trials":16552,"activeCount":103},[],{"trials":16554,"activeCount":103},[16555],{"nctId":13802,"briefTitle":13803,"status":111,"phases":16556,"completion":4616,"start":7676,"enrollment":1702,"conditions":16557,"interventions":16558},[94],[13806],[13808,13809,13810,13811,13812],{"trials":16560,"activeCount":103},[],{"intervention":16562,"totalTrials":302,"cells":16563},"anidulafungin and voriconazole",{"EARLY_PHASE1":16564,"PHASE1":16566,"PHASE2":16568,"PHASE3":16570,"PHASE4":16572,"NA":16582},{"trials":16565,"activeCount":103},[],{"trials":16567,"activeCount":103},[],{"trials":16569,"activeCount":103},[],{"trials":16571,"activeCount":103},[],{"trials":16573,"activeCount":103},[16574],{"nctId":16575,"briefTitle":16576,"status":111,"phases":16577,"primaryCompletion":4665,"completion":4665,"start":11291,"enrollment":1509,"conditions":16578,"interventions":16581},"NCT00940017","A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects",[94],[16579,16580],"Aspergillosis","Candidemia",[16562],{"trials":16583,"activeCount":103},[],{"intervention":16585,"totalTrials":302,"cells":16586},"Atorvastatin and Omega-3 fatty acids",{"EARLY_PHASE1":16587,"PHASE1":16589,"PHASE2":16591,"PHASE3":16593,"PHASE4":16595,"NA":16604},{"trials":16588,"activeCount":103},[],{"trials":16590,"activeCount":103},[],{"trials":16592,"activeCount":103},[],{"trials":16594,"activeCount":103},[],{"trials":16596,"activeCount":103},[16597],{"nctId":16598,"briefTitle":16599,"status":111,"phases":16600,"completion":12395,"start":12774,"enrollment":16601,"conditions":16602,"interventions":16603},"NCT00141232","Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes",[94],810,[2800],[16585],{"trials":16605,"activeCount":103},[],{"intervention":11749,"totalTrials":302,"cells":16607},{"EARLY_PHASE1":16608,"PHASE1":16610,"PHASE2":16612,"PHASE3":16614,"PHASE4":16616,"NA":16622},{"trials":16609,"activeCount":103},[],{"trials":16611,"activeCount":103},[],{"trials":16613,"activeCount":103},[],{"trials":16615,"activeCount":103},[],{"trials":16617,"activeCount":103},[16618],{"nctId":11742,"briefTitle":11743,"status":111,"phases":16619,"completion":11387,"start":3073,"enrollment":11745,"conditions":16620,"interventions":16621},[94],[11747],[11749,11390],{"trials":16623,"activeCount":103},[],{"intervention":16625,"totalTrials":302,"cells":16626},"desvenlafaxine succinate sustained-release 50 mg\u002Fday",{"EARLY_PHASE1":16627,"PHASE1":16629,"PHASE2":16631,"PHASE3":16633,"PHASE4":16635,"NA":16645},{"trials":16628,"activeCount":103},[],{"trials":16630,"activeCount":103},[],{"trials":16632,"activeCount":103},[],{"trials":16634,"activeCount":103},[],{"trials":16636,"activeCount":103},[16637],{"nctId":16638,"briefTitle":16639,"status":111,"phases":16640,"primaryCompletion":540,"completion":569,"start":114,"enrollment":16641,"conditions":16642,"interventions":16643},"NCT01432457","Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)",[94],924,[6321],[16625,16644],"desvenlafaxine succinate sustained-release 100 mg\u002Fday",{"trials":16646,"activeCount":103},[],{"intervention":16644,"totalTrials":302,"cells":16648},{"EARLY_PHASE1":16649,"PHASE1":16651,"PHASE2":16653,"PHASE3":16655,"PHASE4":16657,"NA":16663},{"trials":16650,"activeCount":103},[],{"trials":16652,"activeCount":103},[],{"trials":16654,"activeCount":103},[],{"trials":16656,"activeCount":103},[],{"trials":16658,"activeCount":103},[16659],{"nctId":16638,"briefTitle":16639,"status":111,"phases":16660,"primaryCompletion":540,"completion":569,"start":114,"enrollment":16641,"conditions":16661,"interventions":16662},[94],[6321],[16625,16644],{"trials":16664,"activeCount":103},[],{"intervention":16666,"totalTrials":302,"cells":16667},"Diclofenac + Omeprazole",{"EARLY_PHASE1":16668,"PHASE1":16670,"PHASE2":16672,"PHASE3":16674,"PHASE4":16676,"NA":16685},{"trials":16669,"activeCount":103},[],{"trials":16671,"activeCount":103},[],{"trials":16673,"activeCount":103},[],{"trials":16675,"activeCount":103},[],{"trials":16677,"activeCount":103},[16678],{"nctId":16679,"briefTitle":16680,"status":111,"phases":16681,"primaryCompletion":11014,"completion":11014,"start":9387,"enrollment":16682,"conditions":16683,"interventions":16684},"NCT00141102","Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis",[94],4484,[11282,4514],[3079,16666],{"trials":16686,"activeCount":103},[],{"intervention":16688,"totalTrials":302,"cells":16689},"methylphenidate HCl ERCT",{"EARLY_PHASE1":16690,"PHASE1":16692,"PHASE2":16694,"PHASE3":16696,"PHASE4":16698,"NA":16708},{"trials":16691,"activeCount":103},[],{"trials":16693,"activeCount":103},[],{"trials":16695,"activeCount":103},[],{"trials":16697,"activeCount":103},[],{"trials":16699,"activeCount":103},[16700],{"nctId":16701,"briefTitle":16702,"status":649,"phases":16703,"primaryCompletion":4776,"completion":4776,"start":16704,"enrollment":103,"conditions":16705,"interventions":16707},"NCT03546400","Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.",[94],"2018-09-25",[16706],"Attention Deficit Hyperactivity Disorder (ADHD)",[16688],{"trials":16709,"activeCount":103},[],{"intervention":16711,"totalTrials":302,"cells":16712},"Ibuprofen plus Omeprazole",{"EARLY_PHASE1":16713,"PHASE1":16715,"PHASE2":16717,"PHASE3":16719,"PHASE4":16721,"NA":16731},{"trials":16714,"activeCount":103},[],{"trials":16716,"activeCount":103},[],{"trials":16718,"activeCount":103},[],{"trials":16720,"activeCount":103},[],{"trials":16722,"activeCount":103},[16723],{"nctId":16724,"briefTitle":16725,"status":111,"phases":16726,"completion":4398,"start":11736,"enrollment":16727,"conditions":16728,"interventions":16730},"NCT00640809","Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole",[94],408,[16729],"Bowel Diseases, Inflammatory",[3079,16711],{"trials":16732,"activeCount":103},[],{"intervention":16734,"totalTrials":302,"cells":16735},"quinapril 20 mg",{"EARLY_PHASE1":16736,"PHASE1":16738,"PHASE2":16740,"PHASE3":16742,"PHASE4":16744,"NA":16754},{"trials":16737,"activeCount":103},[],{"trials":16739,"activeCount":103},[],{"trials":16741,"activeCount":103},[],{"trials":16743,"activeCount":103},[],{"trials":16745,"activeCount":103},[16746],{"nctId":16747,"briefTitle":16748,"status":111,"phases":16749,"completion":13902,"start":9388,"enrollment":162,"conditions":16750,"interventions":16751},"NCT00651287","A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension",[94],[13280],[16734,16752,16753],"quinapril 20 mg plus hydrochlorothiazide 12.5 mg","quinapril 40 mg",{"trials":16755,"activeCount":103},[],{"intervention":16752,"totalTrials":302,"cells":16757},{"EARLY_PHASE1":16758,"PHASE1":16760,"PHASE2":16762,"PHASE3":16764,"PHASE4":16766,"NA":16772},{"trials":16759,"activeCount":103},[],{"trials":16761,"activeCount":103},[],{"trials":16763,"activeCount":103},[],{"trials":16765,"activeCount":103},[],{"trials":16767,"activeCount":103},[16768],{"nctId":16747,"briefTitle":16748,"status":111,"phases":16769,"completion":13902,"start":9388,"enrollment":162,"conditions":16770,"interventions":16771},[94],[13280],[16734,16752,16753],{"trials":16773,"activeCount":103},[],{"intervention":16753,"totalTrials":302,"cells":16775},{"EARLY_PHASE1":16776,"PHASE1":16778,"PHASE2":16780,"PHASE3":16782,"PHASE4":16784,"NA":16790},{"trials":16777,"activeCount":103},[],{"trials":16779,"activeCount":103},[],{"trials":16781,"activeCount":103},[],{"trials":16783,"activeCount":103},[],{"trials":16785,"activeCount":103},[16786],{"nctId":16747,"briefTitle":16748,"status":111,"phases":16787,"completion":13902,"start":9388,"enrollment":162,"conditions":16788,"interventions":16789},[94],[13280],[16734,16752,16753],{"trials":16791,"activeCount":103},[],{"intervention":11070,"totalTrials":302,"cells":16793},{"EARLY_PHASE1":16794,"PHASE1":16796,"PHASE2":16798,"PHASE3":16800,"PHASE4":16802,"NA":16808},{"trials":16795,"activeCount":103},[],{"trials":16797,"activeCount":103},[],{"trials":16799,"activeCount":103},[],{"trials":16801,"activeCount":103},[],{"trials":16803,"activeCount":103},[16804],{"nctId":11064,"briefTitle":11065,"status":111,"phases":16805,"primaryCompletion":4590,"completion":4590,"start":4531,"enrollment":11067,"conditions":16806,"interventions":16807},[94],[11027],[2555,11070,11071,2555,11070,11072,2555,11070,11071,2555,11070,11072,2555,11070],{"trials":16809,"activeCount":103},[],{"intervention":16811,"totalTrials":302,"cells":16812},"Doxazosin gastrointestinal therapeutic system",{"EARLY_PHASE1":16813,"PHASE1":16815,"PHASE2":16817,"PHASE3":16819,"PHASE4":16821,"NA":16829},{"trials":16814,"activeCount":103},[],{"trials":16816,"activeCount":103},[],{"trials":16818,"activeCount":103},[],{"trials":16820,"activeCount":103},[],{"trials":16822,"activeCount":103},[16823],{"nctId":16824,"briefTitle":16825,"status":111,"phases":16826,"primaryCompletion":11512,"completion":11512,"start":11676,"enrollment":13215,"conditions":16827,"interventions":16828},"NCT00646841","Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients",[94],[13280],[16811],{"trials":16830,"activeCount":103},[],{"intervention":11534,"totalTrials":302,"cells":16832},{"EARLY_PHASE1":16833,"PHASE1":16835,"PHASE2":16837,"PHASE3":16839,"PHASE4":16841,"NA":16847},{"trials":16834,"activeCount":103},[],{"trials":16836,"activeCount":103},[],{"trials":16838,"activeCount":103},[],{"trials":16840,"activeCount":103},[],{"trials":16842,"activeCount":103},[16843],{"nctId":11529,"briefTitle":11530,"status":111,"phases":16844,"primaryCompletion":11170,"completion":11170,"start":11170,"enrollment":1509,"conditions":16845,"interventions":16846},[94],[16],[11534,11072],{"trials":16848,"activeCount":103},[],{"intervention":13261,"totalTrials":302,"cells":16850},{"EARLY_PHASE1":16851,"PHASE1":16853,"PHASE2":16855,"PHASE3":16857,"PHASE4":16859,"NA":16865},{"trials":16852,"activeCount":103},[],{"trials":16854,"activeCount":103},[],{"trials":16856,"activeCount":103},[],{"trials":16858,"activeCount":103},[],{"trials":16860,"activeCount":103},[16861],{"nctId":13256,"briefTitle":13257,"status":111,"phases":16862,"primaryCompletion":585,"completion":585,"start":561,"enrollment":1780,"conditions":16863,"interventions":16864},[94],[3396],[4685,13261],{"trials":16866,"activeCount":103},[],{"intervention":16868,"totalTrials":302,"cells":16869},"Rimegepant 75mg daily dosing",{"EARLY_PHASE1":16870,"PHASE1":16872,"PHASE2":16874,"PHASE3":16876,"PHASE4":16878,"NA":16889},{"trials":16871,"activeCount":103},[],{"trials":16873,"activeCount":103},[],{"trials":16875,"activeCount":103},[],{"trials":16877,"activeCount":103},[],{"trials":16879,"activeCount":103},[16880],{"nctId":16881,"briefTitle":16882,"status":111,"phases":16883,"primaryCompletion":2302,"completion":7601,"start":16884,"enrollment":16885,"conditions":16886,"interventions":16887},"NCT05217927","Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens",[94],"2022-03-04",1415,[117],[16868,16888],"Rimegepant 75mg every other day dosing",{"trials":16890,"activeCount":103},[],{"intervention":16888,"totalTrials":302,"cells":16892},{"EARLY_PHASE1":16893,"PHASE1":16895,"PHASE2":16897,"PHASE3":16899,"PHASE4":16901,"NA":16907},{"trials":16894,"activeCount":103},[],{"trials":16896,"activeCount":103},[],{"trials":16898,"activeCount":103},[],{"trials":16900,"activeCount":103},[],{"trials":16902,"activeCount":103},[16903],{"nctId":16881,"briefTitle":16882,"status":111,"phases":16904,"primaryCompletion":2302,"completion":7601,"start":16884,"enrollment":16885,"conditions":16905,"interventions":16906},[94],[117],[16868,16888],{"trials":16908,"activeCount":103},[],{"intervention":3339,"totalTrials":498,"cells":16910},{"EARLY_PHASE1":16911,"PHASE1":16913,"PHASE2":16940,"PHASE3":17000,"PHASE4":17006,"NA":17008},{"trials":16912,"activeCount":103},[],{"trials":16914,"activeCount":103},[16915,16921,16927,16934],{"nctId":16916,"briefTitle":16917,"status":111,"phases":16918,"primaryCompletion":13035,"completion":11727,"start":4399,"enrollment":1530,"conditions":16919,"interventions":16920},"NCT01469052","First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors",[91],[553],[3339,3339,3339,3339,3339,3339],{"nctId":16922,"briefTitle":16923,"status":111,"phases":16924,"primaryCompletion":4627,"completion":4627,"start":4646,"enrollment":1780,"conditions":16925,"interventions":16926},"NCT00918632","Food Effect Study Of AG-013736 In Healthy Volunteers",[91],[19],[3339,3339,3339,3339,3339,3339],{"nctId":16928,"briefTitle":16929,"status":111,"phases":16930,"primaryCompletion":4833,"completion":4833,"start":4627,"enrollment":2240,"conditions":16931,"interventions":16932},"NCT00905814","A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers",[91],[19],[3339,16933],"AG-103736",{"nctId":16935,"briefTitle":16936,"status":111,"phases":16937,"primaryCompletion":11988,"completion":11988,"start":10923,"enrollment":1578,"conditions":16938,"interventions":16939},"NCT01020136","A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers",[91],[1270],[3339,3339],{"trials":16941,"activeCount":103},[16942,16951,16960,16964,16971,16978,16982,16986,16992,16996],{"nctId":16943,"briefTitle":16944,"status":111,"phases":16945,"primaryCompletion":16946,"completion":16947,"start":16948,"enrollment":7363,"conditions":16949,"interventions":16950},"NCT00569946","Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)",[92],"2010-02-26","2012-10-30","2007-12-12",[919],[3339],{"nctId":16952,"briefTitle":16953,"status":111,"phases":16954,"primaryCompletion":13035,"completion":13035,"start":16955,"enrollment":1268,"conditions":16956,"interventions":16959},"NCT00071006","AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)",[92],"2003-09",[16957,16958],"Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome",[3339],{"nctId":8216,"briefTitle":8217,"status":111,"phases":16961,"primaryCompletion":8219,"completion":8219,"start":8220,"enrollment":4360,"conditions":16962,"interventions":16963},[92],[2180],[1764,3339,1764],{"nctId":16965,"briefTitle":16966,"status":111,"phases":16967,"primaryCompletion":11315,"completion":4645,"start":11512,"enrollment":16968,"conditions":16969,"interventions":16970},"NCT00076024","AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer",[91,92],174,[25],[3631,3339,3631],{"nctId":16972,"briefTitle":16973,"status":111,"phases":16974,"primaryCompletion":1700,"completion":1700,"start":4615,"enrollment":748,"conditions":16975,"interventions":16977},"NCT00389441","Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer",[92],[16976],"Thyroid Neoplasms",[3339],{"nctId":3331,"briefTitle":3332,"status":111,"phases":16979,"primaryCompletion":524,"completion":3334,"start":3335,"enrollment":3336,"conditions":16980,"interventions":16981},[92],[1028],[1030,3329,3339,3340,3339,3329,1030,3340],{"nctId":3342,"briefTitle":3343,"status":111,"phases":16983,"primaryCompletion":3334,"completion":3345,"start":2662,"enrollment":1112,"conditions":16984,"interventions":16985},[91,92],[1028],[429,3348,3339],{"nctId":16987,"briefTitle":16988,"status":111,"phases":16989,"primaryCompletion":4608,"completion":4646,"start":6457,"enrollment":23,"conditions":16990,"interventions":16991},"NCT00282048","Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer",[92],[4310,919],[3339],{"nctId":8151,"briefTitle":8152,"status":111,"phases":16993,"primaryCompletion":570,"completion":570,"start":8154,"enrollment":1796,"conditions":16994,"interventions":16995},[92],[947],[3339,8157,2890],{"nctId":3350,"briefTitle":3351,"status":111,"phases":16997,"primaryCompletion":523,"completion":3353,"start":3314,"enrollment":2250,"conditions":16998,"interventions":16999},[92],[3355,3356],[1030,1772,1771,3339,1772,1771],{"trials":17001,"activeCount":103},[17002],{"nctId":8248,"briefTitle":8249,"status":111,"phases":17003,"primaryCompletion":8251,"completion":8252,"start":2641,"enrollment":8253,"conditions":17004,"interventions":17005},[93],[1761],[3339,1764,1764],{"trials":17007,"activeCount":103},[],{"trials":17009,"activeCount":103},[],{"intervention":6111,"totalTrials":562,"cells":17011},{"EARLY_PHASE1":17012,"PHASE1":17014,"PHASE2":17113,"PHASE3":17115,"PHASE4":17126,"NA":17128},{"trials":17013,"activeCount":103},[],{"trials":17015,"activeCount":103},[17016,17020,17028,17036,17045,17053,17060,17068,17075,17084,17092,17100,17107],{"nctId":6102,"briefTitle":6103,"status":111,"phases":17017,"primaryCompletion":6105,"completion":6105,"start":6106,"enrollment":6107,"conditions":17018,"interventions":17019},[91],[16],[6110,1687,6111],{"nctId":17021,"briefTitle":17022,"status":111,"phases":17023,"primaryCompletion":17024,"completion":17024,"start":17025,"enrollment":1530,"conditions":17026,"interventions":17027},"NCT03386279","A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin",[91],"2018-10-01","2018-07-02",[19],[6305,6111],{"nctId":17029,"briefTitle":17030,"status":111,"phases":17031,"primaryCompletion":17032,"completion":17032,"start":757,"enrollment":29,"conditions":17033,"interventions":17034},"NCT02785770","A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects",[91],"2016-10-20",[16],[17035,6111],"PF-04447943",{"nctId":17037,"briefTitle":17038,"status":111,"phases":17039,"primaryCompletion":4627,"completion":4627,"start":8154,"enrollment":35,"conditions":17040,"interventions":17042},"NCT00809289","Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers",[91],[17041],"Fibromyalgia",[17043,17044],"esreboxetine","moxifloxacin",{"nctId":17046,"briefTitle":17047,"status":111,"phases":17048,"primaryCompletion":17049,"completion":17049,"start":17050,"enrollment":5987,"conditions":17051,"interventions":17052},"NCT03656952","A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers",[91],"2019-02-06","2018-09-05",[16],[7595,17044],{"nctId":17054,"briefTitle":17055,"status":111,"phases":17056,"primaryCompletion":4656,"completion":4656,"start":586,"enrollment":29,"conditions":17057,"interventions":17058},"NCT01140425","Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects",[91],[16],[17059,17059,6111],"PF-00232798",{"nctId":17061,"briefTitle":17062,"status":111,"phases":17063,"primaryCompletion":2313,"completion":2313,"start":7387,"enrollment":1548,"conditions":17064,"interventions":17065},"NCT02651623","Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects",[91],[16],[17066,6111,17067],"Sertraline","Drug - Placebo",{"nctId":17069,"briefTitle":17070,"status":111,"phases":17071,"primaryCompletion":3642,"completion":3642,"start":10923,"enrollment":4825,"conditions":17072,"interventions":17073},"NCT00936871","The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects",[91],[19],[17074,17074,17074,6111],"Lersivirine",{"nctId":17076,"briefTitle":17077,"status":111,"phases":17078,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":1548,"conditions":17079,"interventions":17081},"NCT01290900","A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT\u002FQTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers",[91],[17080],"Healthy Male Volunteers",[17082,13798,17083,6111],"NXL104","Ceftazidime",{"nctId":17085,"briefTitle":17086,"status":111,"phases":17087,"primaryCompletion":17088,"completion":17088,"start":213,"enrollment":32,"conditions":17089,"interventions":17090},"NCT05878522","A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.",[91],"2023-10-30",[16],[17091,17044,17091],"sisunatovir",{"nctId":17093,"briefTitle":17094,"status":111,"phases":17095,"completion":3627,"start":4692,"enrollment":1530,"conditions":17096,"interventions":17098},"NCT00174512","A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade",[91],[17097],"Patients With Pace Makers But no Evidence of Ischemic Heart Disease",[17099,6111],"GTN",{"nctId":17101,"briefTitle":17102,"status":111,"phases":17103,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":17104,"interventions":17105},"NCT01287793","Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects",[91],[16],[13326,13326,17044,17106],"100 mL 0.9% Sodium Chloride intravenous",{"nctId":17108,"briefTitle":17109,"status":111,"phases":17110,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":4369,"conditions":17111,"interventions":17112},"NCT01862887","A Study to Investigate the Effect of PH-797804 on QTc Interval",[91],[16],[11326,6111],{"trials":17114,"activeCount":103},[],{"trials":17116,"activeCount":103},[17117],{"nctId":17118,"briefTitle":17119,"status":111,"phases":17120,"primaryCompletion":8115,"completion":8115,"start":12416,"enrollment":17121,"conditions":17122,"interventions":17124},"NCT00254566","A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)",[93],398,[17123],"Chronic Bronchitis",[6111,17125],"Azithromycin SR",{"trials":17127,"activeCount":103},[],{"trials":17129,"activeCount":103},[],{"intervention":12083,"totalTrials":3254,"cells":17131},{"EARLY_PHASE1":17132,"PHASE1":17134,"PHASE2":17150,"PHASE3":17192,"PHASE4":17255,"NA":17257},{"trials":17133,"activeCount":103},[],{"trials":17135,"activeCount":103},[17136,17144],{"nctId":17137,"briefTitle":17138,"status":111,"phases":17139,"primaryCompletion":560,"completion":560,"start":4221,"enrollment":5909,"conditions":17140,"interventions":17143},"NCT01030640","Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected",[91],[17141,11358,17142],"Osteoarthritis Pain","Pain Due to Interstitial Cystitis",[12083],{"nctId":17145,"briefTitle":17146,"status":111,"phases":17147,"primaryCompletion":4646,"completion":4646,"start":4645,"enrollment":407,"conditions":17148,"interventions":17149},"NCT00788294","Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously",[91],[19],[12083,12083,12083,12083],{"trials":17151,"activeCount":103},[17152,17164,17174,17182],{"nctId":17153,"briefTitle":17154,"status":168,"phases":17155,"primaryCompletion":17156,"completion":17157,"start":17158,"enrollment":17159,"conditions":17160,"interventions":17162},"NCT00999518","A Study To Investigate Tanezumab In Patients With Interstitial Cystitis\u002F Painful Bladder Syndrome",[92],"2010-11-17","2011-01-21","2010-01-22",205,[17161],"Cystitis, Interstitial",[17163,17163,17163,17163],"Tanezumab",{"nctId":17165,"briefTitle":17166,"status":111,"phases":17167,"primaryCompletion":17168,"completion":17169,"start":17170,"enrollment":23,"conditions":17171,"interventions":17173},"NCT00826514","An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis",[92],"2010-01-11","2010-03-17","2009-03-25",[17172],"Chronic Prostatitis With Chronic Pelvic Pain Syndrome",[17163],{"nctId":17175,"briefTitle":17176,"status":168,"phases":17177,"primaryCompletion":515,"completion":515,"start":17178,"enrollment":1087,"conditions":17179,"interventions":17181},"NCT01146561","Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis",[92],"2010-10-13",[17180],"Chronic Pancreatitis",[17163],{"nctId":17183,"briefTitle":17184,"status":168,"phases":17185,"primaryCompletion":17186,"completion":17187,"start":17188,"enrollment":463,"conditions":17189,"interventions":17191},"NCT01087203","A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy",[92],"2010-11-18","2011-07-06","2010-03-30",[17190],"Diabetic Peripheral Neuropathy",[17163],{"trials":17193,"activeCount":103},[17194,17205,17215,17219,17227,17236,17247],{"nctId":17195,"briefTitle":17196,"status":168,"phases":17197,"primaryCompletion":17198,"completion":17199,"start":17200,"enrollment":17201,"conditions":17202,"interventions":17203},"NCT00809354","Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip",[93],"2010-10-28","2011-01-12","2009-02-12",2720,[11282,11409],[17204,12083,12083,12083,17204,12083,17204],"NSAID",{"nctId":17206,"briefTitle":17207,"status":111,"phases":17208,"primaryCompletion":17209,"completion":17210,"start":17211,"enrollment":17212,"conditions":17213,"interventions":17214},"NCT00744471","Tanezumab in Osteoarthritis Of The Hip",[93],"2010-03-15","2010-08-13","2008-11-17",627,[11409,11282,12099],[12083,12083,12083],{"nctId":12075,"briefTitle":12076,"status":168,"phases":17216,"primaryCompletion":12078,"completion":12079,"start":12080,"enrollment":3425,"conditions":17217,"interventions":17218},[93],[11282],[12083,11722,12083,11722,12083,11722,11722],{"nctId":17220,"briefTitle":17221,"status":111,"phases":17222,"primaryCompletion":17223,"completion":17224,"start":2422,"enrollment":5821,"conditions":17225,"interventions":17226},"NCT00733902","Tanezumab in Osteoarthritis of the Knee",[93],"2009-08-24","2010-01-14",[11409,11282],[12083,12083,12083],{"nctId":17228,"briefTitle":17229,"status":168,"phases":17230,"primaryCompletion":17231,"completion":17232,"start":11799,"enrollment":17233,"conditions":17234,"interventions":17235},"NCT00809783","Extension Study Of Tanezumab In Osteoarthritis",[93],"2010-11-02","2011-06-23",2147,[11282],[12083,12083,12083],{"nctId":17237,"briefTitle":17238,"status":111,"phases":17239,"primaryCompletion":17240,"completion":17241,"start":17242,"enrollment":2020,"conditions":17243,"interventions":17246},"NCT02609828","Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy",[93],"2020-09-17","2021-06-25","2015-10-28",[17244,17245],"Bone Metastasis","Cancer Pain",[17163],{"nctId":17248,"briefTitle":17249,"status":111,"phases":17250,"primaryCompletion":17251,"completion":151,"start":17252,"enrollment":11370,"conditions":17253,"interventions":17254},"NCT02709486","Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.",[93],"2018-06-08","2016-03-02",[12099,11347],[17163,17163],{"trials":17256,"activeCount":103},[],{"trials":17258,"activeCount":103},[],{"intervention":12983,"totalTrials":3254,"cells":17260},{"EARLY_PHASE1":17261,"PHASE1":17263,"PHASE2":17265,"PHASE3":17267,"PHASE4":17359,"NA":17361},{"trials":17262,"activeCount":103},[],{"trials":17264,"activeCount":103},[],{"trials":17266,"activeCount":103},[],{"trials":17268,"activeCount":103},[17269,17277,17285,17292,17300,17308,17316,17320,17328,17334,17340,17346,17352],{"nctId":17270,"briefTitle":17271,"status":111,"phases":17272,"completion":4847,"start":4258,"enrollment":4981,"conditions":17273,"interventions":17276},"NCT00134498","A Study Comparing The Efficacy & Safety Of Torcetrapib\u002FAtorvastatin And Atorvastatin In Subjects With High Triglycerides",[93],[17274,17275],"Hypertriglyceridemia","Hyperlipoproteinemia Type IV",[12983,12996],{"nctId":17278,"briefTitle":17279,"status":111,"phases":17280,"completion":12004,"start":4692,"enrollment":1326,"conditions":17281,"interventions":17282},"NCT00139061","Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib\u002FAtorvastatin Vs. Fenofibrate",[93],[12979],[17283,17284],"Torcetrapib\u002FAtorvastatin","Fenofibrate",{"nctId":17286,"briefTitle":17287,"status":111,"phases":17288,"completion":4847,"start":2672,"enrollment":1017,"conditions":17289,"interventions":17291},"NCT00136981","Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib\u002FAtorvastatin to Atorvastatin Alone.",[93],[17290,12979],"Hypercholesterolemia, Familial",[12983,12996],{"nctId":17293,"briefTitle":17294,"status":168,"phases":17295,"primaryCompletion":4615,"completion":4615,"start":3611,"enrollment":17296,"conditions":17297,"interventions":17299},"NCT00134238","Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib\u002FAtorvastatin to Atorvastatin.",[93],755,[17298],"Mixed Hyperlipidemia",[12983,12996],{"nctId":17301,"briefTitle":17302,"status":168,"phases":17303,"primaryCompletion":3643,"completion":3643,"start":13035,"enrollment":17304,"conditions":17305,"interventions":17307},"NCT00134264","A Study Examining Torcetrapib\u002FAtorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease",[93],15067,[17306,6117],"Coronary Disease",[12983,12996],{"nctId":17309,"briefTitle":17310,"status":168,"phases":17311,"primaryCompletion":4615,"completion":4615,"start":4692,"enrollment":713,"conditions":17312,"interventions":17314},"NCT00145431","Study To Evaluate The Effect Of Torcetrapib\u002FAtorvastatin In Subjects With A Genetic Cholesterol Disorder.",[93],[17313],"Hyperlipoproteinemia Type III",[12983,12996,17315],"fenofibrate",{"nctId":12975,"briefTitle":12976,"status":111,"phases":17317,"completion":12773,"start":2662,"enrollment":194,"conditions":17318,"interventions":17319},[93],[12979,12980,12981],[12983,12984],{"nctId":17321,"briefTitle":17322,"status":168,"phases":17323,"completion":11315,"start":2662,"enrollment":17324,"conditions":17325,"interventions":17326},"NCT00267267","A Clinical Trial Comparing Torcetrapib\u002FAtorvastatin to Ezetimibe\u002FSimvastatin In Subjects With A Cholesterol Disorder.",[93],1784,[12979,12980],[12983,17327],"ezetimibe\u002Fsimvastatin",{"nctId":17329,"briefTitle":17330,"status":111,"phases":17331,"completion":6457,"start":4692,"enrollment":267,"conditions":17332,"interventions":17333},"NCT00134485","Study To Evaluate The Safety And Efficacy Of Torcetrapib\u002FAtorvastatin In Subjects With Familial Hypercholerolemia",[93],[17290,12979],[12983,12996],{"nctId":17335,"briefTitle":17336,"status":111,"phases":17337,"completion":3854,"start":11736,"enrollment":1941,"conditions":17338,"interventions":17339},"NCT00134173","A Coronary IVUS Study to Compare Torcetrapib\u002FAtorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease",[93],[17306,16072,12979],[12983,12996],{"nctId":17341,"briefTitle":17342,"status":111,"phases":17343,"completion":3854,"start":12774,"enrollment":2303,"conditions":17344,"interventions":17345},"NCT00137462","Lipitor Trial To Study The Effect Of Torcetrpib\u002FAtorvastatin To Atorvastatin Alone.",[93],[12979],[12983,12996],{"nctId":17347,"briefTitle":17348,"status":111,"phases":17349,"primaryCompletion":12773,"completion":12773,"start":13035,"enrollment":11783,"conditions":17350,"interventions":17351},"NCT00138762","A Study of Torcetrapib\u002FAtorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol",[93],[12979],[12983,12996],{"nctId":17353,"briefTitle":17354,"status":111,"phases":17355,"completion":8170,"start":4692,"enrollment":1780,"conditions":17356,"interventions":17357},"NCT00134511","Study To Evaluate The Effect Of Torcetrapib\u002FAtorvastatin In Patients With Genetic High Cholesterol Disorder",[93],[17290],[17358],"Torcetrapib\u002Fatorvastatin",{"trials":17360,"activeCount":103},[],{"trials":17362,"activeCount":103},[],{"intervention":1705,"totalTrials":1268,"cells":17364},{"EARLY_PHASE1":17365,"PHASE1":17367,"PHASE2":17406,"PHASE3":17429,"PHASE4":17439,"NA":17441},{"trials":17366,"activeCount":103},[],{"trials":17368,"activeCount":103},[17369,17375,17382,17389,17395,17399],{"nctId":17370,"briefTitle":17371,"status":168,"phases":17372,"primaryCompletion":4531,"completion":6208,"start":11291,"enrollment":8373,"conditions":17373,"interventions":17374},"NCT00729833","Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors",[91],[543,553],[1705,4327],{"nctId":17376,"briefTitle":17377,"status":111,"phases":17378,"primaryCompletion":4608,"completion":4608,"start":4692,"enrollment":787,"conditions":17379,"interventions":17381},"NCT01653158","CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies",[91],[17380],"Advanced Non-Hematologic Malignancies",[1705,3631],{"nctId":17383,"briefTitle":17384,"status":111,"phases":17385,"primaryCompletion":3601,"completion":3353,"start":15716,"enrollment":4726,"conditions":17386,"interventions":17388},"NCT00474760","Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors",[91],[17387],"Sarcoma, Ewing's",[1705],{"nctId":17390,"briefTitle":17391,"status":111,"phases":17392,"primaryCompletion":3839,"completion":3839,"start":2672,"enrollment":8414,"conditions":17393,"interventions":17394},"NCT01536145","CP-751,871 Treatment For Patients With Multiple Myeloma",[91],[1062],[1705],{"nctId":3836,"briefTitle":3837,"status":111,"phases":17396,"primaryCompletion":3839,"completion":3642,"start":2964,"enrollment":787,"conditions":17397,"interventions":17398},[91],[376],[1705,1770,1764,3842],{"nctId":17400,"briefTitle":17401,"status":168,"phases":17402,"primaryCompletion":2660,"completion":2660,"start":4627,"enrollment":5909,"conditions":17403,"interventions":17404},"NCT00926263","A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects",[91],[19],[1705,1705,17405],"CP-751,871, moxifloxacin, saline",{"trials":17407,"activeCount":103},[17408,17414,17421,17425],{"nctId":17409,"briefTitle":17410,"status":649,"phases":17411,"primaryCompletion":9544,"completion":9544,"start":4222,"enrollment":103,"conditions":17412,"interventions":17413},"NCT00678626","Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer",[92],[31],[1705,3631],{"nctId":17415,"briefTitle":17416,"status":111,"phases":17417,"primaryCompletion":3642,"completion":3353,"start":3335,"enrollment":885,"conditions":17418,"interventions":17420},"NCT00560235","Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors",[91,92],[17419],"Ewing's Sarcoma Family of Tumors",[1705],{"nctId":1697,"briefTitle":1698,"status":168,"phases":17422,"primaryCompletion":1700,"completion":1288,"start":1701,"enrollment":1702,"conditions":17423,"interventions":17424},[92],[25],[1705,1643,1643,1305],{"nctId":12001,"briefTitle":12002,"status":111,"phases":17426,"primaryCompletion":523,"completion":2883,"start":12004,"enrollment":9,"conditions":17427,"interventions":17428},[92],[11998],[1705,432,12007,432,12007],{"trials":17430,"activeCount":103},[17431,17435],{"nctId":8161,"briefTitle":8162,"status":649,"phases":17432,"primaryCompletion":652,"completion":652,"start":586,"enrollment":103,"conditions":17433,"interventions":17434},[93],[376],[1705,1770,1764,1770,1764],{"nctId":9430,"briefTitle":9431,"status":168,"phases":17436,"primaryCompletion":524,"completion":1700,"start":3314,"enrollment":9433,"conditions":17437,"interventions":17438},[93],[9435,9436,9437,376],[1705,1772,1771,1772,1771],{"trials":17440,"activeCount":103},[],{"trials":17442,"activeCount":103},[],{"intervention":17444,"totalTrials":627,"cells":17445},"MEK162",{"EARLY_PHASE1":17446,"PHASE1":17448,"PHASE2":17450,"PHASE3":17521,"PHASE4":17545,"NA":17547},{"trials":17447,"activeCount":103},[],{"trials":17449,"activeCount":103},[],{"trials":17451,"activeCount":103},[17452,17462,17473,17483,17492,17501,17509],{"nctId":17453,"briefTitle":17454,"status":111,"phases":17455,"primaryCompletion":17456,"completion":17457,"start":17458,"enrollment":8123,"conditions":17459,"interventions":17461},"NCT01885195","MEK162 for Patients With RAS\u002FRAF\u002FMEK Activated Tumors",[92],"2015-10-01","2017-04-11","2013-10-10",[17460],"Solid Tumor and Hematologic Malignancies",[17444],{"nctId":17463,"briefTitle":17464,"status":168,"phases":17465,"primaryCompletion":17466,"completion":17466,"start":17467,"enrollment":5647,"conditions":17468,"interventions":17471},"NCT01562899","A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors",[91,92],"2015-04-01","2012-08-27",[17469,17470],"Metastatic Pancreatic Adenocarcinoma","BRAF Mutated Melanoma",[17444,17472],"AMG 479",{"nctId":17474,"briefTitle":17475,"status":111,"phases":17476,"primaryCompletion":17477,"completion":17478,"start":13117,"enrollment":10190,"conditions":17479,"interventions":17481},"NCT01781572","A Phase Ib\u002FII Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma",[91,92],"2018-01-15","2018-02-20",[17480],"Locally Advanced or Metastatic NRAS Mutant Melanoma",[17482,17444],"LEE011",{"nctId":17484,"briefTitle":17485,"status":111,"phases":17486,"primaryCompletion":17487,"completion":17487,"start":17488,"enrollment":336,"conditions":17489,"interventions":17490},"NCT01927341","Phase Ib\u002FII Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",[91,92],"2016-01-25","2013-11-19",[1810],[17444,17491],"Panitumumab",{"nctId":17493,"briefTitle":17494,"status":111,"phases":17495,"primaryCompletion":17496,"completion":4547,"start":17497,"enrollment":1915,"conditions":17498,"interventions":17500},"NCT01320085","A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma",[92],"2014-01-07","2011-03-24",[17499],"BRAF or NRAS Mutant Metastatic Melanoma",[17444],{"nctId":17502,"briefTitle":17503,"status":111,"phases":17504,"primaryCompletion":1914,"completion":1914,"start":17505,"enrollment":2935,"conditions":17506,"interventions":17508},"NCT01543698","A Phase Ib\u002FII Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors",[91,92],"2012-05-28",[17507],"Solid Tumors Harboring a BRAF V600 Mutation",[2024,17444,17482],{"nctId":17510,"briefTitle":17511,"status":111,"phases":17512,"primaryCompletion":17513,"completion":17513,"start":17514,"enrollment":17515,"conditions":17516,"interventions":17517},"NCT02159066","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",[92],"2023-01-10","2014-07-23",158,[1798],[2024,17444,17482,17518,17519,17520],"BGJ398","BKM120","INC280",{"trials":17522,"activeCount":103},[17523,17534],{"nctId":17524,"briefTitle":17525,"status":111,"phases":17526,"primaryCompletion":17527,"completion":3240,"start":17528,"enrollment":17529,"conditions":17530,"interventions":17532},"NCT01763164","Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma",[93],"2015-12-01","2013-07-12",402,[17531],"Metastatic or Unresectable Cutaneous Melanoma",[17444,17533],"Dacarbazine",{"nctId":17535,"briefTitle":17536,"status":111,"phases":17537,"primaryCompletion":17538,"completion":17539,"start":17540,"enrollment":17541,"conditions":17542,"interventions":17543},"NCT01909453","Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma",[93],"2016-11-09","2024-09-03","2013-09-12",921,[1798],[2024,17444,17544],"vemurafenib",{"trials":17546,"activeCount":103},[],{"trials":17548,"activeCount":103},[],{"intervention":17550,"totalTrials":627,"cells":17551},"PD 0332334",{"EARLY_PHASE1":17552,"PHASE1":17554,"PHASE2":17585,"PHASE3":17587,"PHASE4":17624,"NA":17626},{"trials":17553,"activeCount":103},[],{"trials":17555,"activeCount":103},[17556,17563,17571,17578],{"nctId":17557,"briefTitle":17558,"status":168,"phases":17559,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":1509,"conditions":17560,"interventions":17562},"NCT00809536","Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time",[91],[17561],"Generalized Anxiety Disorder",[6170,6170,17550,17550],{"nctId":17564,"briefTitle":17565,"status":649,"phases":17566,"primaryCompletion":4646,"completion":4646,"start":11014,"enrollment":103,"conditions":17567,"interventions":17569},"NCT00820794","A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects",[91],[17568],"Generalized Anxiety Disease",[17570,17550,17570,17550],"Lithium",{"nctId":17572,"briefTitle":17573,"status":168,"phases":17574,"primaryCompletion":4608,"completion":4608,"start":8115,"enrollment":314,"conditions":17575,"interventions":17577},"NCT00721422","A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.",[91],[17576,3396],"Renal Insufficiency",[17550,17550,17550,17550],{"nctId":17579,"briefTitle":17580,"status":168,"phases":17581,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":1268,"conditions":17582,"interventions":17583},"NCT00800280","Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body",[91],[17561],[17550,17550,17584],"cimetidine",{"trials":17586,"activeCount":103},[],{"trials":17588,"activeCount":103},[17589,17596,17603,17610,17616],{"nctId":17590,"briefTitle":17591,"status":168,"phases":17592,"primaryCompletion":11290,"completion":11290,"start":2884,"enrollment":1621,"conditions":17593,"interventions":17594},"NCT00658372","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)",[93],[17561],[17550,17550,17595],"Paroxetine",{"nctId":17597,"briefTitle":17598,"status":168,"phases":17599,"primaryCompletion":4222,"completion":4222,"start":4665,"enrollment":17600,"conditions":17601,"interventions":17602},"NCT00735267","A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)",[93],468,[17561],[17550],{"nctId":17604,"briefTitle":17605,"status":168,"phases":17606,"primaryCompletion":11290,"completion":11290,"start":3314,"enrollment":17607,"conditions":17608,"interventions":17609},"NCT00658008","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)",[93],501,[17561],[17550,17550,17550,17595],{"nctId":17611,"briefTitle":17612,"status":111,"phases":17613,"primaryCompletion":8154,"completion":8154,"start":11609,"enrollment":10983,"conditions":17614,"interventions":17615},"NCT00542685","A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder",[93],[17561],[17550,17550,17550],{"nctId":17617,"briefTitle":17618,"status":168,"phases":17619,"primaryCompletion":4222,"completion":4222,"start":2884,"enrollment":17620,"conditions":17621,"interventions":17622},"NCT00658762","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)",[93],286,[17561],[17550,17550,17623],"paroxetine",{"trials":17625,"activeCount":103},[],{"trials":17627,"activeCount":103},[],{"intervention":17629,"totalTrials":1487,"cells":17630},"Bococizumab",{"EARLY_PHASE1":17631,"PHASE1":17633,"PHASE2":17642,"PHASE3":17644,"PHASE4":17706,"NA":17708},{"trials":17632,"activeCount":103},[],{"trials":17634,"activeCount":103},[17635],{"nctId":17636,"briefTitle":17637,"status":111,"phases":17638,"primaryCompletion":17639,"completion":17639,"start":7578,"enrollment":4755,"conditions":17640,"interventions":17641},"NCT02043301","Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm",[91],"2014-11",[12981],[17629,17629,17629],{"trials":17643,"activeCount":103},[],{"trials":17645,"activeCount":103},[17646,17656,17663,17671,17681,17690,17698],{"nctId":17647,"briefTitle":17648,"status":111,"phases":17649,"primaryCompletion":17650,"completion":17651,"start":17652,"enrollment":17653,"conditions":17654,"interventions":17655},"NCT01968967","Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events",[93],"2016-07-05","2017-07-10","2013-10-29",2139,[12979],[17629],{"nctId":17657,"briefTitle":17658,"status":111,"phases":17659,"primaryCompletion":12811,"completion":12811,"start":1249,"enrollment":17660,"conditions":17661,"interventions":17662},"NCT01968954","Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events",[93],711,[12979],[17629],{"nctId":17664,"briefTitle":17665,"status":649,"phases":17666,"primaryCompletion":2216,"completion":2216,"start":17667,"enrollment":103,"conditions":17668,"interventions":17670},"NCT02947334","Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects",[93],"2016-10-31",[17669],"Primary Hyperlipidemia or Mixed Dyslipidemia",[17629],{"nctId":17672,"briefTitle":17673,"status":168,"phases":17674,"primaryCompletion":17675,"completion":17675,"start":17652,"enrollment":17676,"conditions":17677,"interventions":17679},"NCT01975376","The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects",[93],"2017-03-22",16784,[17678],"Cardiovascular Disease",[17680],"bococizumab",{"nctId":17682,"briefTitle":17683,"status":111,"phases":17684,"primaryCompletion":1389,"completion":1389,"start":17685,"enrollment":17686,"conditions":17687,"interventions":17689},"NCT01968980","A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia",[93],"2013-10-23",370,[17688],"Heterozygous Familial Hypercholesterolemia",[17629],{"nctId":17691,"briefTitle":17692,"status":168,"phases":17693,"primaryCompletion":17694,"completion":17694,"start":17652,"enrollment":17695,"conditions":17696,"interventions":17697},"NCT01975389","The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects",[93],"2017-04-03",10564,[17678],[17680],{"nctId":17699,"briefTitle":17700,"status":111,"phases":17701,"primaryCompletion":7999,"completion":17651,"start":17702,"enrollment":17703,"conditions":17704,"interventions":17705},"NCT02100514","Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events",[93],"2014-10-28",746,[12979],[17629],{"trials":17707,"activeCount":103},[],{"trials":17709,"activeCount":103},[],{"intervention":17711,"totalTrials":1487,"cells":17712},"Dimebon",{"EARLY_PHASE1":17713,"PHASE1":17715,"PHASE2":17758,"PHASE3":17760,"PHASE4":17776,"NA":17778},{"trials":17714,"activeCount":103},[],{"trials":17716,"activeCount":103},[17717,17723,17731,17738,17746,17752],{"nctId":17718,"briefTitle":17719,"status":111,"phases":17720,"primaryCompletion":4627,"completion":4627,"start":4646,"enrollment":1268,"conditions":17721,"interventions":17722},"NCT00907322","A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults",[91],[19],[17711,17711,17711,17711],{"nctId":17724,"briefTitle":17725,"status":111,"phases":17726,"primaryCompletion":4846,"completion":4846,"start":4608,"enrollment":2159,"conditions":17727,"interventions":17730},"NCT00824590","A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function",[91],[17728,17729],"Alzheimer's Disease","Huntington's Disease",[17711,17711],{"nctId":17732,"briefTitle":17733,"status":111,"phases":17734,"primaryCompletion":4214,"completion":4214,"start":4608,"enrollment":2218,"conditions":17735,"interventions":17737},"NCT00831532","Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function",[91],[17736],"Hepatic Failure",[17711,17711,17711,17711],{"nctId":17739,"briefTitle":17740,"status":111,"phases":17741,"primaryCompletion":11014,"completion":11014,"start":4608,"enrollment":1268,"conditions":17742,"interventions":17743},"NCT00831506","Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects",[91],[13445,13444],[17744,17744,17745],"digoxin","dimebon",{"nctId":17747,"briefTitle":17748,"status":111,"phases":17749,"primaryCompletion":11014,"completion":11014,"start":4608,"enrollment":8373,"conditions":17750,"interventions":17751},"NCT00825084","A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects",[91],[17728,17729],[17711,17711,17711,17711],{"nctId":17753,"briefTitle":17754,"status":111,"phases":17755,"primaryCompletion":4222,"completion":4222,"start":4608,"enrollment":562,"conditions":17756,"interventions":17757},"NCT00827034","A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects",[91],[17728,17729],[9578,17711,9578],{"trials":17759,"activeCount":103},[],{"trials":17761,"activeCount":103},[17762,17769],{"nctId":17763,"briefTitle":17764,"status":168,"phases":17765,"primaryCompletion":561,"completion":561,"start":4833,"enrollment":17766,"conditions":17767,"interventions":17768},"NCT00939783","An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease",[93],649,[17728],[17711],{"nctId":17770,"briefTitle":17771,"status":111,"phases":17772,"primaryCompletion":10923,"completion":10923,"start":4608,"enrollment":17773,"conditions":17774,"interventions":17775},"NCT00838110","A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease",[93],742,[17728],[17711,17711],{"trials":17777,"activeCount":103},[],{"trials":17779,"activeCount":103},[],{"intervention":4945,"totalTrials":3659,"cells":17781},{"EARLY_PHASE1":17782,"PHASE1":17784,"PHASE2":17797,"PHASE3":17810,"PHASE4":17838,"NA":17840},{"trials":17783,"activeCount":103},[],{"trials":17785,"activeCount":103},[17786,17793],{"nctId":17787,"briefTitle":17788,"status":649,"phases":17789,"primaryCompletion":3601,"completion":3601,"start":4656,"enrollment":103,"conditions":17790,"interventions":17791},"NCT01251835","Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan",[91],[4942],[17792,4945,1252],"Sitaxsentan alone",{"nctId":4938,"briefTitle":4939,"status":649,"phases":17794,"primaryCompletion":4666,"completion":4666,"start":3601,"enrollment":103,"conditions":17795,"interventions":17796},[91],[4942],[4944,4904,4945,4904],{"trials":17798,"activeCount":103},[17799],{"nctId":17800,"briefTitle":17801,"status":111,"phases":17802,"primaryCompletion":17803,"completion":17803,"start":17804,"enrollment":350,"conditions":17805,"interventions":17808},"NCT00838383","Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery",[92],"2008-03-31","2006-08-10",[17806,17807],"Cardiac Surgery Subjects","Subjects Undergoing CABG and\u002For Cardiac Valve Replacement",[17809,17809],"sitaxsentan",{"trials":17811,"activeCount":103},[17812,17818,17825,17832],{"nctId":17813,"briefTitle":17814,"status":168,"phases":17815,"primaryCompletion":524,"completion":524,"start":8154,"enrollment":1915,"conditions":17816,"interventions":17817},"NCT00795639","Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)",[93],[4942,7083],[4945],{"nctId":17819,"briefTitle":17820,"status":168,"phases":17821,"primaryCompletion":524,"completion":524,"start":11014,"enrollment":1390,"conditions":17822,"interventions":17823},"NCT00796666","Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil",[93],[4942,7083],[4945,17824],"Sitaxsentan and Sildenafil",{"nctId":17826,"briefTitle":17827,"status":168,"phases":17828,"primaryCompletion":3313,"completion":3313,"start":3628,"enrollment":17829,"conditions":17830,"interventions":17831},"NCT00811018","A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension",[93],1192,[4942],[4945],{"nctId":17833,"briefTitle":17834,"status":168,"phases":17835,"primaryCompletion":3601,"completion":3601,"start":586,"enrollment":502,"conditions":17836,"interventions":17837},"NCT00796510","Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety",[93],[4942,7083],[4945,17824],{"trials":17839,"activeCount":103},[],{"trials":17841,"activeCount":103},[],{"intervention":17843,"totalTrials":2070,"cells":17844},"[S,S]-Reboxetine",{"EARLY_PHASE1":17845,"PHASE1":17847,"PHASE2":17849,"PHASE3":17878,"PHASE4":17896,"NA":17898},{"trials":17846,"activeCount":103},[],{"trials":17848,"activeCount":103},[],{"trials":17850,"activeCount":103},[17851,17857,17863,17870],{"nctId":17852,"briefTitle":17853,"status":168,"phases":17854,"completion":11609,"start":4847,"enrollment":130,"conditions":17855,"interventions":17856},"NCT00354094","[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.",[92],[34],[17843],{"nctId":17858,"briefTitle":17859,"status":111,"phases":17860,"primaryCompletion":11895,"completion":11895,"start":12773,"enrollment":3685,"conditions":17861,"interventions":17862},"NCT00357825","A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia",[92],[34],[17843],{"nctId":17864,"briefTitle":17865,"status":168,"phases":17866,"primaryCompletion":4645,"completion":4645,"start":4636,"enrollment":1759,"conditions":17867,"interventions":17869},"NCT00625833","A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.",[92],[17868],"Diabetic Neuropathies",[17843],{"nctId":17871,"briefTitle":17872,"status":168,"phases":17873,"primaryCompletion":11609,"completion":11609,"start":12395,"enrollment":17874,"conditions":17875,"interventions":17876},"NCT00348894","[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.",[92],136,[34],[17843,17877],"Any",{"trials":17879,"activeCount":103},[17880,17889],{"nctId":17881,"briefTitle":17882,"status":168,"phases":17883,"primaryCompletion":17884,"completion":17884,"start":17885,"enrollment":1893,"conditions":17886,"interventions":17887},"NCT00607256","Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia",[93],"2009-05-18","2007-10-20",[17041],[17888],"[S,S]-reboxetine",{"nctId":17890,"briefTitle":17891,"status":168,"phases":17892,"primaryCompletion":11014,"completion":11014,"start":2884,"enrollment":17893,"conditions":17894,"interventions":17895},"NCT00754221","Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia",[93],390,[17041],[17843],{"trials":17897,"activeCount":103},[],{"trials":17899,"activeCount":103},[],{"intervention":2969,"totalTrials":2070,"cells":17901},{"EARLY_PHASE1":17902,"PHASE1":17904,"PHASE2":17916,"PHASE3":17926,"PHASE4":17940,"NA":17942},{"trials":17903,"activeCount":103},[],{"trials":17905,"activeCount":103},[17906],{"nctId":17907,"briefTitle":17908,"status":111,"phases":17909,"primaryCompletion":17910,"completion":17910,"start":17911,"enrollment":8278,"conditions":17912,"interventions":17914},"NCT01307267","A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab",[91],"2019-02-20","2011-06-21",[7426,2966,17913,376,919,9054,4728],"Lymphoma, Large B-Cell, Diffuse",[17915,2969,17915],"PF-05082566",{"trials":17917,"activeCount":103},[17918,17922],{"nctId":7358,"briefTitle":7359,"status":111,"phases":17919,"primaryCompletion":7361,"completion":7361,"start":7362,"enrollment":7363,"conditions":17920,"interventions":17921},[92],[7365],[2968,2969],{"nctId":7372,"briefTitle":7373,"status":111,"phases":17923,"primaryCompletion":7375,"completion":7376,"start":7377,"enrollment":7378,"conditions":17924,"interventions":17925},[91,92],[7380],[2968,2968,2968,2917],{"trials":17927,"activeCount":103},[17928,17932,17936],{"nctId":7419,"briefTitle":7420,"status":168,"phases":17929,"primaryCompletion":7422,"completion":7422,"start":7423,"enrollment":7424,"conditions":17930,"interventions":17931},[93],[7426],[7006,2917,7428,7429],{"nctId":2961,"briefTitle":2962,"status":168,"phases":17933,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":17934,"interventions":17935},[93],[2966],[2968,2969,2969,2970,2971,2972,2973,2974,2975],{"nctId":2908,"briefTitle":2909,"status":168,"phases":17937,"primaryCompletion":2911,"completion":2911,"start":2912,"enrollment":350,"conditions":17938,"interventions":17939},[93],[2914],[663,2916,2917,2918,1764,1767],{"trials":17941,"activeCount":103},[],{"trials":17943,"activeCount":103},[],{"intervention":2940,"totalTrials":2070,"cells":17945},{"EARLY_PHASE1":17946,"PHASE1":17948,"PHASE2":17986,"PHASE3":17988,"PHASE4":18012,"NA":18014},{"trials":17947,"activeCount":103},[],{"trials":17949,"activeCount":103},[17950,17961,17965,17975],{"nctId":17951,"briefTitle":17952,"status":168,"phases":17953,"primaryCompletion":17954,"completion":17954,"start":5820,"enrollment":1487,"conditions":17955,"interventions":17956},"NCT02954653","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",[91],"2017-12-05",[2938],[17957,17958,17959,2940,17960],"PF-06747143","Cytarabine","Daunorubicin","Decitabine",{"nctId":2930,"briefTitle":2931,"status":168,"phases":17962,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":2935,"conditions":17963,"interventions":17964},[91],[2937,1062,2938,2914],[1065,2940,2941,1064,1139,2942,2943],{"nctId":17966,"briefTitle":17967,"status":111,"phases":17968,"primaryCompletion":17969,"completion":4980,"start":17970,"enrollment":463,"conditions":17971,"interventions":17973},"NCT02367456","A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients",[91],"2020-01-29","2015-04-28",[16958,2938,17972],"Chronic Myelomonocytic Leukemia",[17974,2940],"PF-04449913",{"nctId":17976,"briefTitle":17977,"status":111,"phases":17978,"primaryCompletion":17979,"completion":17980,"start":17981,"enrollment":4369,"conditions":17982,"interventions":17983},"NCT02038777","A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies",[91],"2021-02-12","2023-12-28","2014-03-25",[2938],[17974,17974,17984,17974,17959,17958,17974,2940,17974,17985],"Low dose ARA-C","LDAC",{"trials":17987,"activeCount":103},[],{"trials":17989,"activeCount":103},[17990,17999],{"nctId":17991,"briefTitle":17992,"status":111,"phases":17993,"primaryCompletion":17994,"completion":17994,"start":17995,"enrollment":562,"conditions":17996,"interventions":17997},"NCT04842604","Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML",[93],"2022-12-02","2021-05-17",[2938,16958,17972],[17998,2940],"Glasdegib",{"nctId":18000,"briefTitle":18001,"status":111,"phases":18002,"primaryCompletion":13669,"completion":3285,"start":18003,"enrollment":18004,"conditions":18005,"interventions":18007},"NCT03416179","A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia",[93],"2018-04-20",730,[18006],"Leukemia, Myeloid, Acute",[18008,18009,18010,18008,18011],"glasdegib","daunorubicin + cytarabine","azacitidine","cytarabine",{"trials":18013,"activeCount":103},[],{"trials":18015,"activeCount":103},[],{"intervention":12291,"totalTrials":2070,"cells":18017},{"EARLY_PHASE1":18018,"PHASE1":18020,"PHASE2":18030,"PHASE3":18036,"PHASE4":18063,"NA":18065},{"trials":18019,"activeCount":103},[],{"trials":18021,"activeCount":103},[18022],{"nctId":18023,"briefTitle":18024,"status":111,"phases":18025,"primaryCompletion":540,"completion":540,"start":18026,"enrollment":5909,"conditions":18027,"interventions":18028},"NCT01534247","A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately",[91],"2012-02",[16],[12302,12312,18029],"CAZ-AVI + metronidazole",{"trials":18031,"activeCount":103},[18032],{"nctId":12283,"briefTitle":12284,"status":111,"phases":18033,"primaryCompletion":12286,"completion":12286,"start":12287,"enrollment":3603,"conditions":18034,"interventions":18035},[92],[12278],[12290,12262,12291],{"trials":18037,"activeCount":103},[18038,18046,18050,18054],{"nctId":18039,"briefTitle":18040,"status":111,"phases":18041,"primaryCompletion":3353,"completion":3353,"start":570,"enrollment":1796,"conditions":18042,"interventions":18044},"NCT01473836","A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection",[93],[18043],"Intra-abdominal Infections",[12291,18045],"Ceftriaxone sodium",{"nctId":12295,"briefTitle":12296,"status":111,"phases":18047,"primaryCompletion":7578,"completion":7578,"start":2450,"enrollment":12298,"conditions":18048,"interventions":18049},[93],[12300],[12302,12291,12262],{"nctId":12304,"briefTitle":12305,"status":111,"phases":18051,"primaryCompletion":12307,"completion":12307,"start":4590,"enrollment":12308,"conditions":18052,"interventions":18053},[93],[6505],[12311,12312,12262],{"nctId":18055,"briefTitle":18056,"status":111,"phases":18057,"primaryCompletion":18058,"completion":18058,"start":18059,"enrollment":2240,"conditions":18060,"interventions":18061},"NCT04927312","Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection",[93],"2022-09-15","2021-10-01",[6505],[18062,12291],"PF-06947386",{"trials":18064,"activeCount":103},[],{"trials":18066,"activeCount":103},[],{"intervention":2024,"totalTrials":2070,"cells":18068},{"EARLY_PHASE1":18069,"PHASE1":18071,"PHASE2":18082,"PHASE3":18106,"PHASE4":18112,"NA":18114},{"trials":18070,"activeCount":103},[],{"trials":18072,"activeCount":103},[18073],{"nctId":18074,"briefTitle":18075,"status":111,"phases":18076,"primaryCompletion":18077,"completion":288,"start":18078,"enrollment":1808,"conditions":18079,"interventions":18081},"NCT01436656","A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma",[91],"2012-10-01","2011-09-05",[18080],"Melanoma and Metastatic Colorectal Cancer",[2024],{"trials":18083,"activeCount":103},[18084,18094,18098,18102],{"nctId":18085,"briefTitle":18086,"status":168,"phases":18087,"primaryCompletion":18088,"completion":18089,"start":18090,"enrollment":1268,"conditions":18091,"interventions":18093},"NCT01981187","LGX818 for Patients With BRAFV600 Mutated Tumors",[92],"2015-09-01","2015-10-13","2014-01-14",[338,18092],"Hematologic Malignancies",[2024],{"nctId":17502,"briefTitle":17503,"status":111,"phases":18095,"primaryCompletion":1914,"completion":1914,"start":17505,"enrollment":2935,"conditions":18096,"interventions":18097},[91,92],[17507],[2024,17444,17482],{"nctId":2014,"briefTitle":2015,"status":111,"phases":18099,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":2020,"conditions":18100,"interventions":18101},[92],[2022],[2024,1304,2025],{"nctId":17510,"briefTitle":17511,"status":111,"phases":18103,"primaryCompletion":17513,"completion":17513,"start":17514,"enrollment":17515,"conditions":18104,"interventions":18105},[92],[1798],[2024,17444,17482,17518,17519,17520],{"trials":18107,"activeCount":103},[18108],{"nctId":17535,"briefTitle":17536,"status":111,"phases":18109,"primaryCompletion":17538,"completion":17539,"start":17540,"enrollment":17541,"conditions":18110,"interventions":18111},[93],[1798],[2024,17444,17544],{"trials":18113,"activeCount":103},[],{"trials":18115,"activeCount":103},[],{"intervention":8296,"totalTrials":2070,"cells":18117},{"EARLY_PHASE1":18118,"PHASE1":18120,"PHASE2":18122,"PHASE3":18148,"PHASE4":18165,"NA":18167},{"trials":18119,"activeCount":103},[],{"trials":18121,"activeCount":103},[],{"trials":18123,"activeCount":103},[18124,18132,18144],{"nctId":18125,"briefTitle":18126,"status":111,"phases":18127,"primaryCompletion":3324,"completion":3324,"start":18128,"enrollment":3254,"conditions":18129,"interventions":18131},"NCT01768117","Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age",[92],"2013-02",[18130],"Meningitis, Meningococcal, Serogroup B",[8296],{"nctId":18133,"briefTitle":18134,"status":111,"phases":18135,"primaryCompletion":18136,"completion":18136,"start":18137,"enrollment":18138,"conditions":18139,"interventions":18141},"NCT01461993","A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17",[92],"2013-07-06","2011-09-28",2499,[10626,18140],"Meningococcal Vaccines",[18142,8296,18143],"rLP2086 and Gardasil","Gardasil",{"nctId":8287,"briefTitle":8288,"status":111,"phases":18145,"primaryCompletion":8290,"completion":8291,"start":8292,"enrollment":8293,"conditions":18146,"interventions":18147},[92],[8295,8296,8297,8298,8299],[8296,8297,2515,8297],{"trials":18149,"activeCount":103},[18150,18157,18161],{"nctId":18151,"briefTitle":18152,"status":111,"phases":18153,"primaryCompletion":2227,"completion":2227,"start":6198,"enrollment":18154,"conditions":18155,"interventions":18156},"NCT01352845","A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to \u003C26 Years.",[93],3301,[16],[8296],{"nctId":8323,"briefTitle":8324,"status":111,"phases":18158,"primaryCompletion":4589,"completion":4589,"start":6208,"enrollment":8326,"conditions":18159,"interventions":18160},[93],[8295],[8296,8296,8296,8329,2515],{"nctId":8331,"briefTitle":8332,"status":111,"phases":18162,"primaryCompletion":8334,"completion":8334,"start":8335,"enrollment":8336,"conditions":18163,"interventions":18164},[93],[8295],[8309,2515,8296,8321],{"trials":18166,"activeCount":103},[],{"trials":18168,"activeCount":103},[],{"intervention":2403,"totalTrials":578,"cells":18170},{"EARLY_PHASE1":18171,"PHASE1":18173,"PHASE2":18191,"PHASE3":18197,"PHASE4":18203,"NA":18205},{"trials":18172,"activeCount":103},[],{"trials":18174,"activeCount":103},[18175,18181,18187],{"nctId":18176,"briefTitle":18177,"status":111,"phases":18178,"primaryCompletion":3642,"completion":2450,"start":3610,"enrollment":7500,"conditions":18179,"interventions":18180},"NCT00420056","An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.",[91],[4349],[2403],{"nctId":18182,"briefTitle":18183,"status":111,"phases":18184,"primaryCompletion":3345,"completion":3345,"start":113,"enrollment":1509,"conditions":18185,"interventions":18186},"NCT01602887","Relative Bioavailability Study",[91],[16],[2403,2403,2403,2403],{"nctId":6260,"briefTitle":6261,"status":111,"phases":18188,"primaryCompletion":6263,"completion":6263,"start":6198,"enrollment":1239,"conditions":18189,"interventions":18190},[91],[16],[1687,2403,1687,2403],{"trials":18192,"activeCount":103},[18193],{"nctId":2394,"briefTitle":2395,"status":111,"phases":18194,"primaryCompletion":2397,"completion":2398,"start":2399,"enrollment":2400,"conditions":18195,"interventions":18196},[92],[2053,25],[2403,2403,1381,2403,1381],{"trials":18198,"activeCount":103},[18199],{"nctId":2464,"briefTitle":2465,"status":111,"phases":18200,"primaryCompletion":2467,"completion":2468,"start":2469,"enrollment":2470,"conditions":18201,"interventions":18202},[93],[25],[2403,1243,1243],{"trials":18204,"activeCount":103},[],{"trials":18206,"activeCount":103},[],{"intervention":18208,"totalTrials":578,"cells":18209},"CP-945,598",{"EARLY_PHASE1":18210,"PHASE1":18212,"PHASE2":18227,"PHASE3":18229,"PHASE4":18253,"NA":18255},{"trials":18211,"activeCount":103},[],{"trials":18213,"activeCount":103},[18214,18221],{"nctId":18215,"briefTitle":18216,"status":111,"phases":18217,"primaryCompletion":4665,"completion":4665,"start":3314,"enrollment":1509,"conditions":18218,"interventions":18220},"NCT00645021","Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug",[91],[2761,18219],"Hepatic Insufficiency",[18208,18208,18208],{"nctId":18222,"briefTitle":18223,"status":111,"phases":18224,"primaryCompletion":4665,"completion":4665,"start":3643,"enrollment":7500,"conditions":18225,"interventions":18226},"NCT00472836","Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug",[91],[2761],[18208,18208],{"trials":18228,"activeCount":103},[],{"trials":18230,"activeCount":103},[18231,18238,18245],{"nctId":18232,"briefTitle":18233,"status":111,"phases":18234,"completion":8170,"start":4692,"enrollment":15543,"conditions":18235,"interventions":18236},"NCT00134199","A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects",[92,93],[2761],[18208,18237],"sibutramine",{"nctId":18239,"briefTitle":18240,"status":168,"phases":18241,"primaryCompletion":8251,"completion":8251,"start":3853,"enrollment":18242,"conditions":18243,"interventions":18244},"NCT00483171","A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients",[93],699,[2761],[18208],{"nctId":18246,"briefTitle":18247,"status":168,"phases":18248,"primaryCompletion":8154,"completion":8251,"start":4847,"enrollment":18249,"conditions":18250,"interventions":18251},"NCT00391196","A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients",[93],975,[2761],[18208,18252],"CP-945,598 Treatment B",{"trials":18254,"activeCount":103},[],{"trials":18256,"activeCount":103},[],{"intervention":12904,"totalTrials":578,"cells":18258},{"EARLY_PHASE1":18259,"PHASE1":18261,"PHASE2":18263,"PHASE3":18265,"PHASE4":18303,"NA":18305},{"trials":18260,"activeCount":103},[],{"trials":18262,"activeCount":103},[],{"trials":18264,"activeCount":103},[],{"trials":18266,"activeCount":103},[18267,18278,18282,18289,18296],{"nctId":18268,"briefTitle":18269,"status":111,"phases":18270,"primaryCompletion":18271,"completion":18271,"start":18272,"enrollment":1982,"conditions":18273,"interventions":18275},"NCT00751062","A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia",[93],"1993-12","1992-11",[18274,12882],"Open Angle Glaucoma",[18276,18277],"timolol","PhXA41",{"nctId":12898,"briefTitle":12899,"status":111,"phases":18279,"primaryCompletion":6016,"completion":6016,"start":4207,"enrollment":12901,"conditions":18280,"interventions":18281},[93],[12881],[12904,12870],{"nctId":18283,"briefTitle":18284,"status":111,"phases":18285,"primaryCompletion":3643,"completion":3643,"start":11417,"enrollment":1893,"conditions":18286,"interventions":18287},"NCT00159653","A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma",[93],[12891,12882],[15314,18288,12904],"Xalatan",{"nctId":18290,"briefTitle":18291,"status":111,"phases":18292,"primaryCompletion":18271,"completion":18271,"start":18293,"enrollment":7696,"conditions":18294,"interventions":18295},"NCT00751049","A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom",[93],"1992-12",[12882,18274],[18276,18277],{"nctId":18297,"briefTitle":18298,"status":111,"phases":18299,"completion":3643,"start":2671,"enrollment":18300,"conditions":18301,"interventions":18302},"NCT00277498","A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma",[93],528,[18274,12882],[15314,18288,12904],{"trials":18304,"activeCount":103},[],{"trials":18306,"activeCount":103},[],{"intervention":18308,"totalTrials":578,"cells":18309},"Clostridium difficile vaccine",{"EARLY_PHASE1":18310,"PHASE1":18312,"PHASE2":18323,"PHASE3":18341,"PHASE4":18360,"NA":18362},{"trials":18311,"activeCount":103},[],{"trials":18313,"activeCount":103},[18314],{"nctId":18315,"briefTitle":18316,"status":111,"phases":18317,"primaryCompletion":18318,"completion":18318,"start":4280,"enrollment":397,"conditions":18319,"interventions":18321},"NCT02725437","Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults",[91],"2017-02",[18320],"Clostridium Difficile Associated Disease",[18322],"Clostridium difficile Vaccine",{"trials":18324,"activeCount":103},[18325,18334],{"nctId":18326,"briefTitle":18327,"status":111,"phases":18328,"primaryCompletion":18329,"completion":18330,"start":18331,"enrollment":1613,"conditions":18332,"interventions":18333},"NCT02561195","A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years",[92],"2017-03-07","2020-02-13","2015-07-16",[18320],[18322],{"nctId":18335,"briefTitle":18336,"status":111,"phases":18337,"primaryCompletion":3586,"completion":3586,"start":7971,"enrollment":18338,"conditions":18339,"interventions":18340},"NCT02117570","A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",[92],185,[18320],[18308,18308],{"trials":18342,"activeCount":103},[18343,18351],{"nctId":18344,"briefTitle":18345,"status":111,"phases":18346,"primaryCompletion":18347,"completion":18347,"start":1236,"enrollment":18348,"conditions":18349,"interventions":18350},"NCT03579459","Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age",[93],"2019-08-06",1317,[18320],[18308],{"nctId":18352,"briefTitle":18353,"status":111,"phases":18354,"primaryCompletion":1096,"completion":1096,"start":18355,"enrollment":18356,"conditions":18357,"interventions":18359},"NCT03090191","Clostridium Difficile Vaccine Efficacy Trial",[93],"2017-03-29",17535,[18358],"Clostridium Difficile Infection",[18308],{"trials":18361,"activeCount":103},[],{"trials":18363,"activeCount":103},[],{"intervention":18365,"totalTrials":578,"cells":18366},"Fx-1006A",{"EARLY_PHASE1":18367,"PHASE1":18369,"PHASE2":18379,"PHASE3":18395,"PHASE4":18410,"NA":18412},{"trials":18368,"activeCount":103},[],{"trials":18370,"activeCount":103},[18371],{"nctId":18372,"briefTitle":18373,"status":111,"phases":18374,"primaryCompletion":523,"completion":523,"start":8252,"enrollment":314,"conditions":18375,"interventions":18378},"NCT01358565","Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction",[91],[18376,18377],"Mild Hepatic Dysfunction","Moderate Hepatic Dysfunction",[18365,18365],{"trials":18380,"activeCount":103},[18381,18388],{"nctId":18382,"briefTitle":18383,"status":111,"phases":18384,"primaryCompletion":10923,"completion":10923,"start":8115,"enrollment":472,"conditions":18385,"interventions":18387},"NCT00694161","The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy",[92],[18386],"Cardiomyopathy",[18365],{"nctId":18389,"briefTitle":18390,"status":111,"phases":18391,"primaryCompletion":10923,"completion":10923,"start":3839,"enrollment":360,"conditions":18392,"interventions":18394},"NCT00630864","The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis",[92],[18393],"Transthyretin-associated Amyloidosis With Polyneuropathy",[18365],{"trials":18396,"activeCount":103},[18397,18404],{"nctId":18398,"briefTitle":18399,"status":111,"phases":18400,"primaryCompletion":8115,"completion":585,"start":4207,"enrollment":1122,"conditions":18401,"interventions":18403},"NCT00791492","An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy",[92,93],[18402,8015],"Familial Amyloid Polyneuropathy",[18365],{"nctId":18405,"briefTitle":18406,"status":111,"phases":18407,"primaryCompletion":11014,"completion":11014,"start":11315,"enrollment":1326,"conditions":18408,"interventions":18409},"NCT00409175","Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis",[92,93],[18402],[18365],{"trials":18411,"activeCount":103},[],{"trials":18413,"activeCount":103},[],{"intervention":18415,"totalTrials":578,"cells":18416},"Vehicle",{"EARLY_PHASE1":18417,"PHASE1":18419,"PHASE2":18430,"PHASE3":18462,"PHASE4":18472,"NA":18474},{"trials":18418,"activeCount":103},[],{"trials":18420,"activeCount":103},[18421],{"nctId":18422,"briefTitle":18423,"status":111,"phases":18424,"primaryCompletion":18425,"completion":18425,"start":18426,"enrollment":4259,"conditions":18427,"interventions":18428},"NCT03260595","A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis",[91],"2017-11-27","2017-09-13",[16,1589],[18429,18415],"Crisaborole ointment 2%",{"trials":18431,"activeCount":103},[18432,18444,18453],{"nctId":18433,"briefTitle":18434,"status":111,"phases":18435,"primaryCompletion":18436,"completion":18436,"start":18437,"enrollment":5909,"conditions":18438,"interventions":18440},"NCT00679770","Study of Different Doses of a Novel Treatment for Onychomycosis",[92],"2007-08-31","2006-06-30",[18439],"Distal, Subungual Onychomycosis",[18441,18442,18443,18415],"AN2690, 2.5%","AN2690, 5%","AN2690, 7.5%",{"nctId":18445,"briefTitle":18446,"status":111,"phases":18447,"primaryCompletion":18448,"completion":18448,"start":18449,"enrollment":18450,"conditions":18451,"interventions":18452},"NCT03903822","Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis",[92],"2020-05-07","2019-05-13",292,[1589],[7595,18415],{"nctId":18454,"briefTitle":18455,"status":111,"phases":18456,"primaryCompletion":18457,"completion":18457,"start":18458,"enrollment":18459,"conditions":18460,"interventions":18461},"NCT03850483","Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis",[92],"2021-04-20","2019-04-08",344,[4401],[7595,18415],{"trials":18463,"activeCount":103},[18464],{"nctId":18465,"briefTitle":18466,"status":111,"phases":18467,"primaryCompletion":7515,"completion":7515,"start":18468,"enrollment":6762,"conditions":18469,"interventions":18470},"NCT04040192","A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis",[93],"2019-09-12",[1589],[18471,18415],"Crisaborole 2%",{"trials":18473,"activeCount":103},[],{"trials":18475,"activeCount":103},[],{"intervention":11551,"totalTrials":578,"cells":18477},{"EARLY_PHASE1":18478,"PHASE1":18480,"PHASE2":18486,"PHASE3":18488,"PHASE4":18506,"NA":18508},{"trials":18479,"activeCount":103},[],{"trials":18481,"activeCount":103},[18482],{"nctId":11545,"briefTitle":11546,"status":111,"phases":18483,"primaryCompletion":7812,"completion":7812,"start":11548,"enrollment":267,"conditions":18484,"interventions":18485},[91],[2526],[11551,11538],{"trials":18487,"activeCount":103},[],{"trials":18489,"activeCount":103},[18490,18494,18498,18502],{"nctId":11575,"briefTitle":11576,"status":111,"phases":18491,"primaryCompletion":11578,"completion":11578,"start":11579,"enrollment":11580,"conditions":18492,"interventions":18493},[93],[2526],[11551,11538,11583],{"nctId":11585,"briefTitle":11586,"status":111,"phases":18495,"primaryCompletion":5899,"completion":5899,"start":2018,"enrollment":11588,"conditions":18496,"interventions":18497},[93],[2526],[11538,11583,11551],{"nctId":11592,"briefTitle":11593,"status":111,"phases":18499,"primaryCompletion":11595,"completion":11595,"start":2281,"enrollment":11596,"conditions":18500,"interventions":18501},[93],[2526],[11551,11551,11551,11538],{"nctId":11614,"briefTitle":11615,"status":111,"phases":18503,"primaryCompletion":11617,"completion":11617,"start":11618,"enrollment":11619,"conditions":18504,"interventions":18505},[93],[2526],[11551,11538,11583],{"trials":18507,"activeCount":103},[],{"trials":18509,"activeCount":103},[],{"intervention":17998,"totalTrials":578,"cells":18511},{"EARLY_PHASE1":18512,"PHASE1":18514,"PHASE2":18542,"PHASE3":18544,"PHASE4":18554,"NA":18556},{"trials":18513,"activeCount":103},[],{"trials":18515,"activeCount":103},[18516,18524,18530],{"nctId":18517,"briefTitle":18518,"status":111,"phases":18519,"primaryCompletion":18520,"completion":1267,"start":18521,"enrollment":1509,"conditions":18522,"interventions":18523},"NCT03130556","A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation",[91],"2017-07-06","2017-05-01",[19],[17998,1272],{"nctId":18525,"briefTitle":18526,"status":111,"phases":18527,"primaryCompletion":4438,"completion":4438,"start":4458,"enrollment":1268,"conditions":18528,"interventions":18529},"NCT02430545","Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics",[91],[19],[17998,1252],{"nctId":18531,"briefTitle":18532,"status":111,"phases":18533,"primaryCompletion":18534,"completion":18535,"start":18536,"enrollment":1268,"conditions":18537,"interventions":18539},"NCT03270878","Glasdegib Absolute Bioavailability Study",[91],"2017-10-06","2017-10-30","2017-09-07",[18538],"Healthy Volunteer Study",[18540,18541],"Glasdegib Oral","Glasdegib IV",{"trials":18543,"activeCount":103},[],{"trials":18545,"activeCount":103},[18546,18550],{"nctId":17991,"briefTitle":17992,"status":111,"phases":18547,"primaryCompletion":17994,"completion":17994,"start":17995,"enrollment":562,"conditions":18548,"interventions":18549},[93],[2938,16958,17972],[17998,2940],{"nctId":18000,"briefTitle":18001,"status":111,"phases":18551,"primaryCompletion":13669,"completion":3285,"start":18003,"enrollment":18004,"conditions":18552,"interventions":18553},[93],[18006],[18008,18009,18010,18008,18011],{"trials":18555,"activeCount":103},[],{"trials":18557,"activeCount":103},[],{"intervention":18559,"totalTrials":578,"cells":18560},"SPM 907",{"EARLY_PHASE1":18561,"PHASE1":18563,"PHASE2":18565,"PHASE3":18573,"PHASE4":18600,"NA":18602},{"trials":18562,"activeCount":103},[],{"trials":18564,"activeCount":103},[],{"trials":18566,"activeCount":103},[18567],{"nctId":18568,"briefTitle":18569,"status":111,"phases":18570,"primaryCompletion":3643,"completion":3643,"start":4679,"conditions":18571,"interventions":18572},"NCT00220389","Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase",[92],[12489],[18559],{"trials":18574,"activeCount":103},[18575,18581,18588,18594],{"nctId":18576,"briefTitle":18577,"status":111,"phases":18578,"primaryCompletion":4258,"completion":4258,"start":11736,"conditions":18579,"interventions":18580},"NCT00138723","Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome",[93],[12489],[18559],{"nctId":18582,"briefTitle":18583,"status":111,"phases":18584,"primaryCompletion":2641,"completion":2641,"start":13035,"conditions":18585,"interventions":18587},"NCT00220402","Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome",[93],[18586],"Overactive Bladder Syndrome",[18559],{"nctId":18589,"briefTitle":18590,"status":111,"phases":18591,"primaryCompletion":4258,"completion":4258,"start":11666,"conditions":18592,"interventions":18593},"NCT00220363","A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome",[93],[18586],[18559],{"nctId":18595,"briefTitle":18596,"status":111,"phases":18597,"primaryCompletion":2641,"completion":2641,"start":4398,"conditions":18598,"interventions":18599},"NCT00220376","Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome",[93],[18586],[18559],{"trials":18601,"activeCount":103},[],{"trials":18603,"activeCount":103},[],{"intervention":18605,"totalTrials":578,"cells":18606},"PF-04965842 200 mg",{"EARLY_PHASE1":18607,"PHASE1":18609,"PHASE2":18611,"PHASE3":18622,"PHASE4":18672,"NA":18674},{"trials":18608,"activeCount":103},[],{"trials":18610,"activeCount":103},[],{"trials":18612,"activeCount":103},[18613],{"nctId":18614,"briefTitle":18615,"status":111,"phases":18616,"primaryCompletion":18617,"completion":18617,"start":18618,"enrollment":787,"conditions":18619,"interventions":18620},"NCT03915496","Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis",[92],"2021-11-16","2020-06-18",[1589],[18605,18621],"PF-04965842 100 mg",{"trials":18623,"activeCount":103},[18624,18633,18654,18662],{"nctId":18625,"briefTitle":18626,"status":111,"phases":18627,"primaryCompletion":18628,"completion":18628,"start":18629,"enrollment":18630,"conditions":18631,"interventions":18632},"NCT03575871","Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis",[93],"2019-08-13","2018-06-29",391,[1933],[18621,18605],{"nctId":18634,"briefTitle":18635,"status":111,"phases":18636,"primaryCompletion":18637,"completion":18638,"start":18639,"enrollment":18640,"conditions":18641,"interventions":18650},"NCT03720470","Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy",[93],"2019-12-27","2020-03-06","2018-10-29",838,[18642,1933,1591,18643,18644,18645,18646,18647,18648,18649],"Dermatitis","Skin Diseases","Skin Diseases, Genetic","Genetic Diseases, Inborn","Skin Diseases, Eczematous","Hypersensitivity","Hypersensitivity, Immediate","Immune System Diseases",[18621,18605,18651,18652,18653],"Dupilumab","Oral Placebo","Injectable Placebo",{"nctId":18655,"briefTitle":18656,"status":111,"phases":18657,"primaryCompletion":16280,"completion":16280,"start":18658,"enrollment":18659,"conditions":18660,"interventions":18661},"NCT03349060","Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis",[93],"2017-12-07",387,[1933],[18621,18605],{"nctId":18663,"briefTitle":18664,"status":111,"phases":18665,"primaryCompletion":18666,"completion":18667,"start":18668,"enrollment":18669,"conditions":18670,"interventions":18671},"NCT03627767","Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects",[93],"2020-09-02","2020-10-07","2018-06-11",1235,[18642,1933,1591,18643,18644,18645,18646,18647,18648,18649],[18621,18605],{"trials":18673,"activeCount":103},[],{"trials":18675,"activeCount":103},[],{"intervention":18621,"totalTrials":578,"cells":18677},{"EARLY_PHASE1":18678,"PHASE1":18680,"PHASE2":18682,"PHASE3":18688,"PHASE4":18706,"NA":18708},{"trials":18679,"activeCount":103},[],{"trials":18681,"activeCount":103},[],{"trials":18683,"activeCount":103},[18684],{"nctId":18614,"briefTitle":18615,"status":111,"phases":18685,"primaryCompletion":18617,"completion":18617,"start":18618,"enrollment":787,"conditions":18686,"interventions":18687},[92],[1589],[18605,18621],{"trials":18689,"activeCount":103},[18690,18694,18698,18702],{"nctId":18625,"briefTitle":18626,"status":111,"phases":18691,"primaryCompletion":18628,"completion":18628,"start":18629,"enrollment":18630,"conditions":18692,"interventions":18693},[93],[1933],[18621,18605],{"nctId":18634,"briefTitle":18635,"status":111,"phases":18695,"primaryCompletion":18637,"completion":18638,"start":18639,"enrollment":18640,"conditions":18696,"interventions":18697},[93],[18642,1933,1591,18643,18644,18645,18646,18647,18648,18649],[18621,18605,18651,18652,18653],{"nctId":18655,"briefTitle":18656,"status":111,"phases":18699,"primaryCompletion":16280,"completion":16280,"start":18658,"enrollment":18659,"conditions":18700,"interventions":18701},[93],[1933],[18621,18605],{"nctId":18663,"briefTitle":18664,"status":111,"phases":18703,"primaryCompletion":18666,"completion":18667,"start":18668,"enrollment":18669,"conditions":18704,"interventions":18705},[93],[18642,1933,1591,18643,18644,18645,18646,18647,18648,18649],[18621,18605],{"trials":18707,"activeCount":103},[],{"trials":18709,"activeCount":103},[],{"intervention":17958,"totalTrials":257,"cells":18711},{"EARLY_PHASE1":18712,"PHASE1":18714,"PHASE2":18724,"PHASE3":18736,"PHASE4":18742,"NA":18744},{"trials":18713,"activeCount":103},[],{"trials":18715,"activeCount":103},[18716,18720],{"nctId":17951,"briefTitle":17952,"status":168,"phases":18717,"primaryCompletion":17954,"completion":17954,"start":5820,"enrollment":1487,"conditions":18718,"interventions":18719},[91],[2938],[17957,17958,17959,2940,17960],{"nctId":17976,"briefTitle":17977,"status":111,"phases":18721,"primaryCompletion":17979,"completion":17980,"start":17981,"enrollment":4369,"conditions":18722,"interventions":18723},[91],[2938],[17974,17974,17984,17974,17959,17958,17974,2940,17974,17985],{"trials":18725,"activeCount":103},[18726],{"nctId":18727,"briefTitle":18728,"status":111,"phases":18729,"primaryCompletion":18730,"completion":18731,"start":18732,"enrollment":18733,"conditions":18734,"interventions":18735},"NCT01546038","A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",[92],"2017-01-03","2019-03-04","2012-06-27",255,[2938],[17974,17984,17974,17960,17974,17959,17958,17974,17959,17958,17974,17984],{"trials":18737,"activeCount":103},[18738],{"nctId":18000,"briefTitle":18001,"status":111,"phases":18739,"primaryCompletion":13669,"completion":3285,"start":18003,"enrollment":18004,"conditions":18740,"interventions":18741},[93],[18006],[18008,18009,18010,18008,18011],{"trials":18743,"activeCount":103},[],{"trials":18745,"activeCount":103},[],{"intervention":12302,"totalTrials":257,"cells":18747},{"EARLY_PHASE1":18748,"PHASE1":18750,"PHASE2":18773,"PHASE3":18775,"PHASE4":18781,"NA":18783},{"trials":18749,"activeCount":103},[],{"trials":18751,"activeCount":103},[18752,18756,18765],{"nctId":18023,"briefTitle":18024,"status":111,"phases":18753,"primaryCompletion":540,"completion":540,"start":18026,"enrollment":5909,"conditions":18754,"interventions":18755},[91],[16],[12302,12312,18029],{"nctId":18757,"briefTitle":18758,"status":111,"phases":18759,"primaryCompletion":605,"completion":605,"start":6207,"enrollment":4369,"conditions":18760,"interventions":18764},"NCT01789528","A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers",[91],[3396,18761,12302,18762,18763,10629],"Open Label","CXL","Effect on Intestinal Flora",[12302,18762],{"nctId":18766,"briefTitle":18767,"status":111,"phases":18768,"primaryCompletion":18769,"completion":18769,"start":1249,"enrollment":1578,"conditions":18770,"interventions":18771},"NCT01920399","A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects",[91],"2013-11",[19],[12302,18772],"0.9% Normal Saline",{"trials":18774,"activeCount":103},[],{"trials":18776,"activeCount":103},[18777],{"nctId":12295,"briefTitle":12296,"status":111,"phases":18778,"primaryCompletion":7578,"completion":7578,"start":2450,"enrollment":12298,"conditions":18779,"interventions":18780},[93],[12300],[12302,12291,12262],{"trials":18782,"activeCount":103},[],{"trials":18784,"activeCount":103},[],{"intervention":12704,"totalTrials":257,"cells":18786},{"EARLY_PHASE1":18787,"PHASE1":18789,"PHASE2":18807,"PHASE3":18809,"PHASE4":18819,"NA":18821},{"trials":18788,"activeCount":103},[],{"trials":18790,"activeCount":103},[18791,18799],{"nctId":18792,"briefTitle":18793,"status":111,"phases":18794,"primaryCompletion":3324,"completion":3324,"start":6198,"enrollment":18795,"conditions":18796,"interventions":18797},"NCT01870986","Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)",[91],210,[16],[12704,18798,18798],"Humira",{"nctId":18800,"briefTitle":18801,"status":111,"phases":18802,"primaryCompletion":12307,"completion":12307,"start":9572,"enrollment":1682,"conditions":18803,"interventions":18804},"NCT02237729","A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))",[91],[10985],[12704,18805,18806],"Adalimumab-US","Adalimumab-EU",{"trials":18808,"activeCount":103},[],{"trials":18810,"activeCount":103},[18811,18815],{"nctId":12696,"briefTitle":12697,"status":111,"phases":18812,"primaryCompletion":12699,"completion":12699,"start":12700,"enrollment":12701,"conditions":18813,"interventions":18814},[93],[22],[12704,4516],{"nctId":12715,"briefTitle":12716,"status":111,"phases":18816,"primaryCompletion":12718,"completion":12719,"start":12720,"enrollment":12721,"conditions":18817,"interventions":18818},[93],[22],[12704,12676],{"trials":18820,"activeCount":103},[],{"trials":18822,"activeCount":103},[],{"intervention":18824,"totalTrials":257,"cells":18825},"Epoetin Hospira",{"EARLY_PHASE1":18826,"PHASE1":18828,"PHASE2":18830,"PHASE3":18832,"PHASE4":18874,"NA":18876},{"trials":18827,"activeCount":103},[],{"trials":18829,"activeCount":103},[],{"trials":18831,"activeCount":103},[],{"trials":18833,"activeCount":103},[18834,18844,18855,18864],{"nctId":18835,"briefTitle":18836,"status":111,"phases":18837,"primaryCompletion":18838,"completion":18838,"start":18839,"enrollment":18840,"conditions":18841,"interventions":18843},"NCT01628107","A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin",[93],"2015-01-02","2012-07-16",406,[18842],"Chronic Renal Failure Requiring Hemodialysis",[18824],{"nctId":18845,"briefTitle":18846,"status":111,"phases":18847,"primaryCompletion":18848,"completion":18848,"start":18849,"enrollment":1313,"conditions":18850,"interventions":18853},"NCT01473420","A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin",[93],"2014-02-28","2012-01-17",[18851,18852],"Chronic Renal Failure","Chronic Kidney Disease",[18824,18854],"Epogen Amgen",{"nctId":18856,"briefTitle":18857,"status":111,"phases":18858,"primaryCompletion":18859,"completion":18859,"start":18860,"enrollment":18861,"conditions":18862,"interventions":18863},"NCT01628120","A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin",[93],"2015-02-13","2012-05-31",170,[18842],[18824],{"nctId":18865,"briefTitle":18866,"status":111,"phases":18867,"primaryCompletion":18868,"completion":18868,"start":18869,"enrollment":18870,"conditions":18871,"interventions":18872},"NCT01473407","A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin",[93],"2014-02-11","2012-01-31",612,[18852,18851],[18824,18873],"Epogen",{"trials":18875,"activeCount":103},[],{"trials":18877,"activeCount":103},[],{"intervention":18879,"totalTrials":257,"cells":18880},"Azithromycin plus chloroquine",{"EARLY_PHASE1":18881,"PHASE1":18883,"PHASE2":18885,"PHASE3":18893,"PHASE4":18922,"NA":18924},{"trials":18882,"activeCount":103},[],{"trials":18884,"activeCount":103},[],{"trials":18886,"activeCount":103},[18887],{"nctId":18888,"briefTitle":18889,"status":111,"phases":18890,"primaryCompletion":10937,"completion":10937,"start":6457,"enrollment":8123,"conditions":18891,"interventions":18892},"NCT00282919","A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria",[92],[14263],[18879],{"trials":18894,"activeCount":103},[18895,18905,18914],{"nctId":18896,"briefTitle":18897,"status":111,"phases":18898,"primaryCompletion":7665,"completion":7665,"start":4847,"enrollment":18899,"conditions":18900,"interventions":18902},"NCT00367653","Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.",[93],397,[18901],"Malaria",[18903,18904],"Azithromycin plus Chloroquine","Mefloquine",{"nctId":18906,"briefTitle":18907,"status":168,"phases":18908,"primaryCompletion":1249,"completion":18769,"start":585,"enrollment":18909,"conditions":18910,"interventions":18912},"NCT01103063","Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa",[93],2891,[18911],"Intermittent Preventive Treatment In Pregnancy (IPTp)",[18879,18913],"sulfadoxine-pyrimethamine",{"nctId":18915,"briefTitle":18916,"status":168,"phases":18917,"primaryCompletion":13117,"completion":1249,"start":524,"enrollment":18918,"conditions":18919,"interventions":18921},"NCT01103713","Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa",[93],168,[18920],"Asymptomatic Parasitemia In Pregnancy",[18879],{"trials":18923,"activeCount":103},[],{"trials":18925,"activeCount":103},[],{"intervention":11583,"totalTrials":257,"cells":18927},{"EARLY_PHASE1":18928,"PHASE1":18930,"PHASE2":18932,"PHASE3":18944,"PHASE4":18958,"NA":18960},{"trials":18929,"activeCount":103},[],{"trials":18931,"activeCount":103},[],{"trials":18933,"activeCount":103},[18934],{"nctId":18935,"briefTitle":18936,"status":111,"phases":18937,"primaryCompletion":18938,"completion":18938,"start":18939,"enrollment":18940,"conditions":18941,"interventions":18942},"NCT03313037","Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age",[92],"2018-12-10","2017-10-10",444,[10940],[11571,18943,11583],"Prevnar 13",{"trials":18945,"activeCount":103},[18946,18950,18954],{"nctId":11575,"briefTitle":11576,"status":111,"phases":18947,"primaryCompletion":11578,"completion":11578,"start":11579,"enrollment":11580,"conditions":18948,"interventions":18949},[93],[2526],[11551,11538,11583],{"nctId":11585,"briefTitle":11586,"status":111,"phases":18951,"primaryCompletion":5899,"completion":5899,"start":2018,"enrollment":11588,"conditions":18952,"interventions":18953},[93],[2526],[11538,11583,11551],{"nctId":11614,"briefTitle":11615,"status":111,"phases":18955,"primaryCompletion":11617,"completion":11617,"start":11618,"enrollment":11619,"conditions":18956,"interventions":18957},[93],[2526],[11551,11538,11583],{"trials":18959,"activeCount":103},[],{"trials":18961,"activeCount":103},[],{"intervention":12151,"totalTrials":257,"cells":18963},{"EARLY_PHASE1":18964,"PHASE1":18966,"PHASE2":18968,"PHASE3":18970,"PHASE4":18988,"NA":18990},{"trials":18965,"activeCount":103},[],{"trials":18967,"activeCount":103},[],{"trials":18969,"activeCount":103},[],{"trials":18971,"activeCount":103},[18972,18976,18980,18984],{"nctId":12145,"briefTitle":12146,"status":168,"phases":18973,"primaryCompletion":8154,"completion":8154,"start":11807,"enrollment":12148,"conditions":18974,"interventions":18975},[93],[12130],[12151,12116],{"nctId":12160,"briefTitle":12161,"status":111,"phases":18977,"primaryCompletion":4665,"completion":4665,"start":3073,"enrollment":12163,"conditions":18978,"interventions":18979},[93],[6589,6117],[12116,12151],{"nctId":12167,"briefTitle":12168,"status":168,"phases":18981,"primaryCompletion":8154,"completion":8154,"start":4616,"enrollment":12170,"conditions":18982,"interventions":18983},[93],[6117],[12116,12173],{"nctId":12175,"briefTitle":12176,"status":168,"phases":18985,"primaryCompletion":11609,"completion":11609,"start":11609,"enrollment":1087,"conditions":18986,"interventions":18987},[93],[12130],[12132,12151],{"trials":18989,"activeCount":103},[],{"trials":18991,"activeCount":103},[],{"intervention":9417,"totalTrials":257,"cells":18993},{"EARLY_PHASE1":18994,"PHASE1":18996,"PHASE2":19005,"PHASE3":19025,"PHASE4":19031,"NA":19033},{"trials":18995,"activeCount":103},[],{"trials":18997,"activeCount":103},[18998],{"nctId":18999,"briefTitle":19000,"status":111,"phases":19001,"primaryCompletion":3324,"completion":7578,"start":1248,"enrollment":19002,"conditions":19003,"interventions":19004},"NCT02015156","A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)",[91],162,[16],[9416,9417],{"trials":19006,"activeCount":103},[19007,19018],{"nctId":19008,"briefTitle":19009,"status":111,"phases":19010,"primaryCompletion":11736,"completion":11736,"start":15036,"enrollment":314,"conditions":19011,"interventions":19013},"NCT00043394","CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer",[92],[19012],"Carcinoma, Breast",[19014,9417,19015,9417,19016,9417,19017,9417],"0.04 mg\u002Fkg CpG 7909","0.08 mg\u002Fkg CpG 7909","0.12 mg\u002Fkg CpG 7909","0.16 mg\u002Fkg CpG 7909",{"nctId":19019,"briefTitle":19020,"status":111,"phases":19021,"primaryCompletion":4679,"completion":4679,"start":11782,"enrollment":1268,"conditions":19022,"interventions":19024},"NCT00031278","Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer",[91,92],[19023],"Carcinoma, Metastatic Breast",[2647,9417,2647,9417,2647,9417,2647,9417],{"trials":19026,"activeCount":103},[19027],{"nctId":9407,"briefTitle":9408,"status":111,"phases":19028,"primaryCompletion":9410,"completion":9411,"start":9412,"enrollment":9413,"conditions":19029,"interventions":19030},[93],[1369],[9416,1771,9417,1771],{"trials":19032,"activeCount":103},[],{"trials":19034,"activeCount":103},[],{"intervention":19036,"totalTrials":257,"cells":19037},"UK-390,957",{"EARLY_PHASE1":19038,"PHASE1":19040,"PHASE2":19042,"PHASE3":19044,"PHASE4":19072,"NA":19074},{"trials":19039,"activeCount":103},[],{"trials":19041,"activeCount":103},[],{"trials":19043,"activeCount":103},[],{"trials":19045,"activeCount":103},[19046,19054,19060,19066],{"nctId":19047,"briefTitle":19048,"status":111,"phases":19049,"primaryCompletion":6457,"completion":6457,"start":12069,"enrollment":19050,"conditions":19051,"interventions":19053},"NCT00219609","Assessment Of Safety Of UK-390,957",[92,93],1058,[19052],"Ejaculation",[19036],{"nctId":19055,"briefTitle":19056,"status":111,"phases":19057,"primaryCompletion":14118,"completion":14118,"start":11727,"enrollment":4421,"conditions":19058,"interventions":19059},"NCT00143117","Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation",[92,93],[19052],[19036],{"nctId":19061,"briefTitle":19062,"status":111,"phases":19063,"primaryCompletion":11417,"completion":11417,"start":12069,"enrollment":885,"conditions":19064,"interventions":19065},"NCT00219635","Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation",[92,93],[19052],[19036],{"nctId":19067,"briefTitle":19068,"status":111,"phases":19069,"primaryCompletion":14118,"completion":14118,"start":11727,"enrollment":4421,"conditions":19070,"interventions":19071},"NCT00219583","Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation",[92,93],[19052],[19036],{"trials":19073,"activeCount":103},[],{"trials":19075,"activeCount":103},[],{"intervention":19077,"totalTrials":257,"cells":19078},"Azithromycin\u002FChloroquine",{"EARLY_PHASE1":19079,"PHASE1":19081,"PHASE2":19083,"PHASE3":19085,"PHASE4":19116,"NA":19118},{"trials":19080,"activeCount":103},[],{"trials":19082,"activeCount":103},[],{"trials":19084,"activeCount":103},[],{"trials":19086,"activeCount":103},[19087,19095,19102,19108],{"nctId":19088,"briefTitle":19089,"status":168,"phases":19090,"completion":4657,"start":11686,"enrollment":4259,"conditions":19091,"interventions":19093},"NCT00084240","Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia",[92,93],[19092],"Malaria, Falciparum",[19077,19094],"Sulfadoxine-Pyrimethamine\u002FChloroquine",{"nctId":19096,"briefTitle":19097,"status":111,"phases":19098,"completion":11417,"start":13035,"enrollment":12110,"conditions":19099,"interventions":19100},"NCT00084227","Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America",[92,93],[19092],[19077,19101],"Atovaquone\u002FProguanil",{"nctId":19103,"briefTitle":19104,"status":111,"phases":19105,"completion":12004,"start":13902,"enrollment":15310,"conditions":19106,"interventions":19107},"NCT00082576","Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa",[92,93],[19092],[19077,18904],{"nctId":19109,"briefTitle":19110,"status":111,"phases":19111,"completion":12069,"start":16955,"enrollment":19112,"conditions":19113,"interventions":19115},"NCT00074841","Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India",[92,93],230,[19114],"PLASMODIUM FALCIPARUM MALARIA",[19077,19094],{"trials":19117,"activeCount":103},[],{"trials":19119,"activeCount":103},[],{"intervention":8174,"totalTrials":257,"cells":19121},{"EARLY_PHASE1":19122,"PHASE1":19124,"PHASE2":19126,"PHASE3":19148,"PHASE4":19154,"NA":19156},{"trials":19123,"activeCount":103},[],{"trials":19125,"activeCount":103},[],{"trials":19127,"activeCount":103},[19128,19134,19141],{"nctId":19129,"briefTitle":19130,"status":649,"phases":19131,"start":11314,"enrollment":103,"conditions":19132,"interventions":19133},"NCT00471159","A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.",[92],[25],[432,8174],{"nctId":19135,"briefTitle":19136,"status":111,"phases":19137,"primaryCompletion":11895,"completion":11895,"start":3073,"enrollment":1578,"conditions":19138,"interventions":19140},"NCT00043420","CPG 7909 in Patients With Cutaneous T-Cell Lymphoma",[91,92],[19139],"Lymphoma, T-Cell, Cutaneous",[8174,8174,8174,8174,8174,8174,8174,8174],{"nctId":19142,"briefTitle":19143,"status":111,"phases":19144,"primaryCompletion":3643,"completion":3643,"start":15036,"enrollment":1257,"conditions":19145,"interventions":19147},"NCT00043368","PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)",[92],[1798,25,919,19146,376],"Lymphoma, T-Cell",[8174],{"trials":19149,"activeCount":103},[19150],{"nctId":8167,"briefTitle":8168,"status":168,"phases":19151,"primaryCompletion":3839,"completion":3839,"start":8170,"enrollment":8171,"conditions":19152,"interventions":19153},[93],[376],[1770,1764,8174,1770,8175],{"trials":19155,"activeCount":103},[],{"trials":19157,"activeCount":103},[],{"intervention":8309,"totalTrials":257,"cells":19159},{"EARLY_PHASE1":19160,"PHASE1":19162,"PHASE2":19164,"PHASE3":19183,"PHASE4":19193,"NA":19195},{"trials":19161,"activeCount":103},[],{"trials":19163,"activeCount":103},[],{"trials":19165,"activeCount":103},[19166,19170],{"nctId":8302,"briefTitle":8303,"status":111,"phases":19167,"primaryCompletion":8305,"completion":8305,"start":3798,"enrollment":8306,"conditions":19168,"interventions":19169},[92],[8295],[8309,2515],{"nctId":19171,"briefTitle":19172,"status":168,"phases":19173,"primaryCompletion":18058,"completion":18058,"start":19174,"enrollment":7411,"conditions":19175,"interventions":19176},"NCT04645966","A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants",[92],"2020-11-26",[8295],[8309,19177,19177,19178,19179,19180,19181,19182],"Bivalent rLP2086","Bexsero","Prophylactic Liquid Paracetamol","Nimenrix","Scheduled Liquid Paracetamol","Therapeutic Liquid Paracetamol",{"trials":19184,"activeCount":103},[19185,19189],{"nctId":8313,"briefTitle":8314,"status":111,"phases":19186,"primaryCompletion":8316,"completion":8316,"start":3798,"enrollment":8317,"conditions":19187,"interventions":19188},[93],[8295],[8309,2515,8320,8321],{"nctId":8331,"briefTitle":8332,"status":111,"phases":19190,"primaryCompletion":8334,"completion":8334,"start":8335,"enrollment":8336,"conditions":19191,"interventions":19192},[93],[8295],[8309,2515,8296,8321],{"trials":19194,"activeCount":103},[],{"trials":19196,"activeCount":103},[],{"intervention":9416,"totalTrials":257,"cells":19198},{"EARLY_PHASE1":19199,"PHASE1":19201,"PHASE2":19214,"PHASE3":19216,"PHASE4":19233,"NA":19235},{"trials":19200,"activeCount":103},[],{"trials":19202,"activeCount":103},[19203,19207],{"nctId":18999,"briefTitle":19000,"status":111,"phases":19204,"primaryCompletion":3324,"completion":7578,"start":1248,"enrollment":19002,"conditions":19205,"interventions":19206},[91],[16],[9416,9417],{"nctId":19208,"briefTitle":19209,"status":111,"phases":19210,"primaryCompletion":2449,"completion":2449,"start":113,"enrollment":3587,"conditions":19211,"interventions":19212},"NCT01603264","A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)",[91],[16],[9416,19213,19213],"Herceptin",{"trials":19215,"activeCount":103},[],{"trials":19217,"activeCount":103},[19218,19229],{"nctId":19219,"briefTitle":19220,"status":111,"phases":19221,"primaryCompletion":1401,"completion":1401,"start":19222,"enrollment":19223,"conditions":19224,"interventions":19225},"NCT02187744","A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)",[93],"2014-09-23",226,[5921],[9416,19226,19227,19228,19226,19227],"Taxotere®","Paraplatin®","Trastuzumab-EU",{"nctId":9407,"briefTitle":9408,"status":111,"phases":19230,"primaryCompletion":9410,"completion":9411,"start":9412,"enrollment":9413,"conditions":19231,"interventions":19232},[93],[1369],[9416,1771,9417,1771],{"trials":19234,"activeCount":103},[],{"trials":19236,"activeCount":103},[],{"intervention":19238,"totalTrials":257,"cells":19239},"Tanezumab 10 mg",{"EARLY_PHASE1":19240,"PHASE1":19242,"PHASE2":19244,"PHASE3":19268,"PHASE4":19278,"NA":19280},{"trials":19241,"activeCount":103},[],{"trials":19243,"activeCount":103},[],{"trials":19245,"activeCount":103},[19246,19258],{"nctId":19247,"briefTitle":19248,"status":168,"phases":19249,"primaryCompletion":19250,"completion":19251,"start":19252,"enrollment":19253,"conditions":19254,"interventions":19255},"NCT00994890","A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections",[92],"2010-12-07","2011-03-01","2009-11-17",679,[11347,12099],[19256,19257,19238],"Tanezumab 2.5 mg","Tanezumab 5 mg",{"nctId":19259,"briefTitle":19260,"status":168,"phases":19261,"primaryCompletion":19262,"completion":19263,"start":19264,"enrollment":11370,"conditions":19265,"interventions":19266},"NCT00924664","Long Term Safety Study of Tanezumab in Chronic Low Back Pain",[92],"2010-11-30","2011-06-22","2009-08-20",[11337],[19267,19238],"Tanezumab 20 mg",{"trials":19269,"activeCount":103},[19270,19274],{"nctId":11364,"briefTitle":11365,"status":111,"phases":19271,"primaryCompletion":11367,"completion":11368,"start":11369,"enrollment":11370,"conditions":19272,"interventions":19273},[93],[11282],[11373,11374,11309],{"nctId":11401,"briefTitle":11402,"status":111,"phases":19275,"primaryCompletion":11404,"completion":11405,"start":11406,"enrollment":11407,"conditions":19276,"interventions":19277},[93],[11409,11282],[11373,11374,11309],{"trials":19279,"activeCount":103},[],{"trials":19281,"activeCount":103},[],{"intervention":19283,"totalTrials":502,"cells":19284},"AN2728 Topical Ointment, 2%",{"EARLY_PHASE1":19285,"PHASE1":19287,"PHASE2":19289,"PHASE3":19297,"PHASE4":19314,"NA":19316},{"trials":19286,"activeCount":103},[],{"trials":19288,"activeCount":103},[],{"trials":19290,"activeCount":103},[19291],{"nctId":19292,"briefTitle":19293,"status":111,"phases":19294,"primaryCompletion":3353,"completion":3345,"start":540,"enrollment":2218,"conditions":19295,"interventions":19296},"NCT01652885","Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis",[91,92],[1933],[19283],{"trials":19298,"activeCount":103},[19299,19307],{"nctId":19300,"briefTitle":19301,"status":111,"phases":19302,"primaryCompletion":4589,"completion":4589,"start":605,"enrollment":19303,"conditions":19304,"interventions":19305},"NCT02118766","Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis",[93],763,[1933],[19283,19306],"Matching vehicle control",{"nctId":19308,"briefTitle":19309,"status":111,"phases":19310,"primaryCompletion":4589,"completion":4589,"start":605,"enrollment":19311,"conditions":19312,"interventions":19313},"NCT02118792","Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis",[93],764,[1933],[19283,19306],{"trials":19315,"activeCount":103},[],{"trials":19317,"activeCount":103},[],{"intervention":19319,"totalTrials":502,"cells":19320},"Taxotere",{"EARLY_PHASE1":19321,"PHASE1":19323,"PHASE2":19337,"PHASE3":19339,"PHASE4":19348,"NA":19350},{"trials":19322,"activeCount":103},[],{"trials":19324,"activeCount":103},[19325,19331],{"nctId":19326,"briefTitle":19327,"status":111,"phases":19328,"primaryCompletion":4665,"completion":4608,"start":12395,"enrollment":525,"conditions":19329,"interventions":19330},"NCT00291577","Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer",[91],[25],[4327,19319],{"nctId":19332,"briefTitle":19333,"status":111,"phases":19334,"primaryCompletion":9544,"completion":9544,"start":4615,"enrollment":1239,"conditions":19335,"interventions":19336},"NCT00372424","Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive",[91],[31],[19213,4327,19319],{"trials":19338,"activeCount":103},[],{"trials":19340,"activeCount":103},[19341],{"nctId":19342,"briefTitle":19343,"status":111,"phases":19344,"primaryCompletion":11988,"completion":3313,"start":1701,"enrollment":19345,"conditions":19346,"interventions":19347},"NCT00393939","Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer",[93],594,[25],[4851,19319],{"trials":19349,"activeCount":103},[],{"trials":19351,"activeCount":103},[],{"intervention":19353,"totalTrials":502,"cells":19354},"Anidulafungin, VER002",{"EARLY_PHASE1":19355,"PHASE1":19357,"PHASE2":19359,"PHASE3":19373,"PHASE4":19381,"NA":19383},{"trials":19356,"activeCount":103},[],{"trials":19358,"activeCount":103},[],{"trials":19360,"activeCount":103},[19361,19367],{"nctId":19362,"briefTitle":19363,"status":111,"phases":19364,"completion":4399,"start":4667,"enrollment":941,"conditions":19365,"interventions":19366},"NCT00037219","The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.",[92],[15545],[19353],{"nctId":19368,"briefTitle":19369,"status":111,"phases":19370,"completion":11727,"start":11765,"enrollment":99,"conditions":19371,"interventions":19372},"NCT00041704","The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)",[92],[15545],[19353],{"trials":19374,"activeCount":103},[19375],{"nctId":19376,"briefTitle":19377,"status":111,"phases":19378,"completion":11676,"start":11807,"enrollment":1780,"conditions":19379,"interventions":19380},"NCT00037206","A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).",[92,93],[16579],[19353],{"trials":19382,"activeCount":103},[],{"trials":19384,"activeCount":103},[],{"intervention":19386,"totalTrials":502,"cells":19387},"Novel Ibuprofen",{"EARLY_PHASE1":19388,"PHASE1":19390,"PHASE2":19392,"PHASE3":19394,"PHASE4":19417,"NA":19419},{"trials":19389,"activeCount":103},[],{"trials":19391,"activeCount":103},[],{"trials":19393,"activeCount":103},[],{"trials":19395,"activeCount":103},[19396,19403,19410],{"nctId":19397,"briefTitle":19398,"status":111,"phases":19399,"primaryCompletion":585,"completion":585,"start":3642,"enrollment":162,"conditions":19400,"interventions":19401},"NCT01077973","Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache",[93],[34],[19386,19402],"Standard Ibuprofen",{"nctId":19404,"briefTitle":19405,"status":111,"phases":19406,"primaryCompletion":586,"completion":561,"start":4206,"enrollment":19407,"conditions":19408,"interventions":19409},"NCT01098747","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain",[93],335,[34],[19386,19402,19402],{"nctId":19411,"briefTitle":19405,"status":111,"phases":19412,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":19413,"conditions":19414,"interventions":19415},"NCT01216163",[93],218,[34],[19386,19416],"Acetaminophen",{"trials":19418,"activeCount":103},[],{"trials":19420,"activeCount":103},[],{"intervention":19402,"totalTrials":502,"cells":19422},{"EARLY_PHASE1":19423,"PHASE1":19425,"PHASE2":19427,"PHASE3":19429,"PHASE4":19446,"NA":19448},{"trials":19424,"activeCount":103},[],{"trials":19426,"activeCount":103},[],{"trials":19428,"activeCount":103},[],{"trials":19430,"activeCount":103},[19431,19435,19439],{"nctId":19397,"briefTitle":19398,"status":111,"phases":19432,"primaryCompletion":585,"completion":585,"start":3642,"enrollment":162,"conditions":19433,"interventions":19434},[93],[34],[19386,19402],{"nctId":19404,"briefTitle":19405,"status":111,"phases":19436,"primaryCompletion":586,"completion":561,"start":4206,"enrollment":19407,"conditions":19437,"interventions":19438},[93],[34],[19386,19402,19402],{"nctId":19440,"briefTitle":19441,"status":111,"phases":19442,"primaryCompletion":2450,"completion":2450,"start":2661,"enrollment":19223,"conditions":19443,"interventions":19444},"NCT01362491","Ibuprofen Sodium Tension Headache Study",[93],[34],[19445,19402],"Ibuprofen Sodium",{"trials":19447,"activeCount":103},[],{"trials":19449,"activeCount":103},[],{"intervention":17284,"totalTrials":502,"cells":19451},{"EARLY_PHASE1":19452,"PHASE1":19454,"PHASE2":19463,"PHASE3":19465,"PHASE4":19475,"NA":19477},{"trials":19453,"activeCount":103},[],{"trials":19455,"activeCount":103},[19456],{"nctId":19457,"briefTitle":19458,"status":649,"phases":19459,"start":4847,"enrollment":103,"conditions":19460,"interventions":19461},"NCT00376285","Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033",[91],[2761],[19462,17284],"CP-742,033",{"trials":19464,"activeCount":103},[],{"trials":19466,"activeCount":103},[19467,19471],{"nctId":17278,"briefTitle":17279,"status":111,"phases":19468,"completion":12004,"start":4692,"enrollment":1326,"conditions":19469,"interventions":19470},[93],[12979],[17283,17284],{"nctId":17309,"briefTitle":17310,"status":168,"phases":19472,"primaryCompletion":4615,"completion":4615,"start":4692,"enrollment":713,"conditions":19473,"interventions":19474},[93],[17313],[12983,12996,17315],{"trials":19476,"activeCount":103},[],{"trials":19478,"activeCount":103},[],{"intervention":19480,"totalTrials":502,"cells":19481},"Ceftaroline fosamil",{"EARLY_PHASE1":19482,"PHASE1":19484,"PHASE2":19486,"PHASE3":19500,"PHASE4":19518,"NA":19520},{"trials":19483,"activeCount":103},[],{"trials":19485,"activeCount":103},[],{"trials":19487,"activeCount":103},[19488],{"nctId":19489,"briefTitle":19490,"status":168,"phases":19491,"primaryCompletion":19492,"completion":19492,"start":19493,"enrollment":1625,"conditions":19494,"interventions":19496},"NCT02424734","Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis",[92],"2017-12-26","2015-08-04",[19495],"Late-onset Sepsis",[19497,19498,19499],"Ceftaroline Fosamil","Ampicillin","Aminoglycoside",{"trials":19501,"activeCount":103},[19502,19512],{"nctId":19503,"briefTitle":19504,"status":111,"phases":19505,"primaryCompletion":1288,"completion":11956,"start":113,"enrollment":19506,"conditions":19507,"interventions":19509},"NCT01499277","Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections",[93],802,[19508],"Complicated Skin and Soft Tissue Infection",[19480,19510,19511],"Vancomycin","Aztreonam",{"nctId":19513,"briefTitle":19514,"status":168,"phases":19515,"primaryCompletion":11956,"completion":11956,"start":1288,"enrollment":257,"conditions":19516,"interventions":19517},"NCT02202135","Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.",[93],[19508],[19480,19510,19511],{"trials":19519,"activeCount":103},[],{"trials":19521,"activeCount":103},[],{"intervention":19523,"totalTrials":502,"cells":19524},"sumanirole",{"EARLY_PHASE1":19525,"PHASE1":19527,"PHASE2":19529,"PHASE3":19531,"PHASE4":19555,"NA":19557},{"trials":19526,"activeCount":103},[],{"trials":19528,"activeCount":103},[],{"trials":19530,"activeCount":103},[],{"trials":19532,"activeCount":103},[19533,19539,19547],{"nctId":19534,"briefTitle":19535,"status":111,"phases":19536,"completion":7675,"start":12607,"enrollment":1147,"conditions":19537,"interventions":19538},"NCT00058838","Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease",[93],[13750],[19523],{"nctId":19540,"briefTitle":19541,"status":111,"phases":19542,"completion":12607,"start":19543,"enrollment":130,"conditions":19544,"interventions":19545},"NCT00036218","Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.",[93],"2001-12",[13750],[19523,19546],"ropinirole",{"nctId":19548,"briefTitle":19549,"status":168,"phases":19550,"completion":4702,"start":19551,"enrollment":19552,"conditions":19553,"interventions":19554},"NCT00036205","Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease",[93],"2000-08",984,[13750],[19523],{"trials":19556,"activeCount":103},[],{"trials":19558,"activeCount":103},[],{"intervention":7669,"totalTrials":502,"cells":19560},{"EARLY_PHASE1":19561,"PHASE1":19563,"PHASE2":19574,"PHASE3":19576,"PHASE4":19586,"NA":19588},{"trials":19562,"activeCount":103},[],{"trials":19564,"activeCount":103},[19565],{"nctId":19566,"briefTitle":19567,"status":111,"phases":19568,"enrollment":8373,"conditions":19569,"interventions":19571},"NCT00000966","A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS",[91],[19570,10974],"Toxoplasmosis, Cerebral",[15250,19572,19573],"Pyrimethamine","Leucovorin calcium",{"trials":19575,"activeCount":103},[],{"trials":19577,"activeCount":103},[19578,19582],{"nctId":7662,"briefTitle":7663,"status":111,"phases":19579,"primaryCompletion":7665,"completion":7665,"start":7666,"conditions":19580,"interventions":19581},[93],[2022],[1990,7669,7670],{"nctId":7672,"briefTitle":7673,"status":111,"phases":19583,"primaryCompletion":7675,"start":7676,"conditions":19584,"interventions":19585},[93],[2022],[3328,1990,7679,7669],{"trials":19587,"activeCount":103},[],{"trials":19589,"activeCount":103},[],{"intervention":13798,"totalTrials":502,"cells":19591},{"EARLY_PHASE1":19592,"PHASE1":19594,"PHASE2":19606,"PHASE3":19608,"PHASE4":19614,"NA":19616},{"trials":19593,"activeCount":103},[],{"trials":19595,"activeCount":103},[19596,19602],{"nctId":19597,"briefTitle":19598,"status":111,"phases":19599,"primaryCompletion":3334,"completion":3334,"start":114,"enrollment":1509,"conditions":19600,"interventions":19601},"NCT01458743","Ceftaroline China Pharmacokinetics Study",[91],[16],[13798,13798],{"nctId":17076,"briefTitle":17077,"status":111,"phases":19603,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":1548,"conditions":19604,"interventions":19605},[91],[17080],[17082,13798,17083,6111],{"trials":19607,"activeCount":103},[],{"trials":19609,"activeCount":103},[19610],{"nctId":13790,"briefTitle":13791,"status":111,"phases":19611,"primaryCompletion":6198,"completion":6198,"start":2883,"enrollment":13793,"conditions":19612,"interventions":19613},[93],[13795,13796],[13798,13779],{"trials":19615,"activeCount":103},[],{"trials":19617,"activeCount":103},[],{"intervention":3080,"totalTrials":502,"cells":19619},{"EARLY_PHASE1":19620,"PHASE1":19622,"PHASE2":19628,"PHASE3":19634,"PHASE4":19640,"NA":19642},{"trials":19621,"activeCount":103},[],{"trials":19623,"activeCount":103},[19624],{"nctId":8112,"briefTitle":8113,"status":111,"phases":19625,"primaryCompletion":4221,"completion":561,"start":8115,"enrollment":3229,"conditions":19626,"interventions":19627},[91],[2886],[3080,2890,2889],{"trials":19629,"activeCount":103},[19630],{"nctId":3070,"briefTitle":3071,"status":168,"phases":19631,"completion":3073,"start":3074,"enrollment":3075,"conditions":19632,"interventions":19633},[92],[3077,1028],[3079,1335,3080,1768],{"trials":19635,"activeCount":103},[19636],{"nctId":2033,"briefTitle":2034,"status":111,"phases":19637,"primaryCompletion":2036,"completion":1169,"start":2037,"enrollment":2038,"conditions":19638,"interventions":19639},[93],[2040],[1812,1832,1304,1335,2042,2043],{"trials":19641,"activeCount":103},[],{"trials":19643,"activeCount":103},[],{"intervention":18252,"totalTrials":502,"cells":19645},{"EARLY_PHASE1":19646,"PHASE1":19648,"PHASE2":19650,"PHASE3":19652,"PHASE4":19673,"NA":19675},{"trials":19647,"activeCount":103},[],{"trials":19649,"activeCount":103},[],{"trials":19651,"activeCount":103},[],{"trials":19653,"activeCount":103},[19654,19662,19666],{"nctId":19655,"briefTitle":19656,"status":168,"phases":19657,"primaryCompletion":8251,"completion":8251,"start":12128,"enrollment":19658,"conditions":19659,"interventions":19660},"NCT00375401","A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety",[93],2536,[2761],[19661,18252],"CP-945,598 Treatment A",{"nctId":18246,"briefTitle":18247,"status":168,"phases":19663,"primaryCompletion":8154,"completion":8251,"start":4847,"enrollment":18249,"conditions":19664,"interventions":19665},[93],[2761],[18208,18252],{"nctId":19667,"briefTitle":19668,"status":168,"phases":19669,"primaryCompletion":4608,"completion":4608,"start":1701,"enrollment":19670,"conditions":19671,"interventions":19672},"NCT00396448","Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.",[93],1253,[2761],[18252,19661],{"trials":19674,"activeCount":103},[],{"trials":19676,"activeCount":103},[],{"intervention":19678,"totalTrials":502,"cells":19679},"Esreboxetine",{"EARLY_PHASE1":19680,"PHASE1":19682,"PHASE2":19688,"PHASE3":19696,"PHASE4":19707,"NA":19709},{"trials":19681,"activeCount":103},[],{"trials":19683,"activeCount":103},[19684],{"nctId":17037,"briefTitle":17038,"status":111,"phases":19685,"primaryCompletion":4627,"completion":4627,"start":8154,"enrollment":35,"conditions":19686,"interventions":19687},[91],[17041],[17043,17044],{"trials":19689,"activeCount":103},[19690],{"nctId":19691,"briefTitle":19692,"status":111,"phases":19693,"primaryCompletion":4646,"completion":4646,"start":8115,"enrollment":13215,"conditions":19694,"interventions":19695},"NCT00752505","A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.",[92],[17041],[19678,19678],{"trials":19697,"activeCount":103},[19698],{"nctId":19699,"briefTitle":19700,"status":649,"phases":19701,"primaryCompletion":19702,"completion":19703,"start":19704,"enrollment":103,"conditions":19705,"interventions":19706},"NCT00796601","Maintenance of Efficacy.",[93],"2010-05-01","2010-11-01","2009-05-01",[17041],[19678],{"trials":19708,"activeCount":103},[],{"trials":19710,"activeCount":103},[],{"intervention":19712,"totalTrials":502,"cells":19713},"Eletriptan 40 mg",{"EARLY_PHASE1":19714,"PHASE1":19716,"PHASE2":19718,"PHASE3":19720,"PHASE4":19753,"NA":19755},{"trials":19715,"activeCount":103},[],{"trials":19717,"activeCount":103},[],{"trials":19719,"activeCount":103},[],{"trials":19721,"activeCount":103},[19722,19734,19744],{"nctId":19723,"briefTitle":19724,"status":111,"phases":19725,"primaryCompletion":19726,"completion":19726,"start":19727,"enrollment":19728,"conditions":19729,"interventions":19730},"NCT01986270","Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo",[93],"1998-01","1996-12",1141,[10577],[19712,19731,19732,19733],"Eletriptan 80 mg","Sumatriptan 25 mg","Sumatriptan 50 mg",{"nctId":19735,"briefTitle":19736,"status":111,"phases":19737,"primaryCompletion":19738,"completion":19738,"start":19739,"enrollment":19740,"conditions":19741,"interventions":19742},"NCT01978496","Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine",[93],"1997-12","1996-07",1334,[10577],[19743,19712,19731],"Eletriptan 20 mg",{"nctId":19745,"briefTitle":19746,"status":111,"phases":19747,"primaryCompletion":19726,"completion":19726,"start":19748,"enrollment":19749,"conditions":19750,"interventions":19751},"NCT01986088","Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study",[93],"1996-11",1008,[10577],[19712,19731,19733,19752],"Sumatriptan 100 mg",{"trials":19754,"activeCount":103},[],{"trials":19756,"activeCount":103},[],{"intervention":19731,"totalTrials":502,"cells":19758},{"EARLY_PHASE1":19759,"PHASE1":19761,"PHASE2":19763,"PHASE3":19765,"PHASE4":19779,"NA":19781},{"trials":19760,"activeCount":103},[],{"trials":19762,"activeCount":103},[],{"trials":19764,"activeCount":103},[],{"trials":19766,"activeCount":103},[19767,19771,19775],{"nctId":19723,"briefTitle":19724,"status":111,"phases":19768,"primaryCompletion":19726,"completion":19726,"start":19727,"enrollment":19728,"conditions":19769,"interventions":19770},[93],[10577],[19712,19731,19732,19733],{"nctId":19735,"briefTitle":19736,"status":111,"phases":19772,"primaryCompletion":19738,"completion":19738,"start":19739,"enrollment":19740,"conditions":19773,"interventions":19774},[93],[10577],[19743,19712,19731],{"nctId":19745,"briefTitle":19746,"status":111,"phases":19776,"primaryCompletion":19726,"completion":19726,"start":19748,"enrollment":19749,"conditions":19777,"interventions":19778},[93],[10577],[19712,19731,19733,19752],{"trials":19780,"activeCount":103},[],{"trials":19782,"activeCount":103},[],{"intervention":9427,"totalTrials":502,"cells":19784},{"EARLY_PHASE1":19785,"PHASE1":19787,"PHASE2":19801,"PHASE3":19803,"PHASE4":19809,"NA":19811},{"trials":19786,"activeCount":103},[],{"trials":19788,"activeCount":103},[19789,19793],{"nctId":10187,"briefTitle":10188,"status":111,"phases":19790,"primaryCompletion":7386,"completion":7386,"start":1248,"enrollment":10190,"conditions":19791,"interventions":19792},[91],[16],[9427,10180,10180],{"nctId":19794,"briefTitle":19795,"status":649,"phases":19796,"primaryCompletion":19797,"completion":19797,"start":4557,"enrollment":103,"conditions":19798,"interventions":19799},"NCT04126044","A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS",[91],"2021-07-10",[3396],[9427,19800],"bevacizumab - EU",{"trials":19802,"activeCount":103},[],{"trials":19804,"activeCount":103},[19805],{"nctId":9419,"briefTitle":9420,"status":168,"phases":19806,"primaryCompletion":9422,"completion":9422,"start":9423,"enrollment":1487,"conditions":19807,"interventions":19808},[93],[9425],[9427,9428,1771,1772],{"trials":19810,"activeCount":103},[],{"trials":19812,"activeCount":103},[],{"intervention":19511,"totalTrials":502,"cells":19814},{"EARLY_PHASE1":19815,"PHASE1":19817,"PHASE2":19829,"PHASE3":19831,"PHASE4":19841,"NA":19843},{"trials":19816,"activeCount":103},[],{"trials":19818,"activeCount":103},[19819],{"nctId":19820,"briefTitle":19821,"status":111,"phases":19822,"primaryCompletion":11448,"completion":11448,"start":1700,"enrollment":9553,"conditions":19823,"interventions":19826},"NCT01689207","To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)",[91],[19824,19825],"Complicated Infection","Bacterial Infections",[19827,19511,19828],"Avibactam","combination of Aztreonam - Avibactam",{"trials":19830,"activeCount":103},[],{"trials":19832,"activeCount":103},[19833,19837],{"nctId":19503,"briefTitle":19504,"status":111,"phases":19834,"primaryCompletion":1288,"completion":11956,"start":113,"enrollment":19506,"conditions":19835,"interventions":19836},[93],[19508],[19480,19510,19511],{"nctId":19513,"briefTitle":19514,"status":168,"phases":19838,"primaryCompletion":11956,"completion":11956,"start":1288,"enrollment":257,"conditions":19839,"interventions":19840},[93],[19508],[19480,19510,19511],{"trials":19842,"activeCount":103},[],{"trials":19844,"activeCount":103},[],{"intervention":19846,"totalTrials":502,"cells":19847},"bapineuzumab",{"EARLY_PHASE1":19848,"PHASE1":19850,"PHASE2":19852,"PHASE3":19860,"PHASE4":19875,"NA":19877},{"trials":19849,"activeCount":103},[],{"trials":19851,"activeCount":103},[],{"trials":19853,"activeCount":103},[19854],{"nctId":19855,"briefTitle":19856,"status":168,"phases":19857,"primaryCompletion":1700,"completion":1700,"start":4646,"enrollment":23,"conditions":19858,"interventions":19859},"NCT00916617","Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab",[92],[13445],[19846],{"trials":19861,"activeCount":103},[19862,19868],{"nctId":19863,"briefTitle":19864,"status":168,"phases":19865,"primaryCompletion":3353,"completion":3345,"start":3853,"enrollment":1941,"conditions":19866,"interventions":19867},"NCT00676143","Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients",[93],[13445],[19846],{"nctId":19869,"briefTitle":19870,"status":168,"phases":19871,"primaryCompletion":3353,"completion":6207,"start":3839,"enrollment":19872,"conditions":19873,"interventions":19874},"NCT00667810","Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients",[93],901,[13445],[19846,19846],{"trials":19876,"activeCount":103},[],{"trials":19878,"activeCount":103},[],{"intervention":18288,"totalTrials":502,"cells":19880},{"EARLY_PHASE1":19881,"PHASE1":19883,"PHASE2":19885,"PHASE3":19887,"PHASE4":19903,"NA":19905},{"trials":19882,"activeCount":103},[],{"trials":19884,"activeCount":103},[],{"trials":19886,"activeCount":103},[],{"trials":19888,"activeCount":103},[19889,19893,19899],{"nctId":18283,"briefTitle":18284,"status":111,"phases":19890,"primaryCompletion":3643,"completion":3643,"start":11417,"enrollment":1893,"conditions":19891,"interventions":19892},[93],[12891,12882],[15314,18288,12904],{"nctId":19894,"briefTitle":19895,"status":649,"phases":19896,"enrollment":103,"conditions":19897,"interventions":19898},"NCT00283764","Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device",[93],[12891,12882],[18288],{"nctId":18297,"briefTitle":18298,"status":111,"phases":19900,"completion":3643,"start":2671,"enrollment":18300,"conditions":19901,"interventions":19902},[93],[18274,12882],[15314,18288,12904],{"trials":19904,"activeCount":103},[],{"trials":19906,"activeCount":103},[],{"intervention":19908,"totalTrials":502,"cells":19909},"Meningococcal vaccine GSK134612",{"EARLY_PHASE1":19910,"PHASE1":19912,"PHASE2":19914,"PHASE3":19916,"PHASE4":19945,"NA":19947},{"trials":19911,"activeCount":103},[],{"trials":19913,"activeCount":103},[],{"trials":19915,"activeCount":103},[],{"trials":19917,"activeCount":103},[19918,19926,19935],{"nctId":19919,"briefTitle":19920,"status":111,"phases":19921,"primaryCompletion":625,"completion":19922,"start":1249,"enrollment":16174,"conditions":19923,"interventions":19925},"NCT01962207","The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination",[93],"2018-06",[19924],"Infections, Meningococcal",[19908],{"nctId":19927,"briefTitle":19928,"status":111,"phases":19929,"primaryCompletion":19930,"completion":19931,"start":7578,"enrollment":19932,"conditions":19933,"interventions":19934},"NCT01934140","Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination",[93],"2018-02","2018-08",311,[19924],[19908],{"nctId":19936,"briefTitle":19937,"status":111,"phases":19938,"primaryCompletion":19939,"completion":19939,"start":19940,"enrollment":19941,"conditions":19942,"interventions":19943},"NCT01939158","Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine",[93],"2019-12-05","2013-10-02",803,[19924],[19908,19944],"Prevenar 13™",{"trials":19946,"activeCount":103},[],{"trials":19948,"activeCount":103},[],{"intervention":19950,"totalTrials":502,"cells":19951},"levofloxacin",{"EARLY_PHASE1":19952,"PHASE1":19954,"PHASE2":19956,"PHASE3":19958,"PHASE4":19982,"NA":19984},{"trials":19953,"activeCount":103},[],{"trials":19955,"activeCount":103},[],{"trials":19957,"activeCount":103},[],{"trials":19959,"activeCount":103},[19960,19968,19975],{"nctId":19961,"briefTitle":19962,"status":111,"phases":19963,"completion":11686,"start":3073,"enrollment":10983,"conditions":19964,"interventions":19966},"NCT00644449","A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis",[93],[19965],"Bronchitis, Chronic",[19967,19950],"azithromycin SR",{"nctId":19969,"briefTitle":19970,"status":111,"phases":19971,"completion":11512,"start":3073,"enrollment":2610,"conditions":19972,"interventions":19974},"NCT00643409","A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults",[93],[19973],"Maxillary Sinusitis",[19967,19950],{"nctId":19976,"briefTitle":19977,"status":111,"phases":19978,"completion":4398,"start":12607,"enrollment":17600,"conditions":19979,"interventions":19980},"NCT00643734","A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients",[93],[9107],[19981,19950],"azithromycin sustained release",{"trials":19983,"activeCount":103},[],{"trials":19985,"activeCount":103},[],{"intervention":4944,"totalTrials":502,"cells":19987},{"EARLY_PHASE1":19988,"PHASE1":19990,"PHASE2":19996,"PHASE3":19998,"PHASE4":20013,"NA":20015},{"trials":19989,"activeCount":103},[],{"trials":19991,"activeCount":103},[19992],{"nctId":4938,"briefTitle":4939,"status":649,"phases":19993,"primaryCompletion":4666,"completion":4666,"start":3601,"enrollment":103,"conditions":19994,"interventions":19995},[91],[4942],[4944,4904,4945,4904],{"trials":19997,"activeCount":103},[],{"trials":19999,"activeCount":103},[20000,20007],{"nctId":20001,"briefTitle":20002,"status":168,"phases":20003,"primaryCompletion":4656,"completion":4656,"start":8252,"enrollment":1087,"conditions":20004,"interventions":20006},"NCT01210443","Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients",[93],[20005],"Hypertension, Pulmonary",[4944],{"nctId":20008,"briefTitle":20009,"status":168,"phases":20010,"primaryCompletion":8252,"completion":8252,"start":561,"enrollment":1087,"conditions":20011,"interventions":20012},"NCT01204853","A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients",[93],[20005],[4944],{"trials":20014,"activeCount":103},[],{"trials":20016,"activeCount":103},[],{"intervention":11374,"totalTrials":502,"cells":20018},{"EARLY_PHASE1":20019,"PHASE1":20021,"PHASE2":20023,"PHASE3":20029,"PHASE4":20039,"NA":20041},{"trials":20020,"activeCount":103},[],{"trials":20022,"activeCount":103},[],{"trials":20024,"activeCount":103},[20025],{"nctId":19247,"briefTitle":19248,"status":168,"phases":20026,"primaryCompletion":19250,"completion":19251,"start":19252,"enrollment":19253,"conditions":20027,"interventions":20028},[92],[11347,12099],[19256,19257,19238],{"trials":20030,"activeCount":103},[20031,20035],{"nctId":11364,"briefTitle":11365,"status":111,"phases":20032,"primaryCompletion":11367,"completion":11368,"start":11369,"enrollment":11370,"conditions":20033,"interventions":20034},[93],[11282],[11373,11374,11309],{"nctId":11401,"briefTitle":11402,"status":111,"phases":20036,"primaryCompletion":11404,"completion":11405,"start":11406,"enrollment":11407,"conditions":20037,"interventions":20038},[93],[11409,11282],[11373,11374,11309],{"trials":20040,"activeCount":103},[],{"trials":20042,"activeCount":103},[],{"intervention":20044,"totalTrials":502,"cells":20045},"13 valent pneumococcal conjugate vaccine",{"EARLY_PHASE1":20046,"PHASE1":20048,"PHASE2":20050,"PHASE3":20052,"PHASE4":20074,"NA":20076},{"trials":20047,"activeCount":103},[],{"trials":20049,"activeCount":103},[],{"trials":20051,"activeCount":103},[],{"trials":20053,"activeCount":103},[20054,20060,20066],{"nctId":20055,"briefTitle":20056,"status":111,"phases":20057,"primaryCompletion":586,"completion":586,"start":8154,"enrollment":9970,"conditions":20058,"interventions":20059},"NCT00761631","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years",[93],[10985],[20044],{"nctId":20061,"briefTitle":20062,"status":111,"phases":20063,"primaryCompletion":606,"completion":606,"start":7665,"enrollment":1170,"conditions":20064,"interventions":20065},"NCT00521586","Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine",[93],[10138],[20044,20044],{"nctId":20067,"briefTitle":20068,"status":111,"phases":20069,"primaryCompletion":3839,"completion":3839,"start":3854,"enrollment":2470,"conditions":20070,"interventions":20072},"NCT00373958","Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine",[93],[20071],"Vaccines, Pneumococcal",[20044,20073],"7vPnc pneumococcal conjugate vaccine",{"trials":20075,"activeCount":103},[],{"trials":20077,"activeCount":103},[],{"intervention":20079,"totalTrials":502,"cells":20080},"Risperidone",{"EARLY_PHASE1":20081,"PHASE1":20083,"PHASE2":20085,"PHASE3":20104,"PHASE4":20113,"NA":20115},{"trials":20082,"activeCount":103},[],{"trials":20084,"activeCount":103},[],{"trials":20086,"activeCount":103},[20087,20095],{"nctId":20088,"briefTitle":20089,"status":111,"phases":20090,"primaryCompletion":4531,"completion":4531,"start":585,"enrollment":20091,"conditions":20092,"interventions":20093},"NCT01175135","An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia",[92],259,[12632],[20094,20094,20079],"PF-02545920",{"nctId":20096,"briefTitle":20097,"status":111,"phases":20098,"primaryCompletion":3839,"completion":3839,"start":4636,"enrollment":20099,"conditions":20100,"interventions":20101},"NCT00563706","Study Evaluating Vabicaserin in Subjects With Schizophrenia",[92],199,[12632],[20102,20103],"vabicaserin","risperidone",{"trials":20105,"activeCount":103},[20106],{"nctId":20107,"briefTitle":20108,"status":111,"phases":20109,"completion":11829,"start":13035,"enrollment":20110,"conditions":20111,"interventions":20112},"NCT00645372","A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients",[93],242,[12632],[20079,12666],{"trials":20114,"activeCount":103},[],{"trials":20116,"activeCount":103},[],{"intervention":19306,"totalTrials":1087,"cells":20118},{"EARLY_PHASE1":20119,"PHASE1":20121,"PHASE2":20123,"PHASE3":20125,"PHASE4":20135,"NA":20137},{"trials":20120,"activeCount":103},[],{"trials":20122,"activeCount":103},[],{"trials":20124,"activeCount":103},[],{"trials":20126,"activeCount":103},[20127,20131],{"nctId":19300,"briefTitle":19301,"status":111,"phases":20128,"primaryCompletion":4589,"completion":4589,"start":605,"enrollment":19303,"conditions":20129,"interventions":20130},[93],[1933],[19283,19306],{"nctId":19308,"briefTitle":19309,"status":111,"phases":20132,"primaryCompletion":4589,"completion":4589,"start":605,"enrollment":19311,"conditions":20133,"interventions":20134},[93],[1933],[19283,19306],{"trials":20136,"activeCount":103},[],{"trials":20138,"activeCount":103},[],{"intervention":20140,"totalTrials":1087,"cells":20141},"Inclacumab",{"EARLY_PHASE1":20142,"PHASE1":20144,"PHASE2":20146,"PHASE3":20148,"PHASE4":20168,"NA":20170},{"trials":20143,"activeCount":103},[],{"trials":20145,"activeCount":103},[],{"trials":20147,"activeCount":103},[],{"trials":20149,"activeCount":103},[20150,20160],{"nctId":20151,"briefTitle":20152,"status":168,"phases":20153,"primaryCompletion":20154,"completion":20154,"start":20155,"enrollment":20110,"conditions":20156,"interventions":20159},"NCT05348915","A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease",[93],"2025-11-07","2022-03-29",[4181,20157,20158],"Vaso-occlusive Crisis","Vaso-occlusive Pain Episode in Sickle Cell Disease",[20140],{"nctId":20161,"briefTitle":20162,"status":111,"phases":20163,"primaryCompletion":20164,"completion":20164,"start":1133,"enrollment":20165,"conditions":20166,"interventions":20167},"NCT04935879","A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises",[93],"2024-06-06",241,[4181,20158,20157],[20140],{"trials":20169,"activeCount":103},[],{"trials":20171,"activeCount":103},[],{"intervention":1642,"totalTrials":1087,"cells":20173},{"EARLY_PHASE1":20174,"PHASE1":20176,"PHASE2":20182,"PHASE3":20184,"PHASE4":20190,"NA":20192},{"trials":20175,"activeCount":103},[],{"trials":20177,"activeCount":103},[20178],{"nctId":1632,"briefTitle":1633,"status":111,"phases":20179,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1638,"conditions":20180,"interventions":20181},[91],[31],[1641,1642,1643,1644,1641,1643],{"trials":20183,"activeCount":103},[],{"trials":20185,"activeCount":103},[20186],{"nctId":4653,"briefTitle":4654,"status":111,"phases":20187,"primaryCompletion":4656,"completion":4656,"start":4657,"enrollment":4658,"conditions":20188,"interventions":20189},[93],[25],[1643,1642],{"trials":20191,"activeCount":103},[],{"trials":20193,"activeCount":103},[],{"intervention":20195,"totalTrials":1087,"cells":20196},"DVS SR",{"EARLY_PHASE1":20197,"PHASE1":20199,"PHASE2":20201,"PHASE3":20203,"PHASE4":20220,"NA":20222},{"trials":20198,"activeCount":103},[],{"trials":20200,"activeCount":103},[],{"trials":20202,"activeCount":103},[],{"trials":20204,"activeCount":103},[20205,20214],{"nctId":20206,"briefTitle":20207,"status":111,"phases":20208,"primaryCompletion":20209,"completion":20209,"start":20210,"enrollment":20211,"conditions":20212,"interventions":20213},"NCT01371708","A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD",[93],"2016-04-22","2012-02-02",283,[6321],[20195],{"nctId":20215,"briefTitle":20216,"status":111,"phases":20217,"primaryCompletion":626,"completion":626,"start":18026,"enrollment":4449,"conditions":20218,"interventions":20219},"NCT01371721","A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD",[93],[6321],[20195],{"trials":20221,"activeCount":103},[],{"trials":20223,"activeCount":103},[],{"intervention":17824,"totalTrials":1087,"cells":20225},{"EARLY_PHASE1":20226,"PHASE1":20228,"PHASE2":20230,"PHASE3":20232,"PHASE4":20242,"NA":20244},{"trials":20227,"activeCount":103},[],{"trials":20229,"activeCount":103},[],{"trials":20231,"activeCount":103},[],{"trials":20233,"activeCount":103},[20234,20238],{"nctId":17819,"briefTitle":17820,"status":168,"phases":20235,"primaryCompletion":524,"completion":524,"start":11014,"enrollment":1390,"conditions":20236,"interventions":20237},[93],[4942,7083],[4945,17824],{"nctId":17833,"briefTitle":17834,"status":168,"phases":20239,"primaryCompletion":3601,"completion":3601,"start":586,"enrollment":502,"conditions":20240,"interventions":20241},[93],[4942,7083],[4945,17824],{"trials":20243,"activeCount":103},[],{"trials":20245,"activeCount":103},[],{"intervention":20247,"totalTrials":1087,"cells":20248},"AN2690 Topical Solution, 5%",{"EARLY_PHASE1":20249,"PHASE1":20251,"PHASE2":20253,"PHASE3":20255,"PHASE4":20277,"NA":20279},{"trials":20250,"activeCount":103},[],{"trials":20252,"activeCount":103},[],{"trials":20254,"activeCount":103},[],{"trials":20256,"activeCount":103},[20257,20268],{"nctId":20258,"briefTitle":20259,"status":111,"phases":20260,"primaryCompletion":20261,"completion":20262,"start":4666,"enrollment":20263,"conditions":20264,"interventions":20266},"NCT01302119","Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail",[93],"2012-12-31","2013-02-20",604,[20265],"Onychomycosis of Toenails",[20247,20267],"Solution Vehicle",{"nctId":20269,"briefTitle":20270,"status":111,"phases":20271,"primaryCompletion":20272,"completion":20273,"start":20274,"enrollment":19345,"conditions":20275,"interventions":20276},"NCT01270971","Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail",[93],"2012-11-30","2013-01-08","2010-12-01",[20265],[20247,20267],{"trials":20278,"activeCount":103},[],{"trials":20280,"activeCount":103},[],{"intervention":20267,"totalTrials":1087,"cells":20282},{"EARLY_PHASE1":20283,"PHASE1":20285,"PHASE2":20287,"PHASE3":20289,"PHASE4":20299,"NA":20301},{"trials":20284,"activeCount":103},[],{"trials":20286,"activeCount":103},[],{"trials":20288,"activeCount":103},[],{"trials":20290,"activeCount":103},[20291,20295],{"nctId":20258,"briefTitle":20259,"status":111,"phases":20292,"primaryCompletion":20261,"completion":20262,"start":4666,"enrollment":20263,"conditions":20293,"interventions":20294},[93],[20265],[20247,20267],{"nctId":20269,"briefTitle":20270,"status":111,"phases":20296,"primaryCompletion":20272,"completion":20273,"start":20274,"enrollment":19345,"conditions":20297,"interventions":20298},[93],[20265],[20247,20267],{"trials":20300,"activeCount":103},[],{"trials":20302,"activeCount":103},[],{"intervention":20304,"totalTrials":1087,"cells":20305},"Investigational medical product (IMP) administered in parent study",{"EARLY_PHASE1":20306,"PHASE1":20308,"PHASE2":20310,"PHASE3":20312,"PHASE4":20331,"NA":20333},{"trials":20307,"activeCount":103},[],{"trials":20309,"activeCount":103},[],{"trials":20311,"activeCount":103},[],{"trials":20313,"activeCount":103},[20314,20323],{"nctId":20315,"briefTitle":20316,"status":111,"phases":20317,"primaryCompletion":20318,"completion":20318,"start":20319,"enrollment":257,"conditions":20320,"interventions":20322},"NCT03031938","Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies",[93],"2020-06-04","2017-11-03",[11282,17245,20321],"Recurrent Low Back Pain",[20304],{"nctId":20324,"briefTitle":20325,"status":111,"phases":20326,"primaryCompletion":252,"completion":252,"start":20327,"enrollment":11745,"conditions":20328,"interventions":20329},"NCT02674386","Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement",[93],"2016-08-23",[11282],[20330],"Investigational Medical Product (IMP) administered in parent study",{"trials":20332,"activeCount":103},[],{"trials":20334,"activeCount":103},[],{"intervention":18277,"totalTrials":1087,"cells":20336},{"EARLY_PHASE1":20337,"PHASE1":20339,"PHASE2":20341,"PHASE3":20343,"PHASE4":20353,"NA":20355},{"trials":20338,"activeCount":103},[],{"trials":20340,"activeCount":103},[],{"trials":20342,"activeCount":103},[],{"trials":20344,"activeCount":103},[20345,20349],{"nctId":18268,"briefTitle":18269,"status":111,"phases":20346,"primaryCompletion":18271,"completion":18271,"start":18272,"enrollment":1982,"conditions":20347,"interventions":20348},[93],[18274,12882],[18276,18277],{"nctId":18290,"briefTitle":18291,"status":111,"phases":20350,"primaryCompletion":18271,"completion":18271,"start":18293,"enrollment":7696,"conditions":20351,"interventions":20352},[93],[12882,18274],[18276,18277],{"trials":20354,"activeCount":103},[],{"trials":20356,"activeCount":103},[],{"intervention":20358,"totalTrials":1087,"cells":20359},"7-valent Pneumococcal Conjugate Vaccine",{"EARLY_PHASE1":20360,"PHASE1":20362,"PHASE2":20364,"PHASE3":20366,"PHASE4":20380,"NA":20382},{"trials":20361,"activeCount":103},[],{"trials":20363,"activeCount":103},[],{"trials":20365,"activeCount":103},[],{"trials":20367,"activeCount":103},[20368,20376],{"nctId":20369,"briefTitle":20370,"status":111,"phases":20371,"primaryCompletion":7578,"completion":7578,"start":1700,"enrollment":20372,"conditions":20373,"interventions":20374},"NCT01692886","A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China",[93],1674,[10914],[20358,20375,20375,20375],"13-valent Pnumococcal Conjugate vaccine",{"nctId":10978,"briefTitle":10979,"status":111,"phases":20377,"primaryCompletion":10981,"completion":10981,"start":10982,"enrollment":10983,"conditions":20378,"interventions":20379},[93],[10985],[2555,10987,10988,10989,10989],{"trials":20381,"activeCount":103},[],{"trials":20383,"activeCount":103},[],{"intervention":20385,"totalTrials":1087,"cells":20386},"Abrocitinib 200 mg",{"EARLY_PHASE1":20387,"PHASE1":20389,"PHASE2":20391,"PHASE3":20393,"PHASE4":20412,"NA":20414},{"trials":20388,"activeCount":103},[],{"trials":20390,"activeCount":103},[],{"trials":20392,"activeCount":103},[],{"trials":20394,"activeCount":103},[20395,20403],{"nctId":20396,"briefTitle":20397,"status":111,"phases":20398,"primaryCompletion":5854,"completion":5854,"start":9423,"enrollment":20399,"conditions":20400,"interventions":20401},"NCT04345367","Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy",[93],727,[1589],[20385,20402],"Dupilumab 300 mg",{"nctId":20404,"briefTitle":20405,"status":111,"phases":20406,"primaryCompletion":2711,"completion":2711,"start":20407,"enrollment":20408,"conditions":20409,"interventions":20410},"NCT03422822","Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis",[93],"2018-03-08",3166,[1933],[20411,20385,20411,20411,20385],"Abrocitinib 100 mg",{"trials":20413,"activeCount":103},[],{"trials":20415,"activeCount":103},[],{"intervention":20417,"totalTrials":1087,"cells":20418},"Triazolam",{"EARLY_PHASE1":20419,"PHASE1":20421,"PHASE2":20429,"PHASE3":20431,"PHASE4":20443,"NA":20445},{"trials":20420,"activeCount":103},[],{"trials":20422,"activeCount":103},[20423],{"nctId":20424,"briefTitle":20425,"status":649,"phases":20426,"primaryCompletion":560,"completion":560,"start":561,"enrollment":103,"conditions":20427,"interventions":20428},"NCT01017926","Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption",[91],[19],[20417,20417],{"trials":20430,"activeCount":103},[],{"trials":20432,"activeCount":103},[20433],{"nctId":20434,"briefTitle":20435,"status":111,"phases":20436,"primaryCompletion":20437,"completion":20437,"start":20438,"enrollment":1060,"conditions":20439,"interventions":20440},"NCT01888497","Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers",[93],"2013-12-14","2013-07-29",[16],[20441,20442,20417],"Gabapentin","Diphenhydramine citrate",{"trials":20444,"activeCount":103},[],{"trials":20446,"activeCount":103},[],{"intervention":18904,"totalTrials":1087,"cells":20448},{"EARLY_PHASE1":20449,"PHASE1":20451,"PHASE2":20453,"PHASE3":20455,"PHASE4":20465,"NA":20467},{"trials":20450,"activeCount":103},[],{"trials":20452,"activeCount":103},[],{"trials":20454,"activeCount":103},[],{"trials":20456,"activeCount":103},[20457,20461],{"nctId":18896,"briefTitle":18897,"status":111,"phases":20458,"primaryCompletion":7665,"completion":7665,"start":4847,"enrollment":18899,"conditions":20459,"interventions":20460},[93],[18901],[18903,18904],{"nctId":19103,"briefTitle":19104,"status":111,"phases":20462,"completion":12004,"start":13902,"enrollment":15310,"conditions":20463,"interventions":20464},[92,93],[19092],[19077,18904],{"trials":20466,"activeCount":103},[],{"trials":20468,"activeCount":103},[],{"intervention":20470,"totalTrials":1087,"cells":20471},"SD-6010",{"EARLY_PHASE1":20472,"PHASE1":20474,"PHASE2":20476,"PHASE3":20485,"PHASE4":20494,"NA":20496},{"trials":20473,"activeCount":103},[],{"trials":20475,"activeCount":103},[],{"trials":20477,"activeCount":103},[20478],{"nctId":20479,"briefTitle":20480,"status":111,"phases":20481,"primaryCompletion":114,"completion":570,"start":2964,"enrollment":20482,"conditions":20483,"interventions":20484},"NCT00565812","A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee",[92],1457,[11282],[20470,20470],{"trials":20486,"activeCount":103},[20487],{"nctId":20488,"briefTitle":20489,"status":649,"phases":20490,"primaryCompletion":3586,"completion":3586,"start":2450,"enrollment":103,"conditions":20491,"interventions":20493},"NCT01438918","X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee",[93],[20492],"Knee Osteoarthritis",[20470,20470],{"trials":20495,"activeCount":103},[],{"trials":20497,"activeCount":103},[],{"intervention":6462,"totalTrials":1087,"cells":20499},{"EARLY_PHASE1":20500,"PHASE1":20502,"PHASE2":20504,"PHASE3":20512,"PHASE4":20518,"NA":20520},{"trials":20501,"activeCount":103},[],{"trials":20503,"activeCount":103},[],{"trials":20505,"activeCount":103},[20506],{"nctId":20507,"briefTitle":20508,"status":111,"phases":20509,"primaryCompletion":14118,"completion":14118,"start":4398,"enrollment":5909,"conditions":20510,"interventions":20511},"NCT00087503","Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy",[92],[2886],[6462],{"trials":20513,"activeCount":103},[20514],{"nctId":6454,"briefTitle":6455,"status":111,"phases":20515,"completion":6457,"start":6458,"enrollment":2250,"conditions":20516,"interventions":20517},[93],[6460],[6462,1334,6463,6464],{"trials":20519,"activeCount":103},[],{"trials":20521,"activeCount":103},[],{"intervention":20523,"totalTrials":1087,"cells":20524},"PD-0332334",{"EARLY_PHASE1":20525,"PHASE1":20527,"PHASE2":20536,"PHASE3":20538,"PHASE4":20546,"NA":20548},{"trials":20526,"activeCount":103},[],{"trials":20528,"activeCount":103},[20529],{"nctId":20530,"briefTitle":20531,"status":111,"phases":20532,"primaryCompletion":8251,"completion":8251,"start":11291,"enrollment":1487,"conditions":20533,"interventions":20535},"NCT00730145","A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis",[91],[20534,3396],"Renal Dialysis",[20523],{"trials":20537,"activeCount":103},[],{"trials":20539,"activeCount":103},[20540],{"nctId":20541,"briefTitle":20542,"status":649,"phases":20543,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":103,"conditions":20544,"interventions":20545},"NCT00738738","6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)",[93],[17561],[20523],{"trials":20547,"activeCount":103},[],{"trials":20549,"activeCount":103},[],{"intervention":20551,"totalTrials":1087,"cells":20552},"Celebrex",{"EARLY_PHASE1":20553,"PHASE1":20555,"PHASE2":20566,"PHASE3":20568,"PHASE4":20577,"NA":20579},{"trials":20554,"activeCount":103},[],{"trials":20556,"activeCount":103},[20557],{"nctId":20558,"briefTitle":20559,"status":111,"phases":20560,"primaryCompletion":4214,"completion":4214,"start":4627,"enrollment":314,"conditions":20561,"interventions":20562},"NCT00925106","Pharmacokinetics Of Celecoxib Test Formulations",[91],[19],[20551,20563,20564,20565],"Test formulation D1","Test formulation D2","Test formulation D3",{"trials":20567,"activeCount":103},[],{"trials":20569,"activeCount":103},[20570],{"nctId":20571,"briefTitle":20572,"status":111,"phases":20573,"primaryCompletion":6457,"completion":6457,"start":4399,"enrollment":162,"conditions":20574,"interventions":20576},"NCT00137410","Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee",[93],[20575],"Osteoarthritis,Knee",[20551],{"trials":20578,"activeCount":103},[],{"trials":20580,"activeCount":103},[],{"intervention":20582,"totalTrials":1087,"cells":20583},"Ibuprofen 250 mg \u002F Acetaminophen 500 mg",{"EARLY_PHASE1":20584,"PHASE1":20586,"PHASE2":20588,"PHASE3":20590,"PHASE4":20612,"NA":20614},{"trials":20585,"activeCount":103},[],{"trials":20587,"activeCount":103},[],{"trials":20589,"activeCount":103},[],{"trials":20591,"activeCount":103},[20592,20603],{"nctId":20593,"briefTitle":20594,"status":111,"phases":20595,"primaryCompletion":12719,"completion":12719,"start":20596,"enrollment":20597,"conditions":20598,"interventions":20600},"NCT02761980","A Study of Ibuprofen 250 mg \u002F Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers",[93],"2016-12-06",290,[20599],"Fever",[20582,20601,20602],"Ibuprofen 250 mg","Acetaminophen 500 mg",{"nctId":20604,"briefTitle":20605,"status":111,"phases":20606,"primaryCompletion":539,"completion":539,"start":12853,"enrollment":20607,"conditions":20608,"interventions":20610},"NCT02912650","A Safety And Efficacy Study of Ibuprofen 250 mg \u002F Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain",[93],568,[20609],"Post-surgical Pain Following Extraction of Molar Teeth",[20582,20601,20611],"Acetaminophen 650 mg",{"trials":20613,"activeCount":103},[],{"trials":20615,"activeCount":103},[],{"intervention":20601,"totalTrials":1087,"cells":20617},{"EARLY_PHASE1":20618,"PHASE1":20620,"PHASE2":20622,"PHASE3":20624,"PHASE4":20634,"NA":20636},{"trials":20619,"activeCount":103},[],{"trials":20621,"activeCount":103},[],{"trials":20623,"activeCount":103},[],{"trials":20625,"activeCount":103},[20626,20630],{"nctId":20593,"briefTitle":20594,"status":111,"phases":20627,"primaryCompletion":12719,"completion":12719,"start":20596,"enrollment":20597,"conditions":20628,"interventions":20629},[93],[20599],[20582,20601,20602],{"nctId":20604,"briefTitle":20605,"status":111,"phases":20631,"primaryCompletion":539,"completion":539,"start":12853,"enrollment":20607,"conditions":20632,"interventions":20633},[93],[20609],[20582,20601,20611],{"trials":20635,"activeCount":103},[],{"trials":20637,"activeCount":103},[],{"intervention":6441,"totalTrials":1087,"cells":20639},{"EARLY_PHASE1":20640,"PHASE1":20642,"PHASE2":20644,"PHASE3":20650,"PHASE4":20656,"NA":20658},{"trials":20641,"activeCount":103},[],{"trials":20643,"activeCount":103},[],{"trials":20645,"activeCount":103},[20646],{"nctId":6434,"briefTitle":6435,"status":111,"phases":20647,"primaryCompletion":4647,"start":6437,"conditions":20648,"interventions":20649},[92],[6439],[6441,6442],{"trials":20651,"activeCount":103},[20652],{"nctId":8177,"briefTitle":8178,"status":111,"phases":20653,"primaryCompletion":8180,"start":2629,"conditions":20654,"interventions":20655},[93],[981],[2890,8183,6441],{"trials":20657,"activeCount":103},[],{"trials":20659,"activeCount":103},[],{"intervention":4312,"totalTrials":1087,"cells":20661},{"EARLY_PHASE1":20662,"PHASE1":20664,"PHASE2":20666,"PHASE3":20668,"PHASE4":20682,"NA":20684},{"trials":20663,"activeCount":103},[],{"trials":20665,"activeCount":103},[],{"trials":20667,"activeCount":103},[],{"trials":20669,"activeCount":103},[20670,20674],{"nctId":4303,"briefTitle":4304,"status":111,"phases":20671,"primaryCompletion":4306,"completion":4307,"start":4308,"enrollment":1158,"conditions":20672,"interventions":20673},[93],[4310],[933,4312],{"nctId":20675,"briefTitle":20676,"status":111,"phases":20677,"primaryCompletion":10912,"completion":4590,"start":7665,"enrollment":20678,"conditions":20679,"interventions":20680},"NCT00474786","Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib",[93],512,[1859],[4312,20681],"temsirolimus",{"trials":20683,"activeCount":103},[],{"trials":20685,"activeCount":103},[],{"intervention":19094,"totalTrials":1087,"cells":20687},{"EARLY_PHASE1":20688,"PHASE1":20690,"PHASE2":20692,"PHASE3":20694,"PHASE4":20704,"NA":20706},{"trials":20689,"activeCount":103},[],{"trials":20691,"activeCount":103},[],{"trials":20693,"activeCount":103},[],{"trials":20695,"activeCount":103},[20696,20700],{"nctId":19088,"briefTitle":19089,"status":168,"phases":20697,"completion":4657,"start":11686,"enrollment":4259,"conditions":20698,"interventions":20699},[92,93],[19092],[19077,19094],{"nctId":19109,"briefTitle":19110,"status":111,"phases":20701,"completion":12069,"start":16955,"enrollment":19112,"conditions":20702,"interventions":20703},[92,93],[19114],[19077,19094],{"trials":20705,"activeCount":103},[],{"trials":20707,"activeCount":103},[],{"intervention":19661,"totalTrials":1087,"cells":20709},{"EARLY_PHASE1":20710,"PHASE1":20712,"PHASE2":20714,"PHASE3":20716,"PHASE4":20726,"NA":20728},{"trials":20711,"activeCount":103},[],{"trials":20713,"activeCount":103},[],{"trials":20715,"activeCount":103},[],{"trials":20717,"activeCount":103},[20718,20722],{"nctId":19655,"briefTitle":19656,"status":168,"phases":20719,"primaryCompletion":8251,"completion":8251,"start":12128,"enrollment":19658,"conditions":20720,"interventions":20721},[93],[2761],[19661,18252],{"nctId":19667,"briefTitle":19668,"status":168,"phases":20723,"primaryCompletion":4608,"completion":4608,"start":1701,"enrollment":19670,"conditions":20724,"interventions":20725},[93],[2761],[18252,19661],{"trials":20727,"activeCount":103},[],{"trials":20729,"activeCount":103},[],{"intervention":11681,"totalTrials":1087,"cells":20731},{"EARLY_PHASE1":20732,"PHASE1":20734,"PHASE2":20736,"PHASE3":20738,"PHASE4":20748,"NA":20750},{"trials":20733,"activeCount":103},[],{"trials":20735,"activeCount":103},[],{"trials":20737,"activeCount":103},[],{"trials":20739,"activeCount":103},[20740,20744],{"nctId":11673,"briefTitle":11674,"status":111,"phases":20741,"completion":11676,"start":11379,"enrollment":11677,"conditions":20742,"interventions":20743},[93],[34,11679],[11390,11390,11681],{"nctId":11691,"briefTitle":11692,"status":111,"phases":20745,"completion":3628,"start":9388,"enrollment":1621,"conditions":20746,"interventions":20747},[93],[11695],[11390,11681],{"trials":20749,"activeCount":103},[],{"trials":20751,"activeCount":103},[],{"intervention":19733,"totalTrials":1087,"cells":20753},{"EARLY_PHASE1":20754,"PHASE1":20756,"PHASE2":20758,"PHASE3":20760,"PHASE4":20770,"NA":20772},{"trials":20755,"activeCount":103},[],{"trials":20757,"activeCount":103},[],{"trials":20759,"activeCount":103},[],{"trials":20761,"activeCount":103},[20762,20766],{"nctId":19723,"briefTitle":19724,"status":111,"phases":20763,"primaryCompletion":19726,"completion":19726,"start":19727,"enrollment":19728,"conditions":20764,"interventions":20765},[93],[10577],[19712,19731,19732,19733],{"nctId":19745,"briefTitle":19746,"status":111,"phases":20767,"primaryCompletion":19726,"completion":19726,"start":19748,"enrollment":19749,"conditions":20768,"interventions":20769},[93],[10577],[19712,19731,19733,19752],{"trials":20771,"activeCount":103},[],{"trials":20773,"activeCount":103},[],{"intervention":8321,"totalTrials":1087,"cells":20775},{"EARLY_PHASE1":20776,"PHASE1":20778,"PHASE2":20780,"PHASE3":20782,"PHASE4":20792,"NA":20794},{"trials":20777,"activeCount":103},[],{"trials":20779,"activeCount":103},[],{"trials":20781,"activeCount":103},[],{"trials":20783,"activeCount":103},[20784,20788],{"nctId":8313,"briefTitle":8314,"status":111,"phases":20785,"primaryCompletion":8316,"completion":8316,"start":3798,"enrollment":8317,"conditions":20786,"interventions":20787},[93],[8295],[8309,2515,8320,8321],{"nctId":8331,"briefTitle":8332,"status":111,"phases":20789,"primaryCompletion":8334,"completion":8334,"start":8335,"enrollment":8336,"conditions":20790,"interventions":20791},[93],[8295],[8309,2515,8296,8321],{"trials":20793,"activeCount":103},[],{"trials":20795,"activeCount":103},[],{"intervention":3328,"totalTrials":1087,"cells":20797},{"EARLY_PHASE1":20798,"PHASE1":20800,"PHASE2":20802,"PHASE3":20808,"PHASE4":20814,"NA":20816},{"trials":20799,"activeCount":103},[],{"trials":20801,"activeCount":103},[],{"trials":20803,"activeCount":103},[20804],{"nctId":3320,"briefTitle":3321,"status":168,"phases":20805,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":597,"conditions":20806,"interventions":20807},[91,92],[3326],[2003,3328,1030,3329],{"trials":20809,"activeCount":103},[20810],{"nctId":7672,"briefTitle":7673,"status":111,"phases":20811,"primaryCompletion":7675,"start":7676,"conditions":20812,"interventions":20813},[93],[2022],[3328,1990,7679,7669],{"trials":20815,"activeCount":103},[],{"trials":20817,"activeCount":103},[],{"intervention":20819,"totalTrials":1087,"cells":20820},"Clarithromycin",{"EARLY_PHASE1":20821,"PHASE1":20823,"PHASE2":20829,"PHASE3":20831,"PHASE4":20841,"NA":20843},{"trials":20822,"activeCount":103},[],{"trials":20824,"activeCount":103},[20825],{"nctId":7823,"briefTitle":7824,"status":111,"phases":20826,"primaryCompletion":7826,"completion":7826,"start":7827,"enrollment":1239,"conditions":20827,"interventions":20828},[91],[2715],[7801,7830,7831],{"trials":20830,"activeCount":103},[],{"trials":20832,"activeCount":103},[20833],{"nctId":20834,"briefTitle":20835,"status":111,"phases":20836,"conditions":20837,"interventions":20839},"NCT00002140","A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients",[93],[20838,10974],"Mycobacterium Avium-intracellulare Infection",[20840,20819,15250],"Ethambutol hydrochloride",{"trials":20842,"activeCount":103},[],{"trials":20844,"activeCount":103},[],{"intervention":20846,"totalTrials":1087,"cells":20847},"binodenoson",{"EARLY_PHASE1":20848,"PHASE1":20850,"PHASE2":20852,"PHASE3":20854,"PHASE4":20871,"NA":20873},{"trials":20849,"activeCount":103},[],{"trials":20851,"activeCount":103},[],{"trials":20853,"activeCount":103},[],{"trials":20855,"activeCount":103},[20856,20865],{"nctId":20857,"briefTitle":20858,"status":111,"phases":20859,"primaryCompletion":12030,"completion":12030,"start":11512,"enrollment":20860,"conditions":20861,"interventions":20863},"NCT00944294","Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia",[93],419,[20862],"Coronary Artery Disease",[20846,20864],"adenosine",{"nctId":20866,"briefTitle":20858,"status":111,"phases":20867,"primaryCompletion":4615,"completion":4615,"start":9387,"enrollment":20868,"conditions":20869,"interventions":20870},"NCT00944970",[93],578,[20862],[20846,20864],{"trials":20872,"activeCount":103},[],{"trials":20874,"activeCount":103},[],{"intervention":20864,"totalTrials":1087,"cells":20876},{"EARLY_PHASE1":20877,"PHASE1":20879,"PHASE2":20881,"PHASE3":20883,"PHASE4":20893,"NA":20895},{"trials":20878,"activeCount":103},[],{"trials":20880,"activeCount":103},[],{"trials":20882,"activeCount":103},[],{"trials":20884,"activeCount":103},[20885,20889],{"nctId":20857,"briefTitle":20858,"status":111,"phases":20886,"primaryCompletion":12030,"completion":12030,"start":11512,"enrollment":20860,"conditions":20887,"interventions":20888},[93],[20862],[20846,20864],{"nctId":20866,"briefTitle":20858,"status":111,"phases":20890,"primaryCompletion":4615,"completion":4615,"start":9387,"enrollment":20868,"conditions":20891,"interventions":20892},[93],[20862],[20846,20864],{"trials":20894,"activeCount":103},[],{"trials":20896,"activeCount":103},[],{"intervention":20898,"totalTrials":1087,"cells":20899},"bivalent rLP2086",{"EARLY_PHASE1":20900,"PHASE1":20902,"PHASE2":20904,"PHASE3":20910,"PHASE4":20922,"NA":20924},{"trials":20901,"activeCount":103},[],{"trials":20903,"activeCount":103},[],{"trials":20905,"activeCount":103},[20906],{"nctId":19171,"briefTitle":19172,"status":168,"phases":20907,"primaryCompletion":18058,"completion":18058,"start":19174,"enrollment":7411,"conditions":20908,"interventions":20909},[92],[8295],[8309,19177,19177,19178,19179,19180,19181,19182],{"trials":20911,"activeCount":103},[20912],{"nctId":20913,"briefTitle":20914,"status":111,"phases":20915,"primaryCompletion":20916,"completion":20916,"start":20917,"enrollment":20918,"conditions":20919,"interventions":20921},"NCT01543087","Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose",[93],"2018-01-05","2012-09-07",698,[20920],"Meningococcal Infection",[20898],{"trials":20923,"activeCount":103},[],{"trials":20925,"activeCount":103},[],{"intervention":4974,"totalTrials":1087,"cells":20927},{"EARLY_PHASE1":20928,"PHASE1":20930,"PHASE2":20940,"PHASE3":20942,"PHASE4":20948,"NA":20950},{"trials":20929,"activeCount":103},[],{"trials":20931,"activeCount":103},[20932],{"nctId":20933,"briefTitle":20934,"status":111,"phases":20935,"primaryCompletion":20936,"completion":20936,"start":20937,"enrollment":1268,"conditions":20938,"interventions":20939},"NCT05263895","Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation",[91],"2022-05-16","2022-03-03",[12580],[4936,4936,4936,4936,4974],{"trials":20941,"activeCount":103},[],{"trials":20943,"activeCount":103},[20944],{"nctId":4966,"briefTitle":4967,"status":111,"phases":20945,"primaryCompletion":4969,"completion":4969,"start":4970,"enrollment":4971,"conditions":20946,"interventions":20947},[92,93],[2592],[4974,4904],{"trials":20949,"activeCount":103},[],{"trials":20951,"activeCount":103},[],{"intervention":20953,"totalTrials":1087,"cells":20954},"crisaborole ointment",{"EARLY_PHASE1":20955,"PHASE1":20957,"PHASE2":20959,"PHASE3":20970,"PHASE4":20982,"NA":20984},{"trials":20956,"activeCount":103},[],{"trials":20958,"activeCount":103},[],{"trials":20960,"activeCount":103},[20961],{"nctId":20962,"briefTitle":20963,"status":111,"phases":20964,"primaryCompletion":20965,"completion":20965,"start":20966,"enrollment":4825,"conditions":20967,"interventions":20969},"NCT04091087","Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis",[92],"2021-10-19","2020-06-26",[20968],"Stasis Dermatitis",[20953],{"trials":20971,"activeCount":103},[20972],{"nctId":20973,"briefTitle":20974,"status":111,"phases":20975,"primaryCompletion":20976,"completion":20976,"start":20977,"enrollment":18630,"conditions":20978,"interventions":20979},"NCT04360187","Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis",[93],"2021-09-08","2020-07-27",[1589],[20980,20981],"Crisaborole Ointment","Crisaborole Placebo Vehicle",{"trials":20983,"activeCount":103},[],{"trials":20985,"activeCount":103},[],{"intervention":20987,"totalTrials":1087,"cells":20988},"Active Anidulafungin",{"EARLY_PHASE1":20989,"PHASE1":20991,"PHASE2":20993,"PHASE3":20995,"PHASE4":21013,"NA":21015},{"trials":20990,"activeCount":103},[],{"trials":20992,"activeCount":103},[],{"trials":20994,"activeCount":103},[],{"trials":20996,"activeCount":103},[20997,21006],{"nctId":20998,"briefTitle":20999,"status":168,"phases":21000,"primaryCompletion":114,"completion":114,"start":4214,"enrollment":360,"conditions":21001,"interventions":21004},"NCT00806351","An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System",[93],[21002,21003,15545],"Fungemia","Neutropenia",[20987,21005],"Active Caspofungin",{"nctId":21007,"briefTitle":21008,"status":168,"phases":21009,"primaryCompletion":4459,"completion":4459,"start":4222,"enrollment":713,"conditions":21010,"interventions":21011},"NCT00805740","An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida",[93],[15545,21002],[21012,21005],"Active anidulafungin",{"trials":21014,"activeCount":103},[],{"trials":21016,"activeCount":103},[],{"intervention":21005,"totalTrials":1087,"cells":21018},{"EARLY_PHASE1":21019,"PHASE1":21021,"PHASE2":21023,"PHASE3":21025,"PHASE4":21035,"NA":21037},{"trials":21020,"activeCount":103},[],{"trials":21022,"activeCount":103},[],{"trials":21024,"activeCount":103},[],{"trials":21026,"activeCount":103},[21027,21031],{"nctId":20998,"briefTitle":20999,"status":168,"phases":21028,"primaryCompletion":114,"completion":114,"start":4214,"enrollment":360,"conditions":21029,"interventions":21030},[93],[21002,21003,15545],[20987,21005],{"nctId":21007,"briefTitle":21008,"status":168,"phases":21032,"primaryCompletion":4459,"completion":4459,"start":4222,"enrollment":713,"conditions":21033,"interventions":21034},[93],[15545,21002],[21012,21005],{"trials":21036,"activeCount":103},[],{"trials":21038,"activeCount":103},[],{"intervention":21040,"totalTrials":1087,"cells":21041},"Geodon",{"EARLY_PHASE1":21042,"PHASE1":21044,"PHASE2":21046,"PHASE3":21048,"PHASE4":21065,"NA":21067},{"trials":21043,"activeCount":103},[],{"trials":21045,"activeCount":103},[],{"trials":21047,"activeCount":103},[],{"trials":21049,"activeCount":103},[21050,21058],{"nctId":21051,"briefTitle":21052,"status":111,"phases":21053,"primaryCompletion":3335,"completion":3335,"start":12416,"enrollment":21054,"conditions":21055,"interventions":21057},"NCT00282464","A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.",[93],392,[21056],"Bipolar Disorder",[21040],{"nctId":21059,"briefTitle":21060,"status":111,"phases":21061,"primaryCompletion":10937,"completion":10937,"start":11417,"enrollment":21062,"conditions":21063,"interventions":21064},"NCT00141271","A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression",[93],536,[21056],[21040,21040],{"trials":21066,"activeCount":103},[],{"trials":21068,"activeCount":103},[],{"intervention":21070,"totalTrials":1087,"cells":21071},"active comparator",{"EARLY_PHASE1":21072,"PHASE1":21074,"PHASE2":21076,"PHASE3":21090,"PHASE4":21102,"NA":21104},{"trials":21073,"activeCount":103},[],{"trials":21075,"activeCount":103},[],{"trials":21077,"activeCount":103},[21078],{"nctId":21079,"briefTitle":21080,"status":111,"phases":21081,"primaryCompletion":577,"completion":577,"start":10923,"enrollment":525,"conditions":21082,"interventions":21086},"NCT01033487","A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease",[92],[21083,9108,9106,21084,21085],"Pulmonary Disease, Chronic Obstructive","Chronic Obstructive Airway Disease","COPD",[21070,21087,21088,21089],"Low Dose PF-03635659","Mid Dose PF-03635659","High Dose PF-03635659",{"trials":21091,"activeCount":103},[21092],{"nctId":21093,"briefTitle":21094,"status":111,"phases":21095,"primaryCompletion":640,"completion":21096,"start":21097,"enrollment":21098,"conditions":21099,"interventions":21100},"NCT01360554","ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer",[93],"2015-09-14","2011-06-16",878,[422],[8126,21101],"Active Comparator",{"trials":21103,"activeCount":103},[],{"trials":21105,"activeCount":103},[],{"intervention":19180,"totalTrials":1087,"cells":21107},{"EARLY_PHASE1":21108,"PHASE1":21110,"PHASE2":21112,"PHASE3":21118,"PHASE4":21129,"NA":21131},{"trials":21109,"activeCount":103},[],{"trials":21111,"activeCount":103},[],{"trials":21113,"activeCount":103},[21114],{"nctId":19171,"briefTitle":19172,"status":168,"phases":21115,"primaryCompletion":18058,"completion":18058,"start":19174,"enrollment":7411,"conditions":21116,"interventions":21117},[92],[8295],[8309,19177,19177,19178,19179,19180,19181,19182],{"trials":21119,"activeCount":103},[21120],{"nctId":21121,"briefTitle":21122,"status":111,"phases":21123,"primaryCompletion":21124,"completion":21124,"start":21125,"enrollment":21126,"conditions":21127,"interventions":21128},"NCT04819113","Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age",[93],"2022-09-09","2021-04-09",149,[8295],[19180],{"trials":21130,"activeCount":103},[],{"trials":21132,"activeCount":103},[],{"intervention":18471,"totalTrials":1087,"cells":21134},{"EARLY_PHASE1":21135,"PHASE1":21137,"PHASE2":21139,"PHASE3":21141,"PHASE4":21153,"NA":21155},{"trials":21136,"activeCount":103},[],{"trials":21138,"activeCount":103},[],{"trials":21140,"activeCount":103},[],{"trials":21142,"activeCount":103},[21143,21149],{"nctId":21144,"briefTitle":21145,"status":168,"phases":21146,"primaryCompletion":4381,"completion":4381,"start":4540,"enrollment":35,"conditions":21147,"interventions":21148},"NCT04498403","A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis",[93],[1589],[18471],{"nctId":18465,"briefTitle":18466,"status":111,"phases":21150,"primaryCompletion":7515,"completion":7515,"start":18468,"enrollment":6762,"conditions":21151,"interventions":21152},[93],[1589],[18471,18415],{"trials":21154,"activeCount":103},[],{"trials":21156,"activeCount":103},[],{"intervention":2677,"totalTrials":1087,"cells":21158},{"EARLY_PHASE1":21159,"PHASE1":21161,"PHASE2":21163,"PHASE3":21169,"PHASE4":21175,"NA":21177},{"trials":21160,"activeCount":103},[],{"trials":21162,"activeCount":103},[],{"trials":21164,"activeCount":103},[21165],{"nctId":2668,"briefTitle":2669,"status":111,"phases":21166,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":2673,"conditions":21167,"interventions":21168},[92],[2675],[2647,2677,968,2647,2647],{"trials":21170,"activeCount":103},[21171],{"nctId":17524,"briefTitle":17525,"status":111,"phases":21172,"primaryCompletion":17527,"completion":3240,"start":17528,"enrollment":17529,"conditions":21173,"interventions":21174},[93],[17531],[17444,17533],{"trials":21176,"activeCount":103},[],{"trials":21178,"activeCount":103},[],{"intervention":8183,"totalTrials":1087,"cells":21180},{"EARLY_PHASE1":21181,"PHASE1":21183,"PHASE2":21185,"PHASE3":21195,"PHASE4":21201,"NA":21203},{"trials":21182,"activeCount":103},[],{"trials":21184,"activeCount":103},[],{"trials":21186,"activeCount":103},[21187],{"nctId":21188,"briefTitle":21189,"status":111,"phases":21190,"completion":21191,"start":6437,"conditions":21192,"interventions":21193},"NCT00004861","Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer",[92],"2001-09",[4778],[8183,21194],"tacedinaline",{"trials":21196,"activeCount":103},[21197],{"nctId":8177,"briefTitle":8178,"status":111,"phases":21198,"primaryCompletion":8180,"start":2629,"conditions":21199,"interventions":21200},[93],[981],[2890,8183,6441],{"trials":21202,"activeCount":103},[],{"trials":21204,"activeCount":103},[],{"intervention":21206,"totalTrials":302,"cells":21207},"treatment",{"EARLY_PHASE1":21208,"PHASE1":21210,"PHASE2":21212,"PHASE3":21214,"PHASE4":21226,"NA":21228},{"trials":21209,"activeCount":103},[],{"trials":21211,"activeCount":103},[],{"trials":21213,"activeCount":103},[],{"trials":21215,"activeCount":103},[21216],{"nctId":21217,"briefTitle":21218,"status":111,"phases":21219,"primaryCompletion":2202,"completion":21220,"start":21221,"enrollment":21222,"conditions":21223,"interventions":21225},"NCT01154140","A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung",[93],"2016-11-30","2011-01-13",343,[21224],"Non Squamous Lung Cancer",[21206,21206],{"trials":21227,"activeCount":103},[],{"trials":21229,"activeCount":103},[],{"intervention":21231,"totalTrials":302,"cells":21232},"Treatment with Genotropin in different dosages",{"EARLY_PHASE1":21233,"PHASE1":21235,"PHASE2":21237,"PHASE3":21239,"PHASE4":21248,"NA":21250},{"trials":21234,"activeCount":103},[],{"trials":21236,"activeCount":103},[],{"trials":21238,"activeCount":103},[],{"trials":21240,"activeCount":103},[21241],{"nctId":21242,"briefTitle":21243,"status":111,"phases":21244,"completion":15716,"start":14824,"enrollment":1530,"conditions":21245,"interventions":21247},"NCT00174421","Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height",[93],[21246],"Growth Disorder",[21231],{"trials":21249,"activeCount":103},[],{"trials":21251,"activeCount":103},[],{"intervention":21253,"totalTrials":302,"cells":21254},"PF-06462700",{"EARLY_PHASE1":21255,"PHASE1":21257,"PHASE2":21259,"PHASE3":21261,"PHASE4":21271,"NA":21273},{"trials":21256,"activeCount":103},[],{"trials":21258,"activeCount":103},[],{"trials":21260,"activeCount":103},[],{"trials":21262,"activeCount":103},[21263],{"nctId":21264,"briefTitle":21265,"status":111,"phases":21266,"primaryCompletion":4557,"completion":21267,"start":21268,"enrollment":502,"conditions":21269,"interventions":21270},"NCT04350606","A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia",[93],"2021-04-19","2020-07-25",[10601],[21253],{"trials":21272,"activeCount":103},[],{"trials":21274,"activeCount":103},[],{"intervention":21276,"totalTrials":302,"cells":21277},"Interferon-alfa",{"EARLY_PHASE1":21278,"PHASE1":21280,"PHASE2":21282,"PHASE3":21284,"PHASE4":21293,"NA":21295},{"trials":21279,"activeCount":103},[],{"trials":21281,"activeCount":103},[],{"trials":21283,"activeCount":103},[],{"trials":21285,"activeCount":103},[21286],{"nctId":21287,"briefTitle":21288,"status":111,"phases":21289,"primaryCompletion":11291,"completion":11291,"start":11727,"enrollment":21290,"conditions":21291,"interventions":21292},"NCT00083889","SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma",[93],750,[919],[21276,2666],{"trials":21294,"activeCount":103},[],{"trials":21296,"activeCount":103},[],{"intervention":18237,"totalTrials":302,"cells":21298},{"EARLY_PHASE1":21299,"PHASE1":21301,"PHASE2":21303,"PHASE3":21305,"PHASE4":21311,"NA":21313},{"trials":21300,"activeCount":103},[],{"trials":21302,"activeCount":103},[],{"trials":21304,"activeCount":103},[],{"trials":21306,"activeCount":103},[21307],{"nctId":18232,"briefTitle":18233,"status":111,"phases":21308,"completion":8170,"start":4692,"enrollment":15543,"conditions":21309,"interventions":21310},[92,93],[2761],[18208,18237],{"trials":21312,"activeCount":103},[],{"trials":21314,"activeCount":103},[],{"intervention":21316,"totalTrials":302,"cells":21317},"Topical IBU twice daily",{"EARLY_PHASE1":21318,"PHASE1":21320,"PHASE2":21322,"PHASE3":21324,"PHASE4":21334,"NA":21336},{"trials":21319,"activeCount":103},[],{"trials":21321,"activeCount":103},[],{"trials":21323,"activeCount":103},[],{"trials":21325,"activeCount":103},[21326],{"nctId":21327,"briefTitle":21328,"status":111,"phases":21329,"primaryCompletion":2227,"completion":2227,"start":18769,"enrollment":12550,"conditions":21330,"interventions":21332},"NCT01945034","5% Topical Ibuprofen (IBU) for Ankle Sprain",[93],[21331],"Ankle Injuries",[21316,21333],"Topical IBU three times daily",{"trials":21335,"activeCount":103},[],{"trials":21337,"activeCount":103},[],{"intervention":21333,"totalTrials":302,"cells":21339},{"EARLY_PHASE1":21340,"PHASE1":21342,"PHASE2":21344,"PHASE3":21346,"PHASE4":21352,"NA":21354},{"trials":21341,"activeCount":103},[],{"trials":21343,"activeCount":103},[],{"trials":21345,"activeCount":103},[],{"trials":21347,"activeCount":103},[21348],{"nctId":21327,"briefTitle":21328,"status":111,"phases":21349,"primaryCompletion":2227,"completion":2227,"start":18769,"enrollment":12550,"conditions":21350,"interventions":21351},[93],[21331],[21316,21333],{"trials":21353,"activeCount":103},[],{"trials":21355,"activeCount":103},[],{"intervention":20375,"totalTrials":302,"cells":21357},{"EARLY_PHASE1":21358,"PHASE1":21360,"PHASE2":21362,"PHASE3":21364,"PHASE4":21370,"NA":21372},{"trials":21359,"activeCount":103},[],{"trials":21361,"activeCount":103},[],{"trials":21363,"activeCount":103},[],{"trials":21365,"activeCount":103},[21366],{"nctId":20369,"briefTitle":20370,"status":111,"phases":21367,"primaryCompletion":7578,"completion":7578,"start":1700,"enrollment":20372,"conditions":21368,"interventions":21369},[93],[10914],[20358,20375,20375,20375],{"trials":21371,"activeCount":103},[],{"trials":21373,"activeCount":103},[],{"intervention":20402,"totalTrials":302,"cells":21375},{"EARLY_PHASE1":21376,"PHASE1":21378,"PHASE2":21380,"PHASE3":21382,"PHASE4":21388,"NA":21390},{"trials":21377,"activeCount":103},[],{"trials":21379,"activeCount":103},[],{"trials":21381,"activeCount":103},[],{"trials":21383,"activeCount":103},[21384],{"nctId":20396,"briefTitle":20397,"status":111,"phases":21385,"primaryCompletion":5854,"completion":5854,"start":9423,"enrollment":20399,"conditions":21386,"interventions":21387},[93],[1589],[20385,20402],{"trials":21389,"activeCount":103},[],{"trials":21391,"activeCount":103},[],{"intervention":21393,"totalTrials":302,"cells":21394},"Quillivant Oral Suspension XR",{"EARLY_PHASE1":21395,"PHASE1":21397,"PHASE2":21399,"PHASE3":21401,"PHASE4":21409,"NA":21411},{"trials":21396,"activeCount":103},[],{"trials":21398,"activeCount":103},[],{"trials":21400,"activeCount":103},[],{"trials":21402,"activeCount":103},[21403],{"nctId":21404,"briefTitle":21405,"status":111,"phases":21406,"primaryCompletion":4214,"completion":4214,"start":4222,"enrollment":8373,"conditions":21407,"interventions":21408},"NCT00904670","Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)",[93],[15099],[21393],{"trials":21410,"activeCount":103},[],{"trials":21412,"activeCount":103},[],{"intervention":21414,"totalTrials":302,"cells":21415},"NWP09",{"EARLY_PHASE1":21416,"PHASE1":21418,"PHASE2":21420,"PHASE3":21422,"PHASE4":21430,"NA":21432},{"trials":21417,"activeCount":103},[],{"trials":21419,"activeCount":103},[],{"trials":21421,"activeCount":103},[],{"trials":21423,"activeCount":103},[21424],{"nctId":21425,"briefTitle":21426,"status":111,"phases":21427,"primaryCompletion":3353,"completion":3353,"start":540,"enrollment":481,"conditions":21428,"interventions":21429},"NCT01654250","NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)",[93],[15099],[21414],{"trials":21431,"activeCount":103},[],{"trials":21433,"activeCount":103},[],{"intervention":21435,"totalTrials":302,"cells":21436},"pramipexole",{"EARLY_PHASE1":21437,"PHASE1":21439,"PHASE2":21441,"PHASE3":21443,"PHASE4":21452,"NA":21454},{"trials":21438,"activeCount":103},[],{"trials":21440,"activeCount":103},[],{"trials":21442,"activeCount":103},[],{"trials":21444,"activeCount":103},[21445],{"nctId":21446,"briefTitle":21447,"status":111,"phases":21448,"primaryCompletion":2661,"completion":2661,"start":4221,"enrollment":20,"conditions":21449,"interventions":21450},"NCT00991276","Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance",[93],[13741],[21451,21435],"pregabalin",{"trials":21453,"activeCount":103},[],{"trials":21455,"activeCount":103},[],{"intervention":21457,"totalTrials":302,"cells":21458},"celecoxib and ibuprofen SR",{"EARLY_PHASE1":21459,"PHASE1":21461,"PHASE2":21463,"PHASE3":21465,"PHASE4":21473,"NA":21475},{"trials":21460,"activeCount":103},[],{"trials":21462,"activeCount":103},[],{"trials":21464,"activeCount":103},[],{"trials":21466,"activeCount":103},[21467],{"nctId":21468,"briefTitle":21469,"status":111,"phases":21470,"completion":11417,"start":12109,"enrollment":903,"conditions":21471,"interventions":21472},"NCT00150280","Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery",[93],[11730],[21457],{"trials":21474,"activeCount":103},[],{"trials":21476,"activeCount":103},[],{"intervention":12064,"totalTrials":302,"cells":21478},{"EARLY_PHASE1":21479,"PHASE1":21481,"PHASE2":21483,"PHASE3":21485,"PHASE4":21491,"NA":21493},{"trials":21480,"activeCount":103},[],{"trials":21482,"activeCount":103},[],{"trials":21484,"activeCount":103},[],{"trials":21486,"activeCount":103},[21487],{"nctId":12058,"briefTitle":12059,"status":168,"phases":21488,"completion":4398,"start":3074,"enrollment":26,"conditions":21489,"interventions":21490},[93],[12062],[12064,12047],{"trials":21492,"activeCount":103},[],{"trials":21494,"activeCount":103},[],{"intervention":21496,"totalTrials":302,"cells":21497},"Fragmin\u002F Dalteparin Sodium",{"EARLY_PHASE1":21498,"PHASE1":21500,"PHASE2":21502,"PHASE3":21504,"PHASE4":21514,"NA":21516},{"trials":21499,"activeCount":103},[],{"trials":21501,"activeCount":103},[],{"trials":21503,"activeCount":103},[],{"trials":21505,"activeCount":103},[21506],{"nctId":21507,"briefTitle":21508,"status":111,"phases":21509,"primaryCompletion":585,"completion":585,"start":3314,"enrollment":21510,"conditions":21511,"interventions":21513},"NCT00662831","Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients",[92,93],276,[21512],"Diabetic Foot Ulcer",[21496],{"trials":21515,"activeCount":103},[],{"trials":21517,"activeCount":103},[],{"intervention":21519,"totalTrials":302,"cells":21520},"clarithromycin extended release",{"EARLY_PHASE1":21521,"PHASE1":21523,"PHASE2":21525,"PHASE3":21527,"PHASE4":21536,"NA":21538},{"trials":21522,"activeCount":103},[],{"trials":21524,"activeCount":103},[],{"trials":21526,"activeCount":103},[],{"trials":21528,"activeCount":103},[21529],{"nctId":21530,"briefTitle":21531,"status":111,"phases":21532,"completion":11686,"start":3073,"enrollment":21533,"conditions":21534,"interventions":21535},"NCT00643227","A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients",[93],504,[9107],[21519,19967],{"trials":21537,"activeCount":103},[],{"trials":21539,"activeCount":103},[],{"intervention":7415,"totalTrials":302,"cells":21541},{"EARLY_PHASE1":21542,"PHASE1":21544,"PHASE2":21546,"PHASE3":21548,"PHASE4":21554,"NA":21556},{"trials":21543,"activeCount":103},[],{"trials":21545,"activeCount":103},[],{"trials":21547,"activeCount":103},[],{"trials":21549,"activeCount":103},[21550],{"nctId":7405,"briefTitle":7406,"status":111,"phases":21551,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":7411,"conditions":21552,"interventions":21553},[93],[7413],[2968,7415,7416,7417],{"trials":21555,"activeCount":103},[],{"trials":21557,"activeCount":103},[],{"intervention":7416,"totalTrials":302,"cells":21559},{"EARLY_PHASE1":21560,"PHASE1":21562,"PHASE2":21564,"PHASE3":21566,"PHASE4":21572,"NA":21574},{"trials":21561,"activeCount":103},[],{"trials":21563,"activeCount":103},[],{"trials":21565,"activeCount":103},[],{"trials":21567,"activeCount":103},[21568],{"nctId":7405,"briefTitle":7406,"status":111,"phases":21569,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":7411,"conditions":21570,"interventions":21571},[93],[7413],[2968,7415,7416,7417],{"trials":21573,"activeCount":103},[],{"trials":21575,"activeCount":103},[],{"intervention":7417,"totalTrials":302,"cells":21577},{"EARLY_PHASE1":21578,"PHASE1":21580,"PHASE2":21582,"PHASE3":21584,"PHASE4":21590,"NA":21592},{"trials":21579,"activeCount":103},[],{"trials":21581,"activeCount":103},[],{"trials":21583,"activeCount":103},[],{"trials":21585,"activeCount":103},[21586],{"nctId":7405,"briefTitle":7406,"status":111,"phases":21587,"primaryCompletion":7408,"completion":7409,"start":7410,"enrollment":7411,"conditions":21588,"interventions":21589},[93],[7413],[2968,7415,7416,7417],{"trials":21591,"activeCount":103},[],{"trials":21593,"activeCount":103},[],{"intervention":7428,"totalTrials":302,"cells":21595},{"EARLY_PHASE1":21596,"PHASE1":21598,"PHASE2":21600,"PHASE3":21602,"PHASE4":21608,"NA":21610},{"trials":21597,"activeCount":103},[],{"trials":21599,"activeCount":103},[],{"trials":21601,"activeCount":103},[],{"trials":21603,"activeCount":103},[21604],{"nctId":7419,"briefTitle":7420,"status":168,"phases":21605,"primaryCompletion":7422,"completion":7422,"start":7423,"enrollment":7424,"conditions":21606,"interventions":21607},[93],[7426],[7006,2917,7428,7429],{"trials":21609,"activeCount":103},[],{"trials":21611,"activeCount":103},[],{"intervention":7429,"totalTrials":302,"cells":21613},{"EARLY_PHASE1":21614,"PHASE1":21616,"PHASE2":21618,"PHASE3":21620,"PHASE4":21626,"NA":21628},{"trials":21615,"activeCount":103},[],{"trials":21617,"activeCount":103},[],{"trials":21619,"activeCount":103},[],{"trials":21621,"activeCount":103},[21622],{"nctId":7419,"briefTitle":7420,"status":168,"phases":21623,"primaryCompletion":7422,"completion":7422,"start":7423,"enrollment":7424,"conditions":21624,"interventions":21625},[93],[7426],[7006,2917,7428,7429],{"trials":21627,"activeCount":103},[],{"trials":21629,"activeCount":103},[],{"intervention":21631,"totalTrials":302,"cells":21632},"\"Investigational\"Auto-injector",{"EARLY_PHASE1":21633,"PHASE1":21635,"PHASE2":21637,"PHASE3":21639,"PHASE4":21647,"NA":21649},{"trials":21634,"activeCount":103},[],{"trials":21636,"activeCount":103},[],{"trials":21638,"activeCount":103},[],{"trials":21640,"activeCount":103},[21641],{"nctId":21642,"briefTitle":21643,"status":111,"phases":21644,"primaryCompletion":4636,"completion":4636,"start":2641,"enrollment":463,"conditions":21645,"interventions":21646},"NCT00510419","A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack",[93],[117],[21631],{"trials":21648,"activeCount":103},[],{"trials":21650,"activeCount":103},[],{"intervention":17204,"totalTrials":302,"cells":21652},{"EARLY_PHASE1":21653,"PHASE1":21655,"PHASE2":21657,"PHASE3":21659,"PHASE4":21665,"NA":21667},{"trials":21654,"activeCount":103},[],{"trials":21656,"activeCount":103},[],{"trials":21658,"activeCount":103},[],{"trials":21660,"activeCount":103},[21661],{"nctId":17195,"briefTitle":17196,"status":168,"phases":21662,"primaryCompletion":17198,"completion":17199,"start":17200,"enrollment":17201,"conditions":21663,"interventions":21664},[93],[11282,11409],[17204,12083,12083,12083,17204,12083,17204],{"trials":21666,"activeCount":103},[],{"trials":21668,"activeCount":103},[],{"intervention":10942,"totalTrials":302,"cells":21670},{"EARLY_PHASE1":21671,"PHASE1":21673,"PHASE2":21675,"PHASE3":21677,"PHASE4":21683,"NA":21685},{"trials":21672,"activeCount":103},[],{"trials":21674,"activeCount":103},[],{"trials":21676,"activeCount":103},[],{"trials":21678,"activeCount":103},[21679],{"nctId":10934,"briefTitle":10935,"status":111,"phases":21680,"primaryCompletion":10937,"completion":10937,"start":7665,"enrollment":10938,"conditions":21681,"interventions":21682},[93],[10940],[2555,10942],{"trials":21684,"activeCount":103},[],{"trials":21686,"activeCount":103},[],{"intervention":20411,"totalTrials":302,"cells":21688},{"EARLY_PHASE1":21689,"PHASE1":21691,"PHASE2":21693,"PHASE3":21695,"PHASE4":21701,"NA":21703},{"trials":21690,"activeCount":103},[],{"trials":21692,"activeCount":103},[],{"trials":21694,"activeCount":103},[],{"trials":21696,"activeCount":103},[21697],{"nctId":20404,"briefTitle":20405,"status":111,"phases":21698,"primaryCompletion":2711,"completion":2711,"start":20407,"enrollment":20408,"conditions":21699,"interventions":21700},[93],[1933],[20411,20385,20411,20411,20385],{"trials":21702,"activeCount":103},[],{"trials":21704,"activeCount":103},[],{"intervention":21706,"totalTrials":302,"cells":21707},"fordadistrogene movaparvovec",{"EARLY_PHASE1":21708,"PHASE1":21710,"PHASE2":21712,"PHASE3":21714,"PHASE4":21724,"NA":21726},{"trials":21709,"activeCount":103},[],{"trials":21711,"activeCount":103},[],{"trials":21713,"activeCount":103},[],{"trials":21715,"activeCount":103},[21716],{"nctId":21717,"briefTitle":21718,"status":168,"phases":21719,"primaryCompletion":21720,"completion":21720,"start":21721,"enrollment":3659,"conditions":21722,"interventions":21723},"NCT05689164","A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.",[93],"2025-09-24","2023-03-13",[5093],[21706],{"trials":21725,"activeCount":103},[],{"trials":21727,"activeCount":103},[],{"intervention":21729,"totalTrials":302,"cells":21730},"Irinotecan + 5 FU + folinic acid",{"EARLY_PHASE1":21731,"PHASE1":21733,"PHASE2":21735,"PHASE3":21737,"PHASE4":21747,"NA":21749},{"trials":21732,"activeCount":103},[],{"trials":21734,"activeCount":103},[],{"trials":21736,"activeCount":103},[],{"trials":21738,"activeCount":103},[21739],{"nctId":21740,"briefTitle":21741,"status":111,"phases":21742,"primaryCompletion":10937,"completion":4833,"start":19543,"enrollment":21743,"conditions":21744,"interventions":21745},"NCT00143403","Comparing Irinotecan and 5 FU\u002FFA To 5-FU\u002FFA After Resection Of Liver Metastases For Colorectal Cancer",[93],321,[1028,891],[21729,21746],"Folinic Acid + 5 FU",{"trials":21748,"activeCount":103},[],{"trials":21750,"activeCount":103},[],{"intervention":21746,"totalTrials":302,"cells":21752},{"EARLY_PHASE1":21753,"PHASE1":21755,"PHASE2":21757,"PHASE3":21759,"PHASE4":21765,"NA":21767},{"trials":21754,"activeCount":103},[],{"trials":21756,"activeCount":103},[],{"trials":21758,"activeCount":103},[],{"trials":21760,"activeCount":103},[21761],{"nctId":21740,"briefTitle":21741,"status":111,"phases":21762,"primaryCompletion":10937,"completion":4833,"start":19543,"enrollment":21743,"conditions":21763,"interventions":21764},[93],[1028,891],[21729,21746],{"trials":21766,"activeCount":103},[],{"trials":21768,"activeCount":103},[],{"intervention":21770,"totalTrials":302,"cells":21771},"Venlafaxine ER",{"EARLY_PHASE1":21772,"PHASE1":21774,"PHASE2":21776,"PHASE3":21778,"PHASE4":21786,"NA":21788},{"trials":21773,"activeCount":103},[],{"trials":21775,"activeCount":103},[],{"trials":21777,"activeCount":103},[],{"trials":21779,"activeCount":103},[21780],{"nctId":21781,"briefTitle":21782,"status":111,"phases":21783,"primaryCompletion":1248,"completion":1248,"start":10912,"enrollment":26,"conditions":21784,"interventions":21785},"NCT01485887","Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)",[93],[6321],[21770],{"trials":21787,"activeCount":103},[],{"trials":21789,"activeCount":103},[],{"intervention":689,"totalTrials":302,"cells":21791},{"EARLY_PHASE1":21792,"PHASE1":21794,"PHASE2":21796,"PHASE3":21798,"PHASE4":21804,"NA":21806},{"trials":21793,"activeCount":103},[],{"trials":21795,"activeCount":103},[],{"trials":21797,"activeCount":103},[],{"trials":21799,"activeCount":103},[21800],{"nctId":679,"briefTitle":680,"status":111,"phases":21801,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":21802,"interventions":21803},[93],[687],[388,689,690],{"trials":21805,"activeCount":103},[],{"trials":21807,"activeCount":103},[],{"intervention":690,"totalTrials":302,"cells":21809},{"EARLY_PHASE1":21810,"PHASE1":21812,"PHASE2":21814,"PHASE3":21816,"PHASE4":21822,"NA":21824},{"trials":21811,"activeCount":103},[],{"trials":21813,"activeCount":103},[],{"trials":21815,"activeCount":103},[],{"trials":21817,"activeCount":103},[21818],{"nctId":679,"briefTitle":680,"status":111,"phases":21819,"primaryCompletion":682,"completion":683,"start":684,"enrollment":685,"conditions":21820,"interventions":21821},[93],[687],[388,689,690],{"trials":21823,"activeCount":103},[],{"trials":21825,"activeCount":103},[],{"intervention":21827,"totalTrials":302,"cells":21828},"desvenlafaxine succinate (DVS) SR",{"EARLY_PHASE1":21829,"PHASE1":21831,"PHASE2":21833,"PHASE3":21835,"PHASE4":21844,"NA":21846},{"trials":21830,"activeCount":103},[],{"trials":21832,"activeCount":103},[],{"trials":21834,"activeCount":103},[],{"trials":21836,"activeCount":103},[21837],{"nctId":21838,"briefTitle":21839,"status":111,"phases":21840,"primaryCompletion":2660,"completion":2660,"start":3839,"enrollment":21841,"conditions":21842,"interventions":21843},"NCT00683800","Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women",[93],2186,[12558],[21827],{"trials":21845,"activeCount":103},[],{"trials":21847,"activeCount":103},[],{"intervention":18913,"totalTrials":302,"cells":21849},{"EARLY_PHASE1":21850,"PHASE1":21852,"PHASE2":21854,"PHASE3":21856,"PHASE4":21862,"NA":21864},{"trials":21851,"activeCount":103},[],{"trials":21853,"activeCount":103},[],{"trials":21855,"activeCount":103},[],{"trials":21857,"activeCount":103},[21858],{"nctId":18906,"briefTitle":18907,"status":168,"phases":21859,"primaryCompletion":1249,"completion":18769,"start":585,"enrollment":18909,"conditions":21860,"interventions":21861},[93],[18911],[18879,18913],{"trials":21863,"activeCount":103},[],{"trials":21865,"activeCount":103},[],{"intervention":21867,"totalTrials":302,"cells":21868},"Modified Bolus 5-FU\u002FLV with Irinotecan",{"EARLY_PHASE1":21869,"PHASE1":21871,"PHASE2":21873,"PHASE3":21875,"PHASE4":21887,"NA":21889},{"trials":21870,"activeCount":103},[],{"trials":21872,"activeCount":103},[],{"trials":21874,"activeCount":103},[],{"trials":21876,"activeCount":103},[21877],{"nctId":21878,"briefTitle":21879,"status":111,"phases":21880,"primaryCompletion":4665,"completion":4665,"start":11676,"enrollment":4460,"conditions":21881,"interventions":21882},"NCT00101686","Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.",[93],[1028],[21867,21883,21884,21885,21886],"FOLFIRI + bevacizumab","miFL + bevacizumab","Infusional 5-FU\u002FLV with Irinotecan","Oral Capecitabine with Irinotecan",{"trials":21888,"activeCount":103},[],{"trials":21890,"activeCount":103},[],{"intervention":21883,"totalTrials":302,"cells":21892},{"EARLY_PHASE1":21893,"PHASE1":21895,"PHASE2":21897,"PHASE3":21899,"PHASE4":21905,"NA":21907},{"trials":21894,"activeCount":103},[],{"trials":21896,"activeCount":103},[],{"trials":21898,"activeCount":103},[],{"trials":21900,"activeCount":103},[21901],{"nctId":21878,"briefTitle":21879,"status":111,"phases":21902,"primaryCompletion":4665,"completion":4665,"start":11676,"enrollment":4460,"conditions":21903,"interventions":21904},[93],[1028],[21867,21883,21884,21885,21886],{"trials":21906,"activeCount":103},[],{"trials":21908,"activeCount":103},[],{"intervention":21884,"totalTrials":302,"cells":21910},{"EARLY_PHASE1":21911,"PHASE1":21913,"PHASE2":21915,"PHASE3":21917,"PHASE4":21923,"NA":21925},{"trials":21912,"activeCount":103},[],{"trials":21914,"activeCount":103},[],{"trials":21916,"activeCount":103},[],{"trials":21918,"activeCount":103},[21919],{"nctId":21878,"briefTitle":21879,"status":111,"phases":21920,"primaryCompletion":4665,"completion":4665,"start":11676,"enrollment":4460,"conditions":21921,"interventions":21922},[93],[1028],[21867,21883,21884,21885,21886],{"trials":21924,"activeCount":103},[],{"trials":21926,"activeCount":103},[],{"intervention":21885,"totalTrials":302,"cells":21928},{"EARLY_PHASE1":21929,"PHASE1":21931,"PHASE2":21933,"PHASE3":21935,"PHASE4":21941,"NA":21943},{"trials":21930,"activeCount":103},[],{"trials":21932,"activeCount":103},[],{"trials":21934,"activeCount":103},[],{"trials":21936,"activeCount":103},[21937],{"nctId":21878,"briefTitle":21879,"status":111,"phases":21938,"primaryCompletion":4665,"completion":4665,"start":11676,"enrollment":4460,"conditions":21939,"interventions":21940},[93],[1028],[21867,21883,21884,21885,21886],{"trials":21942,"activeCount":103},[],{"trials":21944,"activeCount":103},[],{"intervention":21886,"totalTrials":302,"cells":21946},{"EARLY_PHASE1":21947,"PHASE1":21949,"PHASE2":21951,"PHASE3":21953,"PHASE4":21959,"NA":21961},{"trials":21948,"activeCount":103},[],{"trials":21950,"activeCount":103},[],{"trials":21952,"activeCount":103},[],{"trials":21954,"activeCount":103},[21955],{"nctId":21878,"briefTitle":21879,"status":111,"phases":21956,"primaryCompletion":4665,"completion":4665,"start":11676,"enrollment":4460,"conditions":21957,"interventions":21958},[93],[1028],[21867,21883,21884,21885,21886],{"trials":21960,"activeCount":103},[],{"trials":21962,"activeCount":103},[],{"intervention":21964,"totalTrials":302,"cells":21965},"Genotonorm",{"EARLY_PHASE1":21966,"PHASE1":21968,"PHASE2":21970,"PHASE3":21972,"PHASE4":21982,"NA":21984},{"trials":21967,"activeCount":103},[],{"trials":21969,"activeCount":103},[],{"trials":21971,"activeCount":103},[],{"trials":21973,"activeCount":103},[21974],{"nctId":21975,"briefTitle":21976,"status":111,"phases":21977,"primaryCompletion":11014,"completion":11014,"start":21978,"enrollment":12803,"conditions":21979,"interventions":21981},"NCT01073605","Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation",[93],"1993-07",[13074,21980],"Intrauterine Growth Retardation",[21964,21964,21964],{"trials":21983,"activeCount":103},[],{"trials":21985,"activeCount":103},[],{"intervention":4640,"totalTrials":302,"cells":21987},{"EARLY_PHASE1":21988,"PHASE1":21990,"PHASE2":21992,"PHASE3":21994,"PHASE4":22000,"NA":22002},{"trials":21989,"activeCount":103},[],{"trials":21991,"activeCount":103},[],{"trials":21993,"activeCount":103},[],{"trials":21995,"activeCount":103},[21996],{"nctId":4633,"briefTitle":4634,"status":111,"phases":21997,"primaryCompletion":4636,"completion":4221,"start":4601,"enrollment":4637,"conditions":21998,"interventions":21999},[93],[1369],[4640,1643],{"trials":22001,"activeCount":103},[],{"trials":22003,"activeCount":103},[],{"intervention":22005,"totalTrials":302,"cells":22006},"ziprasidone versus olanzapine , risperidone or quetiapine",{"EARLY_PHASE1":22007,"PHASE1":22009,"PHASE2":22011,"PHASE3":22013,"PHASE4":22022,"NA":22024},{"trials":22008,"activeCount":103},[],{"trials":22010,"activeCount":103},[],{"trials":22012,"activeCount":103},[],{"trials":22014,"activeCount":103},[22015],{"nctId":22016,"briefTitle":22017,"status":111,"phases":22018,"completion":7675,"start":4601,"enrollment":20597,"conditions":22019,"interventions":22021},"NCT00159770","Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients",[93],[12632,22020,12644],"Schizoaffective Disorder",[22005],{"trials":22023,"activeCount":103},[],{"trials":22025,"activeCount":103},[],{"intervention":20602,"totalTrials":302,"cells":22027},{"EARLY_PHASE1":22028,"PHASE1":22030,"PHASE2":22032,"PHASE3":22034,"PHASE4":22040,"NA":22042},{"trials":22029,"activeCount":103},[],{"trials":22031,"activeCount":103},[],{"trials":22033,"activeCount":103},[],{"trials":22035,"activeCount":103},[22036],{"nctId":20593,"briefTitle":20594,"status":111,"phases":22037,"primaryCompletion":12719,"completion":12719,"start":20596,"enrollment":20597,"conditions":22038,"interventions":22039},[93],[20599],[20582,20601,20602],{"trials":22041,"activeCount":103},[],{"trials":22043,"activeCount":103},[],{"intervention":12419,"totalTrials":302,"cells":22045},{"EARLY_PHASE1":22046,"PHASE1":22048,"PHASE2":22050,"PHASE3":22052,"PHASE4":22058,"NA":22060},{"trials":22047,"activeCount":103},[],{"trials":22049,"activeCount":103},[],{"trials":22051,"activeCount":103},[],{"trials":22053,"activeCount":103},[22054],{"nctId":12413,"briefTitle":12414,"status":168,"phases":22055,"completion":11895,"start":12416,"enrollment":525,"conditions":22056,"interventions":22057},[93],[6117],[12402,12419],{"trials":22059,"activeCount":103},[],{"trials":22061,"activeCount":103},[],{"intervention":22063,"totalTrials":302,"cells":22064},"Epirubicin with Cyclophosphamide, followed by a Taxane",{"EARLY_PHASE1":22065,"PHASE1":22067,"PHASE2":22069,"PHASE3":22071,"PHASE4":22082,"NA":22084},{"trials":22066,"activeCount":103},[],{"trials":22068,"activeCount":103},[],{"trials":22070,"activeCount":103},[],{"trials":22072,"activeCount":103},[22073],{"nctId":22074,"briefTitle":22075,"status":111,"phases":22076,"primaryCompletion":12773,"completion":12773,"start":22077,"enrollment":22078,"conditions":22079,"interventions":22080},"NCT00140075","Adjuvant Epirubicin\u002FCytoxan Followed By A Taxane VS. Epirubicin\u002FTaxane As Treatment For Node-Positive Breast Cancer",[93],"2000-11",606,[3356],[22063,22081],"Epirubicin with a Taxane",{"trials":22083,"activeCount":103},[],{"trials":22085,"activeCount":103},[],{"intervention":22081,"totalTrials":302,"cells":22087},{"EARLY_PHASE1":22088,"PHASE1":22090,"PHASE2":22092,"PHASE3":22094,"PHASE4":22100,"NA":22102},{"trials":22089,"activeCount":103},[],{"trials":22091,"activeCount":103},[],{"trials":22093,"activeCount":103},[],{"trials":22095,"activeCount":103},[22096],{"nctId":22074,"briefTitle":22075,"status":111,"phases":22097,"primaryCompletion":12773,"completion":12773,"start":22077,"enrollment":22078,"conditions":22098,"interventions":22099},[93],[3356],[22063,22081],{"trials":22101,"activeCount":103},[],{"trials":22103,"activeCount":103},[],{"intervention":22105,"totalTrials":302,"cells":22106},"CP-690, 550",{"EARLY_PHASE1":22107,"PHASE1":22109,"PHASE2":22111,"PHASE3":22113,"PHASE4":22122,"NA":22124},{"trials":22108,"activeCount":103},[],{"trials":22110,"activeCount":103},[],{"trials":22112,"activeCount":103},[],{"trials":22114,"activeCount":103},[22115],{"nctId":22116,"briefTitle":22117,"status":111,"phases":22118,"primaryCompletion":1248,"completion":1248,"start":2450,"enrollment":22119,"conditions":22120,"interventions":22121},"NCT01519089","A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And\u002FOr Psoriatic Arthritis",[93],95,[4401],[12692,22105],{"trials":22123,"activeCount":103},[],{"trials":22125,"activeCount":103},[],{"intervention":22127,"totalTrials":302,"cells":22128},"Background NSAID",{"EARLY_PHASE1":22129,"PHASE1":22131,"PHASE2":22133,"PHASE3":22135,"PHASE4":22143,"NA":22145},{"trials":22130,"activeCount":103},[],{"trials":22132,"activeCount":103},[],{"trials":22134,"activeCount":103},[],{"trials":22136,"activeCount":103},[22137],{"nctId":22138,"briefTitle":22139,"status":111,"phases":22140,"primaryCompletion":3345,"completion":11356,"start":4666,"enrollment":5690,"conditions":22141,"interventions":22142},"NCT01258738","Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes",[93],[12072],[4517,22127,22127],{"trials":22144,"activeCount":103},[],{"trials":22146,"activeCount":103},[],{"intervention":6463,"totalTrials":302,"cells":22148},{"EARLY_PHASE1":22149,"PHASE1":22151,"PHASE2":22153,"PHASE3":22155,"PHASE4":22161,"NA":22163},{"trials":22150,"activeCount":103},[],{"trials":22152,"activeCount":103},[],{"trials":22154,"activeCount":103},[],{"trials":22156,"activeCount":103},[22157],{"nctId":6454,"briefTitle":6455,"status":111,"phases":22158,"completion":6457,"start":6458,"enrollment":2250,"conditions":22159,"interventions":22160},[93],[6460],[6462,1334,6463,6464],{"trials":22162,"activeCount":103},[],{"trials":22164,"activeCount":103},[],{"intervention":6464,"totalTrials":302,"cells":22166},{"EARLY_PHASE1":22167,"PHASE1":22169,"PHASE2":22171,"PHASE3":22173,"PHASE4":22179,"NA":22181},{"trials":22168,"activeCount":103},[],{"trials":22170,"activeCount":103},[],{"trials":22172,"activeCount":103},[],{"trials":22174,"activeCount":103},[22175],{"nctId":6454,"briefTitle":6455,"status":111,"phases":22176,"completion":6457,"start":6458,"enrollment":2250,"conditions":22177,"interventions":22178},[93],[6460],[6462,1334,6463,6464],{"trials":22180,"activeCount":103},[],{"trials":22182,"activeCount":103},[],{"intervention":7670,"totalTrials":302,"cells":22184},{"EARLY_PHASE1":22185,"PHASE1":22187,"PHASE2":22189,"PHASE3":22191,"PHASE4":22197,"NA":22199},{"trials":22186,"activeCount":103},[],{"trials":22188,"activeCount":103},[],{"trials":22190,"activeCount":103},[],{"trials":22192,"activeCount":103},[22193],{"nctId":7662,"briefTitle":7663,"status":111,"phases":22194,"primaryCompletion":7665,"completion":7665,"start":7666,"conditions":22195,"interventions":22196},[93],[2022],[1990,7669,7670],{"trials":22198,"activeCount":103},[],{"trials":22200,"activeCount":103},[],{"intervention":22202,"totalTrials":302,"cells":22203},"amoxicillin",{"EARLY_PHASE1":22204,"PHASE1":22206,"PHASE2":22208,"PHASE3":22210,"PHASE4":22218,"NA":22220},{"trials":22205,"activeCount":103},[],{"trials":22207,"activeCount":103},[],{"trials":22209,"activeCount":103},[],{"trials":22211,"activeCount":103},[22212],{"nctId":22213,"briefTitle":22214,"status":111,"phases":22215,"completion":11686,"start":2642,"enrollment":1423,"conditions":22216,"interventions":22217},"NCT00643149","A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of Azithromycin SR Versus Amoxicillin For The Treatment Of Strep Throat In Children",[93],[16030],[22202,19967],{"trials":22219,"activeCount":103},[],{"trials":22221,"activeCount":103},[],{"intervention":18045,"totalTrials":302,"cells":22223},{"EARLY_PHASE1":22224,"PHASE1":22226,"PHASE2":22228,"PHASE3":22230,"PHASE4":22236,"NA":22238},{"trials":22225,"activeCount":103},[],{"trials":22227,"activeCount":103},[],{"trials":22229,"activeCount":103},[],{"trials":22231,"activeCount":103},[22232],{"nctId":18039,"briefTitle":18040,"status":111,"phases":22233,"primaryCompletion":3353,"completion":3353,"start":570,"enrollment":1796,"conditions":22234,"interventions":22235},[93],[18043],[12291,18045],{"trials":22237,"activeCount":103},[],{"trials":22239,"activeCount":103},[],{"intervention":22241,"totalTrials":302,"cells":22242},"Ibuprofen 400 mg caplet",{"EARLY_PHASE1":22243,"PHASE1":22245,"PHASE2":22247,"PHASE3":22249,"PHASE4":22259,"NA":22261},{"trials":22244,"activeCount":103},[],{"trials":22246,"activeCount":103},[],{"trials":22248,"activeCount":103},[],{"trials":22250,"activeCount":103},[22251],{"nctId":22252,"briefTitle":22253,"status":111,"phases":22254,"primaryCompletion":4458,"completion":4458,"start":17639,"enrollment":22255,"conditions":22256,"interventions":22258},"NCT02294019","Actual Use Trial of Ibuprofen 400 mg",[93],738,[22257],"Patient Compliance",[22241],{"trials":22260,"activeCount":103},[],{"trials":22262,"activeCount":103},[],{"intervention":22264,"totalTrials":302,"cells":22265},"Paracoxib",{"EARLY_PHASE1":22266,"PHASE1":22268,"PHASE2":22270,"PHASE3":22272,"PHASE4":22280,"NA":22282},{"trials":22267,"activeCount":103},[],{"trials":22269,"activeCount":103},[],{"trials":22271,"activeCount":103},[],{"trials":22273,"activeCount":103},[22274],{"nctId":22275,"briefTitle":22276,"status":168,"phases":22277,"completion":12069,"start":15036,"enrollment":2240,"conditions":22278,"interventions":22279},"NCT00139607","Parecoxib In Post Surgery (Hemicolectomy) Pain",[93],[15500],[22264],{"trials":22281,"activeCount":103},[],{"trials":22283,"activeCount":103},[],{"intervention":22285,"totalTrials":302,"cells":22286},"rimegepant 75 mg ODT",{"EARLY_PHASE1":22287,"PHASE1":22289,"PHASE2":22291,"PHASE3":22293,"PHASE4":22305,"NA":22307},{"trials":22288,"activeCount":103},[],{"trials":22290,"activeCount":103},[],{"trials":22292,"activeCount":103},[],{"trials":22294,"activeCount":103},[22295],{"nctId":22296,"briefTitle":22297,"status":111,"phases":22298,"primaryCompletion":22299,"completion":22300,"start":22301,"enrollment":12442,"conditions":22302,"interventions":22304},"NCT05248997","Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis",[93],"2024-03-11","2024-04-02","2022-02-17",[22303],"Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps",[22285],{"trials":22306,"activeCount":103},[],{"trials":22308,"activeCount":103},[],{"intervention":22310,"totalTrials":302,"cells":22311},"tramadol HCL",{"EARLY_PHASE1":22312,"PHASE1":22314,"PHASE2":22316,"PHASE3":22318,"PHASE4":22326,"NA":22328},{"trials":22313,"activeCount":103},[],{"trials":22315,"activeCount":103},[],{"trials":22317,"activeCount":103},[],{"trials":22319,"activeCount":103},[22320],{"nctId":22321,"briefTitle":22322,"status":111,"phases":22323,"primaryCompletion":11291,"completion":11291,"start":3853,"enrollment":19506,"conditions":22324,"interventions":22325},"NCT00662558","A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain",[93],[11337],[11523,22310],{"trials":22327,"activeCount":103},[],{"trials":22329,"activeCount":103},[],{"intervention":22331,"totalTrials":302,"cells":22332},"i. Fixed combination of latanoprost 0.005% and timolol 0.5%",{"EARLY_PHASE1":22333,"PHASE1":22335,"PHASE2":22337,"PHASE3":22339,"PHASE4":22352,"NA":22354},{"trials":22334,"activeCount":103},[],{"trials":22336,"activeCount":103},[],{"trials":22338,"activeCount":103},[],{"trials":22340,"activeCount":103},[22341],{"nctId":22342,"briefTitle":22343,"status":111,"phases":22344,"primaryCompletion":11790,"completion":11790,"start":22345,"enrollment":22346,"conditions":22347,"interventions":22349},"NCT00856622","A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients",[93],"1997-08",436,[12882,12881,22348],"Open-angle Glaucoma",[22331,22350,22351],"timolol 0.5% ophthalmic solution","latanoprost 0.005% ophthalmic solution",{"trials":22353,"activeCount":103},[],{"trials":22355,"activeCount":103},[],{"intervention":22350,"totalTrials":302,"cells":22357},{"EARLY_PHASE1":22358,"PHASE1":22360,"PHASE2":22362,"PHASE3":22364,"PHASE4":22370,"NA":22372},{"trials":22359,"activeCount":103},[],{"trials":22361,"activeCount":103},[],{"trials":22363,"activeCount":103},[],{"trials":22365,"activeCount":103},[22366],{"nctId":22342,"briefTitle":22343,"status":111,"phases":22367,"primaryCompletion":11790,"completion":11790,"start":22345,"enrollment":22346,"conditions":22368,"interventions":22369},[93],[12882,12881,22348],[22331,22350,22351],{"trials":22371,"activeCount":103},[],{"trials":22373,"activeCount":103},[],{"intervention":22351,"totalTrials":302,"cells":22375},{"EARLY_PHASE1":22376,"PHASE1":22378,"PHASE2":22380,"PHASE3":22382,"PHASE4":22388,"NA":22390},{"trials":22377,"activeCount":103},[],{"trials":22379,"activeCount":103},[],{"trials":22381,"activeCount":103},[],{"trials":22383,"activeCount":103},[22384],{"nctId":22342,"briefTitle":22343,"status":111,"phases":22385,"primaryCompletion":11790,"completion":11790,"start":22345,"enrollment":22346,"conditions":22386,"interventions":22387},[93],[12882,12881,22348],[22331,22350,22351],{"trials":22389,"activeCount":103},[],{"trials":22391,"activeCount":103},[],{"intervention":22393,"totalTrials":302,"cells":22394},"oxycodone HCl and naltrexone HCl extended-release",{"EARLY_PHASE1":22395,"PHASE1":22397,"PHASE2":22399,"PHASE3":22401,"PHASE4":22411,"NA":22413},{"trials":22396,"activeCount":103},[],{"trials":22398,"activeCount":103},[],{"trials":22400,"activeCount":103},[],{"trials":22402,"activeCount":103},[22403],{"nctId":22404,"briefTitle":22405,"status":111,"phases":22406,"primaryCompletion":113,"completion":113,"start":4656,"enrollment":22407,"conditions":22408,"interventions":22410},"NCT01428583","Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain",[93],395,[22409],"Chronic Noncancer Pain",[22393],{"trials":22412,"activeCount":103},[],{"trials":22414,"activeCount":103},[],{"intervention":22416,"totalTrials":302,"cells":22417},"Varenicline Tartarate",{"EARLY_PHASE1":22418,"PHASE1":22420,"PHASE2":22422,"PHASE3":22424,"PHASE4":22432,"NA":22434},{"trials":22419,"activeCount":103},[],{"trials":22421,"activeCount":103},[],{"trials":22423,"activeCount":103},[],{"trials":22425,"activeCount":103},[22426],{"nctId":22427,"briefTitle":22428,"status":111,"phases":22429,"primaryCompletion":4207,"completion":4222,"start":12004,"enrollment":21533,"conditions":22430,"interventions":22431},"NCT00285012","Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).",[93],[11904],[22416],{"trials":22433,"activeCount":103},[],{"trials":22435,"activeCount":103},[],{"intervention":22437,"totalTrials":302,"cells":22438},"CP690,550",{"EARLY_PHASE1":22439,"PHASE1":22441,"PHASE2":22443,"PHASE3":22445,"PHASE4":22455,"NA":22457},{"trials":22440,"activeCount":103},[],{"trials":22442,"activeCount":103},[],{"trials":22444,"activeCount":103},[],{"trials":22446,"activeCount":103},[22447],{"nctId":22448,"briefTitle":22449,"status":111,"phases":22450,"primaryCompletion":22451,"completion":22451,"start":22452,"enrollment":11932,"conditions":22453,"interventions":22454},"NCT01458574","A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",[93],"2016-05-27","2012-07-20",[1532],[22437,12692],{"trials":22456,"activeCount":103},[],{"trials":22458,"activeCount":103},[],{"intervention":22460,"totalTrials":302,"cells":22461},"In open-label phase: treatment with tofacitinib",{"EARLY_PHASE1":22462,"PHASE1":22464,"PHASE2":22466,"PHASE3":22468,"PHASE4":22480,"NA":22482},{"trials":22463,"activeCount":103},[],{"trials":22465,"activeCount":103},[],{"trials":22467,"activeCount":103},[],{"trials":22469,"activeCount":103},[22470],{"nctId":22471,"briefTitle":22472,"status":111,"phases":22473,"primaryCompletion":22474,"completion":22474,"start":22475,"enrollment":397,"conditions":22476,"interventions":22478},"NCT03000439","A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA",[93],"2024-03-27","2018-05-10",[22477],"Arthritis Juvenile Idiopathic",[22460,22479],"In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio",{"trials":22481,"activeCount":103},[],{"trials":22483,"activeCount":103},[],{"intervention":22479,"totalTrials":302,"cells":22485},{"EARLY_PHASE1":22486,"PHASE1":22488,"PHASE2":22490,"PHASE3":22492,"PHASE4":22498,"NA":22500},{"trials":22487,"activeCount":103},[],{"trials":22489,"activeCount":103},[],{"trials":22491,"activeCount":103},[],{"trials":22493,"activeCount":103},[22494],{"nctId":22471,"briefTitle":22472,"status":111,"phases":22495,"primaryCompletion":22474,"completion":22474,"start":22475,"enrollment":397,"conditions":22496,"interventions":22497},[93],[22477],[22460,22479],{"trials":22499,"activeCount":103},[],{"trials":22501,"activeCount":103},[],{"intervention":22503,"totalTrials":302,"cells":22504},"Eletriptan HBr 40 mg",{"EARLY_PHASE1":22505,"PHASE1":22507,"PHASE2":22509,"PHASE3":22511,"PHASE4":22525,"NA":22527},{"trials":22506,"activeCount":103},[],{"trials":22508,"activeCount":103},[],{"trials":22510,"activeCount":103},[],{"trials":22512,"activeCount":103},[22513],{"nctId":22514,"briefTitle":22515,"status":111,"phases":22516,"primaryCompletion":22517,"completion":22517,"start":22518,"enrollment":22519,"conditions":22520,"interventions":22523},"NCT01859481","Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study",[93],"2002-03","2000-03",971,[22521,22522],"Migraine Without Aura","Migraine With Aura",[22503,22524],"Eletriptan HBr 80 mg",{"trials":22526,"activeCount":103},[],{"trials":22528,"activeCount":103},[],{"intervention":22524,"totalTrials":302,"cells":22530},{"EARLY_PHASE1":22531,"PHASE1":22533,"PHASE2":22535,"PHASE3":22537,"PHASE4":22543,"NA":22545},{"trials":22532,"activeCount":103},[],{"trials":22534,"activeCount":103},[],{"trials":22536,"activeCount":103},[],{"trials":22538,"activeCount":103},[22539],{"nctId":22514,"briefTitle":22515,"status":111,"phases":22540,"primaryCompletion":22517,"completion":22517,"start":22518,"enrollment":22519,"conditions":22541,"interventions":22542},[93],[22521,22522],[22503,22524],{"trials":22544,"activeCount":103},[],{"trials":22546,"activeCount":103},[],{"intervention":22548,"totalTrials":302,"cells":22549},"IBU BID",{"EARLY_PHASE1":22550,"PHASE1":22552,"PHASE2":22554,"PHASE3":22556,"PHASE4":22567,"NA":22569},{"trials":22551,"activeCount":103},[],{"trials":22553,"activeCount":103},[],{"trials":22555,"activeCount":103},[],{"trials":22557,"activeCount":103},[22558],{"nctId":22559,"briefTitle":22560,"status":111,"phases":22561,"primaryCompletion":22562,"completion":22562,"start":22563,"enrollment":17159,"conditions":22564,"interventions":22565},"NCT01794923","Topical Ibuprofen for Delayed Onset Mulscle Soreness",[93],"2014-03-29","2013-06-13",[34],[22548,22566],"IBU TID",{"trials":22568,"activeCount":103},[],{"trials":22570,"activeCount":103},[],{"intervention":22566,"totalTrials":302,"cells":22572},{"EARLY_PHASE1":22573,"PHASE1":22575,"PHASE2":22577,"PHASE3":22579,"PHASE4":22585,"NA":22587},{"trials":22574,"activeCount":103},[],{"trials":22576,"activeCount":103},[],{"trials":22578,"activeCount":103},[],{"trials":22580,"activeCount":103},[22581],{"nctId":22559,"briefTitle":22560,"status":111,"phases":22582,"primaryCompletion":22562,"completion":22562,"start":22563,"enrollment":17159,"conditions":22583,"interventions":22584},[93],[34],[22548,22566],{"trials":22586,"activeCount":103},[],{"trials":22588,"activeCount":103},[],{"intervention":22590,"totalTrials":302,"cells":22591},"Rimegepant 25 MG",{"EARLY_PHASE1":22592,"PHASE1":22594,"PHASE2":22596,"PHASE3":22598,"PHASE4":22608,"NA":22610},{"trials":22593,"activeCount":103},[],{"trials":22595,"activeCount":103},[],{"trials":22597,"activeCount":103},[],{"trials":22599,"activeCount":103},[22600],{"nctId":22601,"briefTitle":22602,"status":111,"phases":22603,"primaryCompletion":3168,"completion":3168,"start":203,"enrollment":22604,"conditions":22605,"interventions":22606},"NCT05399459","Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)",[93],897,[117],[22590,22607],"Rimegepant 75 MG",{"trials":22609,"activeCount":103},[],{"trials":22611,"activeCount":103},[],{"intervention":22607,"totalTrials":302,"cells":22613},{"EARLY_PHASE1":22614,"PHASE1":22616,"PHASE2":22618,"PHASE3":22620,"PHASE4":22626,"NA":22628},{"trials":22615,"activeCount":103},[],{"trials":22617,"activeCount":103},[],{"trials":22619,"activeCount":103},[],{"trials":22621,"activeCount":103},[22622],{"nctId":22601,"briefTitle":22602,"status":111,"phases":22623,"primaryCompletion":3168,"completion":3168,"start":203,"enrollment":22604,"conditions":22624,"interventions":22625},[93],[117],[22590,22607],{"trials":22627,"activeCount":103},[],{"trials":22629,"activeCount":103},[],{"intervention":22631,"totalTrials":302,"cells":22632},"Dimebon 20 mg po TID",{"EARLY_PHASE1":22633,"PHASE1":22635,"PHASE2":22637,"PHASE3":22639,"PHASE4":22647,"NA":22649},{"trials":22634,"activeCount":103},[],{"trials":22636,"activeCount":103},[],{"trials":22638,"activeCount":103},[],{"trials":22640,"activeCount":103},[22641],{"nctId":22642,"briefTitle":22643,"status":168,"phases":22644,"primaryCompletion":561,"completion":561,"start":4833,"enrollment":1122,"conditions":22645,"interventions":22646},"NCT00912288","A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease",[93],[13445],[22631],{"trials":22648,"activeCount":103},[],{"trials":22650,"activeCount":103},[],{"intervention":22652,"totalTrials":302,"cells":22653},"Bapineuzumab 0.5 mg\u002Fkg",{"EARLY_PHASE1":22654,"PHASE1":22656,"PHASE2":22658,"PHASE3":22660,"PHASE4":22670,"NA":22672},{"trials":22655,"activeCount":103},[],{"trials":22657,"activeCount":103},[],{"trials":22659,"activeCount":103},[],{"trials":22661,"activeCount":103},[22662],{"nctId":22663,"briefTitle":22664,"status":168,"phases":22665,"primaryCompletion":3345,"completion":3345,"start":4221,"enrollment":22666,"conditions":22667,"interventions":22668},"NCT00996918","A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients",[93],198,[13445],[22652,22669],"Bapineuzumab 1.0 m\u002Fkg",{"trials":22671,"activeCount":103},[],{"trials":22673,"activeCount":103},[],{"intervention":22669,"totalTrials":302,"cells":22675},{"EARLY_PHASE1":22676,"PHASE1":22678,"PHASE2":22680,"PHASE3":22682,"PHASE4":22688,"NA":22690},{"trials":22677,"activeCount":103},[],{"trials":22679,"activeCount":103},[],{"trials":22681,"activeCount":103},[],{"trials":22683,"activeCount":103},[22684],{"nctId":22663,"briefTitle":22664,"status":168,"phases":22685,"primaryCompletion":3345,"completion":3345,"start":4221,"enrollment":22666,"conditions":22686,"interventions":22687},[93],[13445],[22652,22669],{"trials":22689,"activeCount":103},[],{"trials":22691,"activeCount":103},[],{"intervention":22693,"totalTrials":302,"cells":22694},"Rimegepant 75mg Orally Disintegrating",{"EARLY_PHASE1":22695,"PHASE1":22697,"PHASE2":22699,"PHASE3":22701,"PHASE4":22711,"NA":22713},{"trials":22696,"activeCount":103},[],{"trials":22698,"activeCount":103},[],{"trials":22700,"activeCount":103},[],{"trials":22702,"activeCount":103},[22703],{"nctId":22704,"briefTitle":22705,"status":111,"phases":22706,"primaryCompletion":22707,"completion":22707,"start":22708,"enrollment":20165,"conditions":22709,"interventions":22710},"NCT05371652","A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants",[93],"2024-02-06","2022-05-19",[236],[22693],{"trials":22712,"activeCount":103},[],{"trials":22714,"activeCount":103},[],{"intervention":22716,"totalTrials":302,"cells":22717},"Zyvox - linezolid",{"EARLY_PHASE1":22718,"PHASE1":22720,"PHASE2":22722,"PHASE3":22724,"PHASE4":22734,"NA":22736},{"trials":22719,"activeCount":103},[],{"trials":22721,"activeCount":103},[],{"trials":22723,"activeCount":103},[],{"trials":22725,"activeCount":103},[22726],{"nctId":22727,"briefTitle":22728,"status":168,"phases":22729,"primaryCompletion":606,"completion":606,"start":4645,"enrollment":3229,"conditions":22730,"interventions":22732},"NCT00359632","Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater",[93],[22731],"Optic Nerve Diseases",[22716,22733],"Matched control",{"trials":22735,"activeCount":103},[],{"trials":22737,"activeCount":103},[],{"intervention":22733,"totalTrials":302,"cells":22739},{"EARLY_PHASE1":22740,"PHASE1":22742,"PHASE2":22744,"PHASE3":22746,"PHASE4":22752,"NA":22754},{"trials":22741,"activeCount":103},[],{"trials":22743,"activeCount":103},[],{"trials":22745,"activeCount":103},[],{"trials":22747,"activeCount":103},[22748],{"nctId":22727,"briefTitle":22728,"status":168,"phases":22749,"primaryCompletion":606,"completion":606,"start":4645,"enrollment":3229,"conditions":22750,"interventions":22751},[93],[22731],[22716,22733],{"trials":22753,"activeCount":103},[],{"trials":22755,"activeCount":103},[],{"intervention":22757,"totalTrials":302,"cells":22758},"TBE vaccine 0.5 mL",{"EARLY_PHASE1":22759,"PHASE1":22761,"PHASE2":22763,"PHASE3":22765,"PHASE4":22775,"NA":22777},{"trials":22760,"activeCount":103},[],{"trials":22762,"activeCount":103},[],{"trials":22764,"activeCount":103},[],{"trials":22766,"activeCount":103},[22767],{"nctId":22768,"briefTitle":22769,"status":111,"phases":22770,"primaryCompletion":22771,"completion":22771,"start":461,"enrollment":6352,"conditions":22772,"interventions":22773},"NCT04648241","Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older",[93],"2022-02-21",[11753],[22757,22774],"TBE vaccine 0.25 mL",{"trials":22776,"activeCount":103},[],{"trials":22778,"activeCount":103},[],{"intervention":22774,"totalTrials":302,"cells":22780},{"EARLY_PHASE1":22781,"PHASE1":22783,"PHASE2":22785,"PHASE3":22787,"PHASE4":22793,"NA":22795},{"trials":22782,"activeCount":103},[],{"trials":22784,"activeCount":103},[],{"trials":22786,"activeCount":103},[],{"trials":22788,"activeCount":103},[22789],{"nctId":22768,"briefTitle":22769,"status":111,"phases":22790,"primaryCompletion":22771,"completion":22771,"start":461,"enrollment":6352,"conditions":22791,"interventions":22792},[93],[11753],[22757,22774],{"trials":22794,"activeCount":103},[],{"trials":22796,"activeCount":103},[],{"intervention":22798,"totalTrials":302,"cells":22799},"Clostridium difficile",{"EARLY_PHASE1":22800,"PHASE1":22802,"PHASE2":22804,"PHASE3":22806,"PHASE4":22817,"NA":22819},{"trials":22801,"activeCount":103},[],{"trials":22803,"activeCount":103},[],{"trials":22805,"activeCount":103},[],{"trials":22807,"activeCount":103},[22808],{"nctId":22809,"briefTitle":22810,"status":111,"phases":22811,"primaryCompletion":22812,"completion":22812,"start":22813,"enrollment":22814,"conditions":22815,"interventions":22816},"NCT03918629","Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study",[93],"2020-12-22","2019-04-01",1994,[18320],[22798],{"trials":22818,"activeCount":103},[],{"trials":22820,"activeCount":103},[],{"intervention":19732,"totalTrials":302,"cells":22822},{"EARLY_PHASE1":22823,"PHASE1":22825,"PHASE2":22827,"PHASE3":22829,"PHASE4":22835,"NA":22837},{"trials":22824,"activeCount":103},[],{"trials":22826,"activeCount":103},[],{"trials":22828,"activeCount":103},[],{"trials":22830,"activeCount":103},[22831],{"nctId":19723,"briefTitle":19724,"status":111,"phases":22832,"primaryCompletion":19726,"completion":19726,"start":19727,"enrollment":19728,"conditions":22833,"interventions":22834},[93],[10577],[19712,19731,19732,19733],{"trials":22836,"activeCount":103},[],{"trials":22838,"activeCount":103},[],{"intervention":22840,"totalTrials":302,"cells":22841},"RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE",{"EARLY_PHASE1":22842,"PHASE1":22844,"PHASE2":22846,"PHASE3":22848,"PHASE4":22860,"NA":22862},{"trials":22843,"activeCount":103},[],{"trials":22845,"activeCount":103},[],{"trials":22847,"activeCount":103},[],{"trials":22849,"activeCount":103},[22850],{"nctId":22851,"briefTitle":22852,"status":111,"phases":22853,"primaryCompletion":22854,"completion":22854,"start":22855,"enrollment":22856,"conditions":22857,"interventions":22858},"NCT06890416","A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults",[93],"2025-09-30","2025-04-04",526,[3809],[22840,22859],"HZ\u002Fsu VACCINE",{"trials":22861,"activeCount":103},[],{"trials":22863,"activeCount":103},[],{"intervention":22859,"totalTrials":302,"cells":22865},{"EARLY_PHASE1":22866,"PHASE1":22868,"PHASE2":22870,"PHASE3":22872,"PHASE4":22878,"NA":22880},{"trials":22867,"activeCount":103},[],{"trials":22869,"activeCount":103},[],{"trials":22871,"activeCount":103},[],{"trials":22873,"activeCount":103},[22874],{"nctId":22851,"briefTitle":22852,"status":111,"phases":22875,"primaryCompletion":22854,"completion":22854,"start":22855,"enrollment":22856,"conditions":22876,"interventions":22877},[93],[3809],[22840,22859],{"trials":22879,"activeCount":103},[],{"trials":22881,"activeCount":103},[],{"intervention":22883,"totalTrials":302,"cells":22884},"Diclofenac SR",{"EARLY_PHASE1":22885,"PHASE1":22887,"PHASE2":22889,"PHASE3":22891,"PHASE4":22900,"NA":22902},{"trials":22886,"activeCount":103},[],{"trials":22888,"activeCount":103},[],{"trials":22890,"activeCount":103},[],{"trials":22892,"activeCount":103},[22893],{"nctId":22894,"briefTitle":22895,"status":111,"phases":22896,"primaryCompletion":577,"completion":561,"start":4627,"enrollment":22897,"conditions":22898,"interventions":22899},"NCT00762463","Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis",[93],240,[15038],[3079,22883],{"trials":22901,"activeCount":103},[],{"trials":22903,"activeCount":103},[],{"intervention":22905,"totalTrials":302,"cells":22906},"Standard of Care FIX Replacement therapy",{"EARLY_PHASE1":22907,"PHASE1":22909,"PHASE2":22911,"PHASE3":22913,"PHASE4":22924,"NA":22926},{"trials":22908,"activeCount":103},[],{"trials":22910,"activeCount":103},[],{"trials":22912,"activeCount":103},[],{"trials":22914,"activeCount":103},[22915],{"nctId":22916,"briefTitle":22917,"status":111,"phases":22918,"primaryCompletion":22919,"completion":22919,"start":22920,"enrollment":3075,"conditions":22921,"interventions":22922},"NCT03587116","A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)",[93],"2024-12-13","2018-07-26",[3552,3551],[22905,22923],"Standard of Care FVIII Replacement therapy",{"trials":22925,"activeCount":103},[],{"trials":22927,"activeCount":103},[],{"intervention":22923,"totalTrials":302,"cells":22929},{"EARLY_PHASE1":22930,"PHASE1":22932,"PHASE2":22934,"PHASE3":22936,"PHASE4":22942,"NA":22944},{"trials":22931,"activeCount":103},[],{"trials":22933,"activeCount":103},[],{"trials":22935,"activeCount":103},[],{"trials":22937,"activeCount":103},[22938],{"nctId":22916,"briefTitle":22917,"status":111,"phases":22939,"primaryCompletion":22919,"completion":22919,"start":22920,"enrollment":3075,"conditions":22940,"interventions":22941},[93],[3552,3551],[22905,22923],{"trials":22943,"activeCount":103},[],{"trials":22945,"activeCount":103},[],{"intervention":22947,"totalTrials":302,"cells":22948},"Pregabalin add-on therapy",{"EARLY_PHASE1":22949,"PHASE1":22951,"PHASE2":22953,"PHASE3":22955,"PHASE4":22967,"NA":22969},{"trials":22950,"activeCount":103},[],{"trials":22952,"activeCount":103},[],{"trials":22954,"activeCount":103},[],{"trials":22956,"activeCount":103},[22957],{"nctId":22958,"briefTitle":22959,"status":111,"phases":22960,"primaryCompletion":22961,"completion":22961,"start":22962,"enrollment":22963,"conditions":22964,"interventions":22966},"NCT01389596","A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years",[93],"2016-08-10","2011-09-27",295,[22965],"Epilepsy, Partial Seizures",[22947,22947,22947],{"trials":22968,"activeCount":103},[],{"trials":22970,"activeCount":103},[],{"intervention":22972,"totalTrials":302,"cells":22973},"Experimental 20-valent pneumococcal conjugate vaccine",{"EARLY_PHASE1":22974,"PHASE1":22976,"PHASE2":22978,"PHASE3":22980,"PHASE4":22991,"NA":22993},{"trials":22975,"activeCount":103},[],{"trials":22977,"activeCount":103},[],{"trials":22979,"activeCount":103},[],{"trials":22981,"activeCount":103},[22982],{"nctId":22983,"briefTitle":22984,"status":111,"phases":22985,"primaryCompletion":10829,"completion":10829,"start":22986,"enrollment":22987,"conditions":22988,"interventions":22989},"NCT04526574","Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age",[93],"2020-09-01",1796,[2526],[22972,22990],"Influenza vaccine",{"trials":22992,"activeCount":103},[],{"trials":22994,"activeCount":103},[],{"intervention":22990,"totalTrials":302,"cells":22996},{"EARLY_PHASE1":22997,"PHASE1":22999,"PHASE2":23001,"PHASE3":23003,"PHASE4":23009,"NA":23011},{"trials":22998,"activeCount":103},[],{"trials":23000,"activeCount":103},[],{"trials":23002,"activeCount":103},[],{"trials":23004,"activeCount":103},[23005],{"nctId":22983,"briefTitle":22984,"status":111,"phases":23006,"primaryCompletion":10829,"completion":10829,"start":22986,"enrollment":22987,"conditions":23007,"interventions":23008},[93],[2526],[22972,22990],{"trials":23010,"activeCount":103},[],{"trials":23012,"activeCount":103},[],{"intervention":23014,"totalTrials":302,"cells":23015},"Pregabalin Dose Level 1",{"EARLY_PHASE1":23016,"PHASE1":23018,"PHASE2":23020,"PHASE3":23022,"PHASE4":23034,"NA":23036},{"trials":23017,"activeCount":103},[],{"trials":23019,"activeCount":103},[],{"trials":23021,"activeCount":103},[],{"trials":23023,"activeCount":103},[23024],{"nctId":23025,"briefTitle":23026,"status":111,"phases":23027,"primaryCompletion":23028,"completion":23028,"start":4244,"enrollment":23029,"conditions":23030,"interventions":23032},"NCT02072824","A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects \u003C4 Years of Age With Partial Onset Seizures.",[93],"2018-03-13",175,[23031],"Partial Onset Seizures",[23014,23033],"Pregabalin Dose Level 2",{"trials":23035,"activeCount":103},[],{"trials":23037,"activeCount":103},[],{"intervention":23033,"totalTrials":302,"cells":23039},{"EARLY_PHASE1":23040,"PHASE1":23042,"PHASE2":23044,"PHASE3":23046,"PHASE4":23052,"NA":23054},{"trials":23041,"activeCount":103},[],{"trials":23043,"activeCount":103},[],{"trials":23045,"activeCount":103},[],{"trials":23047,"activeCount":103},[23048],{"nctId":23025,"briefTitle":23026,"status":111,"phases":23049,"primaryCompletion":23028,"completion":23028,"start":4244,"enrollment":23029,"conditions":23050,"interventions":23051},[93],[23031],[23014,23033],{"trials":23053,"activeCount":103},[],{"trials":23055,"activeCount":103},[],{"intervention":23057,"totalTrials":302,"cells":23058},"bazedoxifene 20 mg\u002F conjugated estrogens 0.45 mg",{"EARLY_PHASE1":23059,"PHASE1":23061,"PHASE2":23063,"PHASE3":23065,"PHASE4":23079,"NA":23081},{"trials":23060,"activeCount":103},[],{"trials":23062,"activeCount":103},[],{"trials":23064,"activeCount":103},[],{"trials":23066,"activeCount":103},[23067],{"nctId":23068,"briefTitle":23069,"status":111,"phases":23070,"primaryCompletion":4666,"completion":4666,"start":8251,"enrollment":23071,"conditions":23072,"interventions":23075},"NCT00808132","Study Evaluating The Effects Of Bazedoxifene\u002FConjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis",[93],1886,[23073,23074],"Menopause","Osteoporosis",[23057,23076,23077,23078],"bazedoxifene 20 mg\u002F conjugated estrogens 0.625 mg","bazedoxifene 20 mg","conjugated estrogens 0.45 mg\u002F medroxyprogesterone acetate 1.5 mg",{"trials":23080,"activeCount":103},[],{"trials":23082,"activeCount":103},[],{"intervention":23076,"totalTrials":302,"cells":23084},{"EARLY_PHASE1":23085,"PHASE1":23087,"PHASE2":23089,"PHASE3":23091,"PHASE4":23097,"NA":23099},{"trials":23086,"activeCount":103},[],{"trials":23088,"activeCount":103},[],{"trials":23090,"activeCount":103},[],{"trials":23092,"activeCount":103},[23093],{"nctId":23068,"briefTitle":23069,"status":111,"phases":23094,"primaryCompletion":4666,"completion":4666,"start":8251,"enrollment":23071,"conditions":23095,"interventions":23096},[93],[23073,23074],[23057,23076,23077,23078],{"trials":23098,"activeCount":103},[],{"trials":23100,"activeCount":103},[],{"intervention":23077,"totalTrials":302,"cells":23102},{"EARLY_PHASE1":23103,"PHASE1":23105,"PHASE2":23107,"PHASE3":23109,"PHASE4":23115,"NA":23117},{"trials":23104,"activeCount":103},[],{"trials":23106,"activeCount":103},[],{"trials":23108,"activeCount":103},[],{"trials":23110,"activeCount":103},[23111],{"nctId":23068,"briefTitle":23069,"status":111,"phases":23112,"primaryCompletion":4666,"completion":4666,"start":8251,"enrollment":23071,"conditions":23113,"interventions":23114},[93],[23073,23074],[23057,23076,23077,23078],{"trials":23116,"activeCount":103},[],{"trials":23118,"activeCount":103},[],{"intervention":23078,"totalTrials":302,"cells":23120},{"EARLY_PHASE1":23121,"PHASE1":23123,"PHASE2":23125,"PHASE3":23127,"PHASE4":23133,"NA":23135},{"trials":23122,"activeCount":103},[],{"trials":23124,"activeCount":103},[],{"trials":23126,"activeCount":103},[],{"trials":23128,"activeCount":103},[23129],{"nctId":23068,"briefTitle":23069,"status":111,"phases":23130,"primaryCompletion":4666,"completion":4666,"start":8251,"enrollment":23071,"conditions":23131,"interventions":23132},[93],[23073,23074],[23057,23076,23077,23078],{"trials":23134,"activeCount":103},[],{"trials":23136,"activeCount":103},[],{"intervention":23138,"totalTrials":302,"cells":23139},"Xiapex",{"EARLY_PHASE1":23140,"PHASE1":23142,"PHASE2":23144,"PHASE3":23146,"PHASE4":23155,"NA":23157},{"trials":23141,"activeCount":103},[],{"trials":23143,"activeCount":103},[],{"trials":23145,"activeCount":103},[],{"trials":23147,"activeCount":103},[23148],{"nctId":23149,"briefTitle":23150,"status":111,"phases":23151,"primaryCompletion":3353,"completion":3353,"start":4656,"enrollment":13189,"conditions":23152,"interventions":23154},"NCT01229436","Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)",[93],[23153],"Dupuytren's Contracture",[23138],{"trials":23156,"activeCount":103},[],{"trials":23158,"activeCount":103},[],{"intervention":8320,"totalTrials":302,"cells":23160},{"EARLY_PHASE1":23161,"PHASE1":23163,"PHASE2":23165,"PHASE3":23167,"PHASE4":23173,"NA":23175},{"trials":23162,"activeCount":103},[],{"trials":23164,"activeCount":103},[],{"trials":23166,"activeCount":103},[],{"trials":23168,"activeCount":103},[23169],{"nctId":8313,"briefTitle":8314,"status":111,"phases":23170,"primaryCompletion":8316,"completion":8316,"start":3798,"enrollment":8317,"conditions":23171,"interventions":23172},[93],[8295],[8309,2515,8320,8321],{"trials":23174,"activeCount":103},[],{"trials":23176,"activeCount":103},[],{"intervention":2042,"totalTrials":302,"cells":23178},{"EARLY_PHASE1":23179,"PHASE1":23181,"PHASE2":23183,"PHASE3":23185,"PHASE4":23191,"NA":23193},{"trials":23180,"activeCount":103},[],{"trials":23182,"activeCount":103},[],{"trials":23184,"activeCount":103},[],{"trials":23186,"activeCount":103},[23187],{"nctId":2033,"briefTitle":2034,"status":111,"phases":23188,"primaryCompletion":2036,"completion":1169,"start":2037,"enrollment":2038,"conditions":23189,"interventions":23190},[93],[2040],[1812,1832,1304,1335,2042,2043],{"trials":23192,"activeCount":103},[],{"trials":23194,"activeCount":103},[],{"intervention":7679,"totalTrials":302,"cells":23196},{"EARLY_PHASE1":23197,"PHASE1":23199,"PHASE2":23201,"PHASE3":23203,"PHASE4":23209,"NA":23211},{"trials":23198,"activeCount":103},[],{"trials":23200,"activeCount":103},[],{"trials":23202,"activeCount":103},[],{"trials":23204,"activeCount":103},[23205],{"nctId":7672,"briefTitle":7673,"status":111,"phases":23206,"primaryCompletion":7675,"start":7676,"conditions":23207,"interventions":23208},[93],[2022],[3328,1990,7679,7669],{"trials":23210,"activeCount":103},[],{"trials":23212,"activeCount":103},[],{"intervention":18854,"totalTrials":302,"cells":23214},{"EARLY_PHASE1":23215,"PHASE1":23217,"PHASE2":23219,"PHASE3":23221,"PHASE4":23227,"NA":23229},{"trials":23216,"activeCount":103},[],{"trials":23218,"activeCount":103},[],{"trials":23220,"activeCount":103},[],{"trials":23222,"activeCount":103},[23223],{"nctId":18845,"briefTitle":18846,"status":111,"phases":23224,"primaryCompletion":18848,"completion":18848,"start":18849,"enrollment":1313,"conditions":23225,"interventions":23226},[93],[18851,18852],[18824,18854],{"trials":23228,"activeCount":103},[],{"trials":23230,"activeCount":103},[],{"intervention":19546,"totalTrials":302,"cells":23232},{"EARLY_PHASE1":23233,"PHASE1":23235,"PHASE2":23237,"PHASE3":23239,"PHASE4":23245,"NA":23247},{"trials":23234,"activeCount":103},[],{"trials":23236,"activeCount":103},[],{"trials":23238,"activeCount":103},[],{"trials":23240,"activeCount":103},[23241],{"nctId":19540,"briefTitle":19541,"status":111,"phases":23242,"completion":12607,"start":19543,"enrollment":130,"conditions":23243,"interventions":23244},[93],[13750],[19523,19546],{"trials":23246,"activeCount":103},[],{"trials":23248,"activeCount":103},[],{"intervention":12712,"totalTrials":302,"cells":23250},{"EARLY_PHASE1":23251,"PHASE1":23253,"PHASE2":23255,"PHASE3":23257,"PHASE4":23263,"NA":23265},{"trials":23252,"activeCount":103},[],{"trials":23254,"activeCount":103},[],{"trials":23256,"activeCount":103},[],{"trials":23258,"activeCount":103},[23259],{"nctId":12706,"briefTitle":12707,"status":111,"phases":23260,"primaryCompletion":660,"completion":660,"start":12709,"enrollment":6503,"conditions":23261,"interventions":23262},[93],[4469],[12712,12713,12676],{"trials":23264,"activeCount":103},[],{"trials":23266,"activeCount":103},[],{"intervention":12713,"totalTrials":302,"cells":23268},{"EARLY_PHASE1":23269,"PHASE1":23271,"PHASE2":23273,"PHASE3":23275,"PHASE4":23281,"NA":23283},{"trials":23270,"activeCount":103},[],{"trials":23272,"activeCount":103},[],{"trials":23274,"activeCount":103},[],{"trials":23276,"activeCount":103},[23277],{"nctId":12706,"briefTitle":12707,"status":111,"phases":23278,"primaryCompletion":660,"completion":660,"start":12709,"enrollment":6503,"conditions":23279,"interventions":23280},[93],[4469],[12712,12713,12676],{"trials":23282,"activeCount":103},[],{"trials":23284,"activeCount":103},[],{"intervention":23286,"totalTrials":302,"cells":23287},"Ramipril and hydrochlorothiazide",{"EARLY_PHASE1":23288,"PHASE1":23290,"PHASE2":23292,"PHASE3":23294,"PHASE4":23303,"NA":23305},{"trials":23289,"activeCount":103},[],{"trials":23291,"activeCount":103},[],{"trials":23293,"activeCount":103},[],{"trials":23295,"activeCount":103},[23296],{"nctId":23297,"briefTitle":23298,"status":111,"phases":23299,"primaryCompletion":11895,"completion":11895,"start":12395,"conditions":23300,"interventions":23302},"NCT00355589","Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension",[93],[13280,23301],"Blood Pressure, High",[23286],{"trials":23304,"activeCount":103},[],{"trials":23306,"activeCount":103},[],{"intervention":23308,"totalTrials":302,"cells":23309},"venlafaxine ER 75 mg\u002Fday",{"EARLY_PHASE1":23310,"PHASE1":23312,"PHASE2":23314,"PHASE3":23316,"PHASE4":23326,"NA":23328},{"trials":23311,"activeCount":103},[],{"trials":23313,"activeCount":103},[],{"trials":23315,"activeCount":103},[],{"trials":23317,"activeCount":103},[23318],{"nctId":23319,"briefTitle":23320,"status":111,"phases":23321,"primaryCompletion":605,"completion":605,"start":570,"enrollment":23322,"conditions":23323,"interventions":23324},"NCT01441440","Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)",[93],538,[6321],[23308,23325],"venlafaxine ER 75 mg\u002Fday to 225 mg\u002Fday",{"trials":23327,"activeCount":103},[],{"trials":23329,"activeCount":103},[],{"intervention":23325,"totalTrials":302,"cells":23331},{"EARLY_PHASE1":23332,"PHASE1":23334,"PHASE2":23336,"PHASE3":23338,"PHASE4":23344,"NA":23346},{"trials":23333,"activeCount":103},[],{"trials":23335,"activeCount":103},[],{"trials":23337,"activeCount":103},[],{"trials":23339,"activeCount":103},[23340],{"nctId":23319,"briefTitle":23320,"status":111,"phases":23341,"primaryCompletion":605,"completion":605,"start":570,"enrollment":23322,"conditions":23342,"interventions":23343},[93],[6321],[23308,23325],{"trials":23345,"activeCount":103},[],{"trials":23347,"activeCount":103},[],{"intervention":20840,"totalTrials":302,"cells":23349},{"EARLY_PHASE1":23350,"PHASE1":23352,"PHASE2":23354,"PHASE3":23356,"PHASE4":23362,"NA":23364},{"trials":23351,"activeCount":103},[],{"trials":23353,"activeCount":103},[],{"trials":23355,"activeCount":103},[],{"trials":23357,"activeCount":103},[23358],{"nctId":20834,"briefTitle":20835,"status":111,"phases":23359,"conditions":23360,"interventions":23361},[93],[20838,10974],[20840,20819,15250],{"trials":23363,"activeCount":103},[],{"trials":23365,"activeCount":103},[],{"intervention":19101,"totalTrials":302,"cells":23367},{"EARLY_PHASE1":23368,"PHASE1":23370,"PHASE2":23372,"PHASE3":23374,"PHASE4":23380,"NA":23382},{"trials":23369,"activeCount":103},[],{"trials":23371,"activeCount":103},[],{"trials":23373,"activeCount":103},[],{"trials":23375,"activeCount":103},[23376],{"nctId":19096,"briefTitle":19097,"status":111,"phases":23377,"completion":11417,"start":13035,"enrollment":12110,"conditions":23378,"interventions":23379},[92,93],[19092],[19077,19101],{"trials":23381,"activeCount":103},[],{"trials":23383,"activeCount":103},[],{"intervention":23385,"totalTrials":302,"cells":23386},"Genotropin (PN-180,307) Somatropin",{"EARLY_PHASE1":23387,"PHASE1":23389,"PHASE2":23391,"PHASE3":23393,"PHASE4":23403,"NA":23405},{"trials":23388,"activeCount":103},[],{"trials":23390,"activeCount":103},[],{"trials":23392,"activeCount":103},[],{"trials":23394,"activeCount":103},[23395],{"nctId":23396,"briefTitle":23397,"status":111,"phases":23398,"primaryCompletion":606,"completion":606,"start":10937,"enrollment":32,"conditions":23399,"interventions":23401},"NCT00627523","Genotropin Treatment In Very Young Children Born Small For Gestational Age",[93],[23400],"Infant, Small for Gestational Age",[23385,23402],"Control-no treatment",{"trials":23404,"activeCount":103},[],{"trials":23406,"activeCount":103},[],{"intervention":23402,"totalTrials":302,"cells":23408},{"EARLY_PHASE1":23409,"PHASE1":23411,"PHASE2":23413,"PHASE3":23415,"PHASE4":23421,"NA":23423},{"trials":23410,"activeCount":103},[],{"trials":23412,"activeCount":103},[],{"trials":23414,"activeCount":103},[],{"trials":23416,"activeCount":103},[23417],{"nctId":23396,"briefTitle":23397,"status":111,"phases":23418,"primaryCompletion":606,"completion":606,"start":10937,"enrollment":32,"conditions":23419,"interventions":23420},[93],[23400],[23385,23402],{"trials":23422,"activeCount":103},[],{"trials":23424,"activeCount":103},[],{"intervention":10976,"totalTrials":302,"cells":23426},{"EARLY_PHASE1":23427,"PHASE1":23429,"PHASE2":23431,"PHASE3":23433,"PHASE4":23439,"NA":23441},{"trials":23428,"activeCount":103},[],{"trials":23430,"activeCount":103},[],{"trials":23432,"activeCount":103},[],{"trials":23434,"activeCount":103},[23435],{"nctId":10969,"briefTitle":10970,"status":111,"phases":23436,"primaryCompletion":6208,"completion":6208,"start":3642,"enrollment":10972,"conditions":23437,"interventions":23438},[93],[10974,10940],[10916,10976],{"trials":23440,"activeCount":103},[],{"trials":23442,"activeCount":103},[],{"intervention":3647,"totalTrials":302,"cells":23444},{"EARLY_PHASE1":23445,"PHASE1":23447,"PHASE2":23449,"PHASE3":23451,"PHASE4":23457,"NA":23459},{"trials":23446,"activeCount":103},[],{"trials":23448,"activeCount":103},[],{"trials":23450,"activeCount":103},[],{"trials":23452,"activeCount":103},[23453],{"nctId":3639,"briefTitle":3640,"status":111,"phases":23454,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":23455,"interventions":23456},[93],[1810],[3647,2004,3648,3317,3647,2004,3648],{"trials":23458,"activeCount":103},[],{"trials":23460,"activeCount":103},[],{"intervention":3648,"totalTrials":302,"cells":23462},{"EARLY_PHASE1":23463,"PHASE1":23465,"PHASE2":23467,"PHASE3":23469,"PHASE4":23475,"NA":23477},{"trials":23464,"activeCount":103},[],{"trials":23466,"activeCount":103},[],{"trials":23468,"activeCount":103},[],{"trials":23470,"activeCount":103},[23471],{"nctId":3639,"briefTitle":3640,"status":111,"phases":23472,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":23473,"interventions":23474},[93],[1810],[3647,2004,3648,3317,3647,2004,3648],{"trials":23476,"activeCount":103},[],{"trials":23478,"activeCount":103},[],{"intervention":23480,"totalTrials":302,"cells":23481},"vaccine-13vPnC",{"EARLY_PHASE1":23482,"PHASE1":23484,"PHASE2":23486,"PHASE3":23488,"PHASE4":23497,"NA":23499},{"trials":23483,"activeCount":103},[],{"trials":23485,"activeCount":103},[],{"trials":23487,"activeCount":103},[],{"trials":23489,"activeCount":103},[23490],{"nctId":23491,"briefTitle":23492,"status":111,"phases":23493,"primaryCompletion":2883,"completion":2883,"start":3313,"enrollment":23494,"conditions":23495,"interventions":23496},"NCT01432262","13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico",[93],324,[10940],[23480,23480],{"trials":23498,"activeCount":103},[],{"trials":23500,"activeCount":103},[],{"intervention":23502,"totalTrials":302,"cells":23503},"Disease-modifying antirheumatic drug",{"EARLY_PHASE1":23504,"PHASE1":23506,"PHASE2":23508,"PHASE3":23510,"PHASE4":23519,"NA":23521},{"trials":23505,"activeCount":103},[],{"trials":23507,"activeCount":103},[],{"trials":23509,"activeCount":103},[],{"trials":23511,"activeCount":103},[23512],{"nctId":23513,"briefTitle":23514,"status":111,"phases":23515,"primaryCompletion":4680,"completion":4680,"start":10923,"enrollment":23516,"conditions":23517,"interventions":23518},"NCT01039688","Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX",[93],956,[4514],[12692,12692,23502],{"trials":23520,"activeCount":103},[],{"trials":23522,"activeCount":103},[],{"intervention":23524,"totalTrials":302,"cells":23525},"MEK162, MEK inhibitor;",{"EARLY_PHASE1":23526,"PHASE1":23528,"PHASE2":23530,"PHASE3":23532,"PHASE4":23547,"NA":23549},{"trials":23527,"activeCount":103},[],{"trials":23529,"activeCount":103},[],{"trials":23531,"activeCount":103},[],{"trials":23533,"activeCount":103},[23534],{"nctId":23535,"briefTitle":23536,"status":168,"phases":23537,"primaryCompletion":23538,"completion":23539,"start":7398,"enrollment":23540,"conditions":23541,"interventions":23545},"NCT01849874","A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",[93],"2016-01-20","2022-08-23",341,[23542,23543,23544],"Low-grade Serous Ovarian Cancer","Low-grade Serous Fallopian Tube Cancer","Low-grade Serous Peritoneal Cancer",[23524,23546],"Physician's choice chemotherapy",{"trials":23548,"activeCount":103},[],{"trials":23550,"activeCount":103},[],{"intervention":23546,"totalTrials":302,"cells":23552},{"EARLY_PHASE1":23553,"PHASE1":23555,"PHASE2":23557,"PHASE3":23559,"PHASE4":23565,"NA":23567},{"trials":23554,"activeCount":103},[],{"trials":23556,"activeCount":103},[],{"trials":23558,"activeCount":103},[],{"trials":23560,"activeCount":103},[23561],{"nctId":23535,"briefTitle":23536,"status":168,"phases":23562,"primaryCompletion":23538,"completion":23539,"start":7398,"enrollment":23540,"conditions":23563,"interventions":23564},[93],[23542,23543,23544],[23524,23546],{"trials":23566,"activeCount":103},[],{"trials":23568,"activeCount":103},[],{"intervention":23570,"totalTrials":302,"cells":23571},"MenACWY-TT",{"EARLY_PHASE1":23572,"PHASE1":23574,"PHASE2":23576,"PHASE3":23578,"PHASE4":23589,"NA":23591},{"trials":23573,"activeCount":103},[],{"trials":23575,"activeCount":103},[],{"trials":23577,"activeCount":103},[],{"trials":23579,"activeCount":103},[23580],{"nctId":23581,"briefTitle":23582,"status":111,"phases":23583,"primaryCompletion":23584,"completion":23584,"start":23585,"enrollment":13288,"conditions":23586,"interventions":23588},"NCT03189745","A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).",[93],"2018-04-11","2017-08-01",[23587],"Meningococcal ACWY Disease",[23570],{"trials":23590,"activeCount":103},[],{"trials":23592,"activeCount":103},[],{"intervention":10987,"totalTrials":302,"cells":23594},{"EARLY_PHASE1":23595,"PHASE1":23597,"PHASE2":23599,"PHASE3":23601,"PHASE4":23607,"NA":23609},{"trials":23596,"activeCount":103},[],{"trials":23598,"activeCount":103},[],{"trials":23600,"activeCount":103},[],{"trials":23602,"activeCount":103},[23603],{"nctId":10978,"briefTitle":10979,"status":111,"phases":23604,"primaryCompletion":10981,"completion":10981,"start":10982,"enrollment":10983,"conditions":23605,"interventions":23606},[93],[10985],[2555,10987,10988,10989,10989],{"trials":23608,"activeCount":103},[],{"trials":23610,"activeCount":103},[],{"intervention":10989,"totalTrials":302,"cells":23612},{"EARLY_PHASE1":23613,"PHASE1":23615,"PHASE2":23617,"PHASE3":23619,"PHASE4":23625,"NA":23627},{"trials":23614,"activeCount":103},[],{"trials":23616,"activeCount":103},[],{"trials":23618,"activeCount":103},[],{"trials":23620,"activeCount":103},[23621],{"nctId":10978,"briefTitle":10979,"status":111,"phases":23622,"primaryCompletion":10981,"completion":10981,"start":10982,"enrollment":10983,"conditions":23623,"interventions":23624},[93],[10985],[2555,10987,10988,10989,10989],{"trials":23626,"activeCount":103},[],{"trials":23628,"activeCount":103},[],{"intervention":23630,"totalTrials":302,"cells":23631},"(PN-152,243)\u002FPN-196,444",{"EARLY_PHASE1":23632,"PHASE1":23634,"PHASE2":23636,"PHASE3":23638,"PHASE4":23650,"NA":23652},{"trials":23633,"activeCount":103},[],{"trials":23635,"activeCount":103},[],{"trials":23637,"activeCount":103},[],{"trials":23639,"activeCount":103},[23640],{"nctId":23641,"briefTitle":23642,"status":111,"phases":23643,"completion":15036,"start":23644,"enrollment":23645,"conditions":23646,"interventions":23649},"NCT00037791","Safety and Efficacy of (PN-152,243)\u002FPN-196,444 in the Prevention of Thrombocytopenia",[93],"1999-12",180,[2053,23647,1062,23648],"Thrombocytopenia","Lymphoma, Malignant",[23630],{"trials":23651,"activeCount":103},[],{"trials":23653,"activeCount":103},[],{"intervention":23655,"totalTrials":302,"cells":23656},"Anidulafungin\u002FFluconazole",{"EARLY_PHASE1":23657,"PHASE1":23659,"PHASE2":23661,"PHASE3":23663,"PHASE4":23671,"NA":23673},{"trials":23658,"activeCount":103},[],{"trials":23660,"activeCount":103},[],{"trials":23662,"activeCount":103},[],{"trials":23664,"activeCount":103},[23665],{"nctId":23666,"briefTitle":23667,"status":168,"phases":23668,"primaryCompletion":570,"completion":570,"start":4656,"enrollment":7500,"conditions":23669,"interventions":23670},"NCT01176058","A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And\u002FOr Other Forms Of Invasive Candidiasis",[93],[16580],[23655],{"trials":23672,"activeCount":103},[],{"trials":23674,"activeCount":103},[],{"intervention":12849,"totalTrials":302,"cells":23676},{"EARLY_PHASE1":23677,"PHASE1":23679,"PHASE2":23681,"PHASE3":23683,"PHASE4":23689,"NA":23691},{"trials":23678,"activeCount":103},[],{"trials":23680,"activeCount":103},[],{"trials":23682,"activeCount":103},[],{"trials":23684,"activeCount":103},[23685],{"nctId":12842,"briefTitle":12843,"status":111,"phases":23686,"primaryCompletion":7665,"completion":7665,"start":3854,"enrollment":12845,"conditions":23687,"interventions":23688},[93],[12847],[12824,12824,12849],{"trials":23690,"activeCount":103},[],{"trials":23692,"activeCount":103},[],{"intervention":8329,"totalTrials":302,"cells":23694},{"EARLY_PHASE1":23695,"PHASE1":23697,"PHASE2":23699,"PHASE3":23701,"PHASE4":23707,"NA":23709},{"trials":23696,"activeCount":103},[],{"trials":23698,"activeCount":103},[],{"trials":23700,"activeCount":103},[],{"trials":23702,"activeCount":103},[23703],{"nctId":8323,"briefTitle":8324,"status":111,"phases":23704,"primaryCompletion":4589,"completion":4589,"start":6208,"enrollment":8326,"conditions":23705,"interventions":23706},[93],[8295],[8296,8296,8296,8329,2515],{"trials":23708,"activeCount":103},[],{"trials":23710,"activeCount":103},[],{"intervention":7634,"totalTrials":302,"cells":23712},{"EARLY_PHASE1":23713,"PHASE1":23715,"PHASE2":23717,"PHASE3":23719,"PHASE4":23725,"NA":23727},{"trials":23714,"activeCount":103},[],{"trials":23716,"activeCount":103},[],{"trials":23718,"activeCount":103},[],{"trials":23720,"activeCount":103},[23721],{"nctId":7627,"briefTitle":7628,"status":111,"phases":23722,"primaryCompletion":4608,"completion":4608,"start":6457,"enrollment":7630,"conditions":23723,"interventions":23724},[93],[7632],[2082,7634],{"trials":23726,"activeCount":103},[],{"trials":23728,"activeCount":103},[],{"intervention":23730,"totalTrials":302,"cells":23731},"Tanezumab SC",{"EARLY_PHASE1":23732,"PHASE1":23734,"PHASE2":23736,"PHASE3":23738,"PHASE4":23750,"NA":23752},{"trials":23733,"activeCount":103},[],{"trials":23735,"activeCount":103},[],{"trials":23737,"activeCount":103},[],{"trials":23739,"activeCount":103},[23740],{"nctId":23741,"briefTitle":23742,"status":168,"phases":23743,"primaryCompletion":23744,"completion":23745,"start":17188,"enrollment":23746,"conditions":23747,"interventions":23748},"NCT01089725","Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous\u002FIntravenous Bridging Study",[93],"2010-11-08","2011-02-18",385,[11282,11409,34],[23730,23730,23730,23749],"Tanezumab IV",{"trials":23751,"activeCount":103},[],{"trials":23753,"activeCount":103},[],{"intervention":23749,"totalTrials":302,"cells":23755},{"EARLY_PHASE1":23756,"PHASE1":23758,"PHASE2":23760,"PHASE3":23762,"PHASE4":23768,"NA":23770},{"trials":23757,"activeCount":103},[],{"trials":23759,"activeCount":103},[],{"trials":23761,"activeCount":103},[],{"trials":23763,"activeCount":103},[23764],{"nctId":23741,"briefTitle":23742,"status":168,"phases":23765,"primaryCompletion":23744,"completion":23745,"start":17188,"enrollment":23746,"conditions":23766,"interventions":23767},[93],[11282,11409,34],[23730,23730,23730,23749],{"trials":23769,"activeCount":103},[],{"trials":23771,"activeCount":103},[],{"intervention":23773,"totalTrials":302,"cells":23774},"Azithromycin microspheres",{"EARLY_PHASE1":23775,"PHASE1":23777,"PHASE2":23779,"PHASE3":23781,"PHASE4":23792,"NA":23794},{"trials":23776,"activeCount":103},[],{"trials":23778,"activeCount":103},[],{"trials":23780,"activeCount":103},[],{"trials":23782,"activeCount":103},[23783],{"nctId":23784,"briefTitle":23785,"status":168,"phases":23786,"primaryCompletion":3839,"completion":3839,"start":11609,"enrollment":2250,"conditions":23787,"interventions":23788},"NCT00392223","Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne",[93],[15353],[23773,23789,23790,23791],"minocycline-placebo","Azithromycin microspheres-placebo","Minocycline capsules,",{"trials":23793,"activeCount":103},[],{"trials":23795,"activeCount":103},[],{"intervention":23789,"totalTrials":302,"cells":23797},{"EARLY_PHASE1":23798,"PHASE1":23800,"PHASE2":23802,"PHASE3":23804,"PHASE4":23810,"NA":23812},{"trials":23799,"activeCount":103},[],{"trials":23801,"activeCount":103},[],{"trials":23803,"activeCount":103},[],{"trials":23805,"activeCount":103},[23806],{"nctId":23784,"briefTitle":23785,"status":168,"phases":23807,"primaryCompletion":3839,"completion":3839,"start":11609,"enrollment":2250,"conditions":23808,"interventions":23809},[93],[15353],[23773,23789,23790,23791],{"trials":23811,"activeCount":103},[],{"trials":23813,"activeCount":103},[],{"intervention":23790,"totalTrials":302,"cells":23815},{"EARLY_PHASE1":23816,"PHASE1":23818,"PHASE2":23820,"PHASE3":23822,"PHASE4":23828,"NA":23830},{"trials":23817,"activeCount":103},[],{"trials":23819,"activeCount":103},[],{"trials":23821,"activeCount":103},[],{"trials":23823,"activeCount":103},[23824],{"nctId":23784,"briefTitle":23785,"status":168,"phases":23825,"primaryCompletion":3839,"completion":3839,"start":11609,"enrollment":2250,"conditions":23826,"interventions":23827},[93],[15353],[23773,23789,23790,23791],{"trials":23829,"activeCount":103},[],{"trials":23831,"activeCount":103},[],{"intervention":23791,"totalTrials":302,"cells":23833},{"EARLY_PHASE1":23834,"PHASE1":23836,"PHASE2":23838,"PHASE3":23840,"PHASE4":23846,"NA":23848},{"trials":23835,"activeCount":103},[],{"trials":23837,"activeCount":103},[],{"trials":23839,"activeCount":103},[],{"trials":23841,"activeCount":103},[23842],{"nctId":23784,"briefTitle":23785,"status":168,"phases":23843,"primaryCompletion":3839,"completion":3839,"start":11609,"enrollment":2250,"conditions":23844,"interventions":23845},[93],[15353],[23773,23789,23790,23791],{"trials":23847,"activeCount":103},[],{"trials":23849,"activeCount":103},[],{"intervention":23851,"totalTrials":302,"cells":23852},"Synercid",{"EARLY_PHASE1":23853,"PHASE1":23855,"PHASE2":23857,"PHASE3":23859,"PHASE4":23869,"NA":23871},{"trials":23854,"activeCount":103},[],{"trials":23856,"activeCount":103},[],{"trials":23858,"activeCount":103},[],{"trials":23860,"activeCount":103},[23861],{"nctId":23862,"briefTitle":23863,"status":168,"phases":23864,"completion":12069,"start":23865,"conditions":23866,"interventions":23868},"NCT00240747","Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients",[93],"2000-06",[23867],"Gram-Positive Bacterial Infections",[23851],{"trials":23870,"activeCount":103},[],{"trials":23872,"activeCount":103},[],{"intervention":23874,"totalTrials":302,"cells":23875},"matched placebo",{"EARLY_PHASE1":23876,"PHASE1":23878,"PHASE2":23880,"PHASE3":23882,"PHASE4":23890,"NA":23892},{"trials":23877,"activeCount":103},[],{"trials":23879,"activeCount":103},[],{"trials":23881,"activeCount":103},[],{"trials":23883,"activeCount":103},[23884],{"nctId":23885,"briefTitle":23886,"status":111,"phases":23887,"primaryCompletion":2660,"completion":585,"start":3643,"enrollment":17607,"conditions":23888,"interventions":23889},"NCT00468845","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy",[93],[11730],[21451,21451,23874],{"trials":23891,"activeCount":103},[],{"trials":23893,"activeCount":103},[],{"intervention":23895,"totalTrials":302,"cells":23896},"BHV-3500",{"EARLY_PHASE1":23897,"PHASE1":23899,"PHASE2":23901,"PHASE3":23903,"PHASE4":23914,"NA":23916},{"trials":23898,"activeCount":103},[],{"trials":23900,"activeCount":103},[],{"trials":23902,"activeCount":103},[],{"trials":23904,"activeCount":103},[23905],{"nctId":23906,"briefTitle":23907,"status":168,"phases":23908,"primaryCompletion":23909,"completion":23909,"start":23910,"enrollment":23911,"conditions":23912,"interventions":23913},"NCT04804033","A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention",[92,93],"2024-03-21","2021-03-26",1753,[117],[23895],{"trials":23915,"activeCount":103},[],{"trials":23917,"activeCount":103},[],{"intervention":19226,"totalTrials":302,"cells":23919},{"EARLY_PHASE1":23920,"PHASE1":23922,"PHASE2":23924,"PHASE3":23926,"PHASE4":23932,"NA":23934},{"trials":23921,"activeCount":103},[],{"trials":23923,"activeCount":103},[],{"trials":23925,"activeCount":103},[],{"trials":23927,"activeCount":103},[23928],{"nctId":19219,"briefTitle":19220,"status":111,"phases":23929,"primaryCompletion":1401,"completion":1401,"start":19222,"enrollment":19223,"conditions":23930,"interventions":23931},[93],[5921],[9416,19226,19227,19228,19226,19227],{"trials":23933,"activeCount":103},[],{"trials":23935,"activeCount":103},[],{"intervention":19227,"totalTrials":302,"cells":23937},{"EARLY_PHASE1":23938,"PHASE1":23940,"PHASE2":23942,"PHASE3":23944,"PHASE4":23950,"NA":23952},{"trials":23939,"activeCount":103},[],{"trials":23941,"activeCount":103},[],{"trials":23943,"activeCount":103},[],{"trials":23945,"activeCount":103},[23946],{"nctId":19219,"briefTitle":19220,"status":111,"phases":23947,"primaryCompletion":1401,"completion":1401,"start":19222,"enrollment":19223,"conditions":23948,"interventions":23949},[93],[5921],[9416,19226,19227,19228,19226,19227],{"trials":23951,"activeCount":103},[],{"trials":23953,"activeCount":103},[],{"intervention":19228,"totalTrials":302,"cells":23955},{"EARLY_PHASE1":23956,"PHASE1":23958,"PHASE2":23960,"PHASE3":23962,"PHASE4":23968,"NA":23970},{"trials":23957,"activeCount":103},[],{"trials":23959,"activeCount":103},[],{"trials":23961,"activeCount":103},[],{"trials":23963,"activeCount":103},[23964],{"nctId":19219,"briefTitle":19220,"status":111,"phases":23965,"primaryCompletion":1401,"completion":1401,"start":19222,"enrollment":19223,"conditions":23966,"interventions":23967},[93],[5921],[9416,19226,19227,19228,19226,19227],{"trials":23969,"activeCount":103},[],{"trials":23971,"activeCount":103},[],{"intervention":23973,"totalTrials":302,"cells":23974},"FSME-IMMUN NEW 0.25 ml",{"EARLY_PHASE1":23975,"PHASE1":23977,"PHASE2":23979,"PHASE3":23981,"PHASE4":23989,"NA":23991},{"trials":23976,"activeCount":103},[],{"trials":23978,"activeCount":103},[],{"trials":23980,"activeCount":103},[],{"trials":23982,"activeCount":103},[23983],{"nctId":23984,"briefTitle":23985,"status":111,"phases":23986,"completion":3073,"start":15036,"conditions":23987,"interventions":23988},"NCT00161863","Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years",[93],[15165],[23973],{"trials":23990,"activeCount":103},[],{"trials":23992,"activeCount":103},[],{"intervention":23994,"totalTrials":302,"cells":23995},"Indomethacin",{"EARLY_PHASE1":23996,"PHASE1":23998,"PHASE2":24000,"PHASE3":24002,"PHASE4":24011,"NA":24013},{"trials":23997,"activeCount":103},[],{"trials":23999,"activeCount":103},[],{"trials":24001,"activeCount":103},[],{"trials":24003,"activeCount":103},[24004],{"nctId":24005,"briefTitle":24006,"status":111,"phases":24007,"primaryCompletion":4221,"completion":4221,"start":10937,"enrollment":17529,"conditions":24008,"interventions":24010},"NCT00549549","Celebrex In Acute Gouty Arthritis Study",[93],[24009],"Arthritis, Gouty",[23994,3079,3079,3079],{"trials":24012,"activeCount":103},[],{"trials":24014,"activeCount":103},[],{"intervention":12024,"totalTrials":302,"cells":24016},{"EARLY_PHASE1":24017,"PHASE1":24019,"PHASE2":24021,"PHASE3":24023,"PHASE4":24029,"NA":24031},{"trials":24018,"activeCount":103},[],{"trials":24020,"activeCount":103},[],{"trials":24022,"activeCount":103},[],{"trials":24024,"activeCount":103},[24025],{"nctId":12018,"briefTitle":12019,"status":111,"phases":24026,"primaryCompletion":7665,"completion":7665,"start":12021,"conditions":24027,"interventions":24028},[92,93],[1684],[12024,12025,12007],{"trials":24030,"activeCount":103},[],{"trials":24032,"activeCount":103},[],{"intervention":12025,"totalTrials":302,"cells":24034},{"EARLY_PHASE1":24035,"PHASE1":24037,"PHASE2":24039,"PHASE3":24041,"PHASE4":24047,"NA":24049},{"trials":24036,"activeCount":103},[],{"trials":24038,"activeCount":103},[],{"trials":24040,"activeCount":103},[],{"trials":24042,"activeCount":103},[24043],{"nctId":12018,"briefTitle":12019,"status":111,"phases":24044,"primaryCompletion":7665,"completion":7665,"start":12021,"conditions":24045,"interventions":24046},[92,93],[1684],[12024,12025,12007],{"trials":24048,"activeCount":103},[],{"trials":24050,"activeCount":103},[],{"intervention":5813,"totalTrials":302,"cells":24052},{"EARLY_PHASE1":24053,"PHASE1":24055,"PHASE2":24057,"PHASE3":24059,"PHASE4":24065,"NA":24067},{"trials":24054,"activeCount":103},[],{"trials":24056,"activeCount":103},[],{"trials":24058,"activeCount":103},[],{"trials":24060,"activeCount":103},[24061],{"nctId":5804,"briefTitle":5805,"status":111,"phases":24062,"primaryCompletion":5807,"completion":5808,"start":5809,"enrollment":5810,"conditions":24063,"interventions":24064},[93],[1653],[4372,5813],{"trials":24066,"activeCount":103},[],{"trials":24068,"activeCount":103},[],{"intervention":24070,"totalTrials":302,"cells":24071},"Ibuprofen 600 mg Immediate Release\u002FExtended Release Caplet",{"EARLY_PHASE1":24072,"PHASE1":24074,"PHASE2":24076,"PHASE3":24078,"PHASE4":24088,"NA":24090},{"trials":24073,"activeCount":103},[],{"trials":24075,"activeCount":103},[],{"trials":24077,"activeCount":103},[],{"trials":24079,"activeCount":103},[24080],{"nctId":24081,"briefTitle":24082,"status":168,"phases":24083,"primaryCompletion":24084,"completion":24084,"start":1278,"enrollment":24085,"conditions":24086,"interventions":24087},"NCT03722238","Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release\u002FExtended Release Tablets In At-Risk OTC Consumers",[93],"2019-10-28",613,[34],[24070],{"trials":24089,"activeCount":103},[],{"trials":24091,"activeCount":103},[],{"intervention":24093,"totalTrials":302,"cells":24094},"Desvenlafaxine succinate sustained release 50 mg",{"EARLY_PHASE1":24095,"PHASE1":24097,"PHASE2":24099,"PHASE3":24101,"PHASE4":24111,"NA":24113},{"trials":24096,"activeCount":103},[],{"trials":24098,"activeCount":103},[],{"trials":24100,"activeCount":103},[],{"trials":24102,"activeCount":103},[24103],{"nctId":24104,"briefTitle":24105,"status":111,"phases":24106,"primaryCompletion":524,"completion":524,"start":4646,"enrollment":24107,"conditions":24108,"interventions":24109},"NCT00887224","Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder",[93],874,[6321],[24093,24110],"Desvenlafaxine succinate sustained release 25 mg",{"trials":24112,"activeCount":103},[],{"trials":24114,"activeCount":103},[],{"intervention":24110,"totalTrials":302,"cells":24116},{"EARLY_PHASE1":24117,"PHASE1":24119,"PHASE2":24121,"PHASE3":24123,"PHASE4":24129,"NA":24131},{"trials":24118,"activeCount":103},[],{"trials":24120,"activeCount":103},[],{"trials":24122,"activeCount":103},[],{"trials":24124,"activeCount":103},[24125],{"nctId":24104,"briefTitle":24105,"status":111,"phases":24126,"primaryCompletion":524,"completion":524,"start":4646,"enrollment":24107,"conditions":24127,"interventions":24128},[93],[6321],[24093,24110],{"trials":24130,"activeCount":103},[],{"trials":24132,"activeCount":103},[],{"intervention":24134,"totalTrials":302,"cells":24135},"Epoetin Hospira Arm",{"EARLY_PHASE1":24136,"PHASE1":24138,"PHASE2":24140,"PHASE3":24142,"PHASE4":24155,"NA":24157},{"trials":24137,"activeCount":103},[],{"trials":24139,"activeCount":103},[],{"trials":24141,"activeCount":103},[],{"trials":24143,"activeCount":103},[24144],{"nctId":24145,"briefTitle":24146,"status":111,"phases":24147,"primaryCompletion":24148,"completion":24149,"start":24150,"enrollment":11939,"conditions":24151,"interventions":24153},"NCT02504294","A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis",[93],"2016-07-02","2016-07-16","2015-07-13",[24152],"Chronic Kidney Disease (CKD)",[24134,24154],"IV Iron",{"trials":24156,"activeCount":103},[],{"trials":24158,"activeCount":103},[],{"intervention":24154,"totalTrials":302,"cells":24160},{"EARLY_PHASE1":24161,"PHASE1":24163,"PHASE2":24165,"PHASE3":24167,"PHASE4":24173,"NA":24175},{"trials":24162,"activeCount":103},[],{"trials":24164,"activeCount":103},[],{"trials":24166,"activeCount":103},[],{"trials":24168,"activeCount":103},[24169],{"nctId":24145,"briefTitle":24146,"status":111,"phases":24170,"primaryCompletion":24148,"completion":24149,"start":24150,"enrollment":11939,"conditions":24171,"interventions":24172},[93],[24152],[24134,24154],{"trials":24174,"activeCount":103},[],{"trials":24176,"activeCount":103},[],{"intervention":9428,"totalTrials":302,"cells":24178},{"EARLY_PHASE1":24179,"PHASE1":24181,"PHASE2":24183,"PHASE3":24185,"PHASE4":24191,"NA":24193},{"trials":24180,"activeCount":103},[],{"trials":24182,"activeCount":103},[],{"trials":24184,"activeCount":103},[],{"trials":24186,"activeCount":103},[24187],{"nctId":9419,"briefTitle":9420,"status":168,"phases":24188,"primaryCompletion":9422,"completion":9422,"start":9423,"enrollment":1487,"conditions":24189,"interventions":24190},[93],[9425],[9427,9428,1771,1772],{"trials":24192,"activeCount":103},[],{"trials":24194,"activeCount":103},[],{"intervention":24196,"totalTrials":302,"cells":24197},"somatropin - GH naïve pediatric cohort",{"EARLY_PHASE1":24198,"PHASE1":24200,"PHASE2":24202,"PHASE3":24204,"PHASE4":24218,"NA":24220},{"trials":24199,"activeCount":103},[],{"trials":24201,"activeCount":103},[],{"trials":24203,"activeCount":103},[],{"trials":24205,"activeCount":103},[24206],{"nctId":24207,"briefTitle":24208,"status":111,"phases":24209,"primaryCompletion":24210,"completion":24211,"start":24212,"enrollment":5987,"conditions":24213,"interventions":24215},"NCT04697381","Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS",[93],"2022-12-06","2024-04-15","2021-02-09",[24214],"Prader-Willi Syndrome",[24196,24216,24217],"somatropin - GH treated cohort","somatropin - adult cohort",{"trials":24219,"activeCount":103},[],{"trials":24221,"activeCount":103},[],{"intervention":24216,"totalTrials":302,"cells":24223},{"EARLY_PHASE1":24224,"PHASE1":24226,"PHASE2":24228,"PHASE3":24230,"PHASE4":24236,"NA":24238},{"trials":24225,"activeCount":103},[],{"trials":24227,"activeCount":103},[],{"trials":24229,"activeCount":103},[],{"trials":24231,"activeCount":103},[24232],{"nctId":24207,"briefTitle":24208,"status":111,"phases":24233,"primaryCompletion":24210,"completion":24211,"start":24212,"enrollment":5987,"conditions":24234,"interventions":24235},[93],[24214],[24196,24216,24217],{"trials":24237,"activeCount":103},[],{"trials":24239,"activeCount":103},[],{"intervention":24217,"totalTrials":302,"cells":24241},{"EARLY_PHASE1":24242,"PHASE1":24244,"PHASE2":24246,"PHASE3":24248,"PHASE4":24254,"NA":24256},{"trials":24243,"activeCount":103},[],{"trials":24245,"activeCount":103},[],{"trials":24247,"activeCount":103},[],{"trials":24249,"activeCount":103},[24250],{"nctId":24207,"briefTitle":24208,"status":111,"phases":24251,"primaryCompletion":24210,"completion":24211,"start":24212,"enrollment":5987,"conditions":24252,"interventions":24253},[93],[24214],[24196,24216,24217],{"trials":24255,"activeCount":103},[],{"trials":24257,"activeCount":103},[],{"intervention":24259,"totalTrials":302,"cells":24260},"ARRY-371797",{"EARLY_PHASE1":24261,"PHASE1":24263,"PHASE2":24265,"PHASE3":24267,"PHASE4":24278,"NA":24280},{"trials":24262,"activeCount":103},[],{"trials":24264,"activeCount":103},[],{"trials":24266,"activeCount":103},[],{"trials":24268,"activeCount":103},[24269],{"nctId":24270,"briefTitle":24271,"status":168,"phases":24272,"primaryCompletion":24273,"completion":24273,"start":2189,"enrollment":5647,"conditions":24274,"interventions":24277},"NCT03439514","A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A\u002FC Gene Mutation",[93],"2022-10-13",[24275,24276],"Dilated Cardiomyopathy","Lamin A\u002FC Gene Mutation",[24259],{"trials":24279,"activeCount":103},[],{"trials":24281,"activeCount":103},[],{"intervention":24283,"totalTrials":302,"cells":24284},"Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate",{"EARLY_PHASE1":24285,"PHASE1":24287,"PHASE2":24289,"PHASE3":24291,"PHASE4":24302,"NA":24304},{"trials":24286,"activeCount":103},[],{"trials":24288,"activeCount":103},[],{"trials":24290,"activeCount":103},[],{"trials":24292,"activeCount":103},[24293],{"nctId":24294,"briefTitle":24295,"status":111,"phases":24296,"primaryCompletion":4214,"completion":4221,"start":3335,"enrollment":1759,"conditions":24297,"interventions":24300},"NCT00617760","Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)",[93],[24298,24299],"Neisseria Meningitidis (Bacterial Meningitis)","Invasive Pneumococcal Disease (IPD)",[24283,24301,24283],"7-valent Pneumococcal CRM197-conjugate vaccine",{"trials":24303,"activeCount":103},[],{"trials":24305,"activeCount":103},[],{"intervention":24301,"totalTrials":302,"cells":24307},{"EARLY_PHASE1":24308,"PHASE1":24310,"PHASE2":24312,"PHASE3":24314,"PHASE4":24320,"NA":24322},{"trials":24309,"activeCount":103},[],{"trials":24311,"activeCount":103},[],{"trials":24313,"activeCount":103},[],{"trials":24315,"activeCount":103},[24316],{"nctId":24294,"briefTitle":24295,"status":111,"phases":24317,"primaryCompletion":4214,"completion":4221,"start":3335,"enrollment":1759,"conditions":24318,"interventions":24319},[93],[24298,24299],[24283,24301,24283],{"trials":24321,"activeCount":103},[],{"trials":24323,"activeCount":103},[],{"intervention":24325,"totalTrials":302,"cells":24326},"Dimebon tablet for oral administration",{"EARLY_PHASE1":24327,"PHASE1":24329,"PHASE2":24331,"PHASE3":24333,"PHASE4":24341,"NA":24343},{"trials":24328,"activeCount":103},[],{"trials":24330,"activeCount":103},[],{"trials":24332,"activeCount":103},[],{"trials":24334,"activeCount":103},[24335],{"nctId":24336,"briefTitle":24337,"status":168,"phases":24338,"primaryCompletion":586,"completion":586,"start":4206,"enrollment":578,"conditions":24339,"interventions":24340},"NCT01066546","An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease",[93],[17728],[24325],{"trials":24342,"activeCount":103},[],{"trials":24344,"activeCount":103},[],{"intervention":13419,"totalTrials":302,"cells":24346},{"EARLY_PHASE1":24347,"PHASE1":24349,"PHASE2":24351,"PHASE3":24353,"PHASE4":24359,"NA":24361},{"trials":24348,"activeCount":103},[],{"trials":24350,"activeCount":103},[],{"trials":24352,"activeCount":103},[],{"trials":24354,"activeCount":103},[24355],{"nctId":13412,"briefTitle":13413,"status":111,"phases":24356,"primaryCompletion":11790,"completion":11790,"start":13415,"enrollment":13416,"conditions":24357,"interventions":24358},[93],[12882,12881],[13383,13419,13420],{"trials":24360,"activeCount":103},[],{"trials":24362,"activeCount":103},[],{"intervention":13420,"totalTrials":302,"cells":24364},{"EARLY_PHASE1":24365,"PHASE1":24367,"PHASE2":24369,"PHASE3":24371,"PHASE4":24377,"NA":24379},{"trials":24366,"activeCount":103},[],{"trials":24368,"activeCount":103},[],{"trials":24370,"activeCount":103},[],{"trials":24372,"activeCount":103},[24373],{"nctId":13412,"briefTitle":13413,"status":111,"phases":24374,"primaryCompletion":11790,"completion":11790,"start":13415,"enrollment":13416,"conditions":24375,"interventions":24376},[93],[12882,12881],[13383,13419,13420],{"trials":24378,"activeCount":103},[],{"trials":24380,"activeCount":103},[],{"intervention":24382,"totalTrials":302,"cells":24383},"Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine",{"EARLY_PHASE1":24384,"PHASE1":24386,"PHASE2":24388,"PHASE3":24390,"PHASE4":24399,"NA":24401},{"trials":24385,"activeCount":103},[],{"trials":24387,"activeCount":103},[],{"trials":24389,"activeCount":103},[],{"trials":24391,"activeCount":103},[24392],{"nctId":24393,"briefTitle":24394,"status":111,"phases":24395,"completion":3073,"start":3074,"enrollment":1759,"conditions":24396,"interventions":24398},"NCT00161928","Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants",[93],[24397],"Meningitis, Meningococcal",[24382],{"trials":24400,"activeCount":103},[],{"trials":24402,"activeCount":103},[],{"intervention":24404,"totalTrials":302,"cells":24405},"Amoxicillin\u002Fclavulinic acid",{"EARLY_PHASE1":24406,"PHASE1":24408,"PHASE2":24410,"PHASE3":24412,"PHASE4":24420,"NA":24422},{"trials":24407,"activeCount":103},[],{"trials":24409,"activeCount":103},[],{"trials":24411,"activeCount":103},[],{"trials":24413,"activeCount":103},[24414],{"nctId":24415,"briefTitle":24416,"status":111,"phases":24417,"completion":4679,"start":11379,"enrollment":8827,"conditions":24418,"interventions":24419},"NCT00649831","A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis",[93],[19965],[24404,15250],{"trials":24421,"activeCount":103},[],{"trials":24423,"activeCount":103},[],{"intervention":24425,"totalTrials":302,"cells":24426},"iv sildenafil",{"EARLY_PHASE1":24427,"PHASE1":24429,"PHASE2":24431,"PHASE3":24433,"PHASE4":24445,"NA":24447},{"trials":24428,"activeCount":103},[],{"trials":24430,"activeCount":103},[],{"trials":24432,"activeCount":103},[],{"trials":24434,"activeCount":103},[24435],{"nctId":24436,"briefTitle":24437,"status":111,"phases":24438,"primaryCompletion":24439,"completion":24440,"start":24441,"enrollment":1060,"conditions":24442,"interventions":24444},"NCT01720524","A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn",[93],"2018-10-17","2020-09-28","2013-08-05",[24443],"Pulmonary Hypertension, Familial Persistent, of the Newborn",[24425],{"trials":24446,"activeCount":103},[],{"trials":24448,"activeCount":103},[],{"intervention":24450,"totalTrials":302,"cells":24451},"Venlafaxine XR",{"EARLY_PHASE1":24452,"PHASE1":24454,"PHASE2":24456,"PHASE3":24458,"PHASE4":24467,"NA":24469},{"trials":24453,"activeCount":103},[],{"trials":24455,"activeCount":103},[],{"trials":24457,"activeCount":103},[],{"trials":24459,"activeCount":103},[24460],{"nctId":24461,"briefTitle":24462,"status":111,"phases":24463,"completion":4847,"start":4692,"enrollment":17893,"conditions":24464,"interventions":24466},"NCT00151450","Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder",[93],[24465],"Anxiety",[11452,24450],{"trials":24468,"activeCount":103},[],{"trials":24470,"activeCount":103},[],{"intervention":24472,"totalTrials":302,"cells":24473},"Bazedoxifene\u002FConjugated Estrogen",{"EARLY_PHASE1":24474,"PHASE1":24476,"PHASE2":24478,"PHASE3":24480,"PHASE4":24490,"NA":24492},{"trials":24475,"activeCount":103},[],{"trials":24477,"activeCount":103},[],{"trials":24479,"activeCount":103},[],{"trials":24481,"activeCount":103},[24482],{"nctId":24483,"briefTitle":24484,"status":111,"phases":24485,"primaryCompletion":11291,"completion":11291,"start":6017,"enrollment":2360,"conditions":24486,"interventions":24488},"NCT00242710","Study Evaluating Bazedoxifene\u002FConjugated Estrogens Combinations In Postmenopausal Women",[93],[24487,23074],"Endometrial Hyperplasia",[24472,24472,24489],"CE 0.45 mg\u002FMPA 1.5mg",{"trials":24491,"activeCount":103},[],{"trials":24493,"activeCount":103},[],{"intervention":24489,"totalTrials":302,"cells":24495},{"EARLY_PHASE1":24496,"PHASE1":24498,"PHASE2":24500,"PHASE3":24502,"PHASE4":24508,"NA":24510},{"trials":24497,"activeCount":103},[],{"trials":24499,"activeCount":103},[],{"trials":24501,"activeCount":103},[],{"trials":24503,"activeCount":103},[24504],{"nctId":24483,"briefTitle":24484,"status":111,"phases":24505,"primaryCompletion":11291,"completion":11291,"start":6017,"enrollment":2360,"conditions":24506,"interventions":24507},[93],[24487,23074],[24472,24472,24489],{"trials":24509,"activeCount":103},[],{"trials":24511,"activeCount":103},[],{"intervention":24513,"totalTrials":302,"cells":24514},"PF-3512676 + Paclitaxel + Carboplatin",{"EARLY_PHASE1":24515,"PHASE1":24517,"PHASE2":24519,"PHASE3":24521,"PHASE4":24531,"NA":24533},{"trials":24516,"activeCount":103},[],{"trials":24518,"activeCount":103},[],{"trials":24520,"activeCount":103},[],{"trials":24522,"activeCount":103},[24523],{"nctId":24524,"briefTitle":24525,"status":168,"phases":24526,"primaryCompletion":4207,"completion":4207,"start":8170,"enrollment":24527,"conditions":24528,"interventions":24529},"NCT00254891","Trial of Paclitaxel\u002FCarboplatin + PF-3512676 vs Paclitaxel\u002FCarboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer",[93],828,[376],[24513,24530],"Paclitaxel + Carboplatin",{"trials":24532,"activeCount":103},[],{"trials":24534,"activeCount":103},[],{"intervention":24530,"totalTrials":302,"cells":24536},{"EARLY_PHASE1":24537,"PHASE1":24539,"PHASE2":24541,"PHASE3":24543,"PHASE4":24549,"NA":24551},{"trials":24538,"activeCount":103},[],{"trials":24540,"activeCount":103},[],{"trials":24542,"activeCount":103},[],{"trials":24544,"activeCount":103},[24545],{"nctId":24524,"briefTitle":24525,"status":168,"phases":24546,"primaryCompletion":4207,"completion":4207,"start":8170,"enrollment":24527,"conditions":24547,"interventions":24548},[93],[376],[24513,24530],{"trials":24550,"activeCount":103},[],{"trials":24552,"activeCount":103},[],{"intervention":20073,"totalTrials":302,"cells":24554},{"EARLY_PHASE1":24555,"PHASE1":24557,"PHASE2":24559,"PHASE3":24561,"PHASE4":24567,"NA":24569},{"trials":24556,"activeCount":103},[],{"trials":24558,"activeCount":103},[],{"trials":24560,"activeCount":103},[],{"trials":24562,"activeCount":103},[24563],{"nctId":20067,"briefTitle":20068,"status":111,"phases":24564,"primaryCompletion":3839,"completion":3839,"start":3854,"enrollment":2470,"conditions":24565,"interventions":24566},[93],[20071],[20044,20073],{"trials":24568,"activeCount":103},[],{"trials":24570,"activeCount":103},[],{"intervention":12545,"totalTrials":302,"cells":24572},{"EARLY_PHASE1":24573,"PHASE1":24575,"PHASE2":24577,"PHASE3":24579,"PHASE4":24585,"NA":24587},{"trials":24574,"activeCount":103},[],{"trials":24576,"activeCount":103},[],{"trials":24578,"activeCount":103},[],{"trials":24580,"activeCount":103},[24581],{"nctId":12538,"briefTitle":12539,"status":111,"phases":24582,"primaryCompletion":12541,"completion":12541,"start":12542,"enrollment":11719,"conditions":24583,"interventions":24584},[93],[6321],[12520,12545],{"trials":24586,"activeCount":103},[],{"trials":24588,"activeCount":103},[],{"intervention":24590,"totalTrials":302,"cells":24591},"Xyntha",{"EARLY_PHASE1":24592,"PHASE1":24594,"PHASE2":24596,"PHASE3":24598,"PHASE4":24606,"NA":24608},{"trials":24593,"activeCount":103},[],{"trials":24595,"activeCount":103},[],{"trials":24597,"activeCount":103},[],{"trials":24599,"activeCount":103},[24600],{"nctId":24601,"briefTitle":24602,"status":111,"phases":24603,"primaryCompletion":4221,"completion":4221,"start":11291,"enrollment":336,"conditions":24604,"interventions":24605},"NCT00868530","Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects",[93],[3551],[24590],{"trials":24607,"activeCount":103},[],{"trials":24609,"activeCount":103},[],{"intervention":20442,"totalTrials":302,"cells":24611},{"EARLY_PHASE1":24612,"PHASE1":24614,"PHASE2":24616,"PHASE3":24618,"PHASE4":24624,"NA":24626},{"trials":24613,"activeCount":103},[],{"trials":24615,"activeCount":103},[],{"trials":24617,"activeCount":103},[],{"trials":24619,"activeCount":103},[24620],{"nctId":20434,"briefTitle":20435,"status":111,"phases":24621,"primaryCompletion":20437,"completion":20437,"start":20438,"enrollment":1060,"conditions":24622,"interventions":24623},[93],[16],[20441,20442,20417],{"trials":24625,"activeCount":103},[],{"trials":24627,"activeCount":103},[],{"intervention":19743,"totalTrials":302,"cells":24629},{"EARLY_PHASE1":24630,"PHASE1":24632,"PHASE2":24634,"PHASE3":24636,"PHASE4":24642,"NA":24644},{"trials":24631,"activeCount":103},[],{"trials":24633,"activeCount":103},[],{"trials":24635,"activeCount":103},[],{"trials":24637,"activeCount":103},[24638],{"nctId":19735,"briefTitle":19736,"status":111,"phases":24639,"primaryCompletion":19738,"completion":19738,"start":19739,"enrollment":19740,"conditions":24640,"interventions":24641},[93],[10577],[19743,19712,19731],{"trials":24643,"activeCount":103},[],{"trials":24645,"activeCount":103},[],{"intervention":19752,"totalTrials":302,"cells":24647},{"EARLY_PHASE1":24648,"PHASE1":24650,"PHASE2":24652,"PHASE3":24654,"PHASE4":24660,"NA":24662},{"trials":24649,"activeCount":103},[],{"trials":24651,"activeCount":103},[],{"trials":24653,"activeCount":103},[],{"trials":24655,"activeCount":103},[24656],{"nctId":19745,"briefTitle":19746,"status":111,"phases":24657,"primaryCompletion":19726,"completion":19726,"start":19748,"enrollment":19749,"conditions":24658,"interventions":24659},[93],[10577],[19712,19731,19733,19752],{"trials":24661,"activeCount":103},[],{"trials":24663,"activeCount":103},[],{"intervention":24665,"totalTrials":302,"cells":24666},"PN-152,243)\u002FPN-196,444",{"EARLY_PHASE1":24667,"PHASE1":24669,"PHASE2":24671,"PHASE3":24673,"PHASE4":24681,"NA":24683},{"trials":24668,"activeCount":103},[],{"trials":24670,"activeCount":103},[],{"trials":24672,"activeCount":103},[],{"trials":24674,"activeCount":103},[24675],{"nctId":24676,"briefTitle":23642,"status":111,"phases":24677,"completion":3628,"start":24678,"enrollment":941,"conditions":24679,"interventions":24680},"NCT00038311",[93],"2000-09",[12588],[24665],{"trials":24682,"activeCount":103},[],{"trials":24684,"activeCount":103},[],{"intervention":24686,"totalTrials":302,"cells":24687},"IV Diclofenac",{"EARLY_PHASE1":24688,"PHASE1":24690,"PHASE2":24692,"PHASE3":24694,"PHASE4":24707,"NA":24709},{"trials":24689,"activeCount":103},[],{"trials":24691,"activeCount":103},[],{"trials":24693,"activeCount":103},[],{"trials":24695,"activeCount":103},[24696],{"nctId":24697,"briefTitle":24698,"status":111,"phases":24699,"primaryCompletion":24700,"completion":24700,"start":24701,"enrollment":24702,"conditions":24703,"interventions":24705},"NCT00507026","Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery",[93],"2008-10-14","2007-07-25",277,[24704],"Postoperative Pain",[24686,24706],"IV ketorolac",{"trials":24708,"activeCount":103},[],{"trials":24710,"activeCount":103},[],{"intervention":24706,"totalTrials":302,"cells":24712},{"EARLY_PHASE1":24713,"PHASE1":24715,"PHASE2":24717,"PHASE3":24719,"PHASE4":24725,"NA":24727},{"trials":24714,"activeCount":103},[],{"trials":24716,"activeCount":103},[],{"trials":24718,"activeCount":103},[],{"trials":24720,"activeCount":103},[24721],{"nctId":24697,"briefTitle":24698,"status":111,"phases":24722,"primaryCompletion":24700,"completion":24700,"start":24701,"enrollment":24702,"conditions":24723,"interventions":24724},[93],[24704],[24686,24706],{"trials":24726,"activeCount":103},[],{"trials":24728,"activeCount":103},[],{"intervention":24730,"totalTrials":302,"cells":24731},"FDC IBU\u002FAPAP 250 mg\u002F500 mg",{"EARLY_PHASE1":24732,"PHASE1":24734,"PHASE2":24736,"PHASE3":24738,"PHASE4":24747,"NA":24749},{"trials":24733,"activeCount":103},[],{"trials":24735,"activeCount":103},[],{"trials":24737,"activeCount":103},[],{"trials":24739,"activeCount":103},[24740],{"nctId":24741,"briefTitle":24742,"status":111,"phases":24743,"primaryCompletion":24744,"completion":24744,"start":12718,"enrollment":3462,"conditions":24745,"interventions":24746},"NCT02837952","A Study of Ibuprofen (IBU) 250mg\u002FAPAP 500mg In The Treatment Of Post-Surgical Dental Pain",[93],"2017-02-01",[34],[24730],{"trials":24748,"activeCount":103},[],{"trials":24750,"activeCount":103},[],{"intervention":17327,"totalTrials":302,"cells":24752},{"EARLY_PHASE1":24753,"PHASE1":24755,"PHASE2":24757,"PHASE3":24759,"PHASE4":24765,"NA":24767},{"trials":24754,"activeCount":103},[],{"trials":24756,"activeCount":103},[],{"trials":24758,"activeCount":103},[],{"trials":24760,"activeCount":103},[24761],{"nctId":17321,"briefTitle":17322,"status":168,"phases":24762,"completion":11315,"start":2662,"enrollment":17324,"conditions":24763,"interventions":24764},[93],[12979,12980],[12983,17327],{"trials":24766,"activeCount":103},[],{"trials":24768,"activeCount":103},[],{"intervention":24770,"totalTrials":302,"cells":24771},"Tanezumab 5 mg SC",{"EARLY_PHASE1":24772,"PHASE1":24774,"PHASE2":24776,"PHASE3":24778,"PHASE4":24790,"NA":24792},{"trials":24773,"activeCount":103},[],{"trials":24775,"activeCount":103},[],{"trials":24777,"activeCount":103},[],{"trials":24779,"activeCount":103},[24780],{"nctId":24781,"briefTitle":24782,"status":111,"phases":24783,"primaryCompletion":595,"completion":9617,"start":24784,"enrollment":24785,"conditions":24786,"interventions":24787},"NCT02528253","A Phase 3 Study of Tanezumab for Chronic Low Back Pain",[93],"2015-08-18",1832,[11337],[24770,24788,24789],"Tanezumab 10 mg SC","Tramadol PR",{"trials":24791,"activeCount":103},[],{"trials":24793,"activeCount":103},[],{"intervention":24788,"totalTrials":302,"cells":24795},{"EARLY_PHASE1":24796,"PHASE1":24798,"PHASE2":24800,"PHASE3":24802,"PHASE4":24808,"NA":24810},{"trials":24797,"activeCount":103},[],{"trials":24799,"activeCount":103},[],{"trials":24801,"activeCount":103},[],{"trials":24803,"activeCount":103},[24804],{"nctId":24781,"briefTitle":24782,"status":111,"phases":24805,"primaryCompletion":595,"completion":9617,"start":24784,"enrollment":24785,"conditions":24806,"interventions":24807},[93],[11337],[24770,24788,24789],{"trials":24809,"activeCount":103},[],{"trials":24811,"activeCount":103},[],{"intervention":24789,"totalTrials":302,"cells":24813},{"EARLY_PHASE1":24814,"PHASE1":24816,"PHASE2":24818,"PHASE3":24820,"PHASE4":24826,"NA":24828},{"trials":24815,"activeCount":103},[],{"trials":24817,"activeCount":103},[],{"trials":24819,"activeCount":103},[],{"trials":24821,"activeCount":103},[24822],{"nctId":24781,"briefTitle":24782,"status":111,"phases":24823,"primaryCompletion":595,"completion":9617,"start":24784,"enrollment":24785,"conditions":24824,"interventions":24825},[93],[11337],[24770,24788,24789],{"trials":24827,"activeCount":103},[],{"trials":24829,"activeCount":103},[],{"intervention":24831,"totalTrials":302,"cells":24832},"Placebp",{"EARLY_PHASE1":24833,"PHASE1":24835,"PHASE2":24837,"PHASE3":24839,"PHASE4":24850,"NA":24852},{"trials":24834,"activeCount":103},[],{"trials":24836,"activeCount":103},[],{"trials":24838,"activeCount":103},[],{"trials":24840,"activeCount":103},[24841],{"nctId":24842,"briefTitle":24843,"status":111,"phases":24844,"primaryCompletion":7826,"completion":7826,"start":24845,"enrollment":24846,"conditions":24847,"interventions":24848},"NCT06325657","A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants",[93],"2024-03-12",648,[9529],[24849,24831],"RSVpreF vaccine",{"trials":24851,"activeCount":103},[],{"trials":24853,"activeCount":103},[],{"intervention":24855,"totalTrials":302,"cells":24856},"Bococizumab 150mg",{"EARLY_PHASE1":24857,"PHASE1":24859,"PHASE2":24861,"PHASE3":24863,"PHASE4":24875,"NA":24877},{"trials":24858,"activeCount":103},[],{"trials":24860,"activeCount":103},[],{"trials":24862,"activeCount":103},[],{"trials":24864,"activeCount":103},[24865],{"nctId":24866,"briefTitle":24867,"status":111,"phases":24868,"primaryCompletion":4280,"completion":4280,"start":4438,"enrollment":24869,"conditions":24870,"interventions":24871},"NCT02458287","Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",[93],299,[12979],[24855,24872,24873,24874],"Bococizumab 75mg","Bococizumab 150mg placebo","Bococizumab 75mg placebo",{"trials":24876,"activeCount":103},[],{"trials":24878,"activeCount":103},[],{"intervention":24872,"totalTrials":302,"cells":24880},{"EARLY_PHASE1":24881,"PHASE1":24883,"PHASE2":24885,"PHASE3":24887,"PHASE4":24893,"NA":24895},{"trials":24882,"activeCount":103},[],{"trials":24884,"activeCount":103},[],{"trials":24886,"activeCount":103},[],{"trials":24888,"activeCount":103},[24889],{"nctId":24866,"briefTitle":24867,"status":111,"phases":24890,"primaryCompletion":4280,"completion":4280,"start":4438,"enrollment":24869,"conditions":24891,"interventions":24892},[93],[12979],[24855,24872,24873,24874],{"trials":24894,"activeCount":103},[],{"trials":24896,"activeCount":103},[],{"intervention":24873,"totalTrials":302,"cells":24898},{"EARLY_PHASE1":24899,"PHASE1":24901,"PHASE2":24903,"PHASE3":24905,"PHASE4":24911,"NA":24913},{"trials":24900,"activeCount":103},[],{"trials":24902,"activeCount":103},[],{"trials":24904,"activeCount":103},[],{"trials":24906,"activeCount":103},[24907],{"nctId":24866,"briefTitle":24867,"status":111,"phases":24908,"primaryCompletion":4280,"completion":4280,"start":4438,"enrollment":24869,"conditions":24909,"interventions":24910},[93],[12979],[24855,24872,24873,24874],{"trials":24912,"activeCount":103},[],{"trials":24914,"activeCount":103},[],{"intervention":24874,"totalTrials":302,"cells":24916},{"EARLY_PHASE1":24917,"PHASE1":24919,"PHASE2":24921,"PHASE3":24923,"PHASE4":24929,"NA":24931},{"trials":24918,"activeCount":103},[],{"trials":24920,"activeCount":103},[],{"trials":24922,"activeCount":103},[],{"trials":24924,"activeCount":103},[24925],{"nctId":24866,"briefTitle":24867,"status":111,"phases":24926,"primaryCompletion":4280,"completion":4280,"start":4438,"enrollment":24869,"conditions":24927,"interventions":24928},[93],[12979],[24855,24872,24873,24874],{"trials":24930,"activeCount":103},[],{"trials":24932,"activeCount":103},[],{"intervention":24934,"totalTrials":302,"cells":24935},"LATANOPROST 0.005% \u002F TIMOLOL 0.5% FIXED COMBINATION",{"EARLY_PHASE1":24936,"PHASE1":24938,"PHASE2":24940,"PHASE3":24942,"PHASE4":24951,"NA":24953},{"trials":24937,"activeCount":103},[],{"trials":24939,"activeCount":103},[],{"trials":24941,"activeCount":103},[],{"trials":24943,"activeCount":103},[24944],{"nctId":24945,"briefTitle":24946,"status":111,"phases":24947,"primaryCompletion":11609,"completion":11609,"start":6017,"enrollment":2229,"conditions":24948,"interventions":24950},"NCT00230763","Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure",[93],[24949,12882],"Glaucoma, Primary Open Angle (POAG)",[24934],{"trials":24952,"activeCount":103},[],{"trials":24954,"activeCount":103},[],{"intervention":24956,"totalTrials":302,"cells":24957},"Antibiotic",{"EARLY_PHASE1":24958,"PHASE1":24960,"PHASE2":24962,"PHASE3":24964,"PHASE4":24974,"NA":24976},{"trials":24959,"activeCount":103},[],{"trials":24961,"activeCount":103},[],{"trials":24963,"activeCount":103},[],{"trials":24965,"activeCount":103},[24966],{"nctId":24967,"briefTitle":24968,"status":111,"phases":24969,"completion":2642,"start":19543,"enrollment":19112,"conditions":24970,"interventions":24973},"NCT00035269","New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)",[93],[14286,24971,24972],"Community Acquired Infections","Gram-positive Bacterial Infections",[24956],{"trials":24975,"activeCount":103},[],{"trials":24977,"activeCount":103},[],{"intervention":19944,"totalTrials":302,"cells":24979},{"EARLY_PHASE1":24980,"PHASE1":24982,"PHASE2":24984,"PHASE3":24986,"PHASE4":24992,"NA":24994},{"trials":24981,"activeCount":103},[],{"trials":24983,"activeCount":103},[],{"trials":24985,"activeCount":103},[],{"trials":24987,"activeCount":103},[24988],{"nctId":19936,"briefTitle":19937,"status":111,"phases":24989,"primaryCompletion":19939,"completion":19939,"start":19940,"enrollment":19941,"conditions":24990,"interventions":24991},[93],[19924],[19908,19944],{"trials":24993,"activeCount":103},[],{"trials":24995,"activeCount":103},[],{"intervention":24997,"totalTrials":302,"cells":24998},"Ceftazidime - Avibactam",{"EARLY_PHASE1":24999,"PHASE1":25001,"PHASE2":25003,"PHASE3":25005,"PHASE4":25018,"NA":25020},{"trials":25000,"activeCount":103},[],{"trials":25002,"activeCount":103},[],{"trials":25004,"activeCount":103},[],{"trials":25006,"activeCount":103},[25007],{"nctId":25008,"briefTitle":25009,"status":111,"phases":25010,"primaryCompletion":7386,"completion":7386,"start":3353,"enrollment":25011,"conditions":25012,"interventions":25014},"NCT01599806","Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)",[93],641,[25013],"Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis",[24997,25015,25016,25017],"Doripenem","Either switch to oral therapy: 500 mg of Ciprofloxacin","or switch to oral therapy: 800 mg\u002F160 mg of sulfamethoxazole\u002Ftrimethoprim",{"trials":25019,"activeCount":103},[],{"trials":25021,"activeCount":103},[],{"intervention":25015,"totalTrials":302,"cells":25023},{"EARLY_PHASE1":25024,"PHASE1":25026,"PHASE2":25028,"PHASE3":25030,"PHASE4":25036,"NA":25038},{"trials":25025,"activeCount":103},[],{"trials":25027,"activeCount":103},[],{"trials":25029,"activeCount":103},[],{"trials":25031,"activeCount":103},[25032],{"nctId":25008,"briefTitle":25009,"status":111,"phases":25033,"primaryCompletion":7386,"completion":7386,"start":3353,"enrollment":25011,"conditions":25034,"interventions":25035},[93],[25013],[24997,25015,25016,25017],{"trials":25037,"activeCount":103},[],{"trials":25039,"activeCount":103},[],{"intervention":25016,"totalTrials":302,"cells":25041},{"EARLY_PHASE1":25042,"PHASE1":25044,"PHASE2":25046,"PHASE3":25048,"PHASE4":25054,"NA":25056},{"trials":25043,"activeCount":103},[],{"trials":25045,"activeCount":103},[],{"trials":25047,"activeCount":103},[],{"trials":25049,"activeCount":103},[25050],{"nctId":25008,"briefTitle":25009,"status":111,"phases":25051,"primaryCompletion":7386,"completion":7386,"start":3353,"enrollment":25011,"conditions":25052,"interventions":25053},[93],[25013],[24997,25015,25016,25017],{"trials":25055,"activeCount":103},[],{"trials":25057,"activeCount":103},[],{"intervention":25017,"totalTrials":302,"cells":25059},{"EARLY_PHASE1":25060,"PHASE1":25062,"PHASE2":25064,"PHASE3":25066,"PHASE4":25072,"NA":25074},{"trials":25061,"activeCount":103},[],{"trials":25063,"activeCount":103},[],{"trials":25065,"activeCount":103},[],{"trials":25067,"activeCount":103},[25068],{"nctId":25008,"briefTitle":25009,"status":111,"phases":25069,"primaryCompletion":7386,"completion":7386,"start":3353,"enrollment":25011,"conditions":25070,"interventions":25071},[93],[25013],[24997,25015,25016,25017],{"trials":25073,"activeCount":103},[],{"trials":25075,"activeCount":103},[],{"intervention":25077,"totalTrials":302,"cells":25078},"Recombinant Coagulation Factor IX",{"EARLY_PHASE1":25079,"PHASE1":25081,"PHASE2":25083,"PHASE3":25085,"PHASE4":25093,"NA":25095},{"trials":25080,"activeCount":103},[],{"trials":25082,"activeCount":103},[],{"trials":25084,"activeCount":103},[],{"trials":25086,"activeCount":103},[25087],{"nctId":25088,"briefTitle":25089,"status":111,"phases":25090,"primaryCompletion":585,"completion":585,"start":3610,"enrollment":26,"conditions":25091,"interventions":25092},"NCT00364182","Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B",[93],[3552],[25077,25077],{"trials":25094,"activeCount":103},[],{"trials":25096,"activeCount":103},[],{"intervention":25098,"totalTrials":302,"cells":25099},"unfixed Latanoprost and Timolol",{"EARLY_PHASE1":25100,"PHASE1":25102,"PHASE2":25104,"PHASE3":25106,"PHASE4":25114,"NA":25116},{"trials":25101,"activeCount":103},[],{"trials":25103,"activeCount":103},[],{"trials":25105,"activeCount":103},[],{"trials":25107,"activeCount":103},[25108],{"nctId":25109,"briefTitle":25110,"status":111,"phases":25111,"completion":3854,"start":14118,"enrollment":22897,"conditions":25112,"interventions":25113},"NCT00219596","Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension",[93],[15312,12882],[15314,25098],{"trials":25115,"activeCount":103},[],{"trials":25117,"activeCount":103},[],{"intervention":25119,"totalTrials":302,"cells":25120},"Amlodipine 2.5mg\u002FAtorvastatin 5mg",{"EARLY_PHASE1":25121,"PHASE1":25123,"PHASE2":25125,"PHASE3":25127,"PHASE4":25138,"NA":25140},{"trials":25122,"activeCount":103},[],{"trials":25124,"activeCount":103},[],{"trials":25126,"activeCount":103},[],{"trials":25128,"activeCount":103},[25129],{"nctId":25130,"briefTitle":25131,"status":111,"phases":25132,"primaryCompletion":3314,"completion":3314,"start":7665,"enrollment":6352,"conditions":25133,"interventions":25134},"NCT00530946","A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin",[93],[13280,12981],[25119,25135,25136,25137],"Amlodipine 2.5mg\u002FAtorvastatin 10mg","Amlodipine 5mg\u002FAtorvastatin 5mg","Amlodipine 5mg\u002FAtorvastatin 10mg",{"trials":25139,"activeCount":103},[],{"trials":25141,"activeCount":103},[],{"intervention":25135,"totalTrials":302,"cells":25143},{"EARLY_PHASE1":25144,"PHASE1":25146,"PHASE2":25148,"PHASE3":25150,"PHASE4":25156,"NA":25158},{"trials":25145,"activeCount":103},[],{"trials":25147,"activeCount":103},[],{"trials":25149,"activeCount":103},[],{"trials":25151,"activeCount":103},[25152],{"nctId":25130,"briefTitle":25131,"status":111,"phases":25153,"primaryCompletion":3314,"completion":3314,"start":7665,"enrollment":6352,"conditions":25154,"interventions":25155},[93],[13280,12981],[25119,25135,25136,25137],{"trials":25157,"activeCount":103},[],{"trials":25159,"activeCount":103},[],{"intervention":25136,"totalTrials":302,"cells":25161},{"EARLY_PHASE1":25162,"PHASE1":25164,"PHASE2":25166,"PHASE3":25168,"PHASE4":25174,"NA":25176},{"trials":25163,"activeCount":103},[],{"trials":25165,"activeCount":103},[],{"trials":25167,"activeCount":103},[],{"trials":25169,"activeCount":103},[25170],{"nctId":25130,"briefTitle":25131,"status":111,"phases":25171,"primaryCompletion":3314,"completion":3314,"start":7665,"enrollment":6352,"conditions":25172,"interventions":25173},[93],[13280,12981],[25119,25135,25136,25137],{"trials":25175,"activeCount":103},[],{"trials":25177,"activeCount":103},[],{"intervention":25137,"totalTrials":302,"cells":25179},{"EARLY_PHASE1":25180,"PHASE1":25182,"PHASE2":25184,"PHASE3":25186,"PHASE4":25192,"NA":25194},{"trials":25181,"activeCount":103},[],{"trials":25183,"activeCount":103},[],{"trials":25185,"activeCount":103},[],{"trials":25187,"activeCount":103},[25188],{"nctId":25130,"briefTitle":25131,"status":111,"phases":25189,"primaryCompletion":3314,"completion":3314,"start":7665,"enrollment":6352,"conditions":25190,"interventions":25191},[93],[13280,12981],[25119,25135,25136,25137],{"trials":25193,"activeCount":103},[],{"trials":25195,"activeCount":103},[],{"intervention":25197,"totalTrials":302,"cells":25198},"(PN-152,243)\u002F PN-196,444",{"EARLY_PHASE1":25199,"PHASE1":25201,"PHASE2":25203,"PHASE3":25205,"PHASE4":25214,"NA":25216},{"trials":25200,"activeCount":103},[],{"trials":25202,"activeCount":103},[],{"trials":25204,"activeCount":103},[],{"trials":25206,"activeCount":103},[25207],{"nctId":25208,"briefTitle":23642,"status":111,"phases":25209,"completion":3628,"start":25210,"enrollment":22897,"conditions":25211,"interventions":25213},"NCT00039910",[93],"2000-07",[8451,25212,23647],"Hodgkin Disease",[25197],{"trials":25215,"activeCount":103},[],{"trials":25217,"activeCount":103},[],{"intervention":18651,"totalTrials":302,"cells":25219},{"EARLY_PHASE1":25220,"PHASE1":25222,"PHASE2":25224,"PHASE3":25226,"PHASE4":25232,"NA":25234},{"trials":25221,"activeCount":103},[],{"trials":25223,"activeCount":103},[],{"trials":25225,"activeCount":103},[],{"trials":25227,"activeCount":103},[25228],{"nctId":18634,"briefTitle":18635,"status":111,"phases":25229,"primaryCompletion":18637,"completion":18638,"start":18639,"enrollment":18640,"conditions":25230,"interventions":25231},[93],[18642,1933,1591,18643,18644,18645,18646,18647,18648,18649],[18621,18605,18651,18652,18653],{"trials":25233,"activeCount":103},[],{"trials":25235,"activeCount":103},[],{"intervention":18652,"totalTrials":302,"cells":25237},{"EARLY_PHASE1":25238,"PHASE1":25240,"PHASE2":25242,"PHASE3":25244,"PHASE4":25250,"NA":25252},{"trials":25239,"activeCount":103},[],{"trials":25241,"activeCount":103},[],{"trials":25243,"activeCount":103},[],{"trials":25245,"activeCount":103},[25246],{"nctId":18634,"briefTitle":18635,"status":111,"phases":25247,"primaryCompletion":18637,"completion":18638,"start":18639,"enrollment":18640,"conditions":25248,"interventions":25249},[93],[18642,1933,1591,18643,18644,18645,18646,18647,18648,18649],[18621,18605,18651,18652,18653],{"trials":25251,"activeCount":103},[],{"trials":25253,"activeCount":103},[],{"intervention":18653,"totalTrials":302,"cells":25255},{"EARLY_PHASE1":25256,"PHASE1":25258,"PHASE2":25260,"PHASE3":25262,"PHASE4":25268,"NA":25270},{"trials":25257,"activeCount":103},[],{"trials":25259,"activeCount":103},[],{"trials":25261,"activeCount":103},[],{"trials":25263,"activeCount":103},[25264],{"nctId":18634,"briefTitle":18635,"status":111,"phases":25265,"primaryCompletion":18637,"completion":18638,"start":18639,"enrollment":18640,"conditions":25266,"interventions":25267},[93],[18642,1933,1591,18643,18644,18645,18646,18647,18648,18649],[18621,18605,18651,18652,18653],{"trials":25269,"activeCount":103},[],{"trials":25271,"activeCount":103},[],{"intervention":25273,"totalTrials":302,"cells":25274},"DIC075V",{"EARLY_PHASE1":25275,"PHASE1":25277,"PHASE2":25279,"PHASE3":25281,"PHASE4":25291,"NA":25293},{"trials":25276,"activeCount":103},[],{"trials":25278,"activeCount":103},[],{"trials":25280,"activeCount":103},[],{"trials":25282,"activeCount":103},[25283],{"nctId":25284,"briefTitle":25285,"status":111,"phases":25286,"primaryCompletion":25287,"completion":25287,"start":2422,"enrollment":25288,"conditions":25289,"interventions":25290},"NCT00726388","An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain",[93],"2009-05-08",1050,[11730],[25273],{"trials":25292,"activeCount":103},[],{"trials":25294,"activeCount":103},[],{"intervention":25296,"totalTrials":302,"cells":25297},"13-valent Pneumoccocal Conjugate Vaccine",{"EARLY_PHASE1":25298,"PHASE1":25300,"PHASE2":25302,"PHASE3":25304,"PHASE4":25312,"NA":25314},{"trials":25299,"activeCount":103},[],{"trials":25301,"activeCount":103},[],{"trials":25303,"activeCount":103},[],{"trials":25305,"activeCount":103},[25306],{"nctId":25307,"briefTitle":25308,"status":111,"phases":25309,"primaryCompletion":4680,"completion":4680,"start":6016,"enrollment":17515,"conditions":25310,"interventions":25311},"NCT00918580","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease",[93],[10925],[25296],{"trials":25313,"activeCount":103},[],{"trials":25315,"activeCount":103},[],{"intervention":25317,"totalTrials":302,"cells":25318},"Interferon Alfa",{"EARLY_PHASE1":25319,"PHASE1":25321,"PHASE2":25323,"PHASE3":25325,"PHASE4":25335,"NA":25337},{"trials":25320,"activeCount":103},[],{"trials":25322,"activeCount":103},[],{"trials":25324,"activeCount":103},[],{"trials":25326,"activeCount":103},[25327],{"nctId":25328,"briefTitle":25329,"status":111,"phases":25330,"primaryCompletion":3627,"completion":524,"start":11387,"enrollment":12156,"conditions":25331,"interventions":25332},"NCT00065468","Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma",[93],[919,4310],[25317,25333,25334],"CCI-779","Interferon Alfa and CCI-779",{"trials":25336,"activeCount":103},[],{"trials":25338,"activeCount":103},[],{"intervention":25333,"totalTrials":302,"cells":25340},{"EARLY_PHASE1":25341,"PHASE1":25343,"PHASE2":25345,"PHASE3":25347,"PHASE4":25353,"NA":25355},{"trials":25342,"activeCount":103},[],{"trials":25344,"activeCount":103},[],{"trials":25346,"activeCount":103},[],{"trials":25348,"activeCount":103},[25349],{"nctId":25328,"briefTitle":25329,"status":111,"phases":25350,"primaryCompletion":3627,"completion":524,"start":11387,"enrollment":12156,"conditions":25351,"interventions":25352},[93],[919,4310],[25317,25333,25334],{"trials":25354,"activeCount":103},[],{"trials":25356,"activeCount":103},[],{"intervention":25334,"totalTrials":302,"cells":25358},{"EARLY_PHASE1":25359,"PHASE1":25361,"PHASE2":25363,"PHASE3":25365,"PHASE4":25371,"NA":25373},{"trials":25360,"activeCount":103},[],{"trials":25362,"activeCount":103},[],{"trials":25364,"activeCount":103},[],{"trials":25366,"activeCount":103},[25367],{"nctId":25328,"briefTitle":25329,"status":111,"phases":25368,"primaryCompletion":3627,"completion":524,"start":11387,"enrollment":12156,"conditions":25369,"interventions":25370},[93],[919,4310],[25317,25333,25334],{"trials":25372,"activeCount":103},[],{"trials":25374,"activeCount":103},[],{"intervention":18009,"totalTrials":302,"cells":25376},{"EARLY_PHASE1":25377,"PHASE1":25379,"PHASE2":25381,"PHASE3":25383,"PHASE4":25389,"NA":25391},{"trials":25378,"activeCount":103},[],{"trials":25380,"activeCount":103},[],{"trials":25382,"activeCount":103},[],{"trials":25384,"activeCount":103},[25385],{"nctId":18000,"briefTitle":18001,"status":111,"phases":25386,"primaryCompletion":13669,"completion":3285,"start":18003,"enrollment":18004,"conditions":25387,"interventions":25388},[93],[18006],[18008,18009,18010,18008,18011],{"trials":25390,"activeCount":103},[],{"trials":25392,"activeCount":103},[],{"intervention":18062,"totalTrials":302,"cells":25394},{"EARLY_PHASE1":25395,"PHASE1":25397,"PHASE2":25399,"PHASE3":25401,"PHASE4":25407,"NA":25409},{"trials":25396,"activeCount":103},[],{"trials":25398,"activeCount":103},[],{"trials":25400,"activeCount":103},[],{"trials":25402,"activeCount":103},[25403],{"nctId":18055,"briefTitle":18056,"status":111,"phases":25404,"primaryCompletion":18058,"completion":18058,"start":18059,"enrollment":2240,"conditions":25405,"interventions":25406},[93],[6505],[18062,12291],{"trials":25408,"activeCount":103},[],{"trials":25410,"activeCount":103},[],{"intervention":13862,"totalTrials":302,"cells":25412},{"EARLY_PHASE1":25413,"PHASE1":25415,"PHASE2":25417,"PHASE3":25419,"PHASE4":25425,"NA":25427},{"trials":25414,"activeCount":103},[],{"trials":25416,"activeCount":103},[],{"trials":25418,"activeCount":103},[],{"trials":25420,"activeCount":103},[25421],{"nctId":13856,"briefTitle":13857,"status":168,"phases":25422,"primaryCompletion":6458,"completion":6458,"start":3073,"enrollment":7500,"conditions":25423,"interventions":25424},[93],[13860],[13862,13863,13864,13865,13863,13866],{"trials":25426,"activeCount":103},[],{"trials":25428,"activeCount":103},[],{"intervention":13864,"totalTrials":302,"cells":25430},{"EARLY_PHASE1":25431,"PHASE1":25433,"PHASE2":25435,"PHASE3":25437,"PHASE4":25443,"NA":25445},{"trials":25432,"activeCount":103},[],{"trials":25434,"activeCount":103},[],{"trials":25436,"activeCount":103},[],{"trials":25438,"activeCount":103},[25439],{"nctId":13856,"briefTitle":13857,"status":168,"phases":25440,"primaryCompletion":6458,"completion":6458,"start":3073,"enrollment":7500,"conditions":25441,"interventions":25442},[93],[13860],[13862,13863,13864,13865,13863,13866],{"trials":25444,"activeCount":103},[],{"trials":25446,"activeCount":103},[],{"intervention":13865,"totalTrials":302,"cells":25448},{"EARLY_PHASE1":25449,"PHASE1":25451,"PHASE2":25453,"PHASE3":25455,"PHASE4":25461,"NA":25463},{"trials":25450,"activeCount":103},[],{"trials":25452,"activeCount":103},[],{"trials":25454,"activeCount":103},[],{"trials":25456,"activeCount":103},[25457],{"nctId":13856,"briefTitle":13857,"status":168,"phases":25458,"primaryCompletion":6458,"completion":6458,"start":3073,"enrollment":7500,"conditions":25459,"interventions":25460},[93],[13860],[13862,13863,13864,13865,13863,13866],{"trials":25462,"activeCount":103},[],{"trials":25464,"activeCount":103},[],{"intervention":13866,"totalTrials":302,"cells":25466},{"EARLY_PHASE1":25467,"PHASE1":25469,"PHASE2":25471,"PHASE3":25473,"PHASE4":25479,"NA":25481},{"trials":25468,"activeCount":103},[],{"trials":25470,"activeCount":103},[],{"trials":25472,"activeCount":103},[],{"trials":25474,"activeCount":103},[25475],{"nctId":13856,"briefTitle":13857,"status":168,"phases":25476,"primaryCompletion":6458,"completion":6458,"start":3073,"enrollment":7500,"conditions":25477,"interventions":25478},[93],[13860],[13862,13863,13864,13865,13863,13866],{"trials":25480,"activeCount":103},[],{"trials":25482,"activeCount":103},[],{"intervention":4670,"totalTrials":302,"cells":25484},{"EARLY_PHASE1":25485,"PHASE1":25487,"PHASE2":25489,"PHASE3":25491,"PHASE4":25497,"NA":25499},{"trials":25486,"activeCount":103},[],{"trials":25488,"activeCount":103},[],{"trials":25490,"activeCount":103},[],{"trials":25492,"activeCount":103},[25493],{"nctId":4662,"briefTitle":4663,"status":111,"phases":25494,"primaryCompletion":4665,"completion":4666,"start":4667,"enrollment":4648,"conditions":25495,"interventions":25496},[93],[25],[1643,4670],{"trials":25498,"activeCount":103},[],{"trials":25500,"activeCount":103},[],{"intervention":25502,"totalTrials":302,"cells":25503},"Etoposide + cisplatin",{"EARLY_PHASE1":25504,"PHASE1":25506,"PHASE2":25508,"PHASE3":25510,"PHASE4":25520,"NA":25522},{"trials":25505,"activeCount":103},[],{"trials":25507,"activeCount":103},[],{"trials":25509,"activeCount":103},[],{"trials":25511,"activeCount":103},[25512],{"nctId":25513,"briefTitle":25514,"status":111,"phases":25515,"primaryCompletion":8154,"completion":8154,"start":4616,"enrollment":25516,"conditions":25517,"interventions":25518},"NCT00143455","Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer",[93],485,[8146],[25502,25519],"Irinotecan + cisplatin",{"trials":25521,"activeCount":103},[],{"trials":25523,"activeCount":103},[],{"intervention":25519,"totalTrials":302,"cells":25525},{"EARLY_PHASE1":25526,"PHASE1":25528,"PHASE2":25530,"PHASE3":25532,"PHASE4":25538,"NA":25540},{"trials":25527,"activeCount":103},[],{"trials":25529,"activeCount":103},[],{"trials":25531,"activeCount":103},[],{"trials":25533,"activeCount":103},[25534],{"nctId":25513,"briefTitle":25514,"status":111,"phases":25535,"primaryCompletion":8154,"completion":8154,"start":4616,"enrollment":25516,"conditions":25536,"interventions":25537},[93],[8146],[25502,25519],{"trials":25539,"activeCount":103},[],{"trials":25541,"activeCount":103},[],{"intervention":25543,"totalTrials":302,"cells":25544},"Parecoxib and placebo",{"EARLY_PHASE1":25545,"PHASE1":25547,"PHASE2":25549,"PHASE3":25551,"PHASE4":25559,"NA":25561},{"trials":25546,"activeCount":103},[],{"trials":25548,"activeCount":103},[],{"trials":25550,"activeCount":103},[],{"trials":25552,"activeCount":103},[25553],{"nctId":25554,"briefTitle":25555,"status":111,"phases":25556,"completion":14118,"start":7675,"enrollment":12763,"conditions":25557,"interventions":25558},"NCT00143169","Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain",[93],[11730],[25543],{"trials":25560,"activeCount":103},[],{"trials":25562,"activeCount":103},[],{"intervention":19445,"totalTrials":302,"cells":25564},{"EARLY_PHASE1":25565,"PHASE1":25567,"PHASE2":25569,"PHASE3":25571,"PHASE4":25577,"NA":25579},{"trials":25566,"activeCount":103},[],{"trials":25568,"activeCount":103},[],{"trials":25570,"activeCount":103},[],{"trials":25572,"activeCount":103},[25573],{"nctId":19440,"briefTitle":19441,"status":111,"phases":25574,"primaryCompletion":2450,"completion":2450,"start":2661,"enrollment":19223,"conditions":25575,"interventions":25576},[93],[34],[19445,19402],{"trials":25578,"activeCount":103},[],{"trials":25580,"activeCount":103},[],{"intervention":20611,"totalTrials":302,"cells":25582},{"EARLY_PHASE1":25583,"PHASE1":25585,"PHASE2":25587,"PHASE3":25589,"PHASE4":25595,"NA":25597},{"trials":25584,"activeCount":103},[],{"trials":25586,"activeCount":103},[],{"trials":25588,"activeCount":103},[],{"trials":25590,"activeCount":103},[25591],{"nctId":20604,"briefTitle":20605,"status":111,"phases":25592,"primaryCompletion":539,"completion":539,"start":12853,"enrollment":20607,"conditions":25593,"interventions":25594},[93],[20609],[20582,20601,20611],{"trials":25596,"activeCount":103},[],{"trials":25598,"activeCount":103},[],{"intervention":14085,"totalTrials":302,"cells":25600},{"EARLY_PHASE1":25601,"PHASE1":25603,"PHASE2":25605,"PHASE3":25607,"PHASE4":25613,"NA":25615},{"trials":25602,"activeCount":103},[],{"trials":25604,"activeCount":103},[],{"trials":25606,"activeCount":103},[],{"trials":25608,"activeCount":103},[25609],{"nctId":14080,"briefTitle":14081,"status":649,"phases":25610,"primaryCompletion":7571,"completion":7571,"start":12811,"enrollment":103,"conditions":25611,"interventions":25612},[93],[13463],[14085,14086,11071],{"trials":25614,"activeCount":103},[],{"trials":25616,"activeCount":103},[],{"intervention":14086,"totalTrials":302,"cells":25618},{"EARLY_PHASE1":25619,"PHASE1":25621,"PHASE2":25623,"PHASE3":25625,"PHASE4":25631,"NA":25633},{"trials":25620,"activeCount":103},[],{"trials":25622,"activeCount":103},[],{"trials":25624,"activeCount":103},[],{"trials":25626,"activeCount":103},[25627],{"nctId":14080,"briefTitle":14081,"status":649,"phases":25628,"primaryCompletion":7571,"completion":7571,"start":12811,"enrollment":103,"conditions":25629,"interventions":25630},[93],[13463],[14085,14086,11071],{"trials":25632,"activeCount":103},[],{"trials":25634,"activeCount":103},[],{"intervention":2971,"totalTrials":302,"cells":25636},{"EARLY_PHASE1":25637,"PHASE1":25639,"PHASE2":25641,"PHASE3":25643,"PHASE4":25649,"NA":25651},{"trials":25638,"activeCount":103},[],{"trials":25640,"activeCount":103},[],{"trials":25642,"activeCount":103},[],{"trials":25644,"activeCount":103},[25645],{"nctId":2961,"briefTitle":2962,"status":168,"phases":25646,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":25647,"interventions":25648},[93],[2966],[2968,2969,2969,2970,2971,2972,2973,2974,2975],{"trials":25650,"activeCount":103},[],{"trials":25652,"activeCount":103},[],{"intervention":2972,"totalTrials":302,"cells":25654},{"EARLY_PHASE1":25655,"PHASE1":25657,"PHASE2":25659,"PHASE3":25661,"PHASE4":25667,"NA":25669},{"trials":25656,"activeCount":103},[],{"trials":25658,"activeCount":103},[],{"trials":25660,"activeCount":103},[],{"trials":25662,"activeCount":103},[25663],{"nctId":2961,"briefTitle":2962,"status":168,"phases":25664,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":25665,"interventions":25666},[93],[2966],[2968,2969,2969,2970,2971,2972,2973,2974,2975],{"trials":25668,"activeCount":103},[],{"trials":25670,"activeCount":103},[],{"intervention":2973,"totalTrials":302,"cells":25672},{"EARLY_PHASE1":25673,"PHASE1":25675,"PHASE2":25677,"PHASE3":25679,"PHASE4":25685,"NA":25687},{"trials":25674,"activeCount":103},[],{"trials":25676,"activeCount":103},[],{"trials":25678,"activeCount":103},[],{"trials":25680,"activeCount":103},[25681],{"nctId":2961,"briefTitle":2962,"status":168,"phases":25682,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":25683,"interventions":25684},[93],[2966],[2968,2969,2969,2970,2971,2972,2973,2974,2975],{"trials":25686,"activeCount":103},[],{"trials":25688,"activeCount":103},[],{"intervention":2974,"totalTrials":302,"cells":25690},{"EARLY_PHASE1":25691,"PHASE1":25693,"PHASE2":25695,"PHASE3":25697,"PHASE4":25703,"NA":25705},{"trials":25692,"activeCount":103},[],{"trials":25694,"activeCount":103},[],{"trials":25696,"activeCount":103},[],{"trials":25698,"activeCount":103},[25699],{"nctId":2961,"briefTitle":2962,"status":168,"phases":25700,"primaryCompletion":523,"completion":523,"start":2964,"enrollment":350,"conditions":25701,"interventions":25702},[93],[2966],[2968,2969,2969,2970,2971,2972,2973,2974,2975],{"trials":25704,"activeCount":103},[],{"trials":25706,"activeCount":103},[],{"intervention":2918,"totalTrials":302,"cells":25708},{"EARLY_PHASE1":25709,"PHASE1":25711,"PHASE2":25713,"PHASE3":25715,"PHASE4":25721,"NA":25723},{"trials":25710,"activeCount":103},[],{"trials":25712,"activeCount":103},[],{"trials":25714,"activeCount":103},[],{"trials":25716,"activeCount":103},[25717],{"nctId":2908,"briefTitle":2909,"status":168,"phases":25718,"primaryCompletion":2911,"completion":2911,"start":2912,"enrollment":350,"conditions":25719,"interventions":25720},[93],[2914],[663,2916,2917,2918,1764,1767],{"trials":25722,"activeCount":103},[],{"trials":25724,"activeCount":103},[],{"intervention":19416,"totalTrials":302,"cells":25726},{"EARLY_PHASE1":25727,"PHASE1":25729,"PHASE2":25731,"PHASE3":25733,"PHASE4":25739,"NA":25741},{"trials":25728,"activeCount":103},[],{"trials":25730,"activeCount":103},[],{"trials":25732,"activeCount":103},[],{"trials":25734,"activeCount":103},[25735],{"nctId":19411,"briefTitle":19405,"status":111,"phases":25736,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":19413,"conditions":25737,"interventions":25738},[93],[34],[19386,19416],{"trials":25740,"activeCount":103},[],{"trials":25742,"activeCount":103},[],{"intervention":18873,"totalTrials":302,"cells":25744},{"EARLY_PHASE1":25745,"PHASE1":25747,"PHASE2":25749,"PHASE3":25751,"PHASE4":25757,"NA":25759},{"trials":25746,"activeCount":103},[],{"trials":25748,"activeCount":103},[],{"trials":25750,"activeCount":103},[],{"trials":25752,"activeCount":103},[25753],{"nctId":18865,"briefTitle":18866,"status":111,"phases":25754,"primaryCompletion":18868,"completion":18868,"start":18869,"enrollment":18870,"conditions":25755,"interventions":25756},[93],[18852,18851],[18824,18873],{"trials":25758,"activeCount":103},[],{"trials":25760,"activeCount":103},[],{"intervention":25762,"totalTrials":302,"cells":25763},"CP 690,550 5 mg",{"EARLY_PHASE1":25764,"PHASE1":25766,"PHASE2":25768,"PHASE3":25770,"PHASE4":25781,"NA":25783},{"trials":25765,"activeCount":103},[],{"trials":25767,"activeCount":103},[],{"trials":25769,"activeCount":103},[],{"trials":25771,"activeCount":103},[25772],{"nctId":25773,"briefTitle":25774,"status":111,"phases":25775,"primaryCompletion":4590,"completion":4590,"start":8252,"enrollment":25776,"conditions":25777,"interventions":25778},"NCT01241591","A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis",[93],1101,[4401],[25762,25779,25780],"CP 690,550 10 mg","Etanercept 50 mg",{"trials":25782,"activeCount":103},[],{"trials":25784,"activeCount":103},[],{"intervention":25779,"totalTrials":302,"cells":25786},{"EARLY_PHASE1":25787,"PHASE1":25789,"PHASE2":25791,"PHASE3":25793,"PHASE4":25799,"NA":25801},{"trials":25788,"activeCount":103},[],{"trials":25790,"activeCount":103},[],{"trials":25792,"activeCount":103},[],{"trials":25794,"activeCount":103},[25795],{"nctId":25773,"briefTitle":25774,"status":111,"phases":25796,"primaryCompletion":4590,"completion":4590,"start":8252,"enrollment":25776,"conditions":25797,"interventions":25798},[93],[4401],[25762,25779,25780],{"trials":25800,"activeCount":103},[],{"trials":25802,"activeCount":103},[],{"intervention":25780,"totalTrials":302,"cells":25804},{"EARLY_PHASE1":25805,"PHASE1":25807,"PHASE2":25809,"PHASE3":25811,"PHASE4":25817,"NA":25819},{"trials":25806,"activeCount":103},[],{"trials":25808,"activeCount":103},[],{"trials":25810,"activeCount":103},[],{"trials":25812,"activeCount":103},[25813],{"nctId":25773,"briefTitle":25774,"status":111,"phases":25814,"primaryCompletion":4590,"completion":4590,"start":8252,"enrollment":25776,"conditions":25815,"interventions":25816},[93],[4401],[25762,25779,25780],{"trials":25818,"activeCount":103},[],{"trials":25820,"activeCount":103},[],{"intervention":25822,"totalTrials":302,"cells":25823},"lecozotan SR",{"EARLY_PHASE1":25824,"PHASE1":25826,"PHASE2":25828,"PHASE3":25830,"PHASE4":25838,"NA":25840},{"trials":25825,"activeCount":103},[],{"trials":25827,"activeCount":103},[],{"trials":25829,"activeCount":103},[],{"trials":25831,"activeCount":103},[25832],{"nctId":25833,"briefTitle":25834,"status":111,"phases":25835,"primaryCompletion":3839,"completion":3839,"start":6457,"enrollment":8827,"conditions":25836,"interventions":25837},"NCT00277810","Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease",[92,93],[13445],[25822],{"trials":25839,"activeCount":103},[],{"trials":25841,"activeCount":103},[],{"intervention":25843,"totalTrials":302,"cells":25844},"CP 751,871",{"EARLY_PHASE1":25845,"PHASE1":25847,"PHASE2":25849,"PHASE3":25851,"PHASE4":25862,"NA":25864},{"trials":25846,"activeCount":103},[],{"trials":25848,"activeCount":103},[],{"trials":25850,"activeCount":103},[],{"trials":25852,"activeCount":103},[25853],{"nctId":25854,"briefTitle":25855,"status":168,"phases":25856,"primaryCompletion":524,"completion":3334,"start":2884,"enrollment":25857,"conditions":25858,"interventions":25860},"NCT00673049","Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer",[93],583,[9437,376,9435,25859],"Carcinoma, Adenosquamous Cell",[25843,25861,25861],"Erlotinib",{"trials":25863,"activeCount":103},[],{"trials":25865,"activeCount":103},[],{"intervention":11632,"totalTrials":302,"cells":25867},{"EARLY_PHASE1":25868,"PHASE1":25870,"PHASE2":25872,"PHASE3":25874,"PHASE4":25880,"NA":25882},{"trials":25869,"activeCount":103},[],{"trials":25871,"activeCount":103},[],{"trials":25873,"activeCount":103},[],{"trials":25875,"activeCount":103},[25876],{"nctId":11623,"briefTitle":11624,"status":111,"phases":25877,"primaryCompletion":11626,"completion":11627,"start":11628,"enrollment":11629,"conditions":25878,"interventions":25879},[93],[10940,10925],[11538,11632],{"trials":25881,"activeCount":103},[],{"trials":25883,"activeCount":103},[],{"intervention":12036,"totalTrials":302,"cells":25885},{"EARLY_PHASE1":25886,"PHASE1":25888,"PHASE2":25890,"PHASE3":25892,"PHASE4":25898,"NA":25900},{"trials":25887,"activeCount":103},[],{"trials":25889,"activeCount":103},[],{"trials":25891,"activeCount":103},[],{"trials":25893,"activeCount":103},[25894],{"nctId":12027,"briefTitle":12028,"status":168,"phases":25895,"primaryCompletion":4656,"completion":10912,"start":12030,"enrollment":7388,"conditions":25896,"interventions":25897},[93],[12032,12033],[12035,12036,12007,12037,12035,12036,12007],{"trials":25899,"activeCount":103},[],{"trials":25901,"activeCount":103},[],{"intervention":25903,"totalTrials":302,"cells":25904},"amoxicillin\u002Fclavulanate postassium",{"EARLY_PHASE1":25905,"PHASE1":25907,"PHASE2":25909,"PHASE3":25911,"PHASE4":25921,"NA":25923},{"trials":25906,"activeCount":103},[],{"trials":25908,"activeCount":103},[],{"trials":25910,"activeCount":103},[],{"trials":25912,"activeCount":103},[25913],{"nctId":25914,"briefTitle":25915,"status":111,"phases":25916,"completion":11395,"start":3073,"enrollment":25917,"conditions":25918,"interventions":25920},"NCT00643292","A Single, High-Dose Azithromycin Extended Release (60 mg\u002Fkg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent\u002FRecurrent Ear Infections",[93],902,[25919],"Acute Otitis Media",[25903,19967],{"trials":25922,"activeCount":103},[],{"trials":25924,"activeCount":103},[],{"intervention":20981,"totalTrials":302,"cells":25926},{"EARLY_PHASE1":25927,"PHASE1":25929,"PHASE2":25931,"PHASE3":25933,"PHASE4":25939,"NA":25941},{"trials":25928,"activeCount":103},[],{"trials":25930,"activeCount":103},[],{"trials":25932,"activeCount":103},[],{"trials":25934,"activeCount":103},[25935],{"nctId":20973,"briefTitle":20974,"status":111,"phases":25936,"primaryCompletion":20976,"completion":20976,"start":20977,"enrollment":18630,"conditions":25937,"interventions":25938},[93],[1589],[20980,20981],{"trials":25940,"activeCount":103},[],{"trials":25942,"activeCount":103},[],{"intervention":5976,"totalTrials":302,"cells":25944},{"EARLY_PHASE1":25945,"PHASE1":25947,"PHASE2":25949,"PHASE3":25951,"PHASE4":25957,"NA":25959},{"trials":25946,"activeCount":103},[],{"trials":25948,"activeCount":103},[],{"trials":25950,"activeCount":103},[],{"trials":25952,"activeCount":103},[25953],{"nctId":5967,"briefTitle":5968,"status":111,"phases":25954,"primaryCompletion":5970,"completion":5971,"start":5972,"enrollment":5973,"conditions":25955,"interventions":25956},[93],[25,5932,5933],[5912,5976],{"trials":25958,"activeCount":103},[],{"trials":25960,"activeCount":103},[],{"intervention":12322,"totalTrials":302,"cells":25962},{"EARLY_PHASE1":25963,"PHASE1":25965,"PHASE2":25967,"PHASE3":25969,"PHASE4":25975,"NA":25977},{"trials":25964,"activeCount":103},[],{"trials":25966,"activeCount":103},[],{"trials":25968,"activeCount":103},[],{"trials":25970,"activeCount":103},[25971],{"nctId":12314,"briefTitle":12315,"status":111,"phases":25972,"primaryCompletion":7387,"completion":7387,"start":6208,"enrollment":12317,"conditions":25973,"interventions":25974},[93],[12319,12320],[12322,12281],{"trials":25976,"activeCount":103},[],{"trials":25978,"activeCount":103},[],{"intervention":25980,"totalTrials":302,"cells":25981},"Investigator's choice",{"EARLY_PHASE1":25982,"PHASE1":25984,"PHASE2":25986,"PHASE3":25988,"PHASE4":25996,"NA":25998},{"trials":25983,"activeCount":103},[],{"trials":25985,"activeCount":103},[],{"trials":25987,"activeCount":103},[],{"trials":25989,"activeCount":103},[25990],{"nctId":25991,"briefTitle":25992,"status":111,"phases":25993,"primaryCompletion":11314,"completion":3601,"start":11829,"enrollment":13935,"conditions":25994,"interventions":25995},"NCT00117598","Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)",[93],[2937],[4352,4352,25980],{"trials":25997,"activeCount":103},[],{"trials":25999,"activeCount":103},[],{"intervention":19981,"totalTrials":302,"cells":26001},{"EARLY_PHASE1":26002,"PHASE1":26004,"PHASE2":26006,"PHASE3":26008,"PHASE4":26014,"NA":26016},{"trials":26003,"activeCount":103},[],{"trials":26005,"activeCount":103},[],{"trials":26007,"activeCount":103},[],{"trials":26009,"activeCount":103},[26010],{"nctId":19976,"briefTitle":19977,"status":111,"phases":26011,"completion":4398,"start":12607,"enrollment":17600,"conditions":26012,"interventions":26013},[93],[9107],[19981,19950],{"trials":26015,"activeCount":103},[],{"trials":26017,"activeCount":103},[],{"intervention":26019,"totalTrials":302,"cells":26020},"olmesartan alone or in combination with hydrochlorothiazide",{"EARLY_PHASE1":26021,"PHASE1":26023,"PHASE2":26025,"PHASE3":26027,"PHASE4":26036,"NA":26038},{"trials":26022,"activeCount":103},[],{"trials":26024,"activeCount":103},[],{"trials":26026,"activeCount":103},[],{"trials":26028,"activeCount":103},[26029],{"nctId":26030,"briefTitle":26031,"status":111,"phases":26032,"completion":12395,"start":6017,"enrollment":13118,"conditions":26033,"interventions":26035},"NCT00139698","Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension",[93],[26034],"Essential Hypertension",[26019],{"trials":26037,"activeCount":103},[],{"trials":26039,"activeCount":103},[],{"intervention":26041,"totalTrials":302,"cells":26042},"Clozapine",{"EARLY_PHASE1":26043,"PHASE1":26045,"PHASE2":26047,"PHASE3":26049,"PHASE4":26058,"NA":26060},{"trials":26044,"activeCount":103},[],{"trials":26046,"activeCount":103},[],{"trials":26048,"activeCount":103},[],{"trials":26050,"activeCount":103},[26051],{"nctId":26052,"briefTitle":26053,"status":111,"phases":26054,"completion":7675,"start":3073,"enrollment":26055,"conditions":26056,"interventions":26057},"NCT00649844","A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs",[93],147,[12632],[26041,12666],{"trials":26059,"activeCount":103},[],{"trials":26061,"activeCount":103},[],{"intervention":26063,"totalTrials":302,"cells":26064},"VFEND® I.V.,",{"EARLY_PHASE1":26065,"PHASE1":26067,"PHASE2":26069,"PHASE3":26071,"PHASE4":26083,"NA":26085},{"trials":26066,"activeCount":103},[],{"trials":26068,"activeCount":103},[],{"trials":26070,"activeCount":103},[],{"trials":26072,"activeCount":103},[26073],{"nctId":26074,"briefTitle":26075,"status":111,"phases":26076,"completion":2642,"start":26077,"enrollment":26078,"conditions":26079,"interventions":26080},"NCT00163111","A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.",[93],"1998-09",412,[15545],[26063,26081,26082],"Conventional amphotericin B","Diflucan IV,",{"trials":26084,"activeCount":103},[],{"trials":26086,"activeCount":103},[],{"intervention":26081,"totalTrials":302,"cells":26088},{"EARLY_PHASE1":26089,"PHASE1":26091,"PHASE2":26093,"PHASE3":26095,"PHASE4":26101,"NA":26103},{"trials":26090,"activeCount":103},[],{"trials":26092,"activeCount":103},[],{"trials":26094,"activeCount":103},[],{"trials":26096,"activeCount":103},[26097],{"nctId":26074,"briefTitle":26075,"status":111,"phases":26098,"completion":2642,"start":26077,"enrollment":26078,"conditions":26099,"interventions":26100},[93],[15545],[26063,26081,26082],{"trials":26102,"activeCount":103},[],{"trials":26104,"activeCount":103},[],{"intervention":26082,"totalTrials":302,"cells":26106},{"EARLY_PHASE1":26107,"PHASE1":26109,"PHASE2":26111,"PHASE3":26113,"PHASE4":26119,"NA":26121},{"trials":26108,"activeCount":103},[],{"trials":26110,"activeCount":103},[],{"trials":26112,"activeCount":103},[],{"trials":26114,"activeCount":103},[26115],{"nctId":26074,"briefTitle":26075,"status":111,"phases":26116,"completion":2642,"start":26077,"enrollment":26078,"conditions":26117,"interventions":26118},[93],[15545],[26063,26081,26082],{"trials":26120,"activeCount":103},[],{"trials":26122,"activeCount":103},[],{"intervention":26124,"totalTrials":302,"cells":26125},"Parecoxib Sodium\u002FValdecoxib",{"EARLY_PHASE1":26126,"PHASE1":26128,"PHASE2":26130,"PHASE3":26132,"PHASE4":26141,"NA":26143},{"trials":26127,"activeCount":103},[],{"trials":26129,"activeCount":103},[],{"trials":26131,"activeCount":103},[],{"trials":26133,"activeCount":103},[26134],{"nctId":26135,"briefTitle":26136,"status":111,"phases":26137,"completion":11666,"start":3073,"enrollment":26138,"conditions":26139,"interventions":26140},"NCT00636064","A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery",[93],1671,[34],[26124],{"trials":26142,"activeCount":103},[],{"trials":26144,"activeCount":103},[],{"intervention":26146,"totalTrials":302,"cells":26147},"Zavegepant 10 mg",{"EARLY_PHASE1":26148,"PHASE1":26150,"PHASE2":26152,"PHASE3":26154,"PHASE4":26164,"NA":26166},{"trials":26149,"activeCount":103},[],{"trials":26151,"activeCount":103},[],{"trials":26153,"activeCount":103},[],{"trials":26155,"activeCount":103},[26156],{"nctId":26157,"briefTitle":26158,"status":649,"phases":26159,"primaryCompletion":26160,"completion":26160,"start":26161,"enrollment":103,"conditions":26162,"interventions":26163},"NCT06103734","A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants",[93],"2027-08-02","2025-09-15",[117],[26146],{"trials":26165,"activeCount":103},[],{"trials":26167,"activeCount":103},[],{"intervention":26169,"totalTrials":302,"cells":26170},"MERREM I.V. 2g as a 3 hour infusion every 8 hours",{"EARLY_PHASE1":26171,"PHASE1":26173,"PHASE2":26175,"PHASE3":26177,"PHASE4":26189,"NA":26191},{"trials":26172,"activeCount":103},[],{"trials":26174,"activeCount":103},[],{"trials":26176,"activeCount":103},[],{"trials":26178,"activeCount":103},[26179],{"nctId":26180,"briefTitle":26181,"status":111,"phases":26182,"primaryCompletion":7675,"completion":7675,"start":13295,"enrollment":1893,"conditions":26183,"interventions":26184},"NCT00050401","Ventilator-Associated Pneumonia\u002FHospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support",[93],[9107],[26169,26185,26186,26187,26188],"vancomycin I.V. 1 g every 12 hours","tobramycin I.V. 5 mg\u002Fkg every 24 hours","MERREM I.V. 1g as a 30 minute infusion every 8 hours","MERREM I.V. 500 mg as a 3 hour infusion every 8 hours",{"trials":26190,"activeCount":103},[],{"trials":26192,"activeCount":103},[],{"intervention":26185,"totalTrials":302,"cells":26194},{"EARLY_PHASE1":26195,"PHASE1":26197,"PHASE2":26199,"PHASE3":26201,"PHASE4":26207,"NA":26209},{"trials":26196,"activeCount":103},[],{"trials":26198,"activeCount":103},[],{"trials":26200,"activeCount":103},[],{"trials":26202,"activeCount":103},[26203],{"nctId":26180,"briefTitle":26181,"status":111,"phases":26204,"primaryCompletion":7675,"completion":7675,"start":13295,"enrollment":1893,"conditions":26205,"interventions":26206},[93],[9107],[26169,26185,26186,26187,26188],{"trials":26208,"activeCount":103},[],{"trials":26210,"activeCount":103},[],{"intervention":26186,"totalTrials":302,"cells":26212},{"EARLY_PHASE1":26213,"PHASE1":26215,"PHASE2":26217,"PHASE3":26219,"PHASE4":26225,"NA":26227},{"trials":26214,"activeCount":103},[],{"trials":26216,"activeCount":103},[],{"trials":26218,"activeCount":103},[],{"trials":26220,"activeCount":103},[26221],{"nctId":26180,"briefTitle":26181,"status":111,"phases":26222,"primaryCompletion":7675,"completion":7675,"start":13295,"enrollment":1893,"conditions":26223,"interventions":26224},[93],[9107],[26169,26185,26186,26187,26188],{"trials":26226,"activeCount":103},[],{"trials":26228,"activeCount":103},[],{"intervention":26187,"totalTrials":302,"cells":26230},{"EARLY_PHASE1":26231,"PHASE1":26233,"PHASE2":26235,"PHASE3":26237,"PHASE4":26243,"NA":26245},{"trials":26232,"activeCount":103},[],{"trials":26234,"activeCount":103},[],{"trials":26236,"activeCount":103},[],{"trials":26238,"activeCount":103},[26239],{"nctId":26180,"briefTitle":26181,"status":111,"phases":26240,"primaryCompletion":7675,"completion":7675,"start":13295,"enrollment":1893,"conditions":26241,"interventions":26242},[93],[9107],[26169,26185,26186,26187,26188],{"trials":26244,"activeCount":103},[],{"trials":26246,"activeCount":103},[],{"intervention":26188,"totalTrials":302,"cells":26248},{"EARLY_PHASE1":26249,"PHASE1":26251,"PHASE2":26253,"PHASE3":26255,"PHASE4":26261,"NA":26263},{"trials":26250,"activeCount":103},[],{"trials":26252,"activeCount":103},[],{"trials":26254,"activeCount":103},[],{"trials":26256,"activeCount":103},[26257],{"nctId":26180,"briefTitle":26181,"status":111,"phases":26258,"primaryCompletion":7675,"completion":7675,"start":13295,"enrollment":1893,"conditions":26259,"interventions":26260},[93],[9107],[26169,26185,26186,26187,26188],{"trials":26262,"activeCount":103},[],{"trials":26264,"activeCount":103},[],{"intervention":26266,"totalTrials":302,"cells":26267},"Vanquix Auto-Injector",{"EARLY_PHASE1":26268,"PHASE1":26270,"PHASE2":26272,"PHASE3":26274,"PHASE4":26287,"NA":26289},{"trials":26269,"activeCount":103},[],{"trials":26271,"activeCount":103},[],{"trials":26273,"activeCount":103},[],{"trials":26275,"activeCount":103},[26276],{"nctId":26277,"briefTitle":26278,"status":111,"phases":26279,"primaryCompletion":7971,"completion":7971,"start":2662,"enrollment":1539,"conditions":26280,"interventions":26286},"NCT00319501","Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.",[93],[26281,26282,26283,26284,26285],"Seizures","Epilepsies, Partial","Epilepsy, Complex Partial","Epilepsy, Generalized","Epilepsy",[26266],{"trials":26288,"activeCount":103},[],{"trials":26290,"activeCount":103},[],{"intervention":6509,"totalTrials":302,"cells":26292},{"EARLY_PHASE1":26293,"PHASE1":26295,"PHASE2":26297,"PHASE3":26299,"PHASE4":26305,"NA":26307},{"trials":26294,"activeCount":103},[],{"trials":26296,"activeCount":103},[],{"trials":26298,"activeCount":103},[],{"trials":26300,"activeCount":103},[26301],{"nctId":6499,"briefTitle":6500,"status":111,"phases":26302,"primaryCompletion":2079,"completion":2079,"start":6502,"enrollment":6503,"conditions":26303,"interventions":26304},[93],[6505,6506,6507],[6470,6509,6510,6511],{"trials":26306,"activeCount":103},[],{"trials":26308,"activeCount":103},[],{"intervention":6510,"totalTrials":302,"cells":26310},{"EARLY_PHASE1":26311,"PHASE1":26313,"PHASE2":26315,"PHASE3":26317,"PHASE4":26323,"NA":26325},{"trials":26312,"activeCount":103},[],{"trials":26314,"activeCount":103},[],{"trials":26316,"activeCount":103},[],{"trials":26318,"activeCount":103},[26319],{"nctId":6499,"briefTitle":6500,"status":111,"phases":26320,"primaryCompletion":2079,"completion":2079,"start":6502,"enrollment":6503,"conditions":26321,"interventions":26322},[93],[6505,6506,6507],[6470,6509,6510,6511],{"trials":26324,"activeCount":103},[],{"trials":26326,"activeCount":103},[],{"intervention":6511,"totalTrials":302,"cells":26328},{"EARLY_PHASE1":26329,"PHASE1":26331,"PHASE2":26333,"PHASE3":26335,"PHASE4":26341,"NA":26343},{"trials":26330,"activeCount":103},[],{"trials":26332,"activeCount":103},[],{"trials":26334,"activeCount":103},[],{"trials":26336,"activeCount":103},[26337],{"nctId":6499,"briefTitle":6500,"status":111,"phases":26338,"primaryCompletion":2079,"completion":2079,"start":6502,"enrollment":6503,"conditions":26339,"interventions":26340},[93],[6505,6506,6507],[6470,6509,6510,6511],{"trials":26342,"activeCount":103},[],{"trials":26344,"activeCount":103},[],{"intervention":8175,"totalTrials":302,"cells":26346},{"EARLY_PHASE1":26347,"PHASE1":26349,"PHASE2":26351,"PHASE3":26353,"PHASE4":26359,"NA":26361},{"trials":26348,"activeCount":103},[],{"trials":26350,"activeCount":103},[],{"trials":26352,"activeCount":103},[],{"trials":26354,"activeCount":103},[26355],{"nctId":8167,"briefTitle":8168,"status":168,"phases":26356,"primaryCompletion":3839,"completion":3839,"start":8170,"enrollment":8171,"conditions":26357,"interventions":26358},[93],[376],[1770,1764,8174,1770,8175],{"trials":26360,"activeCount":103},[],{"trials":26362,"activeCount":103},[],{"intervention":26364,"totalTrials":302,"cells":26365},"Bazedoxifene Acetate",{"EARLY_PHASE1":26366,"PHASE1":26368,"PHASE2":26370,"PHASE3":26372,"PHASE4":26381,"NA":26383},{"trials":26367,"activeCount":103},[],{"trials":26369,"activeCount":103},[],{"trials":26371,"activeCount":103},[],{"trials":26373,"activeCount":103},[26374],{"nctId":26375,"briefTitle":26376,"status":111,"phases":26377,"primaryCompletion":560,"completion":560,"start":19543,"enrollment":26378,"conditions":26379,"interventions":26380},"NCT00205777","Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women",[93],7609,[23074],[26364],{"trials":26382,"activeCount":103},[],{"trials":26384,"activeCount":103},[],{"intervention":26386,"totalTrials":302,"cells":26387},"Chemotherapy + avelumab followed by avelumab + talazoparib",{"EARLY_PHASE1":26388,"PHASE1":26390,"PHASE2":26392,"PHASE3":26394,"PHASE4":26406,"NA":26408},{"trials":26389,"activeCount":103},[],{"trials":26391,"activeCount":103},[],{"trials":26393,"activeCount":103},[],{"trials":26395,"activeCount":103},[26396],{"nctId":26397,"briefTitle":26398,"status":168,"phases":26399,"primaryCompletion":26400,"completion":26400,"start":1342,"enrollment":26401,"conditions":26402,"interventions":26403},"NCT03642132","Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)",[93],"2021-12-22",79,[1653],[26386,26404,26405],"Chemotherapy followed by talazoparib maintenance","Chemotherapy + bevacizumab followed by bevacizumab",{"trials":26407,"activeCount":103},[],{"trials":26409,"activeCount":103},[],{"intervention":26404,"totalTrials":302,"cells":26411},{"EARLY_PHASE1":26412,"PHASE1":26414,"PHASE2":26416,"PHASE3":26418,"PHASE4":26424,"NA":26426},{"trials":26413,"activeCount":103},[],{"trials":26415,"activeCount":103},[],{"trials":26417,"activeCount":103},[],{"trials":26419,"activeCount":103},[26420],{"nctId":26397,"briefTitle":26398,"status":168,"phases":26421,"primaryCompletion":26400,"completion":26400,"start":1342,"enrollment":26401,"conditions":26422,"interventions":26423},[93],[1653],[26386,26404,26405],{"trials":26425,"activeCount":103},[],{"trials":26427,"activeCount":103},[],{"intervention":26405,"totalTrials":302,"cells":26429},{"EARLY_PHASE1":26430,"PHASE1":26432,"PHASE2":26434,"PHASE3":26436,"PHASE4":26442,"NA":26444},{"trials":26431,"activeCount":103},[],{"trials":26433,"activeCount":103},[],{"trials":26435,"activeCount":103},[],{"trials":26437,"activeCount":103},[26438],{"nctId":26397,"briefTitle":26398,"status":168,"phases":26439,"primaryCompletion":26400,"completion":26400,"start":1342,"enrollment":26401,"conditions":26440,"interventions":26441},[93],[1653],[26386,26404,26405],{"trials":26443,"activeCount":103},[],{"trials":26445,"activeCount":103},[],{"intervention":11036,"totalTrials":302,"cells":26447},{"EARLY_PHASE1":26448,"PHASE1":26450,"PHASE2":26452,"PHASE3":26454,"PHASE4":26460,"NA":26462},{"trials":26449,"activeCount":103},[],{"trials":26451,"activeCount":103},[],{"trials":26453,"activeCount":103},[],{"trials":26455,"activeCount":103},[26456],{"nctId":11030,"briefTitle":11031,"status":111,"phases":26457,"primaryCompletion":4531,"completion":4531,"start":4636,"enrollment":11033,"conditions":26458,"interventions":26459},[93],[10940],[10916,11036],{"trials":26461,"activeCount":103},[],{"trials":26463,"activeCount":103},[],{"intervention":26465,"totalTrials":302,"cells":26466},"Oxacillin",{"EARLY_PHASE1":26467,"PHASE1":26469,"PHASE2":26471,"PHASE3":26473,"PHASE4":26484,"NA":26486},{"trials":26468,"activeCount":103},[],{"trials":26470,"activeCount":103},[],{"trials":26472,"activeCount":103},[],{"trials":26474,"activeCount":103},[26475],{"nctId":26476,"briefTitle":26477,"status":111,"phases":26478,"completion":11417,"start":3074,"enrollment":26479,"conditions":26480,"interventions":26481},"NCT00037050","Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria",[93],739,[19825,23867,15676],[26482,19510,26465,26483],"Linezolid","Dicloxacillin",{"trials":26485,"activeCount":103},[],{"trials":26487,"activeCount":103},[],{"intervention":26483,"totalTrials":302,"cells":26489},{"EARLY_PHASE1":26490,"PHASE1":26492,"PHASE2":26494,"PHASE3":26496,"PHASE4":26502,"NA":26504},{"trials":26491,"activeCount":103},[],{"trials":26493,"activeCount":103},[],{"trials":26495,"activeCount":103},[],{"trials":26497,"activeCount":103},[26498],{"nctId":26476,"briefTitle":26477,"status":111,"phases":26499,"completion":11417,"start":3074,"enrollment":26479,"conditions":26500,"interventions":26501},[93],[19825,23867,15676],[26482,19510,26465,26483],{"trials":26503,"activeCount":103},[],{"trials":26505,"activeCount":103},[],{"intervention":26507,"totalTrials":302,"cells":26508},"levetiracetam",{"EARLY_PHASE1":26509,"PHASE1":26511,"PHASE2":26513,"PHASE3":26515,"PHASE4":26524,"NA":26526},{"trials":26510,"activeCount":103},[],{"trials":26512,"activeCount":103},[],{"trials":26514,"activeCount":103},[],{"trials":26516,"activeCount":103},[26517],{"nctId":26518,"briefTitle":26519,"status":111,"phases":26520,"primaryCompletion":113,"completion":113,"start":11609,"enrollment":2337,"conditions":26521,"interventions":26523},"NCT00537238","Pregabalin Versus Levetiracetam In Partial Seizures",[93],[26522],"Partial Seizures",[21451,26507],{"trials":26525,"activeCount":103},[],{"trials":26527,"activeCount":103},[],{"intervention":11505,"totalTrials":302,"cells":26529},{"EARLY_PHASE1":26530,"PHASE1":26532,"PHASE2":26534,"PHASE3":26536,"PHASE4":26542,"NA":26544},{"trials":26531,"activeCount":103},[],{"trials":26533,"activeCount":103},[],{"trials":26535,"activeCount":103},[],{"trials":26537,"activeCount":103},[26538],{"nctId":11497,"briefTitle":11498,"status":111,"phases":26539,"primaryCompletion":11500,"completion":11500,"start":11501,"enrollment":11502,"conditions":26540,"interventions":26541},[93],[34],[11505,11072],{"trials":26543,"activeCount":103},[],{"trials":26545,"activeCount":103},[],{"intervention":26547,"totalTrials":302,"cells":26548},"RSVpreF MDV",{"EARLY_PHASE1":26549,"PHASE1":26551,"PHASE2":26553,"PHASE3":26555,"PHASE4":26565,"NA":26567},{"trials":26550,"activeCount":103},[],{"trials":26552,"activeCount":103},[],{"trials":26554,"activeCount":103},[],{"trials":26556,"activeCount":103},[26557],{"nctId":26558,"briefTitle":26559,"status":111,"phases":26560,"primaryCompletion":26561,"completion":26561,"start":1457,"enrollment":2190,"conditions":26562,"interventions":26563},"NCT06473519","A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.",[93],"2024-09-20",[3809],[26547,26564],"RSVpreF SDV",{"trials":26566,"activeCount":103},[],{"trials":26568,"activeCount":103},[],{"intervention":26564,"totalTrials":302,"cells":26570},{"EARLY_PHASE1":26571,"PHASE1":26573,"PHASE2":26575,"PHASE3":26577,"PHASE4":26583,"NA":26585},{"trials":26572,"activeCount":103},[],{"trials":26574,"activeCount":103},[],{"trials":26576,"activeCount":103},[],{"trials":26578,"activeCount":103},[26579],{"nctId":26558,"briefTitle":26559,"status":111,"phases":26580,"primaryCompletion":26561,"completion":26561,"start":1457,"enrollment":2190,"conditions":26581,"interventions":26582},[93],[3809],[26547,26564],{"trials":26584,"activeCount":103},[],{"trials":26586,"activeCount":103},[],{"intervention":26588,"totalTrials":302,"cells":26589},"PF-06651600 Induction Dose",{"EARLY_PHASE1":26590,"PHASE1":26592,"PHASE2":26594,"PHASE3":26596,"PHASE4":26610,"NA":26612},{"trials":26591,"activeCount":103},[],{"trials":26593,"activeCount":103},[],{"trials":26595,"activeCount":103},[],{"trials":26597,"activeCount":103},[26598],{"nctId":26599,"briefTitle":26600,"status":111,"phases":26601,"primaryCompletion":26602,"completion":26603,"start":5017,"enrollment":26604,"conditions":26605,"interventions":26606},"NCT03732807","PF-06651600 for the Treatment of Alopecia Areata",[92,93],"2020-12-31","2021-06-24",718,[1521],[26588,26607,26608,26609],"PF-06651600 Maintenance Dose #1","PF-06651600 Maintenance Dose #2","PF-06651600 Maintenance Dose #3",{"trials":26611,"activeCount":103},[],{"trials":26613,"activeCount":103},[],{"intervention":26607,"totalTrials":302,"cells":26615},{"EARLY_PHASE1":26616,"PHASE1":26618,"PHASE2":26620,"PHASE3":26622,"PHASE4":26628,"NA":26630},{"trials":26617,"activeCount":103},[],{"trials":26619,"activeCount":103},[],{"trials":26621,"activeCount":103},[],{"trials":26623,"activeCount":103},[26624],{"nctId":26599,"briefTitle":26600,"status":111,"phases":26625,"primaryCompletion":26602,"completion":26603,"start":5017,"enrollment":26604,"conditions":26626,"interventions":26627},[92,93],[1521],[26588,26607,26608,26609],{"trials":26629,"activeCount":103},[],{"trials":26631,"activeCount":103},[],{"intervention":26608,"totalTrials":302,"cells":26633},{"EARLY_PHASE1":26634,"PHASE1":26636,"PHASE2":26638,"PHASE3":26640,"PHASE4":26646,"NA":26648},{"trials":26635,"activeCount":103},[],{"trials":26637,"activeCount":103},[],{"trials":26639,"activeCount":103},[],{"trials":26641,"activeCount":103},[26642],{"nctId":26599,"briefTitle":26600,"status":111,"phases":26643,"primaryCompletion":26602,"completion":26603,"start":5017,"enrollment":26604,"conditions":26644,"interventions":26645},[92,93],[1521],[26588,26607,26608,26609],{"trials":26647,"activeCount":103},[],{"trials":26649,"activeCount":103},[],{"intervention":26609,"totalTrials":302,"cells":26651},{"EARLY_PHASE1":26652,"PHASE1":26654,"PHASE2":26656,"PHASE3":26658,"PHASE4":26664,"NA":26666},{"trials":26653,"activeCount":103},[],{"trials":26655,"activeCount":103},[],{"trials":26657,"activeCount":103},[],{"trials":26659,"activeCount":103},[26660],{"nctId":26599,"briefTitle":26600,"status":111,"phases":26661,"primaryCompletion":26602,"completion":26603,"start":5017,"enrollment":26604,"conditions":26662,"interventions":26663},[92,93],[1521],[26588,26607,26608,26609],{"trials":26665,"activeCount":103},[],{"trials":26667,"activeCount":103},[],{"intervention":26669,"totalTrials":302,"cells":26670},"CP-464,005",{"EARLY_PHASE1":26671,"PHASE1":26673,"PHASE2":26675,"PHASE3":26677,"PHASE4":26685,"NA":26687},{"trials":26672,"activeCount":103},[],{"trials":26674,"activeCount":103},[],{"trials":26676,"activeCount":103},[],{"trials":26678,"activeCount":103},[26679],{"nctId":26680,"briefTitle":26681,"status":168,"phases":26682,"primaryCompletion":4207,"completion":4207,"start":11314,"enrollment":1509,"conditions":26683,"interventions":26684},"NCT00527397","Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes",[93],[37,12130],[26669,26669,26669],{"trials":26686,"activeCount":103},[],{"trials":26688,"activeCount":103},[],{"intervention":26690,"totalTrials":302,"cells":26691},"Ibuprofen 600 mg ER",{"EARLY_PHASE1":26692,"PHASE1":26694,"PHASE2":26696,"PHASE3":26698,"PHASE4":26709,"NA":26711},{"trials":26693,"activeCount":103},[],{"trials":26695,"activeCount":103},[],{"trials":26697,"activeCount":103},[],{"trials":26699,"activeCount":103},[26700],{"nctId":26701,"briefTitle":26702,"status":111,"phases":26703,"primaryCompletion":26704,"completion":26704,"start":26705,"enrollment":26706,"conditions":26707,"interventions":26708},"NCT01266161","Multiple Dose Dental Pain Study Of Ibuprofen Extended Release",[93],"2011-03-31","2010-11-22",106,[34],[26690],{"trials":26710,"activeCount":103},[],{"trials":26712,"activeCount":103},[],{"intervention":26714,"totalTrials":302,"cells":26715},"propiverine",{"EARLY_PHASE1":26716,"PHASE1":26718,"PHASE2":26720,"PHASE3":26722,"PHASE4":26731,"NA":26733},{"trials":26717,"activeCount":103},[],{"trials":26719,"activeCount":103},[],{"trials":26721,"activeCount":103},[],{"trials":26723,"activeCount":103},[26724],{"nctId":26725,"briefTitle":26726,"status":111,"phases":26727,"completion":6458,"start":3628,"enrollment":713,"conditions":26728,"interventions":26729},"NCT00646880","A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring",[93],[12472],[26714,26730],"tolterodine PR",{"trials":26732,"activeCount":103},[],{"trials":26734,"activeCount":103},[],{"intervention":26730,"totalTrials":302,"cells":26736},{"EARLY_PHASE1":26737,"PHASE1":26739,"PHASE2":26741,"PHASE3":26743,"PHASE4":26749,"NA":26751},{"trials":26738,"activeCount":103},[],{"trials":26740,"activeCount":103},[],{"trials":26742,"activeCount":103},[],{"trials":26744,"activeCount":103},[26745],{"nctId":26725,"briefTitle":26726,"status":111,"phases":26746,"completion":6458,"start":3628,"enrollment":713,"conditions":26747,"interventions":26748},[93],[12472],[26714,26730],{"trials":26750,"activeCount":103},[],{"trials":26752,"activeCount":103},[],{"intervention":6305,"totalTrials":3254,"cells":26754},{"EARLY_PHASE1":26755,"PHASE1":26757,"PHASE2":26835,"PHASE3":26852,"PHASE4":26854,"NA":26856},{"trials":26756,"activeCount":103},[],{"trials":26758,"activeCount":103},[26759,26767,26777,26783,26787,26791,26799,26806,26814,26821,26831],{"nctId":26760,"briefTitle":26761,"status":111,"phases":26762,"primaryCompletion":26763,"completion":26763,"start":26764,"enrollment":1268,"conditions":26765,"interventions":26766},"NCT03937258","A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants",[91],"2019-07-26","2019-05-21",[16],[6305,2717],{"nctId":26768,"briefTitle":26769,"status":111,"phases":26770,"primaryCompletion":26771,"completion":26771,"start":26772,"enrollment":7500,"conditions":26773,"interventions":26775},"NCT03662516","A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects",[91],"2019-01-19","2018-09-26",[26774],"Healthy Females",[6305,26776],"Ethinyl estradiol",{"nctId":26778,"briefTitle":26779,"status":111,"phases":26780,"primaryCompletion":3253,"completion":3253,"start":17024,"enrollment":1509,"conditions":26781,"interventions":26782},"NCT03626415","A Hepatic Impairment Study for PF-04965842.",[91],[7853],[6305],{"nctId":17021,"briefTitle":17022,"status":111,"phases":26784,"primaryCompletion":17024,"completion":17024,"start":17025,"enrollment":1530,"conditions":26785,"interventions":26786},[91],[19],[6305,6111],{"nctId":9716,"briefTitle":9717,"status":111,"phases":26788,"primaryCompletion":9719,"completion":9719,"start":9720,"enrollment":2159,"conditions":26789,"interventions":26790},[91],[16],[6305,9600],{"nctId":26792,"briefTitle":26793,"status":111,"phases":26794,"primaryCompletion":26795,"completion":26796,"start":7963,"enrollment":1268,"conditions":26797,"interventions":26798},"NCT03796182","Study of PF 04965842 Effect on MATE1\u002F2K Activity in Healthy Participants",[91],"2019-02-13","2019-03-12",[16],[6170,6305],{"nctId":26800,"briefTitle":26801,"status":111,"phases":26802,"primaryCompletion":11649,"completion":11649,"start":26803,"enrollment":1268,"conditions":26804,"interventions":26805},"NCT03637790","Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.",[91],"2018-09-13",[16],[6305],{"nctId":26807,"briefTitle":26808,"status":111,"phases":26809,"primaryCompletion":26810,"completion":5767,"start":26811,"enrollment":1268,"conditions":26812,"interventions":26813},"NCT03806101","Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants",[91],"2019-03-15","2019-01-23",[16],[6305,2841],{"nctId":26815,"briefTitle":26816,"status":111,"phases":26817,"primaryCompletion":5970,"completion":5970,"start":17651,"enrollment":2070,"conditions":26818,"interventions":26819},"NCT03250039","Absorption, Metabolism, Excretion and Absolute Bioavailability",[91],[16],[6305,26820],"Absolute Bioavailability",{"nctId":26822,"briefTitle":26823,"status":111,"phases":26824,"primaryCompletion":26825,"completion":26826,"start":26827,"enrollment":3254,"conditions":26828,"interventions":26830},"NCT04099563","Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants",[91],"2019-11-09","2019-12-09","2019-10-14",[26829],"HEALTHY",[6305],{"nctId":6297,"briefTitle":6298,"status":111,"phases":26832,"primaryCompletion":6300,"completion":6300,"start":6301,"enrollment":2713,"conditions":26833,"interventions":26834},[91],[6303],[6305,1687],{"trials":26836,"activeCount":103},[26837,26844],{"nctId":26838,"briefTitle":26839,"status":168,"phases":26840,"primaryCompletion":12853,"completion":12853,"start":17639,"enrollment":1060,"conditions":26841,"interventions":26843},"NCT02201524","Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis",[92],[26842],"Plaque Psoriasis",[6305,6305,6305],{"nctId":26845,"briefTitle":26846,"status":111,"phases":26847,"primaryCompletion":26848,"completion":26849,"start":12811,"enrollment":4449,"conditions":26850,"interventions":26851},"NCT02780167","Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis",[92],"2017-03","2017-04",[1589],[6305,6305,6305,6305],{"trials":26853,"activeCount":103},[],{"trials":26855,"activeCount":103},[],{"trials":26857,"activeCount":103},[],{"intervention":11326,"totalTrials":1268,"cells":26859},{"EARLY_PHASE1":26860,"PHASE1":26862,"PHASE2":26901,"PHASE3":26943,"PHASE4":26945,"NA":26947},{"trials":26861,"activeCount":103},[],{"trials":26863,"activeCount":103},[26864,26872,26879,26885,26891,26897],{"nctId":26865,"briefTitle":26866,"status":111,"phases":26867,"primaryCompletion":2883,"completion":2883,"start":3601,"enrollment":1097,"conditions":26868,"interventions":26870},"NCT01314885","Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers",[91],[26869],"Chronic Obstructive Pulmonary Disease (COPD)",[26871,11326],"PF-03715455",{"nctId":26873,"briefTitle":26874,"status":111,"phases":26875,"primaryCompletion":569,"completion":569,"start":4459,"enrollment":1268,"conditions":26876,"interventions":26877},"NCT01589614","A Study To Investigate The Effect Of Erythromycin On The Pharmacokinetics Of PH-797804",[91],[16],[11326,26878],"PH-797804 + erythromycin",{"nctId":26880,"briefTitle":26881,"status":649,"phases":26882,"primaryCompletion":1288,"completion":1288,"start":605,"enrollment":103,"conditions":26883,"interventions":26884},"NCT01924650","A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804",[91],[16],[11326,11326,11326,11326,11326,11326],{"nctId":26886,"briefTitle":26887,"status":111,"phases":26888,"primaryCompletion":18026,"completion":18026,"start":2883,"enrollment":5909,"conditions":26889,"interventions":26890},"NCT01479647","A Study To Investigate The Effect Of Food On The Pharmacokinetics Of PH-797804",[91],[19],[11326,11326,11326,11326,11326],{"nctId":26892,"briefTitle":26893,"status":111,"phases":26894,"primaryCompletion":3335,"completion":3335,"start":3854,"enrollment":1509,"conditions":26895,"interventions":26896},"NCT02084485","PH-797804 LPS Study in Healthy Volunteers",[91],[16],[11326],{"nctId":17108,"briefTitle":17109,"status":111,"phases":26898,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":4369,"conditions":26899,"interventions":26900},[91],[16],[11326,6111],{"trials":26902,"activeCount":103},[26903,26909,26919,26926,26932,26936],{"nctId":26904,"briefTitle":26905,"status":111,"phases":26906,"primaryCompletion":4665,"completion":4665,"start":3335,"enrollment":504,"conditions":26907,"interventions":26908},"NCT00620685","A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate",[92],[4514],[11326,11326],{"nctId":26910,"briefTitle":26911,"status":111,"phases":26912,"primaryCompletion":26913,"completion":26914,"start":26915,"enrollment":26916,"conditions":26917,"interventions":26918},"NCT00383188","An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis",[92],"2008-07-01","2008-07-16","2006-12-15",305,[4514],[11326,11326,11326,11326],{"nctId":26920,"briefTitle":26921,"status":111,"phases":26922,"primaryCompletion":4645,"completion":8154,"start":3314,"enrollment":1519,"conditions":26923,"interventions":26925},"NCT00614705","PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia",[92],[26924],"Neuralgia, Postherpetic",[11326],{"nctId":26927,"briefTitle":26928,"status":111,"phases":26929,"primaryCompletion":13214,"completion":13214,"start":3334,"enrollment":18004,"conditions":26930,"interventions":26931},"NCT01543919","Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide",[92],[21083],[11326,11326,11326,11326,11326],{"nctId":11320,"briefTitle":11321,"status":111,"phases":26933,"primaryCompletion":4666,"completion":524,"start":2660,"enrollment":11323,"conditions":26934,"interventions":26935},[92],[11282],[11326,11326,11273,11327,11327,11273],{"nctId":26937,"briefTitle":26938,"status":111,"phases":26939,"primaryCompletion":4459,"completion":4459,"start":11170,"enrollment":26940,"conditions":26941,"interventions":26942},"NCT01321463","Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate\u002FFluticasone Propionate Combination",[92],377,[21083],[11326],{"trials":26944,"activeCount":103},[],{"trials":26946,"activeCount":103},[],{"trials":26948,"activeCount":103},[],{"intervention":4425,"totalTrials":1268,"cells":26950},{"EARLY_PHASE1":26951,"PHASE1":26953,"PHASE2":27024,"PHASE3":27048,"PHASE4":27050,"NA":27052},{"trials":26952,"activeCount":103},[],{"trials":26954,"activeCount":103},[26955,26963,26973,26979,26987,26995,27002,27010,27018],{"nctId":26956,"briefTitle":26957,"status":111,"phases":26958,"primaryCompletion":26959,"completion":26959,"start":26960,"enrollment":350,"conditions":26961,"interventions":26962},"NCT04018274","Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids",[91],"2019-10-16","2019-08-09",[16],[4425,26776],{"nctId":26964,"briefTitle":26965,"status":111,"phases":26966,"primaryCompletion":26967,"completion":26967,"start":26968,"enrollment":2070,"conditions":26969,"interventions":26970},"NCT03929510","Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.",[91],"2019-07-05","2019-04-23",[19],[26971,26972,4425],"14C-PF-06651600","14C-PF-06651600 IV",{"nctId":26974,"briefTitle":26975,"status":111,"phases":26976,"primaryCompletion":651,"completion":651,"start":4280,"enrollment":562,"conditions":26977,"interventions":26978},"NCT02684760","Bioavailability Study Of PF-06651600 In Healthy Subjects",[91],[16],[4425],{"nctId":26980,"briefTitle":26981,"status":111,"phases":26982,"primaryCompletion":26983,"completion":26983,"start":26984,"enrollment":1268,"conditions":26985,"interventions":26986},"NCT04266509","Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600",[91],"2020-09-10","2020-06-25",[19],[4425,1252],{"nctId":26988,"briefTitle":26989,"status":111,"phases":26990,"primaryCompletion":26991,"completion":26991,"start":26992,"enrollment":1268,"conditions":26993,"interventions":26994},"NCT03608241","A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)",[91],"2018-11-23","2018-09-21",[26774],[4425,26776],{"nctId":26996,"briefTitle":26997,"status":111,"phases":26998,"primaryCompletion":26999,"completion":26999,"start":24440,"enrollment":13356,"conditions":27000,"interventions":27001},"NCT04390776","Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.",[91],"2021-07-19",[28],[4425],{"nctId":27003,"briefTitle":27004,"status":111,"phases":27005,"primaryCompletion":27006,"completion":27006,"start":27007,"enrollment":1268,"conditions":27008,"interventions":27009},"NCT04092595","A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants",[91],"2020-01-15","2019-09-26",[19],[4425,2841],{"nctId":27011,"briefTitle":27012,"status":111,"phases":27013,"primaryCompletion":27014,"completion":27014,"start":27015,"enrollment":627,"conditions":27016,"interventions":27017},"NCT04634565","PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS",[91],"2020-11-19","2020-10-15",[28],[4425],{"nctId":27019,"briefTitle":27020,"status":111,"phases":27021,"primaryCompletion":4410,"completion":4410,"start":252,"enrollment":1268,"conditions":27022,"interventions":27023},"NCT04004663","Bioavailability Study of PF-06651600 Formulations in Healthy Participants",[91],[19],[4425],{"trials":27025,"activeCount":103},[27026,27030,27038],{"nctId":4417,"briefTitle":4418,"status":111,"phases":27027,"primaryCompletion":4420,"completion":4420,"start":1518,"enrollment":4421,"conditions":27028,"interventions":27029},[92],[22],[4424,4425,4388],{"nctId":27031,"briefTitle":27032,"status":111,"phases":27033,"primaryCompletion":27034,"completion":27034,"start":4268,"enrollment":27035,"conditions":27036,"interventions":27037},"NCT02969044","Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate",[92],"2017-12-12",70,[22],[4425],{"nctId":27039,"briefTitle":27040,"status":111,"phases":27041,"primaryCompletion":9422,"completion":9422,"start":27042,"enrollment":27043,"conditions":27044,"interventions":27045},"NCT02958865","Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis",[92],"2017-02-03",319,[1532],[27046,27047,7595,4425],"PF-06651600 or Placebo","PF-06700841 or Placebo",{"trials":27049,"activeCount":103},[],{"trials":27051,"activeCount":103},[],{"trials":27053,"activeCount":103},[],{"intervention":7595,"totalTrials":1268,"cells":27055},{"EARLY_PHASE1":27056,"PHASE1":27058,"PHASE2":27101,"PHASE3":27140,"PHASE4":27142,"NA":27144},{"trials":27057,"activeCount":103},[],{"trials":27059,"activeCount":103},[27060,27067,27071,27079,27088,27092],{"nctId":27061,"briefTitle":27062,"status":111,"phases":27063,"primaryCompletion":756,"completion":756,"start":27064,"enrollment":1780,"conditions":27065,"interventions":27066},"NCT04260464","Renal Impairment Study of PF-06700841",[91],"2020-07-03",[1270,352],[7595],{"nctId":17046,"briefTitle":17047,"status":111,"phases":27068,"primaryCompletion":17049,"completion":17049,"start":17050,"enrollment":5987,"conditions":27069,"interventions":27070},[91],[16],[7595,17044],{"nctId":27072,"briefTitle":27073,"status":111,"phases":27074,"primaryCompletion":7387,"completion":4280,"start":17639,"enrollment":27075,"conditions":27076,"interventions":27077},"NCT02310750","A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability\u002FFood Effect Investigation",[91],96,[26842],[27078,7595],"PF-06700841 oral solution\u002Fsuspension",{"nctId":27080,"briefTitle":27081,"status":111,"phases":27082,"primaryCompletion":27083,"completion":27083,"start":27084,"enrollment":597,"conditions":27085,"interventions":27087},"NCT04267250","Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids",[91],"2020-11-06","2020-08-24",[27086],"Healthy Female Volunteers",[7595,26776],{"nctId":7587,"briefTitle":7588,"status":111,"phases":27089,"primaryCompletion":7590,"completion":7590,"start":7591,"enrollment":1268,"conditions":27090,"interventions":27091},[91],[7593],[7595,2082],{"nctId":27093,"briefTitle":27094,"status":111,"phases":27095,"primaryCompletion":27096,"completion":27097,"start":27098,"enrollment":1487,"conditions":27099,"interventions":27100},"NCT03236493","Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers",[91],"2017-09-17","2017-10-12","2017-08-16",[16],[7595],{"trials":27102,"activeCount":103},[27103,27107,27111,27115,27123,27132],{"nctId":18445,"briefTitle":18446,"status":111,"phases":27104,"primaryCompletion":18448,"completion":18448,"start":18449,"enrollment":18450,"conditions":27105,"interventions":27106},[92],[1589],[7595,18415],{"nctId":27039,"briefTitle":27040,"status":111,"phases":27108,"primaryCompletion":9422,"completion":9422,"start":27042,"enrollment":27043,"conditions":27109,"interventions":27110},[92],[1532],[27046,27047,7595,4425],{"nctId":18454,"briefTitle":18455,"status":111,"phases":27112,"primaryCompletion":18457,"completion":18457,"start":18458,"enrollment":18459,"conditions":27113,"interventions":27114},[92],[4401],[7595,18415],{"nctId":27116,"briefTitle":27117,"status":111,"phases":27118,"primaryCompletion":27119,"completion":1828,"start":27120,"enrollment":1702,"conditions":27121,"interventions":27122},"NCT03963401","A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis",[92],"2020-04-06","2019-06-13",[4469],[7595],{"nctId":27124,"briefTitle":27125,"status":111,"phases":27126,"primaryCompletion":3402,"completion":3402,"start":2911,"enrollment":27127,"conditions":27128,"interventions":27130},"NCT04092452","A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa",[92],194,[27129],"Acne Inversa",[4424,7595,27131],"PF-06826647",{"nctId":27133,"briefTitle":27134,"status":111,"phases":27135,"primaryCompletion":27136,"completion":27136,"start":15186,"enrollment":3075,"conditions":27137,"interventions":27139},"NCT02969018","Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis",[92],"2018-03",[27138],"Chronic Plaque Psoriasis",[7595],{"trials":27141,"activeCount":103},[],{"trials":27143,"activeCount":103},[],{"trials":27145,"activeCount":103},[],{"intervention":6212,"totalTrials":870,"cells":27147},{"EARLY_PHASE1":27148,"PHASE1":27150,"PHASE2":27188,"PHASE3":27208,"PHASE4":27210,"NA":27212},{"trials":27149,"activeCount":103},[],{"trials":27151,"activeCount":103},[27152,27158,27164,27170,27174,27180,27184],{"nctId":27153,"briefTitle":27154,"status":111,"phases":27155,"primaryCompletion":113,"completion":113,"start":3313,"enrollment":525,"conditions":27156,"interventions":27157},"NCT01433380","A Study To Evaluate PF-05175157 In Healthy Volunteers",[91],[37],[6212],{"nctId":27159,"briefTitle":27160,"status":111,"phases":27161,"primaryCompletion":6208,"completion":6208,"start":4680,"enrollment":1268,"conditions":27162,"interventions":27163},"NCT01821079","A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation",[91],[16],[6212,6212,6212,6212],{"nctId":27165,"briefTitle":27166,"status":111,"phases":27167,"primaryCompletion":1249,"completion":1249,"start":6208,"enrollment":1268,"conditions":27168,"interventions":27169},"NCT01819922","Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters",[91],[16],[6212],{"nctId":6113,"briefTitle":6114,"status":111,"phases":27171,"primaryCompletion":3345,"completion":3345,"start":3353,"enrollment":1268,"conditions":27172,"interventions":27173},[91],[6117,37,6118],[6120,1989],{"nctId":27175,"briefTitle":27176,"status":111,"phases":27177,"primaryCompletion":113,"completion":113,"start":2450,"enrollment":1257,"conditions":27178,"interventions":27179},"NCT01537497","A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers",[91],[37],[6212,6212,6212],{"nctId":12964,"briefTitle":12965,"status":111,"phases":27181,"primaryCompletion":2883,"completion":2883,"start":570,"enrollment":562,"conditions":27182,"interventions":27183},[91],[12968],[12957,6212],{"nctId":6204,"briefTitle":6205,"status":111,"phases":27185,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":498,"conditions":27186,"interventions":27187},[91],[6210],[6212,1687,1687],{"trials":27189,"activeCount":103},[27190,27196,27202],{"nctId":27191,"briefTitle":27192,"status":649,"phases":27193,"primaryCompletion":11356,"completion":11356,"start":7578,"enrollment":103,"conditions":27194,"interventions":27195},"NCT02100527","Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris",[92],[15353],[6212],{"nctId":27197,"briefTitle":27198,"status":168,"phases":27199,"primaryCompletion":7578,"completion":7578,"start":605,"enrollment":1487,"conditions":27200,"interventions":27201},"NCT02053116","A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin",[92],[12968],[6212],{"nctId":27203,"briefTitle":27204,"status":168,"phases":27205,"primaryCompletion":652,"completion":652,"start":2449,"enrollment":99,"conditions":27206,"interventions":27207},"NCT01792635","A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus",[92],[37],[6212],{"trials":27209,"activeCount":103},[],{"trials":27211,"activeCount":103},[],{"trials":27213,"activeCount":103},[],{"intervention":27215,"totalTrials":627,"cells":27216},"PF-00299804",{"EARLY_PHASE1":27217,"PHASE1":27219,"PHASE2":27260,"PHASE3":27297,"PHASE4":27299,"NA":27301},{"trials":27218,"activeCount":103},[],{"trials":27220,"activeCount":103},[27221,27230,27236,27247,27253],{"nctId":27222,"briefTitle":27223,"status":111,"phases":27224,"primaryCompletion":27225,"completion":27226,"start":27227,"enrollment":2442,"conditions":27228,"interventions":27229},"NCT00225121","Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors",[91],"2007-04-03","2010-09-23","2005-10-11",[2053],[27215],{"nctId":27231,"briefTitle":27232,"status":111,"phases":27233,"primaryCompletion":3324,"completion":3324,"start":561,"enrollment":27035,"conditions":27234,"interventions":27235},"NCT01121575","A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer",[91],[643],[7523,27215,7523,27215],{"nctId":27237,"briefTitle":27238,"status":111,"phases":27239,"primaryCompletion":27240,"completion":27241,"start":27242,"enrollment":27243,"conditions":27244,"interventions":27246},"NCT00728390","A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks",[91],"2011-08-09","2013-01-29","2008-12-15",74,[27245,3077],"Carcinoma, Non-Small Cell",[27215],{"nctId":27248,"briefTitle":27249,"status":111,"phases":27250,"primaryCompletion":524,"completion":524,"start":4645,"enrollment":3254,"conditions":27251,"interventions":27252},"NCT00783328","A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors",[91],[2053],[27215],{"nctId":27254,"briefTitle":27255,"status":111,"phases":27256,"primaryCompletion":523,"completion":7971,"start":11291,"enrollment":314,"conditions":27257,"interventions":27259},"NCT00728468","A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients",[91],[27258],"Advanced Malignant Solid Tumors",[27215],{"trials":27261,"activeCount":103},[27262,27269,27279,27288],{"nctId":27263,"briefTitle":27264,"status":111,"phases":27265,"primaryCompletion":585,"completion":7386,"start":4645,"enrollment":27266,"conditions":27267,"interventions":27268},"NCT00769067","A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen",[92],188,[727],[25861,27215],{"nctId":27270,"briefTitle":27271,"status":111,"phases":27272,"primaryCompletion":27273,"completion":27274,"start":27275,"enrollment":6199,"conditions":27276,"interventions":27278},"NCT00768664","Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer",[92],"2010-05-05","2012-04-18","2008-11-04",[27277],"Head and Neck Neoplasms",[27215],{"nctId":27280,"briefTitle":27281,"status":111,"phases":27282,"primaryCompletion":27283,"completion":27284,"start":27285,"enrollment":2631,"conditions":27286,"interventions":27287},"NCT00553254","Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer",[92],"2010-08-03","2014-07-17","2008-02-05",[7761],[27215],{"nctId":27289,"briefTitle":27290,"status":111,"phases":27291,"primaryCompletion":27292,"completion":27293,"start":27294,"enrollment":4825,"conditions":27295,"interventions":27296},"NCT00548093","PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib",[92],"2010-03-16","2012-06-11","2008-04-29",[7761],[27215,27215],{"trials":27298,"activeCount":103},[],{"trials":27300,"activeCount":103},[],{"trials":27302,"activeCount":103},[],{"intervention":11486,"totalTrials":627,"cells":27304},{"EARLY_PHASE1":27305,"PHASE1":27307,"PHASE2":27354,"PHASE3":27368,"PHASE4":27370,"NA":27372},{"trials":27306,"activeCount":103},[],{"trials":27308,"activeCount":103},[27309,27315,27321,27327,27333,27342,27348],{"nctId":27310,"briefTitle":27311,"status":111,"phases":27312,"primaryCompletion":9544,"completion":9544,"start":2661,"enrollment":1780,"conditions":27313,"interventions":27314},"NCT01365637","The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.",[91],[34],[11486,11486,11486,11486],{"nctId":27316,"briefTitle":27317,"status":111,"phases":27318,"primaryCompletion":1700,"completion":1700,"start":1700,"enrollment":1268,"conditions":27319,"interventions":27320},"NCT01690351","A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State",[91],[34],[11486,11486],{"nctId":27322,"briefTitle":27323,"status":111,"phases":27324,"primaryCompletion":18026,"completion":18026,"start":18026,"enrollment":1268,"conditions":27325,"interventions":27326},"NCT01563497","A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State",[91],[34],[11486,11486,11486],{"nctId":27328,"briefTitle":27329,"status":111,"phases":27330,"primaryCompletion":6208,"completion":6208,"start":4590,"enrollment":35,"conditions":27331,"interventions":27332},"NCT01772264","Safety And Tolerability Study Of BID Titration Scheme With PF-05089771",[91],[16],[11486],{"nctId":27334,"briefTitle":27335,"status":111,"phases":27336,"primaryCompletion":561,"completion":561,"start":586,"enrollment":35,"conditions":27337,"interventions":27338},"NCT01165736","To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity",[91],[16],[27339,27339,11486,11486,27340,27340,27341,27341],"PF-05186462","PF-05150122","PF-05241328",{"nctId":27343,"briefTitle":27344,"status":111,"phases":27345,"primaryCompletion":13117,"completion":13117,"start":6198,"enrollment":1268,"conditions":27346,"interventions":27347},"NCT01854996","Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion",[91],[16],[11486,11486,11486],{"nctId":27349,"briefTitle":27350,"status":111,"phases":27351,"primaryCompletion":3353,"completion":3353,"start":10912,"enrollment":1519,"conditions":27352,"interventions":27353},"NCT01529671","A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee",[91],[34],[11486,11486,11486,11486,11486],{"trials":27355,"activeCount":103},[27356,27364],{"nctId":27357,"briefTitle":27358,"status":111,"phases":27359,"primaryCompletion":17528,"completion":17528,"start":27360,"enrollment":578,"conditions":27361,"interventions":27363},"NCT01769274","Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia",[92],"2012-10-22",[27362],"Inherited Erythromelalgia",[11486],{"nctId":11477,"briefTitle":11478,"status":111,"phases":27365,"primaryCompletion":11480,"completion":11480,"start":11481,"enrollment":11482,"conditions":27366,"interventions":27367},[92],[11484],[11486,11486,11486,11072],{"trials":27369,"activeCount":103},[],{"trials":27371,"activeCount":103},[],{"trials":27373,"activeCount":103},[],{"intervention":6224,"totalTrials":627,"cells":27375},{"EARLY_PHASE1":27376,"PHASE1":27378,"PHASE2":27423,"PHASE3":27450,"PHASE4":27452,"NA":27454},{"trials":27377,"activeCount":103},[],{"trials":27379,"activeCount":103},[27380,27389,27397,27405,27412,27416],{"nctId":27381,"briefTitle":27382,"status":111,"phases":27383,"primaryCompletion":27384,"completion":27385,"start":27386,"enrollment":3241,"conditions":27387,"interventions":27388},"NCT03538743","4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes",[91],"2019-05-23","2019-06-10","2018-06-25",[12968],[6224,6224,6224,6224,6224,6224,6224,6224],{"nctId":27390,"briefTitle":27391,"status":111,"phases":27392,"primaryCompletion":27393,"completion":27394,"start":595,"enrollment":2713,"conditions":27395,"interventions":27396},"NCT03309241","First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects",[91],"2018-02-21","2018-03-22",[10985],[6224],{"nctId":27398,"briefTitle":27399,"status":111,"phases":27400,"primaryCompletion":27401,"completion":27401,"start":27402,"enrollment":2849,"conditions":27403,"interventions":27404},"NCT04552470","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus",[91],"2021-03-25","2020-10-26",[12968],[6224],{"nctId":27406,"briefTitle":27407,"status":168,"phases":27408,"primaryCompletion":3946,"completion":6587,"start":27409,"enrollment":360,"conditions":27410,"interventions":27411},"NCT06910839","Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity",[91],"2025-03-13",[2760,2761],[6283,6224],{"nctId":6218,"briefTitle":6219,"status":111,"phases":27413,"primaryCompletion":6221,"completion":6221,"start":1441,"enrollment":314,"conditions":27414,"interventions":27415},[91],[2761],[6224,2841,1687],{"nctId":27417,"briefTitle":27418,"status":111,"phases":27419,"primaryCompletion":22301,"completion":22301,"start":27420,"enrollment":2159,"conditions":27421,"interventions":27422},"NCT04889157","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus",[91],"2021-07-07",[37],[6224],{"trials":27424,"activeCount":103},[27425,27433,27442],{"nctId":27426,"briefTitle":27427,"status":111,"phases":27428,"primaryCompletion":5035,"completion":5035,"start":27429,"enrollment":9562,"conditions":27430,"interventions":27432},"NCT04617275","A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY",[92],"2021-01-06",[27431,2761],"Diabetes",[6224],{"nctId":27434,"briefTitle":27435,"status":111,"phases":27436,"primaryCompletion":27437,"completion":2122,"start":27438,"enrollment":27439,"conditions":27440,"interventions":27441},"NCT04707313","A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity",[92],"2023-09-13","2021-01-29",628,[2761],[6224,6224],{"nctId":27443,"briefTitle":27444,"status":111,"phases":27445,"primaryCompletion":27446,"completion":27420,"start":27447,"enrollment":26078,"conditions":27448,"interventions":27449},"NCT03985293","A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus",[92],"2021-06-08","2019-10-15",[37],[6224],{"trials":27451,"activeCount":103},[],{"trials":27453,"activeCount":103},[],{"trials":27455,"activeCount":103},[],{"intervention":20094,"totalTrials":1487,"cells":27457},{"EARLY_PHASE1":27458,"PHASE1":27460,"PHASE2":27490,"PHASE3":27515,"PHASE4":27517,"NA":27519},{"trials":27459,"activeCount":103},[],{"trials":27461,"activeCount":103},[27462,27470,27477,27483],{"nctId":27463,"briefTitle":27464,"status":111,"phases":27465,"primaryCompletion":27466,"completion":27466,"start":27467,"enrollment":2849,"conditions":27468,"interventions":27469},"NCT01829048","A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia",[91],"2013-10-17","2013-03-06",[12632],[20094,20094,20094],{"nctId":27471,"briefTitle":27472,"status":111,"phases":27473,"primaryCompletion":9572,"completion":9572,"start":605,"enrollment":627,"conditions":27474,"interventions":27475},"NCT01918202","A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers",[91],[16],[27476,20094,20094],"20 mg PF-02545920",{"nctId":27478,"briefTitle":27479,"status":111,"phases":27480,"primaryCompletion":570,"completion":570,"start":2660,"enrollment":3229,"conditions":27481,"interventions":27482},"NCT01103726","Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects",[91],[16],[20094,20094,20094],{"nctId":27484,"briefTitle":27485,"status":111,"phases":27486,"completion":3610,"start":12128,"enrollment":35,"conditions":27487,"interventions":27489},"NCT00463372","Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia",[91],[12632,27488],"Schizo-affective Disorder",[20094],{"trials":27491,"activeCount":103},[27492,27498,27505,27509],{"nctId":27493,"briefTitle":27494,"status":168,"phases":27495,"primaryCompletion":11356,"completion":11356,"start":1249,"enrollment":22897,"conditions":27496,"interventions":27497},"NCT01939548","An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia",[92],[12632],[20094,20094],{"nctId":27499,"briefTitle":27500,"status":168,"phases":27501,"primaryCompletion":27502,"completion":27502,"start":2964,"enrollment":472,"conditions":27503,"interventions":27504},"NCT00570063","Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo",[92],"2008-02-18",[12632],[20094],{"nctId":20088,"briefTitle":20089,"status":111,"phases":27506,"primaryCompletion":4531,"completion":4531,"start":585,"enrollment":20091,"conditions":27507,"interventions":27508},[92],[12632],[20094,20094,20079],{"nctId":27510,"briefTitle":27511,"status":111,"phases":27512,"primaryCompletion":11956,"completion":11956,"start":13214,"enrollment":2849,"conditions":27513,"interventions":27514},"NCT01806896","Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease",[92],[17729],[20094,20094],{"trials":27516,"activeCount":103},[],{"trials":27518,"activeCount":103},[],{"trials":27520,"activeCount":103},[],{"intervention":4424,"totalTrials":3659,"cells":27522},{"EARLY_PHASE1":27523,"PHASE1":27525,"PHASE2":27553,"PHASE3":27567,"PHASE4":27569,"NA":27571},{"trials":27524,"activeCount":103},[],{"trials":27526,"activeCount":103},[27527,27533,27539,27546],{"nctId":27528,"briefTitle":27529,"status":111,"phases":27530,"primaryCompletion":5957,"completion":5957,"start":13581,"enrollment":870,"conditions":27531,"interventions":27532},"NCT02936154","Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects",[91],[16],[4424],{"nctId":27534,"briefTitle":27535,"status":111,"phases":27536,"primaryCompletion":12811,"completion":12811,"start":4438,"enrollment":2137,"conditions":27537,"interventions":27538},"NCT02485769","Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects",[91],[16],[4424,4424],{"nctId":27540,"briefTitle":27541,"status":111,"phases":27542,"primaryCompletion":232,"completion":232,"start":27543,"enrollment":870,"conditions":27544,"interventions":27545},"NCT05064332","A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)",[91],"2021-10-08",[16],[4424,26776],{"nctId":27547,"briefTitle":27548,"status":111,"phases":27549,"primaryCompletion":4280,"completion":4280,"start":27550,"enrollment":597,"conditions":27551,"interventions":27552},"NCT02609139","Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects",[91],"2015-11",[16],[4424,4424,4424,4424,4424,4424],{"trials":27554,"activeCount":103},[27555,27559,27563],{"nctId":4417,"briefTitle":4418,"status":111,"phases":27556,"primaryCompletion":4420,"completion":4420,"start":1518,"enrollment":4421,"conditions":27557,"interventions":27558},[92],[22],[4424,4425,4388],{"nctId":4444,"briefTitle":4445,"status":111,"phases":27560,"primaryCompletion":4447,"completion":4447,"start":4448,"enrollment":4449,"conditions":27561,"interventions":27562},[92],[22],[4424,4388],{"nctId":27124,"briefTitle":27125,"status":111,"phases":27564,"primaryCompletion":3402,"completion":3402,"start":2911,"enrollment":27127,"conditions":27565,"interventions":27566},[92],[27129],[4424,7595,27131],{"trials":27568,"activeCount":103},[],{"trials":27570,"activeCount":103},[],{"trials":27572,"activeCount":103},[],{"intervention":2003,"totalTrials":3659,"cells":27574},{"EARLY_PHASE1":27575,"PHASE1":27577,"PHASE2":27600,"PHASE3":27619,"PHASE4":27621,"NA":27623},{"trials":27576,"activeCount":103},[],{"trials":27578,"activeCount":103},[27579,27586,27590,27596],{"nctId":27580,"briefTitle":27581,"status":111,"phases":27582,"primaryCompletion":4531,"completion":3353,"start":10923,"enrollment":27583,"conditions":27584,"interventions":27585},"NCT00940498","Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors",[91],78,[2053],[2003],{"nctId":8119,"briefTitle":8120,"status":111,"phases":27587,"primaryCompletion":683,"completion":683,"start":8122,"enrollment":8123,"conditions":27588,"interventions":27589},[91],[766],[2003,3631,1770,8126],{"nctId":27591,"briefTitle":27592,"status":111,"phases":27593,"primaryCompletion":7386,"completion":7386,"start":7971,"enrollment":2070,"conditions":27594,"interventions":27595},"NCT02142920","Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers",[91],[16],[2003],{"nctId":3583,"briefTitle":3584,"status":168,"phases":27597,"primaryCompletion":3586,"completion":3586,"start":114,"enrollment":3587,"conditions":27598,"interventions":27599},[91],[543],[2003,3590,2003,2004],{"trials":27601,"activeCount":103},[27602,27606,27610],{"nctId":1996,"briefTitle":1997,"status":168,"phases":27603,"primaryCompletion":1999,"completion":1999,"start":2000,"enrollment":99,"conditions":27604,"interventions":27605},[92],[1810],[2003,2004,1304,1335],{"nctId":3320,"briefTitle":3321,"status":168,"phases":27607,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":597,"conditions":27608,"interventions":27609},[91,92],[3326],[2003,3328,1030,3329],{"nctId":27611,"briefTitle":27612,"status":168,"phases":27613,"primaryCompletion":27614,"completion":27615,"start":27616,"enrollment":13920,"conditions":27617,"interventions":27618},"NCT01420081","A Study Of Two Dual PI3K\u002FmTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer",[92],"2014-04-30","2015-12-25","2012-01-19",[1006],[2003,2003,2003],{"trials":27620,"activeCount":103},[],{"trials":27622,"activeCount":103},[],{"trials":27624,"activeCount":103},[],{"intervention":17035,"totalTrials":2070,"cells":27626},{"EARLY_PHASE1":27627,"PHASE1":27629,"PHASE2":27660,"PHASE3":27670,"PHASE4":27672,"NA":27674},{"trials":27628,"activeCount":103},[],{"trials":27630,"activeCount":103},[27631,27638,27644,27648,27654],{"nctId":27632,"briefTitle":27633,"status":111,"phases":27634,"primaryCompletion":11014,"completion":11014,"start":8251,"enrollment":4259,"conditions":27635,"interventions":27637},"NCT00832052","A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.",[91],[16,27636],"Elderly",[17035,17035,17035,17035,17035],{"nctId":27639,"briefTitle":27640,"status":111,"phases":27641,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":870,"conditions":27642,"interventions":27643},"NCT00886093","A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants",[91],[16],[17035,17035],{"nctId":17029,"briefTitle":17030,"status":111,"phases":27645,"primaryCompletion":17032,"completion":17032,"start":757,"enrollment":29,"conditions":27646,"interventions":27647},[91],[16],[17035,6111],{"nctId":27649,"briefTitle":27650,"status":168,"phases":27651,"primaryCompletion":11291,"completion":11291,"start":8115,"enrollment":870,"conditions":27652,"interventions":27653},"NCT00736528","A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers",[91],[16,27636],[17035,17035,17035],{"nctId":27655,"briefTitle":27656,"status":111,"phases":27657,"primaryCompletion":6016,"completion":6016,"start":4214,"enrollment":7500,"conditions":27658,"interventions":27659},"NCT00959803","Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.",[91],[16],[17035,17035,17035,17035],{"trials":27661,"activeCount":103},[27662],{"nctId":27663,"briefTitle":27664,"status":111,"phases":27665,"primaryCompletion":27666,"completion":27666,"start":27667,"enrollment":1413,"conditions":27668,"interventions":27669},"NCT00930059","A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease",[92],"2010-09-22","2009-09-10",[17728],[17035],{"trials":27671,"activeCount":103},[],{"trials":27673,"activeCount":103},[],{"trials":27675,"activeCount":103},[],{"intervention":17074,"totalTrials":2070,"cells":27677},{"EARLY_PHASE1":27678,"PHASE1":27680,"PHASE2":27712,"PHASE3":27724,"PHASE4":27726,"NA":27728},{"trials":27679,"activeCount":103},[],{"trials":27681,"activeCount":103},[27682,27688,27694,27701,27705],{"nctId":27683,"briefTitle":27684,"status":111,"phases":27685,"primaryCompletion":3642,"completion":3642,"start":11988,"enrollment":1268,"conditions":27686,"interventions":27687},"NCT01050751","Bioavailability Of Lersivirine Single 750 Mg Tablet Versus 3 X 250 Mg Tablets",[91],[19],[17074,17074],{"nctId":27689,"briefTitle":27690,"status":111,"phases":27691,"primaryCompletion":11170,"completion":11170,"start":585,"enrollment":4755,"conditions":27692,"interventions":27693},"NCT01230385","Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects",[91],[19],[17074,17074,17074,17074,17074],{"nctId":27695,"briefTitle":27696,"status":111,"phases":27697,"primaryCompletion":561,"completion":561,"start":2660,"enrollment":597,"conditions":27698,"interventions":27699},"NCT00925535","Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)",[91],[19],[17074,27700,17074,27700],"Rifabutin",{"nctId":17069,"briefTitle":17070,"status":111,"phases":27702,"primaryCompletion":3642,"completion":3642,"start":10923,"enrollment":4825,"conditions":27703,"interventions":27704},[91],[19],[17074,17074,17074,6111],{"nctId":27706,"briefTitle":27707,"status":111,"phases":27708,"primaryCompletion":3601,"completion":3601,"start":8252,"enrollment":562,"conditions":27709,"interventions":27710},"NCT01220232","Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir\u002FLamivudine In Healthy Subjects",[91],[19],[27711,27711,17074],"Abacavir\u002FLamivudine",{"trials":27713,"activeCount":103},[27714],{"nctId":27715,"briefTitle":27716,"status":168,"phases":27717,"primaryCompletion":6208,"completion":6208,"start":4666,"enrollment":1498,"conditions":27718,"interventions":27720},"NCT01254656","A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022",[92],[27719],"HIV-1",[27721,27721,27722,27721,27721,27723],"lersivirine","efavirenz","etravirine",{"trials":27725,"activeCount":103},[],{"trials":27727,"activeCount":103},[],{"trials":27729,"activeCount":103},[],{"intervention":6250,"totalTrials":578,"cells":27731},{"EARLY_PHASE1":27732,"PHASE1":27734,"PHASE2":27748,"PHASE3":27777,"PHASE4":27779,"NA":27781},{"trials":27733,"activeCount":103},[],{"trials":27735,"activeCount":103},[27736,27740],{"nctId":6240,"briefTitle":6241,"status":111,"phases":27737,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":6245,"conditions":27738,"interventions":27739},[91],[6191],[2082,6248,6249,1687,6250],{"nctId":27741,"briefTitle":27742,"status":111,"phases":27743,"primaryCompletion":27744,"completion":27745,"start":18628,"enrollment":627,"conditions":27746,"interventions":27747},"NCT04065698","Pharmacokinetics and Safety of RV521 Formulations",[91],"2019-09-02","2019-09-09",[6191],[6250],{"trials":27749,"activeCount":103},[27750,27758,27767],{"nctId":27751,"briefTitle":27752,"status":111,"phases":27753,"primaryCompletion":27754,"completion":27754,"start":27755,"enrollment":4825,"conditions":27756,"interventions":27757},"NCT03258502","A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection",[92],"2017-10-31","2017-07-19",[6191],[6250],{"nctId":27759,"briefTitle":27760,"status":168,"phases":27761,"primaryCompletion":27762,"completion":27762,"start":27763,"enrollment":5425,"conditions":27764,"interventions":27766},"NCT04225897","A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.",[92],"2022-12-05","2019-11-13",[3809,27765],"Lower Resp Tract Infection",[6250],{"nctId":27768,"briefTitle":27769,"status":649,"phases":27770,"primaryCompletion":1497,"completion":27771,"start":27772,"enrollment":103,"conditions":27773,"interventions":27775},"NCT04267822","Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV",[92],"2023-07-31","2020-06-15",[3781,27774,27765],"Stem Cell Transplant Complications",[27776],"RV521 oral",{"trials":27778,"activeCount":103},[],{"trials":27780,"activeCount":103},[],{"trials":27782,"activeCount":103},[],{"intervention":11360,"totalTrials":578,"cells":27784},{"EARLY_PHASE1":27785,"PHASE1":27787,"PHASE2":27809,"PHASE3":27826,"PHASE4":27828,"NA":27830},{"trials":27786,"activeCount":103},[],{"trials":27788,"activeCount":103},[27789,27795,27803],{"nctId":27790,"briefTitle":27791,"status":111,"phases":27792,"primaryCompletion":17639,"completion":17639,"start":9572,"enrollment":2159,"conditions":27793,"interventions":27794},"NCT02238717","Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints",[91],[16],[11360,11360,11452],{"nctId":27796,"briefTitle":27797,"status":111,"phases":27798,"primaryCompletion":27799,"completion":27799,"start":27800,"enrollment":99,"conditions":27801,"interventions":27802},"NCT03351751","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects",[91],"2018-02-28","2017-11-08",[19],[11360],{"nctId":27804,"briefTitle":27805,"status":111,"phases":27806,"primaryCompletion":7386,"completion":7386,"start":652,"enrollment":578,"conditions":27807,"interventions":27808},"NCT02138500","A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865",[91],[16],[11360,11360,11360],{"trials":27810,"activeCount":103},[27811,27822],{"nctId":27812,"briefTitle":27813,"status":111,"phases":27814,"primaryCompletion":27815,"completion":27816,"start":27817,"enrollment":3659,"conditions":27818,"interventions":27820},"NCT02564029","PF-06372865 in Subjects With Photosensitive Epilepsy",[92],"2017-01-10","2017-02-07","2015-12-16",[27819],"Reflex Epilepsy, Photosensitive",[11360,27821],"Lorazepam",{"nctId":11353,"briefTitle":11354,"status":111,"phases":27823,"primaryCompletion":3323,"completion":3323,"start":11356,"enrollment":4492,"conditions":27824,"interventions":27825},[92],[11358],[11360,11273],{"trials":27827,"activeCount":103},[],{"trials":27829,"activeCount":103},[],{"trials":27831,"activeCount":103},[],{"intervention":11571,"totalTrials":578,"cells":27833},{"EARLY_PHASE1":27834,"PHASE1":27836,"PHASE2":27846,"PHASE3":27871,"PHASE4":27873,"NA":27875},{"trials":27835,"activeCount":103},[],{"trials":27837,"activeCount":103},[27838],{"nctId":27839,"briefTitle":27840,"status":111,"phases":27841,"primaryCompletion":23585,"completion":23585,"start":27842,"enrollment":4825,"conditions":27843,"interventions":27844},"NCT02955160","A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years",[91],"2016-11-03",[10940],[11571,27845],"Tdap",{"trials":27847,"activeCount":103},[27848,27855,27859,27863],{"nctId":27849,"briefTitle":27850,"status":168,"phases":27851,"primaryCompletion":5110,"completion":5110,"start":27852,"enrollment":9845,"conditions":27853,"interventions":27854},"NCT03550313","Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants",[92],"2018-06-01",[10940],[11571,18943],{"nctId":18935,"briefTitle":18936,"status":111,"phases":27856,"primaryCompletion":18938,"completion":18938,"start":18939,"enrollment":18940,"conditions":27857,"interventions":27858},[92],[10940],[11571,18943,11583],{"nctId":11564,"briefTitle":11565,"status":111,"phases":27860,"primaryCompletion":11567,"completion":11567,"start":11568,"enrollment":4421,"conditions":27861,"interventions":27862},[92],[10940],[11571,11538],{"nctId":27864,"briefTitle":27865,"status":111,"phases":27866,"primaryCompletion":1325,"completion":1325,"start":27097,"enrollment":27867,"conditions":27868,"interventions":27869},"NCT03313050","A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age",[92],511,[10940],[11571,27845,27870],"polysaccharide",{"trials":27872,"activeCount":103},[],{"trials":27874,"activeCount":103},[],{"trials":27876,"activeCount":103},[],{"intervention":7523,"totalTrials":578,"cells":27878},{"EARLY_PHASE1":27879,"PHASE1":27881,"PHASE2":27903,"PHASE3":27912,"PHASE4":27914,"NA":27916},{"trials":27880,"activeCount":103},[],{"trials":27882,"activeCount":103},[27883,27887,27891,27897],{"nctId":27231,"briefTitle":27232,"status":111,"phases":27884,"primaryCompletion":3324,"completion":3324,"start":561,"enrollment":27035,"conditions":27885,"interventions":27886},[91],[643],[7523,27215,7523,27215],{"nctId":7511,"briefTitle":7512,"status":111,"phases":27888,"primaryCompletion":7514,"completion":7515,"start":7516,"enrollment":5855,"conditions":27889,"interventions":27890},[91],[448,7518,7519,7520,7521],[7523,1252,2082],{"nctId":27892,"briefTitle":27893,"status":111,"phases":27894,"primaryCompletion":3601,"completion":3601,"start":4656,"enrollment":597,"conditions":27895,"interventions":27896},"NCT01250730","A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066",[91],[16],[7523,7523,7523],{"nctId":27898,"briefTitle":27899,"status":111,"phases":27900,"primaryCompletion":4214,"completion":4214,"start":4627,"enrollment":1509,"conditions":27901,"interventions":27902},"NCT00939731","Relative Drug Exposures Of Two Formulations of PF-02341066",[91],[16],[7523,7523],{"trials":27904,"activeCount":103},[27905],{"nctId":27906,"briefTitle":27907,"status":111,"phases":27908,"primaryCompletion":12307,"completion":3586,"start":10923,"enrollment":27909,"conditions":27910,"interventions":27911},"NCT00932451","An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",[92],1069,[376],[7523],{"trials":27913,"activeCount":103},[],{"trials":27915,"activeCount":103},[],{"trials":27917,"activeCount":103},[],{"intervention":27919,"totalTrials":578,"cells":27920},"EXC 001",{"EARLY_PHASE1":27921,"PHASE1":27923,"PHASE2":27925,"PHASE3":27967,"PHASE4":27969,"NA":27971},{"trials":27922,"activeCount":103},[],{"trials":27924,"activeCount":103},[],{"trials":27926,"activeCount":103},[27927,27936,27945,27952,27960],{"nctId":27928,"briefTitle":27929,"status":111,"phases":27930,"primaryCompletion":27931,"completion":27666,"start":27932,"enrollment":713,"conditions":27933,"interventions":27935},"NCT01037985","Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty",[92],"2010-07-07","2009-12-03",[27934],"Scar Prevention",[27919],{"nctId":27937,"briefTitle":27938,"status":111,"phases":27939,"primaryCompletion":27940,"completion":27940,"start":27941,"enrollment":3866,"conditions":27942,"interventions":27944},"NCT01346969","Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery",[92],"2012-04-16","2011-06-01",[27943],"Reduction in Hypertrophic Skin Scarring",[27919,27919,27919,27919],{"nctId":27946,"briefTitle":27938,"status":111,"phases":27947,"primaryCompletion":27948,"completion":27948,"start":27949,"enrollment":2713,"conditions":27950,"interventions":27951},"NCT01037413",[92],"2010-04-09","2009-12-22",[27934],[27919],{"nctId":27953,"briefTitle":27954,"status":111,"phases":27955,"primaryCompletion":8122,"completion":8122,"start":27956,"enrollment":562,"conditions":27957,"interventions":27959},"NCT01494922","Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001",[92],"2011-12-08",[27958],"Reduction in Severity of Skin Scarring",[27919],{"nctId":27961,"briefTitle":27962,"status":111,"phases":27963,"primaryCompletion":27931,"completion":27931,"start":27964,"enrollment":1780,"conditions":27965,"interventions":27966},"NCT01038297","Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty",[92],"2009-12-01",[27934],[27919],{"trials":27968,"activeCount":103},[],{"trials":27970,"activeCount":103},[],{"trials":27972,"activeCount":103},[],{"intervention":27974,"totalTrials":578,"cells":27975},"PF-06649751",{"EARLY_PHASE1":27976,"PHASE1":27978,"PHASE2":28007,"PHASE3":28018,"PHASE4":28020,"NA":28022},{"trials":27977,"activeCount":103},[],{"trials":27979,"activeCount":103},[27980,27987,27994,28000],{"nctId":27981,"briefTitle":27982,"status":111,"phases":27983,"primaryCompletion":12810,"completion":12810,"start":11356,"enrollment":26,"conditions":27984,"interventions":27986},"NCT02224664","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease",[91],[27985],"Parkinson's Disease",[27974,27974,27974,27974],{"nctId":27988,"briefTitle":27989,"status":111,"phases":27990,"primaryCompletion":11448,"completion":11448,"start":17639,"enrollment":627,"conditions":27991,"interventions":27992},"NCT02262767","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects",[91],[16],[27974,27993],"Trimethobenzamide Hydrochloride",{"nctId":27995,"briefTitle":27996,"status":111,"phases":27997,"primaryCompletion":3324,"completion":3324,"start":18769,"enrollment":597,"conditions":27998,"interventions":27999},"NCT01981694","A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751",[91],[16],[27974,27974],{"nctId":28001,"briefTitle":28002,"status":111,"phases":28003,"primaryCompletion":4280,"completion":12810,"start":12307,"enrollment":597,"conditions":28004,"interventions":28006},"NCT02373072","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease",[91],[28005],"Idiopathic Parkinson Disease",[27974,27993],{"trials":28008,"activeCount":103},[28009],{"nctId":28010,"briefTitle":28011,"status":168,"phases":28012,"primaryCompletion":28013,"completion":28013,"start":28014,"enrollment":28015,"conditions":28016,"interventions":28017},"NCT02847650","Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease",[92],"2018-01-29","2016-10-17",57,[13750],[27974],{"trials":28019,"activeCount":103},[],{"trials":28021,"activeCount":103},[],{"trials":28023,"activeCount":103},[],{"intervention":7559,"totalTrials":578,"cells":28025},{"EARLY_PHASE1":28026,"PHASE1":28028,"PHASE2":28038,"PHASE3":28063,"PHASE4":28065,"NA":28067},{"trials":28027,"activeCount":103},[],{"trials":28029,"activeCount":103},[28030,28034],{"nctId":7552,"briefTitle":7553,"status":111,"phases":28031,"primaryCompletion":296,"completion":296,"start":7555,"enrollment":314,"conditions":28032,"interventions":28033},[91],[16],[7558,7559,2082],{"nctId":7823,"briefTitle":7824,"status":111,"phases":28035,"primaryCompletion":7826,"completion":7826,"start":7827,"enrollment":1239,"conditions":28036,"interventions":28037},[91],[2715],[7801,7830,7831],{"trials":28039,"activeCount":103},[28040,28047,28056],{"nctId":28041,"briefTitle":28042,"status":649,"phases":28043,"start":11314,"enrollment":103,"conditions":28044,"interventions":28045},"NCT00556257","Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients",[92],[4533],[7559,28046],"CP-690-,550",{"nctId":28048,"briefTitle":28049,"status":111,"phases":28050,"primaryCompletion":4846,"completion":4846,"start":4645,"enrollment":28051,"conditions":28052,"interventions":28054},"NCT00784719","A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.",[91,92],327,[28053],"Dry Eye Syndromes",[12692,12692,12692,12692,7559,28055],"CP-690,550 Vehicle",{"nctId":28057,"briefTitle":28058,"status":111,"phases":28059,"primaryCompletion":12307,"completion":4438,"start":8115,"enrollment":28060,"conditions":28061,"interventions":28062},"NCT00658359","Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients",[92],178,[4533],[7559,12692,12692],{"trials":28064,"activeCount":103},[],{"trials":28066,"activeCount":103},[],{"trials":28068,"activeCount":103},[],{"intervention":664,"totalTrials":578,"cells":28070},{"EARLY_PHASE1":28071,"PHASE1":28073,"PHASE2":28092,"PHASE3":28102,"PHASE4":28104,"NA":28106},{"trials":28072,"activeCount":103},[],{"trials":28074,"activeCount":103},[28075,28079,28085],{"nctId":7544,"briefTitle":7545,"status":111,"phases":28076,"primaryCompletion":4242,"completion":7547,"start":7548,"enrollment":314,"conditions":28077,"interventions":28078},[91],[16],[664,664,664,664,2082],{"nctId":28080,"briefTitle":28081,"status":111,"phases":28082,"primaryCompletion":5957,"completion":5957,"start":5008,"enrollment":1268,"conditions":28083,"interventions":28084},"NCT02804399","A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers",[91],[16],[664,589],{"nctId":28086,"briefTitle":28087,"status":111,"phases":28088,"primaryCompletion":12811,"completion":12811,"start":3586,"enrollment":504,"conditions":28089,"interventions":28090},"NCT02569554","PPI And Food Effect Study For PF-06463922 In Healthy Volunteers",[91],[16],[664,28091],"rabeprazole",{"trials":28093,"activeCount":103},[28094,28098],{"nctId":656,"briefTitle":657,"status":168,"phases":28095,"primaryCompletion":150,"completion":659,"start":660,"enrollment":32,"conditions":28096,"interventions":28097},[91,92],[422],[663,664,388],{"nctId":666,"briefTitle":667,"status":111,"phases":28099,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":28100,"interventions":28101},[91,92],[674],[664,388],{"trials":28103,"activeCount":103},[],{"trials":28105,"activeCount":103},[],{"trials":28107,"activeCount":103},[],{"intervention":28109,"totalTrials":578,"cells":28110},"PF-05212377",{"EARLY_PHASE1":28111,"PHASE1":28113,"PHASE2":28142,"PHASE3":28151,"PHASE4":28153,"NA":28155},{"trials":28112,"activeCount":103},[],{"trials":28114,"activeCount":103},[28115,28124,28130,28136],{"nctId":28116,"briefTitle":28117,"status":111,"phases":28118,"primaryCompletion":4531,"completion":4531,"start":523,"enrollment":1796,"conditions":28119,"interventions":28120},"NCT01213355","Scopolamine Challenge Study",[91],[16],[28121,28109,28121,28109,28122,28109,28122,28123,28121],"Scopolamine","scopolamine","Donepezil",{"nctId":28125,"briefTitle":28126,"status":111,"phases":28127,"primaryCompletion":11170,"completion":11170,"start":4656,"enrollment":1268,"conditions":28128,"interventions":28129},"NCT01258751","This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers",[91],[16],[28109],{"nctId":28131,"briefTitle":28132,"status":111,"phases":28133,"primaryCompletion":4656,"completion":4656,"start":586,"enrollment":2240,"conditions":28134,"interventions":28135},"NCT01159496","Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760)",[91],[16],[28109],{"nctId":28137,"briefTitle":28138,"status":111,"phases":28139,"primaryCompletion":1248,"completion":1248,"start":18769,"enrollment":257,"conditions":28140,"interventions":28141},"NCT02005991","A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377",[91],[16],[28109,28109,28109],{"trials":28143,"activeCount":103},[28144],{"nctId":28145,"briefTitle":28146,"status":168,"phases":28147,"primaryCompletion":12853,"completion":12853,"start":3345,"enrollment":28148,"conditions":28149,"interventions":28150},"NCT01712074","Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil",[92],186,[17728],[28109],{"trials":28152,"activeCount":103},[],{"trials":28154,"activeCount":103},[],{"trials":28156,"activeCount":103},[],{"intervention":28158,"totalTrials":578,"cells":28159},"PF-04950615",{"EARLY_PHASE1":28160,"PHASE1":28162,"PHASE2":28180,"PHASE3":28205,"PHASE4":28207,"NA":28209},{"trials":28161,"activeCount":103},[],{"trials":28163,"activeCount":103},[28164,28174],{"nctId":28165,"briefTitle":28166,"status":111,"phases":28167,"primaryCompletion":18026,"completion":3334,"start":114,"enrollment":2175,"conditions":28168,"interventions":28173},"NCT01435382","A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia",[91],[12981,28169,28170,28171,28172],"Dyslipidemias","Hyperlipidemias","Lipid Metabolism Disorders","Metabolic Diseases",[28158,28158,28158,28158],{"nctId":28175,"briefTitle":28176,"status":111,"phases":28177,"primaryCompletion":114,"completion":114,"start":4666,"enrollment":3866,"conditions":28178,"interventions":28179},"NCT01243151","Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia",[91],[12981,12980],[28158,28158,28158,28158,28158],{"trials":28181,"activeCount":103},[28182,28188,28197],{"nctId":28183,"briefTitle":28184,"status":111,"phases":28185,"primaryCompletion":3334,"completion":4459,"start":2661,"enrollment":787,"conditions":28186,"interventions":28187},"NCT01350141","A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins",[92],[12981,12980],[28158,28158],{"nctId":28189,"briefTitle":28190,"status":111,"phases":28191,"primaryCompletion":6208,"completion":6198,"start":540,"enrollment":12141,"conditions":28192,"interventions":28193},"NCT01592240","Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin",[92],[12981],[28194,28195,28196,28194,28158,28158,28158],"PBO","200mg PF-04950615","300mg PF-04950615",{"nctId":28198,"briefTitle":28199,"status":111,"phases":28200,"primaryCompletion":18026,"completion":4459,"start":3313,"enrollment":8013,"conditions":28201,"interventions":28202},"NCT01342211","A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins",[92],[12981,12980],[28203,28158,28203,28158,28203,28158,28204,28158,28203],"Statin","Satin",{"trials":28206,"activeCount":103},[],{"trials":28208,"activeCount":103},[],{"trials":28210,"activeCount":103},[],{"intervention":28212,"totalTrials":257,"cells":28213},"methylprednisolone",{"EARLY_PHASE1":28214,"PHASE1":28216,"PHASE2":28241,"PHASE3":28247,"PHASE4":28249,"NA":28251},{"trials":28215,"activeCount":103},[],{"trials":28217,"activeCount":103},[28218,28224,28234],{"nctId":28219,"briefTitle":28220,"status":111,"phases":28221,"primaryCompletion":4656,"completion":4656,"start":8252,"enrollment":1509,"conditions":28222,"interventions":28223},"NCT01267201","A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form",[91],[9930],[28212,28212,28212],{"nctId":28225,"briefTitle":28226,"status":649,"phases":28227,"primaryCompletion":28228,"completion":28229,"start":28230,"enrollment":103,"conditions":28231,"interventions":28233},"NCT01405170","A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions",[91],"2011-10-28","2012-02-20","2011-10-14",[28232],"Therapeutic Equivalency",[28212,28212],{"nctId":28235,"briefTitle":28236,"status":649,"phases":28237,"primaryCompletion":28229,"completion":28229,"start":28238,"enrollment":103,"conditions":28239,"interventions":28240},"NCT01405131","A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets",[91],"2012-01-01",[28232],[28212,28212],{"trials":28242,"activeCount":103},[28243],{"nctId":11985,"briefTitle":11986,"status":168,"phases":28244,"primaryCompletion":11988,"completion":3353,"start":3335,"enrollment":9553,"conditions":28245,"interventions":28246},[92],[4514],[11991,11992,2341,11991,11992,2341,11991,11992,2341],{"trials":28248,"activeCount":103},[],{"trials":28250,"activeCount":103},[],{"trials":28252,"activeCount":103},[],{"intervention":28254,"totalTrials":257,"cells":28255},"ARRY-371797, p38 inhibitor;",{"EARLY_PHASE1":28256,"PHASE1":28258,"PHASE2":28260,"PHASE3":28295,"PHASE4":28297,"NA":28299},{"trials":28257,"activeCount":103},[],{"trials":28259,"activeCount":103},[],{"trials":28261,"activeCount":103},[28262,28269,28277,28287],{"nctId":28263,"briefTitle":28264,"status":111,"phases":28265,"primaryCompletion":651,"completion":651,"start":3324,"enrollment":1268,"conditions":28266,"interventions":28268},"NCT02057341","A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy",[92],[28267],"LMNA-Related Dilated Cardiomyopathy",[28254],{"nctId":28270,"briefTitle":28271,"status":111,"phases":28272,"primaryCompletion":4459,"completion":4459,"start":2661,"enrollment":7184,"conditions":28273,"interventions":28275},"NCT01366014","A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee",[92],[28274],"Osteoarthritis of the Knee",[28254,28276],"Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist;",{"nctId":28278,"briefTitle":28279,"status":111,"phases":28280,"primaryCompletion":28281,"completion":28281,"start":28282,"enrollment":28283,"conditions":28284,"interventions":28286},"NCT00542035","A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction",[92],"2008-02-11","2007-11-11",103,[28285],"Dental Pain",[28254,28254],{"nctId":28288,"briefTitle":28279,"status":111,"phases":28289,"primaryCompletion":28290,"completion":28290,"start":28291,"enrollment":8827,"conditions":28292,"interventions":28293},"NCT00663767",[92],"2008-06-20","2008-04-07",[28285],[28254,28254,28294,28254],"Celecoxib, COX-2 inhibitor;",{"trials":28296,"activeCount":103},[],{"trials":28298,"activeCount":103},[],{"trials":28300,"activeCount":103},[],{"intervention":28302,"totalTrials":257,"cells":28303},"PF-06291874",{"EARLY_PHASE1":28304,"PHASE1":28306,"PHASE2":28323,"PHASE3":28338,"PHASE4":28340,"NA":28342},{"trials":28305,"activeCount":103},[],{"trials":28307,"activeCount":103},[28308,28314],{"nctId":28309,"briefTitle":28310,"status":111,"phases":28311,"primaryCompletion":4680,"completion":4680,"start":4590,"enrollment":1487,"conditions":28312,"interventions":28313},"NCT01794364","Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects",[91],[16],[28302],{"nctId":28315,"briefTitle":28316,"status":111,"phases":28317,"primaryCompletion":28318,"completion":28319,"start":28320,"enrollment":6280,"conditions":28321,"interventions":28322},"NCT01856595","PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients",[91],"2014-01-10","2014-03-01","2013-05-13",[37],[28302],{"trials":28324,"activeCount":103},[28325,28332],{"nctId":28326,"briefTitle":28327,"status":111,"phases":28328,"primaryCompletion":12307,"completion":12307,"start":7386,"enrollment":11323,"conditions":28329,"interventions":28331},"NCT02175121","Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus",[92],[28330],"Diabetes Mellitus, Type II",[28302,28302,28302,28302],{"nctId":28333,"briefTitle":28334,"status":111,"phases":28335,"primaryCompletion":13581,"completion":13581,"start":626,"enrollment":11007,"conditions":28336,"interventions":28337},"NCT02554877","A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin",[92],[12968],[28302],{"trials":28339,"activeCount":103},[],{"trials":28341,"activeCount":103},[],{"trials":28343,"activeCount":103},[],{"intervention":6110,"totalTrials":257,"cells":28345},{"EARLY_PHASE1":28346,"PHASE1":28348,"PHASE2":28365,"PHASE3":28374,"PHASE4":28376,"NA":28378},{"trials":28347,"activeCount":103},[],{"trials":28349,"activeCount":103},[28350,28354,28361],{"nctId":6102,"briefTitle":6103,"status":111,"phases":28351,"primaryCompletion":6105,"completion":6105,"start":6106,"enrollment":6107,"conditions":28352,"interventions":28353},[91],[16],[6110,1687,6111],{"nctId":28355,"briefTitle":28356,"status":111,"phases":28357,"primaryCompletion":7749,"completion":7749,"start":28358,"enrollment":314,"conditions":28359,"interventions":28360},"NCT06586216","A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.",[91],"2024-09-10",[2592],[6110],{"nctId":7561,"briefTitle":7562,"status":111,"phases":28362,"primaryCompletion":7472,"completion":7472,"start":7564,"enrollment":1268,"conditions":28363,"interventions":28364},[91],[16],[6110,2082],{"trials":28366,"activeCount":103},[28367],{"nctId":28368,"briefTitle":28369,"status":111,"phases":28370,"primaryCompletion":27437,"completion":2122,"start":28371,"enrollment":22897,"conditions":28372,"interventions":28373},"NCT05799495","A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized",[92],"2023-05-23",[2593],[6110],{"trials":28375,"activeCount":103},[],{"trials":28377,"activeCount":103},[],{"trials":28379,"activeCount":103},[],{"intervention":27131,"totalTrials":257,"cells":28381},{"EARLY_PHASE1":28382,"PHASE1":28384,"PHASE2":28404,"PHASE3":28419,"PHASE4":28421,"NA":28423},{"trials":28383,"activeCount":103},[],{"trials":28385,"activeCount":103},[28386,28395],{"nctId":28387,"briefTitle":28388,"status":111,"phases":28389,"primaryCompletion":28390,"completion":28390,"start":28391,"enrollment":374,"conditions":28392,"interventions":28393},"NCT03210961","A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis",[91],"2019-01-25","2017-07-14",[26842],[27131,28394],"PF-06826647 oral suspension",{"nctId":28396,"briefTitle":28397,"status":111,"phases":28398,"primaryCompletion":28399,"completion":28399,"start":28400,"enrollment":498,"conditions":28401,"interventions":28402},"NCT04134715","A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants",[91],"2020-01-09","2019-10-23",[16],[27131,28403],"Oral Contraceptive",{"trials":28405,"activeCount":103},[28406,28410],{"nctId":27124,"briefTitle":27125,"status":111,"phases":28407,"primaryCompletion":3402,"completion":3402,"start":2911,"enrollment":27127,"conditions":28408,"interventions":28409},[92],[27129],[4424,7595,27131],{"nctId":28411,"briefTitle":28412,"status":111,"phases":28413,"primaryCompletion":28414,"completion":19174,"start":28415,"enrollment":14574,"conditions":28416,"interventions":28417},"NCT03895372","A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis",[92],"2020-05-21","2019-06-27",[4401],[28418,27131],"PF-06826647 or Placebo",{"trials":28420,"activeCount":103},[],{"trials":28422,"activeCount":103},[],{"trials":28424,"activeCount":103},[],{"intervention":28426,"totalTrials":257,"cells":28427},"PF-05221304",{"EARLY_PHASE1":28428,"PHASE1":28430,"PHASE2":28448,"PHASE3":28469,"PHASE4":28471,"NA":28473},{"trials":28429,"activeCount":103},[],{"trials":28431,"activeCount":103},[28432,28441],{"nctId":28433,"briefTitle":28434,"status":111,"phases":28435,"primaryCompletion":28436,"completion":28437,"start":28438,"enrollment":1509,"conditions":28439,"interventions":28440},"NCT03309202","Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment",[91],"2018-06-26","2018-07-18","2017-12-19",[7853],[28426],{"nctId":28442,"briefTitle":28443,"status":111,"phases":28444,"primaryCompletion":26848,"completion":26848,"start":13581,"enrollment":27075,"conditions":28445,"interventions":28447},"NCT02871037","Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects",[91],[28446],"Normal Healthy",[28426],{"trials":28449,"activeCount":103},[28450,28461],{"nctId":28451,"briefTitle":28452,"status":111,"phases":28453,"primaryCompletion":28454,"completion":28455,"start":28456,"enrollment":26916,"conditions":28457,"interventions":28460},"NCT03248882","Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)",[92],"2019-02-26","2019-03-27","2017-08-22",[28458,28459],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis",[28426],{"nctId":28462,"briefTitle":28463,"status":111,"phases":28464,"primaryCompletion":28465,"completion":359,"start":371,"enrollment":4755,"conditions":28466,"interventions":28467},"NCT04399538","Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis",[92],"2022-03-31",[28459,28458],[28468,28426],"PF-06865571",{"trials":28470,"activeCount":103},[],{"trials":28472,"activeCount":103},[],{"trials":28474,"activeCount":103},[],{"intervention":26871,"totalTrials":257,"cells":28476},{"EARLY_PHASE1":28477,"PHASE1":28479,"PHASE2":28491,"PHASE3":28505,"PHASE4":28507,"NA":28509},{"trials":28478,"activeCount":103},[],{"trials":28480,"activeCount":103},[28481,28485],{"nctId":26865,"briefTitle":26866,"status":111,"phases":28482,"primaryCompletion":2883,"completion":2883,"start":3601,"enrollment":1097,"conditions":28483,"interventions":28484},[91],[26869],[26871,11326],{"nctId":28486,"briefTitle":28487,"status":111,"phases":28488,"primaryCompletion":3601,"completion":3601,"start":561,"enrollment":1530,"conditions":28489,"interventions":28490},"NCT01186757","Multiple Dose Healthy Volunteer Study of PF-03715455.",[91],[19],[26871,26871,26871],{"trials":28492,"activeCount":103},[28493,28499],{"nctId":28494,"briefTitle":28495,"status":168,"phases":28496,"primaryCompletion":4458,"completion":4458,"start":11956,"enrollment":3254,"conditions":28497,"interventions":28498},"NCT02366637","An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease",[92],[21083],[26871],{"nctId":28500,"briefTitle":28501,"status":168,"phases":28502,"primaryCompletion":4458,"completion":4458,"start":17639,"enrollment":5425,"conditions":28503,"interventions":28504},"NCT02219048","An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma",[92],[6589],[26871],{"trials":28506,"activeCount":103},[],{"trials":28508,"activeCount":103},[],{"trials":28510,"activeCount":103},[],{"intervention":28512,"totalTrials":257,"cells":28513},"PF-00489791",{"EARLY_PHASE1":28514,"PHASE1":28516,"PHASE2":28518,"PHASE3":28553,"PHASE4":28555,"NA":28557},{"trials":28515,"activeCount":103},[],{"trials":28517,"activeCount":103},[],{"trials":28519,"activeCount":103},[28520,28527,28536,28543],{"nctId":28521,"briefTitle":28522,"status":168,"phases":28523,"primaryCompletion":586,"completion":586,"start":4222,"enrollment":4369,"conditions":28524,"interventions":28525},"NCT00853112","A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension",[92],[20005],[28512,28512,28512,28512,28512,28526],"sildenafil",{"nctId":28528,"briefTitle":28529,"status":111,"phases":28530,"primaryCompletion":28531,"completion":28531,"start":28532,"enrollment":28533,"conditions":28534,"interventions":28535},"NCT00422461","A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure",[92],"2008-01-28","2007-02-27",135,[13280],[28512,28512,28512],{"nctId":28537,"briefTitle":28538,"status":111,"phases":28539,"primaryCompletion":6263,"completion":6207,"start":4656,"enrollment":13377,"conditions":28540,"interventions":28542},"NCT01200394","A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy",[92],[28541],"Diabetic Nephropathies",[28512],{"nctId":28544,"briefTitle":28545,"status":111,"phases":28546,"primaryCompletion":28547,"completion":28547,"start":28548,"enrollment":16174,"conditions":28549,"interventions":28552},"NCT01090492","PF-00489791 For The Treatment Of Raynaud's",[92],"2011-05-31","2010-08-04",[28550,28551],"Raynaud's Disease","Peripheral Vascular Disease",[28512,28512,28512,28512,28512,28512,28512,28512],{"trials":28554,"activeCount":103},[],{"trials":28556,"activeCount":103},[],{"trials":28558,"activeCount":103},[],{"intervention":6283,"totalTrials":257,"cells":28560},{"EARLY_PHASE1":28561,"PHASE1":28563,"PHASE2":28583,"PHASE3":28593,"PHASE4":28595,"NA":28597},{"trials":28562,"activeCount":103},[],{"trials":28564,"activeCount":103},[28565,28569,28579],{"nctId":27406,"briefTitle":27407,"status":168,"phases":28566,"primaryCompletion":3946,"completion":6587,"start":27409,"enrollment":360,"conditions":28567,"interventions":28568},[91],[2760,2761],[6283,6224],{"nctId":28570,"briefTitle":28571,"status":111,"phases":28572,"primaryCompletion":28573,"completion":28574,"start":28575,"enrollment":1487,"conditions":28576,"interventions":28577},"NCT07015918","A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men",[91],"2025-07-16","2025-08-14","2025-06-04",[17080],[28578,6283,28578],"[14C] PF-07976016",{"nctId":6276,"briefTitle":6277,"status":111,"phases":28580,"primaryCompletion":6279,"completion":6279,"start":3797,"enrollment":6280,"conditions":28581,"interventions":28582},[91],[16],[6283,1687],{"trials":28584,"activeCount":103},[28585],{"nctId":28586,"briefTitle":28587,"status":111,"phases":28588,"primaryCompletion":28589,"completion":1665,"start":28590,"enrollment":10947,"conditions":28591,"interventions":28592},"NCT06717425","A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity",[92],"2025-10-23","2024-12-09",[2761],[6283],{"trials":28594,"activeCount":103},[],{"trials":28596,"activeCount":103},[],{"trials":28598,"activeCount":103},[],{"intervention":28468,"totalTrials":257,"cells":28600},{"EARLY_PHASE1":28601,"PHASE1":28603,"PHASE2":28629,"PHASE3":28635,"PHASE4":28637,"NA":28639},{"trials":28602,"activeCount":103},[],{"trials":28604,"activeCount":103},[28605,28613,28622],{"nctId":28606,"briefTitle":28607,"status":111,"phases":28608,"primaryCompletion":28609,"completion":26795,"start":28610,"enrollment":597,"conditions":28611,"interventions":28612},"NCT03593707","Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics",[91],"2019-01-17","2018-08-17",[19],[6170,28468],{"nctId":28614,"briefTitle":28615,"status":111,"phases":28616,"primaryCompletion":28617,"completion":28618,"start":28619,"enrollment":7500,"conditions":28620,"interventions":28621},"NCT03092232","Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571",[91],"2017-07-13","2017-07-17","2017-03-16",[16],[28468,28468,28468],{"nctId":28623,"briefTitle":28624,"status":111,"phases":28625,"primaryCompletion":28626,"completion":28626,"start":23585,"enrollment":2240,"conditions":28627,"interventions":28628},"NCT03230383","A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects",[91],"2018-05-03",[10985],[28468,28468,28468,28468,28468,28468,28468],{"trials":28630,"activeCount":103},[28631],{"nctId":28462,"briefTitle":28463,"status":111,"phases":28632,"primaryCompletion":28465,"completion":359,"start":371,"enrollment":4755,"conditions":28633,"interventions":28634},[92],[28459,28458],[28468,28426],{"trials":28636,"activeCount":103},[],{"trials":28638,"activeCount":103},[],{"trials":28640,"activeCount":103},[],{"intervention":2647,"totalTrials":257,"cells":28642},{"EARLY_PHASE1":28643,"PHASE1":28645,"PHASE2":28647,"PHASE3":28667,"PHASE4":28669,"NA":28671},{"trials":28644,"activeCount":103},[],{"trials":28646,"activeCount":103},[],{"trials":28648,"activeCount":103},[28649,28653,28657,28663],{"nctId":19019,"briefTitle":19020,"status":111,"phases":28650,"primaryCompletion":4679,"completion":4679,"start":11782,"enrollment":1268,"conditions":28651,"interventions":28652},[91,92],[19023],[2647,9417,2647,9417,2647,9417,2647,9417],{"nctId":2638,"briefTitle":2639,"status":111,"phases":28654,"completion":2641,"start":2642,"enrollment":2643,"conditions":28655,"interventions":28656},[92],[2645],[2647,968,968],{"nctId":28658,"briefTitle":28659,"status":111,"phases":28660,"primaryCompletion":7675,"completion":7675,"start":22517,"enrollment":1578,"conditions":28661,"interventions":28662},"NCT00043407","CPG 7909 in Patients Wih Stage IV Renal Cell Cancer",[91,92],[919],[2647],{"nctId":2668,"briefTitle":2669,"status":111,"phases":28664,"primaryCompletion":2671,"completion":2671,"start":2672,"enrollment":2673,"conditions":28665,"interventions":28666},[92],[2675],[2647,2677,968,2647,2647],{"trials":28668,"activeCount":103},[],{"trials":28670,"activeCount":103},[],{"trials":28672,"activeCount":103},[],{"intervention":8232,"totalTrials":257,"cells":28674},{"EARLY_PHASE1":28675,"PHASE1":28677,"PHASE2":28695,"PHASE3":28710,"PHASE4":28712,"NA":28714},{"trials":28676,"activeCount":103},[],{"trials":28678,"activeCount":103},[28679,28689],{"nctId":28680,"briefTitle":28681,"status":111,"phases":28682,"primaryCompletion":28683,"completion":28684,"start":28685,"enrollment":7388,"conditions":28686,"interventions":28688},"NCT00878189","A Trial In Patients With Advanced Cancer And Leukemia",[91],"2013-01-10","2016-11-22","2009-06-25",[28687],"Neoplasms by Histologic Type",[8232],{"nctId":28690,"briefTitle":28691,"status":649,"phases":28692,"primaryCompletion":539,"completion":5957,"start":4439,"enrollment":103,"conditions":28693,"interventions":28694},"NCT02462707","A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors",[91],[553],[8232],{"trials":28696,"activeCount":103},[28697,28701],{"nctId":8224,"briefTitle":8225,"status":168,"phases":28698,"primaryCompletion":8227,"completion":8227,"start":8228,"enrollment":502,"conditions":28699,"interventions":28700},[92],[8230],[8232,1764,1765,8232,1764,1765,1764,1765],{"nctId":28702,"briefTitle":28703,"status":168,"phases":28704,"primaryCompletion":28705,"completion":28705,"start":28706,"enrollment":99,"conditions":28707,"interventions":28709},"NCT02299635","A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations",[92],"2016-01-14","2015-02-03",[28708],"Triple Negative Breast Neoplasms",[8232,8232,8232],{"trials":28711,"activeCount":103},[],{"trials":28713,"activeCount":103},[],{"trials":28715,"activeCount":103},[],{"intervention":28717,"totalTrials":257,"cells":28718},"CP-526,555",{"EARLY_PHASE1":28719,"PHASE1":28721,"PHASE2":28723,"PHASE3":28749,"PHASE4":28751,"NA":28753},{"trials":28720,"activeCount":103},[],{"trials":28722,"activeCount":103},[],{"trials":28724,"activeCount":103},[28725,28731,28737,28743],{"nctId":28726,"briefTitle":28727,"status":111,"phases":28728,"completion":4647,"start":15120,"enrollment":3694,"conditions":28729,"interventions":28730},"NCT00150241","A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation",[92],[11904],[28717],{"nctId":28732,"briefTitle":28733,"status":111,"phases":28734,"completion":12416,"start":4702,"enrollment":130,"conditions":28735,"interventions":28736},"NCT00139750","12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation",[92],[11904],[28717],{"nctId":28738,"briefTitle":28739,"status":111,"phases":28740,"completion":15036,"start":19543,"enrollment":1613,"conditions":28741,"interventions":28742},"NCT00150228","12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation",[92],[11904],[28717],{"nctId":28744,"briefTitle":28745,"status":111,"phases":28746,"completion":11379,"start":21191,"enrollment":3694,"conditions":28747,"interventions":28748},"NCT00150254","12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.",[92],[11904],[28717],{"trials":28750,"activeCount":103},[],{"trials":28752,"activeCount":103},[],{"trials":28754,"activeCount":103},[],{"intervention":17974,"totalTrials":257,"cells":28756},{"EARLY_PHASE1":28757,"PHASE1":28759,"PHASE2":28778,"PHASE3":28784,"PHASE4":28786,"NA":28788},{"trials":28758,"activeCount":103},[],{"trials":28760,"activeCount":103},[28761,28770,28774],{"nctId":28762,"briefTitle":28763,"status":111,"phases":28764,"primaryCompletion":28765,"completion":28766,"start":28767,"enrollment":2218,"conditions":28768,"interventions":28769},"NCT01286467","A Study Of PF-04449913 Administered Alone In Select Solid Tumors",[91],"2012-05-10","2012-12-28","2011-05-11",[750],[17974],{"nctId":17966,"briefTitle":17967,"status":111,"phases":28771,"primaryCompletion":17969,"completion":4980,"start":17970,"enrollment":463,"conditions":28772,"interventions":28773},[91],[16958,2938,17972],[17974,2940],{"nctId":17976,"briefTitle":17977,"status":111,"phases":28775,"primaryCompletion":17979,"completion":17980,"start":17981,"enrollment":4369,"conditions":28776,"interventions":28777},[91],[2938],[17974,17974,17984,17974,17959,17958,17974,2940,17974,17985],{"trials":28779,"activeCount":103},[28780],{"nctId":18727,"briefTitle":18728,"status":111,"phases":28781,"primaryCompletion":18730,"completion":18731,"start":18732,"enrollment":18733,"conditions":28782,"interventions":28783},[92],[2938],[17974,17984,17974,17960,17974,17959,17958,17974,17959,17958,17974,17984],{"trials":28785,"activeCount":103},[],{"trials":28787,"activeCount":103},[],{"trials":28789,"activeCount":103},[],{"intervention":28791,"totalTrials":257,"cells":28792},"PD 0200390",{"EARLY_PHASE1":28793,"PHASE1":28795,"PHASE2":28804,"PHASE3":28826,"PHASE4":28828,"NA":28830},{"trials":28794,"activeCount":103},[],{"trials":28796,"activeCount":103},[28797],{"nctId":28798,"briefTitle":28799,"status":111,"phases":28800,"primaryCompletion":2884,"completion":2884,"start":2884,"enrollment":2070,"conditions":28801,"interventions":28803},"NCT00722306","A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers",[91],[28802],"Insomnia",[28791],{"trials":28805,"activeCount":103},[28806,28813,28819],{"nctId":28807,"briefTitle":28808,"status":111,"phases":28809,"primaryCompletion":8251,"completion":8251,"start":11609,"enrollment":28810,"conditions":28811,"interventions":28812},"NCT00569972","A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia",[92],682,[28802],[28791,28791,28791,28791],{"nctId":28814,"briefTitle":28815,"status":649,"phases":28816,"primaryCompletion":4646,"completion":4646,"start":8251,"enrollment":103,"conditions":28817,"interventions":28818},"NCT00748592","A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia",[92],[28802],[28791,28791,28791],{"nctId":28820,"briefTitle":28821,"status":111,"phases":28822,"primaryCompletion":3853,"completion":3853,"start":11609,"enrollment":6152,"conditions":28823,"interventions":28825},"NCT00551148","A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia",[92],[28824],"Primary Insomnia",[28791,28791,28791,28791],{"trials":28827,"activeCount":103},[],{"trials":28829,"activeCount":103},[],{"trials":28831,"activeCount":103},[],{"intervention":28833,"totalTrials":502,"cells":28834},"PF-04236921",{"EARLY_PHASE1":28835,"PHASE1":28837,"PHASE2":28845,"PHASE3":28859,"PHASE4":28861,"NA":28863},{"trials":28836,"activeCount":103},[],{"trials":28838,"activeCount":103},[28839],{"nctId":28840,"briefTitle":28841,"status":111,"phases":28842,"primaryCompletion":585,"completion":585,"start":2660,"enrollment":870,"conditions":28843,"interventions":28844},"NCT01166555","Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers",[91],[16],[28833],{"trials":28846,"activeCount":103},[28847,28853],{"nctId":28848,"briefTitle":28849,"status":111,"phases":28850,"primaryCompletion":605,"completion":605,"start":2883,"enrollment":1915,"conditions":28851,"interventions":28852},"NCT01405196","Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus",[92],[5141],[28833,28833,28833,28833],{"nctId":28854,"briefTitle":28855,"status":111,"phases":28856,"primaryCompletion":12810,"completion":12810,"start":2661,"enrollment":1413,"conditions":28857,"interventions":28858},"NCT01345318","B0151005 Open-Label Extension Study",[92],[1570],[28833,28833],{"trials":28860,"activeCount":103},[],{"trials":28862,"activeCount":103},[],{"trials":28864,"activeCount":103},[],{"intervention":2455,"totalTrials":502,"cells":28866},{"EARLY_PHASE1":28867,"PHASE1":28869,"PHASE2":28877,"PHASE3":28887,"PHASE4":28889,"NA":28891},{"trials":28868,"activeCount":103},[],{"trials":28870,"activeCount":103},[28871],{"nctId":28872,"briefTitle":28873,"status":111,"phases":28874,"primaryCompletion":524,"completion":3334,"start":4221,"enrollment":2849,"conditions":28875,"interventions":28876},"NCT00927823","A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients",[91],[5950],[2455],{"trials":28878,"activeCount":103},[28879,28883],{"nctId":4586,"briefTitle":4587,"status":649,"phases":28880,"primaryCompletion":4589,"completion":4589,"start":4590,"enrollment":103,"conditions":28881,"interventions":28882},[92],[25],[2455,1674,1674],{"nctId":2446,"briefTitle":2447,"status":168,"phases":28884,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":562,"conditions":28885,"interventions":28886},[92],[2452,2453],[2455,2456,1243],{"trials":28888,"activeCount":103},[],{"trials":28890,"activeCount":103},[],{"trials":28892,"activeCount":103},[],{"intervention":28894,"totalTrials":502,"cells":28895},"PF-04136309",{"EARLY_PHASE1":28896,"PHASE1":28898,"PHASE2":28906,"PHASE3":28926,"PHASE4":28928,"NA":28930},{"trials":28897,"activeCount":103},[],{"trials":28899,"activeCount":103},[28900],{"nctId":28901,"briefTitle":28902,"status":111,"phases":28903,"primaryCompletion":651,"completion":651,"start":3586,"enrollment":597,"conditions":28904,"interventions":28905},"NCT02598206","Food Effect Study PF-04136309",[91],[16],[28894],{"trials":28907,"activeCount":103},[28908,28917],{"nctId":28909,"briefTitle":28910,"status":168,"phases":28911,"primaryCompletion":28912,"completion":28912,"start":28913,"enrollment":1509,"conditions":28914,"interventions":28916},"NCT01226797","Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes",[92],"2012-02-09","2011-01-17",[28915],"Hepatitis C, Chronic",[28894],{"nctId":28918,"briefTitle":28919,"status":111,"phases":28920,"primaryCompletion":28921,"completion":28921,"start":28922,"enrollment":28923,"conditions":28924,"interventions":28925},"NCT00689273","Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee",[92],"2008-11-27","2008-08-05",159,[11347],[28894],{"trials":28927,"activeCount":103},[],{"trials":28929,"activeCount":103},[],{"trials":28931,"activeCount":103},[],{"intervention":28933,"totalTrials":502,"cells":28934},"AN2690",{"EARLY_PHASE1":28935,"PHASE1":28937,"PHASE2":28939,"PHASE3":28964,"PHASE4":28966,"NA":28968},{"trials":28936,"activeCount":103},[],{"trials":28938,"activeCount":103},[],{"trials":28940,"activeCount":103},[28941,28948,28956],{"nctId":28942,"briefTitle":28943,"status":111,"phases":28944,"primaryCompletion":18436,"completion":18436,"start":18437,"enrollment":2240,"conditions":28945,"interventions":28947},"NCT00680134","Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis",[92],[28946],"Onychomycosis",[28933,28933],{"nctId":28949,"briefTitle":28950,"status":111,"phases":28951,"primaryCompletion":28952,"completion":28952,"start":28953,"enrollment":2159,"conditions":28954,"interventions":28955},"NCT00679601","Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)",[92],"2007-05-31","2007-03-31",[28946],[28933],{"nctId":28957,"briefTitle":28958,"status":111,"phases":28959,"primaryCompletion":28960,"completion":28960,"start":28961,"enrollment":498,"conditions":28962,"interventions":28963},"NCT00680160","Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)",[92],"2007-05-09","2006-04-30",[28946],[28933],{"trials":28965,"activeCount":103},[],{"trials":28967,"activeCount":103},[],{"trials":28969,"activeCount":103},[],{"intervention":11349,"totalTrials":502,"cells":28971},{"EARLY_PHASE1":28972,"PHASE1":28974,"PHASE2":28982,"PHASE3":28995,"PHASE4":28997,"NA":28999},{"trials":28973,"activeCount":103},[],{"trials":28975,"activeCount":103},[28976],{"nctId":28977,"briefTitle":28978,"status":649,"phases":28979,"primaryCompletion":3601,"completion":3601,"start":4656,"enrollment":103,"conditions":28980,"interventions":28981},"NCT01265732","A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers",[91],[16],[11349,11349,11349],{"trials":28983,"activeCount":103},[28984,28991],{"nctId":28985,"briefTitle":28986,"status":111,"phases":28987,"primaryCompletion":8154,"completion":4627,"start":4207,"enrollment":498,"conditions":28988,"interventions":28989},"NCT00723021","PF-04191834 Single Dose Bronchodilatory Study In Asthma.",[92],[6589],[11349,11349,11349,28990],"zileuton",{"nctId":11343,"briefTitle":11344,"status":168,"phases":28992,"primaryCompletion":4666,"completion":4666,"start":586,"enrollment":8278,"conditions":28993,"interventions":28994},[92],[11347],[11349,11350,11351,11350,11349,11351,11349,11273,11350,11273,11350,11349],{"trials":28996,"activeCount":103},[],{"trials":28998,"activeCount":103},[],{"trials":29000,"activeCount":103},[],{"intervention":17959,"totalTrials":502,"cells":29002},{"EARLY_PHASE1":29003,"PHASE1":29005,"PHASE2":29015,"PHASE3":29021,"PHASE4":29023,"NA":29025},{"trials":29004,"activeCount":103},[],{"trials":29006,"activeCount":103},[29007,29011],{"nctId":17951,"briefTitle":17952,"status":168,"phases":29008,"primaryCompletion":17954,"completion":17954,"start":5820,"enrollment":1487,"conditions":29009,"interventions":29010},[91],[2938],[17957,17958,17959,2940,17960],{"nctId":17976,"briefTitle":17977,"status":111,"phases":29012,"primaryCompletion":17979,"completion":17980,"start":17981,"enrollment":4369,"conditions":29013,"interventions":29014},[91],[2938],[17974,17974,17984,17974,17959,17958,17974,2940,17974,17985],{"trials":29016,"activeCount":103},[29017],{"nctId":18727,"briefTitle":18728,"status":111,"phases":29018,"primaryCompletion":18730,"completion":18731,"start":18732,"enrollment":18733,"conditions":29019,"interventions":29020},[92],[2938],[17974,17984,17974,17960,17974,17959,17958,17974,17959,17958,17974,17984],{"trials":29022,"activeCount":103},[],{"trials":29024,"activeCount":103},[],{"trials":29026,"activeCount":103},[],{"intervention":29028,"totalTrials":502,"cells":29029},"PF-03654746",{"EARLY_PHASE1":29030,"PHASE1":29032,"PHASE2":29040,"PHASE3":29058,"PHASE4":29060,"NA":29062},{"trials":29031,"activeCount":103},[],{"trials":29033,"activeCount":103},[29034],{"nctId":29035,"briefTitle":29036,"status":168,"phases":29037,"primaryCompletion":2660,"completion":2660,"start":4221,"enrollment":627,"conditions":29038,"interventions":29039},"NCT01028911","A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease",[91],[17728],[29028],{"trials":29041,"activeCount":103},[29042,29050],{"nctId":29043,"briefTitle":29044,"status":111,"phases":29045,"primaryCompletion":8115,"completion":8115,"start":4636,"enrollment":360,"conditions":29046,"interventions":29047},"NCT00562120","A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge",[92],[8280],[29048,29049,29028],"Allegra","Allegra-D",{"nctId":29051,"briefTitle":29052,"status":111,"phases":29053,"primaryCompletion":8252,"completion":8252,"start":6016,"enrollment":22119,"conditions":29054,"interventions":29057},"NCT01006122","A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy",[92],[29055,29056],"Excessive Daytime Sleepiness","Narcolepsy",[29028],{"trials":29059,"activeCount":103},[],{"trials":29061,"activeCount":103},[],{"trials":29063,"activeCount":103},[],{"intervention":18943,"totalTrials":502,"cells":29065},{"EARLY_PHASE1":29066,"PHASE1":29068,"PHASE2":29081,"PHASE3":29091,"PHASE4":29093,"NA":29095},{"trials":29067,"activeCount":103},[],{"trials":29069,"activeCount":103},[29070],{"nctId":29071,"briefTitle":29072,"status":111,"phases":29073,"primaryCompletion":29074,"completion":29074,"start":29075,"enrollment":29076,"conditions":29077,"interventions":29078},"NCT03642847","Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age",[91],"2019-03-29","2018-08-29",104,[10940],[18943,29079,29080],"multivalent pneumococcal conjugate formulation 1","multivalent pneumococcal conjugate formulation 2",{"trials":29082,"activeCount":103},[29083,29087],{"nctId":27849,"briefTitle":27850,"status":168,"phases":29084,"primaryCompletion":5110,"completion":5110,"start":27852,"enrollment":9845,"conditions":29085,"interventions":29086},[92],[10940],[11571,18943],{"nctId":18935,"briefTitle":18936,"status":111,"phases":29088,"primaryCompletion":18938,"completion":18938,"start":18939,"enrollment":18940,"conditions":29089,"interventions":29090},[92],[10940],[11571,18943,11583],{"trials":29092,"activeCount":103},[],{"trials":29094,"activeCount":103},[],{"trials":29096,"activeCount":103},[],{"intervention":29098,"totalTrials":502,"cells":29099},"SBI-087",{"EARLY_PHASE1":29100,"PHASE1":29102,"PHASE2":29116,"PHASE3":29125,"PHASE4":29127,"NA":29129},{"trials":29101,"activeCount":103},[],{"trials":29103,"activeCount":103},[29104,29110],{"nctId":29105,"briefTitle":29106,"status":111,"phases":29107,"primaryCompletion":26704,"completion":26704,"start":17803,"enrollment":2240,"conditions":29108,"interventions":29109},"NCT00641225","Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis",[91],[22],[29098],{"nctId":29111,"briefTitle":29112,"status":111,"phases":29113,"primaryCompletion":3334,"completion":113,"start":8154,"enrollment":2159,"conditions":29114,"interventions":29115},"NCT00815906","Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis",[91],[4514],[29098,29098,29098,29098],{"trials":29117,"activeCount":103},[29118],{"nctId":29119,"briefTitle":29120,"status":111,"phases":29121,"primaryCompletion":9544,"completion":6263,"start":4221,"enrollment":18795,"conditions":29122,"interventions":29124},"NCT01008852","Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis",[92],[29123],"Active Rheumatoid Arthritis",[29098,29098,29098,29098],{"trials":29126,"activeCount":103},[],{"trials":29128,"activeCount":103},[],{"trials":29130,"activeCount":103},[],{"intervention":17482,"totalTrials":502,"cells":29132},{"EARLY_PHASE1":29133,"PHASE1":29135,"PHASE2":29137,"PHASE3":29151,"PHASE4":29153,"NA":29155},{"trials":29134,"activeCount":103},[],{"trials":29136,"activeCount":103},[],{"trials":29138,"activeCount":103},[29139,29143,29147],{"nctId":17474,"briefTitle":17475,"status":111,"phases":29140,"primaryCompletion":17477,"completion":17478,"start":13117,"enrollment":10190,"conditions":29141,"interventions":29142},[91,92],[17480],[17482,17444],{"nctId":17502,"briefTitle":17503,"status":111,"phases":29144,"primaryCompletion":1914,"completion":1914,"start":17505,"enrollment":2935,"conditions":29145,"interventions":29146},[91,92],[17507],[2024,17444,17482],{"nctId":17510,"briefTitle":17511,"status":111,"phases":29148,"primaryCompletion":17513,"completion":17513,"start":17514,"enrollment":17515,"conditions":29149,"interventions":29150},[92],[1798],[2024,17444,17482,17518,17519,17520],{"trials":29152,"activeCount":103},[],{"trials":29154,"activeCount":103},[],{"trials":29156,"activeCount":103},[],{"intervention":29158,"totalTrials":502,"cells":29159},"Multivalent Group B streptococcus vaccine",{"EARLY_PHASE1":29160,"PHASE1":29162,"PHASE2":29164,"PHASE3":29196,"PHASE4":29198,"NA":29200},{"trials":29161,"activeCount":103},[],{"trials":29163,"activeCount":103},[],{"trials":29165,"activeCount":103},[29166,29176,29186],{"nctId":29167,"briefTitle":29168,"status":111,"phases":29169,"primaryCompletion":29170,"completion":29170,"start":29171,"enrollment":29172,"conditions":29173,"interventions":29175},"NCT03765073","Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants",[92],"2024-03-04","2019-01-14",1208,[29174],"Group B Streptococcus Infections",[29158],{"nctId":29177,"briefTitle":29178,"status":111,"phases":29179,"primaryCompletion":27386,"completion":27386,"start":29180,"enrollment":29181,"conditions":29182,"interventions":29184},"NCT03170609","A Phase 1\u002F2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age",[92],"2017-06-05",365,[29183],"Group B Streptococcal Infections",[29185],"Multivalent group B streptococcus vaccine",{"nctId":29187,"briefTitle":29188,"status":111,"phases":29189,"primaryCompletion":29190,"completion":29190,"start":29191,"enrollment":29192,"conditions":29193,"interventions":29194},"NCT04766086","Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women",[92],"2023-04-27","2022-08-12",306,[29174],[29158,29195],"Tetanus, diphtheria, and acellular pertussis vaccine",{"trials":29197,"activeCount":103},[],{"trials":29199,"activeCount":103},[],{"trials":29201,"activeCount":103},[],{"intervention":29203,"totalTrials":502,"cells":29204},"PF-06835919",{"EARLY_PHASE1":29205,"PHASE1":29207,"PHASE2":29224,"PHASE3":29236,"PHASE4":29238,"NA":29240},{"trials":29206,"activeCount":103},[],{"trials":29208,"activeCount":103},[29209,29217],{"nctId":29210,"briefTitle":29211,"status":111,"phases":29212,"primaryCompletion":29213,"completion":29213,"start":5957,"enrollment":314,"conditions":29214,"interventions":29216},"NCT02974374","Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects",[91],"2017-01",[29215],"Non-alcoholic Fatty Liver Disease",[29203],{"nctId":29218,"briefTitle":29219,"status":111,"phases":29220,"primaryCompletion":29221,"completion":29221,"start":29213,"enrollment":23,"conditions":29222,"interventions":29223},"NCT03031119","Multiple Ascending Dose and DDI Study",[91],"2017-07",[19],[29203,12996],{"trials":29225,"activeCount":103},[29226],{"nctId":29227,"briefTitle":29228,"status":111,"phases":29229,"primaryCompletion":29230,"completion":29231,"start":29232,"enrollment":13356,"conditions":29233,"interventions":29235},"NCT03969719","A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus",[92],"2021-03-02","2021-03-30","2019-07-18",[29234],"Non-alcoholic Steatohepatitis",[29203,29203],{"trials":29237,"activeCount":103},[],{"trials":29239,"activeCount":103},[],{"trials":29241,"activeCount":103},[],{"intervention":8148,"totalTrials":502,"cells":29243},{"EARLY_PHASE1":29244,"PHASE1":29246,"PHASE2":29258,"PHASE3":29264,"PHASE4":29266,"NA":29268},{"trials":29245,"activeCount":103},[],{"trials":29247,"activeCount":103},[29248,29254],{"nctId":29249,"briefTitle":29250,"status":649,"phases":29251,"enrollment":103,"conditions":29252,"interventions":29253},"NCT00635245","CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery",[91],[31],[8148],{"nctId":12584,"briefTitle":12585,"status":168,"phases":29255,"primaryCompletion":9544,"completion":3353,"start":6016,"enrollment":1509,"conditions":29256,"interventions":29257},[91],[1028,946,25,11998,12588],[8148,12582],{"trials":29259,"activeCount":103},[29260],{"nctId":8142,"briefTitle":8143,"status":168,"phases":29261,"primaryCompletion":114,"completion":114,"start":4206,"enrollment":627,"conditions":29262,"interventions":29263},[92],[8146],[8148,1770,8149,1770,8149],{"trials":29265,"activeCount":103},[],{"trials":29267,"activeCount":103},[],{"trials":29269,"activeCount":103},[],{"intervention":29271,"totalTrials":502,"cells":29272},"ACC-001",{"EARLY_PHASE1":29273,"PHASE1":29275,"PHASE2":29277,"PHASE3":29299,"PHASE4":29301,"NA":29303},{"trials":29274,"activeCount":103},[],{"trials":29276,"activeCount":103},[],{"trials":29278,"activeCount":103},[29279,29287,29293],{"nctId":29280,"briefTitle":29281,"status":111,"phases":29282,"primaryCompletion":4590,"completion":4590,"start":3610,"enrollment":1122,"conditions":29283,"interventions":29284},"NCT00479557","Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",[92],[13445],[29285,29271,29286],"ACC-001 + QS-21","QS-21",{"nctId":29288,"briefTitle":29289,"status":111,"phases":29290,"primaryCompletion":18128,"completion":18128,"start":2964,"enrollment":4981,"conditions":29291,"interventions":29292},"NCT00498602","Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",[92],[13445],[29285,29286,29271],{"nctId":29294,"briefTitle":29295,"status":111,"phases":29296,"primaryCompletion":540,"completion":540,"start":8154,"enrollment":35,"conditions":29297,"interventions":29298},"NCT00752232","Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease",[92],[13445],[29271,29271],{"trials":29300,"activeCount":103},[],{"trials":29302,"activeCount":103},[],{"trials":29304,"activeCount":103},[],{"intervention":29306,"totalTrials":502,"cells":29307},"AN2728 ointment, 2%",{"EARLY_PHASE1":29308,"PHASE1":29310,"PHASE2":29326,"PHASE3":29347,"PHASE4":29349,"NA":29351},{"trials":29309,"activeCount":103},[],{"trials":29311,"activeCount":103},[29312],{"nctId":29313,"briefTitle":29314,"status":111,"phases":29315,"primaryCompletion":29316,"completion":29316,"start":29317,"enrollment":1268,"conditions":29318,"interventions":29319},"NCT00762658","A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test",[91],"2007-12-07","2007-11-30",[4401],[29320,29321,29322,29323,29324,29325],"AN2728 Ointment, 5%","AN2728 Ointment, 2%","AN2728 Ointment, 0.5%","AN2728 Ointment Vehicle","Betnesol®-V Creme, 0.1%","Protopic® Ointment, 0.1 %",{"trials":29327,"activeCount":103},[29328,29337],{"nctId":29329,"briefTitle":29330,"status":111,"phases":29331,"primaryCompletion":29332,"completion":29332,"start":29333,"enrollment":3866,"conditions":29334,"interventions":29335},"NCT01300052","AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis",[92],"2011-06-06","2011-01-26",[4401],[29306,29336],"Ointment Vehicle",{"nctId":29338,"briefTitle":29339,"status":111,"phases":29340,"primaryCompletion":29341,"completion":29341,"start":11170,"enrollment":787,"conditions":29342,"interventions":29343},"NCT01301508","Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis",[92],"2011-11-11",[1933],[29306,29344,29345,29346],"AN2898 ointment, 1%","AN2898 ointment vehicle","AN2728 ointment vehicle",{"trials":29348,"activeCount":103},[],{"trials":29350,"activeCount":103},[],{"trials":29352,"activeCount":103},[],{"intervention":29354,"totalTrials":502,"cells":29355},"Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous",{"EARLY_PHASE1":29356,"PHASE1":29358,"PHASE2":29360,"PHASE3":29390,"PHASE4":29392,"NA":29394},{"trials":29357,"activeCount":103},[],{"trials":29359,"activeCount":103},[],{"trials":29361,"activeCount":103},[29362,29372,29380],{"nctId":29363,"briefTitle":29364,"status":111,"phases":29365,"primaryCompletion":4280,"completion":651,"start":18769,"enrollment":5647,"conditions":29366,"interventions":29368},"NCT01989325","A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma",[92],[29367],"Advanced Multiple Myeloma",[29369,29370,29371,29354],"Carfilzomib, proteasome inhibitor; intravenous","Filanesib, KSP(Eg5) inhibitor; intravenous","Dexamethasone, steroid; oral or intravenous",{"nctId":29373,"briefTitle":29374,"status":111,"phases":29375,"primaryCompletion":5008,"completion":29376,"start":652,"enrollment":11745,"conditions":29377,"interventions":29378},"NCT02092922","A Phase 2 Trial of Filanesib in Relapsed\u002FRefractory Multiple Myeloma (AfFIRM)",[92],"2017-09-05",[29367],[29379,29354],"Filanesib, KSP (Eg5) inhibitor; intravenous",{"nctId":29381,"briefTitle":29382,"status":111,"phases":29383,"primaryCompletion":29384,"completion":29384,"start":8251,"enrollment":2631,"conditions":29385,"interventions":29387},"NCT00821249","A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma",[91,92],"2016-03-16",[1062,29386],"Plasma Cell Leukemia",[29388,29354,29389],"ARRY-520, KSP(Eg5) inhibitor; intravenous","Dexamethasone, steroid;",{"trials":29391,"activeCount":103},[],{"trials":29393,"activeCount":103},[],{"trials":29395,"activeCount":103},[],{"intervention":29323,"totalTrials":502,"cells":29397},{"EARLY_PHASE1":29398,"PHASE1":29400,"PHASE2":29406,"PHASE3":29419,"PHASE4":29421,"NA":29423},{"trials":29399,"activeCount":103},[],{"trials":29401,"activeCount":103},[29402],{"nctId":29313,"briefTitle":29314,"status":111,"phases":29403,"primaryCompletion":29316,"completion":29316,"start":29317,"enrollment":1268,"conditions":29404,"interventions":29405},[91],[4401],[29320,29321,29322,29323,29324,29325],{"trials":29407,"activeCount":103},[29408,29412],{"nctId":29338,"briefTitle":29339,"status":111,"phases":29409,"primaryCompletion":29341,"completion":29341,"start":11170,"enrollment":787,"conditions":29410,"interventions":29411},[92],[1933],[29306,29344,29345,29346],{"nctId":29413,"briefTitle":29414,"status":111,"phases":29415,"primaryCompletion":3335,"completion":3335,"start":2964,"enrollment":472,"conditions":29416,"interventions":29417},"NCT00759161","Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis",[92],[4401],[29418,29323],"AN2728",{"trials":29420,"activeCount":103},[],{"trials":29422,"activeCount":103},[],{"trials":29424,"activeCount":103},[],{"intervention":29426,"totalTrials":502,"cells":29427},"CE-224,535",{"EARLY_PHASE1":29428,"PHASE1":29430,"PHASE2":29446,"PHASE3":29455,"PHASE4":29457,"NA":29459},{"trials":29429,"activeCount":103},[],{"trials":29431,"activeCount":103},[29432,29439],{"nctId":29433,"briefTitle":29434,"status":111,"phases":29435,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":1625,"conditions":29436,"interventions":29437},"NCT00838058","A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.",[91],[22,19],[29426,29426,29426,29426,29426,29426,29438,29438],"CE 224,535",{"nctId":29440,"briefTitle":29441,"status":111,"phases":29442,"primaryCompletion":11314,"completion":11314,"start":3602,"enrollment":2159,"conditions":29443,"interventions":29444},"NCT00446784","Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis",[91],[4514],[29426,29445],"Methotrexate",{"trials":29447,"activeCount":103},[29448],{"nctId":29449,"briefTitle":29450,"status":111,"phases":29451,"primaryCompletion":29452,"completion":29452,"start":28291,"enrollment":397,"conditions":29453,"interventions":29454},"NCT00628095","Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate",[92],"2009-02-04",[4514],[29426],{"trials":29456,"activeCount":103},[],{"trials":29458,"activeCount":103},[],{"trials":29460,"activeCount":103},[],{"intervention":29462,"totalTrials":502,"cells":29463},"Recifercept",{"EARLY_PHASE1":29464,"PHASE1":29466,"PHASE2":29476,"PHASE3":29495,"PHASE4":29497,"NA":29499},{"trials":29465,"activeCount":103},[],{"trials":29467,"activeCount":103},[29468],{"nctId":29469,"briefTitle":29470,"status":649,"phases":29471,"primaryCompletion":8354,"completion":29472,"start":29473,"enrollment":103,"conditions":29474,"interventions":29475},"NCT05061277","Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants",[91],"2024-06-16","2023-10-25",[16],[29462],{"trials":29477,"activeCount":103},[29478,29487],{"nctId":29479,"briefTitle":29480,"status":168,"phases":29481,"primaryCompletion":1529,"completion":29482,"start":29483,"enrollment":472,"conditions":29484,"interventions":29486},"NCT05116046","Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia",[92],"2023-03-30","2021-12-24",[29485],"Achondroplasia",[29462],{"nctId":29488,"briefTitle":29489,"status":168,"phases":29490,"primaryCompletion":29491,"completion":8529,"start":29492,"enrollment":2240,"conditions":29493,"interventions":29494},"NCT04638153","A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia",[92],"2023-01-16","2020-12-02",[29485],[29462],{"trials":29496,"activeCount":103},[],{"trials":29498,"activeCount":103},[],{"trials":29500,"activeCount":103},[],{"intervention":29418,"totalTrials":502,"cells":29502},{"EARLY_PHASE1":29503,"PHASE1":29505,"PHASE2":29507,"PHASE3":29526,"PHASE4":29528,"NA":29530},{"trials":29504,"activeCount":103},[],{"trials":29506,"activeCount":103},[],{"trials":29508,"activeCount":103},[29509,29515,29519],{"nctId":29510,"briefTitle":29414,"status":111,"phases":29511,"primaryCompletion":8154,"completion":8154,"start":11291,"enrollment":1780,"conditions":29512,"interventions":29513},"NCT00755196",[92],[4401],[29418,29514],"Ointment vehicle",{"nctId":29413,"briefTitle":29414,"status":111,"phases":29516,"primaryCompletion":3335,"completion":3335,"start":2964,"enrollment":472,"conditions":29517,"interventions":29518},[92],[4401],[29418,29323],{"nctId":29520,"briefTitle":29521,"status":111,"phases":29522,"primaryCompletion":2660,"completion":577,"start":6016,"enrollment":29523,"conditions":29524,"interventions":29525},"NCT01029405","Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis",[92],145,[4401],[29418],{"trials":29527,"activeCount":103},[],{"trials":29529,"activeCount":103},[],{"trials":29531,"activeCount":103},[],{"intervention":29533,"totalTrials":502,"cells":29534},"CP-866,087",{"EARLY_PHASE1":29535,"PHASE1":29537,"PHASE2":29539,"PHASE3":29561,"PHASE4":29563,"NA":29565},{"trials":29536,"activeCount":103},[],{"trials":29538,"activeCount":103},[],{"trials":29540,"activeCount":103},[29541,29547,29554],{"nctId":29542,"briefTitle":29543,"status":111,"phases":29544,"primaryCompletion":3853,"completion":3853,"start":3643,"enrollment":6107,"conditions":29545,"interventions":29546},"NCT00479492","Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers",[92],[2761],[29533,29533,29533],{"nctId":29548,"briefTitle":29549,"status":111,"phases":29550,"completion":4702,"start":2672,"enrollment":541,"conditions":29551,"interventions":29553},"NCT00147576","Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.",[92],[29552],"Alcoholism",[29533],{"nctId":29555,"briefTitle":29556,"status":111,"phases":29557,"primaryCompletion":11291,"completion":4665,"start":2641,"enrollment":4637,"conditions":29558,"interventions":29560},"NCT00482664","The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.",[92],[29559],"Sexual Dysfunction, Physiological",[29533,29533,29533],{"trials":29562,"activeCount":103},[],{"trials":29564,"activeCount":103},[],{"trials":29566,"activeCount":103},[],{"intervention":27845,"totalTrials":502,"cells":29568},{"EARLY_PHASE1":29569,"PHASE1":29571,"PHASE2":29577,"PHASE3":29593,"PHASE4":29595,"NA":29597},{"trials":29570,"activeCount":103},[],{"trials":29572,"activeCount":103},[29573],{"nctId":27839,"briefTitle":27840,"status":111,"phases":29574,"primaryCompletion":23585,"completion":23585,"start":27842,"enrollment":4825,"conditions":29575,"interventions":29576},[91],[10940],[11571,27845],{"trials":29578,"activeCount":103},[29579,29583],{"nctId":27864,"briefTitle":27865,"status":111,"phases":29580,"primaryCompletion":1325,"completion":1325,"start":27097,"enrollment":27867,"conditions":29581,"interventions":29582},[92],[10940],[11571,27845,27870],{"nctId":29584,"briefTitle":29585,"status":111,"phases":29586,"primaryCompletion":29587,"completion":29587,"start":29588,"enrollment":29589,"conditions":29590,"interventions":29591},"NCT04071158","A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS",[92],"2019-12-11","2019-10-01",713,[3801],[29592,27845],"RSV Vaccine",{"trials":29594,"activeCount":103},[],{"trials":29596,"activeCount":103},[],{"trials":29598,"activeCount":103},[],{"intervention":29600,"totalTrials":1087,"cells":29601},"PF-04360365 1 mg\u002Fkg",{"EARLY_PHASE1":29602,"PHASE1":29604,"PHASE2":29615,"PHASE3":29628,"PHASE4":29630,"NA":29632},{"trials":29603,"activeCount":103},[],{"trials":29605,"activeCount":103},[29606],{"nctId":29607,"briefTitle":29608,"status":111,"phases":29609,"primaryCompletion":4627,"completion":4627,"start":8115,"enrollment":498,"conditions":29610,"interventions":29611},"NCT00733642","Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease",[91],[17728],[29600,29612,29613,29614],"PF-04360365 3 mg\u002Fkg","PF-04360365 5 mg\u002Fkg","PF-04360365 10 mg\u002Fkg",{"trials":29616,"activeCount":103},[29617],{"nctId":29618,"briefTitle":29619,"status":111,"phases":29620,"primaryCompletion":29621,"completion":29621,"start":29622,"enrollment":22666,"conditions":29623,"interventions":29624},"NCT00722046","Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease",[92],"2011-08-16","2008-12-05",[17728],[29625,29626,29600,29612,29627],"PF-04360365 0.1 mg\u002Fkg","PF-04360365 0.5 mg\u002Fkg","PF-04360365 8.5 mg\u002Fkg",{"trials":29629,"activeCount":103},[],{"trials":29631,"activeCount":103},[],{"trials":29633,"activeCount":103},[],{"intervention":29612,"totalTrials":1087,"cells":29635},{"EARLY_PHASE1":29636,"PHASE1":29638,"PHASE2":29644,"PHASE3":29650,"PHASE4":29652,"NA":29654},{"trials":29637,"activeCount":103},[],{"trials":29639,"activeCount":103},[29640],{"nctId":29607,"briefTitle":29608,"status":111,"phases":29641,"primaryCompletion":4627,"completion":4627,"start":8115,"enrollment":498,"conditions":29642,"interventions":29643},[91],[17728],[29600,29612,29613,29614],{"trials":29645,"activeCount":103},[29646],{"nctId":29618,"briefTitle":29619,"status":111,"phases":29647,"primaryCompletion":29621,"completion":29621,"start":29622,"enrollment":22666,"conditions":29648,"interventions":29649},[92],[17728],[29625,29626,29600,29612,29627],{"trials":29651,"activeCount":103},[],{"trials":29653,"activeCount":103},[],{"trials":29655,"activeCount":103},[],{"intervention":29614,"totalTrials":1087,"cells":29657},{"EARLY_PHASE1":29658,"PHASE1":29660,"PHASE2":29666,"PHASE3":29676,"PHASE4":29678,"NA":29680},{"trials":29659,"activeCount":103},[],{"trials":29661,"activeCount":103},[29662],{"nctId":29607,"briefTitle":29608,"status":111,"phases":29663,"primaryCompletion":4627,"completion":4627,"start":8115,"enrollment":498,"conditions":29664,"interventions":29665},[91],[17728],[29600,29612,29613,29614],{"trials":29667,"activeCount":103},[29668],{"nctId":29669,"briefTitle":29670,"status":111,"phases":29671,"primaryCompletion":27941,"completion":27941,"start":29672,"enrollment":1530,"conditions":29673,"interventions":29674},"NCT00945672","A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease",[92],"2009-08-06",[17728],[29614,29675],"PF-04360365 7.5 mg\u002Fkg",{"trials":29677,"activeCount":103},[],{"trials":29679,"activeCount":103},[],{"trials":29681,"activeCount":103},[],{"intervention":29683,"totalTrials":1087,"cells":29684},"852A",{"EARLY_PHASE1":29685,"PHASE1":29687,"PHASE2":29695,"PHASE3":29704,"PHASE4":29706,"NA":29708},{"trials":29686,"activeCount":103},[],{"trials":29688,"activeCount":103},[29689],{"nctId":29690,"briefTitle":29691,"status":111,"phases":29692,"primaryCompletion":2662,"completion":2662,"start":7675,"conditions":29693,"interventions":29694},"NCT00091689","Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions",[91],[1798],[29683],{"trials":29696,"activeCount":103},[29697],{"nctId":29698,"briefTitle":29699,"status":111,"phases":29700,"primaryCompletion":12773,"completion":12773,"start":4258,"enrollment":5909,"conditions":29701,"interventions":29703},"NCT00189332","Use of 852A in Metastatic Cutaneous Melanoma.",[92],[1798,29702],"Unresectable Metatstatic Cutaneous Melanoma",[29683],{"trials":29705,"activeCount":103},[],{"trials":29707,"activeCount":103},[],{"trials":29709,"activeCount":103},[],{"intervention":29711,"totalTrials":1087,"cells":29712},"PHA-794428",{"EARLY_PHASE1":29713,"PHASE1":29715,"PHASE2":29717,"PHASE3":29731,"PHASE4":29733,"NA":29735},{"trials":29714,"activeCount":103},[],{"trials":29716,"activeCount":103},[],{"trials":29718,"activeCount":103},[29719,29725],{"nctId":29720,"briefTitle":29721,"status":168,"phases":29722,"primaryCompletion":2964,"completion":2964,"start":12030,"enrollment":4259,"conditions":29723,"interventions":29724},"NCT00314938","A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency",[92],[10227],[29711],{"nctId":29726,"briefTitle":29727,"status":168,"phases":29728,"primaryCompletion":4636,"completion":4636,"start":12395,"enrollment":17874,"conditions":29729,"interventions":29730},"NCT00308464","A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency",[92],[10227],[29711],{"trials":29732,"activeCount":103},[],{"trials":29734,"activeCount":103},[],{"trials":29736,"activeCount":103},[],{"intervention":29738,"totalTrials":1087,"cells":29739},"Tolterodine",{"EARLY_PHASE1":29740,"PHASE1":29742,"PHASE2":29750,"PHASE3":29759,"PHASE4":29761,"NA":29763},{"trials":29741,"activeCount":103},[],{"trials":29743,"activeCount":103},[29744],{"nctId":29745,"briefTitle":29746,"status":111,"phases":29747,"primaryCompletion":8154,"completion":8154,"start":3643,"enrollment":5909,"conditions":29748,"interventions":29749},"NCT00481728","Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.",[91],[12489],[29738],{"trials":29751,"activeCount":103},[29752],{"nctId":29753,"briefTitle":29754,"status":111,"phases":29755,"completion":4847,"start":2671,"enrollment":27266,"conditions":29756,"interventions":29757},"NCT00746681","Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder",[92],[12489],[29758,29738,29758,11452],"Tolterodine & Pregabalin",{"trials":29760,"activeCount":103},[],{"trials":29762,"activeCount":103},[],{"trials":29764,"activeCount":103},[],{"intervention":17960,"totalTrials":1087,"cells":29766},{"EARLY_PHASE1":29767,"PHASE1":29769,"PHASE2":29775,"PHASE3":29781,"PHASE4":29783,"NA":29785},{"trials":29768,"activeCount":103},[],{"trials":29770,"activeCount":103},[29771],{"nctId":17951,"briefTitle":17952,"status":168,"phases":29772,"primaryCompletion":17954,"completion":17954,"start":5820,"enrollment":1487,"conditions":29773,"interventions":29774},[91],[2938],[17957,17958,17959,2940,17960],{"trials":29776,"activeCount":103},[29777],{"nctId":18727,"briefTitle":18728,"status":111,"phases":29778,"primaryCompletion":18730,"completion":18731,"start":18732,"enrollment":18733,"conditions":29779,"interventions":29780},[92],[2938],[17974,17984,17974,17960,17974,17959,17958,17974,17959,17958,17974,17984],{"trials":29782,"activeCount":103},[],{"trials":29784,"activeCount":103},[],{"trials":29786,"activeCount":103},[],{"intervention":18441,"totalTrials":1087,"cells":29788},{"EARLY_PHASE1":29789,"PHASE1":29791,"PHASE2":29793,"PHASE3":29807,"PHASE4":29809,"NA":29811},{"trials":29790,"activeCount":103},[],{"trials":29792,"activeCount":103},[],{"trials":29794,"activeCount":103},[29795,29799],{"nctId":18433,"briefTitle":18434,"status":111,"phases":29796,"primaryCompletion":18436,"completion":18436,"start":18437,"enrollment":5909,"conditions":29797,"interventions":29798},[92],[18439],[18441,18442,18443,18415],{"nctId":29800,"briefTitle":18434,"status":111,"phases":29801,"primaryCompletion":29802,"completion":29802,"start":29803,"enrollment":28923,"conditions":29804,"interventions":29805},"NCT00679965",[92],"2007-07-31","2006-02-28",[18439],[18441,18442,18443,29806],"AN2690 Solution Vehicle",{"trials":29808,"activeCount":103},[],{"trials":29810,"activeCount":103},[],{"trials":29812,"activeCount":103},[],{"intervention":18442,"totalTrials":1087,"cells":29814},{"EARLY_PHASE1":29815,"PHASE1":29817,"PHASE2":29819,"PHASE3":29829,"PHASE4":29831,"NA":29833},{"trials":29816,"activeCount":103},[],{"trials":29818,"activeCount":103},[],{"trials":29820,"activeCount":103},[29821,29825],{"nctId":18433,"briefTitle":18434,"status":111,"phases":29822,"primaryCompletion":18436,"completion":18436,"start":18437,"enrollment":5909,"conditions":29823,"interventions":29824},[92],[18439],[18441,18442,18443,18415],{"nctId":29800,"briefTitle":18434,"status":111,"phases":29826,"primaryCompletion":29802,"completion":29802,"start":29803,"enrollment":28923,"conditions":29827,"interventions":29828},[92],[18439],[18441,18442,18443,29806],{"trials":29830,"activeCount":103},[],{"trials":29832,"activeCount":103},[],{"trials":29834,"activeCount":103},[],{"intervention":18443,"totalTrials":1087,"cells":29836},{"EARLY_PHASE1":29837,"PHASE1":29839,"PHASE2":29841,"PHASE3":29851,"PHASE4":29853,"NA":29855},{"trials":29838,"activeCount":103},[],{"trials":29840,"activeCount":103},[],{"trials":29842,"activeCount":103},[29843,29847],{"nctId":18433,"briefTitle":18434,"status":111,"phases":29844,"primaryCompletion":18436,"completion":18436,"start":18437,"enrollment":5909,"conditions":29845,"interventions":29846},[92],[18439],[18441,18442,18443,18415],{"nctId":29800,"briefTitle":18434,"status":111,"phases":29848,"primaryCompletion":29802,"completion":29802,"start":29803,"enrollment":28923,"conditions":29849,"interventions":29850},[92],[18439],[18441,18442,18443,29806],{"trials":29852,"activeCount":103},[],{"trials":29854,"activeCount":103},[],{"trials":29856,"activeCount":103},[],{"intervention":11340,"totalTrials":1087,"cells":29858},{"EARLY_PHASE1":29859,"PHASE1":29861,"PHASE2":29863,"PHASE3":29880,"PHASE4":29882,"NA":29884},{"trials":29860,"activeCount":103},[],{"trials":29862,"activeCount":103},[],{"trials":29864,"activeCount":103},[29865,29876],{"nctId":29866,"briefTitle":29867,"status":111,"phases":29868,"primaryCompletion":29869,"completion":29870,"start":29871,"enrollment":1060,"conditions":29872,"interventions":29874},"NCT00545129","A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone",[92],"2011-12-24","2012-02-07","2009-04-29",[3077,29873],"Palliative Care",[11340,29875],"IV Placebo for tanezumab",{"nctId":11329,"briefTitle":11330,"status":111,"phases":29877,"primaryCompletion":11332,"completion":11333,"start":11334,"enrollment":11335,"conditions":29878,"interventions":29879},[92],[11337],[11339,11340,11341,11273],{"trials":29881,"activeCount":103},[],{"trials":29883,"activeCount":103},[],{"trials":29885,"activeCount":103},[],{"intervention":29048,"totalTrials":1087,"cells":29887},{"EARLY_PHASE1":29888,"PHASE1":29890,"PHASE2":29892,"PHASE3":29905,"PHASE4":29907,"NA":29909},{"trials":29889,"activeCount":103},[],{"trials":29891,"activeCount":103},[],{"trials":29893,"activeCount":103},[29894,29898],{"nctId":29043,"briefTitle":29044,"status":111,"phases":29895,"primaryCompletion":8115,"completion":8115,"start":4636,"enrollment":360,"conditions":29896,"interventions":29897},[92],[8280],[29048,29049,29028],{"nctId":29899,"briefTitle":29900,"status":111,"phases":29901,"primaryCompletion":2660,"completion":2660,"start":10923,"enrollment":7363,"conditions":29902,"interventions":29903},"NCT01033396","The Effect Of PF-03654764 +\u002F- Allegra On Symptoms Of Allergic Rhinitis",[92],[8280],[29904,29048,29904,29049],"PF-03654764",{"trials":29906,"activeCount":103},[],{"trials":29908,"activeCount":103},[],{"trials":29910,"activeCount":103},[],{"intervention":29049,"totalTrials":1087,"cells":29912},{"EARLY_PHASE1":29913,"PHASE1":29915,"PHASE2":29917,"PHASE3":29927,"PHASE4":29929,"NA":29931},{"trials":29914,"activeCount":103},[],{"trials":29916,"activeCount":103},[],{"trials":29918,"activeCount":103},[29919,29923],{"nctId":29043,"briefTitle":29044,"status":111,"phases":29920,"primaryCompletion":8115,"completion":8115,"start":4636,"enrollment":360,"conditions":29921,"interventions":29922},[92],[8280],[29048,29049,29028],{"nctId":29899,"briefTitle":29900,"status":111,"phases":29924,"primaryCompletion":2660,"completion":2660,"start":10923,"enrollment":7363,"conditions":29925,"interventions":29926},[92],[8280],[29904,29048,29904,29049],{"trials":29928,"activeCount":103},[],{"trials":29930,"activeCount":103},[],{"trials":29932,"activeCount":103},[],{"intervention":29934,"totalTrials":1087,"cells":29935},"tofacitinib 10 mg",{"EARLY_PHASE1":29936,"PHASE1":29938,"PHASE2":29947,"PHASE3":29958,"PHASE4":29960,"NA":29962},{"trials":29937,"activeCount":103},[],{"trials":29939,"activeCount":103},[29940],{"nctId":29941,"briefTitle":29942,"status":111,"phases":29943,"primaryCompletion":540,"completion":540,"start":113,"enrollment":26,"conditions":29944,"interventions":29945},"NCT01599377","Tofacitinib Bioequivalence Study Comparing Tablets And Capsules",[91],[16],[29934,29946],"tofacitinib 5 mg",{"trials":29948,"activeCount":103},[29949],{"nctId":29950,"briefTitle":29951,"status":111,"phases":29952,"primaryCompletion":12307,"completion":12307,"start":6208,"enrollment":12803,"conditions":29953,"interventions":29954},"NCT01786668","Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis",[92],[15038],[29955,29956,29957],"Tofacitinib 2 mg","Tofacitinib 5 mg","Tofacitinib 10 mg",{"trials":29959,"activeCount":103},[],{"trials":29961,"activeCount":103},[],{"trials":29963,"activeCount":103},[],{"intervention":29946,"totalTrials":1087,"cells":29965},{"EARLY_PHASE1":29966,"PHASE1":29968,"PHASE2":29974,"PHASE3":29980,"PHASE4":29982,"NA":29984},{"trials":29967,"activeCount":103},[],{"trials":29969,"activeCount":103},[29970],{"nctId":29941,"briefTitle":29942,"status":111,"phases":29971,"primaryCompletion":540,"completion":540,"start":113,"enrollment":26,"conditions":29972,"interventions":29973},[91],[16],[29934,29946],{"trials":29975,"activeCount":103},[29976],{"nctId":29950,"briefTitle":29951,"status":111,"phases":29977,"primaryCompletion":12307,"completion":12307,"start":6208,"enrollment":12803,"conditions":29978,"interventions":29979},[92],[15038],[29955,29956,29957],{"trials":29981,"activeCount":103},[],{"trials":29983,"activeCount":103},[],{"trials":29985,"activeCount":103},[],{"intervention":29987,"totalTrials":1087,"cells":29988},"Filibuvir",{"EARLY_PHASE1":29989,"PHASE1":29991,"PHASE2":30001,"PHASE3":30010,"PHASE4":30012,"NA":30014},{"trials":29990,"activeCount":103},[],{"trials":29992,"activeCount":103},[29993],{"nctId":29994,"briefTitle":29995,"status":111,"phases":29996,"primaryCompletion":11170,"completion":2661,"start":4666,"enrollment":1268,"conditions":29997,"interventions":29999},"NCT01210404","Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance",[91],[29998],"Chronic Hepatitis C",[30000],"filibuvir",{"trials":30002,"activeCount":103},[30003],{"nctId":30004,"briefTitle":30005,"status":111,"phases":30006,"primaryCompletion":10912,"completion":10912,"start":6016,"enrollment":12163,"conditions":30007,"interventions":30009},"NCT00987337","Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects",[92],[30008,15803],"Hepatitis",[29987,29987],{"trials":30011,"activeCount":103},[],{"trials":30013,"activeCount":103},[],{"trials":30015,"activeCount":103},[],{"intervention":30017,"totalTrials":1087,"cells":30018},"Vupanorsen",{"EARLY_PHASE1":30019,"PHASE1":30021,"PHASE2":30030,"PHASE3":30039,"PHASE4":30041,"NA":30043},{"trials":30020,"activeCount":103},[],{"trials":30022,"activeCount":103},[30023],{"nctId":30024,"briefTitle":30025,"status":111,"phases":30026,"primaryCompletion":20965,"completion":20965,"start":30027,"enrollment":597,"conditions":30028,"interventions":30029},"NCT04916795","A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults",[91],"2021-06-17",[16],[30017,30017],{"trials":30031,"activeCount":103},[30032],{"nctId":30033,"briefTitle":30034,"status":111,"phases":30035,"primaryCompletion":3865,"completion":9727,"start":24440,"enrollment":17620,"conditions":30036,"interventions":30038},"NCT04516291","A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)",[92],[28169,28170,30037],"Hyperlipoproteinemias",[30017],{"trials":30040,"activeCount":103},[],{"trials":30042,"activeCount":103},[],{"trials":30044,"activeCount":103},[],{"intervention":30046,"totalTrials":1087,"cells":30047},"PF-06252616",{"EARLY_PHASE1":30048,"PHASE1":30050,"PHASE2":30059,"PHASE3":30069,"PHASE4":30071,"NA":30073},{"trials":30049,"activeCount":103},[],{"trials":30051,"activeCount":103},[30052],{"nctId":30053,"briefTitle":30054,"status":111,"phases":30055,"primaryCompletion":7386,"completion":7386,"start":4459,"enrollment":1122,"conditions":30056,"interventions":30057},"NCT01616277","A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects",[91],[16],[30046,30046,30058,30046,30046,30046,30046],"PF-06252161",{"trials":30060,"activeCount":103},[30061],{"nctId":30062,"briefTitle":30063,"status":168,"phases":30064,"primaryCompletion":30065,"completion":26991,"start":30066,"enrollment":2442,"conditions":30067,"interventions":30068},"NCT02310763","A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy",[92],"2018-04-30","2014-11-24",[5093],[30046],{"trials":30070,"activeCount":103},[],{"trials":30072,"activeCount":103},[],{"trials":30074,"activeCount":103},[],{"intervention":30076,"totalTrials":1087,"cells":30077},"PF-00868554",{"EARLY_PHASE1":30078,"PHASE1":30080,"PHASE2":30088,"PHASE3":30096,"PHASE4":30098,"NA":30100},{"trials":30079,"activeCount":103},[],{"trials":30081,"activeCount":103},[30082],{"nctId":30083,"briefTitle":30084,"status":111,"phases":30085,"primaryCompletion":3839,"completion":3839,"start":11315,"enrollment":4259,"conditions":30086,"interventions":30087},"NCT00445315","A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients",[91],[15803],[30076,30076,30076,30076],{"trials":30089,"activeCount":103},[30090],{"nctId":30091,"briefTitle":30092,"status":111,"phases":30093,"primaryCompletion":3642,"completion":3642,"start":8115,"enrollment":472,"conditions":30094,"interventions":30095},"NCT00720434","A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection",[92],[15803],[30076,30076,30076],{"trials":30097,"activeCount":103},[],{"trials":30099,"activeCount":103},[],{"trials":30101,"activeCount":103},[],{"intervention":5219,"totalTrials":1087,"cells":30103},{"EARLY_PHASE1":30104,"PHASE1":30106,"PHASE2":30117,"PHASE3":30123,"PHASE4":30125,"NA":30127},{"trials":30105,"activeCount":103},[],{"trials":30107,"activeCount":103},[30108],{"nctId":30109,"briefTitle":30110,"status":111,"phases":30111,"primaryCompletion":30112,"completion":30112,"start":30113,"enrollment":16968,"conditions":30114,"interventions":30115},"NCT02315066","Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566",[91],"2020-11-12","2015-04-23",[2053],[5219,5219,30116,30116],"PF-04518600 plus PF-05082566",{"trials":30118,"activeCount":103},[30119],{"nctId":5211,"briefTitle":5212,"status":168,"phases":30120,"primaryCompletion":5214,"completion":5214,"start":5215,"enrollment":5216,"conditions":30121,"interventions":30122},[91,92],[543],[663,2916,5219,5220,5221],{"trials":30124,"activeCount":103},[],{"trials":30126,"activeCount":103},[],{"trials":30128,"activeCount":103},[],{"intervention":30130,"totalTrials":1087,"cells":30131},"PF-04383119",{"EARLY_PHASE1":30132,"PHASE1":30134,"PHASE2":30136,"PHASE3":30154,"PHASE4":30156,"NA":30158},{"trials":30133,"activeCount":103},[],{"trials":30135,"activeCount":103},[],{"trials":30137,"activeCount":103},[30138,30146],{"nctId":30139,"briefTitle":30140,"status":111,"phases":30141,"primaryCompletion":30142,"completion":30142,"start":30143,"enrollment":3603,"conditions":30144,"interventions":30145},"NCT00669409","A Phase 1\u002F2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee",[92],"2009-12-25","2008-06-06",[11347],[30130,30130,30130,30130,30130,30130],{"nctId":30147,"briefTitle":30148,"status":111,"phases":30149,"primaryCompletion":30150,"completion":30150,"start":30151,"enrollment":4726,"conditions":30152,"interventions":30153},"NCT00601484","An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis",[92],"2009-04-15","2008-03-17",[17161],[30130],{"trials":30155,"activeCount":103},[],{"trials":30157,"activeCount":103},[],{"trials":30159,"activeCount":103},[],{"intervention":30161,"totalTrials":1087,"cells":30162},"Salmeterol",{"EARLY_PHASE1":30163,"PHASE1":30165,"PHASE2":30167,"PHASE3":30187,"PHASE4":30189,"NA":30191},{"trials":30164,"activeCount":103},[],{"trials":30166,"activeCount":103},[],{"trials":30168,"activeCount":103},[30169,30176],{"nctId":30170,"briefTitle":30171,"status":111,"phases":30172,"start":3610,"enrollment":1578,"conditions":30173,"interventions":30174},"NCT00468975","A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.",[92],[6589],[30175,30161],"PF-610,355",{"nctId":30177,"briefTitle":30178,"status":111,"phases":30179,"primaryCompletion":4656,"completion":4656,"start":3642,"enrollment":30180,"conditions":30181,"interventions":30183},"NCT00808288","A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.",[92],405,[21083,9108,30182],"Lung Diseases, Obstructive",[30184,30185,30186,30161],"PF-00610355","PF - 00610355","PF- 00610355",{"trials":30188,"activeCount":103},[],{"trials":30190,"activeCount":103},[],{"trials":30192,"activeCount":103},[],{"intervention":12290,"totalTrials":1087,"cells":30194},{"EARLY_PHASE1":30195,"PHASE1":30197,"PHASE2":30199,"PHASE3":30214,"PHASE4":30216,"NA":30218},{"trials":30196,"activeCount":103},[],{"trials":30198,"activeCount":103},[],{"trials":30200,"activeCount":103},[30201,30205],{"nctId":12283,"briefTitle":12284,"status":111,"phases":30202,"primaryCompletion":12286,"completion":12286,"start":12287,"enrollment":3603,"conditions":30203,"interventions":30204},[92],[12278],[12290,12262,12291],{"nctId":30206,"briefTitle":30207,"status":111,"phases":30208,"primaryCompletion":5970,"completion":5970,"start":30209,"enrollment":725,"conditions":30210,"interventions":30212},"NCT02497781","Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)",[92],"2015-09-24",[30211],"Complicated Urinary Tract Infections",[12290,30213],"Cefepime",{"trials":30215,"activeCount":103},[],{"trials":30217,"activeCount":103},[],{"trials":30219,"activeCount":103},[],{"intervention":30221,"totalTrials":1087,"cells":30222},"PF-03463275",{"EARLY_PHASE1":30223,"PHASE1":30225,"PHASE2":30233,"PHASE3":30241,"PHASE4":30243,"NA":30245},{"trials":30224,"activeCount":103},[],{"trials":30226,"activeCount":103},[30227],{"nctId":30228,"briefTitle":30229,"status":111,"phases":30230,"primaryCompletion":8252,"completion":8252,"start":586,"enrollment":35,"conditions":30231,"interventions":30232},"NCT01159626","Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects",[91],[16],[30221,30221,30221,30221],{"trials":30234,"activeCount":103},[30235],{"nctId":30236,"briefTitle":30237,"status":168,"phases":30238,"primaryCompletion":560,"completion":560,"start":6016,"enrollment":685,"conditions":30239,"interventions":30240},"NCT00977522","A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia",[92],[12632],[30221],{"trials":30242,"activeCount":103},[],{"trials":30244,"activeCount":103},[],{"trials":30246,"activeCount":103},[],{"intervention":30248,"totalTrials":1087,"cells":30249},"Temanogrel",{"EARLY_PHASE1":30250,"PHASE1":30252,"PHASE2":30254,"PHASE3":30271,"PHASE4":30273,"NA":30275},{"trials":30251,"activeCount":103},[],{"trials":30253,"activeCount":103},[],{"trials":30255,"activeCount":103},[30256,30264],{"nctId":30257,"briefTitle":30258,"status":168,"phases":30259,"primaryCompletion":2579,"completion":2579,"start":30260,"enrollment":3254,"conditions":30261,"interventions":30263},"NCT04915950","A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis",[92],"2021-11-03",[30262],"Raynaud's Phenomenon Secondary to Systemic Sclerosis",[30248],{"nctId":30265,"briefTitle":30266,"status":168,"phases":30267,"primaryCompletion":23539,"completion":2335,"start":2589,"enrollment":350,"conditions":30268,"interventions":30270},"NCT04848220","A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention",[92],[30269],"Microvascular Obstruction",[30248],{"trials":30272,"activeCount":103},[],{"trials":30274,"activeCount":103},[],{"trials":30276,"activeCount":103},[],{"intervention":12894,"totalTrials":1087,"cells":30278},{"EARLY_PHASE1":30279,"PHASE1":30281,"PHASE2":30283,"PHASE3":30293,"PHASE4":30295,"NA":30297},{"trials":30280,"activeCount":103},[],{"trials":30282,"activeCount":103},[],{"trials":30284,"activeCount":103},[30285,30289],{"nctId":12887,"briefTitle":12888,"status":111,"phases":30286,"primaryCompletion":577,"completion":577,"start":10923,"enrollment":1257,"conditions":30287,"interventions":30288},[92],[12891,12882],[12893,12894,12893,12870],{"nctId":13392,"briefTitle":13393,"status":111,"phases":30290,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":30291,"interventions":30292},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":30294,"activeCount":103},[],{"trials":30296,"activeCount":103},[],{"trials":30298,"activeCount":103},[],{"intervention":30300,"totalTrials":1087,"cells":30301},"PF-06687234",{"EARLY_PHASE1":30302,"PHASE1":30304,"PHASE2":30312,"PHASE3":30321,"PHASE4":30323,"NA":30325},{"trials":30303,"activeCount":103},[],{"trials":30305,"activeCount":103},[30306],{"nctId":30307,"briefTitle":30308,"status":168,"phases":30309,"primaryCompletion":13581,"completion":13581,"start":4280,"enrollment":870,"conditions":30310,"interventions":30311},"NCT02711462","Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234",[91],[16],[30300],{"trials":30313,"activeCount":103},[30314],{"nctId":30315,"briefTitle":30316,"status":168,"phases":30317,"primaryCompletion":30318,"completion":30318,"start":2421,"enrollment":2159,"conditions":30319,"interventions":30320},"NCT03269695","Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.",[92],"2021-01-07",[1532],[30300],{"trials":30322,"activeCount":103},[],{"trials":30324,"activeCount":103},[],{"trials":30326,"activeCount":103},[],{"intervention":30328,"totalTrials":1087,"cells":30329},"MRE0094",{"EARLY_PHASE1":30330,"PHASE1":30332,"PHASE2":30334,"PHASE3":30352,"PHASE4":30354,"NA":30356},{"trials":30331,"activeCount":103},[],{"trials":30333,"activeCount":103},[],{"trials":30335,"activeCount":103},[30336,30345],{"nctId":30337,"briefTitle":30338,"status":168,"phases":30339,"primaryCompletion":10937,"completion":10937,"start":3627,"enrollment":314,"conditions":30340,"interventions":30343},"NCT00318214","Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers",[92],[30341,30342],"Foot Ulcer, Diabetic","Diabetes Complications",[30328,30344],"Vehicle gel",{"nctId":30346,"briefTitle":30347,"status":111,"phases":30348,"primaryCompletion":4636,"completion":4636,"start":2671,"enrollment":30349,"conditions":30350,"interventions":30351},"NCT00312364","Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers",[92],322,[30341,30342],[30328],{"trials":30353,"activeCount":103},[],{"trials":30355,"activeCount":103},[],{"trials":30357,"activeCount":103},[],{"intervention":30359,"totalTrials":1087,"cells":30360},"RN624",{"EARLY_PHASE1":30361,"PHASE1":30363,"PHASE2":30365,"PHASE3":30386,"PHASE4":30388,"NA":30390},{"trials":30362,"activeCount":103},[],{"trials":30364,"activeCount":103},[],{"trials":30366,"activeCount":103},[30367,30377],{"nctId":30368,"briefTitle":30369,"status":111,"phases":30370,"primaryCompletion":30371,"completion":30372,"start":30373,"enrollment":30374,"conditions":30375,"interventions":30376},"NCT00568321","RN624 For Pain Of Post-Herpetic Neuralgia",[92],"2008-12-20","2009-01-07","2007-12-19",99,[26924],[30359,30359],{"nctId":30378,"briefTitle":30379,"status":111,"phases":30380,"primaryCompletion":28281,"completion":28281,"start":30381,"enrollment":30382,"conditions":30383,"interventions":30385},"NCT00399490","Open-label Extension Study Of RN624",[92],"2006-09-15",287,[11282,30384,11409],"OA Knee Pain",[30359],{"trials":30387,"activeCount":103},[],{"trials":30389,"activeCount":103},[],{"trials":30391,"activeCount":103},[],{"intervention":29388,"totalTrials":1087,"cells":30393},{"EARLY_PHASE1":30394,"PHASE1":30396,"PHASE2":30398,"PHASE3":30413,"PHASE4":30415,"NA":30417},{"trials":30395,"activeCount":103},[],{"trials":30397,"activeCount":103},[],{"trials":30399,"activeCount":103},[30400,30409],{"nctId":30401,"briefTitle":30402,"status":111,"phases":30403,"primaryCompletion":30404,"completion":30404,"start":30405,"enrollment":1530,"conditions":30406,"interventions":30408},"NCT00637052","A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia",[91,92],"2010-06-21","2008-03-18",[30407,2938],"Advanced MDS",[29388],{"nctId":29381,"briefTitle":29382,"status":111,"phases":30410,"primaryCompletion":29384,"completion":29384,"start":8251,"enrollment":2631,"conditions":30411,"interventions":30412},[91,92],[1062,29386],[29388,29354,29389],{"trials":30414,"activeCount":103},[],{"trials":30416,"activeCount":103},[],{"trials":30418,"activeCount":103},[],{"intervention":30420,"totalTrials":1087,"cells":30421},"SU014813",{"EARLY_PHASE1":30422,"PHASE1":30424,"PHASE2":30432,"PHASE3":30440,"PHASE4":30442,"NA":30444},{"trials":30423,"activeCount":103},[],{"trials":30425,"activeCount":103},[30426],{"nctId":30427,"briefTitle":30428,"status":111,"phases":30429,"primaryCompletion":4645,"completion":2661,"start":2672,"enrollment":5647,"conditions":30430,"interventions":30431},"NCT00982267","A Trial Of SU14813 In Patients With Advanced Solid Malignancies",[91],[2053,750],[30420],{"trials":30433,"activeCount":103},[30434],{"nctId":30435,"briefTitle":30436,"status":111,"phases":30437,"primaryCompletion":3839,"completion":4627,"start":12030,"enrollment":481,"conditions":30438,"interventions":30439},"NCT00322517","Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer",[92],[25],[30420],{"trials":30441,"activeCount":103},[],{"trials":30443,"activeCount":103},[],{"trials":30445,"activeCount":103},[],{"intervention":30447,"totalTrials":1087,"cells":30448},"Vehicle ointment",{"EARLY_PHASE1":30449,"PHASE1":30451,"PHASE2":30453,"PHASE3":30473,"PHASE4":30475,"NA":30477},{"trials":30450,"activeCount":103},[],{"trials":30452,"activeCount":103},[],{"trials":30454,"activeCount":103},[30455,30463],{"nctId":30456,"briefTitle":30457,"status":111,"phases":30458,"primaryCompletion":30459,"completion":30459,"start":2050,"enrollment":29076,"conditions":30460,"interventions":30461},"NCT04664153","Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis",[92],"2021-08-18",[1589,26842],[30462,30447],"PF-07038124 ointment",{"nctId":30464,"briefTitle":30465,"status":111,"phases":30466,"primaryCompletion":27771,"completion":27771,"start":30467,"enrollment":10947,"conditions":30468,"interventions":30469},"NCT05375955","A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.",[92],"2022-09-26",[1589,26842],[30470,30447,30471,30472],"PF-07038124 ointment 0.01%","PF-07038124 ointment 0.03%","PF-07038124 ointment 0.06%",{"trials":30474,"activeCount":103},[],{"trials":30476,"activeCount":103},[],{"trials":30478,"activeCount":103},[],{"intervention":29285,"totalTrials":1087,"cells":30480},{"EARLY_PHASE1":30481,"PHASE1":30483,"PHASE2":30485,"PHASE3":30495,"PHASE4":30497,"NA":30499},{"trials":30482,"activeCount":103},[],{"trials":30484,"activeCount":103},[],{"trials":30486,"activeCount":103},[30487,30491],{"nctId":29280,"briefTitle":29281,"status":111,"phases":30488,"primaryCompletion":4590,"completion":4590,"start":3610,"enrollment":1122,"conditions":30489,"interventions":30490},[92],[13445],[29285,29271,29286],{"nctId":29288,"briefTitle":29289,"status":111,"phases":30492,"primaryCompletion":18128,"completion":18128,"start":2964,"enrollment":4981,"conditions":30493,"interventions":30494},[92],[13445],[29285,29286,29271],{"trials":30496,"activeCount":103},[],{"trials":30498,"activeCount":103},[],{"trials":30500,"activeCount":103},[],{"intervention":29286,"totalTrials":1087,"cells":30502},{"EARLY_PHASE1":30503,"PHASE1":30505,"PHASE2":30507,"PHASE3":30517,"PHASE4":30519,"NA":30521},{"trials":30504,"activeCount":103},[],{"trials":30506,"activeCount":103},[],{"trials":30508,"activeCount":103},[30509,30513],{"nctId":29280,"briefTitle":29281,"status":111,"phases":30510,"primaryCompletion":4590,"completion":4590,"start":3610,"enrollment":1122,"conditions":30511,"interventions":30512},[92],[13445],[29285,29271,29286],{"nctId":29288,"briefTitle":29289,"status":111,"phases":30514,"primaryCompletion":18128,"completion":18128,"start":2964,"enrollment":4981,"conditions":30515,"interventions":30516},[92],[13445],[29285,29286,29271],{"trials":30518,"activeCount":103},[],{"trials":30520,"activeCount":103},[],{"trials":30522,"activeCount":103},[],{"intervention":29336,"totalTrials":1087,"cells":30524},{"EARLY_PHASE1":30525,"PHASE1":30527,"PHASE2":30529,"PHASE3":30539,"PHASE4":30541,"NA":30543},{"trials":30526,"activeCount":103},[],{"trials":30528,"activeCount":103},[],{"trials":30530,"activeCount":103},[30531,30535],{"nctId":29329,"briefTitle":29330,"status":111,"phases":30532,"primaryCompletion":29332,"completion":29332,"start":29333,"enrollment":3866,"conditions":30533,"interventions":30534},[92],[4401],[29306,29336],{"nctId":29510,"briefTitle":29414,"status":111,"phases":30536,"primaryCompletion":8154,"completion":8154,"start":11291,"enrollment":1780,"conditions":30537,"interventions":30538},[92],[4401],[29418,29514],{"trials":30540,"activeCount":103},[],{"trials":30542,"activeCount":103},[],{"trials":30544,"activeCount":103},[],{"intervention":30184,"totalTrials":1087,"cells":30546},{"EARLY_PHASE1":30547,"PHASE1":30549,"PHASE2":30551,"PHASE3":30563,"PHASE4":30565,"NA":30567},{"trials":30548,"activeCount":103},[],{"trials":30550,"activeCount":103},[],{"trials":30552,"activeCount":103},[30553,30557],{"nctId":30177,"briefTitle":30178,"status":111,"phases":30554,"primaryCompletion":4656,"completion":4656,"start":3642,"enrollment":30180,"conditions":30555,"interventions":30556},[92],[21083,9108,30182],[30184,30185,30186,30161],{"nctId":30558,"briefTitle":30559,"status":111,"phases":30560,"primaryCompletion":11290,"completion":11290,"start":4665,"enrollment":2159,"conditions":30561,"interventions":30562},"NCT00783406","Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.",[92],[21083],[30184,30184,30184],{"trials":30564,"activeCount":103},[],{"trials":30566,"activeCount":103},[],{"trials":30568,"activeCount":103},[],{"intervention":30570,"totalTrials":1087,"cells":30571},"CP-547,632",{"EARLY_PHASE1":30572,"PHASE1":30574,"PHASE2":30576,"PHASE3":30592,"PHASE4":30594,"NA":30596},{"trials":30573,"activeCount":103},[],{"trials":30575,"activeCount":103},[],{"trials":30577,"activeCount":103},[30578,30586],{"nctId":30579,"briefTitle":30580,"status":111,"phases":30581,"completion":7675,"start":11736,"enrollment":350,"conditions":30582,"interventions":30585},"NCT00074867","Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer",[92],[8476,30583,30584],"Peritoneal Neoplasms","Fallopian Tube Neoplasms",[30570],{"nctId":30587,"briefTitle":30588,"status":111,"phases":30589,"completion":4692,"start":11807,"enrollment":1083,"conditions":30590,"interventions":30591},"NCT00074854","A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy",[91,92],[946],[30570],{"trials":30593,"activeCount":103},[],{"trials":30595,"activeCount":103},[],{"trials":30597,"activeCount":103},[],{"intervention":29627,"totalTrials":1087,"cells":30599},{"EARLY_PHASE1":30600,"PHASE1":30602,"PHASE2":30610,"PHASE3":30616,"PHASE4":30618,"NA":30620},{"trials":30601,"activeCount":103},[],{"trials":30603,"activeCount":103},[30604],{"nctId":30605,"briefTitle":30606,"status":111,"phases":30607,"primaryCompletion":4531,"completion":4531,"start":2660,"enrollment":1487,"conditions":30608,"interventions":30609},"NCT01125631","Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",[91],[17728],[29627],{"trials":30611,"activeCount":103},[30612],{"nctId":29618,"briefTitle":29619,"status":111,"phases":30613,"primaryCompletion":29621,"completion":29621,"start":29622,"enrollment":22666,"conditions":30614,"interventions":30615},[92],[17728],[29625,29626,29600,29612,29627],{"trials":30617,"activeCount":103},[],{"trials":30619,"activeCount":103},[],{"trials":30621,"activeCount":103},[],{"intervention":9391,"totalTrials":1087,"cells":30623},{"EARLY_PHASE1":30624,"PHASE1":30626,"PHASE2":30632,"PHASE3":30641,"PHASE4":30643,"NA":30645},{"trials":30625,"activeCount":103},[],{"trials":30627,"activeCount":103},[30628],{"nctId":9384,"briefTitle":9385,"status":111,"phases":30629,"completion":9387,"start":9388,"enrollment":1097,"conditions":30630,"interventions":30631},[91],[2645],[9391,9392,9393],{"trials":30633,"activeCount":103},[30634],{"nctId":30635,"briefTitle":30636,"status":111,"phases":30637,"completion":8170,"start":3073,"enrollment":30638,"conditions":30639,"interventions":30640},"NCT00050830","A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer",[92],163,[946],[9391],{"trials":30642,"activeCount":103},[],{"trials":30644,"activeCount":103},[],{"trials":30646,"activeCount":103},[],{"intervention":30648,"totalTrials":1087,"cells":30649},"UK-369,003",{"EARLY_PHASE1":30650,"PHASE1":30652,"PHASE2":30654,"PHASE3":30671,"PHASE4":30673,"NA":30675},{"trials":30651,"activeCount":103},[],{"trials":30653,"activeCount":103},[],{"trials":30655,"activeCount":103},[30656,30662],{"nctId":30657,"briefTitle":30658,"status":111,"phases":30659,"completion":2671,"start":4702,"enrollment":17874,"conditions":30660,"interventions":30661},"NCT00163098","A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD",[91,92],[21083],[30648],{"nctId":30663,"briefTitle":30664,"status":111,"phases":30665,"primaryCompletion":3314,"completion":3314,"start":3610,"enrollment":30666,"conditions":30667,"interventions":30669},"NCT00457457","Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.",[92],609,[30668],"Prostatic Hyperplasia",[30670,30648],"Tamsulosin",{"trials":30672,"activeCount":103},[],{"trials":30674,"activeCount":103},[],{"trials":30676,"activeCount":103},[],{"intervention":30678,"totalTrials":1087,"cells":30679},"PF-00734200 20 mg QD",{"EARLY_PHASE1":30680,"PHASE1":30682,"PHASE2":30684,"PHASE3":30703,"PHASE4":30705,"NA":30707},{"trials":30681,"activeCount":103},[],{"trials":30683,"activeCount":103},[],{"trials":30685,"activeCount":103},[30686,30695],{"nctId":30687,"briefTitle":30688,"status":111,"phases":30689,"primaryCompletion":3839,"completion":3839,"start":2641,"enrollment":10972,"conditions":30690,"interventions":30691},"NCT00473525","12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin",[92],[37],[30692,30678,30693,30694],"PF-00734200 10 mg QD","PF-00734200 5 mg QD","PF-00734200 2 mg QD",{"nctId":30696,"briefTitle":30697,"status":111,"phases":30698,"primaryCompletion":8115,"completion":8115,"start":10937,"enrollment":30699,"conditions":30700,"interventions":30701},"NCT00618007","Effect of PF-00734200 in Subjects With Type 2 Diabetes",[92],289,[37],[30702,30678],"PF-00734200 30 mg QD",{"trials":30704,"activeCount":103},[],{"trials":30706,"activeCount":103},[],{"trials":30708,"activeCount":103},[],{"intervention":29904,"totalTrials":1087,"cells":30710},{"EARLY_PHASE1":30711,"PHASE1":30713,"PHASE2":30721,"PHASE3":30727,"PHASE4":30729,"NA":30731},{"trials":30712,"activeCount":103},[],{"trials":30714,"activeCount":103},[30715],{"nctId":30716,"briefTitle":30717,"status":111,"phases":30718,"primaryCompletion":4221,"completion":4221,"start":4846,"enrollment":1530,"conditions":30719,"interventions":30720},"NCT00989391","A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth",[91],[16],[29904,29904,29904],{"trials":30722,"activeCount":103},[30723],{"nctId":29899,"briefTitle":29900,"status":111,"phases":30724,"primaryCompletion":2660,"completion":2660,"start":10923,"enrollment":7363,"conditions":30725,"interventions":30726},[92],[8280],[29904,29048,29904,29049],{"trials":30728,"activeCount":103},[],{"trials":30730,"activeCount":103},[],{"trials":30732,"activeCount":103},[],{"intervention":17059,"totalTrials":1087,"cells":30734},{"EARLY_PHASE1":30735,"PHASE1":30737,"PHASE2":30743,"PHASE3":30752,"PHASE4":30754,"NA":30756},{"trials":30736,"activeCount":103},[],{"trials":30738,"activeCount":103},[30739],{"nctId":17054,"briefTitle":17055,"status":111,"phases":30740,"primaryCompletion":4656,"completion":4656,"start":586,"enrollment":29,"conditions":30741,"interventions":30742},[91],[16],[17059,17059,6111],{"trials":30744,"activeCount":103},[30745],{"nctId":30746,"briefTitle":30747,"status":111,"phases":30748,"primaryCompletion":11291,"completion":11291,"start":3643,"enrollment":32,"conditions":30749,"interventions":30751},"NCT00495677","A Phase 2 Study Of PF-00232798 In HIV Positive Patients",[92],[30750],"HIV",[17059,17059,17059,17059,17059,17059],{"trials":30753,"activeCount":103},[],{"trials":30755,"activeCount":103},[],{"trials":30757,"activeCount":103},[],{"intervention":30759,"totalTrials":1087,"cells":30760},"UK-453,061",{"EARLY_PHASE1":30761,"PHASE1":30763,"PHASE2":30772,"PHASE3":30780,"PHASE4":30782,"NA":30784},{"trials":30762,"activeCount":103},[],{"trials":30764,"activeCount":103},[30765],{"nctId":30766,"briefTitle":30767,"status":111,"phases":30768,"primaryCompletion":4645,"completion":4645,"start":11291,"enrollment":597,"conditions":30769,"interventions":30770},"NCT00784420","Drug Interaction Study Between Raltegravir And UK-453,061",[91],[19],[30759,30759,30771,30771],"Raltegravir",{"trials":30773,"activeCount":103},[30774],{"nctId":30775,"briefTitle":30776,"status":111,"phases":30777,"primaryCompletion":1701,"completion":1701,"start":12416,"enrollment":2175,"conditions":30778,"interventions":30779},"NCT00348673","A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061",[92],[27719],[30759,30759],{"trials":30781,"activeCount":103},[],{"trials":30783,"activeCount":103},[],{"trials":30785,"activeCount":103},[],{"intervention":30787,"totalTrials":1087,"cells":30788},"capravirine",{"EARLY_PHASE1":30789,"PHASE1":30791,"PHASE2":30793,"PHASE3":30811,"PHASE4":30813,"NA":30815},{"trials":30790,"activeCount":103},[],{"trials":30792,"activeCount":103},[],{"trials":30794,"activeCount":103},[30795,30803],{"nctId":30796,"briefTitle":30797,"status":111,"phases":30798,"completion":11829,"start":3073,"enrollment":1613,"conditions":30799,"interventions":30800},"NCT00052117","Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens",[92],[10974],[30787,30801,30802],"Kaletra","2 NRTIs",{"nctId":30804,"briefTitle":30805,"status":111,"phases":30806,"completion":12774,"start":11765,"enrollment":14574,"conditions":30807,"interventions":30809},"NCT00051844","Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen",[92],[30808],"Human Immunodeficiency Virus",[30810],"Capravirine",{"trials":30812,"activeCount":103},[],{"trials":30814,"activeCount":103},[],{"trials":30816,"activeCount":103},[],{"intervention":3754,"totalTrials":1087,"cells":30818},{"EARLY_PHASE1":30819,"PHASE1":30821,"PHASE2":30827,"PHASE3":30842,"PHASE4":30844,"NA":30846},{"trials":30820,"activeCount":103},[],{"trials":30822,"activeCount":103},[30823],{"nctId":3747,"briefTitle":3748,"status":111,"phases":30824,"primaryCompletion":3750,"completion":3750,"start":1914,"enrollment":1191,"conditions":30825,"interventions":30826},[91],[16],[3753,3754,3740,3755,3756],{"trials":30828,"activeCount":103},[30829],{"nctId":30830,"briefTitle":30831,"status":111,"phases":30832,"primaryCompletion":2819,"completion":2819,"start":30833,"enrollment":30834,"conditions":30835,"interventions":30837},"NCT05052697","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza",[91,92],"2021-09-13",1158,[30836],"Influenza, Human",[30838,30839,3754,3770,30840,30841],"mIRV","bIRV AB","bIRV AA","bIRV BB",{"trials":30843,"activeCount":103},[],{"trials":30845,"activeCount":103},[],{"trials":30847,"activeCount":103},[],{"intervention":3770,"totalTrials":1087,"cells":30849},{"EARLY_PHASE1":30850,"PHASE1":30852,"PHASE2":30854,"PHASE3":30864,"PHASE4":30866,"NA":30868},{"trials":30851,"activeCount":103},[],{"trials":30853,"activeCount":103},[],{"trials":30855,"activeCount":103},[30856,30860],{"nctId":30830,"briefTitle":30831,"status":111,"phases":30857,"primaryCompletion":2819,"completion":2819,"start":30833,"enrollment":30834,"conditions":30858,"interventions":30859},[91,92],[30836],[30838,30839,3754,3770,30840,30841],{"nctId":3760,"briefTitle":3761,"status":111,"phases":30861,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":30862,"interventions":30863},[92],[28],[3768,3769,3740,3770,3771],{"trials":30865,"activeCount":103},[],{"trials":30867,"activeCount":103},[],{"trials":30869,"activeCount":103},[],{"intervention":17984,"totalTrials":1087,"cells":30871},{"EARLY_PHASE1":30872,"PHASE1":30874,"PHASE2":30880,"PHASE3":30886,"PHASE4":30888,"NA":30890},{"trials":30873,"activeCount":103},[],{"trials":30875,"activeCount":103},[30876],{"nctId":17976,"briefTitle":17977,"status":111,"phases":30877,"primaryCompletion":17979,"completion":17980,"start":17981,"enrollment":4369,"conditions":30878,"interventions":30879},[91],[2938],[17974,17974,17984,17974,17959,17958,17974,2940,17974,17985],{"trials":30881,"activeCount":103},[30882],{"nctId":18727,"briefTitle":18728,"status":111,"phases":30883,"primaryCompletion":18730,"completion":18731,"start":18732,"enrollment":18733,"conditions":30884,"interventions":30885},[92],[2938],[17974,17984,17974,17960,17974,17959,17958,17974,17959,17958,17974,17984],{"trials":30887,"activeCount":103},[],{"trials":30889,"activeCount":103},[],{"trials":30891,"activeCount":103},[],{"intervention":3329,"totalTrials":1087,"cells":30893},{"EARLY_PHASE1":30894,"PHASE1":30896,"PHASE2":30898,"PHASE3":30908,"PHASE4":30910,"NA":30912},{"trials":30895,"activeCount":103},[],{"trials":30897,"activeCount":103},[],{"trials":30899,"activeCount":103},[30900,30904],{"nctId":3320,"briefTitle":3321,"status":168,"phases":30901,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":597,"conditions":30902,"interventions":30903},[91,92],[3326],[2003,3328,1030,3329],{"nctId":3331,"briefTitle":3332,"status":111,"phases":30905,"primaryCompletion":524,"completion":3334,"start":3335,"enrollment":3336,"conditions":30906,"interventions":30907},[92],[1028],[1030,3329,3339,3340,3339,3329,1030,3340],{"trials":30909,"activeCount":103},[],{"trials":30911,"activeCount":103},[],{"trials":30913,"activeCount":103},[],{"intervention":30915,"totalTrials":1087,"cells":30916},"RN6G",{"EARLY_PHASE1":30917,"PHASE1":30919,"PHASE2":30934,"PHASE3":30942,"PHASE4":30944,"NA":30946},{"trials":30918,"activeCount":103},[],{"trials":30920,"activeCount":103},[30921],{"nctId":30922,"briefTitle":30923,"status":111,"phases":30924,"primaryCompletion":30925,"completion":30926,"start":30927,"enrollment":1509,"conditions":30928,"interventions":30933},"NCT01003691","Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy",[91],"2013-03-05","2013-04-19","2010-08-05",[30929,30930,30931,30932,15014],"Age-Related Maculopathy","Age-Related Maculopathies","Eye Diseases","Retinal Degeneration",[30915],{"trials":30935,"activeCount":103},[30936],{"nctId":30937,"briefTitle":30938,"status":168,"phases":30939,"primaryCompletion":13214,"completion":1249,"start":569,"enrollment":870,"conditions":30940,"interventions":30941},"NCT01577381","Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration",[92],[30929],[30915],{"trials":30943,"activeCount":103},[],{"trials":30945,"activeCount":103},[],{"trials":30947,"activeCount":103},[],{"intervention":27046,"totalTrials":1087,"cells":30949},{"EARLY_PHASE1":30950,"PHASE1":30952,"PHASE2":30960,"PHASE3":30966,"PHASE4":30968,"NA":30970},{"trials":30951,"activeCount":103},[],{"trials":30953,"activeCount":103},[30954],{"nctId":30955,"briefTitle":30956,"status":111,"phases":30957,"primaryCompletion":12811,"completion":12811,"start":11448,"enrollment":1519,"conditions":30958,"interventions":30959},"NCT02309827","Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers",[91],[16],[27046],{"trials":30961,"activeCount":103},[30962],{"nctId":27039,"briefTitle":27040,"status":111,"phases":30963,"primaryCompletion":9422,"completion":9422,"start":27042,"enrollment":27043,"conditions":30964,"interventions":30965},[92],[1532],[27046,27047,7595,4425],{"trials":30967,"activeCount":103},[],{"trials":30969,"activeCount":103},[],{"trials":30971,"activeCount":103},[],{"intervention":3590,"totalTrials":1087,"cells":30973},{"EARLY_PHASE1":30974,"PHASE1":30976,"PHASE2":30982,"PHASE3":30991,"PHASE4":30993,"NA":30995},{"trials":30975,"activeCount":103},[],{"trials":30977,"activeCount":103},[30978],{"nctId":3583,"briefTitle":3584,"status":168,"phases":30979,"primaryCompletion":3586,"completion":3586,"start":114,"enrollment":3587,"conditions":30980,"interventions":30981},[91],[543],[2003,3590,2003,2004],{"trials":30983,"activeCount":103},[30984],{"nctId":30985,"briefTitle":30986,"status":168,"phases":30987,"primaryCompletion":3610,"completion":6263,"start":11512,"enrollment":26401,"conditions":30988,"interventions":30990},"NCT00147550","MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.",[91,92],[1798,30989,25],"Colonic Neoplasms",[3590],{"trials":30992,"activeCount":103},[],{"trials":30994,"activeCount":103},[],{"trials":30996,"activeCount":103},[],{"intervention":30998,"totalTrials":1087,"cells":30999},"AN2690 Solution, 5.0%",{"EARLY_PHASE1":31000,"PHASE1":31002,"PHASE2":31004,"PHASE3":31018,"PHASE4":31020,"NA":31022},{"trials":31001,"activeCount":103},[],{"trials":31003,"activeCount":103},[],{"trials":31005,"activeCount":103},[31006,31012],{"nctId":31007,"briefTitle":31008,"status":111,"phases":31009,"primaryCompletion":4207,"completion":4207,"start":11895,"enrollment":350,"conditions":31010,"interventions":31011},"NCT01278394","Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail",[92],[28946],[30998],{"nctId":31013,"briefTitle":31008,"status":111,"phases":31014,"primaryCompletion":1701,"completion":1701,"start":8170,"enrollment":2240,"conditions":31015,"interventions":31016},"NCT00679523",[92],[28946],[30998,31017],"AN2690 Solution, 7.5%",{"trials":31019,"activeCount":103},[],{"trials":31021,"activeCount":103},[],{"trials":31023,"activeCount":103},[],{"intervention":31025,"totalTrials":1087,"cells":31026},"Etravirine",{"EARLY_PHASE1":31027,"PHASE1":31029,"PHASE2":31031,"PHASE3":31046,"PHASE4":31048,"NA":31050},{"trials":31028,"activeCount":103},[],{"trials":31030,"activeCount":103},[],{"trials":31032,"activeCount":103},[31033,31042],{"nctId":31034,"briefTitle":31035,"status":168,"phases":31036,"primaryCompletion":31037,"completion":31037,"start":17170,"enrollment":3587,"conditions":31038,"interventions":31039},"NCT00823979","A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir\u002FRitonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1",[92],"2012-10-18",[27719],[31040,31041,31025],"UK-453,061 Dose 1","UK-453,061 Dose 2",{"nctId":27715,"briefTitle":27716,"status":168,"phases":31043,"primaryCompletion":6208,"completion":6208,"start":4666,"enrollment":1498,"conditions":31044,"interventions":31045},[92],[27719],[27721,27721,27722,27721,27721,27723],{"trials":31047,"activeCount":103},[],{"trials":31049,"activeCount":103},[],{"trials":31051,"activeCount":103},[],{"intervention":31053,"totalTrials":1087,"cells":31054},"PF-04457845",{"EARLY_PHASE1":31055,"PHASE1":31057,"PHASE2":31065,"PHASE3":31074,"PHASE4":31076,"NA":31078},{"trials":31056,"activeCount":103},[],{"trials":31058,"activeCount":103},[31059],{"nctId":31060,"briefTitle":31061,"status":111,"phases":31062,"primaryCompletion":4627,"completion":4627,"start":11014,"enrollment":1268,"conditions":31063,"interventions":31064},"NCT00918164","Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects",[91],[19],[31053],{"trials":31066,"activeCount":103},[31067],{"nctId":31068,"briefTitle":31069,"status":168,"phases":31070,"primaryCompletion":12307,"completion":12307,"start":11356,"enrollment":562,"conditions":31071,"interventions":31073},"NCT02216097","A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder",[92],[31072],"Post-Traumatic Stress Disorder",[31053],{"trials":31075,"activeCount":103},[],{"trials":31077,"activeCount":103},[],{"trials":31079,"activeCount":103},[],{"intervention":31081,"totalTrials":1087,"cells":31082},"pregabalin 300 mg",{"EARLY_PHASE1":31083,"PHASE1":31085,"PHASE2":31096,"PHASE3":31113,"PHASE4":31115,"NA":31117},{"trials":31084,"activeCount":103},[],{"trials":31086,"activeCount":103},[31087],{"nctId":31088,"briefTitle":31089,"status":111,"phases":31090,"primaryCompletion":12307,"completion":12307,"start":11956,"enrollment":2713,"conditions":31091,"interventions":31092},"NCT02349607","Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints",[91],[16],[31093,31094,31081,31095],"PF-05089771 300mg","PF-05089771 300 mg + pregabalin 300 mg","ibuprofen 600 mg",{"trials":31097,"activeCount":103},[31098],{"nctId":31099,"briefTitle":31100,"status":111,"phases":31101,"primaryCompletion":31102,"completion":31103,"start":31104,"enrollment":31105,"conditions":31106,"interventions":31108},"NCT02215252","A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)",[92],"2015-07-15","2015-09-28","2014-11-10",141,[31107],"Diabetic Neuropathy, Painful",[31109,31110,31111,31112],"PF-05089771 150 mg","Matched placebo for PF-05089771 150 mg and pregabalin 300 mg","Pregabalin 300 mg","PF-05089771 150 mg + Pregabalin 300 mg",{"trials":31114,"activeCount":103},[],{"trials":31116,"activeCount":103},[],{"trials":31118,"activeCount":103},[],{"intervention":31120,"totalTrials":1087,"cells":31121},"SS-RBX",{"EARLY_PHASE1":31122,"PHASE1":31124,"PHASE2":31126,"PHASE3":31141,"PHASE4":31143,"NA":31145},{"trials":31123,"activeCount":103},[],{"trials":31125,"activeCount":103},[],{"trials":31127,"activeCount":103},[31128,31135],{"nctId":31129,"briefTitle":31130,"status":111,"phases":31131,"completion":3627,"start":2671,"enrollment":597,"conditions":31132,"interventions":31134},"NCT00141128","Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.",[92],[31133],"Urinary Incontinence, Stress",[31120],{"nctId":31136,"briefTitle":31137,"status":111,"phases":31138,"primaryCompletion":12773,"completion":12773,"start":12774,"enrollment":17529,"conditions":31139,"interventions":31140},"NCT00138749","An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.",[92],[31133],[31120],{"trials":31142,"activeCount":103},[],{"trials":31144,"activeCount":103},[],{"trials":31146,"activeCount":103},[],{"intervention":3206,"totalTrials":1087,"cells":31148},{"EARLY_PHASE1":31149,"PHASE1":31151,"PHASE2":31157,"PHASE3":31168,"PHASE4":31170,"NA":31172},{"trials":31150,"activeCount":103},[],{"trials":31152,"activeCount":103},[31153],{"nctId":3197,"briefTitle":3198,"status":111,"phases":31154,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":31155,"interventions":31156},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"trials":31158,"activeCount":103},[31159],{"nctId":31160,"briefTitle":31161,"status":168,"phases":31162,"completion":16955,"start":12607,"enrollment":31163,"conditions":31164,"interventions":31165},"NCT00649311","A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension",[92],248,[13280],[31166,31167],"eplerenone","Losartan",{"trials":31169,"activeCount":103},[],{"trials":31171,"activeCount":103},[],{"trials":31173,"activeCount":103},[],{"intervention":29592,"totalTrials":1087,"cells":31175},{"EARLY_PHASE1":31176,"PHASE1":31178,"PHASE2":31180,"PHASE3":31195,"PHASE4":31197,"NA":31199},{"trials":31177,"activeCount":103},[],{"trials":31179,"activeCount":103},[],{"trials":31181,"activeCount":103},[31182,31186],{"nctId":29584,"briefTitle":29585,"status":111,"phases":31183,"primaryCompletion":29587,"completion":29587,"start":29588,"enrollment":29589,"conditions":31184,"interventions":31185},[92],[3801],[29592,27845],{"nctId":31187,"briefTitle":31188,"status":111,"phases":31189,"primaryCompletion":7536,"completion":7536,"start":31190,"enrollment":31191,"conditions":31192,"interventions":31193},"NCT04032093","A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN",[92],"2019-08-07",1153,[3801],[31194],"RSV vaccine",{"trials":31196,"activeCount":103},[],{"trials":31198,"activeCount":103},[],{"trials":31200,"activeCount":103},[],{"intervention":31202,"totalTrials":1087,"cells":31203},"Formulation A",{"EARLY_PHASE1":31204,"PHASE1":31206,"PHASE2":31216,"PHASE3":31228,"PHASE4":31230,"NA":31232},{"trials":31205,"activeCount":103},[],{"trials":31207,"activeCount":103},[31208],{"nctId":31209,"briefTitle":31210,"status":111,"phases":31211,"primaryCompletion":31212,"completion":31212,"start":1586,"enrollment":2159,"conditions":31213,"interventions":31214},"NCT05677867","A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese",[91],"2023-03-14",[2760,2761],[31202,31215],"Formulation B",{"trials":31217,"activeCount":103},[31218],{"nctId":31219,"briefTitle":31220,"status":168,"phases":31221,"primaryCompletion":31222,"completion":31223,"start":31224,"enrollment":6018,"conditions":31225,"interventions":31226},"NCT03572062","A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults",[92],"2020-06-23","2020-08-19","2018-06-05",[3801],[31202,31215,31227],"Formulation C",{"trials":31229,"activeCount":103},[],{"trials":31231,"activeCount":103},[],{"trials":31233,"activeCount":103},[],{"intervention":31215,"totalTrials":1087,"cells":31235},{"EARLY_PHASE1":31236,"PHASE1":31238,"PHASE2":31244,"PHASE3":31250,"PHASE4":31252,"NA":31254},{"trials":31237,"activeCount":103},[],{"trials":31239,"activeCount":103},[31240],{"nctId":31209,"briefTitle":31210,"status":111,"phases":31241,"primaryCompletion":31212,"completion":31212,"start":1586,"enrollment":2159,"conditions":31242,"interventions":31243},[91],[2760,2761],[31202,31215],{"trials":31245,"activeCount":103},[31246],{"nctId":31219,"briefTitle":31220,"status":168,"phases":31247,"primaryCompletion":31222,"completion":31223,"start":31224,"enrollment":6018,"conditions":31248,"interventions":31249},[92],[3801],[31202,31215,31227],{"trials":31251,"activeCount":103},[],{"trials":31253,"activeCount":103},[],{"trials":31255,"activeCount":103},[],{"intervention":3318,"totalTrials":302,"cells":31257},{"EARLY_PHASE1":31258,"PHASE1":31260,"PHASE2":31262,"PHASE3":31268,"PHASE4":31270,"NA":31272},{"trials":31259,"activeCount":103},[],{"trials":31261,"activeCount":103},[],{"trials":31263,"activeCount":103},[31264],{"nctId":3310,"briefTitle":3311,"status":168,"phases":31265,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":1413,"conditions":31266,"interventions":31267},[92],[1028],[3317,3318,429,3318],{"trials":31269,"activeCount":103},[],{"trials":31271,"activeCount":103},[],{"trials":31273,"activeCount":103},[],{"intervention":3232,"totalTrials":302,"cells":31275},{"EARLY_PHASE1":31276,"PHASE1":31278,"PHASE2":31280,"PHASE3":31286,"PHASE4":31288,"NA":31290},{"trials":31277,"activeCount":103},[],{"trials":31279,"activeCount":103},[],{"trials":31281,"activeCount":103},[31282],{"nctId":3224,"briefTitle":3225,"status":168,"phases":31283,"primaryCompletion":1071,"completion":3227,"start":3228,"enrollment":3229,"conditions":31284,"interventions":31285},[91,92],[376],[3232,1812,1832,1773,933,3233],{"trials":31287,"activeCount":103},[],{"trials":31289,"activeCount":103},[],{"trials":31291,"activeCount":103},[],{"intervention":3233,"totalTrials":302,"cells":31293},{"EARLY_PHASE1":31294,"PHASE1":31296,"PHASE2":31298,"PHASE3":31304,"PHASE4":31306,"NA":31308},{"trials":31295,"activeCount":103},[],{"trials":31297,"activeCount":103},[],{"trials":31299,"activeCount":103},[31300],{"nctId":3224,"briefTitle":3225,"status":168,"phases":31301,"primaryCompletion":1071,"completion":3227,"start":3228,"enrollment":3229,"conditions":31302,"interventions":31303},[91,92],[376],[3232,1812,1832,1773,933,3233],{"trials":31305,"activeCount":103},[],{"trials":31307,"activeCount":103},[],{"trials":31309,"activeCount":103},[],{"intervention":2206,"totalTrials":302,"cells":31311},{"EARLY_PHASE1":31312,"PHASE1":31314,"PHASE2":31316,"PHASE3":31322,"PHASE4":31324,"NA":31326},{"trials":31313,"activeCount":103},[],{"trials":31315,"activeCount":103},[],{"trials":31317,"activeCount":103},[31318],{"nctId":2199,"briefTitle":2200,"status":111,"phases":31319,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":748,"conditions":31320,"interventions":31321},[92],[1684],[63,2206,2207],{"trials":31323,"activeCount":103},[],{"trials":31325,"activeCount":103},[],{"trials":31327,"activeCount":103},[],{"intervention":2207,"totalTrials":302,"cells":31329},{"EARLY_PHASE1":31330,"PHASE1":31332,"PHASE2":31334,"PHASE3":31340,"PHASE4":31342,"NA":31344},{"trials":31331,"activeCount":103},[],{"trials":31333,"activeCount":103},[],{"trials":31335,"activeCount":103},[31336],{"nctId":2199,"briefTitle":2200,"status":111,"phases":31337,"primaryCompletion":2202,"completion":2202,"start":2203,"enrollment":748,"conditions":31338,"interventions":31339},[92],[1684],[63,2206,2207],{"trials":31341,"activeCount":103},[],{"trials":31343,"activeCount":103},[],{"trials":31345,"activeCount":103},[],{"intervention":31347,"totalTrials":302,"cells":31348},"20 mg BID of PF-02545920",{"EARLY_PHASE1":31349,"PHASE1":31351,"PHASE2":31353,"PHASE3":31363,"PHASE4":31365,"NA":31367},{"trials":31350,"activeCount":103},[],{"trials":31352,"activeCount":103},[],{"trials":31354,"activeCount":103},[31355],{"nctId":31356,"briefTitle":31357,"status":168,"phases":31358,"primaryCompletion":31359,"completion":31359,"start":31360,"enrollment":27266,"conditions":31361,"interventions":31362},"NCT02342548","Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021",[92],"2017-02-06","2015-02-25",[17729],[31347],{"trials":31364,"activeCount":103},[],{"trials":31366,"activeCount":103},[],{"trials":31368,"activeCount":103},[],{"intervention":31370,"totalTrials":302,"cells":31371},"Sunitinib Malate Continuous Daily Dosing",{"EARLY_PHASE1":31372,"PHASE1":31374,"PHASE2":31376,"PHASE3":31385,"PHASE4":31387,"NA":31389},{"trials":31373,"activeCount":103},[],{"trials":31375,"activeCount":103},[],{"trials":31377,"activeCount":103},[31378],{"nctId":31379,"briefTitle":31380,"status":111,"phases":31381,"primaryCompletion":577,"completion":577,"start":2671,"enrollment":6018,"conditions":31382,"interventions":31383},"NCT00267748","Sunitinib Malate Schedule 4\u002F2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)",[92],[919],[31370,31384],"Sunitinib Malate Schedule 4\u002F2",{"trials":31386,"activeCount":103},[],{"trials":31388,"activeCount":103},[],{"trials":31390,"activeCount":103},[],{"intervention":31384,"totalTrials":302,"cells":31392},{"EARLY_PHASE1":31393,"PHASE1":31395,"PHASE2":31397,"PHASE3":31403,"PHASE4":31405,"NA":31407},{"trials":31394,"activeCount":103},[],{"trials":31396,"activeCount":103},[],{"trials":31398,"activeCount":103},[31399],{"nctId":31379,"briefTitle":31380,"status":111,"phases":31400,"primaryCompletion":577,"completion":577,"start":2671,"enrollment":6018,"conditions":31401,"interventions":31402},[92],[919],[31370,31384],{"trials":31404,"activeCount":103},[],{"trials":31406,"activeCount":103},[],{"trials":31408,"activeCount":103},[],{"intervention":29758,"totalTrials":302,"cells":31410},{"EARLY_PHASE1":31411,"PHASE1":31413,"PHASE2":31415,"PHASE3":31421,"PHASE4":31423,"NA":31425},{"trials":31412,"activeCount":103},[],{"trials":31414,"activeCount":103},[],{"trials":31416,"activeCount":103},[31417],{"nctId":29753,"briefTitle":29754,"status":111,"phases":31418,"completion":4847,"start":2671,"enrollment":27266,"conditions":31419,"interventions":31420},[92],[12489],[29758,29738,29758,11452],{"trials":31422,"activeCount":103},[],{"trials":31424,"activeCount":103},[],{"trials":31426,"activeCount":103},[],{"intervention":11991,"totalTrials":302,"cells":31428},{"EARLY_PHASE1":31429,"PHASE1":31431,"PHASE2":31433,"PHASE3":31439,"PHASE4":31441,"NA":31443},{"trials":31430,"activeCount":103},[],{"trials":31432,"activeCount":103},[],{"trials":31434,"activeCount":103},[31435],{"nctId":11985,"briefTitle":11986,"status":168,"phases":31436,"primaryCompletion":11988,"completion":3353,"start":3335,"enrollment":9553,"conditions":31437,"interventions":31438},[92],[4514],[11991,11992,2341,11991,11992,2341,11991,11992,2341],{"trials":31440,"activeCount":103},[],{"trials":31442,"activeCount":103},[],{"trials":31444,"activeCount":103},[],{"intervention":12280,"totalTrials":302,"cells":31446},{"EARLY_PHASE1":31447,"PHASE1":31449,"PHASE2":31451,"PHASE3":31457,"PHASE4":31459,"NA":31461},{"trials":31448,"activeCount":103},[],{"trials":31450,"activeCount":103},[],{"trials":31452,"activeCount":103},[31453],{"nctId":12271,"briefTitle":12272,"status":111,"phases":31454,"primaryCompletion":12274,"completion":12275,"start":12276,"enrollment":9,"conditions":31455,"interventions":31456},[92],[12278],[12280,12281],{"trials":31458,"activeCount":103},[],{"trials":31460,"activeCount":103},[],{"trials":31462,"activeCount":103},[],{"intervention":31464,"totalTrials":302,"cells":31465},"PF-03049423",{"EARLY_PHASE1":31466,"PHASE1":31468,"PHASE2":31470,"PHASE3":31480,"PHASE4":31482,"NA":31484},{"trials":31467,"activeCount":103},[],{"trials":31469,"activeCount":103},[],{"trials":31471,"activeCount":103},[31472],{"nctId":31473,"briefTitle":31474,"status":168,"phases":31475,"primaryCompletion":606,"completion":606,"start":4656,"enrollment":31476,"conditions":31477,"interventions":31479},"NCT01208233","Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke",[92],181,[31478],"Ischemic Stroke",[31464,31464,31464],{"trials":31481,"activeCount":103},[],{"trials":31483,"activeCount":103},[],{"trials":31485,"activeCount":103},[],{"intervention":28990,"totalTrials":302,"cells":31487},{"EARLY_PHASE1":31488,"PHASE1":31490,"PHASE2":31492,"PHASE3":31498,"PHASE4":31500,"NA":31502},{"trials":31489,"activeCount":103},[],{"trials":31491,"activeCount":103},[],{"trials":31493,"activeCount":103},[31494],{"nctId":28985,"briefTitle":28986,"status":111,"phases":31495,"primaryCompletion":8154,"completion":4627,"start":4207,"enrollment":498,"conditions":31496,"interventions":31497},[92],[6589],[11349,11349,11349,28990],{"trials":31499,"activeCount":103},[],{"trials":31501,"activeCount":103},[],{"trials":31503,"activeCount":103},[],{"intervention":31505,"totalTrials":302,"cells":31506},"Atorvastatin Placebo",{"EARLY_PHASE1":31507,"PHASE1":31509,"PHASE2":31511,"PHASE3":31519,"PHASE4":31521,"NA":31523},{"trials":31508,"activeCount":103},[],{"trials":31510,"activeCount":103},[],{"trials":31512,"activeCount":103},[31513],{"nctId":31514,"briefTitle":31515,"status":111,"phases":31516,"primaryCompletion":8252,"completion":8252,"start":11988,"enrollment":4360,"conditions":31517,"interventions":31518},"NCT01059864","Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550",[92],[22],[12692,13004,12692,31505],{"trials":31520,"activeCount":103},[],{"trials":31522,"activeCount":103},[],{"trials":31524,"activeCount":103},[],{"intervention":31526,"totalTrials":302,"cells":31527},"ARRY-371797, p38 inhibitor,",{"EARLY_PHASE1":31528,"PHASE1":31530,"PHASE2":31532,"PHASE3":31541,"PHASE4":31543,"NA":31545},{"trials":31529,"activeCount":103},[],{"trials":31531,"activeCount":103},[],{"trials":31533,"activeCount":103},[31534],{"nctId":31535,"briefTitle":31536,"status":111,"phases":31537,"primaryCompletion":2050,"completion":2050,"start":31538,"enrollment":1487,"conditions":31539,"interventions":31540},"NCT02351856","A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy",[92],"2015-02-02",[28267],[31526],{"trials":31542,"activeCount":103},[],{"trials":31544,"activeCount":103},[],{"trials":31546,"activeCount":103},[],{"intervention":31548,"totalTrials":302,"cells":31549},"Open",{"EARLY_PHASE1":31550,"PHASE1":31552,"PHASE2":31554,"PHASE3":31564,"PHASE4":31566,"NA":31568},{"trials":31551,"activeCount":103},[],{"trials":31553,"activeCount":103},[],{"trials":31555,"activeCount":103},[31556],{"nctId":31557,"briefTitle":31558,"status":111,"phases":31559,"primaryCompletion":31560,"completion":31560,"start":28960,"enrollment":504,"conditions":31561,"interventions":31562},"NCT00810732","Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects",[92],"2009-03-06",[18852],[31548,31563],"Nifedipine",{"trials":31565,"activeCount":103},[],{"trials":31567,"activeCount":103},[],{"trials":31569,"activeCount":103},[],{"intervention":31563,"totalTrials":302,"cells":31571},{"EARLY_PHASE1":31572,"PHASE1":31574,"PHASE2":31576,"PHASE3":31582,"PHASE4":31584,"NA":31586},{"trials":31573,"activeCount":103},[],{"trials":31575,"activeCount":103},[],{"trials":31577,"activeCount":103},[31578],{"nctId":31557,"briefTitle":31558,"status":111,"phases":31579,"primaryCompletion":31560,"completion":31560,"start":28960,"enrollment":504,"conditions":31580,"interventions":31581},[92],[18852],[31548,31563],{"trials":31583,"activeCount":103},[],{"trials":31585,"activeCount":103},[],{"trials":31587,"activeCount":103},[],{"intervention":29875,"totalTrials":302,"cells":31589},{"EARLY_PHASE1":31590,"PHASE1":31592,"PHASE2":31594,"PHASE3":31600,"PHASE4":31602,"NA":31604},{"trials":31591,"activeCount":103},[],{"trials":31593,"activeCount":103},[],{"trials":31595,"activeCount":103},[31596],{"nctId":29866,"briefTitle":29867,"status":111,"phases":31597,"primaryCompletion":29869,"completion":29870,"start":29871,"enrollment":1060,"conditions":31598,"interventions":31599},[92],[3077,29873],[11340,29875],{"trials":31601,"activeCount":103},[],{"trials":31603,"activeCount":103},[],{"trials":31605,"activeCount":103},[],{"intervention":31607,"totalTrials":302,"cells":31608},"Gefitinib + Sunitinib",{"EARLY_PHASE1":31609,"PHASE1":31611,"PHASE2":31613,"PHASE3":31621,"PHASE4":31623,"NA":31625},{"trials":31610,"activeCount":103},[],{"trials":31612,"activeCount":103},[],{"trials":31614,"activeCount":103},[31615],{"nctId":31616,"briefTitle":31617,"status":111,"phases":31618,"primaryCompletion":7665,"completion":4665,"start":12109,"enrollment":1578,"conditions":31619,"interventions":31620},"NCT00113529","Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma",[91,92],[919],[31607],{"trials":31622,"activeCount":103},[],{"trials":31624,"activeCount":103},[],{"trials":31626,"activeCount":103},[],{"intervention":31628,"totalTrials":302,"cells":31629},"PD 0299685 at 15mg BID",{"EARLY_PHASE1":31630,"PHASE1":31632,"PHASE2":31634,"PHASE3":31646,"PHASE4":31648,"NA":31650},{"trials":31631,"activeCount":103},[],{"trials":31633,"activeCount":103},[],{"trials":31635,"activeCount":103},[31636],{"nctId":31637,"briefTitle":31638,"status":111,"phases":31639,"primaryCompletion":10923,"completion":10923,"start":8115,"enrollment":31640,"conditions":31641,"interventions":31644},"NCT00739739","An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis",[92],161,[31642,31643],"Interstitial Cystitis","Painful Bladder Syndrome",[31628,31645],"PD 0299685 at 30mg BID",{"trials":31647,"activeCount":103},[],{"trials":31649,"activeCount":103},[],{"trials":31651,"activeCount":103},[],{"intervention":31645,"totalTrials":302,"cells":31653},{"EARLY_PHASE1":31654,"PHASE1":31656,"PHASE2":31658,"PHASE3":31664,"PHASE4":31666,"NA":31668},{"trials":31655,"activeCount":103},[],{"trials":31657,"activeCount":103},[],{"trials":31659,"activeCount":103},[31660],{"nctId":31637,"briefTitle":31638,"status":111,"phases":31661,"primaryCompletion":10923,"completion":10923,"start":8115,"enrollment":31640,"conditions":31662,"interventions":31663},[92],[31642,31643],[31628,31645],{"trials":31665,"activeCount":103},[],{"trials":31667,"activeCount":103},[],{"trials":31669,"activeCount":103},[],{"intervention":31671,"totalTrials":302,"cells":31672},"PF-04937319 10 mg",{"EARLY_PHASE1":31673,"PHASE1":31675,"PHASE2":31677,"PHASE3":31688,"PHASE4":31690,"NA":31692},{"trials":31674,"activeCount":103},[],{"trials":31676,"activeCount":103},[],{"trials":31678,"activeCount":103},[31679],{"nctId":31680,"briefTitle":31681,"status":111,"phases":31682,"primaryCompletion":4590,"completion":4590,"start":18026,"enrollment":12550,"conditions":31683,"interventions":31684},"NCT01517373","Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin",[92],[37],[31671,31685,31686,31687],"PF-04937319 50 mg","PF-04937319 100 mg","Glimepiride",{"trials":31689,"activeCount":103},[],{"trials":31691,"activeCount":103},[],{"trials":31693,"activeCount":103},[],{"intervention":31685,"totalTrials":302,"cells":31695},{"EARLY_PHASE1":31696,"PHASE1":31698,"PHASE2":31700,"PHASE3":31706,"PHASE4":31708,"NA":31710},{"trials":31697,"activeCount":103},[],{"trials":31699,"activeCount":103},[],{"trials":31701,"activeCount":103},[31702],{"nctId":31680,"briefTitle":31681,"status":111,"phases":31703,"primaryCompletion":4590,"completion":4590,"start":18026,"enrollment":12550,"conditions":31704,"interventions":31705},[92],[37],[31671,31685,31686,31687],{"trials":31707,"activeCount":103},[],{"trials":31709,"activeCount":103},[],{"trials":31711,"activeCount":103},[],{"intervention":31686,"totalTrials":302,"cells":31713},{"EARLY_PHASE1":31714,"PHASE1":31716,"PHASE2":31718,"PHASE3":31724,"PHASE4":31726,"NA":31728},{"trials":31715,"activeCount":103},[],{"trials":31717,"activeCount":103},[],{"trials":31719,"activeCount":103},[31720],{"nctId":31680,"briefTitle":31681,"status":111,"phases":31721,"primaryCompletion":4590,"completion":4590,"start":18026,"enrollment":12550,"conditions":31722,"interventions":31723},[92],[37],[31671,31685,31686,31687],{"trials":31725,"activeCount":103},[],{"trials":31727,"activeCount":103},[],{"trials":31729,"activeCount":103},[],{"intervention":31687,"totalTrials":302,"cells":31731},{"EARLY_PHASE1":31732,"PHASE1":31734,"PHASE2":31736,"PHASE3":31742,"PHASE4":31744,"NA":31746},{"trials":31733,"activeCount":103},[],{"trials":31735,"activeCount":103},[],{"trials":31737,"activeCount":103},[31738],{"nctId":31680,"briefTitle":31681,"status":111,"phases":31739,"primaryCompletion":4590,"completion":4590,"start":18026,"enrollment":12550,"conditions":31740,"interventions":31741},[92],[37],[31671,31685,31686,31687],{"trials":31743,"activeCount":103},[],{"trials":31745,"activeCount":103},[],{"trials":31747,"activeCount":103},[],{"intervention":31749,"totalTrials":302,"cells":31750},"CP- 690 550",{"EARLY_PHASE1":31751,"PHASE1":31753,"PHASE2":31755,"PHASE3":31764,"PHASE4":31766,"NA":31768},{"trials":31752,"activeCount":103},[],{"trials":31754,"activeCount":103},[],{"trials":31756,"activeCount":103},[31757],{"nctId":31758,"briefTitle":31759,"status":111,"phases":31760,"primaryCompletion":560,"completion":560,"start":8154,"enrollment":31761,"conditions":31762,"interventions":31763},"NCT00787202","A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.",[92],195,[1532],[31749,31749,31749,31749],{"trials":31765,"activeCount":103},[],{"trials":31767,"activeCount":103},[],{"trials":31769,"activeCount":103},[],{"intervention":31771,"totalTrials":302,"cells":31772},"Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for",{"EARLY_PHASE1":31773,"PHASE1":31775,"PHASE2":31777,"PHASE3":31796,"PHASE4":31798,"NA":31800},{"trials":31774,"activeCount":103},[],{"trials":31776,"activeCount":103},[],{"trials":31778,"activeCount":103},[31779],{"nctId":31780,"briefTitle":31781,"status":168,"phases":31782,"primaryCompletion":31783,"completion":31783,"start":31784,"enrollment":31785,"conditions":31786,"interventions":31790},"NCT05703607","A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults",[91,92],"2025-09-23","2023-01-25",484,[31787,31788,31789],"Shingles","Herpes Zoster Infection","Human",[31771,31791,31792,31793,31794,31795],"Candidate 1: PF-07915234: VZV modRNA Suspension for","Candidate 2: PF-07921188: VZV modRNA Suspension for","Candidate 3: PF-07921186: VZV modRNA Suspension for","Shingrix","Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for",{"trials":31797,"activeCount":103},[],{"trials":31799,"activeCount":103},[],{"trials":31801,"activeCount":103},[],{"intervention":31791,"totalTrials":302,"cells":31803},{"EARLY_PHASE1":31804,"PHASE1":31806,"PHASE2":31808,"PHASE3":31814,"PHASE4":31816,"NA":31818},{"trials":31805,"activeCount":103},[],{"trials":31807,"activeCount":103},[],{"trials":31809,"activeCount":103},[31810],{"nctId":31780,"briefTitle":31781,"status":168,"phases":31811,"primaryCompletion":31783,"completion":31783,"start":31784,"enrollment":31785,"conditions":31812,"interventions":31813},[91,92],[31787,31788,31789],[31771,31791,31792,31793,31794,31795],{"trials":31815,"activeCount":103},[],{"trials":31817,"activeCount":103},[],{"trials":31819,"activeCount":103},[],{"intervention":31792,"totalTrials":302,"cells":31821},{"EARLY_PHASE1":31822,"PHASE1":31824,"PHASE2":31826,"PHASE3":31832,"PHASE4":31834,"NA":31836},{"trials":31823,"activeCount":103},[],{"trials":31825,"activeCount":103},[],{"trials":31827,"activeCount":103},[31828],{"nctId":31780,"briefTitle":31781,"status":168,"phases":31829,"primaryCompletion":31783,"completion":31783,"start":31784,"enrollment":31785,"conditions":31830,"interventions":31831},[91,92],[31787,31788,31789],[31771,31791,31792,31793,31794,31795],{"trials":31833,"activeCount":103},[],{"trials":31835,"activeCount":103},[],{"trials":31837,"activeCount":103},[],{"intervention":31793,"totalTrials":302,"cells":31839},{"EARLY_PHASE1":31840,"PHASE1":31842,"PHASE2":31844,"PHASE3":31850,"PHASE4":31852,"NA":31854},{"trials":31841,"activeCount":103},[],{"trials":31843,"activeCount":103},[],{"trials":31845,"activeCount":103},[31846],{"nctId":31780,"briefTitle":31781,"status":168,"phases":31847,"primaryCompletion":31783,"completion":31783,"start":31784,"enrollment":31785,"conditions":31848,"interventions":31849},[91,92],[31787,31788,31789],[31771,31791,31792,31793,31794,31795],{"trials":31851,"activeCount":103},[],{"trials":31853,"activeCount":103},[],{"trials":31855,"activeCount":103},[],{"intervention":31794,"totalTrials":302,"cells":31857},{"EARLY_PHASE1":31858,"PHASE1":31860,"PHASE2":31862,"PHASE3":31868,"PHASE4":31870,"NA":31872},{"trials":31859,"activeCount":103},[],{"trials":31861,"activeCount":103},[],{"trials":31863,"activeCount":103},[31864],{"nctId":31780,"briefTitle":31781,"status":168,"phases":31865,"primaryCompletion":31783,"completion":31783,"start":31784,"enrollment":31785,"conditions":31866,"interventions":31867},[91,92],[31787,31788,31789],[31771,31791,31792,31793,31794,31795],{"trials":31869,"activeCount":103},[],{"trials":31871,"activeCount":103},[],{"trials":31873,"activeCount":103},[],{"intervention":31795,"totalTrials":302,"cells":31875},{"EARLY_PHASE1":31876,"PHASE1":31878,"PHASE2":31880,"PHASE3":31886,"PHASE4":31888,"NA":31890},{"trials":31877,"activeCount":103},[],{"trials":31879,"activeCount":103},[],{"trials":31881,"activeCount":103},[31882],{"nctId":31780,"briefTitle":31781,"status":168,"phases":31883,"primaryCompletion":31783,"completion":31783,"start":31784,"enrollment":31785,"conditions":31884,"interventions":31885},[91,92],[31787,31788,31789],[31771,31791,31792,31793,31794,31795],{"trials":31887,"activeCount":103},[],{"trials":31889,"activeCount":103},[],{"trials":31891,"activeCount":103},[],{"intervention":19498,"totalTrials":302,"cells":31893},{"EARLY_PHASE1":31894,"PHASE1":31896,"PHASE2":31898,"PHASE3":31904,"PHASE4":31906,"NA":31908},{"trials":31895,"activeCount":103},[],{"trials":31897,"activeCount":103},[],{"trials":31899,"activeCount":103},[31900],{"nctId":19489,"briefTitle":19490,"status":168,"phases":31901,"primaryCompletion":19492,"completion":19492,"start":19493,"enrollment":1625,"conditions":31902,"interventions":31903},[92],[19495],[19497,19498,19499],{"trials":31905,"activeCount":103},[],{"trials":31907,"activeCount":103},[],{"trials":31909,"activeCount":103},[],{"intervention":19499,"totalTrials":302,"cells":31911},{"EARLY_PHASE1":31912,"PHASE1":31914,"PHASE2":31916,"PHASE3":31922,"PHASE4":31924,"NA":31926},{"trials":31913,"activeCount":103},[],{"trials":31915,"activeCount":103},[],{"trials":31917,"activeCount":103},[31918],{"nctId":19489,"briefTitle":19490,"status":168,"phases":31919,"primaryCompletion":19492,"completion":19492,"start":19493,"enrollment":1625,"conditions":31920,"interventions":31921},[92],[19495],[19497,19498,19499],{"trials":31923,"activeCount":103},[],{"trials":31925,"activeCount":103},[],{"trials":31927,"activeCount":103},[],{"intervention":31929,"totalTrials":302,"cells":31930},"Vfend®; I.V.",{"EARLY_PHASE1":31931,"PHASE1":31933,"PHASE2":31935,"PHASE3":31943,"PHASE4":31945,"NA":31947},{"trials":31932,"activeCount":103},[],{"trials":31934,"activeCount":103},[],{"trials":31936,"activeCount":103},[31937],{"nctId":31938,"briefTitle":31939,"status":168,"phases":31940,"primaryCompletion":9387,"completion":9387,"start":14118,"enrollment":302,"conditions":31941,"interventions":31942},"NCT00150319","An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend",[91,92],[12033],[31929],{"trials":31944,"activeCount":103},[],{"trials":31946,"activeCount":103},[],{"trials":31948,"activeCount":103},[],{"intervention":31950,"totalTrials":302,"cells":31951},"Zithromax™ (azithromycin) 500mg",{"EARLY_PHASE1":31952,"PHASE1":31954,"PHASE2":31956,"PHASE3":31964,"PHASE4":31966,"NA":31968},{"trials":31953,"activeCount":103},[],{"trials":31955,"activeCount":103},[],{"trials":31957,"activeCount":103},[31958],{"nctId":31959,"briefTitle":31960,"status":111,"phases":31961,"primaryCompletion":3627,"completion":3627,"start":8170,"enrollment":7388,"conditions":31962,"interventions":31963},"NCT00232154","A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To",[92],[14364],[31950],{"trials":31965,"activeCount":103},[],{"trials":31967,"activeCount":103},[],{"trials":31969,"activeCount":103},[],{"intervention":31971,"totalTrials":302,"cells":31972},"paclitaxel + carboplatin + bevacizumab",{"EARLY_PHASE1":31973,"PHASE1":31975,"PHASE2":31977,"PHASE3":31986,"PHASE4":31988,"NA":31990},{"trials":31974,"activeCount":103},[],{"trials":31976,"activeCount":103},[],{"trials":31978,"activeCount":103},[31979],{"nctId":31980,"briefTitle":31981,"status":168,"phases":31982,"primaryCompletion":2884,"completion":2884,"start":2671,"enrollment":2218,"conditions":31983,"interventions":31984},"NCT00313768","Randomized Ph 2 Trial Of Paclitaxel\u002FCarboplatin \u002FBevacizumab + PF-3512676 And P\u002FC\u002FB Alone In Advanced Nonsquamous NSCLC",[92],[376],[31971,31985],"carboplatin + paclitaxel + bevacizumab + PF-3512676",{"trials":31987,"activeCount":103},[],{"trials":31989,"activeCount":103},[],{"trials":31991,"activeCount":103},[],{"intervention":31985,"totalTrials":302,"cells":31993},{"EARLY_PHASE1":31994,"PHASE1":31996,"PHASE2":31998,"PHASE3":32004,"PHASE4":32006,"NA":32008},{"trials":31995,"activeCount":103},[],{"trials":31997,"activeCount":103},[],{"trials":31999,"activeCount":103},[32000],{"nctId":31980,"briefTitle":31981,"status":168,"phases":32001,"primaryCompletion":2884,"completion":2884,"start":2671,"enrollment":2218,"conditions":32002,"interventions":32003},[92],[376],[31971,31985],{"trials":32005,"activeCount":103},[],{"trials":32007,"activeCount":103},[],{"trials":32009,"activeCount":103},[],{"intervention":32011,"totalTrials":302,"cells":32012},"ACC-001(3µg) + QS21",{"EARLY_PHASE1":32013,"PHASE1":32015,"PHASE2":32017,"PHASE3":32029,"PHASE4":32031,"NA":32033},{"trials":32014,"activeCount":103},[],{"trials":32016,"activeCount":103},[],{"trials":32018,"activeCount":103},[32019],{"nctId":32020,"briefTitle":32021,"status":111,"phases":32022,"primaryCompletion":32023,"completion":32023,"start":32024,"enrollment":4981,"conditions":32025,"interventions":32026},"NCT00955409","Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease",[92],"2013-12-17","2009-11-05",[13445],[32011,32027,32028],"ACC-001(10µg) + QS21","ACC-001(30µg) + QS21",{"trials":32030,"activeCount":103},[],{"trials":32032,"activeCount":103},[],{"trials":32034,"activeCount":103},[],{"intervention":32027,"totalTrials":302,"cells":32036},{"EARLY_PHASE1":32037,"PHASE1":32039,"PHASE2":32041,"PHASE3":32047,"PHASE4":32049,"NA":32051},{"trials":32038,"activeCount":103},[],{"trials":32040,"activeCount":103},[],{"trials":32042,"activeCount":103},[32043],{"nctId":32020,"briefTitle":32021,"status":111,"phases":32044,"primaryCompletion":32023,"completion":32023,"start":32024,"enrollment":4981,"conditions":32045,"interventions":32046},[92],[13445],[32011,32027,32028],{"trials":32048,"activeCount":103},[],{"trials":32050,"activeCount":103},[],{"trials":32052,"activeCount":103},[],{"intervention":32028,"totalTrials":302,"cells":32054},{"EARLY_PHASE1":32055,"PHASE1":32057,"PHASE2":32059,"PHASE3":32065,"PHASE4":32067,"NA":32069},{"trials":32056,"activeCount":103},[],{"trials":32058,"activeCount":103},[],{"trials":32060,"activeCount":103},[32061],{"nctId":32020,"briefTitle":32021,"status":111,"phases":32062,"primaryCompletion":32023,"completion":32023,"start":32024,"enrollment":4981,"conditions":32063,"interventions":32064},[92],[13445],[32011,32027,32028],{"trials":32066,"activeCount":103},[],{"trials":32068,"activeCount":103},[],{"trials":32070,"activeCount":103},[],{"intervention":32072,"totalTrials":302,"cells":32073},"CP-690,550 Eye drops",{"EARLY_PHASE1":32074,"PHASE1":32076,"PHASE2":32078,"PHASE3":32089,"PHASE4":32091,"NA":32093},{"trials":32075,"activeCount":103},[],{"trials":32077,"activeCount":103},[],{"trials":32079,"activeCount":103},[32080],{"nctId":32081,"briefTitle":32082,"status":111,"phases":32083,"primaryCompletion":523,"completion":523,"start":586,"enrollment":32084,"conditions":32085,"interventions":32086},"NCT01135511","A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease",[92],285,[28053],[32072,32072,32072,32087,32088],"CP-690,550 Eye drops-vehicle","Sodium Hyaluronate",{"trials":32090,"activeCount":103},[],{"trials":32092,"activeCount":103},[],{"trials":32094,"activeCount":103},[],{"intervention":32087,"totalTrials":302,"cells":32096},{"EARLY_PHASE1":32097,"PHASE1":32099,"PHASE2":32101,"PHASE3":32107,"PHASE4":32109,"NA":32111},{"trials":32098,"activeCount":103},[],{"trials":32100,"activeCount":103},[],{"trials":32102,"activeCount":103},[32103],{"nctId":32081,"briefTitle":32082,"status":111,"phases":32104,"primaryCompletion":523,"completion":523,"start":586,"enrollment":32084,"conditions":32105,"interventions":32106},[92],[28053],[32072,32072,32072,32087,32088],{"trials":32108,"activeCount":103},[],{"trials":32110,"activeCount":103},[],{"trials":32112,"activeCount":103},[],{"intervention":32088,"totalTrials":302,"cells":32114},{"EARLY_PHASE1":32115,"PHASE1":32117,"PHASE2":32119,"PHASE3":32125,"PHASE4":32127,"NA":32129},{"trials":32116,"activeCount":103},[],{"trials":32118,"activeCount":103},[],{"trials":32120,"activeCount":103},[32121],{"nctId":32081,"briefTitle":32082,"status":111,"phases":32122,"primaryCompletion":523,"completion":523,"start":586,"enrollment":32084,"conditions":32123,"interventions":32124},[92],[28053],[32072,32072,32072,32087,32088],{"trials":32126,"activeCount":103},[],{"trials":32128,"activeCount":103},[],{"trials":32130,"activeCount":103},[],{"intervention":17472,"totalTrials":302,"cells":32132},{"EARLY_PHASE1":32133,"PHASE1":32135,"PHASE2":32137,"PHASE3":32143,"PHASE4":32145,"NA":32147},{"trials":32134,"activeCount":103},[],{"trials":32136,"activeCount":103},[],{"trials":32138,"activeCount":103},[32139],{"nctId":17463,"briefTitle":17464,"status":168,"phases":32140,"primaryCompletion":17466,"completion":17466,"start":17467,"enrollment":5647,"conditions":32141,"interventions":32142},[91,92],[17469,17470],[17444,17472],{"trials":32144,"activeCount":103},[],{"trials":32146,"activeCount":103},[],{"trials":32148,"activeCount":103},[],{"intervention":30175,"totalTrials":302,"cells":32150},{"EARLY_PHASE1":32151,"PHASE1":32153,"PHASE2":32155,"PHASE3":32161,"PHASE4":32163,"NA":32165},{"trials":32152,"activeCount":103},[],{"trials":32154,"activeCount":103},[],{"trials":32156,"activeCount":103},[32157],{"nctId":30170,"briefTitle":30171,"status":111,"phases":32158,"start":3610,"enrollment":1578,"conditions":32159,"interventions":32160},[92],[6589],[30175,30161],{"trials":32162,"activeCount":103},[],{"trials":32164,"activeCount":103},[],{"trials":32166,"activeCount":103},[],{"intervention":32168,"totalTrials":302,"cells":32169},"meningococcal B rLP2086 vaccine",{"EARLY_PHASE1":32170,"PHASE1":32172,"PHASE2":32174,"PHASE3":32183,"PHASE4":32185,"NA":32187},{"trials":32171,"activeCount":103},[],{"trials":32173,"activeCount":103},[],{"trials":32175,"activeCount":103},[32176],{"nctId":32177,"briefTitle":32178,"status":168,"phases":32179,"primaryCompletion":4646,"completion":4833,"start":8251,"enrollment":787,"conditions":32180,"interventions":32181},"NCT00798304","Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants",[92],[24397],[32168,32182,32168,32182,32182],"Routine age appropriate childhood vaccines",{"trials":32184,"activeCount":103},[],{"trials":32186,"activeCount":103},[],{"trials":32188,"activeCount":103},[],{"intervention":32182,"totalTrials":302,"cells":32190},{"EARLY_PHASE1":32191,"PHASE1":32193,"PHASE2":32195,"PHASE3":32201,"PHASE4":32203,"NA":32205},{"trials":32192,"activeCount":103},[],{"trials":32194,"activeCount":103},[],{"trials":32196,"activeCount":103},[32197],{"nctId":32177,"briefTitle":32178,"status":168,"phases":32198,"primaryCompletion":4646,"completion":4833,"start":8251,"enrollment":787,"conditions":32199,"interventions":32200},[92],[24397],[32168,32182,32168,32182,32182],{"trials":32202,"activeCount":103},[],{"trials":32204,"activeCount":103},[],{"trials":32206,"activeCount":103},[],{"intervention":32208,"totalTrials":302,"cells":32209},"Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.",{"EARLY_PHASE1":32210,"PHASE1":32212,"PHASE2":32214,"PHASE3":32222,"PHASE4":32224,"NA":32226},{"trials":32211,"activeCount":103},[],{"trials":32213,"activeCount":103},[],{"trials":32215,"activeCount":103},[32216],{"nctId":32217,"briefTitle":32218,"status":168,"phases":32219,"primaryCompletion":3854,"completion":3854,"start":2662,"enrollment":1087,"conditions":32220,"interventions":32221},"NCT00106054","Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases",[92],[1028,891],[32208],{"trials":32223,"activeCount":103},[],{"trials":32225,"activeCount":103},[],{"trials":32227,"activeCount":103},[],{"intervention":32229,"totalTrials":302,"cells":32230},"AG-014699",{"EARLY_PHASE1":32231,"PHASE1":32233,"PHASE2":32235,"PHASE3":32244,"PHASE4":32246,"NA":32248},{"trials":32232,"activeCount":103},[],{"trials":32234,"activeCount":103},[],{"trials":32236,"activeCount":103},[32237],{"nctId":32238,"briefTitle":32239,"status":649,"phases":32240,"start":3643,"enrollment":103,"conditions":32241,"interventions":32243},"NCT00457470","A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)",[92],[6117,32242],"Diabetic Retinopathy",[32229],{"trials":32245,"activeCount":103},[],{"trials":32247,"activeCount":103},[],{"trials":32249,"activeCount":103},[],{"intervention":32251,"totalTrials":302,"cells":32252},"T-62 Dose 1",{"EARLY_PHASE1":32253,"PHASE1":32255,"PHASE2":32257,"PHASE3":32267,"PHASE4":32269,"NA":32271},{"trials":32254,"activeCount":103},[],{"trials":32256,"activeCount":103},[],{"trials":32258,"activeCount":103},[32259],{"nctId":32260,"briefTitle":32261,"status":168,"phases":32262,"primaryCompletion":4646,"completion":4646,"start":8154,"enrollment":99,"conditions":32263,"interventions":32265},"NCT00809679","Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia",[92],[32264],"Postherpetic Neuralgia",[32251,32266],"T-62 Dose 2",{"trials":32268,"activeCount":103},[],{"trials":32270,"activeCount":103},[],{"trials":32272,"activeCount":103},[],{"intervention":32266,"totalTrials":302,"cells":32274},{"EARLY_PHASE1":32275,"PHASE1":32277,"PHASE2":32279,"PHASE3":32285,"PHASE4":32287,"NA":32289},{"trials":32276,"activeCount":103},[],{"trials":32278,"activeCount":103},[],{"trials":32280,"activeCount":103},[32281],{"nctId":32260,"briefTitle":32261,"status":168,"phases":32282,"primaryCompletion":4646,"completion":4646,"start":8154,"enrollment":99,"conditions":32283,"interventions":32284},[92],[32264],[32251,32266],{"trials":32286,"activeCount":103},[],{"trials":32288,"activeCount":103},[],{"trials":32290,"activeCount":103},[],{"intervention":32292,"totalTrials":302,"cells":32293},"CP-316,311",{"EARLY_PHASE1":32294,"PHASE1":32296,"PHASE2":32298,"PHASE3":32306,"PHASE4":32308,"NA":32310},{"trials":32295,"activeCount":103},[],{"trials":32297,"activeCount":103},[],{"trials":32299,"activeCount":103},[32300],{"nctId":32301,"briefTitle":32302,"status":168,"phases":32303,"completion":12030,"start":4657,"enrollment":162,"conditions":32304,"interventions":32305},"NCT00143091","Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder",[92],[12847],[32292,17066],{"trials":32307,"activeCount":103},[],{"trials":32309,"activeCount":103},[],{"trials":32311,"activeCount":103},[],{"intervention":3950,"totalTrials":302,"cells":32313},{"EARLY_PHASE1":32314,"PHASE1":32316,"PHASE2":32318,"PHASE3":32324,"PHASE4":32326,"NA":32328},{"trials":32315,"activeCount":103},[],{"trials":32317,"activeCount":103},[],{"trials":32319,"activeCount":103},[32320],{"nctId":3942,"briefTitle":3943,"status":168,"phases":32321,"primaryCompletion":3945,"completion":3946,"start":3947,"enrollment":2070,"conditions":32322,"interventions":32323},[91,92],[2914],[1065,3950,1150],{"trials":32325,"activeCount":103},[],{"trials":32327,"activeCount":103},[],{"trials":32329,"activeCount":103},[],{"intervention":32331,"totalTrials":302,"cells":32332},"No drug will be administered",{"EARLY_PHASE1":32333,"PHASE1":32335,"PHASE2":32337,"PHASE3":32345,"PHASE4":32347,"NA":32349},{"trials":32334,"activeCount":103},[],{"trials":32336,"activeCount":103},[],{"trials":32338,"activeCount":103},[32339],{"nctId":32340,"briefTitle":32341,"status":168,"phases":32342,"primaryCompletion":6263,"completion":6263,"start":4627,"enrollment":748,"conditions":32343,"interventions":32344},"NCT00824369","A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1",[92],[27719],[32331],{"trials":32346,"activeCount":103},[],{"trials":32348,"activeCount":103},[],{"trials":32350,"activeCount":103},[],{"intervention":32352,"totalTrials":302,"cells":32353},"Torisel",{"EARLY_PHASE1":32354,"PHASE1":32356,"PHASE2":32358,"PHASE3":32366,"PHASE4":32368,"NA":32370},{"trials":32355,"activeCount":103},[],{"trials":32357,"activeCount":103},[],{"trials":32359,"activeCount":103},[32360],{"nctId":32361,"briefTitle":32362,"status":111,"phases":32363,"primaryCompletion":4846,"completion":10912,"start":4692,"enrollment":2137,"conditions":32364,"interventions":32365},"NCT00106353","Study Evaluating Biomarkers In Relapsed\u002FRefractory Pediatric Solid Tumors",[91,92],[3356,2053],[32352],{"trials":32367,"activeCount":103},[],{"trials":32369,"activeCount":103},[],{"trials":32371,"activeCount":103},[],{"intervention":32373,"totalTrials":302,"cells":32374},"rLP2086 + MCV4 + Tdap",{"EARLY_PHASE1":32375,"PHASE1":32377,"PHASE2":32379,"PHASE3":32391,"PHASE4":32393,"NA":32395},{"trials":32376,"activeCount":103},[],{"trials":32378,"activeCount":103},[],{"trials":32380,"activeCount":103},[32381],{"nctId":32382,"briefTitle":32383,"status":111,"phases":32384,"primaryCompletion":32385,"completion":32385,"start":18137,"enrollment":32386,"conditions":32387,"interventions":32388},"NCT01461980","A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age",[92],"2014-05-08",2648,[10626,18140],[32373,32389,32390],"MCV4 + Tdap + saline","rLP2086 + saline",{"trials":32392,"activeCount":103},[],{"trials":32394,"activeCount":103},[],{"trials":32396,"activeCount":103},[],{"intervention":32389,"totalTrials":302,"cells":32398},{"EARLY_PHASE1":32399,"PHASE1":32401,"PHASE2":32403,"PHASE3":32409,"PHASE4":32411,"NA":32413},{"trials":32400,"activeCount":103},[],{"trials":32402,"activeCount":103},[],{"trials":32404,"activeCount":103},[32405],{"nctId":32382,"briefTitle":32383,"status":111,"phases":32406,"primaryCompletion":32385,"completion":32385,"start":18137,"enrollment":32386,"conditions":32407,"interventions":32408},[92],[10626,18140],[32373,32389,32390],{"trials":32410,"activeCount":103},[],{"trials":32412,"activeCount":103},[],{"trials":32414,"activeCount":103},[],{"intervention":32390,"totalTrials":302,"cells":32416},{"EARLY_PHASE1":32417,"PHASE1":32419,"PHASE2":32421,"PHASE3":32427,"PHASE4":32429,"NA":32431},{"trials":32418,"activeCount":103},[],{"trials":32420,"activeCount":103},[],{"trials":32422,"activeCount":103},[32423],{"nctId":32382,"briefTitle":32383,"status":111,"phases":32424,"primaryCompletion":32385,"completion":32385,"start":18137,"enrollment":32386,"conditions":32425,"interventions":32426},[92],[10626,18140],[32373,32389,32390],{"trials":32428,"activeCount":103},[],{"trials":32430,"activeCount":103},[],{"trials":32432,"activeCount":103},[],{"intervention":17491,"totalTrials":302,"cells":32434},{"EARLY_PHASE1":32435,"PHASE1":32437,"PHASE2":32439,"PHASE3":32445,"PHASE4":32447,"NA":32449},{"trials":32436,"activeCount":103},[],{"trials":32438,"activeCount":103},[],{"trials":32440,"activeCount":103},[32441],{"nctId":17484,"briefTitle":17485,"status":111,"phases":32442,"primaryCompletion":17487,"completion":17487,"start":17488,"enrollment":336,"conditions":32443,"interventions":32444},[91,92],[1810],[17444,17491],{"trials":32446,"activeCount":103},[],{"trials":32448,"activeCount":103},[],{"trials":32450,"activeCount":103},[],{"intervention":32452,"totalTrials":302,"cells":32453},"Doxycycline",{"EARLY_PHASE1":32454,"PHASE1":32456,"PHASE2":32458,"PHASE3":32472,"PHASE4":32474,"NA":32476},{"trials":32455,"activeCount":103},[],{"trials":32457,"activeCount":103},[],{"trials":32459,"activeCount":103},[32460],{"nctId":32461,"briefTitle":32462,"status":111,"phases":32463,"primaryCompletion":32464,"completion":32464,"start":32465,"enrollment":32466,"conditions":32467,"interventions":32469},"NCT01465802","Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO",[92],"2015-05-18","2011-12-26",236,[32468],"Non Small Cell Lung Cancer (NSCLC)",[8126,8126,32452,32470,32471],"Probiotic","Alclometasone cream",{"trials":32473,"activeCount":103},[],{"trials":32475,"activeCount":103},[],{"trials":32477,"activeCount":103},[],{"intervention":32470,"totalTrials":302,"cells":32479},{"EARLY_PHASE1":32480,"PHASE1":32482,"PHASE2":32484,"PHASE3":32490,"PHASE4":32492,"NA":32494},{"trials":32481,"activeCount":103},[],{"trials":32483,"activeCount":103},[],{"trials":32485,"activeCount":103},[32486],{"nctId":32461,"briefTitle":32462,"status":111,"phases":32487,"primaryCompletion":32464,"completion":32464,"start":32465,"enrollment":32466,"conditions":32488,"interventions":32489},[92],[32468],[8126,8126,32452,32470,32471],{"trials":32491,"activeCount":103},[],{"trials":32493,"activeCount":103},[],{"trials":32495,"activeCount":103},[],{"intervention":32471,"totalTrials":302,"cells":32497},{"EARLY_PHASE1":32498,"PHASE1":32500,"PHASE2":32502,"PHASE3":32508,"PHASE4":32510,"NA":32512},{"trials":32499,"activeCount":103},[],{"trials":32501,"activeCount":103},[],{"trials":32503,"activeCount":103},[32504],{"nctId":32461,"briefTitle":32462,"status":111,"phases":32505,"primaryCompletion":32464,"completion":32464,"start":32465,"enrollment":32466,"conditions":32506,"interventions":32507},[92],[32468],[8126,8126,32452,32470,32471],{"trials":32509,"activeCount":103},[],{"trials":32511,"activeCount":103},[],{"trials":32513,"activeCount":103},[],{"intervention":19014,"totalTrials":302,"cells":32515},{"EARLY_PHASE1":32516,"PHASE1":32518,"PHASE2":32520,"PHASE3":32526,"PHASE4":32528,"NA":32530},{"trials":32517,"activeCount":103},[],{"trials":32519,"activeCount":103},[],{"trials":32521,"activeCount":103},[32522],{"nctId":19008,"briefTitle":19009,"status":111,"phases":32523,"primaryCompletion":11736,"completion":11736,"start":15036,"enrollment":314,"conditions":32524,"interventions":32525},[92],[19012],[19014,9417,19015,9417,19016,9417,19017,9417],{"trials":32527,"activeCount":103},[],{"trials":32529,"activeCount":103},[],{"trials":32531,"activeCount":103},[],{"intervention":19015,"totalTrials":302,"cells":32533},{"EARLY_PHASE1":32534,"PHASE1":32536,"PHASE2":32538,"PHASE3":32544,"PHASE4":32546,"NA":32548},{"trials":32535,"activeCount":103},[],{"trials":32537,"activeCount":103},[],{"trials":32539,"activeCount":103},[32540],{"nctId":19008,"briefTitle":19009,"status":111,"phases":32541,"primaryCompletion":11736,"completion":11736,"start":15036,"enrollment":314,"conditions":32542,"interventions":32543},[92],[19012],[19014,9417,19015,9417,19016,9417,19017,9417],{"trials":32545,"activeCount":103},[],{"trials":32547,"activeCount":103},[],{"trials":32549,"activeCount":103},[],{"intervention":19016,"totalTrials":302,"cells":32551},{"EARLY_PHASE1":32552,"PHASE1":32554,"PHASE2":32556,"PHASE3":32562,"PHASE4":32564,"NA":32566},{"trials":32553,"activeCount":103},[],{"trials":32555,"activeCount":103},[],{"trials":32557,"activeCount":103},[32558],{"nctId":19008,"briefTitle":19009,"status":111,"phases":32559,"primaryCompletion":11736,"completion":11736,"start":15036,"enrollment":314,"conditions":32560,"interventions":32561},[92],[19012],[19014,9417,19015,9417,19016,9417,19017,9417],{"trials":32563,"activeCount":103},[],{"trials":32565,"activeCount":103},[],{"trials":32567,"activeCount":103},[],{"intervention":19017,"totalTrials":302,"cells":32569},{"EARLY_PHASE1":32570,"PHASE1":32572,"PHASE2":32574,"PHASE3":32580,"PHASE4":32582,"NA":32584},{"trials":32571,"activeCount":103},[],{"trials":32573,"activeCount":103},[],{"trials":32575,"activeCount":103},[32576],{"nctId":19008,"briefTitle":19009,"status":111,"phases":32577,"primaryCompletion":11736,"completion":11736,"start":15036,"enrollment":314,"conditions":32578,"interventions":32579},[92],[19012],[19014,9417,19015,9417,19016,9417,19017,9417],{"trials":32581,"activeCount":103},[],{"trials":32583,"activeCount":103},[],{"trials":32585,"activeCount":103},[],{"intervention":12893,"totalTrials":302,"cells":32587},{"EARLY_PHASE1":32588,"PHASE1":32590,"PHASE2":32592,"PHASE3":32598,"PHASE4":32600,"NA":32602},{"trials":32589,"activeCount":103},[],{"trials":32591,"activeCount":103},[],{"trials":32593,"activeCount":103},[32594],{"nctId":12887,"briefTitle":12888,"status":111,"phases":32595,"primaryCompletion":577,"completion":577,"start":10923,"enrollment":1257,"conditions":32596,"interventions":32597},[92],[12891,12882],[12893,12894,12893,12870],{"trials":32599,"activeCount":103},[],{"trials":32601,"activeCount":103},[],{"trials":32603,"activeCount":103},[],{"intervention":32605,"totalTrials":302,"cells":32606},"traxiprodil",{"EARLY_PHASE1":32607,"PHASE1":32609,"PHASE2":32611,"PHASE3":32619,"PHASE4":32621,"NA":32623},{"trials":32608,"activeCount":103},[],{"trials":32610,"activeCount":103},[],{"trials":32612,"activeCount":103},[32613],{"nctId":32614,"briefTitle":32615,"status":168,"phases":32616,"completion":4258,"start":16955,"enrollment":1613,"conditions":32617,"interventions":32618},"NCT00073476","A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke",[92],[9685],[32605],{"trials":32620,"activeCount":103},[],{"trials":32622,"activeCount":103},[],{"trials":32624,"activeCount":103},[],{"intervention":32626,"totalTrials":302,"cells":32627},"PF-06700841 15 mg",{"EARLY_PHASE1":32628,"PHASE1":32630,"PHASE2":32632,"PHASE3":32644,"PHASE4":32646,"NA":32648},{"trials":32629,"activeCount":103},[],{"trials":32631,"activeCount":103},[],{"trials":32633,"activeCount":103},[32634],{"nctId":32635,"briefTitle":32636,"status":111,"phases":32637,"primaryCompletion":32638,"completion":32638,"start":6135,"enrollment":12382,"conditions":32639,"interventions":32641},"NCT03845517","A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",[92],"2023-10-05",[32640],"Systemic Lupus Erythematosus",[32626,32642,32643],"PF-06700841 30 mg","PF-06700841 45 mg",{"trials":32645,"activeCount":103},[],{"trials":32647,"activeCount":103},[],{"trials":32649,"activeCount":103},[],{"intervention":32642,"totalTrials":302,"cells":32651},{"EARLY_PHASE1":32652,"PHASE1":32654,"PHASE2":32656,"PHASE3":32662,"PHASE4":32664,"NA":32666},{"trials":32653,"activeCount":103},[],{"trials":32655,"activeCount":103},[],{"trials":32657,"activeCount":103},[32658],{"nctId":32635,"briefTitle":32636,"status":111,"phases":32659,"primaryCompletion":32638,"completion":32638,"start":6135,"enrollment":12382,"conditions":32660,"interventions":32661},[92],[32640],[32626,32642,32643],{"trials":32663,"activeCount":103},[],{"trials":32665,"activeCount":103},[],{"trials":32667,"activeCount":103},[],{"intervention":32643,"totalTrials":302,"cells":32669},{"EARLY_PHASE1":32670,"PHASE1":32672,"PHASE2":32674,"PHASE3":32680,"PHASE4":32682,"NA":32684},{"trials":32671,"activeCount":103},[],{"trials":32673,"activeCount":103},[],{"trials":32675,"activeCount":103},[32676],{"nctId":32635,"briefTitle":32636,"status":111,"phases":32677,"primaryCompletion":32638,"completion":32638,"start":6135,"enrollment":12382,"conditions":32678,"interventions":32679},[92],[32640],[32626,32642,32643],{"trials":32681,"activeCount":103},[],{"trials":32683,"activeCount":103},[],{"trials":32685,"activeCount":103},[],{"intervention":32687,"totalTrials":302,"cells":32688},"CP-601,927",{"EARLY_PHASE1":32689,"PHASE1":32691,"PHASE2":32693,"PHASE3":32704,"PHASE4":32706,"NA":32708},{"trials":32690,"activeCount":103},[],{"trials":32692,"activeCount":103},[],{"trials":32694,"activeCount":103},[32695],{"nctId":32696,"briefTitle":32697,"status":168,"phases":32698,"primaryCompletion":32699,"completion":32699,"start":32700,"enrollment":32701,"conditions":32702,"interventions":32703},"NCT01098240","A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression",[92],"2011-09-12","2010-06-14",297,[6321],[32687],{"trials":32705,"activeCount":103},[],{"trials":32707,"activeCount":103},[],{"trials":32709,"activeCount":103},[],{"intervention":30344,"totalTrials":302,"cells":32711},{"EARLY_PHASE1":32712,"PHASE1":32714,"PHASE2":32716,"PHASE3":32722,"PHASE4":32724,"NA":32726},{"trials":32713,"activeCount":103},[],{"trials":32715,"activeCount":103},[],{"trials":32717,"activeCount":103},[32718],{"nctId":30337,"briefTitle":30338,"status":168,"phases":32719,"primaryCompletion":10937,"completion":10937,"start":3627,"enrollment":314,"conditions":32720,"interventions":32721},[92],[30341,30342],[30328,30344],{"trials":32723,"activeCount":103},[],{"trials":32725,"activeCount":103},[],{"trials":32727,"activeCount":103},[],{"intervention":3857,"totalTrials":302,"cells":32729},{"EARLY_PHASE1":32730,"PHASE1":32732,"PHASE2":32734,"PHASE3":32740,"PHASE4":32742,"NA":32744},{"trials":32731,"activeCount":103},[],{"trials":32733,"activeCount":103},[],{"trials":32735,"activeCount":103},[32736],{"nctId":3850,"briefTitle":3851,"status":168,"phases":32737,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":1530,"conditions":32738,"interventions":32739},[92],[2645],[1769,3857],{"trials":32741,"activeCount":103},[],{"trials":32743,"activeCount":103},[],{"trials":32745,"activeCount":103},[],{"intervention":2232,"totalTrials":302,"cells":32747},{"EARLY_PHASE1":32748,"PHASE1":32750,"PHASE2":32752,"PHASE3":32758,"PHASE4":32760,"NA":32762},{"trials":32749,"activeCount":103},[],{"trials":32751,"activeCount":103},[],{"trials":32753,"activeCount":103},[32754],{"nctId":2224,"briefTitle":2225,"status":111,"phases":32755,"primaryCompletion":2227,"completion":2228,"start":569,"enrollment":2229,"conditions":32756,"interventions":32757},[92],[1684],[63,2232],{"trials":32759,"activeCount":103},[],{"trials":32761,"activeCount":103},[],{"trials":32763,"activeCount":103},[],{"intervention":8149,"totalTrials":302,"cells":32765},{"EARLY_PHASE1":32766,"PHASE1":32768,"PHASE2":32770,"PHASE3":32776,"PHASE4":32778,"NA":32780},{"trials":32767,"activeCount":103},[],{"trials":32769,"activeCount":103},[],{"trials":32771,"activeCount":103},[32772],{"nctId":8142,"briefTitle":8143,"status":168,"phases":32773,"primaryCompletion":114,"completion":114,"start":4206,"enrollment":627,"conditions":32774,"interventions":32775},[92],[8146],[8148,1770,8149,1770,8149],{"trials":32777,"activeCount":103},[],{"trials":32779,"activeCount":103},[],{"trials":32781,"activeCount":103},[],{"intervention":28046,"totalTrials":302,"cells":32783},{"EARLY_PHASE1":32784,"PHASE1":32786,"PHASE2":32788,"PHASE3":32794,"PHASE4":32796,"NA":32798},{"trials":32785,"activeCount":103},[],{"trials":32787,"activeCount":103},[],{"trials":32789,"activeCount":103},[32790],{"nctId":28041,"briefTitle":28042,"status":649,"phases":32791,"start":11314,"enrollment":103,"conditions":32792,"interventions":32793},[92],[4533],[7559,28046],{"trials":32795,"activeCount":103},[],{"trials":32797,"activeCount":103},[],{"trials":32799,"activeCount":103},[],{"intervention":32801,"totalTrials":302,"cells":32802},"PELITREXOL\u002FAG-2037",{"EARLY_PHASE1":32803,"PHASE1":32805,"PHASE2":32807,"PHASE3":32815,"PHASE4":32817,"NA":32819},{"trials":32804,"activeCount":103},[],{"trials":32806,"activeCount":103},[],{"trials":32808,"activeCount":103},[32809],{"nctId":32810,"briefTitle":32811,"status":111,"phases":32812,"completion":7675,"start":2672,"enrollment":3202,"conditions":32813,"interventions":32814},"NCT00078468","Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment",[92],[1028],[32801],{"trials":32816,"activeCount":103},[],{"trials":32818,"activeCount":103},[],{"trials":32820,"activeCount":103},[],{"intervention":30462,"totalTrials":302,"cells":32822},{"EARLY_PHASE1":32823,"PHASE1":32825,"PHASE2":32827,"PHASE3":32833,"PHASE4":32835,"NA":32837},{"trials":32824,"activeCount":103},[],{"trials":32826,"activeCount":103},[],{"trials":32828,"activeCount":103},[32829],{"nctId":30456,"briefTitle":30457,"status":111,"phases":32830,"primaryCompletion":30459,"completion":30459,"start":2050,"enrollment":29076,"conditions":32831,"interventions":32832},[92],[1589,26842],[30462,30447],{"trials":32834,"activeCount":103},[],{"trials":32836,"activeCount":103},[],{"trials":32838,"activeCount":103},[],{"intervention":32840,"totalTrials":302,"cells":32841},"PD 0348292",{"EARLY_PHASE1":32842,"PHASE1":32844,"PHASE2":32846,"PHASE3":32857,"PHASE4":32859,"NA":32861},{"trials":32843,"activeCount":103},[],{"trials":32845,"activeCount":103},[],{"trials":32847,"activeCount":103},[32848],{"nctId":32849,"briefTitle":32850,"status":111,"phases":32851,"completion":2641,"start":6457,"enrollment":32852,"conditions":32853,"interventions":32855},"NCT00306254","Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery",[92],1225,[32854],"Venous Thrombosis",[32840,32856],"Enoxaparin",{"trials":32858,"activeCount":103},[],{"trials":32860,"activeCount":103},[],{"trials":32862,"activeCount":103},[],{"intervention":32856,"totalTrials":302,"cells":32864},{"EARLY_PHASE1":32865,"PHASE1":32867,"PHASE2":32869,"PHASE3":32875,"PHASE4":32877,"NA":32879},{"trials":32866,"activeCount":103},[],{"trials":32868,"activeCount":103},[],{"trials":32870,"activeCount":103},[32871],{"nctId":32849,"briefTitle":32850,"status":111,"phases":32872,"completion":2641,"start":6457,"enrollment":32852,"conditions":32873,"interventions":32874},[92],[32854],[32840,32856],{"trials":32876,"activeCount":103},[],{"trials":32878,"activeCount":103},[],{"trials":32880,"activeCount":103},[],{"intervention":30185,"totalTrials":302,"cells":32882},{"EARLY_PHASE1":32883,"PHASE1":32885,"PHASE2":32887,"PHASE3":32893,"PHASE4":32895,"NA":32897},{"trials":32884,"activeCount":103},[],{"trials":32886,"activeCount":103},[],{"trials":32888,"activeCount":103},[32889],{"nctId":30177,"briefTitle":30178,"status":111,"phases":32890,"primaryCompletion":4656,"completion":4656,"start":3642,"enrollment":30180,"conditions":32891,"interventions":32892},[92],[21083,9108,30182],[30184,30185,30186,30161],{"trials":32894,"activeCount":103},[],{"trials":32896,"activeCount":103},[],{"trials":32898,"activeCount":103},[],{"intervention":30186,"totalTrials":302,"cells":32900},{"EARLY_PHASE1":32901,"PHASE1":32903,"PHASE2":32905,"PHASE3":32911,"PHASE4":32913,"NA":32915},{"trials":32902,"activeCount":103},[],{"trials":32904,"activeCount":103},[],{"trials":32906,"activeCount":103},[32907],{"nctId":30177,"briefTitle":30178,"status":111,"phases":32908,"primaryCompletion":4656,"completion":4656,"start":3642,"enrollment":30180,"conditions":32909,"interventions":32910},[92],[21083,9108,30182],[30184,30185,30186,30161],{"trials":32912,"activeCount":103},[],{"trials":32914,"activeCount":103},[],{"trials":32916,"activeCount":103},[],{"intervention":32918,"totalTrials":302,"cells":32919},"rLP2086 vaccine",{"EARLY_PHASE1":32920,"PHASE1":32922,"PHASE2":32924,"PHASE3":32937,"PHASE4":32939,"NA":32941},{"trials":32921,"activeCount":103},[],{"trials":32923,"activeCount":103},[],{"trials":32925,"activeCount":103},[32926],{"nctId":32927,"briefTitle":32928,"status":111,"phases":32929,"primaryCompletion":32930,"completion":32931,"start":32932,"enrollment":2229,"conditions":32933,"interventions":32935},"NCT02534935","Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.",[92],"2017-08-21","2020-03-17","2015-08-31",[32934],"Meningococcal B Disease",[32918,32936],"Pediatric HAV vaccine",{"trials":32938,"activeCount":103},[],{"trials":32940,"activeCount":103},[],{"trials":32942,"activeCount":103},[],{"intervention":32936,"totalTrials":302,"cells":32944},{"EARLY_PHASE1":32945,"PHASE1":32947,"PHASE2":32949,"PHASE3":32955,"PHASE4":32957,"NA":32959},{"trials":32946,"activeCount":103},[],{"trials":32948,"activeCount":103},[],{"trials":32950,"activeCount":103},[32951],{"nctId":32927,"briefTitle":32928,"status":111,"phases":32952,"primaryCompletion":32930,"completion":32931,"start":32932,"enrollment":2229,"conditions":32953,"interventions":32954},[92],[32934],[32918,32936],{"trials":32956,"activeCount":103},[],{"trials":32958,"activeCount":103},[],{"trials":32960,"activeCount":103},[],{"intervention":32962,"totalTrials":302,"cells":32963},"CP-533, 536",{"EARLY_PHASE1":32964,"PHASE1":32966,"PHASE2":32968,"PHASE3":32978,"PHASE4":32980,"NA":32982},{"trials":32965,"activeCount":103},[],{"trials":32967,"activeCount":103},[],{"trials":32969,"activeCount":103},[32970],{"nctId":32971,"briefTitle":32972,"status":111,"phases":32973,"primaryCompletion":2660,"completion":2660,"start":3853,"enrollment":21510,"conditions":32974,"interventions":32976},"NCT00533377","ACTiF- Assessment of Closed Tibial Fractures",[92],[32975],"Tibial Fractures",[32962,32977,32977,32977],"CP-533,536",{"trials":32979,"activeCount":103},[],{"trials":32981,"activeCount":103},[],{"trials":32983,"activeCount":103},[],{"intervention":32977,"totalTrials":302,"cells":32985},{"EARLY_PHASE1":32986,"PHASE1":32988,"PHASE2":32990,"PHASE3":32996,"PHASE4":32998,"NA":33000},{"trials":32987,"activeCount":103},[],{"trials":32989,"activeCount":103},[],{"trials":32991,"activeCount":103},[32992],{"nctId":32971,"briefTitle":32972,"status":111,"phases":32993,"primaryCompletion":2660,"completion":2660,"start":3853,"enrollment":21510,"conditions":32994,"interventions":32995},[92],[32975],[32962,32977,32977,32977],{"trials":32997,"activeCount":103},[],{"trials":32999,"activeCount":103},[],{"trials":33001,"activeCount":103},[],{"intervention":33003,"totalTrials":302,"cells":33004},"latanoprost 75 ug",{"EARLY_PHASE1":33005,"PHASE1":33007,"PHASE2":33009,"PHASE3":33021,"PHASE4":33023,"NA":33025},{"trials":33006,"activeCount":103},[],{"trials":33008,"activeCount":103},[],{"trials":33010,"activeCount":103},[33011],{"nctId":33012,"briefTitle":33013,"status":111,"phases":33014,"primaryCompletion":3628,"completion":12607,"start":3073,"enrollment":15543,"conditions":33015,"interventions":33017},"NCT01379144","A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug\u002Fml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension",[92],[33016,12882],"Primary Open Angle Glaucoma",[33003,33018,33019,33020],"latanoprost 100 ug","latanoprost 125 ug","latanoprost 50 ug",{"trials":33022,"activeCount":103},[],{"trials":33024,"activeCount":103},[],{"trials":33026,"activeCount":103},[],{"intervention":33018,"totalTrials":302,"cells":33028},{"EARLY_PHASE1":33029,"PHASE1":33031,"PHASE2":33033,"PHASE3":33039,"PHASE4":33041,"NA":33043},{"trials":33030,"activeCount":103},[],{"trials":33032,"activeCount":103},[],{"trials":33034,"activeCount":103},[33035],{"nctId":33012,"briefTitle":33013,"status":111,"phases":33036,"primaryCompletion":3628,"completion":12607,"start":3073,"enrollment":15543,"conditions":33037,"interventions":33038},[92],[33016,12882],[33003,33018,33019,33020],{"trials":33040,"activeCount":103},[],{"trials":33042,"activeCount":103},[],{"trials":33044,"activeCount":103},[],{"intervention":33019,"totalTrials":302,"cells":33046},{"EARLY_PHASE1":33047,"PHASE1":33049,"PHASE2":33051,"PHASE3":33057,"PHASE4":33059,"NA":33061},{"trials":33048,"activeCount":103},[],{"trials":33050,"activeCount":103},[],{"trials":33052,"activeCount":103},[33053],{"nctId":33012,"briefTitle":33013,"status":111,"phases":33054,"primaryCompletion":3628,"completion":12607,"start":3073,"enrollment":15543,"conditions":33055,"interventions":33056},[92],[33016,12882],[33003,33018,33019,33020],{"trials":33058,"activeCount":103},[],{"trials":33060,"activeCount":103},[],{"trials":33062,"activeCount":103},[],{"intervention":33020,"totalTrials":302,"cells":33064},{"EARLY_PHASE1":33065,"PHASE1":33067,"PHASE2":33069,"PHASE3":33075,"PHASE4":33077,"NA":33079},{"trials":33066,"activeCount":103},[],{"trials":33068,"activeCount":103},[],{"trials":33070,"activeCount":103},[33071],{"nctId":33012,"briefTitle":33013,"status":111,"phases":33072,"primaryCompletion":3628,"completion":12607,"start":3073,"enrollment":15543,"conditions":33073,"interventions":33074},[92],[33016,12882],[33003,33018,33019,33020],{"trials":33076,"activeCount":103},[],{"trials":33078,"activeCount":103},[],{"trials":33080,"activeCount":103},[],{"intervention":29369,"totalTrials":302,"cells":33082},{"EARLY_PHASE1":33083,"PHASE1":33085,"PHASE2":33087,"PHASE3":33093,"PHASE4":33095,"NA":33097},{"trials":33084,"activeCount":103},[],{"trials":33086,"activeCount":103},[],{"trials":33088,"activeCount":103},[33089],{"nctId":29363,"briefTitle":29364,"status":111,"phases":33090,"primaryCompletion":4280,"completion":651,"start":18769,"enrollment":5647,"conditions":33091,"interventions":33092},[92],[29367],[29369,29370,29371,29354],{"trials":33094,"activeCount":103},[],{"trials":33096,"activeCount":103},[],{"trials":33098,"activeCount":103},[],{"intervention":29370,"totalTrials":302,"cells":33100},{"EARLY_PHASE1":33101,"PHASE1":33103,"PHASE2":33105,"PHASE3":33111,"PHASE4":33113,"NA":33115},{"trials":33102,"activeCount":103},[],{"trials":33104,"activeCount":103},[],{"trials":33106,"activeCount":103},[33107],{"nctId":29363,"briefTitle":29364,"status":111,"phases":33108,"primaryCompletion":4280,"completion":651,"start":18769,"enrollment":5647,"conditions":33109,"interventions":33110},[92],[29367],[29369,29370,29371,29354],{"trials":33112,"activeCount":103},[],{"trials":33114,"activeCount":103},[],{"trials":33116,"activeCount":103},[],{"intervention":29371,"totalTrials":302,"cells":33118},{"EARLY_PHASE1":33119,"PHASE1":33121,"PHASE2":33123,"PHASE3":33129,"PHASE4":33131,"NA":33133},{"trials":33120,"activeCount":103},[],{"trials":33122,"activeCount":103},[],{"trials":33124,"activeCount":103},[33125],{"nctId":29363,"briefTitle":29364,"status":111,"phases":33126,"primaryCompletion":4280,"completion":651,"start":18769,"enrollment":5647,"conditions":33127,"interventions":33128},[92],[29367],[29369,29370,29371,29354],{"trials":33130,"activeCount":103},[],{"trials":33132,"activeCount":103},[],{"trials":33134,"activeCount":103},[],{"intervention":33136,"totalTrials":302,"cells":33137},"PF-04937319 - 3mg",{"EARLY_PHASE1":33138,"PHASE1":33140,"PHASE2":33142,"PHASE3":33155,"PHASE4":33157,"NA":33159},{"trials":33139,"activeCount":103},[],{"trials":33141,"activeCount":103},[],{"trials":33143,"activeCount":103},[33144],{"nctId":33145,"briefTitle":33146,"status":111,"phases":33147,"primaryCompletion":4590,"completion":4590,"start":570,"enrollment":33148,"conditions":33149,"interventions":33150},"NCT01475461","Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes",[92],345,[12968],[33136,33151,33152,33153,33154],"PF-04937319 - 20mg","PF-04937319 - 50mg","PF-04937319 - 100mg","Sitagliptin - 100mg",{"trials":33156,"activeCount":103},[],{"trials":33158,"activeCount":103},[],{"trials":33160,"activeCount":103},[],{"intervention":33151,"totalTrials":302,"cells":33162},{"EARLY_PHASE1":33163,"PHASE1":33165,"PHASE2":33167,"PHASE3":33173,"PHASE4":33175,"NA":33177},{"trials":33164,"activeCount":103},[],{"trials":33166,"activeCount":103},[],{"trials":33168,"activeCount":103},[33169],{"nctId":33145,"briefTitle":33146,"status":111,"phases":33170,"primaryCompletion":4590,"completion":4590,"start":570,"enrollment":33148,"conditions":33171,"interventions":33172},[92],[12968],[33136,33151,33152,33153,33154],{"trials":33174,"activeCount":103},[],{"trials":33176,"activeCount":103},[],{"trials":33178,"activeCount":103},[],{"intervention":33152,"totalTrials":302,"cells":33180},{"EARLY_PHASE1":33181,"PHASE1":33183,"PHASE2":33185,"PHASE3":33191,"PHASE4":33193,"NA":33195},{"trials":33182,"activeCount":103},[],{"trials":33184,"activeCount":103},[],{"trials":33186,"activeCount":103},[33187],{"nctId":33145,"briefTitle":33146,"status":111,"phases":33188,"primaryCompletion":4590,"completion":4590,"start":570,"enrollment":33148,"conditions":33189,"interventions":33190},[92],[12968],[33136,33151,33152,33153,33154],{"trials":33192,"activeCount":103},[],{"trials":33194,"activeCount":103},[],{"trials":33196,"activeCount":103},[],{"intervention":33153,"totalTrials":302,"cells":33198},{"EARLY_PHASE1":33199,"PHASE1":33201,"PHASE2":33203,"PHASE3":33209,"PHASE4":33211,"NA":33213},{"trials":33200,"activeCount":103},[],{"trials":33202,"activeCount":103},[],{"trials":33204,"activeCount":103},[33205],{"nctId":33145,"briefTitle":33146,"status":111,"phases":33206,"primaryCompletion":4590,"completion":4590,"start":570,"enrollment":33148,"conditions":33207,"interventions":33208},[92],[12968],[33136,33151,33152,33153,33154],{"trials":33210,"activeCount":103},[],{"trials":33212,"activeCount":103},[],{"trials":33214,"activeCount":103},[],{"intervention":33154,"totalTrials":302,"cells":33216},{"EARLY_PHASE1":33217,"PHASE1":33219,"PHASE2":33221,"PHASE3":33227,"PHASE4":33229,"NA":33231},{"trials":33218,"activeCount":103},[],{"trials":33220,"activeCount":103},[],{"trials":33222,"activeCount":103},[33223],{"nctId":33145,"briefTitle":33146,"status":111,"phases":33224,"primaryCompletion":4590,"completion":4590,"start":570,"enrollment":33148,"conditions":33225,"interventions":33226},[92],[12968],[33136,33151,33152,33153,33154],{"trials":33228,"activeCount":103},[],{"trials":33230,"activeCount":103},[],{"trials":33232,"activeCount":103},[],{"intervention":30213,"totalTrials":302,"cells":33234},{"EARLY_PHASE1":33235,"PHASE1":33237,"PHASE2":33239,"PHASE3":33245,"PHASE4":33247,"NA":33249},{"trials":33236,"activeCount":103},[],{"trials":33238,"activeCount":103},[],{"trials":33240,"activeCount":103},[33241],{"nctId":30206,"briefTitle":30207,"status":111,"phases":33242,"primaryCompletion":5970,"completion":5970,"start":30209,"enrollment":725,"conditions":33243,"interventions":33244},[92],[30211],[12290,30213],{"trials":33246,"activeCount":103},[],{"trials":33248,"activeCount":103},[],{"trials":33250,"activeCount":103},[],{"intervention":28055,"totalTrials":302,"cells":33252},{"EARLY_PHASE1":33253,"PHASE1":33255,"PHASE2":33257,"PHASE3":33263,"PHASE4":33265,"NA":33267},{"trials":33254,"activeCount":103},[],{"trials":33256,"activeCount":103},[],{"trials":33258,"activeCount":103},[33259],{"nctId":28048,"briefTitle":28049,"status":111,"phases":33260,"primaryCompletion":4846,"completion":4846,"start":4645,"enrollment":28051,"conditions":33261,"interventions":33262},[91,92],[28053],[12692,12692,12692,12692,7559,28055],{"trials":33264,"activeCount":103},[],{"trials":33266,"activeCount":103},[],{"trials":33268,"activeCount":103},[],{"intervention":33270,"totalTrials":302,"cells":33271},"NMDA Antagonist, CP-101,606",{"EARLY_PHASE1":33272,"PHASE1":33274,"PHASE2":33276,"PHASE3":33284,"PHASE4":33286,"NA":33288},{"trials":33273,"activeCount":103},[],{"trials":33275,"activeCount":103},[],{"trials":33277,"activeCount":103},[33278],{"nctId":33279,"briefTitle":33280,"status":111,"phases":33281,"completion":2671,"start":11395,"enrollment":1780,"conditions":33282,"interventions":33283},"NCT00163059","The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD",[92],[12847],[33270],{"trials":33285,"activeCount":103},[],{"trials":33287,"activeCount":103},[],{"trials":33289,"activeCount":103},[],{"intervention":33291,"totalTrials":302,"cells":33292},"PF-04494700",{"EARLY_PHASE1":33293,"PHASE1":33295,"PHASE2":33297,"PHASE3":33305,"PHASE4":33307,"NA":33309},{"trials":33294,"activeCount":103},[],{"trials":33296,"activeCount":103},[],{"trials":33298,"activeCount":103},[33299],{"nctId":33300,"briefTitle":33301,"status":111,"phases":33302,"primaryCompletion":4656,"completion":4656,"start":4636,"enrollment":17529,"conditions":33303,"interventions":33304},"NCT00566397","A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease",[92],[17728],[33291,33291],{"trials":33306,"activeCount":103},[],{"trials":33308,"activeCount":103},[],{"trials":33310,"activeCount":103},[],{"intervention":13359,"totalTrials":302,"cells":33312},{"EARLY_PHASE1":33313,"PHASE1":33315,"PHASE2":33317,"PHASE3":33323,"PHASE4":33325,"NA":33327},{"trials":33314,"activeCount":103},[],{"trials":33316,"activeCount":103},[],{"trials":33318,"activeCount":103},[33319],{"nctId":13353,"briefTitle":13354,"status":111,"phases":33320,"primaryCompletion":11291,"completion":11291,"start":2964,"enrollment":13356,"conditions":33321,"interventions":33322},[92],[12632],[13359,13344,13359,13359],{"trials":33324,"activeCount":103},[],{"trials":33326,"activeCount":103},[],{"trials":33328,"activeCount":103},[],{"intervention":33330,"totalTrials":302,"cells":33331},"IMA-638 is a biologic",{"EARLY_PHASE1":33332,"PHASE1":33334,"PHASE2":33336,"PHASE3":33344,"PHASE4":33346,"NA":33348},{"trials":33333,"activeCount":103},[],{"trials":33335,"activeCount":103},[],{"trials":33337,"activeCount":103},[33338],{"nctId":33339,"briefTitle":33340,"status":111,"phases":33341,"primaryCompletion":2884,"completion":2884,"start":11895,"enrollment":1780,"conditions":33342,"interventions":33343},"NCT00410280","Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma",[92],[6589],[33330],{"trials":33345,"activeCount":103},[],{"trials":33347,"activeCount":103},[],{"trials":33349,"activeCount":103},[],{"intervention":33351,"totalTrials":302,"cells":33352},"PF-04236921 SC",{"EARLY_PHASE1":33353,"PHASE1":33355,"PHASE2":33357,"PHASE3":33365,"PHASE4":33367,"NA":33369},{"trials":33354,"activeCount":103},[],{"trials":33356,"activeCount":103},[],{"trials":33358,"activeCount":103},[33359],{"nctId":33360,"briefTitle":33361,"status":111,"phases":33362,"primaryCompletion":9572,"completion":2227,"start":4666,"enrollment":8827,"conditions":33363,"interventions":33364},"NCT01287897","A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy",[92],[1570],[33351,33351,33351],{"trials":33366,"activeCount":103},[],{"trials":33368,"activeCount":103},[],{"trials":33370,"activeCount":103},[],{"intervention":33372,"totalTrials":302,"cells":33373},"Axitinib [AG-013736]",{"EARLY_PHASE1":33374,"PHASE1":33376,"PHASE2":33378,"PHASE3":33387,"PHASE4":33389,"NA":33391},{"trials":33375,"activeCount":103},[],{"trials":33377,"activeCount":103},[],{"trials":33379,"activeCount":103},[33380],{"nctId":33381,"briefTitle":33382,"status":111,"phases":33383,"primaryCompletion":3314,"completion":3314,"start":4702,"enrollment":4259,"conditions":33384,"interventions":33386},"NCT00094107","Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma",[92],[1798,33385],"Skin Neoplasms",[33372],{"trials":33388,"activeCount":103},[],{"trials":33390,"activeCount":103},[],{"trials":33392,"activeCount":103},[],{"intervention":13317,"totalTrials":302,"cells":33394},{"EARLY_PHASE1":33395,"PHASE1":33397,"PHASE2":33399,"PHASE3":33405,"PHASE4":33407,"NA":33409},{"trials":33396,"activeCount":103},[],{"trials":33398,"activeCount":103},[],{"trials":33400,"activeCount":103},[33401],{"nctId":13310,"briefTitle":13311,"status":111,"phases":33402,"primaryCompletion":577,"completion":586,"start":4645,"enrollment":13313,"conditions":33403,"interventions":33404},[92],[13315],[13317,13318],{"trials":33406,"activeCount":103},[],{"trials":33408,"activeCount":103},[],{"trials":33410,"activeCount":103},[],{"intervention":30692,"totalTrials":302,"cells":33412},{"EARLY_PHASE1":33413,"PHASE1":33415,"PHASE2":33417,"PHASE3":33423,"PHASE4":33425,"NA":33427},{"trials":33414,"activeCount":103},[],{"trials":33416,"activeCount":103},[],{"trials":33418,"activeCount":103},[33419],{"nctId":30687,"briefTitle":30688,"status":111,"phases":33420,"primaryCompletion":3839,"completion":3839,"start":2641,"enrollment":10972,"conditions":33421,"interventions":33422},[92],[37],[30692,30678,30693,30694],{"trials":33424,"activeCount":103},[],{"trials":33426,"activeCount":103},[],{"trials":33428,"activeCount":103},[],{"intervention":30693,"totalTrials":302,"cells":33430},{"EARLY_PHASE1":33431,"PHASE1":33433,"PHASE2":33435,"PHASE3":33441,"PHASE4":33443,"NA":33445},{"trials":33432,"activeCount":103},[],{"trials":33434,"activeCount":103},[],{"trials":33436,"activeCount":103},[33437],{"nctId":30687,"briefTitle":30688,"status":111,"phases":33438,"primaryCompletion":3839,"completion":3839,"start":2641,"enrollment":10972,"conditions":33439,"interventions":33440},[92],[37],[30692,30678,30693,30694],{"trials":33442,"activeCount":103},[],{"trials":33444,"activeCount":103},[],{"trials":33446,"activeCount":103},[],{"intervention":30694,"totalTrials":302,"cells":33448},{"EARLY_PHASE1":33449,"PHASE1":33451,"PHASE2":33453,"PHASE3":33459,"PHASE4":33461,"NA":33463},{"trials":33450,"activeCount":103},[],{"trials":33452,"activeCount":103},[],{"trials":33454,"activeCount":103},[33455],{"nctId":30687,"briefTitle":30688,"status":111,"phases":33456,"primaryCompletion":3839,"completion":3839,"start":2641,"enrollment":10972,"conditions":33457,"interventions":33458},[92],[37],[30692,30678,30693,30694],{"trials":33460,"activeCount":103},[],{"trials":33462,"activeCount":103},[],{"trials":33464,"activeCount":103},[],{"intervention":33466,"totalTrials":302,"cells":33467},"PF-04171327 10 mg",{"EARLY_PHASE1":33468,"PHASE1":33470,"PHASE2":33472,"PHASE3":33484,"PHASE4":33486,"NA":33488},{"trials":33469,"activeCount":103},[],{"trials":33471,"activeCount":103},[],{"trials":33473,"activeCount":103},[33474],{"nctId":33475,"briefTitle":33476,"status":111,"phases":33477,"primaryCompletion":33478,"completion":33478,"start":33479,"enrollment":1122,"conditions":33480,"interventions":33481},"NCT00938587","A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis",[92],"2010-07-29","2009-10-07",[22],[33466,33482,33483],"PF-04171327 25 mg","Prednisone 5 mg",{"trials":33485,"activeCount":103},[],{"trials":33487,"activeCount":103},[],{"trials":33489,"activeCount":103},[],{"intervention":33482,"totalTrials":302,"cells":33491},{"EARLY_PHASE1":33492,"PHASE1":33494,"PHASE2":33496,"PHASE3":33502,"PHASE4":33504,"NA":33506},{"trials":33493,"activeCount":103},[],{"trials":33495,"activeCount":103},[],{"trials":33497,"activeCount":103},[33498],{"nctId":33475,"briefTitle":33476,"status":111,"phases":33499,"primaryCompletion":33478,"completion":33478,"start":33479,"enrollment":1122,"conditions":33500,"interventions":33501},[92],[22],[33466,33482,33483],{"trials":33503,"activeCount":103},[],{"trials":33505,"activeCount":103},[],{"trials":33507,"activeCount":103},[],{"intervention":33483,"totalTrials":302,"cells":33509},{"EARLY_PHASE1":33510,"PHASE1":33512,"PHASE2":33514,"PHASE3":33520,"PHASE4":33522,"NA":33524},{"trials":33511,"activeCount":103},[],{"trials":33513,"activeCount":103},[],{"trials":33515,"activeCount":103},[33516],{"nctId":33475,"briefTitle":33476,"status":111,"phases":33517,"primaryCompletion":33478,"completion":33478,"start":33479,"enrollment":1122,"conditions":33518,"interventions":33519},[92],[22],[33466,33482,33483],{"trials":33521,"activeCount":103},[],{"trials":33523,"activeCount":103},[],{"trials":33525,"activeCount":103},[],{"intervention":33527,"totalTrials":302,"cells":33528},"ARRY-502, CRTh2 antagonist;",{"EARLY_PHASE1":33529,"PHASE1":33531,"PHASE2":33533,"PHASE3":33544,"PHASE4":33546,"NA":33548},{"trials":33530,"activeCount":103},[],{"trials":33532,"activeCount":103},[],{"trials":33534,"activeCount":103},[33535],{"nctId":33536,"briefTitle":33537,"status":111,"phases":33538,"primaryCompletion":33539,"completion":33540,"start":33541,"enrollment":2673,"conditions":33542,"interventions":33543},"NCT01561690","A Study of ARRY-502 in Patients With Persistent Asthma",[92],"2013-05-31","2013-06-10","2012-04-02",[6589],[33527],{"trials":33545,"activeCount":103},[],{"trials":33547,"activeCount":103},[],{"trials":33549,"activeCount":103},[],{"intervention":33551,"totalTrials":302,"cells":33552},"60 mg\u002Fkg azithromycin ER",{"EARLY_PHASE1":33553,"PHASE1":33555,"PHASE2":33557,"PHASE3":33566,"PHASE4":33568,"NA":33570},{"trials":33554,"activeCount":103},[],{"trials":33556,"activeCount":103},[],{"trials":33558,"activeCount":103},[33559],{"nctId":33560,"briefTitle":33561,"status":111,"phases":33562,"primaryCompletion":4608,"completion":4608,"start":8154,"enrollment":1796,"conditions":33563,"interventions":33564},"NCT00796224","Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media",[92],[25919],[33551,33565],"30 mg\u002Fkg azithromycin IR",{"trials":33567,"activeCount":103},[],{"trials":33569,"activeCount":103},[],{"trials":33571,"activeCount":103},[],{"intervention":33565,"totalTrials":302,"cells":33573},{"EARLY_PHASE1":33574,"PHASE1":33576,"PHASE2":33578,"PHASE3":33584,"PHASE4":33586,"NA":33588},{"trials":33575,"activeCount":103},[],{"trials":33577,"activeCount":103},[],{"trials":33579,"activeCount":103},[33580],{"nctId":33560,"briefTitle":33561,"status":111,"phases":33581,"primaryCompletion":4608,"completion":4608,"start":8154,"enrollment":1796,"conditions":33582,"interventions":33583},[92],[25919],[33551,33565],{"trials":33585,"activeCount":103},[],{"trials":33587,"activeCount":103},[],{"trials":33589,"activeCount":103},[],{"intervention":33591,"totalTrials":302,"cells":33592},"PF-06873600",{"EARLY_PHASE1":33593,"PHASE1":33595,"PHASE2":33597,"PHASE3":33611,"PHASE4":33613,"NA":33615},{"trials":33594,"activeCount":103},[],{"trials":33596,"activeCount":103},[],{"trials":33598,"activeCount":103},[33599],{"nctId":33600,"briefTitle":33601,"status":168,"phases":33602,"primaryCompletion":7837,"completion":33603,"start":33604,"enrollment":33605,"conditions":33606,"interventions":33608},"NCT03519178","A Study of PF-06873600 in People With Cancer",[91,92],"2024-10-30","2018-03-07",155,[33607],"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer",[33591,33609,33610],"Endocrine Therapy 1","Endocrine Therapy 2",{"trials":33612,"activeCount":103},[],{"trials":33614,"activeCount":103},[],{"trials":33616,"activeCount":103},[],{"intervention":33609,"totalTrials":302,"cells":33618},{"EARLY_PHASE1":33619,"PHASE1":33621,"PHASE2":33623,"PHASE3":33629,"PHASE4":33631,"NA":33633},{"trials":33620,"activeCount":103},[],{"trials":33622,"activeCount":103},[],{"trials":33624,"activeCount":103},[33625],{"nctId":33600,"briefTitle":33601,"status":168,"phases":33626,"primaryCompletion":7837,"completion":33603,"start":33604,"enrollment":33605,"conditions":33627,"interventions":33628},[91,92],[33607],[33591,33609,33610],{"trials":33630,"activeCount":103},[],{"trials":33632,"activeCount":103},[],{"trials":33634,"activeCount":103},[],{"intervention":33610,"totalTrials":302,"cells":33636},{"EARLY_PHASE1":33637,"PHASE1":33639,"PHASE2":33641,"PHASE3":33647,"PHASE4":33649,"NA":33651},{"trials":33638,"activeCount":103},[],{"trials":33640,"activeCount":103},[],{"trials":33642,"activeCount":103},[33643],{"nctId":33600,"briefTitle":33601,"status":168,"phases":33644,"primaryCompletion":7837,"completion":33603,"start":33604,"enrollment":33605,"conditions":33645,"interventions":33646},[91,92],[33607],[33591,33609,33610],{"trials":33648,"activeCount":103},[],{"trials":33650,"activeCount":103},[],{"trials":33652,"activeCount":103},[],{"intervention":33654,"totalTrials":302,"cells":33655},"Elranatamab + Nirogacestat",{"EARLY_PHASE1":33656,"PHASE1":33658,"PHASE2":33660,"PHASE3":33670,"PHASE4":33672,"NA":33674},{"trials":33657,"activeCount":103},[],{"trials":33659,"activeCount":103},[],{"trials":33661,"activeCount":103},[33662],{"nctId":33663,"briefTitle":33664,"status":168,"phases":33665,"primaryCompletion":7749,"completion":902,"start":33666,"enrollment":787,"conditions":33667,"interventions":33668},"NCT05090566","MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma",[92],"2021-10-27",[1062],[33654,33669],"Elranatamab + lenalidomide + dexamethasone",{"trials":33671,"activeCount":103},[],{"trials":33673,"activeCount":103},[],{"trials":33675,"activeCount":103},[],{"intervention":33669,"totalTrials":302,"cells":33677},{"EARLY_PHASE1":33678,"PHASE1":33680,"PHASE2":33682,"PHASE3":33688,"PHASE4":33690,"NA":33692},{"trials":33679,"activeCount":103},[],{"trials":33681,"activeCount":103},[],{"trials":33683,"activeCount":103},[33684],{"nctId":33663,"briefTitle":33664,"status":168,"phases":33685,"primaryCompletion":7749,"completion":902,"start":33666,"enrollment":787,"conditions":33686,"interventions":33687},[92],[1062],[33654,33669],{"trials":33689,"activeCount":103},[],{"trials":33691,"activeCount":103},[],{"trials":33693,"activeCount":103},[],{"intervention":33695,"totalTrials":302,"cells":33696},"UK-432,097",{"EARLY_PHASE1":33697,"PHASE1":33699,"PHASE2":33701,"PHASE3":33709,"PHASE4":33711,"NA":33713},{"trials":33698,"activeCount":103},[],{"trials":33700,"activeCount":103},[],{"trials":33702,"activeCount":103},[33703],{"nctId":33704,"briefTitle":33705,"status":168,"phases":33706,"primaryCompletion":4207,"completion":4207,"start":11315,"enrollment":1083,"conditions":33707,"interventions":33708},"NCT00430300","Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.",[92],[21083],[33695],{"trials":33710,"activeCount":103},[],{"trials":33712,"activeCount":103},[],{"trials":33714,"activeCount":103},[],{"intervention":33716,"totalTrials":302,"cells":33717},"SAM-531 1.5 mg",{"EARLY_PHASE1":33718,"PHASE1":33720,"PHASE2":33722,"PHASE3":33732,"PHASE4":33734,"NA":33736},{"trials":33719,"activeCount":103},[],{"trials":33721,"activeCount":103},[],{"trials":33723,"activeCount":103},[33724],{"nctId":33725,"briefTitle":33726,"status":168,"phases":33727,"primaryCompletion":11170,"completion":11170,"start":11014,"enrollment":22856,"conditions":33728,"interventions":33729},"NCT00895895","Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",[92],[13445],[33716,33730,33731,28123],"SAM-531 3.0 mg","SAM-531 5.0 mg",{"trials":33733,"activeCount":103},[],{"trials":33735,"activeCount":103},[],{"trials":33737,"activeCount":103},[],{"intervention":33730,"totalTrials":302,"cells":33739},{"EARLY_PHASE1":33740,"PHASE1":33742,"PHASE2":33744,"PHASE3":33750,"PHASE4":33752,"NA":33754},{"trials":33741,"activeCount":103},[],{"trials":33743,"activeCount":103},[],{"trials":33745,"activeCount":103},[33746],{"nctId":33725,"briefTitle":33726,"status":168,"phases":33747,"primaryCompletion":11170,"completion":11170,"start":11014,"enrollment":22856,"conditions":33748,"interventions":33749},[92],[13445],[33716,33730,33731,28123],{"trials":33751,"activeCount":103},[],{"trials":33753,"activeCount":103},[],{"trials":33755,"activeCount":103},[],{"intervention":33731,"totalTrials":302,"cells":33757},{"EARLY_PHASE1":33758,"PHASE1":33760,"PHASE2":33762,"PHASE3":33768,"PHASE4":33770,"NA":33772},{"trials":33759,"activeCount":103},[],{"trials":33761,"activeCount":103},[],{"trials":33763,"activeCount":103},[33764],{"nctId":33725,"briefTitle":33726,"status":168,"phases":33765,"primaryCompletion":11170,"completion":11170,"start":11014,"enrollment":22856,"conditions":33766,"interventions":33767},[92],[13445],[33716,33730,33731,28123],{"trials":33769,"activeCount":103},[],{"trials":33771,"activeCount":103},[],{"trials":33773,"activeCount":103},[],{"intervention":30702,"totalTrials":302,"cells":33775},{"EARLY_PHASE1":33776,"PHASE1":33778,"PHASE2":33780,"PHASE3":33786,"PHASE4":33788,"NA":33790},{"trials":33777,"activeCount":103},[],{"trials":33779,"activeCount":103},[],{"trials":33781,"activeCount":103},[33782],{"nctId":30696,"briefTitle":30697,"status":111,"phases":33783,"primaryCompletion":8115,"completion":8115,"start":10937,"enrollment":30699,"conditions":33784,"interventions":33785},[92],[37],[30702,30678],{"trials":33787,"activeCount":103},[],{"trials":33789,"activeCount":103},[],{"trials":33791,"activeCount":103},[],{"intervention":33793,"totalTrials":302,"cells":33794},"pregabalin\u002FPF-00489791",{"EARLY_PHASE1":33795,"PHASE1":33797,"PHASE2":33799,"PHASE3":33810,"PHASE4":33812,"NA":33814},{"trials":33796,"activeCount":103},[],{"trials":33798,"activeCount":103},[],{"trials":33800,"activeCount":103},[33801],{"nctId":33802,"briefTitle":33803,"status":111,"phases":33804,"primaryCompletion":33805,"completion":33806,"start":33807,"enrollment":7388,"conditions":33808,"interventions":33809},"NCT00599638","A Study To Compare Pregabalin\u002FPF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia",[92],"2008-12-16","2008-12-23","2008-04-09",[32264],[21451,33793],{"trials":33811,"activeCount":103},[],{"trials":33813,"activeCount":103},[],{"trials":33815,"activeCount":103},[],{"intervention":30470,"totalTrials":302,"cells":33817},{"EARLY_PHASE1":33818,"PHASE1":33820,"PHASE2":33822,"PHASE3":33828,"PHASE4":33830,"NA":33832},{"trials":33819,"activeCount":103},[],{"trials":33821,"activeCount":103},[],{"trials":33823,"activeCount":103},[33824],{"nctId":30464,"briefTitle":30465,"status":111,"phases":33825,"primaryCompletion":27771,"completion":27771,"start":30467,"enrollment":10947,"conditions":33826,"interventions":33827},[92],[1589,26842],[30470,30447,30471,30472],{"trials":33829,"activeCount":103},[],{"trials":33831,"activeCount":103},[],{"trials":33833,"activeCount":103},[],{"intervention":30471,"totalTrials":302,"cells":33835},{"EARLY_PHASE1":33836,"PHASE1":33838,"PHASE2":33840,"PHASE3":33846,"PHASE4":33848,"NA":33850},{"trials":33837,"activeCount":103},[],{"trials":33839,"activeCount":103},[],{"trials":33841,"activeCount":103},[33842],{"nctId":30464,"briefTitle":30465,"status":111,"phases":33843,"primaryCompletion":27771,"completion":27771,"start":30467,"enrollment":10947,"conditions":33844,"interventions":33845},[92],[1589,26842],[30470,30447,30471,30472],{"trials":33847,"activeCount":103},[],{"trials":33849,"activeCount":103},[],{"trials":33851,"activeCount":103},[],{"intervention":30472,"totalTrials":302,"cells":33853},{"EARLY_PHASE1":33854,"PHASE1":33856,"PHASE2":33858,"PHASE3":33864,"PHASE4":33866,"NA":33868},{"trials":33855,"activeCount":103},[],{"trials":33857,"activeCount":103},[],{"trials":33859,"activeCount":103},[33860],{"nctId":30464,"briefTitle":30465,"status":111,"phases":33861,"primaryCompletion":27771,"completion":27771,"start":30467,"enrollment":10947,"conditions":33862,"interventions":33863},[92],[1589,26842],[30470,30447,30471,30472],{"trials":33865,"activeCount":103},[],{"trials":33867,"activeCount":103},[],{"trials":33869,"activeCount":103},[],{"intervention":29379,"totalTrials":302,"cells":33871},{"EARLY_PHASE1":33872,"PHASE1":33874,"PHASE2":33876,"PHASE3":33882,"PHASE4":33884,"NA":33886},{"trials":33873,"activeCount":103},[],{"trials":33875,"activeCount":103},[],{"trials":33877,"activeCount":103},[33878],{"nctId":29373,"briefTitle":29374,"status":111,"phases":33879,"primaryCompletion":5008,"completion":29376,"start":652,"enrollment":11745,"conditions":33880,"interventions":33881},[92],[29367],[29379,29354],{"trials":33883,"activeCount":103},[],{"trials":33885,"activeCount":103},[],{"trials":33887,"activeCount":103},[],{"intervention":33889,"totalTrials":302,"cells":33890},"Ponezumab",{"EARLY_PHASE1":33891,"PHASE1":33893,"PHASE2":33895,"PHASE3":33904,"PHASE4":33906,"NA":33908},{"trials":33892,"activeCount":103},[],{"trials":33894,"activeCount":103},[],{"trials":33896,"activeCount":103},[33897],{"nctId":33898,"briefTitle":33899,"status":111,"phases":33900,"primaryCompletion":12853,"completion":12853,"start":13117,"enrollment":1530,"conditions":33901,"interventions":33903},"NCT01821118","Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy",[92],[33902],"Cerebral Amyloid Angiopathy",[33889],{"trials":33905,"activeCount":103},[],{"trials":33907,"activeCount":103},[],{"trials":33909,"activeCount":103},[],{"intervention":11467,"totalTrials":302,"cells":33911},{"EARLY_PHASE1":33912,"PHASE1":33914,"PHASE2":33916,"PHASE3":33922,"PHASE4":33924,"NA":33926},{"trials":33913,"activeCount":103},[],{"trials":33915,"activeCount":103},[],{"trials":33917,"activeCount":103},[33918],{"nctId":11460,"briefTitle":11461,"status":111,"phases":33919,"primaryCompletion":11463,"completion":11463,"start":11464,"enrollment":3169,"conditions":33920,"interventions":33921},[92],[34],[11467,11467,11467,11072],{"trials":33923,"activeCount":103},[],{"trials":33925,"activeCount":103},[],{"trials":33927,"activeCount":103},[],{"intervention":30801,"totalTrials":302,"cells":33929},{"EARLY_PHASE1":33930,"PHASE1":33932,"PHASE2":33934,"PHASE3":33940,"PHASE4":33942,"NA":33944},{"trials":33931,"activeCount":103},[],{"trials":33933,"activeCount":103},[],{"trials":33935,"activeCount":103},[33936],{"nctId":30796,"briefTitle":30797,"status":111,"phases":33937,"completion":11829,"start":3073,"enrollment":1613,"conditions":33938,"interventions":33939},[92],[10974],[30787,30801,30802],{"trials":33941,"activeCount":103},[],{"trials":33943,"activeCount":103},[],{"trials":33945,"activeCount":103},[],{"intervention":30802,"totalTrials":302,"cells":33947},{"EARLY_PHASE1":33948,"PHASE1":33950,"PHASE2":33952,"PHASE3":33958,"PHASE4":33960,"NA":33962},{"trials":33949,"activeCount":103},[],{"trials":33951,"activeCount":103},[],{"trials":33953,"activeCount":103},[33954],{"nctId":30796,"briefTitle":30797,"status":111,"phases":33955,"completion":11829,"start":3073,"enrollment":1613,"conditions":33956,"interventions":33957},[92],[10974],[30787,30801,30802],{"trials":33959,"activeCount":103},[],{"trials":33961,"activeCount":103},[],{"trials":33963,"activeCount":103},[],{"intervention":33965,"totalTrials":302,"cells":33966},"PF-04494700 - Low Dose Arm",{"EARLY_PHASE1":33967,"PHASE1":33969,"PHASE2":33971,"PHASE3":33980,"PHASE4":33982,"NA":33984},{"trials":33968,"activeCount":103},[],{"trials":33970,"activeCount":103},[],{"trials":33972,"activeCount":103},[33973],{"nctId":33974,"briefTitle":33975,"status":111,"phases":33976,"primaryCompletion":3627,"completion":3627,"start":9387,"enrollment":13920,"conditions":33977,"interventions":33978},"NCT00141661","A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients",[92],[13445],[33965,33979],"PF-04494700 - High Dose Arm",{"trials":33981,"activeCount":103},[],{"trials":33983,"activeCount":103},[],{"trials":33985,"activeCount":103},[],{"intervention":33979,"totalTrials":302,"cells":33987},{"EARLY_PHASE1":33988,"PHASE1":33990,"PHASE2":33992,"PHASE3":33998,"PHASE4":34000,"NA":34002},{"trials":33989,"activeCount":103},[],{"trials":33991,"activeCount":103},[],{"trials":33993,"activeCount":103},[33994],{"nctId":33974,"briefTitle":33975,"status":111,"phases":33995,"primaryCompletion":3627,"completion":3627,"start":9387,"enrollment":13920,"conditions":33996,"interventions":33997},[92],[13445],[33965,33979],{"trials":33999,"activeCount":103},[],{"trials":34001,"activeCount":103},[],{"trials":34003,"activeCount":103},[],{"intervention":30838,"totalTrials":302,"cells":34005},{"EARLY_PHASE1":34006,"PHASE1":34008,"PHASE2":34010,"PHASE3":34016,"PHASE4":34018,"NA":34020},{"trials":34007,"activeCount":103},[],{"trials":34009,"activeCount":103},[],{"trials":34011,"activeCount":103},[34012],{"nctId":30830,"briefTitle":30831,"status":111,"phases":34013,"primaryCompletion":2819,"completion":2819,"start":30833,"enrollment":30834,"conditions":34014,"interventions":34015},[91,92],[30836],[30838,30839,3754,3770,30840,30841],{"trials":34017,"activeCount":103},[],{"trials":34019,"activeCount":103},[],{"trials":34021,"activeCount":103},[],{"intervention":30839,"totalTrials":302,"cells":34023},{"EARLY_PHASE1":34024,"PHASE1":34026,"PHASE2":34028,"PHASE3":34034,"PHASE4":34036,"NA":34038},{"trials":34025,"activeCount":103},[],{"trials":34027,"activeCount":103},[],{"trials":34029,"activeCount":103},[34030],{"nctId":30830,"briefTitle":30831,"status":111,"phases":34031,"primaryCompletion":2819,"completion":2819,"start":30833,"enrollment":30834,"conditions":34032,"interventions":34033},[91,92],[30836],[30838,30839,3754,3770,30840,30841],{"trials":34035,"activeCount":103},[],{"trials":34037,"activeCount":103},[],{"trials":34039,"activeCount":103},[],{"intervention":30840,"totalTrials":302,"cells":34041},{"EARLY_PHASE1":34042,"PHASE1":34044,"PHASE2":34046,"PHASE3":34052,"PHASE4":34054,"NA":34056},{"trials":34043,"activeCount":103},[],{"trials":34045,"activeCount":103},[],{"trials":34047,"activeCount":103},[34048],{"nctId":30830,"briefTitle":30831,"status":111,"phases":34049,"primaryCompletion":2819,"completion":2819,"start":30833,"enrollment":30834,"conditions":34050,"interventions":34051},[91,92],[30836],[30838,30839,3754,3770,30840,30841],{"trials":34053,"activeCount":103},[],{"trials":34055,"activeCount":103},[],{"trials":34057,"activeCount":103},[],{"intervention":30841,"totalTrials":302,"cells":34059},{"EARLY_PHASE1":34060,"PHASE1":34062,"PHASE2":34064,"PHASE3":34070,"PHASE4":34072,"NA":34074},{"trials":34061,"activeCount":103},[],{"trials":34063,"activeCount":103},[],{"trials":34065,"activeCount":103},[34066],{"nctId":30830,"briefTitle":30831,"status":111,"phases":34067,"primaryCompletion":2819,"completion":2819,"start":30833,"enrollment":30834,"conditions":34068,"interventions":34069},[91,92],[30836],[30838,30839,3754,3770,30840,30841],{"trials":34071,"activeCount":103},[],{"trials":34073,"activeCount":103},[],{"trials":34075,"activeCount":103},[],{"intervention":34077,"totalTrials":302,"cells":34078},"sunitinib malate dose escalation",{"EARLY_PHASE1":34079,"PHASE1":34081,"PHASE2":34083,"PHASE3":34093,"PHASE4":34095,"NA":34097},{"trials":34080,"activeCount":103},[],{"trials":34082,"activeCount":103},[],{"trials":34084,"activeCount":103},[34085],{"nctId":34086,"briefTitle":34087,"status":111,"phases":34088,"primaryCompletion":34089,"completion":34089,"start":4459,"enrollment":2070,"conditions":34090,"interventions":34092},"NCT01396148","A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor",[92],"2017-08",[34091],"Gastrointestinal Stromal Tumors",[34077,2889],{"trials":34094,"activeCount":103},[],{"trials":34096,"activeCount":103},[],{"trials":34098,"activeCount":103},[],{"intervention":34100,"totalTrials":302,"cells":34101},"Varenicline Controlled Release 1.2 mg",{"EARLY_PHASE1":34102,"PHASE1":34104,"PHASE2":34106,"PHASE3":34117,"PHASE4":34119,"NA":34121},{"trials":34103,"activeCount":103},[],{"trials":34105,"activeCount":103},[],{"trials":34107,"activeCount":103},[34108],{"nctId":34109,"briefTitle":34110,"status":649,"phases":34111,"primaryCompletion":4531,"completion":4531,"start":561,"enrollment":103,"conditions":34112,"interventions":34113},"NCT00741884","A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation",[92],[11904],[34100,34114,34115,34116],"Varenicline Controlled Release 1.8 mg","Varenicline Controlled Release 2.4 mg","Varenicline Immediate Release 1 mg",{"trials":34118,"activeCount":103},[],{"trials":34120,"activeCount":103},[],{"trials":34122,"activeCount":103},[],{"intervention":34114,"totalTrials":302,"cells":34124},{"EARLY_PHASE1":34125,"PHASE1":34127,"PHASE2":34129,"PHASE3":34135,"PHASE4":34137,"NA":34139},{"trials":34126,"activeCount":103},[],{"trials":34128,"activeCount":103},[],{"trials":34130,"activeCount":103},[34131],{"nctId":34109,"briefTitle":34110,"status":649,"phases":34132,"primaryCompletion":4531,"completion":4531,"start":561,"enrollment":103,"conditions":34133,"interventions":34134},[92],[11904],[34100,34114,34115,34116],{"trials":34136,"activeCount":103},[],{"trials":34138,"activeCount":103},[],{"trials":34140,"activeCount":103},[],{"intervention":34115,"totalTrials":302,"cells":34142},{"EARLY_PHASE1":34143,"PHASE1":34145,"PHASE2":34147,"PHASE3":34153,"PHASE4":34155,"NA":34157},{"trials":34144,"activeCount":103},[],{"trials":34146,"activeCount":103},[],{"trials":34148,"activeCount":103},[34149],{"nctId":34109,"briefTitle":34110,"status":649,"phases":34150,"primaryCompletion":4531,"completion":4531,"start":561,"enrollment":103,"conditions":34151,"interventions":34152},[92],[11904],[34100,34114,34115,34116],{"trials":34154,"activeCount":103},[],{"trials":34156,"activeCount":103},[],{"trials":34158,"activeCount":103},[],{"intervention":34116,"totalTrials":302,"cells":34160},{"EARLY_PHASE1":34161,"PHASE1":34163,"PHASE2":34165,"PHASE3":34171,"PHASE4":34173,"NA":34175},{"trials":34162,"activeCount":103},[],{"trials":34164,"activeCount":103},[],{"trials":34166,"activeCount":103},[34167],{"nctId":34109,"briefTitle":34110,"status":649,"phases":34168,"primaryCompletion":4531,"completion":4531,"start":561,"enrollment":103,"conditions":34169,"interventions":34170},[92],[11904],[34100,34114,34115,34116],{"trials":34172,"activeCount":103},[],{"trials":34174,"activeCount":103},[],{"trials":34176,"activeCount":103},[],{"intervention":34178,"totalTrials":302,"cells":34179},"Sitexsentin sodium",{"EARLY_PHASE1":34180,"PHASE1":34182,"PHASE2":34184,"PHASE3":34195,"PHASE4":34197,"NA":34199},{"trials":34181,"activeCount":103},[],{"trials":34183,"activeCount":103},[],{"trials":34185,"activeCount":103},[34186],{"nctId":34187,"briefTitle":34188,"status":111,"phases":34189,"primaryCompletion":34190,"completion":34190,"start":34191,"enrollment":162,"conditions":34192,"interventions":34194},"NCT00303498","A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure",[92],"2008-05-01","2006-03-27",[34193],"Diastolic Heart Failure",[34178],{"trials":34196,"activeCount":103},[],{"trials":34198,"activeCount":103},[],{"trials":34200,"activeCount":103},[],{"intervention":34202,"totalTrials":302,"cells":34203},"CP-751, 871",{"EARLY_PHASE1":34204,"PHASE1":34206,"PHASE2":34208,"PHASE3":34217,"PHASE4":34219,"NA":34221},{"trials":34205,"activeCount":103},[],{"trials":34207,"activeCount":103},[],{"trials":34209,"activeCount":103},[34210],{"nctId":34211,"briefTitle":34212,"status":111,"phases":34213,"primaryCompletion":560,"completion":560,"start":4636,"enrollment":18918,"conditions":34214,"interventions":34216},"NCT00560560","Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments",[92],[34215],"Colorectal Neoplasm",[34202],{"trials":34218,"activeCount":103},[],{"trials":34220,"activeCount":103},[],{"trials":34222,"activeCount":103},[],{"intervention":12691,"totalTrials":302,"cells":34224},{"EARLY_PHASE1":34225,"PHASE1":34227,"PHASE2":34229,"PHASE3":34235,"PHASE4":34237,"NA":34239},{"trials":34226,"activeCount":103},[],{"trials":34228,"activeCount":103},[],{"trials":34230,"activeCount":103},[34231],{"nctId":12685,"briefTitle":12686,"status":111,"phases":34232,"primaryCompletion":8251,"completion":8251,"start":7665,"enrollment":12688,"conditions":34233,"interventions":34234},[92],[4514],[12676,12691,12691,12691,12692,12692],{"trials":34236,"activeCount":103},[],{"trials":34238,"activeCount":103},[],{"trials":34240,"activeCount":103},[],{"intervention":34242,"totalTrials":302,"cells":34243},"ACC-001+ QS21",{"EARLY_PHASE1":34244,"PHASE1":34246,"PHASE2":34248,"PHASE3":34258,"PHASE4":34260,"NA":34262},{"trials":34245,"activeCount":103},[],{"trials":34247,"activeCount":103},[],{"trials":34249,"activeCount":103},[34250],{"nctId":34251,"briefTitle":34252,"status":168,"phases":34253,"primaryCompletion":606,"completion":606,"start":4627,"enrollment":4981,"conditions":34254,"interventions":34255},"NCT00960531","A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease",[92],[13445],[34242,34256,34257],"ACC-001 (10 mcg) + QS-21","ACC-001+QS-21",{"trials":34259,"activeCount":103},[],{"trials":34261,"activeCount":103},[],{"trials":34263,"activeCount":103},[],{"intervention":34256,"totalTrials":302,"cells":34265},{"EARLY_PHASE1":34266,"PHASE1":34268,"PHASE2":34270,"PHASE3":34276,"PHASE4":34278,"NA":34280},{"trials":34267,"activeCount":103},[],{"trials":34269,"activeCount":103},[],{"trials":34271,"activeCount":103},[34272],{"nctId":34251,"briefTitle":34252,"status":168,"phases":34273,"primaryCompletion":606,"completion":606,"start":4627,"enrollment":4981,"conditions":34274,"interventions":34275},[92],[13445],[34242,34256,34257],{"trials":34277,"activeCount":103},[],{"trials":34279,"activeCount":103},[],{"trials":34281,"activeCount":103},[],{"intervention":34257,"totalTrials":302,"cells":34283},{"EARLY_PHASE1":34284,"PHASE1":34286,"PHASE2":34288,"PHASE3":34294,"PHASE4":34296,"NA":34298},{"trials":34285,"activeCount":103},[],{"trials":34287,"activeCount":103},[],{"trials":34289,"activeCount":103},[34290],{"nctId":34251,"briefTitle":34252,"status":168,"phases":34291,"primaryCompletion":606,"completion":606,"start":4627,"enrollment":4981,"conditions":34292,"interventions":34293},[92],[13445],[34242,34256,34257],{"trials":34295,"activeCount":103},[],{"trials":34297,"activeCount":103},[],{"trials":34299,"activeCount":103},[],{"intervention":34301,"totalTrials":302,"cells":34302},"Staphylococcus aureus 4-antigen vaccine",{"EARLY_PHASE1":34303,"PHASE1":34305,"PHASE2":34307,"PHASE3":34316,"PHASE4":34318,"NA":34320},{"trials":34304,"activeCount":103},[],{"trials":34306,"activeCount":103},[],{"trials":34308,"activeCount":103},[34309],{"nctId":34310,"briefTitle":34311,"status":111,"phases":34312,"primaryCompletion":2313,"completion":2313,"start":4438,"enrollment":17874,"conditions":34313,"interventions":34315},"NCT02492958","SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults",[92],[34314],"Staphylococcal Infections",[34301],{"trials":34317,"activeCount":103},[],{"trials":34319,"activeCount":103},[],{"trials":34321,"activeCount":103},[],{"intervention":34323,"totalTrials":302,"cells":34324},"PF-06459988",{"EARLY_PHASE1":34325,"PHASE1":34327,"PHASE2":34329,"PHASE3":34338,"PHASE4":34340,"NA":34342},{"trials":34326,"activeCount":103},[],{"trials":34328,"activeCount":103},[],{"trials":34330,"activeCount":103},[34331],{"nctId":34332,"briefTitle":34333,"status":649,"phases":34334,"primaryCompletion":27136,"completion":27136,"start":11956,"enrollment":103,"conditions":34335,"interventions":34337},"NCT02297425","A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer",[92],[34336],"Advanced EGFRm (Del 19 or L858R +\u002F- T790M) NSCLC",[34323],{"trials":34339,"activeCount":103},[],{"trials":34341,"activeCount":103},[],{"trials":34343,"activeCount":103},[],{"intervention":19256,"totalTrials":302,"cells":34345},{"EARLY_PHASE1":34346,"PHASE1":34348,"PHASE2":34350,"PHASE3":34356,"PHASE4":34358,"NA":34360},{"trials":34347,"activeCount":103},[],{"trials":34349,"activeCount":103},[],{"trials":34351,"activeCount":103},[34352],{"nctId":19247,"briefTitle":19248,"status":168,"phases":34353,"primaryCompletion":19250,"completion":19251,"start":19252,"enrollment":19253,"conditions":34354,"interventions":34355},[92],[11347,12099],[19256,19257,19238],{"trials":34357,"activeCount":103},[],{"trials":34359,"activeCount":103},[],{"trials":34361,"activeCount":103},[],{"intervention":34363,"totalTrials":302,"cells":34364},"MultiStem low dose",{"EARLY_PHASE1":34365,"PHASE1":34367,"PHASE2":34369,"PHASE3":34378,"PHASE4":34380,"NA":34382},{"trials":34366,"activeCount":103},[],{"trials":34368,"activeCount":103},[],{"trials":34370,"activeCount":103},[34371],{"nctId":34372,"briefTitle":34373,"status":111,"phases":34374,"primaryCompletion":17639,"completion":17639,"start":4666,"enrollment":3587,"conditions":34375,"interventions":34376},"NCT01240915","A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis",[92],[1511],[34363,34363,34377,34377,34377,34377],"MultiStem high dose",{"trials":34379,"activeCount":103},[],{"trials":34381,"activeCount":103},[],{"trials":34383,"activeCount":103},[],{"intervention":34377,"totalTrials":302,"cells":34385},{"EARLY_PHASE1":34386,"PHASE1":34388,"PHASE2":34390,"PHASE3":34396,"PHASE4":34398,"NA":34400},{"trials":34387,"activeCount":103},[],{"trials":34389,"activeCount":103},[],{"trials":34391,"activeCount":103},[34392],{"nctId":34372,"briefTitle":34373,"status":111,"phases":34393,"primaryCompletion":17639,"completion":17639,"start":4666,"enrollment":3587,"conditions":34394,"interventions":34395},[92],[1511],[34363,34363,34377,34377,34377,34377],{"trials":34397,"activeCount":103},[],{"trials":34399,"activeCount":103},[],{"trials":34401,"activeCount":103},[],{"intervention":34403,"totalTrials":302,"cells":34404},"APD418",{"EARLY_PHASE1":34405,"PHASE1":34407,"PHASE2":34409,"PHASE3":34418,"PHASE4":34420,"NA":34422},{"trials":34406,"activeCount":103},[],{"trials":34408,"activeCount":103},[],{"trials":34410,"activeCount":103},[34411],{"nctId":34412,"briefTitle":34413,"status":168,"phases":34414,"primaryCompletion":7768,"completion":7768,"start":406,"enrollment":525,"conditions":34415,"interventions":34417},"NCT05139615","A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction",[92],[34416],"Acute Heart Failure With Reduced Ejection Fraction",[34403,34403],{"trials":34419,"activeCount":103},[],{"trials":34421,"activeCount":103},[],{"trials":34423,"activeCount":103},[],{"intervention":2426,"totalTrials":302,"cells":34425},{"EARLY_PHASE1":34426,"PHASE1":34428,"PHASE2":34430,"PHASE3":34436,"PHASE4":34438,"NA":34440},{"trials":34427,"activeCount":103},[],{"trials":34429,"activeCount":103},[],{"trials":34431,"activeCount":103},[34432],{"nctId":2417,"briefTitle":2418,"status":111,"phases":34433,"primaryCompletion":2420,"completion":2421,"start":2422,"enrollment":2423,"conditions":34434,"interventions":34435},[92],[31],[2426,1381,1381],{"trials":34437,"activeCount":103},[],{"trials":34439,"activeCount":103},[],{"trials":34441,"activeCount":103},[],{"intervention":34443,"totalTrials":302,"cells":34444},"ACC-001 3 μg\u002F QS-21 50 μg",{"EARLY_PHASE1":34445,"PHASE1":34447,"PHASE2":34449,"PHASE3":34458,"PHASE4":34460,"NA":34462},{"trials":34446,"activeCount":103},[],{"trials":34448,"activeCount":103},[],{"trials":34450,"activeCount":103},[34451],{"nctId":34452,"briefTitle":34453,"status":111,"phases":34454,"primaryCompletion":3324,"completion":3324,"start":4666,"enrollment":4818,"conditions":34455,"interventions":34456},"NCT01227564","Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease",[92],[17728],[34443,34457],"ACC-001 10 μg\u002F QS-21 50 μg",{"trials":34459,"activeCount":103},[],{"trials":34461,"activeCount":103},[],{"trials":34463,"activeCount":103},[],{"intervention":34457,"totalTrials":302,"cells":34465},{"EARLY_PHASE1":34466,"PHASE1":34468,"PHASE2":34470,"PHASE3":34476,"PHASE4":34478,"NA":34480},{"trials":34467,"activeCount":103},[],{"trials":34469,"activeCount":103},[],{"trials":34471,"activeCount":103},[34472],{"nctId":34452,"briefTitle":34453,"status":111,"phases":34473,"primaryCompletion":3324,"completion":3324,"start":4666,"enrollment":4818,"conditions":34474,"interventions":34475},[92],[17728],[34443,34457],{"trials":34477,"activeCount":103},[],{"trials":34479,"activeCount":103},[],{"trials":34481,"activeCount":103},[],{"intervention":19267,"totalTrials":302,"cells":34483},{"EARLY_PHASE1":34484,"PHASE1":34486,"PHASE2":34488,"PHASE3":34494,"PHASE4":34496,"NA":34498},{"trials":34485,"activeCount":103},[],{"trials":34487,"activeCount":103},[],{"trials":34489,"activeCount":103},[34490],{"nctId":19259,"briefTitle":19260,"status":168,"phases":34491,"primaryCompletion":19262,"completion":19263,"start":19264,"enrollment":11370,"conditions":34492,"interventions":34493},[92],[11337],[19267,19238],{"trials":34495,"activeCount":103},[],{"trials":34497,"activeCount":103},[],{"trials":34499,"activeCount":103},[],{"intervention":34501,"totalTrials":302,"cells":34502},"CP-741,952",{"EARLY_PHASE1":34503,"PHASE1":34505,"PHASE2":34507,"PHASE3":34515,"PHASE4":34517,"NA":34519},{"trials":34504,"activeCount":103},[],{"trials":34506,"activeCount":103},[],{"trials":34508,"activeCount":103},[34509],{"nctId":34510,"briefTitle":34511,"status":168,"phases":34512,"completion":3602,"start":3627,"enrollment":397,"conditions":34513,"interventions":34514},"NCT00367783","Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity",[92],[2761],[34501],{"trials":34516,"activeCount":103},[],{"trials":34518,"activeCount":103},[],{"trials":34520,"activeCount":103},[],{"intervention":28276,"totalTrials":302,"cells":34522},{"EARLY_PHASE1":34523,"PHASE1":34525,"PHASE2":34527,"PHASE3":34533,"PHASE4":34535,"NA":34537},{"trials":34524,"activeCount":103},[],{"trials":34526,"activeCount":103},[],{"trials":34528,"activeCount":103},[34529],{"nctId":28270,"briefTitle":28271,"status":111,"phases":34530,"primaryCompletion":4459,"completion":4459,"start":2661,"enrollment":7184,"conditions":34531,"interventions":34532},[92],[28274],[28254,28276],{"trials":34534,"activeCount":103},[],{"trials":34536,"activeCount":103},[],{"trials":34538,"activeCount":103},[],{"intervention":34540,"totalTrials":302,"cells":34541},"PD-0299685",{"EARLY_PHASE1":34542,"PHASE1":34544,"PHASE2":34546,"PHASE3":34556,"PHASE4":34558,"NA":34560},{"trials":34543,"activeCount":103},[],{"trials":34545,"activeCount":103},[],{"trials":34547,"activeCount":103},[34548],{"nctId":34549,"briefTitle":34550,"status":111,"phases":34551,"completion":2641,"start":12773,"enrollment":34552,"conditions":34553,"interventions":34555},"NCT00314964","Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes \u002F Flushes) Associated With Menopause",[92],527,[34554],"Hot Flashes",[34540],{"trials":34557,"activeCount":103},[],{"trials":34559,"activeCount":103},[],{"trials":34561,"activeCount":103},[],{"intervention":18142,"totalTrials":302,"cells":34563},{"EARLY_PHASE1":34564,"PHASE1":34566,"PHASE2":34568,"PHASE3":34574,"PHASE4":34576,"NA":34578},{"trials":34565,"activeCount":103},[],{"trials":34567,"activeCount":103},[],{"trials":34569,"activeCount":103},[34570],{"nctId":18133,"briefTitle":18134,"status":111,"phases":34571,"primaryCompletion":18136,"completion":18136,"start":18137,"enrollment":18138,"conditions":34572,"interventions":34573},[92],[10626,18140],[18142,8296,18143],{"trials":34575,"activeCount":103},[],{"trials":34577,"activeCount":103},[],{"trials":34579,"activeCount":103},[],{"intervention":18143,"totalTrials":302,"cells":34581},{"EARLY_PHASE1":34582,"PHASE1":34584,"PHASE2":34586,"PHASE3":34592,"PHASE4":34594,"NA":34596},{"trials":34583,"activeCount":103},[],{"trials":34585,"activeCount":103},[],{"trials":34587,"activeCount":103},[34588],{"nctId":18133,"briefTitle":18134,"status":111,"phases":34589,"primaryCompletion":18136,"completion":18136,"start":18137,"enrollment":18138,"conditions":34590,"interventions":34591},[92],[10626,18140],[18142,8296,18143],{"trials":34593,"activeCount":103},[],{"trials":34595,"activeCount":103},[],{"trials":34597,"activeCount":103},[],{"intervention":34599,"totalTrials":302,"cells":34600},"NR2B NMDA Antagonist CP-101,606",{"EARLY_PHASE1":34601,"PHASE1":34603,"PHASE2":34605,"PHASE3":34613,"PHASE4":34615,"NA":34617},{"trials":34602,"activeCount":103},[],{"trials":34604,"activeCount":103},[],{"trials":34606,"activeCount":103},[34607],{"nctId":34608,"briefTitle":34609,"status":111,"phases":34610,"completion":2662,"start":11829,"enrollment":1268,"conditions":34611,"interventions":34612},"NCT00163085","The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease",[92],[27985],[34599],{"trials":34614,"activeCount":103},[],{"trials":34616,"activeCount":103},[],{"trials":34618,"activeCount":103},[],{"intervention":27047,"totalTrials":302,"cells":34620},{"EARLY_PHASE1":34621,"PHASE1":34623,"PHASE2":34625,"PHASE3":34631,"PHASE4":34633,"NA":34635},{"trials":34622,"activeCount":103},[],{"trials":34624,"activeCount":103},[],{"trials":34626,"activeCount":103},[34627],{"nctId":27039,"briefTitle":27040,"status":111,"phases":34628,"primaryCompletion":9422,"completion":9422,"start":27042,"enrollment":27043,"conditions":34629,"interventions":34630},[92],[1532],[27046,27047,7595,4425],{"trials":34632,"activeCount":103},[],{"trials":34634,"activeCount":103},[],{"trials":34636,"activeCount":103},[],{"intervention":34638,"totalTrials":302,"cells":34639},"Irinotecan plus capecitabine",{"EARLY_PHASE1":34640,"PHASE1":34642,"PHASE2":34644,"PHASE3":34652,"PHASE4":34654,"NA":34656},{"trials":34641,"activeCount":103},[],{"trials":34643,"activeCount":103},[],{"trials":34645,"activeCount":103},[34646],{"nctId":34647,"briefTitle":34648,"status":111,"phases":34649,"completion":11829,"start":4399,"enrollment":463,"conditions":34650,"interventions":34651},"NCT00635323","Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma",[92],[887],[34638],{"trials":34653,"activeCount":103},[],{"trials":34655,"activeCount":103},[],{"trials":34657,"activeCount":103},[],{"intervention":34659,"totalTrials":302,"cells":34660},"25 mg PF-04991532",{"EARLY_PHASE1":34661,"PHASE1":34663,"PHASE2":34665,"PHASE3":34677,"PHASE4":34679,"NA":34681},{"trials":34662,"activeCount":103},[],{"trials":34664,"activeCount":103},[],{"trials":34666,"activeCount":103},[34667],{"nctId":34668,"briefTitle":34669,"status":111,"phases":34670,"primaryCompletion":2450,"completion":2450,"start":2661,"enrollment":11641,"conditions":34671,"interventions":34672},"NCT01338870","Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes",[92],[37],[34659,34673,34674,34675,34676],"75 mg PF-04991532","150 mg PF-04991532","300 mg PF-04991532","Sitagliptin 100 mg",{"trials":34678,"activeCount":103},[],{"trials":34680,"activeCount":103},[],{"trials":34682,"activeCount":103},[],{"intervention":34673,"totalTrials":302,"cells":34684},{"EARLY_PHASE1":34685,"PHASE1":34687,"PHASE2":34689,"PHASE3":34695,"PHASE4":34697,"NA":34699},{"trials":34686,"activeCount":103},[],{"trials":34688,"activeCount":103},[],{"trials":34690,"activeCount":103},[34691],{"nctId":34668,"briefTitle":34669,"status":111,"phases":34692,"primaryCompletion":2450,"completion":2450,"start":2661,"enrollment":11641,"conditions":34693,"interventions":34694},[92],[37],[34659,34673,34674,34675,34676],{"trials":34696,"activeCount":103},[],{"trials":34698,"activeCount":103},[],{"trials":34700,"activeCount":103},[],{"intervention":34674,"totalTrials":302,"cells":34702},{"EARLY_PHASE1":34703,"PHASE1":34705,"PHASE2":34707,"PHASE3":34713,"PHASE4":34715,"NA":34717},{"trials":34704,"activeCount":103},[],{"trials":34706,"activeCount":103},[],{"trials":34708,"activeCount":103},[34709],{"nctId":34668,"briefTitle":34669,"status":111,"phases":34710,"primaryCompletion":2450,"completion":2450,"start":2661,"enrollment":11641,"conditions":34711,"interventions":34712},[92],[37],[34659,34673,34674,34675,34676],{"trials":34714,"activeCount":103},[],{"trials":34716,"activeCount":103},[],{"trials":34718,"activeCount":103},[],{"intervention":34675,"totalTrials":302,"cells":34720},{"EARLY_PHASE1":34721,"PHASE1":34723,"PHASE2":34725,"PHASE3":34731,"PHASE4":34733,"NA":34735},{"trials":34722,"activeCount":103},[],{"trials":34724,"activeCount":103},[],{"trials":34726,"activeCount":103},[34727],{"nctId":34668,"briefTitle":34669,"status":111,"phases":34728,"primaryCompletion":2450,"completion":2450,"start":2661,"enrollment":11641,"conditions":34729,"interventions":34730},[92],[37],[34659,34673,34674,34675,34676],{"trials":34732,"activeCount":103},[],{"trials":34734,"activeCount":103},[],{"trials":34736,"activeCount":103},[],{"intervention":34676,"totalTrials":302,"cells":34738},{"EARLY_PHASE1":34739,"PHASE1":34741,"PHASE2":34743,"PHASE3":34749,"PHASE4":34751,"NA":34753},{"trials":34740,"activeCount":103},[],{"trials":34742,"activeCount":103},[],{"trials":34744,"activeCount":103},[34745],{"nctId":34668,"briefTitle":34669,"status":111,"phases":34746,"primaryCompletion":2450,"completion":2450,"start":2661,"enrollment":11641,"conditions":34747,"interventions":34748},[92],[37],[34659,34673,34674,34675,34676],{"trials":34750,"activeCount":103},[],{"trials":34752,"activeCount":103},[],{"trials":34754,"activeCount":103},[],{"intervention":34756,"totalTrials":302,"cells":34757},"SU-011,248",{"EARLY_PHASE1":34758,"PHASE1":34760,"PHASE2":34762,"PHASE3":34770,"PHASE4":34772,"NA":34774},{"trials":34759,"activeCount":103},[],{"trials":34761,"activeCount":103},[],{"trials":34763,"activeCount":103},[34764],{"nctId":34765,"briefTitle":34766,"status":111,"phases":34767,"completion":11727,"start":3073,"enrollment":4818,"conditions":34768,"interventions":34769},"NCT00054886","Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer",[92],[4310],[34756],{"trials":34771,"activeCount":103},[],{"trials":34773,"activeCount":103},[],{"trials":34775,"activeCount":103},[],{"intervention":34777,"totalTrials":302,"cells":34778},"ILV-094",{"EARLY_PHASE1":34779,"PHASE1":34781,"PHASE2":34783,"PHASE3":34792,"PHASE4":34794,"NA":34796},{"trials":34780,"activeCount":103},[],{"trials":34782,"activeCount":103},[],{"trials":34784,"activeCount":103},[34785],{"nctId":34786,"briefTitle":34787,"status":111,"phases":34788,"primaryCompletion":23745,"completion":23745,"start":34789,"enrollment":31761,"conditions":34790,"interventions":34791},"NCT00883896","Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis",[92],"2009-06-18",[22],[34777,34777,34777],{"trials":34793,"activeCount":103},[],{"trials":34795,"activeCount":103},[],{"trials":34797,"activeCount":103},[],{"intervention":34799,"totalTrials":302,"cells":34800},"TBC3711",{"EARLY_PHASE1":34801,"PHASE1":34803,"PHASE2":34805,"PHASE3":34814,"PHASE4":34816,"NA":34818},{"trials":34802,"activeCount":103},[],{"trials":34804,"activeCount":103},[],{"trials":34806,"activeCount":103},[34807],{"nctId":34808,"briefTitle":34809,"status":168,"phases":34810,"primaryCompletion":8115,"completion":8115,"start":2662,"enrollment":2240,"conditions":34811,"interventions":34813},"NCT00272961","A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.",[92],[34812],"Resistant Hypertension",[34799,34799,34799,34799],{"trials":34815,"activeCount":103},[],{"trials":34817,"activeCount":103},[],{"trials":34819,"activeCount":103},[],{"intervention":3340,"totalTrials":302,"cells":34821},{"EARLY_PHASE1":34822,"PHASE1":34824,"PHASE2":34826,"PHASE3":34832,"PHASE4":34834,"NA":34836},{"trials":34823,"activeCount":103},[],{"trials":34825,"activeCount":103},[],{"trials":34827,"activeCount":103},[34828],{"nctId":3331,"briefTitle":3332,"status":111,"phases":34829,"primaryCompletion":524,"completion":3334,"start":3335,"enrollment":3336,"conditions":34830,"interventions":34831},[92],[1028],[1030,3329,3339,3340,3339,3329,1030,3340],{"trials":34833,"activeCount":103},[],{"trials":34835,"activeCount":103},[],{"trials":34837,"activeCount":103},[],{"intervention":9557,"totalTrials":302,"cells":34839},{"EARLY_PHASE1":34840,"PHASE1":34842,"PHASE2":34844,"PHASE3":34850,"PHASE4":34852,"NA":34854},{"trials":34841,"activeCount":103},[],{"trials":34843,"activeCount":103},[],{"trials":34845,"activeCount":103},[34846],{"nctId":9550,"briefTitle":9551,"status":111,"phases":34847,"primaryCompletion":4833,"completion":4833,"start":3839,"enrollment":9553,"conditions":34848,"interventions":34849},[92],[9555],[9534,9534,9557],{"trials":34851,"activeCount":103},[],{"trials":34853,"activeCount":103},[],{"trials":34855,"activeCount":103},[],{"intervention":34857,"totalTrials":302,"cells":34858},"azithromycin immediate release",{"EARLY_PHASE1":34859,"PHASE1":34861,"PHASE2":34863,"PHASE3":34871,"PHASE4":34873,"NA":34875},{"trials":34860,"activeCount":103},[],{"trials":34862,"activeCount":103},[],{"trials":34864,"activeCount":103},[34865],{"nctId":34866,"briefTitle":34867,"status":111,"phases":34868,"completion":4657,"start":12774,"enrollment":4825,"conditions":34869,"interventions":34870},"NCT00644176","A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery",[92],[3396],[34857,19967],{"trials":34872,"activeCount":103},[],{"trials":34874,"activeCount":103},[],{"trials":34876,"activeCount":103},[],{"intervention":34878,"totalTrials":302,"cells":34879},"AG013736",{"EARLY_PHASE1":34880,"PHASE1":34882,"PHASE2":34884,"PHASE3":34892,"PHASE4":34894,"NA":34896},{"trials":34881,"activeCount":103},[],{"trials":34883,"activeCount":103},[],{"trials":34885,"activeCount":103},[34886],{"nctId":34887,"briefTitle":34888,"status":111,"phases":34889,"primaryCompletion":8251,"completion":8251,"start":7675,"enrollment":2240,"conditions":34890,"interventions":34891},"NCT00094055","Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer",[92],[16976],[34878],{"trials":34893,"activeCount":103},[],{"trials":34895,"activeCount":103},[],{"trials":34897,"activeCount":103},[],{"intervention":34899,"totalTrials":302,"cells":34900},"Anti-NGF AB",{"EARLY_PHASE1":34901,"PHASE1":34903,"PHASE2":34905,"PHASE3":34916,"PHASE4":34918,"NA":34920},{"trials":34902,"activeCount":103},[],{"trials":34904,"activeCount":103},[],{"trials":34906,"activeCount":103},[34907],{"nctId":34908,"briefTitle":34909,"status":111,"phases":34910,"primaryCompletion":34911,"completion":34911,"start":34912,"enrollment":713,"conditions":34913,"interventions":34915},"NCT00830180","Open Label Extension In Cancer Patients",[92],"2013-02-14","2009-10-29",[2053,34914],"Bone Metastases",[34899],{"trials":34917,"activeCount":103},[],{"trials":34919,"activeCount":103},[],{"trials":34921,"activeCount":103},[],{"intervention":2025,"totalTrials":302,"cells":34923},{"EARLY_PHASE1":34924,"PHASE1":34926,"PHASE2":34928,"PHASE3":34934,"PHASE4":34936,"NA":34938},{"trials":34925,"activeCount":103},[],{"trials":34927,"activeCount":103},[],{"trials":34929,"activeCount":103},[34930],{"nctId":2014,"briefTitle":2015,"status":111,"phases":34931,"primaryCompletion":2017,"completion":2018,"start":2019,"enrollment":2020,"conditions":34932,"interventions":34933},[92],[2022],[2024,1304,2025],{"trials":34935,"activeCount":103},[],{"trials":34937,"activeCount":103},[],{"trials":34939,"activeCount":103},[],{"intervention":34941,"totalTrials":302,"cells":34942},"PF-00446687",{"EARLY_PHASE1":34943,"PHASE1":34945,"PHASE2":34947,"PHASE3":34956,"PHASE4":34958,"NA":34960},{"trials":34944,"activeCount":103},[],{"trials":34946,"activeCount":103},[],{"trials":34948,"activeCount":103},[34949],{"nctId":34950,"briefTitle":34951,"status":111,"phases":34952,"primaryCompletion":10937,"completion":10937,"start":3643,"enrollment":2218,"conditions":34953,"interventions":34955},"NCT00479570","Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.",[92],[34954],"Female Sexual Dysfunction",[34941],{"trials":34957,"activeCount":103},[],{"trials":34959,"activeCount":103},[],{"trials":34961,"activeCount":103},[],{"intervention":34963,"totalTrials":302,"cells":34964},"SB-525",{"EARLY_PHASE1":34965,"PHASE1":34967,"PHASE2":34969,"PHASE3":34979,"PHASE4":34981,"NA":34983},{"trials":34966,"activeCount":103},[],{"trials":34968,"activeCount":103},[],{"trials":34970,"activeCount":103},[34971],{"nctId":34972,"briefTitle":34973,"status":111,"phases":34974,"primaryCompletion":34975,"completion":34975,"start":34976,"enrollment":3254,"conditions":34977,"interventions":34978},"NCT03061201","A Study of Recombinant AAV2\u002F6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A",[92],"2024-07-16","2017-06-21",[3551],[34963],{"trials":34980,"activeCount":103},[],{"trials":34982,"activeCount":103},[],{"trials":34984,"activeCount":103},[],{"intervention":34986,"totalTrials":302,"cells":34987},"moxidectin",{"EARLY_PHASE1":34988,"PHASE1":34990,"PHASE2":34992,"PHASE3":35001,"PHASE4":35003,"NA":35005},{"trials":34989,"activeCount":103},[],{"trials":34991,"activeCount":103},[],{"trials":34993,"activeCount":103},[34994],{"nctId":34995,"briefTitle":34996,"status":649,"phases":34997,"primaryCompletion":523,"completion":523,"start":523,"enrollment":103,"conditions":34998,"interventions":35000},"NCT01035619","Pediatric Pharmacokinetics And Safety Study Of Moxidectin",[92],[34999],"Onchocerciasis",[34986],{"trials":35002,"activeCount":103},[],{"trials":35004,"activeCount":103},[],{"trials":35006,"activeCount":103},[],{"intervention":35008,"totalTrials":302,"cells":35009},"Vaccine",{"EARLY_PHASE1":35010,"PHASE1":35012,"PHASE2":35014,"PHASE3":35026,"PHASE4":35028,"NA":35030},{"trials":35011,"activeCount":103},[],{"trials":35013,"activeCount":103},[],{"trials":35015,"activeCount":103},[35016],{"nctId":35017,"briefTitle":35018,"status":111,"phases":35019,"primaryCompletion":35020,"completion":35021,"start":35022,"enrollment":35023,"conditions":35024,"interventions":35025},"NCT01299480","A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To \u003C19 Years",[92],"2012-05-03","2012-09-18","2011-03-03",1714,[8295],[35008,35008,35008,35008,35008],{"trials":35027,"activeCount":103},[],{"trials":35029,"activeCount":103},[],{"trials":35031,"activeCount":103},[],{"intervention":31040,"totalTrials":302,"cells":35033},{"EARLY_PHASE1":35034,"PHASE1":35036,"PHASE2":35038,"PHASE3":35044,"PHASE4":35046,"NA":35048},{"trials":35035,"activeCount":103},[],{"trials":35037,"activeCount":103},[],{"trials":35039,"activeCount":103},[35040],{"nctId":31034,"briefTitle":31035,"status":168,"phases":35041,"primaryCompletion":31037,"completion":31037,"start":17170,"enrollment":3587,"conditions":35042,"interventions":35043},[92],[27719],[31040,31041,31025],{"trials":35045,"activeCount":103},[],{"trials":35047,"activeCount":103},[],{"trials":35049,"activeCount":103},[],{"intervention":31041,"totalTrials":302,"cells":35051},{"EARLY_PHASE1":35052,"PHASE1":35054,"PHASE2":35056,"PHASE3":35062,"PHASE4":35064,"NA":35066},{"trials":35053,"activeCount":103},[],{"trials":35055,"activeCount":103},[],{"trials":35057,"activeCount":103},[35058],{"nctId":31034,"briefTitle":31035,"status":168,"phases":35059,"primaryCompletion":31037,"completion":31037,"start":17170,"enrollment":3587,"conditions":35060,"interventions":35061},[92],[27719],[31040,31041,31025],{"trials":35063,"activeCount":103},[],{"trials":35065,"activeCount":103},[],{"trials":35067,"activeCount":103},[],{"intervention":35069,"totalTrials":302,"cells":35070},"PF-06372865.",{"EARLY_PHASE1":35071,"PHASE1":35073,"PHASE2":35075,"PHASE3":35083,"PHASE4":35085,"NA":35087},{"trials":35072,"activeCount":103},[],{"trials":35074,"activeCount":103},[],{"trials":35076,"activeCount":103},[35077],{"nctId":35078,"briefTitle":35079,"status":168,"phases":35080,"primaryCompletion":626,"completion":626,"start":17639,"enrollment":481,"conditions":35081,"interventions":35082},"NCT02310568","POC Study in Partially Responsive Generalized Anxiety Disorder",[92],[17561],[35069],{"trials":35084,"activeCount":103},[],{"trials":35086,"activeCount":103},[],{"trials":35088,"activeCount":103},[],{"intervention":27870,"totalTrials":302,"cells":35090},{"EARLY_PHASE1":35091,"PHASE1":35093,"PHASE2":35095,"PHASE3":35101,"PHASE4":35103,"NA":35105},{"trials":35092,"activeCount":103},[],{"trials":35094,"activeCount":103},[],{"trials":35096,"activeCount":103},[35097],{"nctId":27864,"briefTitle":27865,"status":111,"phases":35098,"primaryCompletion":1325,"completion":1325,"start":27097,"enrollment":27867,"conditions":35099,"interventions":35100},[92],[10940],[11571,27845,27870],{"trials":35102,"activeCount":103},[],{"trials":35104,"activeCount":103},[],{"trials":35106,"activeCount":103},[],{"intervention":35108,"totalTrials":302,"cells":35109},"SU011248\u002FTrastuzumab",{"EARLY_PHASE1":35110,"PHASE1":35112,"PHASE2":35114,"PHASE3":35122,"PHASE4":35124,"NA":35126},{"trials":35111,"activeCount":103},[],{"trials":35113,"activeCount":103},[],{"trials":35115,"activeCount":103},[35116],{"nctId":35117,"briefTitle":35118,"status":111,"phases":35119,"primaryCompletion":4222,"completion":586,"start":12416,"enrollment":2240,"conditions":35120,"interventions":35121},"NCT00243503","Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer",[92],[25],[35108],{"trials":35123,"activeCount":103},[],{"trials":35125,"activeCount":103},[],{"trials":35127,"activeCount":103},[],{"intervention":27722,"totalTrials":302,"cells":35129},{"EARLY_PHASE1":35130,"PHASE1":35132,"PHASE2":35134,"PHASE3":35140,"PHASE4":35142,"NA":35144},{"trials":35131,"activeCount":103},[],{"trials":35133,"activeCount":103},[],{"trials":35135,"activeCount":103},[35136],{"nctId":27715,"briefTitle":27716,"status":168,"phases":35137,"primaryCompletion":6208,"completion":6208,"start":4666,"enrollment":1498,"conditions":35138,"interventions":35139},[92],[27719],[27721,27721,27722,27721,27721,27723],{"trials":35141,"activeCount":103},[],{"trials":35143,"activeCount":103},[],{"trials":35145,"activeCount":103},[],{"intervention":29344,"totalTrials":302,"cells":35147},{"EARLY_PHASE1":35148,"PHASE1":35150,"PHASE2":35152,"PHASE3":35158,"PHASE4":35160,"NA":35162},{"trials":35149,"activeCount":103},[],{"trials":35151,"activeCount":103},[],{"trials":35153,"activeCount":103},[35154],{"nctId":29338,"briefTitle":29339,"status":111,"phases":35155,"primaryCompletion":29341,"completion":29341,"start":11170,"enrollment":787,"conditions":35156,"interventions":35157},[92],[1933],[29306,29344,29345,29346],{"trials":35159,"activeCount":103},[],{"trials":35161,"activeCount":103},[],{"trials":35163,"activeCount":103},[],{"intervention":29345,"totalTrials":302,"cells":35165},{"EARLY_PHASE1":35166,"PHASE1":35168,"PHASE2":35170,"PHASE3":35176,"PHASE4":35178,"NA":35180},{"trials":35167,"activeCount":103},[],{"trials":35169,"activeCount":103},[],{"trials":35171,"activeCount":103},[35172],{"nctId":29338,"briefTitle":29339,"status":111,"phases":35173,"primaryCompletion":29341,"completion":29341,"start":11170,"enrollment":787,"conditions":35174,"interventions":35175},[92],[1933],[29306,29344,29345,29346],{"trials":35177,"activeCount":103},[],{"trials":35179,"activeCount":103},[],{"trials":35181,"activeCount":103},[],{"intervention":35183,"totalTrials":302,"cells":35184},"[S,S]-Reboxetine + Pregabalin",{"EARLY_PHASE1":35185,"PHASE1":35187,"PHASE2":35189,"PHASE3":35200,"PHASE4":35202,"NA":35204},{"trials":35186,"activeCount":103},[],{"trials":35188,"activeCount":103},[],{"trials":35190,"activeCount":103},[35191],{"nctId":35192,"briefTitle":35193,"status":168,"phases":35194,"primaryCompletion":35195,"completion":35196,"start":35197,"enrollment":17874,"conditions":35198,"interventions":35199},"NCT00334685","[S,S]-Reboxetine Add-On Trial",[92],"2007-10-04","2007-10-11","2006-08-22",[34],[35183,11452],{"trials":35201,"activeCount":103},[],{"trials":35203,"activeCount":103},[],{"trials":35205,"activeCount":103},[],{"intervention":35207,"totalTrials":302,"cells":35208},"PF-06649751 low dose",{"EARLY_PHASE1":35209,"PHASE1":35211,"PHASE2":35213,"PHASE3":35226,"PHASE4":35228,"NA":35230},{"trials":35210,"activeCount":103},[],{"trials":35212,"activeCount":103},[],{"trials":35214,"activeCount":103},[35215],{"nctId":35216,"briefTitle":35217,"status":168,"phases":35218,"primaryCompletion":35219,"completion":35219,"start":35220,"enrollment":1498,"conditions":35221,"interventions":35222},"NCT02687542","Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations",[92],"2017-11-10","2016-03-03",[13750],[35207,35223,35224,35225],"PF-06649751 middle dose 1","PF-06649751 middle dose 2","PF-06649751 high dose",{"trials":35227,"activeCount":103},[],{"trials":35229,"activeCount":103},[],{"trials":35231,"activeCount":103},[],{"intervention":35223,"totalTrials":302,"cells":35233},{"EARLY_PHASE1":35234,"PHASE1":35236,"PHASE2":35238,"PHASE3":35244,"PHASE4":35246,"NA":35248},{"trials":35235,"activeCount":103},[],{"trials":35237,"activeCount":103},[],{"trials":35239,"activeCount":103},[35240],{"nctId":35216,"briefTitle":35217,"status":168,"phases":35241,"primaryCompletion":35219,"completion":35219,"start":35220,"enrollment":1498,"conditions":35242,"interventions":35243},[92],[13750],[35207,35223,35224,35225],{"trials":35245,"activeCount":103},[],{"trials":35247,"activeCount":103},[],{"trials":35249,"activeCount":103},[],{"intervention":35224,"totalTrials":302,"cells":35251},{"EARLY_PHASE1":35252,"PHASE1":35254,"PHASE2":35256,"PHASE3":35262,"PHASE4":35264,"NA":35266},{"trials":35253,"activeCount":103},[],{"trials":35255,"activeCount":103},[],{"trials":35257,"activeCount":103},[35258],{"nctId":35216,"briefTitle":35217,"status":168,"phases":35259,"primaryCompletion":35219,"completion":35219,"start":35220,"enrollment":1498,"conditions":35260,"interventions":35261},[92],[13750],[35207,35223,35224,35225],{"trials":35263,"activeCount":103},[],{"trials":35265,"activeCount":103},[],{"trials":35267,"activeCount":103},[],{"intervention":35225,"totalTrials":302,"cells":35269},{"EARLY_PHASE1":35270,"PHASE1":35272,"PHASE2":35274,"PHASE3":35280,"PHASE4":35282,"NA":35284},{"trials":35271,"activeCount":103},[],{"trials":35273,"activeCount":103},[],{"trials":35275,"activeCount":103},[35276],{"nctId":35216,"briefTitle":35217,"status":168,"phases":35277,"primaryCompletion":35219,"completion":35219,"start":35220,"enrollment":1498,"conditions":35278,"interventions":35279},[92],[13750],[35207,35223,35224,35225],{"trials":35281,"activeCount":103},[],{"trials":35283,"activeCount":103},[],{"trials":35285,"activeCount":103},[],{"intervention":35287,"totalTrials":302,"cells":35288},"UK0369,003",{"EARLY_PHASE1":35289,"PHASE1":35291,"PHASE2":35293,"PHASE3":35302,"PHASE4":35304,"NA":35306},{"trials":35290,"activeCount":103},[],{"trials":35292,"activeCount":103},[],{"trials":35294,"activeCount":103},[35295],{"nctId":35296,"briefTitle":35297,"status":111,"phases":35298,"completion":14118,"start":4258,"enrollment":1613,"conditions":35299,"interventions":35300},"NCT00174486","Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction",[92],[12375],[35287,35301],"Cialis",{"trials":35303,"activeCount":103},[],{"trials":35305,"activeCount":103},[],{"trials":35307,"activeCount":103},[],{"intervention":35301,"totalTrials":302,"cells":35309},{"EARLY_PHASE1":35310,"PHASE1":35312,"PHASE2":35314,"PHASE3":35320,"PHASE4":35322,"NA":35324},{"trials":35311,"activeCount":103},[],{"trials":35313,"activeCount":103},[],{"trials":35315,"activeCount":103},[35316],{"nctId":35296,"briefTitle":35297,"status":111,"phases":35317,"completion":14118,"start":4258,"enrollment":1613,"conditions":35318,"interventions":35319},[92],[12375],[35287,35301],{"trials":35321,"activeCount":103},[],{"trials":35323,"activeCount":103},[],{"trials":35325,"activeCount":103},[],{"intervention":35327,"totalTrials":302,"cells":35328},"ALO-01",{"EARLY_PHASE1":35329,"PHASE1":35331,"PHASE2":35333,"PHASE3":35342,"PHASE4":35344,"NA":35346},{"trials":35330,"activeCount":103},[],{"trials":35332,"activeCount":103},[],{"trials":35334,"activeCount":103},[35335],{"nctId":35336,"briefTitle":35337,"status":111,"phases":35338,"primaryCompletion":3610,"completion":3610,"start":11895,"enrollment":4259,"conditions":35339,"interventions":35340},"NCT00751478","Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)",[91,92],[16],[35327,35341],"MSIR",{"trials":35343,"activeCount":103},[],{"trials":35345,"activeCount":103},[],{"trials":35347,"activeCount":103},[],{"intervention":35341,"totalTrials":302,"cells":35349},{"EARLY_PHASE1":35350,"PHASE1":35352,"PHASE2":35354,"PHASE3":35360,"PHASE4":35362,"NA":35364},{"trials":35351,"activeCount":103},[],{"trials":35353,"activeCount":103},[],{"trials":35355,"activeCount":103},[35356],{"nctId":35336,"briefTitle":35337,"status":111,"phases":35357,"primaryCompletion":3610,"completion":3610,"start":11895,"enrollment":4259,"conditions":35358,"interventions":35359},[91,92],[16],[35327,35341],{"trials":35361,"activeCount":103},[],{"trials":35363,"activeCount":103},[],{"trials":35365,"activeCount":103},[],{"intervention":120,"totalTrials":302,"cells":35367},{"EARLY_PHASE1":35368,"PHASE1":35370,"PHASE2":35372,"PHASE3":35378,"PHASE4":35380,"NA":35382},{"trials":35369,"activeCount":103},[],{"trials":35371,"activeCount":103},[],{"trials":35373,"activeCount":103},[35374],{"nctId":109,"briefTitle":110,"status":111,"phases":35375,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":35376,"interventions":35377},[92],[117,118],[98,120],{"trials":35379,"activeCount":103},[],{"trials":35381,"activeCount":103},[],{"trials":35383,"activeCount":103},[],{"intervention":35385,"totalTrials":302,"cells":35386},"Exubera®",{"EARLY_PHASE1":35387,"PHASE1":35389,"PHASE2":35391,"PHASE3":35399,"PHASE4":35401,"NA":35403},{"trials":35388,"activeCount":103},[],{"trials":35390,"activeCount":103},[],{"trials":35392,"activeCount":103},[35393],{"nctId":35394,"briefTitle":35395,"status":168,"phases":35396,"primaryCompletion":3853,"completion":3853,"start":3628,"enrollment":14035,"conditions":35397,"interventions":35398},"NCT00143247","Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus",[92],[6117],[35385],{"trials":35400,"activeCount":103},[],{"trials":35402,"activeCount":103},[],{"trials":35404,"activeCount":103},[],{"intervention":29675,"totalTrials":302,"cells":35406},{"EARLY_PHASE1":35407,"PHASE1":35409,"PHASE2":35411,"PHASE3":35417,"PHASE4":35419,"NA":35421},{"trials":35408,"activeCount":103},[],{"trials":35410,"activeCount":103},[],{"trials":35412,"activeCount":103},[35413],{"nctId":29669,"briefTitle":29670,"status":111,"phases":35414,"primaryCompletion":27941,"completion":27941,"start":29672,"enrollment":1530,"conditions":35415,"interventions":35416},[92],[17728],[29614,29675],{"trials":35418,"activeCount":103},[],{"trials":35420,"activeCount":103},[],{"trials":35422,"activeCount":103},[],{"intervention":35424,"totalTrials":302,"cells":35425},"PD-217,014",{"EARLY_PHASE1":35426,"PHASE1":35428,"PHASE2":35430,"PHASE3":35439,"PHASE4":35441,"NA":35443},{"trials":35427,"activeCount":103},[],{"trials":35429,"activeCount":103},[],{"trials":35431,"activeCount":103},[35432],{"nctId":35433,"briefTitle":35434,"status":111,"phases":35435,"primaryCompletion":4258,"completion":4258,"start":11666,"enrollment":1759,"conditions":35436,"interventions":35438},"NCT00139672","A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain\u002FDiscomfort In Patients With IBS.",[92],[35437],"Irritable Bowel Syndrome",[35424],{"trials":35440,"activeCount":103},[],{"trials":35442,"activeCount":103},[],{"trials":35444,"activeCount":103},[],{"intervention":35446,"totalTrials":302,"cells":35447},"tofimilast",{"EARLY_PHASE1":35448,"PHASE1":35450,"PHASE2":35452,"PHASE3":35460,"PHASE4":35462,"NA":35464},{"trials":35449,"activeCount":103},[],{"trials":35451,"activeCount":103},[],{"trials":35453,"activeCount":103},[35454],{"nctId":35455,"briefTitle":35456,"status":111,"phases":35457,"primaryCompletion":11417,"completion":11417,"start":11395,"enrollment":1613,"conditions":35458,"interventions":35459},"NCT00219622","A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease",[92],[21083],[35446],{"trials":35461,"activeCount":103},[],{"trials":35463,"activeCount":103},[],{"trials":35465,"activeCount":103},[],{"intervention":35467,"totalTrials":302,"cells":35468},"CPG10101",{"EARLY_PHASE1":35469,"PHASE1":35471,"PHASE2":35473,"PHASE3":35484,"PHASE4":35486,"NA":35488},{"trials":35470,"activeCount":103},[],{"trials":35472,"activeCount":103},[],{"trials":35474,"activeCount":103},[35475],{"nctId":35476,"briefTitle":35477,"status":111,"phases":35478,"primaryCompletion":2641,"completion":2641,"start":12416,"enrollment":35479,"conditions":35480,"interventions":35482},"NCT00277238","CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects",[92],113,[35481],"Hepatitis, Chronic Active",[35467,35467,35483,35467],"Control",{"trials":35485,"activeCount":103},[],{"trials":35487,"activeCount":103},[],{"trials":35489,"activeCount":103},[],{"intervention":35483,"totalTrials":302,"cells":35491},{"EARLY_PHASE1":35492,"PHASE1":35494,"PHASE2":35496,"PHASE3":35502,"PHASE4":35504,"NA":35506},{"trials":35493,"activeCount":103},[],{"trials":35495,"activeCount":103},[],{"trials":35497,"activeCount":103},[35498],{"nctId":35476,"briefTitle":35477,"status":111,"phases":35499,"primaryCompletion":2641,"completion":2641,"start":12416,"enrollment":35479,"conditions":35500,"interventions":35501},[92],[35481],[35467,35467,35483,35467],{"trials":35503,"activeCount":103},[],{"trials":35505,"activeCount":103},[],{"trials":35507,"activeCount":103},[],{"intervention":3348,"totalTrials":302,"cells":35509},{"EARLY_PHASE1":35510,"PHASE1":35512,"PHASE2":35514,"PHASE3":35520,"PHASE4":35522,"NA":35524},{"trials":35511,"activeCount":103},[],{"trials":35513,"activeCount":103},[],{"trials":35515,"activeCount":103},[35516],{"nctId":3342,"briefTitle":3343,"status":111,"phases":35517,"primaryCompletion":3334,"completion":3345,"start":2662,"enrollment":1112,"conditions":35518,"interventions":35519},[91,92],[1028],[429,3348,3339],{"trials":35521,"activeCount":103},[],{"trials":35523,"activeCount":103},[],{"trials":35525,"activeCount":103},[],{"intervention":35527,"totalTrials":302,"cells":35528},"SKI-606",{"EARLY_PHASE1":35529,"PHASE1":35531,"PHASE2":35533,"PHASE3":35541,"PHASE4":35543,"NA":35545},{"trials":35530,"activeCount":103},[],{"trials":35532,"activeCount":103},[],{"trials":35534,"activeCount":103},[35535],{"nctId":35536,"briefTitle":35537,"status":111,"phases":35538,"primaryCompletion":4608,"completion":4608,"start":12004,"enrollment":4755,"conditions":35539,"interventions":35540},"NCT00319254","Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer",[92],[25,3077],[35527],{"trials":35542,"activeCount":103},[],{"trials":35544,"activeCount":103},[],{"trials":35546,"activeCount":103},[],{"intervention":17877,"totalTrials":302,"cells":35548},{"EARLY_PHASE1":35549,"PHASE1":35551,"PHASE2":35553,"PHASE3":35559,"PHASE4":35561,"NA":35563},{"trials":35550,"activeCount":103},[],{"trials":35552,"activeCount":103},[],{"trials":35554,"activeCount":103},[35555],{"nctId":17871,"briefTitle":17872,"status":168,"phases":35556,"primaryCompletion":11609,"completion":11609,"start":12395,"enrollment":17874,"conditions":35557,"interventions":35558},[92],[34],[17843,17877],{"trials":35560,"activeCount":103},[],{"trials":35562,"activeCount":103},[],{"trials":35564,"activeCount":103},[],{"intervention":29195,"totalTrials":302,"cells":35566},{"EARLY_PHASE1":35567,"PHASE1":35569,"PHASE2":35571,"PHASE3":35577,"PHASE4":35579,"NA":35581},{"trials":35568,"activeCount":103},[],{"trials":35570,"activeCount":103},[],{"trials":35572,"activeCount":103},[35573],{"nctId":29187,"briefTitle":29188,"status":111,"phases":35574,"primaryCompletion":29190,"completion":29190,"start":29191,"enrollment":29192,"conditions":35575,"interventions":35576},[92],[29174],[29158,29195],{"trials":35578,"activeCount":103},[],{"trials":35580,"activeCount":103},[],{"trials":35582,"activeCount":103},[],{"intervention":8297,"totalTrials":302,"cells":35584},{"EARLY_PHASE1":35585,"PHASE1":35587,"PHASE2":35589,"PHASE3":35595,"PHASE4":35597,"NA":35599},{"trials":35586,"activeCount":103},[],{"trials":35588,"activeCount":103},[],{"trials":35590,"activeCount":103},[35591],{"nctId":8287,"briefTitle":8288,"status":111,"phases":35592,"primaryCompletion":8290,"completion":8291,"start":8292,"enrollment":8293,"conditions":35593,"interventions":35594},[92],[8295,8296,8297,8298,8299],[8296,8297,2515,8297],{"trials":35596,"activeCount":103},[],{"trials":35598,"activeCount":103},[],{"trials":35600,"activeCount":103},[],{"intervention":5220,"totalTrials":302,"cells":35602},{"EARLY_PHASE1":35603,"PHASE1":35605,"PHASE2":35607,"PHASE3":35613,"PHASE4":35615,"NA":35617},{"trials":35604,"activeCount":103},[],{"trials":35606,"activeCount":103},[],{"trials":35608,"activeCount":103},[35609],{"nctId":5211,"briefTitle":5212,"status":168,"phases":35610,"primaryCompletion":5214,"completion":5214,"start":5215,"enrollment":5216,"conditions":35611,"interventions":35612},[91,92],[543],[663,2916,5219,5220,5221],{"trials":35614,"activeCount":103},[],{"trials":35616,"activeCount":103},[],{"trials":35618,"activeCount":103},[],{"intervention":5221,"totalTrials":302,"cells":35620},{"EARLY_PHASE1":35621,"PHASE1":35623,"PHASE2":35625,"PHASE3":35631,"PHASE4":35633,"NA":35635},{"trials":35622,"activeCount":103},[],{"trials":35624,"activeCount":103},[],{"trials":35626,"activeCount":103},[35627],{"nctId":5211,"briefTitle":5212,"status":168,"phases":35628,"primaryCompletion":5214,"completion":5214,"start":5215,"enrollment":5216,"conditions":35629,"interventions":35630},[91,92],[543],[663,2916,5219,5220,5221],{"trials":35632,"activeCount":103},[],{"trials":35634,"activeCount":103},[],{"trials":35636,"activeCount":103},[],{"intervention":21087,"totalTrials":302,"cells":35638},{"EARLY_PHASE1":35639,"PHASE1":35641,"PHASE2":35643,"PHASE3":35649,"PHASE4":35651,"NA":35653},{"trials":35640,"activeCount":103},[],{"trials":35642,"activeCount":103},[],{"trials":35644,"activeCount":103},[35645],{"nctId":21079,"briefTitle":21080,"status":111,"phases":35646,"primaryCompletion":577,"completion":577,"start":10923,"enrollment":525,"conditions":35647,"interventions":35648},[92],[21083,9108,9106,21084,21085],[21070,21087,21088,21089],{"trials":35650,"activeCount":103},[],{"trials":35652,"activeCount":103},[],{"trials":35654,"activeCount":103},[],{"intervention":21088,"totalTrials":302,"cells":35656},{"EARLY_PHASE1":35657,"PHASE1":35659,"PHASE2":35661,"PHASE3":35667,"PHASE4":35669,"NA":35671},{"trials":35658,"activeCount":103},[],{"trials":35660,"activeCount":103},[],{"trials":35662,"activeCount":103},[35663],{"nctId":21079,"briefTitle":21080,"status":111,"phases":35664,"primaryCompletion":577,"completion":577,"start":10923,"enrollment":525,"conditions":35665,"interventions":35666},[92],[21083,9108,9106,21084,21085],[21070,21087,21088,21089],{"trials":35668,"activeCount":103},[],{"trials":35670,"activeCount":103},[],{"trials":35672,"activeCount":103},[],{"intervention":21089,"totalTrials":302,"cells":35674},{"EARLY_PHASE1":35675,"PHASE1":35677,"PHASE2":35679,"PHASE3":35685,"PHASE4":35687,"NA":35689},{"trials":35676,"activeCount":103},[],{"trials":35678,"activeCount":103},[],{"trials":35680,"activeCount":103},[35681],{"nctId":21079,"briefTitle":21080,"status":111,"phases":35682,"primaryCompletion":577,"completion":577,"start":10923,"enrollment":525,"conditions":35683,"interventions":35684},[92],[21083,9108,9106,21084,21085],[21070,21087,21088,21089],{"trials":35686,"activeCount":103},[],{"trials":35688,"activeCount":103},[],{"trials":35690,"activeCount":103},[],{"intervention":35692,"totalTrials":302,"cells":35693},"PF-06835919 Low Dose",{"EARLY_PHASE1":35694,"PHASE1":35696,"PHASE2":35698,"PHASE3":35709,"PHASE4":35711,"NA":35713},{"trials":35695,"activeCount":103},[],{"trials":35697,"activeCount":103},[],{"trials":35699,"activeCount":103},[35700],{"nctId":35701,"briefTitle":35702,"status":111,"phases":35703,"primaryCompletion":35704,"completion":16094,"start":35705,"enrollment":336,"conditions":35706,"interventions":35707},"NCT03256526","6-week Safety and PD Study in Adults With NAFLD",[92],"2018-03-30","2017-09-27",[29215],[35692,35708],"PF-06835919 High Dose",{"trials":35710,"activeCount":103},[],{"trials":35712,"activeCount":103},[],{"trials":35714,"activeCount":103},[],{"intervention":35708,"totalTrials":302,"cells":35716},{"EARLY_PHASE1":35717,"PHASE1":35719,"PHASE2":35721,"PHASE3":35727,"PHASE4":35729,"NA":35731},{"trials":35718,"activeCount":103},[],{"trials":35720,"activeCount":103},[],{"trials":35722,"activeCount":103},[35723],{"nctId":35701,"briefTitle":35702,"status":111,"phases":35724,"primaryCompletion":35704,"completion":16094,"start":35705,"enrollment":336,"conditions":35725,"interventions":35726},[92],[29215],[35692,35708],{"trials":35728,"activeCount":103},[],{"trials":35730,"activeCount":103},[],{"trials":35732,"activeCount":103},[],{"intervention":8467,"totalTrials":302,"cells":35734},{"EARLY_PHASE1":35735,"PHASE1":35737,"PHASE2":35739,"PHASE3":35745,"PHASE4":35747,"NA":35749},{"trials":35736,"activeCount":103},[],{"trials":35738,"activeCount":103},[],{"trials":35740,"activeCount":103},[35741],{"nctId":8460,"briefTitle":8461,"status":168,"phases":35742,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":35,"conditions":35743,"interventions":35744},[91,92],[2914],[8435,8467,8468],{"trials":35746,"activeCount":103},[],{"trials":35748,"activeCount":103},[],{"trials":35750,"activeCount":103},[],{"intervention":8468,"totalTrials":302,"cells":35752},{"EARLY_PHASE1":35753,"PHASE1":35755,"PHASE2":35757,"PHASE3":35763,"PHASE4":35765,"NA":35767},{"trials":35754,"activeCount":103},[],{"trials":35756,"activeCount":103},[],{"trials":35758,"activeCount":103},[35759],{"nctId":8460,"briefTitle":8461,"status":168,"phases":35760,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":35,"conditions":35761,"interventions":35762},[91,92],[2914],[8435,8467,8468],{"trials":35764,"activeCount":103},[],{"trials":35766,"activeCount":103},[],{"trials":35768,"activeCount":103},[],{"intervention":35770,"totalTrials":302,"cells":35771},"ICA-105665",{"EARLY_PHASE1":35772,"PHASE1":35774,"PHASE2":35776,"PHASE3":35784,"PHASE4":35786,"NA":35788},{"trials":35773,"activeCount":103},[],{"trials":35775,"activeCount":103},[],{"trials":35777,"activeCount":103},[35778],{"nctId":35779,"briefTitle":35780,"status":168,"phases":35781,"primaryCompletion":560,"completion":560,"start":4833,"enrollment":3254,"conditions":35782,"interventions":35783},"NCT00979004","A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients",[92],[26285],[35770],{"trials":35785,"activeCount":103},[],{"trials":35787,"activeCount":103},[],{"trials":35789,"activeCount":103},[],{"intervention":35791,"totalTrials":302,"cells":35792},"PF-06473871",{"EARLY_PHASE1":35793,"PHASE1":35795,"PHASE2":35797,"PHASE3":35806,"PHASE4":35808,"NA":35810},{"trials":35794,"activeCount":103},[],{"trials":35796,"activeCount":103},[],{"trials":35798,"activeCount":103},[35799],{"nctId":35800,"briefTitle":35801,"status":111,"phases":35802,"primaryCompletion":11356,"completion":11356,"start":2449,"enrollment":28283,"conditions":35803,"interventions":35805},"NCT01730339","Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery",[92],[35804],"Reduction of Hypertrophic Skin Scarring",[35791,35791],{"trials":35807,"activeCount":103},[],{"trials":35809,"activeCount":103},[],{"trials":35811,"activeCount":103},[],{"intervention":35813,"totalTrials":302,"cells":35814},"Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3",{"EARLY_PHASE1":35815,"PHASE1":35817,"PHASE2":35819,"PHASE3":35829,"PHASE4":35831,"NA":35833},{"trials":35816,"activeCount":103},[],{"trials":35818,"activeCount":103},[],{"trials":35820,"activeCount":103},[35821],{"nctId":35822,"briefTitle":35823,"status":168,"phases":35824,"primaryCompletion":35825,"completion":35825,"start":325,"enrollment":4369,"conditions":35826,"interventions":35827},"NCT04126031","Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.",[92],"2022-12-30",[7322],[35813,35828],"Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3",{"trials":35830,"activeCount":103},[],{"trials":35832,"activeCount":103},[],{"trials":35834,"activeCount":103},[],{"intervention":35828,"totalTrials":302,"cells":35836},{"EARLY_PHASE1":35837,"PHASE1":35839,"PHASE2":35841,"PHASE3":35847,"PHASE4":35849,"NA":35851},{"trials":35838,"activeCount":103},[],{"trials":35840,"activeCount":103},[],{"trials":35842,"activeCount":103},[35843],{"nctId":35822,"briefTitle":35823,"status":168,"phases":35844,"primaryCompletion":35825,"completion":35825,"start":325,"enrollment":4369,"conditions":35845,"interventions":35846},[92],[7322],[35813,35828],{"trials":35848,"activeCount":103},[],{"trials":35850,"activeCount":103},[],{"trials":35852,"activeCount":103},[],{"intervention":30670,"totalTrials":302,"cells":35854},{"EARLY_PHASE1":35855,"PHASE1":35857,"PHASE2":35859,"PHASE3":35865,"PHASE4":35867,"NA":35869},{"trials":35856,"activeCount":103},[],{"trials":35858,"activeCount":103},[],{"trials":35860,"activeCount":103},[35861],{"nctId":30663,"briefTitle":30664,"status":111,"phases":35862,"primaryCompletion":3314,"completion":3314,"start":3610,"enrollment":30666,"conditions":35863,"interventions":35864},[92],[30668],[30670,30648],{"trials":35866,"activeCount":103},[],{"trials":35868,"activeCount":103},[],{"trials":35870,"activeCount":103},[],{"intervention":35872,"totalTrials":302,"cells":35873},"AG2037",{"EARLY_PHASE1":35874,"PHASE1":35876,"PHASE2":35878,"PHASE3":35886,"PHASE4":35888,"NA":35890},{"trials":35875,"activeCount":103},[],{"trials":35877,"activeCount":103},[],{"trials":35879,"activeCount":103},[35880],{"nctId":35881,"briefTitle":35882,"status":649,"phases":35883,"start":7675,"enrollment":103,"conditions":35884,"interventions":35885},"NCT00090701","A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer",[92],[946],[35872],{"trials":35887,"activeCount":103},[],{"trials":35889,"activeCount":103},[],{"trials":35891,"activeCount":103},[],{"intervention":2456,"totalTrials":302,"cells":35893},{"EARLY_PHASE1":35894,"PHASE1":35896,"PHASE2":35898,"PHASE3":35904,"PHASE4":35906,"NA":35908},{"trials":35895,"activeCount":103},[],{"trials":35897,"activeCount":103},[],{"trials":35899,"activeCount":103},[35900],{"nctId":2446,"briefTitle":2447,"status":168,"phases":35901,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":562,"conditions":35902,"interventions":35903},[92],[2452,2453],[2455,2456,1243],{"trials":35905,"activeCount":103},[],{"trials":35907,"activeCount":103},[],{"trials":35909,"activeCount":103},[],{"intervention":35911,"totalTrials":302,"cells":35912},"CP-424,391",{"EARLY_PHASE1":35913,"PHASE1":35915,"PHASE2":35917,"PHASE3":35927,"PHASE4":35929,"NA":35931},{"trials":35914,"activeCount":103},[],{"trials":35916,"activeCount":103},[],{"trials":35918,"activeCount":103},[35919],{"nctId":35920,"briefTitle":35921,"status":168,"phases":35922,"primaryCompletion":11782,"completion":11782,"start":23644,"enrollment":2229,"conditions":35923,"interventions":35926},"NCT00527046","Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults",[92],[35924,35925],"Aging","Frail Older Adults",[35911],{"trials":35928,"activeCount":103},[],{"trials":35930,"activeCount":103},[],{"trials":35932,"activeCount":103},[],{"intervention":35934,"totalTrials":302,"cells":35935},"PF-01913539 5 mg",{"EARLY_PHASE1":35936,"PHASE1":35938,"PHASE2":35940,"PHASE3":35950,"PHASE4":35952,"NA":35954},{"trials":35937,"activeCount":103},[],{"trials":35939,"activeCount":103},[],{"trials":35941,"activeCount":103},[35942],{"nctId":35943,"briefTitle":35944,"status":649,"phases":35945,"primaryCompletion":2450,"completion":3334,"start":4206,"enrollment":103,"conditions":35946,"interventions":35949},"NCT01066481","A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease",[92],[17728,35947,17711,35948],"Dementia","Investigational Drug",[35934,35934],{"trials":35951,"activeCount":103},[],{"trials":35953,"activeCount":103},[],{"trials":35955,"activeCount":103},[],{"intervention":35957,"totalTrials":302,"cells":35958},"Maraviroc",{"EARLY_PHASE1":35959,"PHASE1":35961,"PHASE2":35963,"PHASE3":35972,"PHASE4":35974,"NA":35976},{"trials":35960,"activeCount":103},[],{"trials":35962,"activeCount":103},[],{"trials":35964,"activeCount":103},[35965],{"nctId":35966,"briefTitle":35967,"status":168,"phases":35968,"primaryCompletion":4665,"completion":4665,"start":1701,"enrollment":1326,"conditions":35969,"interventions":35970},"NCT00427934","Maraviroc in Rheumatoid Arthritis",[92],[4514],[35957,35971],"Maraviroc Placebo",{"trials":35973,"activeCount":103},[],{"trials":35975,"activeCount":103},[],{"trials":35977,"activeCount":103},[],{"intervention":35971,"totalTrials":302,"cells":35979},{"EARLY_PHASE1":35980,"PHASE1":35982,"PHASE2":35984,"PHASE3":35990,"PHASE4":35992,"NA":35994},{"trials":35981,"activeCount":103},[],{"trials":35983,"activeCount":103},[],{"trials":35985,"activeCount":103},[35986],{"nctId":35966,"briefTitle":35967,"status":168,"phases":35987,"primaryCompletion":4665,"completion":4665,"start":1701,"enrollment":1326,"conditions":35988,"interventions":35989},[92],[4514],[35957,35971],{"trials":35991,"activeCount":103},[],{"trials":35993,"activeCount":103},[],{"trials":35995,"activeCount":103},[],{"intervention":35997,"totalTrials":302,"cells":35998},"tofacitinib ointment 20 mg\u002Fg",{"EARLY_PHASE1":35999,"PHASE1":36001,"PHASE2":36003,"PHASE3":36014,"PHASE4":36016,"NA":36018},{"trials":36000,"activeCount":103},[],{"trials":36002,"activeCount":103},[],{"trials":36004,"activeCount":103},[36005],{"nctId":36006,"briefTitle":36007,"status":111,"phases":36008,"primaryCompletion":9572,"completion":9572,"start":6198,"enrollment":36009,"conditions":36010,"interventions":36012},"NCT01831466","Tofacitinib Ointment For Chronic Plaque Psoriasis",[92],476,[36011,4401],"Psoriasis Vulgaris",[35997,36013,35997,36013],"tofacitinib ointment 10 mg\u002Fg",{"trials":36015,"activeCount":103},[],{"trials":36017,"activeCount":103},[],{"trials":36019,"activeCount":103},[],{"intervention":36013,"totalTrials":302,"cells":36021},{"EARLY_PHASE1":36022,"PHASE1":36024,"PHASE2":36026,"PHASE3":36032,"PHASE4":36034,"NA":36036},{"trials":36023,"activeCount":103},[],{"trials":36025,"activeCount":103},[],{"trials":36027,"activeCount":103},[36028],{"nctId":36006,"briefTitle":36007,"status":111,"phases":36029,"primaryCompletion":9572,"completion":9572,"start":6198,"enrollment":36009,"conditions":36030,"interventions":36031},[92],[36011,4401],[35997,36013,35997,36013],{"trials":36033,"activeCount":103},[],{"trials":36035,"activeCount":103},[],{"trials":36037,"activeCount":103},[],{"intervention":11318,"totalTrials":302,"cells":36039},{"EARLY_PHASE1":36040,"PHASE1":36042,"PHASE2":36044,"PHASE3":36050,"PHASE4":36052,"NA":36054},{"trials":36041,"activeCount":103},[],{"trials":36043,"activeCount":103},[],{"trials":36045,"activeCount":103},[36046],{"nctId":11311,"briefTitle":11312,"status":168,"phases":36047,"completion":11314,"start":11315,"enrollment":3075,"conditions":36048,"interventions":36049},[92],[11282],[11309,11318],{"trials":36051,"activeCount":103},[],{"trials":36053,"activeCount":103},[],{"trials":36055,"activeCount":103},[],{"intervention":36057,"totalTrials":302,"cells":36058},"(CP-6890,550) Tofacitinib",{"EARLY_PHASE1":36059,"PHASE1":36061,"PHASE2":36063,"PHASE3":36072,"PHASE4":36074,"NA":36076},{"trials":36060,"activeCount":103},[],{"trials":36062,"activeCount":103},[],{"trials":36064,"activeCount":103},[36065],{"nctId":36066,"briefTitle":36067,"status":111,"phases":36068,"primaryCompletion":18769,"completion":18769,"start":4680,"enrollment":1268,"conditions":36069,"interventions":36070},"NCT01710046","Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis",[92],[26842],[36057,36071],"(CP-690,550) Tofacitinib",{"trials":36073,"activeCount":103},[],{"trials":36075,"activeCount":103},[],{"trials":36077,"activeCount":103},[],{"intervention":36071,"totalTrials":302,"cells":36079},{"EARLY_PHASE1":36080,"PHASE1":36082,"PHASE2":36084,"PHASE3":36090,"PHASE4":36092,"NA":36094},{"trials":36081,"activeCount":103},[],{"trials":36083,"activeCount":103},[],{"trials":36085,"activeCount":103},[36086],{"nctId":36066,"briefTitle":36067,"status":111,"phases":36087,"primaryCompletion":18769,"completion":18769,"start":4680,"enrollment":1268,"conditions":36088,"interventions":36089},[92],[26842],[36057,36071],{"trials":36091,"activeCount":103},[],{"trials":36093,"activeCount":103},[],{"trials":36095,"activeCount":103},[],{"intervention":36097,"totalTrials":302,"cells":36098},"PF-06826647 100 mg QD",{"EARLY_PHASE1":36099,"PHASE1":36101,"PHASE2":36103,"PHASE3":36115,"PHASE4":36117,"NA":36119},{"trials":36100,"activeCount":103},[],{"trials":36102,"activeCount":103},[],{"trials":36104,"activeCount":103},[36105],{"nctId":36106,"briefTitle":36107,"status":649,"phases":36108,"primaryCompletion":8037,"completion":8037,"start":36109,"enrollment":103,"conditions":36110,"interventions":36111},"NCT04209556","A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis",[92],"2020-09-30",[1532],[36097,36112,36113,36114],"PF-06826647 300 mg QD","PF-06826647 600 mg QD","PF-6826647 400 mg QD",{"trials":36116,"activeCount":103},[],{"trials":36118,"activeCount":103},[],{"trials":36120,"activeCount":103},[],{"intervention":36112,"totalTrials":302,"cells":36122},{"EARLY_PHASE1":36123,"PHASE1":36125,"PHASE2":36127,"PHASE3":36133,"PHASE4":36135,"NA":36137},{"trials":36124,"activeCount":103},[],{"trials":36126,"activeCount":103},[],{"trials":36128,"activeCount":103},[36129],{"nctId":36106,"briefTitle":36107,"status":649,"phases":36130,"primaryCompletion":8037,"completion":8037,"start":36109,"enrollment":103,"conditions":36131,"interventions":36132},[92],[1532],[36097,36112,36113,36114],{"trials":36134,"activeCount":103},[],{"trials":36136,"activeCount":103},[],{"trials":36138,"activeCount":103},[],{"intervention":36113,"totalTrials":302,"cells":36140},{"EARLY_PHASE1":36141,"PHASE1":36143,"PHASE2":36145,"PHASE3":36151,"PHASE4":36153,"NA":36155},{"trials":36142,"activeCount":103},[],{"trials":36144,"activeCount":103},[],{"trials":36146,"activeCount":103},[36147],{"nctId":36106,"briefTitle":36107,"status":649,"phases":36148,"primaryCompletion":8037,"completion":8037,"start":36109,"enrollment":103,"conditions":36149,"interventions":36150},[92],[1532],[36097,36112,36113,36114],{"trials":36152,"activeCount":103},[],{"trials":36154,"activeCount":103},[],{"trials":36156,"activeCount":103},[],{"intervention":36114,"totalTrials":302,"cells":36158},{"EARLY_PHASE1":36159,"PHASE1":36161,"PHASE2":36163,"PHASE3":36169,"PHASE4":36171,"NA":36173},{"trials":36160,"activeCount":103},[],{"trials":36162,"activeCount":103},[],{"trials":36164,"activeCount":103},[36165],{"nctId":36106,"briefTitle":36107,"status":649,"phases":36166,"primaryCompletion":8037,"completion":8037,"start":36109,"enrollment":103,"conditions":36167,"interventions":36168},[92],[1532],[36097,36112,36113,36114],{"trials":36170,"activeCount":103},[],{"trials":36172,"activeCount":103},[],{"trials":36174,"activeCount":103},[],{"intervention":28194,"totalTrials":302,"cells":36176},{"EARLY_PHASE1":36177,"PHASE1":36179,"PHASE2":36181,"PHASE3":36187,"PHASE4":36189,"NA":36191},{"trials":36178,"activeCount":103},[],{"trials":36180,"activeCount":103},[],{"trials":36182,"activeCount":103},[36183],{"nctId":28189,"briefTitle":28190,"status":111,"phases":36184,"primaryCompletion":6208,"completion":6198,"start":540,"enrollment":12141,"conditions":36185,"interventions":36186},[92],[12981],[28194,28195,28196,28194,28158,28158,28158],{"trials":36188,"activeCount":103},[],{"trials":36190,"activeCount":103},[],{"trials":36192,"activeCount":103},[],{"intervention":28195,"totalTrials":302,"cells":36194},{"EARLY_PHASE1":36195,"PHASE1":36197,"PHASE2":36199,"PHASE3":36205,"PHASE4":36207,"NA":36209},{"trials":36196,"activeCount":103},[],{"trials":36198,"activeCount":103},[],{"trials":36200,"activeCount":103},[36201],{"nctId":28189,"briefTitle":28190,"status":111,"phases":36202,"primaryCompletion":6208,"completion":6198,"start":540,"enrollment":12141,"conditions":36203,"interventions":36204},[92],[12981],[28194,28195,28196,28194,28158,28158,28158],{"trials":36206,"activeCount":103},[],{"trials":36208,"activeCount":103},[],{"trials":36210,"activeCount":103},[],{"intervention":28196,"totalTrials":302,"cells":36212},{"EARLY_PHASE1":36213,"PHASE1":36215,"PHASE2":36217,"PHASE3":36223,"PHASE4":36225,"NA":36227},{"trials":36214,"activeCount":103},[],{"trials":36216,"activeCount":103},[],{"trials":36218,"activeCount":103},[36219],{"nctId":28189,"briefTitle":28190,"status":111,"phases":36220,"primaryCompletion":6208,"completion":6198,"start":540,"enrollment":12141,"conditions":36221,"interventions":36222},[92],[12981],[28194,28195,28196,28194,28158,28158,28158],{"trials":36224,"activeCount":103},[],{"trials":36226,"activeCount":103},[],{"trials":36228,"activeCount":103},[],{"intervention":29806,"totalTrials":302,"cells":36230},{"EARLY_PHASE1":36231,"PHASE1":36233,"PHASE2":36235,"PHASE3":36241,"PHASE4":36243,"NA":36245},{"trials":36232,"activeCount":103},[],{"trials":36234,"activeCount":103},[],{"trials":36236,"activeCount":103},[36237],{"nctId":29800,"briefTitle":18434,"status":111,"phases":36238,"primaryCompletion":29802,"completion":29802,"start":29803,"enrollment":28923,"conditions":36239,"interventions":36240},[92],[18439],[18441,18442,18443,29806],{"trials":36242,"activeCount":103},[],{"trials":36244,"activeCount":103},[],{"trials":36246,"activeCount":103},[],{"intervention":36248,"totalTrials":302,"cells":36249},"PF-06823859 low",{"EARLY_PHASE1":36250,"PHASE1":36252,"PHASE2":36254,"PHASE3":36264,"PHASE4":36266,"NA":36268},{"trials":36251,"activeCount":103},[],{"trials":36253,"activeCount":103},[],{"trials":36255,"activeCount":103},[36256],{"nctId":36257,"briefTitle":36258,"status":111,"phases":36259,"primaryCompletion":1070,"completion":36260,"start":5091,"enrollment":4755,"conditions":36261,"interventions":36262},"NCT03181893","A Study In Adults With Moderate To Severe Dermatomyositis",[92],"2022-11-28",[5319],[36248,36263],"PF-06823859 high",{"trials":36265,"activeCount":103},[],{"trials":36267,"activeCount":103},[],{"trials":36269,"activeCount":103},[],{"intervention":36263,"totalTrials":302,"cells":36271},{"EARLY_PHASE1":36272,"PHASE1":36274,"PHASE2":36276,"PHASE3":36282,"PHASE4":36284,"NA":36286},{"trials":36273,"activeCount":103},[],{"trials":36275,"activeCount":103},[],{"trials":36277,"activeCount":103},[36278],{"nctId":36257,"briefTitle":36258,"status":111,"phases":36279,"primaryCompletion":1070,"completion":36260,"start":5091,"enrollment":4755,"conditions":36280,"interventions":36281},[92],[5319],[36248,36263],{"trials":36283,"activeCount":103},[],{"trials":36285,"activeCount":103},[],{"trials":36287,"activeCount":103},[],{"intervention":29955,"totalTrials":302,"cells":36289},{"EARLY_PHASE1":36290,"PHASE1":36292,"PHASE2":36294,"PHASE3":36300,"PHASE4":36302,"NA":36304},{"trials":36291,"activeCount":103},[],{"trials":36293,"activeCount":103},[],{"trials":36295,"activeCount":103},[36296],{"nctId":29950,"briefTitle":29951,"status":111,"phases":36297,"primaryCompletion":12307,"completion":12307,"start":6208,"enrollment":12803,"conditions":36298,"interventions":36299},[92],[15038],[29955,29956,29957],{"trials":36301,"activeCount":103},[],{"trials":36303,"activeCount":103},[],{"trials":36305,"activeCount":103},[],{"intervention":31017,"totalTrials":302,"cells":36307},{"EARLY_PHASE1":36308,"PHASE1":36310,"PHASE2":36312,"PHASE3":36318,"PHASE4":36320,"NA":36322},{"trials":36309,"activeCount":103},[],{"trials":36311,"activeCount":103},[],{"trials":36313,"activeCount":103},[36314],{"nctId":31013,"briefTitle":31008,"status":111,"phases":36315,"primaryCompletion":1701,"completion":1701,"start":8170,"enrollment":2240,"conditions":36316,"interventions":36317},[92],[28946],[30998,31017],{"trials":36319,"activeCount":103},[],{"trials":36321,"activeCount":103},[],{"trials":36323,"activeCount":103},[],{"intervention":8481,"totalTrials":302,"cells":36325},{"EARLY_PHASE1":36326,"PHASE1":36328,"PHASE2":36330,"PHASE3":36336,"PHASE4":36338,"NA":36340},{"trials":36327,"activeCount":103},[],{"trials":36329,"activeCount":103},[],{"trials":36331,"activeCount":103},[36332],{"nctId":8470,"briefTitle":8471,"status":168,"phases":36333,"primaryCompletion":2122,"completion":8473,"start":8474,"enrollment":870,"conditions":36334,"interventions":36335},[91,92],[1653,8476,7728,8477,8478,8479],[8435,8481],{"trials":36337,"activeCount":103},[],{"trials":36339,"activeCount":103},[],{"trials":36341,"activeCount":103},[],{"intervention":36343,"totalTrials":302,"cells":36344},"1 mg QD to 15 mg QD PF-06649751",{"EARLY_PHASE1":36345,"PHASE1":36347,"PHASE2":36349,"PHASE3":36365,"PHASE4":36367,"NA":36369},{"trials":36346,"activeCount":103},[],{"trials":36348,"activeCount":103},[],{"trials":36350,"activeCount":103},[36351],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36354,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36355,"interventions":36357},"NCT03185481","Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations",[92],[36356],"Parkinson's Disease With Motor Fluctuations",[36343,36358,36359,36360,36361,36362,36363,36364],"3 mg QD to 15 mg QD PF-06649751","7 mg QD to 15 mg QD PF-06649751","15 mg QD PF-06649751","1 mg QD to 7 mg QD PF-06649751","3 mg QD to 7 mg QD PF-06649751","7 mg QD to 7 mg QD PF-06649751","15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD",{"trials":36366,"activeCount":103},[],{"trials":36368,"activeCount":103},[],{"trials":36370,"activeCount":103},[],{"intervention":36358,"totalTrials":302,"cells":36372},{"EARLY_PHASE1":36373,"PHASE1":36375,"PHASE2":36377,"PHASE3":36383,"PHASE4":36385,"NA":36387},{"trials":36374,"activeCount":103},[],{"trials":36376,"activeCount":103},[],{"trials":36378,"activeCount":103},[36379],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36380,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36381,"interventions":36382},[92],[36356],[36343,36358,36359,36360,36361,36362,36363,36364],{"trials":36384,"activeCount":103},[],{"trials":36386,"activeCount":103},[],{"trials":36388,"activeCount":103},[],{"intervention":36359,"totalTrials":302,"cells":36390},{"EARLY_PHASE1":36391,"PHASE1":36393,"PHASE2":36395,"PHASE3":36401,"PHASE4":36403,"NA":36405},{"trials":36392,"activeCount":103},[],{"trials":36394,"activeCount":103},[],{"trials":36396,"activeCount":103},[36397],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36398,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36399,"interventions":36400},[92],[36356],[36343,36358,36359,36360,36361,36362,36363,36364],{"trials":36402,"activeCount":103},[],{"trials":36404,"activeCount":103},[],{"trials":36406,"activeCount":103},[],{"intervention":36360,"totalTrials":302,"cells":36408},{"EARLY_PHASE1":36409,"PHASE1":36411,"PHASE2":36413,"PHASE3":36419,"PHASE4":36421,"NA":36423},{"trials":36410,"activeCount":103},[],{"trials":36412,"activeCount":103},[],{"trials":36414,"activeCount":103},[36415],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36416,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36417,"interventions":36418},[92],[36356],[36343,36358,36359,36360,36361,36362,36363,36364],{"trials":36420,"activeCount":103},[],{"trials":36422,"activeCount":103},[],{"trials":36424,"activeCount":103},[],{"intervention":36361,"totalTrials":302,"cells":36426},{"EARLY_PHASE1":36427,"PHASE1":36429,"PHASE2":36431,"PHASE3":36437,"PHASE4":36439,"NA":36441},{"trials":36428,"activeCount":103},[],{"trials":36430,"activeCount":103},[],{"trials":36432,"activeCount":103},[36433],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36434,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36435,"interventions":36436},[92],[36356],[36343,36358,36359,36360,36361,36362,36363,36364],{"trials":36438,"activeCount":103},[],{"trials":36440,"activeCount":103},[],{"trials":36442,"activeCount":103},[],{"intervention":36362,"totalTrials":302,"cells":36444},{"EARLY_PHASE1":36445,"PHASE1":36447,"PHASE2":36449,"PHASE3":36455,"PHASE4":36457,"NA":36459},{"trials":36446,"activeCount":103},[],{"trials":36448,"activeCount":103},[],{"trials":36450,"activeCount":103},[36451],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36452,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36453,"interventions":36454},[92],[36356],[36343,36358,36359,36360,36361,36362,36363,36364],{"trials":36456,"activeCount":103},[],{"trials":36458,"activeCount":103},[],{"trials":36460,"activeCount":103},[],{"intervention":36363,"totalTrials":302,"cells":36462},{"EARLY_PHASE1":36463,"PHASE1":36465,"PHASE2":36467,"PHASE3":36473,"PHASE4":36475,"NA":36477},{"trials":36464,"activeCount":103},[],{"trials":36466,"activeCount":103},[],{"trials":36468,"activeCount":103},[36469],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36470,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36471,"interventions":36472},[92],[36356],[36343,36358,36359,36360,36361,36362,36363,36364],{"trials":36474,"activeCount":103},[],{"trials":36476,"activeCount":103},[],{"trials":36478,"activeCount":103},[],{"intervention":36364,"totalTrials":302,"cells":36480},{"EARLY_PHASE1":36481,"PHASE1":36483,"PHASE2":36485,"PHASE3":36491,"PHASE4":36493,"NA":36495},{"trials":36482,"activeCount":103},[],{"trials":36484,"activeCount":103},[],{"trials":36486,"activeCount":103},[36487],{"nctId":36352,"briefTitle":36353,"status":168,"phases":36488,"primaryCompletion":11501,"completion":724,"start":18520,"enrollment":578,"conditions":36489,"interventions":36490},[92],[36356],[36343,36358,36359,36360,36361,36362,36363,36364],{"trials":36492,"activeCount":103},[],{"trials":36494,"activeCount":103},[],{"trials":36496,"activeCount":103},[],{"intervention":36498,"totalTrials":302,"cells":36499},"Main cohort (Cohort A): Ponsegromab low dose",{"EARLY_PHASE1":36500,"PHASE1":36502,"PHASE2":36504,"PHASE3":36520,"PHASE4":36522,"NA":36524},{"trials":36501,"activeCount":103},[],{"trials":36503,"activeCount":103},[],{"trials":36505,"activeCount":103},[36506],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36509,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36511,"interventions":36512},"NCT05492500","A Study of Ponsegromab in People With Heart Failure",[92],"2025-03-05",[6764],[36498,36513,36514,36515,36516,36517,36518,36519],"Main cohort (Cohort A): Ponsegromab medium dose","Main cohort (Cohort A): ponsegromab high dose","Open-label, PK Cohort (Cohort B): ponsegromab low dose","Open-label, PK Cohort (Cohort B): ponsegromab medium dose","Open-label, PK Cohort (Cohort B): ponsegromab high dose","Optional Cohort C: Ponsegromab low dose","Optional Cohort D: Ponsegromab high dose",{"trials":36521,"activeCount":103},[],{"trials":36523,"activeCount":103},[],{"trials":36525,"activeCount":103},[],{"intervention":36513,"totalTrials":302,"cells":36527},{"EARLY_PHASE1":36528,"PHASE1":36530,"PHASE2":36532,"PHASE3":36538,"PHASE4":36540,"NA":36542},{"trials":36529,"activeCount":103},[],{"trials":36531,"activeCount":103},[],{"trials":36533,"activeCount":103},[36534],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36535,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36536,"interventions":36537},[92],[6764],[36498,36513,36514,36515,36516,36517,36518,36519],{"trials":36539,"activeCount":103},[],{"trials":36541,"activeCount":103},[],{"trials":36543,"activeCount":103},[],{"intervention":36514,"totalTrials":302,"cells":36545},{"EARLY_PHASE1":36546,"PHASE1":36548,"PHASE2":36550,"PHASE3":36556,"PHASE4":36558,"NA":36560},{"trials":36547,"activeCount":103},[],{"trials":36549,"activeCount":103},[],{"trials":36551,"activeCount":103},[36552],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36553,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36554,"interventions":36555},[92],[6764],[36498,36513,36514,36515,36516,36517,36518,36519],{"trials":36557,"activeCount":103},[],{"trials":36559,"activeCount":103},[],{"trials":36561,"activeCount":103},[],{"intervention":36515,"totalTrials":302,"cells":36563},{"EARLY_PHASE1":36564,"PHASE1":36566,"PHASE2":36568,"PHASE3":36574,"PHASE4":36576,"NA":36578},{"trials":36565,"activeCount":103},[],{"trials":36567,"activeCount":103},[],{"trials":36569,"activeCount":103},[36570],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36571,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36572,"interventions":36573},[92],[6764],[36498,36513,36514,36515,36516,36517,36518,36519],{"trials":36575,"activeCount":103},[],{"trials":36577,"activeCount":103},[],{"trials":36579,"activeCount":103},[],{"intervention":36516,"totalTrials":302,"cells":36581},{"EARLY_PHASE1":36582,"PHASE1":36584,"PHASE2":36586,"PHASE3":36592,"PHASE4":36594,"NA":36596},{"trials":36583,"activeCount":103},[],{"trials":36585,"activeCount":103},[],{"trials":36587,"activeCount":103},[36588],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36589,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36590,"interventions":36591},[92],[6764],[36498,36513,36514,36515,36516,36517,36518,36519],{"trials":36593,"activeCount":103},[],{"trials":36595,"activeCount":103},[],{"trials":36597,"activeCount":103},[],{"intervention":36517,"totalTrials":302,"cells":36599},{"EARLY_PHASE1":36600,"PHASE1":36602,"PHASE2":36604,"PHASE3":36610,"PHASE4":36612,"NA":36614},{"trials":36601,"activeCount":103},[],{"trials":36603,"activeCount":103},[],{"trials":36605,"activeCount":103},[36606],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36607,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36608,"interventions":36609},[92],[6764],[36498,36513,36514,36515,36516,36517,36518,36519],{"trials":36611,"activeCount":103},[],{"trials":36613,"activeCount":103},[],{"trials":36615,"activeCount":103},[],{"intervention":36518,"totalTrials":302,"cells":36617},{"EARLY_PHASE1":36618,"PHASE1":36620,"PHASE2":36622,"PHASE3":36628,"PHASE4":36630,"NA":36632},{"trials":36619,"activeCount":103},[],{"trials":36621,"activeCount":103},[],{"trials":36623,"activeCount":103},[36624],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36625,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36626,"interventions":36627},[92],[6764],[36498,36513,36514,36515,36516,36517,36518,36519],{"trials":36629,"activeCount":103},[],{"trials":36631,"activeCount":103},[],{"trials":36633,"activeCount":103},[],{"intervention":36519,"totalTrials":302,"cells":36635},{"EARLY_PHASE1":36636,"PHASE1":36638,"PHASE2":36640,"PHASE3":36646,"PHASE4":36648,"NA":36650},{"trials":36637,"activeCount":103},[],{"trials":36639,"activeCount":103},[],{"trials":36641,"activeCount":103},[36642],{"nctId":36507,"briefTitle":36508,"status":168,"phases":36643,"primaryCompletion":36510,"completion":36510,"start":30467,"enrollment":12701,"conditions":36644,"interventions":36645},[92],[6764],[36498,36513,36514,36515,36516,36517,36518,36519],{"trials":36647,"activeCount":103},[],{"trials":36649,"activeCount":103},[],{"trials":36651,"activeCount":103},[],{"intervention":3768,"totalTrials":302,"cells":36653},{"EARLY_PHASE1":36654,"PHASE1":36656,"PHASE2":36658,"PHASE3":36664,"PHASE4":36666,"NA":36668},{"trials":36655,"activeCount":103},[],{"trials":36657,"activeCount":103},[],{"trials":36659,"activeCount":103},[36660],{"nctId":3760,"briefTitle":3761,"status":111,"phases":36661,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":36662,"interventions":36663},[92],[28],[3768,3769,3740,3770,3771],{"trials":36665,"activeCount":103},[],{"trials":36667,"activeCount":103},[],{"trials":36669,"activeCount":103},[],{"intervention":3769,"totalTrials":302,"cells":36671},{"EARLY_PHASE1":36672,"PHASE1":36674,"PHASE2":36676,"PHASE3":36682,"PHASE4":36684,"NA":36686},{"trials":36673,"activeCount":103},[],{"trials":36675,"activeCount":103},[],{"trials":36677,"activeCount":103},[36678],{"nctId":3760,"briefTitle":3761,"status":111,"phases":36679,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":36680,"interventions":36681},[92],[28],[3768,3769,3740,3770,3771],{"trials":36683,"activeCount":103},[],{"trials":36685,"activeCount":103},[],{"trials":36687,"activeCount":103},[],{"intervention":3771,"totalTrials":302,"cells":36689},{"EARLY_PHASE1":36690,"PHASE1":36692,"PHASE2":36694,"PHASE3":36700,"PHASE4":36702,"NA":36704},{"trials":36691,"activeCount":103},[],{"trials":36693,"activeCount":103},[],{"trials":36695,"activeCount":103},[36696],{"nctId":3760,"briefTitle":3761,"status":111,"phases":36697,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":36698,"interventions":36699},[92],[28],[3768,3769,3740,3770,3771],{"trials":36701,"activeCount":103},[],{"trials":36703,"activeCount":103},[],{"trials":36705,"activeCount":103},[],{"intervention":19178,"totalTrials":302,"cells":36707},{"EARLY_PHASE1":36708,"PHASE1":36710,"PHASE2":36712,"PHASE3":36718,"PHASE4":36720,"NA":36722},{"trials":36709,"activeCount":103},[],{"trials":36711,"activeCount":103},[],{"trials":36713,"activeCount":103},[36714],{"nctId":19171,"briefTitle":19172,"status":168,"phases":36715,"primaryCompletion":18058,"completion":18058,"start":19174,"enrollment":7411,"conditions":36716,"interventions":36717},[92],[8295],[8309,19177,19177,19178,19179,19180,19181,19182],{"trials":36719,"activeCount":103},[],{"trials":36721,"activeCount":103},[],{"trials":36723,"activeCount":103},[],{"intervention":19179,"totalTrials":302,"cells":36725},{"EARLY_PHASE1":36726,"PHASE1":36728,"PHASE2":36730,"PHASE3":36736,"PHASE4":36738,"NA":36740},{"trials":36727,"activeCount":103},[],{"trials":36729,"activeCount":103},[],{"trials":36731,"activeCount":103},[36732],{"nctId":19171,"briefTitle":19172,"status":168,"phases":36733,"primaryCompletion":18058,"completion":18058,"start":19174,"enrollment":7411,"conditions":36734,"interventions":36735},[92],[8295],[8309,19177,19177,19178,19179,19180,19181,19182],{"trials":36737,"activeCount":103},[],{"trials":36739,"activeCount":103},[],{"trials":36741,"activeCount":103},[],{"intervention":19181,"totalTrials":302,"cells":36743},{"EARLY_PHASE1":36744,"PHASE1":36746,"PHASE2":36748,"PHASE3":36754,"PHASE4":36756,"NA":36758},{"trials":36745,"activeCount":103},[],{"trials":36747,"activeCount":103},[],{"trials":36749,"activeCount":103},[36750],{"nctId":19171,"briefTitle":19172,"status":168,"phases":36751,"primaryCompletion":18058,"completion":18058,"start":19174,"enrollment":7411,"conditions":36752,"interventions":36753},[92],[8295],[8309,19177,19177,19178,19179,19180,19181,19182],{"trials":36755,"activeCount":103},[],{"trials":36757,"activeCount":103},[],{"trials":36759,"activeCount":103},[],{"intervention":19182,"totalTrials":302,"cells":36761},{"EARLY_PHASE1":36762,"PHASE1":36764,"PHASE2":36766,"PHASE3":36772,"PHASE4":36774,"NA":36776},{"trials":36763,"activeCount":103},[],{"trials":36765,"activeCount":103},[],{"trials":36767,"activeCount":103},[36768],{"nctId":19171,"briefTitle":19172,"status":168,"phases":36769,"primaryCompletion":18058,"completion":18058,"start":19174,"enrollment":7411,"conditions":36770,"interventions":36771},[92],[8295],[8309,19177,19177,19178,19179,19180,19181,19182],{"trials":36773,"activeCount":103},[],{"trials":36775,"activeCount":103},[],{"trials":36777,"activeCount":103},[],{"intervention":29625,"totalTrials":302,"cells":36779},{"EARLY_PHASE1":36780,"PHASE1":36782,"PHASE2":36784,"PHASE3":36790,"PHASE4":36792,"NA":36794},{"trials":36781,"activeCount":103},[],{"trials":36783,"activeCount":103},[],{"trials":36785,"activeCount":103},[36786],{"nctId":29618,"briefTitle":29619,"status":111,"phases":36787,"primaryCompletion":29621,"completion":29621,"start":29622,"enrollment":22666,"conditions":36788,"interventions":36789},[92],[17728],[29625,29626,29600,29612,29627],{"trials":36791,"activeCount":103},[],{"trials":36793,"activeCount":103},[],{"trials":36795,"activeCount":103},[],{"intervention":29626,"totalTrials":302,"cells":36797},{"EARLY_PHASE1":36798,"PHASE1":36800,"PHASE2":36802,"PHASE3":36808,"PHASE4":36810,"NA":36812},{"trials":36799,"activeCount":103},[],{"trials":36801,"activeCount":103},[],{"trials":36803,"activeCount":103},[36804],{"nctId":29618,"briefTitle":29619,"status":111,"phases":36805,"primaryCompletion":29621,"completion":29621,"start":29622,"enrollment":22666,"conditions":36806,"interventions":36807},[92],[17728],[29625,29626,29600,29612,29627],{"trials":36809,"activeCount":103},[],{"trials":36811,"activeCount":103},[],{"trials":36813,"activeCount":103},[],{"intervention":11327,"totalTrials":302,"cells":36815},{"EARLY_PHASE1":36816,"PHASE1":36818,"PHASE2":36820,"PHASE3":36826,"PHASE4":36828,"NA":36830},{"trials":36817,"activeCount":103},[],{"trials":36819,"activeCount":103},[],{"trials":36821,"activeCount":103},[36822],{"nctId":11320,"briefTitle":11321,"status":111,"phases":36823,"primaryCompletion":4666,"completion":524,"start":2660,"enrollment":11323,"conditions":36824,"interventions":36825},[92],[11282],[11326,11326,11273,11327,11327,11273],{"trials":36827,"activeCount":103},[],{"trials":36829,"activeCount":103},[],{"trials":36831,"activeCount":103},[],{"intervention":28203,"totalTrials":302,"cells":36833},{"EARLY_PHASE1":36834,"PHASE1":36836,"PHASE2":36838,"PHASE3":36844,"PHASE4":36846,"NA":36848},{"trials":36835,"activeCount":103},[],{"trials":36837,"activeCount":103},[],{"trials":36839,"activeCount":103},[36840],{"nctId":28198,"briefTitle":28199,"status":111,"phases":36841,"primaryCompletion":18026,"completion":4459,"start":3313,"enrollment":8013,"conditions":36842,"interventions":36843},[92],[12981,12980],[28203,28158,28203,28158,28203,28158,28204,28158,28203],{"trials":36845,"activeCount":103},[],{"trials":36847,"activeCount":103},[],{"trials":36849,"activeCount":103},[],{"intervention":28204,"totalTrials":302,"cells":36851},{"EARLY_PHASE1":36852,"PHASE1":36854,"PHASE2":36856,"PHASE3":36862,"PHASE4":36864,"NA":36866},{"trials":36853,"activeCount":103},[],{"trials":36855,"activeCount":103},[],{"trials":36857,"activeCount":103},[36858],{"nctId":28198,"briefTitle":28199,"status":111,"phases":36859,"primaryCompletion":18026,"completion":4459,"start":3313,"enrollment":8013,"conditions":36860,"interventions":36861},[92],[12981,12980],[28203,28158,28203,28158,28203,28158,28204,28158,28203],{"trials":36863,"activeCount":103},[],{"trials":36865,"activeCount":103},[],{"trials":36867,"activeCount":103},[],{"intervention":36869,"totalTrials":302,"cells":36870},"CVX-060 + sunitinib",{"EARLY_PHASE1":36871,"PHASE1":36873,"PHASE2":36875,"PHASE3":36883,"PHASE4":36885,"NA":36887},{"trials":36872,"activeCount":103},[],{"trials":36874,"activeCount":103},[],{"trials":36876,"activeCount":103},[36877],{"nctId":36878,"briefTitle":36879,"status":168,"phases":36880,"primaryCompletion":605,"completion":605,"start":4833,"enrollment":3229,"conditions":36881,"interventions":36882},"NCT00982657","A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma",[92],[338],[36869,36869,36869,36869,36869,4327],{"trials":36884,"activeCount":103},[],{"trials":36886,"activeCount":103},[],{"trials":36888,"activeCount":103},[],{"intervention":20102,"totalTrials":302,"cells":36890},{"EARLY_PHASE1":36891,"PHASE1":36893,"PHASE2":36895,"PHASE3":36901,"PHASE4":36903,"NA":36905},{"trials":36892,"activeCount":103},[],{"trials":36894,"activeCount":103},[],{"trials":36896,"activeCount":103},[36897],{"nctId":20096,"briefTitle":20097,"status":111,"phases":36898,"primaryCompletion":3839,"completion":3839,"start":4636,"enrollment":20099,"conditions":36899,"interventions":36900},[92],[12632],[20102,20103],{"trials":36902,"activeCount":103},[],{"trials":36904,"activeCount":103},[],{"trials":36906,"activeCount":103},[],{"intervention":36908,"totalTrials":302,"cells":36909},"CE-326,597 100 mg QD",{"EARLY_PHASE1":36910,"PHASE1":36912,"PHASE2":36914,"PHASE3":36927,"PHASE4":36929,"NA":36931},{"trials":36911,"activeCount":103},[],{"trials":36913,"activeCount":103},[],{"trials":36915,"activeCount":103},[36916],{"nctId":36917,"briefTitle":36918,"status":111,"phases":36919,"primaryCompletion":4645,"completion":4645,"start":4636,"enrollment":1402,"conditions":36920,"interventions":36923},"NCT00542009","A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight",[92],[36921,36922],"Weight Management","Treatment Of Obesity",[36908,36924,36925,36926],"CE-326,597 50 mg QD","CE-326,597 25 mg QD","CE-326,597 5mg QD",{"trials":36928,"activeCount":103},[],{"trials":36930,"activeCount":103},[],{"trials":36932,"activeCount":103},[],{"intervention":36924,"totalTrials":302,"cells":36934},{"EARLY_PHASE1":36935,"PHASE1":36937,"PHASE2":36939,"PHASE3":36945,"PHASE4":36947,"NA":36949},{"trials":36936,"activeCount":103},[],{"trials":36938,"activeCount":103},[],{"trials":36940,"activeCount":103},[36941],{"nctId":36917,"briefTitle":36918,"status":111,"phases":36942,"primaryCompletion":4645,"completion":4645,"start":4636,"enrollment":1402,"conditions":36943,"interventions":36944},[92],[36921,36922],[36908,36924,36925,36926],{"trials":36946,"activeCount":103},[],{"trials":36948,"activeCount":103},[],{"trials":36950,"activeCount":103},[],{"intervention":36925,"totalTrials":302,"cells":36952},{"EARLY_PHASE1":36953,"PHASE1":36955,"PHASE2":36957,"PHASE3":36963,"PHASE4":36965,"NA":36967},{"trials":36954,"activeCount":103},[],{"trials":36956,"activeCount":103},[],{"trials":36958,"activeCount":103},[36959],{"nctId":36917,"briefTitle":36918,"status":111,"phases":36960,"primaryCompletion":4645,"completion":4645,"start":4636,"enrollment":1402,"conditions":36961,"interventions":36962},[92],[36921,36922],[36908,36924,36925,36926],{"trials":36964,"activeCount":103},[],{"trials":36966,"activeCount":103},[],{"trials":36968,"activeCount":103},[],{"intervention":36926,"totalTrials":302,"cells":36970},{"EARLY_PHASE1":36971,"PHASE1":36973,"PHASE2":36975,"PHASE3":36981,"PHASE4":36983,"NA":36985},{"trials":36972,"activeCount":103},[],{"trials":36974,"activeCount":103},[],{"trials":36976,"activeCount":103},[36977],{"nctId":36917,"briefTitle":36918,"status":111,"phases":36978,"primaryCompletion":4645,"completion":4645,"start":4636,"enrollment":1402,"conditions":36979,"interventions":36980},[92],[36921,36922],[36908,36924,36925,36926],{"trials":36982,"activeCount":103},[],{"trials":36984,"activeCount":103},[],{"trials":36986,"activeCount":103},[],{"intervention":36988,"totalTrials":302,"cells":36989},"sertraline\u002F[S,S]-reboxetine",{"EARLY_PHASE1":36990,"PHASE1":36992,"PHASE2":36994,"PHASE3":37005,"PHASE4":37007,"NA":37009},{"trials":36991,"activeCount":103},[],{"trials":36993,"activeCount":103},[],{"trials":36995,"activeCount":103},[36996],{"nctId":36997,"briefTitle":36998,"status":111,"phases":36999,"completion":15716,"start":13902,"enrollment":37000,"conditions":37001,"interventions":37002},"NCT00636246","A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.",[92],510,[12847],[36988,36988,37003,37003,36988,36988,37004],"sertraline","[S,S]-reboxetine monotherapy",{"trials":37006,"activeCount":103},[],{"trials":37008,"activeCount":103},[],{"trials":37010,"activeCount":103},[],{"intervention":37004,"totalTrials":302,"cells":37012},{"EARLY_PHASE1":37013,"PHASE1":37015,"PHASE2":37017,"PHASE3":37023,"PHASE4":37025,"NA":37027},{"trials":37014,"activeCount":103},[],{"trials":37016,"activeCount":103},[],{"trials":37018,"activeCount":103},[37019],{"nctId":36997,"briefTitle":36998,"status":111,"phases":37020,"completion":15716,"start":13902,"enrollment":37000,"conditions":37021,"interventions":37022},[92],[12847],[36988,36988,37003,37003,36988,36988,37004],{"trials":37024,"activeCount":103},[],{"trials":37026,"activeCount":103},[],{"trials":37028,"activeCount":103},[],{"intervention":37030,"totalTrials":302,"cells":37031},"Group B streptoccous 6-valent polysaccharide conjugate vaccine",{"EARLY_PHASE1":37032,"PHASE1":37034,"PHASE2":37036,"PHASE3":37045,"PHASE4":37047,"NA":37049},{"trials":37033,"activeCount":103},[],{"trials":37035,"activeCount":103},[],{"trials":37037,"activeCount":103},[37038],{"nctId":37039,"briefTitle":37040,"status":111,"phases":37041,"primaryCompletion":37042,"completion":37042,"start":11567,"enrollment":9562,"conditions":37043,"interventions":37044},"NCT04258995","A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS",[92],"2020-09-15",[29183],[37030],{"trials":37046,"activeCount":103},[],{"trials":37048,"activeCount":103},[],{"trials":37050,"activeCount":103},[],{"intervention":31109,"totalTrials":302,"cells":37052},{"EARLY_PHASE1":37053,"PHASE1":37055,"PHASE2":37057,"PHASE3":37063,"PHASE4":37065,"NA":37067},{"trials":37054,"activeCount":103},[],{"trials":37056,"activeCount":103},[],{"trials":37058,"activeCount":103},[37059],{"nctId":31099,"briefTitle":31100,"status":111,"phases":37060,"primaryCompletion":31102,"completion":31103,"start":31104,"enrollment":31105,"conditions":37061,"interventions":37062},[92],[31107],[31109,31110,31111,31112],{"trials":37064,"activeCount":103},[],{"trials":37066,"activeCount":103},[],{"trials":37068,"activeCount":103},[],{"intervention":31110,"totalTrials":302,"cells":37070},{"EARLY_PHASE1":37071,"PHASE1":37073,"PHASE2":37075,"PHASE3":37081,"PHASE4":37083,"NA":37085},{"trials":37072,"activeCount":103},[],{"trials":37074,"activeCount":103},[],{"trials":37076,"activeCount":103},[37077],{"nctId":31099,"briefTitle":31100,"status":111,"phases":37078,"primaryCompletion":31102,"completion":31103,"start":31104,"enrollment":31105,"conditions":37079,"interventions":37080},[92],[31107],[31109,31110,31111,31112],{"trials":37082,"activeCount":103},[],{"trials":37084,"activeCount":103},[],{"trials":37086,"activeCount":103},[],{"intervention":31112,"totalTrials":302,"cells":37088},{"EARLY_PHASE1":37089,"PHASE1":37091,"PHASE2":37093,"PHASE3":37099,"PHASE4":37101,"NA":37103},{"trials":37090,"activeCount":103},[],{"trials":37092,"activeCount":103},[],{"trials":37094,"activeCount":103},[37095],{"nctId":31099,"briefTitle":31100,"status":111,"phases":37096,"primaryCompletion":31102,"completion":31103,"start":31104,"enrollment":31105,"conditions":37097,"interventions":37098},[92],[31107],[31109,31110,31111,31112],{"trials":37100,"activeCount":103},[],{"trials":37102,"activeCount":103},[],{"trials":37104,"activeCount":103},[],{"intervention":37106,"totalTrials":302,"cells":37107},"PF-06730512",{"EARLY_PHASE1":37108,"PHASE1":37110,"PHASE2":37112,"PHASE3":37122,"PHASE4":37124,"NA":37126},{"trials":37109,"activeCount":103},[],{"trials":37111,"activeCount":103},[],{"trials":37113,"activeCount":103},[37114],{"nctId":37115,"briefTitle":37116,"status":168,"phases":37117,"primaryCompletion":37118,"completion":37118,"start":181,"enrollment":8414,"conditions":37119,"interventions":37121},"NCT03448692","A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)",[92],"2023-02-14",[37120],"Focal Segmental Glomerulosclerosis (FSGS)",[37106],{"trials":37123,"activeCount":103},[],{"trials":37125,"activeCount":103},[],{"trials":37127,"activeCount":103},[],{"intervention":13400,"totalTrials":302,"cells":37129},{"EARLY_PHASE1":37130,"PHASE1":37132,"PHASE2":37134,"PHASE3":37140,"PHASE4":37142,"NA":37144},{"trials":37131,"activeCount":103},[],{"trials":37133,"activeCount":103},[],{"trials":37135,"activeCount":103},[37136],{"nctId":13392,"briefTitle":13393,"status":111,"phases":37137,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":37138,"interventions":37139},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":37141,"activeCount":103},[],{"trials":37143,"activeCount":103},[],{"trials":37145,"activeCount":103},[],{"intervention":13401,"totalTrials":302,"cells":37147},{"EARLY_PHASE1":37148,"PHASE1":37150,"PHASE2":37152,"PHASE3":37158,"PHASE4":37160,"NA":37162},{"trials":37149,"activeCount":103},[],{"trials":37151,"activeCount":103},[],{"trials":37153,"activeCount":103},[37154],{"nctId":13392,"briefTitle":13393,"status":111,"phases":37155,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":37156,"interventions":37157},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":37159,"activeCount":103},[],{"trials":37161,"activeCount":103},[],{"trials":37163,"activeCount":103},[],{"intervention":13402,"totalTrials":302,"cells":37165},{"EARLY_PHASE1":37166,"PHASE1":37168,"PHASE2":37170,"PHASE3":37176,"PHASE4":37178,"NA":37180},{"trials":37167,"activeCount":103},[],{"trials":37169,"activeCount":103},[],{"trials":37171,"activeCount":103},[37172],{"nctId":13392,"briefTitle":13393,"status":111,"phases":37173,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":37174,"interventions":37175},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":37177,"activeCount":103},[],{"trials":37179,"activeCount":103},[],{"trials":37181,"activeCount":103},[],{"intervention":13403,"totalTrials":302,"cells":37183},{"EARLY_PHASE1":37184,"PHASE1":37186,"PHASE2":37188,"PHASE3":37194,"PHASE4":37196,"NA":37198},{"trials":37185,"activeCount":103},[],{"trials":37187,"activeCount":103},[],{"trials":37189,"activeCount":103},[37190],{"nctId":13392,"briefTitle":13393,"status":111,"phases":37191,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":37192,"interventions":37193},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":37195,"activeCount":103},[],{"trials":37197,"activeCount":103},[],{"trials":37199,"activeCount":103},[],{"intervention":13404,"totalTrials":302,"cells":37201},{"EARLY_PHASE1":37202,"PHASE1":37204,"PHASE2":37206,"PHASE3":37212,"PHASE4":37214,"NA":37216},{"trials":37203,"activeCount":103},[],{"trials":37205,"activeCount":103},[],{"trials":37207,"activeCount":103},[37208],{"nctId":13392,"briefTitle":13393,"status":111,"phases":37209,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":37210,"interventions":37211},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":37213,"activeCount":103},[],{"trials":37215,"activeCount":103},[],{"trials":37217,"activeCount":103},[],{"intervention":13405,"totalTrials":302,"cells":37219},{"EARLY_PHASE1":37220,"PHASE1":37222,"PHASE2":37224,"PHASE3":37230,"PHASE4":37232,"NA":37234},{"trials":37221,"activeCount":103},[],{"trials":37223,"activeCount":103},[],{"trials":37225,"activeCount":103},[37226],{"nctId":13392,"briefTitle":13393,"status":111,"phases":37227,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":37228,"interventions":37229},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":37231,"activeCount":103},[],{"trials":37233,"activeCount":103},[],{"trials":37235,"activeCount":103},[],{"intervention":13406,"totalTrials":302,"cells":37237},{"EARLY_PHASE1":37238,"PHASE1":37240,"PHASE2":37242,"PHASE3":37248,"PHASE4":37250,"NA":37252},{"trials":37239,"activeCount":103},[],{"trials":37241,"activeCount":103},[],{"trials":37243,"activeCount":103},[37244],{"nctId":13392,"briefTitle":13393,"status":111,"phases":37245,"primaryCompletion":13395,"completion":13395,"start":13396,"enrollment":5152,"conditions":37246,"interventions":37247},[92],[13398,12882],[13400,13401,13402,13403,13404,13405,13406,13407,13401,13407,13402,13407,13404,13408,13401,13408,13402,13408,13404,13408,13406],{"trials":37249,"activeCount":103},[],{"trials":37251,"activeCount":103},[],{"trials":37253,"activeCount":103},[],{"intervention":37255,"totalTrials":302,"cells":37256},"SPK-9001",{"EARLY_PHASE1":37257,"PHASE1":37259,"PHASE2":37261,"PHASE3":37270,"PHASE4":37272,"NA":37274},{"trials":37258,"activeCount":103},[],{"trials":37260,"activeCount":103},[],{"trials":37262,"activeCount":103},[37263],{"nctId":37264,"briefTitle":37265,"status":111,"phases":37266,"primaryCompletion":18458,"completion":18458,"start":37267,"enrollment":498,"conditions":37268,"interventions":37269},"NCT02484092","A Gene Therapy Study for Hemophilia B",[92],"2015-11-18",[3552],[37255],{"trials":37271,"activeCount":103},[],{"trials":37273,"activeCount":103},[],{"trials":37275,"activeCount":103},[],{"intervention":28294,"totalTrials":302,"cells":37277},{"EARLY_PHASE1":37278,"PHASE1":37280,"PHASE2":37282,"PHASE3":37288,"PHASE4":37290,"NA":37292},{"trials":37279,"activeCount":103},[],{"trials":37281,"activeCount":103},[],{"trials":37283,"activeCount":103},[37284],{"nctId":28288,"briefTitle":28279,"status":111,"phases":37285,"primaryCompletion":28290,"completion":28290,"start":28291,"enrollment":8827,"conditions":37286,"interventions":37287},[92],[28285],[28254,28254,28294,28254],{"trials":37289,"activeCount":103},[],{"trials":37291,"activeCount":103},[],{"trials":37293,"activeCount":103},[],{"intervention":37295,"totalTrials":302,"cells":37296},"AG-013,958",{"EARLY_PHASE1":37297,"PHASE1":37299,"PHASE2":37301,"PHASE3":37310,"PHASE4":37312,"NA":37314},{"trials":37298,"activeCount":103},[],{"trials":37300,"activeCount":103},[],{"trials":37302,"activeCount":103},[37303],{"nctId":37304,"briefTitle":37305,"status":168,"phases":37306,"completion":12773,"start":11666,"enrollment":33605,"conditions":37307,"interventions":37309},"NCT00090532","A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration",[91,92],[37308],"Age-Related Macular Degeneration",[37295],{"trials":37311,"activeCount":103},[],{"trials":37313,"activeCount":103},[],{"trials":37315,"activeCount":103},[],{"intervention":11339,"totalTrials":302,"cells":37317},{"EARLY_PHASE1":37318,"PHASE1":37320,"PHASE2":37322,"PHASE3":37328,"PHASE4":37330,"NA":37332},{"trials":37319,"activeCount":103},[],{"trials":37321,"activeCount":103},[],{"trials":37323,"activeCount":103},[37324],{"nctId":11329,"briefTitle":11330,"status":111,"phases":37325,"primaryCompletion":11332,"completion":11333,"start":11334,"enrollment":11335,"conditions":37326,"interventions":37327},[92],[11337],[11339,11340,11341,11273],{"trials":37329,"activeCount":103},[],{"trials":37331,"activeCount":103},[],{"trials":37333,"activeCount":103},[],{"intervention":11341,"totalTrials":302,"cells":37335},{"EARLY_PHASE1":37336,"PHASE1":37338,"PHASE2":37340,"PHASE3":37346,"PHASE4":37348,"NA":37350},{"trials":37337,"activeCount":103},[],{"trials":37339,"activeCount":103},[],{"trials":37341,"activeCount":103},[37342],{"nctId":11329,"briefTitle":11330,"status":111,"phases":37343,"primaryCompletion":11332,"completion":11333,"start":11334,"enrollment":11335,"conditions":37344,"interventions":37345},[92],[11337],[11339,11340,11341,11273],{"trials":37347,"activeCount":103},[],{"trials":37349,"activeCount":103},[],{"trials":37351,"activeCount":103},[],{"intervention":37353,"totalTrials":302,"cells":37354},"Anti-Beta Interferon",{"EARLY_PHASE1":37355,"PHASE1":37357,"PHASE2":37359,"PHASE3":37369,"PHASE4":37371,"NA":37373},{"trials":37356,"activeCount":103},[],{"trials":37358,"activeCount":103},[],{"trials":37360,"activeCount":103},[37361],{"nctId":37362,"briefTitle":37363,"status":111,"phases":37364,"primaryCompletion":37365,"completion":37365,"start":37366,"enrollment":1509,"conditions":37367,"interventions":37368},"NCT05192200","An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study",[92],"2023-11-20","2021-12-20",[5319],[37353],{"trials":37370,"activeCount":103},[],{"trials":37372,"activeCount":103},[],{"trials":37374,"activeCount":103},[],{"intervention":37376,"totalTrials":302,"cells":37377},"Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor",{"EARLY_PHASE1":37378,"PHASE1":37380,"PHASE2":37382,"PHASE3":37390,"PHASE4":37392,"NA":37394},{"trials":37379,"activeCount":103},[],{"trials":37381,"activeCount":103},[],{"trials":37383,"activeCount":103},[37384],{"nctId":37385,"briefTitle":37386,"status":111,"phases":37387,"primaryCompletion":1701,"completion":1701,"start":11736,"enrollment":748,"conditions":37388,"interventions":37389},"NCT00076011","Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma",[92],[4310],[37376],{"trials":37391,"activeCount":103},[],{"trials":37393,"activeCount":103},[],{"trials":37395,"activeCount":103},[],{"intervention":29389,"totalTrials":302,"cells":37397},{"EARLY_PHASE1":37398,"PHASE1":37400,"PHASE2":37402,"PHASE3":37408,"PHASE4":37410,"NA":37412},{"trials":37399,"activeCount":103},[],{"trials":37401,"activeCount":103},[],{"trials":37403,"activeCount":103},[37404],{"nctId":29381,"briefTitle":29382,"status":111,"phases":37405,"primaryCompletion":29384,"completion":29384,"start":8251,"enrollment":2631,"conditions":37406,"interventions":37407},[91,92],[1062,29386],[29388,29354,29389],{"trials":37409,"activeCount":103},[],{"trials":37411,"activeCount":103},[],{"trials":37413,"activeCount":103},[],{"intervention":37415,"totalTrials":302,"cells":37416},"PF-00915275",{"EARLY_PHASE1":37417,"PHASE1":37419,"PHASE2":37421,"PHASE3":37429,"PHASE4":37431,"NA":37433},{"trials":37418,"activeCount":103},[],{"trials":37420,"activeCount":103},[],{"trials":37422,"activeCount":103},[37423],{"nctId":37424,"briefTitle":37425,"status":168,"phases":37426,"completion":3643,"start":1701,"enrollment":35,"conditions":37427,"interventions":37428},"NCT00427401","A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks",[92],[37],[37415],{"trials":37430,"activeCount":103},[],{"trials":37432,"activeCount":103},[],{"trials":37434,"activeCount":103},[],{"intervention":37436,"totalTrials":302,"cells":37437},"PF-05221304 Monotherapy",{"EARLY_PHASE1":37438,"PHASE1":37440,"PHASE2":37442,"PHASE3":37453,"PHASE4":37455,"NA":37457},{"trials":37439,"activeCount":103},[],{"trials":37441,"activeCount":103},[],{"trials":37443,"activeCount":103},[37444],{"nctId":37445,"briefTitle":37446,"status":111,"phases":37447,"primaryCompletion":27745,"completion":4410,"start":4548,"enrollment":30374,"conditions":37448,"interventions":37450},"NCT03776175","A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.",[92],[37449],"Non-Alcoholic Fatty Liver Disease (NAFLD)",[37436,37451,37452],"PF-06865571 Monotherapy","PF-05221304 and PF-06865571 Combination",{"trials":37454,"activeCount":103},[],{"trials":37456,"activeCount":103},[],{"trials":37458,"activeCount":103},[],{"intervention":37451,"totalTrials":302,"cells":37460},{"EARLY_PHASE1":37461,"PHASE1":37463,"PHASE2":37465,"PHASE3":37471,"PHASE4":37473,"NA":37475},{"trials":37462,"activeCount":103},[],{"trials":37464,"activeCount":103},[],{"trials":37466,"activeCount":103},[37467],{"nctId":37445,"briefTitle":37446,"status":111,"phases":37468,"primaryCompletion":27745,"completion":4410,"start":4548,"enrollment":30374,"conditions":37469,"interventions":37470},[92],[37449],[37436,37451,37452],{"trials":37472,"activeCount":103},[],{"trials":37474,"activeCount":103},[],{"trials":37476,"activeCount":103},[],{"intervention":37452,"totalTrials":302,"cells":37478},{"EARLY_PHASE1":37479,"PHASE1":37481,"PHASE2":37483,"PHASE3":37489,"PHASE4":37491,"NA":37493},{"trials":37480,"activeCount":103},[],{"trials":37482,"activeCount":103},[],{"trials":37484,"activeCount":103},[37485],{"nctId":37445,"briefTitle":37446,"status":111,"phases":37486,"primaryCompletion":27745,"completion":4410,"start":4548,"enrollment":30374,"conditions":37487,"interventions":37488},[92],[37449],[37436,37451,37452],{"trials":37490,"activeCount":103},[],{"trials":37492,"activeCount":103},[],{"trials":37494,"activeCount":103},[],{"intervention":4292,"totalTrials":302,"cells":37496},{"EARLY_PHASE1":37497,"PHASE1":37499,"PHASE2":37501,"PHASE3":37507,"PHASE4":37509,"NA":37511},{"trials":37498,"activeCount":103},[],{"trials":37500,"activeCount":103},[],{"trials":37502,"activeCount":103},[37503],{"nctId":4285,"briefTitle":4286,"status":168,"phases":37504,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":597,"conditions":37505,"interventions":37506},[92],[924],[4292,933,933],{"trials":37508,"activeCount":103},[],{"trials":37510,"activeCount":103},[],{"trials":37512,"activeCount":103},[],{"intervention":37514,"totalTrials":302,"cells":37515},"Bivalent rLP2086 Vaccine",{"EARLY_PHASE1":37516,"PHASE1":37518,"PHASE2":37520,"PHASE3":37530,"PHASE4":37532,"NA":37534},{"trials":37517,"activeCount":103},[],{"trials":37519,"activeCount":103},[],{"trials":37521,"activeCount":103},[37522],{"nctId":37523,"briefTitle":37524,"status":111,"phases":37525,"primaryCompletion":26848,"completion":26848,"start":3323,"enrollment":267,"conditions":37526,"interventions":37528},"NCT02531698","A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to \u003C10 Years",[92],[37527],"MENINGOCOCCAL INFECTION",[37514,37529],"Licensed pediatric hepatits A vaccine",{"trials":37531,"activeCount":103},[],{"trials":37533,"activeCount":103},[],{"trials":37535,"activeCount":103},[],{"intervention":37529,"totalTrials":302,"cells":37537},{"EARLY_PHASE1":37538,"PHASE1":37540,"PHASE2":37542,"PHASE3":37548,"PHASE4":37550,"NA":37552},{"trials":37539,"activeCount":103},[],{"trials":37541,"activeCount":103},[],{"trials":37543,"activeCount":103},[37544],{"nctId":37523,"briefTitle":37524,"status":111,"phases":37545,"primaryCompletion":26848,"completion":26848,"start":3323,"enrollment":267,"conditions":37546,"interventions":37547},[92],[37527],[37514,37529],{"trials":37549,"activeCount":103},[],{"trials":37551,"activeCount":103},[],{"trials":37553,"activeCount":103},[],{"intervention":37555,"totalTrials":302,"cells":37556},"Sertraline and Elzasonan Combination",{"EARLY_PHASE1":37557,"PHASE1":37559,"PHASE2":37561,"PHASE3":37570,"PHASE4":37572,"NA":37574},{"trials":37558,"activeCount":103},[],{"trials":37560,"activeCount":103},[],{"trials":37562,"activeCount":103},[37563],{"nctId":37564,"briefTitle":37565,"status":111,"phases":37566,"completion":2641,"start":2671,"enrollment":37567,"conditions":37568,"interventions":37569},"NCT00275197","A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)",[92],262,[12847],[37555,17066],{"trials":37571,"activeCount":103},[],{"trials":37573,"activeCount":103},[],{"trials":37575,"activeCount":103},[],{"intervention":28418,"totalTrials":302,"cells":37577},{"EARLY_PHASE1":37578,"PHASE1":37580,"PHASE2":37582,"PHASE3":37588,"PHASE4":37590,"NA":37592},{"trials":37579,"activeCount":103},[],{"trials":37581,"activeCount":103},[],{"trials":37583,"activeCount":103},[37584],{"nctId":28411,"briefTitle":28412,"status":111,"phases":37585,"primaryCompletion":28414,"completion":19174,"start":28415,"enrollment":14574,"conditions":37586,"interventions":37587},[92],[4401],[28418,27131],{"trials":37589,"activeCount":103},[],{"trials":37591,"activeCount":103},[],{"trials":37593,"activeCount":103},[],{"intervention":37595,"totalTrials":302,"cells":37596},"oprelvekin",{"EARLY_PHASE1":37597,"PHASE1":37599,"PHASE2":37601,"PHASE3":37610,"PHASE4":37612,"NA":37614},{"trials":37598,"activeCount":103},[],{"trials":37600,"activeCount":103},[],{"trials":37602,"activeCount":103},[37603],{"nctId":37604,"briefTitle":37605,"status":168,"phases":37606,"primaryCompletion":3586,"completion":3586,"start":4833,"enrollment":99,"conditions":37607,"interventions":37609},"NCT00886743","Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia",[92],[37608],"Severe Thrombocytopenia",[37595],{"trials":37611,"activeCount":103},[],{"trials":37613,"activeCount":103},[],{"trials":37615,"activeCount":103},[],{"intervention":37617,"totalTrials":302,"cells":37618},"Atomoxetine",{"EARLY_PHASE1":37619,"PHASE1":37621,"PHASE2":37623,"PHASE3":37632,"PHASE4":37634,"NA":37636},{"trials":37620,"activeCount":103},[],{"trials":37622,"activeCount":103},[],{"trials":37624,"activeCount":103},[37625],{"nctId":37626,"briefTitle":37627,"status":649,"phases":37628,"start":2964,"enrollment":103,"conditions":37629,"interventions":37630},"NCT00562055","Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.",[92],[15099],[37617,37631],"PNU-165442G; [S,S]-reboxetine",{"trials":37633,"activeCount":103},[],{"trials":37635,"activeCount":103},[],{"trials":37637,"activeCount":103},[],{"intervention":37631,"totalTrials":302,"cells":37639},{"EARLY_PHASE1":37640,"PHASE1":37642,"PHASE2":37644,"PHASE3":37650,"PHASE4":37652,"NA":37654},{"trials":37641,"activeCount":103},[],{"trials":37643,"activeCount":103},[],{"trials":37645,"activeCount":103},[37646],{"nctId":37626,"briefTitle":37627,"status":649,"phases":37647,"start":2964,"enrollment":103,"conditions":37648,"interventions":37649},[92],[15099],[37617,37631],{"trials":37651,"activeCount":103},[],{"trials":37653,"activeCount":103},[],{"trials":37655,"activeCount":103},[],{"intervention":11350,"totalTrials":302,"cells":37657},{"EARLY_PHASE1":37658,"PHASE1":37660,"PHASE2":37662,"PHASE3":37668,"PHASE4":37670,"NA":37672},{"trials":37659,"activeCount":103},[],{"trials":37661,"activeCount":103},[],{"trials":37663,"activeCount":103},[37664],{"nctId":11343,"briefTitle":11344,"status":168,"phases":37665,"primaryCompletion":4666,"completion":4666,"start":586,"enrollment":8278,"conditions":37666,"interventions":37667},[92],[11347],[11349,11350,11351,11350,11349,11351,11349,11273,11350,11273,11350,11349],{"trials":37669,"activeCount":103},[],{"trials":37671,"activeCount":103},[],{"trials":37673,"activeCount":103},[],{"intervention":11351,"totalTrials":302,"cells":37675},{"EARLY_PHASE1":37676,"PHASE1":37678,"PHASE2":37680,"PHASE3":37686,"PHASE4":37688,"NA":37690},{"trials":37677,"activeCount":103},[],{"trials":37679,"activeCount":103},[],{"trials":37681,"activeCount":103},[37682],{"nctId":11343,"briefTitle":11344,"status":168,"phases":37683,"primaryCompletion":4666,"completion":4666,"start":586,"enrollment":8278,"conditions":37684,"interventions":37685},[92],[11347],[11349,11350,11351,11350,11349,11351,11349,11273,11350,11273,11350,11349],{"trials":37687,"activeCount":103},[],{"trials":37689,"activeCount":103},[],{"trials":37691,"activeCount":103},[],{"intervention":37693,"totalTrials":302,"cells":37694},"CP-690,550 Ointment 1",{"EARLY_PHASE1":37695,"PHASE1":37697,"PHASE2":37699,"PHASE3":37712,"PHASE4":37714,"NA":37716},{"trials":37696,"activeCount":103},[],{"trials":37698,"activeCount":103},[],{"trials":37700,"activeCount":103},[37701],{"nctId":37702,"briefTitle":37703,"status":111,"phases":37704,"primaryCompletion":37705,"completion":37705,"start":37706,"enrollment":2137,"conditions":37707,"interventions":37708},"NCT01246583","CP-690-550 Ointment For Chronic Plaque Psoriasis",[92],"2011-11-29","2011-02-16",[4401],[37693,37709,37710,37711],"Vehicle 1","CP-690,550 Ointment 2","Vehicle 2",{"trials":37713,"activeCount":103},[],{"trials":37715,"activeCount":103},[],{"trials":37717,"activeCount":103},[],{"intervention":37709,"totalTrials":302,"cells":37719},{"EARLY_PHASE1":37720,"PHASE1":37722,"PHASE2":37724,"PHASE3":37730,"PHASE4":37732,"NA":37734},{"trials":37721,"activeCount":103},[],{"trials":37723,"activeCount":103},[],{"trials":37725,"activeCount":103},[37726],{"nctId":37702,"briefTitle":37703,"status":111,"phases":37727,"primaryCompletion":37705,"completion":37705,"start":37706,"enrollment":2137,"conditions":37728,"interventions":37729},[92],[4401],[37693,37709,37710,37711],{"trials":37731,"activeCount":103},[],{"trials":37733,"activeCount":103},[],{"trials":37735,"activeCount":103},[],{"intervention":37710,"totalTrials":302,"cells":37737},{"EARLY_PHASE1":37738,"PHASE1":37740,"PHASE2":37742,"PHASE3":37748,"PHASE4":37750,"NA":37752},{"trials":37739,"activeCount":103},[],{"trials":37741,"activeCount":103},[],{"trials":37743,"activeCount":103},[37744],{"nctId":37702,"briefTitle":37703,"status":111,"phases":37745,"primaryCompletion":37705,"completion":37705,"start":37706,"enrollment":2137,"conditions":37746,"interventions":37747},[92],[4401],[37693,37709,37710,37711],{"trials":37749,"activeCount":103},[],{"trials":37751,"activeCount":103},[],{"trials":37753,"activeCount":103},[],{"intervention":37711,"totalTrials":302,"cells":37755},{"EARLY_PHASE1":37756,"PHASE1":37758,"PHASE2":37760,"PHASE3":37766,"PHASE4":37768,"NA":37770},{"trials":37757,"activeCount":103},[],{"trials":37759,"activeCount":103},[],{"trials":37761,"activeCount":103},[37762],{"nctId":37702,"briefTitle":37703,"status":111,"phases":37763,"primaryCompletion":37705,"completion":37705,"start":37706,"enrollment":2137,"conditions":37764,"interventions":37765},[92],[4401],[37693,37709,37710,37711],{"trials":37767,"activeCount":103},[],{"trials":37769,"activeCount":103},[],{"trials":37771,"activeCount":103},[],{"intervention":37773,"totalTrials":302,"cells":37774},"CI-1040",{"EARLY_PHASE1":37775,"PHASE1":37777,"PHASE2":37779,"PHASE3":37787,"PHASE4":37789,"NA":37791},{"trials":37776,"activeCount":103},[],{"trials":37778,"activeCount":103},[],{"trials":37780,"activeCount":103},[37781],{"nctId":37782,"briefTitle":37783,"status":111,"phases":37784,"completion":2642,"start":4647,"enrollment":11323,"conditions":37785,"interventions":37786},"NCT00034827","A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer",[92],[1028,25,376,2180],[37773],{"trials":37788,"activeCount":103},[],{"trials":37790,"activeCount":103},[],{"trials":37792,"activeCount":103},[],{"intervention":37794,"totalTrials":302,"cells":37795},"Influenza ModRNA Vaccine",{"EARLY_PHASE1":37796,"PHASE1":37798,"PHASE2":37800,"PHASE3":37812,"PHASE4":37814,"NA":37816},{"trials":37797,"activeCount":103},[],{"trials":37799,"activeCount":103},[],{"trials":37801,"activeCount":103},[37802],{"nctId":37803,"briefTitle":37804,"status":111,"phases":37805,"primaryCompletion":37806,"completion":37806,"start":37807,"enrollment":37808,"conditions":37809,"interventions":37810},"NCT06436703","A Study About Modified RNA Vaccines Against Influenza in Healthy Adults",[92],"2025-02-05","2024-05-23",1202,[30836],[37794,37811],"Quadrivalent Influenza Vaccine",{"trials":37813,"activeCount":103},[],{"trials":37815,"activeCount":103},[],{"trials":37817,"activeCount":103},[],{"intervention":37819,"totalTrials":302,"cells":37820},"CI-1033",{"EARLY_PHASE1":37821,"PHASE1":37823,"PHASE2":37825,"PHASE3":37833,"PHASE4":37835,"NA":37837},{"trials":37822,"activeCount":103},[],{"trials":37824,"activeCount":103},[],{"trials":37826,"activeCount":103},[37827],{"nctId":37828,"briefTitle":37829,"status":111,"phases":37830,"completion":11829,"start":9388,"enrollment":18918,"conditions":37831,"interventions":37832},"NCT00051051","A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer",[92],[25],[37819],{"trials":37834,"activeCount":103},[],{"trials":37836,"activeCount":103},[],{"trials":37838,"activeCount":103},[],{"intervention":17518,"totalTrials":302,"cells":37840},{"EARLY_PHASE1":37841,"PHASE1":37843,"PHASE2":37845,"PHASE3":37851,"PHASE4":37853,"NA":37855},{"trials":37842,"activeCount":103},[],{"trials":37844,"activeCount":103},[],{"trials":37846,"activeCount":103},[37847],{"nctId":17510,"briefTitle":17511,"status":111,"phases":37848,"primaryCompletion":17513,"completion":17513,"start":17514,"enrollment":17515,"conditions":37849,"interventions":37850},[92],[1798],[2024,17444,17482,17518,17519,17520],{"trials":37852,"activeCount":103},[],{"trials":37854,"activeCount":103},[],{"trials":37856,"activeCount":103},[],{"intervention":17519,"totalTrials":302,"cells":37858},{"EARLY_PHASE1":37859,"PHASE1":37861,"PHASE2":37863,"PHASE3":37869,"PHASE4":37871,"NA":37873},{"trials":37860,"activeCount":103},[],{"trials":37862,"activeCount":103},[],{"trials":37864,"activeCount":103},[37865],{"nctId":17510,"briefTitle":17511,"status":111,"phases":37866,"primaryCompletion":17513,"completion":17513,"start":17514,"enrollment":17515,"conditions":37867,"interventions":37868},[92],[1798],[2024,17444,17482,17518,17519,17520],{"trials":37870,"activeCount":103},[],{"trials":37872,"activeCount":103},[],{"trials":37874,"activeCount":103},[],{"intervention":17520,"totalTrials":302,"cells":37876},{"EARLY_PHASE1":37877,"PHASE1":37879,"PHASE2":37881,"PHASE3":37887,"PHASE4":37889,"NA":37891},{"trials":37878,"activeCount":103},[],{"trials":37880,"activeCount":103},[],{"trials":37882,"activeCount":103},[37883],{"nctId":17510,"briefTitle":17511,"status":111,"phases":37884,"primaryCompletion":17513,"completion":17513,"start":17514,"enrollment":17515,"conditions":37885,"interventions":37886},[92],[1798],[2024,17444,17482,17518,17519,17520],{"trials":37888,"activeCount":103},[],{"trials":37890,"activeCount":103},[],{"trials":37892,"activeCount":103},[],{"intervention":21194,"totalTrials":302,"cells":37894},{"EARLY_PHASE1":37895,"PHASE1":37897,"PHASE2":37899,"PHASE3":37905,"PHASE4":37907,"NA":37909},{"trials":37896,"activeCount":103},[],{"trials":37898,"activeCount":103},[],{"trials":37900,"activeCount":103},[37901],{"nctId":21188,"briefTitle":21189,"status":111,"phases":37902,"completion":21191,"start":6437,"conditions":37903,"interventions":37904},[92],[4778],[8183,21194],{"trials":37906,"activeCount":103},[],{"trials":37908,"activeCount":103},[],{"trials":37910,"activeCount":103},[],{"intervention":37912,"totalTrials":302,"cells":37913},"AN2728 Topical Ointment, 2% QD",{"EARLY_PHASE1":37914,"PHASE1":37916,"PHASE2":37918,"PHASE3":37929,"PHASE4":37931,"NA":37933},{"trials":37915,"activeCount":103},[],{"trials":37917,"activeCount":103},[],{"trials":37919,"activeCount":103},[37920],{"nctId":37921,"briefTitle":37922,"status":111,"phases":37923,"primaryCompletion":4590,"completion":4590,"start":569,"enrollment":1122,"conditions":37924,"interventions":37925},"NCT01602341","Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis",[92],[1933],[37912,37926,37927,37928],"AN2728 Topical Ointment, 0.5% QD","AN2728 Topical Ointment, 2% BID","AN2728 Topical Ointment, 0.5% BID",{"trials":37930,"activeCount":103},[],{"trials":37932,"activeCount":103},[],{"trials":37934,"activeCount":103},[],{"intervention":37926,"totalTrials":302,"cells":37936},{"EARLY_PHASE1":37937,"PHASE1":37939,"PHASE2":37941,"PHASE3":37947,"PHASE4":37949,"NA":37951},{"trials":37938,"activeCount":103},[],{"trials":37940,"activeCount":103},[],{"trials":37942,"activeCount":103},[37943],{"nctId":37921,"briefTitle":37922,"status":111,"phases":37944,"primaryCompletion":4590,"completion":4590,"start":569,"enrollment":1122,"conditions":37945,"interventions":37946},[92],[1933],[37912,37926,37927,37928],{"trials":37948,"activeCount":103},[],{"trials":37950,"activeCount":103},[],{"trials":37952,"activeCount":103},[],{"intervention":37927,"totalTrials":302,"cells":37954},{"EARLY_PHASE1":37955,"PHASE1":37957,"PHASE2":37959,"PHASE3":37965,"PHASE4":37967,"NA":37969},{"trials":37956,"activeCount":103},[],{"trials":37958,"activeCount":103},[],{"trials":37960,"activeCount":103},[37961],{"nctId":37921,"briefTitle":37922,"status":111,"phases":37962,"primaryCompletion":4590,"completion":4590,"start":569,"enrollment":1122,"conditions":37963,"interventions":37964},[92],[1933],[37912,37926,37927,37928],{"trials":37966,"activeCount":103},[],{"trials":37968,"activeCount":103},[],{"trials":37970,"activeCount":103},[],{"intervention":37928,"totalTrials":302,"cells":37972},{"EARLY_PHASE1":37973,"PHASE1":37975,"PHASE2":37977,"PHASE3":37983,"PHASE4":37985,"NA":37987},{"trials":37974,"activeCount":103},[],{"trials":37976,"activeCount":103},[],{"trials":37978,"activeCount":103},[37979],{"nctId":37921,"briefTitle":37922,"status":111,"phases":37980,"primaryCompletion":4590,"completion":4590,"start":569,"enrollment":1122,"conditions":37981,"interventions":37982},[92],[1933],[37912,37926,37927,37928],{"trials":37984,"activeCount":103},[],{"trials":37986,"activeCount":103},[],{"trials":37988,"activeCount":103},[],{"intervention":37990,"totalTrials":302,"cells":37991},"Tasocitinib",{"EARLY_PHASE1":37992,"PHASE1":37994,"PHASE2":37996,"PHASE3":38006,"PHASE4":38008,"NA":38010},{"trials":37993,"activeCount":103},[],{"trials":37995,"activeCount":103},[],{"trials":37997,"activeCount":103},[37998],{"nctId":37999,"briefTitle":38000,"status":649,"phases":38001,"primaryCompletion":2399,"completion":2399,"start":20274,"enrollment":103,"conditions":38002,"interventions":38004},"NCT01226680","A Study Of Tasocitinib In Dry Eye Subjects",[92],[38003],"Keratoconjunctivitis Sicca",[37990,37990,38005],"vehicle for Tasocitinib",{"trials":38007,"activeCount":103},[],{"trials":38009,"activeCount":103},[],{"trials":38011,"activeCount":103},[],{"intervention":38005,"totalTrials":302,"cells":38013},{"EARLY_PHASE1":38014,"PHASE1":38016,"PHASE2":38018,"PHASE3":38024,"PHASE4":38026,"NA":38028},{"trials":38015,"activeCount":103},[],{"trials":38017,"activeCount":103},[],{"trials":38019,"activeCount":103},[38020],{"nctId":37999,"briefTitle":38000,"status":649,"phases":38021,"primaryCompletion":2399,"completion":2399,"start":20274,"enrollment":103,"conditions":38022,"interventions":38023},[92],[38003],[37990,37990,38005],{"trials":38025,"activeCount":103},[],{"trials":38027,"activeCount":103},[],{"trials":38029,"activeCount":103},[],{"intervention":38031,"totalTrials":302,"cells":38032},"mPnC candidate",{"EARLY_PHASE1":38033,"PHASE1":38035,"PHASE2":38037,"PHASE3":38047,"PHASE4":38049,"NA":38051},{"trials":38034,"activeCount":103},[],{"trials":38036,"activeCount":103},[],{"trials":38038,"activeCount":103},[38039],{"nctId":38040,"briefTitle":38041,"status":111,"phases":38042,"primaryCompletion":38043,"completion":38043,"start":3439,"enrollment":3587,"conditions":38044,"interventions":38045},"NCT06116591","A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers",[92],"2024-05-27",[28],[38031,38046],"mPnC control",{"trials":38048,"activeCount":103},[],{"trials":38050,"activeCount":103},[],{"trials":38052,"activeCount":103},[],{"intervention":38046,"totalTrials":302,"cells":38054},{"EARLY_PHASE1":38055,"PHASE1":38057,"PHASE2":38059,"PHASE3":38065,"PHASE4":38067,"NA":38069},{"trials":38056,"activeCount":103},[],{"trials":38058,"activeCount":103},[],{"trials":38060,"activeCount":103},[38061],{"nctId":38040,"briefTitle":38041,"status":111,"phases":38062,"primaryCompletion":38043,"completion":38043,"start":3439,"enrollment":3587,"conditions":38063,"interventions":38064},[92],[28],[38031,38046],{"trials":38066,"activeCount":103},[],{"trials":38068,"activeCount":103},[],{"trials":38070,"activeCount":103},[],{"intervention":31227,"totalTrials":302,"cells":38072},{"EARLY_PHASE1":38073,"PHASE1":38075,"PHASE2":38077,"PHASE3":38083,"PHASE4":38085,"NA":38087},{"trials":38074,"activeCount":103},[],{"trials":38076,"activeCount":103},[],{"trials":38078,"activeCount":103},[38079],{"nctId":31219,"briefTitle":31220,"status":168,"phases":38080,"primaryCompletion":31222,"completion":31223,"start":31224,"enrollment":6018,"conditions":38081,"interventions":38082},[92],[3801],[31202,31215,31227],{"trials":38084,"activeCount":103},[],{"trials":38086,"activeCount":103},[],{"trials":38088,"activeCount":103},[],{"intervention":38090,"totalTrials":302,"cells":38091},"Avelumab Phase 1b",{"EARLY_PHASE1":38092,"PHASE1":38094,"PHASE2":38096,"PHASE3":38112,"PHASE4":38114,"NA":38116},{"trials":38093,"activeCount":103},[],{"trials":38095,"activeCount":103},[],{"trials":38097,"activeCount":103},[38098],{"nctId":38099,"briefTitle":38100,"status":168,"phases":38101,"primaryCompletion":38102,"completion":38103,"start":38104,"enrollment":38105,"conditions":38106,"interventions":38108},"NCT03330405","Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors",[91,92],"2022-02-22","2023-01-04","2017-10-19",223,[38107],"Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors",[38090,38109,38110,38111],"Talazoparib Phase 1b","Avelumab Phase 2","Talazoparib Phase 2",{"trials":38113,"activeCount":103},[],{"trials":38115,"activeCount":103},[],{"trials":38117,"activeCount":103},[],{"intervention":38109,"totalTrials":302,"cells":38119},{"EARLY_PHASE1":38120,"PHASE1":38122,"PHASE2":38124,"PHASE3":38130,"PHASE4":38132,"NA":38134},{"trials":38121,"activeCount":103},[],{"trials":38123,"activeCount":103},[],{"trials":38125,"activeCount":103},[38126],{"nctId":38099,"briefTitle":38100,"status":168,"phases":38127,"primaryCompletion":38102,"completion":38103,"start":38104,"enrollment":38105,"conditions":38128,"interventions":38129},[91,92],[38107],[38090,38109,38110,38111],{"trials":38131,"activeCount":103},[],{"trials":38133,"activeCount":103},[],{"trials":38135,"activeCount":103},[],{"intervention":38110,"totalTrials":302,"cells":38137},{"EARLY_PHASE1":38138,"PHASE1":38140,"PHASE2":38142,"PHASE3":38148,"PHASE4":38150,"NA":38152},{"trials":38139,"activeCount":103},[],{"trials":38141,"activeCount":103},[],{"trials":38143,"activeCount":103},[38144],{"nctId":38099,"briefTitle":38100,"status":168,"phases":38145,"primaryCompletion":38102,"completion":38103,"start":38104,"enrollment":38105,"conditions":38146,"interventions":38147},[91,92],[38107],[38090,38109,38110,38111],{"trials":38149,"activeCount":103},[],{"trials":38151,"activeCount":103},[],{"trials":38153,"activeCount":103},[],{"intervention":38111,"totalTrials":302,"cells":38155},{"EARLY_PHASE1":38156,"PHASE1":38158,"PHASE2":38160,"PHASE3":38166,"PHASE4":38168,"NA":38170},{"trials":38157,"activeCount":103},[],{"trials":38159,"activeCount":103},[],{"trials":38161,"activeCount":103},[38162],{"nctId":38099,"briefTitle":38100,"status":168,"phases":38163,"primaryCompletion":38102,"completion":38103,"start":38104,"enrollment":38105,"conditions":38164,"interventions":38165},[91,92],[38107],[38090,38109,38110,38111],{"trials":38167,"activeCount":103},[],{"trials":38169,"activeCount":103},[],{"trials":38171,"activeCount":103},[],{"intervention":2841,"totalTrials":870,"cells":38173},{"EARLY_PHASE1":38174,"PHASE1":38176,"PHASE2":38223,"PHASE3":38225,"PHASE4":38227,"NA":38229},{"trials":38175,"activeCount":103},[],{"trials":38177,"activeCount":103},[38178,38182,38191,38195,38199,38203,38207,38211,38215,38219],{"nctId":8525,"briefTitle":8526,"status":168,"phases":38179,"primaryCompletion":8528,"completion":8528,"start":8529,"enrollment":314,"conditions":38180,"interventions":38181},[91],[16],[2822,2841,7531],{"nctId":38183,"briefTitle":38184,"status":111,"phases":38185,"primaryCompletion":38186,"completion":38187,"start":38188,"enrollment":6245,"conditions":38189,"interventions":38190},"NCT06567327","A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese",[91],"2025-03-16","2025-04-14","2024-08-28",[2761],[7558,13004,2841],{"nctId":9935,"briefTitle":9936,"status":111,"phases":38192,"primaryCompletion":9938,"completion":9938,"start":9939,"enrollment":1268,"conditions":38193,"interventions":38194},[91],[3396,19],[2841,9933],{"nctId":6158,"briefTitle":6159,"status":111,"phases":38196,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":38197,"interventions":38198},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"nctId":27003,"briefTitle":27004,"status":111,"phases":38200,"primaryCompletion":27006,"completion":27006,"start":27007,"enrollment":1268,"conditions":38201,"interventions":38202},[91],[19],[4425,2841],{"nctId":26807,"briefTitle":26808,"status":111,"phases":38204,"primaryCompletion":26810,"completion":5767,"start":26811,"enrollment":1268,"conditions":38205,"interventions":38206},[91],[16],[6305,2841],{"nctId":3197,"briefTitle":3198,"status":111,"phases":38208,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":38209,"interventions":38210},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"nctId":6218,"briefTitle":6219,"status":111,"phases":38212,"primaryCompletion":6221,"completion":6221,"start":1441,"enrollment":314,"conditions":38213,"interventions":38214},[91],[2761],[6224,2841,1687],{"nctId":2833,"briefTitle":2834,"status":111,"phases":38216,"primaryCompletion":2836,"completion":2837,"start":2838,"enrollment":1268,"conditions":38217,"interventions":38218},[91],[16],[1718,2841],{"nctId":6252,"briefTitle":6253,"status":111,"phases":38220,"primaryCompletion":6255,"completion":6255,"start":1082,"enrollment":26,"conditions":38221,"interventions":38222},[91],[3020,2761],[2841,1687,6169,6258],{"trials":38224,"activeCount":103},[],{"trials":38226,"activeCount":103},[],{"trials":38228,"activeCount":103},[],{"trials":38230,"activeCount":103},[],{"intervention":7531,"totalTrials":3659,"cells":38232},{"EARLY_PHASE1":38233,"PHASE1":38235,"PHASE2":38284,"PHASE3":38286,"PHASE4":38288,"NA":38290},{"trials":38234,"activeCount":103},[],{"trials":38236,"activeCount":103},[38237,38241,38245,38254,38261,38268,38275],{"nctId":8525,"briefTitle":8526,"status":168,"phases":38238,"primaryCompletion":8528,"completion":8528,"start":8529,"enrollment":314,"conditions":38239,"interventions":38240},[91],[16],[2822,2841,7531],{"nctId":7525,"briefTitle":7526,"status":111,"phases":38242,"primaryCompletion":3200,"completion":3200,"start":7528,"enrollment":314,"conditions":38243,"interventions":38244},[91],[16],[7531,2082],{"nctId":38246,"briefTitle":38247,"status":168,"phases":38248,"primaryCompletion":38249,"completion":38249,"start":38250,"enrollment":4259,"conditions":38251,"interventions":38252},"NCT05671653","A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range",[91],"2023-11-03","2023-01-19",[2761],[7531,38253],"Semaglutide",{"nctId":38255,"briefTitle":38256,"status":168,"phases":38257,"primaryCompletion":38258,"completion":38258,"start":2348,"enrollment":597,"conditions":38259,"interventions":38260},"NCT05510245","A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction",[91],"2023-07-20",[2801,352],[7531],{"nctId":38262,"briefTitle":38263,"status":111,"phases":38264,"primaryCompletion":38265,"completion":38265,"start":26400,"enrollment":3229,"conditions":38266,"interventions":38267},"NCT05158244","Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus",[91],"2022-06-15",[12968],[7531],{"nctId":38269,"briefTitle":38270,"status":111,"phases":38271,"primaryCompletion":32931,"completion":32931,"start":38272,"enrollment":525,"conditions":38273,"interventions":38274},"NCT04148209","Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants",[91],"2019-11-05",[16],[7531],{"nctId":38276,"briefTitle":38277,"status":111,"phases":38278,"primaryCompletion":38279,"completion":38279,"start":38280,"enrollment":4825,"conditions":38281,"interventions":38282},"NCT04305587","Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus",[91],"2021-07-14","2020-03-16",[6210],[7531,38283],"Clopidogrel",{"trials":38285,"activeCount":103},[],{"trials":38287,"activeCount":103},[],{"trials":38289,"activeCount":103},[],{"trials":38291,"activeCount":103},[],{"intervention":1252,"totalTrials":3659,"cells":38293},{"EARLY_PHASE1":38294,"PHASE1":38296,"PHASE2":38326,"PHASE3":38328,"PHASE4":38330,"NA":38332},{"trials":38295,"activeCount":103},[],{"trials":38297,"activeCount":103},[38298,38302,38306,38310,38314,38318,38322],{"nctId":7511,"briefTitle":7512,"status":111,"phases":38299,"primaryCompletion":7514,"completion":7515,"start":7516,"enrollment":5855,"conditions":38300,"interventions":38301},[91],[448,7518,7519,7520,7521],[7523,1252,2082],{"nctId":1245,"briefTitle":1246,"status":111,"phases":38303,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":498,"conditions":38304,"interventions":38305},[91],[16],[88,1252],{"nctId":17787,"briefTitle":17788,"status":649,"phases":38307,"primaryCompletion":3601,"completion":3601,"start":4656,"enrollment":103,"conditions":38308,"interventions":38309},[91],[4942],[17792,4945,1252],{"nctId":26980,"briefTitle":26981,"status":111,"phases":38311,"primaryCompletion":26983,"completion":26983,"start":26984,"enrollment":1268,"conditions":38312,"interventions":38313},[91],[19],[4425,1252],{"nctId":28080,"briefTitle":28081,"status":111,"phases":38315,"primaryCompletion":5957,"completion":5957,"start":5008,"enrollment":1268,"conditions":38316,"interventions":38317},[91],[16],[664,589],{"nctId":18525,"briefTitle":18526,"status":111,"phases":38319,"primaryCompletion":4438,"completion":4438,"start":4458,"enrollment":1268,"conditions":38320,"interventions":38321},[91],[19],[17998,1252],{"nctId":582,"briefTitle":583,"status":111,"phases":38323,"primaryCompletion":585,"completion":585,"start":586,"enrollment":498,"conditions":38324,"interventions":38325},[91],[16],[424,589,424],{"trials":38327,"activeCount":103},[],{"trials":38329,"activeCount":103},[],{"trials":38331,"activeCount":103},[],{"trials":38333,"activeCount":103},[],{"intervention":4936,"totalTrials":3659,"cells":38335},{"EARLY_PHASE1":38336,"PHASE1":38338,"PHASE2":38382,"PHASE3":38384,"PHASE4":38386,"NA":38388},{"trials":38337,"activeCount":103},[],{"trials":38339,"activeCount":103},[38340,38348,38354,38358,38367,38374,38378],{"nctId":38341,"briefTitle":38342,"status":111,"phases":38343,"primaryCompletion":38344,"completion":38344,"start":38345,"enrollment":562,"conditions":38346,"interventions":38347},"NCT05339334","A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.",[91],"2022-04-21","2022-03-10",[28],[4936],{"nctId":38349,"briefTitle":38350,"status":111,"phases":38351,"primaryCompletion":22708,"completion":22708,"start":38345,"enrollment":1268,"conditions":38352,"interventions":38353},"NCT05263921","Relative Bioavailability Study of PF-07321332\u002FRitonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants",[91],[12580],[4936,4936,4936,4936],{"nctId":7533,"briefTitle":7534,"status":111,"phases":38355,"primaryCompletion":7536,"completion":7536,"start":5947,"enrollment":1268,"conditions":38356,"interventions":38357},[91],[1489],[4936,2082,4936],{"nctId":38359,"briefTitle":38360,"status":111,"phases":38361,"primaryCompletion":38362,"completion":38362,"start":38363,"enrollment":1268,"conditions":38364,"interventions":38365},"NCT04962230","Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir",[91],"2021-10-09","2021-07-15",[1489],[4936,2127,38366],"PF 07321332\u002Fritonavir",{"nctId":38368,"briefTitle":38369,"status":111,"phases":38370,"primaryCompletion":1121,"completion":1121,"start":38371,"enrollment":472,"conditions":38372,"interventions":38373},"NCT04909853","Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.",[91],"2021-06-15",[352],[4936],{"nctId":20933,"briefTitle":20934,"status":111,"phases":38375,"primaryCompletion":20936,"completion":20936,"start":20937,"enrollment":1268,"conditions":38376,"interventions":38377},[91],[12580],[4936,4936,4936,4936,4974],{"nctId":4929,"briefTitle":4930,"status":111,"phases":38379,"primaryCompletion":4932,"completion":4932,"start":4933,"enrollment":1268,"conditions":38380,"interventions":38381},[91],[28],[4936,4904],{"trials":38383,"activeCount":103},[],{"trials":38385,"activeCount":103},[],{"trials":38387,"activeCount":103},[],{"trials":38389,"activeCount":103},[],{"intervention":11099,"totalTrials":2070,"cells":38391},{"EARLY_PHASE1":38392,"PHASE1":38394,"PHASE2":38420,"PHASE3":38422,"PHASE4":38424,"NA":38426},{"trials":38393,"activeCount":103},[],{"trials":38395,"activeCount":103},[38396,38400,38404,38408,38412,38416],{"nctId":11090,"briefTitle":11091,"status":649,"phases":38397,"primaryCompletion":11093,"completion":11094,"start":11095,"enrollment":103,"conditions":38398,"interventions":38399},[91],[16],[11076,11088,11098,11099],{"nctId":11122,"briefTitle":11123,"status":111,"phases":38401,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":1578,"conditions":38402,"interventions":38403},[91],[3396],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11143,"briefTitle":11144,"status":111,"phases":38405,"primaryCompletion":4206,"completion":4206,"start":10923,"enrollment":2159,"conditions":38406,"interventions":38407},[91],[6589],[11076,11088,11098,11099,11127],{"nctId":11149,"briefTitle":11150,"status":111,"phases":38409,"primaryCompletion":4846,"completion":4846,"start":4627,"enrollment":1530,"conditions":38410,"interventions":38411},[91],[16],[11076,11088,11098,11099],{"nctId":11167,"briefTitle":11168,"status":111,"phases":38413,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":38414,"interventions":38415},[91],[16],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11174,"briefTitle":11175,"status":111,"phases":38417,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":38418,"interventions":38419},[91],[19],[11076,11088,11098,11099,11127,11128,11129,11181],{"trials":38421,"activeCount":103},[],{"trials":38423,"activeCount":103},[],{"trials":38425,"activeCount":103},[],{"trials":38427,"activeCount":103},[],{"intervention":38429,"totalTrials":2070,"cells":38430},"PF-04991532",{"EARLY_PHASE1":38431,"PHASE1":38433,"PHASE2":38472,"PHASE3":38474,"PHASE4":38476,"NA":38478},{"trials":38432,"activeCount":103},[],{"trials":38434,"activeCount":103},[38435,38441,38447,38453,38459,38465],{"nctId":38436,"briefTitle":38437,"status":111,"phases":38438,"primaryCompletion":18026,"completion":18026,"start":3313,"enrollment":504,"conditions":38439,"interventions":38440},"NCT01369602","Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532",[91],[12968,16],[38429,38429,38429,38429],{"nctId":38442,"briefTitle":38443,"status":111,"phases":38444,"primaryCompletion":570,"completion":570,"start":570,"enrollment":2070,"conditions":38445,"interventions":38446},"NCT01469481","Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532",[91],[16],[38429],{"nctId":38448,"briefTitle":38449,"status":111,"phases":38450,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":597,"conditions":38451,"interventions":38452},"NCT01102673","Single Dose Study of PF-04991532 in Healthy Subjects",[91],[6117,37,6118],[38429],{"nctId":38454,"briefTitle":38455,"status":111,"phases":38456,"primaryCompletion":9544,"completion":9544,"start":2661,"enrollment":525,"conditions":38457,"interventions":38458},"NCT01369277","A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532",[91],[6117,37,6118],[38429,38429],{"nctId":38460,"briefTitle":38461,"status":111,"phases":38462,"primaryCompletion":4656,"completion":4656,"start":577,"enrollment":8123,"conditions":38463,"interventions":38464},"NCT01129258","Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes",[91],[6117,37,6118],[38429],{"nctId":38466,"briefTitle":38467,"status":111,"phases":38468,"primaryCompletion":113,"completion":113,"start":2883,"enrollment":6245,"conditions":38469,"interventions":38470},"NCT01469065","A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes",[91],[37],[38429,38429,38429,38471],"PF-0499132",{"trials":38473,"activeCount":103},[],{"trials":38475,"activeCount":103},[],{"trials":38477,"activeCount":103},[],{"trials":38479,"activeCount":103},[],{"intervention":26776,"totalTrials":578,"cells":38481},{"EARLY_PHASE1":38482,"PHASE1":38484,"PHASE2":38506,"PHASE3":38508,"PHASE4":38510,"NA":38512},{"trials":38483,"activeCount":103},[],{"trials":38485,"activeCount":103},[38486,38490,38494,38498,38502],{"nctId":26768,"briefTitle":26769,"status":111,"phases":38487,"primaryCompletion":26771,"completion":26771,"start":26772,"enrollment":7500,"conditions":38488,"interventions":38489},[91],[26774],[6305,26776],{"nctId":26956,"briefTitle":26957,"status":111,"phases":38491,"primaryCompletion":26959,"completion":26959,"start":26960,"enrollment":350,"conditions":38492,"interventions":38493},[91],[16],[4425,26776],{"nctId":26988,"briefTitle":26989,"status":111,"phases":38495,"primaryCompletion":26991,"completion":26991,"start":26992,"enrollment":1268,"conditions":38496,"interventions":38497},[91],[26774],[4425,26776],{"nctId":27080,"briefTitle":27081,"status":111,"phases":38499,"primaryCompletion":27083,"completion":27083,"start":27084,"enrollment":597,"conditions":38500,"interventions":38501},[91],[27086],[7595,26776],{"nctId":27540,"briefTitle":27541,"status":111,"phases":38503,"primaryCompletion":232,"completion":232,"start":27543,"enrollment":870,"conditions":38504,"interventions":38505},[91],[16],[4424,26776],{"trials":38507,"activeCount":103},[],{"trials":38509,"activeCount":103},[],{"trials":38511,"activeCount":103},[],{"trials":38513,"activeCount":103},[],{"intervention":1272,"totalTrials":578,"cells":38515},{"EARLY_PHASE1":38516,"PHASE1":38518,"PHASE2":38550,"PHASE3":38552,"PHASE4":38554,"NA":38556},{"trials":38517,"activeCount":103},[],{"trials":38519,"activeCount":103},[38520,38529,38533,38537,38546],{"nctId":38521,"briefTitle":38522,"status":111,"phases":38523,"primaryCompletion":1288,"completion":1288,"start":7578,"enrollment":504,"conditions":38524,"interventions":38525},"NCT02097329","Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food",[91],[16],[38526,38527,28091,38526,38528,38528],"palbociclib commercial free base","famotidine","antacid",{"nctId":18517,"briefTitle":18518,"status":111,"phases":38530,"primaryCompletion":18520,"completion":1267,"start":18521,"enrollment":1509,"conditions":38531,"interventions":38532},[91],[19],[17998,1272],{"nctId":1262,"briefTitle":1263,"status":111,"phases":38534,"primaryCompletion":1265,"completion":1266,"start":1267,"enrollment":1268,"conditions":38535,"interventions":38536},[91],[1270],[88,1272],{"nctId":38538,"briefTitle":38539,"status":111,"phases":38540,"primaryCompletion":496,"completion":496,"start":9628,"enrollment":597,"conditions":38541,"interventions":38542},"NCT05446142","A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations",[91],[16],[38543,38544,38545,1272],"Encorafenib capsule formulation","Encorafenib first formulation","Encorafenib second formulation",{"nctId":28086,"briefTitle":28087,"status":111,"phases":38547,"primaryCompletion":12811,"completion":12811,"start":3586,"enrollment":504,"conditions":38548,"interventions":38549},[91],[16],[664,28091],{"trials":38551,"activeCount":103},[],{"trials":38553,"activeCount":103},[],{"trials":38555,"activeCount":103},[],{"trials":38557,"activeCount":103},[],{"intervention":38559,"totalTrials":578,"cells":38560},"PF-04620110",{"EARLY_PHASE1":38561,"PHASE1":38563,"PHASE2":38596,"PHASE3":38598,"PHASE4":38600,"NA":38602},{"trials":38562,"activeCount":103},[],{"trials":38564,"activeCount":103},[38565,38572,38578,38584,38590],{"nctId":38566,"briefTitle":38567,"status":111,"phases":38568,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":4369,"conditions":38569,"interventions":38571},"NCT01298518","A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients",[91],[38570],"Type 2 Diabetes Patients",[38559,38559],{"nctId":38573,"briefTitle":38574,"status":111,"phases":38575,"primaryCompletion":2660,"completion":2660,"start":4214,"enrollment":2137,"conditions":38576,"interventions":38577},"NCT00959426","A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers",[91],[2761,2760,16],[38559],{"nctId":38579,"briefTitle":38580,"status":111,"phases":38581,"primaryCompletion":3601,"completion":3601,"start":577,"enrollment":2240,"conditions":38582,"interventions":38583},"NCT01146327","A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects",[91],[16],[38559,38559,38559,38559],{"nctId":38585,"briefTitle":38586,"status":111,"phases":38587,"primaryCompletion":4646,"completion":4646,"start":4645,"enrollment":504,"conditions":38588,"interventions":38589},"NCT00799006","A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers",[91],[2760],[38559],{"nctId":38591,"briefTitle":38592,"status":111,"phases":38593,"primaryCompletion":561,"completion":561,"start":586,"enrollment":1268,"conditions":38594,"interventions":38595},"NCT01166217","A Single Dose Study Of PF-04620110 In Healthy Subjects",[91],[16],[38559],{"trials":38597,"activeCount":103},[],{"trials":38599,"activeCount":103},[],{"trials":38601,"activeCount":103},[],{"trials":38603,"activeCount":103},[],{"intervention":38605,"totalTrials":257,"cells":38606},"PF-06305591",{"EARLY_PHASE1":38607,"PHASE1":38609,"PHASE2":38635,"PHASE3":38637,"PHASE4":38639,"NA":38641},{"trials":38608,"activeCount":103},[],{"trials":38610,"activeCount":103},[38611,38617,38623,38629],{"nctId":38612,"briefTitle":38613,"status":111,"phases":38614,"primaryCompletion":6198,"completion":6198,"start":3345,"enrollment":1780,"conditions":38615,"interventions":38616},"NCT01747941","Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects",[91],[16],[38605,38605,38605],{"nctId":38618,"briefTitle":38619,"status":111,"phases":38620,"primaryCompletion":6263,"completion":6263,"start":6208,"enrollment":314,"conditions":38621,"interventions":38622},"NCT01797796","Effect Of PF-06305591 On Capsaicin And Capsaicin\u002FHeat-Induced Neurogenic Flare",[91],[16],[38605],{"nctId":38624,"briefTitle":38625,"status":111,"phases":38626,"primaryCompletion":18769,"completion":18769,"start":6208,"enrollment":32,"conditions":38627,"interventions":38628},"NCT01776619","Safety and Tolerability Study of Multiple Doses of PF-06305591",[91],[16],[38605,38605,38605,38605,38605],{"nctId":38630,"briefTitle":38631,"status":111,"phases":38632,"primaryCompletion":6207,"completion":6207,"start":13117,"enrollment":314,"conditions":38633,"interventions":38634},"NCT01812265","Cold Pressor Test is Used in This Study to Assess the Effect of PF-06305591 on Pain Intensity Evoked by Cold in Healthy Male Subjects",[91],[16],[38605,38605],{"trials":38636,"activeCount":103},[],{"trials":38638,"activeCount":103},[],{"trials":38640,"activeCount":103},[],{"trials":38642,"activeCount":103},[],{"intervention":38644,"totalTrials":257,"cells":38645},"PF-05180999",{"EARLY_PHASE1":38646,"PHASE1":38648,"PHASE2":38677,"PHASE3":38679,"PHASE4":38681,"NA":38683},{"trials":38647,"activeCount":103},[],{"trials":38649,"activeCount":103},[38650,38656,38665,38671],{"nctId":38651,"briefTitle":38652,"status":111,"phases":38653,"primaryCompletion":3334,"completion":3334,"start":10912,"enrollment":1268,"conditions":38654,"interventions":38655},"NCT01530529","A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999",[91],[16],[38644,38644,38644,38644],{"nctId":38657,"briefTitle":38658,"status":168,"phases":38659,"primaryCompletion":7578,"completion":7578,"start":1248,"enrollment":1257,"conditions":38660,"interventions":38661},"NCT01981499","A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults",[91],[117],[38644,38662,38663,38664],"120 mg MR PF-05180999","360 mg MR PF-05180999","10 mg cetirizine",{"nctId":38666,"briefTitle":38667,"status":111,"phases":38668,"primaryCompletion":2883,"completion":2883,"start":4531,"enrollment":350,"conditions":38669,"interventions":38670},"NCT01429740","A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults",[91],[12632],[38644],{"nctId":38672,"briefTitle":38673,"status":649,"phases":38674,"primaryCompletion":11956,"completion":11956,"start":1288,"enrollment":103,"conditions":38675,"interventions":38676},"NCT01981486","A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults",[91],[117],[38644],{"trials":38678,"activeCount":103},[],{"trials":38680,"activeCount":103},[],{"trials":38682,"activeCount":103},[],{"trials":38684,"activeCount":103},[],{"intervention":17091,"totalTrials":257,"cells":38686},{"EARLY_PHASE1":38687,"PHASE1":38689,"PHASE2":38720,"PHASE3":38722,"PHASE4":38724,"NA":38726},{"trials":38688,"activeCount":103},[],{"trials":38690,"activeCount":103},[38691,38701,38709,38713],{"nctId":38692,"briefTitle":38693,"status":111,"phases":38694,"primaryCompletion":4566,"completion":4566,"start":38249,"enrollment":35,"conditions":38695,"interventions":38696},"NCT06105983","A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.",[91],[16],[38697,38698,38699,38700],"Sisunatovir","Rabeprazole 40 mg","Sisunatovir suspension","Rabeprazole 20 mg",{"nctId":38702,"briefTitle":38703,"status":111,"phases":38704,"primaryCompletion":38705,"completion":38705,"start":38706,"enrollment":1268,"conditions":38707,"interventions":38708},"NCT05712460","A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants",[91],"2023-04-28","2023-02-08",[10530],[17091],{"nctId":17085,"briefTitle":17086,"status":111,"phases":38710,"primaryCompletion":17088,"completion":17088,"start":213,"enrollment":32,"conditions":38711,"interventions":38712},[91],[16],[17091,17044,17091],{"nctId":38714,"briefTitle":38715,"status":111,"phases":38716,"primaryCompletion":38717,"completion":38717,"start":1182,"enrollment":2713,"conditions":38718,"interventions":38719},"NCT05994963","A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.",[91],"2024-02-26",[16],[17091],{"trials":38721,"activeCount":103},[],{"trials":38723,"activeCount":103},[],{"trials":38725,"activeCount":103},[],{"trials":38727,"activeCount":103},[],{"intervention":38729,"totalTrials":257,"cells":38730},"PF-06946860",{"EARLY_PHASE1":38731,"PHASE1":38733,"PHASE2":38766,"PHASE3":38768,"PHASE4":38770,"NA":38772},{"trials":38732,"activeCount":103},[],{"trials":38734,"activeCount":103},[38735,38742,38750,38758],{"nctId":38736,"briefTitle":38737,"status":111,"phases":38738,"primaryCompletion":2173,"completion":2173,"start":38739,"enrollment":1625,"conditions":38740,"interventions":38741},"NCT04299048","Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.",[91],"2020-11-17",[5185,409,4778,2022],[38729],{"nctId":38743,"briefTitle":38744,"status":111,"phases":38745,"primaryCompletion":9896,"completion":203,"start":38746,"enrollment":597,"conditions":38747,"interventions":38749},"NCT04803305","Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia",[91],"2021-05-11",[727,4778,2022,1684,31,1653,5183,5184,5185,38748],"Anorexia",[38729],{"nctId":38751,"briefTitle":38752,"status":111,"phases":38753,"primaryCompletion":38754,"completion":38754,"start":38755,"enrollment":1487,"conditions":38756,"interventions":38757},"NCT03974776","Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants",[91],"2020-01-10","2019-07-08",[16],[38729],{"nctId":38759,"briefTitle":38760,"status":111,"phases":38761,"primaryCompletion":38762,"completion":38762,"start":38763,"enrollment":4818,"conditions":38764,"interventions":38765},"NCT03599063","Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects",[91],"2019-09-18","2018-07-30",[16],[38729],{"trials":38767,"activeCount":103},[],{"trials":38769,"activeCount":103},[],{"trials":38771,"activeCount":103},[],{"trials":38773,"activeCount":103},[],{"intervention":38775,"totalTrials":257,"cells":38776},"PF-04427429",{"EARLY_PHASE1":38777,"PHASE1":38779,"PHASE2":38806,"PHASE3":38808,"PHASE4":38810,"NA":38812},{"trials":38778,"activeCount":103},[],{"trials":38780,"activeCount":103},[38781,38787,38794,38800],{"nctId":38782,"briefTitle":38783,"status":111,"phases":38784,"primaryCompletion":114,"completion":114,"start":561,"enrollment":1268,"conditions":38785,"interventions":38786},"NCT01147432","Acute Response Capsaicin Flare Study",[91],[16],[38775],{"nctId":38788,"briefTitle":38789,"status":111,"phases":38790,"primaryCompletion":4590,"completion":4590,"start":114,"enrollment":1257,"conditions":38791,"interventions":38793},"NCT01511497","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers",[91],[34,38792],"Migraine Disorders",[38775],{"nctId":38795,"briefTitle":38796,"status":111,"phases":38797,"primaryCompletion":2660,"completion":2660,"start":4221,"enrollment":1509,"conditions":38798,"interventions":38799},"NCT01011296","First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers",[91],[19],[38775,38775,38775],{"nctId":38801,"briefTitle":38802,"status":111,"phases":38803,"primaryCompletion":570,"completion":570,"start":2660,"enrollment":35,"conditions":38804,"interventions":38805},"NCT01117233","Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429",[91],[16],[38775,38775,38775,38775,38775],{"trials":38807,"activeCount":103},[],{"trials":38809,"activeCount":103},[],{"trials":38811,"activeCount":103},[],{"trials":38813,"activeCount":103},[],{"intervention":38815,"totalTrials":257,"cells":38816},"PF-04455242",{"EARLY_PHASE1":38817,"PHASE1":38819,"PHASE2":38847,"PHASE3":38849,"PHASE4":38851,"NA":38853},{"trials":38818,"activeCount":103},[],{"trials":38820,"activeCount":103},[38821,38828,38835,38841],{"nctId":38822,"briefTitle":38823,"status":111,"phases":38824,"primaryCompletion":4627,"completion":4627,"start":4222,"enrollment":597,"conditions":38825,"interventions":38827},"NCT00938301","A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers",[91],[38826],"Bipolar Depression",[38815],{"nctId":38829,"briefTitle":38830,"status":111,"phases":38831,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":1509,"conditions":38832,"interventions":38833},"NCT00988949","Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release",[91],[38826],[38815,38834,38834,38815,38834],"spiradoline",{"nctId":38836,"briefTitle":38837,"status":111,"phases":38838,"primaryCompletion":4221,"completion":4221,"start":4833,"enrollment":1530,"conditions":38839,"interventions":38840},"NCT00956956","A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects",[91],[16],[38815],{"nctId":38842,"briefTitle":38843,"status":168,"phases":38844,"primaryCompletion":4221,"completion":4221,"start":4833,"enrollment":1268,"conditions":38845,"interventions":38846},"NCT00939887","A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)",[91],[21056,12376],[38815],{"trials":38848,"activeCount":103},[],{"trials":38850,"activeCount":103},[],{"trials":38852,"activeCount":103},[],{"trials":38854,"activeCount":103},[],{"intervention":6184,"totalTrials":257,"cells":38856},{"EARLY_PHASE1":38857,"PHASE1":38859,"PHASE2":38882,"PHASE3":38884,"PHASE4":38886,"NA":38888},{"trials":38858,"activeCount":103},[],{"trials":38860,"activeCount":103},[38861,38868,38872,38876],{"nctId":38862,"briefTitle":38863,"status":111,"phases":38864,"primaryCompletion":9883,"completion":9883,"start":38865,"enrollment":350,"conditions":38866,"interventions":38867},"NCT04628793","A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants",[91],"2021-03-16",[28],[6184],{"nctId":6177,"briefTitle":6178,"status":111,"phases":38869,"primaryCompletion":6180,"completion":6180,"start":6181,"enrollment":941,"conditions":38870,"interventions":38871},[91],[28],[6184,1687],{"nctId":7597,"briefTitle":7598,"status":111,"phases":38873,"primaryCompletion":7600,"completion":7600,"start":7601,"enrollment":1239,"conditions":38874,"interventions":38875},[91],[16],[6184,2082],{"nctId":38877,"briefTitle":38878,"status":168,"phases":38879,"primaryCompletion":10504,"completion":10504,"start":1729,"enrollment":3659,"conditions":38880,"interventions":38881},"NCT07086664","A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition",[91],[19],[6184],{"trials":38883,"activeCount":103},[],{"trials":38885,"activeCount":103},[],{"trials":38887,"activeCount":103},[],{"trials":38889,"activeCount":103},[],{"intervention":11127,"totalTrials":257,"cells":38891},{"EARLY_PHASE1":38892,"PHASE1":38894,"PHASE2":38912,"PHASE3":38914,"PHASE4":38916,"NA":38918},{"trials":38893,"activeCount":103},[],{"trials":38895,"activeCount":103},[38896,38900,38904,38908],{"nctId":11122,"briefTitle":11123,"status":111,"phases":38897,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":1578,"conditions":38898,"interventions":38899},[91],[3396],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11143,"briefTitle":11144,"status":111,"phases":38901,"primaryCompletion":4206,"completion":4206,"start":10923,"enrollment":2159,"conditions":38902,"interventions":38903},[91],[6589],[11076,11088,11098,11099,11127],{"nctId":11167,"briefTitle":11168,"status":111,"phases":38905,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":38906,"interventions":38907},[91],[16],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11174,"briefTitle":11175,"status":111,"phases":38909,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":38910,"interventions":38911},[91],[19],[11076,11088,11098,11099,11127,11128,11129,11181],{"trials":38913,"activeCount":103},[],{"trials":38915,"activeCount":103},[],{"trials":38917,"activeCount":103},[],{"trials":38919,"activeCount":103},[],{"intervention":17915,"totalTrials":502,"cells":38921},{"EARLY_PHASE1":38922,"PHASE1":38924,"PHASE2":38945,"PHASE3":38947,"PHASE4":38949,"NA":38951},{"trials":38923,"activeCount":103},[],{"trials":38925,"activeCount":103},[38926,38935,38939],{"nctId":38927,"briefTitle":38928,"status":168,"phases":38929,"primaryCompletion":38930,"completion":38931,"start":4458,"enrollment":1509,"conditions":38932,"interventions":38933},"NCT02444793","A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors",[91],"2017-09","2017-10",[9053],[17915,38934],"KW-0761",{"nctId":17907,"briefTitle":17908,"status":111,"phases":38936,"primaryCompletion":17910,"completion":17910,"start":17911,"enrollment":8278,"conditions":38937,"interventions":38938},[91],[7426,2966,17913,376,919,9054,4728],[17915,2969,17915],{"nctId":38940,"briefTitle":38941,"status":111,"phases":38942,"primaryCompletion":18318,"completion":18318,"start":7386,"enrollment":2218,"conditions":38943,"interventions":38944},"NCT02179918","A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003\u002FKEYNOTE-0036)",[91],[553],[17915,4247],{"trials":38946,"activeCount":103},[],{"trials":38948,"activeCount":103},[],{"trials":38950,"activeCount":103},[],{"trials":38952,"activeCount":103},[],{"intervention":38954,"totalTrials":502,"cells":38955},"PF-07304814",{"EARLY_PHASE1":38956,"PHASE1":38958,"PHASE2":38983,"PHASE3":38985,"PHASE4":38987,"NA":38989},{"trials":38957,"activeCount":103},[],{"trials":38959,"activeCount":103},[38960,38967,38975],{"nctId":38961,"briefTitle":38962,"status":111,"phases":38963,"primaryCompletion":38964,"completion":38964,"start":1121,"enrollment":578,"conditions":38965,"interventions":38966},"NCT05050682","Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants",[91],"2021-12-10",[16],[38954],{"nctId":38968,"briefTitle":38969,"status":111,"phases":38970,"primaryCompletion":38971,"completion":38971,"start":38972,"enrollment":314,"conditions":38973,"interventions":38974},"NCT04627532","Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants",[91],"2020-12-17","2020-10-23",[16],[38954],{"nctId":38976,"briefTitle":38977,"status":111,"phases":38978,"primaryCompletion":38979,"completion":38979,"start":2562,"enrollment":1239,"conditions":38980,"interventions":38982},"NCT04535167","First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.",[91],"2021-06-07",[38981],"Viral Disease",[38954],{"trials":38984,"activeCount":103},[],{"trials":38986,"activeCount":103},[],{"trials":38988,"activeCount":103},[],{"trials":38990,"activeCount":103},[],{"intervention":6156,"totalTrials":502,"cells":38992},{"EARLY_PHASE1":38993,"PHASE1":38995,"PHASE2":39011,"PHASE3":39013,"PHASE4":39015,"NA":39017},{"trials":38994,"activeCount":103},[],{"trials":38996,"activeCount":103},[38997,39003,39007],{"nctId":38998,"briefTitle":38999,"status":111,"phases":39000,"primaryCompletion":12307,"completion":12307,"start":11448,"enrollment":597,"conditions":39001,"interventions":39002},"NCT02316756","A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects",[91],[10985],[6156],{"nctId":6149,"briefTitle":6150,"status":111,"phases":39004,"primaryCompletion":5957,"completion":5957,"start":4458,"enrollment":6152,"conditions":39005,"interventions":39006},[91],[6154],[6156,1687],{"nctId":7568,"briefTitle":7569,"status":111,"phases":39008,"primaryCompletion":7571,"completion":7571,"start":2313,"enrollment":1268,"conditions":39009,"interventions":39010},[91],[16],[6156,2082],{"trials":39012,"activeCount":103},[],{"trials":39014,"activeCount":103},[],{"trials":39016,"activeCount":103},[],{"trials":39018,"activeCount":103},[],{"intervention":39020,"totalTrials":502,"cells":39021},"PF-04360365",{"EARLY_PHASE1":39022,"PHASE1":39024,"PHASE2":39044,"PHASE3":39046,"PHASE4":39048,"NA":39050},{"trials":39023,"activeCount":103},[],{"trials":39025,"activeCount":103},[39026,39032,39038],{"nctId":39027,"briefTitle":39028,"status":111,"phases":39029,"primaryCompletion":4833,"completion":4833,"start":11895,"enrollment":2849,"conditions":39030,"interventions":39031},"NCT00455000","A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease",[91],[17728],[39020],{"nctId":39033,"briefTitle":39034,"status":111,"phases":39035,"primaryCompletion":585,"completion":585,"start":10937,"enrollment":2159,"conditions":39036,"interventions":39037},"NCT00607308","A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",[91],[17728],[39020,39020,39020,39020,39020],{"nctId":39039,"briefTitle":39040,"status":111,"phases":39041,"primaryCompletion":1700,"completion":1700,"start":3642,"enrollment":7500,"conditions":39042,"interventions":39043},"NCT01005862","Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers",[91],[17728],[39020],{"trials":39045,"activeCount":103},[],{"trials":39047,"activeCount":103},[],{"trials":39049,"activeCount":103},[],{"trials":39051,"activeCount":103},[],{"intervention":39053,"totalTrials":502,"cells":39054},"Palbociclib alone",{"EARLY_PHASE1":39055,"PHASE1":39057,"PHASE2":39081,"PHASE3":39083,"PHASE4":39085,"NA":39087},{"trials":39056,"activeCount":103},[],{"trials":39058,"activeCount":103},[39059,39066,39074],{"nctId":39060,"briefTitle":39061,"status":111,"phases":39062,"primaryCompletion":606,"completion":606,"start":13214,"enrollment":1239,"conditions":39063,"interventions":39064},"NCT01918176","Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)",[91],[16],[39053,39065],"Palbociclib + Rabeprazole",{"nctId":39067,"briefTitle":39068,"status":111,"phases":39069,"primaryCompletion":11448,"completion":11448,"start":11356,"enrollment":562,"conditions":39070,"interventions":39071},"NCT02222441","Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)",[91],[16],[39053,39072,39053,39073],"Palbociclib plus Modafinil","Palbociclib plus pioglitazone",{"nctId":39075,"briefTitle":39076,"status":111,"phases":39077,"primaryCompletion":4589,"completion":4589,"start":11956,"enrollment":2240,"conditions":39078,"interventions":39079},"NCT02311946","A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib",[91],[16],[39080,39065],"Palbociclib Alone",{"trials":39082,"activeCount":103},[],{"trials":39084,"activeCount":103},[],{"trials":39086,"activeCount":103},[],{"trials":39088,"activeCount":103},[],{"intervention":39090,"totalTrials":502,"cells":39091},"Pregabalin controlled release, 82.5 mg",{"EARLY_PHASE1":39092,"PHASE1":39094,"PHASE2":39119,"PHASE3":39121,"PHASE4":39123,"NA":39125},{"trials":39093,"activeCount":103},[],{"trials":39095,"activeCount":103},[39096,39104,39111],{"nctId":39097,"briefTitle":39098,"status":111,"phases":39099,"primaryCompletion":3601,"completion":3601,"start":8252,"enrollment":1509,"conditions":39100,"interventions":39101},"NCT01220219","An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers",[91],[16],[39090,39102,39103],"Pregabalin controlled release, 165 mg","Pregabalin immediate release, 75mg",{"nctId":39105,"briefTitle":39106,"status":111,"phases":39107,"primaryCompletion":8252,"completion":8252,"start":585,"enrollment":597,"conditions":39108,"interventions":39109},"NCT01202435","An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule",[91],[16],[39090,39110],"Pregabalin immediate release, 25 mg",{"nctId":39112,"briefTitle":39113,"status":111,"phases":39114,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":2159,"conditions":39115,"interventions":39116},"NCT01009541","An Investigation of the Absorption and Pharmacokinetics of Multiple Doses of Three Controlled Release Pregabalin Tablets as Compared to Multiple Doses of the Immediate Release Pregabalin Capsule",[91],[16],[39090,39102,39117,39118],"Pregabalin controlled release, 330 mg","Pregabalin immediate release, 150 mg",{"trials":39120,"activeCount":103},[],{"trials":39122,"activeCount":103},[],{"trials":39124,"activeCount":103},[],{"trials":39126,"activeCount":103},[],{"intervention":39102,"totalTrials":502,"cells":39128},{"EARLY_PHASE1":39129,"PHASE1":39131,"PHASE2":39147,"PHASE3":39149,"PHASE4":39151,"NA":39153},{"trials":39130,"activeCount":103},[],{"trials":39132,"activeCount":103},[39133,39137,39143],{"nctId":39097,"briefTitle":39098,"status":111,"phases":39134,"primaryCompletion":3601,"completion":3601,"start":8252,"enrollment":1509,"conditions":39135,"interventions":39136},[91],[16],[39090,39102,39103],{"nctId":39138,"briefTitle":39139,"status":111,"phases":39140,"primaryCompletion":8252,"completion":8252,"start":585,"enrollment":1509,"conditions":39141,"interventions":39142},"NCT01202422","An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule",[91],[16],[39102,39117,39118],{"nctId":39112,"briefTitle":39113,"status":111,"phases":39144,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":2159,"conditions":39145,"interventions":39146},[91],[16],[39090,39102,39117,39118],{"trials":39148,"activeCount":103},[],{"trials":39150,"activeCount":103},[],{"trials":39152,"activeCount":103},[],{"trials":39154,"activeCount":103},[],{"intervention":11443,"totalTrials":502,"cells":39156},{"EARLY_PHASE1":39157,"PHASE1":39159,"PHASE2":39179,"PHASE3":39181,"PHASE4":39183,"NA":39185},{"trials":39158,"activeCount":103},[],{"trials":39160,"activeCount":103},[39161,39168,39175],{"nctId":39162,"briefTitle":39163,"status":111,"phases":39164,"primaryCompletion":10912,"completion":10912,"start":3313,"enrollment":7500,"conditions":39165,"interventions":39166},"NCT01364519","A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers",[91],[21083],[39167],"Fluticasone Propionate",{"nctId":39169,"briefTitle":39170,"status":111,"phases":39171,"primaryCompletion":4221,"completion":586,"start":4646,"enrollment":350,"conditions":39172,"interventions":39173},"NCT00877539","A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects",[91],[6589],[39174,11443],"PF-03526299",{"nctId":11438,"briefTitle":11439,"status":111,"phases":39176,"primaryCompletion":4206,"completion":4206,"start":4846,"enrollment":597,"conditions":39177,"interventions":39178},[91],[8280],[11072,11443],{"trials":39180,"activeCount":103},[],{"trials":39182,"activeCount":103},[],{"trials":39184,"activeCount":103},[],{"trials":39186,"activeCount":103},[],{"intervention":39117,"totalTrials":502,"cells":39188},{"EARLY_PHASE1":39189,"PHASE1":39191,"PHASE2":39208,"PHASE3":39210,"PHASE4":39212,"NA":39214},{"trials":39190,"activeCount":103},[],{"trials":39192,"activeCount":103},[39193,39197,39204],{"nctId":39138,"briefTitle":39139,"status":111,"phases":39194,"primaryCompletion":8252,"completion":8252,"start":585,"enrollment":1509,"conditions":39195,"interventions":39196},[91],[16],[39102,39117,39118],{"nctId":39198,"briefTitle":39199,"status":111,"phases":39200,"primaryCompletion":3313,"completion":3313,"start":2661,"enrollment":597,"conditions":39201,"interventions":39202},"NCT01342198","An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet",[91],[16],[39117,39117,39203],"erythromycin",{"nctId":39112,"briefTitle":39113,"status":111,"phases":39205,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":2159,"conditions":39206,"interventions":39207},[91],[16],[39090,39102,39117,39118],{"trials":39209,"activeCount":103},[],{"trials":39211,"activeCount":103},[],{"trials":39213,"activeCount":103},[],{"trials":39215,"activeCount":103},[],{"intervention":7558,"totalTrials":502,"cells":39217},{"EARLY_PHASE1":39218,"PHASE1":39220,"PHASE2":39238,"PHASE3":39240,"PHASE4":39242,"NA":39244},{"trials":39219,"activeCount":103},[],{"trials":39221,"activeCount":103},[39222,39226,39230],{"nctId":38183,"briefTitle":38184,"status":111,"phases":39223,"primaryCompletion":38186,"completion":38187,"start":38188,"enrollment":6245,"conditions":39224,"interventions":39225},[91],[2761],[7558,13004,2841],{"nctId":7552,"briefTitle":7553,"status":111,"phases":39227,"primaryCompletion":296,"completion":296,"start":7555,"enrollment":314,"conditions":39228,"interventions":39229},[91],[16],[7558,7559,2082],{"nctId":39231,"briefTitle":39232,"status":111,"phases":39233,"primaryCompletion":39234,"completion":39234,"start":39235,"enrollment":2218,"conditions":39236,"interventions":39237},"NCT06568731","A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity",[91],"2024-12-18","2024-08-23",[2761],[7558],{"trials":39239,"activeCount":103},[],{"trials":39241,"activeCount":103},[],{"trials":39243,"activeCount":103},[],{"trials":39245,"activeCount":103},[],{"intervention":39247,"totalTrials":502,"cells":39248},"PF-04634817",{"EARLY_PHASE1":39249,"PHASE1":39251,"PHASE2":39274,"PHASE3":39276,"PHASE4":39278,"NA":39280},{"trials":39250,"activeCount":103},[],{"trials":39252,"activeCount":103},[39253,39259,39266],{"nctId":39254,"briefTitle":39255,"status":111,"phases":39256,"primaryCompletion":4656,"completion":4656,"start":585,"enrollment":3254,"conditions":39257,"interventions":39258},"NCT01247883","A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers",[91],[16],[39247,39247],{"nctId":39260,"briefTitle":39261,"status":111,"phases":39262,"primaryCompletion":560,"completion":560,"start":4206,"enrollment":504,"conditions":39263,"interventions":39264},"NCT01098877","First In Human Study Of Increasing Oral Doses Of PF-04634817",[91],[16],[39265,39247,39247,39247,39247,39247,39247,39247,39247,39247,39265],"PF-04634817 Placebo",{"nctId":39267,"briefTitle":39268,"status":111,"phases":39269,"primaryCompletion":39270,"completion":39270,"start":39271,"enrollment":4259,"conditions":39272,"interventions":39273},"NCT01791855","PF-04634817 Renal Impairment Study",[91],"2013-09-03","2013-05-10",[17576],[39247,39247,39247,39247],{"trials":39275,"activeCount":103},[],{"trials":39277,"activeCount":103},[],{"trials":39279,"activeCount":103},[],{"trials":39281,"activeCount":103},[],{"intervention":534,"totalTrials":502,"cells":39283},{"EARLY_PHASE1":39284,"PHASE1":39286,"PHASE2":39300,"PHASE3":39302,"PHASE4":39304,"NA":39306},{"trials":39285,"activeCount":103},[],{"trials":39287,"activeCount":103},[39288,39292,39296],{"nctId":529,"briefTitle":530,"status":111,"phases":39289,"primaryCompletion":113,"completion":113,"start":113,"enrollment":314,"conditions":39290,"interventions":39291},[91],[16],[424,534],{"nctId":2110,"briefTitle":2111,"status":111,"phases":39293,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":1268,"conditions":39294,"interventions":39295},[91],[16],[68,534],{"nctId":591,"briefTitle":592,"status":111,"phases":39297,"primaryCompletion":594,"completion":595,"start":596,"enrollment":597,"conditions":39298,"interventions":39299},[91],[16],[388,600],{"trials":39301,"activeCount":103},[],{"trials":39303,"activeCount":103},[],{"trials":39305,"activeCount":103},[],{"trials":39307,"activeCount":103},[],{"intervention":39309,"totalTrials":502,"cells":39310},"PF-06801591",{"EARLY_PHASE1":39311,"PHASE1":39313,"PHASE2":39352,"PHASE3":39354,"PHASE4":39356,"NA":39358},{"trials":39312,"activeCount":103},[],{"trials":39314,"activeCount":103},[39315,39330,39340],{"nctId":39316,"briefTitle":39317,"status":111,"phases":39318,"primaryCompletion":27014,"completion":27014,"start":39319,"enrollment":26055,"conditions":39320,"interventions":39329},"NCT02573259","A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors",[91],"2016-02-10",[39321,39322,39323,39324,39325,39326,39327,410,39328],"Part 1","MELANOMA","SCCHN","OVCA","SARCOMA","OTHER SOLID TUMORS","Part 1 and 2","UROTHELIAL CARCINOMA",[39309,39309],{"nctId":39331,"briefTitle":39332,"status":168,"phases":39333,"primaryCompletion":1779,"completion":1779,"start":27763,"enrollment":20,"conditions":39334,"interventions":39338},"NCT04152018","Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",[91],[5823,1859,1653,7780,8829,39335,4778,39336,1007,39337,905],"Lung Squamous Cell Carcinoma","Bile Duct Cancer","Melanoma Cancer",[39339,39309],"PF-06940434",{"nctId":39341,"briefTitle":39342,"status":168,"phases":39343,"primaryCompletion":39344,"completion":39344,"start":39345,"enrollment":13892,"conditions":39346,"interventions":39347},"NCT02616185","A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)",[91],"2021-02-23","2015-12-30",[11998],[39348,39349,39350,39309,39351],"PF-06755992","PF-06755990","Tremelimumab","PF-06753512",{"trials":39353,"activeCount":103},[],{"trials":39355,"activeCount":103},[],{"trials":39357,"activeCount":103},[],{"trials":39359,"activeCount":103},[],{"intervention":11981,"totalTrials":502,"cells":39361},{"EARLY_PHASE1":39362,"PHASE1":39364,"PHASE2":39383,"PHASE3":39385,"PHASE4":39387,"NA":39389},{"trials":39363,"activeCount":103},[],{"trials":39365,"activeCount":103},[39366,39373,39377],{"nctId":39367,"briefTitle":39368,"status":111,"phases":39369,"primaryCompletion":4627,"completion":4627,"start":8251,"enrollment":27583,"conditions":39370,"interventions":39371},"NCT00812825","A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers",[91],[19],[11981,39372,11981],"Prednisolone",{"nctId":11976,"briefTitle":11977,"status":111,"phases":39374,"primaryCompletion":560,"completion":560,"start":561,"enrollment":597,"conditions":39375,"interventions":39376},[91],[16],[11981,11981,2341,11981,11981,2341,2341],{"nctId":39378,"briefTitle":39379,"status":111,"phases":39380,"primaryCompletion":4531,"completion":4531,"start":11170,"enrollment":504,"conditions":39381,"interventions":39382},"NCT01362673","PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions",[91],[16],[11981,11981,11981,11981],{"trials":39384,"activeCount":103},[],{"trials":39386,"activeCount":103},[],{"trials":39388,"activeCount":103},[],{"trials":39390,"activeCount":103},[],{"intervention":39392,"totalTrials":502,"cells":39393},"varenicline free base patch",{"EARLY_PHASE1":39394,"PHASE1":39396,"PHASE2":39418,"PHASE3":39420,"PHASE4":39422,"NA":39424},{"trials":39395,"activeCount":103},[],{"trials":39397,"activeCount":103},[39398,39404,39412],{"nctId":39399,"briefTitle":39400,"status":111,"phases":39401,"primaryCompletion":524,"completion":524,"start":8252,"enrollment":8373,"conditions":39402,"interventions":39403},"NCT01234142","A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days",[91],[11904],[39392,39392,39392,39392],{"nctId":39405,"briefTitle":39406,"status":111,"phases":39407,"primaryCompletion":8154,"completion":8154,"start":8154,"enrollment":1268,"conditions":39408,"interventions":39409},"NCT00774605","A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin",[91],[11904],[39410,39411],"Varenicline free base solution","Varenicline free base patch",{"nctId":39413,"briefTitle":39414,"status":111,"phases":39415,"primaryCompletion":4221,"completion":4221,"start":4221,"enrollment":1268,"conditions":39416,"interventions":39417},"NCT01013454","A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Patch Applied To The Skin",[91],[11904],[39392],{"trials":39419,"activeCount":103},[],{"trials":39421,"activeCount":103},[],{"trials":39423,"activeCount":103},[],{"trials":39425,"activeCount":103},[],{"intervention":39427,"totalTrials":502,"cells":39428},"GBT021601",{"EARLY_PHASE1":39429,"PHASE1":39431,"PHASE2":39455,"PHASE3":39457,"PHASE4":39459,"NA":39461},{"trials":39430,"activeCount":103},[],{"trials":39432,"activeCount":103},[39433,39440,39448],{"nctId":39434,"briefTitle":39435,"status":111,"phases":39436,"primaryCompletion":9938,"completion":9938,"start":39437,"enrollment":627,"conditions":39438,"interventions":39439},"NCT05718687","A GBT021601 ADME Microtracer Study in Healthy Volunteers",[91],"2022-12-22",[4181],[39427],{"nctId":39441,"briefTitle":39442,"status":168,"phases":39443,"primaryCompletion":39444,"completion":39444,"start":39445,"enrollment":1487,"conditions":39446,"interventions":39447},"NCT05878704","Study of GBT021601 in Participants With Renal Impairment",[91],"2024-07-29","2023-06-29",[352],[39427],{"nctId":39449,"briefTitle":39450,"status":111,"phases":39451,"primaryCompletion":24210,"completion":24210,"start":39452,"enrollment":2070,"conditions":39453,"interventions":39454},"NCT04983264","A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)",[91],"2021-05-21",[4181],[39427],{"trials":39456,"activeCount":103},[],{"trials":39458,"activeCount":103},[],{"trials":39460,"activeCount":103},[],{"trials":39462,"activeCount":103},[],{"intervention":11128,"totalTrials":502,"cells":39464},{"EARLY_PHASE1":39465,"PHASE1":39467,"PHASE2":39481,"PHASE3":39483,"PHASE4":39485,"NA":39487},{"trials":39466,"activeCount":103},[],{"trials":39468,"activeCount":103},[39469,39473,39477],{"nctId":11122,"briefTitle":11123,"status":111,"phases":39470,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":1578,"conditions":39471,"interventions":39472},[91],[3396],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11167,"briefTitle":11168,"status":111,"phases":39474,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":39475,"interventions":39476},[91],[16],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11174,"briefTitle":11175,"status":111,"phases":39478,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":39479,"interventions":39480},[91],[19],[11076,11088,11098,11099,11127,11128,11129,11181],{"trials":39482,"activeCount":103},[],{"trials":39484,"activeCount":103},[],{"trials":39486,"activeCount":103},[],{"trials":39488,"activeCount":103},[],{"intervention":11129,"totalTrials":502,"cells":39490},{"EARLY_PHASE1":39491,"PHASE1":39493,"PHASE2":39507,"PHASE3":39509,"PHASE4":39511,"NA":39513},{"trials":39492,"activeCount":103},[],{"trials":39494,"activeCount":103},[39495,39499,39503],{"nctId":11122,"briefTitle":11123,"status":111,"phases":39496,"primaryCompletion":3601,"completion":3601,"start":585,"enrollment":1578,"conditions":39497,"interventions":39498},[91],[3396],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11167,"briefTitle":11168,"status":111,"phases":39500,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":39501,"interventions":39502},[91],[16],[11076,11088,11098,11099,11127,11128,11129],{"nctId":11174,"briefTitle":11175,"status":111,"phases":39504,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":39505,"interventions":39506},[91],[19],[11076,11088,11098,11099,11127,11128,11129,11181],{"trials":39508,"activeCount":103},[],{"trials":39510,"activeCount":103},[],{"trials":39512,"activeCount":103},[],{"trials":39514,"activeCount":103},[],{"intervention":2127,"totalTrials":502,"cells":39516},{"EARLY_PHASE1":39517,"PHASE1":39519,"PHASE2":39533,"PHASE3":39535,"PHASE4":39537,"NA":39539},{"trials":39518,"activeCount":103},[],{"trials":39520,"activeCount":103},[39521,39525,39529],{"nctId":38359,"briefTitle":38360,"status":111,"phases":39522,"primaryCompletion":38362,"completion":38362,"start":38363,"enrollment":1268,"conditions":39523,"interventions":39524},[91],[1489],[4936,2127,38366],{"nctId":2119,"briefTitle":2120,"status":111,"phases":39526,"primaryCompletion":2122,"completion":2123,"start":2124,"enrollment":1268,"conditions":39527,"interventions":39528},[91],[28],[1359,2127],{"nctId":3108,"briefTitle":3109,"status":111,"phases":39530,"primaryCompletion":3111,"completion":3112,"start":3113,"enrollment":1268,"conditions":39531,"interventions":39532},[91],[2715],[1319,2127],{"trials":39534,"activeCount":103},[],{"trials":39536,"activeCount":103},[],{"trials":39538,"activeCount":103},[],{"trials":39540,"activeCount":103},[],{"intervention":6169,"totalTrials":502,"cells":39542},{"EARLY_PHASE1":39543,"PHASE1":39545,"PHASE2":39559,"PHASE3":39561,"PHASE4":39563,"NA":39565},{"trials":39544,"activeCount":103},[],{"trials":39546,"activeCount":103},[39547,39551,39555],{"nctId":6158,"briefTitle":6159,"status":111,"phases":39548,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":39549,"interventions":39550},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"nctId":3197,"briefTitle":3198,"status":111,"phases":39552,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":39553,"interventions":39554},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"nctId":6252,"briefTitle":6253,"status":111,"phases":39556,"primaryCompletion":6255,"completion":6255,"start":1082,"enrollment":26,"conditions":39557,"interventions":39558},[91],[3020,2761],[2841,1687,6169,6258],{"trials":39560,"activeCount":103},[],{"trials":39562,"activeCount":103},[],{"trials":39564,"activeCount":103},[],{"trials":39566,"activeCount":103},[],{"intervention":39568,"totalTrials":502,"cells":39569},"PF-04995274",{"EARLY_PHASE1":39570,"PHASE1":39572,"PHASE2":39592,"PHASE3":39594,"PHASE4":39596,"NA":39598},{"trials":39571,"activeCount":103},[],{"trials":39573,"activeCount":103},[39574,39580,39586],{"nctId":39575,"briefTitle":39576,"status":111,"phases":39577,"primaryCompletion":8252,"completion":8252,"start":561,"enrollment":1487,"conditions":39578,"interventions":39579},"NCT01173757","To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers",[91],[16],[39568],{"nctId":39581,"briefTitle":39582,"status":111,"phases":39583,"primaryCompletion":561,"completion":560,"start":4206,"enrollment":5909,"conditions":39584,"interventions":39585},"NCT01091272","A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers",[91],[16],[39568,39568,39568,39568],{"nctId":39587,"briefTitle":39588,"status":111,"phases":39589,"primaryCompletion":3601,"completion":3601,"start":560,"enrollment":597,"conditions":39590,"interventions":39591},"NCT01193062","Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274",[91],[16],[39568,39568],{"trials":39593,"activeCount":103},[],{"trials":39595,"activeCount":103},[],{"trials":39597,"activeCount":103},[],{"trials":39599,"activeCount":103},[],{"intervention":39601,"totalTrials":502,"cells":39602},"Active",{"EARLY_PHASE1":39603,"PHASE1":39605,"PHASE2":39625,"PHASE3":39627,"PHASE4":39629,"NA":39631},{"trials":39604,"activeCount":103},[],{"trials":39606,"activeCount":103},[39607,39613,39619],{"nctId":39608,"briefTitle":39609,"status":168,"phases":39610,"primaryCompletion":17539,"completion":17539,"start":8473,"enrollment":870,"conditions":39611,"interventions":39612},"NCT06102174","A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV",[91],[6191],[39601],{"nctId":39614,"briefTitle":39615,"status":111,"phases":39616,"primaryCompletion":4206,"completion":4206,"start":11988,"enrollment":1509,"conditions":39617,"interventions":39618},"NCT01051232","A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers",[91],[16],[39601,39601,39601],{"nctId":39620,"briefTitle":39621,"status":649,"phases":39622,"primaryCompletion":18026,"completion":18026,"start":4666,"enrollment":103,"conditions":39623,"interventions":39624},"NCT01299467","A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge",[91],[6589],[39601,39601,39601,39601],{"trials":39626,"activeCount":103},[],{"trials":39628,"activeCount":103},[],{"trials":39630,"activeCount":103},[],{"trials":39632,"activeCount":103},[],{"intervention":39634,"totalTrials":502,"cells":39635},"Pregabalin immediate release, 300 mg",{"EARLY_PHASE1":39636,"PHASE1":39638,"PHASE2":39666,"PHASE3":39668,"PHASE4":39670,"NA":39672},{"trials":39637,"activeCount":103},[],{"trials":39639,"activeCount":103},[39640,39649,39658],{"nctId":39641,"briefTitle":39642,"status":111,"phases":39643,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":39644,"interventions":39645},"NCT01257529","An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers",[91],[16],[39646,39647,39648,39634],"Pregabalin controlled release, 330 mg, low-fat","Pregabalin controlled release, 330 mg, medium-fat","Pregabalin controlled release, 330 mg, high-fat",{"nctId":39650,"briefTitle":39651,"status":111,"phases":39652,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":39653,"interventions":39654},"NCT01270815","An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following Various Sized Lunches As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers",[91],[16],[39655,39656,39657,39634],"Pregabalin controlled release, 330 mg, 400 to 500 calories","Pregabalin controlled release, 330 mg, 600 to 750 calories","Pregabalin controlled release, 330 mg, 800 to 1000 calories",{"nctId":39659,"briefTitle":39660,"status":111,"phases":39661,"primaryCompletion":2661,"completion":2661,"start":523,"enrollment":1509,"conditions":39662,"interventions":39663},"NCT01321671","Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers",[91],[16],[39664,39665,39634],"Pregabalin controlled release, 330 mg, 600- 750 calorie","Pregabalin controlled release, 330 mg, fasted",{"trials":39667,"activeCount":103},[],{"trials":39669,"activeCount":103},[],{"trials":39671,"activeCount":103},[],{"trials":39673,"activeCount":103},[],{"intervention":39675,"totalTrials":502,"cells":39676},"Filgrastim Hospira",{"EARLY_PHASE1":39677,"PHASE1":39679,"PHASE2":39703,"PHASE3":39705,"PHASE4":39707,"NA":39709},{"trials":39678,"activeCount":103},[],{"trials":39680,"activeCount":103},[39681,39688,39696],{"nctId":39682,"briefTitle":39683,"status":111,"phases":39684,"primaryCompletion":29213,"completion":29213,"start":5957,"enrollment":13377,"conditions":39685,"interventions":39686},"NCT02923791","A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.",[91],[19],[39675,39687],"US-Approved Neupogen",{"nctId":39689,"briefTitle":39690,"status":111,"phases":39691,"primaryCompletion":539,"completion":539,"start":12810,"enrollment":2240,"conditions":39692,"interventions":39694},"NCT02766634","A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)",[91],[39693],"Neutropenia (Low White Blood Cell Count)",[39675,39695],"U.S.-approved Neupogen®",{"nctId":39697,"briefTitle":39698,"status":111,"phases":39699,"primaryCompletion":4280,"completion":12810,"start":3586,"enrollment":1509,"conditions":39700,"interventions":39701},"NCT02766647","A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)",[91],[39693],[39675,39702],"US-approved Neupogen®",{"trials":39704,"activeCount":103},[],{"trials":39706,"activeCount":103},[],{"trials":39708,"activeCount":103},[],{"trials":39710,"activeCount":103},[],{"intervention":39712,"totalTrials":502,"cells":39713},"PF-06412562",{"EARLY_PHASE1":39714,"PHASE1":39716,"PHASE2":39737,"PHASE3":39739,"PHASE4":39741,"NA":39743},{"trials":39715,"activeCount":103},[],{"trials":39717,"activeCount":103},[39718,39725,39731],{"nctId":39719,"briefTitle":39720,"status":111,"phases":39721,"primaryCompletion":11356,"completion":11356,"start":9572,"enrollment":578,"conditions":39722,"interventions":39723},"NCT02124213","A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers",[91],[16],[39724,39712,39712],"30 mg PF-06412562",{"nctId":39726,"briefTitle":39727,"status":111,"phases":39728,"primaryCompletion":7386,"completion":7386,"start":605,"enrollment":99,"conditions":39729,"interventions":39730},"NCT02006290","Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease",[91],[27985],[39712],{"nctId":39732,"briefTitle":39733,"status":111,"phases":39734,"primaryCompletion":606,"completion":606,"start":6207,"enrollment":1097,"conditions":39735,"interventions":39736},"NCT01914796","A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562",[91],[16],[39712,39712],{"trials":39738,"activeCount":103},[],{"trials":39740,"activeCount":103},[],{"trials":39742,"activeCount":103},[],{"trials":39744,"activeCount":103},[],{"intervention":39746,"totalTrials":502,"cells":39747},"PF-06427878",{"EARLY_PHASE1":39748,"PHASE1":39750,"PHASE2":39771,"PHASE3":39773,"PHASE4":39775,"NA":39777},{"trials":39749,"activeCount":103},[],{"trials":39751,"activeCount":103},[39752,39758,39765],{"nctId":39753,"briefTitle":39754,"status":111,"phases":39755,"primaryCompletion":17639,"completion":11448,"start":17639,"enrollment":2070,"conditions":39756,"interventions":39757},"NCT02237742","A Study To Understand How The Body Reacts To A Low Dose Of PF-06427878 When Given In A Vein To Healthy, Adult, Males",[91],[16],[39746],{"nctId":39759,"briefTitle":39760,"status":111,"phases":39761,"primaryCompletion":39762,"completion":39762,"start":9410,"enrollment":1509,"conditions":39763,"interventions":39764},"NCT02855177","A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects",[91],"2017-04-12",[19],[39746],{"nctId":39766,"briefTitle":39767,"status":111,"phases":39768,"primaryCompletion":4280,"completion":4280,"start":12307,"enrollment":35,"conditions":39769,"interventions":39770},"NCT02391623","A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects",[91],[10985],[39746,39746],{"trials":39772,"activeCount":103},[],{"trials":39774,"activeCount":103},[],{"trials":39776,"activeCount":103},[],{"trials":39778,"activeCount":103},[],{"intervention":39780,"totalTrials":502,"cells":39781},"PF-06743649",{"EARLY_PHASE1":39782,"PHASE1":39784,"PHASE2":39806,"PHASE3":39808,"PHASE4":39810,"NA":39812},{"trials":39783,"activeCount":103},[],{"trials":39785,"activeCount":103},[39786,39793,39799],{"nctId":39787,"briefTitle":39788,"status":168,"phases":39789,"primaryCompletion":9572,"completion":9572,"start":7971,"enrollment":1509,"conditions":39790,"interventions":39792},"NCT02170012","A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649",[91],[39791],"Healthy Elderly",[39780,39780,39780,39780,39780],{"nctId":39794,"briefTitle":39795,"status":111,"phases":39796,"primaryCompletion":11448,"completion":11448,"start":1288,"enrollment":35,"conditions":39797,"interventions":39798},"NCT02151617","A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649",[91],[16],[39780,39780,39780,39780,39780],{"nctId":39800,"briefTitle":39801,"status":168,"phases":39802,"primaryCompletion":11448,"completion":11448,"start":7971,"enrollment":1780,"conditions":39803,"interventions":39805},"NCT02187029","Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.",[91],[39804],"Gout",[39780,39780],{"trials":39807,"activeCount":103},[],{"trials":39809,"activeCount":103},[],{"trials":39811,"activeCount":103},[],{"trials":39813,"activeCount":103},[],{"intervention":11451,"totalTrials":502,"cells":39815},{"EARLY_PHASE1":39816,"PHASE1":39818,"PHASE2":39836,"PHASE3":39838,"PHASE4":39840,"NA":39842},{"trials":39817,"activeCount":103},[],{"trials":39819,"activeCount":103},[39820,39826,39830],{"nctId":39821,"briefTitle":39822,"status":111,"phases":39823,"primaryCompletion":4590,"completion":4590,"start":3345,"enrollment":1268,"conditions":39824,"interventions":39825},"NCT01706796","A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State",[91],[16],[11451,11451,11451,11451,11451,11451],{"nctId":11445,"briefTitle":11446,"status":111,"phases":39827,"primaryCompletion":11448,"completion":11448,"start":11356,"enrollment":2159,"conditions":39828,"interventions":39829},[91],[16],[11451,11451,11452,11072],{"nctId":39831,"briefTitle":39832,"status":111,"phases":39833,"primaryCompletion":605,"completion":605,"start":1249,"enrollment":748,"conditions":39834,"interventions":39835},"NCT01934738","A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)",[91],[16],[11451,11451,11451,11451,11451,11451],{"trials":39837,"activeCount":103},[],{"trials":39839,"activeCount":103},[],{"trials":39841,"activeCount":103},[],{"trials":39843,"activeCount":103},[],{"intervention":39845,"totalTrials":502,"cells":39846},"CAZ104",{"EARLY_PHASE1":39847,"PHASE1":39849,"PHASE2":39870,"PHASE3":39872,"PHASE4":39874,"NA":39876},{"trials":39848,"activeCount":103},[],{"trials":39850,"activeCount":103},[39851,39858,39864],{"nctId":39852,"briefTitle":39853,"status":111,"phases":39854,"primaryCompletion":523,"completion":523,"start":4666,"enrollment":498,"conditions":39855,"interventions":39857},"NCT01291602","A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects",[91],[39856],"Healthy Male and Female Japanese Volunteers",[17082,39845],{"nctId":39859,"briefTitle":39860,"status":111,"phases":39861,"primaryCompletion":3353,"completion":3353,"start":9544,"enrollment":32,"conditions":39862,"interventions":39863},"NCT01430910","A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately",[91],[16],[39845,19827,17083],{"nctId":39865,"briefTitle":39866,"status":111,"phases":39867,"primaryCompletion":540,"completion":540,"start":4531,"enrollment":8373,"conditions":39868,"interventions":39869},"NCT01395420","Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma",[91],[16],[39845,39845],{"trials":39871,"activeCount":103},[],{"trials":39873,"activeCount":103},[],{"trials":39875,"activeCount":103},[],{"trials":39877,"activeCount":103},[],{"intervention":39879,"totalTrials":502,"cells":39880},"PF-04937319",{"EARLY_PHASE1":39881,"PHASE1":39883,"PHASE2":39905,"PHASE3":39907,"PHASE4":39909,"NA":39911},{"trials":39882,"activeCount":103},[],{"trials":39884,"activeCount":103},[39885,39892,39899],{"nctId":39886,"briefTitle":39887,"status":111,"phases":39888,"primaryCompletion":3313,"completion":3313,"start":4666,"enrollment":2400,"conditions":39889,"interventions":39891},"NCT01272804","Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes",[91],[37,39890],"NIDDM",[39879],{"nctId":39893,"briefTitle":39894,"status":111,"phases":39895,"primaryCompletion":18026,"completion":18026,"start":10912,"enrollment":1268,"conditions":39896,"interventions":39897},"NCT01513928","A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects",[91],[16],[39898,39898,39898],"Pf-04937319",{"nctId":39900,"briefTitle":39901,"status":111,"phases":39902,"primaryCompletion":2660,"completion":2660,"start":11988,"enrollment":26,"conditions":39903,"interventions":39904},"NCT01044537","A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus",[91],[12968],[39879],{"trials":39906,"activeCount":103},[],{"trials":39908,"activeCount":103},[],{"trials":39910,"activeCount":103},[],{"trials":39912,"activeCount":103},[],{"intervention":13484,"totalTrials":1087,"cells":39914},{"EARLY_PHASE1":39915,"PHASE1":39917,"PHASE2":39930,"PHASE3":39932,"PHASE4":39934,"NA":39936},{"trials":39916,"activeCount":103},[],{"trials":39918,"activeCount":103},[39919,39923],{"nctId":13476,"briefTitle":13477,"status":111,"phases":39920,"primaryCompletion":13479,"completion":13480,"start":13481,"enrollment":525,"conditions":39921,"interventions":39922},[91],[16],[13484,13469],{"nctId":39924,"briefTitle":39925,"status":111,"phases":39926,"primaryCompletion":39927,"completion":39927,"start":2348,"enrollment":1268,"conditions":39928,"interventions":39929},"NCT05482308","A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants",[91],"2022-10-28",[16],[13484,13484],{"trials":39931,"activeCount":103},[],{"trials":39933,"activeCount":103},[],{"trials":39935,"activeCount":103},[],{"trials":39937,"activeCount":103},[],{"intervention":39939,"totalTrials":1087,"cells":39940},"Period 1",{"EARLY_PHASE1":39941,"PHASE1":39943,"PHASE2":39959,"PHASE3":39961,"PHASE4":39963,"NA":39965},{"trials":39942,"activeCount":103},[],{"trials":39944,"activeCount":103},[39945,39952],{"nctId":39946,"briefTitle":39947,"status":111,"phases":39948,"primaryCompletion":2661,"completion":2661,"start":524,"enrollment":562,"conditions":39949,"interventions":39950},"NCT01318031","Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects",[91],[19],[39939,39951],"Period 2",{"nctId":39953,"briefTitle":39954,"status":111,"phases":39955,"primaryCompletion":6208,"completion":6208,"start":4590,"enrollment":1578,"conditions":39956,"interventions":39957},"NCT01775761","A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)",[91],[7957],[39939,39951,39958],"Period 3",{"trials":39960,"activeCount":103},[],{"trials":39962,"activeCount":103},[],{"trials":39964,"activeCount":103},[],{"trials":39966,"activeCount":103},[],{"intervention":39951,"totalTrials":1087,"cells":39968},{"EARLY_PHASE1":39969,"PHASE1":39971,"PHASE2":39981,"PHASE3":39983,"PHASE4":39985,"NA":39987},{"trials":39970,"activeCount":103},[],{"trials":39972,"activeCount":103},[39973,39977],{"nctId":39946,"briefTitle":39947,"status":111,"phases":39974,"primaryCompletion":2661,"completion":2661,"start":524,"enrollment":562,"conditions":39975,"interventions":39976},[91],[19],[39939,39951],{"nctId":39953,"briefTitle":39954,"status":111,"phases":39978,"primaryCompletion":6208,"completion":6208,"start":4590,"enrollment":1578,"conditions":39979,"interventions":39980},[91],[7957],[39939,39951,39958],{"trials":39982,"activeCount":103},[],{"trials":39984,"activeCount":103},[],{"trials":39986,"activeCount":103},[],{"trials":39988,"activeCount":103},[],{"intervention":39990,"totalTrials":1087,"cells":39991},"PF-05230907",{"EARLY_PHASE1":39992,"PHASE1":39994,"PHASE2":40009,"PHASE3":40011,"PHASE4":40013,"NA":40015},{"trials":39993,"activeCount":103},[],{"trials":39995,"activeCount":103},[39996,40002],{"nctId":39997,"briefTitle":39998,"status":111,"phases":39999,"primaryCompletion":12307,"completion":12307,"start":13214,"enrollment":2175,"conditions":40000,"interventions":40001},"NCT01897142","A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers",[91],[16],[39990,39990,39990,39990,39990,39990],{"nctId":40003,"briefTitle":40004,"status":168,"phases":40005,"primaryCompletion":2228,"completion":2228,"start":7571,"enrollment":360,"conditions":40006,"interventions":40008},"NCT02687191","Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage",[91],[40007],"Intracerebral Hemorrhage",[39990],{"trials":40010,"activeCount":103},[],{"trials":40012,"activeCount":103},[],{"trials":40014,"activeCount":103},[],{"trials":40016,"activeCount":103},[],{"intervention":12205,"totalTrials":1087,"cells":40018},{"EARLY_PHASE1":40019,"PHASE1":40021,"PHASE2":40031,"PHASE3":40033,"PHASE4":40035,"NA":40037},{"trials":40020,"activeCount":103},[],{"trials":40022,"activeCount":103},[40023,40027],{"nctId":12200,"briefTitle":12201,"status":111,"phases":40024,"primaryCompletion":4846,"completion":4846,"start":4214,"enrollment":2218,"conditions":40025,"interventions":40026},[91],[16],[12205,12206],{"nctId":12232,"briefTitle":12233,"status":111,"phases":40028,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":5909,"conditions":40029,"interventions":40030},[91],[12236],[12193,12238],{"trials":40032,"activeCount":103},[],{"trials":40034,"activeCount":103},[],{"trials":40036,"activeCount":103},[],{"trials":40038,"activeCount":103},[],{"intervention":40040,"totalTrials":1087,"cells":40041},"PF-06669571",{"EARLY_PHASE1":40042,"PHASE1":40044,"PHASE2":40061,"PHASE3":40063,"PHASE4":40065,"NA":40067},{"trials":40043,"activeCount":103},[],{"trials":40045,"activeCount":103},[40046,40055],{"nctId":40047,"briefTitle":40048,"status":111,"phases":40049,"primaryCompletion":40050,"completion":40050,"start":40051,"enrollment":2159,"conditions":40052,"interventions":40054},"NCT02565628","PF-06669571 In Subjects With Idiopathic Parkinson's Disease",[91],"2016-05-13","2015-11-16",[40053],"Idiopathic Parkinson's Disease",[40040],{"nctId":40056,"briefTitle":40057,"status":111,"phases":40058,"primaryCompletion":12307,"completion":12307,"start":7971,"enrollment":3202,"conditions":40059,"interventions":40060},"NCT02184429","A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions",[91],[16],[40040,40040,40040,40040,40040,40040,40040],{"trials":40062,"activeCount":103},[],{"trials":40064,"activeCount":103},[],{"trials":40066,"activeCount":103},[],{"trials":40068,"activeCount":103},[],{"intervention":40070,"totalTrials":1087,"cells":40071},"5 mg",{"EARLY_PHASE1":40072,"PHASE1":40074,"PHASE2":40099,"PHASE3":40101,"PHASE4":40103,"NA":40105},{"trials":40073,"activeCount":103},[],{"trials":40075,"activeCount":103},[40076,40091],{"nctId":40077,"briefTitle":40078,"status":168,"phases":40079,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":40080,"interventions":40081},"NCT00857571","A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.",[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],"150 mg Suspension","30 mg Suspension","400 mg Suspension","5 mg Suspension","750 mg Suspension","150 mg","30 mg","400 mg","750 mg",{"nctId":40092,"briefTitle":40093,"status":111,"phases":40094,"primaryCompletion":4666,"completion":4666,"start":585,"enrollment":1780,"conditions":40095,"interventions":40096},"NCT01217918","Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects",[91],[16],[40097,40070,40098],"1 mg","10 mg",{"trials":40100,"activeCount":103},[],{"trials":40102,"activeCount":103},[],{"trials":40104,"activeCount":103},[],{"trials":40106,"activeCount":103},[],{"intervention":2717,"totalTrials":1087,"cells":40108},{"EARLY_PHASE1":40109,"PHASE1":40111,"PHASE2":40121,"PHASE3":40123,"PHASE4":40125,"NA":40127},{"trials":40110,"activeCount":103},[],{"trials":40112,"activeCount":103},[40113,40117],{"nctId":26760,"briefTitle":26761,"status":111,"phases":40114,"primaryCompletion":26763,"completion":26763,"start":26764,"enrollment":1268,"conditions":40115,"interventions":40116},[91],[16],[6305,2717],{"nctId":2707,"briefTitle":2708,"status":111,"phases":40118,"primaryCompletion":2710,"completion":2711,"start":2712,"enrollment":2713,"conditions":40119,"interventions":40120},[91],[2715],[1320,2082,2717],{"trials":40122,"activeCount":103},[],{"trials":40124,"activeCount":103},[],{"trials":40126,"activeCount":103},[],{"trials":40128,"activeCount":103},[],{"intervention":40130,"totalTrials":1087,"cells":40131},"Sildenafil ODT",{"EARLY_PHASE1":40132,"PHASE1":40134,"PHASE2":40148,"PHASE3":40150,"PHASE4":40152,"NA":40154},{"trials":40133,"activeCount":103},[],{"trials":40135,"activeCount":103},[40136,40144],{"nctId":40137,"briefTitle":40138,"status":111,"phases":40139,"primaryCompletion":524,"completion":524,"start":4656,"enrollment":1530,"conditions":40140,"interventions":40142},"NCT01254383","Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.",[91],[40141],"Erectile Dysfunction",[40143,40130,40130],"Sildenafil",{"nctId":12357,"briefTitle":12358,"status":111,"phases":40145,"primaryCompletion":1700,"completion":1700,"start":569,"enrollment":336,"conditions":40146,"interventions":40147},[91],[16],[12342,12362,12362],{"trials":40149,"activeCount":103},[],{"trials":40151,"activeCount":103},[],{"trials":40153,"activeCount":103},[],{"trials":40155,"activeCount":103},[],{"intervention":40157,"totalTrials":1087,"cells":40158},"PF-07054894",{"EARLY_PHASE1":40159,"PHASE1":40161,"PHASE2":40176,"PHASE3":40178,"PHASE4":40180,"NA":40182},{"trials":40160,"activeCount":103},[],{"trials":40162,"activeCount":103},[40163,40170],{"nctId":40164,"briefTitle":40165,"status":111,"phases":40166,"primaryCompletion":40167,"completion":40167,"start":20977,"enrollment":4637,"conditions":40168,"interventions":40169},"NCT04388878","Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants",[91],"2022-06-21",[16],[40157],{"nctId":40171,"briefTitle":40172,"status":111,"phases":40173,"primaryCompletion":9051,"completion":1095,"start":9191,"enrollment":870,"conditions":40174,"interventions":40175},"NCT07009353","A Study to Learn How the Study Medicine Called [14C]PF-07054894 is Processed by the Body",[91],[16],[40157,40157],{"trials":40177,"activeCount":103},[],{"trials":40179,"activeCount":103},[],{"trials":40181,"activeCount":103},[],{"trials":40183,"activeCount":103},[],{"intervention":38526,"totalTrials":1087,"cells":40185},{"EARLY_PHASE1":40186,"PHASE1":40188,"PHASE2":40201,"PHASE3":40203,"PHASE4":40205,"NA":40207},{"trials":40187,"activeCount":103},[],{"trials":40189,"activeCount":103},[40190,40197],{"nctId":40191,"briefTitle":40192,"status":111,"phases":40193,"primaryCompletion":605,"completion":605,"start":1248,"enrollment":1530,"conditions":40194,"interventions":40195},"NCT02041273","Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions",[91],[16],[40196,40196,38526],"palbociclib isethionate",{"nctId":38521,"briefTitle":38522,"status":111,"phases":40198,"primaryCompletion":1288,"completion":1288,"start":7578,"enrollment":504,"conditions":40199,"interventions":40200},[91],[16],[38526,38527,28091,38526,38528,38528],{"trials":40202,"activeCount":103},[],{"trials":40204,"activeCount":103},[],{"trials":40206,"activeCount":103},[],{"trials":40208,"activeCount":103},[],{"intervention":40210,"totalTrials":1087,"cells":40211},"PF-04603629",{"EARLY_PHASE1":40212,"PHASE1":40214,"PHASE2":40228,"PHASE3":40230,"PHASE4":40232,"NA":40234},{"trials":40213,"activeCount":103},[],{"trials":40215,"activeCount":103},[40216,40222],{"nctId":40217,"briefTitle":40218,"status":111,"phases":40219,"completion":10937,"start":11314,"enrollment":2137,"conditions":40220,"interventions":40221},"NCT00638313","Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects",[91],[37],[40210],{"nctId":40223,"briefTitle":40224,"status":168,"phases":40225,"primaryCompletion":11291,"completion":11291,"start":3314,"enrollment":1578,"conditions":40226,"interventions":40227},"NCT00637338","Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus",[91],[37],[40210],{"trials":40229,"activeCount":103},[],{"trials":40231,"activeCount":103},[],{"trials":40233,"activeCount":103},[],{"trials":40235,"activeCount":103},[],{"intervention":40237,"totalTrials":1087,"cells":40238},"Aztreonam-Avibactam",{"EARLY_PHASE1":40239,"PHASE1":40241,"PHASE2":40257,"PHASE3":40259,"PHASE4":40261,"NA":40263},{"trials":40240,"activeCount":103},[],{"trials":40242,"activeCount":103},[40243,40250],{"nctId":40244,"briefTitle":40245,"status":111,"phases":40246,"primaryCompletion":40247,"completion":8372,"start":371,"enrollment":1625,"conditions":40248,"interventions":40249},"NCT04486625","Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment",[91],"2021-09-20",[17576],[40237,40237],{"nctId":40251,"briefTitle":40252,"status":111,"phases":40253,"primaryCompletion":40254,"completion":40254,"start":5995,"enrollment":1268,"conditions":40255,"interventions":40256},"NCT04973826","Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.",[91],"2021-09-27",[16],[40237],{"trials":40258,"activeCount":103},[],{"trials":40260,"activeCount":103},[],{"trials":40262,"activeCount":103},[],{"trials":40264,"activeCount":103},[],{"intervention":39065,"totalTrials":1087,"cells":40266},{"EARLY_PHASE1":40267,"PHASE1":40269,"PHASE2":40279,"PHASE3":40281,"PHASE4":40283,"NA":40285},{"trials":40268,"activeCount":103},[],{"trials":40270,"activeCount":103},[40271,40275],{"nctId":39060,"briefTitle":39061,"status":111,"phases":40272,"primaryCompletion":606,"completion":606,"start":13214,"enrollment":1239,"conditions":40273,"interventions":40274},[91],[16],[39053,39065],{"nctId":39075,"briefTitle":39076,"status":111,"phases":40276,"primaryCompletion":4589,"completion":4589,"start":11956,"enrollment":2240,"conditions":40277,"interventions":40278},[91],[16],[39080,39065],{"trials":40280,"activeCount":103},[],{"trials":40282,"activeCount":103},[],{"trials":40284,"activeCount":103},[],{"trials":40286,"activeCount":103},[],{"intervention":40288,"totalTrials":1087,"cells":40289},"PF-06412562 3mg BID",{"EARLY_PHASE1":40290,"PHASE1":40292,"PHASE2":40311,"PHASE3":40313,"PHASE4":40315,"NA":40317},{"trials":40291,"activeCount":103},[],{"trials":40293,"activeCount":103},[40294,40302],{"nctId":40295,"briefTitle":40296,"status":111,"phases":40297,"primaryCompletion":5957,"completion":5957,"start":4589,"enrollment":28283,"conditions":40298,"interventions":40299},"NCT02418819","A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia",[91],[12632],[40288,40300,40301],"PF-06412562 9mg BID","PF-06412562 45mg BID",{"nctId":40303,"briefTitle":40304,"status":168,"phases":40305,"primaryCompletion":40306,"completion":40306,"start":40307,"enrollment":5647,"conditions":40308,"interventions":40309},"NCT02306876","A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males",[91],"2016-06-14","2015-01-19",[16],[40288,40310],"PF-06412562 15mg BID",{"trials":40312,"activeCount":103},[],{"trials":40314,"activeCount":103},[],{"trials":40316,"activeCount":103},[],{"trials":40318,"activeCount":103},[],{"intervention":9932,"totalTrials":1087,"cells":40320},{"EARLY_PHASE1":40321,"PHASE1":40323,"PHASE2":40333,"PHASE3":40335,"PHASE4":40337,"NA":40339},{"trials":40322,"activeCount":103},[],{"trials":40324,"activeCount":103},[40325,40329],{"nctId":9925,"briefTitle":9926,"status":111,"phases":40326,"primaryCompletion":9928,"completion":9928,"start":1365,"enrollment":1268,"conditions":40327,"interventions":40328},[91],[9930],[9932,9918,9918,9933,9933],{"nctId":9943,"briefTitle":9944,"status":111,"phases":40330,"primaryCompletion":288,"completion":288,"start":2335,"enrollment":498,"conditions":40331,"interventions":40332},[91],[9930,28],[9932,9933,9933,9932,9932],{"trials":40334,"activeCount":103},[],{"trials":40336,"activeCount":103},[],{"trials":40338,"activeCount":103},[],{"trials":40340,"activeCount":103},[],{"intervention":39118,"totalTrials":1087,"cells":40342},{"EARLY_PHASE1":40343,"PHASE1":40345,"PHASE2":40355,"PHASE3":40357,"PHASE4":40359,"NA":40361},{"trials":40344,"activeCount":103},[],{"trials":40346,"activeCount":103},[40347,40351],{"nctId":39138,"briefTitle":39139,"status":111,"phases":40348,"primaryCompletion":8252,"completion":8252,"start":585,"enrollment":1509,"conditions":40349,"interventions":40350},[91],[16],[39102,39117,39118],{"nctId":39112,"briefTitle":39113,"status":111,"phases":40352,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":2159,"conditions":40353,"interventions":40354},[91],[16],[39090,39102,39117,39118],{"trials":40356,"activeCount":103},[],{"trials":40358,"activeCount":103},[],{"trials":40360,"activeCount":103},[],{"trials":40362,"activeCount":103},[],{"intervention":40364,"totalTrials":1087,"cells":40365},"Phenytoin",{"EARLY_PHASE1":40366,"PHASE1":40368,"PHASE2":40385,"PHASE3":40387,"PHASE4":40389,"NA":40391},{"trials":40367,"activeCount":103},[],{"trials":40369,"activeCount":103},[40370,40378],{"nctId":40371,"briefTitle":40372,"status":111,"phases":40373,"primaryCompletion":40374,"completion":40374,"start":40375,"enrollment":472,"conditions":40376,"interventions":40377},"NCT06466473","A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults",[91],"2024-10-04","2024-07-03",[16],[40364,40364],{"nctId":40379,"briefTitle":40380,"status":111,"phases":40381,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":3229,"conditions":40382,"interventions":40383},"NCT01122953","Bioequivalence Study Of PHENYTOIN Suspension Made By Pfizer, Versus EPAMIN® Made By McNeil LA LLC In Healthy Volunteers Under Fasting Conditions",[91],[16],[40364,40384],"Epamin",{"trials":40386,"activeCount":103},[],{"trials":40388,"activeCount":103},[],{"trials":40390,"activeCount":103},[],{"trials":40392,"activeCount":103},[],{"intervention":40394,"totalTrials":1087,"cells":40395},"PF-05161704 or Placebo",{"EARLY_PHASE1":40396,"PHASE1":40398,"PHASE2":40413,"PHASE3":40415,"PHASE4":40417,"NA":40419},{"trials":40397,"activeCount":103},[],{"trials":40399,"activeCount":103},[40400,40406],{"nctId":40401,"briefTitle":40402,"status":168,"phases":40403,"primaryCompletion":4656,"completion":4656,"start":561,"enrollment":4259,"conditions":40404,"interventions":40405},"NCT01202266","A Multiple Dose Study Of PF-05161704 In Healthy Volunteers",[91],[37],[40394,40394,40394,40394,40394,40394,40394,40394],{"nctId":40407,"briefTitle":40408,"status":111,"phases":40409,"primaryCompletion":560,"completion":560,"start":586,"enrollment":597,"conditions":40410,"interventions":40411},"NCT01183715","A Single Dose Study Of PF-05161704 In Healthy Volunteers",[91],[37],[40412,40412],"PF-05161704 or placebo",{"trials":40414,"activeCount":103},[],{"trials":40416,"activeCount":103},[],{"trials":40418,"activeCount":103},[],{"trials":40420,"activeCount":103},[],{"intervention":38527,"totalTrials":1087,"cells":40422},{"EARLY_PHASE1":40423,"PHASE1":40425,"PHASE2":40435,"PHASE3":40437,"PHASE4":40439,"NA":40441},{"trials":40424,"activeCount":103},[],{"trials":40426,"activeCount":103},[40427,40431],{"nctId":38521,"briefTitle":38522,"status":111,"phases":40428,"primaryCompletion":1288,"completion":1288,"start":7578,"enrollment":504,"conditions":40429,"interventions":40430},[91],[16],[38526,38527,28091,38526,38528,38528],{"nctId":1869,"briefTitle":1870,"status":111,"phases":40432,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":40433,"interventions":40434},[91],[19],[1862,1876,1877,1878,1879,1880,1881,1882],{"trials":40436,"activeCount":103},[],{"trials":40438,"activeCount":103},[],{"trials":40440,"activeCount":103},[],{"trials":40442,"activeCount":103},[],{"intervention":40444,"totalTrials":1087,"cells":40445},"single dose of vepdegestrant as tablet formulation",{"EARLY_PHASE1":40446,"PHASE1":40448,"PHASE2":40465,"PHASE3":40467,"PHASE4":40469,"NA":40471},{"trials":40447,"activeCount":103},[],{"trials":40449,"activeCount":103},[40450,40458],{"nctId":40451,"briefTitle":40452,"status":111,"phases":40453,"primaryCompletion":40454,"completion":40455,"start":22300,"enrollment":748,"conditions":40456,"interventions":40457},"NCT06347861","A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults",[91],"2024-07-22","2024-08-08",[16],[40444,40444,40444],{"nctId":40459,"briefTitle":40460,"status":111,"phases":40461,"primaryCompletion":7600,"completion":3016,"start":40462,"enrollment":1268,"conditions":40463,"interventions":40464},"NCT06645938","A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults",[91],"2024-10-16",[16],[40444,40444],{"trials":40466,"activeCount":103},[],{"trials":40468,"activeCount":103},[],{"trials":40470,"activeCount":103},[],{"trials":40472,"activeCount":103},[],{"intervention":40474,"totalTrials":1087,"cells":40475},"PF-06342674 Dose A",{"EARLY_PHASE1":40476,"PHASE1":40478,"PHASE2":40503,"PHASE3":40505,"PHASE4":40507,"NA":40509},{"trials":40477,"activeCount":103},[],{"trials":40479,"activeCount":103},[40480,40495],{"nctId":40481,"briefTitle":40482,"status":111,"phases":40483,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":40484,"interventions":40485},"NCT01740609","A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers",[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],"PF-06342674 Dose B","PF-06342674 Dose C","PF-06342674 Dose D","PF-06342674 Dose E","PF-06342674 Dose F","PF-06342674 Dose G","PF-06342674 Dose H","PF-06342674 Dose I","PF-06342674 Dose J",{"nctId":40496,"briefTitle":40497,"status":111,"phases":40498,"primaryCompletion":40499,"completion":40499,"start":40500,"enrollment":2849,"conditions":40501,"interventions":40502},"NCT02038764","A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes",[91],"2016-09-13","2014-06-04",[12130],[40474,40486,40487,40488],{"trials":40504,"activeCount":103},[],{"trials":40506,"activeCount":103},[],{"trials":40508,"activeCount":103},[],{"trials":40510,"activeCount":103},[],{"intervention":40486,"totalTrials":1087,"cells":40512},{"EARLY_PHASE1":40513,"PHASE1":40515,"PHASE2":40525,"PHASE3":40527,"PHASE4":40529,"NA":40531},{"trials":40514,"activeCount":103},[],{"trials":40516,"activeCount":103},[40517,40521],{"nctId":40481,"briefTitle":40482,"status":111,"phases":40518,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":40519,"interventions":40520},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"nctId":40496,"briefTitle":40497,"status":111,"phases":40522,"primaryCompletion":40499,"completion":40499,"start":40500,"enrollment":2849,"conditions":40523,"interventions":40524},[91],[12130],[40474,40486,40487,40488],{"trials":40526,"activeCount":103},[],{"trials":40528,"activeCount":103},[],{"trials":40530,"activeCount":103},[],{"trials":40532,"activeCount":103},[],{"intervention":40487,"totalTrials":1087,"cells":40534},{"EARLY_PHASE1":40535,"PHASE1":40537,"PHASE2":40547,"PHASE3":40549,"PHASE4":40551,"NA":40553},{"trials":40536,"activeCount":103},[],{"trials":40538,"activeCount":103},[40539,40543],{"nctId":40481,"briefTitle":40482,"status":111,"phases":40540,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":40541,"interventions":40542},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"nctId":40496,"briefTitle":40497,"status":111,"phases":40544,"primaryCompletion":40499,"completion":40499,"start":40500,"enrollment":2849,"conditions":40545,"interventions":40546},[91],[12130],[40474,40486,40487,40488],{"trials":40548,"activeCount":103},[],{"trials":40550,"activeCount":103},[],{"trials":40552,"activeCount":103},[],{"trials":40554,"activeCount":103},[],{"intervention":40488,"totalTrials":1087,"cells":40556},{"EARLY_PHASE1":40557,"PHASE1":40559,"PHASE2":40569,"PHASE3":40571,"PHASE4":40573,"NA":40575},{"trials":40558,"activeCount":103},[],{"trials":40560,"activeCount":103},[40561,40565],{"nctId":40481,"briefTitle":40482,"status":111,"phases":40562,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":40563,"interventions":40564},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"nctId":40496,"briefTitle":40497,"status":111,"phases":40566,"primaryCompletion":40499,"completion":40499,"start":40500,"enrollment":2849,"conditions":40567,"interventions":40568},[91],[12130],[40474,40486,40487,40488],{"trials":40570,"activeCount":103},[],{"trials":40572,"activeCount":103},[],{"trials":40574,"activeCount":103},[],{"trials":40576,"activeCount":103},[],{"intervention":40578,"totalTrials":1087,"cells":40579},"PF-07038124 or vehicle",{"EARLY_PHASE1":40580,"PHASE1":40582,"PHASE2":40601,"PHASE3":40603,"PHASE4":40605,"NA":40607},{"trials":40581,"activeCount":103},[],{"trials":40583,"activeCount":103},[40584,40591],{"nctId":40585,"briefTitle":40586,"status":111,"phases":40587,"primaryCompletion":4970,"completion":4970,"start":40588,"enrollment":1268,"conditions":40589,"interventions":40590},"NCT04863417","Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants",[91],"2021-06-30",[16],[40578,40578],{"nctId":40592,"briefTitle":40593,"status":111,"phases":40594,"primaryCompletion":40595,"completion":40595,"start":40596,"enrollment":3229,"conditions":40597,"interventions":40599},"NCT04135560","A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants",[91],"2020-04-10","2019-10-29",[40598],"Dermatitis Atopic",[40600,40578,40578,40578,40578,40578,40578],"PF-07038124 and Vehicle",{"trials":40602,"activeCount":103},[],{"trials":40604,"activeCount":103},[],{"trials":40606,"activeCount":103},[],{"trials":40608,"activeCount":103},[],{"intervention":40610,"totalTrials":1087,"cells":40611},"Test formulation",{"EARLY_PHASE1":40612,"PHASE1":40614,"PHASE2":40631,"PHASE3":40633,"PHASE4":40635,"NA":40637},{"trials":40613,"activeCount":103},[],{"trials":40615,"activeCount":103},[40616,40625],{"nctId":40617,"briefTitle":40618,"status":111,"phases":40619,"primaryCompletion":40620,"completion":40620,"start":26771,"enrollment":27243,"conditions":40621,"interventions":40623},"NCT03792477","A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males",[91],"2020-04-02",[40622],"Hypogonadism",[40610,40624],"Reference formulation",{"nctId":40626,"briefTitle":40627,"status":111,"phases":40628,"primaryCompletion":9168,"completion":9168,"start":2710,"enrollment":7363,"conditions":40629,"interventions":40630},"NCT07261371","A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults",[91],[1270],[40610,40624,40610,40610],{"trials":40632,"activeCount":103},[],{"trials":40634,"activeCount":103},[],{"trials":40636,"activeCount":103},[],{"trials":40638,"activeCount":103},[],{"intervention":40624,"totalTrials":1087,"cells":40640},{"EARLY_PHASE1":40641,"PHASE1":40643,"PHASE2":40653,"PHASE3":40655,"PHASE4":40657,"NA":40659},{"trials":40642,"activeCount":103},[],{"trials":40644,"activeCount":103},[40645,40649],{"nctId":40617,"briefTitle":40618,"status":111,"phases":40646,"primaryCompletion":40620,"completion":40620,"start":26771,"enrollment":27243,"conditions":40647,"interventions":40648},[91],[40622],[40610,40624],{"nctId":40626,"briefTitle":40627,"status":111,"phases":40650,"primaryCompletion":9168,"completion":9168,"start":2710,"enrollment":7363,"conditions":40651,"interventions":40652},[91],[1270],[40610,40624,40610,40610],{"trials":40654,"activeCount":103},[],{"trials":40656,"activeCount":103},[],{"trials":40658,"activeCount":103},[],{"trials":40660,"activeCount":103},[],{"intervention":29324,"totalTrials":1087,"cells":40662},{"EARLY_PHASE1":40663,"PHASE1":40665,"PHASE2":40683,"PHASE3":40685,"PHASE4":40687,"NA":40689},{"trials":40664,"activeCount":103},[],{"trials":40666,"activeCount":103},[40667,40671],{"nctId":29313,"briefTitle":29314,"status":111,"phases":40668,"primaryCompletion":29316,"completion":29316,"start":29317,"enrollment":1268,"conditions":40669,"interventions":40670},[91],[4401],[29320,29321,29322,29323,29324,29325],{"nctId":40672,"briefTitle":40673,"status":111,"phases":40674,"primaryCompletion":40675,"completion":40675,"start":40676,"enrollment":1268,"conditions":40677,"interventions":40678},"NCT00763204","A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test",[91],"2008-03-07","2008-02-29",[4401],[40679,40680,40681,40682,29324],"AN2728 Cream, 2%","AN2728 Cream, 1%","AN2728 Cream, 0.3%","AN2728 Cream Vehicle",{"trials":40684,"activeCount":103},[],{"trials":40686,"activeCount":103},[],{"trials":40688,"activeCount":103},[],{"trials":40690,"activeCount":103},[],{"intervention":40692,"totalTrials":1087,"cells":40693},"SA4Ag vaccine low dose",{"EARLY_PHASE1":40694,"PHASE1":40696,"PHASE2":40715,"PHASE3":40717,"PHASE4":40719,"NA":40721},{"trials":40695,"activeCount":103},[],{"trials":40697,"activeCount":103},[40698,40707],{"nctId":40699,"briefTitle":40700,"status":111,"phases":40701,"primaryCompletion":4590,"completion":4590,"start":4531,"enrollment":40702,"conditions":40703,"interventions":40704},"NCT01364571","Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to \u003C65 Years",[91],456,[34314],[40692,40705,40706],"SA4Ag vaccine mid dose","SA4Ag vaccine high dose",{"nctId":40708,"briefTitle":40709,"status":111,"phases":40710,"primaryCompletion":6198,"completion":605,"start":569,"enrollment":40711,"conditions":40712,"interventions":40713},"NCT01643941","Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to \u003C86 Years",[91],284,[34314],[40692,40705,40706,40714],"SA3Ag vaccine",{"trials":40716,"activeCount":103},[],{"trials":40718,"activeCount":103},[],{"trials":40720,"activeCount":103},[],{"trials":40722,"activeCount":103},[],{"intervention":40705,"totalTrials":1087,"cells":40724},{"EARLY_PHASE1":40725,"PHASE1":40727,"PHASE2":40737,"PHASE3":40739,"PHASE4":40741,"NA":40743},{"trials":40726,"activeCount":103},[],{"trials":40728,"activeCount":103},[40729,40733],{"nctId":40699,"briefTitle":40700,"status":111,"phases":40730,"primaryCompletion":4590,"completion":4590,"start":4531,"enrollment":40702,"conditions":40731,"interventions":40732},[91],[34314],[40692,40705,40706],{"nctId":40708,"briefTitle":40709,"status":111,"phases":40734,"primaryCompletion":6198,"completion":605,"start":569,"enrollment":40711,"conditions":40735,"interventions":40736},[91],[34314],[40692,40705,40706,40714],{"trials":40738,"activeCount":103},[],{"trials":40740,"activeCount":103},[],{"trials":40742,"activeCount":103},[],{"trials":40744,"activeCount":103},[],{"intervention":40706,"totalTrials":1087,"cells":40746},{"EARLY_PHASE1":40747,"PHASE1":40749,"PHASE2":40759,"PHASE3":40761,"PHASE4":40763,"NA":40765},{"trials":40748,"activeCount":103},[],{"trials":40750,"activeCount":103},[40751,40755],{"nctId":40699,"briefTitle":40700,"status":111,"phases":40752,"primaryCompletion":4590,"completion":4590,"start":4531,"enrollment":40702,"conditions":40753,"interventions":40754},[91],[34314],[40692,40705,40706],{"nctId":40708,"briefTitle":40709,"status":111,"phases":40756,"primaryCompletion":6198,"completion":605,"start":569,"enrollment":40711,"conditions":40757,"interventions":40758},[91],[34314],[40692,40705,40706,40714],{"trials":40760,"activeCount":103},[],{"trials":40762,"activeCount":103},[],{"trials":40764,"activeCount":103},[],{"trials":40766,"activeCount":103},[],{"intervention":6291,"totalTrials":1087,"cells":40768},{"EARLY_PHASE1":40769,"PHASE1":40771,"PHASE2":40784,"PHASE3":40786,"PHASE4":40788,"NA":40790},{"trials":40770,"activeCount":103},[],{"trials":40772,"activeCount":103},[40773,40780],{"nctId":40774,"briefTitle":40775,"status":111,"phases":40776,"primaryCompletion":40777,"completion":40777,"start":1356,"enrollment":1780,"conditions":40778,"interventions":40779},"NCT05907395","A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults",[91],"2024-03-22",[28],[6291],{"nctId":6285,"briefTitle":6286,"status":111,"phases":40781,"primaryCompletion":6288,"completion":6288,"start":2523,"enrollment":541,"conditions":40782,"interventions":40783},[91],[28],[6291,1687],{"trials":40785,"activeCount":103},[],{"trials":40787,"activeCount":103},[],{"trials":40789,"activeCount":103},[],{"trials":40791,"activeCount":103},[],{"intervention":19213,"totalTrials":1087,"cells":40793},{"EARLY_PHASE1":40794,"PHASE1":40796,"PHASE2":40806,"PHASE3":40808,"PHASE4":40810,"NA":40812},{"trials":40795,"activeCount":103},[],{"trials":40797,"activeCount":103},[40798,40802],{"nctId":19332,"briefTitle":19333,"status":111,"phases":40799,"primaryCompletion":9544,"completion":9544,"start":4615,"enrollment":1239,"conditions":40800,"interventions":40801},[91],[31],[19213,4327,19319],{"nctId":19208,"briefTitle":19209,"status":111,"phases":40803,"primaryCompletion":2449,"completion":2449,"start":113,"enrollment":3587,"conditions":40804,"interventions":40805},[91],[16],[9416,19213,19213],{"trials":40807,"activeCount":103},[],{"trials":40809,"activeCount":103},[],{"trials":40811,"activeCount":103},[],{"trials":40813,"activeCount":103},[],{"intervention":40815,"totalTrials":1087,"cells":40816},"alprazolam test sublingual",{"EARLY_PHASE1":40817,"PHASE1":40819,"PHASE2":40835,"PHASE3":40837,"PHASE4":40839,"NA":40841},{"trials":40818,"activeCount":103},[],{"trials":40820,"activeCount":103},[40821,40828],{"nctId":40822,"briefTitle":40823,"status":649,"phases":40824,"primaryCompletion":2661,"completion":2661,"start":523,"enrollment":103,"conditions":40825,"interventions":40826},"NCT01285505","Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation",[91],[16],[40827,40815],"alprazolam commercial sublingual formulation",{"nctId":40829,"briefTitle":40830,"status":649,"phases":40831,"primaryCompletion":2661,"completion":2661,"start":523,"enrollment":103,"conditions":40832,"interventions":40833},"NCT01027689","Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation",[91],[16],[40834,40815],"alprazolam commercial immediate release oral",{"trials":40836,"activeCount":103},[],{"trials":40838,"activeCount":103},[],{"trials":40840,"activeCount":103},[],{"trials":40842,"activeCount":103},[],{"intervention":40844,"totalTrials":1087,"cells":40845},"US-approved Neulasta",{"EARLY_PHASE1":40846,"PHASE1":40848,"PHASE2":40867,"PHASE3":40869,"PHASE4":40871,"NA":40873},{"trials":40847,"activeCount":103},[],{"trials":40849,"activeCount":103},[40850,40859],{"nctId":40851,"briefTitle":40852,"status":111,"phases":40853,"primaryCompletion":40854,"completion":40854,"start":40855,"enrollment":6503,"conditions":40856,"interventions":40857},"NCT03273842","A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers",[91],"2018-07-25","2017-10-27",[19],[40858,40844],"PF-06881894",{"nctId":40860,"briefTitle":40861,"status":111,"phases":40862,"primaryCompletion":539,"completion":539,"start":3323,"enrollment":12497,"conditions":40863,"interventions":40864},"NCT02629289","A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants",[91],[21003],[40865,40844,40866],"HSP-130","EU-approved Neulasta",{"trials":40868,"activeCount":103},[],{"trials":40870,"activeCount":103},[],{"trials":40872,"activeCount":103},[],{"trials":40874,"activeCount":103},[],{"intervention":40876,"totalTrials":1087,"cells":40877},"BMN 673",{"EARLY_PHASE1":40878,"PHASE1":40880,"PHASE2":40900,"PHASE3":40902,"PHASE4":40904,"NA":40906},{"trials":40879,"activeCount":103},[],{"trials":40881,"activeCount":103},[40882,40893],{"nctId":40883,"briefTitle":40884,"status":111,"phases":40885,"primaryCompletion":40886,"completion":40887,"start":40888,"enrollment":5987,"conditions":40889,"interventions":40892},"NCT01399840","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies",[91],"2014-03-31","2014-05-31","2011-06-30",[2938,16958,40890,40891],"Chronic Lymphocytic Leukemia","Mantle Cell Lymphoma",[40876],{"nctId":40894,"briefTitle":40895,"status":111,"phases":40896,"primaryCompletion":6198,"completion":6263,"start":18128,"enrollment":597,"conditions":40897,"interventions":40899},"NCT01776437","Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers",[91],[40898],"Human Volunteers",[40876],{"trials":40901,"activeCount":103},[],{"trials":40903,"activeCount":103},[],{"trials":40905,"activeCount":103},[],{"trials":40907,"activeCount":103},[],{"intervention":40909,"totalTrials":1087,"cells":40910},"Tafamidis 61 mg free acid",{"EARLY_PHASE1":40911,"PHASE1":40913,"PHASE2":40930,"PHASE3":40932,"PHASE4":40934,"NA":40936},{"trials":40912,"activeCount":103},[],{"trials":40914,"activeCount":103},[40915,40923],{"nctId":40916,"briefTitle":40917,"status":111,"phases":40918,"primaryCompletion":38043,"completion":38043,"start":40919,"enrollment":1268,"conditions":40920,"interventions":40921},"NCT06273839","A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults",[91],"2024-02-27",[16],[40909,40922,40909],"Tafamidis 70 mg free acid",{"nctId":40924,"briefTitle":40925,"status":111,"phases":40926,"primaryCompletion":22855,"completion":22855,"start":40927,"enrollment":525,"conditions":40928,"interventions":40929},"NCT06705569","A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults",[91],"2024-12-20",[16],[40909,40909],{"trials":40931,"activeCount":103},[],{"trials":40933,"activeCount":103},[],{"trials":40935,"activeCount":103},[],{"trials":40937,"activeCount":103},[],{"intervention":40939,"totalTrials":1087,"cells":40940},"tofacitinib modified-release (MR) formulation",{"EARLY_PHASE1":40941,"PHASE1":40943,"PHASE2":40959,"PHASE3":40961,"PHASE4":40963,"NA":40965},{"trials":40942,"activeCount":103},[],{"trials":40944,"activeCount":103},[40945,40951],{"nctId":40946,"briefTitle":40947,"status":111,"phases":40948,"primaryCompletion":2449,"completion":2449,"start":3345,"enrollment":2159,"conditions":40949,"interventions":40950},"NCT01731327","A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers",[91],[16],[40939,40939],{"nctId":40952,"briefTitle":40953,"status":111,"phases":40954,"primaryCompletion":40955,"completion":40955,"start":40956,"enrollment":1509,"conditions":40957,"interventions":40958},"NCT02084875","A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers",[91],"2014-05-25","2014-04-11",[16],[40939,40939],{"trials":40960,"activeCount":103},[],{"trials":40962,"activeCount":103},[],{"trials":40964,"activeCount":103},[],{"trials":40966,"activeCount":103},[],{"intervention":40968,"totalTrials":1087,"cells":40969},"PF-03446962",{"EARLY_PHASE1":40970,"PHASE1":40972,"PHASE2":40986,"PHASE3":40988,"PHASE4":40990,"NA":40992},{"trials":40971,"activeCount":103},[],{"trials":40973,"activeCount":103},[40974,40980],{"nctId":40975,"briefTitle":40976,"status":111,"phases":40977,"primaryCompletion":606,"completion":605,"start":3313,"enrollment":1530,"conditions":40978,"interventions":40979},"NCT01337050","Asian Phase I Study Of PF-03446962",[91],[2053],[40968],{"nctId":40981,"briefTitle":40982,"status":111,"phases":40983,"primaryCompletion":4680,"completion":4680,"start":2964,"enrollment":27035,"conditions":40984,"interventions":40985},"NCT00557856","A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors",[91],[553],[40968],{"trials":40987,"activeCount":103},[],{"trials":40989,"activeCount":103},[],{"trials":40991,"activeCount":103},[],{"trials":40993,"activeCount":103},[],{"intervention":40995,"totalTrials":1087,"cells":40996},"PF-06751979 multiple ascending dose",{"EARLY_PHASE1":40997,"PHASE1":40999,"PHASE2":41017,"PHASE3":41019,"PHASE4":41021,"NA":41023},{"trials":40998,"activeCount":103},[],{"trials":41000,"activeCount":103},[41001,41010],{"nctId":41002,"briefTitle":41003,"status":111,"phases":41004,"primaryCompletion":41005,"completion":41005,"start":8039,"enrollment":787,"conditions":41006,"interventions":41007},"NCT02793232","Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.",[91],"2017-01-05",[10985],[41008,40995,41009],"PF-06751979 single dose","PF-06751979 multiple dose",{"nctId":41011,"briefTitle":41012,"status":111,"phases":41013,"primaryCompletion":5008,"completion":5008,"start":4439,"enrollment":2631,"conditions":41014,"interventions":41015},"NCT02509117","First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979",[91],[10985],[41016,40995,41009,41009],"PF-06751979 single ascending dose",{"trials":41018,"activeCount":103},[],{"trials":41020,"activeCount":103},[],{"trials":41022,"activeCount":103},[],{"trials":41024,"activeCount":103},[],{"intervention":41009,"totalTrials":1087,"cells":41026},{"EARLY_PHASE1":41027,"PHASE1":41029,"PHASE2":41039,"PHASE3":41041,"PHASE4":41043,"NA":41045},{"trials":41028,"activeCount":103},[],{"trials":41030,"activeCount":103},[41031,41035],{"nctId":41002,"briefTitle":41003,"status":111,"phases":41032,"primaryCompletion":41005,"completion":41005,"start":8039,"enrollment":787,"conditions":41033,"interventions":41034},[91],[10985],[41008,40995,41009],{"nctId":41011,"briefTitle":41012,"status":111,"phases":41036,"primaryCompletion":5008,"completion":5008,"start":4439,"enrollment":2631,"conditions":41037,"interventions":41038},[91],[10985],[41016,40995,41009,41009],{"trials":41040,"activeCount":103},[],{"trials":41042,"activeCount":103},[],{"trials":41044,"activeCount":103},[],{"trials":41046,"activeCount":103},[],{"intervention":340,"totalTrials":1087,"cells":41048},{"EARLY_PHASE1":41049,"PHASE1":41051,"PHASE2":41061,"PHASE3":41063,"PHASE4":41065,"NA":41067},{"trials":41050,"activeCount":103},[],{"trials":41052,"activeCount":103},[41053,41057],{"nctId":331,"briefTitle":332,"status":168,"phases":41054,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":41055,"interventions":41056},[91],[338],[340,329,341,342,343],{"nctId":1775,"briefTitle":1776,"status":168,"phases":41058,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":41059,"interventions":41060},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":41062,"activeCount":103},[],{"trials":41064,"activeCount":103},[],{"trials":41066,"activeCount":103},[],{"trials":41068,"activeCount":103},[],{"intervention":4247,"totalTrials":1087,"cells":41070},{"EARLY_PHASE1":41071,"PHASE1":41073,"PHASE2":41083,"PHASE3":41085,"PHASE4":41087,"NA":41089},{"trials":41072,"activeCount":103},[],{"trials":41074,"activeCount":103},[41075,41079],{"nctId":38940,"briefTitle":38941,"status":111,"phases":41076,"primaryCompletion":18318,"completion":18318,"start":7386,"enrollment":2218,"conditions":41077,"interventions":41078},[91],[553],[17915,4247],{"nctId":4239,"briefTitle":4240,"status":111,"phases":41080,"primaryCompletion":4242,"completion":4243,"start":4244,"enrollment":748,"conditions":41081,"interventions":41082},[91],[1859],[933,4247],{"trials":41084,"activeCount":103},[],{"trials":41086,"activeCount":103},[],{"trials":41088,"activeCount":103},[],{"trials":41090,"activeCount":103},[],{"intervention":6193,"totalTrials":1087,"cells":41092},{"EARLY_PHASE1":41093,"PHASE1":41095,"PHASE2":41107,"PHASE3":41109,"PHASE4":41111,"NA":41113},{"trials":41094,"activeCount":103},[],{"trials":41096,"activeCount":103},[41097,41103],{"nctId":41098,"briefTitle":41099,"status":111,"phases":41100,"primaryCompletion":17994,"completion":17994,"start":5101,"enrollment":6245,"conditions":41101,"interventions":41102},"NCT06067191","Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)",[91],[3809],[6193],{"nctId":6186,"briefTitle":6187,"status":111,"phases":41104,"primaryCompletion":6189,"completion":6189,"start":4933,"enrollment":26,"conditions":41105,"interventions":41106},[91],[6191],[6193,1687],{"trials":41108,"activeCount":103},[],{"trials":41110,"activeCount":103},[],{"trials":41112,"activeCount":103},[],{"trials":41114,"activeCount":103},[],{"intervention":41116,"totalTrials":1087,"cells":41117},"PF-04457845 \u002F matched placebo",{"EARLY_PHASE1":41118,"PHASE1":41120,"PHASE2":41135,"PHASE3":41137,"PHASE4":41139,"NA":41141},{"trials":41119,"activeCount":103},[],{"trials":41121,"activeCount":103},[41122,41129],{"nctId":41123,"briefTitle":41124,"status":168,"phases":41125,"primaryCompletion":10923,"completion":10923,"start":6016,"enrollment":597,"conditions":41126,"interventions":41128},"NCT01002625","A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers",[91],[41127,19],"Sleep",[41116,41116],{"nctId":41130,"briefTitle":41131,"status":111,"phases":41132,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":1780,"conditions":41133,"interventions":41134},"NCT01092845","Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers",[91],[16,41127],[41116,41116],{"trials":41136,"activeCount":103},[],{"trials":41138,"activeCount":103},[],{"trials":41140,"activeCount":103},[],{"trials":41142,"activeCount":103},[],{"intervention":27993,"totalTrials":1087,"cells":41144},{"EARLY_PHASE1":41145,"PHASE1":41147,"PHASE2":41157,"PHASE3":41159,"PHASE4":41161,"NA":41163},{"trials":41146,"activeCount":103},[],{"trials":41148,"activeCount":103},[41149,41153],{"nctId":27988,"briefTitle":27989,"status":111,"phases":41150,"primaryCompletion":11448,"completion":11448,"start":17639,"enrollment":627,"conditions":41151,"interventions":41152},[91],[16],[27974,27993],{"nctId":28001,"briefTitle":28002,"status":111,"phases":41154,"primaryCompletion":4280,"completion":12810,"start":12307,"enrollment":597,"conditions":41155,"interventions":41156},[91],[28005],[27974,27993],{"trials":41158,"activeCount":103},[],{"trials":41160,"activeCount":103},[],{"trials":41162,"activeCount":103},[],{"trials":41164,"activeCount":103},[],{"intervention":6202,"totalTrials":1087,"cells":41166},{"EARLY_PHASE1":41167,"PHASE1":41169,"PHASE2":41181,"PHASE3":41183,"PHASE4":41185,"NA":41187},{"trials":41168,"activeCount":103},[],{"trials":41170,"activeCount":103},[41171,41175],{"nctId":6195,"briefTitle":6196,"status":111,"phases":41172,"primaryCompletion":6198,"completion":6198,"start":3353,"enrollment":6199,"conditions":41173,"interventions":41174},[91],[16],[6202,6202,6202,6202,6202,1989,6202,1989,6202],{"nctId":41176,"briefTitle":41177,"status":111,"phases":41178,"primaryCompletion":4680,"completion":4680,"start":4459,"enrollment":1578,"conditions":41179,"interventions":41180},"NCT01626976","A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects",[91],[16],[6202,6202,6202,6202,6202],{"trials":41182,"activeCount":103},[],{"trials":41184,"activeCount":103},[],{"trials":41186,"activeCount":103},[],{"trials":41188,"activeCount":103},[],{"intervention":40714,"totalTrials":1087,"cells":41190},{"EARLY_PHASE1":41191,"PHASE1":41193,"PHASE2":41211,"PHASE3":41213,"PHASE4":41215,"NA":41217},{"trials":41192,"activeCount":103},[],{"trials":41194,"activeCount":103},[41195,41199],{"nctId":40708,"briefTitle":40709,"status":111,"phases":41196,"primaryCompletion":6198,"completion":605,"start":569,"enrollment":40711,"conditions":41197,"interventions":41198},[91],[34314],[40692,40705,40706,40714],{"nctId":41200,"briefTitle":41201,"status":111,"phases":41202,"primaryCompletion":3601,"completion":3313,"start":10923,"enrollment":41203,"conditions":41204,"interventions":41208},"NCT01018641","An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults",[91],449,[19825,41205,41206,41207,34314],"Staphylococcal Vaccines","Immunotherapy, Active","Staphylococcal Skin Infections",[40714,41209,41210],"SA3Ag followed by Placebo","SA3Ag with no booster in stage 2",{"trials":41212,"activeCount":103},[],{"trials":41214,"activeCount":103},[],{"trials":41216,"activeCount":103},[],{"trials":41218,"activeCount":103},[],{"intervention":17082,"totalTrials":1087,"cells":41220},{"EARLY_PHASE1":41221,"PHASE1":41223,"PHASE2":41233,"PHASE3":41235,"PHASE4":41237,"NA":41239},{"trials":41222,"activeCount":103},[],{"trials":41224,"activeCount":103},[41225,41229],{"nctId":17076,"briefTitle":17077,"status":111,"phases":41226,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":1548,"conditions":41227,"interventions":41228},[91],[17080],[17082,13798,17083,6111],{"nctId":39852,"briefTitle":39853,"status":111,"phases":41230,"primaryCompletion":523,"completion":523,"start":4666,"enrollment":498,"conditions":41231,"interventions":41232},[91],[39856],[17082,39845],{"trials":41234,"activeCount":103},[],{"trials":41236,"activeCount":103},[],{"trials":41238,"activeCount":103},[],{"trials":41240,"activeCount":103},[],{"intervention":17083,"totalTrials":1087,"cells":41242},{"EARLY_PHASE1":41243,"PHASE1":41245,"PHASE2":41255,"PHASE3":41257,"PHASE4":41259,"NA":41261},{"trials":41244,"activeCount":103},[],{"trials":41246,"activeCount":103},[41247,41251],{"nctId":17076,"briefTitle":17077,"status":111,"phases":41248,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":1548,"conditions":41249,"interventions":41250},[91],[17080],[17082,13798,17083,6111],{"nctId":39859,"briefTitle":39860,"status":111,"phases":41252,"primaryCompletion":3353,"completion":3353,"start":9544,"enrollment":32,"conditions":41253,"interventions":41254},[91],[16],[39845,19827,17083],{"trials":41256,"activeCount":103},[],{"trials":41258,"activeCount":103},[],{"trials":41260,"activeCount":103},[],{"trials":41262,"activeCount":103},[],{"intervention":19827,"totalTrials":1087,"cells":41264},{"EARLY_PHASE1":41265,"PHASE1":41267,"PHASE2":41277,"PHASE3":41279,"PHASE4":41281,"NA":41283},{"trials":41266,"activeCount":103},[],{"trials":41268,"activeCount":103},[41269,41273],{"nctId":19820,"briefTitle":19821,"status":111,"phases":41270,"primaryCompletion":11448,"completion":11448,"start":1700,"enrollment":9553,"conditions":41271,"interventions":41272},[91],[19824,19825],[19827,19511,19828],{"nctId":39859,"briefTitle":39860,"status":111,"phases":41274,"primaryCompletion":3353,"completion":3353,"start":9544,"enrollment":32,"conditions":41275,"interventions":41276},[91],[16],[39845,19827,17083],{"trials":41278,"activeCount":103},[],{"trials":41280,"activeCount":103},[],{"trials":41282,"activeCount":103},[],{"trials":41284,"activeCount":103},[],{"intervention":41286,"totalTrials":1087,"cells":41287},"PF-04856883",{"EARLY_PHASE1":41288,"PHASE1":41290,"PHASE2":41305,"PHASE3":41307,"PHASE4":41309,"NA":41311},{"trials":41289,"activeCount":103},[],{"trials":41291,"activeCount":103},[41292,41299],{"nctId":41293,"briefTitle":41294,"status":111,"phases":41295,"primaryCompletion":2883,"completion":3334,"start":524,"enrollment":4637,"conditions":41296,"interventions":41298},"NCT01301456","Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females",[91],[6117,37,6118,28172,41297],"Endocrine System Diseases",[41286,41286,41286,41286,41286,41286,41286,41286,41286,41286],{"nctId":41300,"briefTitle":41301,"status":111,"phases":41302,"primaryCompletion":4590,"completion":4590,"start":569,"enrollment":2175,"conditions":41303,"interventions":41304},"NCT01637285","A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers",[91],[16],[41286,41286,41286,41286],{"trials":41306,"activeCount":103},[],{"trials":41308,"activeCount":103},[],{"trials":41310,"activeCount":103},[],{"trials":41312,"activeCount":103},[],{"intervention":41314,"totalTrials":1087,"cells":41315},"Moxifloxacin 400 mg",{"EARLY_PHASE1":41316,"PHASE1":41318,"PHASE2":41337,"PHASE3":41339,"PHASE4":41341,"NA":41343},{"trials":41317,"activeCount":103},[],{"trials":41319,"activeCount":103},[41320,41328],{"nctId":41321,"briefTitle":41322,"status":111,"phases":41323,"primaryCompletion":7971,"completion":7971,"start":652,"enrollment":3866,"conditions":41324,"interventions":41325},"NCT02207699","Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers",[91],[19],[41326,41327,41314],"Benzonatate 200 mg","Benzonatate 800 mg",{"nctId":41329,"briefTitle":41330,"status":111,"phases":41331,"primaryCompletion":11290,"completion":11290,"start":8154,"enrollment":2175,"conditions":41332,"interventions":41333},"NCT00795145","A Study To Assess The Effect Of Linezolid On QTc Interval",[91],[19825],[41334,41335,41336,41335,41314],"Linezolid 900 mg","Linezolid 1200 mg","Linezolid 600 mg",{"trials":41338,"activeCount":103},[],{"trials":41340,"activeCount":103},[],{"trials":41342,"activeCount":103},[],{"trials":41344,"activeCount":103},[],{"intervention":29613,"totalTrials":302,"cells":41346},{"EARLY_PHASE1":41347,"PHASE1":41349,"PHASE2":41355,"PHASE3":41357,"PHASE4":41359,"NA":41361},{"trials":41348,"activeCount":103},[],{"trials":41350,"activeCount":103},[41351],{"nctId":29607,"briefTitle":29608,"status":111,"phases":41352,"primaryCompletion":4627,"completion":4627,"start":8115,"enrollment":498,"conditions":41353,"interventions":41354},[91],[17728],[29600,29612,29613,29614],{"trials":41356,"activeCount":103},[],{"trials":41358,"activeCount":103},[],{"trials":41360,"activeCount":103},[],{"trials":41362,"activeCount":103},[],{"intervention":41364,"totalTrials":302,"cells":41365},"330 mg pregabalin controlled release",{"EARLY_PHASE1":41366,"PHASE1":41368,"PHASE2":41377,"PHASE3":41379,"PHASE4":41381,"NA":41383},{"trials":41367,"activeCount":103},[],{"trials":41369,"activeCount":103},[41370],{"nctId":41371,"briefTitle":41372,"status":111,"phases":41373,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":1509,"conditions":41374,"interventions":41375},"NCT01080612","A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation",[91],[16],[41364,41364,41364,41376],"300 mg pregabalin immediate release",{"trials":41378,"activeCount":103},[],{"trials":41380,"activeCount":103},[],{"trials":41382,"activeCount":103},[],{"trials":41384,"activeCount":103},[],{"intervention":41376,"totalTrials":302,"cells":41386},{"EARLY_PHASE1":41387,"PHASE1":41389,"PHASE2":41395,"PHASE3":41397,"PHASE4":41399,"NA":41401},{"trials":41388,"activeCount":103},[],{"trials":41390,"activeCount":103},[41391],{"nctId":41371,"briefTitle":41372,"status":111,"phases":41392,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":1509,"conditions":41393,"interventions":41394},[91],[16],[41364,41364,41364,41376],{"trials":41396,"activeCount":103},[],{"trials":41398,"activeCount":103},[],{"trials":41400,"activeCount":103},[],{"trials":41402,"activeCount":103},[],{"intervention":41404,"totalTrials":302,"cells":41405},"Myrin© 2",{"EARLY_PHASE1":41406,"PHASE1":41408,"PHASE2":41418,"PHASE3":41420,"PHASE4":41422,"NA":41424},{"trials":41407,"activeCount":103},[],{"trials":41409,"activeCount":103},[41410],{"nctId":41411,"briefTitle":41412,"status":111,"phases":41413,"primaryCompletion":11170,"completion":11170,"start":523,"enrollment":360,"conditions":41414,"interventions":41416},"NCT01311505","Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)",[91],[41415],"Tuberculosis",[41404,41417],"Rimactane®",{"trials":41419,"activeCount":103},[],{"trials":41421,"activeCount":103},[],{"trials":41423,"activeCount":103},[],{"trials":41425,"activeCount":103},[],{"intervention":41417,"totalTrials":302,"cells":41427},{"EARLY_PHASE1":41428,"PHASE1":41430,"PHASE2":41436,"PHASE3":41438,"PHASE4":41440,"NA":41442},{"trials":41429,"activeCount":103},[],{"trials":41431,"activeCount":103},[41432],{"nctId":41411,"briefTitle":41412,"status":111,"phases":41433,"primaryCompletion":11170,"completion":11170,"start":523,"enrollment":360,"conditions":41434,"interventions":41435},[91],[41415],[41404,41417],{"trials":41437,"activeCount":103},[],{"trials":41439,"activeCount":103},[],{"trials":41441,"activeCount":103},[],{"trials":41443,"activeCount":103},[],{"intervention":41445,"totalTrials":302,"cells":41446},"Eletriptan commercial",{"EARLY_PHASE1":41447,"PHASE1":41449,"PHASE2":41457,"PHASE3":41459,"PHASE4":41461,"NA":41463},{"trials":41448,"activeCount":103},[],{"trials":41450,"activeCount":103},[41451],{"nctId":41452,"briefTitle":41453,"status":111,"phases":41454,"primaryCompletion":586,"completion":586,"start":586,"enrollment":314,"conditions":41455,"interventions":41456},"NCT01139515","Eletriptan Pharmacokinetics In Korean Males",[91],[16],[41445,41445,41445,41445],{"trials":41458,"activeCount":103},[],{"trials":41460,"activeCount":103},[],{"trials":41462,"activeCount":103},[],{"trials":41464,"activeCount":103},[],{"intervention":41466,"totalTrials":302,"cells":41467},"desvenlafaxine",{"EARLY_PHASE1":41468,"PHASE1":41470,"PHASE2":41478,"PHASE3":41480,"PHASE4":41482,"NA":41484},{"trials":41469,"activeCount":103},[],{"trials":41471,"activeCount":103},[41472],{"nctId":41473,"briefTitle":41474,"status":111,"phases":41475,"primaryCompletion":2883,"completion":2883,"start":570,"enrollment":1530,"conditions":41476,"interventions":41477},"NCT01443208","Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet",[91],[6321],[41466,41466,41466],{"trials":41479,"activeCount":103},[],{"trials":41481,"activeCount":103},[],{"trials":41483,"activeCount":103},[],{"trials":41485,"activeCount":103},[],{"intervention":41487,"totalTrials":302,"cells":41488},"[14C]PF00299804",{"EARLY_PHASE1":41489,"PHASE1":41491,"PHASE2":41499,"PHASE3":41501,"PHASE4":41503,"NA":41505},{"trials":41490,"activeCount":103},[],{"trials":41492,"activeCount":103},[41493],{"nctId":41494,"briefTitle":41495,"status":111,"phases":41496,"primaryCompletion":11988,"completion":11988,"start":10923,"enrollment":2070,"conditions":41497,"interventions":41498},"NCT01034748","A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers",[91],[376],[41487],{"trials":41500,"activeCount":103},[],{"trials":41502,"activeCount":103},[],{"trials":41504,"activeCount":103},[],{"trials":41506,"activeCount":103},[],{"intervention":41508,"totalTrials":302,"cells":41509},"PF-04418948",{"EARLY_PHASE1":41510,"PHASE1":41512,"PHASE2":41520,"PHASE3":41522,"PHASE4":41524,"NA":41526},{"trials":41511,"activeCount":103},[],{"trials":41513,"activeCount":103},[41514],{"nctId":41515,"briefTitle":41516,"status":111,"phases":41517,"primaryCompletion":11988,"completion":11988,"start":4833,"enrollment":3202,"conditions":41518,"interventions":41519},"NCT01002963","A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers",[91],[16],[41508,41508,41508,41508,41508,41508,41508],{"trials":41521,"activeCount":103},[],{"trials":41523,"activeCount":103},[],{"trials":41525,"activeCount":103},[],{"trials":41527,"activeCount":103},[],{"intervention":41529,"totalTrials":302,"cells":41530},"PF-06342674 0.25 mg\u002Fkg",{"EARLY_PHASE1":41531,"PHASE1":41533,"PHASE2":41544,"PHASE3":41546,"PHASE4":41548,"NA":41550},{"trials":41532,"activeCount":103},[],{"trials":41534,"activeCount":103},[41535],{"nctId":41536,"briefTitle":41537,"status":168,"phases":41538,"primaryCompletion":626,"completion":626,"start":9572,"enrollment":257,"conditions":41539,"interventions":41541},"NCT02045732","A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)",[91],[41540],"Multiple Sclerosis",[41529,41542,41543],"PF-06342674 1.5 mg\u002Fkg","PF-06342674 6.0 mg\u002Fkg",{"trials":41545,"activeCount":103},[],{"trials":41547,"activeCount":103},[],{"trials":41549,"activeCount":103},[],{"trials":41551,"activeCount":103},[],{"intervention":41542,"totalTrials":302,"cells":41553},{"EARLY_PHASE1":41554,"PHASE1":41556,"PHASE2":41562,"PHASE3":41564,"PHASE4":41566,"NA":41568},{"trials":41555,"activeCount":103},[],{"trials":41557,"activeCount":103},[41558],{"nctId":41536,"briefTitle":41537,"status":168,"phases":41559,"primaryCompletion":626,"completion":626,"start":9572,"enrollment":257,"conditions":41560,"interventions":41561},[91],[41540],[41529,41542,41543],{"trials":41563,"activeCount":103},[],{"trials":41565,"activeCount":103},[],{"trials":41567,"activeCount":103},[],{"trials":41569,"activeCount":103},[],{"intervention":41543,"totalTrials":302,"cells":41571},{"EARLY_PHASE1":41572,"PHASE1":41574,"PHASE2":41580,"PHASE3":41582,"PHASE4":41584,"NA":41586},{"trials":41573,"activeCount":103},[],{"trials":41575,"activeCount":103},[41576],{"nctId":41536,"briefTitle":41537,"status":168,"phases":41577,"primaryCompletion":626,"completion":626,"start":9572,"enrollment":257,"conditions":41578,"interventions":41579},[91],[41540],[41529,41542,41543],{"trials":41581,"activeCount":103},[],{"trials":41583,"activeCount":103},[],{"trials":41585,"activeCount":103},[],{"trials":41587,"activeCount":103},[],{"intervention":41589,"totalTrials":302,"cells":41590},"P3-Fast",{"EARLY_PHASE1":41591,"PHASE1":41593,"PHASE2":41605,"PHASE3":41607,"PHASE4":41609,"NA":41611},{"trials":41592,"activeCount":103},[],{"trials":41594,"activeCount":103},[41595],{"nctId":41596,"briefTitle":41597,"status":111,"phases":41598,"primaryCompletion":41599,"completion":41599,"start":29232,"enrollment":787,"conditions":41600,"interventions":41601},"NCT04065633","Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation",[91],"2019-12-14",[1933],[41589,41602,41603,41604],"Comm-Fast","Vari-Fast","Comm-Fed",{"trials":41606,"activeCount":103},[],{"trials":41608,"activeCount":103},[],{"trials":41610,"activeCount":103},[],{"trials":41612,"activeCount":103},[],{"intervention":41602,"totalTrials":302,"cells":41614},{"EARLY_PHASE1":41615,"PHASE1":41617,"PHASE2":41623,"PHASE3":41625,"PHASE4":41627,"NA":41629},{"trials":41616,"activeCount":103},[],{"trials":41618,"activeCount":103},[41619],{"nctId":41596,"briefTitle":41597,"status":111,"phases":41620,"primaryCompletion":41599,"completion":41599,"start":29232,"enrollment":787,"conditions":41621,"interventions":41622},[91],[1933],[41589,41602,41603,41604],{"trials":41624,"activeCount":103},[],{"trials":41626,"activeCount":103},[],{"trials":41628,"activeCount":103},[],{"trials":41630,"activeCount":103},[],{"intervention":41603,"totalTrials":302,"cells":41632},{"EARLY_PHASE1":41633,"PHASE1":41635,"PHASE2":41641,"PHASE3":41643,"PHASE4":41645,"NA":41647},{"trials":41634,"activeCount":103},[],{"trials":41636,"activeCount":103},[41637],{"nctId":41596,"briefTitle":41597,"status":111,"phases":41638,"primaryCompletion":41599,"completion":41599,"start":29232,"enrollment":787,"conditions":41639,"interventions":41640},[91],[1933],[41589,41602,41603,41604],{"trials":41642,"activeCount":103},[],{"trials":41644,"activeCount":103},[],{"trials":41646,"activeCount":103},[],{"trials":41648,"activeCount":103},[],{"intervention":41604,"totalTrials":302,"cells":41650},{"EARLY_PHASE1":41651,"PHASE1":41653,"PHASE2":41659,"PHASE3":41661,"PHASE4":41663,"NA":41665},{"trials":41652,"activeCount":103},[],{"trials":41654,"activeCount":103},[41655],{"nctId":41596,"briefTitle":41597,"status":111,"phases":41656,"primaryCompletion":41599,"completion":41599,"start":29232,"enrollment":787,"conditions":41657,"interventions":41658},[91],[1933],[41589,41602,41603,41604],{"trials":41660,"activeCount":103},[],{"trials":41662,"activeCount":103},[],{"trials":41664,"activeCount":103},[],{"trials":41666,"activeCount":103},[],{"intervention":41668,"totalTrials":302,"cells":41669},"UK369,003",{"EARLY_PHASE1":41670,"PHASE1":41672,"PHASE2":41680,"PHASE3":41682,"PHASE4":41684,"NA":41686},{"trials":41671,"activeCount":103},[],{"trials":41673,"activeCount":103},[41674],{"nctId":41675,"briefTitle":41676,"status":111,"phases":41677,"primaryCompletion":11291,"completion":11291,"start":8115,"enrollment":525,"conditions":41678,"interventions":41679},"NCT00814736","A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031",[91],[30668,12472,40141],[41668,28526],{"trials":41681,"activeCount":103},[],{"trials":41683,"activeCount":103},[],{"trials":41685,"activeCount":103},[],{"trials":41687,"activeCount":103},[],{"intervention":41689,"totalTrials":302,"cells":41690},"Small Molecule Agent",{"EARLY_PHASE1":41691,"PHASE1":41693,"PHASE2":41703,"PHASE3":41705,"PHASE4":41707,"NA":41709},{"trials":41692,"activeCount":103},[],{"trials":41694,"activeCount":103},[41695],{"nctId":41696,"briefTitle":41697,"status":111,"phases":41698,"primaryCompletion":8154,"completion":8154,"start":3314,"enrollment":2159,"conditions":41699,"interventions":41702},"NCT00671671","Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.",[91],[41700,41701],"Hepatitis, Chronic","Hepatitis C Virus",[41689,41689],{"trials":41704,"activeCount":103},[],{"trials":41706,"activeCount":103},[],{"trials":41708,"activeCount":103},[],{"trials":41710,"activeCount":103},[],{"intervention":41712,"totalTrials":302,"cells":41713},"EMBEDA - morphine sulfate\u002F naltrexone hydrochloride",{"EARLY_PHASE1":41714,"PHASE1":41716,"PHASE2":41727,"PHASE3":41729,"PHASE4":41731,"NA":41733},{"trials":41715,"activeCount":103},[],{"trials":41717,"activeCount":103},[41718],{"nctId":41719,"briefTitle":41720,"status":111,"phases":41721,"primaryCompletion":3601,"completion":3601,"start":561,"enrollment":5987,"conditions":41722,"interventions":41725},"NCT01595867","Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo",[91],[41723,41724,13121,13120],"Narcotic Abuse","Opioid-related Disorders",[41712,41726],"morphine sulfate CR crushed.",{"trials":41728,"activeCount":103},[],{"trials":41730,"activeCount":103},[],{"trials":41732,"activeCount":103},[],{"trials":41734,"activeCount":103},[],{"intervention":41726,"totalTrials":302,"cells":41736},{"EARLY_PHASE1":41737,"PHASE1":41739,"PHASE2":41745,"PHASE3":41747,"PHASE4":41749,"NA":41751},{"trials":41738,"activeCount":103},[],{"trials":41740,"activeCount":103},[41741],{"nctId":41719,"briefTitle":41720,"status":111,"phases":41742,"primaryCompletion":3601,"completion":3601,"start":561,"enrollment":5987,"conditions":41743,"interventions":41744},[91],[41723,41724,13121,13120],[41712,41726],{"trials":41746,"activeCount":103},[],{"trials":41748,"activeCount":103},[],{"trials":41750,"activeCount":103},[],{"trials":41752,"activeCount":103},[],{"intervention":40082,"totalTrials":302,"cells":41754},{"EARLY_PHASE1":41755,"PHASE1":41757,"PHASE2":41763,"PHASE3":41765,"PHASE4":41767,"NA":41769},{"trials":41756,"activeCount":103},[],{"trials":41758,"activeCount":103},[41759],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41760,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41761,"interventions":41762},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41764,"activeCount":103},[],{"trials":41766,"activeCount":103},[],{"trials":41768,"activeCount":103},[],{"trials":41770,"activeCount":103},[],{"intervention":40083,"totalTrials":302,"cells":41772},{"EARLY_PHASE1":41773,"PHASE1":41775,"PHASE2":41781,"PHASE3":41783,"PHASE4":41785,"NA":41787},{"trials":41774,"activeCount":103},[],{"trials":41776,"activeCount":103},[41777],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41778,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41779,"interventions":41780},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41782,"activeCount":103},[],{"trials":41784,"activeCount":103},[],{"trials":41786,"activeCount":103},[],{"trials":41788,"activeCount":103},[],{"intervention":40084,"totalTrials":302,"cells":41790},{"EARLY_PHASE1":41791,"PHASE1":41793,"PHASE2":41799,"PHASE3":41801,"PHASE4":41803,"NA":41805},{"trials":41792,"activeCount":103},[],{"trials":41794,"activeCount":103},[41795],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41796,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41797,"interventions":41798},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41800,"activeCount":103},[],{"trials":41802,"activeCount":103},[],{"trials":41804,"activeCount":103},[],{"trials":41806,"activeCount":103},[],{"intervention":40085,"totalTrials":302,"cells":41808},{"EARLY_PHASE1":41809,"PHASE1":41811,"PHASE2":41817,"PHASE3":41819,"PHASE4":41821,"NA":41823},{"trials":41810,"activeCount":103},[],{"trials":41812,"activeCount":103},[41813],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41814,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41815,"interventions":41816},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41818,"activeCount":103},[],{"trials":41820,"activeCount":103},[],{"trials":41822,"activeCount":103},[],{"trials":41824,"activeCount":103},[],{"intervention":40086,"totalTrials":302,"cells":41826},{"EARLY_PHASE1":41827,"PHASE1":41829,"PHASE2":41835,"PHASE3":41837,"PHASE4":41839,"NA":41841},{"trials":41828,"activeCount":103},[],{"trials":41830,"activeCount":103},[41831],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41832,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41833,"interventions":41834},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41836,"activeCount":103},[],{"trials":41838,"activeCount":103},[],{"trials":41840,"activeCount":103},[],{"trials":41842,"activeCount":103},[],{"intervention":40087,"totalTrials":302,"cells":41844},{"EARLY_PHASE1":41845,"PHASE1":41847,"PHASE2":41853,"PHASE3":41855,"PHASE4":41857,"NA":41859},{"trials":41846,"activeCount":103},[],{"trials":41848,"activeCount":103},[41849],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41850,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41851,"interventions":41852},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41854,"activeCount":103},[],{"trials":41856,"activeCount":103},[],{"trials":41858,"activeCount":103},[],{"trials":41860,"activeCount":103},[],{"intervention":40088,"totalTrials":302,"cells":41862},{"EARLY_PHASE1":41863,"PHASE1":41865,"PHASE2":41871,"PHASE3":41873,"PHASE4":41875,"NA":41877},{"trials":41864,"activeCount":103},[],{"trials":41866,"activeCount":103},[41867],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41868,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41869,"interventions":41870},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41872,"activeCount":103},[],{"trials":41874,"activeCount":103},[],{"trials":41876,"activeCount":103},[],{"trials":41878,"activeCount":103},[],{"intervention":40089,"totalTrials":302,"cells":41880},{"EARLY_PHASE1":41881,"PHASE1":41883,"PHASE2":41889,"PHASE3":41891,"PHASE4":41893,"NA":41895},{"trials":41882,"activeCount":103},[],{"trials":41884,"activeCount":103},[41885],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41886,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41887,"interventions":41888},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41890,"activeCount":103},[],{"trials":41892,"activeCount":103},[],{"trials":41894,"activeCount":103},[],{"trials":41896,"activeCount":103},[],{"intervention":40090,"totalTrials":302,"cells":41898},{"EARLY_PHASE1":41899,"PHASE1":41901,"PHASE2":41907,"PHASE3":41909,"PHASE4":41911,"NA":41913},{"trials":41900,"activeCount":103},[],{"trials":41902,"activeCount":103},[41903],{"nctId":40077,"briefTitle":40078,"status":168,"phases":41904,"primaryCompletion":11014,"completion":11014,"start":4222,"enrollment":1268,"conditions":41905,"interventions":41906},[91],[16],[40082,40083,40084,40085,40086,40087,40088,40089,40070,40090],{"trials":41908,"activeCount":103},[],{"trials":41910,"activeCount":103},[],{"trials":41912,"activeCount":103},[],{"trials":41914,"activeCount":103},[],{"intervention":41916,"totalTrials":302,"cells":41917},"Nicergoline from China",{"EARLY_PHASE1":41918,"PHASE1":41920,"PHASE2":41931,"PHASE3":41933,"PHASE4":41935,"NA":41937},{"trials":41919,"activeCount":103},[],{"trials":41921,"activeCount":103},[41922],{"nctId":41923,"briefTitle":41924,"status":111,"phases":41925,"primaryCompletion":41926,"completion":41926,"start":41927,"enrollment":35,"conditions":41928,"interventions":41929},"NCT04176367","An Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactured in Italy Under Fasted and Fed Conditions in Healthy Chinese Participants",[91],"2020-09-29","2019-12-17",[3396],[41916,41930],"Nicergoline from Italy",{"trials":41932,"activeCount":103},[],{"trials":41934,"activeCount":103},[],{"trials":41936,"activeCount":103},[],{"trials":41938,"activeCount":103},[],{"intervention":41930,"totalTrials":302,"cells":41940},{"EARLY_PHASE1":41941,"PHASE1":41943,"PHASE2":41949,"PHASE3":41951,"PHASE4":41953,"NA":41955},{"trials":41942,"activeCount":103},[],{"trials":41944,"activeCount":103},[41945],{"nctId":41923,"briefTitle":41924,"status":111,"phases":41946,"primaryCompletion":41926,"completion":41926,"start":41927,"enrollment":35,"conditions":41947,"interventions":41948},[91],[3396],[41916,41930],{"trials":41950,"activeCount":103},[],{"trials":41952,"activeCount":103},[],{"trials":41954,"activeCount":103},[],{"trials":41956,"activeCount":103},[],{"intervention":38934,"totalTrials":302,"cells":41958},{"EARLY_PHASE1":41959,"PHASE1":41961,"PHASE2":41967,"PHASE3":41969,"PHASE4":41971,"NA":41973},{"trials":41960,"activeCount":103},[],{"trials":41962,"activeCount":103},[41963],{"nctId":38927,"briefTitle":38928,"status":168,"phases":41964,"primaryCompletion":38930,"completion":38931,"start":4458,"enrollment":1509,"conditions":41965,"interventions":41966},[91],[9053],[17915,38934],{"trials":41968,"activeCount":103},[],{"trials":41970,"activeCount":103},[],{"trials":41972,"activeCount":103},[],{"trials":41974,"activeCount":103},[],{"intervention":41976,"totalTrials":302,"cells":41977},"PSI-697",{"EARLY_PHASE1":41978,"PHASE1":41980,"PHASE2":41989,"PHASE3":41991,"PHASE4":41993,"NA":41995},{"trials":41979,"activeCount":103},[],{"trials":41981,"activeCount":103},[41982],{"nctId":41983,"briefTitle":41984,"status":111,"phases":41985,"primaryCompletion":26913,"completion":26913,"start":41986,"enrollment":1780,"conditions":41987,"interventions":41988},"NCT03860506","Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke",[91],"2008-04-01",[16],[41976],{"trials":41990,"activeCount":103},[],{"trials":41992,"activeCount":103},[],{"trials":41994,"activeCount":103},[],{"trials":41996,"activeCount":103},[],{"intervention":41998,"totalTrials":302,"cells":41999},"PF-03882845",{"EARLY_PHASE1":42000,"PHASE1":42002,"PHASE2":42010,"PHASE3":42012,"PHASE4":42014,"NA":42016},{"trials":42001,"activeCount":103},[],{"trials":42003,"activeCount":103},[42004],{"nctId":42005,"briefTitle":42006,"status":111,"phases":42007,"primaryCompletion":4666,"completion":4666,"start":3601,"enrollment":1268,"conditions":42008,"interventions":42009},"NCT01366287","A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption",[91],[37],[41998,41998,41998],{"trials":42011,"activeCount":103},[],{"trials":42013,"activeCount":103},[],{"trials":42015,"activeCount":103},[],{"trials":42017,"activeCount":103},[],{"intervention":42019,"totalTrials":302,"cells":42020},"Varenicline Tartrate Controlled Release",{"EARLY_PHASE1":42021,"PHASE1":42023,"PHASE2":42031,"PHASE3":42033,"PHASE4":42035,"NA":42037},{"trials":42022,"activeCount":103},[],{"trials":42024,"activeCount":103},[42025],{"nctId":42026,"briefTitle":42027,"status":111,"phases":42028,"primaryCompletion":11291,"completion":11291,"start":4207,"enrollment":1509,"conditions":42029,"interventions":42030},"NCT00731562","An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation",[91],[3396,12580,11904],[42019,42019],{"trials":42032,"activeCount":103},[],{"trials":42034,"activeCount":103},[],{"trials":42036,"activeCount":103},[],{"trials":42038,"activeCount":103},[],{"intervention":42040,"totalTrials":302,"cells":42041},"SU011248; Capecitabine",{"EARLY_PHASE1":42042,"PHASE1":42044,"PHASE2":42052,"PHASE3":42054,"PHASE4":42056,"NA":42058},{"trials":42043,"activeCount":103},[],{"trials":42045,"activeCount":103},[42046],{"nctId":42047,"briefTitle":42048,"status":111,"phases":42049,"primaryCompletion":4207,"completion":4207,"start":11829,"enrollment":5647,"conditions":42050,"interventions":42051},"NCT00618124","A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together",[91],[750,31,2053],[42040],{"trials":42053,"activeCount":103},[],{"trials":42055,"activeCount":103},[],{"trials":42057,"activeCount":103},[],{"trials":42059,"activeCount":103},[],{"intervention":42061,"totalTrials":302,"cells":42062},"SAM-760",{"EARLY_PHASE1":42063,"PHASE1":42065,"PHASE2":42073,"PHASE3":42075,"PHASE4":42077,"NA":42079},{"trials":42064,"activeCount":103},[],{"trials":42066,"activeCount":103},[42067],{"nctId":42068,"briefTitle":42069,"status":111,"phases":42070,"primaryCompletion":4656,"completion":4656,"start":4833,"enrollment":7905,"conditions":42071,"interventions":42072},"NCT00948662","Study Evaluating The Safety And Tolerability Of Administration Of Single Oral Doses Of SAM-760 To Healthy Subjects",[91],[16],[42061,620],{"trials":42074,"activeCount":103},[],{"trials":42076,"activeCount":103},[],{"trials":42078,"activeCount":103},[],{"trials":42080,"activeCount":103},[],{"intervention":8102,"totalTrials":302,"cells":42082},{"EARLY_PHASE1":42083,"PHASE1":42085,"PHASE2":42091,"PHASE3":42093,"PHASE4":42095,"NA":42097},{"trials":42084,"activeCount":103},[],{"trials":42086,"activeCount":103},[42087],{"nctId":8097,"briefTitle":8098,"status":111,"phases":42088,"primaryCompletion":4627,"completion":605,"start":2964,"enrollment":504,"conditions":42089,"interventions":42090},[91],[2886],[1770,8102,4327],{"trials":42092,"activeCount":103},[],{"trials":42094,"activeCount":103},[],{"trials":42096,"activeCount":103},[],{"trials":42098,"activeCount":103},[],{"intervention":42100,"totalTrials":302,"cells":42101},"Ibuprofen 5% topical gel",{"EARLY_PHASE1":42102,"PHASE1":42104,"PHASE2":42115,"PHASE3":42117,"PHASE4":42119,"NA":42121},{"trials":42103,"activeCount":103},[],{"trials":42105,"activeCount":103},[42106],{"nctId":42107,"briefTitle":42108,"status":111,"phases":42109,"primaryCompletion":18128,"completion":18128,"start":4590,"enrollment":26,"conditions":42110,"interventions":42111},"NCT01771822","Ibuprofen 5% Topical Gel CIPT",[91],[34],[42100,42112,42113,42114],"Topical gel vehicle","Sodium lauryl sulfate 0.2%","Sodium chloride solution 0.9%",{"trials":42116,"activeCount":103},[],{"trials":42118,"activeCount":103},[],{"trials":42120,"activeCount":103},[],{"trials":42122,"activeCount":103},[],{"intervention":42112,"totalTrials":302,"cells":42124},{"EARLY_PHASE1":42125,"PHASE1":42127,"PHASE2":42133,"PHASE3":42135,"PHASE4":42137,"NA":42139},{"trials":42126,"activeCount":103},[],{"trials":42128,"activeCount":103},[42129],{"nctId":42107,"briefTitle":42108,"status":111,"phases":42130,"primaryCompletion":18128,"completion":18128,"start":4590,"enrollment":26,"conditions":42131,"interventions":42132},[91],[34],[42100,42112,42113,42114],{"trials":42134,"activeCount":103},[],{"trials":42136,"activeCount":103},[],{"trials":42138,"activeCount":103},[],{"trials":42140,"activeCount":103},[],{"intervention":42113,"totalTrials":302,"cells":42142},{"EARLY_PHASE1":42143,"PHASE1":42145,"PHASE2":42151,"PHASE3":42153,"PHASE4":42155,"NA":42157},{"trials":42144,"activeCount":103},[],{"trials":42146,"activeCount":103},[42147],{"nctId":42107,"briefTitle":42108,"status":111,"phases":42148,"primaryCompletion":18128,"completion":18128,"start":4590,"enrollment":26,"conditions":42149,"interventions":42150},[91],[34],[42100,42112,42113,42114],{"trials":42152,"activeCount":103},[],{"trials":42154,"activeCount":103},[],{"trials":42156,"activeCount":103},[],{"trials":42158,"activeCount":103},[],{"intervention":42114,"totalTrials":302,"cells":42160},{"EARLY_PHASE1":42161,"PHASE1":42163,"PHASE2":42169,"PHASE3":42171,"PHASE4":42173,"NA":42175},{"trials":42162,"activeCount":103},[],{"trials":42164,"activeCount":103},[42165],{"nctId":42107,"briefTitle":42108,"status":111,"phases":42166,"primaryCompletion":18128,"completion":18128,"start":4590,"enrollment":26,"conditions":42167,"interventions":42168},[91],[34],[42100,42112,42113,42114],{"trials":42170,"activeCount":103},[],{"trials":42172,"activeCount":103},[],{"trials":42174,"activeCount":103},[],{"trials":42176,"activeCount":103},[],{"intervention":17957,"totalTrials":302,"cells":42178},{"EARLY_PHASE1":42179,"PHASE1":42181,"PHASE2":42187,"PHASE3":42189,"PHASE4":42191,"NA":42193},{"trials":42180,"activeCount":103},[],{"trials":42182,"activeCount":103},[42183],{"nctId":17951,"briefTitle":17952,"status":168,"phases":42184,"primaryCompletion":17954,"completion":17954,"start":5820,"enrollment":1487,"conditions":42185,"interventions":42186},[91],[2938],[17957,17958,17959,2940,17960],{"trials":42188,"activeCount":103},[],{"trials":42190,"activeCount":103},[],{"trials":42192,"activeCount":103},[],{"trials":42194,"activeCount":103},[],{"intervention":42196,"totalTrials":302,"cells":42197},"[phenyl-14C]ARV-471",{"EARLY_PHASE1":42198,"PHASE1":42200,"PHASE2":42210,"PHASE3":42212,"PHASE4":42214,"NA":42216},{"trials":42199,"activeCount":103},[],{"trials":42201,"activeCount":103},[42202],{"nctId":42203,"briefTitle":42204,"status":111,"phases":42205,"primaryCompletion":6180,"completion":746,"start":42206,"enrollment":1268,"conditions":42207,"interventions":42208},"NCT05930925","A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults",[91],"2023-06-12",[16],[42196,42209],"[oxoisoindolin-14C]ARV-471",{"trials":42211,"activeCount":103},[],{"trials":42213,"activeCount":103},[],{"trials":42215,"activeCount":103},[],{"trials":42217,"activeCount":103},[],{"intervention":42209,"totalTrials":302,"cells":42219},{"EARLY_PHASE1":42220,"PHASE1":42222,"PHASE2":42228,"PHASE3":42230,"PHASE4":42232,"NA":42234},{"trials":42221,"activeCount":103},[],{"trials":42223,"activeCount":103},[42224],{"nctId":42203,"briefTitle":42204,"status":111,"phases":42225,"primaryCompletion":6180,"completion":746,"start":42206,"enrollment":1268,"conditions":42226,"interventions":42227},[91],[16],[42196,42209],{"trials":42229,"activeCount":103},[],{"trials":42231,"activeCount":103},[],{"trials":42233,"activeCount":103},[],{"trials":42235,"activeCount":103},[],{"intervention":18029,"totalTrials":302,"cells":42237},{"EARLY_PHASE1":42238,"PHASE1":42240,"PHASE2":42246,"PHASE3":42248,"PHASE4":42250,"NA":42252},{"trials":42239,"activeCount":103},[],{"trials":42241,"activeCount":103},[42242],{"nctId":18023,"briefTitle":18024,"status":111,"phases":42243,"primaryCompletion":540,"completion":540,"start":18026,"enrollment":5909,"conditions":42244,"interventions":42245},[91],[16],[12302,12312,18029],{"trials":42247,"activeCount":103},[],{"trials":42249,"activeCount":103},[],{"trials":42251,"activeCount":103},[],{"trials":42253,"activeCount":103},[],{"intervention":42255,"totalTrials":302,"cells":42256},"PF-04895162",{"EARLY_PHASE1":42257,"PHASE1":42259,"PHASE2":42267,"PHASE3":42269,"PHASE4":42271,"NA":42273},{"trials":42258,"activeCount":103},[],{"trials":42260,"activeCount":103},[42261],{"nctId":42262,"briefTitle":42263,"status":111,"phases":42264,"primaryCompletion":4680,"completion":4680,"start":3353,"enrollment":870,"conditions":42265,"interventions":42266},"NCT01691274","A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162",[91],[16],[42255,42255,42255],{"trials":42268,"activeCount":103},[],{"trials":42270,"activeCount":103},[],{"trials":42272,"activeCount":103},[],{"trials":42274,"activeCount":103},[],{"intervention":19462,"totalTrials":302,"cells":42276},{"EARLY_PHASE1":42277,"PHASE1":42279,"PHASE2":42285,"PHASE3":42287,"PHASE4":42289,"NA":42291},{"trials":42278,"activeCount":103},[],{"trials":42280,"activeCount":103},[42281],{"nctId":19457,"briefTitle":19458,"status":649,"phases":42282,"start":4847,"enrollment":103,"conditions":42283,"interventions":42284},[91],[2761],[19462,17284],{"trials":42286,"activeCount":103},[],{"trials":42288,"activeCount":103},[],{"trials":42290,"activeCount":103},[],{"trials":42292,"activeCount":103},[],{"intervention":18798,"totalTrials":302,"cells":42294},{"EARLY_PHASE1":42295,"PHASE1":42297,"PHASE2":42303,"PHASE3":42305,"PHASE4":42307,"NA":42309},{"trials":42296,"activeCount":103},[],{"trials":42298,"activeCount":103},[42299],{"nctId":18792,"briefTitle":18793,"status":111,"phases":42300,"primaryCompletion":3324,"completion":3324,"start":6198,"enrollment":18795,"conditions":42301,"interventions":42302},[91],[16],[12704,18798,18798],{"trials":42304,"activeCount":103},[],{"trials":42306,"activeCount":103},[],{"trials":42308,"activeCount":103},[],{"trials":42310,"activeCount":103},[],{"intervention":28394,"totalTrials":302,"cells":42312},{"EARLY_PHASE1":42313,"PHASE1":42315,"PHASE2":42321,"PHASE3":42323,"PHASE4":42325,"NA":42327},{"trials":42314,"activeCount":103},[],{"trials":42316,"activeCount":103},[42317],{"nctId":28387,"briefTitle":28388,"status":111,"phases":42318,"primaryCompletion":28390,"completion":28390,"start":28391,"enrollment":374,"conditions":42319,"interventions":42320},[91],[26842],[27131,28394],{"trials":42322,"activeCount":103},[],{"trials":42324,"activeCount":103},[],{"trials":42326,"activeCount":103},[],{"trials":42328,"activeCount":103},[],{"intervention":40196,"totalTrials":302,"cells":42330},{"EARLY_PHASE1":42331,"PHASE1":42333,"PHASE2":42339,"PHASE3":42341,"PHASE4":42343,"NA":42345},{"trials":42332,"activeCount":103},[],{"trials":42334,"activeCount":103},[42335],{"nctId":40191,"briefTitle":40192,"status":111,"phases":42336,"primaryCompletion":605,"completion":605,"start":1248,"enrollment":1530,"conditions":42337,"interventions":42338},[91],[16],[40196,40196,38526],{"trials":42340,"activeCount":103},[],{"trials":42342,"activeCount":103},[],{"trials":42344,"activeCount":103},[],{"trials":42346,"activeCount":103},[],{"intervention":42348,"totalTrials":302,"cells":42349},"pdmFlu vaccine",{"EARLY_PHASE1":42350,"PHASE1":42352,"PHASE2":42363,"PHASE3":42365,"PHASE4":42367,"NA":42369},{"trials":42351,"activeCount":103},[],{"trials":42353,"activeCount":103},[42354],{"nctId":42355,"briefTitle":42356,"status":111,"phases":42357,"primaryCompletion":31783,"completion":31783,"start":42358,"enrollment":7184,"conditions":42359,"interventions":42361},"NCT06179446","A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza",[91],"2023-12-13",[42360,10138,10626],"Grippe",[42348,42362],"Licensed influenza vaccine",{"trials":42364,"activeCount":103},[],{"trials":42366,"activeCount":103},[],{"trials":42368,"activeCount":103},[],{"trials":42370,"activeCount":103},[],{"intervention":42362,"totalTrials":302,"cells":42372},{"EARLY_PHASE1":42373,"PHASE1":42375,"PHASE2":42381,"PHASE3":42383,"PHASE4":42385,"NA":42387},{"trials":42374,"activeCount":103},[],{"trials":42376,"activeCount":103},[42377],{"nctId":42355,"briefTitle":42356,"status":111,"phases":42378,"primaryCompletion":31783,"completion":31783,"start":42358,"enrollment":7184,"conditions":42379,"interventions":42380},[91],[42360,10138,10626],[42348,42362],{"trials":42382,"activeCount":103},[],{"trials":42384,"activeCount":103},[],{"trials":42386,"activeCount":103},[],{"trials":42388,"activeCount":103},[],{"intervention":38698,"totalTrials":302,"cells":42390},{"EARLY_PHASE1":42391,"PHASE1":42393,"PHASE2":42399,"PHASE3":42401,"PHASE4":42403,"NA":42405},{"trials":42392,"activeCount":103},[],{"trials":42394,"activeCount":103},[42395],{"nctId":38692,"briefTitle":38693,"status":111,"phases":42396,"primaryCompletion":4566,"completion":4566,"start":38249,"enrollment":35,"conditions":42397,"interventions":42398},[91],[16],[38697,38698,38699,38700],{"trials":42400,"activeCount":103},[],{"trials":42402,"activeCount":103},[],{"trials":42404,"activeCount":103},[],{"trials":42406,"activeCount":103},[],{"intervention":38699,"totalTrials":302,"cells":42408},{"EARLY_PHASE1":42409,"PHASE1":42411,"PHASE2":42417,"PHASE3":42419,"PHASE4":42421,"NA":42423},{"trials":42410,"activeCount":103},[],{"trials":42412,"activeCount":103},[42413],{"nctId":38692,"briefTitle":38693,"status":111,"phases":42414,"primaryCompletion":4566,"completion":4566,"start":38249,"enrollment":35,"conditions":42415,"interventions":42416},[91],[16],[38697,38698,38699,38700],{"trials":42418,"activeCount":103},[],{"trials":42420,"activeCount":103},[],{"trials":42422,"activeCount":103},[],{"trials":42424,"activeCount":103},[],{"intervention":38700,"totalTrials":302,"cells":42426},{"EARLY_PHASE1":42427,"PHASE1":42429,"PHASE2":42435,"PHASE3":42437,"PHASE4":42439,"NA":42441},{"trials":42428,"activeCount":103},[],{"trials":42430,"activeCount":103},[42431],{"nctId":38692,"briefTitle":38693,"status":111,"phases":42432,"primaryCompletion":4566,"completion":4566,"start":38249,"enrollment":35,"conditions":42433,"interventions":42434},[91],[16],[38697,38698,38699,38700],{"trials":42436,"activeCount":103},[],{"trials":42438,"activeCount":103},[],{"trials":42440,"activeCount":103},[],{"trials":42442,"activeCount":103},[],{"intervention":42444,"totalTrials":302,"cells":42445},"UK-396,082",{"EARLY_PHASE1":42446,"PHASE1":42448,"PHASE2":42459,"PHASE3":42461,"PHASE4":42463,"NA":42465},{"trials":42447,"activeCount":103},[],{"trials":42449,"activeCount":103},[42450],{"nctId":42451,"briefTitle":42452,"status":111,"phases":42453,"primaryCompletion":586,"completion":586,"start":3642,"enrollment":4369,"conditions":42454,"interventions":42458},"NCT01091532","A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.",[91],[6303,42455,10629,42456,42457],"Multiple Dose","Toleration","Pharmacokinetic",[42444,42444,42444,42444],{"trials":42460,"activeCount":103},[],{"trials":42462,"activeCount":103},[],{"trials":42464,"activeCount":103},[],{"trials":42466,"activeCount":103},[],{"intervention":42468,"totalTrials":302,"cells":42469},"PF-04805712",{"EARLY_PHASE1":42470,"PHASE1":42472,"PHASE2":42480,"PHASE3":42482,"PHASE4":42484,"NA":42486},{"trials":42471,"activeCount":103},[],{"trials":42473,"activeCount":103},[42474],{"nctId":42475,"briefTitle":42476,"status":168,"phases":42477,"primaryCompletion":561,"completion":561,"start":4846,"enrollment":2400,"conditions":42478,"interventions":42479},"NCT00991016","Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers",[91],[19],[42468],{"trials":42481,"activeCount":103},[],{"trials":42483,"activeCount":103},[],{"trials":42485,"activeCount":103},[],{"trials":42487,"activeCount":103},[],{"intervention":42489,"totalTrials":302,"cells":42490},"Fesoterodine ER",{"EARLY_PHASE1":42491,"PHASE1":42493,"PHASE2":42503,"PHASE3":42505,"PHASE4":42507,"NA":42509},{"trials":42492,"activeCount":103},[],{"trials":42494,"activeCount":103},[42495],{"nctId":42496,"briefTitle":42497,"status":111,"phases":42498,"primaryCompletion":11448,"completion":11448,"start":7971,"enrollment":1509,"conditions":42499,"interventions":42500},"NCT02160158","Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers",[91],[16],[42489,42501,42501,42489,42501,42489,42502,42502,42489,42502],"Fesoterodine SR3","Fesoterodine SR4",{"trials":42504,"activeCount":103},[],{"trials":42506,"activeCount":103},[],{"trials":42508,"activeCount":103},[],{"trials":42510,"activeCount":103},[],{"intervention":42501,"totalTrials":302,"cells":42512},{"EARLY_PHASE1":42513,"PHASE1":42515,"PHASE2":42521,"PHASE3":42523,"PHASE4":42525,"NA":42527},{"trials":42514,"activeCount":103},[],{"trials":42516,"activeCount":103},[42517],{"nctId":42496,"briefTitle":42497,"status":111,"phases":42518,"primaryCompletion":11448,"completion":11448,"start":7971,"enrollment":1509,"conditions":42519,"interventions":42520},[91],[16],[42489,42501,42501,42489,42501,42489,42502,42502,42489,42502],{"trials":42522,"activeCount":103},[],{"trials":42524,"activeCount":103},[],{"trials":42526,"activeCount":103},[],{"trials":42528,"activeCount":103},[],{"intervention":42502,"totalTrials":302,"cells":42530},{"EARLY_PHASE1":42531,"PHASE1":42533,"PHASE2":42539,"PHASE3":42541,"PHASE4":42543,"NA":42545},{"trials":42532,"activeCount":103},[],{"trials":42534,"activeCount":103},[42535],{"nctId":42496,"briefTitle":42497,"status":111,"phases":42536,"primaryCompletion":11448,"completion":11448,"start":7971,"enrollment":1509,"conditions":42537,"interventions":42538},[91],[16],[42489,42501,42501,42489,42501,42489,42502,42502,42489,42502],{"trials":42540,"activeCount":103},[],{"trials":42542,"activeCount":103},[],{"trials":42544,"activeCount":103},[],{"trials":42546,"activeCount":103},[],{"intervention":42548,"totalTrials":302,"cells":42549},"PF-07321332 (nirmatrelvir)\u002Fritonavir",{"EARLY_PHASE1":42550,"PHASE1":42552,"PHASE2":42561,"PHASE3":42563,"PHASE4":42565,"NA":42567},{"trials":42551,"activeCount":103},[],{"trials":42553,"activeCount":103},[42554],{"nctId":42555,"briefTitle":42556,"status":168,"phases":42557,"primaryCompletion":42558,"completion":42558,"start":1343,"enrollment":498,"conditions":42559,"interventions":42560},"NCT05487040","A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease",[91],"2023-07-11",[2592],[42548],{"trials":42562,"activeCount":103},[],{"trials":42564,"activeCount":103},[],{"trials":42566,"activeCount":103},[],{"trials":42568,"activeCount":103},[],{"intervention":42570,"totalTrials":302,"cells":42571},"Oral [14C] PF-06821497",{"EARLY_PHASE1":42572,"PHASE1":42574,"PHASE2":42585,"PHASE3":42587,"PHASE4":42589,"NA":42591},{"trials":42573,"activeCount":103},[],{"trials":42575,"activeCount":103},[42576],{"nctId":42577,"briefTitle":42578,"status":111,"phases":42579,"primaryCompletion":7740,"completion":7740,"start":42580,"enrollment":2070,"conditions":42581,"interventions":42582},"NCT06392230","A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.",[91],"2024-08-30",[28],[42570,42583,42584],"Oral PF-06821497","IV [14C] PF-06821497",{"trials":42586,"activeCount":103},[],{"trials":42588,"activeCount":103},[],{"trials":42590,"activeCount":103},[],{"trials":42592,"activeCount":103},[],{"intervention":42583,"totalTrials":302,"cells":42594},{"EARLY_PHASE1":42595,"PHASE1":42597,"PHASE2":42603,"PHASE3":42605,"PHASE4":42607,"NA":42609},{"trials":42596,"activeCount":103},[],{"trials":42598,"activeCount":103},[42599],{"nctId":42577,"briefTitle":42578,"status":111,"phases":42600,"primaryCompletion":7740,"completion":7740,"start":42580,"enrollment":2070,"conditions":42601,"interventions":42602},[91],[28],[42570,42583,42584],{"trials":42604,"activeCount":103},[],{"trials":42606,"activeCount":103},[],{"trials":42608,"activeCount":103},[],{"trials":42610,"activeCount":103},[],{"intervention":42584,"totalTrials":302,"cells":42612},{"EARLY_PHASE1":42613,"PHASE1":42615,"PHASE2":42621,"PHASE3":42623,"PHASE4":42625,"NA":42627},{"trials":42614,"activeCount":103},[],{"trials":42616,"activeCount":103},[42617],{"nctId":42577,"briefTitle":42578,"status":111,"phases":42618,"primaryCompletion":7740,"completion":7740,"start":42580,"enrollment":2070,"conditions":42619,"interventions":42620},[91],[28],[42570,42583,42584],{"trials":42622,"activeCount":103},[],{"trials":42624,"activeCount":103},[],{"trials":42626,"activeCount":103},[],{"trials":42628,"activeCount":103},[],{"intervention":42630,"totalTrials":302,"cells":42631},"Marstacimab PFP",{"EARLY_PHASE1":42632,"PHASE1":42634,"PHASE2":42644,"PHASE3":42646,"PHASE4":42648,"NA":42650},{"trials":42633,"activeCount":103},[],{"trials":42635,"activeCount":103},[42636],{"nctId":42637,"briefTitle":42638,"status":168,"phases":42639,"primaryCompletion":42640,"completion":42640,"start":29231,"enrollment":525,"conditions":42641,"interventions":42642},"NCT04832139","A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device",[91],"2021-11-22",[19],[42630,42643],"Marstacimab PFS",{"trials":42645,"activeCount":103},[],{"trials":42647,"activeCount":103},[],{"trials":42649,"activeCount":103},[],{"trials":42651,"activeCount":103},[],{"intervention":42643,"totalTrials":302,"cells":42653},{"EARLY_PHASE1":42654,"PHASE1":42656,"PHASE2":42662,"PHASE3":42664,"PHASE4":42666,"NA":42668},{"trials":42655,"activeCount":103},[],{"trials":42657,"activeCount":103},[42658],{"nctId":42637,"briefTitle":42638,"status":168,"phases":42659,"primaryCompletion":42640,"completion":42640,"start":29231,"enrollment":525,"conditions":42660,"interventions":42661},[91],[19],[42630,42643],{"trials":42663,"activeCount":103},[],{"trials":42665,"activeCount":103},[],{"trials":42667,"activeCount":103},[],{"trials":42669,"activeCount":103},[],{"intervention":42671,"totalTrials":302,"cells":42672},"suspension IR",{"EARLY_PHASE1":42673,"PHASE1":42675,"PHASE2":42686,"PHASE3":42688,"PHASE4":42690,"NA":42692},{"trials":42674,"activeCount":103},[],{"trials":42676,"activeCount":103},[42677],{"nctId":42678,"briefTitle":42679,"status":111,"phases":42680,"primaryCompletion":8115,"completion":8115,"start":4207,"enrollment":314,"conditions":42681,"interventions":42682},"NCT00782600","Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers",[91],[22],[42671,42683,42684,42685],"CR 1","CR 2","CR 3",{"trials":42687,"activeCount":103},[],{"trials":42689,"activeCount":103},[],{"trials":42691,"activeCount":103},[],{"trials":42693,"activeCount":103},[],{"intervention":42683,"totalTrials":302,"cells":42695},{"EARLY_PHASE1":42696,"PHASE1":42698,"PHASE2":42704,"PHASE3":42706,"PHASE4":42708,"NA":42710},{"trials":42697,"activeCount":103},[],{"trials":42699,"activeCount":103},[42700],{"nctId":42678,"briefTitle":42679,"status":111,"phases":42701,"primaryCompletion":8115,"completion":8115,"start":4207,"enrollment":314,"conditions":42702,"interventions":42703},[91],[22],[42671,42683,42684,42685],{"trials":42705,"activeCount":103},[],{"trials":42707,"activeCount":103},[],{"trials":42709,"activeCount":103},[],{"trials":42711,"activeCount":103},[],{"intervention":42684,"totalTrials":302,"cells":42713},{"EARLY_PHASE1":42714,"PHASE1":42716,"PHASE2":42722,"PHASE3":42724,"PHASE4":42726,"NA":42728},{"trials":42715,"activeCount":103},[],{"trials":42717,"activeCount":103},[42718],{"nctId":42678,"briefTitle":42679,"status":111,"phases":42719,"primaryCompletion":8115,"completion":8115,"start":4207,"enrollment":314,"conditions":42720,"interventions":42721},[91],[22],[42671,42683,42684,42685],{"trials":42723,"activeCount":103},[],{"trials":42725,"activeCount":103},[],{"trials":42727,"activeCount":103},[],{"trials":42729,"activeCount":103},[],{"intervention":42685,"totalTrials":302,"cells":42731},{"EARLY_PHASE1":42732,"PHASE1":42734,"PHASE2":42740,"PHASE3":42742,"PHASE4":42744,"NA":42746},{"trials":42733,"activeCount":103},[],{"trials":42735,"activeCount":103},[42736],{"nctId":42678,"briefTitle":42679,"status":111,"phases":42737,"primaryCompletion":8115,"completion":8115,"start":4207,"enrollment":314,"conditions":42738,"interventions":42739},[91],[22],[42671,42683,42684,42685],{"trials":42741,"activeCount":103},[],{"trials":42743,"activeCount":103},[],{"trials":42745,"activeCount":103},[],{"trials":42747,"activeCount":103},[],{"intervention":30058,"totalTrials":302,"cells":42749},{"EARLY_PHASE1":42750,"PHASE1":42752,"PHASE2":42758,"PHASE3":42760,"PHASE4":42762,"NA":42764},{"trials":42751,"activeCount":103},[],{"trials":42753,"activeCount":103},[42754],{"nctId":30053,"briefTitle":30054,"status":111,"phases":42755,"primaryCompletion":7386,"completion":7386,"start":4459,"enrollment":1122,"conditions":42756,"interventions":42757},[91],[16],[30046,30046,30058,30046,30046,30046,30046],{"trials":42759,"activeCount":103},[],{"trials":42761,"activeCount":103},[],{"trials":42763,"activeCount":103},[],{"trials":42765,"activeCount":103},[],{"intervention":30116,"totalTrials":302,"cells":42767},{"EARLY_PHASE1":42768,"PHASE1":42770,"PHASE2":42776,"PHASE3":42778,"PHASE4":42780,"NA":42782},{"trials":42769,"activeCount":103},[],{"trials":42771,"activeCount":103},[42772],{"nctId":30109,"briefTitle":30110,"status":111,"phases":42773,"primaryCompletion":30112,"completion":30112,"start":30113,"enrollment":16968,"conditions":42774,"interventions":42775},[91],[2053],[5219,5219,30116,30116],{"trials":42777,"activeCount":103},[],{"trials":42779,"activeCount":103},[],{"trials":42781,"activeCount":103},[],{"trials":42783,"activeCount":103},[],{"intervention":42785,"totalTrials":302,"cells":42786},"PF-0791800",{"EARLY_PHASE1":42787,"PHASE1":42789,"PHASE2":42802,"PHASE3":42804,"PHASE4":42806,"NA":42808},{"trials":42788,"activeCount":103},[],{"trials":42790,"activeCount":103},[42791],{"nctId":42792,"briefTitle":42793,"status":168,"phases":42794,"primaryCompletion":42795,"completion":42795,"start":42796,"enrollment":42797,"conditions":42798,"interventions":42799},"NCT02663518","A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors",[91],"2022-11-23","2016-01-28",249,[18092,338],[42785,42800,42801],"PF-07901800 (TTI-621) plus Rituximab","PF-07901800 (TTI-621) plus Nivolumab",{"trials":42803,"activeCount":103},[],{"trials":42805,"activeCount":103},[],{"trials":42807,"activeCount":103},[],{"trials":42809,"activeCount":103},[],{"intervention":42800,"totalTrials":302,"cells":42811},{"EARLY_PHASE1":42812,"PHASE1":42814,"PHASE2":42820,"PHASE3":42822,"PHASE4":42824,"NA":42826},{"trials":42813,"activeCount":103},[],{"trials":42815,"activeCount":103},[42816],{"nctId":42792,"briefTitle":42793,"status":168,"phases":42817,"primaryCompletion":42795,"completion":42795,"start":42796,"enrollment":42797,"conditions":42818,"interventions":42819},[91],[18092,338],[42785,42800,42801],{"trials":42821,"activeCount":103},[],{"trials":42823,"activeCount":103},[],{"trials":42825,"activeCount":103},[],{"trials":42827,"activeCount":103},[],{"intervention":42801,"totalTrials":302,"cells":42829},{"EARLY_PHASE1":42830,"PHASE1":42832,"PHASE2":42838,"PHASE3":42840,"PHASE4":42842,"NA":42844},{"trials":42831,"activeCount":103},[],{"trials":42833,"activeCount":103},[42834],{"nctId":42792,"briefTitle":42793,"status":168,"phases":42835,"primaryCompletion":42795,"completion":42795,"start":42796,"enrollment":42797,"conditions":42836,"interventions":42837},[91],[18092,338],[42785,42800,42801],{"trials":42839,"activeCount":103},[],{"trials":42841,"activeCount":103},[],{"trials":42843,"activeCount":103},[],{"trials":42845,"activeCount":103},[],{"intervention":42847,"totalTrials":302,"cells":42848},"sunitinib + mFOLFOX6",{"EARLY_PHASE1":42849,"PHASE1":42851,"PHASE2":42859,"PHASE3":42861,"PHASE4":42863,"NA":42865},{"trials":42850,"activeCount":103},[],{"trials":42852,"activeCount":103},[42853],{"nctId":42854,"briefTitle":42855,"status":111,"phases":42856,"primaryCompletion":4627,"completion":3642,"start":3853,"enrollment":1268,"conditions":42857,"interventions":42858},"NCT00631410","Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer",[91],[1028],[42847,42847],{"trials":42860,"activeCount":103},[],{"trials":42862,"activeCount":103},[],{"trials":42864,"activeCount":103},[],{"trials":42866,"activeCount":103},[],{"intervention":42868,"totalTrials":302,"cells":42869},"bazedoxifene\u002Fconjugated estrogens",{"EARLY_PHASE1":42870,"PHASE1":42872,"PHASE2":42881,"PHASE3":42883,"PHASE4":42885,"NA":42887},{"trials":42871,"activeCount":103},[],{"trials":42873,"activeCount":103},[42874],{"nctId":42875,"briefTitle":42876,"status":168,"phases":42877,"primaryCompletion":3345,"completion":3345,"start":569,"enrollment":1087,"conditions":42878,"interventions":42879},"NCT01634789","A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene\u002FConjugated Estrogens in Healthy Postmenopausal Women",[91],[16],[42880,42880,42880,42868],"bazedoxifene",{"trials":42882,"activeCount":103},[],{"trials":42884,"activeCount":103},[],{"trials":42886,"activeCount":103},[],{"trials":42888,"activeCount":103},[],{"intervention":42890,"totalTrials":302,"cells":42891},"fesoterodine plus fluconazole",{"EARLY_PHASE1":42892,"PHASE1":42894,"PHASE2":42903,"PHASE3":42905,"PHASE4":42907,"NA":42909},{"trials":42893,"activeCount":103},[],{"trials":42895,"activeCount":103},[42896],{"nctId":42897,"briefTitle":42898,"status":111,"phases":42899,"primaryCompletion":4627,"completion":4627,"start":11014,"enrollment":5909,"conditions":42900,"interventions":42902},"NCT00911235","The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects",[91],[42901],"Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence",[12750,42890],{"trials":42904,"activeCount":103},[],{"trials":42906,"activeCount":103},[],{"trials":42908,"activeCount":103},[],{"trials":42910,"activeCount":103},[],{"intervention":42912,"totalTrials":302,"cells":42913},"PF-06865571 Immediate release suspension",{"EARLY_PHASE1":42914,"PHASE1":42916,"PHASE2":42930,"PHASE3":42932,"PHASE4":42934,"NA":42936},{"trials":42915,"activeCount":103},[],{"trials":42917,"activeCount":103},[42918],{"nctId":42919,"briefTitle":42920,"status":111,"phases":42921,"primaryCompletion":42922,"completion":42923,"start":42924,"enrollment":1268,"conditions":42925,"interventions":42926},"NCT03372044","A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects",[91],"2018-03-09","2018-04-04","2018-01-19",[16],[42912,42927,42928,42929],"PF-06865571 Slow release MR","PF-06865571 Fast release MR","PF-06865571 Immediate release",{"trials":42931,"activeCount":103},[],{"trials":42933,"activeCount":103},[],{"trials":42935,"activeCount":103},[],{"trials":42937,"activeCount":103},[],{"intervention":42927,"totalTrials":302,"cells":42939},{"EARLY_PHASE1":42940,"PHASE1":42942,"PHASE2":42948,"PHASE3":42950,"PHASE4":42952,"NA":42954},{"trials":42941,"activeCount":103},[],{"trials":42943,"activeCount":103},[42944],{"nctId":42919,"briefTitle":42920,"status":111,"phases":42945,"primaryCompletion":42922,"completion":42923,"start":42924,"enrollment":1268,"conditions":42946,"interventions":42947},[91],[16],[42912,42927,42928,42929],{"trials":42949,"activeCount":103},[],{"trials":42951,"activeCount":103},[],{"trials":42953,"activeCount":103},[],{"trials":42955,"activeCount":103},[],{"intervention":42928,"totalTrials":302,"cells":42957},{"EARLY_PHASE1":42958,"PHASE1":42960,"PHASE2":42966,"PHASE3":42968,"PHASE4":42970,"NA":42972},{"trials":42959,"activeCount":103},[],{"trials":42961,"activeCount":103},[42962],{"nctId":42919,"briefTitle":42920,"status":111,"phases":42963,"primaryCompletion":42922,"completion":42923,"start":42924,"enrollment":1268,"conditions":42964,"interventions":42965},[91],[16],[42912,42927,42928,42929],{"trials":42967,"activeCount":103},[],{"trials":42969,"activeCount":103},[],{"trials":42971,"activeCount":103},[],{"trials":42973,"activeCount":103},[],{"intervention":42929,"totalTrials":302,"cells":42975},{"EARLY_PHASE1":42976,"PHASE1":42978,"PHASE2":42984,"PHASE3":42986,"PHASE4":42988,"NA":42990},{"trials":42977,"activeCount":103},[],{"trials":42979,"activeCount":103},[42980],{"nctId":42919,"briefTitle":42920,"status":111,"phases":42981,"primaryCompletion":42922,"completion":42923,"start":42924,"enrollment":1268,"conditions":42982,"interventions":42983},[91],[16],[42912,42927,42928,42929],{"trials":42985,"activeCount":103},[],{"trials":42987,"activeCount":103},[],{"trials":42989,"activeCount":103},[],{"trials":42991,"activeCount":103},[],{"intervention":42993,"totalTrials":302,"cells":42994},"Spironolactone\u002FHydrochlorothiazide (25 mg\u002F25 mg) film coated tablets from Viatris",{"EARLY_PHASE1":42995,"PHASE1":42997,"PHASE2":43008,"PHASE3":43010,"PHASE4":43012,"NA":43014},{"trials":42996,"activeCount":103},[],{"trials":42998,"activeCount":103},[42999],{"nctId":43000,"briefTitle":43001,"status":111,"phases":43002,"primaryCompletion":43003,"completion":43003,"start":43004,"enrollment":1578,"conditions":43005,"interventions":43006},"NCT06205407","A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma",[91],"2024-03-01","2023-12-26",[28],[42993,43007],"Spironolactone\u002FHydrochlorothiazide (25 mg\u002F25 mg) film coated tablets from Neolpharma.",{"trials":43009,"activeCount":103},[],{"trials":43011,"activeCount":103},[],{"trials":43013,"activeCount":103},[],{"trials":43015,"activeCount":103},[],{"intervention":43007,"totalTrials":302,"cells":43017},{"EARLY_PHASE1":43018,"PHASE1":43020,"PHASE2":43026,"PHASE3":43028,"PHASE4":43030,"NA":43032},{"trials":43019,"activeCount":103},[],{"trials":43021,"activeCount":103},[43022],{"nctId":43000,"briefTitle":43001,"status":111,"phases":43023,"primaryCompletion":43003,"completion":43003,"start":43004,"enrollment":1578,"conditions":43024,"interventions":43025},[91],[28],[42993,43007],{"trials":43027,"activeCount":103},[],{"trials":43029,"activeCount":103},[],{"trials":43031,"activeCount":103},[],{"trials":43033,"activeCount":103},[],{"intervention":43035,"totalTrials":302,"cells":43036},"PF-07905428",{"EARLY_PHASE1":43037,"PHASE1":43039,"PHASE2":43048,"PHASE3":43050,"PHASE4":43052,"NA":43054},{"trials":43038,"activeCount":103},[],{"trials":43040,"activeCount":103},[43041],{"nctId":43042,"briefTitle":43043,"status":111,"phases":43044,"primaryCompletion":43045,"completion":43045,"start":11105,"enrollment":748,"conditions":43046,"interventions":43047},"NCT06671834","A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris",[91],"2025-12-04",[15353],[43035],{"trials":43049,"activeCount":103},[],{"trials":43051,"activeCount":103},[],{"trials":43053,"activeCount":103},[],{"trials":43055,"activeCount":103},[],{"intervention":43057,"totalTrials":302,"cells":43058},"PF-06263726",{"EARLY_PHASE1":43059,"PHASE1":43061,"PHASE2":43069,"PHASE3":43071,"PHASE4":43073,"NA":43075},{"trials":43060,"activeCount":103},[],{"trials":43062,"activeCount":103},[43063],{"nctId":43064,"briefTitle":43065,"status":111,"phases":43066,"primaryCompletion":1288,"completion":1288,"start":18769,"enrollment":8414,"conditions":43067,"interventions":43068},"NCT01981681","A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects",[91],[16],[43057,43057,43057,43057],{"trials":43070,"activeCount":103},[],{"trials":43072,"activeCount":103},[],{"trials":43074,"activeCount":103},[],{"trials":43076,"activeCount":103},[],{"intervention":43078,"totalTrials":302,"cells":43079},"PF-03382792 Cohort 1",{"EARLY_PHASE1":43080,"PHASE1":43082,"PHASE2":43094,"PHASE3":43096,"PHASE4":43098,"NA":43100},{"trials":43081,"activeCount":103},[],{"trials":43083,"activeCount":103},[43084],{"nctId":43085,"briefTitle":43086,"status":168,"phases":43087,"primaryCompletion":577,"completion":577,"start":11988,"enrollment":870,"conditions":43088,"interventions":43089},"NCT01045863","To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers",[91],[16],[43078,43090,43091,43092,43093],"PF-03382792 Cohort 2","PF-03382792","Food Effect cohort","CSF cohort",{"trials":43095,"activeCount":103},[],{"trials":43097,"activeCount":103},[],{"trials":43099,"activeCount":103},[],{"trials":43101,"activeCount":103},[],{"intervention":43090,"totalTrials":302,"cells":43103},{"EARLY_PHASE1":43104,"PHASE1":43106,"PHASE2":43112,"PHASE3":43114,"PHASE4":43116,"NA":43118},{"trials":43105,"activeCount":103},[],{"trials":43107,"activeCount":103},[43108],{"nctId":43085,"briefTitle":43086,"status":168,"phases":43109,"primaryCompletion":577,"completion":577,"start":11988,"enrollment":870,"conditions":43110,"interventions":43111},[91],[16],[43078,43090,43091,43092,43093],{"trials":43113,"activeCount":103},[],{"trials":43115,"activeCount":103},[],{"trials":43117,"activeCount":103},[],{"trials":43119,"activeCount":103},[],{"intervention":43091,"totalTrials":302,"cells":43121},{"EARLY_PHASE1":43122,"PHASE1":43124,"PHASE2":43130,"PHASE3":43132,"PHASE4":43134,"NA":43136},{"trials":43123,"activeCount":103},[],{"trials":43125,"activeCount":103},[43126],{"nctId":43085,"briefTitle":43086,"status":168,"phases":43127,"primaryCompletion":577,"completion":577,"start":11988,"enrollment":870,"conditions":43128,"interventions":43129},[91],[16],[43078,43090,43091,43092,43093],{"trials":43131,"activeCount":103},[],{"trials":43133,"activeCount":103},[],{"trials":43135,"activeCount":103},[],{"trials":43137,"activeCount":103},[],{"intervention":43092,"totalTrials":302,"cells":43139},{"EARLY_PHASE1":43140,"PHASE1":43142,"PHASE2":43148,"PHASE3":43150,"PHASE4":43152,"NA":43154},{"trials":43141,"activeCount":103},[],{"trials":43143,"activeCount":103},[43144],{"nctId":43085,"briefTitle":43086,"status":168,"phases":43145,"primaryCompletion":577,"completion":577,"start":11988,"enrollment":870,"conditions":43146,"interventions":43147},[91],[16],[43078,43090,43091,43092,43093],{"trials":43149,"activeCount":103},[],{"trials":43151,"activeCount":103},[],{"trials":43153,"activeCount":103},[],{"trials":43155,"activeCount":103},[],{"intervention":43093,"totalTrials":302,"cells":43157},{"EARLY_PHASE1":43158,"PHASE1":43160,"PHASE2":43166,"PHASE3":43168,"PHASE4":43170,"NA":43172},{"trials":43159,"activeCount":103},[],{"trials":43161,"activeCount":103},[43162],{"nctId":43085,"briefTitle":43086,"status":168,"phases":43163,"primaryCompletion":577,"completion":577,"start":11988,"enrollment":870,"conditions":43164,"interventions":43165},[91],[16],[43078,43090,43091,43092,43093],{"trials":43167,"activeCount":103},[],{"trials":43169,"activeCount":103},[],{"trials":43171,"activeCount":103},[],{"trials":43173,"activeCount":103},[],{"intervention":26878,"totalTrials":302,"cells":43175},{"EARLY_PHASE1":43176,"PHASE1":43178,"PHASE2":43184,"PHASE3":43186,"PHASE4":43188,"NA":43190},{"trials":43177,"activeCount":103},[],{"trials":43179,"activeCount":103},[43180],{"nctId":26873,"briefTitle":26874,"status":111,"phases":43181,"primaryCompletion":569,"completion":569,"start":4459,"enrollment":1268,"conditions":43182,"interventions":43183},[91],[16],[11326,26878],{"trials":43185,"activeCount":103},[],{"trials":43187,"activeCount":103},[],{"trials":43189,"activeCount":103},[],{"trials":43191,"activeCount":103},[],{"intervention":43193,"totalTrials":302,"cells":43194},"PF-06700841 Immediate release",{"EARLY_PHASE1":43195,"PHASE1":43197,"PHASE2":43208,"PHASE3":43210,"PHASE4":43212,"NA":43214},{"trials":43196,"activeCount":103},[],{"trials":43198,"activeCount":103},[43199],{"nctId":43200,"briefTitle":43201,"status":111,"phases":43202,"primaryCompletion":43203,"completion":43203,"start":43204,"enrollment":1487,"conditions":43205,"interventions":43206},"NCT03765554","Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations",[91],"2019-04-03","2019-01-07",[28],[43193,43207],"PF-06700841 Modified release",{"trials":43209,"activeCount":103},[],{"trials":43211,"activeCount":103},[],{"trials":43213,"activeCount":103},[],{"trials":43215,"activeCount":103},[],{"intervention":43207,"totalTrials":302,"cells":43217},{"EARLY_PHASE1":43218,"PHASE1":43220,"PHASE2":43226,"PHASE3":43228,"PHASE4":43230,"NA":43232},{"trials":43219,"activeCount":103},[],{"trials":43221,"activeCount":103},[43222],{"nctId":43200,"briefTitle":43201,"status":111,"phases":43223,"primaryCompletion":43203,"completion":43203,"start":43204,"enrollment":1487,"conditions":43224,"interventions":43225},[91],[28],[43193,43207],{"trials":43227,"activeCount":103},[],{"trials":43229,"activeCount":103},[],{"trials":43231,"activeCount":103},[],{"trials":43233,"activeCount":103},[],{"intervention":43235,"totalTrials":302,"cells":43236},"1 x 30 mg\u002FmL pegvisomant",{"EARLY_PHASE1":43237,"PHASE1":43239,"PHASE2":43248,"PHASE3":43250,"PHASE4":43252,"NA":43254},{"trials":43238,"activeCount":103},[],{"trials":43240,"activeCount":103},[43241],{"nctId":43242,"briefTitle":43243,"status":111,"phases":43244,"primaryCompletion":1249,"completion":1249,"start":6207,"enrollment":7500,"conditions":43245,"interventions":43246},"NCT01893866","A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects",[91],[19],[43235,43247],"2 x 15 mg\u002FmL pegvisomant",{"trials":43249,"activeCount":103},[],{"trials":43251,"activeCount":103},[],{"trials":43253,"activeCount":103},[],{"trials":43255,"activeCount":103},[],{"intervention":43247,"totalTrials":302,"cells":43257},{"EARLY_PHASE1":43258,"PHASE1":43260,"PHASE2":43266,"PHASE3":43268,"PHASE4":43270,"NA":43272},{"trials":43259,"activeCount":103},[],{"trials":43261,"activeCount":103},[43262],{"nctId":43242,"briefTitle":43243,"status":111,"phases":43263,"primaryCompletion":1249,"completion":1249,"start":6207,"enrollment":7500,"conditions":43264,"interventions":43265},[91],[19],[43235,43247],{"trials":43267,"activeCount":103},[],{"trials":43269,"activeCount":103},[],{"trials":43271,"activeCount":103},[],{"trials":43273,"activeCount":103},[],{"intervention":43275,"totalTrials":302,"cells":43276},"PF-04629991",{"EARLY_PHASE1":43277,"PHASE1":43279,"PHASE2":43287,"PHASE3":43289,"PHASE4":43291,"NA":43293},{"trials":43278,"activeCount":103},[],{"trials":43280,"activeCount":103},[43281],{"nctId":43282,"briefTitle":43283,"status":111,"phases":43284,"primaryCompletion":4222,"completion":4222,"start":8154,"enrollment":504,"conditions":43285,"interventions":43286},"NCT00797342","A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers",[91],[19],[43275,43275,43275],{"trials":43288,"activeCount":103},[],{"trials":43290,"activeCount":103},[],{"trials":43292,"activeCount":103},[],{"trials":43294,"activeCount":103},[],{"intervention":43296,"totalTrials":302,"cells":43297},"Zavegepant 100mg non-enteric coated soft gel",{"EARLY_PHASE1":43298,"PHASE1":43300,"PHASE2":43313,"PHASE3":43315,"PHASE4":43317,"NA":43319},{"trials":43299,"activeCount":103},[],{"trials":43301,"activeCount":103},[43302],{"nctId":43303,"briefTitle":43304,"status":111,"phases":43305,"primaryCompletion":43306,"completion":43306,"start":43307,"enrollment":748,"conditions":43308,"interventions":43309},"NCT06137703","A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers",[91],"2022-12-07","2022-08-24",[9930],[43296,43310,43311,43312],"Zavegepant 100mg immediate release","Zavegepant 2 x 100mg immediate release","Zavegepant 4 x 25mg enteric coated soft gel",{"trials":43314,"activeCount":103},[],{"trials":43316,"activeCount":103},[],{"trials":43318,"activeCount":103},[],{"trials":43320,"activeCount":103},[],{"intervention":43310,"totalTrials":302,"cells":43322},{"EARLY_PHASE1":43323,"PHASE1":43325,"PHASE2":43331,"PHASE3":43333,"PHASE4":43335,"NA":43337},{"trials":43324,"activeCount":103},[],{"trials":43326,"activeCount":103},[43327],{"nctId":43303,"briefTitle":43304,"status":111,"phases":43328,"primaryCompletion":43306,"completion":43306,"start":43307,"enrollment":748,"conditions":43329,"interventions":43330},[91],[9930],[43296,43310,43311,43312],{"trials":43332,"activeCount":103},[],{"trials":43334,"activeCount":103},[],{"trials":43336,"activeCount":103},[],{"trials":43338,"activeCount":103},[],{"intervention":43311,"totalTrials":302,"cells":43340},{"EARLY_PHASE1":43341,"PHASE1":43343,"PHASE2":43349,"PHASE3":43351,"PHASE4":43353,"NA":43355},{"trials":43342,"activeCount":103},[],{"trials":43344,"activeCount":103},[43345],{"nctId":43303,"briefTitle":43304,"status":111,"phases":43346,"primaryCompletion":43306,"completion":43306,"start":43307,"enrollment":748,"conditions":43347,"interventions":43348},[91],[9930],[43296,43310,43311,43312],{"trials":43350,"activeCount":103},[],{"trials":43352,"activeCount":103},[],{"trials":43354,"activeCount":103},[],{"trials":43356,"activeCount":103},[],{"intervention":43312,"totalTrials":302,"cells":43358},{"EARLY_PHASE1":43359,"PHASE1":43361,"PHASE2":43367,"PHASE3":43369,"PHASE4":43371,"NA":43373},{"trials":43360,"activeCount":103},[],{"trials":43362,"activeCount":103},[43363],{"nctId":43303,"briefTitle":43304,"status":111,"phases":43364,"primaryCompletion":43306,"completion":43306,"start":43307,"enrollment":748,"conditions":43365,"interventions":43366},[91],[9930],[43296,43310,43311,43312],{"trials":43368,"activeCount":103},[],{"trials":43370,"activeCount":103},[],{"trials":43372,"activeCount":103},[],{"trials":43374,"activeCount":103},[],{"intervention":43376,"totalTrials":302,"cells":43377},"AAB-003",{"EARLY_PHASE1":43378,"PHASE1":43380,"PHASE2":43388,"PHASE3":43390,"PHASE4":43392,"NA":43394},{"trials":43379,"activeCount":103},[],{"trials":43381,"activeCount":103},[43382],{"nctId":43383,"briefTitle":43384,"status":111,"phases":43385,"primaryCompletion":7386,"completion":7386,"start":3313,"enrollment":748,"conditions":43386,"interventions":43387},"NCT01369225","Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease",[91],[17728],[43376,43376,43376,43376,43376],{"trials":43389,"activeCount":103},[],{"trials":43391,"activeCount":103},[],{"trials":43393,"activeCount":103},[],{"trials":43395,"activeCount":103},[],{"intervention":43397,"totalTrials":302,"cells":43398},"10 mg dose MR formulations,10 mg dose of tofacitinib IR solution",{"EARLY_PHASE1":43399,"PHASE1":43401,"PHASE2":43411,"PHASE3":43413,"PHASE4":43415,"NA":43417},{"trials":43400,"activeCount":103},[],{"trials":43402,"activeCount":103},[43403],{"nctId":43404,"briefTitle":43405,"status":111,"phases":43406,"primaryCompletion":43407,"completion":43407,"start":43408,"enrollment":1509,"conditions":43409,"interventions":43410},"NCT03112148","PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations",[91],"2017-11-15","2017-09-11",[16],[43397],{"trials":43412,"activeCount":103},[],{"trials":43414,"activeCount":103},[],{"trials":43416,"activeCount":103},[],{"trials":43418,"activeCount":103},[],{"intervention":7715,"totalTrials":302,"cells":43420},{"EARLY_PHASE1":43421,"PHASE1":43423,"PHASE2":43429,"PHASE3":43431,"PHASE4":43433,"NA":43435},{"trials":43422,"activeCount":103},[],{"trials":43424,"activeCount":103},[43425],{"nctId":7704,"briefTitle":7705,"status":168,"phases":43426,"primaryCompletion":7707,"completion":7707,"start":7708,"enrollment":2070,"conditions":43427,"interventions":43428},[91],[7710,7711,7712,7713,1798,422],[7715,1773],{"trials":43430,"activeCount":103},[],{"trials":43432,"activeCount":103},[],{"trials":43434,"activeCount":103},[],{"trials":43436,"activeCount":103},[],{"intervention":43438,"totalTrials":302,"cells":43439},"PF-04937319 \u002F ketoconazole",{"EARLY_PHASE1":43440,"PHASE1":43442,"PHASE2":43450,"PHASE3":43452,"PHASE4":43454,"NA":43456},{"trials":43441,"activeCount":103},[],{"trials":43443,"activeCount":103},[43444],{"nctId":43445,"briefTitle":43446,"status":111,"phases":43447,"primaryCompletion":114,"completion":114,"start":114,"enrollment":870,"conditions":43448,"interventions":43449},"NCT01468714","A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects",[91],[40898],[43438],{"trials":43451,"activeCount":103},[],{"trials":43453,"activeCount":103},[],{"trials":43455,"activeCount":103},[],{"trials":43457,"activeCount":103},[],{"intervention":11296,"totalTrials":302,"cells":43459},{"EARLY_PHASE1":43460,"PHASE1":43462,"PHASE2":43468,"PHASE3":43470,"PHASE4":43472,"NA":43474},{"trials":43461,"activeCount":103},[],{"trials":43463,"activeCount":103},[43464],{"nctId":11287,"briefTitle":11288,"status":111,"phases":43465,"primaryCompletion":11290,"completion":11290,"start":11291,"enrollment":1530,"conditions":43466,"interventions":43467},[91],[11293],[11295,11296,11273],{"trials":43469,"activeCount":103},[],{"trials":43471,"activeCount":103},[],{"trials":43473,"activeCount":103},[],{"trials":43475,"activeCount":103},[],{"intervention":43477,"totalTrials":302,"cells":43478},"PF-06651600 20 mg",{"EARLY_PHASE1":43479,"PHASE1":43481,"PHASE2":43491,"PHASE3":43493,"PHASE4":43495,"NA":43497},{"trials":43480,"activeCount":103},[],{"trials":43482,"activeCount":103},[43483],{"nctId":43484,"briefTitle":43485,"status":111,"phases":43486,"primaryCompletion":43487,"completion":43487,"start":43488,"enrollment":870,"conditions":43489,"interventions":43490},"NCT03916393","PF-06651600 Taste Study.",[91],"2019-05-10","2019-04-15",[28],[43477],{"trials":43492,"activeCount":103},[],{"trials":43494,"activeCount":103},[],{"trials":43496,"activeCount":103},[],{"trials":43498,"activeCount":103},[],{"intervention":38662,"totalTrials":302,"cells":43500},{"EARLY_PHASE1":43501,"PHASE1":43503,"PHASE2":43509,"PHASE3":43511,"PHASE4":43513,"NA":43515},{"trials":43502,"activeCount":103},[],{"trials":43504,"activeCount":103},[43505],{"nctId":38657,"briefTitle":38658,"status":168,"phases":43506,"primaryCompletion":7578,"completion":7578,"start":1248,"enrollment":1257,"conditions":43507,"interventions":43508},[91],[117],[38644,38662,38663,38664],{"trials":43510,"activeCount":103},[],{"trials":43512,"activeCount":103},[],{"trials":43514,"activeCount":103},[],{"trials":43516,"activeCount":103},[],{"intervention":38663,"totalTrials":302,"cells":43518},{"EARLY_PHASE1":43519,"PHASE1":43521,"PHASE2":43527,"PHASE3":43529,"PHASE4":43531,"NA":43533},{"trials":43520,"activeCount":103},[],{"trials":43522,"activeCount":103},[43523],{"nctId":38657,"briefTitle":38658,"status":168,"phases":43524,"primaryCompletion":7578,"completion":7578,"start":1248,"enrollment":1257,"conditions":43525,"interventions":43526},[91],[117],[38644,38662,38663,38664],{"trials":43528,"activeCount":103},[],{"trials":43530,"activeCount":103},[],{"trials":43532,"activeCount":103},[],{"trials":43534,"activeCount":103},[],{"intervention":38664,"totalTrials":302,"cells":43536},{"EARLY_PHASE1":43537,"PHASE1":43539,"PHASE2":43545,"PHASE3":43547,"PHASE4":43549,"NA":43551},{"trials":43538,"activeCount":103},[],{"trials":43540,"activeCount":103},[43541],{"nctId":38657,"briefTitle":38658,"status":168,"phases":43542,"primaryCompletion":7578,"completion":7578,"start":1248,"enrollment":1257,"conditions":43543,"interventions":43544},[91],[117],[38644,38662,38663,38664],{"trials":43546,"activeCount":103},[],{"trials":43548,"activeCount":103},[],{"trials":43550,"activeCount":103},[],{"trials":43552,"activeCount":103},[],{"intervention":43554,"totalTrials":302,"cells":43555},"PF-07202954 Repeat Dose",{"EARLY_PHASE1":43556,"PHASE1":43558,"PHASE2":43570,"PHASE3":43572,"PHASE4":43574,"NA":43576},{"trials":43557,"activeCount":103},[],{"trials":43559,"activeCount":103},[43560],{"nctId":43561,"briefTitle":43562,"status":111,"phases":43563,"primaryCompletion":43564,"completion":43564,"start":6221,"enrollment":1268,"conditions":43565,"interventions":43568},"NCT04857437","Study in Healthy Adults Evaluating PF-07202954",[91],"2021-09-17",[43566,43567],"Non-Alcoholic Fatty Liver Disease","Liver Fibrosis",[43554,43569],"PF-07202954 Single Dose",{"trials":43571,"activeCount":103},[],{"trials":43573,"activeCount":103},[],{"trials":43575,"activeCount":103},[],{"trials":43577,"activeCount":103},[],{"intervention":43569,"totalTrials":302,"cells":43579},{"EARLY_PHASE1":43580,"PHASE1":43582,"PHASE2":43588,"PHASE3":43590,"PHASE4":43592,"NA":43594},{"trials":43581,"activeCount":103},[],{"trials":43583,"activeCount":103},[43584],{"nctId":43561,"briefTitle":43562,"status":111,"phases":43585,"primaryCompletion":43564,"completion":43564,"start":6221,"enrollment":1268,"conditions":43586,"interventions":43587},[91],[43566,43567],[43554,43569],{"trials":43589,"activeCount":103},[],{"trials":43591,"activeCount":103},[],{"trials":43593,"activeCount":103},[],{"trials":43595,"activeCount":103},[],{"intervention":40300,"totalTrials":302,"cells":43597},{"EARLY_PHASE1":43598,"PHASE1":43600,"PHASE2":43606,"PHASE3":43608,"PHASE4":43610,"NA":43612},{"trials":43599,"activeCount":103},[],{"trials":43601,"activeCount":103},[43602],{"nctId":40295,"briefTitle":40296,"status":111,"phases":43603,"primaryCompletion":5957,"completion":5957,"start":4589,"enrollment":28283,"conditions":43604,"interventions":43605},[91],[12632],[40288,40300,40301],{"trials":43607,"activeCount":103},[],{"trials":43609,"activeCount":103},[],{"trials":43611,"activeCount":103},[],{"trials":43613,"activeCount":103},[],{"intervention":40301,"totalTrials":302,"cells":43615},{"EARLY_PHASE1":43616,"PHASE1":43618,"PHASE2":43624,"PHASE3":43626,"PHASE4":43628,"NA":43630},{"trials":43617,"activeCount":103},[],{"trials":43619,"activeCount":103},[43620],{"nctId":40295,"briefTitle":40296,"status":111,"phases":43621,"primaryCompletion":5957,"completion":5957,"start":4589,"enrollment":28283,"conditions":43622,"interventions":43623},[91],[12632],[40288,40300,40301],{"trials":43625,"activeCount":103},[],{"trials":43627,"activeCount":103},[],{"trials":43629,"activeCount":103},[],{"trials":43631,"activeCount":103},[],{"intervention":39103,"totalTrials":302,"cells":43633},{"EARLY_PHASE1":43634,"PHASE1":43636,"PHASE2":43642,"PHASE3":43644,"PHASE4":43646,"NA":43648},{"trials":43635,"activeCount":103},[],{"trials":43637,"activeCount":103},[43638],{"nctId":39097,"briefTitle":39098,"status":111,"phases":43639,"primaryCompletion":3601,"completion":3601,"start":8252,"enrollment":1509,"conditions":43640,"interventions":43641},[91],[16],[39090,39102,39103],{"trials":43643,"activeCount":103},[],{"trials":43645,"activeCount":103},[],{"trials":43647,"activeCount":103},[],{"trials":43649,"activeCount":103},[],{"intervention":43651,"totalTrials":302,"cells":43652},"SA4Ag vaccine",{"EARLY_PHASE1":43653,"PHASE1":43655,"PHASE2":43663,"PHASE3":43665,"PHASE4":43667,"NA":43669},{"trials":43654,"activeCount":103},[],{"trials":43656,"activeCount":103},[43657],{"nctId":43658,"briefTitle":43659,"status":111,"phases":43660,"primaryCompletion":2227,"completion":2227,"start":11956,"enrollment":397,"conditions":43661,"interventions":43662},"NCT02364596","Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to \u003C65 Years",[91],[34314],[43651],{"trials":43664,"activeCount":103},[],{"trials":43666,"activeCount":103},[],{"trials":43668,"activeCount":103},[],{"trials":43670,"activeCount":103},[],{"intervention":43672,"totalTrials":302,"cells":43673},"Test drug",{"EARLY_PHASE1":43674,"PHASE1":43676,"PHASE2":43687,"PHASE3":43689,"PHASE4":43691,"NA":43693},{"trials":43675,"activeCount":103},[],{"trials":43677,"activeCount":103},[43678],{"nctId":43679,"briefTitle":43680,"status":111,"phases":43681,"primaryCompletion":43682,"completion":43682,"start":712,"enrollment":5909,"conditions":43683,"interventions":43685},"NCT03821480","Diflucan Bioequivalence Study For Transferring The Manufacture",[91],"2019-03-06",[43684],"Bioequivalence",[43672,43686],"Reference drug",{"trials":43688,"activeCount":103},[],{"trials":43690,"activeCount":103},[],{"trials":43692,"activeCount":103},[],{"trials":43694,"activeCount":103},[],{"intervention":43686,"totalTrials":302,"cells":43696},{"EARLY_PHASE1":43697,"PHASE1":43699,"PHASE2":43705,"PHASE3":43707,"PHASE4":43709,"NA":43711},{"trials":43698,"activeCount":103},[],{"trials":43700,"activeCount":103},[43701],{"nctId":43679,"briefTitle":43680,"status":111,"phases":43702,"primaryCompletion":43682,"completion":43682,"start":712,"enrollment":5909,"conditions":43703,"interventions":43704},[91],[43684],[43672,43686],{"trials":43706,"activeCount":103},[],{"trials":43708,"activeCount":103},[],{"trials":43710,"activeCount":103},[],{"trials":43712,"activeCount":103},[],{"intervention":6129,"totalTrials":302,"cells":43714},{"EARLY_PHASE1":43715,"PHASE1":43717,"PHASE2":43723,"PHASE3":43725,"PHASE4":43727,"NA":43729},{"trials":43716,"activeCount":103},[],{"trials":43718,"activeCount":103},[43719],{"nctId":6122,"briefTitle":6123,"status":111,"phases":43720,"primaryCompletion":6125,"completion":6125,"start":6126,"enrollment":1268,"conditions":43721,"interventions":43722},[91],[16],[1989,6129],{"trials":43724,"activeCount":103},[],{"trials":43726,"activeCount":103},[],{"trials":43728,"activeCount":103},[],{"trials":43730,"activeCount":103},[],{"intervention":13599,"totalTrials":302,"cells":43732},{"EARLY_PHASE1":43733,"PHASE1":43735,"PHASE2":43741,"PHASE3":43743,"PHASE4":43745,"NA":43747},{"trials":43734,"activeCount":103},[],{"trials":43736,"activeCount":103},[43737],{"nctId":13594,"briefTitle":13595,"status":111,"phases":43738,"primaryCompletion":4608,"completion":4608,"start":4645,"enrollment":407,"conditions":43739,"interventions":43740},[91],[12981],[13587,13599],{"trials":43742,"activeCount":103},[],{"trials":43744,"activeCount":103},[],{"trials":43746,"activeCount":103},[],{"trials":43748,"activeCount":103},[],{"intervention":43750,"totalTrials":302,"cells":43751},"Peptide YY3-36",{"EARLY_PHASE1":43752,"PHASE1":43754,"PHASE2":43762,"PHASE3":43764,"PHASE4":43766,"NA":43768},{"trials":43753,"activeCount":103},[],{"trials":43755,"activeCount":103},[43756],{"nctId":43757,"briefTitle":43758,"status":111,"phases":43759,"completion":4615,"start":12395,"enrollment":1257,"conditions":43760,"interventions":43761},"NCT00331175","Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults",[91],[2761],[43750],{"trials":43763,"activeCount":103},[],{"trials":43765,"activeCount":103},[],{"trials":43767,"activeCount":103},[],{"trials":43769,"activeCount":103},[],{"intervention":43771,"totalTrials":302,"cells":43772},"Dalbavancin",{"EARLY_PHASE1":43773,"PHASE1":43775,"PHASE2":43783,"PHASE3":43785,"PHASE4":43787,"NA":43789},{"trials":43774,"activeCount":103},[],{"trials":43776,"activeCount":103},[43777],{"nctId":43778,"briefTitle":43779,"status":111,"phases":43780,"primaryCompletion":4627,"completion":4627,"start":11291,"enrollment":870,"conditions":43781,"interventions":43782},"NCT00678106","Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections",[91],[19825],[43771],{"trials":43784,"activeCount":103},[],{"trials":43786,"activeCount":103},[],{"trials":43788,"activeCount":103},[],{"trials":43790,"activeCount":103},[],{"intervention":20563,"totalTrials":302,"cells":43792},{"EARLY_PHASE1":43793,"PHASE1":43795,"PHASE2":43801,"PHASE3":43803,"PHASE4":43805,"NA":43807},{"trials":43794,"activeCount":103},[],{"trials":43796,"activeCount":103},[43797],{"nctId":20558,"briefTitle":20559,"status":111,"phases":43798,"primaryCompletion":4214,"completion":4214,"start":4627,"enrollment":314,"conditions":43799,"interventions":43800},[91],[19],[20551,20563,20564,20565],{"trials":43802,"activeCount":103},[],{"trials":43804,"activeCount":103},[],{"trials":43806,"activeCount":103},[],{"trials":43808,"activeCount":103},[],{"intervention":20564,"totalTrials":302,"cells":43810},{"EARLY_PHASE1":43811,"PHASE1":43813,"PHASE2":43819,"PHASE3":43821,"PHASE4":43823,"NA":43825},{"trials":43812,"activeCount":103},[],{"trials":43814,"activeCount":103},[43815],{"nctId":20558,"briefTitle":20559,"status":111,"phases":43816,"primaryCompletion":4214,"completion":4214,"start":4627,"enrollment":314,"conditions":43817,"interventions":43818},[91],[19],[20551,20563,20564,20565],{"trials":43820,"activeCount":103},[],{"trials":43822,"activeCount":103},[],{"trials":43824,"activeCount":103},[],{"trials":43826,"activeCount":103},[],{"intervention":20565,"totalTrials":302,"cells":43828},{"EARLY_PHASE1":43829,"PHASE1":43831,"PHASE2":43837,"PHASE3":43839,"PHASE4":43841,"NA":43843},{"trials":43830,"activeCount":103},[],{"trials":43832,"activeCount":103},[43833],{"nctId":20558,"briefTitle":20559,"status":111,"phases":43834,"primaryCompletion":4214,"completion":4214,"start":4627,"enrollment":314,"conditions":43835,"interventions":43836},[91],[19],[20551,20563,20564,20565],{"trials":43838,"activeCount":103},[],{"trials":43840,"activeCount":103},[],{"trials":43842,"activeCount":103},[],{"trials":43844,"activeCount":103},[],{"intervention":6138,"totalTrials":302,"cells":43846},{"EARLY_PHASE1":43847,"PHASE1":43849,"PHASE2":43855,"PHASE3":43857,"PHASE4":43859,"NA":43861},{"trials":43848,"activeCount":103},[],{"trials":43850,"activeCount":103},[43851],{"nctId":6131,"briefTitle":6132,"status":111,"phases":43852,"primaryCompletion":6134,"completion":6134,"start":6135,"enrollment":870,"conditions":43853,"interventions":43854},[91],[1270],[6138,1687],{"trials":43856,"activeCount":103},[],{"trials":43858,"activeCount":103},[],{"trials":43860,"activeCount":103},[],{"trials":43862,"activeCount":103},[],{"intervention":43864,"totalTrials":302,"cells":43865},"inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone",{"EARLY_PHASE1":43866,"PHASE1":43868,"PHASE2":43877,"PHASE3":43879,"PHASE4":43881,"NA":43883},{"trials":43867,"activeCount":103},[],{"trials":43869,"activeCount":103},[43870],{"nctId":43871,"briefTitle":43872,"status":111,"phases":43873,"primaryCompletion":6263,"completion":605,"start":3642,"enrollment":28283,"conditions":43874,"interventions":43875},"NCT01055496","Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma",[91],[7365],[43864,43876],"inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone",{"trials":43878,"activeCount":103},[],{"trials":43880,"activeCount":103},[],{"trials":43882,"activeCount":103},[],{"trials":43884,"activeCount":103},[],{"intervention":43876,"totalTrials":302,"cells":43886},{"EARLY_PHASE1":43887,"PHASE1":43889,"PHASE2":43895,"PHASE3":43897,"PHASE4":43899,"NA":43901},{"trials":43888,"activeCount":103},[],{"trials":43890,"activeCount":103},[43891],{"nctId":43871,"briefTitle":43872,"status":111,"phases":43892,"primaryCompletion":6263,"completion":605,"start":3642,"enrollment":28283,"conditions":43893,"interventions":43894},[91],[7365],[43864,43876],{"trials":43896,"activeCount":103},[],{"trials":43898,"activeCount":103},[],{"trials":43900,"activeCount":103},[],{"trials":43902,"activeCount":103},[],{"intervention":18805,"totalTrials":302,"cells":43904},{"EARLY_PHASE1":43905,"PHASE1":43907,"PHASE2":43913,"PHASE3":43915,"PHASE4":43917,"NA":43919},{"trials":43906,"activeCount":103},[],{"trials":43908,"activeCount":103},[43909],{"nctId":18800,"briefTitle":18801,"status":111,"phases":43910,"primaryCompletion":12307,"completion":12307,"start":9572,"enrollment":1682,"conditions":43911,"interventions":43912},[91],[10985],[12704,18805,18806],{"trials":43914,"activeCount":103},[],{"trials":43916,"activeCount":103},[],{"trials":43918,"activeCount":103},[],{"trials":43920,"activeCount":103},[],{"intervention":18806,"totalTrials":302,"cells":43922},{"EARLY_PHASE1":43923,"PHASE1":43925,"PHASE2":43931,"PHASE3":43933,"PHASE4":43935,"NA":43937},{"trials":43924,"activeCount":103},[],{"trials":43926,"activeCount":103},[43927],{"nctId":18800,"briefTitle":18801,"status":111,"phases":43928,"primaryCompletion":12307,"completion":12307,"start":9572,"enrollment":1682,"conditions":43929,"interventions":43930},[91],[10985],[12704,18805,18806],{"trials":43932,"activeCount":103},[],{"trials":43934,"activeCount":103},[],{"trials":43936,"activeCount":103},[],{"trials":43938,"activeCount":103},[],{"intervention":43940,"totalTrials":302,"cells":43941},"PF-06882961 Immediate Release",{"EARLY_PHASE1":43942,"PHASE1":43944,"PHASE2":43954,"PHASE3":43956,"PHASE4":43958,"NA":43960},{"trials":43943,"activeCount":103},[],{"trials":43945,"activeCount":103},[43946],{"nctId":43947,"briefTitle":43948,"status":111,"phases":43949,"primaryCompletion":28437,"completion":28437,"start":30065,"enrollment":1268,"conditions":43950,"interventions":43951},"NCT03492697","A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961",[91],[10985],[43940,43952,43952,43953],"PF-06882961 Controlled Release","PF-06882961 Immediate Release Solution",{"trials":43955,"activeCount":103},[],{"trials":43957,"activeCount":103},[],{"trials":43959,"activeCount":103},[],{"trials":43961,"activeCount":103},[],{"intervention":43952,"totalTrials":302,"cells":43963},{"EARLY_PHASE1":43964,"PHASE1":43966,"PHASE2":43972,"PHASE3":43974,"PHASE4":43976,"NA":43978},{"trials":43965,"activeCount":103},[],{"trials":43967,"activeCount":103},[43968],{"nctId":43947,"briefTitle":43948,"status":111,"phases":43969,"primaryCompletion":28437,"completion":28437,"start":30065,"enrollment":1268,"conditions":43970,"interventions":43971},[91],[10985],[43940,43952,43952,43953],{"trials":43973,"activeCount":103},[],{"trials":43975,"activeCount":103},[],{"trials":43977,"activeCount":103},[],{"trials":43979,"activeCount":103},[],{"intervention":43953,"totalTrials":302,"cells":43981},{"EARLY_PHASE1":43982,"PHASE1":43984,"PHASE2":43990,"PHASE3":43992,"PHASE4":43994,"NA":43996},{"trials":43983,"activeCount":103},[],{"trials":43985,"activeCount":103},[43986],{"nctId":43947,"briefTitle":43948,"status":111,"phases":43987,"primaryCompletion":28437,"completion":28437,"start":30065,"enrollment":1268,"conditions":43988,"interventions":43989},[91],[10985],[43940,43952,43952,43953],{"trials":43991,"activeCount":103},[],{"trials":43993,"activeCount":103},[],{"trials":43995,"activeCount":103},[],{"trials":43997,"activeCount":103},[],{"intervention":43999,"totalTrials":302,"cells":44000},"Vycavert",{"EARLY_PHASE1":44001,"PHASE1":44003,"PHASE2":44012,"PHASE3":44014,"PHASE4":44016,"NA":44018},{"trials":44002,"activeCount":103},[],{"trials":44004,"activeCount":103},[44005],{"nctId":44006,"briefTitle":44007,"status":111,"phases":44008,"primaryCompletion":10912,"completion":10912,"start":114,"enrollment":8414,"conditions":44009,"interventions":44010},"NCT01456520","Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate\u002F325 mg Acetaminophen) Compared to the Reference Drug Norco",[91],[16],[43999,44011],"Norco",{"trials":44013,"activeCount":103},[],{"trials":44015,"activeCount":103},[],{"trials":44017,"activeCount":103},[],{"trials":44019,"activeCount":103},[],{"intervention":44011,"totalTrials":302,"cells":44021},{"EARLY_PHASE1":44022,"PHASE1":44024,"PHASE2":44030,"PHASE3":44032,"PHASE4":44034,"NA":44036},{"trials":44023,"activeCount":103},[],{"trials":44025,"activeCount":103},[44026],{"nctId":44006,"briefTitle":44007,"status":111,"phases":44027,"primaryCompletion":10912,"completion":10912,"start":114,"enrollment":8414,"conditions":44028,"interventions":44029},[91],[16],[43999,44011],{"trials":44031,"activeCount":103},[],{"trials":44033,"activeCount":103},[],{"trials":44035,"activeCount":103},[],{"trials":44037,"activeCount":103},[],{"intervention":44039,"totalTrials":302,"cells":44040},"PF-03732010",{"EARLY_PHASE1":44041,"PHASE1":44043,"PHASE2":44051,"PHASE3":44053,"PHASE4":44055,"NA":44057},{"trials":44042,"activeCount":103},[],{"trials":44044,"activeCount":103},[44045],{"nctId":44046,"briefTitle":44047,"status":111,"phases":44048,"primaryCompletion":4666,"completion":4666,"start":4636,"enrollment":32,"conditions":44049,"interventions":44050},"NCT00557505","A Study Of PF-03732010 In Patients With Advanced Solid Tumors",[91],[2053],[44039],{"trials":44052,"activeCount":103},[],{"trials":44054,"activeCount":103},[],{"trials":44056,"activeCount":103},[],{"trials":44058,"activeCount":103},[],{"intervention":3979,"totalTrials":302,"cells":44060},{"EARLY_PHASE1":44061,"PHASE1":44063,"PHASE2":44069,"PHASE3":44071,"PHASE4":44073,"NA":44075},{"trials":44062,"activeCount":103},[],{"trials":44064,"activeCount":103},[44065],{"nctId":3972,"briefTitle":3973,"status":111,"phases":44066,"primaryCompletion":3975,"completion":3975,"start":3976,"enrollment":314,"conditions":44067,"interventions":44068},[91],[16],[3160,3979],{"trials":44070,"activeCount":103},[],{"trials":44072,"activeCount":103},[],{"trials":44074,"activeCount":103},[],{"trials":44076,"activeCount":103},[],{"intervention":39265,"totalTrials":302,"cells":44078},{"EARLY_PHASE1":44079,"PHASE1":44081,"PHASE2":44087,"PHASE3":44089,"PHASE4":44091,"NA":44093},{"trials":44080,"activeCount":103},[],{"trials":44082,"activeCount":103},[44083],{"nctId":39260,"briefTitle":39261,"status":111,"phases":44084,"primaryCompletion":560,"completion":560,"start":4206,"enrollment":504,"conditions":44085,"interventions":44086},[91],[16],[39265,39247,39247,39247,39247,39247,39247,39247,39247,39247,39265],{"trials":44088,"activeCount":103},[],{"trials":44090,"activeCount":103},[],{"trials":44092,"activeCount":103},[],{"trials":44094,"activeCount":103},[],{"intervention":44096,"totalTrials":302,"cells":44097},"Benzonatate - 400 mg",{"EARLY_PHASE1":44098,"PHASE1":44100,"PHASE2":44109,"PHASE3":44111,"PHASE4":44113,"NA":44115},{"trials":44099,"activeCount":103},[],{"trials":44101,"activeCount":103},[44102],{"nctId":44103,"briefTitle":44104,"status":111,"phases":44105,"primaryCompletion":569,"completion":569,"start":540,"enrollment":627,"conditions":44106,"interventions":44107},"NCT01690975","Benzonatate Dose Tolerance Study",[91],[15628],[44096,44108],"Benzonatate - 600 mg",{"trials":44110,"activeCount":103},[],{"trials":44112,"activeCount":103},[],{"trials":44114,"activeCount":103},[],{"trials":44116,"activeCount":103},[],{"intervention":44108,"totalTrials":302,"cells":44118},{"EARLY_PHASE1":44119,"PHASE1":44121,"PHASE2":44127,"PHASE3":44129,"PHASE4":44131,"NA":44133},{"trials":44120,"activeCount":103},[],{"trials":44122,"activeCount":103},[44123],{"nctId":44103,"briefTitle":44104,"status":111,"phases":44124,"primaryCompletion":569,"completion":569,"start":540,"enrollment":627,"conditions":44125,"interventions":44126},[91],[15628],[44096,44108],{"trials":44128,"activeCount":103},[],{"trials":44130,"activeCount":103},[],{"trials":44132,"activeCount":103},[],{"trials":44134,"activeCount":103},[],{"intervention":44136,"totalTrials":302,"cells":44137},"PF-05221304 Formulation A",{"EARLY_PHASE1":44138,"PHASE1":44140,"PHASE2":44151,"PHASE3":44153,"PHASE4":44155,"NA":44157},{"trials":44139,"activeCount":103},[],{"trials":44141,"activeCount":103},[44142],{"nctId":44143,"briefTitle":44144,"status":111,"phases":44145,"primaryCompletion":44146,"completion":44146,"start":44147,"enrollment":870,"conditions":44148,"interventions":44149},"NCT03871439","OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS",[91],"2019-05-08","2019-03-13",[16],[44136,44150],"PF-05221304 Formulation B",{"trials":44152,"activeCount":103},[],{"trials":44154,"activeCount":103},[],{"trials":44156,"activeCount":103},[],{"trials":44158,"activeCount":103},[],{"intervention":44150,"totalTrials":302,"cells":44160},{"EARLY_PHASE1":44161,"PHASE1":44163,"PHASE2":44169,"PHASE3":44171,"PHASE4":44173,"NA":44175},{"trials":44162,"activeCount":103},[],{"trials":44164,"activeCount":103},[44165],{"nctId":44143,"briefTitle":44144,"status":111,"phases":44166,"primaryCompletion":44146,"completion":44146,"start":44147,"enrollment":870,"conditions":44167,"interventions":44168},[91],[16],[44136,44150],{"trials":44170,"activeCount":103},[],{"trials":44172,"activeCount":103},[],{"trials":44174,"activeCount":103},[],{"trials":44176,"activeCount":103},[],{"intervention":38528,"totalTrials":302,"cells":44178},{"EARLY_PHASE1":44179,"PHASE1":44181,"PHASE2":44187,"PHASE3":44189,"PHASE4":44191,"NA":44193},{"trials":44180,"activeCount":103},[],{"trials":44182,"activeCount":103},[44183],{"nctId":38521,"briefTitle":38522,"status":111,"phases":44184,"primaryCompletion":1288,"completion":1288,"start":7578,"enrollment":504,"conditions":44185,"interventions":44186},[91],[16],[38526,38527,28091,38526,38528,38528],{"trials":44188,"activeCount":103},[],{"trials":44190,"activeCount":103},[],{"trials":44192,"activeCount":103},[],{"trials":44194,"activeCount":103},[],{"intervention":7730,"totalTrials":302,"cells":44196},{"EARLY_PHASE1":44197,"PHASE1":44199,"PHASE2":44205,"PHASE3":44207,"PHASE4":44209,"NA":44211},{"trials":44198,"activeCount":103},[],{"trials":44200,"activeCount":103},[44201],{"nctId":7721,"briefTitle":7722,"status":168,"phases":44202,"primaryCompletion":3239,"completion":3239,"start":7724,"enrollment":870,"conditions":44203,"interventions":44204},[91],[2053,7726,5823,1859,7727,7728],[7730,7731],{"trials":44206,"activeCount":103},[],{"trials":44208,"activeCount":103},[],{"trials":44210,"activeCount":103},[],{"trials":44212,"activeCount":103},[],{"intervention":39174,"totalTrials":302,"cells":44214},{"EARLY_PHASE1":44215,"PHASE1":44217,"PHASE2":44223,"PHASE3":44225,"PHASE4":44227,"NA":44229},{"trials":44216,"activeCount":103},[],{"trials":44218,"activeCount":103},[44219],{"nctId":39169,"briefTitle":39170,"status":111,"phases":44220,"primaryCompletion":4221,"completion":586,"start":4646,"enrollment":350,"conditions":44221,"interventions":44222},[91],[6589],[39174,11443],{"trials":44224,"activeCount":103},[],{"trials":44226,"activeCount":103},[],{"trials":44228,"activeCount":103},[],{"trials":44230,"activeCount":103},[],{"intervention":40489,"totalTrials":302,"cells":44232},{"EARLY_PHASE1":44233,"PHASE1":44235,"PHASE2":44241,"PHASE3":44243,"PHASE4":44245,"NA":44247},{"trials":44234,"activeCount":103},[],{"trials":44236,"activeCount":103},[44237],{"nctId":40481,"briefTitle":40482,"status":111,"phases":44238,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":44239,"interventions":44240},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"trials":44242,"activeCount":103},[],{"trials":44244,"activeCount":103},[],{"trials":44246,"activeCount":103},[],{"trials":44248,"activeCount":103},[],{"intervention":40490,"totalTrials":302,"cells":44250},{"EARLY_PHASE1":44251,"PHASE1":44253,"PHASE2":44259,"PHASE3":44261,"PHASE4":44263,"NA":44265},{"trials":44252,"activeCount":103},[],{"trials":44254,"activeCount":103},[44255],{"nctId":40481,"briefTitle":40482,"status":111,"phases":44256,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":44257,"interventions":44258},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"trials":44260,"activeCount":103},[],{"trials":44262,"activeCount":103},[],{"trials":44264,"activeCount":103},[],{"trials":44266,"activeCount":103},[],{"intervention":40491,"totalTrials":302,"cells":44268},{"EARLY_PHASE1":44269,"PHASE1":44271,"PHASE2":44277,"PHASE3":44279,"PHASE4":44281,"NA":44283},{"trials":44270,"activeCount":103},[],{"trials":44272,"activeCount":103},[44273],{"nctId":40481,"briefTitle":40482,"status":111,"phases":44274,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":44275,"interventions":44276},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"trials":44278,"activeCount":103},[],{"trials":44280,"activeCount":103},[],{"trials":44282,"activeCount":103},[],{"trials":44284,"activeCount":103},[],{"intervention":40492,"totalTrials":302,"cells":44286},{"EARLY_PHASE1":44287,"PHASE1":44289,"PHASE2":44295,"PHASE3":44297,"PHASE4":44299,"NA":44301},{"trials":44288,"activeCount":103},[],{"trials":44290,"activeCount":103},[44291],{"nctId":40481,"briefTitle":40482,"status":111,"phases":44292,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":44293,"interventions":44294},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"trials":44296,"activeCount":103},[],{"trials":44298,"activeCount":103},[],{"trials":44300,"activeCount":103},[],{"trials":44302,"activeCount":103},[],{"intervention":40493,"totalTrials":302,"cells":44304},{"EARLY_PHASE1":44305,"PHASE1":44307,"PHASE2":44313,"PHASE3":44315,"PHASE4":44317,"NA":44319},{"trials":44306,"activeCount":103},[],{"trials":44308,"activeCount":103},[44309],{"nctId":40481,"briefTitle":40482,"status":111,"phases":44310,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":44311,"interventions":44312},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"trials":44314,"activeCount":103},[],{"trials":44316,"activeCount":103},[],{"trials":44318,"activeCount":103},[],{"trials":44320,"activeCount":103},[],{"intervention":40494,"totalTrials":302,"cells":44322},{"EARLY_PHASE1":44323,"PHASE1":44325,"PHASE2":44331,"PHASE3":44333,"PHASE4":44335,"NA":44337},{"trials":44324,"activeCount":103},[],{"trials":44326,"activeCount":103},[44327],{"nctId":40481,"briefTitle":40482,"status":111,"phases":44328,"primaryCompletion":1288,"completion":1288,"start":3345,"enrollment":1519,"conditions":44329,"interventions":44330},[91],[16],[40474,40486,40487,40488,40489,40490,40491,40492,40493,40494],{"trials":44332,"activeCount":103},[],{"trials":44334,"activeCount":103},[],{"trials":44336,"activeCount":103},[],{"trials":44338,"activeCount":103},[],{"intervention":44340,"totalTrials":302,"cells":44341},"PF-04449913, ketoconazole",{"EARLY_PHASE1":44342,"PHASE1":44344,"PHASE2":44352,"PHASE3":44354,"PHASE4":44356,"NA":44358},{"trials":44343,"activeCount":103},[],{"trials":44345,"activeCount":103},[44346],{"nctId":44347,"briefTitle":44348,"status":111,"phases":44349,"primaryCompletion":18128,"completion":18128,"start":2449,"enrollment":562,"conditions":44350,"interventions":44351},"NCT01749085","Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels",[91],[19],[44340,44340],{"trials":44353,"activeCount":103},[],{"trials":44355,"activeCount":103},[],{"trials":44357,"activeCount":103},[],{"trials":44359,"activeCount":103},[],{"intervention":44361,"totalTrials":302,"cells":44362},"Tofacitinib MR 22 mg",{"EARLY_PHASE1":44363,"PHASE1":44365,"PHASE2":44373,"PHASE3":44375,"PHASE4":44377,"NA":44379},{"trials":44364,"activeCount":103},[],{"trials":44366,"activeCount":103},[44367],{"nctId":44368,"briefTitle":44369,"status":111,"phases":44370,"primaryCompletion":4439,"completion":4439,"start":4438,"enrollment":597,"conditions":44371,"interventions":44372},"NCT02487433","A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers",[91],[16],[44361,44361],{"trials":44374,"activeCount":103},[],{"trials":44376,"activeCount":103},[],{"trials":44378,"activeCount":103},[],{"trials":44380,"activeCount":103},[],{"intervention":44382,"totalTrials":302,"cells":44383},"PF-06438179",{"EARLY_PHASE1":44384,"PHASE1":44386,"PHASE2":44396,"PHASE3":44398,"PHASE4":44400,"NA":44402},{"trials":44385,"activeCount":103},[],{"trials":44387,"activeCount":103},[44388],{"nctId":44389,"briefTitle":44390,"status":111,"phases":44391,"primaryCompletion":18769,"completion":18769,"start":6198,"enrollment":44392,"conditions":44393,"interventions":44394},"NCT01844804","A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)",[91],146,[16],[44382,44395,44395],"Remicade",{"trials":44397,"activeCount":103},[],{"trials":44399,"activeCount":103},[],{"trials":44401,"activeCount":103},[],{"trials":44403,"activeCount":103},[],{"intervention":10162,"totalTrials":302,"cells":44405},{"EARLY_PHASE1":44406,"PHASE1":44408,"PHASE2":44414,"PHASE3":44416,"PHASE4":44418,"NA":44420},{"trials":44407,"activeCount":103},[],{"trials":44409,"activeCount":103},[44410],{"nctId":10155,"briefTitle":10156,"status":111,"phases":44411,"primaryCompletion":10158,"completion":10159,"start":2050,"enrollment":463,"conditions":44412,"interventions":44413},[91],[553,750,1653,31,1684,410,4778,2022],[10148,10162,10162],{"trials":44415,"activeCount":103},[],{"trials":44417,"activeCount":103},[],{"trials":44419,"activeCount":103},[],{"trials":44421,"activeCount":103},[],{"intervention":44423,"totalTrials":302,"cells":44424},"Dimebon alone",{"EARLY_PHASE1":44425,"PHASE1":44427,"PHASE2":44437,"PHASE3":44439,"PHASE4":44441,"NA":44443},{"trials":44426,"activeCount":103},[],{"trials":44428,"activeCount":103},[44429],{"nctId":44430,"briefTitle":44431,"status":111,"phases":44432,"primaryCompletion":4846,"completion":4846,"start":4627,"enrollment":1509,"conditions":44433,"interventions":44434},"NCT00931073","A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers",[91],[17728,17729],[44423,44435,44436],"Dimebon + Ketoconazole","Dimebon + Omeprazole",{"trials":44438,"activeCount":103},[],{"trials":44440,"activeCount":103},[],{"trials":44442,"activeCount":103},[],{"trials":44444,"activeCount":103},[],{"intervention":44435,"totalTrials":302,"cells":44446},{"EARLY_PHASE1":44447,"PHASE1":44449,"PHASE2":44455,"PHASE3":44457,"PHASE4":44459,"NA":44461},{"trials":44448,"activeCount":103},[],{"trials":44450,"activeCount":103},[44451],{"nctId":44430,"briefTitle":44431,"status":111,"phases":44452,"primaryCompletion":4846,"completion":4846,"start":4627,"enrollment":1509,"conditions":44453,"interventions":44454},[91],[17728,17729],[44423,44435,44436],{"trials":44456,"activeCount":103},[],{"trials":44458,"activeCount":103},[],{"trials":44460,"activeCount":103},[],{"trials":44462,"activeCount":103},[],{"intervention":44436,"totalTrials":302,"cells":44464},{"EARLY_PHASE1":44465,"PHASE1":44467,"PHASE2":44473,"PHASE3":44475,"PHASE4":44477,"NA":44479},{"trials":44466,"activeCount":103},[],{"trials":44468,"activeCount":103},[44469],{"nctId":44430,"briefTitle":44431,"status":111,"phases":44470,"primaryCompletion":4846,"completion":4846,"start":4627,"enrollment":1509,"conditions":44471,"interventions":44472},[91],[17728,17729],[44423,44435,44436],{"trials":44474,"activeCount":103},[],{"trials":44476,"activeCount":103},[],{"trials":44478,"activeCount":103},[],{"trials":44480,"activeCount":103},[],{"intervention":44482,"totalTrials":302,"cells":44483},"Fluconazole 150mg Capsule Originator",{"EARLY_PHASE1":44484,"PHASE1":44486,"PHASE2":44497,"PHASE3":44499,"PHASE4":44501,"NA":44503},{"trials":44485,"activeCount":103},[],{"trials":44487,"activeCount":103},[44488],{"nctId":44489,"briefTitle":44490,"status":111,"phases":44491,"primaryCompletion":44492,"completion":44492,"start":44493,"enrollment":1530,"conditions":44494,"interventions":44495},"NCT03621072","Bioequivalence (BE) Study Comparing Fluconazole 150mg Capsule Manufactured in China and in France",[91],"2019-07-20","2019-06-03",[43684],[44482,44496],"Fluconazole 150mg Capsule Localized Originator",{"trials":44498,"activeCount":103},[],{"trials":44500,"activeCount":103},[],{"trials":44502,"activeCount":103},[],{"trials":44504,"activeCount":103},[],{"intervention":44496,"totalTrials":302,"cells":44506},{"EARLY_PHASE1":44507,"PHASE1":44509,"PHASE2":44515,"PHASE3":44517,"PHASE4":44519,"NA":44521},{"trials":44508,"activeCount":103},[],{"trials":44510,"activeCount":103},[44511],{"nctId":44489,"briefTitle":44490,"status":111,"phases":44512,"primaryCompletion":44492,"completion":44492,"start":44493,"enrollment":1530,"conditions":44513,"interventions":44514},[91],[43684],[44482,44496],{"trials":44516,"activeCount":103},[],{"trials":44518,"activeCount":103},[],{"trials":44520,"activeCount":103},[],{"trials":44522,"activeCount":103},[],{"intervention":44524,"totalTrials":302,"cells":44525},"reference [dextromethorphan]",{"EARLY_PHASE1":44526,"PHASE1":44528,"PHASE2":44537,"PHASE3":44539,"PHASE4":44541,"NA":44543},{"trials":44527,"activeCount":103},[],{"trials":44529,"activeCount":103},[44530],{"nctId":44531,"briefTitle":44532,"status":111,"phases":44533,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":562,"conditions":44534,"interventions":44535},"NCT00999817","A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers",[91],[19],[44524,44536],"test [PF-00299804 + dextromethorphan]",{"trials":44538,"activeCount":103},[],{"trials":44540,"activeCount":103},[],{"trials":44542,"activeCount":103},[],{"trials":44544,"activeCount":103},[],{"intervention":44536,"totalTrials":302,"cells":44546},{"EARLY_PHASE1":44547,"PHASE1":44549,"PHASE2":44555,"PHASE3":44557,"PHASE4":44559,"NA":44561},{"trials":44548,"activeCount":103},[],{"trials":44550,"activeCount":103},[44551],{"nctId":44531,"briefTitle":44532,"status":111,"phases":44552,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":562,"conditions":44553,"interventions":44554},[91],[19],[44524,44536],{"trials":44556,"activeCount":103},[],{"trials":44558,"activeCount":103},[],{"trials":44560,"activeCount":103},[],{"trials":44562,"activeCount":103},[],{"intervention":44564,"totalTrials":302,"cells":44565},"IFN-β inhibitor treatment",{"EARLY_PHASE1":44566,"PHASE1":44568,"PHASE2":44577,"PHASE3":44579,"PHASE4":44581,"NA":44583},{"trials":44567,"activeCount":103},[],{"trials":44569,"activeCount":103},[44570],{"nctId":44571,"briefTitle":44572,"status":111,"phases":44573,"primaryCompletion":44574,"completion":44574,"start":193,"enrollment":597,"conditions":44575,"interventions":44576},"NCT05257798","A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants",[91],"2023-03-21",[16],[44564],{"trials":44578,"activeCount":103},[],{"trials":44580,"activeCount":103},[],{"trials":44582,"activeCount":103},[],{"trials":44584,"activeCount":103},[],{"intervention":44586,"totalTrials":302,"cells":44587},"CVX-045",{"EARLY_PHASE1":44588,"PHASE1":44590,"PHASE2":44599,"PHASE3":44601,"PHASE4":44603,"NA":44605},{"trials":44589,"activeCount":103},[],{"trials":44591,"activeCount":103},[44592],{"nctId":44593,"briefTitle":44594,"status":111,"phases":44595,"primaryCompletion":11290,"completion":8252,"start":1701,"enrollment":35,"conditions":44596,"interventions":44598},"NCT00879554","A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors",[91],[553,2053,943,5950,44597],"Malignancy",[44586],{"trials":44600,"activeCount":103},[],{"trials":44602,"activeCount":103},[],{"trials":44604,"activeCount":103},[],{"trials":44606,"activeCount":103},[],{"intervention":44608,"totalTrials":302,"cells":44609},"Active treatment",{"EARLY_PHASE1":44610,"PHASE1":44612,"PHASE2":44621,"PHASE3":44623,"PHASE4":44625,"NA":44627},{"trials":44611,"activeCount":103},[],{"trials":44613,"activeCount":103},[44614],{"nctId":44615,"briefTitle":44616,"status":111,"phases":44617,"primaryCompletion":4645,"completion":4645,"start":4207,"enrollment":627,"conditions":44618,"interventions":44620},"NCT00706537","Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH",[91],[44619],"Non-Alcoholic Steatohepatitis(NASH)",[44608],{"trials":44622,"activeCount":103},[],{"trials":44624,"activeCount":103},[],{"trials":44626,"activeCount":103},[],{"trials":44628,"activeCount":103},[],{"intervention":44630,"totalTrials":302,"cells":44631},"4 mg Fesoterodine ER tablet from Zwickau",{"EARLY_PHASE1":44632,"PHASE1":44634,"PHASE2":44647,"PHASE3":44649,"PHASE4":44651,"NA":44653},{"trials":44633,"activeCount":103},[],{"trials":44635,"activeCount":103},[44636],{"nctId":44637,"briefTitle":44638,"status":111,"phases":44639,"primaryCompletion":30112,"completion":30112,"start":44640,"enrollment":597,"conditions":44641,"interventions":44643},"NCT04478357","BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG",[91],"2019-11-12",[44642],"Neurogenic Detrusor Overactivity",[44630,44644,44645,44646],"4 mg fesoterodine ER tablet from Freiburg","8 mg fesoterodine ER tablet from Zwickau","8 mg fesoterodine ER tablet from Freiburg",{"trials":44648,"activeCount":103},[],{"trials":44650,"activeCount":103},[],{"trials":44652,"activeCount":103},[],{"trials":44654,"activeCount":103},[],{"intervention":44644,"totalTrials":302,"cells":44656},{"EARLY_PHASE1":44657,"PHASE1":44659,"PHASE2":44665,"PHASE3":44667,"PHASE4":44669,"NA":44671},{"trials":44658,"activeCount":103},[],{"trials":44660,"activeCount":103},[44661],{"nctId":44637,"briefTitle":44638,"status":111,"phases":44662,"primaryCompletion":30112,"completion":30112,"start":44640,"enrollment":597,"conditions":44663,"interventions":44664},[91],[44642],[44630,44644,44645,44646],{"trials":44666,"activeCount":103},[],{"trials":44668,"activeCount":103},[],{"trials":44670,"activeCount":103},[],{"trials":44672,"activeCount":103},[],{"intervention":44645,"totalTrials":302,"cells":44674},{"EARLY_PHASE1":44675,"PHASE1":44677,"PHASE2":44683,"PHASE3":44685,"PHASE4":44687,"NA":44689},{"trials":44676,"activeCount":103},[],{"trials":44678,"activeCount":103},[44679],{"nctId":44637,"briefTitle":44638,"status":111,"phases":44680,"primaryCompletion":30112,"completion":30112,"start":44640,"enrollment":597,"conditions":44681,"interventions":44682},[91],[44642],[44630,44644,44645,44646],{"trials":44684,"activeCount":103},[],{"trials":44686,"activeCount":103},[],{"trials":44688,"activeCount":103},[],{"trials":44690,"activeCount":103},[],{"intervention":44646,"totalTrials":302,"cells":44692},{"EARLY_PHASE1":44693,"PHASE1":44695,"PHASE2":44701,"PHASE3":44703,"PHASE4":44705,"NA":44707},{"trials":44694,"activeCount":103},[],{"trials":44696,"activeCount":103},[44697],{"nctId":44637,"briefTitle":44638,"status":111,"phases":44698,"primaryCompletion":30112,"completion":30112,"start":44640,"enrollment":597,"conditions":44699,"interventions":44700},[91],[44642],[44630,44644,44645,44646],{"trials":44702,"activeCount":103},[],{"trials":44704,"activeCount":103},[],{"trials":44706,"activeCount":103},[],{"trials":44708,"activeCount":103},[],{"intervention":38253,"totalTrials":302,"cells":44710},{"EARLY_PHASE1":44711,"PHASE1":44713,"PHASE2":44719,"PHASE3":44721,"PHASE4":44723,"NA":44725},{"trials":44712,"activeCount":103},[],{"trials":44714,"activeCount":103},[44715],{"nctId":38246,"briefTitle":38247,"status":168,"phases":44716,"primaryCompletion":38249,"completion":38249,"start":38250,"enrollment":4259,"conditions":44717,"interventions":44718},[91],[2761],[7531,38253],{"trials":44720,"activeCount":103},[],{"trials":44722,"activeCount":103},[],{"trials":44724,"activeCount":103},[],{"trials":44726,"activeCount":103},[],{"intervention":44728,"totalTrials":302,"cells":44729},"PF-03893787",{"EARLY_PHASE1":44730,"PHASE1":44732,"PHASE2":44740,"PHASE3":44742,"PHASE4":44744,"NA":44746},{"trials":44731,"activeCount":103},[],{"trials":44733,"activeCount":103},[44734],{"nctId":44735,"briefTitle":44736,"status":111,"phases":44737,"primaryCompletion":3642,"completion":3642,"start":6016,"enrollment":1530,"conditions":44738,"interventions":44739},"NCT00992342","A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers",[91],[16],[44728,44728,44728],{"trials":44741,"activeCount":103},[],{"trials":44743,"activeCount":103},[],{"trials":44745,"activeCount":103},[],{"trials":44747,"activeCount":103},[],{"intervention":12634,"totalTrials":302,"cells":44749},{"EARLY_PHASE1":44750,"PHASE1":44752,"PHASE2":44758,"PHASE3":44760,"PHASE4":44762,"NA":44764},{"trials":44751,"activeCount":103},[],{"trials":44753,"activeCount":103},[44754],{"nctId":12628,"briefTitle":12629,"status":111,"phases":44755,"completion":9387,"start":11417,"enrollment":597,"conditions":44756,"interventions":44757},[91],[12632],[12634,12621],{"trials":44759,"activeCount":103},[],{"trials":44761,"activeCount":103},[],{"trials":44763,"activeCount":103},[],{"trials":44765,"activeCount":103},[],{"intervention":44767,"totalTrials":302,"cells":44768},"tofacitinib MR 11 mg",{"EARLY_PHASE1":44769,"PHASE1":44771,"PHASE2":44780,"PHASE3":44782,"PHASE4":44784,"NA":44786},{"trials":44770,"activeCount":103},[],{"trials":44772,"activeCount":103},[44773],{"nctId":44774,"briefTitle":44775,"status":111,"phases":44776,"primaryCompletion":2018,"completion":2018,"start":5017,"enrollment":1239,"conditions":44777,"interventions":44778},"NCT04403776","PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation",[91],[16],[44767,44779],"tofacitinib IR 5 mg",{"trials":44781,"activeCount":103},[],{"trials":44783,"activeCount":103},[],{"trials":44785,"activeCount":103},[],{"trials":44787,"activeCount":103},[],{"intervention":44779,"totalTrials":302,"cells":44789},{"EARLY_PHASE1":44790,"PHASE1":44792,"PHASE2":44798,"PHASE3":44800,"PHASE4":44802,"NA":44804},{"trials":44791,"activeCount":103},[],{"trials":44793,"activeCount":103},[44794],{"nctId":44774,"briefTitle":44775,"status":111,"phases":44795,"primaryCompletion":2018,"completion":2018,"start":5017,"enrollment":1239,"conditions":44796,"interventions":44797},[91],[16],[44767,44779],{"trials":44799,"activeCount":103},[],{"trials":44801,"activeCount":103},[],{"trials":44803,"activeCount":103},[],{"trials":44805,"activeCount":103},[],{"intervention":26971,"totalTrials":302,"cells":44807},{"EARLY_PHASE1":44808,"PHASE1":44810,"PHASE2":44816,"PHASE3":44818,"PHASE4":44820,"NA":44822},{"trials":44809,"activeCount":103},[],{"trials":44811,"activeCount":103},[44812],{"nctId":26964,"briefTitle":26965,"status":111,"phases":44813,"primaryCompletion":26967,"completion":26967,"start":26968,"enrollment":2070,"conditions":44814,"interventions":44815},[91],[19],[26971,26972,4425],{"trials":44817,"activeCount":103},[],{"trials":44819,"activeCount":103},[],{"trials":44821,"activeCount":103},[],{"trials":44823,"activeCount":103},[],{"intervention":26972,"totalTrials":302,"cells":44825},{"EARLY_PHASE1":44826,"PHASE1":44828,"PHASE2":44834,"PHASE3":44836,"PHASE4":44838,"NA":44840},{"trials":44827,"activeCount":103},[],{"trials":44829,"activeCount":103},[44830],{"nctId":26964,"briefTitle":26965,"status":111,"phases":44831,"primaryCompletion":26967,"completion":26967,"start":26968,"enrollment":2070,"conditions":44832,"interventions":44833},[91],[19],[26971,26972,4425],{"trials":44835,"activeCount":103},[],{"trials":44837,"activeCount":103},[],{"trials":44839,"activeCount":103},[],{"trials":44841,"activeCount":103},[],{"intervention":44843,"totalTrials":302,"cells":44844},"Epamin: Reference Drug",{"EARLY_PHASE1":44845,"PHASE1":44847,"PHASE2":44856,"PHASE3":44858,"PHASE4":44860,"NA":44862},{"trials":44846,"activeCount":103},[],{"trials":44848,"activeCount":103},[44849],{"nctId":44850,"briefTitle":44851,"status":111,"phases":44852,"primaryCompletion":561,"completion":561,"start":586,"enrollment":4259,"conditions":44853,"interventions":44854},"NCT01122940","Bioequivalence Study Of Phenytoin Suspension Versus Epamin® In 34 Healthy Volunteers.",[91],[16],[44843,44855],"Phenytoin: Study Drug",{"trials":44857,"activeCount":103},[],{"trials":44859,"activeCount":103},[],{"trials":44861,"activeCount":103},[],{"trials":44863,"activeCount":103},[],{"intervention":44855,"totalTrials":302,"cells":44865},{"EARLY_PHASE1":44866,"PHASE1":44868,"PHASE2":44874,"PHASE3":44876,"PHASE4":44878,"NA":44880},{"trials":44867,"activeCount":103},[],{"trials":44869,"activeCount":103},[44870],{"nctId":44850,"briefTitle":44851,"status":111,"phases":44871,"primaryCompletion":561,"completion":561,"start":586,"enrollment":4259,"conditions":44872,"interventions":44873},[91],[16],[44843,44855],{"trials":44875,"activeCount":103},[],{"trials":44877,"activeCount":103},[],{"trials":44879,"activeCount":103},[],{"trials":44881,"activeCount":103},[],{"intervention":44883,"totalTrials":302,"cells":44884},"MET233",{"EARLY_PHASE1":44885,"PHASE1":44887,"PHASE2":44896,"PHASE3":44898,"PHASE4":44900,"NA":44902},{"trials":44886,"activeCount":103},[],{"trials":44888,"activeCount":103},[44889],{"nctId":44890,"briefTitle":44891,"status":111,"phases":44892,"primaryCompletion":44893,"completion":44893,"start":8448,"enrollment":4897,"conditions":44894,"interventions":44895},"NCT07022977","A Study of MET233 in Individuals With Obesity or Overweight",[91],"2026-04-21",[3043],[44883],{"trials":44897,"activeCount":103},[],{"trials":44899,"activeCount":103},[],{"trials":44901,"activeCount":103},[],{"trials":44903,"activeCount":103},[],{"intervention":44905,"totalTrials":302,"cells":44906},"PF-06815345",{"EARLY_PHASE1":44907,"PHASE1":44909,"PHASE2":44917,"PHASE3":44919,"PHASE4":44921,"NA":44923},{"trials":44908,"activeCount":103},[],{"trials":44910,"activeCount":103},[44911],{"nctId":44912,"briefTitle":44913,"status":168,"phases":44914,"primaryCompletion":12810,"completion":12810,"start":27550,"enrollment":2713,"conditions":44915,"interventions":44916},"NCT02654899","Single Dose Study of PF-06815345 in Healthy Subjects",[91],[12981],[44905,44905],{"trials":44918,"activeCount":103},[],{"trials":44920,"activeCount":103},[],{"trials":44922,"activeCount":103},[],{"trials":44924,"activeCount":103},[],{"intervention":44926,"totalTrials":302,"cells":44927},"Fixed combination of Azithromycin and Chloroquine",{"EARLY_PHASE1":44928,"PHASE1":44930,"PHASE2":44939,"PHASE3":44941,"PHASE4":44943,"NA":44945},{"trials":44929,"activeCount":103},[],{"trials":44931,"activeCount":103},[44932],{"nctId":44933,"briefTitle":44934,"status":111,"phases":44935,"primaryCompletion":4222,"completion":4222,"start":4608,"enrollment":35,"conditions":44936,"interventions":44937},"NCT00844207","A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine",[91],[18901],[44926,44938],"Azithromycin and Chloroquine",{"trials":44940,"activeCount":103},[],{"trials":44942,"activeCount":103},[],{"trials":44944,"activeCount":103},[],{"trials":44946,"activeCount":103},[],{"intervention":44938,"totalTrials":302,"cells":44948},{"EARLY_PHASE1":44949,"PHASE1":44951,"PHASE2":44957,"PHASE3":44959,"PHASE4":44961,"NA":44963},{"trials":44950,"activeCount":103},[],{"trials":44952,"activeCount":103},[44953],{"nctId":44933,"briefTitle":44934,"status":111,"phases":44954,"primaryCompletion":4222,"completion":4222,"start":4608,"enrollment":35,"conditions":44955,"interventions":44956},[91],[18901],[44926,44938],{"trials":44958,"activeCount":103},[],{"trials":44960,"activeCount":103},[],{"trials":44962,"activeCount":103},[],{"trials":44964,"activeCount":103},[],{"intervention":44966,"totalTrials":302,"cells":44967},"intact ALO-02 60 mg\u002F7.2 mg",{"EARLY_PHASE1":44968,"PHASE1":44970,"PHASE2":44983,"PHASE3":44985,"PHASE4":44987,"NA":44989},{"trials":44969,"activeCount":103},[],{"trials":44971,"activeCount":103},[44972],{"nctId":44973,"briefTitle":44974,"status":111,"phases":44975,"primaryCompletion":44976,"completion":44976,"start":18128,"enrollment":7399,"conditions":44977,"interventions":44978},"NCT01746901","A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers",[91],"2013-08-09",[16],[44966,44979,44980,44981,44982],"crushed ALO-02 60 mg\u002F7.2 mg","crushed oxycodone IR 60 mg","crushed ALO-02 40 mg\u002F4.8 mg","crushed oxycodone IR 40 mg",{"trials":44984,"activeCount":103},[],{"trials":44986,"activeCount":103},[],{"trials":44988,"activeCount":103},[],{"trials":44990,"activeCount":103},[],{"intervention":44979,"totalTrials":302,"cells":44992},{"EARLY_PHASE1":44993,"PHASE1":44995,"PHASE2":45001,"PHASE3":45003,"PHASE4":45005,"NA":45007},{"trials":44994,"activeCount":103},[],{"trials":44996,"activeCount":103},[44997],{"nctId":44973,"briefTitle":44974,"status":111,"phases":44998,"primaryCompletion":44976,"completion":44976,"start":18128,"enrollment":7399,"conditions":44999,"interventions":45000},[91],[16],[44966,44979,44980,44981,44982],{"trials":45002,"activeCount":103},[],{"trials":45004,"activeCount":103},[],{"trials":45006,"activeCount":103},[],{"trials":45008,"activeCount":103},[],{"intervention":44980,"totalTrials":302,"cells":45010},{"EARLY_PHASE1":45011,"PHASE1":45013,"PHASE2":45019,"PHASE3":45021,"PHASE4":45023,"NA":45025},{"trials":45012,"activeCount":103},[],{"trials":45014,"activeCount":103},[45015],{"nctId":44973,"briefTitle":44974,"status":111,"phases":45016,"primaryCompletion":44976,"completion":44976,"start":18128,"enrollment":7399,"conditions":45017,"interventions":45018},[91],[16],[44966,44979,44980,44981,44982],{"trials":45020,"activeCount":103},[],{"trials":45022,"activeCount":103},[],{"trials":45024,"activeCount":103},[],{"trials":45026,"activeCount":103},[],{"intervention":44981,"totalTrials":302,"cells":45028},{"EARLY_PHASE1":45029,"PHASE1":45031,"PHASE2":45037,"PHASE3":45039,"PHASE4":45041,"NA":45043},{"trials":45030,"activeCount":103},[],{"trials":45032,"activeCount":103},[45033],{"nctId":44973,"briefTitle":44974,"status":111,"phases":45034,"primaryCompletion":44976,"completion":44976,"start":18128,"enrollment":7399,"conditions":45035,"interventions":45036},[91],[16],[44966,44979,44980,44981,44982],{"trials":45038,"activeCount":103},[],{"trials":45040,"activeCount":103},[],{"trials":45042,"activeCount":103},[],{"trials":45044,"activeCount":103},[],{"intervention":44982,"totalTrials":302,"cells":45046},{"EARLY_PHASE1":45047,"PHASE1":45049,"PHASE2":45055,"PHASE3":45057,"PHASE4":45059,"NA":45061},{"trials":45048,"activeCount":103},[],{"trials":45050,"activeCount":103},[45051],{"nctId":44973,"briefTitle":44974,"status":111,"phases":45052,"primaryCompletion":44976,"completion":44976,"start":18128,"enrollment":7399,"conditions":45053,"interventions":45054},[91],[16],[44966,44979,44980,44981,44982],{"trials":45056,"activeCount":103},[],{"trials":45058,"activeCount":103},[],{"trials":45060,"activeCount":103},[],{"trials":45062,"activeCount":103},[],{"intervention":45064,"totalTrials":302,"cells":45065},"BMS-927711",{"EARLY_PHASE1":45066,"PHASE1":45068,"PHASE2":45076,"PHASE3":45078,"PHASE4":45080,"NA":45082},{"trials":45067,"activeCount":103},[],{"trials":45069,"activeCount":103},[45070],{"nctId":45071,"briefTitle":45072,"status":111,"phases":45073,"primaryCompletion":1700,"completion":1700,"start":570,"enrollment":4369,"conditions":45074,"interventions":45075},"NCT01445067","Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition",[91],[117],[45064,45064],{"trials":45077,"activeCount":103},[],{"trials":45079,"activeCount":103},[],{"trials":45081,"activeCount":103},[],{"trials":45083,"activeCount":103},[],{"intervention":45085,"totalTrials":302,"cells":45086},"PF-04937319 IR MST",{"EARLY_PHASE1":45087,"PHASE1":45089,"PHASE2":45100,"PHASE3":45102,"PHASE4":45104,"NA":45106},{"trials":45088,"activeCount":103},[],{"trials":45090,"activeCount":103},[45091],{"nctId":45092,"briefTitle":45093,"status":111,"phases":45094,"primaryCompletion":11956,"completion":11956,"start":9572,"enrollment":1097,"conditions":45095,"interventions":45096},"NCT02206607","Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.",[91],[12968],[45085,45097,45098,45099],"PF-04937319 MR 1","PF-04937319 MR 2","PF-04937319 MR 3",{"trials":45101,"activeCount":103},[],{"trials":45103,"activeCount":103},[],{"trials":45105,"activeCount":103},[],{"trials":45107,"activeCount":103},[],{"intervention":45097,"totalTrials":302,"cells":45109},{"EARLY_PHASE1":45110,"PHASE1":45112,"PHASE2":45118,"PHASE3":45120,"PHASE4":45122,"NA":45124},{"trials":45111,"activeCount":103},[],{"trials":45113,"activeCount":103},[45114],{"nctId":45092,"briefTitle":45093,"status":111,"phases":45115,"primaryCompletion":11956,"completion":11956,"start":9572,"enrollment":1097,"conditions":45116,"interventions":45117},[91],[12968],[45085,45097,45098,45099],{"trials":45119,"activeCount":103},[],{"trials":45121,"activeCount":103},[],{"trials":45123,"activeCount":103},[],{"trials":45125,"activeCount":103},[],{"intervention":45098,"totalTrials":302,"cells":45127},{"EARLY_PHASE1":45128,"PHASE1":45130,"PHASE2":45136,"PHASE3":45138,"PHASE4":45140,"NA":45142},{"trials":45129,"activeCount":103},[],{"trials":45131,"activeCount":103},[45132],{"nctId":45092,"briefTitle":45093,"status":111,"phases":45133,"primaryCompletion":11956,"completion":11956,"start":9572,"enrollment":1097,"conditions":45134,"interventions":45135},[91],[12968],[45085,45097,45098,45099],{"trials":45137,"activeCount":103},[],{"trials":45139,"activeCount":103},[],{"trials":45141,"activeCount":103},[],{"trials":45143,"activeCount":103},[],{"intervention":45099,"totalTrials":302,"cells":45145},{"EARLY_PHASE1":45146,"PHASE1":45148,"PHASE2":45154,"PHASE3":45156,"PHASE4":45158,"NA":45160},{"trials":45147,"activeCount":103},[],{"trials":45149,"activeCount":103},[45150],{"nctId":45092,"briefTitle":45093,"status":111,"phases":45151,"primaryCompletion":11956,"completion":11956,"start":9572,"enrollment":1097,"conditions":45152,"interventions":45153},[91],[12968],[45085,45097,45098,45099],{"trials":45155,"activeCount":103},[],{"trials":45157,"activeCount":103},[],{"trials":45159,"activeCount":103},[],{"trials":45161,"activeCount":103},[],{"intervention":4237,"totalTrials":302,"cells":45163},{"EARLY_PHASE1":45164,"PHASE1":45166,"PHASE2":45172,"PHASE3":45174,"PHASE4":45176,"NA":45178},{"trials":45165,"activeCount":103},[],{"trials":45167,"activeCount":103},[45168],{"nctId":4231,"briefTitle":4232,"status":168,"phases":45169,"primaryCompletion":161,"completion":161,"start":4234,"enrollment":541,"conditions":45170,"interventions":45171},[91],[3077],[4237,1773,933],{"trials":45173,"activeCount":103},[],{"trials":45175,"activeCount":103},[],{"trials":45177,"activeCount":103},[],{"trials":45179,"activeCount":103},[],{"intervention":45181,"totalTrials":302,"cells":45182},"Lorlatinib 50 mg",{"EARLY_PHASE1":45183,"PHASE1":45185,"PHASE2":45198,"PHASE3":45200,"PHASE4":45202,"NA":45204},{"trials":45184,"activeCount":103},[],{"trials":45186,"activeCount":103},[45187],{"nctId":45188,"briefTitle":45189,"status":111,"phases":45190,"primaryCompletion":26826,"completion":26826,"start":45191,"enrollment":314,"conditions":45192,"interventions":45195},"NCT03961997","Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants",[91],"2019-08-22",[3395,45193,19,45194],"Drug Interactions","Humans",[45181,45196,45197],"Lorlatinib 75 mg","Lorlatinib 100 mg",{"trials":45199,"activeCount":103},[],{"trials":45201,"activeCount":103},[],{"trials":45203,"activeCount":103},[],{"trials":45205,"activeCount":103},[],{"intervention":45196,"totalTrials":302,"cells":45207},{"EARLY_PHASE1":45208,"PHASE1":45210,"PHASE2":45216,"PHASE3":45218,"PHASE4":45220,"NA":45222},{"trials":45209,"activeCount":103},[],{"trials":45211,"activeCount":103},[45212],{"nctId":45188,"briefTitle":45189,"status":111,"phases":45213,"primaryCompletion":26826,"completion":26826,"start":45191,"enrollment":314,"conditions":45214,"interventions":45215},[91],[3395,45193,19,45194],[45181,45196,45197],{"trials":45217,"activeCount":103},[],{"trials":45219,"activeCount":103},[],{"trials":45221,"activeCount":103},[],{"trials":45223,"activeCount":103},[],{"intervention":45197,"totalTrials":302,"cells":45225},{"EARLY_PHASE1":45226,"PHASE1":45228,"PHASE2":45234,"PHASE3":45236,"PHASE4":45238,"NA":45240},{"trials":45227,"activeCount":103},[],{"trials":45229,"activeCount":103},[45230],{"nctId":45188,"briefTitle":45189,"status":111,"phases":45231,"primaryCompletion":26826,"completion":26826,"start":45191,"enrollment":314,"conditions":45232,"interventions":45233},[91],[3395,45193,19,45194],[45181,45196,45197],{"trials":45235,"activeCount":103},[],{"trials":45237,"activeCount":103},[],{"trials":45239,"activeCount":103},[],{"trials":45241,"activeCount":103},[],{"intervention":45243,"totalTrials":302,"cells":45244},"PF-06700841 cream",{"EARLY_PHASE1":45245,"PHASE1":45247,"PHASE2":45258,"PHASE3":45260,"PHASE4":45262,"NA":45264},{"trials":45246,"activeCount":103},[],{"trials":45248,"activeCount":103},[45249],{"nctId":45250,"briefTitle":45251,"status":111,"phases":45252,"primaryCompletion":43488,"completion":45253,"start":45254,"enrollment":2159,"conditions":45255,"interventions":45256},"NCT03916250","Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants",[91],"2019-05-12","2019-03-23",[16],[45243,45257],"White petrolatum",{"trials":45259,"activeCount":103},[],{"trials":45261,"activeCount":103},[],{"trials":45263,"activeCount":103},[],{"trials":45265,"activeCount":103},[],{"intervention":45257,"totalTrials":302,"cells":45267},{"EARLY_PHASE1":45268,"PHASE1":45270,"PHASE2":45276,"PHASE3":45278,"PHASE4":45280,"NA":45282},{"trials":45269,"activeCount":103},[],{"trials":45271,"activeCount":103},[45272],{"nctId":45250,"briefTitle":45251,"status":111,"phases":45273,"primaryCompletion":43488,"completion":45253,"start":45254,"enrollment":2159,"conditions":45274,"interventions":45275},[91],[16],[45243,45257],{"trials":45277,"activeCount":103},[],{"trials":45279,"activeCount":103},[],{"trials":45281,"activeCount":103},[],{"trials":45283,"activeCount":103},[],{"intervention":45285,"totalTrials":302,"cells":45286},"Palbociclib administered Fasted",{"EARLY_PHASE1":45287,"PHASE1":45289,"PHASE2":45300,"PHASE3":45302,"PHASE4":45304,"NA":45306},{"trials":45288,"activeCount":103},[],{"trials":45290,"activeCount":103},[45291],{"nctId":45292,"briefTitle":45293,"status":111,"phases":45294,"primaryCompletion":1249,"completion":1249,"start":6263,"enrollment":5909,"conditions":45295,"interventions":45296},"NCT01904747","Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption",[91],[16],[45285,45297,45298,45299],"Palbociclib administered Fed high calorie","Palbociclib administered Fed low calorie","Palbociclib administered Fed moderate calorie",{"trials":45301,"activeCount":103},[],{"trials":45303,"activeCount":103},[],{"trials":45305,"activeCount":103},[],{"trials":45307,"activeCount":103},[],{"intervention":45297,"totalTrials":302,"cells":45309},{"EARLY_PHASE1":45310,"PHASE1":45312,"PHASE2":45318,"PHASE3":45320,"PHASE4":45322,"NA":45324},{"trials":45311,"activeCount":103},[],{"trials":45313,"activeCount":103},[45314],{"nctId":45292,"briefTitle":45293,"status":111,"phases":45315,"primaryCompletion":1249,"completion":1249,"start":6263,"enrollment":5909,"conditions":45316,"interventions":45317},[91],[16],[45285,45297,45298,45299],{"trials":45319,"activeCount":103},[],{"trials":45321,"activeCount":103},[],{"trials":45323,"activeCount":103},[],{"trials":45325,"activeCount":103},[],{"intervention":45298,"totalTrials":302,"cells":45327},{"EARLY_PHASE1":45328,"PHASE1":45330,"PHASE2":45336,"PHASE3":45338,"PHASE4":45340,"NA":45342},{"trials":45329,"activeCount":103},[],{"trials":45331,"activeCount":103},[45332],{"nctId":45292,"briefTitle":45293,"status":111,"phases":45333,"primaryCompletion":1249,"completion":1249,"start":6263,"enrollment":5909,"conditions":45334,"interventions":45335},[91],[16],[45285,45297,45298,45299],{"trials":45337,"activeCount":103},[],{"trials":45339,"activeCount":103},[],{"trials":45341,"activeCount":103},[],{"trials":45343,"activeCount":103},[],{"intervention":45299,"totalTrials":302,"cells":45345},{"EARLY_PHASE1":45346,"PHASE1":45348,"PHASE2":45354,"PHASE3":45356,"PHASE4":45358,"NA":45360},{"trials":45347,"activeCount":103},[],{"trials":45349,"activeCount":103},[45350],{"nctId":45292,"briefTitle":45293,"status":111,"phases":45351,"primaryCompletion":1249,"completion":1249,"start":6263,"enrollment":5909,"conditions":45352,"interventions":45353},[91],[16],[45285,45297,45298,45299],{"trials":45355,"activeCount":103},[],{"trials":45357,"activeCount":103},[],{"trials":45359,"activeCount":103},[],{"trials":45361,"activeCount":103},[],{"intervention":45363,"totalTrials":302,"cells":45364},"PF-06273588",{"EARLY_PHASE1":45365,"PHASE1":45367,"PHASE2":45375,"PHASE3":45377,"PHASE4":45379,"NA":45381},{"trials":45366,"activeCount":103},[],{"trials":45368,"activeCount":103},[45369],{"nctId":45370,"briefTitle":45371,"status":111,"phases":45372,"primaryCompletion":4531,"completion":4531,"start":3313,"enrollment":578,"conditions":45373,"interventions":45374},"NCT01408355","A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose.",[91],[19],[45363,45363],{"trials":45376,"activeCount":103},[],{"trials":45378,"activeCount":103},[],{"trials":45380,"activeCount":103},[],{"trials":45382,"activeCount":103},[],{"intervention":45384,"totalTrials":302,"cells":45385},"CP-70,429 and PF-03709270",{"EARLY_PHASE1":45386,"PHASE1":45388,"PHASE2":45396,"PHASE3":45398,"PHASE4":45400,"NA":45402},{"trials":45387,"activeCount":103},[],{"trials":45389,"activeCount":103},[45390],{"nctId":45391,"briefTitle":45392,"status":111,"phases":45393,"primaryCompletion":3642,"completion":3642,"start":4645,"enrollment":350,"conditions":45394,"interventions":45395},"NCT00759564","A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function",[91],[9107],[45384],{"trials":45397,"activeCount":103},[],{"trials":45399,"activeCount":103},[],{"trials":45401,"activeCount":103},[],{"trials":45403,"activeCount":103},[],{"intervention":45405,"totalTrials":302,"cells":45406},"Oral [14C]PF-07081532",{"EARLY_PHASE1":45407,"PHASE1":45409,"PHASE2":45419,"PHASE3":45421,"PHASE4":45423,"NA":45425},{"trials":45408,"activeCount":103},[],{"trials":45410,"activeCount":103},[45411],{"nctId":45412,"briefTitle":45413,"status":111,"phases":45414,"primaryCompletion":2817,"completion":2817,"start":45415,"enrollment":2070,"conditions":45416,"interventions":45417},"NCT05652647","A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men",[91],"2022-12-21",[28],[45405,45418],"Oral PF-07081532 and IV [14C]PF-07081532",{"trials":45420,"activeCount":103},[],{"trials":45422,"activeCount":103},[],{"trials":45424,"activeCount":103},[],{"trials":45426,"activeCount":103},[],{"intervention":45418,"totalTrials":302,"cells":45428},{"EARLY_PHASE1":45429,"PHASE1":45431,"PHASE2":45437,"PHASE3":45439,"PHASE4":45441,"NA":45443},{"trials":45430,"activeCount":103},[],{"trials":45432,"activeCount":103},[45433],{"nctId":45412,"briefTitle":45413,"status":111,"phases":45434,"primaryCompletion":2817,"completion":2817,"start":45415,"enrollment":2070,"conditions":45435,"interventions":45436},[91],[28],[45405,45418],{"trials":45438,"activeCount":103},[],{"trials":45440,"activeCount":103},[],{"trials":45442,"activeCount":103},[],{"trials":45444,"activeCount":103},[],{"intervention":45446,"totalTrials":302,"cells":45447},"B16 Fasted",{"EARLY_PHASE1":45448,"PHASE1":45450,"PHASE2":45459,"PHASE3":45461,"PHASE4":45463,"NA":45465},{"trials":45449,"activeCount":103},[],{"trials":45451,"activeCount":103},[45452],{"nctId":45453,"briefTitle":45454,"status":111,"phases":45455,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":1625,"conditions":45456,"interventions":45457},"NCT00821444","Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules",[91],[16],[12647,45446,45458],"B16 Fed",{"trials":45460,"activeCount":103},[],{"trials":45462,"activeCount":103},[],{"trials":45464,"activeCount":103},[],{"trials":45466,"activeCount":103},[],{"intervention":45458,"totalTrials":302,"cells":45468},{"EARLY_PHASE1":45469,"PHASE1":45471,"PHASE2":45477,"PHASE3":45479,"PHASE4":45481,"NA":45483},{"trials":45470,"activeCount":103},[],{"trials":45472,"activeCount":103},[45473],{"nctId":45453,"briefTitle":45454,"status":111,"phases":45474,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":1625,"conditions":45475,"interventions":45476},[91],[16],[12647,45446,45458],{"trials":45478,"activeCount":103},[],{"trials":45480,"activeCount":103},[],{"trials":45482,"activeCount":103},[],{"trials":45484,"activeCount":103},[],{"intervention":45486,"totalTrials":302,"cells":45487},"[14C]NXL104",{"EARLY_PHASE1":45488,"PHASE1":45490,"PHASE2":45498,"PHASE3":45500,"PHASE4":45502,"NA":45504},{"trials":45489,"activeCount":103},[],{"trials":45491,"activeCount":103},[45492],{"nctId":45493,"briefTitle":45494,"status":111,"phases":45495,"primaryCompletion":570,"completion":570,"start":114,"enrollment":2070,"conditions":45496,"interventions":45497},"NCT01448395","Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104",[91],[16],[45486],{"trials":45499,"activeCount":103},[],{"trials":45501,"activeCount":103},[],{"trials":45503,"activeCount":103},[],{"trials":45505,"activeCount":103},[],{"intervention":45507,"totalTrials":302,"cells":45508},"Formulation 1",{"EARLY_PHASE1":45509,"PHASE1":45511,"PHASE2":45521,"PHASE3":45523,"PHASE4":45525,"NA":45527},{"trials":45510,"activeCount":103},[],{"trials":45512,"activeCount":103},[45513],{"nctId":45514,"briefTitle":45515,"status":111,"phases":45516,"primaryCompletion":2661,"completion":2661,"start":11170,"enrollment":1268,"conditions":45517,"interventions":45518},"NCT01351129","Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers",[91],[16],[45507,45519,45520],"Formulation 2","Formulation 3",{"trials":45522,"activeCount":103},[],{"trials":45524,"activeCount":103},[],{"trials":45526,"activeCount":103},[],{"trials":45528,"activeCount":103},[],{"intervention":45519,"totalTrials":302,"cells":45530},{"EARLY_PHASE1":45531,"PHASE1":45533,"PHASE2":45539,"PHASE3":45541,"PHASE4":45543,"NA":45545},{"trials":45532,"activeCount":103},[],{"trials":45534,"activeCount":103},[45535],{"nctId":45514,"briefTitle":45515,"status":111,"phases":45536,"primaryCompletion":2661,"completion":2661,"start":11170,"enrollment":1268,"conditions":45537,"interventions":45538},[91],[16],[45507,45519,45520],{"trials":45540,"activeCount":103},[],{"trials":45542,"activeCount":103},[],{"trials":45544,"activeCount":103},[],{"trials":45546,"activeCount":103},[],{"intervention":45520,"totalTrials":302,"cells":45548},{"EARLY_PHASE1":45549,"PHASE1":45551,"PHASE2":45557,"PHASE3":45559,"PHASE4":45561,"NA":45563},{"trials":45550,"activeCount":103},[],{"trials":45552,"activeCount":103},[45553],{"nctId":45514,"briefTitle":45515,"status":111,"phases":45554,"primaryCompletion":2661,"completion":2661,"start":11170,"enrollment":1268,"conditions":45555,"interventions":45556},[91],[16],[45507,45519,45520],{"trials":45558,"activeCount":103},[],{"trials":45560,"activeCount":103},[],{"trials":45562,"activeCount":103},[],{"trials":45564,"activeCount":103},[],{"intervention":18762,"totalTrials":302,"cells":45566},{"EARLY_PHASE1":45567,"PHASE1":45569,"PHASE2":45575,"PHASE3":45577,"PHASE4":45579,"NA":45581},{"trials":45568,"activeCount":103},[],{"trials":45570,"activeCount":103},[45571],{"nctId":18757,"briefTitle":18758,"status":111,"phases":45572,"primaryCompletion":605,"completion":605,"start":6207,"enrollment":4369,"conditions":45573,"interventions":45574},[91],[3396,18761,12302,18762,18763,10629],[12302,18762],{"trials":45576,"activeCount":103},[],{"trials":45578,"activeCount":103},[],{"trials":45580,"activeCount":103},[],{"trials":45582,"activeCount":103},[],{"intervention":45584,"totalTrials":302,"cells":45585},"[14C]-PF-00868554",{"EARLY_PHASE1":45586,"PHASE1":45588,"PHASE2":45597,"PHASE3":45599,"PHASE4":45601,"NA":45603},{"trials":45587,"activeCount":103},[],{"trials":45589,"activeCount":103},[45590],{"nctId":45591,"briefTitle":45592,"status":111,"phases":45593,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":3659,"conditions":45594,"interventions":45596},"NCT00823745","Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects",[91],[45595],"HCV",[45584],{"trials":45598,"activeCount":103},[],{"trials":45600,"activeCount":103},[],{"trials":45602,"activeCount":103},[],{"trials":45604,"activeCount":103},[],{"intervention":40384,"totalTrials":302,"cells":45606},{"EARLY_PHASE1":45607,"PHASE1":45609,"PHASE2":45615,"PHASE3":45617,"PHASE4":45619,"NA":45621},{"trials":45608,"activeCount":103},[],{"trials":45610,"activeCount":103},[45611],{"nctId":40379,"briefTitle":40380,"status":111,"phases":45612,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":3229,"conditions":45613,"interventions":45614},[91],[16],[40364,40384],{"trials":45616,"activeCount":103},[],{"trials":45618,"activeCount":103},[],{"trials":45620,"activeCount":103},[],{"trials":45622,"activeCount":103},[],{"intervention":45624,"totalTrials":302,"cells":45625},"bosutinib or bosutinib + aprepitant",{"EARLY_PHASE1":45626,"PHASE1":45628,"PHASE2":45636,"PHASE3":45638,"PHASE4":45640,"NA":45642},{"trials":45627,"activeCount":103},[],{"trials":45629,"activeCount":103},[45630],{"nctId":45631,"briefTitle":45632,"status":111,"phases":45633,"primaryCompletion":1288,"completion":1288,"start":652,"enrollment":2159,"conditions":45634,"interventions":45635},"NCT02058277","A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers",[91],[16],[45624],{"trials":45637,"activeCount":103},[],{"trials":45639,"activeCount":103},[],{"trials":45641,"activeCount":103},[],{"trials":45643,"activeCount":103},[],{"intervention":45645,"totalTrials":302,"cells":45646},"Drug: PF-07817883",{"EARLY_PHASE1":45647,"PHASE1":45649,"PHASE2":45659,"PHASE3":45661,"PHASE4":45663,"NA":45665},{"trials":45648,"activeCount":103},[],{"trials":45650,"activeCount":103},[45651],{"nctId":45652,"briefTitle":45653,"status":111,"phases":45654,"primaryCompletion":45655,"completion":45655,"start":45656,"enrollment":1268,"conditions":45657,"interventions":45658},"NCT06122194","A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers",[91],"2024-01-12","2023-11-23",[16],[45645],{"trials":45660,"activeCount":103},[],{"trials":45662,"activeCount":103},[],{"trials":45664,"activeCount":103},[],{"trials":45666,"activeCount":103},[],{"intervention":45668,"totalTrials":302,"cells":45669},"PF-04457845, FAAH inhibitor",{"EARLY_PHASE1":45670,"PHASE1":45672,"PHASE2":45681,"PHASE3":45683,"PHASE4":45685,"NA":45687},{"trials":45671,"activeCount":103},[],{"trials":45673,"activeCount":103},[45674],{"nctId":45675,"briefTitle":45676,"status":111,"phases":45677,"primaryCompletion":4627,"completion":4627,"start":4608,"enrollment":713,"conditions":45678,"interventions":45680},"NCT00836082","A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers",[91],[45679,13120],"Acute Pain",[45668,45668,45668,45668,45668,45668],{"trials":45682,"activeCount":103},[],{"trials":45684,"activeCount":103},[],{"trials":45686,"activeCount":103},[],{"trials":45688,"activeCount":103},[],{"intervention":29320,"totalTrials":302,"cells":45690},{"EARLY_PHASE1":45691,"PHASE1":45693,"PHASE2":45699,"PHASE3":45701,"PHASE4":45703,"NA":45705},{"trials":45692,"activeCount":103},[],{"trials":45694,"activeCount":103},[45695],{"nctId":29313,"briefTitle":29314,"status":111,"phases":45696,"primaryCompletion":29316,"completion":29316,"start":29317,"enrollment":1268,"conditions":45697,"interventions":45698},[91],[4401],[29320,29321,29322,29323,29324,29325],{"trials":45700,"activeCount":103},[],{"trials":45702,"activeCount":103},[],{"trials":45704,"activeCount":103},[],{"trials":45706,"activeCount":103},[],{"intervention":29322,"totalTrials":302,"cells":45708},{"EARLY_PHASE1":45709,"PHASE1":45711,"PHASE2":45717,"PHASE3":45719,"PHASE4":45721,"NA":45723},{"trials":45710,"activeCount":103},[],{"trials":45712,"activeCount":103},[45713],{"nctId":29313,"briefTitle":29314,"status":111,"phases":45714,"primaryCompletion":29316,"completion":29316,"start":29317,"enrollment":1268,"conditions":45715,"interventions":45716},[91],[4401],[29320,29321,29322,29323,29324,29325],{"trials":45718,"activeCount":103},[],{"trials":45720,"activeCount":103},[],{"trials":45722,"activeCount":103},[],{"trials":45724,"activeCount":103},[],{"intervention":29325,"totalTrials":302,"cells":45726},{"EARLY_PHASE1":45727,"PHASE1":45729,"PHASE2":45735,"PHASE3":45737,"PHASE4":45739,"NA":45741},{"trials":45728,"activeCount":103},[],{"trials":45730,"activeCount":103},[45731],{"nctId":29313,"briefTitle":29314,"status":111,"phases":45732,"primaryCompletion":29316,"completion":29316,"start":29317,"enrollment":1268,"conditions":45733,"interventions":45734},[91],[4401],[29320,29321,29322,29323,29324,29325],{"trials":45736,"activeCount":103},[],{"trials":45738,"activeCount":103},[],{"trials":45740,"activeCount":103},[],{"trials":45742,"activeCount":103},[],{"intervention":45744,"totalTrials":302,"cells":45745},"PF-05105679",{"EARLY_PHASE1":45746,"PHASE1":45748,"PHASE2":45756,"PHASE3":45758,"PHASE4":45760,"NA":45762},{"trials":45747,"activeCount":103},[],{"trials":45749,"activeCount":103},[45750],{"nctId":45751,"briefTitle":45752,"status":111,"phases":45753,"primaryCompletion":9544,"completion":9544,"start":11170,"enrollment":4259,"conditions":45754,"interventions":45755},"NCT01393652","Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679",[91],[19],[45744,45744,45744],{"trials":45757,"activeCount":103},[],{"trials":45759,"activeCount":103},[],{"trials":45761,"activeCount":103},[],{"trials":45763,"activeCount":103},[],{"intervention":45765,"totalTrials":302,"cells":45766},"PF-06273340 or Placebo",{"EARLY_PHASE1":45767,"PHASE1":45769,"PHASE2":45778,"PHASE3":45780,"PHASE4":45782,"NA":45784},{"trials":45768,"activeCount":103},[],{"trials":45770,"activeCount":103},[45771],{"nctId":45772,"briefTitle":45773,"status":111,"phases":45774,"primaryCompletion":4459,"completion":4459,"start":113,"enrollment":2159,"conditions":45775,"interventions":45777},"NCT01601834","A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340",[91],[45776],"PAIN",[45765,45765],{"trials":45779,"activeCount":103},[],{"trials":45781,"activeCount":103},[],{"trials":45783,"activeCount":103},[],{"trials":45785,"activeCount":103},[],{"intervention":45787,"totalTrials":302,"cells":45788},"PF 06260414 solid dose formulation",{"EARLY_PHASE1":45789,"PHASE1":45791,"PHASE2":45800,"PHASE3":45802,"PHASE4":45804,"NA":45806},{"trials":45790,"activeCount":103},[],{"trials":45792,"activeCount":103},[45793],{"nctId":45794,"briefTitle":45795,"status":649,"phases":45796,"primaryCompletion":4439,"completion":4439,"start":4438,"enrollment":103,"conditions":45797,"interventions":45798},"NCT02393807","The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation",[91],[16],[45787,45799],"PF-06260414 nanosuspension",{"trials":45801,"activeCount":103},[],{"trials":45803,"activeCount":103},[],{"trials":45805,"activeCount":103},[],{"trials":45807,"activeCount":103},[],{"intervention":45799,"totalTrials":302,"cells":45809},{"EARLY_PHASE1":45810,"PHASE1":45812,"PHASE2":45818,"PHASE3":45820,"PHASE4":45822,"NA":45824},{"trials":45811,"activeCount":103},[],{"trials":45813,"activeCount":103},[45814],{"nctId":45794,"briefTitle":45795,"status":649,"phases":45815,"primaryCompletion":4439,"completion":4439,"start":4438,"enrollment":103,"conditions":45816,"interventions":45817},[91],[16],[45787,45799],{"trials":45819,"activeCount":103},[],{"trials":45821,"activeCount":103},[],{"trials":45823,"activeCount":103},[],{"trials":45825,"activeCount":103},[],{"intervention":18772,"totalTrials":302,"cells":45827},{"EARLY_PHASE1":45828,"PHASE1":45830,"PHASE2":45836,"PHASE3":45838,"PHASE4":45840,"NA":45842},{"trials":45829,"activeCount":103},[],{"trials":45831,"activeCount":103},[45832],{"nctId":18766,"briefTitle":18767,"status":111,"phases":45833,"primaryCompletion":18769,"completion":18769,"start":1249,"enrollment":1578,"conditions":45834,"interventions":45835},[91],[19],[12302,18772],{"trials":45837,"activeCount":103},[],{"trials":45839,"activeCount":103},[],{"trials":45841,"activeCount":103},[],{"trials":45843,"activeCount":103},[],{"intervention":45845,"totalTrials":302,"cells":45846},"JZoloft",{"EARLY_PHASE1":45847,"PHASE1":45849,"PHASE2":45858,"PHASE3":45860,"PHASE4":45862,"NA":45864},{"trials":45848,"activeCount":103},[],{"trials":45850,"activeCount":103},[45851],{"nctId":45852,"briefTitle":45853,"status":111,"phases":45854,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":1780,"conditions":45855,"interventions":45856},"NCT01699724","Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects",[91],[16],[45845,45857,45857],"sertraline ODT",{"trials":45859,"activeCount":103},[],{"trials":45861,"activeCount":103},[],{"trials":45863,"activeCount":103},[],{"trials":45865,"activeCount":103},[],{"intervention":45857,"totalTrials":302,"cells":45867},{"EARLY_PHASE1":45868,"PHASE1":45870,"PHASE2":45876,"PHASE3":45878,"PHASE4":45880,"NA":45882},{"trials":45869,"activeCount":103},[],{"trials":45871,"activeCount":103},[45872],{"nctId":45852,"briefTitle":45853,"status":111,"phases":45873,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":1780,"conditions":45874,"interventions":45875},[91],[16],[45845,45857,45857],{"trials":45877,"activeCount":103},[],{"trials":45879,"activeCount":103},[],{"trials":45881,"activeCount":103},[],{"trials":45883,"activeCount":103},[],{"intervention":45885,"totalTrials":302,"cells":45886},"CP-481,715",{"EARLY_PHASE1":45887,"PHASE1":45889,"PHASE2":45898,"PHASE3":45900,"PHASE4":45902,"NA":45904},{"trials":45888,"activeCount":103},[],{"trials":45890,"activeCount":103},[45891],{"nctId":45892,"briefTitle":45893,"status":111,"phases":45894,"completion":9387,"start":16955,"enrollment":4369,"conditions":45895,"interventions":45897},"NCT00141180","CP-481,715 Nickel Allergy Study.",[91],[45896],"Dermatitis, Allergic Contact",[45885],{"trials":45899,"activeCount":103},[],{"trials":45901,"activeCount":103},[],{"trials":45903,"activeCount":103},[],{"trials":45905,"activeCount":103},[],{"intervention":45907,"totalTrials":302,"cells":45908},"PF-06678552 or Placebo",{"EARLY_PHASE1":45909,"PHASE1":45911,"PHASE2":45919,"PHASE3":45921,"PHASE4":45923,"NA":45925},{"trials":45910,"activeCount":103},[],{"trials":45912,"activeCount":103},[45913],{"nctId":45914,"briefTitle":45915,"status":111,"phases":45916,"primaryCompletion":605,"completion":605,"start":606,"enrollment":1509,"conditions":45917,"interventions":45918},"NCT01992614","A Single Dose Study Of PF-06678552 In Healthy Subjects",[91],[16],[45907,45907,45907],{"trials":45920,"activeCount":103},[],{"trials":45922,"activeCount":103},[],{"trials":45924,"activeCount":103},[],{"trials":45926,"activeCount":103},[],{"intervention":39110,"totalTrials":302,"cells":45928},{"EARLY_PHASE1":45929,"PHASE1":45931,"PHASE2":45937,"PHASE3":45939,"PHASE4":45941,"NA":45943},{"trials":45930,"activeCount":103},[],{"trials":45932,"activeCount":103},[45933],{"nctId":39105,"briefTitle":39106,"status":111,"phases":45934,"primaryCompletion":8252,"completion":8252,"start":585,"enrollment":597,"conditions":45935,"interventions":45936},[91],[16],[39090,39110],{"trials":45938,"activeCount":103},[],{"trials":45940,"activeCount":103},[],{"trials":45942,"activeCount":103},[],{"trials":45944,"activeCount":103},[],{"intervention":45946,"totalTrials":302,"cells":45947},"Investigational drug",{"EARLY_PHASE1":45948,"PHASE1":45950,"PHASE2":45958,"PHASE3":45960,"PHASE4":45962,"NA":45964},{"trials":45949,"activeCount":103},[],{"trials":45951,"activeCount":103},[45952],{"nctId":45953,"briefTitle":45954,"status":111,"phases":45955,"conditions":45956,"interventions":45957},"NCT00036140","Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma",[91],[1062],[45946],{"trials":45959,"activeCount":103},[],{"trials":45961,"activeCount":103},[],{"trials":45963,"activeCount":103},[],{"trials":45965,"activeCount":103},[],{"intervention":45967,"totalTrials":302,"cells":45968},"PF-06954522 IR",{"EARLY_PHASE1":45969,"PHASE1":45971,"PHASE2":45982,"PHASE3":45984,"PHASE4":45986,"NA":45988},{"trials":45970,"activeCount":103},[],{"trials":45972,"activeCount":103},[45973],{"nctId":45974,"briefTitle":45975,"status":111,"phases":45976,"primaryCompletion":45977,"completion":45977,"start":45978,"enrollment":2218,"conditions":45979,"interventions":45980},"NCT06393517","A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults",[91],"2024-09-01","2024-04-30",[28],[45967,45981,45981],"PF-06954522 MR",{"trials":45983,"activeCount":103},[],{"trials":45985,"activeCount":103},[],{"trials":45987,"activeCount":103},[],{"trials":45989,"activeCount":103},[],{"intervention":45981,"totalTrials":302,"cells":45991},{"EARLY_PHASE1":45992,"PHASE1":45994,"PHASE2":46000,"PHASE3":46002,"PHASE4":46004,"NA":46006},{"trials":45993,"activeCount":103},[],{"trials":45995,"activeCount":103},[45996],{"nctId":45974,"briefTitle":45975,"status":111,"phases":45997,"primaryCompletion":45977,"completion":45977,"start":45978,"enrollment":2218,"conditions":45998,"interventions":45999},[91],[28],[45967,45981,45981],{"trials":46001,"activeCount":103},[],{"trials":46003,"activeCount":103},[],{"trials":46005,"activeCount":103},[],{"trials":46007,"activeCount":103},[],{"intervention":46009,"totalTrials":302,"cells":46010},"Artesunate",{"EARLY_PHASE1":46011,"PHASE1":46013,"PHASE2":46021,"PHASE3":46023,"PHASE4":46025,"NA":46027},{"trials":46012,"activeCount":103},[],{"trials":46014,"activeCount":103},[46015],{"nctId":46016,"briefTitle":46017,"status":111,"phases":46018,"primaryCompletion":4214,"completion":4214,"start":4646,"enrollment":35,"conditions":46019,"interventions":46020},"NCT00894374","Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects",[91],[14263],[46009,46009],{"trials":46022,"activeCount":103},[],{"trials":46024,"activeCount":103},[],{"trials":46026,"activeCount":103},[],{"trials":46028,"activeCount":103},[],{"intervention":46030,"totalTrials":302,"cells":46031},"PF-06882961 20MG",{"EARLY_PHASE1":46032,"PHASE1":46034,"PHASE2":46043,"PHASE3":46045,"PHASE4":46047,"NA":46049},{"trials":46033,"activeCount":103},[],{"trials":46035,"activeCount":103},[46036],{"nctId":46037,"briefTitle":46038,"status":111,"phases":46039,"primaryCompletion":3402,"completion":3402,"start":46040,"enrollment":1509,"conditions":46041,"interventions":46042},"NCT04604496","STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT",[91],"2020-12-30",[7853,19],[46030],{"trials":46044,"activeCount":103},[],{"trials":46046,"activeCount":103},[],{"trials":46048,"activeCount":103},[],{"trials":46050,"activeCount":103},[],{"intervention":39372,"totalTrials":302,"cells":46052},{"EARLY_PHASE1":46053,"PHASE1":46055,"PHASE2":46061,"PHASE3":46063,"PHASE4":46065,"NA":46067},{"trials":46054,"activeCount":103},[],{"trials":46056,"activeCount":103},[46057],{"nctId":39367,"briefTitle":39368,"status":111,"phases":46058,"primaryCompletion":4627,"completion":4627,"start":8251,"enrollment":27583,"conditions":46059,"interventions":46060},[91],[19],[11981,39372,11981],{"trials":46062,"activeCount":103},[],{"trials":46064,"activeCount":103},[],{"trials":46066,"activeCount":103},[],{"trials":46068,"activeCount":103},[],{"intervention":46070,"totalTrials":302,"cells":46071},"PF-06409577 or Placebo",{"EARLY_PHASE1":46072,"PHASE1":46074,"PHASE2":46082,"PHASE3":46084,"PHASE4":46086,"NA":46088},{"trials":46073,"activeCount":103},[],{"trials":46075,"activeCount":103},[46076],{"nctId":46077,"briefTitle":46078,"status":168,"phases":46079,"primaryCompletion":4438,"completion":4438,"start":17639,"enrollment":1097,"conditions":46080,"interventions":46081},"NCT02286882","A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects",[91],[16],[46070],{"trials":46083,"activeCount":103},[],{"trials":46085,"activeCount":103},[],{"trials":46087,"activeCount":103},[],{"trials":46089,"activeCount":103},[],{"intervention":46091,"totalTrials":302,"cells":46092},"14C-PF-06826647-LR 600 mg PO",{"EARLY_PHASE1":46093,"PHASE1":46095,"PHASE2":46106,"PHASE3":46108,"PHASE4":46110,"NA":46112},{"trials":46094,"activeCount":103},[],{"trials":46096,"activeCount":103},[46097],{"nctId":46098,"briefTitle":46099,"status":111,"phases":46100,"primaryCompletion":46101,"completion":46101,"start":3228,"enrollment":2070,"conditions":46102,"interventions":46103},"NCT04591262","A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants",[91],"2021-01-28",[16],[46091,46104,46105],"PF-06826647 600 mg PO","14C-PF-06826647 100 ug IV",{"trials":46107,"activeCount":103},[],{"trials":46109,"activeCount":103},[],{"trials":46111,"activeCount":103},[],{"trials":46113,"activeCount":103},[],{"intervention":46104,"totalTrials":302,"cells":46115},{"EARLY_PHASE1":46116,"PHASE1":46118,"PHASE2":46124,"PHASE3":46126,"PHASE4":46128,"NA":46130},{"trials":46117,"activeCount":103},[],{"trials":46119,"activeCount":103},[46120],{"nctId":46098,"briefTitle":46099,"status":111,"phases":46121,"primaryCompletion":46101,"completion":46101,"start":3228,"enrollment":2070,"conditions":46122,"interventions":46123},[91],[16],[46091,46104,46105],{"trials":46125,"activeCount":103},[],{"trials":46127,"activeCount":103},[],{"trials":46129,"activeCount":103},[],{"trials":46131,"activeCount":103},[],{"intervention":46105,"totalTrials":302,"cells":46133},{"EARLY_PHASE1":46134,"PHASE1":46136,"PHASE2":46142,"PHASE3":46144,"PHASE4":46146,"NA":46148},{"trials":46135,"activeCount":103},[],{"trials":46137,"activeCount":103},[46138],{"nctId":46098,"briefTitle":46099,"status":111,"phases":46139,"primaryCompletion":46101,"completion":46101,"start":3228,"enrollment":2070,"conditions":46140,"interventions":46141},[91],[16],[46091,46104,46105],{"trials":46143,"activeCount":103},[],{"trials":46145,"activeCount":103},[],{"trials":46147,"activeCount":103},[],{"trials":46149,"activeCount":103},[],{"intervention":46151,"totalTrials":302,"cells":46152},"carboplatin + SU011248 (sunitinib) + paclitaxel",{"EARLY_PHASE1":46153,"PHASE1":46155,"PHASE2":46163,"PHASE3":46165,"PHASE4":46167,"NA":46169},{"trials":46154,"activeCount":103},[],{"trials":46156,"activeCount":103},[46157],{"nctId":46158,"briefTitle":46159,"status":111,"phases":46160,"primaryCompletion":4608,"completion":4608,"start":8170,"enrollment":32,"conditions":46161,"interventions":46162},"NCT00511849","Study Of SU011248 In Combination With Paclitaxel\u002FCarboplatin In Patients With Advanced Solid Tumors",[91],[2053],[46151],{"trials":46164,"activeCount":103},[],{"trials":46166,"activeCount":103},[],{"trials":46168,"activeCount":103},[],{"trials":46170,"activeCount":103},[],{"intervention":46172,"totalTrials":302,"cells":46173},"Premarin reference",{"EARLY_PHASE1":46174,"PHASE1":46176,"PHASE2":46188,"PHASE3":46190,"PHASE4":46192,"NA":46194},{"trials":46175,"activeCount":103},[],{"trials":46177,"activeCount":103},[46178],{"nctId":46179,"briefTitle":46180,"status":111,"phases":46181,"primaryCompletion":2450,"completion":2450,"start":114,"enrollment":7388,"conditions":46182,"interventions":46186},"NCT01436513","A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.",[91],[46183,46184,46185,23073],"Primary Ovarian Insufficiency","Vaginitis","Metrorrhagia",[46172,46187,46172,46187],"Premarin new",{"trials":46189,"activeCount":103},[],{"trials":46191,"activeCount":103},[],{"trials":46193,"activeCount":103},[],{"trials":46195,"activeCount":103},[],{"intervention":46187,"totalTrials":302,"cells":46197},{"EARLY_PHASE1":46198,"PHASE1":46200,"PHASE2":46206,"PHASE3":46208,"PHASE4":46210,"NA":46212},{"trials":46199,"activeCount":103},[],{"trials":46201,"activeCount":103},[46202],{"nctId":46179,"briefTitle":46180,"status":111,"phases":46203,"primaryCompletion":2450,"completion":2450,"start":114,"enrollment":7388,"conditions":46204,"interventions":46205},[91],[46183,46184,46185,23073],[46172,46187,46172,46187],{"trials":46207,"activeCount":103},[],{"trials":46209,"activeCount":103},[],{"trials":46211,"activeCount":103},[],{"trials":46213,"activeCount":103},[],{"intervention":46215,"totalTrials":302,"cells":46216},"MDV3100",{"EARLY_PHASE1":46217,"PHASE1":46219,"PHASE2":46231,"PHASE3":46233,"PHASE4":46235,"NA":46237},{"trials":46218,"activeCount":103},[],{"trials":46220,"activeCount":103},[46221],{"nctId":46222,"briefTitle":46223,"status":111,"phases":46224,"primaryCompletion":46225,"completion":46226,"start":46227,"enrollment":12373,"conditions":46228,"interventions":46230},"NCT00510718","A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer",[91],"2008-12-08","2018-04-02","2007-07-23",[1684,46229],"Hormone Refractory Prostate Cancer",[46215],{"trials":46232,"activeCount":103},[],{"trials":46234,"activeCount":103},[],{"trials":46236,"activeCount":103},[],{"trials":46238,"activeCount":103},[],{"intervention":40827,"totalTrials":302,"cells":46240},{"EARLY_PHASE1":46241,"PHASE1":46243,"PHASE2":46249,"PHASE3":46251,"PHASE4":46253,"NA":46255},{"trials":46242,"activeCount":103},[],{"trials":46244,"activeCount":103},[46245],{"nctId":40822,"briefTitle":40823,"status":649,"phases":46246,"primaryCompletion":2661,"completion":2661,"start":523,"enrollment":103,"conditions":46247,"interventions":46248},[91],[16],[40827,40815],{"trials":46250,"activeCount":103},[],{"trials":46252,"activeCount":103},[],{"trials":46254,"activeCount":103},[],{"trials":46256,"activeCount":103},[],{"intervention":40858,"totalTrials":302,"cells":46258},{"EARLY_PHASE1":46259,"PHASE1":46261,"PHASE2":46267,"PHASE3":46269,"PHASE4":46271,"NA":46273},{"trials":46260,"activeCount":103},[],{"trials":46262,"activeCount":103},[46263],{"nctId":40851,"briefTitle":40852,"status":111,"phases":46264,"primaryCompletion":40854,"completion":40854,"start":40855,"enrollment":6503,"conditions":46265,"interventions":46266},[91],[19],[40858,40844],{"trials":46268,"activeCount":103},[],{"trials":46270,"activeCount":103},[],{"trials":46272,"activeCount":103},[],{"trials":46274,"activeCount":103},[],{"intervention":46276,"totalTrials":302,"cells":46277},"PF-06835375",{"EARLY_PHASE1":46278,"PHASE1":46280,"PHASE2":46290,"PHASE3":46292,"PHASE4":46294,"NA":46296},{"trials":46279,"activeCount":103},[],{"trials":46281,"activeCount":103},[46282],{"nctId":46283,"briefTitle":46284,"status":111,"phases":46285,"primaryCompletion":46286,"completion":46286,"start":46287,"enrollment":27243,"conditions":46288,"interventions":46289},"NCT03334851","Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis",[91],"2022-02-15","2017-11-17",[32640,22],[46276],{"trials":46291,"activeCount":103},[],{"trials":46293,"activeCount":103},[],{"trials":46295,"activeCount":103},[],{"trials":46297,"activeCount":103},[],{"intervention":46299,"totalTrials":302,"cells":46300},"PF-06651600 10 mg",{"EARLY_PHASE1":46301,"PHASE1":46303,"PHASE2":46314,"PHASE3":46316,"PHASE4":46318,"NA":46320},{"trials":46302,"activeCount":103},[],{"trials":46304,"activeCount":103},[46305],{"nctId":46306,"briefTitle":46307,"status":111,"phases":46308,"primaryCompletion":46309,"completion":3240,"start":46310,"enrollment":1268,"conditions":46311,"interventions":46312},"NCT03821493","Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy Participants",[91],"2019-04-06","2019-02-21",[28],[46299,46313],"Itraconazole Solution 200 mg",{"trials":46315,"activeCount":103},[],{"trials":46317,"activeCount":103},[],{"trials":46319,"activeCount":103},[],{"trials":46321,"activeCount":103},[],{"intervention":46313,"totalTrials":302,"cells":46323},{"EARLY_PHASE1":46324,"PHASE1":46326,"PHASE2":46332,"PHASE3":46334,"PHASE4":46336,"NA":46338},{"trials":46325,"activeCount":103},[],{"trials":46327,"activeCount":103},[46328],{"nctId":46306,"briefTitle":46307,"status":111,"phases":46329,"primaryCompletion":46309,"completion":3240,"start":46310,"enrollment":1268,"conditions":46330,"interventions":46331},[91],[28],[46299,46313],{"trials":46333,"activeCount":103},[],{"trials":46335,"activeCount":103},[],{"trials":46337,"activeCount":103},[],{"trials":46339,"activeCount":103},[],{"intervention":46341,"totalTrials":302,"cells":46342},"1 mg\u002Fkg every 2 weeks",{"EARLY_PHASE1":46343,"PHASE1":46345,"PHASE2":46358,"PHASE3":46360,"PHASE4":46362,"NA":46364},{"trials":46344,"activeCount":103},[],{"trials":46346,"activeCount":103},[46347],{"nctId":46348,"briefTitle":46349,"status":649,"phases":46350,"primaryCompletion":524,"completion":524,"start":561,"enrollment":103,"conditions":46351,"interventions":46352},"NCT01163838","Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia",[91],[12981,12980],[46341,46353,46354,46355,46356,46357],"2 mg\u002Fkg every 4 weeks","4 mg\u002Fkg every 4 weeks","4 mg\u002Fkg every 8 weeks","8 mg\u002Fkg every 8 weeks","12 mg\u002Fkg every 8 weeks",{"trials":46359,"activeCount":103},[],{"trials":46361,"activeCount":103},[],{"trials":46363,"activeCount":103},[],{"trials":46365,"activeCount":103},[],{"intervention":46353,"totalTrials":302,"cells":46367},{"EARLY_PHASE1":46368,"PHASE1":46370,"PHASE2":46376,"PHASE3":46378,"PHASE4":46380,"NA":46382},{"trials":46369,"activeCount":103},[],{"trials":46371,"activeCount":103},[46372],{"nctId":46348,"briefTitle":46349,"status":649,"phases":46373,"primaryCompletion":524,"completion":524,"start":561,"enrollment":103,"conditions":46374,"interventions":46375},[91],[12981,12980],[46341,46353,46354,46355,46356,46357],{"trials":46377,"activeCount":103},[],{"trials":46379,"activeCount":103},[],{"trials":46381,"activeCount":103},[],{"trials":46383,"activeCount":103},[],{"intervention":46354,"totalTrials":302,"cells":46385},{"EARLY_PHASE1":46386,"PHASE1":46388,"PHASE2":46394,"PHASE3":46396,"PHASE4":46398,"NA":46400},{"trials":46387,"activeCount":103},[],{"trials":46389,"activeCount":103},[46390],{"nctId":46348,"briefTitle":46349,"status":649,"phases":46391,"primaryCompletion":524,"completion":524,"start":561,"enrollment":103,"conditions":46392,"interventions":46393},[91],[12981,12980],[46341,46353,46354,46355,46356,46357],{"trials":46395,"activeCount":103},[],{"trials":46397,"activeCount":103},[],{"trials":46399,"activeCount":103},[],{"trials":46401,"activeCount":103},[],{"intervention":46355,"totalTrials":302,"cells":46403},{"EARLY_PHASE1":46404,"PHASE1":46406,"PHASE2":46412,"PHASE3":46414,"PHASE4":46416,"NA":46418},{"trials":46405,"activeCount":103},[],{"trials":46407,"activeCount":103},[46408],{"nctId":46348,"briefTitle":46349,"status":649,"phases":46409,"primaryCompletion":524,"completion":524,"start":561,"enrollment":103,"conditions":46410,"interventions":46411},[91],[12981,12980],[46341,46353,46354,46355,46356,46357],{"trials":46413,"activeCount":103},[],{"trials":46415,"activeCount":103},[],{"trials":46417,"activeCount":103},[],{"trials":46419,"activeCount":103},[],{"intervention":46356,"totalTrials":302,"cells":46421},{"EARLY_PHASE1":46422,"PHASE1":46424,"PHASE2":46430,"PHASE3":46432,"PHASE4":46434,"NA":46436},{"trials":46423,"activeCount":103},[],{"trials":46425,"activeCount":103},[46426],{"nctId":46348,"briefTitle":46349,"status":649,"phases":46427,"primaryCompletion":524,"completion":524,"start":561,"enrollment":103,"conditions":46428,"interventions":46429},[91],[12981,12980],[46341,46353,46354,46355,46356,46357],{"trials":46431,"activeCount":103},[],{"trials":46433,"activeCount":103},[],{"trials":46435,"activeCount":103},[],{"trials":46437,"activeCount":103},[],{"intervention":46357,"totalTrials":302,"cells":46439},{"EARLY_PHASE1":46440,"PHASE1":46442,"PHASE2":46448,"PHASE3":46450,"PHASE4":46452,"NA":46454},{"trials":46441,"activeCount":103},[],{"trials":46443,"activeCount":103},[46444],{"nctId":46348,"briefTitle":46349,"status":649,"phases":46445,"primaryCompletion":524,"completion":524,"start":561,"enrollment":103,"conditions":46446,"interventions":46447},[91],[12981,12980],[46341,46353,46354,46355,46356,46357],{"trials":46449,"activeCount":103},[],{"trials":46451,"activeCount":103},[],{"trials":46453,"activeCount":103},[],{"trials":46455,"activeCount":103},[],{"intervention":46457,"totalTrials":302,"cells":46458},"PF-04937319 high dose",{"EARLY_PHASE1":46459,"PHASE1":46461,"PHASE2":46470,"PHASE3":46472,"PHASE4":46474,"NA":46476},{"trials":46460,"activeCount":103},[],{"trials":46462,"activeCount":103},[46463],{"nctId":46464,"briefTitle":46465,"status":111,"phases":46466,"primaryCompletion":12307,"completion":12307,"start":11956,"enrollment":1268,"conditions":46467,"interventions":46468},"NCT02292433","A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy",[91],[12968],[46457,46469],"PF-04937319 low dose",{"trials":46471,"activeCount":103},[],{"trials":46473,"activeCount":103},[],{"trials":46475,"activeCount":103},[],{"trials":46477,"activeCount":103},[],{"intervention":46469,"totalTrials":302,"cells":46479},{"EARLY_PHASE1":46480,"PHASE1":46482,"PHASE2":46488,"PHASE3":46490,"PHASE4":46492,"NA":46494},{"trials":46481,"activeCount":103},[],{"trials":46483,"activeCount":103},[46484],{"nctId":46464,"briefTitle":46465,"status":111,"phases":46485,"primaryCompletion":12307,"completion":12307,"start":11956,"enrollment":1268,"conditions":46486,"interventions":46487},[91],[12968],[46457,46469],{"trials":46489,"activeCount":103},[],{"trials":46491,"activeCount":103},[],{"trials":46493,"activeCount":103},[],{"trials":46495,"activeCount":103},[],{"intervention":46497,"totalTrials":302,"cells":46498},"Methadone",{"EARLY_PHASE1":46499,"PHASE1":46501,"PHASE2":46510,"PHASE3":46512,"PHASE4":46514,"NA":46516},{"trials":46500,"activeCount":103},[],{"trials":46502,"activeCount":103},[46503],{"nctId":46504,"briefTitle":46505,"status":111,"phases":46506,"primaryCompletion":577,"completion":577,"start":2660,"enrollment":3254,"conditions":46507,"interventions":46508},"NCT01099748","Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone",[91],[19],[46497,46509],"Lersivirine + Methadone",{"trials":46511,"activeCount":103},[],{"trials":46513,"activeCount":103},[],{"trials":46515,"activeCount":103},[],{"trials":46517,"activeCount":103},[],{"intervention":46509,"totalTrials":302,"cells":46519},{"EARLY_PHASE1":46520,"PHASE1":46522,"PHASE2":46528,"PHASE3":46530,"PHASE4":46532,"NA":46534},{"trials":46521,"activeCount":103},[],{"trials":46523,"activeCount":103},[46524],{"nctId":46504,"briefTitle":46505,"status":111,"phases":46525,"primaryCompletion":577,"completion":577,"start":2660,"enrollment":3254,"conditions":46526,"interventions":46527},[91],[19],[46497,46509],{"trials":46529,"activeCount":103},[],{"trials":46531,"activeCount":103},[],{"trials":46533,"activeCount":103},[],{"trials":46535,"activeCount":103},[],{"intervention":46537,"totalTrials":302,"cells":46538},"4mg fesoterodine",{"EARLY_PHASE1":46539,"PHASE1":46541,"PHASE2":46551,"PHASE3":46553,"PHASE4":46555,"NA":46557},{"trials":46540,"activeCount":103},[],{"trials":46542,"activeCount":103},[46543],{"nctId":46544,"briefTitle":46545,"status":111,"phases":46546,"primaryCompletion":560,"completion":560,"start":586,"enrollment":2159,"conditions":46547,"interventions":46548},"NCT01161472","A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects",[91],[16],[46537,46549,46550],"8mg fesoterodine","alprazolam 1mg",{"trials":46552,"activeCount":103},[],{"trials":46554,"activeCount":103},[],{"trials":46556,"activeCount":103},[],{"trials":46558,"activeCount":103},[],{"intervention":46549,"totalTrials":302,"cells":46560},{"EARLY_PHASE1":46561,"PHASE1":46563,"PHASE2":46569,"PHASE3":46571,"PHASE4":46573,"NA":46575},{"trials":46562,"activeCount":103},[],{"trials":46564,"activeCount":103},[46565],{"nctId":46544,"briefTitle":46545,"status":111,"phases":46566,"primaryCompletion":560,"completion":560,"start":586,"enrollment":2159,"conditions":46567,"interventions":46568},[91],[16],[46537,46549,46550],{"trials":46570,"activeCount":103},[],{"trials":46572,"activeCount":103},[],{"trials":46574,"activeCount":103},[],{"trials":46576,"activeCount":103},[],{"intervention":46550,"totalTrials":302,"cells":46578},{"EARLY_PHASE1":46579,"PHASE1":46581,"PHASE2":46587,"PHASE3":46589,"PHASE4":46591,"NA":46593},{"trials":46580,"activeCount":103},[],{"trials":46582,"activeCount":103},[46583],{"nctId":46544,"briefTitle":46545,"status":111,"phases":46584,"primaryCompletion":560,"completion":560,"start":586,"enrollment":2159,"conditions":46585,"interventions":46586},[91],[16],[46537,46549,46550],{"trials":46588,"activeCount":103},[],{"trials":46590,"activeCount":103},[],{"trials":46592,"activeCount":103},[],{"trials":46594,"activeCount":103},[],{"intervention":46596,"totalTrials":302,"cells":46597},"GBT440",{"EARLY_PHASE1":46598,"PHASE1":46600,"PHASE2":46609,"PHASE3":46611,"PHASE4":46613,"NA":46615},{"trials":46599,"activeCount":103},[],{"trials":46601,"activeCount":103},[46602],{"nctId":46603,"briefTitle":46604,"status":111,"phases":46605,"primaryCompletion":27799,"completion":27394,"start":46606,"enrollment":350,"conditions":46607,"interventions":46608},"NCT03114540","Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment",[91],"2017-03-17",[7853],[46596],{"trials":46610,"activeCount":103},[],{"trials":46612,"activeCount":103},[],{"trials":46614,"activeCount":103},[],{"trials":46616,"activeCount":103},[],{"intervention":27078,"totalTrials":302,"cells":46618},{"EARLY_PHASE1":46619,"PHASE1":46621,"PHASE2":46627,"PHASE3":46629,"PHASE4":46631,"NA":46633},{"trials":46620,"activeCount":103},[],{"trials":46622,"activeCount":103},[46623],{"nctId":27072,"briefTitle":27073,"status":111,"phases":46624,"primaryCompletion":7387,"completion":4280,"start":17639,"enrollment":27075,"conditions":46625,"interventions":46626},[91],[26842],[27078,7595],{"trials":46628,"activeCount":103},[],{"trials":46630,"activeCount":103},[],{"trials":46632,"activeCount":103},[],{"trials":46634,"activeCount":103},[],{"intervention":46636,"totalTrials":302,"cells":46637},"Tafamidis meglumin",{"EARLY_PHASE1":46638,"PHASE1":46640,"PHASE2":46648,"PHASE3":46650,"PHASE4":46652,"NA":46654},{"trials":46639,"activeCount":103},[],{"trials":46641,"activeCount":103},[46642],{"nctId":46643,"briefTitle":46644,"status":111,"phases":46645,"primaryCompletion":4531,"completion":4531,"start":3313,"enrollment":360,"conditions":46646,"interventions":46647},"NCT01369836","Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects",[91],[16],[46636,46636],{"trials":46649,"activeCount":103},[],{"trials":46651,"activeCount":103},[],{"trials":46653,"activeCount":103},[],{"trials":46655,"activeCount":103},[],{"intervention":46657,"totalTrials":302,"cells":46658},"PF-07264660 intravenous single ascending dose",{"EARLY_PHASE1":46659,"PHASE1":46661,"PHASE2":46671,"PHASE3":46673,"PHASE4":46675,"NA":46677},{"trials":46660,"activeCount":103},[],{"trials":46662,"activeCount":103},[46663],{"nctId":46664,"briefTitle":46665,"status":111,"phases":46666,"primaryCompletion":46667,"completion":46667,"start":2069,"enrollment":1060,"conditions":46668,"interventions":46669},"NCT05496738","A Preliminary Study to Evaluate PF-07264660 in Healthy Participants",[91],"2024-05-06",[16],[46657,46670],"PF-07264660 subcutaneous multiple ascending dose",{"trials":46672,"activeCount":103},[],{"trials":46674,"activeCount":103},[],{"trials":46676,"activeCount":103},[],{"trials":46678,"activeCount":103},[],{"intervention":46670,"totalTrials":302,"cells":46680},{"EARLY_PHASE1":46681,"PHASE1":46683,"PHASE2":46689,"PHASE3":46691,"PHASE4":46693,"NA":46695},{"trials":46682,"activeCount":103},[],{"trials":46684,"activeCount":103},[46685],{"nctId":46664,"briefTitle":46665,"status":111,"phases":46686,"primaryCompletion":46667,"completion":46667,"start":2069,"enrollment":1060,"conditions":46687,"interventions":46688},[91],[16],[46657,46670],{"trials":46690,"activeCount":103},[],{"trials":46692,"activeCount":103},[],{"trials":46694,"activeCount":103},[],{"trials":46696,"activeCount":103},[],{"intervention":46698,"totalTrials":302,"cells":46699},"CP-690,550 5 mg BID",{"EARLY_PHASE1":46700,"PHASE1":46702,"PHASE2":46712,"PHASE3":46714,"PHASE4":46716,"NA":46718},{"trials":46701,"activeCount":103},[],{"trials":46703,"activeCount":103},[46704],{"nctId":46705,"briefTitle":46706,"status":111,"phases":46707,"primaryCompletion":4657,"completion":4657,"start":16955,"enrollment":5909,"conditions":46708,"interventions":46709},"NCT01710033","A Study Of CP-690,550 In Stable Kidney Transplant Patients",[91],[13192],[46698,46710,46711],"CP-690,550 15 mg BID","CP-690,550 30 mg BID",{"trials":46713,"activeCount":103},[],{"trials":46715,"activeCount":103},[],{"trials":46717,"activeCount":103},[],{"trials":46719,"activeCount":103},[],{"intervention":46710,"totalTrials":302,"cells":46721},{"EARLY_PHASE1":46722,"PHASE1":46724,"PHASE2":46730,"PHASE3":46732,"PHASE4":46734,"NA":46736},{"trials":46723,"activeCount":103},[],{"trials":46725,"activeCount":103},[46726],{"nctId":46705,"briefTitle":46706,"status":111,"phases":46727,"primaryCompletion":4657,"completion":4657,"start":16955,"enrollment":5909,"conditions":46728,"interventions":46729},[91],[13192],[46698,46710,46711],{"trials":46731,"activeCount":103},[],{"trials":46733,"activeCount":103},[],{"trials":46735,"activeCount":103},[],{"trials":46737,"activeCount":103},[],{"intervention":46711,"totalTrials":302,"cells":46739},{"EARLY_PHASE1":46740,"PHASE1":46742,"PHASE2":46748,"PHASE3":46750,"PHASE4":46752,"NA":46754},{"trials":46741,"activeCount":103},[],{"trials":46743,"activeCount":103},[46744],{"nctId":46705,"briefTitle":46706,"status":111,"phases":46745,"primaryCompletion":4657,"completion":4657,"start":16955,"enrollment":5909,"conditions":46746,"interventions":46747},[91],[13192],[46698,46710,46711],{"trials":46749,"activeCount":103},[],{"trials":46751,"activeCount":103},[],{"trials":46753,"activeCount":103},[],{"trials":46755,"activeCount":103},[],{"intervention":46757,"totalTrials":302,"cells":46758},"PF-3864086",{"EARLY_PHASE1":46759,"PHASE1":46761,"PHASE2":46769,"PHASE3":46771,"PHASE4":46773,"NA":46775},{"trials":46760,"activeCount":103},[],{"trials":46762,"activeCount":103},[46763],{"nctId":46764,"briefTitle":46765,"status":111,"phases":46766,"primaryCompletion":8154,"completion":8154,"start":8115,"enrollment":5909,"conditions":46767,"interventions":46768},"NCT00747058","A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects",[91],[34],[46757],{"trials":46770,"activeCount":103},[],{"trials":46772,"activeCount":103},[],{"trials":46774,"activeCount":103},[],{"trials":46776,"activeCount":103},[],{"intervention":46778,"totalTrials":302,"cells":46779},"3 mg PF-06412562 MR tablets_Fasted",{"EARLY_PHASE1":46780,"PHASE1":46782,"PHASE2":46793,"PHASE3":46795,"PHASE4":46797,"NA":46799},{"trials":46781,"activeCount":103},[],{"trials":46783,"activeCount":103},[46784],{"nctId":46785,"briefTitle":46786,"status":111,"phases":46787,"primaryCompletion":11356,"completion":11356,"start":9572,"enrollment":1268,"conditions":46788,"interventions":46789},"NCT02201511","A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions",[91],[16],[46778,46790,46791,46792],"2 x 15 mg PF-06412562 MR tablets_Fasted","2 x 15 mg PF-06412562 MR tablets_Fed","10 mg PF-06412562 IR",{"trials":46794,"activeCount":103},[],{"trials":46796,"activeCount":103},[],{"trials":46798,"activeCount":103},[],{"trials":46800,"activeCount":103},[],{"intervention":46790,"totalTrials":302,"cells":46802},{"EARLY_PHASE1":46803,"PHASE1":46805,"PHASE2":46811,"PHASE3":46813,"PHASE4":46815,"NA":46817},{"trials":46804,"activeCount":103},[],{"trials":46806,"activeCount":103},[46807],{"nctId":46785,"briefTitle":46786,"status":111,"phases":46808,"primaryCompletion":11356,"completion":11356,"start":9572,"enrollment":1268,"conditions":46809,"interventions":46810},[91],[16],[46778,46790,46791,46792],{"trials":46812,"activeCount":103},[],{"trials":46814,"activeCount":103},[],{"trials":46816,"activeCount":103},[],{"trials":46818,"activeCount":103},[],{"intervention":46791,"totalTrials":302,"cells":46820},{"EARLY_PHASE1":46821,"PHASE1":46823,"PHASE2":46829,"PHASE3":46831,"PHASE4":46833,"NA":46835},{"trials":46822,"activeCount":103},[],{"trials":46824,"activeCount":103},[46825],{"nctId":46785,"briefTitle":46786,"status":111,"phases":46826,"primaryCompletion":11356,"completion":11356,"start":9572,"enrollment":1268,"conditions":46827,"interventions":46828},[91],[16],[46778,46790,46791,46792],{"trials":46830,"activeCount":103},[],{"trials":46832,"activeCount":103},[],{"trials":46834,"activeCount":103},[],{"trials":46836,"activeCount":103},[],{"intervention":46792,"totalTrials":302,"cells":46838},{"EARLY_PHASE1":46839,"PHASE1":46841,"PHASE2":46847,"PHASE3":46849,"PHASE4":46851,"NA":46853},{"trials":46840,"activeCount":103},[],{"trials":46842,"activeCount":103},[46843],{"nctId":46785,"briefTitle":46786,"status":111,"phases":46844,"primaryCompletion":11356,"completion":11356,"start":9572,"enrollment":1268,"conditions":46845,"interventions":46846},[91],[16],[46778,46790,46791,46792],{"trials":46848,"activeCount":103},[],{"trials":46850,"activeCount":103},[],{"trials":46852,"activeCount":103},[],{"trials":46854,"activeCount":103},[],{"intervention":38366,"totalTrials":302,"cells":46856},{"EARLY_PHASE1":46857,"PHASE1":46859,"PHASE2":46865,"PHASE3":46867,"PHASE4":46869,"NA":46871},{"trials":46858,"activeCount":103},[],{"trials":46860,"activeCount":103},[46861],{"nctId":38359,"briefTitle":38360,"status":111,"phases":46862,"primaryCompletion":38362,"completion":38362,"start":38363,"enrollment":1268,"conditions":46863,"interventions":46864},[91],[1489],[4936,2127,38366],{"trials":46866,"activeCount":103},[],{"trials":46868,"activeCount":103},[],{"trials":46870,"activeCount":103},[],{"trials":46872,"activeCount":103},[],{"intervention":39203,"totalTrials":302,"cells":46874},{"EARLY_PHASE1":46875,"PHASE1":46877,"PHASE2":46883,"PHASE3":46885,"PHASE4":46887,"NA":46889},{"trials":46876,"activeCount":103},[],{"trials":46878,"activeCount":103},[46879],{"nctId":39198,"briefTitle":39199,"status":111,"phases":46880,"primaryCompletion":3313,"completion":3313,"start":2661,"enrollment":597,"conditions":46881,"interventions":46882},[91],[16],[39117,39117,39203],{"trials":46884,"activeCount":103},[],{"trials":46886,"activeCount":103},[],{"trials":46888,"activeCount":103},[],{"trials":46890,"activeCount":103},[],{"intervention":40922,"totalTrials":302,"cells":46892},{"EARLY_PHASE1":46893,"PHASE1":46895,"PHASE2":46901,"PHASE3":46903,"PHASE4":46905,"NA":46907},{"trials":46894,"activeCount":103},[],{"trials":46896,"activeCount":103},[46897],{"nctId":40916,"briefTitle":40917,"status":111,"phases":46898,"primaryCompletion":38043,"completion":38043,"start":40919,"enrollment":1268,"conditions":46899,"interventions":46900},[91],[16],[40909,40922,40909],{"trials":46902,"activeCount":103},[],{"trials":46904,"activeCount":103},[],{"trials":46906,"activeCount":103},[],{"trials":46908,"activeCount":103},[],{"intervention":28121,"totalTrials":302,"cells":46910},{"EARLY_PHASE1":46911,"PHASE1":46913,"PHASE2":46919,"PHASE3":46921,"PHASE4":46923,"NA":46925},{"trials":46912,"activeCount":103},[],{"trials":46914,"activeCount":103},[46915],{"nctId":28116,"briefTitle":28117,"status":111,"phases":46916,"primaryCompletion":4531,"completion":4531,"start":523,"enrollment":1796,"conditions":46917,"interventions":46918},[91],[16],[28121,28109,28121,28109,28122,28109,28122,28123,28121],{"trials":46920,"activeCount":103},[],{"trials":46922,"activeCount":103},[],{"trials":46924,"activeCount":103},[],{"trials":46926,"activeCount":103},[],{"intervention":6166,"totalTrials":302,"cells":46928},{"EARLY_PHASE1":46929,"PHASE1":46931,"PHASE2":46937,"PHASE3":46939,"PHASE4":46941,"NA":46943},{"trials":46930,"activeCount":103},[],{"trials":46932,"activeCount":103},[46933],{"nctId":6158,"briefTitle":6159,"status":111,"phases":46934,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":46935,"interventions":46936},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"trials":46938,"activeCount":103},[],{"trials":46940,"activeCount":103},[],{"trials":46942,"activeCount":103},[],{"trials":46944,"activeCount":103},[],{"intervention":6167,"totalTrials":302,"cells":46946},{"EARLY_PHASE1":46947,"PHASE1":46949,"PHASE2":46955,"PHASE3":46957,"PHASE4":46959,"NA":46961},{"trials":46948,"activeCount":103},[],{"trials":46950,"activeCount":103},[46951],{"nctId":6158,"briefTitle":6159,"status":111,"phases":46952,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":46953,"interventions":46954},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"trials":46956,"activeCount":103},[],{"trials":46958,"activeCount":103},[],{"trials":46960,"activeCount":103},[],{"trials":46962,"activeCount":103},[],{"intervention":6168,"totalTrials":302,"cells":46964},{"EARLY_PHASE1":46965,"PHASE1":46967,"PHASE2":46973,"PHASE3":46975,"PHASE4":46977,"NA":46979},{"trials":46966,"activeCount":103},[],{"trials":46968,"activeCount":103},[46969],{"nctId":6158,"briefTitle":6159,"status":111,"phases":46970,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":46971,"interventions":46972},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"trials":46974,"activeCount":103},[],{"trials":46976,"activeCount":103},[],{"trials":46978,"activeCount":103},[],{"trials":46980,"activeCount":103},[],{"intervention":6171,"totalTrials":302,"cells":46982},{"EARLY_PHASE1":46983,"PHASE1":46985,"PHASE2":46991,"PHASE3":46993,"PHASE4":46995,"NA":46997},{"trials":46984,"activeCount":103},[],{"trials":46986,"activeCount":103},[46987],{"nctId":6158,"briefTitle":6159,"status":111,"phases":46988,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":46989,"interventions":46990},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"trials":46992,"activeCount":103},[],{"trials":46994,"activeCount":103},[],{"trials":46996,"activeCount":103},[],{"trials":46998,"activeCount":103},[],{"intervention":47000,"totalTrials":302,"cells":47001},"3 mg PF-03882845",{"EARLY_PHASE1":47002,"PHASE1":47004,"PHASE2":47016,"PHASE3":47018,"PHASE4":47020,"NA":47022},{"trials":47003,"activeCount":103},[],{"trials":47005,"activeCount":103},[47006],{"nctId":47007,"briefTitle":47008,"status":111,"phases":47009,"primaryCompletion":2661,"completion":2661,"start":524,"enrollment":1268,"conditions":47010,"interventions":47011},"NCT01314898","A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers",[91],[19],[47000,47012,47013,47014,47015],"10 mg PF-03882845","30 mg PF-03882845","100 mg PF-03882845","Spironolactone",{"trials":47017,"activeCount":103},[],{"trials":47019,"activeCount":103},[],{"trials":47021,"activeCount":103},[],{"trials":47023,"activeCount":103},[],{"intervention":47012,"totalTrials":302,"cells":47025},{"EARLY_PHASE1":47026,"PHASE1":47028,"PHASE2":47034,"PHASE3":47036,"PHASE4":47038,"NA":47040},{"trials":47027,"activeCount":103},[],{"trials":47029,"activeCount":103},[47030],{"nctId":47007,"briefTitle":47008,"status":111,"phases":47031,"primaryCompletion":2661,"completion":2661,"start":524,"enrollment":1268,"conditions":47032,"interventions":47033},[91],[19],[47000,47012,47013,47014,47015],{"trials":47035,"activeCount":103},[],{"trials":47037,"activeCount":103},[],{"trials":47039,"activeCount":103},[],{"trials":47041,"activeCount":103},[],{"intervention":47013,"totalTrials":302,"cells":47043},{"EARLY_PHASE1":47044,"PHASE1":47046,"PHASE2":47052,"PHASE3":47054,"PHASE4":47056,"NA":47058},{"trials":47045,"activeCount":103},[],{"trials":47047,"activeCount":103},[47048],{"nctId":47007,"briefTitle":47008,"status":111,"phases":47049,"primaryCompletion":2661,"completion":2661,"start":524,"enrollment":1268,"conditions":47050,"interventions":47051},[91],[19],[47000,47012,47013,47014,47015],{"trials":47053,"activeCount":103},[],{"trials":47055,"activeCount":103},[],{"trials":47057,"activeCount":103},[],{"trials":47059,"activeCount":103},[],{"intervention":47014,"totalTrials":302,"cells":47061},{"EARLY_PHASE1":47062,"PHASE1":47064,"PHASE2":47070,"PHASE3":47072,"PHASE4":47074,"NA":47076},{"trials":47063,"activeCount":103},[],{"trials":47065,"activeCount":103},[47066],{"nctId":47007,"briefTitle":47008,"status":111,"phases":47067,"primaryCompletion":2661,"completion":2661,"start":524,"enrollment":1268,"conditions":47068,"interventions":47069},[91],[19],[47000,47012,47013,47014,47015],{"trials":47071,"activeCount":103},[],{"trials":47073,"activeCount":103},[],{"trials":47075,"activeCount":103},[],{"trials":47077,"activeCount":103},[],{"intervention":47015,"totalTrials":302,"cells":47079},{"EARLY_PHASE1":47080,"PHASE1":47082,"PHASE2":47088,"PHASE3":47090,"PHASE4":47092,"NA":47094},{"trials":47081,"activeCount":103},[],{"trials":47083,"activeCount":103},[47084],{"nctId":47007,"briefTitle":47008,"status":111,"phases":47085,"primaryCompletion":2661,"completion":2661,"start":524,"enrollment":1268,"conditions":47086,"interventions":47087},[91],[19],[47000,47012,47013,47014,47015],{"trials":47089,"activeCount":103},[],{"trials":47091,"activeCount":103},[],{"trials":47093,"activeCount":103},[],{"trials":47095,"activeCount":103},[],{"intervention":47097,"totalTrials":302,"cells":47098},"BMP-655\u002FACS or Standard of Care",{"EARLY_PHASE1":47099,"PHASE1":47101,"PHASE2":47110,"PHASE3":47112,"PHASE4":47114,"NA":47116},{"trials":47100,"activeCount":103},[],{"trials":47102,"activeCount":103},[47103],{"nctId":47104,"briefTitle":47105,"status":168,"phases":47106,"primaryCompletion":18026,"completion":18026,"start":560,"enrollment":3254,"conditions":47107,"interventions":47109},"NCT00936559","Study Evaluating Safety Of BMP-655\u002FACS As An Adjuvant Therapy For Rotator Cuff Repair",[91],[47108],"Rotator Cuff Tear",[47097,47097,47097],{"trials":47111,"activeCount":103},[],{"trials":47113,"activeCount":103},[],{"trials":47115,"activeCount":103},[],{"trials":47117,"activeCount":103},[],{"intervention":30771,"totalTrials":302,"cells":47119},{"EARLY_PHASE1":47120,"PHASE1":47122,"PHASE2":47128,"PHASE3":47130,"PHASE4":47132,"NA":47134},{"trials":47121,"activeCount":103},[],{"trials":47123,"activeCount":103},[47124],{"nctId":30766,"briefTitle":30767,"status":111,"phases":47125,"primaryCompletion":4645,"completion":4645,"start":11291,"enrollment":597,"conditions":47126,"interventions":47127},[91],[19],[30759,30759,30771,30771],{"trials":47129,"activeCount":103},[],{"trials":47131,"activeCount":103},[],{"trials":47133,"activeCount":103},[],{"trials":47135,"activeCount":103},[],{"intervention":47137,"totalTrials":302,"cells":47138},"PF 06687234",{"EARLY_PHASE1":47139,"PHASE1":47141,"PHASE2":47153,"PHASE3":47155,"PHASE4":47157,"NA":47159},{"trials":47140,"activeCount":103},[],{"trials":47142,"activeCount":103},[47143],{"nctId":47144,"briefTitle":47145,"status":649,"phases":47146,"primaryCompletion":47147,"completion":47147,"start":47148,"enrollment":103,"conditions":47149,"interventions":47151},"NCT03414788","Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease",[91],"2022-02-01","2020-12-07",[47150],"Inflammatory Bowel Disease",[47137,47152],"[124I]IB PF 06687234",{"trials":47154,"activeCount":103},[],{"trials":47156,"activeCount":103},[],{"trials":47158,"activeCount":103},[],{"trials":47160,"activeCount":103},[],{"intervention":47152,"totalTrials":302,"cells":47162},{"EARLY_PHASE1":47163,"PHASE1":47165,"PHASE2":47171,"PHASE3":47173,"PHASE4":47175,"NA":47177},{"trials":47164,"activeCount":103},[],{"trials":47166,"activeCount":103},[47167],{"nctId":47144,"briefTitle":47145,"status":649,"phases":47168,"primaryCompletion":47147,"completion":47147,"start":47148,"enrollment":103,"conditions":47169,"interventions":47170},[91],[47150],[47137,47152],{"trials":47172,"activeCount":103},[],{"trials":47174,"activeCount":103},[],{"trials":47176,"activeCount":103},[],{"trials":47178,"activeCount":103},[],{"intervention":47180,"totalTrials":302,"cells":47181},"PF-07104091",{"EARLY_PHASE1":47182,"PHASE1":47184,"PHASE2":47193,"PHASE3":47195,"PHASE4":47197,"NA":47199},{"trials":47183,"activeCount":103},[],{"trials":47185,"activeCount":103},[47186],{"nctId":47187,"briefTitle":47188,"status":111,"phases":47189,"primaryCompletion":9079,"completion":20154,"start":47190,"enrollment":627,"conditions":47191,"interventions":47192},"NCT07127770","A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants",[91],"2025-08-28",[2715],[47180],{"trials":47194,"activeCount":103},[],{"trials":47196,"activeCount":103},[],{"trials":47198,"activeCount":103},[],{"trials":47200,"activeCount":103},[],{"intervention":47202,"totalTrials":302,"cells":47203},"Diphenhydramine",{"EARLY_PHASE1":47204,"PHASE1":47206,"PHASE2":47215,"PHASE3":47217,"PHASE4":47219,"NA":47221},{"trials":47205,"activeCount":103},[],{"trials":47207,"activeCount":103},[47208],{"nctId":47209,"briefTitle":47210,"status":111,"phases":47211,"primaryCompletion":4665,"completion":4665,"start":4207,"enrollment":99,"conditions":47212,"interventions":47213},"NCT01119222","Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",[91],[16],[20441,47202,47214],"Morphine",{"trials":47216,"activeCount":103},[],{"trials":47218,"activeCount":103},[],{"trials":47220,"activeCount":103},[],{"trials":47222,"activeCount":103},[],{"intervention":47214,"totalTrials":302,"cells":47224},{"EARLY_PHASE1":47225,"PHASE1":47227,"PHASE2":47233,"PHASE3":47235,"PHASE4":47237,"NA":47239},{"trials":47226,"activeCount":103},[],{"trials":47228,"activeCount":103},[47229],{"nctId":47209,"briefTitle":47210,"status":111,"phases":47230,"primaryCompletion":4665,"completion":4665,"start":4207,"enrollment":99,"conditions":47231,"interventions":47232},[91],[16],[20441,47202,47214],{"trials":47234,"activeCount":103},[],{"trials":47236,"activeCount":103},[],{"trials":47238,"activeCount":103},[],{"trials":47240,"activeCount":103},[],{"intervention":47242,"totalTrials":302,"cells":47243},"PF-06650808",{"EARLY_PHASE1":47244,"PHASE1":47246,"PHASE2":47254,"PHASE3":47256,"PHASE4":47258,"NA":47260},{"trials":47245,"activeCount":103},[],{"trials":47247,"activeCount":103},[47248],{"nctId":47249,"briefTitle":47250,"status":168,"phases":47251,"primaryCompletion":29221,"completion":29221,"start":1288,"enrollment":35,"conditions":47252,"interventions":47253},"NCT02129205","A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors",[91],[2053,31],[47242,47242],{"trials":47255,"activeCount":103},[],{"trials":47257,"activeCount":103},[],{"trials":47259,"activeCount":103},[],{"trials":47261,"activeCount":103},[],{"intervention":8282,"totalTrials":302,"cells":47263},{"EARLY_PHASE1":47264,"PHASE1":47266,"PHASE2":47272,"PHASE3":47274,"PHASE4":47276,"NA":47278},{"trials":47265,"activeCount":103},[],{"trials":47267,"activeCount":103},[47268],{"nctId":8275,"briefTitle":8276,"status":111,"phases":47269,"primaryCompletion":4438,"completion":4438,"start":2449,"enrollment":8278,"conditions":47270,"interventions":47271},[91],[8280],[8282,8283,2515],{"trials":47273,"activeCount":103},[],{"trials":47275,"activeCount":103},[],{"trials":47277,"activeCount":103},[],{"trials":47279,"activeCount":103},[],{"intervention":8283,"totalTrials":302,"cells":47281},{"EARLY_PHASE1":47282,"PHASE1":47284,"PHASE2":47290,"PHASE3":47292,"PHASE4":47294,"NA":47296},{"trials":47283,"activeCount":103},[],{"trials":47285,"activeCount":103},[47286],{"nctId":8275,"briefTitle":8276,"status":111,"phases":47287,"primaryCompletion":4438,"completion":4438,"start":2449,"enrollment":8278,"conditions":47288,"interventions":47289},[91],[8280],[8282,8283,2515],{"trials":47291,"activeCount":103},[],{"trials":47293,"activeCount":103},[],{"trials":47295,"activeCount":103},[],{"trials":47297,"activeCount":103},[],{"intervention":47299,"totalTrials":302,"cells":47300},"PF-04620110 or Placebo",{"EARLY_PHASE1":47301,"PHASE1":47303,"PHASE2":47311,"PHASE3":47313,"PHASE4":47315,"NA":47317},{"trials":47302,"activeCount":103},[],{"trials":47304,"activeCount":103},[47305],{"nctId":47306,"briefTitle":47307,"status":111,"phases":47308,"primaryCompletion":4531,"completion":4531,"start":2661,"enrollment":504,"conditions":47309,"interventions":47310},"NCT01474941","A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects",[91],[16],[47299,47299,47299],{"trials":47312,"activeCount":103},[],{"trials":47314,"activeCount":103},[],{"trials":47316,"activeCount":103},[],{"trials":47318,"activeCount":103},[],{"intervention":47320,"totalTrials":302,"cells":47321},"PF-07853578",{"EARLY_PHASE1":47322,"PHASE1":47324,"PHASE2":47334,"PHASE3":47336,"PHASE4":47338,"NA":47340},{"trials":47323,"activeCount":103},[],{"trials":47325,"activeCount":103},[47326],{"nctId":47327,"briefTitle":47328,"status":111,"phases":47329,"primaryCompletion":47330,"completion":47330,"start":47331,"enrollment":2218,"conditions":47332,"interventions":47333},"NCT05890105","A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults",[91],"2023-12-01","2023-06-02",[28],[47320],{"trials":47335,"activeCount":103},[],{"trials":47337,"activeCount":103},[],{"trials":47339,"activeCount":103},[],{"trials":47341,"activeCount":103},[],{"intervention":47343,"totalTrials":302,"cells":47344},"azithromycin (AZ) microsphere",{"EARLY_PHASE1":47345,"PHASE1":47347,"PHASE2":47359,"PHASE3":47361,"PHASE4":47363,"NA":47365},{"trials":47346,"activeCount":103},[],{"trials":47348,"activeCount":103},[47349],{"nctId":47350,"briefTitle":47351,"status":111,"phases":47352,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":35,"conditions":47353,"interventions":47355},"NCT01100060","A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects",[91],[47354],"Malaria Prophylaxis",[47343,47356,47357,47358],"test chloroquine (CQ) formulation","azithromycin","chloroquine",{"trials":47360,"activeCount":103},[],{"trials":47362,"activeCount":103},[],{"trials":47364,"activeCount":103},[],{"trials":47366,"activeCount":103},[],{"intervention":47356,"totalTrials":302,"cells":47368},{"EARLY_PHASE1":47369,"PHASE1":47371,"PHASE2":47377,"PHASE3":47379,"PHASE4":47381,"NA":47383},{"trials":47370,"activeCount":103},[],{"trials":47372,"activeCount":103},[47373],{"nctId":47350,"briefTitle":47351,"status":111,"phases":47374,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":35,"conditions":47375,"interventions":47376},[91],[47354],[47343,47356,47357,47358],{"trials":47378,"activeCount":103},[],{"trials":47380,"activeCount":103},[],{"trials":47382,"activeCount":103},[],{"trials":47384,"activeCount":103},[],{"intervention":47358,"totalTrials":302,"cells":47386},{"EARLY_PHASE1":47387,"PHASE1":47389,"PHASE2":47395,"PHASE3":47397,"PHASE4":47399,"NA":47401},{"trials":47388,"activeCount":103},[],{"trials":47390,"activeCount":103},[47391],{"nctId":47350,"briefTitle":47351,"status":111,"phases":47392,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":35,"conditions":47393,"interventions":47394},[91],[47354],[47343,47356,47357,47358],{"trials":47396,"activeCount":103},[],{"trials":47398,"activeCount":103},[],{"trials":47400,"activeCount":103},[],{"trials":47402,"activeCount":103},[],{"intervention":47404,"totalTrials":302,"cells":47405},"PF-05231023",{"EARLY_PHASE1":47406,"PHASE1":47408,"PHASE2":47416,"PHASE3":47418,"PHASE4":47420,"NA":47422},{"trials":47407,"activeCount":103},[],{"trials":47409,"activeCount":103},[47410],{"nctId":47411,"briefTitle":47412,"status":111,"phases":47413,"primaryCompletion":3313,"completion":3313,"start":4666,"enrollment":4637,"conditions":47414,"interventions":47415},"NCT01285518","Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes",[91],[37],[47404,47404,47404,47404,47404,47404,47404],{"trials":47417,"activeCount":103},[],{"trials":47419,"activeCount":103},[],{"trials":47421,"activeCount":103},[],{"trials":47423,"activeCount":103},[],{"intervention":47425,"totalTrials":302,"cells":47426},"celecoxib reference formulation",{"EARLY_PHASE1":47427,"PHASE1":47429,"PHASE2":47440,"PHASE3":47442,"PHASE4":47444,"NA":47446},{"trials":47428,"activeCount":103},[],{"trials":47430,"activeCount":103},[47431],{"nctId":47432,"briefTitle":47433,"status":111,"phases":47434,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":314,"conditions":47435,"interventions":47436},"NCT00813241","A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers",[91],[19],[47425,47437,47438,47439],"celecoxib test formulation A1","celecoxib test formulation B2","celecoxib test formulation C1",{"trials":47441,"activeCount":103},[],{"trials":47443,"activeCount":103},[],{"trials":47445,"activeCount":103},[],{"trials":47447,"activeCount":103},[],{"intervention":47437,"totalTrials":302,"cells":47449},{"EARLY_PHASE1":47450,"PHASE1":47452,"PHASE2":47458,"PHASE3":47460,"PHASE4":47462,"NA":47464},{"trials":47451,"activeCount":103},[],{"trials":47453,"activeCount":103},[47454],{"nctId":47432,"briefTitle":47433,"status":111,"phases":47455,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":314,"conditions":47456,"interventions":47457},[91],[19],[47425,47437,47438,47439],{"trials":47459,"activeCount":103},[],{"trials":47461,"activeCount":103},[],{"trials":47463,"activeCount":103},[],{"trials":47465,"activeCount":103},[],{"intervention":47438,"totalTrials":302,"cells":47467},{"EARLY_PHASE1":47468,"PHASE1":47470,"PHASE2":47476,"PHASE3":47478,"PHASE4":47480,"NA":47482},{"trials":47469,"activeCount":103},[],{"trials":47471,"activeCount":103},[47472],{"nctId":47432,"briefTitle":47433,"status":111,"phases":47473,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":314,"conditions":47474,"interventions":47475},[91],[19],[47425,47437,47438,47439],{"trials":47477,"activeCount":103},[],{"trials":47479,"activeCount":103},[],{"trials":47481,"activeCount":103},[],{"trials":47483,"activeCount":103},[],{"intervention":47439,"totalTrials":302,"cells":47485},{"EARLY_PHASE1":47486,"PHASE1":47488,"PHASE2":47494,"PHASE3":47496,"PHASE4":47498,"NA":47500},{"trials":47487,"activeCount":103},[],{"trials":47489,"activeCount":103},[47490],{"nctId":47432,"briefTitle":47433,"status":111,"phases":47491,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":314,"conditions":47492,"interventions":47493},[91],[19],[47425,47437,47438,47439],{"trials":47495,"activeCount":103},[],{"trials":47497,"activeCount":103},[],{"trials":47499,"activeCount":103},[],{"trials":47501,"activeCount":103},[],{"intervention":47503,"totalTrials":302,"cells":47504},"CP-751,871 + carboplatin + paclitaxel",{"EARLY_PHASE1":47505,"PHASE1":47507,"PHASE2":47515,"PHASE3":47517,"PHASE4":47519,"NA":47521},{"trials":47506,"activeCount":103},[],{"trials":47508,"activeCount":103},[47509],{"nctId":47510,"briefTitle":47511,"status":111,"phases":47512,"primaryCompletion":11014,"completion":11014,"start":3853,"enrollment":99,"conditions":47513,"interventions":47514},"NCT00603538","Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer",[91],[376],[47503],{"trials":47516,"activeCount":103},[],{"trials":47518,"activeCount":103},[],{"trials":47520,"activeCount":103},[],{"trials":47522,"activeCount":103},[],{"intervention":47524,"totalTrials":302,"cells":47525},"Pregabalin ER",{"EARLY_PHASE1":47526,"PHASE1":47528,"PHASE2":47539,"PHASE3":47541,"PHASE4":47543,"NA":47545},{"trials":47527,"activeCount":103},[],{"trials":47529,"activeCount":103},[47530],{"nctId":47531,"briefTitle":47532,"status":111,"phases":47533,"primaryCompletion":47534,"completion":47535,"start":47536,"enrollment":2713,"conditions":47537,"interventions":47538},"NCT02725112","Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers",[91],"2016-05-22","2016-06-17","2016-02-12",[16],[47524,47524,47524,47524,47524,47524],{"trials":47540,"activeCount":103},[],{"trials":47542,"activeCount":103},[],{"trials":47544,"activeCount":103},[],{"trials":47546,"activeCount":103},[],{"intervention":47548,"totalTrials":302,"cells":47549},"Pregabalin, then placebo",{"EARLY_PHASE1":47550,"PHASE1":47552,"PHASE2":47560,"PHASE3":47562,"PHASE4":47564,"NA":47566},{"trials":47551,"activeCount":103},[],{"trials":47553,"activeCount":103},[47554],{"nctId":47555,"briefTitle":47556,"status":111,"phases":47557,"primaryCompletion":524,"completion":524,"start":8251,"enrollment":504,"conditions":47558,"interventions":47559},"NCT00760474","An fMRI Study Of Brain Response In Patients With Fibromyalgia",[91],[17041],[47548],{"trials":47561,"activeCount":103},[],{"trials":47563,"activeCount":103},[],{"trials":47565,"activeCount":103},[],{"trials":47567,"activeCount":103},[],{"intervention":41008,"totalTrials":302,"cells":47569},{"EARLY_PHASE1":47570,"PHASE1":47572,"PHASE2":47578,"PHASE3":47580,"PHASE4":47582,"NA":47584},{"trials":47571,"activeCount":103},[],{"trials":47573,"activeCount":103},[47574],{"nctId":41002,"briefTitle":41003,"status":111,"phases":47575,"primaryCompletion":41005,"completion":41005,"start":8039,"enrollment":787,"conditions":47576,"interventions":47577},[91],[10985],[41008,40995,41009],{"trials":47579,"activeCount":103},[],{"trials":47581,"activeCount":103},[],{"trials":47583,"activeCount":103},[],{"trials":47585,"activeCount":103},[],{"intervention":47587,"totalTrials":302,"cells":47588},"PF-03382792 0.5mg",{"EARLY_PHASE1":47589,"PHASE1":47591,"PHASE2":47603,"PHASE3":47605,"PHASE4":47607,"NA":47609},{"trials":47590,"activeCount":103},[],{"trials":47592,"activeCount":103},[47593],{"nctId":47594,"briefTitle":47595,"status":649,"phases":47596,"primaryCompletion":47597,"completion":47597,"start":19703,"enrollment":103,"conditions":47598,"interventions":47599},"NCT01089738","A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals",[91],"2011-04-25",[16],[47587,47600,47601,47602],"PF-03382792 1.5 mg","PF-03382792 5 mg","PF-03382792 15 mg",{"trials":47604,"activeCount":103},[],{"trials":47606,"activeCount":103},[],{"trials":47608,"activeCount":103},[],{"trials":47610,"activeCount":103},[],{"intervention":47600,"totalTrials":302,"cells":47612},{"EARLY_PHASE1":47613,"PHASE1":47615,"PHASE2":47621,"PHASE3":47623,"PHASE4":47625,"NA":47627},{"trials":47614,"activeCount":103},[],{"trials":47616,"activeCount":103},[47617],{"nctId":47594,"briefTitle":47595,"status":649,"phases":47618,"primaryCompletion":47597,"completion":47597,"start":19703,"enrollment":103,"conditions":47619,"interventions":47620},[91],[16],[47587,47600,47601,47602],{"trials":47622,"activeCount":103},[],{"trials":47624,"activeCount":103},[],{"trials":47626,"activeCount":103},[],{"trials":47628,"activeCount":103},[],{"intervention":47601,"totalTrials":302,"cells":47630},{"EARLY_PHASE1":47631,"PHASE1":47633,"PHASE2":47639,"PHASE3":47641,"PHASE4":47643,"NA":47645},{"trials":47632,"activeCount":103},[],{"trials":47634,"activeCount":103},[47635],{"nctId":47594,"briefTitle":47595,"status":649,"phases":47636,"primaryCompletion":47597,"completion":47597,"start":19703,"enrollment":103,"conditions":47637,"interventions":47638},[91],[16],[47587,47600,47601,47602],{"trials":47640,"activeCount":103},[],{"trials":47642,"activeCount":103},[],{"trials":47644,"activeCount":103},[],{"trials":47646,"activeCount":103},[],{"intervention":47602,"totalTrials":302,"cells":47648},{"EARLY_PHASE1":47649,"PHASE1":47651,"PHASE2":47657,"PHASE3":47659,"PHASE4":47661,"NA":47663},{"trials":47650,"activeCount":103},[],{"trials":47652,"activeCount":103},[47653],{"nctId":47594,"briefTitle":47595,"status":649,"phases":47654,"primaryCompletion":47597,"completion":47597,"start":19703,"enrollment":103,"conditions":47655,"interventions":47656},[91],[16],[47587,47600,47601,47602],{"trials":47658,"activeCount":103},[],{"trials":47660,"activeCount":103},[],{"trials":47662,"activeCount":103},[],{"trials":47664,"activeCount":103},[],{"intervention":47666,"totalTrials":302,"cells":47667},"PF-08046031",{"EARLY_PHASE1":47668,"PHASE1":47670,"PHASE2":47678,"PHASE3":47680,"PHASE4":47682,"NA":47684},{"trials":47669,"activeCount":103},[],{"trials":47671,"activeCount":103},[47672],{"nctId":47673,"briefTitle":47674,"status":168,"phases":47675,"primaryCompletion":6336,"completion":6336,"start":3946,"enrollment":1625,"conditions":47676,"interventions":47677},"NCT06799533","A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors",[91],[4728,1798,3204,750],[47666],{"trials":47679,"activeCount":103},[],{"trials":47681,"activeCount":103},[],{"trials":47683,"activeCount":103},[],{"trials":47685,"activeCount":103},[],{"intervention":7743,"totalTrials":302,"cells":47687},{"EARLY_PHASE1":47688,"PHASE1":47690,"PHASE2":47696,"PHASE3":47698,"PHASE4":47700,"NA":47702},{"trials":47689,"activeCount":103},[],{"trials":47691,"activeCount":103},[47692],{"nctId":7737,"briefTitle":7738,"status":168,"phases":47693,"primaryCompletion":3924,"completion":3924,"start":7740,"enrollment":257,"conditions":47694,"interventions":47695},[91],[643,5847,1859,1798,1302,2022],[7743,1773],{"trials":47697,"activeCount":103},[],{"trials":47699,"activeCount":103},[],{"trials":47701,"activeCount":103},[],{"trials":47703,"activeCount":103},[],{"intervention":12214,"totalTrials":302,"cells":47705},{"EARLY_PHASE1":47706,"PHASE1":47708,"PHASE2":47714,"PHASE3":47716,"PHASE4":47718,"NA":47720},{"trials":47707,"activeCount":103},[],{"trials":47709,"activeCount":103},[47710],{"nctId":12208,"briefTitle":12209,"status":168,"phases":47711,"completion":10937,"start":7665,"enrollment":8414,"conditions":47712,"interventions":47713},[91],[16],[12213,12214],{"trials":47715,"activeCount":103},[],{"trials":47717,"activeCount":103},[],{"trials":47719,"activeCount":103},[],{"trials":47721,"activeCount":103},[],{"intervention":47723,"totalTrials":302,"cells":47724},"sunitinib + FOLFOX",{"EARLY_PHASE1":47725,"PHASE1":47727,"PHASE2":47735,"PHASE3":47737,"PHASE4":47739,"NA":47741},{"trials":47726,"activeCount":103},[],{"trials":47728,"activeCount":103},[47729],{"nctId":47730,"briefTitle":47731,"status":111,"phases":47732,"primaryCompletion":4645,"completion":4645,"start":6017,"enrollment":336,"conditions":47733,"interventions":47734},"NCT00599924","Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors",[91],[1028,2053],[47723,47723,47723,47723,47723,47723,47723],{"trials":47736,"activeCount":103},[],{"trials":47738,"activeCount":103},[],{"trials":47740,"activeCount":103},[],{"trials":47742,"activeCount":103},[],{"intervention":47744,"totalTrials":302,"cells":47745},"[14C]-esreboxetine",{"EARLY_PHASE1":47746,"PHASE1":47748,"PHASE2":47756,"PHASE3":47758,"PHASE4":47760,"NA":47762},{"trials":47747,"activeCount":103},[],{"trials":47749,"activeCount":103},[47750],{"nctId":47751,"briefTitle":47752,"status":111,"phases":47753,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":257,"conditions":47754,"interventions":47755},"NCT00800956","Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine",[91],[16],[47744],{"trials":47757,"activeCount":103},[],{"trials":47759,"activeCount":103},[],{"trials":47761,"activeCount":103},[],{"trials":47763,"activeCount":103},[],{"intervention":2941,"totalTrials":302,"cells":47765},{"EARLY_PHASE1":47766,"PHASE1":47768,"PHASE2":47774,"PHASE3":47776,"PHASE4":47778,"NA":47780},{"trials":47767,"activeCount":103},[],{"trials":47769,"activeCount":103},[47770],{"nctId":2930,"briefTitle":2931,"status":168,"phases":47771,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":2935,"conditions":47772,"interventions":47773},[91],[2937,1062,2938,2914],[1065,2940,2941,1064,1139,2942,2943],{"trials":47775,"activeCount":103},[],{"trials":47777,"activeCount":103},[],{"trials":47779,"activeCount":103},[],{"trials":47781,"activeCount":103},[],{"intervention":2942,"totalTrials":302,"cells":47783},{"EARLY_PHASE1":47784,"PHASE1":47786,"PHASE2":47792,"PHASE3":47794,"PHASE4":47796,"NA":47798},{"trials":47785,"activeCount":103},[],{"trials":47787,"activeCount":103},[47788],{"nctId":2930,"briefTitle":2931,"status":168,"phases":47789,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":2935,"conditions":47790,"interventions":47791},[91],[2937,1062,2938,2914],[1065,2940,2941,1064,1139,2942,2943],{"trials":47793,"activeCount":103},[],{"trials":47795,"activeCount":103},[],{"trials":47797,"activeCount":103},[],{"trials":47799,"activeCount":103},[],{"intervention":2943,"totalTrials":302,"cells":47801},{"EARLY_PHASE1":47802,"PHASE1":47804,"PHASE2":47810,"PHASE3":47812,"PHASE4":47814,"NA":47816},{"trials":47803,"activeCount":103},[],{"trials":47805,"activeCount":103},[47806],{"nctId":2930,"briefTitle":2931,"status":168,"phases":47807,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":2935,"conditions":47808,"interventions":47809},[91],[2937,1062,2938,2914],[1065,2940,2941,1064,1139,2942,2943],{"trials":47811,"activeCount":103},[],{"trials":47813,"activeCount":103},[],{"trials":47815,"activeCount":103},[],{"trials":47817,"activeCount":103},[],{"intervention":38543,"totalTrials":302,"cells":47819},{"EARLY_PHASE1":47820,"PHASE1":47822,"PHASE2":47828,"PHASE3":47830,"PHASE4":47832,"NA":47834},{"trials":47821,"activeCount":103},[],{"trials":47823,"activeCount":103},[47824],{"nctId":38538,"briefTitle":38539,"status":111,"phases":47825,"primaryCompletion":496,"completion":496,"start":9628,"enrollment":597,"conditions":47826,"interventions":47827},[91],[16],[38543,38544,38545,1272],{"trials":47829,"activeCount":103},[],{"trials":47831,"activeCount":103},[],{"trials":47833,"activeCount":103},[],{"trials":47835,"activeCount":103},[],{"intervention":38544,"totalTrials":302,"cells":47837},{"EARLY_PHASE1":47838,"PHASE1":47840,"PHASE2":47846,"PHASE3":47848,"PHASE4":47850,"NA":47852},{"trials":47839,"activeCount":103},[],{"trials":47841,"activeCount":103},[47842],{"nctId":38538,"briefTitle":38539,"status":111,"phases":47843,"primaryCompletion":496,"completion":496,"start":9628,"enrollment":597,"conditions":47844,"interventions":47845},[91],[16],[38543,38544,38545,1272],{"trials":47847,"activeCount":103},[],{"trials":47849,"activeCount":103},[],{"trials":47851,"activeCount":103},[],{"trials":47853,"activeCount":103},[],{"intervention":38545,"totalTrials":302,"cells":47855},{"EARLY_PHASE1":47856,"PHASE1":47858,"PHASE2":47864,"PHASE3":47866,"PHASE4":47868,"NA":47870},{"trials":47857,"activeCount":103},[],{"trials":47859,"activeCount":103},[47860],{"nctId":38538,"briefTitle":38539,"status":111,"phases":47861,"primaryCompletion":496,"completion":496,"start":9628,"enrollment":597,"conditions":47862,"interventions":47863},[91],[16],[38543,38544,38545,1272],{"trials":47865,"activeCount":103},[],{"trials":47867,"activeCount":103},[],{"trials":47869,"activeCount":103},[],{"trials":47871,"activeCount":103},[],{"intervention":40600,"totalTrials":302,"cells":47873},{"EARLY_PHASE1":47874,"PHASE1":47876,"PHASE2":47882,"PHASE3":47884,"PHASE4":47886,"NA":47888},{"trials":47875,"activeCount":103},[],{"trials":47877,"activeCount":103},[47878],{"nctId":40592,"briefTitle":40593,"status":111,"phases":47879,"primaryCompletion":40595,"completion":40595,"start":40596,"enrollment":3229,"conditions":47880,"interventions":47881},[91],[40598],[40600,40578,40578,40578,40578,40578,40578],{"trials":47883,"activeCount":103},[],{"trials":47885,"activeCount":103},[],{"trials":47887,"activeCount":103},[],{"trials":47889,"activeCount":103},[],{"intervention":47891,"totalTrials":302,"cells":47892},"PF-04878691 3mg",{"EARLY_PHASE1":47893,"PHASE1":47895,"PHASE2":47905,"PHASE3":47907,"PHASE4":47909,"NA":47911},{"trials":47894,"activeCount":103},[],{"trials":47896,"activeCount":103},[47897],{"nctId":47898,"briefTitle":47899,"status":111,"phases":47900,"primaryCompletion":6016,"completion":6016,"start":8251,"enrollment":1509,"conditions":47901,"interventions":47902},"NCT00810758","Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691",[91],[41701],[47891,47903,47904],"PF-04878691 6mg","PF-04878691 9mg",{"trials":47906,"activeCount":103},[],{"trials":47908,"activeCount":103},[],{"trials":47910,"activeCount":103},[],{"trials":47912,"activeCount":103},[],{"intervention":47903,"totalTrials":302,"cells":47914},{"EARLY_PHASE1":47915,"PHASE1":47917,"PHASE2":47923,"PHASE3":47925,"PHASE4":47927,"NA":47929},{"trials":47916,"activeCount":103},[],{"trials":47918,"activeCount":103},[47919],{"nctId":47898,"briefTitle":47899,"status":111,"phases":47920,"primaryCompletion":6016,"completion":6016,"start":8251,"enrollment":1509,"conditions":47921,"interventions":47922},[91],[41701],[47891,47903,47904],{"trials":47924,"activeCount":103},[],{"trials":47926,"activeCount":103},[],{"trials":47928,"activeCount":103},[],{"trials":47930,"activeCount":103},[],{"intervention":47904,"totalTrials":302,"cells":47932},{"EARLY_PHASE1":47933,"PHASE1":47935,"PHASE2":47941,"PHASE3":47943,"PHASE4":47945,"NA":47947},{"trials":47934,"activeCount":103},[],{"trials":47936,"activeCount":103},[47937],{"nctId":47898,"briefTitle":47899,"status":111,"phases":47938,"primaryCompletion":6016,"completion":6016,"start":8251,"enrollment":1509,"conditions":47939,"interventions":47940},[91],[41701],[47891,47903,47904],{"trials":47942,"activeCount":103},[],{"trials":47944,"activeCount":103},[],{"trials":47946,"activeCount":103},[],{"trials":47948,"activeCount":103},[],{"intervention":17792,"totalTrials":302,"cells":47950},{"EARLY_PHASE1":47951,"PHASE1":47953,"PHASE2":47959,"PHASE3":47961,"PHASE4":47963,"NA":47965},{"trials":47952,"activeCount":103},[],{"trials":47954,"activeCount":103},[47955],{"nctId":17787,"briefTitle":17788,"status":649,"phases":47956,"primaryCompletion":3601,"completion":3601,"start":4656,"enrollment":103,"conditions":47957,"interventions":47958},[91],[4942],[17792,4945,1252],{"trials":47960,"activeCount":103},[],{"trials":47962,"activeCount":103},[],{"trials":47964,"activeCount":103},[],{"trials":47966,"activeCount":103},[],{"intervention":39339,"totalTrials":302,"cells":47968},{"EARLY_PHASE1":47969,"PHASE1":47971,"PHASE2":47977,"PHASE3":47979,"PHASE4":47981,"NA":47983},{"trials":47970,"activeCount":103},[],{"trials":47972,"activeCount":103},[47973],{"nctId":39331,"briefTitle":39332,"status":168,"phases":47974,"primaryCompletion":1779,"completion":1779,"start":27763,"enrollment":20,"conditions":47975,"interventions":47976},[91],[5823,1859,1653,7780,8829,39335,4778,39336,1007,39337,905],[39339,39309],{"trials":47978,"activeCount":103},[],{"trials":47980,"activeCount":103},[],{"trials":47982,"activeCount":103},[],{"trials":47984,"activeCount":103},[],{"intervention":47986,"totalTrials":302,"cells":47987},"PF-07314470",{"EARLY_PHASE1":47988,"PHASE1":47990,"PHASE2":47999,"PHASE3":48001,"PHASE4":48003,"NA":48005},{"trials":47989,"activeCount":103},[],{"trials":47991,"activeCount":103},[47992],{"nctId":47993,"briefTitle":47994,"status":168,"phases":47995,"primaryCompletion":9969,"completion":9969,"start":47996,"enrollment":2218,"conditions":47997,"interventions":47998},"NCT06821750","A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults",[91],"2025-02-11",[16],[47986],{"trials":48000,"activeCount":103},[],{"trials":48002,"activeCount":103},[],{"trials":48004,"activeCount":103},[],{"trials":48006,"activeCount":103},[],{"intervention":48008,"totalTrials":302,"cells":48009},"PF-04937319 once-daily",{"EARLY_PHASE1":48010,"PHASE1":48012,"PHASE2":48022,"PHASE3":48024,"PHASE4":48026,"NA":48028},{"trials":48011,"activeCount":103},[],{"trials":48013,"activeCount":103},[48014],{"nctId":48015,"briefTitle":48016,"status":111,"phases":48017,"primaryCompletion":605,"completion":605,"start":1249,"enrollment":5987,"conditions":48018,"interventions":48019},"NCT01933672","Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes",[91],[12968],[48008,48020,48021],"PF-04937319 split-dose","Sitagliptin once-daily",{"trials":48023,"activeCount":103},[],{"trials":48025,"activeCount":103},[],{"trials":48027,"activeCount":103},[],{"trials":48029,"activeCount":103},[],{"intervention":48020,"totalTrials":302,"cells":48031},{"EARLY_PHASE1":48032,"PHASE1":48034,"PHASE2":48040,"PHASE3":48042,"PHASE4":48044,"NA":48046},{"trials":48033,"activeCount":103},[],{"trials":48035,"activeCount":103},[48036],{"nctId":48015,"briefTitle":48016,"status":111,"phases":48037,"primaryCompletion":605,"completion":605,"start":1249,"enrollment":5987,"conditions":48038,"interventions":48039},[91],[12968],[48008,48020,48021],{"trials":48041,"activeCount":103},[],{"trials":48043,"activeCount":103},[],{"trials":48045,"activeCount":103},[],{"trials":48047,"activeCount":103},[],{"intervention":48021,"totalTrials":302,"cells":48049},{"EARLY_PHASE1":48050,"PHASE1":48052,"PHASE2":48058,"PHASE3":48060,"PHASE4":48062,"NA":48064},{"trials":48051,"activeCount":103},[],{"trials":48053,"activeCount":103},[48054],{"nctId":48015,"briefTitle":48016,"status":111,"phases":48055,"primaryCompletion":605,"completion":605,"start":1249,"enrollment":5987,"conditions":48056,"interventions":48057},[91],[12968],[48008,48020,48021],{"trials":48059,"activeCount":103},[],{"trials":48061,"activeCount":103},[],{"trials":48063,"activeCount":103},[],{"trials":48065,"activeCount":103},[],{"intervention":48067,"totalTrials":302,"cells":48068},"Prazosin HCl 2mg",{"EARLY_PHASE1":48069,"PHASE1":48071,"PHASE2":48082,"PHASE3":48084,"PHASE4":48086,"NA":48088},{"trials":48070,"activeCount":103},[],{"trials":48072,"activeCount":103},[48073],{"nctId":48074,"briefTitle":48075,"status":111,"phases":48076,"primaryCompletion":46286,"completion":46286,"start":48077,"enrollment":7388,"conditions":48078,"interventions":48079},"NCT04967443","Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules",[91],"2021-09-22",[13280,6764],[48067,48080,48081],"Prazosin HCl 1 mg","Prazosin HCl 5 mg",{"trials":48083,"activeCount":103},[],{"trials":48085,"activeCount":103},[],{"trials":48087,"activeCount":103},[],{"trials":48089,"activeCount":103},[],{"intervention":48080,"totalTrials":302,"cells":48091},{"EARLY_PHASE1":48092,"PHASE1":48094,"PHASE2":48100,"PHASE3":48102,"PHASE4":48104,"NA":48106},{"trials":48093,"activeCount":103},[],{"trials":48095,"activeCount":103},[48096],{"nctId":48074,"briefTitle":48075,"status":111,"phases":48097,"primaryCompletion":46286,"completion":46286,"start":48077,"enrollment":7388,"conditions":48098,"interventions":48099},[91],[13280,6764],[48067,48080,48081],{"trials":48101,"activeCount":103},[],{"trials":48103,"activeCount":103},[],{"trials":48105,"activeCount":103},[],{"trials":48107,"activeCount":103},[],{"intervention":48081,"totalTrials":302,"cells":48109},{"EARLY_PHASE1":48110,"PHASE1":48112,"PHASE2":48118,"PHASE3":48120,"PHASE4":48122,"NA":48124},{"trials":48111,"activeCount":103},[],{"trials":48113,"activeCount":103},[48114],{"nctId":48074,"briefTitle":48075,"status":111,"phases":48115,"primaryCompletion":46286,"completion":46286,"start":48077,"enrollment":7388,"conditions":48116,"interventions":48117},[91],[13280,6764],[48067,48080,48081],{"trials":48119,"activeCount":103},[],{"trials":48121,"activeCount":103},[],{"trials":48123,"activeCount":103},[],{"trials":48125,"activeCount":103},[],{"intervention":48127,"totalTrials":302,"cells":48128},"Axitinib + Paclitaxel + Carboplatin",{"EARLY_PHASE1":48129,"PHASE1":48131,"PHASE2":48145,"PHASE3":48147,"PHASE4":48149,"NA":48151},{"trials":48130,"activeCount":103},[],{"trials":48132,"activeCount":103},[48133],{"nctId":48134,"briefTitle":48135,"status":111,"phases":48136,"primaryCompletion":4214,"completion":523,"start":2671,"enrollment":10190,"conditions":48137,"interventions":48138},"NCT00454649","Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor",[91],[2053],[48127,48127,48127,48139,48140,48141,48142,48142,48143,48144],"Axitinib + Paclitaxel","Axitinib + Docetaxel + Carboplatin","Axitinib + Docetaxel","Axitinib + Capecitabine","Axitinib + Gemcitabine + Cisplatin","Axitinib + Pemetrexed + Cisplatin",{"trials":48146,"activeCount":103},[],{"trials":48148,"activeCount":103},[],{"trials":48150,"activeCount":103},[],{"trials":48152,"activeCount":103},[],{"intervention":48139,"totalTrials":302,"cells":48154},{"EARLY_PHASE1":48155,"PHASE1":48157,"PHASE2":48163,"PHASE3":48165,"PHASE4":48167,"NA":48169},{"trials":48156,"activeCount":103},[],{"trials":48158,"activeCount":103},[48159],{"nctId":48134,"briefTitle":48135,"status":111,"phases":48160,"primaryCompletion":4214,"completion":523,"start":2671,"enrollment":10190,"conditions":48161,"interventions":48162},[91],[2053],[48127,48127,48127,48139,48140,48141,48142,48142,48143,48144],{"trials":48164,"activeCount":103},[],{"trials":48166,"activeCount":103},[],{"trials":48168,"activeCount":103},[],{"trials":48170,"activeCount":103},[],{"intervention":48140,"totalTrials":302,"cells":48172},{"EARLY_PHASE1":48173,"PHASE1":48175,"PHASE2":48181,"PHASE3":48183,"PHASE4":48185,"NA":48187},{"trials":48174,"activeCount":103},[],{"trials":48176,"activeCount":103},[48177],{"nctId":48134,"briefTitle":48135,"status":111,"phases":48178,"primaryCompletion":4214,"completion":523,"start":2671,"enrollment":10190,"conditions":48179,"interventions":48180},[91],[2053],[48127,48127,48127,48139,48140,48141,48142,48142,48143,48144],{"trials":48182,"activeCount":103},[],{"trials":48184,"activeCount":103},[],{"trials":48186,"activeCount":103},[],{"trials":48188,"activeCount":103},[],{"intervention":48141,"totalTrials":302,"cells":48190},{"EARLY_PHASE1":48191,"PHASE1":48193,"PHASE2":48199,"PHASE3":48201,"PHASE4":48203,"NA":48205},{"trials":48192,"activeCount":103},[],{"trials":48194,"activeCount":103},[48195],{"nctId":48134,"briefTitle":48135,"status":111,"phases":48196,"primaryCompletion":4214,"completion":523,"start":2671,"enrollment":10190,"conditions":48197,"interventions":48198},[91],[2053],[48127,48127,48127,48139,48140,48141,48142,48142,48143,48144],{"trials":48200,"activeCount":103},[],{"trials":48202,"activeCount":103},[],{"trials":48204,"activeCount":103},[],{"trials":48206,"activeCount":103},[],{"intervention":48142,"totalTrials":302,"cells":48208},{"EARLY_PHASE1":48209,"PHASE1":48211,"PHASE2":48217,"PHASE3":48219,"PHASE4":48221,"NA":48223},{"trials":48210,"activeCount":103},[],{"trials":48212,"activeCount":103},[48213],{"nctId":48134,"briefTitle":48135,"status":111,"phases":48214,"primaryCompletion":4214,"completion":523,"start":2671,"enrollment":10190,"conditions":48215,"interventions":48216},[91],[2053],[48127,48127,48127,48139,48140,48141,48142,48142,48143,48144],{"trials":48218,"activeCount":103},[],{"trials":48220,"activeCount":103},[],{"trials":48222,"activeCount":103},[],{"trials":48224,"activeCount":103},[],{"intervention":48143,"totalTrials":302,"cells":48226},{"EARLY_PHASE1":48227,"PHASE1":48229,"PHASE2":48235,"PHASE3":48237,"PHASE4":48239,"NA":48241},{"trials":48228,"activeCount":103},[],{"trials":48230,"activeCount":103},[48231],{"nctId":48134,"briefTitle":48135,"status":111,"phases":48232,"primaryCompletion":4214,"completion":523,"start":2671,"enrollment":10190,"conditions":48233,"interventions":48234},[91],[2053],[48127,48127,48127,48139,48140,48141,48142,48142,48143,48144],{"trials":48236,"activeCount":103},[],{"trials":48238,"activeCount":103},[],{"trials":48240,"activeCount":103},[],{"trials":48242,"activeCount":103},[],{"intervention":48144,"totalTrials":302,"cells":48244},{"EARLY_PHASE1":48245,"PHASE1":48247,"PHASE2":48253,"PHASE3":48255,"PHASE4":48257,"NA":48259},{"trials":48246,"activeCount":103},[],{"trials":48248,"activeCount":103},[48249],{"nctId":48134,"briefTitle":48135,"status":111,"phases":48250,"primaryCompletion":4214,"completion":523,"start":2671,"enrollment":10190,"conditions":48251,"interventions":48252},[91],[2053],[48127,48127,48127,48139,48140,48141,48142,48142,48143,48144],{"trials":48254,"activeCount":103},[],{"trials":48256,"activeCount":103},[],{"trials":48258,"activeCount":103},[],{"trials":48260,"activeCount":103},[],{"intervention":48262,"totalTrials":302,"cells":48263},"TTI-621 Monotherapy",{"EARLY_PHASE1":48264,"PHASE1":48266,"PHASE2":48282,"PHASE3":48284,"PHASE4":48286,"NA":48288},{"trials":48265,"activeCount":103},[],{"trials":48267,"activeCount":103},[48268],{"nctId":48269,"briefTitle":48270,"status":168,"phases":48271,"primaryCompletion":9637,"completion":9637,"start":2313,"enrollment":3202,"conditions":48272,"interventions":48279},"NCT02890368","Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",[91],[750,48273,1798,48274,48275,48276,48277,48278],"Mycosis Fungoides","Merkel-cell Carcinoma","Squamous Cell Carcinoma","Breast Carcinoma","Human Papillomavirus-Related Malignant Neoplasm","Soft Tissue Sarcoma",[48262,48280,48281],"TTI-621 + PD-1\u002FPD-L1 Inhibitor","TTI-621 + pegylated interferon-α2a",{"trials":48283,"activeCount":103},[],{"trials":48285,"activeCount":103},[],{"trials":48287,"activeCount":103},[],{"trials":48289,"activeCount":103},[],{"intervention":48280,"totalTrials":302,"cells":48291},{"EARLY_PHASE1":48292,"PHASE1":48294,"PHASE2":48300,"PHASE3":48302,"PHASE4":48304,"NA":48306},{"trials":48293,"activeCount":103},[],{"trials":48295,"activeCount":103},[48296],{"nctId":48269,"briefTitle":48270,"status":168,"phases":48297,"primaryCompletion":9637,"completion":9637,"start":2313,"enrollment":3202,"conditions":48298,"interventions":48299},[91],[750,48273,1798,48274,48275,48276,48277,48278],[48262,48280,48281],{"trials":48301,"activeCount":103},[],{"trials":48303,"activeCount":103},[],{"trials":48305,"activeCount":103},[],{"trials":48307,"activeCount":103},[],{"intervention":48281,"totalTrials":302,"cells":48309},{"EARLY_PHASE1":48310,"PHASE1":48312,"PHASE2":48318,"PHASE3":48320,"PHASE4":48322,"NA":48324},{"trials":48311,"activeCount":103},[],{"trials":48313,"activeCount":103},[48314],{"nctId":48269,"briefTitle":48270,"status":168,"phases":48315,"primaryCompletion":9637,"completion":9637,"start":2313,"enrollment":3202,"conditions":48316,"interventions":48317},[91],[750,48273,1798,48274,48275,48276,48277,48278],[48262,48280,48281],{"trials":48319,"activeCount":103},[],{"trials":48321,"activeCount":103},[],{"trials":48323,"activeCount":103},[],{"trials":48325,"activeCount":103},[],{"intervention":48327,"totalTrials":302,"cells":48328},"Sitaxentan sodium\u002FPlacebo",{"EARLY_PHASE1":48329,"PHASE1":48331,"PHASE2":48339,"PHASE3":48341,"PHASE4":48343,"NA":48345},{"trials":48330,"activeCount":103},[],{"trials":48332,"activeCount":103},[48333],{"nctId":48334,"briefTitle":48335,"status":111,"phases":48336,"primaryCompletion":6016,"completion":6016,"start":4833,"enrollment":525,"conditions":48337,"interventions":48338},"NCT00981968","Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects",[91],[16],[48327,48327],{"trials":48340,"activeCount":103},[],{"trials":48342,"activeCount":103},[],{"trials":48344,"activeCount":103},[],{"trials":48346,"activeCount":103},[],{"intervention":38834,"totalTrials":302,"cells":48348},{"EARLY_PHASE1":48349,"PHASE1":48351,"PHASE2":48357,"PHASE3":48359,"PHASE4":48361,"NA":48363},{"trials":48350,"activeCount":103},[],{"trials":48352,"activeCount":103},[48353],{"nctId":38829,"briefTitle":38830,"status":111,"phases":48354,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":1509,"conditions":48355,"interventions":48356},[91],[38826],[38815,38834,38834,38815,38834],{"trials":48358,"activeCount":103},[],{"trials":48360,"activeCount":103},[],{"trials":48362,"activeCount":103},[],{"trials":48364,"activeCount":103},[],{"intervention":48366,"totalTrials":302,"cells":48367},"ALO-02 weight-matched placebo",{"EARLY_PHASE1":48368,"PHASE1":48370,"PHASE2":48381,"PHASE3":48383,"PHASE4":48385,"NA":48387},{"trials":48369,"activeCount":103},[],{"trials":48371,"activeCount":103},[48372],{"nctId":48373,"briefTitle":48374,"status":111,"phases":48375,"primaryCompletion":6263,"completion":6263,"start":18128,"enrollment":8373,"conditions":48376,"interventions":48377},"NCT01775189","A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted",[91],[16],[48366,48378,48379,48380],"crushed ALO-02 30 mg\u002F3.6 mg","oxycodone weight-matched placebo","crushed oxycodone IR 30 mg",{"trials":48382,"activeCount":103},[],{"trials":48384,"activeCount":103},[],{"trials":48386,"activeCount":103},[],{"trials":48388,"activeCount":103},[],{"intervention":48378,"totalTrials":302,"cells":48390},{"EARLY_PHASE1":48391,"PHASE1":48393,"PHASE2":48399,"PHASE3":48401,"PHASE4":48403,"NA":48405},{"trials":48392,"activeCount":103},[],{"trials":48394,"activeCount":103},[48395],{"nctId":48373,"briefTitle":48374,"status":111,"phases":48396,"primaryCompletion":6263,"completion":6263,"start":18128,"enrollment":8373,"conditions":48397,"interventions":48398},[91],[16],[48366,48378,48379,48380],{"trials":48400,"activeCount":103},[],{"trials":48402,"activeCount":103},[],{"trials":48404,"activeCount":103},[],{"trials":48406,"activeCount":103},[],{"intervention":48379,"totalTrials":302,"cells":48408},{"EARLY_PHASE1":48409,"PHASE1":48411,"PHASE2":48417,"PHASE3":48419,"PHASE4":48421,"NA":48423},{"trials":48410,"activeCount":103},[],{"trials":48412,"activeCount":103},[48413],{"nctId":48373,"briefTitle":48374,"status":111,"phases":48414,"primaryCompletion":6263,"completion":6263,"start":18128,"enrollment":8373,"conditions":48415,"interventions":48416},[91],[16],[48366,48378,48379,48380],{"trials":48418,"activeCount":103},[],{"trials":48420,"activeCount":103},[],{"trials":48422,"activeCount":103},[],{"trials":48424,"activeCount":103},[],{"intervention":48380,"totalTrials":302,"cells":48426},{"EARLY_PHASE1":48427,"PHASE1":48429,"PHASE2":48435,"PHASE3":48437,"PHASE4":48439,"NA":48441},{"trials":48428,"activeCount":103},[],{"trials":48430,"activeCount":103},[48431],{"nctId":48373,"briefTitle":48374,"status":111,"phases":48432,"primaryCompletion":6263,"completion":6263,"start":18128,"enrollment":8373,"conditions":48433,"interventions":48434},[91],[16],[48366,48378,48379,48380],{"trials":48436,"activeCount":103},[],{"trials":48438,"activeCount":103},[],{"trials":48440,"activeCount":103},[],{"trials":48442,"activeCount":103},[],{"intervention":48444,"totalTrials":302,"cells":48445},"600 mg ceftaroline fosamil in 50 ml infusion volume",{"EARLY_PHASE1":48446,"PHASE1":48448,"PHASE2":48458,"PHASE3":48460,"PHASE4":48462,"NA":48464},{"trials":48447,"activeCount":103},[],{"trials":48449,"activeCount":103},[48450],{"nctId":48451,"briefTitle":48452,"status":111,"phases":48453,"primaryCompletion":1700,"completion":1700,"start":3334,"enrollment":3229,"conditions":48454,"interventions":48455},"NCT01577589","A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects",[91],[16],[48444,48456,48457],"600 ceftaroline fosamil in 250 ml infusion volume","600 mg ceftaroline in 100 ml infusion volume",{"trials":48459,"activeCount":103},[],{"trials":48461,"activeCount":103},[],{"trials":48463,"activeCount":103},[],{"trials":48465,"activeCount":103},[],{"intervention":48456,"totalTrials":302,"cells":48467},{"EARLY_PHASE1":48468,"PHASE1":48470,"PHASE2":48476,"PHASE3":48478,"PHASE4":48480,"NA":48482},{"trials":48469,"activeCount":103},[],{"trials":48471,"activeCount":103},[48472],{"nctId":48451,"briefTitle":48452,"status":111,"phases":48473,"primaryCompletion":1700,"completion":1700,"start":3334,"enrollment":3229,"conditions":48474,"interventions":48475},[91],[16],[48444,48456,48457],{"trials":48477,"activeCount":103},[],{"trials":48479,"activeCount":103},[],{"trials":48481,"activeCount":103},[],{"trials":48483,"activeCount":103},[],{"intervention":48457,"totalTrials":302,"cells":48485},{"EARLY_PHASE1":48486,"PHASE1":48488,"PHASE2":48494,"PHASE3":48496,"PHASE4":48498,"NA":48500},{"trials":48487,"activeCount":103},[],{"trials":48489,"activeCount":103},[48490],{"nctId":48451,"briefTitle":48452,"status":111,"phases":48491,"primaryCompletion":1700,"completion":1700,"start":3334,"enrollment":3229,"conditions":48492,"interventions":48493},[91],[16],[48444,48456,48457],{"trials":48495,"activeCount":103},[],{"trials":48497,"activeCount":103},[],{"trials":48499,"activeCount":103},[],{"trials":48501,"activeCount":103},[],{"intervention":48503,"totalTrials":302,"cells":48504},"CP- 690,550 and Tacrolimus",{"EARLY_PHASE1":48505,"PHASE1":48507,"PHASE2":48516,"PHASE3":48518,"PHASE4":48520,"NA":48522},{"trials":48506,"activeCount":103},[],{"trials":48508,"activeCount":103},[48509],{"nctId":48510,"briefTitle":48511,"status":111,"phases":48512,"primaryCompletion":4214,"completion":4214,"start":4646,"enrollment":1509,"conditions":48513,"interventions":48514},"NCT00860496","A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers",[91],[19],[48503,48515],"CP- 690,550 and Cyclosporine",{"trials":48517,"activeCount":103},[],{"trials":48519,"activeCount":103},[],{"trials":48521,"activeCount":103},[],{"trials":48523,"activeCount":103},[],{"intervention":48515,"totalTrials":302,"cells":48525},{"EARLY_PHASE1":48526,"PHASE1":48528,"PHASE2":48534,"PHASE3":48536,"PHASE4":48538,"NA":48540},{"trials":48527,"activeCount":103},[],{"trials":48529,"activeCount":103},[48530],{"nctId":48510,"briefTitle":48511,"status":111,"phases":48531,"primaryCompletion":4214,"completion":4214,"start":4646,"enrollment":1509,"conditions":48532,"interventions":48533},[91],[19],[48503,48515],{"trials":48535,"activeCount":103},[],{"trials":48537,"activeCount":103},[],{"trials":48539,"activeCount":103},[],{"trials":48541,"activeCount":103},[],{"intervention":40097,"totalTrials":302,"cells":48543},{"EARLY_PHASE1":48544,"PHASE1":48546,"PHASE2":48552,"PHASE3":48554,"PHASE4":48556,"NA":48558},{"trials":48545,"activeCount":103},[],{"trials":48547,"activeCount":103},[48548],{"nctId":40092,"briefTitle":40093,"status":111,"phases":48549,"primaryCompletion":4666,"completion":4666,"start":585,"enrollment":1780,"conditions":48550,"interventions":48551},[91],[16],[40097,40070,40098],{"trials":48553,"activeCount":103},[],{"trials":48555,"activeCount":103},[],{"trials":48557,"activeCount":103},[],{"trials":48559,"activeCount":103},[],{"intervention":40098,"totalTrials":302,"cells":48561},{"EARLY_PHASE1":48562,"PHASE1":48564,"PHASE2":48570,"PHASE3":48572,"PHASE4":48574,"NA":48576},{"trials":48563,"activeCount":103},[],{"trials":48565,"activeCount":103},[48566],{"nctId":40092,"briefTitle":40093,"status":111,"phases":48567,"primaryCompletion":4666,"completion":4666,"start":585,"enrollment":1780,"conditions":48568,"interventions":48569},[91],[16],[40097,40070,40098],{"trials":48571,"activeCount":103},[],{"trials":48573,"activeCount":103},[],{"trials":48575,"activeCount":103},[],{"trials":48577,"activeCount":103},[],{"intervention":19572,"totalTrials":302,"cells":48579},{"EARLY_PHASE1":48580,"PHASE1":48582,"PHASE2":48588,"PHASE3":48590,"PHASE4":48592,"NA":48594},{"trials":48581,"activeCount":103},[],{"trials":48583,"activeCount":103},[48584],{"nctId":19566,"briefTitle":19567,"status":111,"phases":48585,"enrollment":8373,"conditions":48586,"interventions":48587},[91],[19570,10974],[15250,19572,19573],{"trials":48589,"activeCount":103},[],{"trials":48591,"activeCount":103},[],{"trials":48593,"activeCount":103},[],{"trials":48595,"activeCount":103},[],{"intervention":48597,"totalTrials":302,"cells":48598},"PF 05212389 or placebo",{"EARLY_PHASE1":48599,"PHASE1":48601,"PHASE2":48609,"PHASE3":48611,"PHASE4":48613,"NA":48615},{"trials":48600,"activeCount":103},[],{"trials":48602,"activeCount":103},[48603],{"nctId":48604,"briefTitle":48605,"status":649,"phases":48606,"primaryCompletion":3313,"completion":4531,"start":523,"enrollment":103,"conditions":48607,"interventions":48608},"NCT01472848","A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects",[91],[2761],[48597,48597,48597,48597,48597,48597],{"trials":48610,"activeCount":103},[],{"trials":48612,"activeCount":103},[],{"trials":48614,"activeCount":103},[],{"trials":48616,"activeCount":103},[],{"intervention":48618,"totalTrials":302,"cells":48619},"sildenafil citrate 100 mg CT",{"EARLY_PHASE1":48620,"PHASE1":48622,"PHASE2":48631,"PHASE3":48633,"PHASE4":48635,"NA":48637},{"trials":48621,"activeCount":103},[],{"trials":48623,"activeCount":103},[48624],{"nctId":48625,"briefTitle":48626,"status":111,"phases":48627,"primaryCompletion":3642,"completion":3642,"start":10923,"enrollment":8414,"conditions":48628,"interventions":48629},"NCT00904748","A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate",[91],[40141],[48618,48618,48630],"Viagra®",{"trials":48632,"activeCount":103},[],{"trials":48634,"activeCount":103},[],{"trials":48636,"activeCount":103},[],{"trials":48638,"activeCount":103},[],{"intervention":48630,"totalTrials":302,"cells":48640},{"EARLY_PHASE1":48641,"PHASE1":48643,"PHASE2":48649,"PHASE3":48651,"PHASE4":48653,"NA":48655},{"trials":48642,"activeCount":103},[],{"trials":48644,"activeCount":103},[48645],{"nctId":48625,"briefTitle":48626,"status":111,"phases":48646,"primaryCompletion":3642,"completion":3642,"start":10923,"enrollment":8414,"conditions":48647,"interventions":48648},[91],[40141],[48618,48618,48630],{"trials":48650,"activeCount":103},[],{"trials":48652,"activeCount":103},[],{"trials":48654,"activeCount":103},[],{"trials":48656,"activeCount":103},[],{"intervention":48658,"totalTrials":302,"cells":48659},"PF-04776548",{"EARLY_PHASE1":48660,"PHASE1":48662,"PHASE2":48671,"PHASE3":48673,"PHASE4":48675,"NA":48677},{"trials":48661,"activeCount":103},[],{"trials":48663,"activeCount":103},[48664],{"nctId":48665,"briefTitle":48666,"status":111,"phases":48667,"primaryCompletion":11988,"completion":11988,"start":10923,"enrollment":870,"conditions":48668,"interventions":48670},"NCT01045317","A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body",[91],[48669],"Human Immunodeficiency Virus (HIV)",[48658],{"trials":48672,"activeCount":103},[],{"trials":48674,"activeCount":103},[],{"trials":48676,"activeCount":103},[],{"trials":48678,"activeCount":103},[],{"intervention":48680,"totalTrials":302,"cells":48681},"PF-04531083 100mg",{"EARLY_PHASE1":48682,"PHASE1":48684,"PHASE2":48694,"PHASE3":48696,"PHASE4":48698,"NA":48700},{"trials":48683,"activeCount":103},[],{"trials":48685,"activeCount":103},[48686],{"nctId":48687,"briefTitle":48688,"status":111,"phases":48689,"primaryCompletion":560,"completion":560,"start":577,"enrollment":1530,"conditions":48690,"interventions":48691},"NCT01127906","Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin",[91],[16],[48680,48692,48693],"PF-04531083 2000mg","Oxycodone 20mg",{"trials":48695,"activeCount":103},[],{"trials":48697,"activeCount":103},[],{"trials":48699,"activeCount":103},[],{"trials":48701,"activeCount":103},[],{"intervention":48692,"totalTrials":302,"cells":48703},{"EARLY_PHASE1":48704,"PHASE1":48706,"PHASE2":48712,"PHASE3":48714,"PHASE4":48716,"NA":48718},{"trials":48705,"activeCount":103},[],{"trials":48707,"activeCount":103},[48708],{"nctId":48687,"briefTitle":48688,"status":111,"phases":48709,"primaryCompletion":560,"completion":560,"start":577,"enrollment":1530,"conditions":48710,"interventions":48711},[91],[16],[48680,48692,48693],{"trials":48713,"activeCount":103},[],{"trials":48715,"activeCount":103},[],{"trials":48717,"activeCount":103},[],{"trials":48719,"activeCount":103},[],{"intervention":48693,"totalTrials":302,"cells":48721},{"EARLY_PHASE1":48722,"PHASE1":48724,"PHASE2":48730,"PHASE3":48732,"PHASE4":48734,"NA":48736},{"trials":48723,"activeCount":103},[],{"trials":48725,"activeCount":103},[48726],{"nctId":48687,"briefTitle":48688,"status":111,"phases":48727,"primaryCompletion":560,"completion":560,"start":577,"enrollment":1530,"conditions":48728,"interventions":48729},[91],[16],[48680,48692,48693],{"trials":48731,"activeCount":103},[],{"trials":48733,"activeCount":103},[],{"trials":48735,"activeCount":103},[],{"trials":48737,"activeCount":103},[],{"intervention":48739,"totalTrials":302,"cells":48740},"PF-3463275",{"EARLY_PHASE1":48741,"PHASE1":48743,"PHASE2":48751,"PHASE3":48753,"PHASE4":48755,"NA":48757},{"trials":48742,"activeCount":103},[],{"trials":48744,"activeCount":103},[48745],{"nctId":48746,"briefTitle":48747,"status":111,"phases":48748,"primaryCompletion":2884,"completion":2884,"start":2964,"enrollment":1530,"conditions":48749,"interventions":48750},"NCT00567203","A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia",[91],[12632],[48739,48739],{"trials":48752,"activeCount":103},[],{"trials":48754,"activeCount":103},[],{"trials":48756,"activeCount":103},[],{"trials":48758,"activeCount":103},[],{"intervention":48760,"totalTrials":302,"cells":48761},"100 mg PF-05231023",{"EARLY_PHASE1":48762,"PHASE1":48764,"PHASE2":48772,"PHASE3":48774,"PHASE4":48776,"NA":48778},{"trials":48763,"activeCount":103},[],{"trials":48765,"activeCount":103},[48766],{"nctId":48767,"briefTitle":48768,"status":168,"phases":48769,"primaryCompletion":606,"completion":606,"start":13214,"enrollment":257,"conditions":48770,"interventions":48771},"NCT01923389","Multiple Dose Study Of PF-05231023 In Obese Adult Subjects",[91],[3020],[48760],{"trials":48773,"activeCount":103},[],{"trials":48775,"activeCount":103},[],{"trials":48777,"activeCount":103},[],{"trials":48779,"activeCount":103},[],{"intervention":48781,"totalTrials":302,"cells":48782},"PF03635659",{"EARLY_PHASE1":48783,"PHASE1":48785,"PHASE2":48794,"PHASE3":48796,"PHASE4":48798,"NA":48800},{"trials":48784,"activeCount":103},[],{"trials":48786,"activeCount":103},[48787],{"nctId":48788,"briefTitle":48789,"status":111,"phases":48790,"primaryCompletion":11290,"completion":11290,"start":11291,"enrollment":26,"conditions":48791,"interventions":48793},"NCT00864786","Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study",[91],[48792],"Chronic Obstructive Pulmonary Disease",[48781,48781,48781,48781,48781],{"trials":48795,"activeCount":103},[],{"trials":48797,"activeCount":103},[],{"trials":48799,"activeCount":103},[],{"trials":48801,"activeCount":103},[],{"intervention":48803,"totalTrials":302,"cells":48804},"Azithromycin Tablet manufactured in China",{"EARLY_PHASE1":48805,"PHASE1":48807,"PHASE2":48817,"PHASE3":48819,"PHASE4":48821,"NA":48823},{"trials":48806,"activeCount":103},[],{"trials":48808,"activeCount":103},[48809],{"nctId":48810,"briefTitle":48811,"status":111,"phases":48812,"primaryCompletion":28013,"completion":48813,"start":2421,"enrollment":4825,"conditions":48814,"interventions":48815},"NCT03353480","Bioequivalence (BE) Study Comparing Azithromycin 250 mg Tablet Manufactured in China and in the United States",[91],"2018-02-26",[43684],[48803,48816],"Azithromycin Tablet manufactured in US",{"trials":48818,"activeCount":103},[],{"trials":48820,"activeCount":103},[],{"trials":48822,"activeCount":103},[],{"trials":48824,"activeCount":103},[],{"intervention":48816,"totalTrials":302,"cells":48826},{"EARLY_PHASE1":48827,"PHASE1":48829,"PHASE2":48835,"PHASE3":48837,"PHASE4":48839,"NA":48841},{"trials":48828,"activeCount":103},[],{"trials":48830,"activeCount":103},[48831],{"nctId":48810,"briefTitle":48811,"status":111,"phases":48832,"primaryCompletion":28013,"completion":48813,"start":2421,"enrollment":4825,"conditions":48833,"interventions":48834},[91],[43684],[48803,48816],{"trials":48836,"activeCount":103},[],{"trials":48838,"activeCount":103},[],{"trials":48840,"activeCount":103},[],{"trials":48842,"activeCount":103},[],{"intervention":3902,"totalTrials":302,"cells":48844},{"EARLY_PHASE1":48845,"PHASE1":48847,"PHASE2":48853,"PHASE3":48855,"PHASE4":48857,"NA":48859},{"trials":48846,"activeCount":103},[],{"trials":48848,"activeCount":103},[48849],{"nctId":3895,"briefTitle":3896,"status":111,"phases":48850,"primaryCompletion":3898,"completion":3898,"start":3899,"enrollment":1268,"conditions":48851,"interventions":48852},[91],[16],[3879,3902],{"trials":48854,"activeCount":103},[],{"trials":48856,"activeCount":103},[],{"trials":48858,"activeCount":103},[],{"trials":48860,"activeCount":103},[],{"intervention":48862,"totalTrials":302,"cells":48863},"PF-868554",{"EARLY_PHASE1":48864,"PHASE1":48866,"PHASE2":48875,"PHASE3":48877,"PHASE4":48879,"NA":48881},{"trials":48865,"activeCount":103},[],{"trials":48867,"activeCount":103},[48868],{"nctId":48869,"briefTitle":48870,"status":111,"phases":48871,"primaryCompletion":11291,"completion":11291,"start":10937,"enrollment":1509,"conditions":48872,"interventions":48874},"NCT00651027","Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554",[91],[48873],"HEPATITIS C (HCV)",[48862,48862,48862],{"trials":48876,"activeCount":103},[],{"trials":48878,"activeCount":103},[],{"trials":48880,"activeCount":103},[],{"trials":48882,"activeCount":103},[],{"intervention":39646,"totalTrials":302,"cells":48884},{"EARLY_PHASE1":48885,"PHASE1":48887,"PHASE2":48893,"PHASE3":48895,"PHASE4":48897,"NA":48899},{"trials":48886,"activeCount":103},[],{"trials":48888,"activeCount":103},[48889],{"nctId":39641,"briefTitle":39642,"status":111,"phases":48890,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":48891,"interventions":48892},[91],[16],[39646,39647,39648,39634],{"trials":48894,"activeCount":103},[],{"trials":48896,"activeCount":103},[],{"trials":48898,"activeCount":103},[],{"trials":48900,"activeCount":103},[],{"intervention":39647,"totalTrials":302,"cells":48902},{"EARLY_PHASE1":48903,"PHASE1":48905,"PHASE2":48911,"PHASE3":48913,"PHASE4":48915,"NA":48917},{"trials":48904,"activeCount":103},[],{"trials":48906,"activeCount":103},[48907],{"nctId":39641,"briefTitle":39642,"status":111,"phases":48908,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":48909,"interventions":48910},[91],[16],[39646,39647,39648,39634],{"trials":48912,"activeCount":103},[],{"trials":48914,"activeCount":103},[],{"trials":48916,"activeCount":103},[],{"trials":48918,"activeCount":103},[],{"intervention":39648,"totalTrials":302,"cells":48920},{"EARLY_PHASE1":48921,"PHASE1":48923,"PHASE2":48929,"PHASE3":48931,"PHASE4":48933,"NA":48935},{"trials":48922,"activeCount":103},[],{"trials":48924,"activeCount":103},[48925],{"nctId":39641,"briefTitle":39642,"status":111,"phases":48926,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":48927,"interventions":48928},[91],[16],[39646,39647,39648,39634],{"trials":48930,"activeCount":103},[],{"trials":48932,"activeCount":103},[],{"trials":48934,"activeCount":103},[],{"trials":48936,"activeCount":103},[],{"intervention":48938,"totalTrials":302,"cells":48939},"PF-06821497 Treatment A",{"EARLY_PHASE1":48940,"PHASE1":48942,"PHASE2":48957,"PHASE3":48959,"PHASE4":48961,"NA":48963},{"trials":48941,"activeCount":103},[],{"trials":48943,"activeCount":103},[48944],{"nctId":48945,"briefTitle":48946,"status":111,"phases":48947,"primaryCompletion":48948,"completion":48948,"start":48949,"enrollment":597,"conditions":48950,"interventions":48951},"NCT05767905","A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.",[91],"2023-06-20","2023-03-17",[16],[48938,48952,48953,48954,48955,48956],"PF-06821497 Treatment B","PF-06821497 Treatment C","PF-06821497 Treatment D","PF-06821497 Treatment E","PF-06821497 Treatment F",{"trials":48958,"activeCount":103},[],{"trials":48960,"activeCount":103},[],{"trials":48962,"activeCount":103},[],{"trials":48964,"activeCount":103},[],{"intervention":48952,"totalTrials":302,"cells":48966},{"EARLY_PHASE1":48967,"PHASE1":48969,"PHASE2":48975,"PHASE3":48977,"PHASE4":48979,"NA":48981},{"trials":48968,"activeCount":103},[],{"trials":48970,"activeCount":103},[48971],{"nctId":48945,"briefTitle":48946,"status":111,"phases":48972,"primaryCompletion":48948,"completion":48948,"start":48949,"enrollment":597,"conditions":48973,"interventions":48974},[91],[16],[48938,48952,48953,48954,48955,48956],{"trials":48976,"activeCount":103},[],{"trials":48978,"activeCount":103},[],{"trials":48980,"activeCount":103},[],{"trials":48982,"activeCount":103},[],{"intervention":48953,"totalTrials":302,"cells":48984},{"EARLY_PHASE1":48985,"PHASE1":48987,"PHASE2":48993,"PHASE3":48995,"PHASE4":48997,"NA":48999},{"trials":48986,"activeCount":103},[],{"trials":48988,"activeCount":103},[48989],{"nctId":48945,"briefTitle":48946,"status":111,"phases":48990,"primaryCompletion":48948,"completion":48948,"start":48949,"enrollment":597,"conditions":48991,"interventions":48992},[91],[16],[48938,48952,48953,48954,48955,48956],{"trials":48994,"activeCount":103},[],{"trials":48996,"activeCount":103},[],{"trials":48998,"activeCount":103},[],{"trials":49000,"activeCount":103},[],{"intervention":48954,"totalTrials":302,"cells":49002},{"EARLY_PHASE1":49003,"PHASE1":49005,"PHASE2":49011,"PHASE3":49013,"PHASE4":49015,"NA":49017},{"trials":49004,"activeCount":103},[],{"trials":49006,"activeCount":103},[49007],{"nctId":48945,"briefTitle":48946,"status":111,"phases":49008,"primaryCompletion":48948,"completion":48948,"start":48949,"enrollment":597,"conditions":49009,"interventions":49010},[91],[16],[48938,48952,48953,48954,48955,48956],{"trials":49012,"activeCount":103},[],{"trials":49014,"activeCount":103},[],{"trials":49016,"activeCount":103},[],{"trials":49018,"activeCount":103},[],{"intervention":48955,"totalTrials":302,"cells":49020},{"EARLY_PHASE1":49021,"PHASE1":49023,"PHASE2":49029,"PHASE3":49031,"PHASE4":49033,"NA":49035},{"trials":49022,"activeCount":103},[],{"trials":49024,"activeCount":103},[49025],{"nctId":48945,"briefTitle":48946,"status":111,"phases":49026,"primaryCompletion":48948,"completion":48948,"start":48949,"enrollment":597,"conditions":49027,"interventions":49028},[91],[16],[48938,48952,48953,48954,48955,48956],{"trials":49030,"activeCount":103},[],{"trials":49032,"activeCount":103},[],{"trials":49034,"activeCount":103},[],{"trials":49036,"activeCount":103},[],{"intervention":48956,"totalTrials":302,"cells":49038},{"EARLY_PHASE1":49039,"PHASE1":49041,"PHASE2":49047,"PHASE3":49049,"PHASE4":49051,"NA":49053},{"trials":49040,"activeCount":103},[],{"trials":49042,"activeCount":103},[49043],{"nctId":48945,"briefTitle":48946,"status":111,"phases":49044,"primaryCompletion":48948,"completion":48948,"start":48949,"enrollment":597,"conditions":49045,"interventions":49046},[91],[16],[48938,48952,48953,48954,48955,48956],{"trials":49048,"activeCount":103},[],{"trials":49050,"activeCount":103},[],{"trials":49052,"activeCount":103},[],{"trials":49054,"activeCount":103},[],{"intervention":49056,"totalTrials":302,"cells":49057},"Tasocitinib 10 mg oral",{"EARLY_PHASE1":49058,"PHASE1":49060,"PHASE2":49069,"PHASE3":49071,"PHASE4":49073,"NA":49075},{"trials":49059,"activeCount":103},[],{"trials":49061,"activeCount":103},[49062],{"nctId":49063,"briefTitle":49064,"status":111,"phases":49065,"primaryCompletion":561,"completion":561,"start":586,"enrollment":1268,"conditions":49066,"interventions":49067},"NCT01143805","A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form",[91],[16],[49056,49068],"Tasocitinib 10 mg IV",{"trials":49070,"activeCount":103},[],{"trials":49072,"activeCount":103},[],{"trials":49074,"activeCount":103},[],{"trials":49076,"activeCount":103},[],{"intervention":49068,"totalTrials":302,"cells":49078},{"EARLY_PHASE1":49079,"PHASE1":49081,"PHASE2":49087,"PHASE3":49089,"PHASE4":49091,"NA":49093},{"trials":49080,"activeCount":103},[],{"trials":49082,"activeCount":103},[49083],{"nctId":49063,"briefTitle":49064,"status":111,"phases":49084,"primaryCompletion":561,"completion":561,"start":586,"enrollment":1268,"conditions":49085,"interventions":49086},[91],[16],[49056,49068],{"trials":49088,"activeCount":103},[],{"trials":49090,"activeCount":103},[],{"trials":49092,"activeCount":103},[],{"trials":49094,"activeCount":103},[],{"intervention":49096,"totalTrials":302,"cells":49097},"PF-07062119",{"EARLY_PHASE1":49098,"PHASE1":49100,"PHASE2":49116,"PHASE3":49118,"PHASE4":49120,"NA":49122},{"trials":49099,"activeCount":103},[],{"trials":49101,"activeCount":103},[49102],{"nctId":49103,"briefTitle":49104,"status":168,"phases":49105,"primaryCompletion":49106,"completion":49106,"start":49107,"enrollment":26401,"conditions":49108,"interventions":49113},"NCT04171141","Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.",[91],"2023-11-28","2019-11-19",[49109,49110,49111,49112],"Gastrointestinal Tumors","Colorectal Adenocarcinomas","Gastric Adenocarcinomas","Esophageal Adenocarcinomas",[49096,49114,49115],"Anti-PD1","Anti-VEGF",{"trials":49117,"activeCount":103},[],{"trials":49119,"activeCount":103},[],{"trials":49121,"activeCount":103},[],{"trials":49123,"activeCount":103},[],{"intervention":49114,"totalTrials":302,"cells":49125},{"EARLY_PHASE1":49126,"PHASE1":49128,"PHASE2":49134,"PHASE3":49136,"PHASE4":49138,"NA":49140},{"trials":49127,"activeCount":103},[],{"trials":49129,"activeCount":103},[49130],{"nctId":49103,"briefTitle":49104,"status":168,"phases":49131,"primaryCompletion":49106,"completion":49106,"start":49107,"enrollment":26401,"conditions":49132,"interventions":49133},[91],[49109,49110,49111,49112],[49096,49114,49115],{"trials":49135,"activeCount":103},[],{"trials":49137,"activeCount":103},[],{"trials":49139,"activeCount":103},[],{"trials":49141,"activeCount":103},[],{"intervention":49115,"totalTrials":302,"cells":49143},{"EARLY_PHASE1":49144,"PHASE1":49146,"PHASE2":49152,"PHASE3":49154,"PHASE4":49156,"NA":49158},{"trials":49145,"activeCount":103},[],{"trials":49147,"activeCount":103},[49148],{"nctId":49103,"briefTitle":49104,"status":168,"phases":49149,"primaryCompletion":49106,"completion":49106,"start":49107,"enrollment":26401,"conditions":49150,"interventions":49151},[91],[49109,49110,49111,49112],[49096,49114,49115],{"trials":49153,"activeCount":103},[],{"trials":49155,"activeCount":103},[],{"trials":49157,"activeCount":103},[],{"trials":49159,"activeCount":103},[],{"intervention":3753,"totalTrials":302,"cells":49161},{"EARLY_PHASE1":49162,"PHASE1":49164,"PHASE2":49170,"PHASE3":49172,"PHASE4":49174,"NA":49176},{"trials":49163,"activeCount":103},[],{"trials":49165,"activeCount":103},[49166],{"nctId":3747,"briefTitle":3748,"status":111,"phases":49167,"primaryCompletion":3750,"completion":3750,"start":1914,"enrollment":1191,"conditions":49168,"interventions":49169},[91],[16],[3753,3754,3740,3755,3756],{"trials":49171,"activeCount":103},[],{"trials":49173,"activeCount":103},[],{"trials":49175,"activeCount":103},[],{"trials":49177,"activeCount":103},[],{"intervention":3755,"totalTrials":302,"cells":49179},{"EARLY_PHASE1":49180,"PHASE1":49182,"PHASE2":49188,"PHASE3":49190,"PHASE4":49192,"NA":49194},{"trials":49181,"activeCount":103},[],{"trials":49183,"activeCount":103},[49184],{"nctId":3747,"briefTitle":3748,"status":111,"phases":49185,"primaryCompletion":3750,"completion":3750,"start":1914,"enrollment":1191,"conditions":49186,"interventions":49187},[91],[16],[3753,3754,3740,3755,3756],{"trials":49189,"activeCount":103},[],{"trials":49191,"activeCount":103},[],{"trials":49193,"activeCount":103},[],{"trials":49195,"activeCount":103},[],{"intervention":3756,"totalTrials":302,"cells":49197},{"EARLY_PHASE1":49198,"PHASE1":49200,"PHASE2":49206,"PHASE3":49208,"PHASE4":49210,"NA":49212},{"trials":49199,"activeCount":103},[],{"trials":49201,"activeCount":103},[49202],{"nctId":3747,"briefTitle":3748,"status":111,"phases":49203,"primaryCompletion":3750,"completion":3750,"start":1914,"enrollment":1191,"conditions":49204,"interventions":49205},[91],[16],[3753,3754,3740,3755,3756],{"trials":49207,"activeCount":103},[],{"trials":49209,"activeCount":103},[],{"trials":49211,"activeCount":103},[],{"trials":49213,"activeCount":103},[],{"intervention":49215,"totalTrials":302,"cells":49216},"ILV-095 300 mg in a 4 to 1 ratio",{"EARLY_PHASE1":49217,"PHASE1":49219,"PHASE2":49228,"PHASE3":49230,"PHASE4":49232,"NA":49234},{"trials":49218,"activeCount":103},[],{"trials":49220,"activeCount":103},[49221],{"nctId":49222,"briefTitle":49223,"status":168,"phases":49224,"primaryCompletion":49225,"completion":49225,"start":27964,"enrollment":1097,"conditions":49226,"interventions":49227},"NCT01010542","Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects",[91],"2011-05-20",[26842],[49215,49215],{"trials":49229,"activeCount":103},[],{"trials":49231,"activeCount":103},[],{"trials":49233,"activeCount":103},[],{"trials":49235,"activeCount":103},[],{"intervention":49237,"totalTrials":302,"cells":49238},"Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771",{"EARLY_PHASE1":49239,"PHASE1":49241,"PHASE2":49249,"PHASE3":49251,"PHASE4":49253,"NA":49255},{"trials":49240,"activeCount":103},[],{"trials":49242,"activeCount":103},[49243],{"nctId":49244,"briefTitle":49245,"status":111,"phases":49246,"primaryCompletion":18769,"completion":18769,"start":13214,"enrollment":7500,"conditions":49247,"interventions":49248},"NCT01934569","Drug-Drug Interaction Study With PF-05089771",[91],[16],[49237],{"trials":49250,"activeCount":103},[],{"trials":49252,"activeCount":103},[],{"trials":49254,"activeCount":103},[],{"trials":49256,"activeCount":103},[],{"intervention":49258,"totalTrials":302,"cells":49259},"PF-07261271",{"EARLY_PHASE1":49260,"PHASE1":49262,"PHASE2":49271,"PHASE3":49273,"PHASE4":49275,"NA":49277},{"trials":49261,"activeCount":103},[],{"trials":49263,"activeCount":103},[49264],{"nctId":49265,"briefTitle":49266,"status":111,"phases":49267,"primaryCompletion":49268,"completion":49268,"start":6106,"enrollment":472,"conditions":49269,"interventions":49270},"NCT05536440","A Study to Learn About Study Medicine Called PF-07261271 in Healthy People",[91],"2024-02-29",[16],[49258],{"trials":49272,"activeCount":103},[],{"trials":49274,"activeCount":103},[],{"trials":49276,"activeCount":103},[],{"trials":49278,"activeCount":103},[],{"intervention":39687,"totalTrials":302,"cells":49280},{"EARLY_PHASE1":49281,"PHASE1":49283,"PHASE2":49289,"PHASE3":49291,"PHASE4":49293,"NA":49295},{"trials":49282,"activeCount":103},[],{"trials":49284,"activeCount":103},[49285],{"nctId":39682,"briefTitle":39683,"status":111,"phases":49286,"primaryCompletion":29213,"completion":29213,"start":5957,"enrollment":13377,"conditions":49287,"interventions":49288},[91],[19],[39675,39687],{"trials":49290,"activeCount":103},[],{"trials":49292,"activeCount":103},[],{"trials":49294,"activeCount":103},[],{"trials":49296,"activeCount":103},[],{"intervention":7752,"totalTrials":302,"cells":49298},{"EARLY_PHASE1":49299,"PHASE1":49301,"PHASE2":49307,"PHASE3":49309,"PHASE4":49311,"NA":49313},{"trials":49300,"activeCount":103},[],{"trials":49302,"activeCount":103},[49303],{"nctId":7745,"briefTitle":7746,"status":168,"phases":49304,"primaryCompletion":7748,"completion":7749,"start":1157,"enrollment":627,"conditions":49305,"interventions":49306},[91],[2053,7726,1798,5823,1859,907,7727,7728],[7752,1773],{"trials":49308,"activeCount":103},[],{"trials":49310,"activeCount":103},[],{"trials":49312,"activeCount":103},[],{"trials":49314,"activeCount":103},[],{"intervention":49316,"totalTrials":302,"cells":49317},"Etrasimod Immediate Release",{"EARLY_PHASE1":49318,"PHASE1":49320,"PHASE2":49328,"PHASE3":49330,"PHASE4":49332,"NA":49334},{"trials":49319,"activeCount":103},[],{"trials":49321,"activeCount":103},[49322],{"nctId":49323,"briefTitle":49324,"status":111,"phases":49325,"primaryCompletion":43003,"completion":43003,"start":2523,"enrollment":1487,"conditions":49326,"interventions":49327},"NCT06140290","A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants",[91],[28],[49316],{"trials":49329,"activeCount":103},[],{"trials":49331,"activeCount":103},[],{"trials":49333,"activeCount":103},[],{"trials":49335,"activeCount":103},[],{"intervention":49337,"totalTrials":302,"cells":49338},"palbociclib capsule: phase 1 and 2 studies",{"EARLY_PHASE1":49339,"PHASE1":49341,"PHASE2":49351,"PHASE3":49353,"PHASE4":49355,"NA":49357},{"trials":49340,"activeCount":103},[],{"trials":49342,"activeCount":103},[49343],{"nctId":49344,"briefTitle":49345,"status":111,"phases":49346,"primaryCompletion":1248,"completion":1248,"start":13214,"enrollment":463,"conditions":49347,"interventions":49348},"NCT01906125","A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product",[91],[16],[49337,49349,49350],"Palbociclib capsule: phase 3 studies","Palbociclib capsule: ICH",{"trials":49352,"activeCount":103},[],{"trials":49354,"activeCount":103},[],{"trials":49356,"activeCount":103},[],{"trials":49358,"activeCount":103},[],{"intervention":49349,"totalTrials":302,"cells":49360},{"EARLY_PHASE1":49361,"PHASE1":49363,"PHASE2":49369,"PHASE3":49371,"PHASE4":49373,"NA":49375},{"trials":49362,"activeCount":103},[],{"trials":49364,"activeCount":103},[49365],{"nctId":49344,"briefTitle":49345,"status":111,"phases":49366,"primaryCompletion":1248,"completion":1248,"start":13214,"enrollment":463,"conditions":49367,"interventions":49368},[91],[16],[49337,49349,49350],{"trials":49370,"activeCount":103},[],{"trials":49372,"activeCount":103},[],{"trials":49374,"activeCount":103},[],{"trials":49376,"activeCount":103},[],{"intervention":49350,"totalTrials":302,"cells":49378},{"EARLY_PHASE1":49379,"PHASE1":49381,"PHASE2":49387,"PHASE3":49389,"PHASE4":49391,"NA":49393},{"trials":49380,"activeCount":103},[],{"trials":49382,"activeCount":103},[49383],{"nctId":49344,"briefTitle":49345,"status":111,"phases":49384,"primaryCompletion":1248,"completion":1248,"start":13214,"enrollment":463,"conditions":49385,"interventions":49386},[91],[16],[49337,49349,49350],{"trials":49388,"activeCount":103},[],{"trials":49390,"activeCount":103},[],{"trials":49392,"activeCount":103},[],{"trials":49394,"activeCount":103},[],{"intervention":17067,"totalTrials":302,"cells":49396},{"EARLY_PHASE1":49397,"PHASE1":49399,"PHASE2":49405,"PHASE3":49407,"PHASE4":49409,"NA":49411},{"trials":49398,"activeCount":103},[],{"trials":49400,"activeCount":103},[49401],{"nctId":17061,"briefTitle":17062,"status":111,"phases":49402,"primaryCompletion":2313,"completion":2313,"start":7387,"enrollment":1548,"conditions":49403,"interventions":49404},[91],[16],[17066,6111,17067],{"trials":49406,"activeCount":103},[],{"trials":49408,"activeCount":103},[],{"trials":49410,"activeCount":103},[],{"trials":49412,"activeCount":103},[],{"intervention":39724,"totalTrials":302,"cells":49414},{"EARLY_PHASE1":49415,"PHASE1":49417,"PHASE2":49423,"PHASE3":49425,"PHASE4":49427,"NA":49429},{"trials":49416,"activeCount":103},[],{"trials":49418,"activeCount":103},[49419],{"nctId":39719,"briefTitle":39720,"status":111,"phases":49420,"primaryCompletion":11356,"completion":11356,"start":9572,"enrollment":578,"conditions":49421,"interventions":49422},[91],[16],[39724,39712,39712],{"trials":49424,"activeCount":103},[],{"trials":49426,"activeCount":103},[],{"trials":49428,"activeCount":103},[],{"trials":49430,"activeCount":103},[],{"intervention":49432,"totalTrials":302,"cells":49433},"midazolam; CP-690,550 + midazolam",{"EARLY_PHASE1":49434,"PHASE1":49436,"PHASE2":49445,"PHASE3":49447,"PHASE4":49449,"NA":49451},{"trials":49435,"activeCount":103},[],{"trials":49437,"activeCount":103},[49438],{"nctId":49439,"briefTitle":49440,"status":111,"phases":49441,"primaryCompletion":4627,"completion":4627,"start":4646,"enrollment":2713,"conditions":49442,"interventions":49443},"NCT00902460","CP-690,550 and Midazolam Drug-Drug Interaction Study",[91],[1270],[49432,49444],"CP-690,550 + midazolam; midazolam",{"trials":49446,"activeCount":103},[],{"trials":49448,"activeCount":103},[],{"trials":49450,"activeCount":103},[],{"trials":49452,"activeCount":103},[],{"intervention":49444,"totalTrials":302,"cells":49454},{"EARLY_PHASE1":49455,"PHASE1":49457,"PHASE2":49463,"PHASE3":49465,"PHASE4":49467,"NA":49469},{"trials":49456,"activeCount":103},[],{"trials":49458,"activeCount":103},[49459],{"nctId":49439,"briefTitle":49440,"status":111,"phases":49460,"primaryCompletion":4627,"completion":4627,"start":4646,"enrollment":2713,"conditions":49461,"interventions":49462},[91],[1270],[49432,49444],{"trials":49464,"activeCount":103},[],{"trials":49466,"activeCount":103},[],{"trials":49468,"activeCount":103},[],{"trials":49470,"activeCount":103},[],{"intervention":49472,"totalTrials":302,"cells":49473},"PF-07291177",{"EARLY_PHASE1":49474,"PHASE1":49476,"PHASE2":49484,"PHASE3":49486,"PHASE4":49488,"NA":49490},{"trials":49475,"activeCount":103},[],{"trials":49477,"activeCount":103},[49478],{"nctId":49479,"briefTitle":49480,"status":649,"phases":49481,"primaryCompletion":8370,"completion":8370,"start":11557,"enrollment":103,"conditions":49482,"interventions":49483},"NCT05434091","A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants",[91],[28],[49472],{"trials":49485,"activeCount":103},[],{"trials":49487,"activeCount":103},[],{"trials":49489,"activeCount":103},[],{"trials":49491,"activeCount":103},[],{"intervention":49493,"totalTrials":302,"cells":49494},"PF-05230901",{"EARLY_PHASE1":49495,"PHASE1":49497,"PHASE2":49505,"PHASE3":49507,"PHASE4":49509,"NA":49511},{"trials":49496,"activeCount":103},[],{"trials":49498,"activeCount":103},[49499],{"nctId":49500,"briefTitle":49501,"status":168,"phases":49502,"primaryCompletion":9544,"completion":9544,"start":8252,"enrollment":29,"conditions":49503,"interventions":49504},"NCT01262690","A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin",[91],[5185],[49493,49493],{"trials":49506,"activeCount":103},[],{"trials":49508,"activeCount":103},[],{"trials":49510,"activeCount":103},[],{"trials":49512,"activeCount":103},[],{"intervention":49514,"totalTrials":302,"cells":49515},"Cohort 1: bococizumab 150 mg + rHuPH20",{"EARLY_PHASE1":49516,"PHASE1":49518,"PHASE2":49530,"PHASE3":49532,"PHASE4":49534,"NA":49536},{"trials":49517,"activeCount":103},[],{"trials":49519,"activeCount":103},[49520],{"nctId":49521,"briefTitle":49522,"status":168,"phases":49523,"primaryCompletion":5008,"completion":5008,"start":4280,"enrollment":2240,"conditions":49524,"interventions":49525},"NCT02667223","Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase",[91],[16,12981],[49514,49526,49527,49528,49529],"Cohort 2: bococizumab 300 mg","Cohort 3: bococizumab 300 mg + rHuPH20","Cohort 5: bococizumab 450 mg + rHuPH20","Cohort 4: bococizumab 300 mg + rHuPH20",{"trials":49531,"activeCount":103},[],{"trials":49533,"activeCount":103},[],{"trials":49535,"activeCount":103},[],{"trials":49537,"activeCount":103},[],{"intervention":49526,"totalTrials":302,"cells":49539},{"EARLY_PHASE1":49540,"PHASE1":49542,"PHASE2":49548,"PHASE3":49550,"PHASE4":49552,"NA":49554},{"trials":49541,"activeCount":103},[],{"trials":49543,"activeCount":103},[49544],{"nctId":49521,"briefTitle":49522,"status":168,"phases":49545,"primaryCompletion":5008,"completion":5008,"start":4280,"enrollment":2240,"conditions":49546,"interventions":49547},[91],[16,12981],[49514,49526,49527,49528,49529],{"trials":49549,"activeCount":103},[],{"trials":49551,"activeCount":103},[],{"trials":49553,"activeCount":103},[],{"trials":49555,"activeCount":103},[],{"intervention":49527,"totalTrials":302,"cells":49557},{"EARLY_PHASE1":49558,"PHASE1":49560,"PHASE2":49566,"PHASE3":49568,"PHASE4":49570,"NA":49572},{"trials":49559,"activeCount":103},[],{"trials":49561,"activeCount":103},[49562],{"nctId":49521,"briefTitle":49522,"status":168,"phases":49563,"primaryCompletion":5008,"completion":5008,"start":4280,"enrollment":2240,"conditions":49564,"interventions":49565},[91],[16,12981],[49514,49526,49527,49528,49529],{"trials":49567,"activeCount":103},[],{"trials":49569,"activeCount":103},[],{"trials":49571,"activeCount":103},[],{"trials":49573,"activeCount":103},[],{"intervention":49528,"totalTrials":302,"cells":49575},{"EARLY_PHASE1":49576,"PHASE1":49578,"PHASE2":49584,"PHASE3":49586,"PHASE4":49588,"NA":49590},{"trials":49577,"activeCount":103},[],{"trials":49579,"activeCount":103},[49580],{"nctId":49521,"briefTitle":49522,"status":168,"phases":49581,"primaryCompletion":5008,"completion":5008,"start":4280,"enrollment":2240,"conditions":49582,"interventions":49583},[91],[16,12981],[49514,49526,49527,49528,49529],{"trials":49585,"activeCount":103},[],{"trials":49587,"activeCount":103},[],{"trials":49589,"activeCount":103},[],{"trials":49591,"activeCount":103},[],{"intervention":49529,"totalTrials":302,"cells":49593},{"EARLY_PHASE1":49594,"PHASE1":49596,"PHASE2":49602,"PHASE3":49604,"PHASE4":49606,"NA":49608},{"trials":49595,"activeCount":103},[],{"trials":49597,"activeCount":103},[49598],{"nctId":49521,"briefTitle":49522,"status":168,"phases":49599,"primaryCompletion":5008,"completion":5008,"start":4280,"enrollment":2240,"conditions":49600,"interventions":49601},[91],[16,12981],[49514,49526,49527,49528,49529],{"trials":49603,"activeCount":103},[],{"trials":49605,"activeCount":103},[],{"trials":49607,"activeCount":103},[],{"trials":49609,"activeCount":103},[],{"intervention":49611,"totalTrials":302,"cells":49612},"RIN 150",{"EARLY_PHASE1":49613,"PHASE1":49615,"PHASE2":49624,"PHASE3":49626,"PHASE4":49628,"NA":49630},{"trials":49614,"activeCount":103},[],{"trials":49616,"activeCount":103},[49617],{"nctId":49618,"briefTitle":49619,"status":111,"phases":49620,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":5909,"conditions":49621,"interventions":49622},"NCT02014272","A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers",[91],[19],[49611,49623],"reference drugs",{"trials":49625,"activeCount":103},[],{"trials":49627,"activeCount":103},[],{"trials":49629,"activeCount":103},[],{"trials":49631,"activeCount":103},[],{"intervention":49623,"totalTrials":302,"cells":49633},{"EARLY_PHASE1":49634,"PHASE1":49636,"PHASE2":49642,"PHASE3":49644,"PHASE4":49646,"NA":49648},{"trials":49635,"activeCount":103},[],{"trials":49637,"activeCount":103},[49638],{"nctId":49618,"briefTitle":49619,"status":111,"phases":49639,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":5909,"conditions":49640,"interventions":49641},[91],[19],[49611,49623],{"trials":49643,"activeCount":103},[],{"trials":49645,"activeCount":103},[],{"trials":49647,"activeCount":103},[],{"trials":49649,"activeCount":103},[],{"intervention":49651,"totalTrials":302,"cells":49652},"Atorvastatin pediatric appropriate formulation",{"EARLY_PHASE1":49653,"PHASE1":49655,"PHASE2":49663,"PHASE3":49665,"PHASE4":49667,"NA":49669},{"trials":49654,"activeCount":103},[],{"trials":49656,"activeCount":103},[49657],{"nctId":49658,"briefTitle":49659,"status":111,"phases":49660,"primaryCompletion":11290,"completion":11290,"start":4665,"enrollment":407,"conditions":49661,"interventions":49662},"NCT00758004","Bioequivalence Study Of Pediatric Appropriate Formulation",[91],[12981],[13004,49651],{"trials":49664,"activeCount":103},[],{"trials":49666,"activeCount":103},[],{"trials":49668,"activeCount":103},[],{"trials":49670,"activeCount":103},[],{"intervention":12230,"totalTrials":302,"cells":49672},{"EARLY_PHASE1":49673,"PHASE1":49675,"PHASE2":49681,"PHASE3":49683,"PHASE4":49685,"NA":49687},{"trials":49674,"activeCount":103},[],{"trials":49676,"activeCount":103},[49677],{"nctId":12224,"briefTitle":12225,"status":111,"phases":49678,"primaryCompletion":4645,"completion":4645,"start":4665,"enrollment":1509,"conditions":49679,"interventions":49680},[91],[3396],[12193,12229,12230],{"trials":49682,"activeCount":103},[],{"trials":49684,"activeCount":103},[],{"trials":49686,"activeCount":103},[],{"trials":49688,"activeCount":103},[],{"intervention":49690,"totalTrials":302,"cells":49691},"Liraglutide",{"EARLY_PHASE1":49692,"PHASE1":49694,"PHASE2":49704,"PHASE3":49706,"PHASE4":49708,"NA":49710},{"trials":49693,"activeCount":103},[],{"trials":49695,"activeCount":103},[49696],{"nctId":49697,"briefTitle":49698,"status":111,"phases":49699,"primaryCompletion":49700,"completion":49700,"start":49701,"enrollment":2400,"conditions":49702,"interventions":49703},"NCT03041792","Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects",[91],"2018-01-16","2017-02-20",[2761],[49690],{"trials":49705,"activeCount":103},[],{"trials":49707,"activeCount":103},[],{"trials":49709,"activeCount":103},[],{"trials":49711,"activeCount":103},[],{"intervention":7763,"totalTrials":302,"cells":49713},{"EARLY_PHASE1":49714,"PHASE1":49716,"PHASE2":49722,"PHASE3":49724,"PHASE4":49726,"NA":49728},{"trials":49715,"activeCount":103},[],{"trials":49717,"activeCount":103},[49718],{"nctId":7754,"briefTitle":7755,"status":168,"phases":49719,"primaryCompletion":7757,"completion":7758,"start":7759,"enrollment":1487,"conditions":49720,"interventions":49721},[91],[7761,1761,4728,1347],[7763,7731],{"trials":49723,"activeCount":103},[],{"trials":49725,"activeCount":103},[],{"trials":49727,"activeCount":103},[],{"trials":49729,"activeCount":103},[],{"intervention":49731,"totalTrials":302,"cells":49732},"PF06649751, Itraconazole",{"EARLY_PHASE1":49733,"PHASE1":49735,"PHASE2":49745,"PHASE3":49747,"PHASE4":49749,"NA":49751},{"trials":49734,"activeCount":103},[],{"trials":49736,"activeCount":103},[49737],{"nctId":49738,"briefTitle":49739,"status":111,"phases":49740,"primaryCompletion":49741,"completion":49741,"start":49742,"enrollment":1625,"conditions":49743,"interventions":49744},"NCT03121664","A Study To Estimate The Effects Of Itraconazole On Pharmacokinetics Of Pf-06649751 In Healthy Adult Subjects",[91],"2017-09-14","2017-04-07",[16],[49731],{"trials":49746,"activeCount":103},[],{"trials":49748,"activeCount":103},[],{"trials":49750,"activeCount":103},[],{"trials":49752,"activeCount":103},[],{"intervention":49754,"totalTrials":302,"cells":49755},"PF-04287881",{"EARLY_PHASE1":49756,"PHASE1":49758,"PHASE2":49767,"PHASE3":49769,"PHASE4":49771,"NA":49773},{"trials":49757,"activeCount":103},[],{"trials":49759,"activeCount":103},[49760],{"nctId":49761,"briefTitle":49762,"status":111,"phases":49763,"primaryCompletion":4221,"completion":4221,"start":4645,"enrollment":1519,"conditions":49764,"interventions":49766},"NCT00793000","Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults",[91],[49765],"Respiratory Tract Infections",[49754,49754,49754,49754,49754,49754,49754,49754,49754,49754],{"trials":49768,"activeCount":103},[],{"trials":49770,"activeCount":103},[],{"trials":49772,"activeCount":103},[],{"trials":49774,"activeCount":103},[],{"intervention":49776,"totalTrials":302,"cells":49777},"3 mg PF-06412562",{"EARLY_PHASE1":49778,"PHASE1":49780,"PHASE2":49791,"PHASE3":49793,"PHASE4":49795,"NA":49797},{"trials":49779,"activeCount":103},[],{"trials":49781,"activeCount":103},[49782],{"nctId":49783,"briefTitle":49784,"status":111,"phases":49785,"primaryCompletion":605,"completion":605,"start":18769,"enrollment":35,"conditions":49786,"interventions":49787},"NCT01959594","A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers",[91],[16],[49776,49788,49789,49790,49790],"10 mg PF-06412562","25 mg PF-06412562","PF-06412562 TBD mg",{"trials":49792,"activeCount":103},[],{"trials":49794,"activeCount":103},[],{"trials":49796,"activeCount":103},[],{"trials":49798,"activeCount":103},[],{"intervention":49788,"totalTrials":302,"cells":49800},{"EARLY_PHASE1":49801,"PHASE1":49803,"PHASE2":49809,"PHASE3":49811,"PHASE4":49813,"NA":49815},{"trials":49802,"activeCount":103},[],{"trials":49804,"activeCount":103},[49805],{"nctId":49783,"briefTitle":49784,"status":111,"phases":49806,"primaryCompletion":605,"completion":605,"start":18769,"enrollment":35,"conditions":49807,"interventions":49808},[91],[16],[49776,49788,49789,49790,49790],{"trials":49810,"activeCount":103},[],{"trials":49812,"activeCount":103},[],{"trials":49814,"activeCount":103},[],{"trials":49816,"activeCount":103},[],{"intervention":49789,"totalTrials":302,"cells":49818},{"EARLY_PHASE1":49819,"PHASE1":49821,"PHASE2":49827,"PHASE3":49829,"PHASE4":49831,"NA":49833},{"trials":49820,"activeCount":103},[],{"trials":49822,"activeCount":103},[49823],{"nctId":49783,"briefTitle":49784,"status":111,"phases":49824,"primaryCompletion":605,"completion":605,"start":18769,"enrollment":35,"conditions":49825,"interventions":49826},[91],[16],[49776,49788,49789,49790,49790],{"trials":49828,"activeCount":103},[],{"trials":49830,"activeCount":103},[],{"trials":49832,"activeCount":103},[],{"trials":49834,"activeCount":103},[],{"intervention":49790,"totalTrials":302,"cells":49836},{"EARLY_PHASE1":49837,"PHASE1":49839,"PHASE2":49845,"PHASE3":49847,"PHASE4":49849,"NA":49851},{"trials":49838,"activeCount":103},[],{"trials":49840,"activeCount":103},[49841],{"nctId":49783,"briefTitle":49784,"status":111,"phases":49842,"primaryCompletion":605,"completion":605,"start":18769,"enrollment":35,"conditions":49843,"interventions":49844},[91],[16],[49776,49788,49789,49790,49790],{"trials":49846,"activeCount":103},[],{"trials":49848,"activeCount":103},[],{"trials":49850,"activeCount":103},[],{"trials":49852,"activeCount":103},[],{"intervention":49854,"totalTrials":302,"cells":49855},"PF-06263507",{"EARLY_PHASE1":49856,"PHASE1":49858,"PHASE2":49868,"PHASE3":49870,"PHASE4":49872,"NA":49874},{"trials":49857,"activeCount":103},[],{"trials":49859,"activeCount":103},[49860],{"nctId":49861,"briefTitle":49862,"status":168,"phases":49863,"primaryCompletion":49864,"completion":49864,"start":49865,"enrollment":1239,"conditions":49866,"interventions":49867},"NCT01891669","A Study Of PF-06263507 In Patients With Advanced Solid Tumors",[91],"2015-06-29","2013-08-08",[2053,7761,25,8476],[49854,49854],{"trials":49869,"activeCount":103},[],{"trials":49871,"activeCount":103},[],{"trials":49873,"activeCount":103},[],{"trials":49875,"activeCount":103},[],{"intervention":39410,"totalTrials":302,"cells":49877},{"EARLY_PHASE1":49878,"PHASE1":49880,"PHASE2":49886,"PHASE3":49888,"PHASE4":49890,"NA":49892},{"trials":49879,"activeCount":103},[],{"trials":49881,"activeCount":103},[49882],{"nctId":39405,"briefTitle":39406,"status":111,"phases":49883,"primaryCompletion":8154,"completion":8154,"start":8154,"enrollment":1268,"conditions":49884,"interventions":49885},[91],[11904],[39410,39411],{"trials":49887,"activeCount":103},[],{"trials":49889,"activeCount":103},[],{"trials":49891,"activeCount":103},[],{"trials":49893,"activeCount":103},[],{"intervention":17570,"totalTrials":302,"cells":49895},{"EARLY_PHASE1":49896,"PHASE1":49898,"PHASE2":49904,"PHASE3":49906,"PHASE4":49908,"NA":49910},{"trials":49897,"activeCount":103},[],{"trials":49899,"activeCount":103},[49900],{"nctId":17564,"briefTitle":17565,"status":649,"phases":49901,"primaryCompletion":4646,"completion":4646,"start":11014,"enrollment":103,"conditions":49902,"interventions":49903},[91],[17568],[17570,17550,17570,17550],{"trials":49905,"activeCount":103},[],{"trials":49907,"activeCount":103},[],{"trials":49909,"activeCount":103},[],{"trials":49911,"activeCount":103},[],{"intervention":49913,"totalTrials":302,"cells":49914},"PF-06260414",{"EARLY_PHASE1":49915,"PHASE1":49917,"PHASE2":49925,"PHASE3":49927,"PHASE4":49929,"NA":49931},{"trials":49916,"activeCount":103},[],{"trials":49918,"activeCount":103},[49919],{"nctId":49920,"briefTitle":49921,"status":111,"phases":49922,"primaryCompletion":12307,"completion":12307,"start":3324,"enrollment":7388,"conditions":49923,"interventions":49924},"NCT02070939","Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects",[91],[16],[49913,49913,49913],{"trials":49926,"activeCount":103},[],{"trials":49928,"activeCount":103},[],{"trials":49930,"activeCount":103},[],{"trials":49932,"activeCount":103},[],{"intervention":49934,"totalTrials":302,"cells":49935},"Oral PF-06700841 containing 14C microtracer",{"EARLY_PHASE1":49936,"PHASE1":49938,"PHASE2":49949,"PHASE3":49951,"PHASE4":49953,"NA":49955},{"trials":49937,"activeCount":103},[],{"trials":49939,"activeCount":103},[49940],{"nctId":49941,"briefTitle":49942,"status":111,"phases":49943,"primaryCompletion":46310,"completion":46310,"start":18938,"enrollment":2070,"conditions":49944,"interventions":49946},"NCT03770039","Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects",[91],[49945],"Healthy Male Subjects",[49934,49947,49948],"Oral unlabeled PF-06700841","IV 14C-labeled PF-06700841",{"trials":49950,"activeCount":103},[],{"trials":49952,"activeCount":103},[],{"trials":49954,"activeCount":103},[],{"trials":49956,"activeCount":103},[],{"intervention":49947,"totalTrials":302,"cells":49958},{"EARLY_PHASE1":49959,"PHASE1":49961,"PHASE2":49967,"PHASE3":49969,"PHASE4":49971,"NA":49973},{"trials":49960,"activeCount":103},[],{"trials":49962,"activeCount":103},[49963],{"nctId":49941,"briefTitle":49942,"status":111,"phases":49964,"primaryCompletion":46310,"completion":46310,"start":18938,"enrollment":2070,"conditions":49965,"interventions":49966},[91],[49945],[49934,49947,49948],{"trials":49968,"activeCount":103},[],{"trials":49970,"activeCount":103},[],{"trials":49972,"activeCount":103},[],{"trials":49974,"activeCount":103},[],{"intervention":49948,"totalTrials":302,"cells":49976},{"EARLY_PHASE1":49977,"PHASE1":49979,"PHASE2":49985,"PHASE3":49987,"PHASE4":49989,"NA":49991},{"trials":49978,"activeCount":103},[],{"trials":49980,"activeCount":103},[49981],{"nctId":49941,"briefTitle":49942,"status":111,"phases":49982,"primaryCompletion":46310,"completion":46310,"start":18938,"enrollment":2070,"conditions":49983,"interventions":49984},[91],[49945],[49934,49947,49948],{"trials":49986,"activeCount":103},[],{"trials":49988,"activeCount":103},[],{"trials":49990,"activeCount":103},[],{"trials":49992,"activeCount":103},[],{"intervention":49994,"totalTrials":302,"cells":49995},"[11C]PF-06809247",{"EARLY_PHASE1":49996,"PHASE1":49998,"PHASE2":50009,"PHASE3":50011,"PHASE4":50013,"NA":50015},{"trials":49997,"activeCount":103},[],{"trials":49999,"activeCount":103},[50000],{"nctId":50001,"briefTitle":50002,"status":111,"phases":50003,"primaryCompletion":50004,"completion":50004,"start":50005,"enrollment":3659,"conditions":50006,"interventions":50008},"NCT03100136","Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer",[91],"2017-03-10","2016-11-16",[50007],"Neuroinflammation",[49994],{"trials":50010,"activeCount":103},[],{"trials":50012,"activeCount":103},[],{"trials":50014,"activeCount":103},[],{"trials":50016,"activeCount":103},[],{"intervention":50018,"totalTrials":302,"cells":50019},"PF-06804103",{"EARLY_PHASE1":50020,"PHASE1":50022,"PHASE2":50032,"PHASE3":50034,"PHASE4":50036,"NA":50038},{"trials":50021,"activeCount":103},[],{"trials":50023,"activeCount":103},[50024],{"nctId":50025,"briefTitle":50026,"status":168,"phases":50027,"primaryCompletion":9673,"completion":9673,"start":50028,"enrollment":22119,"conditions":50029,"interventions":50030},"NCT03284723","PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors",[91],"2017-11-01",[25],[50018,50031],"PF-06804103 + Palbociclib +Letrozole",{"trials":50033,"activeCount":103},[],{"trials":50035,"activeCount":103},[],{"trials":50037,"activeCount":103},[],{"trials":50039,"activeCount":103},[],{"intervention":50031,"totalTrials":302,"cells":50041},{"EARLY_PHASE1":50042,"PHASE1":50044,"PHASE2":50050,"PHASE3":50052,"PHASE4":50054,"NA":50056},{"trials":50043,"activeCount":103},[],{"trials":50045,"activeCount":103},[50046],{"nctId":50025,"briefTitle":50026,"status":168,"phases":50047,"primaryCompletion":9673,"completion":9673,"start":50028,"enrollment":22119,"conditions":50048,"interventions":50049},[91],[25],[50018,50031],{"trials":50051,"activeCount":103},[],{"trials":50053,"activeCount":103},[],{"trials":50055,"activeCount":103},[],{"trials":50057,"activeCount":103},[],{"intervention":50059,"totalTrials":302,"cells":50060},"PF-07940369",{"EARLY_PHASE1":50061,"PHASE1":50063,"PHASE2":50072,"PHASE3":50074,"PHASE4":50076,"NA":50078},{"trials":50062,"activeCount":103},[],{"trials":50064,"activeCount":103},[50065],{"nctId":50066,"briefTitle":50067,"status":111,"phases":50068,"primaryCompletion":977,"completion":977,"start":50069,"enrollment":1780,"conditions":50070,"interventions":50071},"NCT07514156","A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.",[91],"2025-07-15",[2715],[50059],{"trials":50073,"activeCount":103},[],{"trials":50075,"activeCount":103},[],{"trials":50077,"activeCount":103},[],{"trials":50079,"activeCount":103},[],{"intervention":50081,"totalTrials":302,"cells":50082},"Crizotinib plus VEGF inhibitor combinations",{"EARLY_PHASE1":50083,"PHASE1":50085,"PHASE2":50097,"PHASE3":50099,"PHASE4":50101,"NA":50103},{"trials":50084,"activeCount":103},[],{"trials":50086,"activeCount":103},[50087],{"nctId":50088,"briefTitle":50089,"status":649,"phases":50090,"primaryCompletion":18769,"completion":18769,"start":2883,"enrollment":103,"conditions":50091,"interventions":50092},"NCT01441388","A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",[91],[919,6460,887],[50081,50093,50094,50093,50094,50095,50096],"Crizotinib plus axitinib","Crizotinib plus sunitinib","Crizotinib plus bevacizumab","Crizotinib plus sorafenib",{"trials":50098,"activeCount":103},[],{"trials":50100,"activeCount":103},[],{"trials":50102,"activeCount":103},[],{"trials":50104,"activeCount":103},[],{"intervention":50093,"totalTrials":302,"cells":50106},{"EARLY_PHASE1":50107,"PHASE1":50109,"PHASE2":50115,"PHASE3":50117,"PHASE4":50119,"NA":50121},{"trials":50108,"activeCount":103},[],{"trials":50110,"activeCount":103},[50111],{"nctId":50088,"briefTitle":50089,"status":649,"phases":50112,"primaryCompletion":18769,"completion":18769,"start":2883,"enrollment":103,"conditions":50113,"interventions":50114},[91],[919,6460,887],[50081,50093,50094,50093,50094,50095,50096],{"trials":50116,"activeCount":103},[],{"trials":50118,"activeCount":103},[],{"trials":50120,"activeCount":103},[],{"trials":50122,"activeCount":103},[],{"intervention":50094,"totalTrials":302,"cells":50124},{"EARLY_PHASE1":50125,"PHASE1":50127,"PHASE2":50133,"PHASE3":50135,"PHASE4":50137,"NA":50139},{"trials":50126,"activeCount":103},[],{"trials":50128,"activeCount":103},[50129],{"nctId":50088,"briefTitle":50089,"status":649,"phases":50130,"primaryCompletion":18769,"completion":18769,"start":2883,"enrollment":103,"conditions":50131,"interventions":50132},[91],[919,6460,887],[50081,50093,50094,50093,50094,50095,50096],{"trials":50134,"activeCount":103},[],{"trials":50136,"activeCount":103},[],{"trials":50138,"activeCount":103},[],{"trials":50140,"activeCount":103},[],{"intervention":50095,"totalTrials":302,"cells":50142},{"EARLY_PHASE1":50143,"PHASE1":50145,"PHASE2":50151,"PHASE3":50153,"PHASE4":50155,"NA":50157},{"trials":50144,"activeCount":103},[],{"trials":50146,"activeCount":103},[50147],{"nctId":50088,"briefTitle":50089,"status":649,"phases":50148,"primaryCompletion":18769,"completion":18769,"start":2883,"enrollment":103,"conditions":50149,"interventions":50150},[91],[919,6460,887],[50081,50093,50094,50093,50094,50095,50096],{"trials":50152,"activeCount":103},[],{"trials":50154,"activeCount":103},[],{"trials":50156,"activeCount":103},[],{"trials":50158,"activeCount":103},[],{"intervention":50096,"totalTrials":302,"cells":50160},{"EARLY_PHASE1":50161,"PHASE1":50163,"PHASE2":50169,"PHASE3":50171,"PHASE4":50173,"NA":50175},{"trials":50162,"activeCount":103},[],{"trials":50164,"activeCount":103},[50165],{"nctId":50088,"briefTitle":50089,"status":649,"phases":50166,"primaryCompletion":18769,"completion":18769,"start":2883,"enrollment":103,"conditions":50167,"interventions":50168},[91],[919,6460,887],[50081,50093,50094,50093,50094,50095,50096],{"trials":50170,"activeCount":103},[],{"trials":50172,"activeCount":103},[],{"trials":50174,"activeCount":103},[],{"trials":50176,"activeCount":103},[],{"intervention":50178,"totalTrials":302,"cells":50179},"PF-07852352 Influenza saRNA 1",{"EARLY_PHASE1":50180,"PHASE1":50182,"PHASE2":50200,"PHASE3":50202,"PHASE4":50204,"NA":50206},{"trials":50181,"activeCount":103},[],{"trials":50183,"activeCount":103},[50184],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50187,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50189,"interventions":50190},"NCT05227001","A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza",[91],440,[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],"PF-07836391 Influenza saRNA","PF-07836394 Influenza saRNA","PF-07836395 Influenza saRNA","PF-07836396 Influenza saRNA","PF-07867246 Influenza saRNA","Quadrivalent influenza vaccine","PF-07871987 Influenza saRNA","PF-07914705 Influenza saRNA","PF-07915048 Influenza saRNA",{"trials":50201,"activeCount":103},[],{"trials":50203,"activeCount":103},[],{"trials":50205,"activeCount":103},[],{"trials":50207,"activeCount":103},[],{"intervention":50191,"totalTrials":302,"cells":50209},{"EARLY_PHASE1":50210,"PHASE1":50212,"PHASE2":50218,"PHASE3":50220,"PHASE4":50222,"NA":50224},{"trials":50211,"activeCount":103},[],{"trials":50213,"activeCount":103},[50214],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50215,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50216,"interventions":50217},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50219,"activeCount":103},[],{"trials":50221,"activeCount":103},[],{"trials":50223,"activeCount":103},[],{"trials":50225,"activeCount":103},[],{"intervention":50192,"totalTrials":302,"cells":50227},{"EARLY_PHASE1":50228,"PHASE1":50230,"PHASE2":50236,"PHASE3":50238,"PHASE4":50240,"NA":50242},{"trials":50229,"activeCount":103},[],{"trials":50231,"activeCount":103},[50232],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50233,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50234,"interventions":50235},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50237,"activeCount":103},[],{"trials":50239,"activeCount":103},[],{"trials":50241,"activeCount":103},[],{"trials":50243,"activeCount":103},[],{"intervention":50193,"totalTrials":302,"cells":50245},{"EARLY_PHASE1":50246,"PHASE1":50248,"PHASE2":50254,"PHASE3":50256,"PHASE4":50258,"NA":50260},{"trials":50247,"activeCount":103},[],{"trials":50249,"activeCount":103},[50250],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50251,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50252,"interventions":50253},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50255,"activeCount":103},[],{"trials":50257,"activeCount":103},[],{"trials":50259,"activeCount":103},[],{"trials":50261,"activeCount":103},[],{"intervention":50194,"totalTrials":302,"cells":50263},{"EARLY_PHASE1":50264,"PHASE1":50266,"PHASE2":50272,"PHASE3":50274,"PHASE4":50276,"NA":50278},{"trials":50265,"activeCount":103},[],{"trials":50267,"activeCount":103},[50268],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50269,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50270,"interventions":50271},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50273,"activeCount":103},[],{"trials":50275,"activeCount":103},[],{"trials":50277,"activeCount":103},[],{"trials":50279,"activeCount":103},[],{"intervention":50195,"totalTrials":302,"cells":50281},{"EARLY_PHASE1":50282,"PHASE1":50284,"PHASE2":50290,"PHASE3":50292,"PHASE4":50294,"NA":50296},{"trials":50283,"activeCount":103},[],{"trials":50285,"activeCount":103},[50286],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50287,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50288,"interventions":50289},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50291,"activeCount":103},[],{"trials":50293,"activeCount":103},[],{"trials":50295,"activeCount":103},[],{"trials":50297,"activeCount":103},[],{"intervention":50197,"totalTrials":302,"cells":50299},{"EARLY_PHASE1":50300,"PHASE1":50302,"PHASE2":50308,"PHASE3":50310,"PHASE4":50312,"NA":50314},{"trials":50301,"activeCount":103},[],{"trials":50303,"activeCount":103},[50304],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50305,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50306,"interventions":50307},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50309,"activeCount":103},[],{"trials":50311,"activeCount":103},[],{"trials":50313,"activeCount":103},[],{"trials":50315,"activeCount":103},[],{"intervention":50198,"totalTrials":302,"cells":50317},{"EARLY_PHASE1":50318,"PHASE1":50320,"PHASE2":50326,"PHASE3":50328,"PHASE4":50330,"NA":50332},{"trials":50319,"activeCount":103},[],{"trials":50321,"activeCount":103},[50322],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50323,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50324,"interventions":50325},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50327,"activeCount":103},[],{"trials":50329,"activeCount":103},[],{"trials":50331,"activeCount":103},[],{"trials":50333,"activeCount":103},[],{"intervention":50199,"totalTrials":302,"cells":50335},{"EARLY_PHASE1":50336,"PHASE1":50338,"PHASE2":50344,"PHASE3":50346,"PHASE4":50348,"NA":50350},{"trials":50337,"activeCount":103},[],{"trials":50339,"activeCount":103},[50340],{"nctId":50185,"briefTitle":50186,"status":111,"phases":50341,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":50342,"interventions":50343},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":50345,"activeCount":103},[],{"trials":50347,"activeCount":103},[],{"trials":50349,"activeCount":103},[],{"trials":50351,"activeCount":103},[],{"intervention":50353,"totalTrials":302,"cells":50354},"PF-06293620",{"EARLY_PHASE1":50355,"PHASE1":50357,"PHASE2":50367,"PHASE3":50369,"PHASE4":50371,"NA":50373},{"trials":50356,"activeCount":103},[],{"trials":50358,"activeCount":103},[50359],{"nctId":50360,"briefTitle":50361,"status":111,"phases":50362,"primaryCompletion":50363,"completion":50363,"start":50364,"enrollment":4637,"conditions":50365,"interventions":50366},"NCT02211261","A Phase 1 Single\u002FMultiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus",[91],"2017-01-27","2014-09-15",[12968],[50353,50353,50353,50353,50353,50353,50353,50353,50353],{"trials":50368,"activeCount":103},[],{"trials":50370,"activeCount":103},[],{"trials":50372,"activeCount":103},[],{"trials":50374,"activeCount":103},[],{"intervention":8204,"totalTrials":302,"cells":50376},{"EARLY_PHASE1":50377,"PHASE1":50379,"PHASE2":50385,"PHASE3":50387,"PHASE4":50389,"NA":50391},{"trials":50378,"activeCount":103},[],{"trials":50380,"activeCount":103},[50381],{"nctId":8199,"briefTitle":8200,"status":168,"phases":50382,"primaryCompletion":523,"completion":523,"start":4615,"enrollment":32,"conditions":50383,"interventions":50384},[91],[2053],[8204,8157],{"trials":50386,"activeCount":103},[],{"trials":50388,"activeCount":103},[],{"trials":50390,"activeCount":103},[],{"trials":50392,"activeCount":103},[],{"intervention":50394,"totalTrials":302,"cells":50395},"filibuvir + Oral Contraceptives",{"EARLY_PHASE1":50396,"PHASE1":50398,"PHASE2":50406,"PHASE3":50408,"PHASE4":50410,"NA":50412},{"trials":50397,"activeCount":103},[],{"trials":50399,"activeCount":103},[50400],{"nctId":50401,"briefTitle":50402,"status":111,"phases":50403,"primaryCompletion":4666,"completion":4666,"start":577,"enrollment":562,"conditions":50404,"interventions":50405},"NCT00918476","Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)",[91],[15803],[50394],{"trials":50407,"activeCount":103},[],{"trials":50409,"activeCount":103},[],{"trials":50411,"activeCount":103},[],{"trials":50413,"activeCount":103},[],{"intervention":50415,"totalTrials":302,"cells":50416},"PF-06700841 IR",{"EARLY_PHASE1":50417,"PHASE1":50419,"PHASE2":50430,"PHASE3":50432,"PHASE4":50434,"NA":50436},{"trials":50418,"activeCount":103},[],{"trials":50420,"activeCount":103},[50421],{"nctId":50422,"briefTitle":50423,"status":111,"phases":50424,"primaryCompletion":5907,"completion":5907,"start":3672,"enrollment":1530,"conditions":50425,"interventions":50426},"NCT04580797","Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations",[91],[28],[50415,50427,50428,50429],"PF-06700841 MR1","PF-06700841 MR2","PF-06700841 MR3",{"trials":50431,"activeCount":103},[],{"trials":50433,"activeCount":103},[],{"trials":50435,"activeCount":103},[],{"trials":50437,"activeCount":103},[],{"intervention":50427,"totalTrials":302,"cells":50439},{"EARLY_PHASE1":50440,"PHASE1":50442,"PHASE2":50448,"PHASE3":50450,"PHASE4":50452,"NA":50454},{"trials":50441,"activeCount":103},[],{"trials":50443,"activeCount":103},[50444],{"nctId":50422,"briefTitle":50423,"status":111,"phases":50445,"primaryCompletion":5907,"completion":5907,"start":3672,"enrollment":1530,"conditions":50446,"interventions":50447},[91],[28],[50415,50427,50428,50429],{"trials":50449,"activeCount":103},[],{"trials":50451,"activeCount":103},[],{"trials":50453,"activeCount":103},[],{"trials":50455,"activeCount":103},[],{"intervention":50428,"totalTrials":302,"cells":50457},{"EARLY_PHASE1":50458,"PHASE1":50460,"PHASE2":50466,"PHASE3":50468,"PHASE4":50470,"NA":50472},{"trials":50459,"activeCount":103},[],{"trials":50461,"activeCount":103},[50462],{"nctId":50422,"briefTitle":50423,"status":111,"phases":50463,"primaryCompletion":5907,"completion":5907,"start":3672,"enrollment":1530,"conditions":50464,"interventions":50465},[91],[28],[50415,50427,50428,50429],{"trials":50467,"activeCount":103},[],{"trials":50469,"activeCount":103},[],{"trials":50471,"activeCount":103},[],{"trials":50473,"activeCount":103},[],{"intervention":50429,"totalTrials":302,"cells":50475},{"EARLY_PHASE1":50476,"PHASE1":50478,"PHASE2":50484,"PHASE3":50486,"PHASE4":50488,"NA":50490},{"trials":50477,"activeCount":103},[],{"trials":50479,"activeCount":103},[50480],{"nctId":50422,"briefTitle":50423,"status":111,"phases":50481,"primaryCompletion":5907,"completion":5907,"start":3672,"enrollment":1530,"conditions":50482,"interventions":50483},[91],[28],[50415,50427,50428,50429],{"trials":50485,"activeCount":103},[],{"trials":50487,"activeCount":103},[],{"trials":50489,"activeCount":103},[],{"trials":50491,"activeCount":103},[],{"intervention":50493,"totalTrials":302,"cells":50494},"[14C]lorlatinib",{"EARLY_PHASE1":50495,"PHASE1":50497,"PHASE2":50508,"PHASE3":50510,"PHASE4":50512,"NA":50514},{"trials":50496,"activeCount":103},[],{"trials":50498,"activeCount":103},[50499],{"nctId":50500,"briefTitle":50501,"status":111,"phases":50502,"primaryCompletion":50503,"completion":50504,"start":50505,"enrollment":2070,"conditions":50506,"interventions":50507},"NCT03184168","Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers",[91],"2017-08-07","2017-08-25","2017-07-05",[19],[50493],{"trials":50509,"activeCount":103},[],{"trials":50511,"activeCount":103},[],{"trials":50513,"activeCount":103},[],{"trials":50515,"activeCount":103},[],{"intervention":31093,"totalTrials":302,"cells":50517},{"EARLY_PHASE1":50518,"PHASE1":50520,"PHASE2":50526,"PHASE3":50528,"PHASE4":50530,"NA":50532},{"trials":50519,"activeCount":103},[],{"trials":50521,"activeCount":103},[50522],{"nctId":31088,"briefTitle":31089,"status":111,"phases":50523,"primaryCompletion":12307,"completion":12307,"start":11956,"enrollment":2713,"conditions":50524,"interventions":50525},[91],[16],[31093,31094,31081,31095],{"trials":50527,"activeCount":103},[],{"trials":50529,"activeCount":103},[],{"trials":50531,"activeCount":103},[],{"trials":50533,"activeCount":103},[],{"intervention":31094,"totalTrials":302,"cells":50535},{"EARLY_PHASE1":50536,"PHASE1":50538,"PHASE2":50544,"PHASE3":50546,"PHASE4":50548,"NA":50550},{"trials":50537,"activeCount":103},[],{"trials":50539,"activeCount":103},[50540],{"nctId":31088,"briefTitle":31089,"status":111,"phases":50541,"primaryCompletion":12307,"completion":12307,"start":11956,"enrollment":2713,"conditions":50542,"interventions":50543},[91],[16],[31093,31094,31081,31095],{"trials":50545,"activeCount":103},[],{"trials":50547,"activeCount":103},[],{"trials":50549,"activeCount":103},[],{"trials":50551,"activeCount":103},[],{"intervention":31095,"totalTrials":302,"cells":50553},{"EARLY_PHASE1":50554,"PHASE1":50556,"PHASE2":50562,"PHASE3":50564,"PHASE4":50566,"NA":50568},{"trials":50555,"activeCount":103},[],{"trials":50557,"activeCount":103},[50558],{"nctId":31088,"briefTitle":31089,"status":111,"phases":50559,"primaryCompletion":12307,"completion":12307,"start":11956,"enrollment":2713,"conditions":50560,"interventions":50561},[91],[16],[31093,31094,31081,31095],{"trials":50563,"activeCount":103},[],{"trials":50565,"activeCount":103},[],{"trials":50567,"activeCount":103},[],{"trials":50569,"activeCount":103},[],{"intervention":9731,"totalTrials":302,"cells":50571},{"EARLY_PHASE1":50572,"PHASE1":50574,"PHASE2":50580,"PHASE3":50582,"PHASE4":50584,"NA":50586},{"trials":50573,"activeCount":103},[],{"trials":50575,"activeCount":103},[50576],{"nctId":9724,"briefTitle":9725,"status":111,"phases":50577,"primaryCompletion":9727,"completion":9727,"start":9728,"enrollment":1509,"conditions":50578,"interventions":50579},[91],[28],[9600,9731,9732],{"trials":50581,"activeCount":103},[],{"trials":50583,"activeCount":103},[],{"trials":50585,"activeCount":103},[],{"trials":50587,"activeCount":103},[],{"intervention":9732,"totalTrials":302,"cells":50589},{"EARLY_PHASE1":50590,"PHASE1":50592,"PHASE2":50598,"PHASE3":50600,"PHASE4":50602,"NA":50604},{"trials":50591,"activeCount":103},[],{"trials":50593,"activeCount":103},[50594],{"nctId":9724,"briefTitle":9725,"status":111,"phases":50595,"primaryCompletion":9727,"completion":9727,"start":9728,"enrollment":1509,"conditions":50596,"interventions":50597},[91],[28],[9600,9731,9732],{"trials":50599,"activeCount":103},[],{"trials":50601,"activeCount":103},[],{"trials":50603,"activeCount":103},[],{"trials":50605,"activeCount":103},[],{"intervention":50607,"totalTrials":302,"cells":50608},"zolpidem",{"EARLY_PHASE1":50609,"PHASE1":50611,"PHASE2":50620,"PHASE3":50622,"PHASE4":50624,"NA":50626},{"trials":50610,"activeCount":103},[],{"trials":50612,"activeCount":103},[50613],{"nctId":50614,"briefTitle":50615,"status":111,"phases":50616,"primaryCompletion":4665,"completion":4665,"start":4207,"enrollment":1625,"conditions":50617,"interventions":50619},"NCT00716521","Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers",[91],[50618],"Methodology Study",[50607,50607],{"trials":50621,"activeCount":103},[],{"trials":50623,"activeCount":103},[],{"trials":50625,"activeCount":103},[],{"trials":50627,"activeCount":103},[],{"intervention":40679,"totalTrials":302,"cells":50629},{"EARLY_PHASE1":50630,"PHASE1":50632,"PHASE2":50638,"PHASE3":50640,"PHASE4":50642,"NA":50644},{"trials":50631,"activeCount":103},[],{"trials":50633,"activeCount":103},[50634],{"nctId":40672,"briefTitle":40673,"status":111,"phases":50635,"primaryCompletion":40675,"completion":40675,"start":40676,"enrollment":1268,"conditions":50636,"interventions":50637},[91],[4401],[40679,40680,40681,40682,29324],{"trials":50639,"activeCount":103},[],{"trials":50641,"activeCount":103},[],{"trials":50643,"activeCount":103},[],{"trials":50645,"activeCount":103},[],{"intervention":40680,"totalTrials":302,"cells":50647},{"EARLY_PHASE1":50648,"PHASE1":50650,"PHASE2":50656,"PHASE3":50658,"PHASE4":50660,"NA":50662},{"trials":50649,"activeCount":103},[],{"trials":50651,"activeCount":103},[50652],{"nctId":40672,"briefTitle":40673,"status":111,"phases":50653,"primaryCompletion":40675,"completion":40675,"start":40676,"enrollment":1268,"conditions":50654,"interventions":50655},[91],[4401],[40679,40680,40681,40682,29324],{"trials":50657,"activeCount":103},[],{"trials":50659,"activeCount":103},[],{"trials":50661,"activeCount":103},[],{"trials":50663,"activeCount":103},[],{"intervention":40681,"totalTrials":302,"cells":50665},{"EARLY_PHASE1":50666,"PHASE1":50668,"PHASE2":50674,"PHASE3":50676,"PHASE4":50678,"NA":50680},{"trials":50667,"activeCount":103},[],{"trials":50669,"activeCount":103},[50670],{"nctId":40672,"briefTitle":40673,"status":111,"phases":50671,"primaryCompletion":40675,"completion":40675,"start":40676,"enrollment":1268,"conditions":50672,"interventions":50673},[91],[4401],[40679,40680,40681,40682,29324],{"trials":50675,"activeCount":103},[],{"trials":50677,"activeCount":103},[],{"trials":50679,"activeCount":103},[],{"trials":50681,"activeCount":103},[],{"intervention":40682,"totalTrials":302,"cells":50683},{"EARLY_PHASE1":50684,"PHASE1":50686,"PHASE2":50692,"PHASE3":50694,"PHASE4":50696,"NA":50698},{"trials":50685,"activeCount":103},[],{"trials":50687,"activeCount":103},[50688],{"nctId":40672,"briefTitle":40673,"status":111,"phases":50689,"primaryCompletion":40675,"completion":40675,"start":40676,"enrollment":1268,"conditions":50690,"interventions":50691},[91],[4401],[40679,40680,40681,40682,29324],{"trials":50693,"activeCount":103},[],{"trials":50695,"activeCount":103},[],{"trials":50697,"activeCount":103},[],{"trials":50699,"activeCount":103},[],{"intervention":12480,"totalTrials":302,"cells":50701},{"EARLY_PHASE1":50702,"PHASE1":50704,"PHASE2":50710,"PHASE3":50712,"PHASE4":50714,"NA":50716},{"trials":50703,"activeCount":103},[],{"trials":50705,"activeCount":103},[50706],{"nctId":12475,"briefTitle":12476,"status":168,"phases":50707,"primaryCompletion":4221,"completion":4221,"start":4222,"enrollment":2240,"conditions":50708,"interventions":50709},[91],[16],[12461,12480],{"trials":50711,"activeCount":103},[],{"trials":50713,"activeCount":103},[],{"trials":50715,"activeCount":103},[],{"trials":50717,"activeCount":103},[],{"intervention":50719,"totalTrials":302,"cells":50720},"Oral [14C]PF-06865571",{"EARLY_PHASE1":50721,"PHASE1":50723,"PHASE2":50734,"PHASE3":50736,"PHASE4":50738,"NA":50740},{"trials":50722,"activeCount":103},[],{"trials":50724,"activeCount":103},[50725],{"nctId":50726,"briefTitle":50727,"status":111,"phases":50728,"primaryCompletion":50729,"completion":4358,"start":38746,"enrollment":2070,"conditions":50730,"interventions":50731},"NCT04866225","A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.",[91],"2021-07-11",[28],[50719,50732,50733],"Oral PF-06865571","IV [14C]PF-06865571",{"trials":50735,"activeCount":103},[],{"trials":50737,"activeCount":103},[],{"trials":50739,"activeCount":103},[],{"trials":50741,"activeCount":103},[],{"intervention":50732,"totalTrials":302,"cells":50743},{"EARLY_PHASE1":50744,"PHASE1":50746,"PHASE2":50752,"PHASE3":50754,"PHASE4":50756,"NA":50758},{"trials":50745,"activeCount":103},[],{"trials":50747,"activeCount":103},[50748],{"nctId":50726,"briefTitle":50727,"status":111,"phases":50749,"primaryCompletion":50729,"completion":4358,"start":38746,"enrollment":2070,"conditions":50750,"interventions":50751},[91],[28],[50719,50732,50733],{"trials":50753,"activeCount":103},[],{"trials":50755,"activeCount":103},[],{"trials":50757,"activeCount":103},[],{"trials":50759,"activeCount":103},[],{"intervention":50733,"totalTrials":302,"cells":50761},{"EARLY_PHASE1":50762,"PHASE1":50764,"PHASE2":50770,"PHASE3":50772,"PHASE4":50774,"NA":50776},{"trials":50763,"activeCount":103},[],{"trials":50765,"activeCount":103},[50766],{"nctId":50726,"briefTitle":50727,"status":111,"phases":50767,"primaryCompletion":50729,"completion":4358,"start":38746,"enrollment":2070,"conditions":50768,"interventions":50769},[91],[28],[50719,50732,50733],{"trials":50771,"activeCount":103},[],{"trials":50773,"activeCount":103},[],{"trials":50775,"activeCount":103},[],{"trials":50777,"activeCount":103},[],{"intervention":50779,"totalTrials":302,"cells":50780},"C. difficile vaccine with adjuvant",{"EARLY_PHASE1":50781,"PHASE1":50783,"PHASE2":50795,"PHASE3":50797,"PHASE4":50799,"NA":50801},{"trials":50782,"activeCount":103},[],{"trials":50784,"activeCount":103},[50785],{"nctId":50786,"briefTitle":50787,"status":111,"phases":50788,"primaryCompletion":50789,"completion":50790,"start":50791,"enrollment":2673,"conditions":50792,"interventions":50794},"NCT02052726","A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",[91],"2015-05-02","2015-05-05","2014-01-22",[50793],"Clostridium Difficile",[50779,50779],{"trials":50796,"activeCount":103},[],{"trials":50798,"activeCount":103},[],{"trials":50800,"activeCount":103},[],{"trials":50802,"activeCount":103},[],{"intervention":39655,"totalTrials":302,"cells":50804},{"EARLY_PHASE1":50805,"PHASE1":50807,"PHASE2":50813,"PHASE3":50815,"PHASE4":50817,"NA":50819},{"trials":50806,"activeCount":103},[],{"trials":50808,"activeCount":103},[50809],{"nctId":39650,"briefTitle":39651,"status":111,"phases":50810,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":50811,"interventions":50812},[91],[16],[39655,39656,39657,39634],{"trials":50814,"activeCount":103},[],{"trials":50816,"activeCount":103},[],{"trials":50818,"activeCount":103},[],{"trials":50820,"activeCount":103},[],{"intervention":39656,"totalTrials":302,"cells":50822},{"EARLY_PHASE1":50823,"PHASE1":50825,"PHASE2":50831,"PHASE3":50833,"PHASE4":50835,"NA":50837},{"trials":50824,"activeCount":103},[],{"trials":50826,"activeCount":103},[50827],{"nctId":39650,"briefTitle":39651,"status":111,"phases":50828,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":50829,"interventions":50830},[91],[16],[39655,39656,39657,39634],{"trials":50832,"activeCount":103},[],{"trials":50834,"activeCount":103},[],{"trials":50836,"activeCount":103},[],{"trials":50838,"activeCount":103},[],{"intervention":39657,"totalTrials":302,"cells":50840},{"EARLY_PHASE1":50841,"PHASE1":50843,"PHASE2":50849,"PHASE3":50851,"PHASE4":50853,"NA":50855},{"trials":50842,"activeCount":103},[],{"trials":50844,"activeCount":103},[50845],{"nctId":39650,"briefTitle":39651,"status":111,"phases":50846,"primaryCompletion":523,"completion":523,"start":524,"enrollment":5909,"conditions":50847,"interventions":50848},[91],[16],[39655,39656,39657,39634],{"trials":50850,"activeCount":103},[],{"trials":50852,"activeCount":103},[],{"trials":50854,"activeCount":103},[],{"trials":50856,"activeCount":103},[],{"intervention":7772,"totalTrials":302,"cells":50858},{"EARLY_PHASE1":50859,"PHASE1":50861,"PHASE2":50867,"PHASE3":50869,"PHASE4":50871,"NA":50873},{"trials":50860,"activeCount":103},[],{"trials":50862,"activeCount":103},[50863],{"nctId":7765,"briefTitle":7766,"status":649,"phases":50864,"primaryCompletion":7768,"completion":7768,"start":7769,"enrollment":103,"conditions":50865,"interventions":50866},[91],[5847],[7772,7731],{"trials":50868,"activeCount":103},[],{"trials":50870,"activeCount":103},[],{"trials":50872,"activeCount":103},[],{"trials":50874,"activeCount":103},[],{"intervention":50876,"totalTrials":302,"cells":50877},"AN2728 Ointment",{"EARLY_PHASE1":50878,"PHASE1":50880,"PHASE2":50890,"PHASE3":50892,"PHASE4":50894,"NA":50896},{"trials":50879,"activeCount":103},[],{"trials":50881,"activeCount":103},[50882],{"nctId":50883,"briefTitle":50884,"status":111,"phases":50885,"primaryCompletion":19250,"completion":19250,"start":19262,"enrollment":314,"conditions":50886,"interventions":50888},"NCT01258088","Safety Study of Ointment for the Treatment of Plaque-type Psoriasis",[91],[50887],"Plaque-type Psoriasis",[50876,50889],"AN2728 Vehicle",{"trials":50891,"activeCount":103},[],{"trials":50893,"activeCount":103},[],{"trials":50895,"activeCount":103},[],{"trials":50897,"activeCount":103},[],{"intervention":50889,"totalTrials":302,"cells":50899},{"EARLY_PHASE1":50900,"PHASE1":50902,"PHASE2":50908,"PHASE3":50910,"PHASE4":50912,"NA":50914},{"trials":50901,"activeCount":103},[],{"trials":50903,"activeCount":103},[50904],{"nctId":50883,"briefTitle":50884,"status":111,"phases":50905,"primaryCompletion":19250,"completion":19250,"start":19262,"enrollment":314,"conditions":50906,"interventions":50907},[91],[50887],[50876,50889],{"trials":50909,"activeCount":103},[],{"trials":50911,"activeCount":103},[],{"trials":50913,"activeCount":103},[],{"trials":50915,"activeCount":103},[],{"intervention":50917,"totalTrials":302,"cells":50918},"Prazosin HCl",{"EARLY_PHASE1":50919,"PHASE1":50921,"PHASE2":50931,"PHASE3":50933,"PHASE4":50935,"NA":50937},{"trials":50920,"activeCount":103},[],{"trials":50922,"activeCount":103},[50923],{"nctId":50924,"briefTitle":50925,"status":111,"phases":50926,"primaryCompletion":50927,"completion":3027,"start":50928,"enrollment":6199,"conditions":50929,"interventions":50930},"NCT07231978","A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults",[91],"2026-04-03","2025-11-14",[16],[50917],{"trials":50932,"activeCount":103},[],{"trials":50934,"activeCount":103},[],{"trials":50936,"activeCount":103},[],{"trials":50938,"activeCount":103},[],{"intervention":50940,"totalTrials":302,"cells":50941},"dacomitinib fasted",{"EARLY_PHASE1":50942,"PHASE1":50944,"PHASE2":50954,"PHASE3":50956,"PHASE4":50958,"NA":50960},{"trials":50943,"activeCount":103},[],{"trials":50945,"activeCount":103},[50946],{"nctId":50947,"briefTitle":50948,"status":111,"phases":50949,"primaryCompletion":4590,"completion":4590,"start":3353,"enrollment":1509,"conditions":50950,"interventions":50951},"NCT01702506","Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)",[91],[19],[50940,50952,50953],"dacomitinib fed","dacomitinib+antacid",{"trials":50955,"activeCount":103},[],{"trials":50957,"activeCount":103},[],{"trials":50959,"activeCount":103},[],{"trials":50961,"activeCount":103},[],{"intervention":50952,"totalTrials":302,"cells":50963},{"EARLY_PHASE1":50964,"PHASE1":50966,"PHASE2":50972,"PHASE3":50974,"PHASE4":50976,"NA":50978},{"trials":50965,"activeCount":103},[],{"trials":50967,"activeCount":103},[50968],{"nctId":50947,"briefTitle":50948,"status":111,"phases":50969,"primaryCompletion":4590,"completion":4590,"start":3353,"enrollment":1509,"conditions":50970,"interventions":50971},[91],[19],[50940,50952,50953],{"trials":50973,"activeCount":103},[],{"trials":50975,"activeCount":103},[],{"trials":50977,"activeCount":103},[],{"trials":50979,"activeCount":103},[],{"intervention":50953,"totalTrials":302,"cells":50981},{"EARLY_PHASE1":50982,"PHASE1":50984,"PHASE2":50990,"PHASE3":50992,"PHASE4":50994,"NA":50996},{"trials":50983,"activeCount":103},[],{"trials":50985,"activeCount":103},[50986],{"nctId":50947,"briefTitle":50948,"status":111,"phases":50987,"primaryCompletion":4590,"completion":4590,"start":3353,"enrollment":1509,"conditions":50988,"interventions":50989},[91],[19],[50940,50952,50953],{"trials":50991,"activeCount":103},[],{"trials":50993,"activeCount":103},[],{"trials":50995,"activeCount":103},[],{"trials":50997,"activeCount":103},[],{"intervention":50999,"totalTrials":302,"cells":51000},"CE-326,597",{"EARLY_PHASE1":51001,"PHASE1":51003,"PHASE2":51011,"PHASE3":51013,"PHASE4":51015,"NA":51017},{"trials":51002,"activeCount":103},[],{"trials":51004,"activeCount":103},[51005],{"nctId":51006,"briefTitle":51007,"status":111,"phases":51008,"completion":11291,"start":3853,"enrollment":713,"conditions":51009,"interventions":51010},"NCT00576589","Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones",[91],[2761],[50999],{"trials":51012,"activeCount":103},[],{"trials":51014,"activeCount":103},[],{"trials":51016,"activeCount":103},[],{"trials":51018,"activeCount":103},[],{"intervention":29438,"totalTrials":302,"cells":51020},{"EARLY_PHASE1":51021,"PHASE1":51023,"PHASE2":51029,"PHASE3":51031,"PHASE4":51033,"NA":51035},{"trials":51022,"activeCount":103},[],{"trials":51024,"activeCount":103},[51025],{"nctId":29433,"briefTitle":29434,"status":111,"phases":51026,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":1625,"conditions":51027,"interventions":51028},[91],[22,19],[29426,29426,29426,29426,29426,29426,29438,29438],{"trials":51030,"activeCount":103},[],{"trials":51032,"activeCount":103},[],{"trials":51034,"activeCount":103},[],{"trials":51036,"activeCount":103},[],{"intervention":51038,"totalTrials":302,"cells":51039},"Inotuzumab ozogamicin [CMC-544]",{"EARLY_PHASE1":51040,"PHASE1":51042,"PHASE2":51050,"PHASE3":51052,"PHASE4":51054,"NA":51056},{"trials":51041,"activeCount":103},[],{"trials":51043,"activeCount":103},[51044],{"nctId":51045,"briefTitle":51046,"status":111,"phases":51047,"primaryCompletion":4656,"completion":4656,"start":6458,"enrollment":26401,"conditions":51048,"interventions":51049},"NCT00073749","Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma",[91],[7365],[51038],{"trials":51051,"activeCount":103},[],{"trials":51053,"activeCount":103},[],{"trials":51055,"activeCount":103},[],{"trials":51057,"activeCount":103},[],{"intervention":51059,"totalTrials":302,"cells":51060},"PF-06372865 or Placebo",{"EARLY_PHASE1":51061,"PHASE1":51063,"PHASE2":51072,"PHASE3":51074,"PHASE4":51076,"NA":51078},{"trials":51062,"activeCount":103},[],{"trials":51064,"activeCount":103},[51065],{"nctId":51066,"briefTitle":51067,"status":111,"phases":51068,"primaryCompletion":7971,"completion":7971,"start":1249,"enrollment":8373,"conditions":51069,"interventions":51070},"NCT01951144","A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865",[91],[16],[51059,51059,51059,51071],"PF-06372865 or Placebo or Lorazepam",{"trials":51073,"activeCount":103},[],{"trials":51075,"activeCount":103},[],{"trials":51077,"activeCount":103},[],{"trials":51079,"activeCount":103},[],{"intervention":51071,"totalTrials":302,"cells":51081},{"EARLY_PHASE1":51082,"PHASE1":51084,"PHASE2":51090,"PHASE3":51092,"PHASE4":51094,"NA":51096},{"trials":51083,"activeCount":103},[],{"trials":51085,"activeCount":103},[51086],{"nctId":51066,"briefTitle":51067,"status":111,"phases":51087,"primaryCompletion":7971,"completion":7971,"start":1249,"enrollment":8373,"conditions":51088,"interventions":51089},[91],[16],[51059,51059,51059,51071],{"trials":51091,"activeCount":103},[],{"trials":51093,"activeCount":103},[],{"trials":51095,"activeCount":103},[],{"trials":51097,"activeCount":103},[],{"intervention":51099,"totalTrials":302,"cells":51100},"Palbociclib 75 mg",{"EARLY_PHASE1":51101,"PHASE1":51103,"PHASE2":51114,"PHASE3":51116,"PHASE4":51118,"NA":51120},{"trials":51102,"activeCount":103},[],{"trials":51104,"activeCount":103},[51105],{"nctId":51106,"briefTitle":51107,"status":111,"phases":51108,"primaryCompletion":51109,"completion":51109,"start":51110,"enrollment":5909,"conditions":51111,"interventions":51113},"NCT02334800","A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib",[91],"2016-10-09","2015-03-31",[51112],"Healthy, Hepatic Insufficiency",[51099],{"trials":51115,"activeCount":103},[],{"trials":51117,"activeCount":103},[],{"trials":51119,"activeCount":103},[],{"trials":51121,"activeCount":103},[],{"intervention":51123,"totalTrials":302,"cells":51124},"Zavegepant 10mg",{"EARLY_PHASE1":51125,"PHASE1":51127,"PHASE2":51137,"PHASE3":51139,"PHASE4":51141,"NA":51143},{"trials":51126,"activeCount":103},[],{"trials":51128,"activeCount":103},[51129],{"nctId":51130,"briefTitle":51131,"status":111,"phases":51132,"primaryCompletion":51133,"completion":51133,"start":51134,"enrollment":1268,"conditions":51135,"interventions":51136},"NCT06453356","A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women",[91],"2024-09-26","2024-06-10",[16],[51123],{"trials":51138,"activeCount":103},[],{"trials":51140,"activeCount":103},[],{"trials":51142,"activeCount":103},[],{"trials":51144,"activeCount":103},[],{"intervention":51146,"totalTrials":302,"cells":51147},"Test formulation administered with water",{"EARLY_PHASE1":51148,"PHASE1":51150,"PHASE2":51160,"PHASE3":51162,"PHASE4":51164,"NA":51166},{"trials":51149,"activeCount":103},[],{"trials":51151,"activeCount":103},[51152],{"nctId":51153,"briefTitle":51154,"status":111,"phases":51155,"primaryCompletion":2449,"completion":2449,"start":1700,"enrollment":99,"conditions":51156,"interventions":51157},"NCT01677039","Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation",[91],[16],[51146,51158,51159],"Test formulation administered with 20% ethanol","Test formulation administered with 40% ethanol",{"trials":51161,"activeCount":103},[],{"trials":51163,"activeCount":103},[],{"trials":51165,"activeCount":103},[],{"trials":51167,"activeCount":103},[],{"intervention":51158,"totalTrials":302,"cells":51169},{"EARLY_PHASE1":51170,"PHASE1":51172,"PHASE2":51178,"PHASE3":51180,"PHASE4":51182,"NA":51184},{"trials":51171,"activeCount":103},[],{"trials":51173,"activeCount":103},[51174],{"nctId":51153,"briefTitle":51154,"status":111,"phases":51175,"primaryCompletion":2449,"completion":2449,"start":1700,"enrollment":99,"conditions":51176,"interventions":51177},[91],[16],[51146,51158,51159],{"trials":51179,"activeCount":103},[],{"trials":51181,"activeCount":103},[],{"trials":51183,"activeCount":103},[],{"trials":51185,"activeCount":103},[],{"intervention":51159,"totalTrials":302,"cells":51187},{"EARLY_PHASE1":51188,"PHASE1":51190,"PHASE2":51196,"PHASE3":51198,"PHASE4":51200,"NA":51202},{"trials":51189,"activeCount":103},[],{"trials":51191,"activeCount":103},[51192],{"nctId":51153,"briefTitle":51154,"status":111,"phases":51193,"primaryCompletion":2449,"completion":2449,"start":1700,"enrollment":99,"conditions":51194,"interventions":51195},[91],[16],[51146,51158,51159],{"trials":51197,"activeCount":103},[],{"trials":51199,"activeCount":103},[],{"trials":51201,"activeCount":103},[],{"trials":51203,"activeCount":103},[],{"intervention":27476,"totalTrials":302,"cells":51205},{"EARLY_PHASE1":51206,"PHASE1":51208,"PHASE2":51214,"PHASE3":51216,"PHASE4":51218,"NA":51220},{"trials":51207,"activeCount":103},[],{"trials":51209,"activeCount":103},[51210],{"nctId":27471,"briefTitle":27472,"status":111,"phases":51211,"primaryCompletion":9572,"completion":9572,"start":605,"enrollment":627,"conditions":51212,"interventions":51213},[91],[16],[27476,20094,20094],{"trials":51215,"activeCount":103},[],{"trials":51217,"activeCount":103},[],{"trials":51219,"activeCount":103},[],{"trials":51221,"activeCount":103},[],{"intervention":51223,"totalTrials":302,"cells":51224},"PF-07265803",{"EARLY_PHASE1":51225,"PHASE1":51227,"PHASE2":51236,"PHASE3":51238,"PHASE4":51240,"NA":51242},{"trials":51226,"activeCount":103},[],{"trials":51228,"activeCount":103},[51229],{"nctId":51230,"briefTitle":51231,"status":111,"phases":51232,"primaryCompletion":51233,"completion":51233,"start":28465,"enrollment":2070,"conditions":51234,"interventions":51235},"NCT05286281","A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803",[91],"2022-05-26",[16],[51223],{"trials":51237,"activeCount":103},[],{"trials":51239,"activeCount":103},[],{"trials":51241,"activeCount":103},[],{"trials":51243,"activeCount":103},[],{"intervention":51245,"totalTrials":302,"cells":51246},"PF-06664178",{"EARLY_PHASE1":51247,"PHASE1":51249,"PHASE2":51257,"PHASE3":51259,"PHASE4":51261,"NA":51263},{"trials":51248,"activeCount":103},[],{"trials":51250,"activeCount":103},[51251],{"nctId":51252,"briefTitle":51253,"status":168,"phases":51254,"primaryCompletion":539,"completion":539,"start":7386,"enrollment":1257,"conditions":51255,"interventions":51256},"NCT02122146","A Study Of PF-06664178 In Patients With Advanced Solid Tumors",[91],[2053],[51245,51245],{"trials":51258,"activeCount":103},[],{"trials":51260,"activeCount":103},[],{"trials":51262,"activeCount":103},[],{"trials":51264,"activeCount":103},[],{"intervention":51266,"totalTrials":302,"cells":51267},"Epoetin Hospira SDV",{"EARLY_PHASE1":51268,"PHASE1":51270,"PHASE2":51280,"PHASE3":51282,"PHASE4":51284,"NA":51286},{"trials":51269,"activeCount":103},[],{"trials":51271,"activeCount":103},[51272],{"nctId":51273,"briefTitle":51274,"status":111,"phases":51275,"primaryCompletion":23584,"completion":51276,"start":221,"enrollment":3866,"conditions":51277,"interventions":51278},"NCT03398473","A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects",[91],"2018-05-07",[16],[51266,51279],"Epoetin Hospira MDV",{"trials":51281,"activeCount":103},[],{"trials":51283,"activeCount":103},[],{"trials":51285,"activeCount":103},[],{"trials":51287,"activeCount":103},[],{"intervention":51279,"totalTrials":302,"cells":51289},{"EARLY_PHASE1":51290,"PHASE1":51292,"PHASE2":51298,"PHASE3":51300,"PHASE4":51302,"NA":51304},{"trials":51291,"activeCount":103},[],{"trials":51293,"activeCount":103},[51294],{"nctId":51273,"briefTitle":51274,"status":111,"phases":51295,"primaryCompletion":23584,"completion":51276,"start":221,"enrollment":3866,"conditions":51296,"interventions":51297},[91],[16],[51266,51279],{"trials":51299,"activeCount":103},[],{"trials":51301,"activeCount":103},[],{"trials":51303,"activeCount":103},[],{"trials":51305,"activeCount":103},[],{"intervention":51307,"totalTrials":302,"cells":51308},"TILACEM",{"EARLY_PHASE1":51309,"PHASE1":51311,"PHASE2":51320,"PHASE3":51322,"PHASE4":51324,"NA":51326},{"trials":51310,"activeCount":103},[],{"trials":51312,"activeCount":103},[51313],{"nctId":51314,"briefTitle":51315,"status":111,"phases":51316,"primaryCompletion":586,"completion":586,"start":577,"enrollment":1239,"conditions":51317,"interventions":51318},"NCT01151345","Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. De C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. De C.V.",[91],[16],[51307,51319],"ANGIOTROFIN",{"trials":51321,"activeCount":103},[],{"trials":51323,"activeCount":103},[],{"trials":51325,"activeCount":103},[],{"trials":51327,"activeCount":103},[],{"intervention":51319,"totalTrials":302,"cells":51329},{"EARLY_PHASE1":51330,"PHASE1":51332,"PHASE2":51338,"PHASE3":51340,"PHASE4":51342,"NA":51344},{"trials":51331,"activeCount":103},[],{"trials":51333,"activeCount":103},[51334],{"nctId":51314,"briefTitle":51315,"status":111,"phases":51335,"primaryCompletion":586,"completion":586,"start":577,"enrollment":1239,"conditions":51336,"interventions":51337},[91],[16],[51307,51319],{"trials":51339,"activeCount":103},[],{"trials":51341,"activeCount":103},[],{"trials":51343,"activeCount":103},[],{"trials":51345,"activeCount":103},[],{"intervention":51347,"totalTrials":302,"cells":51348},"PF-00734200",{"EARLY_PHASE1":51349,"PHASE1":51351,"PHASE2":51360,"PHASE3":51362,"PHASE4":51364,"NA":51366},{"trials":51350,"activeCount":103},[],{"trials":51352,"activeCount":103},[51353],{"nctId":51354,"briefTitle":51355,"status":111,"phases":51356,"primaryCompletion":4207,"completion":4207,"start":11609,"enrollment":1780,"conditions":51357,"interventions":51359},"NCT00596518","A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function",[91],[51358],"Renal Insufficiency, Chronic",[51347],{"trials":51361,"activeCount":103},[],{"trials":51363,"activeCount":103},[],{"trials":51365,"activeCount":103},[],{"trials":51367,"activeCount":103},[],{"intervention":51369,"totalTrials":302,"cells":51370},"SU011248; Gemcitabine",{"EARLY_PHASE1":51371,"PHASE1":51373,"PHASE2":51381,"PHASE3":51383,"PHASE4":51385,"NA":51387},{"trials":51372,"activeCount":103},[],{"trials":51374,"activeCount":103},[51375],{"nctId":51376,"briefTitle":51377,"status":111,"phases":51378,"primaryCompletion":11014,"completion":11014,"start":4692,"enrollment":29,"conditions":51379,"interventions":51380},"NCT00615446","A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors",[91],[750],[51369],{"trials":51382,"activeCount":103},[],{"trials":51384,"activeCount":103},[],{"trials":51386,"activeCount":103},[],{"trials":51388,"activeCount":103},[],{"intervention":51390,"totalTrials":302,"cells":51391},"PF-06865571 400 mg Immediate Release (IR) in Fed State",{"EARLY_PHASE1":51392,"PHASE1":51394,"PHASE2":51405,"PHASE3":51407,"PHASE4":51409,"NA":51411},{"trials":51393,"activeCount":103},[],{"trials":51395,"activeCount":103},[51396],{"nctId":51397,"briefTitle":51398,"status":111,"phases":51399,"primaryCompletion":8384,"completion":8384,"start":18628,"enrollment":1268,"conditions":51400,"interventions":51401},"NCT04044053","Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants",[91],[28],[51390,51402,51403,51404],"PF-06865571 50 mg Modified Release (MR) in Fed State","PF-06865571 400 mg MR in Fed State","PF-06865571 400 mg MR in Fasted State",{"trials":51406,"activeCount":103},[],{"trials":51408,"activeCount":103},[],{"trials":51410,"activeCount":103},[],{"trials":51412,"activeCount":103},[],{"intervention":51402,"totalTrials":302,"cells":51414},{"EARLY_PHASE1":51415,"PHASE1":51417,"PHASE2":51423,"PHASE3":51425,"PHASE4":51427,"NA":51429},{"trials":51416,"activeCount":103},[],{"trials":51418,"activeCount":103},[51419],{"nctId":51397,"briefTitle":51398,"status":111,"phases":51420,"primaryCompletion":8384,"completion":8384,"start":18628,"enrollment":1268,"conditions":51421,"interventions":51422},[91],[28],[51390,51402,51403,51404],{"trials":51424,"activeCount":103},[],{"trials":51426,"activeCount":103},[],{"trials":51428,"activeCount":103},[],{"trials":51430,"activeCount":103},[],{"intervention":51403,"totalTrials":302,"cells":51432},{"EARLY_PHASE1":51433,"PHASE1":51435,"PHASE2":51441,"PHASE3":51443,"PHASE4":51445,"NA":51447},{"trials":51434,"activeCount":103},[],{"trials":51436,"activeCount":103},[51437],{"nctId":51397,"briefTitle":51398,"status":111,"phases":51438,"primaryCompletion":8384,"completion":8384,"start":18628,"enrollment":1268,"conditions":51439,"interventions":51440},[91],[28],[51390,51402,51403,51404],{"trials":51442,"activeCount":103},[],{"trials":51444,"activeCount":103},[],{"trials":51446,"activeCount":103},[],{"trials":51448,"activeCount":103},[],{"intervention":51404,"totalTrials":302,"cells":51450},{"EARLY_PHASE1":51451,"PHASE1":51453,"PHASE2":51459,"PHASE3":51461,"PHASE4":51463,"NA":51465},{"trials":51452,"activeCount":103},[],{"trials":51454,"activeCount":103},[51455],{"nctId":51397,"briefTitle":51398,"status":111,"phases":51456,"primaryCompletion":8384,"completion":8384,"start":18628,"enrollment":1268,"conditions":51457,"interventions":51458},[91],[28],[51390,51402,51403,51404],{"trials":51460,"activeCount":103},[],{"trials":51462,"activeCount":103},[],{"trials":51464,"activeCount":103},[],{"trials":51466,"activeCount":103},[],{"intervention":51468,"totalTrials":302,"cells":51469},"Period 1 - Day 1: PF-04965842 administered",{"EARLY_PHASE1":51470,"PHASE1":51472,"PHASE2":51484,"PHASE3":51486,"PHASE4":51488,"NA":51490},{"trials":51471,"activeCount":103},[],{"trials":51473,"activeCount":103},[51474],{"nctId":51475,"briefTitle":51476,"status":111,"phases":51477,"primaryCompletion":51478,"completion":51478,"start":51479,"enrollment":1509,"conditions":51480,"interventions":51481},"NCT03634345","Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.",[91],"2018-12-13","2018-09-12",[1933],[51468,51482,51483],"Period 2: Cohort 1: Fluvoxamine & PF-04965842","Period 2: Cohort 2: Fluconazole & PF-04965842",{"trials":51485,"activeCount":103},[],{"trials":51487,"activeCount":103},[],{"trials":51489,"activeCount":103},[],{"trials":51491,"activeCount":103},[],{"intervention":51482,"totalTrials":302,"cells":51493},{"EARLY_PHASE1":51494,"PHASE1":51496,"PHASE2":51502,"PHASE3":51504,"PHASE4":51506,"NA":51508},{"trials":51495,"activeCount":103},[],{"trials":51497,"activeCount":103},[51498],{"nctId":51475,"briefTitle":51476,"status":111,"phases":51499,"primaryCompletion":51478,"completion":51478,"start":51479,"enrollment":1509,"conditions":51500,"interventions":51501},[91],[1933],[51468,51482,51483],{"trials":51503,"activeCount":103},[],{"trials":51505,"activeCount":103},[],{"trials":51507,"activeCount":103},[],{"trials":51509,"activeCount":103},[],{"intervention":51483,"totalTrials":302,"cells":51511},{"EARLY_PHASE1":51512,"PHASE1":51514,"PHASE2":51520,"PHASE3":51522,"PHASE4":51524,"NA":51526},{"trials":51513,"activeCount":103},[],{"trials":51515,"activeCount":103},[51516],{"nctId":51475,"briefTitle":51476,"status":111,"phases":51517,"primaryCompletion":51478,"completion":51478,"start":51479,"enrollment":1509,"conditions":51518,"interventions":51519},[91],[1933],[51468,51482,51483],{"trials":51521,"activeCount":103},[],{"trials":51523,"activeCount":103},[],{"trials":51525,"activeCount":103},[],{"trials":51527,"activeCount":103},[],{"intervention":7581,"totalTrials":302,"cells":51529},{"EARLY_PHASE1":51530,"PHASE1":51532,"PHASE2":51538,"PHASE3":51540,"PHASE4":51542,"NA":51544},{"trials":51531,"activeCount":103},[],{"trials":51533,"activeCount":103},[51534],{"nctId":7575,"briefTitle":7576,"status":111,"phases":51535,"primaryCompletion":1288,"completion":1288,"start":7578,"enrollment":1509,"conditions":51536,"interventions":51537},[91],[16],[7581,2082,7581,7581,2082,7581],{"trials":51539,"activeCount":103},[],{"trials":51541,"activeCount":103},[],{"trials":51543,"activeCount":103},[],{"trials":51545,"activeCount":103},[],{"intervention":51547,"totalTrials":302,"cells":51548},"RN316",{"EARLY_PHASE1":51549,"PHASE1":51551,"PHASE2":51559,"PHASE3":51561,"PHASE4":51563,"NA":51565},{"trials":51550,"activeCount":103},[],{"trials":51552,"activeCount":103},[51553],{"nctId":51554,"briefTitle":51555,"status":111,"phases":51556,"primaryCompletion":2660,"completion":2660,"start":6016,"enrollment":4369,"conditions":51557,"interventions":51558},"NCT00991159","A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects",[91],[16],[51547],{"trials":51560,"activeCount":103},[],{"trials":51562,"activeCount":103},[],{"trials":51564,"activeCount":103},[],{"trials":51566,"activeCount":103},[],{"intervention":3396,"totalTrials":302,"cells":51568},{"EARLY_PHASE1":51569,"PHASE1":51571,"PHASE2":51579,"PHASE3":51581,"PHASE4":51583,"NA":51585},{"trials":51570,"activeCount":103},[],{"trials":51572,"activeCount":103},[51573],{"nctId":51574,"briefTitle":51575,"status":111,"phases":51576,"primaryCompletion":4646,"completion":4646,"start":4222,"enrollment":562,"conditions":51577,"interventions":51578},"NCT00861458","Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State",[91],[41701],[3396],{"trials":51580,"activeCount":103},[],{"trials":51582,"activeCount":103},[],{"trials":51584,"activeCount":103},[],{"trials":51586,"activeCount":103},[],{"intervention":51588,"totalTrials":302,"cells":51589},"600 mg Ceftaroline fosamil",{"EARLY_PHASE1":51590,"PHASE1":51592,"PHASE2":51600,"PHASE3":51602,"PHASE4":51604,"NA":51606},{"trials":51591,"activeCount":103},[],{"trials":51593,"activeCount":103},[51594],{"nctId":51595,"briefTitle":51596,"status":111,"phases":51597,"primaryCompletion":3345,"completion":3345,"start":540,"enrollment":713,"conditions":51598,"interventions":51599},"NCT01612507","A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects",[91],[19],[51588,51588],{"trials":51601,"activeCount":103},[],{"trials":51603,"activeCount":103},[],{"trials":51605,"activeCount":103},[],{"trials":51607,"activeCount":103},[],{"intervention":19828,"totalTrials":302,"cells":51609},{"EARLY_PHASE1":51610,"PHASE1":51612,"PHASE2":51618,"PHASE3":51620,"PHASE4":51622,"NA":51624},{"trials":51611,"activeCount":103},[],{"trials":51613,"activeCount":103},[51614],{"nctId":19820,"briefTitle":19821,"status":111,"phases":51615,"primaryCompletion":11448,"completion":11448,"start":1700,"enrollment":9553,"conditions":51616,"interventions":51617},[91],[19824,19825],[19827,19511,19828],{"trials":51619,"activeCount":103},[],{"trials":51621,"activeCount":103},[],{"trials":51623,"activeCount":103},[],{"trials":51625,"activeCount":103},[],{"intervention":13447,"totalTrials":302,"cells":51627},{"EARLY_PHASE1":51628,"PHASE1":51630,"PHASE2":51636,"PHASE3":51638,"PHASE4":51640,"NA":51642},{"trials":51629,"activeCount":103},[],{"trials":51631,"activeCount":103},[51632],{"nctId":13440,"briefTitle":13441,"status":111,"phases":51633,"primaryCompletion":8251,"completion":8251,"start":4645,"enrollment":562,"conditions":51634,"interventions":51635},[91],[13444,13445],[13433,13447],{"trials":51637,"activeCount":103},[],{"trials":51639,"activeCount":103},[],{"trials":51641,"activeCount":103},[],{"trials":51643,"activeCount":103},[],{"intervention":51645,"totalTrials":302,"cells":51646},"Oral Bosutinib",{"EARLY_PHASE1":51647,"PHASE1":51649,"PHASE2":51658,"PHASE3":51660,"PHASE4":51662,"NA":51664},{"trials":51648,"activeCount":103},[],{"trials":51650,"activeCount":103},[51651],{"nctId":51652,"briefTitle":51653,"status":111,"phases":51654,"primaryCompletion":11356,"completion":11356,"start":7386,"enrollment":562,"conditions":51655,"interventions":51656},"NCT02192294","Absolute Bioavailability Of Bosutinib",[91],[16],[51645,51657],"Intravenous infusion of bosutinib",{"trials":51659,"activeCount":103},[],{"trials":51661,"activeCount":103},[],{"trials":51663,"activeCount":103},[],{"trials":51665,"activeCount":103},[],{"intervention":51657,"totalTrials":302,"cells":51667},{"EARLY_PHASE1":51668,"PHASE1":51670,"PHASE2":51676,"PHASE3":51678,"PHASE4":51680,"NA":51682},{"trials":51669,"activeCount":103},[],{"trials":51671,"activeCount":103},[51672],{"nctId":51652,"briefTitle":51653,"status":111,"phases":51673,"primaryCompletion":11356,"completion":11356,"start":7386,"enrollment":562,"conditions":51674,"interventions":51675},[91],[16],[51645,51657],{"trials":51677,"activeCount":103},[],{"trials":51679,"activeCount":103},[],{"trials":51681,"activeCount":103},[],{"trials":51683,"activeCount":103},[],{"intervention":13101,"totalTrials":302,"cells":51685},{"EARLY_PHASE1":51686,"PHASE1":51688,"PHASE2":51694,"PHASE3":51696,"PHASE4":51698,"NA":51700},{"trials":51687,"activeCount":103},[],{"trials":51689,"activeCount":103},[51690],{"nctId":13095,"briefTitle":13096,"status":111,"phases":51691,"primaryCompletion":113,"completion":113,"start":2450,"enrollment":3254,"conditions":51692,"interventions":51693},[91],[13099],[13088,13101,13088,13101,13102,13101],{"trials":51695,"activeCount":103},[],{"trials":51697,"activeCount":103},[],{"trials":51699,"activeCount":103},[],{"trials":51701,"activeCount":103},[],{"intervention":13102,"totalTrials":302,"cells":51703},{"EARLY_PHASE1":51704,"PHASE1":51706,"PHASE2":51712,"PHASE3":51714,"PHASE4":51716,"NA":51718},{"trials":51705,"activeCount":103},[],{"trials":51707,"activeCount":103},[51708],{"nctId":13095,"briefTitle":13096,"status":111,"phases":51709,"primaryCompletion":113,"completion":113,"start":2450,"enrollment":3254,"conditions":51710,"interventions":51711},[91],[13099],[13088,13101,13088,13101,13102,13101],{"trials":51713,"activeCount":103},[],{"trials":51715,"activeCount":103},[],{"trials":51717,"activeCount":103},[],{"trials":51719,"activeCount":103},[],{"intervention":38471,"totalTrials":302,"cells":51721},{"EARLY_PHASE1":51722,"PHASE1":51724,"PHASE2":51730,"PHASE3":51732,"PHASE4":51734,"NA":51736},{"trials":51723,"activeCount":103},[],{"trials":51725,"activeCount":103},[51726],{"nctId":38466,"briefTitle":38467,"status":111,"phases":51727,"primaryCompletion":113,"completion":113,"start":2883,"enrollment":6245,"conditions":51728,"interventions":51729},[91],[37],[38429,38429,38429,38471],{"trials":51731,"activeCount":103},[],{"trials":51733,"activeCount":103},[],{"trials":51735,"activeCount":103},[],{"trials":51737,"activeCount":103},[],{"intervention":51739,"totalTrials":302,"cells":51740},"C. difficile vaccine",{"EARLY_PHASE1":51741,"PHASE1":51743,"PHASE2":51752,"PHASE3":51754,"PHASE4":51756,"NA":51758},{"trials":51742,"activeCount":103},[],{"trials":51744,"activeCount":103},[51745],{"nctId":51746,"briefTitle":51747,"status":111,"phases":51748,"primaryCompletion":1248,"completion":1248,"start":1700,"enrollment":7124,"conditions":51749,"interventions":51750},"NCT01706367","Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years",[91],[18320],[51739,51751,51739,51751,51739,51751],"C. difficile vaccine +adjuvant",{"trials":51753,"activeCount":103},[],{"trials":51755,"activeCount":103},[],{"trials":51757,"activeCount":103},[],{"trials":51759,"activeCount":103},[],{"intervention":51751,"totalTrials":302,"cells":51761},{"EARLY_PHASE1":51762,"PHASE1":51764,"PHASE2":51770,"PHASE3":51772,"PHASE4":51774,"NA":51776},{"trials":51763,"activeCount":103},[],{"trials":51765,"activeCount":103},[51766],{"nctId":51746,"briefTitle":51747,"status":111,"phases":51767,"primaryCompletion":1248,"completion":1248,"start":1700,"enrollment":7124,"conditions":51768,"interventions":51769},[91],[18320],[51739,51751,51739,51751,51739,51751],{"trials":51771,"activeCount":103},[],{"trials":51773,"activeCount":103},[],{"trials":51775,"activeCount":103},[],{"trials":51777,"activeCount":103},[],{"intervention":51779,"totalTrials":302,"cells":51780},"CVX-060",{"EARLY_PHASE1":51781,"PHASE1":51783,"PHASE2":51791,"PHASE3":51793,"PHASE4":51795,"NA":51797},{"trials":51782,"activeCount":103},[],{"trials":51784,"activeCount":103},[51785],{"nctId":51786,"briefTitle":51787,"status":111,"phases":51788,"primaryCompletion":523,"completion":523,"start":3853,"enrollment":3229,"conditions":51789,"interventions":51790},"NCT00879684","Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors",[91],[553,2053,943,5950,44597],[51779],{"trials":51792,"activeCount":103},[],{"trials":51794,"activeCount":103},[],{"trials":51796,"activeCount":103},[],{"trials":51798,"activeCount":103},[],{"intervention":51800,"totalTrials":302,"cells":51801},"PF-06818883",{"EARLY_PHASE1":51802,"PHASE1":51804,"PHASE2":51814,"PHASE3":51816,"PHASE4":51818,"NA":51820},{"trials":51803,"activeCount":103},[],{"trials":51805,"activeCount":103},[51806],{"nctId":51807,"briefTitle":51808,"status":168,"phases":51809,"primaryCompletion":51810,"completion":51810,"start":51811,"enrollment":1780,"conditions":51812,"interventions":51813},"NCT03020784","Safety and Tolerability of PF-06818883 in Healthy Subjects",[91],"2017-06-13","2016-11-11",[16],[51800],{"trials":51815,"activeCount":103},[],{"trials":51817,"activeCount":103},[],{"trials":51819,"activeCount":103},[],{"trials":51821,"activeCount":103},[],{"intervention":3406,"totalTrials":302,"cells":51823},{"EARLY_PHASE1":51824,"PHASE1":51826,"PHASE2":51832,"PHASE3":51834,"PHASE4":51836,"NA":51838},{"trials":51825,"activeCount":103},[],{"trials":51827,"activeCount":103},[51828],{"nctId":3399,"briefTitle":3400,"status":111,"phases":51829,"primaryCompletion":3402,"completion":3402,"start":3403,"enrollment":1268,"conditions":51830,"interventions":51831},[91],[19],[3173,3406],{"trials":51833,"activeCount":103},[],{"trials":51835,"activeCount":103},[],{"trials":51837,"activeCount":103},[],{"trials":51839,"activeCount":103},[],{"intervention":51841,"totalTrials":302,"cells":51842},"PF-03758309",{"EARLY_PHASE1":51843,"PHASE1":51845,"PHASE2":51853,"PHASE3":51855,"PHASE4":51857,"NA":51859},{"trials":51844,"activeCount":103},[],{"trials":51846,"activeCount":103},[51847],{"nctId":51848,"briefTitle":51849,"status":168,"phases":51850,"primaryCompletion":2883,"completion":2883,"start":4833,"enrollment":472,"conditions":51851,"interventions":51852},"NCT00932126","This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors",[91],[553],[51841],{"trials":51854,"activeCount":103},[],{"trials":51856,"activeCount":103},[],{"trials":51858,"activeCount":103},[],{"trials":51860,"activeCount":103},[],{"intervention":19800,"totalTrials":302,"cells":51862},{"EARLY_PHASE1":51863,"PHASE1":51865,"PHASE2":51871,"PHASE3":51873,"PHASE4":51875,"NA":51877},{"trials":51864,"activeCount":103},[],{"trials":51866,"activeCount":103},[51867],{"nctId":19794,"briefTitle":19795,"status":649,"phases":51868,"primaryCompletion":19797,"completion":19797,"start":4557,"enrollment":103,"conditions":51869,"interventions":51870},[91],[3396],[9427,19800],{"trials":51872,"activeCount":103},[],{"trials":51874,"activeCount":103},[],{"trials":51876,"activeCount":103},[],{"trials":51878,"activeCount":103},[],{"intervention":51880,"totalTrials":302,"cells":51881},"PH797804",{"EARLY_PHASE1":51882,"PHASE1":51884,"PHASE2":51892,"PHASE3":51894,"PHASE4":51896,"NA":51898},{"trials":51883,"activeCount":103},[],{"trials":51885,"activeCount":103},[51886],{"nctId":51887,"briefTitle":51888,"status":649,"phases":51889,"primaryCompletion":4222,"completion":11014,"start":4608,"enrollment":103,"conditions":51890,"interventions":51891},"NCT00827515","Relative Bioavailability and Food Effect Study",[91],[34],[51880,51880,51880,51880],{"trials":51893,"activeCount":103},[],{"trials":51895,"activeCount":103},[],{"trials":51897,"activeCount":103},[],{"trials":51899,"activeCount":103},[],{"intervention":51901,"totalTrials":302,"cells":51902},"Glasdegib single 100 mg dose in normal healthy subjects",{"EARLY_PHASE1":51903,"PHASE1":51905,"PHASE2":51917,"PHASE3":51919,"PHASE4":51921,"NA":51923},{"trials":51904,"activeCount":103},[],{"trials":51906,"activeCount":103},[51907],{"nctId":51908,"briefTitle":51909,"status":111,"phases":51910,"primaryCompletion":51911,"completion":5807,"start":51912,"enrollment":597,"conditions":51913,"interventions":51914},"NCT03596567","Glasdegib Renal Impairment Study",[91],"2018-08-28","2018-05-17",[352],[51901,51915,51916],"Glasdegib single 100 mg dose in moderate renal impairment subjects","Glasdegib single 100 mg dose in severe renal impairment subjects",{"trials":51918,"activeCount":103},[],{"trials":51920,"activeCount":103},[],{"trials":51922,"activeCount":103},[],{"trials":51924,"activeCount":103},[],{"intervention":51915,"totalTrials":302,"cells":51926},{"EARLY_PHASE1":51927,"PHASE1":51929,"PHASE2":51935,"PHASE3":51937,"PHASE4":51939,"NA":51941},{"trials":51928,"activeCount":103},[],{"trials":51930,"activeCount":103},[51931],{"nctId":51908,"briefTitle":51909,"status":111,"phases":51932,"primaryCompletion":51911,"completion":5807,"start":51912,"enrollment":597,"conditions":51933,"interventions":51934},[91],[352],[51901,51915,51916],{"trials":51936,"activeCount":103},[],{"trials":51938,"activeCount":103},[],{"trials":51940,"activeCount":103},[],{"trials":51942,"activeCount":103},[],{"intervention":51916,"totalTrials":302,"cells":51944},{"EARLY_PHASE1":51945,"PHASE1":51947,"PHASE2":51953,"PHASE3":51955,"PHASE4":51957,"NA":51959},{"trials":51946,"activeCount":103},[],{"trials":51948,"activeCount":103},[51949],{"nctId":51908,"briefTitle":51909,"status":111,"phases":51950,"primaryCompletion":51911,"completion":5807,"start":51912,"enrollment":597,"conditions":51951,"interventions":51952},[91],[352],[51901,51915,51916],{"trials":51954,"activeCount":103},[],{"trials":51956,"activeCount":103},[],{"trials":51958,"activeCount":103},[],{"trials":51960,"activeCount":103},[],{"intervention":51962,"totalTrials":302,"cells":51963},"PF-05175157 or Placebo",{"EARLY_PHASE1":51964,"PHASE1":51966,"PHASE2":51974,"PHASE3":51976,"PHASE4":51978,"NA":51980},{"trials":51965,"activeCount":103},[],{"trials":51967,"activeCount":103},[51968],{"nctId":51969,"briefTitle":51970,"status":111,"phases":51971,"primaryCompletion":11170,"completion":11170,"start":8252,"enrollment":4818,"conditions":51972,"interventions":51973},"NCT01274663","A Study Of PF-05175157 In Healthy Volunteers",[91],[37],[51962,51962,51962,51962,51962,51962,51962],{"trials":51975,"activeCount":103},[],{"trials":51977,"activeCount":103},[],{"trials":51979,"activeCount":103},[],{"trials":51981,"activeCount":103},[],{"intervention":1876,"totalTrials":302,"cells":51983},{"EARLY_PHASE1":51984,"PHASE1":51986,"PHASE2":51992,"PHASE3":51994,"PHASE4":51996,"NA":51998},{"trials":51985,"activeCount":103},[],{"trials":51987,"activeCount":103},[51988],{"nctId":1869,"briefTitle":1870,"status":111,"phases":51989,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":51990,"interventions":51991},[91],[19],[1862,1876,1877,1878,1879,1880,1881,1882],{"trials":51993,"activeCount":103},[],{"trials":51995,"activeCount":103},[],{"trials":51997,"activeCount":103},[],{"trials":51999,"activeCount":103},[],{"intervention":1877,"totalTrials":302,"cells":52001},{"EARLY_PHASE1":52002,"PHASE1":52004,"PHASE2":52010,"PHASE3":52012,"PHASE4":52014,"NA":52016},{"trials":52003,"activeCount":103},[],{"trials":52005,"activeCount":103},[52006],{"nctId":1869,"briefTitle":1870,"status":111,"phases":52007,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":52008,"interventions":52009},[91],[19],[1862,1876,1877,1878,1879,1880,1881,1882],{"trials":52011,"activeCount":103},[],{"trials":52013,"activeCount":103},[],{"trials":52015,"activeCount":103},[],{"trials":52017,"activeCount":103},[],{"intervention":1878,"totalTrials":302,"cells":52019},{"EARLY_PHASE1":52020,"PHASE1":52022,"PHASE2":52028,"PHASE3":52030,"PHASE4":52032,"NA":52034},{"trials":52021,"activeCount":103},[],{"trials":52023,"activeCount":103},[52024],{"nctId":1869,"briefTitle":1870,"status":111,"phases":52025,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":52026,"interventions":52027},[91],[19],[1862,1876,1877,1878,1879,1880,1881,1882],{"trials":52029,"activeCount":103},[],{"trials":52031,"activeCount":103},[],{"trials":52033,"activeCount":103},[],{"trials":52035,"activeCount":103},[],{"intervention":1879,"totalTrials":302,"cells":52037},{"EARLY_PHASE1":52038,"PHASE1":52040,"PHASE2":52046,"PHASE3":52048,"PHASE4":52050,"NA":52052},{"trials":52039,"activeCount":103},[],{"trials":52041,"activeCount":103},[52042],{"nctId":1869,"briefTitle":1870,"status":111,"phases":52043,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":52044,"interventions":52045},[91],[19],[1862,1876,1877,1878,1879,1880,1881,1882],{"trials":52047,"activeCount":103},[],{"trials":52049,"activeCount":103},[],{"trials":52051,"activeCount":103},[],{"trials":52053,"activeCount":103},[],{"intervention":1880,"totalTrials":302,"cells":52055},{"EARLY_PHASE1":52056,"PHASE1":52058,"PHASE2":52064,"PHASE3":52066,"PHASE4":52068,"NA":52070},{"trials":52057,"activeCount":103},[],{"trials":52059,"activeCount":103},[52060],{"nctId":1869,"briefTitle":1870,"status":111,"phases":52061,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":52062,"interventions":52063},[91],[19],[1862,1876,1877,1878,1879,1880,1881,1882],{"trials":52065,"activeCount":103},[],{"trials":52067,"activeCount":103},[],{"trials":52069,"activeCount":103},[],{"trials":52071,"activeCount":103},[],{"intervention":1881,"totalTrials":302,"cells":52073},{"EARLY_PHASE1":52074,"PHASE1":52076,"PHASE2":52082,"PHASE3":52084,"PHASE4":52086,"NA":52088},{"trials":52075,"activeCount":103},[],{"trials":52077,"activeCount":103},[52078],{"nctId":1869,"briefTitle":1870,"status":111,"phases":52079,"primaryCompletion":1872,"completion":1872,"start":1873,"enrollment":99,"conditions":52080,"interventions":52081},[91],[19],[1862,1876,1877,1878,1879,1880,1881,1882],{"trials":52083,"activeCount":103},[],{"trials":52085,"activeCount":103},[],{"trials":52087,"activeCount":103},[],{"trials":52089,"activeCount":103},[],{"intervention":52091,"totalTrials":302,"cells":52092},"PF-07321332 Dose 1",{"EARLY_PHASE1":52093,"PHASE1":52095,"PHASE2":52109,"PHASE3":52111,"PHASE4":52113,"NA":52115},{"trials":52094,"activeCount":103},[],{"trials":52096,"activeCount":103},[52097],{"nctId":52098,"briefTitle":52099,"status":111,"phases":52100,"primaryCompletion":10000,"completion":10000,"start":52101,"enrollment":27035,"conditions":52102,"interventions":52103},"NCT04756531","STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS",[91],"2021-02-11",[28],[52091,52104,52105,52106,52107,52108],"PF-07321332 Dose 2","PF-07321332 Dose 3","PF-07321332 Dose 4","PF-07321332 Dose 5","PF-07321332 Dose 4 or Placebo",{"trials":52110,"activeCount":103},[],{"trials":52112,"activeCount":103},[],{"trials":52114,"activeCount":103},[],{"trials":52116,"activeCount":103},[],{"intervention":52104,"totalTrials":302,"cells":52118},{"EARLY_PHASE1":52119,"PHASE1":52121,"PHASE2":52127,"PHASE3":52129,"PHASE4":52131,"NA":52133},{"trials":52120,"activeCount":103},[],{"trials":52122,"activeCount":103},[52123],{"nctId":52098,"briefTitle":52099,"status":111,"phases":52124,"primaryCompletion":10000,"completion":10000,"start":52101,"enrollment":27035,"conditions":52125,"interventions":52126},[91],[28],[52091,52104,52105,52106,52107,52108],{"trials":52128,"activeCount":103},[],{"trials":52130,"activeCount":103},[],{"trials":52132,"activeCount":103},[],{"trials":52134,"activeCount":103},[],{"intervention":52105,"totalTrials":302,"cells":52136},{"EARLY_PHASE1":52137,"PHASE1":52139,"PHASE2":52145,"PHASE3":52147,"PHASE4":52149,"NA":52151},{"trials":52138,"activeCount":103},[],{"trials":52140,"activeCount":103},[52141],{"nctId":52098,"briefTitle":52099,"status":111,"phases":52142,"primaryCompletion":10000,"completion":10000,"start":52101,"enrollment":27035,"conditions":52143,"interventions":52144},[91],[28],[52091,52104,52105,52106,52107,52108],{"trials":52146,"activeCount":103},[],{"trials":52148,"activeCount":103},[],{"trials":52150,"activeCount":103},[],{"trials":52152,"activeCount":103},[],{"intervention":52106,"totalTrials":302,"cells":52154},{"EARLY_PHASE1":52155,"PHASE1":52157,"PHASE2":52163,"PHASE3":52165,"PHASE4":52167,"NA":52169},{"trials":52156,"activeCount":103},[],{"trials":52158,"activeCount":103},[52159],{"nctId":52098,"briefTitle":52099,"status":111,"phases":52160,"primaryCompletion":10000,"completion":10000,"start":52101,"enrollment":27035,"conditions":52161,"interventions":52162},[91],[28],[52091,52104,52105,52106,52107,52108],{"trials":52164,"activeCount":103},[],{"trials":52166,"activeCount":103},[],{"trials":52168,"activeCount":103},[],{"trials":52170,"activeCount":103},[],{"intervention":52107,"totalTrials":302,"cells":52172},{"EARLY_PHASE1":52173,"PHASE1":52175,"PHASE2":52181,"PHASE3":52183,"PHASE4":52185,"NA":52187},{"trials":52174,"activeCount":103},[],{"trials":52176,"activeCount":103},[52177],{"nctId":52098,"briefTitle":52099,"status":111,"phases":52178,"primaryCompletion":10000,"completion":10000,"start":52101,"enrollment":27035,"conditions":52179,"interventions":52180},[91],[28],[52091,52104,52105,52106,52107,52108],{"trials":52182,"activeCount":103},[],{"trials":52184,"activeCount":103},[],{"trials":52186,"activeCount":103},[],{"trials":52188,"activeCount":103},[],{"intervention":52108,"totalTrials":302,"cells":52190},{"EARLY_PHASE1":52191,"PHASE1":52193,"PHASE2":52199,"PHASE3":52201,"PHASE4":52203,"NA":52205},{"trials":52192,"activeCount":103},[],{"trials":52194,"activeCount":103},[52195],{"nctId":52098,"briefTitle":52099,"status":111,"phases":52196,"primaryCompletion":10000,"completion":10000,"start":52101,"enrollment":27035,"conditions":52197,"interventions":52198},[91],[28],[52091,52104,52105,52106,52107,52108],{"trials":52200,"activeCount":103},[],{"trials":52202,"activeCount":103},[],{"trials":52204,"activeCount":103},[],{"trials":52206,"activeCount":103},[],{"intervention":3208,"totalTrials":302,"cells":52208},{"EARLY_PHASE1":52209,"PHASE1":52211,"PHASE2":52217,"PHASE3":52219,"PHASE4":52221,"NA":52223},{"trials":52210,"activeCount":103},[],{"trials":52212,"activeCount":103},[52213],{"nctId":3197,"briefTitle":3198,"status":111,"phases":52214,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":52215,"interventions":52216},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"trials":52218,"activeCount":103},[],{"trials":52220,"activeCount":103},[],{"trials":52222,"activeCount":103},[],{"trials":52224,"activeCount":103},[],{"intervention":3211,"totalTrials":302,"cells":52226},{"EARLY_PHASE1":52227,"PHASE1":52229,"PHASE2":52235,"PHASE3":52237,"PHASE4":52239,"NA":52241},{"trials":52228,"activeCount":103},[],{"trials":52230,"activeCount":103},[52231],{"nctId":3197,"briefTitle":3198,"status":111,"phases":52232,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":52233,"interventions":52234},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"trials":52236,"activeCount":103},[],{"trials":52238,"activeCount":103},[],{"trials":52240,"activeCount":103},[],{"trials":52242,"activeCount":103},[],{"intervention":3212,"totalTrials":302,"cells":52244},{"EARLY_PHASE1":52245,"PHASE1":52247,"PHASE2":52253,"PHASE3":52255,"PHASE4":52257,"NA":52259},{"trials":52246,"activeCount":103},[],{"trials":52248,"activeCount":103},[52249],{"nctId":3197,"briefTitle":3198,"status":111,"phases":52250,"primaryCompletion":1807,"completion":3200,"start":3201,"enrollment":3202,"conditions":52251,"interventions":52252},[91],[553,3204],[3206,3207,3208,3209,1989,3210,3211,343,341,3212],{"trials":52254,"activeCount":103},[],{"trials":52256,"activeCount":103},[],{"trials":52258,"activeCount":103},[],{"trials":52260,"activeCount":103},[],{"intervention":39348,"totalTrials":302,"cells":52262},{"EARLY_PHASE1":52263,"PHASE1":52265,"PHASE2":52271,"PHASE3":52273,"PHASE4":52275,"NA":52277},{"trials":52264,"activeCount":103},[],{"trials":52266,"activeCount":103},[52267],{"nctId":39341,"briefTitle":39342,"status":168,"phases":52268,"primaryCompletion":39344,"completion":39344,"start":39345,"enrollment":13892,"conditions":52269,"interventions":52270},[91],[11998],[39348,39349,39350,39309,39351],{"trials":52272,"activeCount":103},[],{"trials":52274,"activeCount":103},[],{"trials":52276,"activeCount":103},[],{"trials":52278,"activeCount":103},[],{"intervention":39349,"totalTrials":302,"cells":52280},{"EARLY_PHASE1":52281,"PHASE1":52283,"PHASE2":52289,"PHASE3":52291,"PHASE4":52293,"NA":52295},{"trials":52282,"activeCount":103},[],{"trials":52284,"activeCount":103},[52285],{"nctId":39341,"briefTitle":39342,"status":168,"phases":52286,"primaryCompletion":39344,"completion":39344,"start":39345,"enrollment":13892,"conditions":52287,"interventions":52288},[91],[11998],[39348,39349,39350,39309,39351],{"trials":52290,"activeCount":103},[],{"trials":52292,"activeCount":103},[],{"trials":52294,"activeCount":103},[],{"trials":52296,"activeCount":103},[],{"intervention":39350,"totalTrials":302,"cells":52298},{"EARLY_PHASE1":52299,"PHASE1":52301,"PHASE2":52307,"PHASE3":52309,"PHASE4":52311,"NA":52313},{"trials":52300,"activeCount":103},[],{"trials":52302,"activeCount":103},[52303],{"nctId":39341,"briefTitle":39342,"status":168,"phases":52304,"primaryCompletion":39344,"completion":39344,"start":39345,"enrollment":13892,"conditions":52305,"interventions":52306},[91],[11998],[39348,39349,39350,39309,39351],{"trials":52308,"activeCount":103},[],{"trials":52310,"activeCount":103},[],{"trials":52312,"activeCount":103},[],{"trials":52314,"activeCount":103},[],{"intervention":39351,"totalTrials":302,"cells":52316},{"EARLY_PHASE1":52317,"PHASE1":52319,"PHASE2":52325,"PHASE3":52327,"PHASE4":52329,"NA":52331},{"trials":52318,"activeCount":103},[],{"trials":52320,"activeCount":103},[52321],{"nctId":39341,"briefTitle":39342,"status":168,"phases":52322,"primaryCompletion":39344,"completion":39344,"start":39345,"enrollment":13892,"conditions":52323,"interventions":52324},[91],[11998],[39348,39349,39350,39309,39351],{"trials":52326,"activeCount":103},[],{"trials":52328,"activeCount":103},[],{"trials":52330,"activeCount":103},[],{"trials":52332,"activeCount":103},[],{"intervention":52334,"totalTrials":302,"cells":52335},"PF-05190457 or Placebo",{"EARLY_PHASE1":52336,"PHASE1":52338,"PHASE2":52346,"PHASE3":52348,"PHASE4":52350,"NA":52352},{"trials":52337,"activeCount":103},[],{"trials":52339,"activeCount":103},[52340],{"nctId":52341,"briefTitle":52342,"status":168,"phases":52343,"primaryCompletion":3334,"completion":3334,"start":3313,"enrollment":472,"conditions":52344,"interventions":52345},"NCT01372163","A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients",[91],[37],[52334,52334,52334,52334,52334,52334,52334],{"trials":52347,"activeCount":103},[],{"trials":52349,"activeCount":103},[],{"trials":52351,"activeCount":103},[],{"trials":52353,"activeCount":103},[],{"intervention":52355,"totalTrials":302,"cells":52356},"Oral Drug Formulation of PD-0332991",{"EARLY_PHASE1":52357,"PHASE1":52359,"PHASE2":52368,"PHASE3":52370,"PHASE4":52372,"NA":52374},{"trials":52358,"activeCount":103},[],{"trials":52360,"activeCount":103},[52361],{"nctId":52362,"briefTitle":52363,"status":111,"phases":52364,"primaryCompletion":13117,"completion":13117,"start":6198,"enrollment":562,"conditions":52365,"interventions":52366},"NCT01802476","A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)",[91],[16],[52355,52367],"Intravenous Formulation of PD-0332991",{"trials":52369,"activeCount":103},[],{"trials":52371,"activeCount":103},[],{"trials":52373,"activeCount":103},[],{"trials":52375,"activeCount":103},[],{"intervention":52367,"totalTrials":302,"cells":52377},{"EARLY_PHASE1":52378,"PHASE1":52380,"PHASE2":52386,"PHASE3":52388,"PHASE4":52390,"NA":52392},{"trials":52379,"activeCount":103},[],{"trials":52381,"activeCount":103},[52382],{"nctId":52362,"briefTitle":52363,"status":111,"phases":52383,"primaryCompletion":13117,"completion":13117,"start":6198,"enrollment":562,"conditions":52384,"interventions":52385},[91],[16],[52355,52367],{"trials":52387,"activeCount":103},[],{"trials":52389,"activeCount":103},[],{"trials":52391,"activeCount":103},[],{"trials":52393,"activeCount":103},[],{"intervention":4413,"totalTrials":302,"cells":52395},{"EARLY_PHASE1":52396,"PHASE1":52398,"PHASE2":52404,"PHASE3":52406,"PHASE4":52408,"NA":52410},{"trials":52397,"activeCount":103},[],{"trials":52399,"activeCount":103},[52400],{"nctId":4406,"briefTitle":4407,"status":111,"phases":52401,"primaryCompletion":4409,"completion":4409,"start":4410,"enrollment":1268,"conditions":52402,"interventions":52403},[91],[16],[4388,4413],{"trials":52405,"activeCount":103},[],{"trials":52407,"activeCount":103},[],{"trials":52409,"activeCount":103},[],{"trials":52411,"activeCount":103},[],{"intervention":2182,"totalTrials":302,"cells":52413},{"EARLY_PHASE1":52414,"PHASE1":52416,"PHASE2":52422,"PHASE3":52424,"PHASE4":52426,"NA":52428},{"trials":52415,"activeCount":103},[],{"trials":52417,"activeCount":103},[52418],{"nctId":2170,"briefTitle":2171,"status":168,"phases":52419,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":2175,"conditions":52420,"interventions":52421},[91],[25,2177,2178,1798,2179,2180,1028,919,891],[2182,63],{"trials":52423,"activeCount":103},[],{"trials":52425,"activeCount":103},[],{"trials":52427,"activeCount":103},[],{"trials":52429,"activeCount":103},[],{"intervention":41209,"totalTrials":302,"cells":52431},{"EARLY_PHASE1":52432,"PHASE1":52434,"PHASE2":52440,"PHASE3":52442,"PHASE4":52444,"NA":52446},{"trials":52433,"activeCount":103},[],{"trials":52435,"activeCount":103},[52436],{"nctId":41200,"briefTitle":41201,"status":111,"phases":52437,"primaryCompletion":3601,"completion":3313,"start":10923,"enrollment":41203,"conditions":52438,"interventions":52439},[91],[19825,41205,41206,41207,34314],[40714,41209,41210],{"trials":52441,"activeCount":103},[],{"trials":52443,"activeCount":103},[],{"trials":52445,"activeCount":103},[],{"trials":52447,"activeCount":103},[],{"intervention":41210,"totalTrials":302,"cells":52449},{"EARLY_PHASE1":52450,"PHASE1":52452,"PHASE2":52458,"PHASE3":52460,"PHASE4":52462,"NA":52464},{"trials":52451,"activeCount":103},[],{"trials":52453,"activeCount":103},[52454],{"nctId":41200,"briefTitle":41201,"status":111,"phases":52455,"primaryCompletion":3601,"completion":3313,"start":10923,"enrollment":41203,"conditions":52456,"interventions":52457},[91],[19825,41205,41206,41207,34314],[40714,41209,41210],{"trials":52459,"activeCount":103},[],{"trials":52461,"activeCount":103},[],{"trials":52463,"activeCount":103},[],{"trials":52465,"activeCount":103},[],{"intervention":52467,"totalTrials":302,"cells":52468},"Myrin P Forte",{"EARLY_PHASE1":52469,"PHASE1":52471,"PHASE2":52480,"PHASE3":52482,"PHASE4":52484,"NA":52486},{"trials":52470,"activeCount":103},[],{"trials":52472,"activeCount":103},[52473],{"nctId":52474,"briefTitle":52475,"status":111,"phases":52476,"primaryCompletion":4531,"completion":4531,"start":3313,"enrollment":1530,"conditions":52477,"interventions":52478},"NCT01399788","A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults",[91],[19],[52467,52479],"Single drug references",{"trials":52481,"activeCount":103},[],{"trials":52483,"activeCount":103},[],{"trials":52485,"activeCount":103},[],{"trials":52487,"activeCount":103},[],{"intervention":52479,"totalTrials":302,"cells":52489},{"EARLY_PHASE1":52490,"PHASE1":52492,"PHASE2":52498,"PHASE3":52500,"PHASE4":52502,"NA":52504},{"trials":52491,"activeCount":103},[],{"trials":52493,"activeCount":103},[52494],{"nctId":52474,"briefTitle":52475,"status":111,"phases":52495,"primaryCompletion":4531,"completion":4531,"start":3313,"enrollment":1530,"conditions":52496,"interventions":52497},[91],[19],[52467,52479],{"trials":52499,"activeCount":103},[],{"trials":52501,"activeCount":103},[],{"trials":52503,"activeCount":103},[],{"trials":52505,"activeCount":103},[],{"intervention":52507,"totalTrials":302,"cells":52508},"PF-06881894 by on-body injector",{"EARLY_PHASE1":52509,"PHASE1":52511,"PHASE2":52522,"PHASE3":52524,"PHASE4":52526,"NA":52528},{"trials":52510,"activeCount":103},[],{"trials":52512,"activeCount":103},[52513],{"nctId":52514,"briefTitle":52515,"status":111,"phases":52516,"primaryCompletion":52517,"completion":52517,"start":52518,"enrollment":31105,"conditions":52519,"interventions":52520},"NCT05194579","Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe",[91],"2022-08-10","2022-02-10",[19],[52507,52521],"PF-06881894 by prefilled syringe",{"trials":52523,"activeCount":103},[],{"trials":52525,"activeCount":103},[],{"trials":52527,"activeCount":103},[],{"trials":52529,"activeCount":103},[],{"intervention":52521,"totalTrials":302,"cells":52531},{"EARLY_PHASE1":52532,"PHASE1":52534,"PHASE2":52540,"PHASE3":52542,"PHASE4":52544,"NA":52546},{"trials":52533,"activeCount":103},[],{"trials":52535,"activeCount":103},[52536],{"nctId":52514,"briefTitle":52515,"status":111,"phases":52537,"primaryCompletion":52517,"completion":52517,"start":52518,"enrollment":31105,"conditions":52538,"interventions":52539},[91],[19],[52507,52521],{"trials":52541,"activeCount":103},[],{"trials":52543,"activeCount":103},[],{"trials":52545,"activeCount":103},[],{"trials":52547,"activeCount":103},[],{"intervention":52549,"totalTrials":302,"cells":52550},"[14C] PF-04449913",{"EARLY_PHASE1":52551,"PHASE1":52553,"PHASE2":52561,"PHASE3":52563,"PHASE4":52565,"NA":52567},{"trials":52552,"activeCount":103},[],{"trials":52554,"activeCount":103},[52555],{"nctId":52556,"briefTitle":52557,"status":111,"phases":52558,"primaryCompletion":1288,"completion":1288,"start":652,"enrollment":2070,"conditions":52559,"interventions":52560},"NCT02110342","A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body",[91],[16],[52549],{"trials":52562,"activeCount":103},[],{"trials":52564,"activeCount":103},[],{"trials":52566,"activeCount":103},[],{"trials":52568,"activeCount":103},[],{"intervention":52570,"totalTrials":302,"cells":52571},"Tasocitinib (CP-690,55) plus Ketoconazole",{"EARLY_PHASE1":52572,"PHASE1":52574,"PHASE2":52582,"PHASE3":52584,"PHASE4":52586,"NA":52588},{"trials":52573,"activeCount":103},[],{"trials":52575,"activeCount":103},[52576],{"nctId":52577,"briefTitle":52578,"status":111,"phases":52579,"primaryCompletion":560,"completion":560,"start":560,"enrollment":1268,"conditions":52580,"interventions":52581},"NCT01202240","Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers",[91],[16],[52570],{"trials":52583,"activeCount":103},[],{"trials":52585,"activeCount":103},[],{"trials":52587,"activeCount":103},[],{"trials":52589,"activeCount":103},[],{"intervention":52591,"totalTrials":302,"cells":52592},"PF-06414300",{"EARLY_PHASE1":52593,"PHASE1":52595,"PHASE2":52605,"PHASE3":52607,"PHASE4":52609,"NA":52611},{"trials":52594,"activeCount":103},[],{"trials":52596,"activeCount":103},[52597],{"nctId":52598,"briefTitle":52599,"status":111,"phases":52600,"primaryCompletion":52601,"completion":52601,"start":52602,"enrollment":4818,"conditions":52603,"interventions":52604},"NCT06659250","A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy Adults",[91],"2025-08-22","2024-09-27",[28],[52591],{"trials":52606,"activeCount":103},[],{"trials":52608,"activeCount":103},[],{"trials":52610,"activeCount":103},[],{"trials":52612,"activeCount":103},[],{"intervention":52614,"totalTrials":302,"cells":52615},"PH-797804 material sparing",{"EARLY_PHASE1":52616,"PHASE1":52618,"PHASE2":52628,"PHASE3":52630,"PHASE4":52632,"NA":52634},{"trials":52617,"activeCount":103},[],{"trials":52619,"activeCount":103},[52620],{"nctId":52621,"briefTitle":52622,"status":111,"phases":52623,"primaryCompletion":524,"completion":524,"start":8252,"enrollment":597,"conditions":52624,"interventions":52625},"NCT01226693","A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804",[91],[16],[52614,52626,52626,52614,52614,52627,52627,52614,52627,52626,52626,52627],"PH-797804 Phase2b\u002F3 with sodium lauryl sulphate","PH-797804 Phase2b\u002F3 without sodium lauryl sulphate",{"trials":52629,"activeCount":103},[],{"trials":52631,"activeCount":103},[],{"trials":52633,"activeCount":103},[],{"trials":52635,"activeCount":103},[],{"intervention":52626,"totalTrials":302,"cells":52637},{"EARLY_PHASE1":52638,"PHASE1":52640,"PHASE2":52646,"PHASE3":52648,"PHASE4":52650,"NA":52652},{"trials":52639,"activeCount":103},[],{"trials":52641,"activeCount":103},[52642],{"nctId":52621,"briefTitle":52622,"status":111,"phases":52643,"primaryCompletion":524,"completion":524,"start":8252,"enrollment":597,"conditions":52644,"interventions":52645},[91],[16],[52614,52626,52626,52614,52614,52627,52627,52614,52627,52626,52626,52627],{"trials":52647,"activeCount":103},[],{"trials":52649,"activeCount":103},[],{"trials":52651,"activeCount":103},[],{"trials":52653,"activeCount":103},[],{"intervention":52627,"totalTrials":302,"cells":52655},{"EARLY_PHASE1":52656,"PHASE1":52658,"PHASE2":52664,"PHASE3":52666,"PHASE4":52668,"NA":52670},{"trials":52657,"activeCount":103},[],{"trials":52659,"activeCount":103},[52660],{"nctId":52621,"briefTitle":52622,"status":111,"phases":52661,"primaryCompletion":524,"completion":524,"start":8252,"enrollment":597,"conditions":52662,"interventions":52663},[91],[16],[52614,52626,52626,52614,52614,52627,52627,52614,52627,52626,52626,52627],{"trials":52665,"activeCount":103},[],{"trials":52667,"activeCount":103},[],{"trials":52669,"activeCount":103},[],{"trials":52671,"activeCount":103},[],{"intervention":52673,"totalTrials":302,"cells":52674},"80 mg PF-06473871",{"EARLY_PHASE1":52675,"PHASE1":52677,"PHASE2":52688,"PHASE3":52690,"PHASE4":52692,"NA":52694},{"trials":52676,"activeCount":103},[],{"trials":52678,"activeCount":103},[52679],{"nctId":52680,"briefTitle":52681,"status":111,"phases":52682,"primaryCompletion":13117,"completion":13117,"start":3345,"enrollment":4259,"conditions":52683,"interventions":52684},"NCT01753791","Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults",[91],[16],[52673,52685,52686,52687],"160 mg PF-06473871","320 mg PF-06473871","480 mg PF-06473871",{"trials":52689,"activeCount":103},[],{"trials":52691,"activeCount":103},[],{"trials":52693,"activeCount":103},[],{"trials":52695,"activeCount":103},[],{"intervention":52685,"totalTrials":302,"cells":52697},{"EARLY_PHASE1":52698,"PHASE1":52700,"PHASE2":52706,"PHASE3":52708,"PHASE4":52710,"NA":52712},{"trials":52699,"activeCount":103},[],{"trials":52701,"activeCount":103},[52702],{"nctId":52680,"briefTitle":52681,"status":111,"phases":52703,"primaryCompletion":13117,"completion":13117,"start":3345,"enrollment":4259,"conditions":52704,"interventions":52705},[91],[16],[52673,52685,52686,52687],{"trials":52707,"activeCount":103},[],{"trials":52709,"activeCount":103},[],{"trials":52711,"activeCount":103},[],{"trials":52713,"activeCount":103},[],{"intervention":52686,"totalTrials":302,"cells":52715},{"EARLY_PHASE1":52716,"PHASE1":52718,"PHASE2":52724,"PHASE3":52726,"PHASE4":52728,"NA":52730},{"trials":52717,"activeCount":103},[],{"trials":52719,"activeCount":103},[52720],{"nctId":52680,"briefTitle":52681,"status":111,"phases":52721,"primaryCompletion":13117,"completion":13117,"start":3345,"enrollment":4259,"conditions":52722,"interventions":52723},[91],[16],[52673,52685,52686,52687],{"trials":52725,"activeCount":103},[],{"trials":52727,"activeCount":103},[],{"trials":52729,"activeCount":103},[],{"trials":52731,"activeCount":103},[],{"intervention":52687,"totalTrials":302,"cells":52733},{"EARLY_PHASE1":52734,"PHASE1":52736,"PHASE2":52742,"PHASE3":52744,"PHASE4":52746,"NA":52748},{"trials":52735,"activeCount":103},[],{"trials":52737,"activeCount":103},[52738],{"nctId":52680,"briefTitle":52681,"status":111,"phases":52739,"primaryCompletion":13117,"completion":13117,"start":3345,"enrollment":4259,"conditions":52740,"interventions":52741},[91],[16],[52673,52685,52686,52687],{"trials":52743,"activeCount":103},[],{"trials":52745,"activeCount":103},[],{"trials":52747,"activeCount":103},[],{"trials":52749,"activeCount":103},[],{"intervention":52751,"totalTrials":302,"cells":52752},"Revatio",{"EARLY_PHASE1":52753,"PHASE1":52755,"PHASE2":52763,"PHASE3":52765,"PHASE4":52767,"NA":52769},{"trials":52754,"activeCount":103},[],{"trials":52756,"activeCount":103},[52757],{"nctId":52758,"briefTitle":52759,"status":111,"phases":52760,"primaryCompletion":4833,"completion":4833,"start":4833,"enrollment":597,"conditions":52761,"interventions":52762},"NCT01027117","A Relative Bioavailability Study of Revatio for the Crushed Tablets, Extemporaneously Prepared Formulation, and the Intact Tablets at 20 mg Dose in Healthy Volunteers",[91],[16],[52751,52751,52751],{"trials":52764,"activeCount":103},[],{"trials":52766,"activeCount":103},[],{"trials":52768,"activeCount":103},[],{"trials":52770,"activeCount":103},[],{"intervention":52772,"totalTrials":302,"cells":52773},"Simvastatin\u002FPF-03882845",{"EARLY_PHASE1":52774,"PHASE1":52776,"PHASE2":52784,"PHASE3":52786,"PHASE4":52788,"NA":52790},{"trials":52775,"activeCount":103},[],{"trials":52777,"activeCount":103},[52778],{"nctId":52779,"briefTitle":52780,"status":111,"phases":52781,"primaryCompletion":9544,"completion":9544,"start":4531,"enrollment":562,"conditions":52782,"interventions":52783},"NCT01445860","Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics",[91],[40898],[52772],{"trials":52785,"activeCount":103},[],{"trials":52787,"activeCount":103},[],{"trials":52789,"activeCount":103},[],{"trials":52791,"activeCount":103},[],{"intervention":52793,"totalTrials":302,"cells":52794},"PD-0360324",{"EARLY_PHASE1":52795,"PHASE1":52797,"PHASE2":52806,"PHASE3":52808,"PHASE4":52810,"NA":52812},{"trials":52796,"activeCount":103},[],{"trials":52798,"activeCount":103},[52799],{"nctId":52800,"briefTitle":52801,"status":168,"phases":52802,"primaryCompletion":18769,"completion":18769,"start":570,"enrollment":5909,"conditions":52803,"interventions":52805},"NCT01470313","A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus",[91],[52804],"Cutaneous Lupus Erythematosus",[52793],{"trials":52807,"activeCount":103},[],{"trials":52809,"activeCount":103},[],{"trials":52811,"activeCount":103},[],{"trials":52813,"activeCount":103},[],{"intervention":52815,"totalTrials":302,"cells":52816},"PF-04531083 or Placebo",{"EARLY_PHASE1":52817,"PHASE1":52819,"PHASE2":52827,"PHASE3":52829,"PHASE4":52831,"NA":52833},{"trials":52818,"activeCount":103},[],{"trials":52820,"activeCount":103},[52821],{"nctId":52822,"briefTitle":52823,"status":111,"phases":52824,"primaryCompletion":11988,"completion":4206,"start":6016,"enrollment":35,"conditions":52825,"interventions":52826},"NCT01012310","Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects",[91],[19],[52815,52815,52815,52815],{"trials":52828,"activeCount":103},[],{"trials":52830,"activeCount":103},[],{"trials":52832,"activeCount":103},[],{"trials":52834,"activeCount":103},[],{"intervention":52836,"totalTrials":302,"cells":52837},"PF-06671008",{"EARLY_PHASE1":52838,"PHASE1":52840,"PHASE2":52849,"PHASE3":52851,"PHASE4":52853,"NA":52855},{"trials":52839,"activeCount":103},[],{"trials":52841,"activeCount":103},[52842],{"nctId":52843,"briefTitle":52844,"status":168,"phases":52845,"primaryCompletion":29074,"completion":29074,"start":52846,"enrollment":5909,"conditions":52847,"interventions":52848},"NCT02659631","PF-06671008 Dose Escalation Study in Advanced Solid Tumors",[91],"2016-04-28",[2053],[52836,52836],{"trials":52850,"activeCount":103},[],{"trials":52852,"activeCount":103},[],{"trials":52854,"activeCount":103},[],{"trials":52856,"activeCount":103},[],{"intervention":52858,"totalTrials":302,"cells":52859},"CP 690,550 oral solutions",{"EARLY_PHASE1":52860,"PHASE1":52862,"PHASE2":52870,"PHASE3":52872,"PHASE4":52874,"NA":52876},{"trials":52861,"activeCount":103},[],{"trials":52863,"activeCount":103},[52864],{"nctId":52865,"briefTitle":52866,"status":111,"phases":52867,"primaryCompletion":3642,"completion":3642,"start":3642,"enrollment":578,"conditions":52868,"interventions":52869},"NCT01023100","A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers",[91],[4514],[52858],{"trials":52871,"activeCount":103},[],{"trials":52873,"activeCount":103},[],{"trials":52875,"activeCount":103},[],{"trials":52877,"activeCount":103},[],{"intervention":27339,"totalTrials":302,"cells":52879},{"EARLY_PHASE1":52880,"PHASE1":52882,"PHASE2":52888,"PHASE3":52890,"PHASE4":52892,"NA":52894},{"trials":52881,"activeCount":103},[],{"trials":52883,"activeCount":103},[52884],{"nctId":27334,"briefTitle":27335,"status":111,"phases":52885,"primaryCompletion":561,"completion":561,"start":586,"enrollment":35,"conditions":52886,"interventions":52887},[91],[16],[27339,27339,11486,11486,27340,27340,27341,27341],{"trials":52889,"activeCount":103},[],{"trials":52891,"activeCount":103},[],{"trials":52893,"activeCount":103},[],{"trials":52895,"activeCount":103},[],{"intervention":27340,"totalTrials":302,"cells":52897},{"EARLY_PHASE1":52898,"PHASE1":52900,"PHASE2":52906,"PHASE3":52908,"PHASE4":52910,"NA":52912},{"trials":52899,"activeCount":103},[],{"trials":52901,"activeCount":103},[52902],{"nctId":27334,"briefTitle":27335,"status":111,"phases":52903,"primaryCompletion":561,"completion":561,"start":586,"enrollment":35,"conditions":52904,"interventions":52905},[91],[16],[27339,27339,11486,11486,27340,27340,27341,27341],{"trials":52907,"activeCount":103},[],{"trials":52909,"activeCount":103},[],{"trials":52911,"activeCount":103},[],{"trials":52913,"activeCount":103},[],{"intervention":27341,"totalTrials":302,"cells":52915},{"EARLY_PHASE1":52916,"PHASE1":52918,"PHASE2":52924,"PHASE3":52926,"PHASE4":52928,"NA":52930},{"trials":52917,"activeCount":103},[],{"trials":52919,"activeCount":103},[52920],{"nctId":27334,"briefTitle":27335,"status":111,"phases":52921,"primaryCompletion":561,"completion":561,"start":586,"enrollment":35,"conditions":52922,"interventions":52923},[91],[16],[27339,27339,11486,11486,27340,27340,27341,27341],{"trials":52925,"activeCount":103},[],{"trials":52927,"activeCount":103},[],{"trials":52929,"activeCount":103},[],{"trials":52931,"activeCount":103},[],{"intervention":52933,"totalTrials":302,"cells":52934},"CP-690,550 or Placebo",{"EARLY_PHASE1":52935,"PHASE1":52937,"PHASE2":52946,"PHASE3":52948,"PHASE4":52950,"NA":52952},{"trials":52936,"activeCount":103},[],{"trials":52938,"activeCount":103},[52939],{"nctId":52940,"briefTitle":52941,"status":111,"phases":52942,"primaryCompletion":4590,"completion":18128,"start":3334,"enrollment":52943,"conditions":52944,"interventions":52945},"NCT01484561","A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis",[91],148,[4514],[52933],{"trials":52947,"activeCount":103},[],{"trials":52949,"activeCount":103},[],{"trials":52951,"activeCount":103},[],{"trials":52953,"activeCount":103},[],{"intervention":52955,"totalTrials":302,"cells":52956},"PD-0332991 alone",{"EARLY_PHASE1":52957,"PHASE1":52959,"PHASE2":52970,"PHASE3":52972,"PHASE4":52974,"NA":52976},{"trials":52958,"activeCount":103},[],{"trials":52960,"activeCount":103},[52961],{"nctId":52962,"briefTitle":52963,"status":111,"phases":52964,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":2713,"conditions":52965,"interventions":52966},"NCT01821066","A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers",[91],[16],[52955,52967,52968,52969],"Tamoxifen 60 mg","Tamoxifen 20 mg","PD-0332991 combination",{"trials":52971,"activeCount":103},[],{"trials":52973,"activeCount":103},[],{"trials":52975,"activeCount":103},[],{"trials":52977,"activeCount":103},[],{"intervention":52967,"totalTrials":302,"cells":52979},{"EARLY_PHASE1":52980,"PHASE1":52982,"PHASE2":52988,"PHASE3":52990,"PHASE4":52992,"NA":52994},{"trials":52981,"activeCount":103},[],{"trials":52983,"activeCount":103},[52984],{"nctId":52962,"briefTitle":52963,"status":111,"phases":52985,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":2713,"conditions":52986,"interventions":52987},[91],[16],[52955,52967,52968,52969],{"trials":52989,"activeCount":103},[],{"trials":52991,"activeCount":103},[],{"trials":52993,"activeCount":103},[],{"trials":52995,"activeCount":103},[],{"intervention":52968,"totalTrials":302,"cells":52997},{"EARLY_PHASE1":52998,"PHASE1":53000,"PHASE2":53006,"PHASE3":53008,"PHASE4":53010,"NA":53012},{"trials":52999,"activeCount":103},[],{"trials":53001,"activeCount":103},[53002],{"nctId":52962,"briefTitle":52963,"status":111,"phases":53003,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":2713,"conditions":53004,"interventions":53005},[91],[16],[52955,52967,52968,52969],{"trials":53007,"activeCount":103},[],{"trials":53009,"activeCount":103},[],{"trials":53011,"activeCount":103},[],{"trials":53013,"activeCount":103},[],{"intervention":52969,"totalTrials":302,"cells":53015},{"EARLY_PHASE1":53016,"PHASE1":53018,"PHASE2":53024,"PHASE3":53026,"PHASE4":53028,"NA":53030},{"trials":53017,"activeCount":103},[],{"trials":53019,"activeCount":103},[53020],{"nctId":52962,"briefTitle":52963,"status":111,"phases":53021,"primaryCompletion":6207,"completion":6207,"start":6208,"enrollment":2713,"conditions":53022,"interventions":53023},[91],[16],[52955,52967,52968,52969],{"trials":53025,"activeCount":103},[],{"trials":53027,"activeCount":103},[],{"trials":53029,"activeCount":103},[],{"trials":53031,"activeCount":103},[],{"intervention":53033,"totalTrials":302,"cells":53034},"Drug: PF-07923568",{"EARLY_PHASE1":53035,"PHASE1":53037,"PHASE2":53045,"PHASE3":53047,"PHASE4":53049,"NA":53051},{"trials":53036,"activeCount":103},[],{"trials":53038,"activeCount":103},[53039],{"nctId":53040,"briefTitle":53041,"status":111,"phases":53042,"primaryCompletion":40375,"completion":40375,"start":17088,"enrollment":314,"conditions":53043,"interventions":53044},"NCT06037031","A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function",[91],[352],[53033],{"trials":53046,"activeCount":103},[],{"trials":53048,"activeCount":103},[],{"trials":53050,"activeCount":103},[],{"trials":53052,"activeCount":103},[],{"intervention":26820,"totalTrials":302,"cells":53054},{"EARLY_PHASE1":53055,"PHASE1":53057,"PHASE2":53063,"PHASE3":53065,"PHASE4":53067,"NA":53069},{"trials":53056,"activeCount":103},[],{"trials":53058,"activeCount":103},[53059],{"nctId":26815,"briefTitle":26816,"status":111,"phases":53060,"primaryCompletion":5970,"completion":5970,"start":17651,"enrollment":2070,"conditions":53061,"interventions":53062},[91],[16],[6305,26820],{"trials":53064,"activeCount":103},[],{"trials":53066,"activeCount":103},[],{"trials":53068,"activeCount":103},[],{"trials":53070,"activeCount":103},[],{"intervention":53072,"totalTrials":302,"cells":53073},"PF-04605412",{"EARLY_PHASE1":53074,"PHASE1":53076,"PHASE2":53084,"PHASE3":53086,"PHASE4":53088,"NA":53090},{"trials":53075,"activeCount":103},[],{"trials":53077,"activeCount":103},[53078],{"nctId":53079,"briefTitle":53080,"status":168,"phases":53081,"primaryCompletion":4590,"completion":4590,"start":4833,"enrollment":5987,"conditions":53082,"interventions":53083},"NCT00915278","A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors",[91],[17380],[53072],{"trials":53085,"activeCount":103},[],{"trials":53087,"activeCount":103},[],{"trials":53089,"activeCount":103},[],{"trials":53091,"activeCount":103},[],{"intervention":28578,"totalTrials":302,"cells":53093},{"EARLY_PHASE1":53094,"PHASE1":53096,"PHASE2":53102,"PHASE3":53104,"PHASE4":53106,"NA":53108},{"trials":53095,"activeCount":103},[],{"trials":53097,"activeCount":103},[53098],{"nctId":28570,"briefTitle":28571,"status":111,"phases":53099,"primaryCompletion":28573,"completion":28574,"start":28575,"enrollment":1487,"conditions":53100,"interventions":53101},[91],[17080],[28578,6283,28578],{"trials":53103,"activeCount":103},[],{"trials":53105,"activeCount":103},[],{"trials":53107,"activeCount":103},[],{"trials":53109,"activeCount":103},[],{"intervention":17099,"totalTrials":302,"cells":53111},{"EARLY_PHASE1":53112,"PHASE1":53114,"PHASE2":53120,"PHASE3":53122,"PHASE4":53124,"NA":53126},{"trials":53113,"activeCount":103},[],{"trials":53115,"activeCount":103},[53116],{"nctId":17093,"briefTitle":17094,"status":111,"phases":53117,"completion":3627,"start":4692,"enrollment":1530,"conditions":53118,"interventions":53119},[91],[17097],[17099,6111],{"trials":53121,"activeCount":103},[],{"trials":53123,"activeCount":103},[],{"trials":53125,"activeCount":103},[],{"trials":53127,"activeCount":103},[],{"intervention":53129,"totalTrials":302,"cells":53130},"MS Contin",{"EARLY_PHASE1":53131,"PHASE1":53133,"PHASE2":53143,"PHASE3":53145,"PHASE4":53147,"NA":53149},{"trials":53132,"activeCount":103},[],{"trials":53134,"activeCount":103},[53135],{"nctId":53136,"briefTitle":53137,"status":111,"phases":53138,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":1519,"conditions":53139,"interventions":53141},"NCT01380093","Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users",[91],[53140],"Nondependent Opioid Abuse, Episodic",[53129,53142],"EMBEDA",{"trials":53144,"activeCount":103},[],{"trials":53146,"activeCount":103},[],{"trials":53148,"activeCount":103},[],{"trials":53150,"activeCount":103},[],{"intervention":53142,"totalTrials":302,"cells":53152},{"EARLY_PHASE1":53153,"PHASE1":53155,"PHASE2":53161,"PHASE3":53163,"PHASE4":53165,"NA":53167},{"trials":53154,"activeCount":103},[],{"trials":53156,"activeCount":103},[53157],{"nctId":53136,"briefTitle":53137,"status":111,"phases":53158,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":1519,"conditions":53159,"interventions":53160},[91],[53140],[53129,53142],{"trials":53162,"activeCount":103},[],{"trials":53164,"activeCount":103},[],{"trials":53166,"activeCount":103},[],{"trials":53168,"activeCount":103},[],{"intervention":17985,"totalTrials":302,"cells":53170},{"EARLY_PHASE1":53171,"PHASE1":53173,"PHASE2":53179,"PHASE3":53181,"PHASE4":53183,"NA":53185},{"trials":53172,"activeCount":103},[],{"trials":53174,"activeCount":103},[53175],{"nctId":17976,"briefTitle":17977,"status":111,"phases":53176,"primaryCompletion":17979,"completion":17980,"start":17981,"enrollment":4369,"conditions":53177,"interventions":53178},[91],[2938],[17974,17974,17984,17974,17959,17958,17974,2940,17974,17985],{"trials":53180,"activeCount":103},[],{"trials":53182,"activeCount":103},[],{"trials":53184,"activeCount":103},[],{"trials":53186,"activeCount":103},[],{"intervention":7783,"totalTrials":302,"cells":53188},{"EARLY_PHASE1":53189,"PHASE1":53191,"PHASE2":53197,"PHASE3":53199,"PHASE4":53201,"NA":53203},{"trials":53190,"activeCount":103},[],{"trials":53192,"activeCount":103},[53193],{"nctId":7774,"briefTitle":7775,"status":168,"phases":53194,"primaryCompletion":7777,"completion":7777,"start":7778,"enrollment":360,"conditions":53195,"interventions":53196},[91],[553,7780,994,905,643,7781],[7783,1773],{"trials":53198,"activeCount":103},[],{"trials":53200,"activeCount":103},[],{"trials":53202,"activeCount":103},[],{"trials":53204,"activeCount":103},[],{"intervention":609,"totalTrials":302,"cells":53206},{"EARLY_PHASE1":53207,"PHASE1":53209,"PHASE2":53215,"PHASE3":53217,"PHASE4":53219,"NA":53221},{"trials":53208,"activeCount":103},[],{"trials":53210,"activeCount":103},[53211],{"nctId":602,"briefTitle":603,"status":111,"phases":53212,"primaryCompletion":605,"completion":605,"start":606,"enrollment":360,"conditions":53213,"interventions":53214},[91],[16],[609,610,611,612,613,610,611,424,612],{"trials":53216,"activeCount":103},[],{"trials":53218,"activeCount":103},[],{"trials":53220,"activeCount":103},[],{"trials":53222,"activeCount":103},[],{"intervention":610,"totalTrials":302,"cells":53224},{"EARLY_PHASE1":53225,"PHASE1":53227,"PHASE2":53233,"PHASE3":53235,"PHASE4":53237,"NA":53239},{"trials":53226,"activeCount":103},[],{"trials":53228,"activeCount":103},[53229],{"nctId":602,"briefTitle":603,"status":111,"phases":53230,"primaryCompletion":605,"completion":605,"start":606,"enrollment":360,"conditions":53231,"interventions":53232},[91],[16],[609,610,611,612,613,610,611,424,612],{"trials":53234,"activeCount":103},[],{"trials":53236,"activeCount":103},[],{"trials":53238,"activeCount":103},[],{"trials":53240,"activeCount":103},[],{"intervention":611,"totalTrials":302,"cells":53242},{"EARLY_PHASE1":53243,"PHASE1":53245,"PHASE2":53251,"PHASE3":53253,"PHASE4":53255,"NA":53257},{"trials":53244,"activeCount":103},[],{"trials":53246,"activeCount":103},[53247],{"nctId":602,"briefTitle":603,"status":111,"phases":53248,"primaryCompletion":605,"completion":605,"start":606,"enrollment":360,"conditions":53249,"interventions":53250},[91],[16],[609,610,611,612,613,610,611,424,612],{"trials":53252,"activeCount":103},[],{"trials":53254,"activeCount":103},[],{"trials":53256,"activeCount":103},[],{"trials":53258,"activeCount":103},[],{"intervention":612,"totalTrials":302,"cells":53260},{"EARLY_PHASE1":53261,"PHASE1":53263,"PHASE2":53269,"PHASE3":53271,"PHASE4":53273,"NA":53275},{"trials":53262,"activeCount":103},[],{"trials":53264,"activeCount":103},[53265],{"nctId":602,"briefTitle":603,"status":111,"phases":53266,"primaryCompletion":605,"completion":605,"start":606,"enrollment":360,"conditions":53267,"interventions":53268},[91],[16],[609,610,611,612,613,610,611,424,612],{"trials":53270,"activeCount":103},[],{"trials":53272,"activeCount":103},[],{"trials":53274,"activeCount":103},[],{"trials":53276,"activeCount":103},[],{"intervention":53278,"totalTrials":302,"cells":53279},"PF-07209326",{"EARLY_PHASE1":53280,"PHASE1":53282,"PHASE2":53292,"PHASE3":53294,"PHASE4":53296,"NA":53298},{"trials":53281,"activeCount":103},[],{"trials":53283,"activeCount":103},[53284],{"nctId":53285,"briefTitle":53286,"status":111,"phases":53287,"primaryCompletion":5139,"completion":5139,"start":53288,"enrollment":748,"conditions":53289,"interventions":53291},"NCT04255875","Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease",[91],"2020-02-05",[16,53290],"Sickle Cell Anemia",[53278,53278],{"trials":53293,"activeCount":103},[],{"trials":53295,"activeCount":103},[],{"trials":53297,"activeCount":103},[],{"trials":53299,"activeCount":103},[],{"intervention":53301,"totalTrials":302,"cells":53302},"Glasdegib Therapeutic Exposure",{"EARLY_PHASE1":53303,"PHASE1":53305,"PHASE2":53318,"PHASE3":53320,"PHASE4":53322,"NA":53324},{"trials":53304,"activeCount":103},[],{"trials":53306,"activeCount":103},[53307],{"nctId":53308,"briefTitle":53309,"status":111,"phases":53310,"primaryCompletion":53311,"completion":53312,"start":53313,"enrollment":1530,"conditions":53314,"interventions":53315},"NCT03162900","A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects",[91],"2017-09-23","2017-10-16","2017-06-09",[19],[53301,53316,53317],"Glasdegib Supra-therapeutic Exposure","Positive Control",{"trials":53319,"activeCount":103},[],{"trials":53321,"activeCount":103},[],{"trials":53323,"activeCount":103},[],{"trials":53325,"activeCount":103},[],{"intervention":53316,"totalTrials":302,"cells":53327},{"EARLY_PHASE1":53328,"PHASE1":53330,"PHASE2":53336,"PHASE3":53338,"PHASE4":53340,"NA":53342},{"trials":53329,"activeCount":103},[],{"trials":53331,"activeCount":103},[53332],{"nctId":53308,"briefTitle":53309,"status":111,"phases":53333,"primaryCompletion":53311,"completion":53312,"start":53313,"enrollment":1530,"conditions":53334,"interventions":53335},[91],[19],[53301,53316,53317],{"trials":53337,"activeCount":103},[],{"trials":53339,"activeCount":103},[],{"trials":53341,"activeCount":103},[],{"trials":53343,"activeCount":103},[],{"intervention":53317,"totalTrials":302,"cells":53345},{"EARLY_PHASE1":53346,"PHASE1":53348,"PHASE2":53354,"PHASE3":53356,"PHASE4":53358,"NA":53360},{"trials":53347,"activeCount":103},[],{"trials":53349,"activeCount":103},[53350],{"nctId":53308,"briefTitle":53309,"status":111,"phases":53351,"primaryCompletion":53311,"completion":53312,"start":53313,"enrollment":1530,"conditions":53352,"interventions":53353},[91],[19],[53301,53316,53317],{"trials":53355,"activeCount":103},[],{"trials":53357,"activeCount":103},[],{"trials":53359,"activeCount":103},[],{"trials":53361,"activeCount":103},[],{"intervention":53363,"totalTrials":302,"cells":53364},"Sinsunatovir",{"EARLY_PHASE1":53365,"PHASE1":53367,"PHASE2":53376,"PHASE3":53378,"PHASE4":53380,"NA":53382},{"trials":53366,"activeCount":103},[],{"trials":53368,"activeCount":103},[53369],{"nctId":53370,"briefTitle":53371,"status":111,"phases":53372,"primaryCompletion":53373,"completion":53373,"start":27771,"enrollment":1268,"conditions":53374,"interventions":53375},"NCT06003829","A Study to Learn About the Tastes of Different Suspensions With the Study Medicine (PF-07923568) in Healthy Adult Participants.",[91],"2023-09-20",[16],[53363],{"trials":53377,"activeCount":103},[],{"trials":53379,"activeCount":103},[],{"trials":53381,"activeCount":103},[],{"trials":53383,"activeCount":103},[],{"intervention":4733,"totalTrials":302,"cells":53385},{"EARLY_PHASE1":53386,"PHASE1":53388,"PHASE2":53394,"PHASE3":53396,"PHASE4":53398,"NA":53400},{"trials":53387,"activeCount":103},[],{"trials":53389,"activeCount":103},[53390],{"nctId":4721,"briefTitle":4722,"status":168,"phases":53391,"primaryCompletion":4724,"completion":4724,"start":4725,"enrollment":4726,"conditions":53392,"interventions":53393},[91],[4728,376,4729,4730,4731],[4733,1832,1687],{"trials":53395,"activeCount":103},[],{"trials":53397,"activeCount":103},[],{"trials":53399,"activeCount":103},[],{"trials":53401,"activeCount":103},[],{"intervention":53403,"totalTrials":302,"cells":53404},"oxycodone hydrochloride",{"EARLY_PHASE1":53405,"PHASE1":53407,"PHASE2":53416,"PHASE3":53418,"PHASE4":53420,"NA":53422},{"trials":53406,"activeCount":103},[],{"trials":53408,"activeCount":103},[53409],{"nctId":53410,"briefTitle":53411,"status":111,"phases":53412,"primaryCompletion":560,"completion":560,"start":586,"enrollment":472,"conditions":53413,"interventions":53414},"NCT01530542","A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers",[91],[13121,45679,13120,41723,41724],[53403,53403,53403,53403,53415],"marketed oxycodone hydrochloride",{"trials":53417,"activeCount":103},[],{"trials":53419,"activeCount":103},[],{"trials":53421,"activeCount":103},[],{"trials":53423,"activeCount":103},[],{"intervention":53415,"totalTrials":302,"cells":53425},{"EARLY_PHASE1":53426,"PHASE1":53428,"PHASE2":53434,"PHASE3":53436,"PHASE4":53438,"NA":53440},{"trials":53427,"activeCount":103},[],{"trials":53429,"activeCount":103},[53430],{"nctId":53410,"briefTitle":53411,"status":111,"phases":53431,"primaryCompletion":560,"completion":560,"start":586,"enrollment":472,"conditions":53432,"interventions":53433},[91],[13121,45679,13120,41723,41724],[53403,53403,53403,53403,53415],{"trials":53435,"activeCount":103},[],{"trials":53437,"activeCount":103},[],{"trials":53439,"activeCount":103},[],{"trials":53441,"activeCount":103},[],{"intervention":1783,"totalTrials":302,"cells":53443},{"EARLY_PHASE1":53444,"PHASE1":53446,"PHASE2":53452,"PHASE3":53454,"PHASE4":53456,"NA":53458},{"trials":53445,"activeCount":103},[],{"trials":53447,"activeCount":103},[53448],{"nctId":1775,"briefTitle":1776,"status":168,"phases":53449,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":53450,"interventions":53451},[91],[1761,1028,376],[1783,1764,1765,1304,1766,1767,1768,1030,631,1773,1769,1770,1771,1772,340],{"trials":53453,"activeCount":103},[],{"trials":53455,"activeCount":103},[],{"trials":53457,"activeCount":103},[],{"trials":53459,"activeCount":103},[],{"intervention":53461,"totalTrials":302,"cells":53462},"Within-Subject Active vs Placebo Topical Applications",{"EARLY_PHASE1":53463,"PHASE1":53465,"PHASE2":53474,"PHASE3":53476,"PHASE4":53478,"NA":53480},{"trials":53464,"activeCount":103},[],{"trials":53466,"activeCount":103},[53467],{"nctId":53468,"briefTitle":53469,"status":111,"phases":53470,"primaryCompletion":43488,"completion":43488,"start":151,"enrollment":4259,"conditions":53471,"interventions":53472},"NCT03760042","Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements",[91],[16],[53461,53473],"Within-Subject Active vs. Placebo Topical Applications",{"trials":53475,"activeCount":103},[],{"trials":53477,"activeCount":103},[],{"trials":53479,"activeCount":103},[],{"trials":53481,"activeCount":103},[],{"intervention":53473,"totalTrials":302,"cells":53483},{"EARLY_PHASE1":53484,"PHASE1":53486,"PHASE2":53492,"PHASE3":53494,"PHASE4":53496,"NA":53498},{"trials":53485,"activeCount":103},[],{"trials":53487,"activeCount":103},[53488],{"nctId":53468,"briefTitle":53469,"status":111,"phases":53489,"primaryCompletion":43488,"completion":43488,"start":151,"enrollment":4259,"conditions":53490,"interventions":53491},[91],[16],[53461,53473],{"trials":53493,"activeCount":103},[],{"trials":53495,"activeCount":103},[],{"trials":53497,"activeCount":103},[],{"trials":53499,"activeCount":103},[],{"intervention":53501,"totalTrials":302,"cells":53502},"[14C]PF-06882961, 50 mg",{"EARLY_PHASE1":53503,"PHASE1":53505,"PHASE2":53514,"PHASE3":53516,"PHASE4":53518,"NA":53520},{"trials":53504,"activeCount":103},[],{"trials":53506,"activeCount":103},[53507],{"nctId":53508,"briefTitle":53509,"status":111,"phases":53510,"primaryCompletion":27015,"completion":27015,"start":462,"enrollment":2070,"conditions":53511,"interventions":53512},"NCT04495140","Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961",[91],[1270],[53501,53513],"PF-06882961, 50 mg and [14C]PF-06882961, 100 ug",{"trials":53515,"activeCount":103},[],{"trials":53517,"activeCount":103},[],{"trials":53519,"activeCount":103},[],{"trials":53521,"activeCount":103},[],{"intervention":53513,"totalTrials":302,"cells":53523},{"EARLY_PHASE1":53524,"PHASE1":53526,"PHASE2":53532,"PHASE3":53534,"PHASE4":53536,"NA":53538},{"trials":53525,"activeCount":103},[],{"trials":53527,"activeCount":103},[53528],{"nctId":53508,"briefTitle":53509,"status":111,"phases":53529,"primaryCompletion":27015,"completion":27015,"start":462,"enrollment":2070,"conditions":53530,"interventions":53531},[91],[1270],[53501,53513],{"trials":53533,"activeCount":103},[],{"trials":53535,"activeCount":103},[],{"trials":53537,"activeCount":103},[],{"trials":53539,"activeCount":103},[],{"intervention":17106,"totalTrials":302,"cells":53541},{"EARLY_PHASE1":53542,"PHASE1":53544,"PHASE2":53550,"PHASE3":53552,"PHASE4":53554,"NA":53556},{"trials":53543,"activeCount":103},[],{"trials":53545,"activeCount":103},[53546],{"nctId":17101,"briefTitle":17102,"status":111,"phases":53547,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":53548,"interventions":53549},[91],[16],[13326,13326,17044,17106],{"trials":53551,"activeCount":103},[],{"trials":53553,"activeCount":103},[],{"trials":53555,"activeCount":103},[],{"trials":53557,"activeCount":103},[],{"intervention":53559,"totalTrials":302,"cells":53560},"Estraimod Immediate Release",{"EARLY_PHASE1":53561,"PHASE1":53563,"PHASE2":53577,"PHASE3":53579,"PHASE4":53581,"NA":53583},{"trials":53562,"activeCount":103},[],{"trials":53564,"activeCount":103},[53565],{"nctId":53566,"briefTitle":53567,"status":111,"phases":53568,"primaryCompletion":53569,"completion":53569,"start":53570,"enrollment":314,"conditions":53571,"interventions":53572},"NCT05956002","A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants",[91],"2024-01-04","2023-09-04",[28],[53559,53573,53574,53575,53576],"Etrasimod Mini Tab in water","Etrasimod Mini Tab in chocolate pudding","Etrasimod Mini Tab in yogurt","Etrasimod Mini Tab in applesauce",{"trials":53578,"activeCount":103},[],{"trials":53580,"activeCount":103},[],{"trials":53582,"activeCount":103},[],{"trials":53584,"activeCount":103},[],{"intervention":53573,"totalTrials":302,"cells":53586},{"EARLY_PHASE1":53587,"PHASE1":53589,"PHASE2":53595,"PHASE3":53597,"PHASE4":53599,"NA":53601},{"trials":53588,"activeCount":103},[],{"trials":53590,"activeCount":103},[53591],{"nctId":53566,"briefTitle":53567,"status":111,"phases":53592,"primaryCompletion":53569,"completion":53569,"start":53570,"enrollment":314,"conditions":53593,"interventions":53594},[91],[28],[53559,53573,53574,53575,53576],{"trials":53596,"activeCount":103},[],{"trials":53598,"activeCount":103},[],{"trials":53600,"activeCount":103},[],{"trials":53602,"activeCount":103},[],{"intervention":53574,"totalTrials":302,"cells":53604},{"EARLY_PHASE1":53605,"PHASE1":53607,"PHASE2":53613,"PHASE3":53615,"PHASE4":53617,"NA":53619},{"trials":53606,"activeCount":103},[],{"trials":53608,"activeCount":103},[53609],{"nctId":53566,"briefTitle":53567,"status":111,"phases":53610,"primaryCompletion":53569,"completion":53569,"start":53570,"enrollment":314,"conditions":53611,"interventions":53612},[91],[28],[53559,53573,53574,53575,53576],{"trials":53614,"activeCount":103},[],{"trials":53616,"activeCount":103},[],{"trials":53618,"activeCount":103},[],{"trials":53620,"activeCount":103},[],{"intervention":53575,"totalTrials":302,"cells":53622},{"EARLY_PHASE1":53623,"PHASE1":53625,"PHASE2":53631,"PHASE3":53633,"PHASE4":53635,"NA":53637},{"trials":53624,"activeCount":103},[],{"trials":53626,"activeCount":103},[53627],{"nctId":53566,"briefTitle":53567,"status":111,"phases":53628,"primaryCompletion":53569,"completion":53569,"start":53570,"enrollment":314,"conditions":53629,"interventions":53630},[91],[28],[53559,53573,53574,53575,53576],{"trials":53632,"activeCount":103},[],{"trials":53634,"activeCount":103},[],{"trials":53636,"activeCount":103},[],{"trials":53638,"activeCount":103},[],{"intervention":53576,"totalTrials":302,"cells":53640},{"EARLY_PHASE1":53641,"PHASE1":53643,"PHASE2":53649,"PHASE3":53651,"PHASE4":53653,"NA":53655},{"trials":53642,"activeCount":103},[],{"trials":53644,"activeCount":103},[53645],{"nctId":53566,"briefTitle":53567,"status":111,"phases":53646,"primaryCompletion":53569,"completion":53569,"start":53570,"enrollment":314,"conditions":53647,"interventions":53648},[91],[28],[53559,53573,53574,53575,53576],{"trials":53650,"activeCount":103},[],{"trials":53652,"activeCount":103},[],{"trials":53654,"activeCount":103},[],{"trials":53656,"activeCount":103},[],{"intervention":53658,"totalTrials":302,"cells":53659},"PF-07923568",{"EARLY_PHASE1":53660,"PHASE1":53662,"PHASE2":53672,"PHASE3":53674,"PHASE4":53676,"NA":53678},{"trials":53661,"activeCount":103},[],{"trials":53663,"activeCount":103},[53664],{"nctId":53665,"briefTitle":53666,"status":111,"phases":53667,"primaryCompletion":53668,"completion":53668,"start":1517,"enrollment":5909,"conditions":53669,"interventions":53671},"NCT05857644","A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.",[91],"2024-02-07",[53670,7853],"Liver Diseases",[53658],{"trials":53673,"activeCount":103},[],{"trials":53675,"activeCount":103},[],{"trials":53677,"activeCount":103},[],{"trials":53679,"activeCount":103},[],{"intervention":53681,"totalTrials":302,"cells":53682},"TA-46",{"EARLY_PHASE1":53683,"PHASE1":53685,"PHASE2":53694,"PHASE3":53696,"PHASE4":53698,"NA":53700},{"trials":53684,"activeCount":103},[],{"trials":53686,"activeCount":103},[53687],{"nctId":53688,"briefTitle":53689,"status":111,"phases":53690,"primaryCompletion":53691,"completion":53691,"start":42924,"enrollment":27583,"conditions":53692,"interventions":53693},"NCT04410809","Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46",[91],"2019-11-27",[16],[53681],{"trials":53695,"activeCount":103},[],{"trials":53697,"activeCount":103},[],{"trials":53699,"activeCount":103},[],{"trials":53701,"activeCount":103},[],{"intervention":53703,"totalTrials":302,"cells":53704},"Lersivirine Immediate-Release",{"EARLY_PHASE1":53705,"PHASE1":53707,"PHASE2":53719,"PHASE3":53721,"PHASE4":53723,"NA":53725},{"trials":53706,"activeCount":103},[],{"trials":53708,"activeCount":103},[53709],{"nctId":53710,"briefTitle":53711,"status":111,"phases":53712,"primaryCompletion":569,"completion":569,"start":4459,"enrollment":314,"conditions":53713,"interventions":53714},"NCT01603485","Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects",[91],[1270],[53703,53715,53716,53717,53718],"Lersivirine Modified-Release #1","Lersivirine Modified-Release #2","Lersivirine Modified-Release #3","Lersivirine Modified-Release",{"trials":53720,"activeCount":103},[],{"trials":53722,"activeCount":103},[],{"trials":53724,"activeCount":103},[],{"trials":53726,"activeCount":103},[],{"intervention":53715,"totalTrials":302,"cells":53728},{"EARLY_PHASE1":53729,"PHASE1":53731,"PHASE2":53737,"PHASE3":53739,"PHASE4":53741,"NA":53743},{"trials":53730,"activeCount":103},[],{"trials":53732,"activeCount":103},[53733],{"nctId":53710,"briefTitle":53711,"status":111,"phases":53734,"primaryCompletion":569,"completion":569,"start":4459,"enrollment":314,"conditions":53735,"interventions":53736},[91],[1270],[53703,53715,53716,53717,53718],{"trials":53738,"activeCount":103},[],{"trials":53740,"activeCount":103},[],{"trials":53742,"activeCount":103},[],{"trials":53744,"activeCount":103},[],{"intervention":53716,"totalTrials":302,"cells":53746},{"EARLY_PHASE1":53747,"PHASE1":53749,"PHASE2":53755,"PHASE3":53757,"PHASE4":53759,"NA":53761},{"trials":53748,"activeCount":103},[],{"trials":53750,"activeCount":103},[53751],{"nctId":53710,"briefTitle":53711,"status":111,"phases":53752,"primaryCompletion":569,"completion":569,"start":4459,"enrollment":314,"conditions":53753,"interventions":53754},[91],[1270],[53703,53715,53716,53717,53718],{"trials":53756,"activeCount":103},[],{"trials":53758,"activeCount":103},[],{"trials":53760,"activeCount":103},[],{"trials":53762,"activeCount":103},[],{"intervention":53717,"totalTrials":302,"cells":53764},{"EARLY_PHASE1":53765,"PHASE1":53767,"PHASE2":53773,"PHASE3":53775,"PHASE4":53777,"NA":53779},{"trials":53766,"activeCount":103},[],{"trials":53768,"activeCount":103},[53769],{"nctId":53710,"briefTitle":53711,"status":111,"phases":53770,"primaryCompletion":569,"completion":569,"start":4459,"enrollment":314,"conditions":53771,"interventions":53772},[91],[1270],[53703,53715,53716,53717,53718],{"trials":53774,"activeCount":103},[],{"trials":53776,"activeCount":103},[],{"trials":53778,"activeCount":103},[],{"trials":53780,"activeCount":103},[],{"intervention":53718,"totalTrials":302,"cells":53782},{"EARLY_PHASE1":53783,"PHASE1":53785,"PHASE2":53791,"PHASE3":53793,"PHASE4":53795,"NA":53797},{"trials":53784,"activeCount":103},[],{"trials":53786,"activeCount":103},[53787],{"nctId":53710,"briefTitle":53711,"status":111,"phases":53788,"primaryCompletion":569,"completion":569,"start":4459,"enrollment":314,"conditions":53789,"interventions":53790},[91],[1270],[53703,53715,53716,53717,53718],{"trials":53792,"activeCount":103},[],{"trials":53794,"activeCount":103},[],{"trials":53796,"activeCount":103},[],{"trials":53798,"activeCount":103},[],{"intervention":28403,"totalTrials":302,"cells":53800},{"EARLY_PHASE1":53801,"PHASE1":53803,"PHASE2":53809,"PHASE3":53811,"PHASE4":53813,"NA":53815},{"trials":53802,"activeCount":103},[],{"trials":53804,"activeCount":103},[53805],{"nctId":28396,"briefTitle":28397,"status":111,"phases":53806,"primaryCompletion":28399,"completion":28399,"start":28400,"enrollment":498,"conditions":53807,"interventions":53808},[91],[16],[27131,28403],{"trials":53810,"activeCount":103},[],{"trials":53812,"activeCount":103},[],{"trials":53814,"activeCount":103},[],{"trials":53816,"activeCount":103},[],{"intervention":53818,"totalTrials":302,"cells":53819},"Epanutin Infatabs",{"EARLY_PHASE1":53820,"PHASE1":53822,"PHASE2":53831,"PHASE3":53833,"PHASE4":53835,"NA":53837},{"trials":53821,"activeCount":103},[],{"trials":53823,"activeCount":103},[53824],{"nctId":53825,"briefTitle":53826,"status":111,"phases":53827,"primaryCompletion":2661,"completion":2661,"start":11170,"enrollment":1239,"conditions":53828,"interventions":53829},"NCT01355068","A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia",[91],[16],[53818,53830],"Dilantin Infatabs",{"trials":53832,"activeCount":103},[],{"trials":53834,"activeCount":103},[],{"trials":53836,"activeCount":103},[],{"trials":53838,"activeCount":103},[],{"intervention":53830,"totalTrials":302,"cells":53840},{"EARLY_PHASE1":53841,"PHASE1":53843,"PHASE2":53849,"PHASE3":53851,"PHASE4":53853,"NA":53855},{"trials":53842,"activeCount":103},[],{"trials":53844,"activeCount":103},[53845],{"nctId":53825,"briefTitle":53826,"status":111,"phases":53846,"primaryCompletion":2661,"completion":2661,"start":11170,"enrollment":1239,"conditions":53847,"interventions":53848},[91],[16],[53818,53830],{"trials":53850,"activeCount":103},[],{"trials":53852,"activeCount":103},[],{"trials":53854,"activeCount":103},[],{"trials":53856,"activeCount":103},[],{"intervention":53858,"totalTrials":302,"cells":53859},"PF-07059013",{"EARLY_PHASE1":53860,"PHASE1":53862,"PHASE2":53871,"PHASE3":53873,"PHASE4":53875,"NA":53877},{"trials":53861,"activeCount":103},[],{"trials":53863,"activeCount":103},[53864],{"nctId":53865,"briefTitle":53866,"status":168,"phases":53867,"primaryCompletion":3816,"completion":3816,"start":53868,"enrollment":2400,"conditions":53869,"interventions":53870},"NCT04323124","Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants",[91],"2020-07-17",[16],[53858],{"trials":53872,"activeCount":103},[],{"trials":53874,"activeCount":103},[],{"trials":53876,"activeCount":103},[],{"trials":53878,"activeCount":103},[],{"intervention":53880,"totalTrials":302,"cells":53881},"PF-06291874 or placebo",{"EARLY_PHASE1":53882,"PHASE1":53884,"PHASE2":53893,"PHASE3":53895,"PHASE4":53897,"NA":53899},{"trials":53883,"activeCount":103},[],{"trials":53885,"activeCount":103},[53886],{"nctId":53887,"briefTitle":53888,"status":168,"phases":53889,"primaryCompletion":10912,"completion":10912,"start":570,"enrollment":627,"conditions":53890,"interventions":53891},"NCT01499017","A Single Dose Study Of PF-06291874 In Healthy Adult Subjects",[91],[16],[53880,53892],"PF-06291874 or Placebo",{"trials":53894,"activeCount":103},[],{"trials":53896,"activeCount":103},[],{"trials":53898,"activeCount":103},[],{"trials":53900,"activeCount":103},[],{"intervention":12355,"totalTrials":302,"cells":53902},{"EARLY_PHASE1":53903,"PHASE1":53905,"PHASE2":53911,"PHASE3":53913,"PHASE4":53915,"NA":53917},{"trials":53904,"activeCount":103},[],{"trials":53906,"activeCount":103},[53907],{"nctId":12349,"briefTitle":12350,"status":649,"phases":53908,"primaryCompletion":129,"completion":129,"start":12352,"enrollment":103,"conditions":53909,"interventions":53910},[91],[16],[12342,12355,12355],{"trials":53912,"activeCount":103},[],{"trials":53914,"activeCount":103},[],{"trials":53916,"activeCount":103},[],{"trials":53918,"activeCount":103},[],{"intervention":53920,"totalTrials":302,"cells":53921},"[11C]PF-06427878",{"EARLY_PHASE1":53922,"PHASE1":53924,"PHASE2":53934,"PHASE3":53936,"PHASE4":53938,"NA":53940},{"trials":53923,"activeCount":103},[],{"trials":53925,"activeCount":103},[53926],{"nctId":53927,"briefTitle":53928,"status":111,"phases":53929,"primaryCompletion":12853,"completion":12853,"start":4458,"enrollment":1487,"conditions":53930,"interventions":53931},"NCT02410525","A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning",[91],[16],[53920,53932,53933],"PF-06427878 10 mg","PF-06427878 600 mg",{"trials":53935,"activeCount":103},[],{"trials":53937,"activeCount":103},[],{"trials":53939,"activeCount":103},[],{"trials":53941,"activeCount":103},[],{"intervention":53932,"totalTrials":302,"cells":53943},{"EARLY_PHASE1":53944,"PHASE1":53946,"PHASE2":53952,"PHASE3":53954,"PHASE4":53956,"NA":53958},{"trials":53945,"activeCount":103},[],{"trials":53947,"activeCount":103},[53948],{"nctId":53927,"briefTitle":53928,"status":111,"phases":53949,"primaryCompletion":12853,"completion":12853,"start":4458,"enrollment":1487,"conditions":53950,"interventions":53951},[91],[16],[53920,53932,53933],{"trials":53953,"activeCount":103},[],{"trials":53955,"activeCount":103},[],{"trials":53957,"activeCount":103},[],{"trials":53959,"activeCount":103},[],{"intervention":53933,"totalTrials":302,"cells":53961},{"EARLY_PHASE1":53962,"PHASE1":53964,"PHASE2":53970,"PHASE3":53972,"PHASE4":53974,"NA":53976},{"trials":53963,"activeCount":103},[],{"trials":53965,"activeCount":103},[53966],{"nctId":53927,"briefTitle":53928,"status":111,"phases":53967,"primaryCompletion":12853,"completion":12853,"start":4458,"enrollment":1487,"conditions":53968,"interventions":53969},[91],[16],[53920,53932,53933],{"trials":53971,"activeCount":103},[],{"trials":53973,"activeCount":103},[],{"trials":53975,"activeCount":103},[],{"trials":53977,"activeCount":103},[],{"intervention":53979,"totalTrials":302,"cells":53980},"PF-06882961 20 mg",{"EARLY_PHASE1":53981,"PHASE1":53983,"PHASE2":53993,"PHASE3":53995,"PHASE4":53997,"NA":53999},{"trials":53982,"activeCount":103},[],{"trials":53984,"activeCount":103},[53985],{"nctId":53986,"briefTitle":53987,"status":111,"phases":53988,"primaryCompletion":53989,"completion":53989,"start":53990,"enrollment":1578,"conditions":53991,"interventions":53992},"NCT04616027","STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT",[91],"2022-02-18","2021-01-13",[37,352,16],[53979],{"trials":53994,"activeCount":103},[],{"trials":53996,"activeCount":103},[],{"trials":53998,"activeCount":103},[],{"trials":54000,"activeCount":103},[],{"intervention":54002,"totalTrials":302,"cells":54003},"PF-06882961 100 mg",{"EARLY_PHASE1":54004,"PHASE1":54006,"PHASE2":54015,"PHASE3":54017,"PHASE4":54019,"NA":54021},{"trials":54005,"activeCount":103},[],{"trials":54007,"activeCount":103},[54008],{"nctId":54009,"briefTitle":54010,"status":111,"phases":54011,"primaryCompletion":26999,"completion":26999,"start":54012,"enrollment":1257,"conditions":54013,"interventions":54014},"NCT04616339","STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY",[91],"2020-11-04",[2781],[54002],{"trials":54016,"activeCount":103},[],{"trials":54018,"activeCount":103},[],{"trials":54020,"activeCount":103},[],{"trials":54022,"activeCount":103},[],{"intervention":54024,"totalTrials":302,"cells":54025},"Warfarin plus Fesoterodine",{"EARLY_PHASE1":54026,"PHASE1":54028,"PHASE2":54036,"PHASE3":54038,"PHASE4":54040,"NA":54042},{"trials":54027,"activeCount":103},[],{"trials":54029,"activeCount":103},[54030],{"nctId":54031,"briefTitle":54032,"status":111,"phases":54033,"primaryCompletion":4214,"completion":4214,"start":4627,"enrollment":562,"conditions":54034,"interventions":54035},"NCT00914667","The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects",[91],[12472],[9621,54024],{"trials":54037,"activeCount":103},[],{"trials":54039,"activeCount":103},[],{"trials":54041,"activeCount":103},[],{"trials":54043,"activeCount":103},[],{"intervention":54045,"totalTrials":302,"cells":54046},"PF-06840003",{"EARLY_PHASE1":54047,"PHASE1":54049,"PHASE2":54062,"PHASE3":54064,"PHASE4":54066,"NA":54068},{"trials":54048,"activeCount":103},[],{"trials":54050,"activeCount":103},[54051],{"nctId":54052,"briefTitle":54053,"status":168,"phases":54054,"primaryCompletion":54055,"completion":54055,"start":54056,"enrollment":7500,"conditions":54057,"interventions":54061},"NCT02764151","First in Patient Study for PF-06840003 in Malignant Gliomas",[91],"2018-12-26","2016-09-09",[54058,54059,54060],"Oligodendroglioma","Astrocytoma","Malignant Glioma",[54045],{"trials":54063,"activeCount":103},[],{"trials":54065,"activeCount":103},[],{"trials":54067,"activeCount":103},[],{"trials":54069,"activeCount":103},[],{"intervention":54071,"totalTrials":302,"cells":54072},"PF-05190457",{"EARLY_PHASE1":54073,"PHASE1":54075,"PHASE2":54083,"PHASE3":54085,"PHASE4":54087,"NA":54089},{"trials":54074,"activeCount":103},[],{"trials":54076,"activeCount":103},[54077],{"nctId":54078,"briefTitle":54079,"status":111,"phases":54080,"primaryCompletion":570,"completion":570,"start":9544,"enrollment":314,"conditions":54081,"interventions":54082},"NCT01522807","A Study Of Three PF-05190457 Formulations In Healthy Volunteers",[91],[37],[54071,54071,54071,54071,54071,54071,54071,54071],{"trials":54084,"activeCount":103},[],{"trials":54086,"activeCount":103},[],{"trials":54088,"activeCount":103},[],{"trials":54090,"activeCount":103},[],{"intervention":27711,"totalTrials":302,"cells":54092},{"EARLY_PHASE1":54093,"PHASE1":54095,"PHASE2":54101,"PHASE3":54103,"PHASE4":54105,"NA":54107},{"trials":54094,"activeCount":103},[],{"trials":54096,"activeCount":103},[54097],{"nctId":27706,"briefTitle":27707,"status":111,"phases":54098,"primaryCompletion":3601,"completion":3601,"start":8252,"enrollment":562,"conditions":54099,"interventions":54100},[91],[19],[27711,27711,17074],{"trials":54102,"activeCount":103},[],{"trials":54104,"activeCount":103},[],{"trials":54106,"activeCount":103},[],{"trials":54108,"activeCount":103},[],{"intervention":1291,"totalTrials":302,"cells":54110},{"EARLY_PHASE1":54111,"PHASE1":54113,"PHASE2":54119,"PHASE3":54121,"PHASE4":54123,"NA":54125},{"trials":54112,"activeCount":103},[],{"trials":54114,"activeCount":103},[54115],{"nctId":1285,"briefTitle":1286,"status":111,"phases":54116,"primaryCompletion":1288,"completion":1288,"start":605,"enrollment":504,"conditions":54117,"interventions":54118},[91],[16],[1291,1292,1293,88,1292],{"trials":54120,"activeCount":103},[],{"trials":54122,"activeCount":103},[],{"trials":54124,"activeCount":103},[],{"trials":54126,"activeCount":103},[],{"intervention":1292,"totalTrials":302,"cells":54128},{"EARLY_PHASE1":54129,"PHASE1":54131,"PHASE2":54137,"PHASE3":54139,"PHASE4":54141,"NA":54143},{"trials":54130,"activeCount":103},[],{"trials":54132,"activeCount":103},[54133],{"nctId":1285,"briefTitle":1286,"status":111,"phases":54134,"primaryCompletion":1288,"completion":1288,"start":605,"enrollment":504,"conditions":54135,"interventions":54136},[91],[16],[1291,1292,1293,88,1292],{"trials":54138,"activeCount":103},[],{"trials":54140,"activeCount":103},[],{"trials":54142,"activeCount":103},[],{"trials":54144,"activeCount":103},[],{"intervention":1293,"totalTrials":302,"cells":54146},{"EARLY_PHASE1":54147,"PHASE1":54149,"PHASE2":54155,"PHASE3":54157,"PHASE4":54159,"NA":54161},{"trials":54148,"activeCount":103},[],{"trials":54150,"activeCount":103},[54151],{"nctId":1285,"briefTitle":1286,"status":111,"phases":54152,"primaryCompletion":1288,"completion":1288,"start":605,"enrollment":504,"conditions":54153,"interventions":54154},[91],[16],[1291,1292,1293,88,1292],{"trials":54156,"activeCount":103},[],{"trials":54158,"activeCount":103},[],{"trials":54160,"activeCount":103},[],{"trials":54162,"activeCount":103},[],{"intervention":54164,"totalTrials":302,"cells":54165},"CVX-096",{"EARLY_PHASE1":54166,"PHASE1":54168,"PHASE2":54176,"PHASE3":54178,"PHASE4":54180,"NA":54182},{"trials":54167,"activeCount":103},[],{"trials":54169,"activeCount":103},[54170],{"nctId":54171,"briefTitle":54172,"status":111,"phases":54173,"primaryCompletion":2661,"completion":2661,"start":4665,"enrollment":5111,"conditions":54174,"interventions":54175},"NCT00886821","A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics",[91],[37],[54164],{"trials":54177,"activeCount":103},[],{"trials":54179,"activeCount":103},[],{"trials":54181,"activeCount":103},[],{"trials":54183,"activeCount":103},[],{"intervention":41326,"totalTrials":302,"cells":54185},{"EARLY_PHASE1":54186,"PHASE1":54188,"PHASE2":54194,"PHASE3":54196,"PHASE4":54198,"NA":54200},{"trials":54187,"activeCount":103},[],{"trials":54189,"activeCount":103},[54190],{"nctId":41321,"briefTitle":41322,"status":111,"phases":54191,"primaryCompletion":7971,"completion":7971,"start":652,"enrollment":3866,"conditions":54192,"interventions":54193},[91],[19],[41326,41327,41314],{"trials":54195,"activeCount":103},[],{"trials":54197,"activeCount":103},[],{"trials":54199,"activeCount":103},[],{"trials":54201,"activeCount":103},[],{"intervention":41327,"totalTrials":302,"cells":54203},{"EARLY_PHASE1":54204,"PHASE1":54206,"PHASE2":54212,"PHASE3":54214,"PHASE4":54216,"NA":54218},{"trials":54205,"activeCount":103},[],{"trials":54207,"activeCount":103},[54208],{"nctId":41321,"briefTitle":41322,"status":111,"phases":54209,"primaryCompletion":7971,"completion":7971,"start":652,"enrollment":3866,"conditions":54210,"interventions":54211},[91],[19],[41326,41327,41314],{"trials":54213,"activeCount":103},[],{"trials":54215,"activeCount":103},[],{"trials":54217,"activeCount":103},[],{"trials":54219,"activeCount":103},[],{"intervention":54221,"totalTrials":302,"cells":54222},"200 Mg capsules of bosutinib in Water solution",{"EARLY_PHASE1":54223,"PHASE1":54225,"PHASE2":54248,"PHASE3":54250,"PHASE4":54252,"NA":54254},{"trials":54224,"activeCount":103},[],{"trials":54226,"activeCount":103},[54227],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54230,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54232,"interventions":54234},"NCT03747679","Palatability (Taste) of Oral Formulations of Bosutinib",[91],"2018-11-22",[54233],"CML",[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],"bosunitib sorbitol","Bosutinib Mannitol","bosutinib in mannitol low sweet","bosutinib in mannitol high sweet","bosutinib taste low flavour","bosutinib high flavour","bosutinib capsules in applesauce","Bosutinib capsules in yogurt","bosutinib capsules in water","Bosutinib capsules in low sweet","bosutinib capsules high sweet","bosutinib capsules low flavour","bosutinib capsules high flavour",{"trials":54249,"activeCount":103},[],{"trials":54251,"activeCount":103},[],{"trials":54253,"activeCount":103},[],{"trials":54255,"activeCount":103},[],{"intervention":54235,"totalTrials":302,"cells":54257},{"EARLY_PHASE1":54258,"PHASE1":54260,"PHASE2":54266,"PHASE3":54268,"PHASE4":54270,"NA":54272},{"trials":54259,"activeCount":103},[],{"trials":54261,"activeCount":103},[54262],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54263,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54264,"interventions":54265},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54267,"activeCount":103},[],{"trials":54269,"activeCount":103},[],{"trials":54271,"activeCount":103},[],{"trials":54273,"activeCount":103},[],{"intervention":54236,"totalTrials":302,"cells":54275},{"EARLY_PHASE1":54276,"PHASE1":54278,"PHASE2":54284,"PHASE3":54286,"PHASE4":54288,"NA":54290},{"trials":54277,"activeCount":103},[],{"trials":54279,"activeCount":103},[54280],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54281,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54282,"interventions":54283},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54285,"activeCount":103},[],{"trials":54287,"activeCount":103},[],{"trials":54289,"activeCount":103},[],{"trials":54291,"activeCount":103},[],{"intervention":54237,"totalTrials":302,"cells":54293},{"EARLY_PHASE1":54294,"PHASE1":54296,"PHASE2":54302,"PHASE3":54304,"PHASE4":54306,"NA":54308},{"trials":54295,"activeCount":103},[],{"trials":54297,"activeCount":103},[54298],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54299,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54300,"interventions":54301},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54303,"activeCount":103},[],{"trials":54305,"activeCount":103},[],{"trials":54307,"activeCount":103},[],{"trials":54309,"activeCount":103},[],{"intervention":54238,"totalTrials":302,"cells":54311},{"EARLY_PHASE1":54312,"PHASE1":54314,"PHASE2":54320,"PHASE3":54322,"PHASE4":54324,"NA":54326},{"trials":54313,"activeCount":103},[],{"trials":54315,"activeCount":103},[54316],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54317,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54318,"interventions":54319},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54321,"activeCount":103},[],{"trials":54323,"activeCount":103},[],{"trials":54325,"activeCount":103},[],{"trials":54327,"activeCount":103},[],{"intervention":54239,"totalTrials":302,"cells":54329},{"EARLY_PHASE1":54330,"PHASE1":54332,"PHASE2":54338,"PHASE3":54340,"PHASE4":54342,"NA":54344},{"trials":54331,"activeCount":103},[],{"trials":54333,"activeCount":103},[54334],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54335,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54336,"interventions":54337},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54339,"activeCount":103},[],{"trials":54341,"activeCount":103},[],{"trials":54343,"activeCount":103},[],{"trials":54345,"activeCount":103},[],{"intervention":54240,"totalTrials":302,"cells":54347},{"EARLY_PHASE1":54348,"PHASE1":54350,"PHASE2":54356,"PHASE3":54358,"PHASE4":54360,"NA":54362},{"trials":54349,"activeCount":103},[],{"trials":54351,"activeCount":103},[54352],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54353,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54354,"interventions":54355},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54357,"activeCount":103},[],{"trials":54359,"activeCount":103},[],{"trials":54361,"activeCount":103},[],{"trials":54363,"activeCount":103},[],{"intervention":54241,"totalTrials":302,"cells":54365},{"EARLY_PHASE1":54366,"PHASE1":54368,"PHASE2":54374,"PHASE3":54376,"PHASE4":54378,"NA":54380},{"trials":54367,"activeCount":103},[],{"trials":54369,"activeCount":103},[54370],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54371,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54372,"interventions":54373},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54375,"activeCount":103},[],{"trials":54377,"activeCount":103},[],{"trials":54379,"activeCount":103},[],{"trials":54381,"activeCount":103},[],{"intervention":54242,"totalTrials":302,"cells":54383},{"EARLY_PHASE1":54384,"PHASE1":54386,"PHASE2":54392,"PHASE3":54394,"PHASE4":54396,"NA":54398},{"trials":54385,"activeCount":103},[],{"trials":54387,"activeCount":103},[54388],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54389,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54390,"interventions":54391},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54393,"activeCount":103},[],{"trials":54395,"activeCount":103},[],{"trials":54397,"activeCount":103},[],{"trials":54399,"activeCount":103},[],{"intervention":54243,"totalTrials":302,"cells":54401},{"EARLY_PHASE1":54402,"PHASE1":54404,"PHASE2":54410,"PHASE3":54412,"PHASE4":54414,"NA":54416},{"trials":54403,"activeCount":103},[],{"trials":54405,"activeCount":103},[54406],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54407,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54408,"interventions":54409},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54411,"activeCount":103},[],{"trials":54413,"activeCount":103},[],{"trials":54415,"activeCount":103},[],{"trials":54417,"activeCount":103},[],{"intervention":54244,"totalTrials":302,"cells":54419},{"EARLY_PHASE1":54420,"PHASE1":54422,"PHASE2":54428,"PHASE3":54430,"PHASE4":54432,"NA":54434},{"trials":54421,"activeCount":103},[],{"trials":54423,"activeCount":103},[54424],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54425,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54426,"interventions":54427},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54429,"activeCount":103},[],{"trials":54431,"activeCount":103},[],{"trials":54433,"activeCount":103},[],{"trials":54435,"activeCount":103},[],{"intervention":54245,"totalTrials":302,"cells":54437},{"EARLY_PHASE1":54438,"PHASE1":54440,"PHASE2":54446,"PHASE3":54448,"PHASE4":54450,"NA":54452},{"trials":54439,"activeCount":103},[],{"trials":54441,"activeCount":103},[54442],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54443,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54444,"interventions":54445},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54447,"activeCount":103},[],{"trials":54449,"activeCount":103},[],{"trials":54451,"activeCount":103},[],{"trials":54453,"activeCount":103},[],{"intervention":54246,"totalTrials":302,"cells":54455},{"EARLY_PHASE1":54456,"PHASE1":54458,"PHASE2":54464,"PHASE3":54466,"PHASE4":54468,"NA":54470},{"trials":54457,"activeCount":103},[],{"trials":54459,"activeCount":103},[54460],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54461,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54462,"interventions":54463},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54465,"activeCount":103},[],{"trials":54467,"activeCount":103},[],{"trials":54469,"activeCount":103},[],{"trials":54471,"activeCount":103},[],{"intervention":54247,"totalTrials":302,"cells":54473},{"EARLY_PHASE1":54474,"PHASE1":54476,"PHASE2":54482,"PHASE3":54484,"PHASE4":54486,"NA":54488},{"trials":54475,"activeCount":103},[],{"trials":54477,"activeCount":103},[54478],{"nctId":54228,"briefTitle":54229,"status":111,"phases":54479,"primaryCompletion":29171,"completion":29171,"start":54231,"enrollment":1487,"conditions":54480,"interventions":54481},[91],[54233],[54221,54235,54236,54237,54238,54239,54240,54241,54242,54243,54244,54245,54246,54247],{"trials":54483,"activeCount":103},[],{"trials":54485,"activeCount":103},[],{"trials":54487,"activeCount":103},[],{"trials":54489,"activeCount":103},[],{"intervention":6248,"totalTrials":302,"cells":54491},{"EARLY_PHASE1":54492,"PHASE1":54494,"PHASE2":54500,"PHASE3":54502,"PHASE4":54504,"NA":54506},{"trials":54493,"activeCount":103},[],{"trials":54495,"activeCount":103},[54496],{"nctId":6240,"briefTitle":6241,"status":111,"phases":54497,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":6245,"conditions":54498,"interventions":54499},[91],[6191],[2082,6248,6249,1687,6250],{"trials":54501,"activeCount":103},[],{"trials":54503,"activeCount":103},[],{"trials":54505,"activeCount":103},[],{"trials":54507,"activeCount":103},[],{"intervention":6249,"totalTrials":302,"cells":54509},{"EARLY_PHASE1":54510,"PHASE1":54512,"PHASE2":54518,"PHASE3":54520,"PHASE4":54522,"NA":54524},{"trials":54511,"activeCount":103},[],{"trials":54513,"activeCount":103},[54514],{"nctId":6240,"briefTitle":6241,"status":111,"phases":54515,"primaryCompletion":6243,"completion":6243,"start":6244,"enrollment":6245,"conditions":54516,"interventions":54517},[91],[6191],[2082,6248,6249,1687,6250],{"trials":54519,"activeCount":103},[],{"trials":54521,"activeCount":103},[],{"trials":54523,"activeCount":103},[],{"trials":54525,"activeCount":103},[],{"intervention":1658,"totalTrials":302,"cells":54527},{"EARLY_PHASE1":54528,"PHASE1":54530,"PHASE2":54536,"PHASE3":54538,"PHASE4":54540,"NA":54542},{"trials":54529,"activeCount":103},[],{"trials":54531,"activeCount":103},[54532],{"nctId":1646,"briefTitle":1647,"status":649,"phases":54533,"primaryCompletion":1649,"completion":1650,"start":1651,"enrollment":103,"conditions":54534,"interventions":54535},[91],[31,1653,1654,1655,1656,750],[1658,1305,1658,1305,1658,1305,1658,1305,1658,1305,1658,1305,1658,1305],{"trials":54537,"activeCount":103},[],{"trials":54539,"activeCount":103},[],{"trials":54541,"activeCount":103},[],{"trials":54543,"activeCount":103},[],{"intervention":11913,"totalTrials":302,"cells":54545},{"EARLY_PHASE1":54546,"PHASE1":54548,"PHASE2":54554,"PHASE3":54556,"PHASE4":54558,"NA":54560},{"trials":54547,"activeCount":103},[],{"trials":54549,"activeCount":103},[54550],{"nctId":11908,"briefTitle":11909,"status":111,"phases":54551,"primaryCompletion":3839,"completion":3839,"start":3314,"enrollment":597,"conditions":54552,"interventions":54553},[91],[11904],[11885,11913],{"trials":54555,"activeCount":103},[],{"trials":54557,"activeCount":103},[],{"trials":54559,"activeCount":103},[],{"trials":54561,"activeCount":103},[],{"intervention":17744,"totalTrials":302,"cells":54563},{"EARLY_PHASE1":54564,"PHASE1":54566,"PHASE2":54572,"PHASE3":54574,"PHASE4":54576,"NA":54578},{"trials":54565,"activeCount":103},[],{"trials":54567,"activeCount":103},[54568],{"nctId":17739,"briefTitle":17740,"status":111,"phases":54569,"primaryCompletion":11014,"completion":11014,"start":4608,"enrollment":1268,"conditions":54570,"interventions":54571},[91],[13445,13444],[17744,17744,17745],{"trials":54573,"activeCount":103},[],{"trials":54575,"activeCount":103},[],{"trials":54577,"activeCount":103},[],{"trials":54579,"activeCount":103},[],{"intervention":39695,"totalTrials":302,"cells":54581},{"EARLY_PHASE1":54582,"PHASE1":54584,"PHASE2":54590,"PHASE3":54592,"PHASE4":54594,"NA":54596},{"trials":54583,"activeCount":103},[],{"trials":54585,"activeCount":103},[54586],{"nctId":39689,"briefTitle":39690,"status":111,"phases":54587,"primaryCompletion":539,"completion":539,"start":12810,"enrollment":2240,"conditions":54588,"interventions":54589},[91],[39693],[39675,39695],{"trials":54591,"activeCount":103},[],{"trials":54593,"activeCount":103},[],{"trials":54595,"activeCount":103},[],{"trials":54597,"activeCount":103},[],{"intervention":54599,"totalTrials":302,"cells":54600},"OAP-189",{"EARLY_PHASE1":54601,"PHASE1":54603,"PHASE2":54613,"PHASE3":54615,"PHASE4":54617,"NA":54619},{"trials":54602,"activeCount":103},[],{"trials":54604,"activeCount":103},[54605],{"nctId":54606,"briefTitle":54607,"status":111,"phases":54608,"primaryCompletion":54609,"completion":54609,"start":54610,"enrollment":6152,"conditions":54611,"interventions":54612},"NCT00970593","Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin",[91],"2011-07-25","2009-09-02",[6117],[54599],{"trials":54614,"activeCount":103},[],{"trials":54616,"activeCount":103},[],{"trials":54618,"activeCount":103},[],{"trials":54620,"activeCount":103},[],{"intervention":54622,"totalTrials":302,"cells":54623},"rLP2086 vaccine or control",{"EARLY_PHASE1":54624,"PHASE1":54626,"PHASE2":54634,"PHASE3":54636,"PHASE4":54638,"NA":54640},{"trials":54625,"activeCount":103},[],{"trials":54627,"activeCount":103},[54628],{"nctId":54629,"briefTitle":54630,"status":111,"phases":54631,"primaryCompletion":540,"completion":540,"start":4222,"enrollment":4369,"conditions":54632,"interventions":54633},"NCT00879814","Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults",[91],[24397],[54622,54622,54622,54622],{"trials":54635,"activeCount":103},[],{"trials":54637,"activeCount":103},[],{"trials":54639,"activeCount":103},[],{"trials":54641,"activeCount":103},[],{"intervention":54643,"totalTrials":302,"cells":54644},"PF-04991532 alone",{"EARLY_PHASE1":54645,"PHASE1":54647,"PHASE2":54657,"PHASE3":54659,"PHASE4":54661,"NA":54663},{"trials":54646,"activeCount":103},[],{"trials":54648,"activeCount":103},[54649],{"nctId":54650,"briefTitle":54651,"status":111,"phases":54652,"primaryCompletion":3313,"completion":3313,"start":3313,"enrollment":1268,"conditions":54653,"interventions":54655},"NCT01370343","Single Dose Study Of The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Health Volunteers",[91],[16,54654],"Drug Interaction",[54643,54656],"PF-04991532 + cyclosporine",{"trials":54658,"activeCount":103},[],{"trials":54660,"activeCount":103},[],{"trials":54662,"activeCount":103},[],{"trials":54664,"activeCount":103},[],{"intervention":54656,"totalTrials":302,"cells":54666},{"EARLY_PHASE1":54667,"PHASE1":54669,"PHASE2":54675,"PHASE3":54677,"PHASE4":54679,"NA":54681},{"trials":54668,"activeCount":103},[],{"trials":54670,"activeCount":103},[54671],{"nctId":54650,"briefTitle":54651,"status":111,"phases":54672,"primaryCompletion":3313,"completion":3313,"start":3313,"enrollment":1268,"conditions":54673,"interventions":54674},[91],[16,54654],[54643,54656],{"trials":54676,"activeCount":103},[],{"trials":54678,"activeCount":103},[],{"trials":54680,"activeCount":103},[],{"trials":54682,"activeCount":103},[],{"intervention":40865,"totalTrials":302,"cells":54684},{"EARLY_PHASE1":54685,"PHASE1":54687,"PHASE2":54693,"PHASE3":54695,"PHASE4":54697,"NA":54699},{"trials":54686,"activeCount":103},[],{"trials":54688,"activeCount":103},[54689],{"nctId":40860,"briefTitle":40861,"status":111,"phases":54690,"primaryCompletion":539,"completion":539,"start":3323,"enrollment":12497,"conditions":54691,"interventions":54692},[91],[21003],[40865,40844,40866],{"trials":54694,"activeCount":103},[],{"trials":54696,"activeCount":103},[],{"trials":54698,"activeCount":103},[],{"trials":54700,"activeCount":103},[],{"intervention":40866,"totalTrials":302,"cells":54702},{"EARLY_PHASE1":54703,"PHASE1":54705,"PHASE2":54711,"PHASE3":54713,"PHASE4":54715,"NA":54717},{"trials":54704,"activeCount":103},[],{"trials":54706,"activeCount":103},[54707],{"nctId":40860,"briefTitle":40861,"status":111,"phases":54708,"primaryCompletion":539,"completion":539,"start":3323,"enrollment":12497,"conditions":54709,"interventions":54710},[91],[21003],[40865,40844,40866],{"trials":54712,"activeCount":103},[],{"trials":54714,"activeCount":103},[],{"trials":54716,"activeCount":103},[],{"trials":54718,"activeCount":103},[],{"intervention":40310,"totalTrials":302,"cells":54720},{"EARLY_PHASE1":54721,"PHASE1":54723,"PHASE2":54729,"PHASE3":54731,"PHASE4":54733,"NA":54735},{"trials":54722,"activeCount":103},[],{"trials":54724,"activeCount":103},[54725],{"nctId":40303,"briefTitle":40304,"status":168,"phases":54726,"primaryCompletion":40306,"completion":40306,"start":40307,"enrollment":5647,"conditions":54727,"interventions":54728},[91],[16],[40288,40310],{"trials":54730,"activeCount":103},[],{"trials":54732,"activeCount":103},[],{"trials":54734,"activeCount":103},[],{"trials":54736,"activeCount":103},[],{"intervention":54738,"totalTrials":302,"cells":54739},"PF-06865571 100 mg",{"EARLY_PHASE1":54740,"PHASE1":54742,"PHASE2":54751,"PHASE3":54753,"PHASE4":54755,"NA":54757},{"trials":54741,"activeCount":103},[],{"trials":54743,"activeCount":103},[54744],{"nctId":54745,"briefTitle":54746,"status":111,"phases":54747,"primaryCompletion":3682,"completion":3682,"start":54748,"enrollment":1509,"conditions":54749,"interventions":54750},"NCT04091061","Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects",[91],"2019-10-03",[7853,19],[54738],{"trials":54752,"activeCount":103},[],{"trials":54754,"activeCount":103},[],{"trials":54756,"activeCount":103},[],{"trials":54758,"activeCount":103},[],{"intervention":13218,"totalTrials":302,"cells":54760},{"EARLY_PHASE1":54761,"PHASE1":54763,"PHASE2":54769,"PHASE3":54771,"PHASE4":54773,"NA":54775},{"trials":54762,"activeCount":103},[],{"trials":54764,"activeCount":103},[54765],{"nctId":13211,"briefTitle":13212,"status":111,"phases":54766,"primaryCompletion":13214,"completion":13214,"start":6263,"enrollment":13215,"conditions":54767,"interventions":54768},[91],[16],[13218,11295],{"trials":54770,"activeCount":103},[],{"trials":54772,"activeCount":103},[],{"trials":54774,"activeCount":103},[],{"trials":54776,"activeCount":103},[],{"intervention":54778,"totalTrials":302,"cells":54779},"metronidazole IV 500 mg",{"EARLY_PHASE1":54780,"PHASE1":54782,"PHASE2":54790,"PHASE3":54792,"PHASE4":54794,"NA":54796},{"trials":54781,"activeCount":103},[],{"trials":54783,"activeCount":103},[54784],{"nctId":54785,"briefTitle":54786,"status":111,"phases":54787,"primaryCompletion":9544,"completion":9544,"start":4531,"enrollment":2070,"conditions":54788,"interventions":54789},"NCT01407016","A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects",[91],[11494],[54778],{"trials":54791,"activeCount":103},[],{"trials":54793,"activeCount":103},[],{"trials":54795,"activeCount":103},[],{"trials":54797,"activeCount":103},[],{"intervention":54799,"totalTrials":302,"cells":54800},"PF-06650833 alone",{"EARLY_PHASE1":54801,"PHASE1":54803,"PHASE2":54814,"PHASE3":54816,"PHASE4":54818,"NA":54820},{"trials":54802,"activeCount":103},[],{"trials":54804,"activeCount":103},[54805],{"nctId":54806,"briefTitle":54807,"status":111,"phases":54808,"primaryCompletion":54809,"completion":54809,"start":10225,"enrollment":498,"conditions":54810,"interventions":54811},"NCT03827668","A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS",[91],"2019-04-29",[16],[54799,54812,54813],"PF-06651600 alone","PF-06650833 together with PF-06651600",{"trials":54815,"activeCount":103},[],{"trials":54817,"activeCount":103},[],{"trials":54819,"activeCount":103},[],{"trials":54821,"activeCount":103},[],{"intervention":54812,"totalTrials":302,"cells":54823},{"EARLY_PHASE1":54824,"PHASE1":54826,"PHASE2":54832,"PHASE3":54834,"PHASE4":54836,"NA":54838},{"trials":54825,"activeCount":103},[],{"trials":54827,"activeCount":103},[54828],{"nctId":54806,"briefTitle":54807,"status":111,"phases":54829,"primaryCompletion":54809,"completion":54809,"start":10225,"enrollment":498,"conditions":54830,"interventions":54831},[91],[16],[54799,54812,54813],{"trials":54833,"activeCount":103},[],{"trials":54835,"activeCount":103},[],{"trials":54837,"activeCount":103},[],{"trials":54839,"activeCount":103},[],{"intervention":54813,"totalTrials":302,"cells":54841},{"EARLY_PHASE1":54842,"PHASE1":54844,"PHASE2":54850,"PHASE3":54852,"PHASE4":54854,"NA":54856},{"trials":54843,"activeCount":103},[],{"trials":54845,"activeCount":103},[54846],{"nctId":54806,"briefTitle":54807,"status":111,"phases":54847,"primaryCompletion":54809,"completion":54809,"start":10225,"enrollment":498,"conditions":54848,"interventions":54849},[91],[16],[54799,54812,54813],{"trials":54851,"activeCount":103},[],{"trials":54853,"activeCount":103},[],{"trials":54855,"activeCount":103},[],{"trials":54857,"activeCount":103},[],{"intervention":54859,"totalTrials":302,"cells":54860},"tofacitinib modified release",{"EARLY_PHASE1":54861,"PHASE1":54863,"PHASE2":54871,"PHASE3":54873,"PHASE4":54875,"NA":54877},{"trials":54862,"activeCount":103},[],{"trials":54864,"activeCount":103},[54865],{"nctId":54866,"briefTitle":54867,"status":111,"phases":54868,"primaryCompletion":37042,"completion":37042,"start":3798,"enrollment":2218,"conditions":54869,"interventions":54870},"NCT04338711","A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations",[91],[16],[54859],{"trials":54872,"activeCount":103},[],{"trials":54874,"activeCount":103},[],{"trials":54876,"activeCount":103},[],{"trials":54878,"activeCount":103},[],{"intervention":54880,"totalTrials":302,"cells":54881},"Single dose of PF-07220060 as first Tablet Formulation",{"EARLY_PHASE1":54882,"PHASE1":54884,"PHASE2":54897,"PHASE3":54899,"PHASE4":54901,"NA":54903},{"trials":54883,"activeCount":103},[],{"trials":54885,"activeCount":103},[54886],{"nctId":54887,"briefTitle":54888,"status":111,"phases":54889,"primaryCompletion":54890,"completion":4566,"start":42558,"enrollment":35479,"conditions":54891,"interventions":54892},"NCT05923411","A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults",[91],"2024-06-23",[28],[54880,54893,54880,54893,54894,54895,54895,54896],"Single dose of PF-07220060 as second Tablet Formulation","Single dose of PF-07220060 as a Tablet Formulation","Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration","Single dose of PF-07220060 as third tablet formulation",{"trials":54898,"activeCount":103},[],{"trials":54900,"activeCount":103},[],{"trials":54902,"activeCount":103},[],{"trials":54904,"activeCount":103},[],{"intervention":54893,"totalTrials":302,"cells":54906},{"EARLY_PHASE1":54907,"PHASE1":54909,"PHASE2":54915,"PHASE3":54917,"PHASE4":54919,"NA":54921},{"trials":54908,"activeCount":103},[],{"trials":54910,"activeCount":103},[54911],{"nctId":54887,"briefTitle":54888,"status":111,"phases":54912,"primaryCompletion":54890,"completion":4566,"start":42558,"enrollment":35479,"conditions":54913,"interventions":54914},[91],[28],[54880,54893,54880,54893,54894,54895,54895,54896],{"trials":54916,"activeCount":103},[],{"trials":54918,"activeCount":103},[],{"trials":54920,"activeCount":103},[],{"trials":54922,"activeCount":103},[],{"intervention":54894,"totalTrials":302,"cells":54924},{"EARLY_PHASE1":54925,"PHASE1":54927,"PHASE2":54933,"PHASE3":54935,"PHASE4":54937,"NA":54939},{"trials":54926,"activeCount":103},[],{"trials":54928,"activeCount":103},[54929],{"nctId":54887,"briefTitle":54888,"status":111,"phases":54930,"primaryCompletion":54890,"completion":4566,"start":42558,"enrollment":35479,"conditions":54931,"interventions":54932},[91],[28],[54880,54893,54880,54893,54894,54895,54895,54896],{"trials":54934,"activeCount":103},[],{"trials":54936,"activeCount":103},[],{"trials":54938,"activeCount":103},[],{"trials":54940,"activeCount":103},[],{"intervention":54895,"totalTrials":302,"cells":54942},{"EARLY_PHASE1":54943,"PHASE1":54945,"PHASE2":54951,"PHASE3":54953,"PHASE4":54955,"NA":54957},{"trials":54944,"activeCount":103},[],{"trials":54946,"activeCount":103},[54947],{"nctId":54887,"briefTitle":54888,"status":111,"phases":54948,"primaryCompletion":54890,"completion":4566,"start":42558,"enrollment":35479,"conditions":54949,"interventions":54950},[91],[28],[54880,54893,54880,54893,54894,54895,54895,54896],{"trials":54952,"activeCount":103},[],{"trials":54954,"activeCount":103},[],{"trials":54956,"activeCount":103},[],{"trials":54958,"activeCount":103},[],{"intervention":54896,"totalTrials":302,"cells":54960},{"EARLY_PHASE1":54961,"PHASE1":54963,"PHASE2":54969,"PHASE3":54971,"PHASE4":54973,"NA":54975},{"trials":54962,"activeCount":103},[],{"trials":54964,"activeCount":103},[54965],{"nctId":54887,"briefTitle":54888,"status":111,"phases":54966,"primaryCompletion":54890,"completion":4566,"start":42558,"enrollment":35479,"conditions":54967,"interventions":54968},[91],[28],[54880,54893,54880,54893,54894,54895,54895,54896],{"trials":54970,"activeCount":103},[],{"trials":54972,"activeCount":103},[],{"trials":54974,"activeCount":103},[],{"trials":54976,"activeCount":103},[],{"intervention":54978,"totalTrials":302,"cells":54979},"Amlodipine - reference",{"EARLY_PHASE1":54980,"PHASE1":54982,"PHASE2":54991,"PHASE3":54993,"PHASE4":54995,"NA":54997},{"trials":54981,"activeCount":103},[],{"trials":54983,"activeCount":103},[54984],{"nctId":54985,"briefTitle":54986,"status":111,"phases":54987,"primaryCompletion":577,"completion":577,"start":3642,"enrollment":562,"conditions":54988,"interventions":54989},"NCT01177293","Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules",[91],[19],[54978,54990],"Amlodipine ODT - test",{"trials":54992,"activeCount":103},[],{"trials":54994,"activeCount":103},[],{"trials":54996,"activeCount":103},[],{"trials":54998,"activeCount":103},[],{"intervention":54990,"totalTrials":302,"cells":55000},{"EARLY_PHASE1":55001,"PHASE1":55003,"PHASE2":55009,"PHASE3":55011,"PHASE4":55013,"NA":55015},{"trials":55002,"activeCount":103},[],{"trials":55004,"activeCount":103},[55005],{"nctId":54985,"briefTitle":54986,"status":111,"phases":55006,"primaryCompletion":577,"completion":577,"start":3642,"enrollment":562,"conditions":55007,"interventions":55008},[91],[19],[54978,54990],{"trials":55010,"activeCount":103},[],{"trials":55012,"activeCount":103},[],{"trials":55014,"activeCount":103},[],{"trials":55016,"activeCount":103},[],{"intervention":55018,"totalTrials":302,"cells":55019},"PF-07260437",{"EARLY_PHASE1":55020,"PHASE1":55022,"PHASE2":55031,"PHASE3":55033,"PHASE4":55035,"NA":55037},{"trials":55021,"activeCount":103},[],{"trials":55023,"activeCount":103},[55024],{"nctId":55025,"briefTitle":55026,"status":168,"phases":55027,"primaryCompletion":55028,"completion":55028,"start":1121,"enrollment":1780,"conditions":55029,"interventions":55030},"NCT05067972","A Study of PF-07260437 in Advanced or Metastatic Solid Tumors",[91],"2023-10-17",[8476,1006,25],[55018],{"trials":55032,"activeCount":103},[],{"trials":55034,"activeCount":103},[],{"trials":55036,"activeCount":103},[],{"trials":55038,"activeCount":103},[],{"intervention":55040,"totalTrials":302,"cells":55041},"PF-06863135 monotherapy IV or SC",{"EARLY_PHASE1":55042,"PHASE1":55044,"PHASE2":55056,"PHASE3":55058,"PHASE4":55060,"NA":55062},{"trials":55043,"activeCount":103},[],{"trials":55045,"activeCount":103},[55046],{"nctId":55047,"briefTitle":55048,"status":111,"phases":55049,"primaryCompletion":3168,"completion":3168,"start":55050,"enrollment":1638,"conditions":55051,"interventions":55052},"NCT03269136","PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse\u002FRefractory Multiple Myeloma",[91],"2017-11-29",[1062],[55040,55053,55054,55055],"PF-06863135 + dexamethasone","PF-06863135 + lenalidomide","PF-06863135 + pomalidomide",{"trials":55057,"activeCount":103},[],{"trials":55059,"activeCount":103},[],{"trials":55061,"activeCount":103},[],{"trials":55063,"activeCount":103},[],{"intervention":55053,"totalTrials":302,"cells":55065},{"EARLY_PHASE1":55066,"PHASE1":55068,"PHASE2":55074,"PHASE3":55076,"PHASE4":55078,"NA":55080},{"trials":55067,"activeCount":103},[],{"trials":55069,"activeCount":103},[55070],{"nctId":55047,"briefTitle":55048,"status":111,"phases":55071,"primaryCompletion":3168,"completion":3168,"start":55050,"enrollment":1638,"conditions":55072,"interventions":55073},[91],[1062],[55040,55053,55054,55055],{"trials":55075,"activeCount":103},[],{"trials":55077,"activeCount":103},[],{"trials":55079,"activeCount":103},[],{"trials":55081,"activeCount":103},[],{"intervention":55054,"totalTrials":302,"cells":55083},{"EARLY_PHASE1":55084,"PHASE1":55086,"PHASE2":55092,"PHASE3":55094,"PHASE4":55096,"NA":55098},{"trials":55085,"activeCount":103},[],{"trials":55087,"activeCount":103},[55088],{"nctId":55047,"briefTitle":55048,"status":111,"phases":55089,"primaryCompletion":3168,"completion":3168,"start":55050,"enrollment":1638,"conditions":55090,"interventions":55091},[91],[1062],[55040,55053,55054,55055],{"trials":55093,"activeCount":103},[],{"trials":55095,"activeCount":103},[],{"trials":55097,"activeCount":103},[],{"trials":55099,"activeCount":103},[],{"intervention":55055,"totalTrials":302,"cells":55101},{"EARLY_PHASE1":55102,"PHASE1":55104,"PHASE2":55110,"PHASE3":55112,"PHASE4":55114,"NA":55116},{"trials":55103,"activeCount":103},[],{"trials":55105,"activeCount":103},[55106],{"nctId":55047,"briefTitle":55048,"status":111,"phases":55107,"primaryCompletion":3168,"completion":3168,"start":55050,"enrollment":1638,"conditions":55108,"interventions":55109},[91],[1062],[55040,55053,55054,55055],{"trials":55111,"activeCount":103},[],{"trials":55113,"activeCount":103},[],{"trials":55115,"activeCount":103},[],{"trials":55117,"activeCount":103},[],{"intervention":55119,"totalTrials":302,"cells":55120},"PF-06817024",{"EARLY_PHASE1":55121,"PHASE1":55123,"PHASE2":55134,"PHASE3":55136,"PHASE4":55138,"NA":55140},{"trials":55122,"activeCount":103},[],{"trials":55124,"activeCount":103},[55125],{"nctId":55126,"briefTitle":55127,"status":111,"phases":55128,"primaryCompletion":55129,"completion":55129,"start":55130,"enrollment":725,"conditions":55131,"interventions":55133},"NCT02743871","Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis",[91],"2021-03-09","2016-04-27",[16,55132,1589],"Chronic Rhinosinusitis With Nasal Polyps",[55119,55119,55119,55119,55119],{"trials":55135,"activeCount":103},[],{"trials":55137,"activeCount":103},[],{"trials":55139,"activeCount":103},[],{"trials":55141,"activeCount":103},[],{"intervention":55143,"totalTrials":302,"cells":55144},"Sunitinib, Pemetrexed",{"EARLY_PHASE1":55145,"PHASE1":55147,"PHASE2":55156,"PHASE3":55158,"PHASE4":55160,"NA":55162},{"trials":55146,"activeCount":103},[],{"trials":55148,"activeCount":103},[55149],{"nctId":55150,"briefTitle":55151,"status":111,"phases":55152,"primaryCompletion":6016,"completion":6016,"start":8115,"enrollment":1268,"conditions":55153,"interventions":55155},"NCT00732992","A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies",[91],[55154],"Neoplasm, Malignant",[55143,55143],{"trials":55157,"activeCount":103},[],{"trials":55159,"activeCount":103},[],{"trials":55161,"activeCount":103},[],{"trials":55163,"activeCount":103},[],{"intervention":55165,"totalTrials":302,"cells":55166},"BMP-655\u002FACS+Standard of care or Standard of care",{"EARLY_PHASE1":55167,"PHASE1":55169,"PHASE2":55177,"PHASE3":55179,"PHASE4":55181,"NA":55183},{"trials":55168,"activeCount":103},[],{"trials":55170,"activeCount":103},[55171],{"nctId":55172,"briefTitle":55173,"status":168,"phases":55174,"primaryCompletion":3334,"completion":3334,"start":577,"enrollment":2218,"conditions":55175,"interventions":55176},"NCT01122498","A Safety Study Of BMP-655\u002FACS As An Adjuvant Therapy For Treatment Of Rotator Cuff Tears",[91],[47108],[55165,55165,55165],{"trials":55178,"activeCount":103},[],{"trials":55180,"activeCount":103},[],{"trials":55182,"activeCount":103},[],{"trials":55184,"activeCount":103},[],{"intervention":6258,"totalTrials":302,"cells":55186},{"EARLY_PHASE1":55187,"PHASE1":55189,"PHASE2":55195,"PHASE3":55197,"PHASE4":55199,"NA":55201},{"trials":55188,"activeCount":103},[],{"trials":55190,"activeCount":103},[55191],{"nctId":6252,"briefTitle":6253,"status":111,"phases":55192,"primaryCompletion":6255,"completion":6255,"start":1082,"enrollment":26,"conditions":55193,"interventions":55194},[91],[3020,2761],[2841,1687,6169,6258],{"trials":55196,"activeCount":103},[],{"trials":55198,"activeCount":103},[],{"trials":55200,"activeCount":103},[],{"trials":55202,"activeCount":103},[],{"intervention":55204,"totalTrials":302,"cells":55205},"Oral [14C]PF-07220060",{"EARLY_PHASE1":55206,"PHASE1":55208,"PHASE2":55219,"PHASE3":55221,"PHASE4":55223,"NA":55225},{"trials":55207,"activeCount":103},[],{"trials":55209,"activeCount":103},[55210],{"nctId":55211,"briefTitle":55212,"status":111,"phases":55213,"primaryCompletion":10439,"completion":10439,"start":55214,"enrollment":1268,"conditions":55215,"interventions":55216},"NCT06267963","A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults",[91],"2024-01-31",[28],[55204,55217,55218],"Oral PF-07220060","IV [14C] PF-07220060",{"trials":55220,"activeCount":103},[],{"trials":55222,"activeCount":103},[],{"trials":55224,"activeCount":103},[],{"trials":55226,"activeCount":103},[],{"intervention":55217,"totalTrials":302,"cells":55228},{"EARLY_PHASE1":55229,"PHASE1":55231,"PHASE2":55237,"PHASE3":55239,"PHASE4":55241,"NA":55243},{"trials":55230,"activeCount":103},[],{"trials":55232,"activeCount":103},[55233],{"nctId":55211,"briefTitle":55212,"status":111,"phases":55234,"primaryCompletion":10439,"completion":10439,"start":55214,"enrollment":1268,"conditions":55235,"interventions":55236},[91],[28],[55204,55217,55218],{"trials":55238,"activeCount":103},[],{"trials":55240,"activeCount":103},[],{"trials":55242,"activeCount":103},[],{"trials":55244,"activeCount":103},[],{"intervention":55218,"totalTrials":302,"cells":55246},{"EARLY_PHASE1":55247,"PHASE1":55249,"PHASE2":55255,"PHASE3":55257,"PHASE4":55259,"NA":55261},{"trials":55248,"activeCount":103},[],{"trials":55250,"activeCount":103},[55251],{"nctId":55211,"briefTitle":55212,"status":111,"phases":55252,"primaryCompletion":10439,"completion":10439,"start":55214,"enrollment":1268,"conditions":55253,"interventions":55254},[91],[28],[55204,55217,55218],{"trials":55256,"activeCount":103},[],{"trials":55258,"activeCount":103},[],{"trials":55260,"activeCount":103},[],{"trials":55262,"activeCount":103},[],{"intervention":55264,"totalTrials":302,"cells":55265},"alprazolam sublingual tablet commercial",{"EARLY_PHASE1":55266,"PHASE1":55268,"PHASE2":55277,"PHASE3":55279,"PHASE4":55281,"NA":55283},{"trials":55267,"activeCount":103},[],{"trials":55269,"activeCount":103},[55270],{"nctId":55271,"briefTitle":55272,"status":649,"phases":55273,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":103,"conditions":55274,"interventions":55275},"NCT00877955","Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation",[91],[16],[55264,55276],"alprazolam sublingual tablet test",{"trials":55278,"activeCount":103},[],{"trials":55280,"activeCount":103},[],{"trials":55282,"activeCount":103},[],{"trials":55284,"activeCount":103},[],{"intervention":55276,"totalTrials":302,"cells":55286},{"EARLY_PHASE1":55287,"PHASE1":55289,"PHASE2":55295,"PHASE3":55297,"PHASE4":55299,"NA":55301},{"trials":55288,"activeCount":103},[],{"trials":55290,"activeCount":103},[55291],{"nctId":55271,"briefTitle":55272,"status":649,"phases":55292,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":103,"conditions":55293,"interventions":55294},[91],[16],[55264,55276],{"trials":55296,"activeCount":103},[],{"trials":55298,"activeCount":103},[],{"trials":55300,"activeCount":103},[],{"trials":55302,"activeCount":103},[],{"intervention":55304,"totalTrials":302,"cells":55305},"Xanax XR tablets 3 mg",{"EARLY_PHASE1":55306,"PHASE1":55308,"PHASE2":55316,"PHASE3":55318,"PHASE4":55320,"NA":55322},{"trials":55307,"activeCount":103},[],{"trials":55309,"activeCount":103},[55310],{"nctId":55311,"briefTitle":55312,"status":111,"phases":55313,"primaryCompletion":2661,"completion":2661,"start":11170,"enrollment":314,"conditions":55314,"interventions":55315},"NCT01330472","An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites",[91],[10985],[55304,55304],{"trials":55317,"activeCount":103},[],{"trials":55319,"activeCount":103},[],{"trials":55321,"activeCount":103},[],{"trials":55323,"activeCount":103},[],{"intervention":55325,"totalTrials":302,"cells":55326},"PF-07612577",{"EARLY_PHASE1":55327,"PHASE1":55329,"PHASE2":55338,"PHASE3":55340,"PHASE4":55342,"NA":55344},{"trials":55328,"activeCount":103},[],{"trials":55330,"activeCount":103},[55331],{"nctId":55332,"briefTitle":55333,"status":111,"phases":55334,"primaryCompletion":419,"completion":419,"start":11556,"enrollment":1578,"conditions":55335,"interventions":55336},"NCT05554237","A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.",[91],[16],[55325,55337],"PF-06264006",{"trials":55339,"activeCount":103},[],{"trials":55341,"activeCount":103},[],{"trials":55343,"activeCount":103},[],{"trials":55345,"activeCount":103},[],{"intervention":55337,"totalTrials":302,"cells":55347},{"EARLY_PHASE1":55348,"PHASE1":55350,"PHASE2":55356,"PHASE3":55358,"PHASE4":55360,"NA":55362},{"trials":55349,"activeCount":103},[],{"trials":55351,"activeCount":103},[55352],{"nctId":55332,"briefTitle":55333,"status":111,"phases":55353,"primaryCompletion":419,"completion":419,"start":11556,"enrollment":1578,"conditions":55354,"interventions":55355},[91],[16],[55325,55337],{"trials":55357,"activeCount":103},[],{"trials":55359,"activeCount":103},[],{"trials":55361,"activeCount":103},[],{"trials":55363,"activeCount":103},[],{"intervention":55365,"totalTrials":302,"cells":55366},"PF 03882845 and Placebo",{"EARLY_PHASE1":55367,"PHASE1":55369,"PHASE2":55377,"PHASE3":55379,"PHASE4":55381,"NA":55383},{"trials":55368,"activeCount":103},[],{"trials":55370,"activeCount":103},[55371],{"nctId":55372,"briefTitle":55373,"status":168,"phases":55374,"primaryCompletion":4646,"completion":4646,"start":11290,"enrollment":870,"conditions":55375,"interventions":55376},"NCT00856258","Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845",[91],[19],[55365,55365,55365,55365],{"trials":55378,"activeCount":103},[],{"trials":55380,"activeCount":103},[],{"trials":55382,"activeCount":103},[],{"trials":55384,"activeCount":103},[],{"intervention":55386,"totalTrials":302,"cells":55387},"ATR-107 (PF-05230900) SC",{"EARLY_PHASE1":55388,"PHASE1":55390,"PHASE2":55399,"PHASE3":55401,"PHASE4":55403,"NA":55405},{"trials":55389,"activeCount":103},[],{"trials":55391,"activeCount":103},[55392],{"nctId":55393,"briefTitle":55394,"status":168,"phases":55395,"primaryCompletion":10912,"completion":10912,"start":577,"enrollment":27035,"conditions":55396,"interventions":55397},"NCT01162889","Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People",[91],[16],[55386,55386,55386,55386,55386,55398,55398,55398,55398],"ATR-107 (PF-05230900) IV",{"trials":55400,"activeCount":103},[],{"trials":55402,"activeCount":103},[],{"trials":55404,"activeCount":103},[],{"trials":55406,"activeCount":103},[],{"intervention":55398,"totalTrials":302,"cells":55408},{"EARLY_PHASE1":55409,"PHASE1":55411,"PHASE2":55417,"PHASE3":55419,"PHASE4":55421,"NA":55423},{"trials":55410,"activeCount":103},[],{"trials":55412,"activeCount":103},[55413],{"nctId":55393,"briefTitle":55394,"status":168,"phases":55414,"primaryCompletion":10912,"completion":10912,"start":577,"enrollment":27035,"conditions":55415,"interventions":55416},[91],[16],[55386,55386,55386,55386,55386,55398,55398,55398,55398],{"trials":55418,"activeCount":103},[],{"trials":55420,"activeCount":103},[],{"trials":55422,"activeCount":103},[],{"trials":55424,"activeCount":103},[],{"intervention":55426,"totalTrials":302,"cells":55427},"PF-06755347 intravenous healthy participant",{"EARLY_PHASE1":55428,"PHASE1":55430,"PHASE2":55443,"PHASE3":55445,"PHASE4":55447,"NA":55449},{"trials":55429,"activeCount":103},[],{"trials":55431,"activeCount":103},[55432],{"nctId":55433,"briefTitle":55434,"status":168,"phases":55435,"primaryCompletion":55436,"completion":55436,"start":28618,"enrollment":1587,"conditions":55437,"interventions":55440},"NCT03275740","A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347",[91],"2023-01-06",[16,55438,55439],"Primary Immune Thrombocytopenia","Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",[55426,55441,55442],"PF-06755347 subcutaneous healthy participant","PF-06755347 subcutaneous ITP",{"trials":55444,"activeCount":103},[],{"trials":55446,"activeCount":103},[],{"trials":55448,"activeCount":103},[],{"trials":55450,"activeCount":103},[],{"intervention":55441,"totalTrials":302,"cells":55452},{"EARLY_PHASE1":55453,"PHASE1":55455,"PHASE2":55461,"PHASE3":55463,"PHASE4":55465,"NA":55467},{"trials":55454,"activeCount":103},[],{"trials":55456,"activeCount":103},[55457],{"nctId":55433,"briefTitle":55434,"status":168,"phases":55458,"primaryCompletion":55436,"completion":55436,"start":28618,"enrollment":1587,"conditions":55459,"interventions":55460},[91],[16,55438,55439],[55426,55441,55442],{"trials":55462,"activeCount":103},[],{"trials":55464,"activeCount":103},[],{"trials":55466,"activeCount":103},[],{"trials":55468,"activeCount":103},[],{"intervention":55442,"totalTrials":302,"cells":55470},{"EARLY_PHASE1":55471,"PHASE1":55473,"PHASE2":55479,"PHASE3":55481,"PHASE4":55483,"NA":55485},{"trials":55472,"activeCount":103},[],{"trials":55474,"activeCount":103},[55475],{"nctId":55433,"briefTitle":55434,"status":168,"phases":55476,"primaryCompletion":55436,"completion":55436,"start":28618,"enrollment":1587,"conditions":55477,"interventions":55478},[91],[16,55438,55439],[55426,55441,55442],{"trials":55480,"activeCount":103},[],{"trials":55482,"activeCount":103},[],{"trials":55484,"activeCount":103},[],{"trials":55486,"activeCount":103},[],{"intervention":55488,"totalTrials":302,"cells":55489},"PF-06763809",{"EARLY_PHASE1":55490,"PHASE1":55492,"PHASE2":55504,"PHASE3":55506,"PHASE4":55508,"NA":55510},{"trials":55491,"activeCount":103},[],{"trials":55493,"activeCount":103},[55494],{"nctId":55495,"briefTitle":55496,"status":111,"phases":55497,"primaryCompletion":55498,"completion":55498,"start":55499,"enrollment":597,"conditions":55500,"interventions":55501},"NCT03469336","Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis",[91],"2019-03-20","2018-04-24",[4401],[55488,55502,55503],"Calcipotriene\u002Fcalcipotriol","Betamethasone",{"trials":55505,"activeCount":103},[],{"trials":55507,"activeCount":103},[],{"trials":55509,"activeCount":103},[],{"trials":55511,"activeCount":103},[],{"intervention":55502,"totalTrials":302,"cells":55513},{"EARLY_PHASE1":55514,"PHASE1":55516,"PHASE2":55522,"PHASE3":55524,"PHASE4":55526,"NA":55528},{"trials":55515,"activeCount":103},[],{"trials":55517,"activeCount":103},[55518],{"nctId":55495,"briefTitle":55496,"status":111,"phases":55519,"primaryCompletion":55498,"completion":55498,"start":55499,"enrollment":597,"conditions":55520,"interventions":55521},[91],[4401],[55488,55502,55503],{"trials":55523,"activeCount":103},[],{"trials":55525,"activeCount":103},[],{"trials":55527,"activeCount":103},[],{"trials":55529,"activeCount":103},[],{"intervention":55503,"totalTrials":302,"cells":55531},{"EARLY_PHASE1":55532,"PHASE1":55534,"PHASE2":55540,"PHASE3":55542,"PHASE4":55544,"NA":55546},{"trials":55533,"activeCount":103},[],{"trials":55535,"activeCount":103},[55536],{"nctId":55495,"briefTitle":55496,"status":111,"phases":55537,"primaryCompletion":55498,"completion":55498,"start":55499,"enrollment":597,"conditions":55538,"interventions":55539},[91],[4401],[55488,55502,55503],{"trials":55541,"activeCount":103},[],{"trials":55543,"activeCount":103},[],{"trials":55545,"activeCount":103},[],{"trials":55547,"activeCount":103},[],{"intervention":39958,"totalTrials":302,"cells":55549},{"EARLY_PHASE1":55550,"PHASE1":55552,"PHASE2":55558,"PHASE3":55560,"PHASE4":55562,"NA":55564},{"trials":55551,"activeCount":103},[],{"trials":55553,"activeCount":103},[55554],{"nctId":39953,"briefTitle":39954,"status":111,"phases":55555,"primaryCompletion":6208,"completion":6208,"start":4590,"enrollment":1578,"conditions":55556,"interventions":55557},[91],[7957],[39939,39951,39958],{"trials":55559,"activeCount":103},[],{"trials":55561,"activeCount":103},[],{"trials":55563,"activeCount":103},[],{"trials":55565,"activeCount":103},[],{"intervention":55567,"totalTrials":302,"cells":55568},"Scopolamine + Donepezil Placebo + PF-04995274 Placebo",{"EARLY_PHASE1":55569,"PHASE1":55571,"PHASE2":55583,"PHASE3":55585,"PHASE4":55587,"NA":55589},{"trials":55570,"activeCount":103},[],{"trials":55572,"activeCount":103},[55573],{"nctId":55574,"briefTitle":55575,"status":168,"phases":55576,"primaryCompletion":3313,"completion":4531,"start":11170,"enrollment":541,"conditions":55577,"interventions":55578},"NCT01345864","Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults",[91],[16],[55567,55579,55580,55581,55582],"Scopolamine + Donepezil 5 mg + PF-04995274 Placebo","Scopolamine + Donepezil 10mg + PF-04995274 Placebo","Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg","Scopolamine + Donepezil Placebo + PF-04995274 15 mg",{"trials":55584,"activeCount":103},[],{"trials":55586,"activeCount":103},[],{"trials":55588,"activeCount":103},[],{"trials":55590,"activeCount":103},[],{"intervention":55579,"totalTrials":302,"cells":55592},{"EARLY_PHASE1":55593,"PHASE1":55595,"PHASE2":55601,"PHASE3":55603,"PHASE4":55605,"NA":55607},{"trials":55594,"activeCount":103},[],{"trials":55596,"activeCount":103},[55597],{"nctId":55574,"briefTitle":55575,"status":168,"phases":55598,"primaryCompletion":3313,"completion":4531,"start":11170,"enrollment":541,"conditions":55599,"interventions":55600},[91],[16],[55567,55579,55580,55581,55582],{"trials":55602,"activeCount":103},[],{"trials":55604,"activeCount":103},[],{"trials":55606,"activeCount":103},[],{"trials":55608,"activeCount":103},[],{"intervention":55580,"totalTrials":302,"cells":55610},{"EARLY_PHASE1":55611,"PHASE1":55613,"PHASE2":55619,"PHASE3":55621,"PHASE4":55623,"NA":55625},{"trials":55612,"activeCount":103},[],{"trials":55614,"activeCount":103},[55615],{"nctId":55574,"briefTitle":55575,"status":168,"phases":55616,"primaryCompletion":3313,"completion":4531,"start":11170,"enrollment":541,"conditions":55617,"interventions":55618},[91],[16],[55567,55579,55580,55581,55582],{"trials":55620,"activeCount":103},[],{"trials":55622,"activeCount":103},[],{"trials":55624,"activeCount":103},[],{"trials":55626,"activeCount":103},[],{"intervention":55581,"totalTrials":302,"cells":55628},{"EARLY_PHASE1":55629,"PHASE1":55631,"PHASE2":55637,"PHASE3":55639,"PHASE4":55641,"NA":55643},{"trials":55630,"activeCount":103},[],{"trials":55632,"activeCount":103},[55633],{"nctId":55574,"briefTitle":55575,"status":168,"phases":55634,"primaryCompletion":3313,"completion":4531,"start":11170,"enrollment":541,"conditions":55635,"interventions":55636},[91],[16],[55567,55579,55580,55581,55582],{"trials":55638,"activeCount":103},[],{"trials":55640,"activeCount":103},[],{"trials":55642,"activeCount":103},[],{"trials":55644,"activeCount":103},[],{"intervention":55582,"totalTrials":302,"cells":55646},{"EARLY_PHASE1":55647,"PHASE1":55649,"PHASE2":55655,"PHASE3":55657,"PHASE4":55659,"NA":55661},{"trials":55648,"activeCount":103},[],{"trials":55650,"activeCount":103},[55651],{"nctId":55574,"briefTitle":55575,"status":168,"phases":55652,"primaryCompletion":3313,"completion":4531,"start":11170,"enrollment":541,"conditions":55653,"interventions":55654},[91],[16],[55567,55579,55580,55581,55582],{"trials":55656,"activeCount":103},[],{"trials":55658,"activeCount":103},[],{"trials":55660,"activeCount":103},[],{"trials":55662,"activeCount":103},[],{"intervention":41334,"totalTrials":302,"cells":55664},{"EARLY_PHASE1":55665,"PHASE1":55667,"PHASE2":55673,"PHASE3":55675,"PHASE4":55677,"NA":55679},{"trials":55666,"activeCount":103},[],{"trials":55668,"activeCount":103},[55669],{"nctId":41329,"briefTitle":41330,"status":111,"phases":55670,"primaryCompletion":11290,"completion":11290,"start":8154,"enrollment":2175,"conditions":55671,"interventions":55672},[91],[19825],[41334,41335,41336,41335,41314],{"trials":55674,"activeCount":103},[],{"trials":55676,"activeCount":103},[],{"trials":55678,"activeCount":103},[],{"trials":55680,"activeCount":103},[],{"intervention":41335,"totalTrials":302,"cells":55682},{"EARLY_PHASE1":55683,"PHASE1":55685,"PHASE2":55691,"PHASE3":55693,"PHASE4":55695,"NA":55697},{"trials":55684,"activeCount":103},[],{"trials":55686,"activeCount":103},[55687],{"nctId":41329,"briefTitle":41330,"status":111,"phases":55688,"primaryCompletion":11290,"completion":11290,"start":8154,"enrollment":2175,"conditions":55689,"interventions":55690},[91],[19825],[41334,41335,41336,41335,41314],{"trials":55692,"activeCount":103},[],{"trials":55694,"activeCount":103},[],{"trials":55696,"activeCount":103},[],{"trials":55698,"activeCount":103},[],{"intervention":41336,"totalTrials":302,"cells":55700},{"EARLY_PHASE1":55701,"PHASE1":55703,"PHASE2":55709,"PHASE3":55711,"PHASE4":55713,"NA":55715},{"trials":55702,"activeCount":103},[],{"trials":55704,"activeCount":103},[55705],{"nctId":41329,"briefTitle":41330,"status":111,"phases":55706,"primaryCompletion":11290,"completion":11290,"start":8154,"enrollment":2175,"conditions":55707,"interventions":55708},[91],[19825],[41334,41335,41336,41335,41314],{"trials":55710,"activeCount":103},[],{"trials":55712,"activeCount":103},[],{"trials":55714,"activeCount":103},[],{"trials":55716,"activeCount":103},[],{"intervention":55718,"totalTrials":302,"cells":55719},"PF-06852231",{"EARLY_PHASE1":55720,"PHASE1":55722,"PHASE2":55731,"PHASE3":55733,"PHASE4":55735,"NA":55737},{"trials":55721,"activeCount":103},[],{"trials":55723,"activeCount":103},[55724],{"nctId":55725,"briefTitle":55726,"status":111,"phases":55727,"primaryCompletion":55728,"completion":55728,"start":28617,"enrollment":7500,"conditions":55729,"interventions":55730},"NCT03217604","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects",[91],"2018-02-01",[19],[55718],{"trials":55732,"activeCount":103},[],{"trials":55734,"activeCount":103},[],{"trials":55736,"activeCount":103},[],{"trials":55738,"activeCount":103},[],{"intervention":55740,"totalTrials":302,"cells":55741},"Vitamin D + Sham Exercise",{"EARLY_PHASE1":55742,"PHASE1":55744,"PHASE2":55754,"PHASE3":55756,"PHASE4":55758,"NA":55760},{"trials":55743,"activeCount":103},[],{"trials":55745,"activeCount":103},[55746],{"nctId":55747,"briefTitle":55748,"status":168,"phases":55749,"completion":3853,"start":9387,"enrollment":7363,"conditions":55750,"interventions":55752},"NCT00249704","Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects",[91],[55751],"Elderly, Frail",[55740,55753],"Vitamin D + Exercise",{"trials":55755,"activeCount":103},[],{"trials":55757,"activeCount":103},[],{"trials":55759,"activeCount":103},[],{"trials":55761,"activeCount":103},[],{"intervention":55753,"totalTrials":302,"cells":55763},{"EARLY_PHASE1":55764,"PHASE1":55766,"PHASE2":55772,"PHASE3":55774,"PHASE4":55776,"NA":55778},{"trials":55765,"activeCount":103},[],{"trials":55767,"activeCount":103},[55768],{"nctId":55747,"briefTitle":55748,"status":168,"phases":55769,"completion":3853,"start":9387,"enrollment":7363,"conditions":55770,"interventions":55771},[91],[55751],[55740,55753],{"trials":55773,"activeCount":103},[],{"trials":55775,"activeCount":103},[],{"trials":55777,"activeCount":103},[],{"trials":55779,"activeCount":103},[],{"intervention":55781,"totalTrials":302,"cells":55782},"AN3365",{"EARLY_PHASE1":55783,"PHASE1":55785,"PHASE2":55794,"PHASE3":55796,"PHASE4":55798,"NA":55800},{"trials":55784,"activeCount":103},[],{"trials":55786,"activeCount":103},[55787],{"nctId":55788,"briefTitle":55789,"status":111,"phases":55790,"primaryCompletion":55791,"completion":55791,"start":32024,"enrollment":7363,"conditions":55792,"interventions":55793},"NCT01015014","Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections",[91],"2010-05-13",[7322],[55781],{"trials":55795,"activeCount":103},[],{"trials":55797,"activeCount":103},[],{"trials":55799,"activeCount":103},[],{"trials":55801,"activeCount":103},[],{"intervention":16933,"totalTrials":302,"cells":55803},{"EARLY_PHASE1":55804,"PHASE1":55806,"PHASE2":55812,"PHASE3":55814,"PHASE4":55816,"NA":55818},{"trials":55805,"activeCount":103},[],{"trials":55807,"activeCount":103},[55808],{"nctId":16928,"briefTitle":16929,"status":111,"phases":55809,"primaryCompletion":4833,"completion":4833,"start":4627,"enrollment":2240,"conditions":55810,"interventions":55811},[91],[19],[3339,16933],{"trials":55813,"activeCount":103},[],{"trials":55815,"activeCount":103},[],{"trials":55817,"activeCount":103},[],{"trials":55819,"activeCount":103},[],{"intervention":55821,"totalTrials":302,"cells":55822},"PF-06647020 Q3W",{"EARLY_PHASE1":55823,"PHASE1":55825,"PHASE2":55837,"PHASE3":55839,"PHASE4":55841,"NA":55843},{"trials":55824,"activeCount":103},[],{"trials":55826,"activeCount":103},[55827],{"nctId":55828,"briefTitle":55829,"status":111,"phases":55830,"primaryCompletion":38272,"completion":38272,"start":55831,"enrollment":885,"conditions":55832,"interventions":55833},"NCT02222922","A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors",[91],"2014-10-17",[2053],[55821,55834,55835,55836],"fluconazole","PF-06647020 Q2W","PF-06647020 combined with Avelumab",{"trials":55838,"activeCount":103},[],{"trials":55840,"activeCount":103},[],{"trials":55842,"activeCount":103},[],{"trials":55844,"activeCount":103},[],{"intervention":55835,"totalTrials":302,"cells":55846},{"EARLY_PHASE1":55847,"PHASE1":55849,"PHASE2":55855,"PHASE3":55857,"PHASE4":55859,"NA":55861},{"trials":55848,"activeCount":103},[],{"trials":55850,"activeCount":103},[55851],{"nctId":55828,"briefTitle":55829,"status":111,"phases":55852,"primaryCompletion":38272,"completion":38272,"start":55831,"enrollment":885,"conditions":55853,"interventions":55854},[91],[2053],[55821,55834,55835,55836],{"trials":55856,"activeCount":103},[],{"trials":55858,"activeCount":103},[],{"trials":55860,"activeCount":103},[],{"trials":55862,"activeCount":103},[],{"intervention":55836,"totalTrials":302,"cells":55864},{"EARLY_PHASE1":55865,"PHASE1":55867,"PHASE2":55873,"PHASE3":55875,"PHASE4":55877,"NA":55879},{"trials":55866,"activeCount":103},[],{"trials":55868,"activeCount":103},[55869],{"nctId":55828,"briefTitle":55829,"status":111,"phases":55870,"primaryCompletion":38272,"completion":38272,"start":55831,"enrollment":885,"conditions":55871,"interventions":55872},[91],[2053],[55821,55834,55835,55836],{"trials":55874,"activeCount":103},[],{"trials":55876,"activeCount":103},[],{"trials":55878,"activeCount":103},[],{"trials":55880,"activeCount":103},[],{"intervention":18541,"totalTrials":302,"cells":55882},{"EARLY_PHASE1":55883,"PHASE1":55885,"PHASE2":55891,"PHASE3":55893,"PHASE4":55895,"NA":55897},{"trials":55884,"activeCount":103},[],{"trials":55886,"activeCount":103},[55887],{"nctId":18531,"briefTitle":18532,"status":111,"phases":55888,"primaryCompletion":18534,"completion":18535,"start":18536,"enrollment":1268,"conditions":55889,"interventions":55890},[91],[18538],[18540,18541],{"trials":55892,"activeCount":103},[],{"trials":55894,"activeCount":103},[],{"trials":55896,"activeCount":103},[],{"trials":55898,"activeCount":103},[],{"intervention":55900,"totalTrials":302,"cells":55901},"PF-06842874",{"EARLY_PHASE1":55902,"PHASE1":55904,"PHASE2":55914,"PHASE3":55916,"PHASE4":55918,"NA":55920},{"trials":55903,"activeCount":103},[],{"trials":55905,"activeCount":103},[55906],{"nctId":55907,"briefTitle":55908,"status":111,"phases":55909,"primaryCompletion":55910,"completion":55910,"start":11177,"enrollment":29,"conditions":55911,"interventions":55912},"NCT04124653","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants",[91],"2021-07-26",[28],[55900,55913],"Relative Bioavailability",{"trials":55915,"activeCount":103},[],{"trials":55917,"activeCount":103},[],{"trials":55919,"activeCount":103},[],{"trials":55921,"activeCount":103},[],{"intervention":55913,"totalTrials":302,"cells":55923},{"EARLY_PHASE1":55924,"PHASE1":55926,"PHASE2":55932,"PHASE3":55934,"PHASE4":55936,"NA":55938},{"trials":55925,"activeCount":103},[],{"trials":55927,"activeCount":103},[55928],{"nctId":55907,"briefTitle":55908,"status":111,"phases":55929,"primaryCompletion":55910,"completion":55910,"start":11177,"enrollment":29,"conditions":55930,"interventions":55931},[91],[28],[55900,55913],{"trials":55933,"activeCount":103},[],{"trials":55935,"activeCount":103},[],{"trials":55937,"activeCount":103},[],{"trials":55939,"activeCount":103},[],{"intervention":55941,"totalTrials":302,"cells":55942},"200 mg RV521\u002F78 µCi [ 14C]-RV521.",{"EARLY_PHASE1":55943,"PHASE1":55945,"PHASE2":55954,"PHASE3":55956,"PHASE4":55958,"NA":55960},{"trials":55944,"activeCount":103},[],{"trials":55946,"activeCount":103},[55947],{"nctId":55948,"briefTitle":55949,"status":111,"phases":55950,"primaryCompletion":5808,"completion":5808,"start":55951,"enrollment":627,"conditions":55952,"interventions":55953},"NCT05873764","A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants",[91],"2022-05-25",[6191],[55941],{"trials":55955,"activeCount":103},[],{"trials":55957,"activeCount":103},[],{"trials":55959,"activeCount":103},[],{"trials":55961,"activeCount":103},[],{"intervention":39664,"totalTrials":302,"cells":55963},{"EARLY_PHASE1":55964,"PHASE1":55966,"PHASE2":55972,"PHASE3":55974,"PHASE4":55976,"NA":55978},{"trials":55965,"activeCount":103},[],{"trials":55967,"activeCount":103},[55968],{"nctId":39659,"briefTitle":39660,"status":111,"phases":55969,"primaryCompletion":2661,"completion":2661,"start":523,"enrollment":1509,"conditions":55970,"interventions":55971},[91],[16],[39664,39665,39634],{"trials":55973,"activeCount":103},[],{"trials":55975,"activeCount":103},[],{"trials":55977,"activeCount":103},[],{"trials":55979,"activeCount":103},[],{"intervention":39665,"totalTrials":302,"cells":55981},{"EARLY_PHASE1":55982,"PHASE1":55984,"PHASE2":55990,"PHASE3":55992,"PHASE4":55994,"NA":55996},{"trials":55983,"activeCount":103},[],{"trials":55985,"activeCount":103},[55986],{"nctId":39659,"briefTitle":39660,"status":111,"phases":55987,"primaryCompletion":2661,"completion":2661,"start":523,"enrollment":1509,"conditions":55988,"interventions":55989},[91],[16],[39664,39665,39634],{"trials":55991,"activeCount":103},[],{"trials":55993,"activeCount":103},[],{"trials":55995,"activeCount":103},[],{"trials":55997,"activeCount":103},[],{"intervention":55999,"totalTrials":302,"cells":56000},"450mg",{"EARLY_PHASE1":56001,"PHASE1":56003,"PHASE2":56013,"PHASE3":56015,"PHASE4":56017,"NA":56019},{"trials":56002,"activeCount":103},[],{"trials":56004,"activeCount":103},[56005],{"nctId":56006,"briefTitle":56007,"status":111,"phases":56008,"primaryCompletion":56009,"completion":56009,"start":3411,"enrollment":1268,"conditions":56010,"interventions":56011},"NCT05107492","Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants",[91],"2022-04-09",[47150],[55999,56012],"150mg",{"trials":56014,"activeCount":103},[],{"trials":56016,"activeCount":103},[],{"trials":56018,"activeCount":103},[],{"trials":56020,"activeCount":103},[],{"intervention":56012,"totalTrials":302,"cells":56022},{"EARLY_PHASE1":56023,"PHASE1":56025,"PHASE2":56031,"PHASE3":56033,"PHASE4":56035,"NA":56037},{"trials":56024,"activeCount":103},[],{"trials":56026,"activeCount":103},[56027],{"nctId":56006,"briefTitle":56007,"status":111,"phases":56028,"primaryCompletion":56009,"completion":56009,"start":3411,"enrollment":1268,"conditions":56029,"interventions":56030},[91],[47150],[55999,56012],{"trials":56032,"activeCount":103},[],{"trials":56034,"activeCount":103},[],{"trials":56036,"activeCount":103},[],{"trials":56038,"activeCount":103},[],{"intervention":6274,"totalTrials":302,"cells":56040},{"EARLY_PHASE1":56041,"PHASE1":56043,"PHASE2":56049,"PHASE3":56051,"PHASE4":56053,"NA":56055},{"trials":56042,"activeCount":103},[],{"trials":56044,"activeCount":103},[56045],{"nctId":6267,"briefTitle":6268,"status":111,"phases":56046,"primaryCompletion":6270,"completion":6270,"start":6271,"enrollment":2713,"conditions":56047,"interventions":56048},[91],[28],[6274,1687],{"trials":56050,"activeCount":103},[],{"trials":56052,"activeCount":103},[],{"trials":56054,"activeCount":103},[],{"trials":56056,"activeCount":103},[],{"intervention":56058,"totalTrials":302,"cells":56059},"dose level 1",{"EARLY_PHASE1":56060,"PHASE1":56062,"PHASE2":56074,"PHASE3":56076,"PHASE4":56078,"NA":56080},{"trials":56061,"activeCount":103},[],{"trials":56063,"activeCount":103},[56064],{"nctId":56065,"briefTitle":56066,"status":111,"phases":56067,"primaryCompletion":20210,"completion":20210,"start":56068,"enrollment":713,"conditions":56069,"interventions":56070},"NCT00838565","Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis",[91],"2009-05-20",[22],[56058,56071,56072,56073],"dose level 2","dose level 3","dose level 4",{"trials":56075,"activeCount":103},[],{"trials":56077,"activeCount":103},[],{"trials":56079,"activeCount":103},[],{"trials":56081,"activeCount":103},[],{"intervention":56071,"totalTrials":302,"cells":56083},{"EARLY_PHASE1":56084,"PHASE1":56086,"PHASE2":56092,"PHASE3":56094,"PHASE4":56096,"NA":56098},{"trials":56085,"activeCount":103},[],{"trials":56087,"activeCount":103},[56088],{"nctId":56065,"briefTitle":56066,"status":111,"phases":56089,"primaryCompletion":20210,"completion":20210,"start":56068,"enrollment":713,"conditions":56090,"interventions":56091},[91],[22],[56058,56071,56072,56073],{"trials":56093,"activeCount":103},[],{"trials":56095,"activeCount":103},[],{"trials":56097,"activeCount":103},[],{"trials":56099,"activeCount":103},[],{"intervention":56072,"totalTrials":302,"cells":56101},{"EARLY_PHASE1":56102,"PHASE1":56104,"PHASE2":56110,"PHASE3":56112,"PHASE4":56114,"NA":56116},{"trials":56103,"activeCount":103},[],{"trials":56105,"activeCount":103},[56106],{"nctId":56065,"briefTitle":56066,"status":111,"phases":56107,"primaryCompletion":20210,"completion":20210,"start":56068,"enrollment":713,"conditions":56108,"interventions":56109},[91],[22],[56058,56071,56072,56073],{"trials":56111,"activeCount":103},[],{"trials":56113,"activeCount":103},[],{"trials":56115,"activeCount":103},[],{"trials":56117,"activeCount":103},[],{"intervention":56073,"totalTrials":302,"cells":56119},{"EARLY_PHASE1":56120,"PHASE1":56122,"PHASE2":56128,"PHASE3":56130,"PHASE4":56132,"NA":56134},{"trials":56121,"activeCount":103},[],{"trials":56123,"activeCount":103},[56124],{"nctId":56065,"briefTitle":56066,"status":111,"phases":56125,"primaryCompletion":20210,"completion":20210,"start":56068,"enrollment":713,"conditions":56126,"interventions":56127},[91],[22],[56058,56071,56072,56073],{"trials":56129,"activeCount":103},[],{"trials":56131,"activeCount":103},[],{"trials":56133,"activeCount":103},[],{"trials":56135,"activeCount":103},[],{"intervention":56137,"totalTrials":302,"cells":56138},"PF-00868554 or Placebo",{"EARLY_PHASE1":56139,"PHASE1":56141,"PHASE2":56149,"PHASE3":56151,"PHASE4":56153,"NA":56155},{"trials":56140,"activeCount":103},[],{"trials":56142,"activeCount":103},[56143],{"nctId":56144,"briefTitle":56145,"status":168,"phases":56146,"primaryCompletion":4222,"completion":4222,"start":4222,"enrollment":1509,"conditions":56147,"interventions":56148},"NCT00875628","A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers",[91],[19],[56137,56137,56137],{"trials":56150,"activeCount":103},[],{"trials":56152,"activeCount":103},[],{"trials":56154,"activeCount":103},[],{"trials":56156,"activeCount":103},[],{"intervention":56158,"totalTrials":302,"cells":56159},"Single dose-group A",{"EARLY_PHASE1":56160,"PHASE1":56162,"PHASE2":56172,"PHASE3":56174,"PHASE4":56176,"NA":56178},{"trials":56161,"activeCount":103},[],{"trials":56163,"activeCount":103},[56164],{"nctId":56165,"briefTitle":56166,"status":111,"phases":56167,"primaryCompletion":3314,"completion":4665,"start":6017,"enrollment":1519,"conditions":56168,"interventions":56169},"NCT00928681","A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis",[91],[1511],[56158,56158,56170,56158,56170,56158,56158,56158,56158,56171,56170,56170,56170,56170,56171],"Multiple dose- Group B","Multiple dose-Group B",{"trials":56173,"activeCount":103},[],{"trials":56175,"activeCount":103},[],{"trials":56177,"activeCount":103},[],{"trials":56179,"activeCount":103},[],{"intervention":56170,"totalTrials":302,"cells":56181},{"EARLY_PHASE1":56182,"PHASE1":56184,"PHASE2":56190,"PHASE3":56192,"PHASE4":56194,"NA":56196},{"trials":56183,"activeCount":103},[],{"trials":56185,"activeCount":103},[56186],{"nctId":56165,"briefTitle":56166,"status":111,"phases":56187,"primaryCompletion":3314,"completion":4665,"start":6017,"enrollment":1519,"conditions":56188,"interventions":56189},[91],[1511],[56158,56158,56170,56158,56170,56158,56158,56158,56158,56171,56170,56170,56170,56170,56171],{"trials":56191,"activeCount":103},[],{"trials":56193,"activeCount":103},[],{"trials":56195,"activeCount":103},[],{"trials":56197,"activeCount":103},[],{"intervention":56171,"totalTrials":302,"cells":56199},{"EARLY_PHASE1":56200,"PHASE1":56202,"PHASE2":56208,"PHASE3":56210,"PHASE4":56212,"NA":56214},{"trials":56201,"activeCount":103},[],{"trials":56203,"activeCount":103},[56204],{"nctId":56165,"briefTitle":56166,"status":111,"phases":56205,"primaryCompletion":3314,"completion":4665,"start":6017,"enrollment":1519,"conditions":56206,"interventions":56207},[91],[1511],[56158,56158,56170,56158,56170,56158,56158,56158,56158,56171,56170,56170,56170,56170,56171],{"trials":56209,"activeCount":103},[],{"trials":56211,"activeCount":103},[],{"trials":56213,"activeCount":103},[],{"trials":56215,"activeCount":103},[],{"intervention":39702,"totalTrials":302,"cells":56217},{"EARLY_PHASE1":56218,"PHASE1":56220,"PHASE2":56226,"PHASE3":56228,"PHASE4":56230,"NA":56232},{"trials":56219,"activeCount":103},[],{"trials":56221,"activeCount":103},[56222],{"nctId":39697,"briefTitle":39698,"status":111,"phases":56223,"primaryCompletion":4280,"completion":12810,"start":3586,"enrollment":1509,"conditions":56224,"interventions":56225},[91],[39693],[39675,39702],{"trials":56227,"activeCount":103},[],{"trials":56229,"activeCount":103},[],{"trials":56231,"activeCount":103},[],{"trials":56233,"activeCount":103},[],{"intervention":41016,"totalTrials":302,"cells":56235},{"EARLY_PHASE1":56236,"PHASE1":56238,"PHASE2":56244,"PHASE3":56246,"PHASE4":56248,"NA":56250},{"trials":56237,"activeCount":103},[],{"trials":56239,"activeCount":103},[56240],{"nctId":41011,"briefTitle":41012,"status":111,"phases":56241,"primaryCompletion":5008,"completion":5008,"start":4439,"enrollment":2631,"conditions":56242,"interventions":56243},[91],[10985],[41016,40995,41009,41009],{"trials":56245,"activeCount":103},[],{"trials":56247,"activeCount":103},[],{"trials":56249,"activeCount":103},[],{"trials":56251,"activeCount":103},[],{"intervention":56253,"totalTrials":302,"cells":56254},"Ceftibuten",{"EARLY_PHASE1":56255,"PHASE1":56257,"PHASE2":56267,"PHASE3":56269,"PHASE4":56271,"NA":56273},{"trials":56256,"activeCount":103},[],{"trials":56258,"activeCount":103},[56259],{"nctId":56260,"briefTitle":56261,"status":111,"phases":56262,"primaryCompletion":10463,"completion":10463,"start":39444,"enrollment":3254,"conditions":56263,"interventions":56264},"NCT06593054","To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults",[91],[16],[56253,56265,56266],"Avibactam prodrug","CTB-AVP in",{"trials":56268,"activeCount":103},[],{"trials":56270,"activeCount":103},[],{"trials":56272,"activeCount":103},[],{"trials":56274,"activeCount":103},[],{"intervention":56265,"totalTrials":302,"cells":56276},{"EARLY_PHASE1":56277,"PHASE1":56279,"PHASE2":56285,"PHASE3":56287,"PHASE4":56289,"NA":56291},{"trials":56278,"activeCount":103},[],{"trials":56280,"activeCount":103},[56281],{"nctId":56260,"briefTitle":56261,"status":111,"phases":56282,"primaryCompletion":10463,"completion":10463,"start":39444,"enrollment":3254,"conditions":56283,"interventions":56284},[91],[16],[56253,56265,56266],{"trials":56286,"activeCount":103},[],{"trials":56288,"activeCount":103},[],{"trials":56290,"activeCount":103},[],{"trials":56292,"activeCount":103},[],{"intervention":56266,"totalTrials":302,"cells":56294},{"EARLY_PHASE1":56295,"PHASE1":56297,"PHASE2":56303,"PHASE3":56305,"PHASE4":56307,"NA":56309},{"trials":56296,"activeCount":103},[],{"trials":56298,"activeCount":103},[56299],{"nctId":56260,"briefTitle":56261,"status":111,"phases":56300,"primaryCompletion":10463,"completion":10463,"start":39444,"enrollment":3254,"conditions":56301,"interventions":56302},[91],[16],[56253,56265,56266],{"trials":56304,"activeCount":103},[],{"trials":56306,"activeCount":103},[],{"trials":56308,"activeCount":103},[],{"trials":56310,"activeCount":103},[],{"intervention":56312,"totalTrials":302,"cells":56313},"PF-07209960",{"EARLY_PHASE1":56314,"PHASE1":56316,"PHASE2":56325,"PHASE3":56327,"PHASE4":56329,"NA":56331},{"trials":56315,"activeCount":103},[],{"trials":56317,"activeCount":103},[56318],{"nctId":56319,"briefTitle":56320,"status":168,"phases":56321,"primaryCompletion":7844,"completion":14760,"start":56322,"enrollment":2849,"conditions":56323,"interventions":56324},"NCT04628780","Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors",[91],"2020-12-16",[7726,5823,1859,907,7727,7728],[56312],{"trials":56326,"activeCount":103},[],{"trials":56328,"activeCount":103},[],{"trials":56330,"activeCount":103},[],{"trials":56332,"activeCount":103},[],{"intervention":56334,"totalTrials":302,"cells":56335},"PF-07940367",{"EARLY_PHASE1":56336,"PHASE1":56338,"PHASE2":56347,"PHASE3":56349,"PHASE4":56351,"NA":56353},{"trials":56337,"activeCount":103},[],{"trials":56339,"activeCount":103},[56340],{"nctId":56341,"briefTitle":56342,"status":111,"phases":56343,"primaryCompletion":56344,"completion":56344,"start":1651,"enrollment":35,"conditions":56345,"interventions":56346},"NCT06190561","A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults",[91],"2024-05-07",[16],[56334,56334],{"trials":56348,"activeCount":103},[],{"trials":56350,"activeCount":103},[],{"trials":56352,"activeCount":103},[],{"trials":56354,"activeCount":103},[],{"intervention":56356,"totalTrials":302,"cells":56357},"Dimebon IR",{"EARLY_PHASE1":56358,"PHASE1":56360,"PHASE2":56369,"PHASE3":56371,"PHASE4":56373,"NA":56375},{"trials":56359,"activeCount":103},[],{"trials":56361,"activeCount":103},[56362],{"nctId":56363,"briefTitle":56364,"status":111,"phases":56365,"primaryCompletion":10923,"completion":10923,"start":4846,"enrollment":99,"conditions":56366,"interventions":56367},"NCT00990613","A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin",[91],[17728,17729],[56356,56368,56368,56356,56368],"Dimebon Transdermal",{"trials":56370,"activeCount":103},[],{"trials":56372,"activeCount":103},[],{"trials":56374,"activeCount":103},[],{"trials":56376,"activeCount":103},[],{"intervention":56368,"totalTrials":302,"cells":56378},{"EARLY_PHASE1":56379,"PHASE1":56381,"PHASE2":56387,"PHASE3":56389,"PHASE4":56391,"NA":56393},{"trials":56380,"activeCount":103},[],{"trials":56382,"activeCount":103},[56383],{"nctId":56363,"briefTitle":56364,"status":111,"phases":56384,"primaryCompletion":10923,"completion":10923,"start":4846,"enrollment":99,"conditions":56385,"interventions":56386},[91],[17728,17729],[56356,56368,56368,56356,56368],{"trials":56388,"activeCount":103},[],{"trials":56390,"activeCount":103},[],{"trials":56392,"activeCount":103},[],{"trials":56394,"activeCount":103},[],{"intervention":56396,"totalTrials":302,"cells":56397},"AG-024322",{"EARLY_PHASE1":56398,"PHASE1":56400,"PHASE2":56408,"PHASE3":56410,"PHASE4":56412,"NA":56414},{"trials":56399,"activeCount":103},[],{"trials":56401,"activeCount":103},[56402],{"nctId":56403,"briefTitle":56404,"status":168,"phases":56405,"primaryCompletion":11314,"completion":11314,"start":4702,"enrollment":2849,"conditions":56406,"interventions":56407},"NCT00147485","A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer",[91],[2053,7426],[56396],{"trials":56409,"activeCount":103},[],{"trials":56411,"activeCount":103},[],{"trials":56413,"activeCount":103},[],{"trials":56415,"activeCount":103},[],{"intervention":38283,"totalTrials":302,"cells":56417},{"EARLY_PHASE1":56418,"PHASE1":56420,"PHASE2":56426,"PHASE3":56428,"PHASE4":56430,"NA":56432},{"trials":56419,"activeCount":103},[],{"trials":56421,"activeCount":103},[56422],{"nctId":38276,"briefTitle":38277,"status":111,"phases":56423,"primaryCompletion":38279,"completion":38279,"start":38280,"enrollment":4825,"conditions":56424,"interventions":56425},[91],[6210],[7531,38283],{"trials":56427,"activeCount":103},[],{"trials":56429,"activeCount":103},[],{"trials":56431,"activeCount":103},[],{"trials":56433,"activeCount":103},[],{"intervention":18429,"totalTrials":302,"cells":56435},{"EARLY_PHASE1":56436,"PHASE1":56438,"PHASE2":56444,"PHASE3":56446,"PHASE4":56448,"NA":56450},{"trials":56437,"activeCount":103},[],{"trials":56439,"activeCount":103},[56440],{"nctId":18422,"briefTitle":18423,"status":111,"phases":56441,"primaryCompletion":18425,"completion":18425,"start":18426,"enrollment":4259,"conditions":56442,"interventions":56443},[91],[16,1589],[18429,18415],{"trials":56445,"activeCount":103},[],{"trials":56447,"activeCount":103},[],{"trials":56449,"activeCount":103},[],{"trials":56451,"activeCount":103},[],{"intervention":56453,"totalTrials":302,"cells":56454},"PF-06678552",{"EARLY_PHASE1":56455,"PHASE1":56457,"PHASE2":56465,"PHASE3":56467,"PHASE4":56469,"NA":56471},{"trials":56456,"activeCount":103},[],{"trials":56458,"activeCount":103},[56459],{"nctId":56460,"briefTitle":56461,"status":111,"phases":56462,"primaryCompletion":7971,"completion":7971,"start":605,"enrollment":1796,"conditions":56463,"interventions":56464},"NCT02079922","A Multiple Dose Study Of PF-06678552 In Healthy Subjects",[91],[16],[56453,56453,56453,56453,56453,56453],{"trials":56466,"activeCount":103},[],{"trials":56468,"activeCount":103},[],{"trials":56470,"activeCount":103},[],{"trials":56472,"activeCount":103},[],{"intervention":9955,"totalTrials":302,"cells":56474},{"EARLY_PHASE1":56475,"PHASE1":56477,"PHASE2":56483,"PHASE3":56485,"PHASE4":56487,"NA":56489},{"trials":56476,"activeCount":103},[],{"trials":56478,"activeCount":103},[56479],{"nctId":9949,"briefTitle":9950,"status":649,"phases":56480,"primaryCompletion":1037,"completion":1037,"start":9952,"enrollment":103,"conditions":56481,"interventions":56482},[91],[9930,28],[9955,9955,9933,9933],{"trials":56484,"activeCount":103},[],{"trials":56486,"activeCount":103},[],{"trials":56488,"activeCount":103},[],{"trials":56490,"activeCount":103},[],{"intervention":56492,"totalTrials":302,"cells":56493},"Zavegepant 10 mg IN",{"EARLY_PHASE1":56494,"PHASE1":56496,"PHASE2":56505,"PHASE3":56507,"PHASE4":56509,"NA":56511},{"trials":56495,"activeCount":103},[],{"trials":56497,"activeCount":103},[56498],{"nctId":56499,"briefTitle":56500,"status":111,"phases":56501,"primaryCompletion":56502,"completion":56502,"start":7472,"enrollment":562,"conditions":56503,"interventions":56504},"NCT05948085","A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling",[91],"2023-09-05",[16],[56492],{"trials":56506,"activeCount":103},[],{"trials":56508,"activeCount":103},[],{"trials":56510,"activeCount":103},[],{"trials":56512,"activeCount":103},[],{"intervention":29079,"totalTrials":302,"cells":56514},{"EARLY_PHASE1":56515,"PHASE1":56517,"PHASE2":56523,"PHASE3":56525,"PHASE4":56527,"NA":56529},{"trials":56516,"activeCount":103},[],{"trials":56518,"activeCount":103},[56519],{"nctId":29071,"briefTitle":29072,"status":111,"phases":56520,"primaryCompletion":29074,"completion":29074,"start":29075,"enrollment":29076,"conditions":56521,"interventions":56522},[91],[10940],[18943,29079,29080],{"trials":56524,"activeCount":103},[],{"trials":56526,"activeCount":103},[],{"trials":56528,"activeCount":103},[],{"trials":56530,"activeCount":103},[],{"intervention":29080,"totalTrials":302,"cells":56532},{"EARLY_PHASE1":56533,"PHASE1":56535,"PHASE2":56541,"PHASE3":56543,"PHASE4":56545,"NA":56547},{"trials":56534,"activeCount":103},[],{"trials":56536,"activeCount":103},[56537],{"nctId":29071,"briefTitle":29072,"status":111,"phases":56538,"primaryCompletion":29074,"completion":29074,"start":29075,"enrollment":29076,"conditions":56539,"interventions":56540},[91],[10940],[18943,29079,29080],{"trials":56542,"activeCount":103},[],{"trials":56544,"activeCount":103},[],{"trials":56546,"activeCount":103},[],{"trials":56548,"activeCount":103},[],{"intervention":11181,"totalTrials":302,"cells":56550},{"EARLY_PHASE1":56551,"PHASE1":56553,"PHASE2":56559,"PHASE3":56561,"PHASE4":56563,"NA":56565},{"trials":56552,"activeCount":103},[],{"trials":56554,"activeCount":103},[56555],{"nctId":11174,"briefTitle":11175,"status":111,"phases":56556,"primaryCompletion":11177,"completion":11177,"start":11178,"enrollment":2713,"conditions":56557,"interventions":56558},[91],[19],[11076,11088,11098,11099,11127,11128,11129,11181],{"trials":56560,"activeCount":103},[],{"trials":56562,"activeCount":103},[],{"trials":56564,"activeCount":103},[],{"trials":56566,"activeCount":103},[],{"intervention":56568,"totalTrials":302,"cells":56569},"Palbociclib Formulation Reference",{"EARLY_PHASE1":56570,"PHASE1":56572,"PHASE2":56581,"PHASE3":56583,"PHASE4":56585,"NA":56587},{"trials":56571,"activeCount":103},[],{"trials":56573,"activeCount":103},[56574],{"nctId":56575,"briefTitle":56576,"status":111,"phases":56577,"primaryCompletion":652,"completion":652,"start":605,"enrollment":1780,"conditions":56578,"interventions":56579},"NCT02083640","Relative Bioavailability For Palbociclib Formulations",[91],[16],[56568,56580,56580],"Palbociclib Formulation Test",{"trials":56582,"activeCount":103},[],{"trials":56584,"activeCount":103},[],{"trials":56586,"activeCount":103},[],{"trials":56588,"activeCount":103},[],{"intervention":56580,"totalTrials":302,"cells":56590},{"EARLY_PHASE1":56591,"PHASE1":56593,"PHASE2":56599,"PHASE3":56601,"PHASE4":56603,"NA":56605},{"trials":56592,"activeCount":103},[],{"trials":56594,"activeCount":103},[56595],{"nctId":56575,"briefTitle":56576,"status":111,"phases":56596,"primaryCompletion":652,"completion":652,"start":605,"enrollment":1780,"conditions":56597,"interventions":56598},[91],[16],[56568,56580,56580],{"trials":56600,"activeCount":103},[],{"trials":56602,"activeCount":103},[],{"trials":56604,"activeCount":103},[],{"trials":56606,"activeCount":103},[],{"intervention":56608,"totalTrials":302,"cells":56609},"PF-06667272",{"EARLY_PHASE1":56610,"PHASE1":56612,"PHASE2":56621,"PHASE3":56623,"PHASE4":56625,"NA":56627},{"trials":56611,"activeCount":103},[],{"trials":56613,"activeCount":103},[56614],{"nctId":56615,"briefTitle":56616,"status":111,"phases":56617,"primaryCompletion":29376,"completion":29376,"start":56618,"enrollment":314,"conditions":56619,"interventions":56620},"NCT03126149","First in Human Study for PF-06667272",[91],"2017-05-11",[16],[56608],{"trials":56622,"activeCount":103},[],{"trials":56624,"activeCount":103},[],{"trials":56626,"activeCount":103},[],{"trials":56628,"activeCount":103},[],{"intervention":56630,"totalTrials":302,"cells":56631},"Fesoterodine BIC SR4 fasted",{"EARLY_PHASE1":56632,"PHASE1":56634,"PHASE2":56647,"PHASE3":56649,"PHASE4":56651,"NA":56653},{"trials":56633,"activeCount":103},[],{"trials":56635,"activeCount":103},[56636],{"nctId":56637,"briefTitle":56638,"status":111,"phases":56639,"primaryCompletion":56640,"completion":56640,"start":20966,"enrollment":2849,"conditions":56641,"interventions":56642},"NCT04452838","Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer",[91],"2021-01-04",[44642],[56630,56643,56644,56645,56646],"Fesoterodine BIC SR7 fasted","Fesoterodine BIC SR7 fed","Fesoterodine BIC SR7 on apple sauce","Fesoterodine BIC SR4 fed",{"trials":56648,"activeCount":103},[],{"trials":56650,"activeCount":103},[],{"trials":56652,"activeCount":103},[],{"trials":56654,"activeCount":103},[],{"intervention":56643,"totalTrials":302,"cells":56656},{"EARLY_PHASE1":56657,"PHASE1":56659,"PHASE2":56665,"PHASE3":56667,"PHASE4":56669,"NA":56671},{"trials":56658,"activeCount":103},[],{"trials":56660,"activeCount":103},[56661],{"nctId":56637,"briefTitle":56638,"status":111,"phases":56662,"primaryCompletion":56640,"completion":56640,"start":20966,"enrollment":2849,"conditions":56663,"interventions":56664},[91],[44642],[56630,56643,56644,56645,56646],{"trials":56666,"activeCount":103},[],{"trials":56668,"activeCount":103},[],{"trials":56670,"activeCount":103},[],{"trials":56672,"activeCount":103},[],{"intervention":56644,"totalTrials":302,"cells":56674},{"EARLY_PHASE1":56675,"PHASE1":56677,"PHASE2":56683,"PHASE3":56685,"PHASE4":56687,"NA":56689},{"trials":56676,"activeCount":103},[],{"trials":56678,"activeCount":103},[56679],{"nctId":56637,"briefTitle":56638,"status":111,"phases":56680,"primaryCompletion":56640,"completion":56640,"start":20966,"enrollment":2849,"conditions":56681,"interventions":56682},[91],[44642],[56630,56643,56644,56645,56646],{"trials":56684,"activeCount":103},[],{"trials":56686,"activeCount":103},[],{"trials":56688,"activeCount":103},[],{"trials":56690,"activeCount":103},[],{"intervention":56645,"totalTrials":302,"cells":56692},{"EARLY_PHASE1":56693,"PHASE1":56695,"PHASE2":56701,"PHASE3":56703,"PHASE4":56705,"NA":56707},{"trials":56694,"activeCount":103},[],{"trials":56696,"activeCount":103},[56697],{"nctId":56637,"briefTitle":56638,"status":111,"phases":56698,"primaryCompletion":56640,"completion":56640,"start":20966,"enrollment":2849,"conditions":56699,"interventions":56700},[91],[44642],[56630,56643,56644,56645,56646],{"trials":56702,"activeCount":103},[],{"trials":56704,"activeCount":103},[],{"trials":56706,"activeCount":103},[],{"trials":56708,"activeCount":103},[],{"intervention":56646,"totalTrials":302,"cells":56710},{"EARLY_PHASE1":56711,"PHASE1":56713,"PHASE2":56719,"PHASE3":56721,"PHASE4":56723,"NA":56725},{"trials":56712,"activeCount":103},[],{"trials":56714,"activeCount":103},[56715],{"nctId":56637,"briefTitle":56638,"status":111,"phases":56716,"primaryCompletion":56640,"completion":56640,"start":20966,"enrollment":2849,"conditions":56717,"interventions":56718},[91],[44642],[56630,56643,56644,56645,56646],{"trials":56720,"activeCount":103},[],{"trials":56722,"activeCount":103},[],{"trials":56724,"activeCount":103},[],{"trials":56726,"activeCount":103},[],{"intervention":56728,"totalTrials":302,"cells":56729},"PF-03814735",{"EARLY_PHASE1":56730,"PHASE1":56732,"PHASE2":56740,"PHASE3":56742,"PHASE4":56744,"NA":56746},{"trials":56731,"activeCount":103},[],{"trials":56733,"activeCount":103},[56734],{"nctId":56735,"briefTitle":56736,"status":111,"phases":56737,"primaryCompletion":4646,"completion":4646,"start":4847,"enrollment":28015,"conditions":56738,"interventions":56739},"NCT00424632","Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors",[91],[750],[56728],{"trials":56741,"activeCount":103},[],{"trials":56743,"activeCount":103},[],{"trials":56745,"activeCount":103},[],{"trials":56747,"activeCount":103},[],{"intervention":17405,"totalTrials":302,"cells":56749},{"EARLY_PHASE1":56750,"PHASE1":56752,"PHASE2":56758,"PHASE3":56760,"PHASE4":56762,"NA":56764},{"trials":56751,"activeCount":103},[],{"trials":56753,"activeCount":103},[56754],{"nctId":17400,"briefTitle":17401,"status":168,"phases":56755,"primaryCompletion":2660,"completion":2660,"start":4627,"enrollment":5909,"conditions":56756,"interventions":56757},[91],[19],[1705,1705,17405],{"trials":56759,"activeCount":103},[],{"trials":56761,"activeCount":103},[],{"trials":56763,"activeCount":103},[],{"trials":56765,"activeCount":103},[],{"intervention":56767,"totalTrials":302,"cells":56768},"Viagra 50 mg",{"EARLY_PHASE1":56769,"PHASE1":56771,"PHASE2":56782,"PHASE3":56784,"PHASE4":56786,"NA":56788},{"trials":56770,"activeCount":103},[],{"trials":56772,"activeCount":103},[56773],{"nctId":56774,"briefTitle":56775,"status":111,"phases":56776,"primaryCompletion":4833,"completion":4833,"start":4214,"enrollment":314,"conditions":56777,"interventions":56778},"NCT00950404","Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet",[91],[19],[56767,56779,56780,56781],"Formulation B ODT tablet 50 mg","Formulation C ODT tablet 50 mg","Formulation D ODT tablet 50 mg",{"trials":56783,"activeCount":103},[],{"trials":56785,"activeCount":103},[],{"trials":56787,"activeCount":103},[],{"trials":56789,"activeCount":103},[],{"intervention":56779,"totalTrials":302,"cells":56791},{"EARLY_PHASE1":56792,"PHASE1":56794,"PHASE2":56800,"PHASE3":56802,"PHASE4":56804,"NA":56806},{"trials":56793,"activeCount":103},[],{"trials":56795,"activeCount":103},[56796],{"nctId":56774,"briefTitle":56775,"status":111,"phases":56797,"primaryCompletion":4833,"completion":4833,"start":4214,"enrollment":314,"conditions":56798,"interventions":56799},[91],[19],[56767,56779,56780,56781],{"trials":56801,"activeCount":103},[],{"trials":56803,"activeCount":103},[],{"trials":56805,"activeCount":103},[],{"trials":56807,"activeCount":103},[],{"intervention":56780,"totalTrials":302,"cells":56809},{"EARLY_PHASE1":56810,"PHASE1":56812,"PHASE2":56818,"PHASE3":56820,"PHASE4":56822,"NA":56824},{"trials":56811,"activeCount":103},[],{"trials":56813,"activeCount":103},[56814],{"nctId":56774,"briefTitle":56775,"status":111,"phases":56815,"primaryCompletion":4833,"completion":4833,"start":4214,"enrollment":314,"conditions":56816,"interventions":56817},[91],[19],[56767,56779,56780,56781],{"trials":56819,"activeCount":103},[],{"trials":56821,"activeCount":103},[],{"trials":56823,"activeCount":103},[],{"trials":56825,"activeCount":103},[],{"intervention":56781,"totalTrials":302,"cells":56827},{"EARLY_PHASE1":56828,"PHASE1":56830,"PHASE2":56836,"PHASE3":56838,"PHASE4":56840,"NA":56842},{"trials":56829,"activeCount":103},[],{"trials":56831,"activeCount":103},[56832],{"nctId":56774,"briefTitle":56775,"status":111,"phases":56833,"primaryCompletion":4833,"completion":4833,"start":4214,"enrollment":314,"conditions":56834,"interventions":56835},[91],[19],[56767,56779,56780,56781],{"trials":56837,"activeCount":103},[],{"trials":56839,"activeCount":103},[],{"trials":56841,"activeCount":103},[],{"trials":56843,"activeCount":103},[],{"intervention":11560,"totalTrials":302,"cells":56845},{"EARLY_PHASE1":56846,"PHASE1":56848,"PHASE2":56854,"PHASE3":56856,"PHASE4":56858,"NA":56860},{"trials":56847,"activeCount":103},[],{"trials":56849,"activeCount":103},[56850],{"nctId":11553,"briefTitle":11554,"status":111,"phases":56851,"primaryCompletion":11556,"completion":11556,"start":11557,"enrollment":3169,"conditions":56852,"interventions":56853},[91],[2526],[11538,11560],{"trials":56855,"activeCount":103},[],{"trials":56857,"activeCount":103},[],{"trials":56859,"activeCount":103},[],{"trials":56861,"activeCount":103},[],{"intervention":39072,"totalTrials":302,"cells":56863},{"EARLY_PHASE1":56864,"PHASE1":56866,"PHASE2":56872,"PHASE3":56874,"PHASE4":56876,"NA":56878},{"trials":56865,"activeCount":103},[],{"trials":56867,"activeCount":103},[56868],{"nctId":39067,"briefTitle":39068,"status":111,"phases":56869,"primaryCompletion":11448,"completion":11448,"start":11356,"enrollment":562,"conditions":56870,"interventions":56871},[91],[16],[39053,39072,39053,39073],{"trials":56873,"activeCount":103},[],{"trials":56875,"activeCount":103},[],{"trials":56877,"activeCount":103},[],{"trials":56879,"activeCount":103},[],{"intervention":39073,"totalTrials":302,"cells":56881},{"EARLY_PHASE1":56882,"PHASE1":56884,"PHASE2":56890,"PHASE3":56892,"PHASE4":56894,"NA":56896},{"trials":56883,"activeCount":103},[],{"trials":56885,"activeCount":103},[56886],{"nctId":39067,"briefTitle":39068,"status":111,"phases":56887,"primaryCompletion":11448,"completion":11448,"start":11356,"enrollment":562,"conditions":56888,"interventions":56889},[91],[16],[39053,39072,39053,39073],{"trials":56891,"activeCount":103},[],{"trials":56893,"activeCount":103},[],{"trials":56895,"activeCount":103},[],{"trials":56897,"activeCount":103},[],{"intervention":56899,"totalTrials":302,"cells":56900},"Amodiaquine",{"EARLY_PHASE1":56901,"PHASE1":56903,"PHASE2":56911,"PHASE3":56913,"PHASE4":56915,"NA":56917},{"trials":56902,"activeCount":103},[],{"trials":56904,"activeCount":103},[56905],{"nctId":56906,"briefTitle":56907,"status":111,"phases":56908,"primaryCompletion":4627,"completion":4627,"start":4646,"enrollment":1796,"conditions":56909,"interventions":56910},"NCT00894660","A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects",[91],[14263],[56899,56899],{"trials":56912,"activeCount":103},[],{"trials":56914,"activeCount":103},[],{"trials":56916,"activeCount":103},[],{"trials":56918,"activeCount":103},[],{"intervention":56920,"totalTrials":302,"cells":56921},"RSVpreF 120 µg",{"EARLY_PHASE1":56922,"PHASE1":56924,"PHASE2":56934,"PHASE3":56936,"PHASE4":56938,"NA":56940},{"trials":56923,"activeCount":103},[],{"trials":56925,"activeCount":103},[56926],{"nctId":56927,"briefTitle":56928,"status":111,"phases":56929,"primaryCompletion":49268,"completion":49268,"start":56930,"enrollment":1326,"conditions":56931,"interventions":56932},"NCT05900154","A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to \u003C18 Years of Age",[91],"2023-06-22",[3791],[56920,56933],"RSVpreF 60 µg",{"trials":56935,"activeCount":103},[],{"trials":56937,"activeCount":103},[],{"trials":56939,"activeCount":103},[],{"trials":56941,"activeCount":103},[],{"intervention":56933,"totalTrials":302,"cells":56943},{"EARLY_PHASE1":56944,"PHASE1":56946,"PHASE2":56952,"PHASE3":56954,"PHASE4":56956,"NA":56958},{"trials":56945,"activeCount":103},[],{"trials":56947,"activeCount":103},[56948],{"nctId":56927,"briefTitle":56928,"status":111,"phases":56949,"primaryCompletion":49268,"completion":49268,"start":56930,"enrollment":1326,"conditions":56950,"interventions":56951},[91],[3791],[56920,56933],{"trials":56953,"activeCount":103},[],{"trials":56955,"activeCount":103},[],{"trials":56957,"activeCount":103},[],{"trials":56959,"activeCount":103},[],{"intervention":56961,"totalTrials":302,"cells":56962},"PF-08049820 MR1",{"EARLY_PHASE1":56963,"PHASE1":56965,"PHASE2":56977,"PHASE3":56979,"PHASE4":56981,"NA":56983},{"trials":56964,"activeCount":103},[],{"trials":56966,"activeCount":103},[56967],{"nctId":56968,"briefTitle":56969,"status":111,"phases":56970,"primaryCompletion":56971,"completion":56972,"start":2134,"enrollment":1268,"conditions":56973,"interventions":56974},"NCT07172321","A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults",[91],"2025-10-04","2025-10-29",[1589],[56961,56975,56976],"PF-08049820 MR2","PF-08049820 IR",{"trials":56978,"activeCount":103},[],{"trials":56980,"activeCount":103},[],{"trials":56982,"activeCount":103},[],{"trials":56984,"activeCount":103},[],{"intervention":56975,"totalTrials":302,"cells":56986},{"EARLY_PHASE1":56987,"PHASE1":56989,"PHASE2":56995,"PHASE3":56997,"PHASE4":56999,"NA":57001},{"trials":56988,"activeCount":103},[],{"trials":56990,"activeCount":103},[56991],{"nctId":56968,"briefTitle":56969,"status":111,"phases":56992,"primaryCompletion":56971,"completion":56972,"start":2134,"enrollment":1268,"conditions":56993,"interventions":56994},[91],[1589],[56961,56975,56976],{"trials":56996,"activeCount":103},[],{"trials":56998,"activeCount":103},[],{"trials":57000,"activeCount":103},[],{"trials":57002,"activeCount":103},[],{"intervention":56976,"totalTrials":302,"cells":57004},{"EARLY_PHASE1":57005,"PHASE1":57007,"PHASE2":57013,"PHASE3":57015,"PHASE4":57017,"NA":57019},{"trials":57006,"activeCount":103},[],{"trials":57008,"activeCount":103},[57009],{"nctId":56968,"briefTitle":56969,"status":111,"phases":57010,"primaryCompletion":56971,"completion":56972,"start":2134,"enrollment":1268,"conditions":57011,"interventions":57012},[91],[1589],[56961,56975,56976],{"trials":57014,"activeCount":103},[],{"trials":57016,"activeCount":103},[],{"trials":57018,"activeCount":103},[],{"trials":57020,"activeCount":103},[],{"intervention":57022,"totalTrials":302,"cells":57023},"PF-03882845 or Placebo",{"EARLY_PHASE1":57024,"PHASE1":57026,"PHASE2":57034,"PHASE3":57036,"PHASE4":57038,"NA":57040},{"trials":57025,"activeCount":103},[],{"trials":57027,"activeCount":103},[57028],{"nctId":57029,"briefTitle":57030,"status":111,"phases":57031,"primaryCompletion":11988,"completion":11988,"start":4833,"enrollment":26,"conditions":57032,"interventions":57033},"NCT00971802","A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers",[91],[19],[57022,57022,57022,57022],{"trials":57035,"activeCount":103},[],{"trials":57037,"activeCount":103},[],{"trials":57039,"activeCount":103},[],{"trials":57041,"activeCount":103},[],{"intervention":17584,"totalTrials":302,"cells":57043},{"EARLY_PHASE1":57044,"PHASE1":57046,"PHASE2":57052,"PHASE3":57054,"PHASE4":57056,"NA":57058},{"trials":57045,"activeCount":103},[],{"trials":57047,"activeCount":103},[57048],{"nctId":17579,"briefTitle":17580,"status":168,"phases":57049,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":1268,"conditions":57050,"interventions":57051},[91],[17561],[17550,17550,17584],{"trials":57053,"activeCount":103},[],{"trials":57055,"activeCount":103},[],{"trials":57057,"activeCount":103},[],{"trials":57059,"activeCount":103},[],{"intervention":57061,"totalTrials":302,"cells":57062},"Glasdegib 100 mg single oral dose",{"EARLY_PHASE1":57063,"PHASE1":57065,"PHASE2":57074,"PHASE3":57076,"PHASE4":57078,"NA":57080},{"trials":57064,"activeCount":103},[],{"trials":57066,"activeCount":103},[57067],{"nctId":57068,"briefTitle":57069,"status":111,"phases":57070,"primaryCompletion":5767,"completion":5767,"start":57071,"enrollment":1509,"conditions":57072,"interventions":57073},"NCT03627754","A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib",[91],"2018-11-05",[7853],[57061],{"trials":57075,"activeCount":103},[],{"trials":57077,"activeCount":103},[],{"trials":57079,"activeCount":103},[],{"trials":57081,"activeCount":103},[],{"intervention":57083,"totalTrials":302,"cells":57084},"Single dose of PF-07104091 as Tablet Formulation A",{"EARLY_PHASE1":57085,"PHASE1":57087,"PHASE2":57099,"PHASE3":57101,"PHASE4":57103,"NA":57105},{"trials":57086,"activeCount":103},[],{"trials":57088,"activeCount":103},[57089],{"nctId":57090,"briefTitle":57091,"status":111,"phases":57092,"primaryCompletion":6106,"completion":6106,"start":57093,"enrollment":1780,"conditions":57094,"interventions":57095},"NCT05431153","A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants",[91],"2022-06-10",[16],[57083,57096,57097,57098,57097],"Single dose of PF-07104091 as Tablet Formulation B","Single dose of PF-07104091 as Tablet Formulation C","Single dose of PF-07104091 as Tablet Formulation D",{"trials":57100,"activeCount":103},[],{"trials":57102,"activeCount":103},[],{"trials":57104,"activeCount":103},[],{"trials":57106,"activeCount":103},[],{"intervention":57096,"totalTrials":302,"cells":57108},{"EARLY_PHASE1":57109,"PHASE1":57111,"PHASE2":57117,"PHASE3":57119,"PHASE4":57121,"NA":57123},{"trials":57110,"activeCount":103},[],{"trials":57112,"activeCount":103},[57113],{"nctId":57090,"briefTitle":57091,"status":111,"phases":57114,"primaryCompletion":6106,"completion":6106,"start":57093,"enrollment":1780,"conditions":57115,"interventions":57116},[91],[16],[57083,57096,57097,57098,57097],{"trials":57118,"activeCount":103},[],{"trials":57120,"activeCount":103},[],{"trials":57122,"activeCount":103},[],{"trials":57124,"activeCount":103},[],{"intervention":57097,"totalTrials":302,"cells":57126},{"EARLY_PHASE1":57127,"PHASE1":57129,"PHASE2":57135,"PHASE3":57137,"PHASE4":57139,"NA":57141},{"trials":57128,"activeCount":103},[],{"trials":57130,"activeCount":103},[57131],{"nctId":57090,"briefTitle":57091,"status":111,"phases":57132,"primaryCompletion":6106,"completion":6106,"start":57093,"enrollment":1780,"conditions":57133,"interventions":57134},[91],[16],[57083,57096,57097,57098,57097],{"trials":57136,"activeCount":103},[],{"trials":57138,"activeCount":103},[],{"trials":57140,"activeCount":103},[],{"trials":57142,"activeCount":103},[],{"intervention":57098,"totalTrials":302,"cells":57144},{"EARLY_PHASE1":57145,"PHASE1":57147,"PHASE2":57153,"PHASE3":57155,"PHASE4":57157,"NA":57159},{"trials":57146,"activeCount":103},[],{"trials":57148,"activeCount":103},[57149],{"nctId":57090,"briefTitle":57091,"status":111,"phases":57150,"primaryCompletion":6106,"completion":6106,"start":57093,"enrollment":1780,"conditions":57151,"interventions":57152},[91],[16],[57083,57096,57097,57098,57097],{"trials":57154,"activeCount":103},[],{"trials":57156,"activeCount":103},[],{"trials":57158,"activeCount":103},[],{"trials":57160,"activeCount":103},[],{"intervention":57162,"totalTrials":302,"cells":57163},"Low dose of multivalent pneumococcal conjugate vaccine control",{"EARLY_PHASE1":57164,"PHASE1":57166,"PHASE2":57175,"PHASE3":57177,"PHASE4":57179,"NA":57181},{"trials":57165,"activeCount":103},[],{"trials":57167,"activeCount":103},[57168],{"nctId":57169,"briefTitle":57170,"status":111,"phases":57171,"primaryCompletion":4322,"completion":4322,"start":2818,"enrollment":481,"conditions":57172,"interventions":57173},"NCT05831124","A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults",[91],[2526],[57162,57174],"Standard dose multivalent pneumococcal conjugate vaccine control",{"trials":57176,"activeCount":103},[],{"trials":57178,"activeCount":103},[],{"trials":57180,"activeCount":103},[],{"trials":57182,"activeCount":103},[],{"intervention":57174,"totalTrials":302,"cells":57184},{"EARLY_PHASE1":57185,"PHASE1":57187,"PHASE2":57193,"PHASE3":57195,"PHASE4":57197,"NA":57199},{"trials":57186,"activeCount":103},[],{"trials":57188,"activeCount":103},[57189],{"nctId":57169,"briefTitle":57170,"status":111,"phases":57190,"primaryCompletion":4322,"completion":4322,"start":2818,"enrollment":481,"conditions":57191,"interventions":57192},[91],[2526],[57162,57174],{"trials":57194,"activeCount":103},[],{"trials":57196,"activeCount":103},[],{"trials":57198,"activeCount":103},[],{"trials":57200,"activeCount":103},[],{"intervention":40834,"totalTrials":302,"cells":57202},{"EARLY_PHASE1":57203,"PHASE1":57205,"PHASE2":57211,"PHASE3":57213,"PHASE4":57215,"NA":57217},{"trials":57204,"activeCount":103},[],{"trials":57206,"activeCount":103},[57207],{"nctId":40829,"briefTitle":40830,"status":649,"phases":57208,"primaryCompletion":2661,"completion":2661,"start":523,"enrollment":103,"conditions":57209,"interventions":57210},[91],[16],[40834,40815],{"trials":57212,"activeCount":103},[],{"trials":57214,"activeCount":103},[],{"trials":57216,"activeCount":103},[],{"trials":57218,"activeCount":103},[],{"intervention":11452,"totalTrials":481,"cells":57220},{"EARLY_PHASE1":57221,"PHASE1":57223,"PHASE2":57240,"PHASE3":57278,"PHASE4":57641,"NA":57751},{"trials":57222,"activeCount":103},[],{"trials":57224,"activeCount":103},[57225,57229,57236],{"nctId":27790,"briefTitle":27791,"status":111,"phases":57226,"primaryCompletion":17639,"completion":17639,"start":9572,"enrollment":2159,"conditions":57227,"interventions":57228},[91],[16],[11360,11360,11452],{"nctId":57230,"briefTitle":57231,"status":111,"phases":57232,"primaryCompletion":4608,"completion":4608,"start":2884,"enrollment":2713,"conditions":57233,"interventions":57235},"NCT00654940","A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients",[91],[57234],"Nerve Pain",[11452],{"nctId":11445,"briefTitle":11446,"status":111,"phases":57237,"primaryCompletion":11448,"completion":11448,"start":11356,"enrollment":2159,"conditions":57238,"interventions":57239},[91],[16],[11451,11451,11452,11072],{"trials":57241,"activeCount":103},[57242,57246,57250,57258,57262,57266,57272],{"nctId":29753,"briefTitle":29754,"status":111,"phases":57243,"completion":4847,"start":2671,"enrollment":27266,"conditions":57244,"interventions":57245},[92],[12489],[29758,29738,29758,11452],{"nctId":12242,"briefTitle":12243,"status":111,"phases":57247,"completion":12128,"start":2662,"enrollment":481,"conditions":57248,"interventions":57249},[92],[12246],[11452,12193],{"nctId":57251,"briefTitle":57252,"status":111,"phases":57253,"completion":9387,"start":57254,"enrollment":6245,"conditions":57255,"interventions":57257},"NCT00141414","To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.",[92],"1997-11",[57256],"Epilepsy, Partial",[11452],{"nctId":33802,"briefTitle":33803,"status":111,"phases":57259,"primaryCompletion":33805,"completion":33806,"start":33807,"enrollment":7388,"conditions":57260,"interventions":57261},[92],[32264],[21451,33793],{"nctId":35192,"briefTitle":35193,"status":168,"phases":57263,"primaryCompletion":35195,"completion":35196,"start":35197,"enrollment":17874,"conditions":57264,"interventions":57265},[92],[34],[35183,11452],{"nctId":57267,"briefTitle":57268,"status":111,"phases":57269,"primaryCompletion":8251,"completion":8251,"start":3314,"enrollment":13313,"conditions":57270,"interventions":57271},"NCT00676403","Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients",[92],[13741],[11452,11452,11452,11452,11452],{"nctId":57273,"briefTitle":57274,"status":111,"phases":57275,"primaryCompletion":3345,"completion":3345,"start":3602,"enrollment":4726,"conditions":57276,"interventions":57277},"NCT00437281","Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures",[91,92],[26282],[11452],{"trials":57279,"activeCount":103},[57280,57289,57296,57302,57309,57316,57323,57330,57334,57341,57348,57356,57366,57374,57380,57386,57393,57399,57407,57413,57420,57426,57432,57439,57443,57449,57456,57464,57471,57477,57483,57490,57497,57501,57507,57514,57520,57526,57532,57538,57545,57551,57559,57566,57572,57578,57584,57591,57598,57604,57610,57617,57623,57627,57634],{"nctId":57281,"briefTitle":57282,"status":111,"phases":57283,"primaryCompletion":2450,"completion":2450,"start":560,"enrollment":29076,"conditions":57284,"interventions":57288},"NCT01202227","An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain",[93],[57285,57286,57287,34],"Spinal Cord Diseases","Spinal Cord Injuries","Neuralgia",[21451],{"nctId":57290,"briefTitle":57291,"status":111,"phases":57292,"primaryCompletion":10937,"completion":10937,"start":12416,"enrollment":12763,"conditions":57293,"interventions":57295},"NCT00264875","Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy",[93],[57294,10974],"Peripheral Neuropathy",[21451],{"nctId":57297,"briefTitle":57298,"status":111,"phases":57299,"completion":4692,"start":12774,"enrollment":4440,"conditions":57300,"interventions":57301},"NCT00631943","A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain",[93],[57287],[11452],{"nctId":57303,"briefTitle":57304,"status":111,"phases":57305,"completion":2662,"start":11765,"enrollment":903,"conditions":57306,"interventions":57308},"NCT00141375","To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.",[93],[57307],"Neuropathic Pain",[11452],{"nctId":57310,"briefTitle":57311,"status":111,"phases":57312,"primaryCompletion":10937,"completion":10937,"start":4615,"enrollment":57313,"conditions":57314,"interventions":57315},"NCT00346034","This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia",[93],357,[17041],[11452],{"nctId":57317,"briefTitle":57318,"status":111,"phases":57319,"completion":7665,"start":4657,"enrollment":57320,"conditions":57321,"interventions":57322},"NCT00143130","Pregabalin In Partial Seizures Extension Study",[93],227,[26281],[11452],{"nctId":57324,"briefTitle":57325,"status":111,"phases":57326,"primaryCompletion":18769,"completion":606,"start":2883,"enrollment":29192,"conditions":57327,"interventions":57329},"NCT01455415","Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain",[93],[57328],"Painful Diabetic Peripheral Neuropathy",[21451],{"nctId":21446,"briefTitle":21447,"status":111,"phases":57331,"primaryCompletion":2661,"completion":2661,"start":4221,"enrollment":20,"conditions":57332,"interventions":57333},[93],[13741],[21451,21435],{"nctId":57335,"briefTitle":57336,"status":111,"phases":57337,"completion":11417,"start":7666,"enrollment":21290,"conditions":57338,"interventions":57340},"NCT00141336","To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.",[93],[57339],"Seizure Disorder, Partial",[11452],{"nctId":57342,"briefTitle":57343,"status":111,"phases":57344,"primaryCompletion":2964,"completion":2964,"start":12395,"enrollment":57345,"conditions":57346,"interventions":57347},"NCT00333866","Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.",[93],747,[17041],[21451,21451,21451],{"nctId":57349,"briefTitle":57350,"status":111,"phases":57351,"primaryCompletion":57352,"completion":57352,"start":57353,"enrollment":172,"conditions":57354,"interventions":57355},"NCT00424372","A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia",[93],"2008-08-19","2007-01-12",[26924],[21451],{"nctId":57357,"briefTitle":57358,"status":111,"phases":57359,"primaryCompletion":57360,"completion":57361,"start":57362,"enrollment":57363,"conditions":57364,"interventions":57365},"NCT01262677","Once-A-Day Pregabalin For Partial Seizures",[93],"2012-07-31","2012-08-01","2011-02-17",325,[26522,26282],[21451,21451,21451,21451,21451,21451],{"nctId":57367,"briefTitle":57368,"status":111,"phases":57369,"primaryCompletion":57370,"completion":57370,"start":57371,"enrollment":1183,"conditions":57372,"interventions":57373},"NCT01057693","Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy",[93],"2012-01-30","2010-03-31",[31107],[21451],{"nctId":57375,"briefTitle":57376,"status":111,"phases":57377,"completion":15716,"start":11782,"enrollment":57363,"conditions":57378,"interventions":57379},"NCT00141362","Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.",[93],[34],[11452],{"nctId":57381,"briefTitle":57382,"status":111,"phases":57383,"primaryCompletion":11290,"completion":11290,"start":11609,"enrollment":4549,"conditions":57384,"interventions":57385},"NCT00553475","Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy",[93],[31107],[21451,21451],{"nctId":57387,"briefTitle":57388,"status":168,"phases":57389,"primaryCompletion":113,"completion":113,"start":586,"enrollment":2663,"conditions":57390,"interventions":57392},"NCT01145417","Pregabalin Trial In HIV Neuropathic Pain",[93],[57391,57307],"HIV-1 Infection",[21451],{"nctId":57394,"briefTitle":57395,"status":111,"phases":57396,"primaryCompletion":6263,"completion":6263,"start":114,"enrollment":2663,"conditions":57397,"interventions":57398},"NCT01474772","Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)",[93],[17190],[11452],{"nctId":57400,"briefTitle":57401,"status":111,"phases":57402,"primaryCompletion":9572,"completion":17639,"start":524,"enrollment":57403,"conditions":57404,"interventions":57406},"NCT01270828","Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia",[93],806,[57405],"Post Herpetic Neuralgia",[11452],{"nctId":57408,"briefTitle":57409,"status":111,"phases":57410,"completion":12773,"start":9387,"enrollment":28060,"conditions":57411,"interventions":57412},"NCT00141258","Pregabalin Epilepsy Add-On Trial",[93],[26522],[21451],{"nctId":57414,"briefTitle":57415,"status":111,"phases":57416,"completion":9387,"start":57417,"enrollment":12701,"conditions":57418,"interventions":57419},"NCT00141388","To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures",[93],"1998-07",[57339],[11452],{"nctId":57421,"briefTitle":57422,"status":111,"phases":57423,"primaryCompletion":1249,"completion":1249,"start":3610,"enrollment":1548,"conditions":57424,"interventions":57425},"NCT00448916","Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures",[93],[26282],[11452],{"nctId":57427,"briefTitle":57428,"status":111,"phases":57429,"primaryCompletion":7578,"completion":1288,"start":3313,"enrollment":12156,"conditions":57430,"interventions":57431},"NCT01332149","Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy",[93],[31107],[11452],{"nctId":57433,"briefTitle":57434,"status":111,"phases":57435,"completion":12395,"start":9387,"enrollment":57436,"conditions":57437,"interventions":57438},"NCT00230776","A Controlled Pregabalin Trial In Fibromyalgia",[93],740,[17041],[21451],{"nctId":23885,"briefTitle":23886,"status":111,"phases":57440,"primaryCompletion":2660,"completion":585,"start":3643,"enrollment":17607,"conditions":57441,"interventions":57442},[93],[11730],[21451,21451,23874],{"nctId":57444,"briefTitle":57445,"status":111,"phases":57446,"primaryCompletion":2964,"completion":2964,"start":9387,"enrollment":4492,"conditions":57447,"interventions":57448},"NCT00232141","Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy",[93],[10974,57294],[21451],{"nctId":57450,"briefTitle":57451,"status":111,"phases":57452,"completion":3627,"start":12069,"enrollment":57453,"conditions":57454,"interventions":57455},"NCT00151528","An Open-Label Trial of Pregabalin in Patients With Fibromyalgia",[93],428,[17041],[11452],{"nctId":57457,"briefTitle":57458,"status":111,"phases":57459,"primaryCompletion":45191,"completion":45191,"start":57460,"enrollment":2539,"conditions":57461,"interventions":57463},"NCT01463306","A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures",[93],"2012-02-21",[22965,57462],"Epilepsy, Primary Generalized Tonic-Clonic Seizures",[11452],{"nctId":57465,"briefTitle":57466,"status":111,"phases":57467,"primaryCompletion":577,"completion":577,"start":4646,"enrollment":7378,"conditions":57468,"interventions":57470},"NCT00883740","Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia",[93],[17041,57469],"Sleep Disorders",[11452],{"nctId":57472,"briefTitle":57473,"status":111,"phases":57474,"completion":7665,"start":12416,"enrollment":8306,"conditions":57475,"interventions":57476},"NCT00301223","A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain",[93],[57307],[11452],{"nctId":57478,"briefTitle":57479,"status":111,"phases":57480,"completion":3610,"start":4692,"enrollment":11677,"conditions":57481,"interventions":57482},"NCT00143156","Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy",[93],[17868],[21451],{"nctId":57484,"briefTitle":57485,"status":111,"phases":57486,"primaryCompletion":11170,"completion":11170,"start":11290,"enrollment":57487,"conditions":57488,"interventions":57489},"NCT00830167","Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia",[93],498,[17041],[11452],{"nctId":57491,"briefTitle":57492,"status":111,"phases":57493,"completion":13902,"start":4399,"enrollment":7500,"conditions":57494,"interventions":57496},"NCT00643136","A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures",[93],[57495,26282],"Sleep Deprivation",[11452],{"nctId":24461,"briefTitle":24462,"status":111,"phases":57498,"completion":4847,"start":4692,"enrollment":17893,"conditions":57499,"interventions":57500},[93],[24465],[11452,24450],{"nctId":57502,"briefTitle":57503,"status":111,"phases":57504,"primaryCompletion":540,"completion":540,"start":524,"enrollment":276,"conditions":57505,"interventions":57506},"NCT01271933","Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients",[93],[17041],[21451],{"nctId":57508,"briefTitle":57509,"status":111,"phases":57510,"completion":11417,"start":7676,"enrollment":57511,"conditions":57512,"interventions":57513},"NCT00150423","To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.",[93],384,[31107],[11452],{"nctId":57515,"briefTitle":57516,"status":111,"phases":57517,"completion":12416,"start":21191,"enrollment":1613,"conditions":57518,"interventions":57519},"NCT00143143","Pregabalin Open-Label Extension Trial in Patients With Partial Seizures",[93],[26282,26283],[11452],{"nctId":57521,"briefTitle":57522,"status":649,"phases":57523,"primaryCompletion":4531,"completion":4531,"start":2660,"enrollment":103,"conditions":57524,"interventions":57525},"NCT01061372","12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects",[93],[13741],[21451,21451],{"nctId":57527,"briefTitle":57528,"status":111,"phases":57529,"primaryCompletion":10923,"completion":10923,"start":10937,"enrollment":3462,"conditions":57530,"interventions":57531},"NCT00553280","A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy",[93],[31107],[21451],{"nctId":57533,"briefTitle":57534,"status":111,"phases":57535,"primaryCompletion":10937,"completion":10937,"start":8170,"enrollment":17515,"conditions":57536,"interventions":57537},"NCT00219544","Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.",[93],[57307],[11452,11452,11452],{"nctId":57539,"briefTitle":57540,"status":168,"phases":57541,"primaryCompletion":113,"completion":113,"start":4206,"enrollment":26940,"conditions":57542,"interventions":57544},"NCT01049217","Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy",[93],[57543],"Neuropathy",[21451],{"nctId":57546,"briefTitle":57547,"status":111,"phases":57548,"completion":11417,"start":2652,"enrollment":21510,"conditions":57549,"interventions":57550},"NCT00150436","To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.",[93],[57287],[11452],{"nctId":57552,"briefTitle":57553,"status":111,"phases":57554,"primaryCompletion":4646,"completion":4833,"start":3853,"enrollment":57555,"conditions":57556,"interventions":57558},"NCT00551135","Surgical Pain After Inguinal Hernia Repair (SPAIHR)",[93],425,[11730,57557],"Hernia, Inguinal",[11452,11452,11452],{"nctId":57560,"briefTitle":57561,"status":111,"phases":57562,"primaryCompletion":17667,"completion":17667,"start":57563,"enrollment":21222,"conditions":57564,"interventions":57565},"NCT01387607","A Study For Pregabalin In Patients With Fibromyalgia",[93],"2012-02-06",[17041],[21451],{"nctId":57567,"briefTitle":57568,"status":111,"phases":57569,"primaryCompletion":8154,"completion":8154,"start":3610,"enrollment":16344,"conditions":57570,"interventions":57571},"NCT00442546","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement",[93],[11282,24704],[21451,21451],{"nctId":57573,"briefTitle":57574,"status":168,"phases":57575,"primaryCompletion":114,"completion":114,"start":11895,"enrollment":360,"conditions":57576,"interventions":57577},"NCT00372528","An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures",[93],[26285],[21451],{"nctId":57579,"briefTitle":57580,"status":111,"phases":57581,"primaryCompletion":10937,"completion":3335,"start":4615,"enrollment":2601,"conditions":57582,"interventions":57583},"NCT00413010","Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).",[93],[17561],[21451],{"nctId":57585,"briefTitle":57586,"status":111,"phases":57587,"completion":14118,"start":7675,"enrollment":57588,"conditions":57589,"interventions":57590},"NCT00645398","A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia",[93],751,[17041],[11452,11452,11452],{"nctId":57592,"briefTitle":57593,"status":111,"phases":57594,"primaryCompletion":2964,"completion":2964,"start":3854,"enrollment":57595,"conditions":57596,"interventions":57597},"NCT00394901","A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia",[93],372,[26924],[11452,11452,11452],{"nctId":57599,"briefTitle":57600,"status":111,"phases":57601,"primaryCompletion":8115,"completion":8115,"start":3854,"enrollment":1498,"conditions":57602,"interventions":57603},"NCT00368745","Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.",[93],[17561],[11452],{"nctId":57605,"briefTitle":57606,"status":111,"phases":57607,"primaryCompletion":4666,"completion":4666,"start":4627,"enrollment":26706,"conditions":57608,"interventions":57609},"NCT00830128","A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia",[93],[17041],[21451],{"nctId":57611,"briefTitle":57612,"status":111,"phases":57613,"primaryCompletion":3323,"completion":3323,"start":3353,"enrollment":57614,"conditions":57615,"interventions":57616},"NCT01701362","Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain",[93],542,[57307],[21451],{"nctId":57618,"briefTitle":57619,"status":111,"phases":57620,"primaryCompletion":4666,"completion":4666,"start":11315,"enrollment":12763,"conditions":57621,"interventions":57622},"NCT00407745","A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury",[93],[57287,57286],[21451],{"nctId":26518,"briefTitle":26519,"status":111,"phases":57624,"primaryCompletion":113,"completion":113,"start":11609,"enrollment":2337,"conditions":57625,"interventions":57626},[93],[26522],[21451,26507],{"nctId":57628,"briefTitle":57629,"status":111,"phases":57630,"completion":3627,"start":4657,"enrollment":57631,"conditions":57632,"interventions":57633},"NCT00151489","Safety and Efficacy Study of Pregabalin in Fibromyalgia",[93],1020,[17041],[21451],{"nctId":57635,"briefTitle":57636,"status":111,"phases":57637,"completion":8170,"start":57638,"enrollment":57363,"conditions":57639,"interventions":57640},"NCT00141245","To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.",[93],"1998-10",[57339],[11452],{"trials":57642,"activeCount":103},[57643,57650,57657,57667,57673,57679,57685,57691,57697,57704,57712,57718,57724,57731,57737,57744],{"nctId":57644,"briefTitle":57645,"status":111,"phases":57646,"completion":9387,"start":7675,"enrollment":57647,"conditions":57648,"interventions":57649},"NCT00159679","Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy",[94],167,[31107],[11452],{"nctId":57651,"briefTitle":57652,"status":111,"phases":57653,"completion":12416,"start":12774,"enrollment":2663,"conditions":57654,"interventions":57656},"NCT00629681","A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia",[94],[57655],"Painful Diabetic Neuropathy and Post Herpetic Neuralgia",[11452],{"nctId":57658,"briefTitle":57659,"status":111,"phases":57660,"primaryCompletion":4207,"completion":4207,"start":11315,"enrollment":2442,"conditions":57661,"interventions":57666},"NCT00407511","Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP",[94],[57662,57663,57664,57665],"Diabetic Peripheral Neuropathic Pain (DPN)","Postherpetic Neuralgia (PHN)","HIV-related Neuropathic Pain (HIV)","Chemotherapy Induced Neuropathic Pain",[11452],{"nctId":57668,"briefTitle":57669,"status":111,"phases":57670,"primaryCompletion":3334,"completion":3334,"start":11014,"enrollment":11766,"conditions":57671,"interventions":57672},"NCT00624780","Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder",[94],[17561],[11452,27821,11452],{"nctId":57674,"briefTitle":57675,"status":111,"phases":57676,"primaryCompletion":11448,"completion":11448,"start":2660,"enrollment":1808,"conditions":57677,"interventions":57678},"NCT01020474","Adolescent Fibromyalgia Study",[94],[17041],[21451],{"nctId":57680,"briefTitle":57681,"status":111,"phases":57682,"primaryCompletion":2884,"completion":2884,"start":2662,"enrollment":18733,"conditions":57683,"interventions":57684},"NCT00292188","P4 (Pregabalin for Peripheral Posttraumatic Pain)",[94],[57287],[21451],{"nctId":57686,"briefTitle":57687,"status":649,"phases":57688,"primaryCompletion":18128,"completion":18128,"start":18026,"enrollment":103,"conditions":57689,"interventions":57690},"NCT01298466","Primary Care Identification Of Patients With Chronic Neuropathic Low Back Pain Study",[94],[11337,57287],[11452],{"nctId":57692,"briefTitle":57693,"status":168,"phases":57694,"primaryCompletion":4214,"completion":4214,"start":11895,"enrollment":17874,"conditions":57695,"interventions":57696},"NCT00407797","Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial",[94],[26522],[11452],{"nctId":57698,"briefTitle":57699,"status":111,"phases":57700,"completion":3627,"start":12109,"enrollment":18733,"conditions":57701,"interventions":57703},"NCT00159666","Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia",[94],[57702],"Post-Herpetic Neuralgia",[21451],{"nctId":57705,"briefTitle":57706,"status":111,"phases":57707,"primaryCompletion":6263,"completion":6263,"start":10937,"enrollment":4848,"conditions":57708,"interventions":57711},"NCT00537940","Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures",[94],[26285,57709,26282,57710],"Partial Seizure Disorder","Complex Partial Seizure Disorder",[11452,20441],{"nctId":57713,"briefTitle":57714,"status":111,"phases":57715,"primaryCompletion":18026,"completion":18026,"start":10937,"enrollment":9553,"conditions":57716,"interventions":57717},"NCT00631696","Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo",[94],[16],[11452],{"nctId":57719,"briefTitle":57720,"status":168,"phases":57721,"primaryCompletion":13117,"completion":13117,"start":3353,"enrollment":627,"conditions":57722,"interventions":57723},"NCT01603394","Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia",[94],[32264],[21451],{"nctId":57725,"briefTitle":57726,"status":168,"phases":57727,"primaryCompletion":3335,"completion":3335,"start":11315,"enrollment":7363,"conditions":57728,"interventions":57730},"NCT00380874","Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer",[94],[57729],"Chemotherapy-Induced Peripheral Neuropathy",[11452],{"nctId":57732,"briefTitle":57733,"status":111,"phases":57734,"completion":12004,"start":12069,"enrollment":4981,"conditions":57735,"interventions":57736},"NCT00159731","Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy",[94],[17190],[11452],{"nctId":57738,"briefTitle":57739,"status":111,"phases":57740,"primaryCompletion":6207,"completion":6207,"start":2449,"enrollment":870,"conditions":57741,"interventions":57743},"NCT01727791","A Study Of Pregabalin (Lyrica) Drug Levels In Urine, Plasma And Breast Milk Of Healthy Lactating Women",[94],[57742],"Healthy Lactating Women",[21451],{"nctId":57745,"briefTitle":57746,"status":111,"phases":57747,"completion":12004,"start":12774,"enrollment":57748,"conditions":57749,"interventions":57750},"NCT00141427","Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.",[94],540,[26281],[11452],{"trials":57752,"activeCount":103},[57753,57761,57767,57775,57785,57792,57799,57805,57812],{"nctId":57754,"briefTitle":57755,"status":111,"phases":57756,"primaryCompletion":29221,"completion":29221,"start":18128,"enrollment":57757,"conditions":57758,"interventions":57760},"NCT01773993","Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)",[],534,[57759],"Pain Associated With Fibromyalgia",[11452],{"nctId":57762,"briefTitle":57763,"status":111,"phases":57764,"primaryCompletion":4833,"completion":4833,"start":4615,"enrollment":1257,"conditions":57765,"interventions":57766},"NCT01117766","Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain",[95],[57307],[11452],{"nctId":57768,"briefTitle":57769,"status":111,"phases":57770,"primaryCompletion":523,"completion":523,"start":12395,"enrollment":57771,"conditions":57772,"interventions":57774},"NCT01220180","Lyrica (Pregabalin) Korean Post Marketing Surveillance Study",[],4175,[26285,57307,17041,57773],"Post-market Surveillance",[21451,21451,21451],{"nctId":57776,"briefTitle":57777,"status":111,"phases":57778,"primaryCompletion":57779,"completion":57779,"start":57780,"enrollment":57781,"conditions":57782,"interventions":57783},"NCT01256593","Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)",[],"2017-07-31","2011-02-05",3827,[57287],[57784],"Pregabalin (Lyrica)",{"nctId":57786,"briefTitle":57787,"status":111,"phases":57788,"primaryCompletion":8115,"completion":8115,"start":3854,"enrollment":57789,"conditions":57790,"interventions":57791},"NCT00892008","A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin",[],2278,[57307],[11452],{"nctId":57793,"briefTitle":57794,"status":111,"phases":57795,"primaryCompletion":29221,"completion":29221,"start":4531,"enrollment":57796,"conditions":57797,"interventions":57798},"NCT01279850","Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)",[],891,[57307],[57784],{"nctId":57800,"briefTitle":57801,"status":168,"phases":57802,"primaryCompletion":4665,"completion":4665,"start":1701,"enrollment":498,"conditions":57803,"interventions":57804},"NCT00978341","Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design",[95],[57286],[11452],{"nctId":57806,"briefTitle":57807,"status":111,"phases":57808,"primaryCompletion":3335,"completion":3335,"start":3854,"enrollment":57809,"conditions":57810,"interventions":57811},"NCT00843284","Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA",[],691,[57307],[11452],{"nctId":57813,"briefTitle":57814,"status":111,"phases":57815,"primaryCompletion":586,"completion":586,"start":11291,"enrollment":597,"conditions":57816,"interventions":57817},"NCT00610155","A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients",[95],[34],[11452,57818],"Tramadol SR",{"intervention":13004,"totalTrials":1796,"cells":57820},{"EARLY_PHASE1":57821,"PHASE1":57823,"PHASE2":57844,"PHASE3":57850,"PHASE4":57906,"NA":58037},{"trials":57822,"activeCount":103},[],{"trials":57824,"activeCount":103},[57825,57829,57833,57840],{"nctId":38183,"briefTitle":38184,"status":111,"phases":57826,"primaryCompletion":38186,"completion":38187,"start":38188,"enrollment":6245,"conditions":57827,"interventions":57828},[91],[2761],[7558,13004,2841],{"nctId":49658,"briefTitle":49659,"status":111,"phases":57830,"primaryCompletion":11290,"completion":11290,"start":4665,"enrollment":407,"conditions":57831,"interventions":57832},[91],[12981],[13004,49651],{"nctId":57834,"briefTitle":57835,"status":111,"phases":57836,"primaryCompletion":11014,"completion":11014,"start":8154,"enrollment":1097,"conditions":57837,"interventions":57839},"NCT00739999","8-Week PK\u002FPD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia",[91],[57838],"Pediatric Heterozygous Hypercholesterolemia",[13004,13004],{"nctId":29218,"briefTitle":29219,"status":111,"phases":57841,"primaryCompletion":29221,"completion":29221,"start":29213,"enrollment":23,"conditions":57842,"interventions":57843},[91],[19],[29203,12996],{"trials":57845,"activeCount":103},[57846],{"nctId":31514,"briefTitle":31515,"status":111,"phases":57847,"primaryCompletion":8252,"completion":8252,"start":11988,"enrollment":4360,"conditions":57848,"interventions":57849},[92],[22],[12692,13004,12692,31505],{"trials":57851,"activeCount":103},[57852,57856,57862,57868,57872,57876,57880,57886,57890,57894,57898,57902],{"nctId":17270,"briefTitle":17271,"status":111,"phases":57853,"completion":4847,"start":4258,"enrollment":4981,"conditions":57854,"interventions":57855},[93],[17274,17275],[12983,12996],{"nctId":57857,"briefTitle":57858,"status":168,"phases":57859,"completion":11314,"start":11315,"enrollment":4981,"conditions":57860,"interventions":57861},"NCT00343655","Evaluation of Atorvastatin Treatment on Carotid Plaque.",[93],[12994],[13004],{"nctId":57863,"briefTitle":57864,"status":111,"phases":57865,"completion":11829,"start":13902,"enrollment":1941,"conditions":57866,"interventions":57867},"NCT00150371","Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration",[93],[12981],[12996],{"nctId":17286,"briefTitle":17287,"status":111,"phases":57869,"completion":4847,"start":2672,"enrollment":1017,"conditions":57870,"interventions":57871},[93],[17290,12979],[12983,12996],{"nctId":17293,"briefTitle":17294,"status":168,"phases":57873,"primaryCompletion":4615,"completion":4615,"start":3611,"enrollment":17296,"conditions":57874,"interventions":57875},[93],[17298],[12983,12996],{"nctId":17301,"briefTitle":17302,"status":168,"phases":57877,"primaryCompletion":3643,"completion":3643,"start":13035,"enrollment":17304,"conditions":57878,"interventions":57879},[93],[17306,6117],[12983,12996],{"nctId":57881,"briefTitle":57882,"status":111,"phases":57883,"start":4657,"enrollment":17686,"conditions":57884,"interventions":57885},"NCT00136942","A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol",[93],[12979],[13004],{"nctId":17309,"briefTitle":17310,"status":168,"phases":57887,"primaryCompletion":4615,"completion":4615,"start":4692,"enrollment":713,"conditions":57888,"interventions":57889},[93],[17313],[12983,12996,17315],{"nctId":17329,"briefTitle":17330,"status":111,"phases":57891,"completion":6457,"start":4692,"enrollment":267,"conditions":57892,"interventions":57893},[93],[17290,12979],[12983,12996],{"nctId":17335,"briefTitle":17336,"status":111,"phases":57895,"completion":3854,"start":11736,"enrollment":1941,"conditions":57896,"interventions":57897},[93],[17306,16072,12979],[12983,12996],{"nctId":17341,"briefTitle":17342,"status":111,"phases":57899,"completion":3854,"start":12774,"enrollment":2303,"conditions":57900,"interventions":57901},[93],[12979],[12983,12996],{"nctId":17347,"briefTitle":17348,"status":111,"phases":57903,"primaryCompletion":12773,"completion":12773,"start":13035,"enrollment":11783,"conditions":57904,"interventions":57905},[93],[12979],[12983,12996],{"trials":57907,"activeCount":103},[57908,57914,57922,57929,57937,57944,57950,57957,57964,57970,57976,57982,57986,57994,57998,58009,58015,58021,58027,58033],{"nctId":57909,"briefTitle":57910,"status":111,"phases":57911,"completion":4258,"start":4398,"enrollment":20678,"conditions":57912,"interventions":57913},"NCT00645151","A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol",[94],[28169],[13004,13004,13004],{"nctId":57915,"briefTitle":57916,"status":111,"phases":57917,"completion":8170,"start":57918,"enrollment":57919,"conditions":57920,"interventions":57921},"NCT00147602","Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke",[94],"1998-11",4732,[17678],[12996],{"nctId":57923,"briefTitle":57924,"status":111,"phases":57925,"primaryCompletion":4206,"completion":4206,"start":11291,"enrollment":57926,"conditions":57927,"interventions":57928},"NCT00728988","Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome",[94],499,[9564],[13004,13004],{"nctId":57930,"briefTitle":57931,"status":111,"phases":57932,"primaryCompletion":11512,"completion":11512,"start":3073,"enrollment":57933,"conditions":57934,"interventions":57936},"NCT00442845","Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)",[94],2080,[16072,37,57935,12980,28551],"Cerebrovascular Accident",[13004],{"nctId":57938,"briefTitle":57939,"status":111,"phases":57940,"completion":11727,"start":11791,"enrollment":12992,"conditions":57941,"interventions":57943},"NCT00327691","A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels",[94],[17678,57935,57942],"Coronary Heart Disease",[13004],{"nctId":57945,"briefTitle":57946,"status":111,"phases":57947,"primaryCompletion":11291,"completion":11291,"start":4207,"enrollment":407,"conditions":57948,"interventions":57949},"NCT00917579","Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet",[94],[12981],[13004,13004],{"nctId":57951,"briefTitle":57952,"status":111,"phases":57953,"completion":11512,"start":3073,"enrollment":57954,"conditions":57955,"interventions":57956},"NCT00442325","Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets",[94],595,[16072,37,57935,12980,28551],[13004],{"nctId":57958,"briefTitle":57959,"status":111,"phases":57960,"completion":11686,"start":4679,"enrollment":57961,"conditions":57962,"interventions":57963},"NCT00644670","A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol",[94],232,[28169],[13004,13004],{"nctId":57965,"briefTitle":57966,"status":111,"phases":57967,"completion":12416,"start":4679,"enrollment":1326,"conditions":57968,"interventions":57969},"NCT00163150","Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke",[94],[57935,12981],[13004],{"nctId":57971,"briefTitle":57972,"status":111,"phases":57973,"completion":12109,"start":2672,"enrollment":33605,"conditions":57974,"interventions":57975},"NCT00645424","A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol",[94],[28170],[12996,12996,12996],{"nctId":57977,"briefTitle":57978,"status":111,"phases":57979,"primaryCompletion":11291,"completion":11291,"start":4207,"enrollment":407,"conditions":57980,"interventions":57981},"NCT00917644","Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet",[94],[12981],[13004,13004],{"nctId":16067,"briefTitle":16068,"status":111,"phases":57983,"completion":12424,"start":16070,"enrollment":130,"conditions":57984,"interventions":57985},[94],[16072],[13004,16054],{"nctId":57987,"briefTitle":57988,"status":111,"phases":57989,"completion":11315,"start":8180,"enrollment":1621,"conditions":57990,"interventions":57992},"NCT00159718","Double Blind Atorvastatin Amlodipine Study",[94],[57991],"Angina",[57993,12996],"amlodipine",{"nctId":12988,"briefTitle":12989,"status":111,"phases":57995,"completion":4692,"start":12991,"enrollment":12992,"conditions":57996,"interventions":57997},[94],[12994],[12996,12984],{"nctId":57999,"briefTitle":58000,"status":111,"phases":58001,"completion":11512,"start":58002,"enrollment":58003,"conditions":58004,"interventions":58008},"NCT00327418","CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events",[94],"1997-01",2800,[58005,57935,58006,14037,58007],"Major Coronary Event","Coronary Artery Bypass Graft","Revascularization",[13004],{"nctId":58010,"briefTitle":58011,"status":111,"phases":58012,"primaryCompletion":2884,"completion":2884,"start":11609,"enrollment":57555,"conditions":58013,"interventions":58014},"NCT00540293","Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study",[94],[28169],[13004],{"nctId":58016,"briefTitle":58017,"status":111,"phases":58018,"completion":4398,"start":6458,"enrollment":20110,"conditions":58019,"interventions":58020},"NCT00647543","Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand",[94],[28169],[13004,13004,13004],{"nctId":58022,"briefTitle":58023,"status":111,"phases":58024,"completion":12416,"start":11829,"enrollment":1759,"conditions":58025,"interventions":58026},"NCT00174330","Comparing Amlodipine\u002FAtorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia",[94],[13280,12979],[12996,57993],{"nctId":58028,"briefTitle":58029,"status":111,"phases":58030,"completion":4692,"start":16955,"enrollment":11305,"conditions":58031,"interventions":58032},"NCT00644709","A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)",[94],[28169],[13004],{"nctId":12998,"briefTitle":12999,"status":111,"phases":58034,"completion":3602,"start":11666,"enrollment":13001,"conditions":58035,"interventions":58036},[94],[12981],[13004,12957],{"trials":58038,"activeCount":103},[58039],{"nctId":58040,"briefTitle":58041,"status":111,"phases":58042,"primaryCompletion":2883,"completion":2883,"start":4206,"enrollment":58043,"conditions":58044,"interventions":58045},"NCT00993915","Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications",[],687,[12994,20862],[13004],{"intervention":3079,"totalTrials":3229,"cells":58047},{"EARLY_PHASE1":58048,"PHASE1":58050,"PHASE2":58058,"PHASE3":58077,"PHASE4":58134,"NA":58219},{"trials":58049,"activeCount":103},[],{"trials":58051,"activeCount":103},[58052],{"nctId":58053,"briefTitle":58054,"status":111,"phases":58055,"completion":6457,"start":12416,"enrollment":1509,"conditions":58056,"interventions":58057},"NCT00296127","Study of Celecoxib Bioavailability in Healthy Subjects",[91],[19],[3079],{"trials":58059,"activeCount":103},[58060,58066,58073],{"nctId":58061,"briefTitle":58062,"status":111,"phases":58063,"primaryCompletion":561,"completion":561,"start":4206,"enrollment":18733,"conditions":58064,"interventions":58065},"NCT01062113","Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain",[92],[34],[3079,3079],{"nctId":58067,"briefTitle":58068,"status":111,"phases":58069,"completion":4398,"start":22077,"enrollment":1578,"conditions":58070,"interventions":58072},"NCT00036283","Chemoprevention of Oral Premalignant Lesions",[92],[58071],"Precancerous Conditions",[3079],{"nctId":3070,"briefTitle":3071,"status":168,"phases":58074,"completion":3073,"start":3074,"enrollment":3075,"conditions":58075,"interventions":58076},[92],[3077,1028],[3079,1335,3080,1768],{"trials":58078,"activeCount":103},[58079,58083,58087,58091,58095,58104,58108,58112,58118,58127],{"nctId":12066,"briefTitle":12067,"status":111,"phases":58080,"completion":12069,"start":3073,"enrollment":12070,"conditions":58081,"interventions":58082},[93],[12072],[3079,3079,12047],{"nctId":13709,"briefTitle":13710,"status":111,"phases":58084,"start":12109,"enrollment":13712,"conditions":58085,"interventions":58086},[93],[11337],[3079,13698],{"nctId":22321,"briefTitle":22322,"status":111,"phases":58088,"primaryCompletion":11291,"completion":11291,"start":3853,"enrollment":19506,"conditions":58089,"interventions":58090},[93],[11337],[11523,22310],{"nctId":22894,"briefTitle":22895,"status":111,"phases":58092,"primaryCompletion":577,"completion":561,"start":4627,"enrollment":22897,"conditions":58093,"interventions":58094},[93],[15038],[3079,22883],{"nctId":58096,"briefTitle":58097,"status":111,"phases":58098,"primaryCompletion":58099,"completion":58099,"start":58100,"enrollment":4449,"conditions":58101,"interventions":58103},"NCT00402987","Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat",[93],"2007-11-15","2006-12-04",[58102],"Pharyngitis",[3079,3079,11523],{"nctId":24005,"briefTitle":24006,"status":111,"phases":58105,"primaryCompletion":4221,"completion":4221,"start":10937,"enrollment":17529,"conditions":58106,"interventions":58107},[93],[24009],[23994,3079,3079,3079],{"nctId":11376,"briefTitle":11377,"status":111,"phases":58109,"primaryCompletion":4398,"completion":4657,"start":11379,"enrollment":5690,"conditions":58110,"interventions":58111},[93],[11381],[3079,3079,11273],{"nctId":58113,"briefTitle":58114,"status":111,"phases":58115,"primaryCompletion":6016,"completion":6016,"start":4833,"enrollment":1519,"conditions":58116,"interventions":58117},"NCT00976716","An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain",[93],[34],[3079],{"nctId":58119,"briefTitle":58120,"status":111,"phases":58121,"primaryCompletion":3610,"completion":3610,"start":58122,"enrollment":58123,"conditions":58124,"interventions":58126},"NCT00141193","Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)",[93],"2001-02",1561,[58125],"Colorectal Adenoma",[3079],{"nctId":58128,"briefTitle":58129,"status":168,"phases":58130,"primaryCompletion":1249,"completion":1249,"start":3854,"enrollment":26706,"conditions":58131,"interventions":58133},"NCT00585312","Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)",[93],[58132],"Adenomatous Polyposis Coli",[3079],{"trials":58135,"activeCount":103},[58136,58142,58146,58150,58154,58158,58165,58169,58175,58181,58185,58189,58193,58199,58203,58207,58211,58215],{"nctId":58137,"briefTitle":58138,"status":168,"phases":58139,"completion":2641,"start":4847,"enrollment":525,"conditions":58140,"interventions":58141},"NCT00359151","Celebrex Total Knee Arthroplasty Study",[94],[11282,34],[3079],{"nctId":13718,"briefTitle":13719,"status":111,"phases":58143,"primaryCompletion":4206,"completion":4206,"start":6016,"enrollment":8278,"conditions":58144,"interventions":58145},[94],[19],[3079,13698],{"nctId":14799,"briefTitle":14800,"status":111,"phases":58147,"primaryCompletion":8252,"completion":8252,"start":12128,"enrollment":14802,"conditions":58148,"interventions":58149},[94],[11282],[3079,14786],{"nctId":11414,"briefTitle":11415,"status":111,"phases":58151,"completion":11417,"start":7675,"enrollment":2539,"conditions":58152,"interventions":58153},[94],[11419],[3079,11273,11421],{"nctId":11509,"briefTitle":11510,"status":111,"phases":58155,"completion":11512,"start":3073,"enrollment":11513,"conditions":58156,"interventions":58157},[94],[11347],[11072,3079],{"nctId":58159,"briefTitle":58160,"status":111,"phases":58161,"completion":13902,"start":11666,"enrollment":9,"conditions":58162,"interventions":58164},"NCT00633438","Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery",[94],[58163],"Arthroscopy",[3079],{"nctId":12095,"briefTitle":12096,"status":111,"phases":58166,"completion":4258,"start":6458,"enrollment":8827,"conditions":58167,"interventions":58168},[94],[12099],[3079,12047],{"nctId":58170,"briefTitle":58171,"status":111,"phases":58172,"completion":7675,"start":2672,"enrollment":2506,"conditions":58173,"interventions":58174},"NCT00640627","Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen",[94],[11347],[3079],{"nctId":58176,"briefTitle":58177,"status":111,"phases":58178,"completion":6458,"start":11676,"enrollment":162,"conditions":58179,"interventions":58180},"NCT00633386","Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery",[94],[58163],[3079],{"nctId":15519,"briefTitle":15520,"status":168,"phases":58182,"primaryCompletion":10923,"completion":10923,"start":6016,"enrollment":1487,"conditions":58183,"interventions":58184},[94],[34],[3079,15506],{"nctId":13226,"briefTitle":13227,"status":168,"phases":58186,"primaryCompletion":13229,"completion":13229,"start":13230,"enrollment":2070,"conditions":58187,"interventions":58188},[94],[11282],[11523,11295],{"nctId":11423,"briefTitle":11424,"status":111,"phases":58190,"primaryCompletion":2449,"completion":2449,"start":4833,"enrollment":11426,"conditions":58191,"interventions":58192},[94],[11381],[3079,11273],{"nctId":58194,"briefTitle":58195,"status":111,"phases":58196,"completion":13035,"start":2672,"enrollment":11513,"conditions":58197,"interventions":58198},"NCT00638807","Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen",[94],[11347],[3079],{"nctId":12106,"briefTitle":12107,"status":111,"phases":58200,"completion":12109,"start":11736,"enrollment":12110,"conditions":58201,"interventions":58202},[94],[11337],[12047,3079],{"nctId":16318,"briefTitle":16319,"status":111,"phases":58204,"primaryCompletion":3314,"completion":3314,"start":3610,"enrollment":16321,"conditions":58205,"interventions":58206},[94],[16323],[16305,3079],{"nctId":11517,"briefTitle":11518,"status":111,"phases":58208,"primaryCompletion":3628,"completion":3628,"start":11379,"enrollment":11520,"conditions":58209,"interventions":58210},[94],[11347],[11072,11523],{"nctId":16679,"briefTitle":16680,"status":111,"phases":58212,"primaryCompletion":11014,"completion":11014,"start":9387,"enrollment":16682,"conditions":58213,"interventions":58214},[94],[11282,4514],[3079,16666],{"nctId":16724,"briefTitle":16725,"status":111,"phases":58216,"completion":4398,"start":11736,"enrollment":16727,"conditions":58217,"interventions":58218},[94],[16729],[3079,16711],{"trials":58220,"activeCount":103},[58221,58229],{"nctId":58222,"briefTitle":58223,"status":168,"phases":58224,"primaryCompletion":10912,"completion":10912,"start":4222,"enrollment":58225,"conditions":58226,"interventions":58227},"NCT00688545","Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis",[],275,[11381],[3079,58228],"nsNSAIDs",{"nctId":58230,"briefTitle":58231,"status":168,"phases":58232,"primaryCompletion":4645,"completion":4645,"start":12774,"enrollment":3866,"conditions":58233,"interventions":58235},"NCT00151476","Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients",[],[58234],"Familial Adenomatous Polyposis (FAP)",[3079],{"intervention":12692,"totalTrials":5987,"cells":58237},{"EARLY_PHASE1":58238,"PHASE1":58240,"PHASE2":58266,"PHASE3":58347,"PHASE4":58432,"NA":58442},{"trials":58239,"activeCount":103},[],{"trials":58241,"activeCount":103},[58242,58248,58254,58260],{"nctId":58243,"briefTitle":58244,"status":111,"phases":58245,"primaryCompletion":10923,"completion":10923,"start":6016,"enrollment":597,"conditions":58246,"interventions":58247},"NCT00969813","A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function",[91],[18219],[12692,12692,12692],{"nctId":58249,"briefTitle":58250,"status":111,"phases":58251,"primaryCompletion":10912,"completion":18026,"start":11170,"enrollment":6199,"conditions":58252,"interventions":58253},"NCT01262118","Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis",[91],[22],[12692],{"nctId":58255,"briefTitle":58256,"status":111,"phases":58257,"primaryCompletion":3586,"completion":3586,"start":4680,"enrollment":1239,"conditions":58258,"interventions":58259},"NCT01513902","Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)",[91],[4494],[12692,12692,12692],{"nctId":58261,"briefTitle":58262,"status":111,"phases":58263,"primaryCompletion":3627,"completion":3627,"start":4657,"enrollment":1268,"conditions":58264,"interventions":58265},"NCT01745055","Co-Administration Of Methotrexate And CP-690,550",[91],[22],[12692,29445],{"trials":58267,"activeCount":103},[58268,58275,58282,58286,58292,58296,58302,58306,58310,58316,58322,58328,58332,58338],{"nctId":58269,"briefTitle":58270,"status":111,"phases":58271,"primaryCompletion":2227,"completion":12307,"start":114,"enrollment":58272,"conditions":58273,"interventions":58274},"NCT01393626","A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease",[92],280,[1570],[12692,12692],{"nctId":58276,"briefTitle":58277,"status":111,"phases":58278,"primaryCompletion":3627,"completion":3627,"start":12069,"enrollment":58279,"conditions":58280,"interventions":58281},"NCT00147498","Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks",[92],264,[22],[12692,12692,12692],{"nctId":31514,"briefTitle":31515,"status":111,"phases":58283,"primaryCompletion":8252,"completion":8252,"start":11988,"enrollment":4360,"conditions":58284,"interventions":58285},[92],[22],[12692,13004,12692,31505],{"nctId":58287,"briefTitle":58288,"status":111,"phases":58289,"primaryCompletion":8115,"completion":8115,"start":11315,"enrollment":2337,"conditions":58290,"interventions":58291},"NCT00413660","Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis",[92],[4514],[12692,12692,12692,12692,12692,12692],{"nctId":13172,"briefTitle":13173,"status":111,"phases":58293,"primaryCompletion":12395,"completion":12395,"start":11829,"enrollment":2400,"conditions":58294,"interventions":58295},[92],[4533],[12692,12692,12035],{"nctId":58297,"briefTitle":58298,"status":111,"phases":58299,"primaryCompletion":586,"completion":586,"start":11290,"enrollment":5152,"conditions":58300,"interventions":58301},"NCT00687193","Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan",[92],[4514],[12692,12692,12692,12692,12692],{"nctId":28048,"briefTitle":28049,"status":111,"phases":58303,"primaryCompletion":4846,"completion":4846,"start":4645,"enrollment":28051,"conditions":58304,"interventions":58305},[91,92],[28053],[12692,12692,12692,12692,7559,28055],{"nctId":12685,"briefTitle":12686,"status":111,"phases":58307,"primaryCompletion":8251,"completion":8251,"start":7665,"enrollment":12688,"conditions":58308,"interventions":58309},[92],[4514],[12676,12691,12691,12691,12692,12692],{"nctId":58311,"briefTitle":58312,"status":111,"phases":58313,"primaryCompletion":18026,"completion":18026,"start":9544,"enrollment":38105,"conditions":58314,"interventions":58315},"NCT01359150","A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo",[92],[22],[12692],{"nctId":58317,"briefTitle":58318,"status":111,"phases":58319,"primaryCompletion":5008,"completion":5008,"start":3334,"enrollment":1210,"conditions":58320,"interventions":58321},"NCT01470599","A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease",[92],[1570],[12692,12692],{"nctId":58323,"briefTitle":58324,"status":111,"phases":58325,"primaryCompletion":11291,"completion":11291,"start":3853,"enrollment":12373,"conditions":58326,"interventions":58327},"NCT00603512","Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan",[92],[4514],[12692,12692,12692,12692],{"nctId":28057,"briefTitle":28058,"status":111,"phases":58329,"primaryCompletion":12307,"completion":4438,"start":8115,"enrollment":28060,"conditions":58330,"interventions":58331},[92],[4533],[7559,12692,12692],{"nctId":58333,"briefTitle":58334,"status":111,"phases":58335,"primaryCompletion":4439,"completion":4439,"start":2450,"enrollment":23645,"conditions":58336,"interventions":58337},"NCT01393899","The Safety And Efficacy Of Maintenance Therapy With CP-690,550",[92],[1570],[12692,12692],{"nctId":58339,"briefTitle":58340,"status":111,"phases":58341,"primaryCompletion":58342,"completion":58343,"start":58344,"enrollment":7399,"conditions":58345,"interventions":58346},"NCT00678561","Topical CP-690,550 For Chronic Plaque Psoriasis",[92],"2009-07-09","2009-07-24","2008-10-13",[4401],[12692,12692,12692,12692,12692,12692],{"trials":58348,"activeCount":103},[58349,58356,58360,58367,58371,58379,58383,58390,58397,58403,58410,58417,58426],{"nctId":58350,"briefTitle":58351,"status":111,"phases":58352,"primaryCompletion":6208,"completion":6208,"start":524,"enrollment":58353,"conditions":58354,"interventions":58355},"NCT01309737","A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",[93],960,[4401],[12692,12692],{"nctId":22116,"briefTitle":22117,"status":111,"phases":58357,"primaryCompletion":1248,"completion":1248,"start":2450,"enrollment":22119,"conditions":58358,"interventions":58359},[93],[4401],[12692,22105],{"nctId":58361,"briefTitle":58362,"status":111,"phases":58363,"primaryCompletion":577,"completion":577,"start":4608,"enrollment":58364,"conditions":58365,"interventions":58366},"NCT00814307","A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis",[93],611,[4514],[12692,12692],{"nctId":22448,"briefTitle":22449,"status":111,"phases":58368,"primaryCompletion":22451,"completion":22451,"start":22452,"enrollment":11932,"conditions":58369,"interventions":58370},[93],[1532],[22437,12692],{"nctId":58372,"briefTitle":58373,"status":111,"phases":58374,"primaryCompletion":58375,"completion":58375,"start":58376,"enrollment":5690,"conditions":58377,"interventions":58378},"NCT02592434","Efficacy Study Of Tofacitinib In Pediatric JIA Population",[93],"2019-05-16","2016-06-10",[4494],[12692],{"nctId":23513,"briefTitle":23514,"status":111,"phases":58380,"primaryCompletion":4680,"completion":4680,"start":10923,"enrollment":23516,"conditions":58381,"interventions":58382},[93],[4514],[12692,12692,23502],{"nctId":58384,"briefTitle":58385,"status":111,"phases":58386,"primaryCompletion":524,"completion":524,"start":4846,"enrollment":58387,"conditions":58388,"interventions":58389},"NCT00960440","Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors",[93],399,[4514],[12692,12692,12692,12692],{"nctId":58391,"briefTitle":58392,"status":111,"phases":58393,"primaryCompletion":58394,"completion":58394,"start":18077,"enrollment":1134,"conditions":58395,"interventions":58396},"NCT01470612","Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis",[93],"2020-08-06",[1532],[12692,12692],{"nctId":58398,"briefTitle":58399,"status":111,"phases":58400,"primaryCompletion":6208,"completion":6208,"start":524,"enrollment":19872,"conditions":58401,"interventions":58402},"NCT01276639","A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",[93],[4401],[12692,12692],{"nctId":58404,"briefTitle":58405,"status":111,"phases":58406,"primaryCompletion":3601,"completion":3601,"start":11014,"enrollment":58407,"conditions":58408,"interventions":58409},"NCT00856544","A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications",[93],795,[4514],[12692,12692],{"nctId":58411,"briefTitle":58412,"status":111,"phases":58413,"primaryCompletion":606,"completion":606,"start":3314,"enrollment":58414,"conditions":58415,"interventions":58416},"NCT00661661","Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan",[93],487,[22],[12692],{"nctId":58418,"briefTitle":58419,"status":111,"phases":58420,"primaryCompletion":21220,"completion":58421,"start":58422,"enrollment":58423,"conditions":58424,"interventions":58425},"NCT00413699","Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis",[93],"2017-10-26","2007-02-05",4488,[4514],[12692,12692],{"nctId":58427,"briefTitle":58428,"status":111,"phases":58429,"primaryCompletion":4590,"completion":4590,"start":560,"enrollment":2470,"conditions":58430,"interventions":58431},"NCT01186744","A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis",[93],[4401],[12692,12692,12692,12692],{"trials":58433,"activeCount":103},[58434],{"nctId":58435,"briefTitle":58436,"status":111,"phases":58437,"primaryCompletion":58438,"completion":3673,"start":5928,"enrollment":58439,"conditions":58440,"interventions":58441},"NCT02831855","Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis",[94],"2018-11-19",694,[22],[12692,29445],{"trials":58443,"activeCount":103},[58444],{"nctId":58445,"briefTitle":58446,"status":111,"phases":58447,"primaryCompletion":18026,"completion":18026,"start":3602,"enrollment":19002,"conditions":58448,"interventions":58449},"NCT00414661","Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550",[],[4514],[12692],{"intervention":4327,"totalTrials":1257,"cells":58451},{"EARLY_PHASE1":58452,"PHASE1":58454,"PHASE2":58478,"PHASE3":58535,"PHASE4":58555,"NA":58566},{"trials":58453,"activeCount":103},[],{"trials":58455,"activeCount":103},[58456,58460,58464,58470,58474],{"nctId":19326,"briefTitle":19327,"status":111,"phases":58457,"primaryCompletion":4665,"completion":4608,"start":12395,"enrollment":525,"conditions":58458,"interventions":58459},[91],[25],[4327,19319],{"nctId":8097,"briefTitle":8098,"status":111,"phases":58461,"primaryCompletion":4627,"completion":605,"start":2964,"enrollment":504,"conditions":58462,"interventions":58463},[91],[2886],[1770,8102,4327],{"nctId":58465,"briefTitle":58466,"status":111,"phases":58467,"primaryCompletion":2964,"completion":2964,"start":13035,"enrollment":2175,"conditions":58468,"interventions":58469},"NCT00712504","Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer",[91],[553,643],[3317,432],{"nctId":19332,"briefTitle":19333,"status":111,"phases":58471,"primaryCompletion":9544,"completion":9544,"start":4615,"enrollment":1239,"conditions":58472,"interventions":58473},[91],[31],[19213,4327,19319],{"nctId":17370,"briefTitle":17371,"status":168,"phases":58475,"primaryCompletion":4531,"completion":6208,"start":11291,"enrollment":8373,"conditions":58476,"interventions":58477},[91],[543,553],[1705,4327],{"trials":58479,"activeCount":103},[58480,58484,58488,58494,58500,58507,58513,58519,58525,58529],{"nctId":3310,"briefTitle":3311,"status":168,"phases":58481,"primaryCompletion":3313,"completion":3313,"start":3314,"enrollment":1413,"conditions":58482,"interventions":58483},[92],[1028],[3317,3318,429,3318],{"nctId":4815,"briefTitle":4816,"status":111,"phases":58485,"primaryCompletion":4221,"completion":113,"start":3314,"enrollment":4818,"conditions":58486,"interventions":58487},[92],[4820],[2056,4327],{"nctId":58489,"briefTitle":58490,"status":111,"phases":58491,"primaryCompletion":10923,"completion":10912,"start":3627,"enrollment":19002,"conditions":58492,"interventions":58493},"NCT00265317","A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone",[92],[376],[433,3317,433],{"nctId":58495,"briefTitle":58496,"status":111,"phases":58497,"primaryCompletion":11315,"completion":3335,"start":4702,"enrollment":2400,"conditions":58498,"interventions":58499},"NCT00089648","SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma",[92],[919],[4327],{"nctId":58501,"briefTitle":58502,"status":111,"phases":58503,"primaryCompletion":3313,"completion":18769,"start":586,"enrollment":1268,"conditions":58504,"interventions":58506},"NCT01121562","Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors",[92],[58505],"Pancreatic Neuroendocrine Tumors",[4327],{"nctId":58508,"briefTitle":58509,"status":111,"phases":58510,"primaryCompletion":4221,"completion":4221,"start":11895,"enrollment":4825,"conditions":58511,"interventions":58512},"NCT00372775","Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases",[92],[422],[4327],{"nctId":58514,"briefTitle":58515,"status":111,"phases":58516,"primaryCompletion":2884,"completion":2884,"start":2662,"enrollment":27583,"conditions":58517,"interventions":58518},"NCT00226811","An International Phase 2 Study Of SU011248 In Patients With Advanced \u002F Metastatic Gastric Cancer Failing Chemotherapy",[92],[2886],[4327],{"nctId":58520,"briefTitle":58521,"status":111,"phases":58522,"primaryCompletion":11895,"completion":11895,"start":12069,"enrollment":4360,"conditions":58523,"interventions":58524},"NCT00092001","Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer",[92],[376],[4327],{"nctId":36878,"briefTitle":36879,"status":168,"phases":58526,"primaryCompletion":605,"completion":605,"start":4833,"enrollment":3229,"conditions":58527,"interventions":58528},[92],[338],[36869,36869,36869,36869,36869,4327],{"nctId":58530,"briefTitle":58531,"status":111,"phases":58532,"primaryCompletion":10937,"completion":4608,"start":12416,"enrollment":2849,"conditions":58533,"interventions":58534},"NCT00247676","An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer",[92],[891,890],[4327],{"trials":58536,"activeCount":103},[58537,58543,58547,58551],{"nctId":58538,"briefTitle":58539,"status":111,"phases":58540,"primaryCompletion":586,"completion":2449,"start":2641,"enrollment":58353,"conditions":58541,"interventions":58542},"NCT00457392","A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone",[93],[2645],[433,3317,433],{"nctId":3639,"briefTitle":3640,"status":111,"phases":58544,"primaryCompletion":3642,"completion":3642,"start":3643,"enrollment":3644,"conditions":58545,"interventions":58546},[93],[1810],[3647,2004,3648,3317,3647,2004,3648],{"nctId":12011,"briefTitle":12012,"status":168,"phases":58548,"primaryCompletion":2883,"completion":2883,"start":4207,"enrollment":12014,"conditions":58549,"interventions":58550},[93],[11998],[2341,3317,2341],{"nctId":4318,"briefTitle":4319,"status":111,"phases":58552,"primaryCompletion":4321,"completion":4322,"start":4323,"enrollment":4324,"conditions":58553,"interventions":58554},[93],[4200],[663,933,4327],{"trials":58556,"activeCount":103},[58557],{"nctId":58558,"briefTitle":58559,"status":111,"phases":58560,"primaryCompletion":58561,"completion":22920,"start":58562,"enrollment":26706,"conditions":58563,"interventions":58565},"NCT01525550","A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors",[94],"2016-03-19","2012-06-06",[58564],"Well-differentiated Pancreatic Neuroendocrine Tumor",[3317],{"trials":58567,"activeCount":103},[58568,58575,58582,58586,58597,58605,58614,58621,58625,58631,58635],{"nctId":58569,"briefTitle":58570,"status":111,"phases":58571,"primaryCompletion":5043,"completion":5043,"start":8384,"enrollment":10190,"conditions":58572,"interventions":58574},"NCT04175262","Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments",[],[58573],"Metastatic Renal Cell Carcinoma (mRCC)",[3317],{"nctId":58576,"briefTitle":58577,"status":111,"phases":58578,"primaryCompletion":3723,"completion":3723,"start":58579,"enrollment":397,"conditions":58580,"interventions":58581},"NCT02282059","The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors",[],"2014-12-12",[58505],[3317],{"nctId":4343,"briefTitle":4344,"status":111,"phases":58583,"primaryCompletion":406,"completion":406,"start":4346,"enrollment":4347,"conditions":58584,"interventions":58585},[],[928,4349,4350],[4352,4352,4327,4327,933],{"nctId":58587,"briefTitle":58588,"status":111,"phases":58589,"primaryCompletion":7386,"completion":9572,"start":2641,"enrollment":38105,"conditions":58590,"interventions":58596},"NCT00428220","A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",[95],[1369,1241,58591,929,422,1984,58592,4224,58593,889,58594,58595],"Metastatic Castration Resistant Prostate Cancer","Advanced\u002FMetastatic Non-Small Cell Lung Cancer","Gastrointestinal Stromal Tumor","Pancreatic Islet Cell Carcinoma","Pancreatic Neuroendocrine Tumor",[3317],{"nctId":58598,"briefTitle":58599,"status":168,"phases":58600,"primaryCompletion":58601,"completion":58601,"start":58602,"enrollment":5647,"conditions":58603,"interventions":58604},"NCT03140176","Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.",[],"2022-01-22","2017-08-15",[924],[4327],{"nctId":58606,"briefTitle":58607,"status":111,"phases":58608,"primaryCompletion":58609,"completion":58609,"start":58610,"enrollment":58611,"conditions":58612,"interventions":58613},"NCT04076787","Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib",[],"2018-09-02","2018-09-01",1769,[924],[4327],{"nctId":58615,"briefTitle":58616,"status":111,"phases":58617,"primaryCompletion":2079,"completion":2079,"start":2079,"enrollment":58618,"conditions":58619,"interventions":58620},"NCT05745142","A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.",[],376,[919,925],[4327],{"nctId":4892,"briefTitle":4893,"status":111,"phases":58622,"primaryCompletion":4895,"completion":4895,"start":4896,"enrollment":4897,"conditions":58623,"interventions":58624},[],[4899],[3317,4901,4902],{"nctId":58626,"briefTitle":58627,"status":111,"phases":58628,"primaryCompletion":2883,"completion":2883,"start":11686,"enrollment":4549,"conditions":58629,"interventions":58630},"NCT00798889","Rollover Protocol for Prior SU011248 Protocols",[95],[750],[4327],{"nctId":4378,"briefTitle":4379,"status":111,"phases":58632,"primaryCompletion":4381,"completion":4381,"start":4382,"enrollment":4383,"conditions":58633,"interventions":58634},[],[943,4385],[4327,933],{"nctId":58636,"briefTitle":58637,"status":168,"phases":58638,"primaryCompletion":4666,"completion":4666,"start":2660,"enrollment":257,"conditions":58639,"interventions":58640},"NCT01033981","Cost Effectiveness Of Sunitinib In Central America And Caribbean",[],[924],[4327],{"intervention":4517,"totalTrials":1780,"cells":58642},{"EARLY_PHASE1":58643,"PHASE1":58645,"PHASE2":58647,"PHASE3":58649,"PHASE4":58668,"NA":58742},{"trials":58644,"activeCount":103},[],{"trials":58646,"activeCount":103},[],{"trials":58648,"activeCount":103},[],{"trials":58650,"activeCount":103},[58651,58658,58662],{"nctId":58652,"briefTitle":58653,"status":111,"phases":58654,"primaryCompletion":2661,"completion":4590,"start":4833,"enrollment":13519,"conditions":58655,"interventions":58657},"NCT00962741","Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis",[93],[58656],"Arthritis, Juvenile Idiopathic",[14680],{"nctId":22138,"briefTitle":22139,"status":111,"phases":58659,"primaryCompletion":3345,"completion":11356,"start":4666,"enrollment":5690,"conditions":58660,"interventions":58661},[93],[12072],[4517,22127,22127],{"nctId":58663,"briefTitle":58664,"status":111,"phases":58665,"primaryCompletion":651,"completion":539,"start":4589,"enrollment":27266,"conditions":58666,"interventions":58667},"NCT02378506","Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects",[93],[4514],[4517],{"trials":58669,"activeCount":103},[58670,58676,58680,58687,58693,58699,58706,58712,58716,58723,58729,58735],{"nctId":58671,"briefTitle":58672,"status":111,"phases":58673,"primaryCompletion":6208,"completion":6208,"start":10923,"enrollment":16968,"conditions":58674,"interventions":58675},"NCT00992394","Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept",[94],[4401],[4517,4517],{"nctId":14674,"briefTitle":14675,"status":111,"phases":58677,"primaryCompletion":523,"completion":523,"start":4627,"enrollment":2240,"conditions":58678,"interventions":58679},[94],[14678],[14680,14661,14681],{"nctId":58681,"briefTitle":58682,"status":111,"phases":58683,"primaryCompletion":1388,"completion":58684,"start":30209,"enrollment":18795,"conditions":58685,"interventions":58686},"NCT02509026","Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA",[94],"2019-09-06",[12072],[14680],{"nctId":58688,"briefTitle":58689,"status":111,"phases":58690,"primaryCompletion":6016,"completion":6016,"start":11609,"enrollment":941,"conditions":58691,"interventions":58692},"NCT00581555","Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy",[94],[4401],[14680],{"nctId":58694,"briefTitle":58695,"status":168,"phases":58696,"primaryCompletion":7386,"completion":7386,"start":13214,"enrollment":314,"conditions":58697,"interventions":58698},"NCT01783015","Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate",[94],[22],[14680,14680],{"nctId":58700,"briefTitle":58701,"status":111,"phases":58702,"primaryCompletion":12307,"completion":12307,"start":540,"enrollment":58703,"conditions":58704,"interventions":58705},"NCT01578850","Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening",[94],491,[22],[14680],{"nctId":58707,"briefTitle":58708,"status":168,"phases":58709,"primaryCompletion":114,"completion":114,"start":4627,"enrollment":3229,"conditions":58710,"interventions":58711},"NCT00910273","Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients",[94],[15038],[4517],{"nctId":4508,"briefTitle":4509,"status":111,"phases":58713,"primaryCompletion":462,"completion":462,"start":4511,"enrollment":4512,"conditions":58714,"interventions":58715},[94],[4514],[4404,4404,4516,4517],{"nctId":58717,"briefTitle":58718,"status":111,"phases":58719,"primaryCompletion":4590,"completion":6208,"start":11170,"enrollment":481,"conditions":58720,"interventions":58722},"NCT01298531","A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis",[94],[58721],"Axial Spondyloarthritis",[4517,4517],{"nctId":58724,"briefTitle":58725,"status":111,"phases":58726,"primaryCompletion":4459,"completion":4459,"start":8251,"enrollment":13892,"conditions":58727,"interventions":58728},"NCT00858780","Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA",[94],[22],[14680,14680],{"nctId":58730,"briefTitle":58731,"status":111,"phases":58732,"primaryCompletion":4459,"completion":2449,"start":4833,"enrollment":29192,"conditions":58733,"interventions":58734},"NCT00913458","Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis",[94],[29123,4514,22],[4517],{"nctId":58736,"briefTitle":58737,"status":111,"phases":58738,"primaryCompletion":11170,"completion":11170,"start":3335,"enrollment":58739,"conditions":58740,"interventions":58741},"NCT00565409","Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis",[94],834,[4514],[14680,29445,14680,29445,29445],{"trials":58743,"activeCount":103},[58744,58752,58760,58767,58774,58782,58789,58795,58802,58809,58816,58824,58831,58839,58845],{"nctId":58745,"briefTitle":58746,"status":111,"phases":58747,"primaryCompletion":58748,"completion":58748,"start":58749,"enrollment":7388,"conditions":58750,"interventions":58751},"NCT01100034","Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis",[],"2018-09-24","2010-11-19",[4401],[14680],{"nctId":58753,"briefTitle":58754,"status":111,"phases":58755,"primaryCompletion":18128,"completion":18128,"start":2662,"enrollment":641,"conditions":58756,"interventions":58759},"NCT00293709","Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists",[],[58757,4401,58758],"Arthritis, Psoriatic","Skin Diseases, Papulosquamous",[4517],{"nctId":58761,"briefTitle":58762,"status":111,"phases":58763,"primaryCompletion":8335,"completion":8335,"start":58764,"enrollment":7184,"conditions":58765,"interventions":58766},"NCT02202837","Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice",[],"2014-08-12",[22],[4517,4517],{"nctId":58768,"briefTitle":58769,"status":111,"phases":58770,"primaryCompletion":6208,"completion":6208,"start":3854,"enrollment":58771,"conditions":58772,"interventions":58773},"NCT00488475","Observational Trial With Enbrel",[],4945,[22],[4517],{"nctId":58775,"briefTitle":58776,"status":111,"phases":58777,"primaryCompletion":569,"completion":569,"start":18026,"enrollment":58778,"conditions":58779,"interventions":58780},"NCT01646385","Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry",[],6393,[22],[4517,58781],"non-biologic anti-rheumatic drugs",{"nctId":58783,"briefTitle":58784,"status":111,"phases":58785,"primaryCompletion":652,"completion":652,"start":11609,"enrollment":58786,"conditions":58787,"interventions":58788},"NCT00544557","Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis",[],1715,[15038],[14680],{"nctId":58790,"briefTitle":58791,"status":111,"phases":58792,"primaryCompletion":4656,"completion":4656,"start":11395,"enrollment":2713,"conditions":58793,"interventions":58794},"NCT00195338","Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg",[],[22],[4517],{"nctId":58796,"briefTitle":58797,"status":111,"phases":58798,"primaryCompletion":606,"completion":606,"start":3839,"enrollment":58799,"conditions":58800,"interventions":58801},"NCT00708708","Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings",[],926,[4401],[4517],{"nctId":58803,"briefTitle":58804,"status":111,"phases":58805,"primaryCompletion":58806,"completion":58806,"start":58764,"enrollment":4637,"conditions":58807,"interventions":58808},"NCT02202850","Defining Remission With Etanercept in AS in Real Life Clinical Practice",[],"2017-04-26",[15038],[4517,4517],{"nctId":58810,"briefTitle":58811,"status":111,"phases":58812,"primaryCompletion":10937,"completion":10937,"start":11395,"enrollment":58813,"conditions":58814,"interventions":58815},"NCT00195403","A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA",[],1014,[22],[14680],{"nctId":58817,"briefTitle":58818,"status":111,"phases":58819,"primaryCompletion":1700,"completion":1700,"start":114,"enrollment":58820,"conditions":58821,"interventions":58822},"NCT01557322","Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)",[],1754,[22],[4517,58823],"methotrexate",{"nctId":58825,"briefTitle":58826,"status":111,"phases":58827,"primaryCompletion":18026,"completion":18026,"start":4656,"enrollment":20,"conditions":58828,"interventions":58829},"NCT01793285","An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial",[],[15038],[58830],"ETANERCEPT",{"nctId":58832,"briefTitle":58833,"status":111,"phases":58834,"primaryCompletion":58835,"completion":58835,"start":58836,"enrollment":19303,"conditions":58837,"interventions":58838},"NCT04507763","Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis",[],"2020-10-01","2020-08-01",[15038],[14680],{"nctId":58840,"briefTitle":58841,"status":111,"phases":58842,"primaryCompletion":4458,"completion":4458,"start":4680,"enrollment":407,"conditions":58843,"interventions":58844},"NCT01558089","Good EULAR Response In Patients With Early Rheumatoid Arthritis",[],[22],[4517,58823],{"nctId":58846,"briefTitle":58847,"status":111,"phases":58848,"primaryCompletion":58835,"completion":58835,"start":22986,"enrollment":19303,"conditions":58849,"interventions":58851},"NCT04507776","Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel",[],[58850],"Spondyloarthrosis",[14680],{"intervention":12666,"totalTrials":1780,"cells":58853},{"EARLY_PHASE1":58854,"PHASE1":58856,"PHASE2":58862,"PHASE3":58870,"PHASE4":58980,"NA":59028},{"trials":58855,"activeCount":103},[],{"trials":58857,"activeCount":103},[58858],{"nctId":45453,"briefTitle":45454,"status":111,"phases":58859,"primaryCompletion":11290,"completion":11290,"start":8251,"enrollment":1625,"conditions":58860,"interventions":58861},[91],[16],[12647,45446,45458],{"trials":58863,"activeCount":103},[58864],{"nctId":58865,"briefTitle":58866,"status":111,"phases":58867,"completion":4692,"start":2672,"enrollment":4818,"conditions":58868,"interventions":58869},"NCT00650611","A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders",[92],[12632,21056,22020],[12666,12666],{"trials":58871,"activeCount":103},[58872,58878,58886,58894,58903,58910,58916,58923,58929,58938,58944,58948,58954,58960,58964,58968,58974],{"nctId":58873,"briefTitle":58874,"status":168,"phases":58875,"completion":4692,"start":7675,"enrollment":302,"conditions":58876,"interventions":58877},"NCT00645229","A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder",[93],[12632,22020],[12666],{"nctId":58879,"briefTitle":58880,"status":168,"phases":58881,"primaryCompletion":58882,"completion":58882,"start":58883,"enrollment":2218,"conditions":58884,"interventions":58885},"NCT03768726","Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder",[93],"2020-07-31","2018-12-21",[21056],[12666],{"nctId":58887,"briefTitle":58888,"status":168,"phases":58889,"primaryCompletion":4646,"completion":4646,"start":3627,"enrollment":58890,"conditions":58891,"interventions":58892},"NCT00265382","Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia",[93],221,[12632],[58893],"Ziprasidone oral",{"nctId":58895,"briefTitle":58896,"status":111,"phases":58897,"primaryCompletion":2884,"completion":2884,"start":2671,"enrollment":58898,"conditions":58899,"interventions":58901},"NCT00280566","Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)",[93],584,[58900,21056],"Bipolar Mania",[58902],"Ziprasidone Oral",{"nctId":58904,"briefTitle":58905,"status":649,"phases":58906,"primaryCompletion":114,"completion":114,"start":586,"enrollment":103,"conditions":58907,"interventions":58908},"NCT01124877","Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)",[93],[21056],[58909],"ziprasidone oral",{"nctId":58911,"briefTitle":58912,"status":111,"phases":58913,"primaryCompletion":4646,"completion":4646,"start":22517,"enrollment":18459,"conditions":58914,"interventions":58915},"NCT00139737","Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia",[93],[12632],[12666],{"nctId":58917,"briefTitle":58918,"status":111,"phases":58919,"primaryCompletion":8154,"completion":8154,"start":11609,"enrollment":4658,"conditions":58920,"interventions":58922},"NCT00483548","Adjunctive Ziprasidone in the Treatment of Bipolar I Depression",[93],[21056,58921],"Depression, Bipolar",[12666],{"nctId":58924,"briefTitle":58925,"status":111,"phases":58926,"completion":8170,"start":3628,"enrollment":4981,"conditions":58927,"interventions":58928},"NCT00136994","IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)",[93],[12632],[12666],{"nctId":58930,"briefTitle":58931,"status":168,"phases":58932,"primaryCompletion":58933,"completion":58934,"start":58935,"enrollment":3336,"conditions":58936,"interventions":58937},"NCT02075047","Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder",[93],"2020-04-11","2020-05-18","2014-05-23",[21056],[58909],{"nctId":58939,"briefTitle":58940,"status":111,"phases":58941,"primaryCompletion":2641,"completion":2641,"start":2662,"enrollment":15310,"conditions":58942,"interventions":58943},"NCT00257166","Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)",[93],[21056],[58893],{"nctId":20107,"briefTitle":20108,"status":111,"phases":58945,"completion":11829,"start":13035,"enrollment":20110,"conditions":58946,"interventions":58947},[93],[12632],[20079,12666],{"nctId":58949,"briefTitle":58950,"status":111,"phases":58951,"primaryCompletion":4665,"completion":4665,"start":11782,"enrollment":32,"conditions":58952,"interventions":58953},"NCT00174447","Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031",[93],[12632],[12666],{"nctId":58955,"briefTitle":58956,"status":111,"phases":58957,"primaryCompletion":8154,"completion":8154,"start":12030,"enrollment":5272,"conditions":58958,"interventions":58959},"NCT00312494","3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects",[93],[21056],[12666,12666],{"nctId":12640,"briefTitle":12641,"status":111,"phases":58961,"completion":8170,"start":3628,"enrollment":397,"conditions":58962,"interventions":58963},[93],[12632,12644],[12646,12647],{"nctId":26052,"briefTitle":26053,"status":111,"phases":58965,"completion":7675,"start":3073,"enrollment":26055,"conditions":58966,"interventions":58967},[93],[12632],[26041,12666],{"nctId":58969,"briefTitle":58970,"status":111,"phases":58971,"completion":6017,"start":4679,"enrollment":4755,"conditions":58972,"interventions":58973},"NCT00143351","Mozart Relapse Study",[93],[12632],[12666],{"nctId":58975,"briefTitle":58976,"status":111,"phases":58977,"primaryCompletion":3853,"completion":3853,"start":6457,"enrollment":13935,"conditions":58978,"interventions":58979},"NCT00265330","Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)",[93],[21056],[58893],{"trials":58981,"activeCount":103},[58982,58988,58994,58998,59007,59011,59017,59021],{"nctId":58983,"briefTitle":58984,"status":111,"phases":58985,"completion":7675,"start":2672,"enrollment":787,"conditions":58986,"interventions":58987},"NCT00649064","A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs",[94],[22020,12632],[12666],{"nctId":58989,"briefTitle":58990,"status":111,"phases":58991,"completion":11829,"start":11736,"enrollment":5909,"conditions":58992,"interventions":58993},"NCT00650429","A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder",[94],[12632,22020],[12666],{"nctId":13374,"briefTitle":13375,"status":111,"phases":58995,"completion":4692,"start":4398,"enrollment":13377,"conditions":58996,"interventions":58997},[94],[12632],[13344,12666],{"nctId":58999,"briefTitle":59000,"status":111,"phases":59001,"completion":11395,"start":11387,"enrollment":13215,"conditions":59002,"interventions":59006},"NCT00644800","A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis",[94],[12632,59003,59004,59005],"Mania","Delusional Disorder","Acute Exacerbation of Psychosis",[12666],{"nctId":12660,"briefTitle":12661,"status":111,"phases":59008,"completion":3602,"start":2652,"enrollment":12663,"conditions":59009,"interventions":59010},[94],[12632],[12666,12621],{"nctId":59012,"briefTitle":59013,"status":111,"phases":59014,"primaryCompletion":8154,"completion":11290,"start":4847,"enrollment":18733,"conditions":59015,"interventions":59016},"NCT00406315","Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone",[94],[12632,22020],[12647],{"nctId":12668,"briefTitle":12669,"status":111,"phases":59018,"completion":1701,"start":12607,"enrollment":4440,"conditions":59019,"interventions":59020},[94],[12632],[12666,12621],{"nctId":59022,"briefTitle":59023,"status":111,"phases":59024,"completion":11727,"start":6458,"enrollment":4755,"conditions":59025,"interventions":59027},"NCT00645320","A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study",[94],[59026],"Pyschotic Disorders",[12666],{"trials":59029,"activeCount":103},[59030,59039,59045],{"nctId":59031,"briefTitle":59032,"status":111,"phases":59033,"primaryCompletion":4636,"completion":4636,"start":3602,"enrollment":59034,"conditions":59035,"interventions":59038},"NCT00454883","Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.",[],379,[59036,59003,59037],"Affective Psychosis, Bipolar","Manic-Depressive Psychosis",[12647],{"nctId":59040,"briefTitle":59041,"status":111,"phases":59042,"primaryCompletion":4222,"completion":4222,"start":11609,"enrollment":11677,"conditions":59043,"interventions":59044},"NCT00579670","Treatment of Schizophrenic Patients With Ziprasidone",[],[12632],[12666],{"nctId":59046,"briefTitle":59047,"status":111,"phases":59048,"primaryCompletion":11988,"completion":11988,"start":14118,"enrollment":59049,"conditions":59050,"interventions":59051},"NCT01053429","A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule",[],3391,[21056,12632],[12647],{"intervention":59053,"totalTrials":2218,"cells":59054},"varenicline",{"EARLY_PHASE1":59055,"PHASE1":59057,"PHASE2":59072,"PHASE3":59087,"PHASE4":59132,"NA":59166},{"trials":59056,"activeCount":103},[],{"trials":59058,"activeCount":103},[59059,59065],{"nctId":59060,"briefTitle":59061,"status":111,"phases":59062,"completion":4636,"start":3610,"enrollment":463,"conditions":59063,"interventions":59064},"NCT00463918","A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers",[91],[11904],[59053],{"nctId":59066,"briefTitle":59067,"status":111,"phases":59068,"primaryCompletion":3839,"completion":3839,"start":3314,"enrollment":26,"conditions":59069,"interventions":59071},"NCT00694044","Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects",[91],[16,59070],"Non-Smoking",[59053,59053,59053],{"trials":59073,"activeCount":103},[59074,59081],{"nctId":59075,"briefTitle":59076,"status":111,"phases":59077,"completion":11727,"start":11395,"enrollment":1780,"conditions":59078,"interventions":59079},"NCT00635401","A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking",[92],[11897],[59080],"Varenicline",{"nctId":59082,"briefTitle":59083,"status":111,"phases":59084,"primaryCompletion":8252,"completion":8252,"start":4627,"enrollment":4825,"conditions":59085,"interventions":59086},"NCT00744978","Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease",[92],[17728],[59080],{"trials":59088,"activeCount":103},[59089,59096,59102,59108,59115,59121,59127],{"nctId":59090,"briefTitle":59091,"status":111,"phases":59092,"completion":4692,"start":12607,"enrollment":59093,"conditions":59094,"interventions":59095},"NCT00143286","A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation",[93],2000,[11904],[59053],{"nctId":59097,"briefTitle":59098,"status":111,"phases":59099,"completion":4692,"start":11736,"enrollment":1568,"conditions":59100,"interventions":59101},"NCT00143299","A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline",[93],[11904],[59053],{"nctId":59103,"briefTitle":59104,"status":111,"phases":59105,"primaryCompletion":4206,"completion":4206,"start":2884,"enrollment":1326,"conditions":59106,"interventions":59107},"NCT00644969","Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder",[93],[11904],[59053],{"nctId":59109,"briefTitle":59110,"status":111,"phases":59111,"completion":4657,"start":2642,"enrollment":59112,"conditions":59113,"interventions":59114},"NCT00141206","A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation",[93],1005,[11904],[59053],{"nctId":59116,"briefTitle":59117,"status":111,"phases":59118,"completion":3627,"start":12069,"enrollment":18004,"conditions":59119,"interventions":59120},"NCT00143325","An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation",[93],[11904],[59053],{"nctId":59122,"briefTitle":59123,"status":111,"phases":59124,"completion":2662,"start":4258,"enrollment":8827,"conditions":59125,"interventions":59126},"NCT00141167","A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation",[93],[11904],[59053],{"nctId":59128,"briefTitle":59110,"status":111,"phases":59129,"completion":4692,"start":4679,"enrollment":59112,"conditions":59130,"interventions":59131},"NCT00143364",[93],[11904],[59053],{"trials":59133,"activeCount":103},[59134,59140,59147,59154,59160],{"nctId":59135,"briefTitle":59136,"status":111,"phases":59137,"primaryCompletion":4627,"completion":4214,"start":11291,"enrollment":8123,"conditions":59138,"interventions":59139},"NCT00749944","Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo",[94],[11904],[59053],{"nctId":59141,"briefTitle":59142,"status":111,"phases":59143,"primaryCompletion":4459,"completion":4459,"start":3642,"enrollment":59144,"conditions":59145,"interventions":59146},"NCT01078298","Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression",[94],525,[11904,12376],[59053],{"nctId":59148,"briefTitle":59149,"status":111,"phases":59150,"primaryCompletion":4833,"completion":4221,"start":11291,"enrollment":59151,"conditions":59152,"interventions":59153},"NCT00691483","Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date",[94],659,[11904],[59053],{"nctId":59155,"briefTitle":59156,"status":111,"phases":59157,"primaryCompletion":3345,"completion":3345,"start":4656,"enrollment":57487,"conditions":59158,"interventions":59159},"NCT01244061","A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider",[94],[11904],[59080],{"nctId":59161,"briefTitle":59162,"status":111,"phases":59163,"primaryCompletion":586,"completion":586,"start":6016,"enrollment":314,"conditions":59164,"interventions":59165},"NCT00889720","A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery",[94],[11904],[59080],{"trials":59167,"activeCount":103},[59168,59178,59184,59191,59198,59205,59212],{"nctId":59169,"briefTitle":59170,"status":111,"phases":59171,"primaryCompletion":59172,"completion":59172,"start":59173,"enrollment":59174,"conditions":59175,"interventions":59177},"NCT01290445","Varenicline Pregnancy Cohort Study",[],"2016-05-01","2007-09-13",885185,[59176],"Malformations",[59053],{"nctId":59179,"briefTitle":59180,"status":111,"phases":59181,"primaryCompletion":6016,"completion":6016,"start":4207,"enrollment":1759,"conditions":59182,"interventions":59183},"NCT00794365","Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients",[],[11904],[59080],{"nctId":59185,"briefTitle":59186,"status":111,"phases":59187,"primaryCompletion":524,"completion":524,"start":2660,"enrollment":59188,"conditions":59189,"interventions":59190},"NCT01104636","\"VIBRATIONS\" - A Study In Smokers Who Are Willing And Motivated To Stop Smoking With The Aid Of Varenicline Which Will Be Prescribed According To Usual Clinical Practice In Germany",[],1177,[11904],[59080],{"nctId":59192,"briefTitle":59193,"status":111,"phases":59194,"primaryCompletion":11170,"completion":11170,"start":3643,"enrollment":59195,"conditions":59196,"interventions":59197},"NCT00483002","Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets",[],3719,[11904],[59053],{"nctId":59199,"briefTitle":59200,"status":111,"phases":59201,"primaryCompletion":2449,"completion":2449,"start":4608,"enrollment":59202,"conditions":59203,"interventions":59204},"NCT00772941","Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)",[],3939,[11904],[59080],{"nctId":59206,"briefTitle":59207,"status":111,"phases":59208,"primaryCompletion":586,"completion":586,"start":4608,"enrollment":59209,"conditions":59210,"interventions":59211},"NCT00808015","ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking",[],1373,[11904],[59053],{"nctId":59213,"briefTitle":59214,"status":111,"phases":59215,"primaryCompletion":3324,"completion":3324,"start":586,"enrollment":2159,"conditions":59216,"interventions":59217},"NCT01061710","Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)",[],[11904],[59053],{"intervention":59219,"totalTrials":360,"cells":59220},"Fluconazole",{"EARLY_PHASE1":59221,"PHASE1":59223,"PHASE2":59229,"PHASE3":59231,"PHASE4":59286,"NA":59288},{"trials":59222,"activeCount":103},[],{"trials":59224,"activeCount":103},[59225],{"nctId":55828,"briefTitle":55829,"status":111,"phases":59226,"primaryCompletion":38272,"completion":38272,"start":55831,"enrollment":885,"conditions":59227,"interventions":59228},[91],[2053],[55821,55834,55835,55836],{"trials":59230,"activeCount":103},[],{"trials":59232,"activeCount":103},[59233,59242,59249,59257,59264,59273,59280],{"nctId":59234,"briefTitle":59235,"status":111,"phases":59236,"enrollment":59237,"conditions":59238,"interventions":59241},"NCT00002122","A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients",[93],720,[59239,59240,10974],"Mycoses","Mycobacterium Avium-Intracellulare Infection",[15250,27700,59219],{"nctId":59243,"briefTitle":59244,"status":111,"phases":59245,"primaryCompletion":19930,"completion":19930,"start":4608,"enrollment":27035,"conditions":59246,"interventions":59247},"NCT00761267","Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis",[93],[16580],[59248,59219],"Anidulafungin",{"nctId":59250,"briefTitle":59251,"status":111,"phases":59252,"primaryCompletion":59253,"completion":59253,"start":30925,"enrollment":7184,"conditions":59254,"interventions":59256},"NCT01806623","The Study Of Fluconazole For Vulvovaginal Candidiasis",[93],"2013-11-22",[59255],"Vulvovaginal Candidiasis",[59219],{"nctId":59258,"briefTitle":59259,"status":111,"phases":59260,"completion":3628,"start":4399,"enrollment":18338,"conditions":59261,"interventions":59263},"NCT00645242","A Study Of Diflucan In Children With Ringworm Of The Scalp",[93],[59262],"Tinea Capitis",[55834],{"nctId":59265,"briefTitle":59266,"status":111,"phases":59267,"primaryCompletion":59268,"enrollment":1759,"conditions":59269,"interventions":59271},"NCT00001017","Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS",[93],"1991-07",[59270,10974],"Meningitis, Cryptococcal",[59219,59272],"Amphotericin B",{"nctId":59274,"briefTitle":59275,"status":111,"phases":59276,"enrollment":397,"conditions":59277,"interventions":59279},"NCT00002339","A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems",[93],[59278,10974],"Candidiasis, Esophageal",[59219],{"nctId":59281,"briefTitle":59282,"status":111,"phases":59283,"completion":12109,"start":3628,"enrollment":13377,"conditions":59284,"interventions":59285},"NCT00056368","The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis",[93],[15545],[59248,59219],{"trials":59287,"activeCount":103},[],{"trials":59289,"activeCount":103},[59290,59297,59305,59311,59317,59323,59329,59336,59343,59350,59356,59362,59368],{"nctId":59291,"briefTitle":59292,"status":111,"phases":59293,"conditions":59294,"interventions":59295},"NCT00002305","A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis",[95],[59270,10974],[59296,59219,59272],"Flucytosine",{"nctId":59298,"briefTitle":59299,"status":111,"phases":59300,"conditions":59301,"interventions":59303},"NCT00002112","Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome",[95],[59302,10974],"Candidiasis, Oral",[59304,59219],"Nystatin",{"nctId":59306,"briefTitle":59307,"status":111,"phases":59308,"conditions":59309,"interventions":59310},"NCT00002068","A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis",[95],[59270,10974],[59219,59272],{"nctId":59312,"briefTitle":59313,"status":111,"phases":59314,"conditions":59315,"interventions":59316},"NCT00002076","Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis",[95],[59270,10974],[59219],{"nctId":59318,"briefTitle":59319,"status":111,"phases":59320,"enrollment":7363,"conditions":59321,"interventions":59322},"NCT00002113","A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.",[95],[59270,10974],[59296,59219],{"nctId":59324,"briefTitle":59325,"status":111,"phases":59326,"conditions":59327,"interventions":59328},"NCT00002294","A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS",[95],[59270,10974],[59219],{"nctId":59330,"briefTitle":59331,"status":111,"phases":59332,"conditions":59333,"interventions":59334},"NCT00002304","A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems",[95],[59278,10974],[59335,59219],"Ketoconazole",{"nctId":59337,"briefTitle":59338,"status":111,"phases":59339,"conditions":59340,"interventions":59342},"NCT00002325","A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common",[95],[59239,10974,59341],"Coccidioidomycosis",[59219],{"nctId":59344,"briefTitle":59345,"status":111,"phases":59346,"primaryCompletion":11356,"completion":11356,"start":3345,"enrollment":1780,"conditions":59347,"interventions":59349},"NCT01680458","Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication",[],[59348],"Deep Mycosis",[59219],{"nctId":59351,"briefTitle":59352,"status":111,"phases":59353,"conditions":59354,"interventions":59355},"NCT00002075","Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis",[95],[59270,10974],[59296,59219,59272],{"nctId":59357,"briefTitle":59358,"status":111,"phases":59359,"conditions":59360,"interventions":59361},"NCT00002306","A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B",[95],[59270,10974],[59219],{"nctId":59363,"briefTitle":59364,"status":111,"phases":59365,"conditions":59366,"interventions":59367},"NCT00002074","Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome",[95],[59270,10974],[59219,59272],{"nctId":59369,"briefTitle":59370,"status":111,"phases":59371,"conditions":59372,"interventions":59373},"NCT00002040","Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis",[95],[59270,10974],[59219],{"intervention":15250,"totalTrials":2159,"cells":59375},{"EARLY_PHASE1":59376,"PHASE1":59378,"PHASE2":59406,"PHASE3":59414,"PHASE4":59442,"NA":59448},{"trials":59377,"activeCount":103},[],{"trials":59379,"activeCount":103},[59380,59386,59392,59396,59400],{"nctId":59381,"briefTitle":59382,"status":111,"phases":59383,"enrollment":1268,"conditions":59384,"interventions":59385},"NCT00002344","A Study of Azithromycin in HIV-Infected Patients",[91],[19825,10974],[15250],{"nctId":59387,"briefTitle":59388,"status":111,"phases":59389,"primaryCompletion":4627,"completion":4627,"start":11014,"enrollment":1509,"conditions":59390,"interventions":59391},"NCT00879983","An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects",[91],[19],[47357,47357],{"nctId":47350,"briefTitle":47351,"status":111,"phases":59393,"primaryCompletion":577,"completion":577,"start":4206,"enrollment":35,"conditions":59394,"interventions":59395},[91],[47354],[47343,47356,47357,47358],{"nctId":19566,"briefTitle":19567,"status":111,"phases":59397,"enrollment":8373,"conditions":59398,"interventions":59399},[91],[19570,10974],[15250,19572,19573],{"nctId":59401,"briefTitle":59402,"status":111,"phases":59403,"conditions":59404,"interventions":59405},"NCT00002139","Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.",[91],[19825,10974],[15250],{"trials":59407,"activeCount":103},[59408],{"nctId":59409,"briefTitle":59410,"status":168,"phases":59411,"primaryCompletion":626,"completion":27550,"start":606,"enrollment":1487,"conditions":59412,"interventions":59413},"NCT01919996","PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients",[92],[58102,16030],[15250],{"trials":59415,"activeCount":103},[59416,59420,59427,59434,59438],{"nctId":59234,"briefTitle":59235,"status":111,"phases":59417,"enrollment":59237,"conditions":59418,"interventions":59419},[93],[59239,59240,10974],[15250,27700,59219],{"nctId":59421,"briefTitle":59422,"status":111,"phases":59423,"primaryCompletion":8252,"completion":8252,"start":11014,"enrollment":407,"conditions":59424,"interventions":59426},"NCT00871494","Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan",[93],[59425],"Pelvic Inflammatory Disease",[15250],{"nctId":59428,"briefTitle":59429,"status":111,"phases":59430,"completion":4398,"start":3073,"enrollment":59431,"conditions":59432,"interventions":59433},"NCT00644293","A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults",[93],598,[58102,16030],[47357,19967],{"nctId":20834,"briefTitle":20835,"status":111,"phases":59435,"conditions":59436,"interventions":59437},[93],[20838,10974],[20840,20819,15250],{"nctId":24415,"briefTitle":24416,"status":111,"phases":59439,"completion":4679,"start":11379,"enrollment":8827,"conditions":59440,"interventions":59441},[93],[19965],[24404,15250],{"trials":59443,"activeCount":103},[59444],{"nctId":15245,"briefTitle":15246,"status":111,"phases":59445,"completion":6017,"start":3611,"enrollment":9562,"conditions":59446,"interventions":59447},[94],[9107],[15250,15232],{"trials":59449,"activeCount":103},[59450,59457,59463,59469,59475,59481,59488,59494],{"nctId":59451,"briefTitle":59452,"status":111,"phases":59453,"conditions":59454,"interventions":59456},"NCT00002085","A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy",[95],[59240,10974,59455],"Tuberculosis, Mycobacterium Infection",[15250],{"nctId":59458,"briefTitle":59459,"status":111,"phases":59460,"primaryCompletion":2450,"completion":2450,"start":13295,"enrollment":36009,"conditions":59461,"interventions":59462},"NCT01227395","Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients",[],[14469],[15250],{"nctId":59464,"briefTitle":59465,"status":111,"phases":59466,"primaryCompletion":8251,"completion":8251,"start":3602,"enrollment":267,"conditions":59467,"interventions":59468},"NCT00939185","Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections",[],[49765],[15250],{"nctId":59470,"briefTitle":59471,"status":111,"phases":59472,"conditions":59473,"interventions":59474},"NCT00002089","An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy",[95],[59240,10974],[15250],{"nctId":59476,"briefTitle":59477,"status":111,"phases":59478,"conditions":59479,"interventions":59480},"NCT00002309","A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients",[95],[59240,10974],[15250],{"nctId":59482,"briefTitle":59483,"status":111,"phases":59484,"conditions":59485,"interventions":59487},"NCT00002082","Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study",[95],[59486,10974],"Cryptosporidiosis",[15250],{"nctId":59489,"briefTitle":59490,"status":111,"phases":59491,"conditions":59492,"interventions":59493},"NCT00002090","An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)",[95],[59240,10974],[15250],{"nctId":59495,"briefTitle":59496,"status":111,"phases":59497,"conditions":59498,"interventions":59499},"NCT00002328","Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs",[95],[59486,10974],[15250],{"intervention":28526,"totalTrials":2159,"cells":59501},{"EARLY_PHASE1":59502,"PHASE1":59504,"PHASE2":59526,"PHASE3":59554,"PHASE4":59562,"NA":59607},{"trials":59503,"activeCount":103},[],{"trials":59505,"activeCount":103},[59506,59510,59516,59520],{"nctId":41675,"briefTitle":41676,"status":111,"phases":59507,"primaryCompletion":11291,"completion":11291,"start":8115,"enrollment":525,"conditions":59508,"interventions":59509},[91],[30668,12472,40141],[41668,28526],{"nctId":59511,"briefTitle":59512,"status":111,"phases":59513,"primaryCompletion":4665,"completion":4665,"start":4665,"enrollment":597,"conditions":59514,"interventions":59515},"NCT00866463","A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects",[91],[40141],[40143,40143,40143],{"nctId":40137,"briefTitle":40138,"status":111,"phases":59517,"primaryCompletion":524,"completion":524,"start":4656,"enrollment":1530,"conditions":59518,"interventions":59519},[91],[40141],[40143,40130,40130],{"nctId":59521,"briefTitle":59522,"status":111,"phases":59523,"primaryCompletion":8154,"completion":8154,"start":4665,"enrollment":1268,"conditions":59524,"interventions":59525},"NCT00800592","Sildenafil IV Bolus Study",[91],[20005],[28526],{"trials":59527,"activeCount":103},[59528,59532,59539,59546],{"nctId":28521,"briefTitle":28522,"status":168,"phases":59529,"primaryCompletion":586,"completion":586,"start":4222,"enrollment":4369,"conditions":59530,"interventions":59531},[92],[20005],[28512,28512,28512,28512,28512,28526],{"nctId":59533,"briefTitle":59534,"status":111,"phases":59535,"completion":11387,"start":4399,"enrollment":2159,"conditions":59536,"interventions":59538},"NCT00645034","A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin",[92],[59537],"Benign Prostatic Hyperplasia",[28526],{"nctId":59540,"briefTitle":59541,"status":649,"phases":59542,"primaryCompletion":6208,"completion":6208,"start":2450,"enrollment":103,"conditions":59543,"interventions":59545},"NCT01360671","IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn",[92],[59544],"Persistent Pulmonary Hypertension of the Newborn",[40143],{"nctId":59547,"briefTitle":59548,"status":111,"phases":59549,"completion":11512,"start":3073,"enrollment":1982,"conditions":59550,"interventions":59553},"NCT00746967","An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder",[92],[59551,59552],"Sexual Dysfunctions, Psychological","Sexual Arousal Disorder",[28526],{"trials":59555,"activeCount":103},[59556],{"nctId":59557,"briefTitle":59558,"status":111,"phases":59559,"completion":3611,"start":11379,"enrollment":58225,"conditions":59560,"interventions":59561},"NCT00644605","A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension",[93],[20005],[28526,28526,28526],{"trials":59563,"activeCount":103},[59564,59570,59579,59585,59594,59601],{"nctId":59565,"briefTitle":59566,"status":111,"phases":59567,"start":9387,"enrollment":941,"conditions":59568,"interventions":59569},"NCT00245596","Evaluation of the Index of Sexual Life Questionnaire",[94],[12375],[28526],{"nctId":59571,"briefTitle":59572,"status":111,"phases":59573,"completion":6458,"start":15036,"enrollment":541,"conditions":59574,"interventions":59578},"NCT00654082","A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction",[94],[59575,40141,59576,59577,12375],"Spinal Cord Injury","Spinal Cord Trauma","Injuries, Spinal Cord",[28526],{"nctId":59580,"briefTitle":59581,"status":111,"phases":59582,"start":9387,"enrollment":37000,"conditions":59583,"interventions":59584},"NCT00249730","Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.",[94],[12375],[40143],{"nctId":59586,"briefTitle":59587,"status":111,"phases":59588,"primaryCompletion":59589,"completion":59590,"start":59591,"enrollment":2070,"conditions":59592,"interventions":59593},"NCT01642407","Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension",[94],"2016-05-20","2018-03-12","2012-08-24",[4942,20005],[40143],{"nctId":59595,"briefTitle":59596,"status":111,"phases":59597,"completion":11395,"start":2642,"enrollment":59598,"conditions":59599,"interventions":59600},"NCT00648596","A Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion",[94],780,[40141],[28526],{"nctId":59602,"briefTitle":59603,"status":111,"phases":59604,"completion":11666,"start":9388,"enrollment":1613,"conditions":59605,"interventions":59606},"NCT00645268","A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes",[94],[40141,37],[28526,28526],{"trials":59608,"activeCount":103},[59609,59615,59623,59629,59635],{"nctId":59610,"briefTitle":59611,"status":111,"phases":59612,"primaryCompletion":114,"completion":114,"start":586,"enrollment":397,"conditions":59613,"interventions":59614},"NCT01108900","A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil",[],[40141],[28526],{"nctId":59616,"briefTitle":59617,"status":111,"phases":59618,"primaryCompletion":4438,"completion":4438,"start":2884,"enrollment":59619,"conditions":59620,"interventions":59621},"NCT00666198","Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)",[],3337,[7083],[59622],"SILDENAFIL",{"nctId":59624,"briefTitle":59625,"status":308,"phases":59626,"conditions":59627,"interventions":59628},"NCT01897740","Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil",[],[4942],[28526],{"nctId":59630,"briefTitle":59631,"status":111,"phases":59632,"primaryCompletion":11290,"completion":11290,"start":3627,"enrollment":4259,"conditions":59633,"interventions":59634},"NCT00946114","To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks",[],[7083],[28526,28526],{"nctId":59636,"briefTitle":59637,"status":111,"phases":59638,"primaryCompletion":3853,"completion":3853,"start":3853,"enrollment":257,"conditions":59639,"interventions":59641},"NCT00768573","Taste Test of a New Formulation of Sildenafil (Revatio)",[],[59640],"None Volunteer",[28526],{"intervention":59643,"totalTrials":99,"cells":59644},"voriconazole",{"EARLY_PHASE1":59645,"PHASE1":59647,"PHASE2":59657,"PHASE3":59684,"PHASE4":59728,"NA":59750},{"trials":59646,"activeCount":103},[],{"trials":59648,"activeCount":103},[59649],{"nctId":59650,"briefTitle":59651,"status":111,"phases":59652,"completion":11829,"start":4657,"enrollment":1268,"conditions":59653,"interventions":59655},"NCT00136968","Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy",[91],[59654],"Fungal Infection",[59656],"Voriconazole",{"trials":59658,"activeCount":103},[59659,59665,59671,59677],{"nctId":59660,"briefTitle":59661,"status":111,"phases":59662,"primaryCompletion":4221,"completion":4221,"start":3839,"enrollment":1239,"conditions":59663,"interventions":59664},"NCT00556998","A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents",[92],[3396],[59656],{"nctId":59666,"briefTitle":59667,"status":111,"phases":59668,"primaryCompletion":4846,"completion":4846,"start":8154,"enrollment":35,"conditions":59669,"interventions":59670},"NCT00739934","Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection",[92],[15545,16580],[59643],{"nctId":59672,"briefTitle":59673,"status":111,"phases":59674,"completion":15716,"start":4679,"enrollment":2175,"conditions":59675,"interventions":59676},"NCT00174473","A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children",[91,92],[21003],[59656],{"nctId":59678,"briefTitle":59679,"status":111,"phases":59680,"primaryCompletion":6198,"completion":6198,"start":9544,"enrollment":360,"conditions":59681,"interventions":59683},"NCT01383993","Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection",[92],[59682],"Aspergillosis, Aspergilloma",[59656,59656],{"trials":59685,"activeCount":103},[59686,59694,59701,59708,59716,59722],{"nctId":59687,"briefTitle":59688,"status":111,"phases":59689,"primaryCompletion":523,"completion":11170,"start":4207,"enrollment":59690,"conditions":59691,"interventions":59692},"NCT00531479","Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis",[93],459,[16579],[59643,59693,59643],"anidulafungin",{"nctId":59695,"briefTitle":59696,"status":111,"phases":59697,"primaryCompletion":4222,"completion":4222,"start":12069,"enrollment":26055,"conditions":59698,"interventions":59700},"NCT00150345","Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients",[93],[59699],"Possible Fungal Infection",[59643,59643],{"nctId":59702,"briefTitle":59703,"status":168,"phases":59704,"primaryCompletion":6198,"completion":6198,"start":11014,"enrollment":1257,"conditions":59705,"interventions":59707},"NCT00836875","A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children",[93],[59706],"Invasive Aspergillosis",[59656],{"nctId":59709,"briefTitle":59710,"status":649,"phases":59711,"primaryCompletion":7386,"completion":7386,"start":113,"enrollment":103,"conditions":59712,"interventions":59715},"NCT01188759","Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects",[93],[16579,59713,59714],"Invasive Pulmonary Aspergillosis","Neuroaspergillosis",[59656,59248,59656],{"nctId":59717,"briefTitle":59718,"status":168,"phases":59719,"primaryCompletion":6198,"completion":13117,"start":585,"enrollment":2218,"conditions":59720,"interventions":59721},"NCT01092832","A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients",[93],[15545],[59643],{"nctId":59723,"briefTitle":59724,"status":111,"phases":59725,"primaryCompletion":8154,"completion":8154,"start":11417,"enrollment":4369,"conditions":59726,"interventions":59727},"NCT00159822","Voriconazole For Chronic Bronchopulmonary Aspergillosis",[92,93],[16579],[59656],{"trials":59729,"activeCount":103},[59730,59737,59743],{"nctId":59731,"briefTitle":59732,"status":111,"phases":59733,"completion":11395,"start":12607,"enrollment":3659,"conditions":59734,"interventions":59736},"NCT00647907","A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections",[94],[15545,59735,16579],"Cryptococcosis",[59656],{"nctId":59738,"briefTitle":59739,"status":168,"phases":59740,"primaryCompletion":4608,"completion":4608,"start":8115,"enrollment":2070,"conditions":59741,"interventions":59742},"NCT00620074","Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)",[94],[16579],[59643,59693],{"nctId":59744,"briefTitle":59745,"status":111,"phases":59746,"primaryCompletion":8115,"completion":8115,"start":11895,"enrollment":1268,"conditions":59747,"interventions":59749},"NCT00300677","To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days",[94],[59748],"Infections, Fungal",[59643],{"trials":59751,"activeCount":103},[59752,59760,59767,59774,59782],{"nctId":59753,"briefTitle":59754,"status":111,"phases":59755,"primaryCompletion":4846,"completion":4846,"start":6457,"enrollment":59756,"conditions":59757,"interventions":59759},"NCT01073631","Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea",[],543,[59758],"Serious Fungal Infections",[59643],{"nctId":59761,"briefTitle":59762,"status":111,"phases":59763,"primaryCompletion":4221,"completion":4221,"start":4222,"enrollment":2218,"conditions":59764,"interventions":59766},"NCT00721578","A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections",[],[59765],"Systemic Fungal Infections",[59643],{"nctId":59768,"briefTitle":59769,"status":111,"phases":59770,"primaryCompletion":113,"completion":113,"start":12395,"enrollment":3254,"conditions":59771,"interventions":59773},"NCT01660334","Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)",[],[59772],"Scedosporium Infection",[59656],{"nctId":59775,"briefTitle":59776,"status":111,"phases":59777,"primaryCompletion":2450,"completion":2450,"start":4531,"enrollment":59778,"conditions":59779,"interventions":59781},"NCT01480219","Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart\u002FLung Transplant Patients, 2002-2009g",[],467,[59780],"Non-Melanoma Skin Carcinoma",[59643],{"nctId":59783,"briefTitle":59784,"status":111,"phases":59785,"primaryCompletion":6016,"completion":6016,"start":3602,"enrollment":2423,"conditions":59786,"interventions":59788},"NCT01137292","Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection",[],[59787],"Invasive Fungal Infections",[59643],{"intervention":59790,"totalTrials":597,"cells":59791},"sildenafil citrate",{"EARLY_PHASE1":59792,"PHASE1":59794,"PHASE2":59810,"PHASE3":59819,"PHASE4":59852,"NA":59905},{"trials":59793,"activeCount":103},[],{"trials":59795,"activeCount":103},[59796,59802],{"nctId":59797,"briefTitle":59798,"status":111,"phases":59799,"primaryCompletion":569,"completion":569,"start":569,"enrollment":1268,"conditions":59800,"interventions":59801},"NCT01656798","Food Effect Study For New Formulation",[91],[16],[59790,59790],{"nctId":59803,"briefTitle":59804,"status":111,"phases":59805,"primaryCompletion":4666,"completion":4666,"start":3601,"enrollment":1578,"conditions":59806,"interventions":59808},"NCT01247805","A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg\u002FMl) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions",[91],[59807],"Pulmonary Arterial Hypertention",[59790,59809,59790],"Sildenafil citrate",{"trials":59811,"activeCount":103},[59812],{"nctId":59813,"briefTitle":59814,"status":168,"phases":59815,"completion":12030,"start":7675,"enrollment":407,"conditions":59816,"interventions":59818},"NCT00141310","Sildenafil Citrate for the Treatment of Established Pre-Eclampsia",[92],[59817],"Pre-eclampsia",[59809],{"trials":59820,"activeCount":103},[59821,59827,59833,59839,59846],{"nctId":59822,"briefTitle":59823,"status":111,"phases":59824,"primaryCompletion":4608,"completion":4608,"start":3602,"enrollment":29,"conditions":59825,"interventions":59826},"NCT00454207","Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension",[93],[7083],[59790],{"nctId":59828,"briefTitle":59829,"status":111,"phases":59830,"completion":2662,"start":11387,"enrollment":1982,"conditions":59831,"interventions":59832},"NCT00159861","The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH",[93],[7083],[59809],{"nctId":59834,"briefTitle":59835,"status":111,"phases":59836,"primaryCompletion":2449,"completion":2449,"start":11666,"enrollment":1539,"conditions":59837,"interventions":59838},"NCT00159874","A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children",[93],[4942],[59809,59809,59809],{"nctId":59840,"briefTitle":59841,"status":111,"phases":59842,"primaryCompletion":3839,"completion":3839,"start":6458,"enrollment":11482,"conditions":59843,"interventions":59845},"NCT00159913","A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.",[93],[59844],"Pulmonary Arterial Hypertension, Children",[59809,59809,59809],{"nctId":59847,"briefTitle":59848,"status":111,"phases":59849,"completion":1701,"start":9388,"enrollment":9914,"conditions":59850,"interventions":59851},"NCT00159887","Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension",[93],[7083],[59809],{"trials":59853,"activeCount":103},[59854,59858,59866,59874,59881,59887,59893,59899],{"nctId":14237,"briefTitle":14238,"status":111,"phases":59855,"primaryCompletion":6207,"completion":6207,"start":3854,"enrollment":3587,"conditions":59856,"interventions":59857},[94],[4942],[14224,14224,14242],{"nctId":59859,"briefTitle":59860,"status":168,"phases":59861,"primaryCompletion":59862,"completion":59862,"start":59863,"enrollment":23746,"conditions":59864,"interventions":59865},"NCT02060487","Effects of Oral Sildenafil on Mortality in Adults With PAH",[94],"2021-02-26","2014-09-22",[4942],[59790,59790,59790],{"nctId":59867,"briefTitle":59868,"status":168,"phases":59869,"primaryCompletion":59870,"completion":59870,"start":59871,"enrollment":3807,"conditions":59872,"interventions":59873},"NCT00430716","To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.",[94],"2010-05-25","2008-04-08",[4942],[59809,59809,59809,59809],{"nctId":59875,"briefTitle":59876,"status":111,"phases":59877,"completion":8170,"start":4692,"enrollment":59878,"conditions":59879,"interventions":59880},"NCT00150358","To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .",[94],253,[12375,13280],[14242],{"nctId":59882,"briefTitle":59883,"status":111,"phases":59884,"completion":2662,"start":11829,"enrollment":1613,"conditions":59885,"interventions":59886},"NCT00159900","Quality of Erection Study",[94],[40141],[14242],{"nctId":59888,"briefTitle":59889,"status":111,"phases":59890,"primaryCompletion":10937,"completion":10937,"start":3643,"enrollment":6280,"conditions":59891,"interventions":59892},"NCT00468650","A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.",[94],[40141],[59790],{"nctId":59894,"briefTitle":59895,"status":111,"phases":59896,"completion":3854,"start":8170,"enrollment":14636,"conditions":59897,"interventions":59898},"NCT00245258","Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction",[94],[12375],[14242],{"nctId":59900,"briefTitle":59901,"status":111,"phases":59902,"start":12069,"enrollment":397,"conditions":59903,"interventions":59904},"NCT00151463","QEQ Treatment Responsiveness Evaluation Study",[94],[12375],[59790],{"trials":59906,"activeCount":103},[59907,59913],{"nctId":59908,"briefTitle":59909,"status":308,"phases":59910,"conditions":59911,"interventions":59912},"NCT00878943","Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study",[],[4942],[59809],{"nctId":59914,"briefTitle":59915,"status":111,"phases":59916,"primaryCompletion":114,"completion":114,"start":3313,"enrollment":57320,"conditions":59917,"interventions":59918},"NCT01365585","Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension",[],[4942],[59790],{"intervention":2435,"totalTrials":7500,"cells":59920},{"EARLY_PHASE1":59921,"PHASE1":59923,"PHASE2":59964,"PHASE3":59997,"PHASE4":60008,"NA":60018},{"trials":59922,"activeCount":103},[],{"trials":59924,"activeCount":103},[59925,59932,59938,59945,59953,59960],{"nctId":59926,"briefTitle":59927,"status":111,"phases":59928,"primaryCompletion":59929,"completion":59929,"start":7515,"enrollment":4259,"conditions":59930,"interventions":59931},"NCT05032690","Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule",[91],"2022-06-25",[28],[2435,2435,2435,2435],{"nctId":59933,"briefTitle":59934,"status":111,"phases":59935,"primaryCompletion":1828,"completion":1828,"start":2551,"enrollment":4825,"conditions":59936,"interventions":59937},"NCT04549480","Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition",[91],[28],[2435,2435],{"nctId":59939,"briefTitle":59940,"status":111,"phases":59941,"primaryCompletion":3252,"completion":3252,"start":59942,"enrollment":597,"conditions":59943,"interventions":59944},"NCT04916769","Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition",[91],"2021-08-13",[28],[2435,2435,2435],{"nctId":59946,"briefTitle":59947,"status":111,"phases":59948,"primaryCompletion":4459,"completion":4459,"start":4656,"enrollment":3229,"conditions":59949,"interventions":59952},"NCT01233882","Bosutinib In Subjects With Renal Impairment",[91],[59950,51358,59951],"Renal Disease, End-Stage","Renal Insufficiency, Acute",[2435,2435,2435,2435],{"nctId":59954,"briefTitle":59955,"status":111,"phases":59956,"primaryCompletion":2964,"completion":2964,"start":12109,"enrollment":9562,"conditions":59957,"interventions":59958},"NCT00195260","Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors",[91],[2053],[59959,59959,59959,59959],"bosutinib",{"nctId":9734,"briefTitle":9735,"status":111,"phases":59961,"primaryCompletion":1288,"completion":1288,"start":652,"enrollment":504,"conditions":59962,"interventions":59963},[91],[16],[9600,2435,9600],{"trials":59965,"activeCount":103},[59966,59974,59978,59982,59986],{"nctId":59967,"briefTitle":59968,"status":111,"phases":59969,"primaryCompletion":26796,"completion":1411,"start":59970,"enrollment":7363,"conditions":59971,"interventions":59973},"NCT03128411","Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",[92],"2017-05-15",[59972],"Leukemia, Chronic Myelogenous",[2435],{"nctId":4605,"briefTitle":4606,"status":168,"phases":59975,"primaryCompletion":577,"completion":577,"start":4608,"enrollment":1578,"conditions":59976,"interventions":59977},[92],[1241],[2435,1643,1674],{"nctId":2428,"briefTitle":2429,"status":168,"phases":59979,"primaryCompletion":2431,"completion":2431,"start":2432,"enrollment":314,"conditions":59980,"interventions":59981},[92],[31],[2435,1243,1243],{"nctId":4830,"briefTitle":4831,"status":168,"phases":59983,"primaryCompletion":524,"completion":524,"start":4833,"enrollment":4259,"conditions":59984,"interventions":59985},[91,92],[4835,4836,1986,4837,4838],[2435,2056],{"nctId":59987,"briefTitle":59988,"status":111,"phases":59989,"primaryCompletion":59990,"completion":59991,"start":59992,"enrollment":59993,"conditions":59994,"interventions":59996},"NCT00261846","Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias",[92],"2009-09-25","2015-08-06","2006-01-18",571,[59995],"Chronic Myeloid Leukemia",[2435],{"trials":59998,"activeCount":103},[59999],{"nctId":60000,"briefTitle":60001,"status":111,"phases":60002,"primaryCompletion":11405,"completion":60003,"start":27285,"enrollment":60004,"conditions":60005,"interventions":60006},"NCT00574873","Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML",[93],"2015-05-27",502,[59995],[2435,60007],"imatinib",{"trials":60009,"activeCount":103},[60010],{"nctId":60011,"briefTitle":60012,"status":168,"phases":60013,"primaryCompletion":4752,"completion":4752,"start":60014,"enrollment":30638,"conditions":60015,"interventions":60017},"NCT02228382","Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors",[94],"2014-11-07",[60016],"Previously Treated PH + CML",[2435],{"trials":60019,"activeCount":103},[60020,60033,60040,60049],{"nctId":60021,"briefTitle":60022,"status":111,"phases":60023,"primaryCompletion":4367,"completion":4367,"start":60024,"enrollment":60025,"conditions":60026,"interventions":60028},"NCT05286528","Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database",[],"2020-11-18",1484,[60027],"Chronic Myeloid Leukaemia",[2435,60029,60030,60031,60032],"Imatinib","Nilotinib","Dasatinib","Ponatinib",{"nctId":60034,"briefTitle":60035,"status":111,"phases":60036,"primaryCompletion":27543,"completion":27543,"start":27543,"enrollment":7500,"conditions":60037,"interventions":60039},"NCT05363488","Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland",[],[60038],"Myeloid Leukemia",[2435],{"nctId":60041,"briefTitle":60042,"status":111,"phases":60043,"primaryCompletion":60044,"completion":60044,"start":60045,"enrollment":2038,"conditions":60046,"interventions":60048},"NCT02501330","Safety And Efficacy Of Bosutinib",[],"2024-02-28","2015-07-01",[60047],"Chronic Myelogenous Leukemia",[2435],{"nctId":60050,"briefTitle":60051,"status":111,"phases":60052,"primaryCompletion":60053,"completion":60053,"start":31102,"enrollment":1083,"conditions":60054,"interventions":60055},"NCT02546375","A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands",[],"2017-01-16",[60027],[2435],{"intervention":20441,"totalTrials":314,"cells":60057},{"EARLY_PHASE1":60058,"PHASE1":60060,"PHASE2":60072,"PHASE3":60074,"PHASE4":60133,"NA":60152},{"trials":60059,"activeCount":103},[],{"trials":60061,"activeCount":103},[60062,60066],{"nctId":47209,"briefTitle":47210,"status":111,"phases":60063,"primaryCompletion":4665,"completion":4665,"start":4207,"enrollment":99,"conditions":60064,"interventions":60065},[91],[16],[20441,47202,47214],{"nctId":60067,"briefTitle":60068,"status":111,"phases":60069,"primaryCompletion":4846,"completion":4846,"start":4846,"enrollment":1239,"conditions":60070,"interventions":60071},"NCT00987779","Bioequivalence Study Of Gabapentin Between Tablet And Liquid Formulation And The Food Effect Study Of Liquid Formulation",[91],[16],[20441,20441],{"trials":60073,"activeCount":103},[],{"trials":60075,"activeCount":103},[60076,60084,60090,60097,60103,60110,60117,60121,60127],{"nctId":60077,"briefTitle":60078,"status":111,"phases":60079,"completion":11315,"start":12773,"enrollment":60080,"conditions":60081,"interventions":60083},"NCT00659100","A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment",[93],1254,[60082],"Transient Insomnia",[20441],{"nctId":60085,"briefTitle":60086,"status":111,"phases":60087,"completion":12773,"start":6457,"enrollment":26940,"conditions":60088,"interventions":60089},"NCT00674752","A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia",[93],[60082],[20441,20441],{"nctId":60091,"briefTitle":60092,"status":111,"phases":60093,"completion":11829,"start":4702,"enrollment":60094,"conditions":60095,"interventions":60096},"NCT00666575","A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness",[93],2105,[60082],[20441],{"nctId":60098,"briefTitle":60099,"status":111,"phases":60100,"completion":12030,"start":9387,"enrollment":13377,"conditions":60101,"interventions":60102},"NCT00163046","A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance",[93],[60082],[20441],{"nctId":60104,"briefTitle":60105,"status":111,"phases":60106,"completion":12069,"start":12109,"enrollment":60107,"conditions":60108,"interventions":60109},"NCT00667108","A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance",[93],784,[60082],[20441,20441],{"nctId":60111,"briefTitle":60112,"status":111,"phases":60113,"primaryCompletion":4221,"completion":4221,"start":3853,"enrollment":6152,"conditions":60114,"interventions":60115},"NCT00603473","A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures",[93],[26282],[60116],"gabapentin",{"nctId":20434,"briefTitle":20435,"status":111,"phases":60118,"primaryCompletion":20437,"completion":20437,"start":20438,"enrollment":1060,"conditions":60119,"interventions":60120},[93],[16],[20441,20442,20417],{"nctId":60122,"briefTitle":60123,"status":111,"phases":60124,"primaryCompletion":4656,"completion":4656,"start":2884,"enrollment":4726,"conditions":60125,"interventions":60126},"NCT00620555","A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures",[93],[26282],[60116],{"nctId":60128,"briefTitle":60129,"status":111,"phases":60130,"completion":12774,"start":12109,"enrollment":8306,"conditions":60131,"interventions":60132},"NCT00666770","A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance",[93],[60082],[20441,20441],{"trials":60134,"activeCount":103},[60135,60142,60148],{"nctId":60136,"briefTitle":60137,"status":168,"phases":60138,"primaryCompletion":4636,"completion":4636,"start":11609,"enrollment":1487,"conditions":60139,"interventions":60141},"NCT00584779","An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis",[94],[60140],"PK Properties Of Gabapentin In Subjects With Impaired Renal Function",[20441,20441,20441,20441],{"nctId":60143,"briefTitle":60144,"status":168,"phases":60145,"primaryCompletion":4206,"completion":4206,"start":3642,"enrollment":302,"conditions":60146,"interventions":60147},"NCT00785772","A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment",[94],[352],[20441,20441,20441],{"nctId":57705,"briefTitle":57706,"status":111,"phases":60149,"primaryCompletion":6263,"completion":6263,"start":10937,"enrollment":4848,"conditions":60150,"interventions":60151},[94],[26285,57709,26282,57710],[11452,20441],{"trials":60153,"activeCount":103},[60154,60161],{"nctId":60155,"briefTitle":60156,"status":111,"phases":60157,"primaryCompletion":652,"completion":652,"start":11314,"enrollment":60158,"conditions":60159,"interventions":60160},"NCT00567268","Drug Use Investigation Of Gabapentin",[],1273,[26282],[20441],{"nctId":60162,"briefTitle":60163,"status":111,"phases":60164,"primaryCompletion":7386,"completion":9572,"start":2883,"enrollment":6245,"conditions":60165,"interventions":60166},"NCT01441401","Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)",[],[26282],[60116],{"intervention":12750,"totalTrials":314,"cells":60168},{"EARLY_PHASE1":60169,"PHASE1":60171,"PHASE2":60211,"PHASE3":60226,"PHASE4":60239,"NA":60253},{"trials":60170,"activeCount":103},[],{"trials":60172,"activeCount":103},[60173,60181,60185,60192,60198,60205],{"nctId":60174,"briefTitle":60175,"status":111,"phases":60176,"primaryCompletion":524,"completion":524,"start":4656,"enrollment":2159,"conditions":60177,"interventions":60179},"NCT01286454","This Is A Study Of Bioavailability And Food Effect For Fesoterodine.",[91],[60178],"Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency",[60180,60180,60180,60180,60180,60180],"fesoterodine",{"nctId":42897,"briefTitle":42898,"status":111,"phases":60182,"primaryCompletion":4627,"completion":4627,"start":11014,"enrollment":5909,"conditions":60183,"interventions":60184},[91],[42901],[12750,42890],{"nctId":60186,"briefTitle":60187,"status":111,"phases":60188,"primaryCompletion":8154,"completion":8154,"start":4665,"enrollment":1498,"conditions":60189,"interventions":60191},"NCT00807118","Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect",[91],[28232,60190],"Food",[12750,12750,12750,12750,12750,12750],{"nctId":60193,"briefTitle":60194,"status":111,"phases":60195,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":2849,"conditions":60196,"interventions":60197},"NCT00786240","Phase1, Single Dose, Crossover Study to Determine Bioequivalence",[91],[16],[12750,12750],{"nctId":60199,"briefTitle":60200,"status":111,"phases":60201,"primaryCompletion":4214,"completion":4214,"start":4646,"enrollment":1530,"conditions":60202,"interventions":60204},"NCT00902681","A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects",[91],[60203],"Treatment of Overactive Bladder",[12750,12750],{"nctId":60206,"briefTitle":60207,"status":111,"phases":60208,"primaryCompletion":4646,"completion":4646,"start":11014,"enrollment":1530,"conditions":60209,"interventions":60210},"NCT00902187","A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects",[91],[60203],[12750,12750],{"trials":60212,"activeCount":103},[60213,60220],{"nctId":60214,"briefTitle":60215,"status":111,"phases":60216,"primaryCompletion":586,"completion":586,"start":8251,"enrollment":525,"conditions":60217,"interventions":60219},"NCT01042236","Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients",[92],[60218],"Stress Urinary Incontinence",[12750],{"nctId":60221,"briefTitle":60222,"status":111,"phases":60223,"primaryCompletion":4656,"completion":4656,"start":11290,"enrollment":360,"conditions":60224,"interventions":60225},"NCT00857896","Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years",[92],[12489,44642],[12750],{"trials":60227,"activeCount":103},[60228,60235],{"nctId":60229,"briefTitle":60230,"status":111,"phases":60231,"primaryCompletion":4608,"completion":4608,"start":2964,"enrollment":60232,"conditions":60233,"interventions":60234},"NCT00546637","Fesoterodine \"add-on\" Male Overactive Bladder Study",[93],947,[18586],[12750],{"nctId":12744,"briefTitle":12745,"status":111,"phases":60236,"primaryCompletion":4846,"completion":4846,"start":10937,"enrollment":12747,"conditions":60237,"interventions":60238},[93],[12489],[12733,12750],{"trials":60240,"activeCount":103},[60241,60247],{"nctId":60242,"briefTitle":60243,"status":111,"phases":60244,"primaryCompletion":10912,"completion":10912,"start":2660,"enrollment":1257,"conditions":60245,"interventions":60246},"NCT01054222","Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder",[94],[12472],[12750,12750],{"nctId":60248,"briefTitle":60249,"status":111,"phases":60250,"primaryCompletion":9544,"completion":9544,"start":4833,"enrollment":5810,"conditions":60251,"interventions":60252},"NCT00928070","A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder",[94],[12489],[12750],{"trials":60254,"activeCount":103},[60255,60264,60271,60278],{"nctId":60256,"briefTitle":60257,"status":111,"phases":60258,"primaryCompletion":60259,"completion":60259,"start":60260,"enrollment":60261,"conditions":60262,"interventions":60263},"NCT01936870","Drug Use Investigation for Toviaz",[],"2016-05-19","2013-10-01",2521,[15781],[12750],{"nctId":60265,"briefTitle":60266,"status":111,"phases":60267,"primaryCompletion":8252,"completion":8252,"start":4627,"enrollment":60268,"conditions":60269,"interventions":60270},"NCT00943735","This Is An Open-Label Study To Evaluate Fesoterodine Plus \"Your Way\" Patient Support Plan In Patients With Symptoms Of Overactive Bladder",[],774,[12489],[12750],{"nctId":60272,"briefTitle":60273,"status":111,"phases":60274,"primaryCompletion":4646,"completion":4646,"start":4207,"enrollment":60275,"conditions":60276,"interventions":60277},"NCT00691093","Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy",[],823,[12489,12776],[60180],{"nctId":60279,"briefTitle":60280,"status":111,"phases":60281,"primaryCompletion":1249,"completion":1249,"start":4666,"enrollment":1191,"conditions":60282,"interventions":60284},"NCT01260311","Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder",[],[60283],"Over Active Bladder",[12750],{"intervention":2889,"totalTrials":498,"cells":60286},{"EARLY_PHASE1":60287,"PHASE1":60289,"PHASE2":60299,"PHASE3":60321,"PHASE4":60348,"NA":60364},{"trials":60288,"activeCount":103},[],{"trials":60290,"activeCount":103},[60291,60295],{"nctId":8112,"briefTitle":8113,"status":111,"phases":60292,"primaryCompletion":4221,"completion":561,"start":8115,"enrollment":3229,"conditions":60293,"interventions":60294},[91],[2886],[3080,2890,2889],{"nctId":2880,"briefTitle":2881,"status":111,"phases":60296,"primaryCompletion":561,"completion":2883,"start":2884,"enrollment":407,"conditions":60297,"interventions":60298},[91],[2886],[2888,1992,2889,2888,2890,2889],{"trials":60300,"activeCount":103},[60301,60307,60313,60317],{"nctId":60302,"briefTitle":60303,"status":111,"phases":60304,"primaryCompletion":8115,"completion":8115,"start":12069,"enrollment":1530,"conditions":60305,"interventions":60306},"NCT00457743","A Phase I\u002FII Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)",[91,92],[34091],[4851],{"nctId":60308,"briefTitle":60309,"status":111,"phases":60310,"primaryCompletion":4222,"completion":4222,"start":3854,"enrollment":941,"conditions":60311,"interventions":60312},"NCT00338884","Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer",[92],[919],[4851],{"nctId":34086,"briefTitle":34087,"status":111,"phases":60314,"primaryCompletion":34089,"completion":34089,"start":4459,"enrollment":2070,"conditions":60315,"interventions":60316},[92],[34091],[34077,2889],{"nctId":4624,"briefTitle":4625,"status":168,"phases":60318,"primaryCompletion":4627,"completion":4627,"start":3643,"enrollment":2070,"conditions":60319,"interventions":60320},[91,92],[25],[1643,2889],{"trials":60322,"activeCount":103},[60323,60332,60340,60344],{"nctId":60324,"briefTitle":60325,"status":111,"phases":60326,"primaryCompletion":60327,"completion":18536,"start":60328,"enrollment":60329,"conditions":60330,"interventions":60331},"NCT00375674","A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer",[93],"2016-04-07","2007-08-01",674,[4310],[4851],{"nctId":60333,"briefTitle":60334,"status":168,"phases":60335,"primaryCompletion":4222,"completion":4222,"start":3643,"enrollment":3336,"conditions":60336,"interventions":60339},"NCT00428597","A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors",[93],[60337,60338],"Carcinoma, Islet Cell","Carcinoma, Pancreas",[2889],{"nctId":4843,"briefTitle":4844,"status":168,"phases":60341,"primaryCompletion":4846,"completion":2661,"start":4847,"enrollment":4848,"conditions":60342,"interventions":60343},[93],[25],[2056,4851],{"nctId":19342,"briefTitle":19343,"status":111,"phases":60345,"primaryCompletion":11988,"completion":3313,"start":1701,"enrollment":19345,"conditions":60346,"interventions":60347},[93],[25],[4851,19319],{"trials":60349,"activeCount":103},[60350,60357],{"nctId":60351,"briefTitle":60352,"status":111,"phases":60353,"primaryCompletion":4531,"completion":4531,"start":4207,"enrollment":3587,"conditions":60354,"interventions":60355},"NCT00706706","Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma",[94],[919],[60356],"Sunitinib Malate",{"nctId":60358,"briefTitle":60359,"status":111,"phases":60360,"primaryCompletion":7578,"completion":11356,"start":4645,"enrollment":2240,"conditions":60361,"interventions":60363},"NCT00793871","Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor",[94],[60362],"Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors",[60356],{"trials":60365,"activeCount":103},[60366,60372,60380],{"nctId":60367,"briefTitle":60368,"status":111,"phases":60369,"primaryCompletion":626,"completion":626,"start":3839,"enrollment":20372,"conditions":60370,"interventions":60371},"NCT00716625","Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)",[],[919],[2889],{"nctId":60373,"briefTitle":60374,"status":111,"phases":60375,"primaryCompletion":626,"completion":2313,"start":3314,"enrollment":60376,"conditions":60377,"interventions":60378},"NCT00716820","Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).",[],472,[34091],[60379],"SUNITINIB MALATE",{"nctId":60381,"briefTitle":60382,"status":168,"phases":60383,"primaryCompletion":4206,"completion":4206,"start":11988,"enrollment":502,"conditions":60384,"interventions":60385},"NCT01073644","Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients",[],[924],[4851],{"intervention":19967,"totalTrials":562,"cells":60387},{"EARLY_PHASE1":60388,"PHASE1":60390,"PHASE2":60392,"PHASE3":60398,"PHASE4":60449,"NA":60451},{"trials":60389,"activeCount":103},[],{"trials":60391,"activeCount":103},[],{"trials":60393,"activeCount":103},[60394],{"nctId":34866,"briefTitle":34867,"status":111,"phases":60395,"completion":4657,"start":12774,"enrollment":4825,"conditions":60396,"interventions":60397},[92],[3396],[34857,19967],{"trials":60399,"activeCount":103},[60400,60404,60408,60412,60416,60420,60427,60434,60438,60442],{"nctId":21530,"briefTitle":21531,"status":111,"phases":60401,"completion":11686,"start":3073,"enrollment":21533,"conditions":60402,"interventions":60403},[93],[9107],[21519,19967],{"nctId":59428,"briefTitle":59429,"status":111,"phases":60405,"completion":4398,"start":3073,"enrollment":59431,"conditions":60406,"interventions":60407},[93],[58102,16030],[47357,19967],{"nctId":22213,"briefTitle":22214,"status":111,"phases":60409,"completion":11686,"start":2642,"enrollment":1423,"conditions":60410,"interventions":60411},[93],[16030],[22202,19967],{"nctId":17118,"briefTitle":17119,"status":111,"phases":60413,"primaryCompletion":8115,"completion":8115,"start":12416,"enrollment":17121,"conditions":60414,"interventions":60415},[93],[17123],[6111,17125],{"nctId":19961,"briefTitle":19962,"status":111,"phases":60417,"completion":11686,"start":3073,"enrollment":10983,"conditions":60418,"interventions":60419},[93],[19965],[19967,19950],{"nctId":60421,"briefTitle":60422,"status":111,"phases":60423,"primaryCompletion":3610,"completion":3610,"start":4847,"enrollment":30374,"conditions":60424,"interventions":60426},"NCT00393835","A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis",[93],[60425],"Upper Respiratory Tract Infection",[17125],{"nctId":60428,"briefTitle":60429,"status":111,"phases":60430,"primaryCompletion":3610,"completion":3610,"start":3854,"enrollment":12497,"conditions":60431,"interventions":60433},"NCT00360295","A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults",[93],[60432],"Pneumonia, Community-Acquired",[17125],{"nctId":19969,"briefTitle":19970,"status":111,"phases":60435,"completion":11512,"start":3073,"enrollment":2610,"conditions":60436,"interventions":60437},[93],[19973],[19967,19950],{"nctId":25914,"briefTitle":25915,"status":111,"phases":60439,"completion":11395,"start":3073,"enrollment":25917,"conditions":60440,"interventions":60441},[93],[25919],[25903,19967],{"nctId":60443,"briefTitle":60444,"status":111,"phases":60445,"primaryCompletion":3643,"completion":3643,"start":12128,"enrollment":7363,"conditions":60446,"interventions":60448},"NCT00360464","A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases",[93],[60447],"Acute Bronchitis",[17125],{"trials":60450,"activeCount":103},[],{"trials":60452,"activeCount":103},[60453,60461,60468],{"nctId":60454,"briefTitle":60455,"status":168,"phases":60456,"primaryCompletion":4656,"completion":4656,"start":4206,"enrollment":1780,"conditions":60457,"interventions":60459},"NCT01032694","Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia",[],[60458],"Community-Acquired Pneumonia",[17125,60460],"Amoxiclav",{"nctId":60462,"briefTitle":60463,"status":111,"phases":60464,"primaryCompletion":524,"completion":524,"start":4206,"enrollment":3462,"conditions":60465,"interventions":60466},"NCT01032174","Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis",[],[19973],[17125,60467],"Amoxiclav 1000 mg",{"nctId":60469,"briefTitle":60470,"status":111,"phases":60471,"primaryCompletion":3601,"completion":3601,"start":4846,"enrollment":60004,"conditions":60472,"interventions":60473},"NCT00998309","Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)",[],[19825],[17125],{"intervention":26482,"totalTrials":3254,"cells":60475},{"EARLY_PHASE1":60476,"PHASE1":60478,"PHASE2":60501,"PHASE3":60503,"PHASE4":60517,"NA":60541},{"trials":60477,"activeCount":103},[],{"trials":60479,"activeCount":103},[60480,60488,60494],{"nctId":60481,"briefTitle":60482,"status":111,"phases":60483,"completion":11315,"start":12004,"enrollment":314,"conditions":60484,"interventions":60486},"NCT00255996","Evaluation Of Linezolid Pk Profile In Burns Patients",[91],[60485],"Burns",[60487],"linezolid",{"nctId":60489,"briefTitle":60490,"status":111,"phases":60491,"primaryCompletion":4206,"completion":4206,"start":3642,"enrollment":2159,"conditions":60492,"interventions":60493},"NCT01055769","Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects",[91],[19],[26482,26482],{"nctId":60495,"briefTitle":60496,"status":111,"phases":60497,"primaryCompletion":3334,"completion":3334,"start":2450,"enrollment":597,"conditions":60498,"interventions":60500},"NCT01544673","Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males",[91],[60499],"Gram Positive Infection",[60487],{"trials":60502,"activeCount":103},[],{"trials":60504,"activeCount":103},[60505,60513],{"nctId":60506,"briefTitle":60507,"status":111,"phases":60508,"completion":4399,"start":4601,"enrollment":941,"conditions":60509,"interventions":60511},"NCT00035425","Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection",[93],[60510],"Febrile Neutropenia",[60487,60512],"vancomycin",{"nctId":26476,"briefTitle":26477,"status":111,"phases":60514,"completion":11417,"start":3074,"enrollment":26479,"conditions":60515,"interventions":60516},[93],[19825,23867,15676],[26482,19510,26465,26483],{"trials":60518,"activeCount":103},[60519,60528,60534],{"nctId":60520,"briefTitle":60521,"status":111,"phases":60522,"primaryCompletion":2641,"completion":2641,"start":12109,"enrollment":60523,"conditions":60524,"interventions":60527},"NCT00087490","Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)",[94],1077,[60525,60526],"Skin\u002FSoft Tissue Infections","Methicillin Resistant Staphylococcus Aureus (MRSA)",[60487,60512],{"nctId":60529,"briefTitle":60530,"status":111,"phases":60531,"primaryCompletion":3642,"completion":3642,"start":12109,"enrollment":32852,"conditions":60532,"interventions":60533},"NCT00084266","Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)",[94],[60526],[60487,60512],{"nctId":60535,"briefTitle":60536,"status":111,"phases":60537,"completion":12069,"start":4399,"enrollment":21126,"conditions":60538,"interventions":60540},"NCT00572559","Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus",[94],[60539],"Pneumonia, Ventilator-Associated",[19510,26482],{"trials":60542,"activeCount":103},[60543,60549,60556,60564,60573],{"nctId":60544,"briefTitle":60545,"status":111,"phases":60546,"primaryCompletion":4692,"completion":4692,"start":11512,"enrollment":30374,"conditions":60547,"interventions":60548},"NCT01564758","Post Marketing Surveillance Study on Linezolid",[],[23867],[26482],{"nctId":60550,"briefTitle":60551,"status":111,"phases":60552,"primaryCompletion":4590,"completion":4590,"start":2449,"enrollment":60553,"conditions":60554,"interventions":60555},"NCT01819935","Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia",[],5271,[9107],[60487,60512],{"nctId":60557,"briefTitle":60558,"status":111,"phases":60559,"primaryCompletion":13117,"completion":13117,"start":4645,"enrollment":27266,"conditions":60560,"interventions":60563},"NCT01561469","Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin",[],[60561,60562],"Methicillin-Resistant Staphylococcus Aureus (MRSA)","Hospital-Acquired Pneumonia",[26482,19510],{"nctId":60565,"briefTitle":60566,"status":111,"phases":60567,"primaryCompletion":113,"completion":113,"start":11170,"enrollment":60568,"conditions":60569,"interventions":60572},"NCT01363271","Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients",[],7260,[60570,60571],"Complicated Skin and Structure Infection","Nosocomial Pneumonia",[26482,19510,26482,19510],{"nctId":60574,"briefTitle":60575,"status":649,"phases":60576,"primaryCompletion":524,"completion":524,"start":586,"enrollment":103,"conditions":60577,"interventions":60579},"NCT01040585","Cost Effectiveness Of Linezolid In Central America",[],[60578],"Ventilator Acquired Pneumonia",[26482],{"intervention":8126,"totalTrials":1625,"cells":60581},{"EARLY_PHASE1":60582,"PHASE1":60584,"PHASE2":60611,"PHASE3":60633,"PHASE4":60650,"NA":60660},{"trials":60583,"activeCount":103},[],{"trials":60585,"activeCount":103},[60586,60593,60599,60603],{"nctId":60587,"briefTitle":60588,"status":111,"phases":60589,"primaryCompletion":569,"completion":569,"start":3334,"enrollment":2713,"conditions":60590,"interventions":60592},"NCT01571388","A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment",[91],[16,60591],"Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction",[436,436,436],{"nctId":60594,"briefTitle":60595,"status":111,"phases":60596,"primaryCompletion":9572,"completion":9572,"start":7971,"enrollment":562,"conditions":60597,"interventions":60598},"NCT02097433","Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers",[91],[16],[8126],{"nctId":8119,"briefTitle":8120,"status":111,"phases":60600,"primaryCompletion":683,"completion":683,"start":8122,"enrollment":8123,"conditions":60601,"interventions":60602},[91],[766],[2003,3631,1770,8126],{"nctId":60604,"briefTitle":60605,"status":111,"phases":60606,"primaryCompletion":60607,"completion":60607,"start":60608,"enrollment":314,"conditions":60609,"interventions":60610},"NCT03865446","Evaluate Severe Hepatic Impairment on Dacomitinib PK",[91],"2019-10-24","2019-04-05",[363],[8126],{"trials":60612,"activeCount":103},[60613,60617,60627],{"nctId":32461,"briefTitle":32462,"status":111,"phases":60614,"primaryCompletion":32464,"completion":32464,"start":32465,"enrollment":32466,"conditions":60615,"interventions":60616},[92],[32468],[8126,8126,32452,32470,32471],{"nctId":60618,"briefTitle":60619,"status":111,"phases":60620,"primaryCompletion":60621,"completion":60622,"start":60623,"enrollment":7378,"conditions":60624,"interventions":60626},"NCT00818441","Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung",[92],"2012-04-27","2015-04-30","2009-03-11",[60625],"Carcinoma, Non-small Cell",[8126,8126],{"nctId":60628,"briefTitle":60629,"status":111,"phases":60630,"primaryCompletion":12853,"completion":12853,"start":6263,"enrollment":713,"conditions":60631,"interventions":60632},"NCT01858389","A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer",[92],[727],[8126,8126],{"trials":60634,"activeCount":103},[60635,60639],{"nctId":21093,"briefTitle":21094,"status":111,"phases":60636,"primaryCompletion":640,"completion":21096,"start":21097,"enrollment":21098,"conditions":60637,"interventions":60638},[93],[422],[8126,21101],{"nctId":60640,"briefTitle":60641,"status":111,"phases":60642,"primaryCompletion":60643,"completion":3252,"start":60644,"enrollment":60645,"conditions":60646,"interventions":60648},"NCT01774721","ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.",[93],"2016-07-29","2013-05-09",452,[60647],"Non-small Cell Lung Cancer With EGFR-Activating Mutations",[8126,60649],"Gefitinib",{"trials":60651,"activeCount":103},[60652],{"nctId":60653,"briefTitle":60654,"status":111,"phases":60655,"primaryCompletion":60656,"completion":60657,"start":396,"enrollment":1638,"conditions":60658,"interventions":60659},"NCT04511533","Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations",[94],"2022-10-15","2022-11-08",[980],[8126],{"trials":60661,"activeCount":103},[60662],{"nctId":415,"briefTitle":416,"status":111,"phases":60663,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":60664,"interventions":60665},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":6165,"totalTrials":1625,"cells":60667},{"EARLY_PHASE1":60668,"PHASE1":60670,"PHASE2":60676,"PHASE3":60691,"PHASE4":60731,"NA":60748},{"trials":60669,"activeCount":103},[],{"trials":60671,"activeCount":103},[60672],{"nctId":6158,"briefTitle":6159,"status":111,"phases":60673,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":60674,"interventions":60675},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"trials":60677,"activeCount":103},[60678,60684],{"nctId":60679,"briefTitle":60680,"status":168,"phases":60681,"primaryCompletion":27446,"completion":27446,"start":28399,"enrollment":2070,"conditions":60682,"interventions":60683},"NCT04247594","Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD",[92],[4181],[6165],{"nctId":60685,"briefTitle":60686,"status":168,"phases":60687,"primaryCompletion":60688,"completion":60688,"start":17650,"enrollment":26055,"conditions":60689,"interventions":60690},"NCT02850406","Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease",[92],"2023-10-02",[4181],[6165],{"trials":60692,"activeCount":103},[60693,60699,60706,60715,60723],{"nctId":60694,"briefTitle":60695,"status":168,"phases":60696,"primaryCompletion":2828,"completion":2828,"start":4895,"enrollment":19002,"conditions":60697,"interventions":60698},"NCT04188509","Open-Label Extension of Voxelotor",[93],[4181],[6165],{"nctId":60700,"briefTitle":60701,"status":168,"phases":60702,"primaryCompletion":201,"completion":8448,"start":60703,"enrollment":32466,"conditions":60704,"interventions":60705},"NCT04218084","Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease",[93],"2020-11-11",[4181],[6165],{"nctId":60707,"briefTitle":60708,"status":168,"phases":60709,"primaryCompletion":4322,"completion":2302,"start":60710,"enrollment":541,"conditions":60711,"interventions":60713},"NCT05561140","Resolution of Sickle Cell Leg Ulcers With Voxelotor",[93],"2022-05-30",[4181,60712],"Leg Ulcers",[60714],"Voxelotor Oral",{"nctId":60716,"briefTitle":60717,"status":111,"phases":60718,"primaryCompletion":60719,"completion":60719,"start":15186,"enrollment":41203,"conditions":60720,"interventions":60721},"NCT03036813","Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)",[93],"2019-10-08",[4181],[60722],"voxelotor",{"nctId":60724,"briefTitle":60725,"status":168,"phases":60726,"primaryCompletion":60727,"completion":60727,"start":60728,"enrollment":14574,"conditions":60729,"interventions":60730},"NCT03573882","Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031",[93],"2024-11-12","2018-06-06",[4181],[6165],{"trials":60732,"activeCount":103},[60733,60740],{"nctId":60734,"briefTitle":60735,"status":649,"phases":60736,"primaryCompletion":60737,"completion":60737,"start":1356,"enrollment":103,"conditions":60738,"interventions":60739},"NCT05228821","Voxelotor Brain Oxygenation and Neurocognitive Study",[94],"2023-08-23",[4181],[60714],{"nctId":60741,"briefTitle":60742,"status":111,"phases":60743,"primaryCompletion":60744,"completion":60745,"start":2050,"enrollment":2713,"conditions":60746,"interventions":60747},"NCT04400487","Actigraphy Improvement With Voxelotor (ActIVe) Study",[94],"2022-09-08","2022-09-13",[4181,53290],[6165],{"trials":60749,"activeCount":103},[60750],{"nctId":60751,"briefTitle":60752,"status":308,"phases":60753,"conditions":60754,"interventions":60755},"NCT03943615","Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options",[],[4181],[6165],{"intervention":3631,"totalTrials":1625,"cells":60757},{"EARLY_PHASE1":60758,"PHASE1":60760,"PHASE2":60774,"PHASE3":60800,"PHASE4":60802,"NA":60804},{"trials":60759,"activeCount":103},[],{"trials":60761,"activeCount":103},[60762,60766,60770],{"nctId":58465,"briefTitle":58466,"status":111,"phases":60763,"primaryCompletion":2964,"completion":2964,"start":13035,"enrollment":2175,"conditions":60764,"interventions":60765},[91],[553,643],[3317,432],{"nctId":8119,"briefTitle":8120,"status":111,"phases":60767,"primaryCompletion":683,"completion":683,"start":8122,"enrollment":8123,"conditions":60768,"interventions":60769},[91],[766],[2003,3631,1770,8126],{"nctId":17376,"briefTitle":17377,"status":111,"phases":60771,"primaryCompletion":4608,"completion":4608,"start":4692,"enrollment":787,"conditions":60772,"interventions":60773},[91],[17380],[1705,3631],{"trials":60775,"activeCount":103},[60776,60780,60784,60788,60792,60796],{"nctId":11994,"briefTitle":11995,"status":111,"phases":60777,"primaryCompletion":2884,"completion":3642,"start":9387,"enrollment":8013,"conditions":60778,"interventions":60779},[91,92],[11998],[3631,2341,2666],{"nctId":16965,"briefTitle":16966,"status":111,"phases":60781,"primaryCompletion":11315,"completion":4645,"start":11512,"enrollment":16968,"conditions":60782,"interventions":60783},[91,92],[25],[3631,3339,3631],{"nctId":19129,"briefTitle":19130,"status":649,"phases":60785,"start":11314,"enrollment":103,"conditions":60786,"interventions":60787},[92],[25],[432,8174],{"nctId":17409,"briefTitle":17410,"status":649,"phases":60789,"primaryCompletion":9544,"completion":9544,"start":4222,"enrollment":103,"conditions":60790,"interventions":60791},[92],[31],[1705,3631],{"nctId":3624,"briefTitle":3625,"status":111,"phases":60793,"completion":3627,"start":3628,"enrollment":885,"conditions":60794,"interventions":60795},[92],[376],[1335,3631],{"nctId":12001,"briefTitle":12002,"status":111,"phases":60797,"primaryCompletion":523,"completion":2883,"start":12004,"enrollment":9,"conditions":60798,"interventions":60799},[92],[11998],[1705,432,12007,432,12007],{"trials":60801,"activeCount":103},[],{"trials":60803,"activeCount":103},[],{"trials":60805,"activeCount":103},[60806,60810],{"nctId":415,"briefTitle":416,"status":111,"phases":60807,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":60808,"interventions":60809},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"nctId":2355,"briefTitle":2356,"status":111,"phases":60811,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":60812,"interventions":60813},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":60815,"totalTrials":870,"cells":60816},"Somatropin",{"EARLY_PHASE1":60817,"PHASE1":60819,"PHASE2":60821,"PHASE3":60831,"PHASE4":60870,"NA":60880},{"trials":60818,"activeCount":103},[],{"trials":60820,"activeCount":103},[],{"trials":60822,"activeCount":103},[60823],{"nctId":60824,"briefTitle":60825,"status":111,"phases":60826,"primaryCompletion":3335,"completion":3642,"start":15716,"enrollment":5987,"conditions":60827,"interventions":60830},"NCT00174460","Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age",[92],[60828,60829],"Growth Hormone Therapy","Infant, Very Low Birth Weight",[60815],{"trials":60832,"activeCount":103},[60833,60839,60846,60852,60858,60864],{"nctId":60834,"briefTitle":60835,"status":168,"phases":60836,"primaryCompletion":524,"completion":524,"start":4207,"enrollment":2218,"conditions":60837,"interventions":60838},"NCT00625872","Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy",[93],[60828,23400],[60815,60815],{"nctId":60840,"briefTitle":60841,"status":111,"phases":60842,"completion":12128,"start":2653,"enrollment":562,"conditions":60843,"interventions":60845},"NCT00174278","Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary",[93],[10227,60844],"Growth Retardation",[60815],{"nctId":60847,"briefTitle":60848,"status":168,"phases":60849,"primaryCompletion":9544,"completion":9544,"start":24678,"enrollment":1780,"conditions":60850,"interventions":60851},"NCT00174187","Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy",[93],[41297],[60815],{"nctId":60853,"briefTitle":60854,"status":168,"phases":60855,"primaryCompletion":114,"completion":114,"start":22517,"enrollment":360,"conditions":60856,"interventions":60857},"NCT00174291","Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy",[93],[41297],[60815],{"nctId":60859,"briefTitle":60860,"status":111,"phases":60861,"primaryCompletion":114,"completion":114,"start":12069,"enrollment":787,"conditions":60862,"interventions":60863},"NCT00163215","Growth Retardation In Children With Special Pathological Conditions Or Disease",[93],[41297],[60815],{"nctId":60865,"briefTitle":60866,"status":111,"phases":60867,"primaryCompletion":11448,"completion":11448,"start":12069,"enrollment":3241,"conditions":60868,"interventions":60869},"NCT00163189","Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm",[93],[10227],[60815],{"trials":60871,"activeCount":103},[60872],{"nctId":60873,"briefTitle":60874,"status":168,"phases":60875,"completion":3611,"start":4399,"enrollment":397,"conditions":60876,"interventions":60878},"NCT00638053","A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and\u002For Head Injury",[94],[13083,60877],"Growth Hormone Deficiency Dwarfism",[60879],"somatropin",{"trials":60881,"activeCount":103},[60882,60892],{"nctId":60883,"briefTitle":60884,"status":111,"phases":60885,"primaryCompletion":60886,"completion":60887,"start":60888,"enrollment":4848,"conditions":60889,"interventions":60891},"NCT01897766","Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age \"Scoped for Japanese\"",[],"2017-02-28","2017-06-07","2013-09-05",[60890],"Small for Gestational Age (SGA)",[60815],{"nctId":60893,"briefTitle":60894,"status":111,"phases":60895,"primaryCompletion":2449,"completion":2449,"start":4608,"enrollment":60896,"conditions":60897,"interventions":60899},"NCT00793325","Long Term Use of Somatropin in Patients Small for Gestational Age",[],920,[60898],"Small for Gestational Age",[60815],{"intervention":19510,"totalTrials":870,"cells":60901},{"EARLY_PHASE1":60902,"PHASE1":60904,"PHASE2":60906,"PHASE3":60908,"PHASE4":60926,"NA":60940},{"trials":60903,"activeCount":103},[],{"trials":60905,"activeCount":103},[],{"trials":60907,"activeCount":103},[],{"trials":60909,"activeCount":103},[60910,60914,60918,60922],{"nctId":19503,"briefTitle":19504,"status":111,"phases":60911,"primaryCompletion":1288,"completion":11956,"start":113,"enrollment":19506,"conditions":60912,"interventions":60913},[93],[19508],[19480,19510,19511],{"nctId":19513,"briefTitle":19514,"status":168,"phases":60915,"primaryCompletion":11956,"completion":11956,"start":1288,"enrollment":257,"conditions":60916,"interventions":60917},[93],[19508],[19480,19510,19511],{"nctId":60506,"briefTitle":60507,"status":111,"phases":60919,"completion":4399,"start":4601,"enrollment":941,"conditions":60920,"interventions":60921},[93],[60510],[60487,60512],{"nctId":26476,"briefTitle":26477,"status":111,"phases":60923,"completion":11417,"start":3074,"enrollment":26479,"conditions":60924,"interventions":60925},[93],[19825,23867,15676],[26482,19510,26465,26483],{"trials":60927,"activeCount":103},[60928,60932,60936],{"nctId":60520,"briefTitle":60521,"status":111,"phases":60929,"primaryCompletion":2641,"completion":2641,"start":12109,"enrollment":60523,"conditions":60930,"interventions":60931},[94],[60525,60526],[60487,60512],{"nctId":60529,"briefTitle":60530,"status":111,"phases":60933,"primaryCompletion":3642,"completion":3642,"start":12109,"enrollment":32852,"conditions":60934,"interventions":60935},[94],[60526],[60487,60512],{"nctId":60535,"briefTitle":60536,"status":111,"phases":60937,"completion":12069,"start":4399,"enrollment":21126,"conditions":60938,"interventions":60939},[94],[60539],[19510,26482],{"trials":60941,"activeCount":103},[60942,60946,60950],{"nctId":60550,"briefTitle":60551,"status":111,"phases":60943,"primaryCompletion":4590,"completion":4590,"start":2449,"enrollment":60553,"conditions":60944,"interventions":60945},[],[9107],[60487,60512],{"nctId":60557,"briefTitle":60558,"status":111,"phases":60947,"primaryCompletion":13117,"completion":13117,"start":4645,"enrollment":27266,"conditions":60948,"interventions":60949},[],[60561,60562],[26482,19510],{"nctId":60565,"briefTitle":60566,"status":111,"phases":60951,"primaryCompletion":113,"completion":113,"start":11170,"enrollment":60568,"conditions":60952,"interventions":60953},[],[60570,60571],[26482,19510,26482,19510],{"intervention":9578,"totalTrials":627,"cells":60955},{"EARLY_PHASE1":60956,"PHASE1":60958,"PHASE2":60968,"PHASE3":60970,"PHASE4":60976,"NA":60978},{"trials":60957,"activeCount":103},[],{"trials":60959,"activeCount":103},[60960,60964],{"nctId":54031,"briefTitle":54032,"status":111,"phases":60961,"primaryCompletion":4214,"completion":4214,"start":4627,"enrollment":562,"conditions":60962,"interventions":60963},[91],[12472],[9621,54024],{"nctId":17753,"briefTitle":17754,"status":111,"phases":60965,"primaryCompletion":4222,"completion":4222,"start":4608,"enrollment":562,"conditions":60966,"interventions":60967},[91],[17728,17729],[9578,17711,9578],{"trials":60969,"activeCount":103},[],{"trials":60971,"activeCount":103},[60972],{"nctId":9569,"briefTitle":9570,"status":111,"phases":60973,"primaryCompletion":9572,"completion":9572,"start":4590,"enrollment":1519,"conditions":60974,"interventions":60975},[93],[9574,9575],[9534,9577,9578],{"trials":60977,"activeCount":103},[],{"trials":60979,"activeCount":103},[60980,60984,60988,60992,60996,61000],{"nctId":9614,"briefTitle":9615,"status":111,"phases":60981,"primaryCompletion":9617,"completion":9617,"start":222,"enrollment":9618,"conditions":60982,"interventions":60983},[],[9555],[9534,9600,9599,9621,9622],{"nctId":9624,"briefTitle":9625,"status":111,"phases":60985,"primaryCompletion":9627,"completion":9627,"start":9628,"enrollment":9629,"conditions":60986,"interventions":60987},[],[9631],[9578,9534],{"nctId":9634,"briefTitle":9635,"status":649,"phases":60989,"primaryCompletion":9637,"completion":9637,"start":4895,"enrollment":103,"conditions":60990,"interventions":60991},[],[9555],[9621,9640],{"nctId":9652,"briefTitle":9653,"status":111,"phases":60993,"primaryCompletion":9655,"completion":9655,"start":9655,"enrollment":9656,"conditions":60994,"interventions":60995},[],[9631],[9534,9578],{"nctId":9660,"briefTitle":9661,"status":111,"phases":60997,"primaryCompletion":9663,"completion":9663,"start":9664,"enrollment":9665,"conditions":60998,"interventions":60999},[],[9667],[9640,9621],{"nctId":9670,"briefTitle":9671,"status":111,"phases":61001,"primaryCompletion":7536,"completion":7536,"start":9673,"enrollment":9674,"conditions":61002,"interventions":61003},[],[9667],[9677,9578,9534,9599,9600,9610],{"intervention":2666,"totalTrials":1487,"cells":61005},{"EARLY_PHASE1":61006,"PHASE1":61008,"PHASE2":61010,"PHASE3":61044,"PHASE4":61050,"NA":61052},{"trials":61007,"activeCount":103},[],{"trials":61009,"activeCount":103},[],{"trials":61011,"activeCount":103},[61012,61018,61022,61028,61032,61038],{"nctId":61013,"briefTitle":61014,"status":111,"phases":61015,"primaryCompletion":7665,"completion":2884,"start":11829,"enrollment":1808,"conditions":61016,"interventions":61017},"NCT00137423","Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer",[92],[926],[2666],{"nctId":11994,"briefTitle":11995,"status":111,"phases":61019,"primaryCompletion":2884,"completion":3642,"start":9387,"enrollment":8013,"conditions":61020,"interventions":61021},[91,92],[11998],[3631,2341,2666],{"nctId":61023,"briefTitle":61024,"status":111,"phases":61025,"primaryCompletion":3314,"completion":3314,"start":6017,"enrollment":2240,"conditions":61026,"interventions":61027},"NCT00137449","Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor",[92],[34091],[2666],{"nctId":2657,"briefTitle":2658,"status":111,"phases":61029,"primaryCompletion":2660,"completion":2661,"start":2662,"enrollment":2663,"conditions":61030,"interventions":61031},[92],[25],[2666,968],{"nctId":61033,"briefTitle":61034,"status":111,"phases":61035,"completion":4657,"start":2672,"enrollment":4637,"conditions":61036,"interventions":61037},"NCT00077987","Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.",[92],[1028],[2666],{"nctId":61039,"briefTitle":61040,"status":111,"phases":61041,"primaryCompletion":4608,"completion":4608,"start":2671,"enrollment":5425,"conditions":61042,"interventions":61043},"NCT00254540","Study of SU011248 in Patients With Advanced Kidney Cancer",[92],[919],[2666],{"trials":61045,"activeCount":103},[61046],{"nctId":21287,"briefTitle":21288,"status":111,"phases":61047,"primaryCompletion":11291,"completion":11291,"start":11727,"enrollment":21290,"conditions":61048,"interventions":61049},[93],[919],[21276,2666],{"trials":61051,"activeCount":103},[],{"trials":61053,"activeCount":103},[61054],{"nctId":61055,"briefTitle":61056,"status":111,"phases":61057,"primaryCompletion":2883,"completion":2883,"start":12004,"enrollment":3462,"conditions":61058,"interventions":61059},"NCT00443534","A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.",[95],[2053],[2666],{"intervention":13340,"totalTrials":1487,"cells":61061},{"EARLY_PHASE1":61062,"PHASE1":61064,"PHASE2":61070,"PHASE3":61076,"PHASE4":61078,"NA":61084},{"trials":61063,"activeCount":103},[],{"trials":61065,"activeCount":103},[61066],{"nctId":17101,"briefTitle":17102,"status":111,"phases":61067,"primaryCompletion":11170,"completion":11170,"start":3601,"enrollment":4369,"conditions":61068,"interventions":61069},[91],[16],[13326,13326,17044,17106],{"trials":61071,"activeCount":103},[61072],{"nctId":13320,"briefTitle":13321,"status":168,"phases":61073,"primaryCompletion":2661,"completion":2661,"start":8154,"enrollment":1498,"conditions":61074,"interventions":61075},[92],[13324],[13326,13326,13327],{"trials":61077,"activeCount":103},[],{"trials":61079,"activeCount":103},[61080],{"nctId":13333,"briefTitle":13334,"status":111,"phases":61081,"primaryCompletion":626,"completion":626,"start":3345,"enrollment":13336,"conditions":61082,"interventions":61083},[94],[13338],[13340,13301],{"trials":61085,"activeCount":103},[61086,61096,61102,61110,61118],{"nctId":61087,"briefTitle":61088,"status":111,"phases":61089,"primaryCompletion":4656,"completion":4656,"start":8115,"enrollment":61090,"conditions":61091,"interventions":61095},"NCT00827541","Post-Authorization Study Evaluating Safety Of Tigecycline",[],115,[61092,61093,61094],"Intra-Abdominal Infections","Skin Disease, Infectious","Soft Tissues Infections",[13340],{"nctId":61097,"briefTitle":61098,"status":111,"phases":61099,"primaryCompletion":3642,"completion":3642,"start":4847,"enrollment":3817,"conditions":61100,"interventions":61101},"NCT00488488","A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting",[],[11494],[13326],{"nctId":61103,"briefTitle":61104,"status":111,"phases":61105,"primaryCompletion":4589,"completion":4589,"start":2660,"enrollment":61106,"conditions":61107,"interventions":61109},"NCT01072539","Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment",[],3172,[61108,12278,13795],"Complicated Skin and Skin Structure Infections",[13326],{"nctId":61111,"briefTitle":61112,"status":111,"phases":61113,"primaryCompletion":61114,"completion":61114,"start":61115,"enrollment":2643,"conditions":61116,"interventions":61117},"NCT01789905","Tygacil Drug Use Investigation",[],"2017-06-16","2013-04-15",[61092,61093],[13340],{"nctId":61119,"briefTitle":61120,"status":111,"phases":61121,"primaryCompletion":2660,"completion":2660,"start":3602,"enrollment":61122,"conditions":61123,"interventions":61124},"NCT00683332","Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)",[],621,[61108,12278],[13340],{"intervention":28123,"totalTrials":1487,"cells":61126},{"EARLY_PHASE1":61127,"PHASE1":61129,"PHASE2":61135,"PHASE3":61141,"PHASE4":61157,"NA":61167},{"trials":61128,"activeCount":103},[],{"trials":61130,"activeCount":103},[61131],{"nctId":28116,"briefTitle":28117,"status":111,"phases":61132,"primaryCompletion":4531,"completion":4531,"start":523,"enrollment":1796,"conditions":61133,"interventions":61134},[91],[16],[28121,28109,28121,28109,28122,28109,28122,28123,28121],{"trials":61136,"activeCount":103},[61137],{"nctId":33725,"briefTitle":33726,"status":168,"phases":61138,"primaryCompletion":11170,"completion":11170,"start":11014,"enrollment":22856,"conditions":61139,"interventions":61140},[92],[13445],[33716,33730,33731,28123],{"trials":61142,"activeCount":103},[61143,61151],{"nctId":61144,"briefTitle":61145,"status":168,"phases":61146,"primaryCompletion":3314,"completion":3314,"start":14118,"enrollment":21126,"conditions":61147,"interventions":61150},"NCT00174382","Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia",[93],[61148,61149],"Dementia, Vascular","Dementia, Mixed",[28123],{"nctId":61152,"briefTitle":61153,"status":111,"phases":61154,"completion":12109,"start":11379,"enrollment":42797,"conditions":61155,"interventions":61156},"NCT00630851","A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes",[93],[13445],[28123],{"trials":61158,"activeCount":103},[61159],{"nctId":61160,"briefTitle":61161,"status":111,"phases":61162,"primaryCompletion":3602,"completion":3602,"start":4258,"enrollment":1780,"conditions":61163,"interventions":61166},"NCT00182845","Donepezil in the Prevention of Post-Operative Cognitive Decline",[94],[61164,61165],"Postoperative Complications","Delirium",[28123],{"trials":61168,"activeCount":103},[61169,61175,61182],{"nctId":61170,"briefTitle":61171,"status":168,"phases":61172,"primaryCompletion":540,"completion":540,"start":586,"enrollment":597,"conditions":61173,"interventions":61174},"NCT01082965","Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease",[95],[17728],[28123],{"nctId":61176,"briefTitle":61177,"status":111,"phases":61178,"primaryCompletion":11988,"completion":11988,"start":4846,"enrollment":1268,"conditions":61179,"interventions":61180},"NCT00987220","Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid",[],[17728,35947],[61181],"donepezil",{"nctId":61183,"briefTitle":61184,"status":111,"phases":61185,"completion":4679,"start":61186,"enrollment":1613,"conditions":61187,"interventions":61189},"NCT00467766","Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease",[95],"1999-07",[13445,61188],"Caregivers",[28123],{"intervention":59248,"totalTrials":1487,"cells":61191},{"EARLY_PHASE1":61192,"PHASE1":61194,"PHASE2":61196,"PHASE3":61204,"PHASE4":61228,"NA":61234},{"trials":61193,"activeCount":103},[],{"trials":61195,"activeCount":103},[],{"trials":61197,"activeCount":103},[61198],{"nctId":61199,"briefTitle":61200,"status":111,"phases":61201,"completion":13902,"start":11387,"enrollment":2713,"conditions":61202,"interventions":61203},"NCT00056381","Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17",[91,92],[21003],[59248],{"trials":61205,"activeCount":103},[61206,61210,61214,61218,61222],{"nctId":59243,"briefTitle":59244,"status":111,"phases":61207,"primaryCompletion":19930,"completion":19930,"start":4608,"enrollment":27035,"conditions":61208,"interventions":61209},[93],[16580],[59248,59219],{"nctId":59687,"briefTitle":59688,"status":111,"phases":61211,"primaryCompletion":523,"completion":11170,"start":4207,"enrollment":59690,"conditions":61212,"interventions":61213},[93],[16579],[59643,59693,59643],{"nctId":59709,"briefTitle":59710,"status":649,"phases":61215,"primaryCompletion":7386,"completion":7386,"start":113,"enrollment":103,"conditions":61216,"interventions":61217},[93],[16579,59713,59714],[59656,59248,59656],{"nctId":59281,"briefTitle":59282,"status":111,"phases":61219,"completion":12109,"start":3628,"enrollment":13377,"conditions":61220,"interventions":61221},[93],[15545],[59248,59219],{"nctId":61223,"briefTitle":61224,"status":111,"phases":61225,"primaryCompletion":11290,"completion":11290,"start":3853,"enrollment":32,"conditions":61226,"interventions":61227},"NCT00537329","Anidulafungin In Treatment Of Candidemia In Asian Subjects",[93],[16580],[59248],{"trials":61229,"activeCount":103},[61230],{"nctId":59738,"briefTitle":59739,"status":168,"phases":61231,"primaryCompletion":4608,"completion":4608,"start":8115,"enrollment":2070,"conditions":61232,"interventions":61233},[94],[16579],[59643,59693],{"trials":61235,"activeCount":103},[61236],{"nctId":61237,"briefTitle":61238,"status":111,"phases":61239,"primaryCompletion":11170,"completion":11170,"start":4666,"enrollment":26,"conditions":61240,"interventions":61241},"NCT01202253","Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom",[],[15545],[59693],{"intervention":14828,"totalTrials":1487,"cells":61243},{"EARLY_PHASE1":61244,"PHASE1":61246,"PHASE2":61254,"PHASE3":61256,"PHASE4":61270,"NA":61290},{"trials":61245,"activeCount":103},[],{"trials":61247,"activeCount":103},[61248],{"nctId":61249,"briefTitle":61250,"status":111,"phases":61251,"primaryCompletion":4221,"completion":4221,"start":6016,"enrollment":4369,"conditions":61252,"interventions":61253},"NCT01004614","Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet",[91],[16],[14828,14828,14828,14828],{"trials":61255,"activeCount":103},[],{"trials":61257,"activeCount":103},[61258,61264],{"nctId":61259,"briefTitle":61260,"status":111,"phases":61261,"primaryCompletion":11609,"completion":11609,"start":11315,"enrollment":26916,"conditions":61262,"interventions":61263},"NCT00415623","A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient",[93],[13280],[14828,14828],{"nctId":61265,"briefTitle":61266,"status":111,"phases":61267,"primaryCompletion":3839,"completion":3839,"start":3610,"enrollment":3612,"conditions":61268,"interventions":61269},"NCT00443456","Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient",[93],[13280],[14828],{"trials":61271,"activeCount":103},[61272,61276,61282,61286],{"nctId":14821,"briefTitle":14822,"status":111,"phases":61273,"completion":12069,"start":14824,"enrollment":162,"conditions":61274,"interventions":61275},[94],[14826],[14828,14808],{"nctId":61277,"briefTitle":61278,"status":111,"phases":61279,"completion":15716,"start":3628,"enrollment":26479,"conditions":61280,"interventions":61281},"NCT00159692","Amlodipine Diabetic Hypertension Efficacy Response Trial",[94],[13280],[14828],{"nctId":57987,"briefTitle":57988,"status":111,"phases":61283,"completion":11315,"start":8180,"enrollment":1621,"conditions":61284,"interventions":61285},[94],[57991],[57993,12996],{"nctId":58022,"briefTitle":58023,"status":111,"phases":61287,"completion":12416,"start":11829,"enrollment":1759,"conditions":61288,"interventions":61289},[94],[13280,12979],[12996,57993],{"trials":61291,"activeCount":103},[61292],{"nctId":61293,"briefTitle":61294,"status":111,"phases":61295,"primaryCompletion":3353,"completion":3353,"start":4656,"enrollment":61296,"conditions":61297,"interventions":61298},"NCT01252563","Amlodipine 10mg Drug Use Investigation",[],14141,[13280],[14828],{"intervention":61300,"totalTrials":3659,"cells":61301},"Eplerenone",{"EARLY_PHASE1":61302,"PHASE1":61304,"PHASE2":61306,"PHASE3":61312,"PHASE4":61339,"NA":61348},{"trials":61303,"activeCount":103},[],{"trials":61305,"activeCount":103},[],{"trials":61307,"activeCount":103},[61308],{"nctId":31160,"briefTitle":31161,"status":168,"phases":61309,"completion":16955,"start":12607,"enrollment":31163,"conditions":61310,"interventions":61311},[92],[13280],[31166,31167],{"trials":61313,"activeCount":103},[61314,61320,61326,61332],{"nctId":61315,"briefTitle":61316,"status":111,"phases":61317,"primaryCompletion":12853,"completion":12853,"start":586,"enrollment":58890,"conditions":61318,"interventions":61319},"NCT01115855","Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure",[93],[6764],[61300],{"nctId":61321,"briefTitle":61322,"status":111,"phases":61323,"completion":3627,"start":12109,"enrollment":12373,"conditions":61324,"interventions":61325},"NCT00147615","The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years",[93],[13280],[61300],{"nctId":61327,"briefTitle":61328,"status":111,"phases":61329,"completion":11315,"start":7675,"enrollment":1313,"conditions":61330,"interventions":61331},"NCT00147589","A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.",[93],[13280],[61300],{"nctId":61333,"briefTitle":61334,"status":111,"phases":61335,"primaryCompletion":2660,"completion":10912,"start":6457,"enrollment":61336,"conditions":61337,"interventions":61338},"NCT00232180","A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines",[93],2743,[6764],[61300],{"trials":61340,"activeCount":103},[61341],{"nctId":61342,"briefTitle":61343,"status":111,"phases":61344,"completion":6457,"start":4398,"enrollment":8827,"conditions":61345,"interventions":61347},"NCT00082589","The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure",[94],[61346],"Heart Failure, Congestive",[61300],{"trials":61349,"activeCount":103},[61350],{"nctId":61351,"briefTitle":61352,"status":111,"phases":61353,"primaryCompletion":61354,"completion":61354,"start":50505,"enrollment":61355,"conditions":61356,"interventions":61358},"NCT03342690","Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)",[],"2020-07-15",1165,[61357],"Chronic Heart Failure",[61300],{"intervention":15314,"totalTrials":3659,"cells":61360},{"EARLY_PHASE1":61361,"PHASE1":61363,"PHASE2":61365,"PHASE3":61367,"PHASE4":61381,"NA":61393},{"trials":61362,"activeCount":103},[],{"trials":61364,"activeCount":103},[],{"trials":61366,"activeCount":103},[],{"trials":61368,"activeCount":103},[61369,61373,61377],{"nctId":18283,"briefTitle":18284,"status":111,"phases":61370,"primaryCompletion":3643,"completion":3643,"start":11417,"enrollment":1893,"conditions":61371,"interventions":61372},[93],[12891,12882],[15314,18288,12904],{"nctId":25109,"briefTitle":25110,"status":111,"phases":61374,"completion":3854,"start":14118,"enrollment":22897,"conditions":61375,"interventions":61376},[93],[15312,12882],[15314,25098],{"nctId":18297,"briefTitle":18298,"status":111,"phases":61378,"completion":3643,"start":2671,"enrollment":18300,"conditions":61379,"interventions":61380},[93],[18274,12882],[15314,18288,12904],{"trials":61382,"activeCount":103},[61383,61387],{"nctId":15307,"briefTitle":15308,"status":111,"phases":61384,"completion":12395,"start":11417,"enrollment":15310,"conditions":61385,"interventions":61386},[94],[15312,12882],[15314,15294],{"nctId":61388,"briefTitle":61389,"status":111,"phases":61390,"completion":12030,"start":2642,"enrollment":8827,"conditions":61391,"interventions":61392},"NCT00143208","Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.",[94],[12881,12882],[15314],{"trials":61394,"activeCount":103},[61395,61405],{"nctId":61396,"briefTitle":61397,"status":111,"phases":61398,"primaryCompletion":561,"completion":561,"start":11988,"enrollment":61399,"conditions":61400,"interventions":61401},"NCT01206361","Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom",[],2015,[12881,12882],[61402,61403,61404],"XALACOM","Duotrav","Ganfort",{"nctId":61406,"briefTitle":61407,"status":111,"phases":61408,"primaryCompletion":4646,"completion":4646,"start":4665,"enrollment":61409,"conditions":61410,"interventions":61412},"NCT00801437","Non Interventional Study With Primary Open Angle Glaucoma and\u002For Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.",[],457,[61411],"Glaucoma, Open-angle",[15314],{"intervention":4352,"totalTrials":3659,"cells":61414},{"EARLY_PHASE1":61415,"PHASE1":61417,"PHASE2":61419,"PHASE3":61427,"PHASE4":61437,"NA":61446},{"trials":61416,"activeCount":103},[],{"trials":61418,"activeCount":103},[],{"trials":61420,"activeCount":103},[61421],{"nctId":61422,"briefTitle":61423,"status":111,"phases":61424,"primaryCompletion":11170,"completion":2450,"start":1701,"enrollment":6245,"conditions":61425,"interventions":61426},"NCT00494091","Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma",[92],[920],[4352,4352],{"trials":61428,"activeCount":103},[61429,61433],{"nctId":20675,"briefTitle":20676,"status":111,"phases":61430,"primaryCompletion":10912,"completion":4590,"start":7665,"enrollment":20678,"conditions":61431,"interventions":61432},[93],[1859],[4312,20681],{"nctId":25991,"briefTitle":25992,"status":111,"phases":61434,"primaryCompletion":11314,"completion":3601,"start":11829,"enrollment":13935,"conditions":61435,"interventions":61436},[93],[2937],[4352,4352,25980],{"trials":61438,"activeCount":103},[61439],{"nctId":61440,"briefTitle":61441,"status":111,"phases":61442,"primaryCompletion":27550,"completion":19922,"start":524,"enrollment":1638,"conditions":61443,"interventions":61445},"NCT01180049","Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma",[94],[61444],"Non-Hodgkin's Lymphoma",[20681,20681],{"trials":61447,"activeCount":103},[61448,61455,61459],{"nctId":61449,"briefTitle":61450,"status":111,"phases":61451,"primaryCompletion":35704,"completion":11640,"start":61452,"enrollment":25288,"conditions":61453,"interventions":61454},"NCT01210482","Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)",[],"2010-08-24",[1859],[4352],{"nctId":4343,"briefTitle":4344,"status":111,"phases":61456,"primaryCompletion":406,"completion":406,"start":4346,"enrollment":4347,"conditions":61457,"interventions":61458},[],[928,4349,4350],[4352,4352,4327,4327,933],{"nctId":61460,"briefTitle":61461,"status":649,"phases":61462,"primaryCompletion":4438,"completion":4438,"start":13117,"enrollment":103,"conditions":61463,"interventions":61464},"NCT01781442","A Post Marketing Surveillance As Required By Philippine Food And Drug Administration",[],[1859],[4352],{"intervention":61466,"totalTrials":2070,"cells":61467},"pegaptanib sodium",{"EARLY_PHASE1":61468,"PHASE1":61470,"PHASE2":61472,"PHASE3":61480,"PHASE4":61505,"NA":61513},{"trials":61469,"activeCount":103},[],{"trials":61471,"activeCount":103},[],{"trials":61473,"activeCount":103},[61474],{"nctId":61475,"briefTitle":61476,"status":111,"phases":61477,"primaryCompletion":4645,"completion":4645,"start":6017,"enrollment":2400,"conditions":61478,"interventions":61479},"NCT00239928","Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration",[92],[15014],[61466],{"trials":61481,"activeCount":103},[61482,61490,61499],{"nctId":61483,"briefTitle":61484,"status":111,"phases":61485,"primaryCompletion":540,"completion":540,"start":3601,"enrollment":787,"conditions":61486,"interventions":61489},"NCT01189461","Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema",[93],[61487,61488,32242],"Anti- VGF Inhibitor","Diabetic Macular Edema",[61466],{"nctId":61491,"briefTitle":61492,"status":111,"phases":61493,"primaryCompletion":569,"completion":569,"start":2660,"enrollment":16174,"conditions":61494,"interventions":61498},"NCT01100307","A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema",[93],[61495,61496,61497],"Macular Edema","Diabetic Mellitus","Retinal Disease",[61466],{"nctId":61500,"briefTitle":61501,"status":111,"phases":61502,"completion":12128,"start":13035,"enrollment":481,"conditions":61503,"interventions":61504},"NCT00150202","Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)",[93],[15014],[61466],{"trials":61506,"activeCount":103},[61507],{"nctId":61508,"briefTitle":61509,"status":111,"phases":61510,"primaryCompletion":8115,"completion":8115,"start":12395,"enrollment":7399,"conditions":61511,"interventions":61512},"NCT00324116","Evaluation Of Safety And Efficacy Of 0.3 Mg\u002FEye Macugen In Patients With Small Age-Related Macular Degeneration Lesions",[94],[15014],[61466],{"trials":61514,"activeCount":103},[61515],{"nctId":61516,"briefTitle":61517,"status":111,"phases":61518,"primaryCompletion":523,"completion":523,"start":3335,"enrollment":1122,"conditions":61519,"interventions":61521},"NCT00858208","Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.",[],[61520],"Neovascular Age-related Macular Degeneration",[61466],{"intervention":17066,"totalTrials":2070,"cells":61523},{"EARLY_PHASE1":61524,"PHASE1":61526,"PHASE2":61532,"PHASE3":61546,"PHASE4":61548,"NA":61556},{"trials":61525,"activeCount":103},[],{"trials":61527,"activeCount":103},[61528],{"nctId":17061,"briefTitle":17062,"status":111,"phases":61529,"primaryCompletion":2313,"completion":2313,"start":7387,"enrollment":1548,"conditions":61530,"interventions":61531},[91],[16],[17066,6111,17067],{"trials":61533,"activeCount":103},[61534,61538,61542],{"nctId":32301,"briefTitle":32302,"status":168,"phases":61535,"completion":12030,"start":4657,"enrollment":162,"conditions":61536,"interventions":61537},[92],[12847],[32292,17066],{"nctId":36997,"briefTitle":36998,"status":111,"phases":61539,"completion":15716,"start":13902,"enrollment":37000,"conditions":61540,"interventions":61541},[92],[12847],[36988,36988,37003,37003,36988,36988,37004],{"nctId":37564,"briefTitle":37565,"status":111,"phases":61543,"completion":2641,"start":2671,"enrollment":37567,"conditions":61544,"interventions":61545},[92],[12847],[37555,17066],{"trials":61547,"activeCount":103},[],{"trials":61549,"activeCount":103},[61550],{"nctId":61551,"briefTitle":61552,"status":111,"phases":61553,"primaryCompletion":10923,"completion":11988,"start":2884,"enrollment":21743,"conditions":61554,"interventions":61555},"NCT00677352","A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder",[94],[13029],[37003,17595],{"trials":61557,"activeCount":103},[61558],{"nctId":61559,"briefTitle":61560,"status":111,"phases":61561,"primaryCompletion":2562,"completion":2562,"start":61562,"enrollment":61563,"conditions":61564,"interventions":61566},"NCT01302080","Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)",[],"2012-04-04",941,[61565],"Obsessive Compulsive Disorder",[37003],{"intervention":61568,"totalTrials":2070,"cells":61569},"Enbrel",{"EARLY_PHASE1":61570,"PHASE1":61572,"PHASE2":61574,"PHASE3":61576,"PHASE4":61578,"NA":61580},{"trials":61571,"activeCount":103},[],{"trials":61573,"activeCount":103},[],{"trials":61575,"activeCount":103},[],{"trials":61577,"activeCount":103},[],{"trials":61579,"activeCount":103},[],{"trials":61581,"activeCount":103},[61582,61588,61594,61602,61608,61614],{"nctId":61583,"briefTitle":61584,"status":168,"phases":61585,"primaryCompletion":4590,"completion":4590,"start":3601,"enrollment":4981,"conditions":61586,"interventions":61587},"NCT01411215","A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department",[],[22,15038],[61568],{"nctId":61589,"briefTitle":61590,"status":111,"phases":61591,"primaryCompletion":606,"completion":606,"start":4846,"enrollment":1519,"conditions":61592,"interventions":61593},"NCT01421303","Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.",[],[15038],[61568],{"nctId":61595,"briefTitle":61596,"status":111,"phases":61597,"primaryCompletion":61598,"completion":61598,"start":61599,"enrollment":13519,"conditions":61600,"interventions":61601},"NCT04428502","Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)",[],"2020-08-30","2020-07-05",[4469],[61568],{"nctId":61603,"briefTitle":61604,"status":111,"phases":61605,"primaryCompletion":3642,"completion":3642,"start":2884,"enrollment":13215,"conditions":61606,"interventions":61607},"NCT01188655","Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis",[],[12072],[61568],{"nctId":61609,"briefTitle":61610,"status":111,"phases":61611,"primaryCompletion":6208,"completion":6208,"start":2641,"enrollment":4383,"conditions":61612,"interventions":61613},"NCT00503139","Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan",[],[22],[61568],{"nctId":61615,"briefTitle":61616,"status":111,"phases":61617,"primaryCompletion":61598,"completion":61598,"start":61599,"enrollment":61618,"conditions":61619,"interventions":61620},"NCT04428424","Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients",[],1493,[4514],[61568],{"intervention":29445,"totalTrials":2070,"cells":61622},{"EARLY_PHASE1":61623,"PHASE1":61625,"PHASE2":61635,"PHASE3":61637,"PHASE4":61639,"NA":61649},{"trials":61624,"activeCount":103},[],{"trials":61626,"activeCount":103},[61627,61631],{"nctId":29440,"briefTitle":29441,"status":111,"phases":61628,"primaryCompletion":11314,"completion":11314,"start":3602,"enrollment":2159,"conditions":61629,"interventions":61630},[91],[4514],[29426,29445],{"nctId":58261,"briefTitle":58262,"status":111,"phases":61632,"primaryCompletion":3627,"completion":3627,"start":4657,"enrollment":1268,"conditions":61633,"interventions":61634},[91],[22],[12692,29445],{"trials":61636,"activeCount":103},[],{"trials":61638,"activeCount":103},[],{"trials":61640,"activeCount":103},[61641,61645],{"nctId":58435,"briefTitle":58436,"status":111,"phases":61642,"primaryCompletion":58438,"completion":3673,"start":5928,"enrollment":58439,"conditions":61643,"interventions":61644},[94],[22],[12692,29445],{"nctId":58736,"briefTitle":58737,"status":111,"phases":61646,"primaryCompletion":11170,"completion":11170,"start":3335,"enrollment":58739,"conditions":61647,"interventions":61648},[94],[4514],[14680,29445,14680,29445,29445],{"trials":61650,"activeCount":103},[61651,61655],{"nctId":58817,"briefTitle":58818,"status":111,"phases":61652,"primaryCompletion":1700,"completion":1700,"start":114,"enrollment":58820,"conditions":61653,"interventions":61654},[],[22],[4517,58823],{"nctId":58840,"briefTitle":58841,"status":111,"phases":61656,"primaryCompletion":4458,"completion":4458,"start":4680,"enrollment":407,"conditions":61657,"interventions":61658},[],[22],[4517,58823],{"intervention":433,"totalTrials":578,"cells":61660},{"EARLY_PHASE1":61661,"PHASE1":61663,"PHASE2":61665,"PHASE3":61675,"PHASE4":61685,"NA":61687},{"trials":61662,"activeCount":103},[],{"trials":61664,"activeCount":103},[],{"trials":61666,"activeCount":103},[61667,61671],{"nctId":27263,"briefTitle":27264,"status":111,"phases":61668,"primaryCompletion":585,"completion":7386,"start":4645,"enrollment":27266,"conditions":61669,"interventions":61670},[92],[727],[25861,27215],{"nctId":58489,"briefTitle":58490,"status":111,"phases":61672,"primaryCompletion":10923,"completion":10912,"start":3627,"enrollment":19002,"conditions":61673,"interventions":61674},[92],[376],[433,3317,433],{"trials":61676,"activeCount":103},[61677,61681],{"nctId":58538,"briefTitle":58539,"status":111,"phases":61678,"primaryCompletion":586,"completion":2449,"start":2641,"enrollment":58353,"conditions":61679,"interventions":61680},[93],[2645],[433,3317,433],{"nctId":25854,"briefTitle":25855,"status":168,"phases":61682,"primaryCompletion":524,"completion":3334,"start":2884,"enrollment":25857,"conditions":61683,"interventions":61684},[93],[9437,376,9435,25859],[25843,25861,25861],{"trials":61686,"activeCount":103},[],{"trials":61688,"activeCount":103},[61689],{"nctId":415,"briefTitle":416,"status":111,"phases":61690,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":61691,"interventions":61692},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":59272,"totalTrials":578,"cells":61694},{"EARLY_PHASE1":61695,"PHASE1":61697,"PHASE2":61699,"PHASE3":61701,"PHASE4":61707,"NA":61709},{"trials":61696,"activeCount":103},[],{"trials":61698,"activeCount":103},[],{"trials":61700,"activeCount":103},[],{"trials":61702,"activeCount":103},[61703],{"nctId":59265,"briefTitle":59266,"status":111,"phases":61704,"primaryCompletion":59268,"enrollment":1759,"conditions":61705,"interventions":61706},[93],[59270,10974],[59219,59272],{"trials":61708,"activeCount":103},[],{"trials":61710,"activeCount":103},[61711,61715,61719,61723],{"nctId":59291,"briefTitle":59292,"status":111,"phases":61712,"conditions":61713,"interventions":61714},[95],[59270,10974],[59296,59219,59272],{"nctId":59306,"briefTitle":59307,"status":111,"phases":61716,"conditions":61717,"interventions":61718},[95],[59270,10974],[59219,59272],{"nctId":59351,"briefTitle":59352,"status":111,"phases":61720,"conditions":61721,"interventions":61722},[95],[59270,10974],[59296,59219,59272],{"nctId":59363,"briefTitle":59364,"status":111,"phases":61724,"conditions":61725,"interventions":61726},[95],[59270,10974],[59219,59272],{"intervention":6170,"totalTrials":578,"cells":61728},{"EARLY_PHASE1":61729,"PHASE1":61731,"PHASE2":61749,"PHASE3":61751,"PHASE4":61753,"NA":61755},{"trials":61730,"activeCount":103},[],{"trials":61732,"activeCount":103},[61733,61737,61741,61745],{"nctId":17557,"briefTitle":17558,"status":168,"phases":61734,"primaryCompletion":4608,"completion":4608,"start":8251,"enrollment":1509,"conditions":61735,"interventions":61736},[91],[17561],[6170,6170,17550,17550],{"nctId":28606,"briefTitle":28607,"status":111,"phases":61738,"primaryCompletion":28609,"completion":26795,"start":28610,"enrollment":597,"conditions":61739,"interventions":61740},[91],[19],[6170,28468],{"nctId":6158,"briefTitle":6159,"status":111,"phases":61742,"primaryCompletion":6161,"completion":6161,"start":6162,"enrollment":29,"conditions":61743,"interventions":61744},[91],[4181],[6165,6166,6167,6168,6169,1687,6170,6171,2841],{"nctId":26792,"briefTitle":26793,"status":111,"phases":61746,"primaryCompletion":26795,"completion":26796,"start":7963,"enrollment":1268,"conditions":61747,"interventions":61748},[91],[16],[6170,6305],{"trials":61750,"activeCount":103},[],{"trials":61752,"activeCount":103},[],{"trials":61754,"activeCount":103},[],{"trials":61756,"activeCount":103},[61757],{"nctId":61758,"briefTitle":61759,"status":168,"phases":61760,"completion":11609,"start":2662,"enrollment":350,"conditions":61761,"interventions":61762},"NCT00282945","Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone",[95],[12968],[61763,6170],"Rosiglitazone",{"intervention":17595,"totalTrials":578,"cells":61765},{"EARLY_PHASE1":61766,"PHASE1":61768,"PHASE2":61770,"PHASE3":61772,"PHASE4":61786,"NA":61792},{"trials":61767,"activeCount":103},[],{"trials":61769,"activeCount":103},[],{"trials":61771,"activeCount":103},[],{"trials":61773,"activeCount":103},[61774,61778,61782],{"nctId":17590,"briefTitle":17591,"status":168,"phases":61775,"primaryCompletion":11290,"completion":11290,"start":2884,"enrollment":1621,"conditions":61776,"interventions":61777},[93],[17561],[17550,17550,17595],{"nctId":17604,"briefTitle":17605,"status":168,"phases":61779,"primaryCompletion":11290,"completion":11290,"start":3314,"enrollment":17607,"conditions":61780,"interventions":61781},[93],[17561],[17550,17550,17550,17595],{"nctId":17617,"briefTitle":17618,"status":168,"phases":61783,"primaryCompletion":4222,"completion":4222,"start":2884,"enrollment":17620,"conditions":61784,"interventions":61785},[93],[17561],[17550,17550,17623],{"trials":61787,"activeCount":103},[61788],{"nctId":61551,"briefTitle":61552,"status":111,"phases":61789,"primaryCompletion":10923,"completion":11988,"start":2884,"enrollment":21743,"conditions":61790,"interventions":61791},[94],[13029],[37003,17595],{"trials":61793,"activeCount":103},[61794],{"nctId":61795,"briefTitle":61796,"status":111,"phases":61797,"completion":11395,"start":11736,"enrollment":13935,"conditions":61798,"interventions":61800},"NCT00715039","Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder",[95],[61799],"Anxiety Disorders",[61801,17623],"lorazepam",{"intervention":27821,"totalTrials":578,"cells":61803},{"EARLY_PHASE1":61804,"PHASE1":61806,"PHASE2":61814,"PHASE3":61820,"PHASE4":61829,"NA":61835},{"trials":61805,"activeCount":103},[],{"trials":61807,"activeCount":103},[61808],{"nctId":61809,"briefTitle":61810,"status":111,"phases":61811,"primaryCompletion":3324,"completion":3324,"start":1248,"enrollment":1487,"conditions":61812,"interventions":61813},"NCT01994668","Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects",[91],[16],[27821],{"trials":61815,"activeCount":103},[61816],{"nctId":27812,"briefTitle":27813,"status":111,"phases":61817,"primaryCompletion":27815,"completion":27816,"start":27817,"enrollment":3659,"conditions":61818,"interventions":61819},[92],[27819],[11360,27821],{"trials":61821,"activeCount":103},[61822],{"nctId":61823,"briefTitle":61824,"status":111,"phases":61825,"primaryCompletion":13581,"completion":13581,"start":17639,"enrollment":1239,"conditions":61826,"interventions":61828},"NCT02239380","Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan",[93],[61827],"Status Epilepticus",[27821],{"trials":61830,"activeCount":103},[61831],{"nctId":57668,"briefTitle":57669,"status":111,"phases":61832,"primaryCompletion":3334,"completion":3334,"start":11014,"enrollment":11766,"conditions":61833,"interventions":61834},[94],[17561],[11452,27821,11452],{"trials":61836,"activeCount":103},[61837],{"nctId":61795,"briefTitle":61796,"status":111,"phases":61838,"completion":11395,"start":11736,"enrollment":13935,"conditions":61839,"interventions":61840},[95],[61799],[61801,17623],{"intervention":12037,"totalTrials":257,"cells":61842},{"EARLY_PHASE1":61843,"PHASE1":61845,"PHASE2":61855,"PHASE3":61857,"PHASE4":61863,"NA":61869},{"trials":61844,"activeCount":103},[],{"trials":61846,"activeCount":103},[61847],{"nctId":61848,"briefTitle":61849,"status":111,"phases":61850,"primaryCompletion":523,"completion":523,"start":4656,"enrollment":1509,"conditions":61851,"interventions":61854},"NCT01236378","Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients",[91],[61852,61853],"Transplant Rejection","Renal Transplantation",[13197],{"trials":61856,"activeCount":103},[],{"trials":61858,"activeCount":103},[61859],{"nctId":12027,"briefTitle":12028,"status":168,"phases":61860,"primaryCompletion":4656,"completion":10912,"start":12030,"enrollment":7388,"conditions":61861,"interventions":61862},[93],[12032,12033],[12035,12036,12007,12037,12035,12036,12007],{"trials":61864,"activeCount":103},[61865],{"nctId":13186,"briefTitle":13187,"status":111,"phases":61866,"primaryCompletion":6207,"completion":6207,"start":4646,"enrollment":13189,"conditions":61867,"interventions":61868},[94],[13191,13192,13193,13194],[13196,13197,13196],{"trials":61870,"activeCount":103},[61871],{"nctId":61872,"briefTitle":61873,"status":111,"phases":61874,"primaryCompletion":4438,"completion":4438,"start":3313,"enrollment":4476,"conditions":61875,"interventions":61876},"NCT00484094","Study Investigating Rapamune For Post-Marketing Surveillance",[],[4533],[12037],{"intervention":61878,"totalTrials":257,"cells":61879},"Tolterodine tartrate",{"EARLY_PHASE1":61880,"PHASE1":61882,"PHASE2":61890,"PHASE3":61892,"PHASE4":61898,"NA":61900},{"trials":61881,"activeCount":103},[],{"trials":61883,"activeCount":103},[61884],{"nctId":61885,"briefTitle":61886,"status":111,"phases":61887,"primaryCompletion":570,"completion":570,"start":114,"enrollment":314,"conditions":61888,"interventions":61889},"NCT01521767","Pharmacokinetics and Relative Bioavailability Study",[91],[12472],[12506,12506,12506,12506,12506],{"trials":61891,"activeCount":103},[],{"trials":61893,"activeCount":103},[61894],{"nctId":12501,"briefTitle":12502,"status":111,"phases":61895,"primaryCompletion":4207,"completion":4207,"start":3602,"enrollment":3732,"conditions":61896,"interventions":61897},[93],[12489],[12461,12506],{"trials":61899,"activeCount":103},[],{"trials":61901,"activeCount":103},[61902,61908],{"nctId":61903,"briefTitle":61904,"status":111,"phases":61905,"primaryCompletion":524,"completion":524,"start":11314,"enrollment":11502,"conditions":61906,"interventions":61907},"NCT00795509","Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).",[],[12472],[61878],{"nctId":61909,"briefTitle":61910,"status":111,"phases":61911,"primaryCompletion":524,"completion":524,"start":4615,"enrollment":61912,"conditions":61913,"interventions":61914},"NCT01488578","Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)",[],11157,[12489],[61878],{"intervention":61916,"totalTrials":257,"cells":61917},"Gemtuzumab Ozogamicin",{"EARLY_PHASE1":61918,"PHASE1":61920,"PHASE2":61922,"PHASE3":61932,"PHASE4":61934,"NA":61944},{"trials":61919,"activeCount":103},[],{"trials":61921,"activeCount":103},[],{"trials":61923,"activeCount":103},[61924,61928],{"nctId":2626,"briefTitle":2627,"status":111,"phases":61925,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":61926,"interventions":61927},[92],[2633],[2635,2636],{"nctId":2649,"briefTitle":2650,"status":111,"phases":61929,"primaryCompletion":2652,"completion":2652,"start":2653,"enrollment":2631,"conditions":61930,"interventions":61931},[92],[2633],[2635,2636],{"trials":61933,"activeCount":103},[],{"trials":61935,"activeCount":103},[61936],{"nctId":61937,"briefTitle":61938,"status":111,"phases":61939,"primaryCompletion":61940,"completion":61940,"start":4243,"enrollment":5425,"conditions":61941,"interventions":61943},"NCT03727750","Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R\u002FR AML",[94],"2021-04-27",[61942,3396,10629],"ECG",[61916],{"trials":61945,"activeCount":103},[61946],{"nctId":61947,"briefTitle":61948,"status":111,"phases":61949,"primaryCompletion":58882,"completion":58882,"start":3682,"enrollment":4259,"conditions":61950,"interventions":61951},"NCT04337138","A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World",[],[18006],[61916],{"intervention":27700,"totalTrials":257,"cells":61953},{"EARLY_PHASE1":61954,"PHASE1":61956,"PHASE2":61962,"PHASE3":61964,"PHASE4":61970,"NA":61972},{"trials":61955,"activeCount":103},[],{"trials":61957,"activeCount":103},[61958],{"nctId":27695,"briefTitle":27696,"status":111,"phases":61959,"primaryCompletion":561,"completion":561,"start":2660,"enrollment":597,"conditions":61960,"interventions":61961},[91],[19],[17074,27700,17074,27700],{"trials":61963,"activeCount":103},[],{"trials":61965,"activeCount":103},[61966],{"nctId":59234,"briefTitle":59235,"status":111,"phases":61967,"enrollment":59237,"conditions":61968,"interventions":61969},[93],[59239,59240,10974],[15250,27700,59219],{"trials":61971,"activeCount":103},[],{"trials":61973,"activeCount":103},[61974,61983],{"nctId":61975,"briefTitle":61976,"status":111,"phases":61977,"primaryCompletion":27136,"completion":27136,"start":4646,"enrollment":7388,"conditions":61978,"interventions":61981},"NCT00810446","Safety And Efficacy Of Rifabutin In HIV Patients",[],[61979,41415,61980],"Non-tuberculous Mycobacterial Diseases","Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections",[61982],"rifabutin",{"nctId":61984,"briefTitle":61985,"status":111,"phases":61986,"primaryCompletion":5008,"completion":5008,"start":4645,"enrollment":27439,"conditions":61987,"interventions":61989},"NCT00810407","Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients",[],[41415,61988],"Non-tuberculous Mycobacterial Diseases (Including MAC Disease)",[61982],{"intervention":13634,"totalTrials":257,"cells":61991},{"EARLY_PHASE1":61992,"PHASE1":61994,"PHASE2":61996,"PHASE3":61998,"PHASE4":62016,"NA":62018},{"trials":61993,"activeCount":103},[],{"trials":61995,"activeCount":103},[],{"trials":61997,"activeCount":103},[],{"trials":61999,"activeCount":103},[62000,62004,62008],{"nctId":13626,"briefTitle":13627,"status":111,"phases":62001,"primaryCompletion":13629,"completion":13629,"start":13630,"enrollment":13631,"conditions":62002,"interventions":62003},[93],[9529],[13634,11047],{"nctId":24842,"briefTitle":24843,"status":111,"phases":62005,"primaryCompletion":7826,"completion":7826,"start":24845,"enrollment":24846,"conditions":62006,"interventions":62007},[93],[9529],[24849,24831],{"nctId":62009,"briefTitle":62010,"status":111,"phases":62011,"primaryCompletion":3461,"completion":3461,"start":62012,"enrollment":62013,"conditions":62014,"interventions":62015},"NCT06593587","A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea",[93],"2024-10-07",378,[9529],[13634],{"trials":62017,"activeCount":103},[],{"trials":62019,"activeCount":103},[62020],{"nctId":62021,"briefTitle":62022,"status":111,"phases":62023,"primaryCompletion":62024,"completion":62024,"start":62025,"enrollment":62026,"conditions":62027,"interventions":62028},"NCT06482099","SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS",[],"2026-02-27","2024-10-01",497,[3801],[24849],{"intervention":62030,"totalTrials":257,"cells":62031},"Dexmedetomidine hydrochloride",{"EARLY_PHASE1":62032,"PHASE1":62034,"PHASE2":62036,"PHASE3":62038,"PHASE4":62058,"NA":62060},{"trials":62033,"activeCount":103},[],{"trials":62035,"activeCount":103},[],{"trials":62037,"activeCount":103},[],{"trials":62039,"activeCount":103},[62040,62049],{"nctId":62041,"briefTitle":62042,"status":111,"phases":62043,"primaryCompletion":62044,"completion":62044,"start":62045,"enrollment":4818,"conditions":62046,"interventions":62048},"NCT02757625","Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit",[93],"2017-05-24","2016-07-20",[62047],"ICU Sedation",[62030],{"nctId":62050,"briefTitle":62051,"status":111,"phases":62052,"primaryCompletion":62053,"completion":62053,"start":62054,"enrollment":7378,"conditions":62055,"interventions":62057},"NCT01438957","Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation",[93],"2011-11-18","2011-06-03",[62056],"Sedation",[62030],{"trials":62059,"activeCount":103},[],{"trials":62061,"activeCount":103},[62062,62070],{"nctId":62063,"briefTitle":62064,"status":111,"phases":62065,"primaryCompletion":9191,"completion":9191,"start":62066,"enrollment":4360,"conditions":62067,"interventions":62068},"NCT06085573","A Study to Learn About the Study Medicine - Precedex in Children From Japan.",[],"2023-10-18",[62056],[62069],"Dexmedetomidine Hydrochloride",{"nctId":62071,"briefTitle":62072,"status":111,"phases":62073,"primaryCompletion":5101,"completion":5101,"start":62074,"enrollment":4360,"conditions":62075,"interventions":62076},"NCT04040439","Precedex Special Investigation (in Pediatric Patients)",[],"2019-07-30",[62056],[62069],{"intervention":62078,"totalTrials":502,"cells":62079},"Amlodipine\u002FAtorvastatin",{"EARLY_PHASE1":62080,"PHASE1":62082,"PHASE2":62084,"PHASE3":62086,"PHASE4":62095,"NA":62103},{"trials":62081,"activeCount":103},[],{"trials":62083,"activeCount":103},[],{"trials":62085,"activeCount":103},[],{"trials":62087,"activeCount":103},[62088],{"nctId":62089,"briefTitle":62090,"status":111,"phases":62091,"completion":6017,"start":12109,"enrollment":62092,"conditions":62093,"interventions":62094},"NCT00330785","Open Label Study Assessing Effectiveness Of Amlodipine\u002FAtorvastatin In Subjects With Hypertension and Dyslipidaemia",[93],1250,[13280,12980],[62078],{"trials":62096,"activeCount":103},[62097],{"nctId":62098,"briefTitle":62099,"status":111,"phases":62100,"completion":15716,"start":13035,"enrollment":1893,"conditions":62101,"interventions":62102},"NCT00150384","Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population",[94],[13280,12980],[62078],{"trials":62104,"activeCount":103},[62105],{"nctId":62106,"briefTitle":62107,"status":111,"phases":62108,"primaryCompletion":3334,"completion":3334,"start":577,"enrollment":62109,"conditions":62110,"interventions":62113},"NCT01107743","Amlodipine\u002FAtorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)",[],1291,[13280,62111,12981,62112],"Angina Pectoris","Familial Hypercholesterolemia",[62078],{"intervention":59296,"totalTrials":502,"cells":62115},{"EARLY_PHASE1":62116,"PHASE1":62118,"PHASE2":62120,"PHASE3":62122,"PHASE4":62124,"NA":62126},{"trials":62117,"activeCount":103},[],{"trials":62119,"activeCount":103},[],{"trials":62121,"activeCount":103},[],{"trials":62123,"activeCount":103},[],{"trials":62125,"activeCount":103},[],{"trials":62127,"activeCount":103},[62128,62132,62136],{"nctId":59291,"briefTitle":59292,"status":111,"phases":62129,"conditions":62130,"interventions":62131},[95],[59270,10974],[59296,59219,59272],{"nctId":59318,"briefTitle":59319,"status":111,"phases":62133,"enrollment":7363,"conditions":62134,"interventions":62135},[95],[59270,10974],[59296,59219],{"nctId":59351,"briefTitle":59352,"status":111,"phases":62137,"conditions":62138,"interventions":62139},[95],[59270,10974],[59296,59219,59272],{"intervention":620,"totalTrials":502,"cells":62141},{"EARLY_PHASE1":62142,"PHASE1":62144,"PHASE2":62154,"PHASE3":62156,"PHASE4":62158,"NA":62160},{"trials":62143,"activeCount":103},[],{"trials":62145,"activeCount":103},[62146,62150],{"nctId":42068,"briefTitle":42069,"status":111,"phases":62147,"primaryCompletion":4656,"completion":4656,"start":4833,"enrollment":7905,"conditions":62148,"interventions":62149},[91],[16],[42061,620],{"nctId":615,"briefTitle":616,"status":111,"phases":62151,"primaryCompletion":560,"completion":560,"start":586,"enrollment":498,"conditions":62152,"interventions":62153},[91],[16],[424,620,424],{"trials":62155,"activeCount":103},[],{"trials":62157,"activeCount":103},[],{"trials":62159,"activeCount":103},[],{"trials":62161,"activeCount":103},[62162],{"nctId":59330,"briefTitle":59331,"status":111,"phases":62163,"conditions":62164,"interventions":62165},[95],[59278,10974],[59335,59219],{"intervention":62167,"totalTrials":502,"cells":62168},"Fragmin",{"EARLY_PHASE1":62169,"PHASE1":62171,"PHASE2":62173,"PHASE3":62175,"PHASE4":62190,"NA":62192},{"trials":62170,"activeCount":103},[],{"trials":62172,"activeCount":103},[],{"trials":62174,"activeCount":103},[],{"trials":62176,"activeCount":103},[62177,62183],{"nctId":62178,"briefTitle":62179,"status":111,"phases":62180,"primaryCompletion":585,"completion":585,"start":4665,"enrollment":23,"conditions":62181,"interventions":62182},"NCT00765063","The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)",[92,93],[21512],[62167],{"nctId":62184,"briefTitle":62185,"status":111,"phases":62186,"primaryCompletion":12810,"completion":12810,"start":1249,"enrollment":62187,"conditions":62188,"interventions":62189},"NCT01879618","Use Of Fragmin In Hemodialysis",[93],152,[18851],[62167],{"trials":62191,"activeCount":103},[],{"trials":62193,"activeCount":103},[62194],{"nctId":62195,"briefTitle":62196,"status":111,"phases":62197,"primaryCompletion":4646,"completion":4646,"start":3643,"enrollment":10190,"conditions":62198,"interventions":62200},"NCT00480636","Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients",[],[62199],"Acute Deep Vein Thrombosis",[62167],{"intervention":11475,"totalTrials":502,"cells":62202},{"EARLY_PHASE1":62203,"PHASE1":62205,"PHASE2":62213,"PHASE3":62219,"PHASE4":62221,"NA":62223},{"trials":62204,"activeCount":103},[],{"trials":62206,"activeCount":103},[62207],{"nctId":62208,"briefTitle":62209,"status":111,"phases":62210,"primaryCompletion":586,"completion":586,"start":2660,"enrollment":1509,"conditions":62211,"interventions":62212},"NCT01119235","A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.",[91],[13120],[11475,11475],{"trials":62214,"activeCount":103},[62215],{"nctId":11469,"briefTitle":11470,"status":168,"phases":62216,"primaryCompletion":2450,"completion":113,"start":114,"enrollment":481,"conditions":62217,"interventions":62218},[92],[11473],[11475,11475,11072],{"trials":62220,"activeCount":103},[],{"trials":62222,"activeCount":103},[],{"trials":62224,"activeCount":103},[62225],{"nctId":62226,"briefTitle":62227,"status":111,"phases":62228,"primaryCompletion":4221,"completion":4221,"start":4214,"enrollment":1519,"conditions":62229,"interventions":62230},"NCT00992316","To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects",[],[34],[11475],{"intervention":62232,"totalTrials":502,"cells":62233},"Bazedoxifene",{"EARLY_PHASE1":62234,"PHASE1":62236,"PHASE2":62242,"PHASE3":62244,"PHASE4":62246,"NA":62248},{"trials":62235,"activeCount":103},[],{"trials":62237,"activeCount":103},[62238],{"nctId":42875,"briefTitle":42876,"status":168,"phases":62239,"primaryCompletion":3345,"completion":3345,"start":569,"enrollment":1087,"conditions":62240,"interventions":62241},[91],[16],[42880,42880,42880,42868],{"trials":62243,"activeCount":103},[],{"trials":62245,"activeCount":103},[],{"trials":62247,"activeCount":103},[],{"trials":62249,"activeCount":103},[62250,62257],{"nctId":62251,"briefTitle":62252,"status":111,"phases":62253,"primaryCompletion":539,"completion":539,"start":570,"enrollment":62254,"conditions":62255,"interventions":62256},"NCT01470326","Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)",[],3187,[23074],[62232],{"nctId":62258,"briefTitle":62259,"status":111,"phases":62260,"primaryCompletion":3253,"completion":3253,"start":54609,"enrollment":62261,"conditions":62262,"interventions":62264},"NCT01416194","Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)",[],10497,[62263],"Osteoporosis, Postmenopausal",[62232,62265,62266],"Bisphosphonate","Raloxifene",{"intervention":62268,"totalTrials":502,"cells":62269},"Sutent",{"EARLY_PHASE1":62270,"PHASE1":62272,"PHASE2":62274,"PHASE3":62276,"PHASE4":62278,"NA":62280},{"trials":62271,"activeCount":103},[],{"trials":62273,"activeCount":103},[],{"trials":62275,"activeCount":103},[],{"trials":62277,"activeCount":103},[],{"trials":62279,"activeCount":103},[],{"trials":62281,"activeCount":103},[62282,62288,62294],{"nctId":62283,"briefTitle":62284,"status":453,"phases":62285,"primaryCompletion":570,"completion":570,"start":11417,"conditions":62286,"interventions":62287},"NCT00130897","Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma",[],[919],[62268],{"nctId":62289,"briefTitle":62290,"status":111,"phases":62291,"primaryCompletion":570,"completion":570,"start":11014,"enrollment":2442,"conditions":62292,"interventions":62293},"NCT00873210","Study In Patients With Kidney Cancer Treated With Sutent",[],[927,921],[62268],{"nctId":62295,"briefTitle":62296,"status":111,"phases":62297,"primaryCompletion":523,"completion":523,"start":3839,"enrollment":28148,"conditions":62298,"interventions":62299},"NCT00684645","Non-Interventional Study (NIS) In Patients With Advanced And\u002FOr Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®",[],[924],[62300],"SUTENT",{"intervention":62302,"totalTrials":502,"cells":62303},"Lyrica",{"EARLY_PHASE1":62304,"PHASE1":62306,"PHASE2":62308,"PHASE3":62310,"PHASE4":62312,"NA":62329},{"trials":62305,"activeCount":103},[],{"trials":62307,"activeCount":103},[],{"trials":62309,"activeCount":103},[],{"trials":62311,"activeCount":103},[],{"trials":62313,"activeCount":103},[62314,62321],{"nctId":62315,"briefTitle":62316,"status":111,"phases":62317,"primaryCompletion":1248,"completion":1248,"start":2883,"enrollment":38105,"conditions":62318,"interventions":62320},"NCT01455428","Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)",[94],[62319],"Postherpetic Neuralgia ( PHN )",[62302],{"nctId":62322,"briefTitle":62323,"status":111,"phases":62324,"primaryCompletion":62325,"completion":62325,"start":62326,"enrollment":1112,"conditions":62327,"interventions":62328},"NCT00351611","Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo",[94],"2020-02-04","2006-07-26",[26282],[62302],{"trials":62330,"activeCount":103},[62331],{"nctId":62332,"briefTitle":62333,"status":111,"phases":62334,"primaryCompletion":577,"completion":577,"start":4833,"enrollment":17620,"conditions":62335,"interventions":62336},"NCT00922987","Clinical Study With Lyrica In Patients Suffering From Epilepsy",[],[57287,26285],[62302],{"intervention":62338,"totalTrials":502,"cells":62339},"Sertraline hydrochloride",{"EARLY_PHASE1":62340,"PHASE1":62342,"PHASE2":62351,"PHASE3":62353,"PHASE4":62355,"NA":62357},{"trials":62341,"activeCount":103},[],{"trials":62343,"activeCount":103},[62344],{"nctId":62345,"briefTitle":62346,"status":111,"phases":62347,"primaryCompletion":4656,"completion":4656,"start":8252,"enrollment":1780,"conditions":62348,"interventions":62349},"NCT01235195","A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions",[91],[16],[62350,62350],"sertraline hydrochloride",{"trials":62352,"activeCount":103},[],{"trials":62354,"activeCount":103},[],{"trials":62356,"activeCount":103},[],{"trials":62358,"activeCount":103},[62359,62366],{"nctId":62360,"briefTitle":62361,"status":111,"phases":62362,"primaryCompletion":9544,"completion":9544,"start":3602,"enrollment":62363,"conditions":62364,"interventions":62365},"NCT00605917","Special Investigation Of J Zoloft For Panic Disorder Patients",[],997,[13029],[62338],{"nctId":62367,"briefTitle":62368,"status":111,"phases":62369,"primaryCompletion":9544,"completion":9544,"start":3602,"enrollment":62370,"conditions":62371,"interventions":62372},"NCT00605865","Drug Use Investigation of Jzoloft.",[],2272,[13029,12376],[62338],{"intervention":62374,"totalTrials":502,"cells":62375},"Caduet",{"EARLY_PHASE1":62376,"PHASE1":62378,"PHASE2":62380,"PHASE3":62382,"PHASE4":62384,"NA":62398},{"trials":62377,"activeCount":103},[],{"trials":62379,"activeCount":103},[],{"trials":62381,"activeCount":103},[],{"trials":62383,"activeCount":103},[],{"trials":62385,"activeCount":103},[62386,62392],{"nctId":62387,"briefTitle":62388,"status":111,"phases":62389,"primaryCompletion":18026,"completion":18026,"start":561,"enrollment":28923,"conditions":62390,"interventions":62391},"NCT01190007","Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients",[94],[13280,12981,62111],[62374],{"nctId":62393,"briefTitle":62394,"status":111,"phases":62395,"completion":7665,"start":3627,"enrollment":12763,"conditions":62396,"interventions":62397},"NCT00332761","Caduet in an Untreated Subject Population",[94],[13280,12980],[62374],{"trials":62399,"activeCount":103},[62400],{"nctId":62401,"briefTitle":62402,"status":168,"phases":62403,"primaryCompletion":2884,"completion":2884,"start":4636,"enrollment":4440,"conditions":62404,"interventions":62406},"NCT00579254","Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors",[],[62405],"Hypertension and Cardiovascular Risk Factors",[62407],"CADUET",{"intervention":12311,"totalTrials":502,"cells":62409},{"EARLY_PHASE1":62410,"PHASE1":62412,"PHASE2":62422,"PHASE3":62424,"PHASE4":62430,"NA":62432},{"trials":62411,"activeCount":103},[],{"trials":62413,"activeCount":103},[62414],{"nctId":62415,"briefTitle":62416,"status":168,"phases":62417,"primaryCompletion":21125,"completion":62418,"start":27772,"enrollment":257,"conditions":62419,"interventions":62421},"NCT04040621","Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia",[91],"2021-05-07",[62420],"Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia",[12311],{"trials":62423,"activeCount":103},[],{"trials":62425,"activeCount":103},[62426],{"nctId":12304,"briefTitle":12305,"status":111,"phases":62427,"primaryCompletion":12307,"completion":12307,"start":4590,"enrollment":12308,"conditions":62428,"interventions":62429},[93],[6505],[12311,12312,12262],{"trials":62431,"activeCount":103},[],{"trials":62433,"activeCount":103},[62434],{"nctId":62435,"briefTitle":62436,"status":111,"phases":62437,"primaryCompletion":62438,"completion":62438,"start":27438,"enrollment":2935,"conditions":62439,"interventions":62441},"NCT04628572","Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections",[],"2022-03-11",[62440],"Gram Negative Infections",[12311],{"intervention":62443,"totalTrials":502,"cells":62444},"BeneFIX",{"EARLY_PHASE1":62445,"PHASE1":62447,"PHASE2":62456,"PHASE3":62458,"PHASE4":62460,"NA":62470},{"trials":62446,"activeCount":103},[],{"trials":62448,"activeCount":103},[62449],{"nctId":62450,"briefTitle":62451,"status":111,"phases":62452,"primaryCompletion":4589,"completion":4589,"start":12307,"enrollment":1268,"conditions":62453,"interventions":62454},"NCT02213250","An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B",[91],[3552],[62455],"BENEFIX",{"trials":62457,"activeCount":103},[],{"trials":62459,"activeCount":103},[],{"trials":62461,"activeCount":103},[62462],{"nctId":62463,"briefTitle":62464,"status":111,"phases":62465,"primaryCompletion":5008,"completion":13581,"start":11956,"enrollment":27035,"conditions":62466,"interventions":62468},"NCT02336178","Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China",[94],[62467],"HEMOPHILIA B",[62469],"Benefix",{"trials":62471,"activeCount":103},[62472],{"nctId":62473,"briefTitle":62474,"status":111,"phases":62475,"primaryCompletion":5957,"completion":5957,"start":3853,"enrollment":1519,"conditions":62476,"interventions":62477},"NCT00714415","Registry For Patients Treated With BeneFix In Usual Care Setting In Germany",[],[3552],[62443],{"intervention":6022,"totalTrials":502,"cells":62479},{"EARLY_PHASE1":62480,"PHASE1":62482,"PHASE2":62484,"PHASE3":62486,"PHASE4":62492,"NA":62494},{"trials":62481,"activeCount":103},[],{"trials":62483,"activeCount":103},[],{"trials":62485,"activeCount":103},[],{"trials":62487,"activeCount":103},[62488],{"nctId":6013,"briefTitle":6014,"status":111,"phases":62489,"primaryCompletion":6016,"completion":3313,"start":6017,"enrollment":6018,"conditions":62490,"interventions":62491},[92,93],[6020],[144,6022],{"trials":62493,"activeCount":103},[],{"trials":62495,"activeCount":103},[62496,62502],{"nctId":62497,"briefTitle":62498,"status":649,"phases":62499,"primaryCompletion":11014,"completion":11014,"start":10937,"enrollment":103,"conditions":62500,"interventions":62501},"NCT00820742","Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.",[],[61520],[6022],{"nctId":62503,"briefTitle":62504,"status":111,"phases":62505,"primaryCompletion":4846,"completion":4846,"start":2964,"enrollment":1796,"conditions":62506,"interventions":62507},"NCT00549055","A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.",[],[61520],[6022],{"intervention":62509,"totalTrials":502,"cells":62510},"Nonacog alfa",{"EARLY_PHASE1":62511,"PHASE1":62513,"PHASE2":62515,"PHASE3":62517,"PHASE4":62525,"NA":62534},{"trials":62512,"activeCount":103},[],{"trials":62514,"activeCount":103},[],{"trials":62516,"activeCount":103},[],{"trials":62518,"activeCount":103},[62519],{"nctId":62520,"briefTitle":62521,"status":111,"phases":62522,"primaryCompletion":7578,"completion":7578,"start":9544,"enrollment":2713,"conditions":62523,"interventions":62524},"NCT01335061","Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B",[93],[3552],[62509,62509],{"trials":62526,"activeCount":103},[62527],{"nctId":62528,"briefTitle":62529,"status":111,"phases":62530,"primaryCompletion":4234,"completion":4234,"start":62531,"enrollment":2713,"conditions":62532,"interventions":62533},"NCT04286412","Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B",[94],"2020-02-10",[3552],[62509],{"trials":62535,"activeCount":103},[62536],{"nctId":62537,"briefTitle":62538,"status":111,"phases":62539,"primaryCompletion":62540,"completion":62541,"start":34912,"enrollment":4549,"conditions":62542,"interventions":62543},"NCT01154231","BeneFIX Drug Use Results Survey [All-Case Surveillance]",[],"2014-08-29","2017-02-27",[3552],[62544],"Nonacog Alfa",{"intervention":14040,"totalTrials":502,"cells":62546},{"EARLY_PHASE1":62547,"PHASE1":62549,"PHASE2":62551,"PHASE3":62560,"PHASE4":62562,"NA":62568},{"trials":62548,"activeCount":103},[],{"trials":62550,"activeCount":103},[],{"trials":62552,"activeCount":103},[62553],{"nctId":62554,"briefTitle":62555,"status":111,"phases":62556,"primaryCompletion":27136,"completion":27136,"start":4214,"enrollment":1796,"conditions":62557,"interventions":62558},"NCT00952380","Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients",[92],[9667],[62559],"dalteparin",{"trials":62561,"activeCount":103},[],{"trials":62563,"activeCount":103},[62564],{"nctId":14032,"briefTitle":14033,"status":168,"phases":62565,"primaryCompletion":8154,"completion":8154,"start":3643,"enrollment":14035,"conditions":62566,"interventions":62567},[94],[14037,14038],[14040,14015],{"trials":62569,"activeCount":103},[62570],{"nctId":62571,"briefTitle":62572,"status":111,"phases":62573,"primaryCompletion":560,"completion":560,"start":11014,"enrollment":62574,"conditions":62575,"interventions":62576},"NCT00922766","Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice",[],618,[9564],[14040],{"intervention":37811,"totalTrials":502,"cells":62578},{"EARLY_PHASE1":62579,"PHASE1":62581,"PHASE2":62587,"PHASE3":62593,"PHASE4":62595,"NA":62597},{"trials":62580,"activeCount":103},[],{"trials":62582,"activeCount":103},[62583],{"nctId":50185,"briefTitle":50186,"status":111,"phases":62584,"primaryCompletion":3947,"completion":3947,"start":359,"enrollment":50188,"conditions":62585,"interventions":62586},[91],[30836],[50178,50191,50192,50193,50194,50195,50196,50197,50198,50199],{"trials":62588,"activeCount":103},[62589],{"nctId":37803,"briefTitle":37804,"status":111,"phases":62590,"primaryCompletion":37806,"completion":37806,"start":37807,"enrollment":37808,"conditions":62591,"interventions":62592},[92],[30836],[37794,37811],{"trials":62594,"activeCount":103},[],{"trials":62596,"activeCount":103},[],{"trials":62598,"activeCount":103},[62599],{"nctId":62600,"briefTitle":62601,"status":111,"phases":62602,"primaryCompletion":62603,"completion":62603,"start":62604,"enrollment":62605,"conditions":62606,"interventions":62607},"NCT05858450","This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.",[],"2023-05-12","2023-05-05",3442996,[30836,2592],[62608,37811],"Comirnaty",{"intervention":62610,"totalTrials":1087,"cells":62611},"Alectinib",{"EARLY_PHASE1":62612,"PHASE1":62614,"PHASE2":62616,"PHASE3":62618,"PHASE4":62620,"NA":62622},{"trials":62613,"activeCount":103},[],{"trials":62615,"activeCount":103},[],{"trials":62617,"activeCount":103},[],{"trials":62619,"activeCount":103},[],{"trials":62621,"activeCount":103},[],{"trials":62623,"activeCount":103},[62624,62632],{"nctId":62625,"briefTitle":62626,"status":111,"phases":62627,"primaryCompletion":62628,"completion":62628,"start":62629,"enrollment":31640,"conditions":62630,"interventions":62631},"NCT04351334","Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns",[],"2022-11-01","2020-03-01",[3355],[62610],{"nctId":415,"briefTitle":416,"status":111,"phases":62633,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":62634,"interventions":62635},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":62637,"totalTrials":1087,"cells":62638},"ReFacto AF",{"EARLY_PHASE1":62639,"PHASE1":62641,"PHASE2":62643,"PHASE3":62645,"PHASE4":62647,"NA":62649},{"trials":62640,"activeCount":103},[],{"trials":62642,"activeCount":103},[],{"trials":62644,"activeCount":103},[],{"trials":62646,"activeCount":103},[],{"trials":62648,"activeCount":103},[],{"trials":62650,"activeCount":103},[62651,62659],{"nctId":62652,"briefTitle":62653,"status":111,"phases":62654,"primaryCompletion":62655,"completion":62655,"start":62656,"enrollment":1638,"conditions":62657,"interventions":62658},"NCT00895037","Study Evaluating Pharmacovigilance Of Refacto AF",[],"2016-10-19","2009-07-17",[3551],[62637],{"nctId":62660,"briefTitle":62661,"status":649,"phases":62662,"primaryCompletion":62663,"completion":62664,"start":62665,"enrollment":103,"conditions":62666,"interventions":62667},"NCT02718677","Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis",[],"2021-05-01","2022-01-01","2019-09-01",[3551],[62668],"Refacto AF",{"intervention":62670,"totalTrials":1087,"cells":62671},"CP-675,206",{"EARLY_PHASE1":62672,"PHASE1":62674,"PHASE2":62676,"PHASE3":62684,"PHASE4":62686,"NA":62688},{"trials":62673,"activeCount":103},[],{"trials":62675,"activeCount":103},[],{"trials":62677,"activeCount":103},[62678],{"nctId":62679,"briefTitle":62680,"status":649,"phases":62681,"start":2641,"enrollment":103,"conditions":62682,"interventions":62683},"NCT00488995","Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients",[92],[30808],[62670],{"trials":62685,"activeCount":103},[],{"trials":62687,"activeCount":103},[],{"trials":62689,"activeCount":103},[62690],{"nctId":62691,"briefTitle":62692,"status":308,"phases":62693,"start":2884,"conditions":62694,"interventions":62696},"NCT00584493","Treatment Use Study for Advanced Melanoma.",[],[62695],"Advanced Unresectable Melanoma",[62670],{"intervention":434,"totalTrials":1087,"cells":62698},{"EARLY_PHASE1":62699,"PHASE1":62701,"PHASE2":62703,"PHASE3":62705,"PHASE4":62711,"NA":62713},{"trials":62700,"activeCount":103},[],{"trials":62702,"activeCount":103},[],{"trials":62704,"activeCount":103},[],{"trials":62706,"activeCount":103},[62707],{"nctId":60640,"briefTitle":60641,"status":111,"phases":62708,"primaryCompletion":60643,"completion":3252,"start":60644,"enrollment":60645,"conditions":62709,"interventions":62710},[93],[60647],[8126,60649],{"trials":62712,"activeCount":103},[],{"trials":62714,"activeCount":103},[62715],{"nctId":415,"briefTitle":416,"status":111,"phases":62716,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":62717,"interventions":62718},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":62720,"totalTrials":1087,"cells":62721},"CT-P13",{"EARLY_PHASE1":62722,"PHASE1":62724,"PHASE2":62726,"PHASE3":62728,"PHASE4":62730,"NA":62732},{"trials":62723,"activeCount":103},[],{"trials":62725,"activeCount":103},[],{"trials":62727,"activeCount":103},[],{"trials":62729,"activeCount":103},[],{"trials":62731,"activeCount":103},[],{"trials":62733,"activeCount":103},[62734,62743],{"nctId":62735,"briefTitle":62736,"status":111,"phases":62737,"primaryCompletion":62738,"completion":62738,"start":1344,"enrollment":62739,"conditions":62740,"interventions":62742},"NCT02605642","Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade",[],"2018-12-31",351,[62741,22,15038,4469],"Rheumatoid Diseases",[62720],{"nctId":62744,"briefTitle":62745,"status":111,"phases":62746,"primaryCompletion":5929,"completion":5929,"start":62747,"enrollment":62748,"conditions":62749,"interventions":62751},"NCT02539368","Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease",[],"2015-04-22",2565,[62750,1532,1570],"Inflammatory Bowel Diseases",[62720,44395],{"intervention":2353,"totalTrials":1087,"cells":62753},{"EARLY_PHASE1":62754,"PHASE1":62756,"PHASE2":62758,"PHASE3":62760,"PHASE4":62762,"NA":62764},{"trials":62755,"activeCount":103},[],{"trials":62757,"activeCount":103},[],{"trials":62759,"activeCount":103},[],{"trials":62761,"activeCount":103},[],{"trials":62763,"activeCount":103},[],{"trials":62765,"activeCount":103},[62766,62770],{"nctId":2345,"briefTitle":2346,"status":111,"phases":62767,"primaryCompletion":1497,"completion":1497,"start":2348,"enrollment":2349,"conditions":62768,"interventions":62769},[],[2351],[63,2353],{"nctId":2373,"briefTitle":2374,"status":111,"phases":62771,"primaryCompletion":2376,"completion":2376,"start":2377,"enrollment":2378,"conditions":62772,"interventions":62773},[],[2351],[63,2353],{"intervention":2363,"totalTrials":1087,"cells":62775},{"EARLY_PHASE1":62776,"PHASE1":62778,"PHASE2":62780,"PHASE3":62782,"PHASE4":62784,"NA":62790},{"trials":62777,"activeCount":103},[],{"trials":62779,"activeCount":103},[],{"trials":62781,"activeCount":103},[],{"trials":62783,"activeCount":103},[],{"trials":62785,"activeCount":103},[62786],{"nctId":2331,"briefTitle":2332,"status":111,"phases":62787,"primaryCompletion":2334,"completion":2335,"start":2336,"enrollment":2337,"conditions":62788,"interventions":62789},[94],[1684],[63,2340,2341],{"trials":62791,"activeCount":103},[62792],{"nctId":2355,"briefTitle":2356,"status":111,"phases":62793,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":62794,"interventions":62795},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":62797,"totalTrials":1087,"cells":62798},"Prevenar",{"EARLY_PHASE1":62799,"PHASE1":62801,"PHASE2":62803,"PHASE3":62805,"PHASE4":62807,"NA":62816},{"trials":62800,"activeCount":103},[],{"trials":62802,"activeCount":103},[],{"trials":62804,"activeCount":103},[],{"trials":62806,"activeCount":103},[],{"trials":62808,"activeCount":103},[62809],{"nctId":62810,"briefTitle":62811,"status":111,"phases":62812,"primaryCompletion":1700,"completion":1700,"start":560,"enrollment":62813,"conditions":62814,"interventions":62815},"NCT01193582","A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria",[94],505,[10940],[62797,62797,62797,62797],{"trials":62817,"activeCount":103},[62818],{"nctId":62819,"briefTitle":62820,"status":111,"phases":62821,"primaryCompletion":651,"completion":651,"start":605,"enrollment":62822,"conditions":62823,"interventions":62825},"NCT02119104","Prevenar (13v) Infant Drug Use Investigation",[],1087,[62824],"Infants",[62797],{"intervention":44395,"totalTrials":1087,"cells":62827},{"EARLY_PHASE1":62828,"PHASE1":62830,"PHASE2":62836,"PHASE3":62838,"PHASE4":62840,"NA":62842},{"trials":62829,"activeCount":103},[],{"trials":62831,"activeCount":103},[62832],{"nctId":44389,"briefTitle":44390,"status":111,"phases":62833,"primaryCompletion":18769,"completion":18769,"start":6198,"enrollment":44392,"conditions":62834,"interventions":62835},[91],[16],[44382,44395,44395],{"trials":62837,"activeCount":103},[],{"trials":62839,"activeCount":103},[],{"trials":62841,"activeCount":103},[],{"trials":62843,"activeCount":103},[62844],{"nctId":62744,"briefTitle":62745,"status":111,"phases":62845,"primaryCompletion":5929,"completion":5929,"start":62747,"enrollment":62748,"conditions":62846,"interventions":62847},[],[62750,1532,1570],[62720,44395],{"intervention":62849,"totalTrials":1087,"cells":62850},"Inflectra",{"EARLY_PHASE1":62851,"PHASE1":62853,"PHASE2":62855,"PHASE3":62857,"PHASE4":62859,"NA":62861},{"trials":62852,"activeCount":103},[],{"trials":62854,"activeCount":103},[],{"trials":62856,"activeCount":103},[],{"trials":62858,"activeCount":103},[],{"trials":62860,"activeCount":103},[],{"trials":62862,"activeCount":103},[62863,62872],{"nctId":62864,"briefTitle":62865,"status":111,"phases":62866,"primaryCompletion":62867,"completion":62867,"start":7938,"enrollment":2250,"conditions":62868,"interventions":62871},"NCT03801928","Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease",[],"2020-02-07",[62869,62870,10877],"Inflammatory Bowel Disease (IBD)","Crohn's Disease (CD)",[62849],{"nctId":62873,"briefTitle":62874,"status":111,"phases":62875,"primaryCompletion":62876,"completion":62876,"start":62876,"enrollment":18733,"conditions":62877,"interventions":62878},"NCT05375942","This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry",[],"2022-11-11",[4514],[62849,62849],{"intervention":62880,"totalTrials":1087,"cells":62881},"Aromasin",{"EARLY_PHASE1":62882,"PHASE1":62884,"PHASE2":62886,"PHASE3":62888,"PHASE4":62890,"NA":62901},{"trials":62883,"activeCount":103},[],{"trials":62885,"activeCount":103},[],{"trials":62887,"activeCount":103},[],{"trials":62889,"activeCount":103},[],{"trials":62891,"activeCount":103},[62892],{"nctId":62893,"briefTitle":62894,"status":111,"phases":62895,"primaryCompletion":62896,"completion":62896,"start":62897,"enrollment":62898,"conditions":62899,"interventions":62900},"NCT01176916","Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China",[94],"2018-11-30","2011-02-09",564,[25],[62880],{"trials":62902,"activeCount":103},[62903],{"nctId":62904,"briefTitle":62905,"status":168,"phases":62906,"primaryCompletion":114,"completion":114,"start":523,"enrollment":787,"conditions":62907,"interventions":62908},"NCT01239745","Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer",[],[25],[62880],{"intervention":62910,"totalTrials":1087,"cells":62911},"Plant cell expressed recombinant glucocerebrosidase",{"EARLY_PHASE1":62912,"PHASE1":62914,"PHASE2":62916,"PHASE3":62918,"PHASE4":62926,"NA":62928},{"trials":62913,"activeCount":103},[],{"trials":62915,"activeCount":103},[],{"trials":62917,"activeCount":103},[],{"trials":62919,"activeCount":103},[62920],{"nctId":62921,"briefTitle":62922,"status":111,"phases":62923,"primaryCompletion":4833,"completion":4846,"start":11314,"enrollment":4259,"conditions":62924,"interventions":62925},"NCT00376168","A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease",[93],[12932],[62910,62910],{"trials":62927,"activeCount":103},[],{"trials":62929,"activeCount":103},[62930],{"nctId":62931,"briefTitle":62932,"status":308,"phases":62933,"conditions":62934,"interventions":62935},"NCT00962260","Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease",[],[12932],[62910],{"intervention":60029,"totalTrials":1087,"cells":62937},{"EARLY_PHASE1":62938,"PHASE1":62940,"PHASE2":62942,"PHASE3":62944,"PHASE4":62950,"NA":62952},{"trials":62939,"activeCount":103},[],{"trials":62941,"activeCount":103},[],{"trials":62943,"activeCount":103},[],{"trials":62945,"activeCount":103},[62946],{"nctId":60000,"briefTitle":60001,"status":111,"phases":62947,"primaryCompletion":11405,"completion":60003,"start":27285,"enrollment":60004,"conditions":62948,"interventions":62949},[93],[59995],[2435,60007],{"trials":62951,"activeCount":103},[],{"trials":62953,"activeCount":103},[62954],{"nctId":60021,"briefTitle":60022,"status":111,"phases":62955,"primaryCompletion":4367,"completion":4367,"start":60024,"enrollment":60025,"conditions":62956,"interventions":62957},[],[60027],[2435,60029,60030,60031,60032],{"intervention":62959,"totalTrials":1087,"cells":62960},"Infliximab [infliximab biosimilar 3]",{"EARLY_PHASE1":62961,"PHASE1":62963,"PHASE2":62965,"PHASE3":62967,"PHASE4":62969,"NA":62971},{"trials":62962,"activeCount":103},[],{"trials":62964,"activeCount":103},[],{"trials":62966,"activeCount":103},[],{"trials":62968,"activeCount":103},[],{"trials":62970,"activeCount":103},[],{"trials":62972,"activeCount":103},[62973,62980],{"nctId":62974,"briefTitle":62975,"status":111,"phases":62976,"primaryCompletion":62977,"completion":62977,"start":55498,"enrollment":5647,"conditions":62978,"interventions":62979},"NCT03885037","Infliximab Biosimilar for Intravenous Drip Infusion 100 mg \"Pfizer\" Drug Use Investigation (Rheumatoid Arthritis)",[],"2024-11-29",[22],[62959],{"nctId":62981,"briefTitle":62982,"status":111,"phases":62983,"primaryCompletion":62984,"completion":62984,"start":62985,"enrollment":57453,"conditions":62986,"interventions":62987},"NCT03884439","Infliximab Biosimilar \"Pfizer\" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)",[],"2024-02-02","2019-03-18",[1570,1532],[62959],{"intervention":14060,"totalTrials":1087,"cells":62989},{"EARLY_PHASE1":62990,"PHASE1":62992,"PHASE2":62994,"PHASE3":62996,"PHASE4":63002,"NA":63004},{"trials":62991,"activeCount":103},[],{"trials":62993,"activeCount":103},[],{"trials":62995,"activeCount":103},[],{"trials":62997,"activeCount":103},[62998],{"nctId":14054,"briefTitle":14055,"status":111,"phases":62999,"primaryCompletion":8115,"completion":8115,"start":3627,"enrollment":1413,"conditions":63000,"interventions":63001},[93],[6117],[14059,14060],{"trials":63003,"activeCount":103},[],{"trials":63005,"activeCount":103},[63006],{"nctId":63007,"briefTitle":63008,"status":111,"phases":63009,"primaryCompletion":10912,"completion":10912,"start":8115,"enrollment":63010,"conditions":63011,"interventions":63012},"NCT00734591","Follow-Up Study for Exubera",[],7439,[6117],[14060],{"intervention":63014,"totalTrials":1087,"cells":63015},"nirmatrelvir, ritonavir",{"EARLY_PHASE1":63016,"PHASE1":63018,"PHASE2":63020,"PHASE3":63022,"PHASE4":63024,"NA":63026},{"trials":63017,"activeCount":103},[],{"trials":63019,"activeCount":103},[],{"trials":63021,"activeCount":103},[],{"trials":63023,"activeCount":103},[],{"trials":63025,"activeCount":103},[],{"trials":63027,"activeCount":103},[63028,63035],{"nctId":63029,"briefTitle":63030,"status":111,"phases":63031,"primaryCompletion":63032,"completion":63032,"start":55028,"enrollment":8827,"conditions":63033,"interventions":63034},"NCT06016556","A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia",[],"2024-04-09",[9887],[63014],{"nctId":63036,"briefTitle":63037,"status":111,"phases":63038,"primaryCompletion":63039,"completion":63039,"start":5180,"enrollment":63040,"conditions":63041,"interventions":63042},"NCT06291831","A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.",[],"2024-05-14",3011,[2592],[63014],{"intervention":10013,"totalTrials":1087,"cells":63044},{"EARLY_PHASE1":63045,"PHASE1":63047,"PHASE2":63049,"PHASE3":63051,"PHASE4":63053,"NA":63055},{"trials":63046,"activeCount":103},[],{"trials":63048,"activeCount":103},[],{"trials":63050,"activeCount":103},[],{"trials":63052,"activeCount":103},[],{"trials":63054,"activeCount":103},[],{"trials":63056,"activeCount":103},[63057,63061],{"nctId":10006,"briefTitle":10007,"status":111,"phases":63058,"primaryCompletion":8394,"completion":8394,"start":10009,"enrollment":10010,"conditions":63059,"interventions":63060},[],[1369],[10013,1460],{"nctId":10015,"briefTitle":10016,"status":111,"phases":63062,"primaryCompletion":8038,"completion":8038,"start":10018,"enrollment":10019,"conditions":63063,"interventions":63064},[],[1369],[10013,1460],{"intervention":63066,"totalTrials":1087,"cells":63067},"Azithromycin IV",{"EARLY_PHASE1":63068,"PHASE1":63070,"PHASE2":63072,"PHASE3":63074,"PHASE4":63076,"NA":63078},{"trials":63069,"activeCount":103},[],{"trials":63071,"activeCount":103},[],{"trials":63073,"activeCount":103},[],{"trials":63075,"activeCount":103},[],{"trials":63077,"activeCount":103},[],{"trials":63079,"activeCount":103},[63080,63088],{"nctId":63081,"briefTitle":63082,"status":111,"phases":63083,"primaryCompletion":20209,"completion":20209,"start":63084,"enrollment":63085,"conditions":63086,"interventions":63087},"NCT01671280","Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)",[],"2012-09-20",403,[9107,59425],[63066],{"nctId":63089,"briefTitle":63090,"status":111,"phases":63091,"primaryCompletion":60643,"completion":60643,"start":63092,"enrollment":360,"conditions":63093,"interventions":63096},"NCT01784770","Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)",[],"2013-03-27",[63094,63095],"Legionnaires' Disease","Legionella Pneumophila Infections",[63066],{"intervention":63098,"totalTrials":1087,"cells":63099},"Novel hormonal therapy",{"EARLY_PHASE1":63100,"PHASE1":63102,"PHASE2":63104,"PHASE3":63106,"PHASE4":63108,"NA":63110},{"trials":63101,"activeCount":103},[],{"trials":63103,"activeCount":103},[],{"trials":63105,"activeCount":103},[],{"trials":63107,"activeCount":103},[],{"trials":63109,"activeCount":103},[],{"trials":63111,"activeCount":103},[63112,63121],{"nctId":63113,"briefTitle":63114,"status":111,"phases":63115,"primaryCompletion":63116,"completion":63116,"start":63117,"enrollment":63118,"conditions":63119,"interventions":63120},"NCT06151418","A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces",[],"2024-04-23","2023-11-22",2313,[11998],[63098],{"nctId":63122,"briefTitle":63123,"status":111,"phases":63124,"primaryCompletion":39234,"completion":39234,"start":6161,"enrollment":63125,"conditions":63126,"interventions":63127},"NCT06072196","A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",[],3017,[11998],[63098],{"intervention":3289,"totalTrials":1087,"cells":63129},{"EARLY_PHASE1":63130,"PHASE1":63132,"PHASE2":63134,"PHASE3":63136,"PHASE4":63142,"NA":63144},{"trials":63131,"activeCount":103},[],{"trials":63133,"activeCount":103},[],{"trials":63135,"activeCount":103},[],{"trials":63137,"activeCount":103},[63138],{"nctId":17535,"briefTitle":17536,"status":111,"phases":63139,"primaryCompletion":17538,"completion":17539,"start":17540,"enrollment":17541,"conditions":63140,"interventions":63141},[93],[1798],[2024,17444,17544],{"trials":63143,"activeCount":103},[],{"trials":63145,"activeCount":103},[63146],{"nctId":3281,"briefTitle":3282,"status":111,"phases":63147,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":3286,"conditions":63148,"interventions":63149},[],[1798],[1812,1832,3289,3290,3291,3292],{"intervention":63151,"totalTrials":302,"cells":63152},"quinapril",{"EARLY_PHASE1":63153,"PHASE1":63155,"PHASE2":63157,"PHASE3":63159,"PHASE4":63161,"NA":63163},{"trials":63154,"activeCount":103},[],{"trials":63156,"activeCount":103},[],{"trials":63158,"activeCount":103},[],{"trials":63160,"activeCount":103},[],{"trials":63162,"activeCount":103},[],{"trials":63164,"activeCount":103},[63165],{"nctId":63166,"briefTitle":63167,"status":111,"phases":63168,"primaryCompletion":577,"completion":577,"start":4646,"enrollment":13427,"conditions":63169,"interventions":63170},"NCT00930722","A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population",[],[13280],[63151],{"intervention":63172,"totalTrials":302,"cells":63173},"Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated",{"EARLY_PHASE1":63174,"PHASE1":63176,"PHASE2":63178,"PHASE3":63180,"PHASE4":63182,"NA":63184},{"trials":63175,"activeCount":103},[],{"trials":63177,"activeCount":103},[],{"trials":63179,"activeCount":103},[],{"trials":63181,"activeCount":103},[],{"trials":63183,"activeCount":103},[],{"trials":63185,"activeCount":103},[63186],{"nctId":63187,"briefTitle":63188,"status":168,"phases":63189,"primaryCompletion":8086,"completion":8086,"start":63190,"enrollment":302,"conditions":63191,"interventions":63192},"NCT06703190","Estimated Vaccine Effectiveness and Durability of Pfizer\u002FBioNTech 2024-2025 COVID-19 Vaccine",[],"2024-11-25",[2592],[63172,63193],"Not vaccinated with 2024-2025 formulated COVID-19 vaccine",{"intervention":63193,"totalTrials":302,"cells":63195},{"EARLY_PHASE1":63196,"PHASE1":63198,"PHASE2":63200,"PHASE3":63202,"PHASE4":63204,"NA":63206},{"trials":63197,"activeCount":103},[],{"trials":63199,"activeCount":103},[],{"trials":63201,"activeCount":103},[],{"trials":63203,"activeCount":103},[],{"trials":63205,"activeCount":103},[],{"trials":63207,"activeCount":103},[63208],{"nctId":63187,"briefTitle":63188,"status":168,"phases":63209,"primaryCompletion":8086,"completion":8086,"start":63190,"enrollment":302,"conditions":63210,"interventions":63211},[],[2592],[63172,63193],{"intervention":63213,"totalTrials":302,"cells":63214},"Hemophilia B standard half-life",{"EARLY_PHASE1":63215,"PHASE1":63217,"PHASE2":63219,"PHASE3":63221,"PHASE4":63223,"NA":63225},{"trials":63216,"activeCount":103},[],{"trials":63218,"activeCount":103},[],{"trials":63220,"activeCount":103},[],{"trials":63222,"activeCount":103},[],{"trials":63224,"activeCount":103},[],{"trials":63226,"activeCount":103},[63227],{"nctId":63228,"briefTitle":63229,"status":168,"phases":63230,"primaryCompletion":63231,"completion":63231,"start":63232,"enrollment":1625,"conditions":63233,"interventions":63234},"NCT03248141","Understanding Hemophilia A and B Drug Dosage Administration Patterns",[],"2018-03-14","2017-09-01",[3551,3552],[63213,63235,63236,63237],"Hemophilia B extended half-life","Hemophilia A standard half-life","Hemophilia A extended half-life",{"intervention":63235,"totalTrials":302,"cells":63239},{"EARLY_PHASE1":63240,"PHASE1":63242,"PHASE2":63244,"PHASE3":63246,"PHASE4":63248,"NA":63250},{"trials":63241,"activeCount":103},[],{"trials":63243,"activeCount":103},[],{"trials":63245,"activeCount":103},[],{"trials":63247,"activeCount":103},[],{"trials":63249,"activeCount":103},[],{"trials":63251,"activeCount":103},[63252],{"nctId":63228,"briefTitle":63229,"status":168,"phases":63253,"primaryCompletion":63231,"completion":63231,"start":63232,"enrollment":1625,"conditions":63254,"interventions":63255},[],[3551,3552],[63213,63235,63236,63237],{"intervention":63236,"totalTrials":302,"cells":63257},{"EARLY_PHASE1":63258,"PHASE1":63260,"PHASE2":63262,"PHASE3":63264,"PHASE4":63266,"NA":63268},{"trials":63259,"activeCount":103},[],{"trials":63261,"activeCount":103},[],{"trials":63263,"activeCount":103},[],{"trials":63265,"activeCount":103},[],{"trials":63267,"activeCount":103},[],{"trials":63269,"activeCount":103},[63270],{"nctId":63228,"briefTitle":63229,"status":168,"phases":63271,"primaryCompletion":63231,"completion":63231,"start":63232,"enrollment":1625,"conditions":63272,"interventions":63273},[],[3551,3552],[63213,63235,63236,63237],{"intervention":63237,"totalTrials":302,"cells":63275},{"EARLY_PHASE1":63276,"PHASE1":63278,"PHASE2":63280,"PHASE3":63282,"PHASE4":63284,"NA":63286},{"trials":63277,"activeCount":103},[],{"trials":63279,"activeCount":103},[],{"trials":63281,"activeCount":103},[],{"trials":63283,"activeCount":103},[],{"trials":63285,"activeCount":103},[],{"trials":63287,"activeCount":103},[63288],{"nctId":63228,"briefTitle":63229,"status":168,"phases":63289,"primaryCompletion":63231,"completion":63231,"start":63232,"enrollment":1625,"conditions":63290,"interventions":63291},[],[3551,3552],[63213,63235,63236,63237],{"intervention":63293,"totalTrials":302,"cells":63294},"desvenlafaxine succinate",{"EARLY_PHASE1":63295,"PHASE1":63297,"PHASE2":63299,"PHASE3":63301,"PHASE4":63303,"NA":63305},{"trials":63296,"activeCount":103},[],{"trials":63298,"activeCount":103},[],{"trials":63300,"activeCount":103},[],{"trials":63302,"activeCount":103},[],{"trials":63304,"activeCount":103},[],{"trials":63306,"activeCount":103},[63307],{"nctId":63308,"briefTitle":63309,"status":168,"phases":63310,"primaryCompletion":569,"completion":569,"start":2450,"enrollment":3254,"conditions":63311,"interventions":63312},"NCT01353963","Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients",[],[6321,12558],[63293],{"intervention":63314,"totalTrials":302,"cells":63315},"COMIRNATY intramuscular",{"EARLY_PHASE1":63316,"PHASE1":63318,"PHASE2":63320,"PHASE3":63322,"PHASE4":63324,"NA":63326},{"trials":63317,"activeCount":103},[],{"trials":63319,"activeCount":103},[],{"trials":63321,"activeCount":103},[],{"trials":63323,"activeCount":103},[],{"trials":63325,"activeCount":103},[],{"trials":63327,"activeCount":103},[63328],{"nctId":63329,"briefTitle":63330,"status":111,"phases":63331,"primaryCompletion":63332,"completion":63332,"start":63333,"enrollment":2713,"conditions":63334,"interventions":63335},"NCT06130410","Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years",[],"2024-07-26","2024-03-06",[10628,2592],[63314],{"intervention":63337,"totalTrials":302,"cells":63338},"Arginine",{"EARLY_PHASE1":63339,"PHASE1":63341,"PHASE2":63343,"PHASE3":63345,"PHASE4":63347,"NA":63349},{"trials":63340,"activeCount":103},[],{"trials":63342,"activeCount":103},[],{"trials":63344,"activeCount":103},[],{"trials":63346,"activeCount":103},[],{"trials":63348,"activeCount":103},[],{"trials":63350,"activeCount":103},[63351],{"nctId":63352,"briefTitle":63353,"status":168,"phases":63354,"completion":2641,"start":2671,"enrollment":350,"conditions":63355,"interventions":63356},"NCT00280085","The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.",[95],[6117],[63337],{"intervention":63358,"totalTrials":302,"cells":63359},"Prevenar 13",{"EARLY_PHASE1":63360,"PHASE1":63362,"PHASE2":63364,"PHASE3":63366,"PHASE4":63368,"NA":63370},{"trials":63361,"activeCount":103},[],{"trials":63363,"activeCount":103},[],{"trials":63365,"activeCount":103},[],{"trials":63367,"activeCount":103},[],{"trials":63369,"activeCount":103},[],{"trials":63371,"activeCount":103},[63372],{"nctId":63373,"briefTitle":63374,"status":111,"phases":63375,"primaryCompletion":652,"completion":652,"start":2883,"enrollment":63376,"conditions":63377,"interventions":63378},"NCT01396434","Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos",[],3006,[2526],[63358],{"intervention":63380,"totalTrials":302,"cells":63381},"No intervention",{"EARLY_PHASE1":63382,"PHASE1":63384,"PHASE2":63386,"PHASE3":63388,"PHASE4":63390,"NA":63392},{"trials":63383,"activeCount":103},[],{"trials":63385,"activeCount":103},[],{"trials":63387,"activeCount":103},[],{"trials":63389,"activeCount":103},[],{"trials":63391,"activeCount":103},[],{"trials":63393,"activeCount":103},[63394],{"nctId":63395,"briefTitle":63396,"status":111,"phases":63397,"primaryCompletion":3353,"completion":3353,"start":4645,"enrollment":63398,"conditions":63399,"interventions":63401},"NCT00759174","A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION",[],673,[63400],"Optic Neuropathy, Ischemic",[63380],{"intervention":63403,"totalTrials":302,"cells":63404},"Glipizide GITS",{"EARLY_PHASE1":63405,"PHASE1":63407,"PHASE2":63409,"PHASE3":63411,"PHASE4":63413,"NA":63415},{"trials":63406,"activeCount":103},[],{"trials":63408,"activeCount":103},[],{"trials":63410,"activeCount":103},[],{"trials":63412,"activeCount":103},[],{"trials":63414,"activeCount":103},[],{"trials":63416,"activeCount":103},[63417],{"nctId":63418,"briefTitle":63419,"status":111,"phases":63420,"completion":2964,"start":11609,"enrollment":4259,"conditions":63421,"interventions":63424},"NCT00550329","Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets",[],[63422,63423],"Diabetes Mellitus, Non-Insulin-Dependent","Hyperglycemia",[63403],{"intervention":1426,"totalTrials":302,"cells":63426},{"EARLY_PHASE1":63427,"PHASE1":63429,"PHASE2":63431,"PHASE3":63433,"PHASE4":63435,"NA":63437},{"trials":63428,"activeCount":103},[],{"trials":63430,"activeCount":103},[],{"trials":63432,"activeCount":103},[],{"trials":63434,"activeCount":103},[],{"trials":63436,"activeCount":103},[],{"trials":63438,"activeCount":103},[63439],{"nctId":1418,"briefTitle":1419,"status":111,"phases":63440,"primaryCompletion":1421,"completion":1421,"start":1422,"enrollment":1423,"conditions":63441,"interventions":63442},[],[31],[88,1426],{"intervention":425,"totalTrials":302,"cells":63444},{"EARLY_PHASE1":63445,"PHASE1":63447,"PHASE2":63449,"PHASE3":63451,"PHASE4":63453,"NA":63455},{"trials":63446,"activeCount":103},[],{"trials":63448,"activeCount":103},[],{"trials":63450,"activeCount":103},[],{"trials":63452,"activeCount":103},[],{"trials":63454,"activeCount":103},[],{"trials":63456,"activeCount":103},[63457],{"nctId":415,"briefTitle":416,"status":111,"phases":63458,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":63459,"interventions":63460},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":426,"totalTrials":302,"cells":63462},{"EARLY_PHASE1":63463,"PHASE1":63465,"PHASE2":63467,"PHASE3":63469,"PHASE4":63471,"NA":63473},{"trials":63464,"activeCount":103},[],{"trials":63466,"activeCount":103},[],{"trials":63468,"activeCount":103},[],{"trials":63470,"activeCount":103},[],{"trials":63472,"activeCount":103},[],{"trials":63474,"activeCount":103},[63475],{"nctId":415,"briefTitle":416,"status":111,"phases":63476,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":63477,"interventions":63478},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":435,"totalTrials":302,"cells":63480},{"EARLY_PHASE1":63481,"PHASE1":63483,"PHASE2":63485,"PHASE3":63487,"PHASE4":63489,"NA":63491},{"trials":63482,"activeCount":103},[],{"trials":63484,"activeCount":103},[],{"trials":63486,"activeCount":103},[],{"trials":63488,"activeCount":103},[],{"trials":63490,"activeCount":103},[],{"trials":63492,"activeCount":103},[63493],{"nctId":415,"briefTitle":416,"status":111,"phases":63494,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":63495,"interventions":63496},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":437,"totalTrials":302,"cells":63498},{"EARLY_PHASE1":63499,"PHASE1":63501,"PHASE2":63503,"PHASE3":63505,"PHASE4":63507,"NA":63509},{"trials":63500,"activeCount":103},[],{"trials":63502,"activeCount":103},[],{"trials":63504,"activeCount":103},[],{"trials":63506,"activeCount":103},[],{"trials":63508,"activeCount":103},[],{"trials":63510,"activeCount":103},[63511],{"nctId":415,"briefTitle":416,"status":111,"phases":63512,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":63513,"interventions":63514},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":440,"totalTrials":302,"cells":63516},{"EARLY_PHASE1":63517,"PHASE1":63519,"PHASE2":63521,"PHASE3":63523,"PHASE4":63525,"NA":63527},{"trials":63518,"activeCount":103},[],{"trials":63520,"activeCount":103},[],{"trials":63522,"activeCount":103},[],{"trials":63524,"activeCount":103},[],{"trials":63526,"activeCount":103},[],{"trials":63528,"activeCount":103},[63529],{"nctId":415,"briefTitle":416,"status":111,"phases":63530,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":63531,"interventions":63532},[],[422],[329,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440],{"intervention":58228,"totalTrials":302,"cells":63534},{"EARLY_PHASE1":63535,"PHASE1":63537,"PHASE2":63539,"PHASE3":63541,"PHASE4":63543,"NA":63545},{"trials":63536,"activeCount":103},[],{"trials":63538,"activeCount":103},[],{"trials":63540,"activeCount":103},[],{"trials":63542,"activeCount":103},[],{"trials":63544,"activeCount":103},[],{"trials":63546,"activeCount":103},[63547],{"nctId":58222,"briefTitle":58223,"status":168,"phases":63548,"primaryCompletion":10912,"completion":10912,"start":4222,"enrollment":58225,"conditions":63549,"interventions":63550},[],[11381],[3079,58228],{"intervention":61403,"totalTrials":302,"cells":63552},{"EARLY_PHASE1":63553,"PHASE1":63555,"PHASE2":63557,"PHASE3":63559,"PHASE4":63561,"NA":63563},{"trials":63554,"activeCount":103},[],{"trials":63556,"activeCount":103},[],{"trials":63558,"activeCount":103},[],{"trials":63560,"activeCount":103},[],{"trials":63562,"activeCount":103},[],{"trials":63564,"activeCount":103},[63565],{"nctId":61396,"briefTitle":61397,"status":111,"phases":63566,"primaryCompletion":561,"completion":561,"start":11988,"enrollment":61399,"conditions":63567,"interventions":63568},[],[12881,12882],[61402,61403,61404],{"intervention":61404,"totalTrials":302,"cells":63570},{"EARLY_PHASE1":63571,"PHASE1":63573,"PHASE2":63575,"PHASE3":63577,"PHASE4":63579,"NA":63581},{"trials":63572,"activeCount":103},[],{"trials":63574,"activeCount":103},[],{"trials":63576,"activeCount":103},[],{"trials":63578,"activeCount":103},[],{"trials":63580,"activeCount":103},[],{"trials":63582,"activeCount":103},[63583],{"nctId":61396,"briefTitle":61397,"status":111,"phases":63584,"primaryCompletion":561,"completion":561,"start":11988,"enrollment":61399,"conditions":63585,"interventions":63586},[],[12881,12882],[61402,61403,61404],{"intervention":2364,"totalTrials":302,"cells":63588},{"EARLY_PHASE1":63589,"PHASE1":63591,"PHASE2":63593,"PHASE3":63595,"PHASE4":63597,"NA":63599},{"trials":63590,"activeCount":103},[],{"trials":63592,"activeCount":103},[],{"trials":63594,"activeCount":103},[],{"trials":63596,"activeCount":103},[],{"trials":63598,"activeCount":103},[],{"trials":63600,"activeCount":103},[63601],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63602,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63603,"interventions":63604},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":2365,"totalTrials":302,"cells":63606},{"EARLY_PHASE1":63607,"PHASE1":63609,"PHASE2":63611,"PHASE3":63613,"PHASE4":63615,"NA":63617},{"trials":63608,"activeCount":103},[],{"trials":63610,"activeCount":103},[],{"trials":63612,"activeCount":103},[],{"trials":63614,"activeCount":103},[],{"trials":63616,"activeCount":103},[],{"trials":63618,"activeCount":103},[63619],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63620,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63621,"interventions":63622},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":2366,"totalTrials":302,"cells":63624},{"EARLY_PHASE1":63625,"PHASE1":63627,"PHASE2":63629,"PHASE3":63631,"PHASE4":63633,"NA":63635},{"trials":63626,"activeCount":103},[],{"trials":63628,"activeCount":103},[],{"trials":63630,"activeCount":103},[],{"trials":63632,"activeCount":103},[],{"trials":63634,"activeCount":103},[],{"trials":63636,"activeCount":103},[63637],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63638,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63639,"interventions":63640},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":2367,"totalTrials":302,"cells":63642},{"EARLY_PHASE1":63643,"PHASE1":63645,"PHASE2":63647,"PHASE3":63649,"PHASE4":63651,"NA":63653},{"trials":63644,"activeCount":103},[],{"trials":63646,"activeCount":103},[],{"trials":63648,"activeCount":103},[],{"trials":63650,"activeCount":103},[],{"trials":63652,"activeCount":103},[],{"trials":63654,"activeCount":103},[63655],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63656,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63657,"interventions":63658},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":2368,"totalTrials":302,"cells":63660},{"EARLY_PHASE1":63661,"PHASE1":63663,"PHASE2":63665,"PHASE3":63667,"PHASE4":63669,"NA":63671},{"trials":63662,"activeCount":103},[],{"trials":63664,"activeCount":103},[],{"trials":63666,"activeCount":103},[],{"trials":63668,"activeCount":103},[],{"trials":63670,"activeCount":103},[],{"trials":63672,"activeCount":103},[63673],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63674,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63675,"interventions":63676},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":2369,"totalTrials":302,"cells":63678},{"EARLY_PHASE1":63679,"PHASE1":63681,"PHASE2":63683,"PHASE3":63685,"PHASE4":63687,"NA":63689},{"trials":63680,"activeCount":103},[],{"trials":63682,"activeCount":103},[],{"trials":63684,"activeCount":103},[],{"trials":63686,"activeCount":103},[],{"trials":63688,"activeCount":103},[],{"trials":63690,"activeCount":103},[63691],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63692,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63693,"interventions":63694},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":2370,"totalTrials":302,"cells":63696},{"EARLY_PHASE1":63697,"PHASE1":63699,"PHASE2":63701,"PHASE3":63703,"PHASE4":63705,"NA":63707},{"trials":63698,"activeCount":103},[],{"trials":63700,"activeCount":103},[],{"trials":63702,"activeCount":103},[],{"trials":63704,"activeCount":103},[],{"trials":63706,"activeCount":103},[],{"trials":63708,"activeCount":103},[63709],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63710,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63711,"interventions":63712},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":2371,"totalTrials":302,"cells":63714},{"EARLY_PHASE1":63715,"PHASE1":63717,"PHASE2":63719,"PHASE3":63721,"PHASE4":63723,"NA":63725},{"trials":63716,"activeCount":103},[],{"trials":63718,"activeCount":103},[],{"trials":63720,"activeCount":103},[],{"trials":63722,"activeCount":103},[],{"trials":63724,"activeCount":103},[],{"trials":63726,"activeCount":103},[63727],{"nctId":2355,"briefTitle":2356,"status":111,"phases":63728,"primaryCompletion":2358,"completion":2358,"start":2359,"enrollment":2360,"conditions":63729,"interventions":63730},[],[2325,2192],[2363,1641,432,2364,2365,2366,2367,2368,2369,2370,2371],{"intervention":59304,"totalTrials":302,"cells":63732},{"EARLY_PHASE1":63733,"PHASE1":63735,"PHASE2":63737,"PHASE3":63739,"PHASE4":63741,"NA":63743},{"trials":63734,"activeCount":103},[],{"trials":63736,"activeCount":103},[],{"trials":63738,"activeCount":103},[],{"trials":63740,"activeCount":103},[],{"trials":63742,"activeCount":103},[],{"trials":63744,"activeCount":103},[63745],{"nctId":59298,"briefTitle":59299,"status":111,"phases":63746,"conditions":63747,"interventions":63748},[95],[59302,10974],[59304,59219],{"intervention":63750,"totalTrials":302,"cells":63751},"Oxbryta® (voxelotor) 500-mg",{"EARLY_PHASE1":63752,"PHASE1":63754,"PHASE2":63756,"PHASE3":63758,"PHASE4":63760,"NA":63762},{"trials":63753,"activeCount":103},[],{"trials":63755,"activeCount":103},[],{"trials":63757,"activeCount":103},[],{"trials":63759,"activeCount":103},[],{"trials":63761,"activeCount":103},[],{"trials":63763,"activeCount":103},[63764],{"nctId":63765,"briefTitle":63766,"status":111,"phases":63767,"primaryCompletion":63768,"completion":63768,"start":9905,"enrollment":63769,"conditions":63770,"interventions":63771},"NCT04930328","Retrospective Real World Oxbryta® Data Collection and Analysis Study",[],"2022-02-25",216,[4181],[63750],{"intervention":63773,"totalTrials":302,"cells":63774},"Olmesartan medoxomil",{"EARLY_PHASE1":63775,"PHASE1":63777,"PHASE2":63779,"PHASE3":63781,"PHASE4":63783,"NA":63785},{"trials":63776,"activeCount":103},[],{"trials":63778,"activeCount":103},[],{"trials":63780,"activeCount":103},[],{"trials":63782,"activeCount":103},[],{"trials":63784,"activeCount":103},[],{"trials":63786,"activeCount":103},[63787],{"nctId":63788,"briefTitle":63789,"status":111,"phases":63790,"primaryCompletion":8154,"completion":8154,"start":2641,"enrollment":63791,"conditions":63792,"interventions":63793},"NCT00796159","Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide",[],1723,[13280],[63773],{"intervention":63795,"totalTrials":302,"cells":63796},"Meloxicam",{"EARLY_PHASE1":63797,"PHASE1":63799,"PHASE2":63801,"PHASE3":63803,"PHASE4":63805,"NA":63807},{"trials":63798,"activeCount":103},[],{"trials":63800,"activeCount":103},[],{"trials":63802,"activeCount":103},[],{"trials":63804,"activeCount":103},[],{"trials":63806,"activeCount":103},[],{"trials":63808,"activeCount":103},[63809],{"nctId":63810,"briefTitle":63811,"status":111,"phases":63812,"primaryCompletion":63092,"completion":63092,"start":63813,"enrollment":16727,"conditions":63814,"interventions":63815},"NCT01430559","Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee",[95],"2011-10-24",[28274],[63795],{"intervention":63817,"totalTrials":302,"cells":63818},"Ibrance",{"EARLY_PHASE1":63819,"PHASE1":63821,"PHASE2":63823,"PHASE3":63825,"PHASE4":63827,"NA":63829},{"trials":63820,"activeCount":103},[],{"trials":63822,"activeCount":103},[],{"trials":63824,"activeCount":103},[],{"trials":63826,"activeCount":103},[],{"trials":63828,"activeCount":103},[],{"trials":63830,"activeCount":103},[63831],{"nctId":63832,"briefTitle":63833,"status":111,"phases":63834,"primaryCompletion":28589,"completion":28589,"start":6720,"enrollment":302,"conditions":63835,"interventions":63836},"NCT06962969","A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database",[],[1670],[63817],{"intervention":63838,"totalTrials":302,"cells":63839},"Antibody Drug Conjugate Chemotherapeutic",{"EARLY_PHASE1":63840,"PHASE1":63842,"PHASE2":63844,"PHASE3":63846,"PHASE4":63848,"NA":63850},{"trials":63841,"activeCount":103},[],{"trials":63843,"activeCount":103},[],{"trials":63845,"activeCount":103},[],{"trials":63847,"activeCount":103},[],{"trials":63849,"activeCount":103},[],{"trials":63851,"activeCount":103},[63852],{"nctId":63853,"briefTitle":63854,"status":308,"phases":63855,"conditions":63856,"interventions":63858},"NCT02312037","Expanded Access \u002FCompassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy",[],[63857],"CD33 Positive Acute Myelogenous Leukemia",[63838],{"intervention":63860,"totalTrials":302,"cells":63861},"Nivestim®",{"EARLY_PHASE1":63862,"PHASE1":63864,"PHASE2":63866,"PHASE3":63868,"PHASE4":63870,"NA":63872},{"trials":63863,"activeCount":103},[],{"trials":63865,"activeCount":103},[],{"trials":63867,"activeCount":103},[],{"trials":63869,"activeCount":103},[],{"trials":63871,"activeCount":103},[],{"trials":63873,"activeCount":103},[63874],{"nctId":63875,"briefTitle":63876,"status":168,"phases":63877,"primaryCompletion":63878,"completion":29213,"start":9572,"enrollment":63879,"conditions":63880,"interventions":63882},"NCT02454530","Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study",[],"2016-10-18",1160,[63881],"Chemotherapy-Induced Neutropenia",[63860],{"intervention":9622,"totalTrials":302,"cells":63884},{"EARLY_PHASE1":63885,"PHASE1":63887,"PHASE2":63889,"PHASE3":63891,"PHASE4":63893,"NA":63895},{"trials":63886,"activeCount":103},[],{"trials":63888,"activeCount":103},[],{"trials":63890,"activeCount":103},[],{"trials":63892,"activeCount":103},[],{"trials":63894,"activeCount":103},[],{"trials":63896,"activeCount":103},[63897],{"nctId":9614,"briefTitle":9615,"status":111,"phases":63898,"primaryCompletion":9617,"completion":9617,"start":222,"enrollment":9618,"conditions":63899,"interventions":63900},[],[9555],[9534,9600,9599,9621,9622],{"intervention":63902,"totalTrials":302,"cells":63903},"Treatment for TTR amyloidosis",{"EARLY_PHASE1":63904,"PHASE1":63906,"PHASE2":63908,"PHASE3":63910,"PHASE4":63912,"NA":63914},{"trials":63905,"activeCount":103},[],{"trials":63907,"activeCount":103},[],{"trials":63909,"activeCount":103},[],{"trials":63911,"activeCount":103},[],{"trials":63913,"activeCount":103},[],{"trials":63915,"activeCount":103},[63916],{"nctId":63917,"briefTitle":63918,"status":111,"phases":63919,"primaryCompletion":63920,"completion":63920,"start":54748,"enrollment":63921,"conditions":63922,"interventions":63923},"NCT04108091","Vyndaqel Capsules Special Investigation (ATTR-CM)",[],"2025-03-27",1214,[8024],[63902,63902],{"intervention":63925,"totalTrials":302,"cells":63926},"Somavert",{"EARLY_PHASE1":63927,"PHASE1":63929,"PHASE2":63931,"PHASE3":63933,"PHASE4":63935,"NA":63937},{"trials":63928,"activeCount":103},[],{"trials":63930,"activeCount":103},[],{"trials":63932,"activeCount":103},[],{"trials":63934,"activeCount":103},[],{"trials":63936,"activeCount":103},[],{"trials":63938,"activeCount":103},[63939],{"nctId":63940,"briefTitle":63941,"status":111,"phases":63942,"primaryCompletion":17538,"completion":17538,"start":63943,"enrollment":63944,"conditions":63945,"interventions":63946},"NCT00658879","Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan",[],"2007-08-07",251,[12599],[63925],{"intervention":63948,"totalTrials":302,"cells":63949},"Viviant",{"EARLY_PHASE1":63950,"PHASE1":63952,"PHASE2":63954,"PHASE3":63956,"PHASE4":63958,"NA":63960},{"trials":63951,"activeCount":103},[],{"trials":63953,"activeCount":103},[],{"trials":63955,"activeCount":103},[],{"trials":63957,"activeCount":103},[],{"trials":63959,"activeCount":103},[],{"trials":63961,"activeCount":103},[63962],{"nctId":63963,"briefTitle":63964,"status":111,"phases":63965,"primaryCompletion":63966,"completion":63966,"start":63967,"enrollment":63968,"conditions":63969,"interventions":63970},"NCT01793142","Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice",[],"2017-05-31","2013-10-24",3430,[23074],[63948],{"intervention":63972,"totalTrials":302,"cells":63973},"Study Drug",{"EARLY_PHASE1":63974,"PHASE1":63976,"PHASE2":63978,"PHASE3":63980,"PHASE4":63982,"NA":63984},{"trials":63975,"activeCount":103},[],{"trials":63977,"activeCount":103},[],{"trials":63979,"activeCount":103},[],{"trials":63981,"activeCount":103},[],{"trials":63983,"activeCount":103},[],{"trials":63985,"activeCount":103},[63986],{"nctId":63987,"briefTitle":63988,"status":111,"phases":63989,"primaryCompletion":18128,"completion":18128,"start":8252,"enrollment":63990,"conditions":63991,"interventions":63993},"NCT01270711","Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)",[],22014,[27985,63992],"Hyperprolactinemia",[63972],{"intervention":63995,"totalTrials":302,"cells":63996},"Xyntha : coagulation factor IIIV",{"EARLY_PHASE1":63997,"PHASE1":63999,"PHASE2":64001,"PHASE3":64003,"PHASE4":64005,"NA":64007},{"trials":63998,"activeCount":103},[],{"trials":64000,"activeCount":103},[],{"trials":64002,"activeCount":103},[],{"trials":64004,"activeCount":103},[],{"trials":64006,"activeCount":103},[],{"trials":64008,"activeCount":103},[64009],{"nctId":64010,"briefTitle":64011,"status":111,"phases":64012,"primaryCompletion":7386,"completion":7386,"start":3324,"enrollment":1578,"conditions":64013,"interventions":64014},"NCT01790828","Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A",[],[3551],[63995],{"intervention":64016,"totalTrials":302,"cells":64017},"Vyndaqel",{"EARLY_PHASE1":64018,"PHASE1":64020,"PHASE2":64022,"PHASE3":64024,"PHASE4":64026,"NA":64028},{"trials":64019,"activeCount":103},[],{"trials":64021,"activeCount":103},[],{"trials":64023,"activeCount":103},[],{"trials":64025,"activeCount":103},[],{"trials":64027,"activeCount":103},[],{"trials":64029,"activeCount":103},[64030],{"nctId":64031,"briefTitle":64032,"status":111,"phases":64033,"primaryCompletion":9664,"completion":9664,"start":28318,"enrollment":1893,"conditions":64034,"interventions":64035},"NCT02146378","Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)",[],[8031],[64016],{"intervention":64037,"totalTrials":302,"cells":64038},"Antibacterial agent for the treatment of febrile neutropenia",{"EARLY_PHASE1":64039,"PHASE1":64041,"PHASE2":64043,"PHASE3":64045,"PHASE4":64047,"NA":64049},{"trials":64040,"activeCount":103},[],{"trials":64042,"activeCount":103},[],{"trials":64044,"activeCount":103},[],{"trials":64046,"activeCount":103},[],{"trials":64048,"activeCount":103},[],{"trials":64050,"activeCount":103},[64051],{"nctId":64052,"briefTitle":64053,"status":111,"phases":64054,"primaryCompletion":585,"completion":585,"start":4646,"enrollment":58279,"conditions":64055,"interventions":64056},"NCT00945555","Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options",[],[60510],[64037],{"intervention":64058,"totalTrials":302,"cells":64059},"Toviaz treatment",{"EARLY_PHASE1":64060,"PHASE1":64062,"PHASE2":64064,"PHASE3":64066,"PHASE4":64068,"NA":64070},{"trials":64061,"activeCount":103},[],{"trials":64063,"activeCount":103},[],{"trials":64065,"activeCount":103},[],{"trials":64067,"activeCount":103},[],{"trials":64069,"activeCount":103},[],{"trials":64071,"activeCount":103},[64072],{"nctId":64073,"briefTitle":64074,"status":111,"phases":64075,"primaryCompletion":7386,"completion":7386,"start":6016,"enrollment":10395,"conditions":64076,"interventions":64077},"NCT00879398","Toviaz Post Marketing Surveillance Study",[],[12489],[64058],{"intervention":64079,"totalTrials":302,"cells":64080},"venlafaxine",{"EARLY_PHASE1":64081,"PHASE1":64083,"PHASE2":64085,"PHASE3":64087,"PHASE4":64089,"NA":64091},{"trials":64082,"activeCount":103},[],{"trials":64084,"activeCount":103},[],{"trials":64086,"activeCount":103},[],{"trials":64088,"activeCount":103},[],{"trials":64090,"activeCount":103},[],{"trials":64092,"activeCount":103},[64093],{"nctId":64094,"briefTitle":64095,"status":111,"phases":64096,"primaryCompletion":64097,"completion":64097,"start":64098,"enrollment":64099,"conditions":64100,"interventions":64102},"NCT02958527","Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)",[],"2020-05-11","2016-10-03",1408,[64101],"Depression\u002FDepressed State",[64079],{"intervention":64104,"totalTrials":302,"cells":64105},"PCV13 PAC study",{"EARLY_PHASE1":64106,"PHASE1":64108,"PHASE2":64110,"PHASE3":64112,"PHASE4":64114,"NA":64116},{"trials":64107,"activeCount":103},[],{"trials":64109,"activeCount":103},[],{"trials":64111,"activeCount":103},[],{"trials":64113,"activeCount":103},[],{"trials":64115,"activeCount":103},[],{"trials":64117,"activeCount":103},[64118],{"nctId":64119,"briefTitle":64120,"status":111,"phases":64121,"primaryCompletion":64122,"completion":64122,"start":64123,"enrollment":1613,"conditions":64124,"interventions":64126},"NCT05372575","A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS",[95],"2021-12-14","2019-08-15",[64125],"Immunogenicity, Vaccine",[64104],{"intervention":64128,"totalTrials":302,"cells":64129},"voriconazole IV",{"EARLY_PHASE1":64130,"PHASE1":64132,"PHASE2":64134,"PHASE3":64136,"PHASE4":64138,"NA":64140},{"trials":64131,"activeCount":103},[],{"trials":64133,"activeCount":103},[],{"trials":64135,"activeCount":103},[],{"trials":64137,"activeCount":103},[],{"trials":64139,"activeCount":103},[],{"trials":64141,"activeCount":103},[64142],{"nctId":64143,"briefTitle":64144,"status":111,"phases":64145,"primaryCompletion":4846,"completion":4846,"start":6457,"enrollment":758,"conditions":64146,"interventions":64147},"NCT01073618","Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV",[],[59758],[64128],{"intervention":64149,"totalTrials":302,"cells":64150},"Amlodipine + Olmesartan medoxomil",{"EARLY_PHASE1":64151,"PHASE1":64153,"PHASE2":64155,"PHASE3":64157,"PHASE4":64159,"NA":64161},{"trials":64152,"activeCount":103},[],{"trials":64154,"activeCount":103},[],{"trials":64156,"activeCount":103},[],{"trials":64158,"activeCount":103},[],{"trials":64160,"activeCount":103},[],{"trials":64162,"activeCount":103},[64163],{"nctId":64164,"briefTitle":64165,"status":168,"phases":64166,"primaryCompletion":64167,"completion":64167,"start":64168,"enrollment":11766,"conditions":64169,"interventions":64170},"NCT01200407","Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients",[],"2014-01-04","2010-06-09",[13280],[64149],{"intervention":64172,"totalTrials":302,"cells":64173},"axitinib: observational study",{"EARLY_PHASE1":64174,"PHASE1":64176,"PHASE2":64178,"PHASE3":64180,"PHASE4":64182,"NA":64184},{"trials":64175,"activeCount":103},[],{"trials":64177,"activeCount":103},[],{"trials":64179,"activeCount":103},[],{"trials":64181,"activeCount":103},[],{"trials":64183,"activeCount":103},[],{"trials":64185,"activeCount":103},[64186],{"nctId":64187,"briefTitle":64188,"status":111,"phases":64189,"primaryCompletion":4656,"completion":4656,"start":4206,"enrollment":748,"conditions":64190,"interventions":64191},"NCT01056263","Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012",[],[919],[64172],{"intervention":64193,"totalTrials":302,"cells":64194},"Zirabev",{"EARLY_PHASE1":64195,"PHASE1":64197,"PHASE2":64199,"PHASE3":64201,"PHASE4":64203,"NA":64205},{"trials":64196,"activeCount":103},[],{"trials":64198,"activeCount":103},[],{"trials":64200,"activeCount":103},[],{"trials":64202,"activeCount":103},[],{"trials":64204,"activeCount":103},[],{"trials":64206,"activeCount":103},[64207],{"nctId":64208,"briefTitle":64209,"status":649,"phases":64210,"primaryCompletion":64211,"completion":64211,"start":8363,"enrollment":103,"conditions":64212,"interventions":64216},"NCT04889495","A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer",[],"2025-08-16",[727,1810,1369,64213,64214,8478,8477,64215],"Metastatic Kidney Cancer","Cervical Cancer","Primary Peritoneal Cancer",[64193],{"intervention":64218,"totalTrials":302,"cells":64219},"Oxbryta® (voxelotor) 500mg",{"EARLY_PHASE1":64220,"PHASE1":64222,"PHASE2":64224,"PHASE3":64226,"PHASE4":64228,"NA":64230},{"trials":64221,"activeCount":103},[],{"trials":64223,"activeCount":103},[],{"trials":64225,"activeCount":103},[],{"trials":64227,"activeCount":103},[],{"trials":64229,"activeCount":103},[],{"trials":64231,"activeCount":103},[64232],{"nctId":64233,"briefTitle":64234,"status":168,"phases":64235,"primaryCompletion":64236,"completion":64236,"start":10158,"enrollment":11396,"conditions":64237,"interventions":64238},"NCT04930445","Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD",[],"2024-10-10",[4181],[64218],{"intervention":64240,"totalTrials":302,"cells":64241},"Vaccination",{"EARLY_PHASE1":64242,"PHASE1":64244,"PHASE2":64246,"PHASE3":64248,"PHASE4":64250,"NA":64252},{"trials":64243,"activeCount":103},[],{"trials":64245,"activeCount":103},[],{"trials":64247,"activeCount":103},[],{"trials":64249,"activeCount":103},[],{"trials":64251,"activeCount":103},[],{"trials":64253,"activeCount":103},[64254],{"nctId":64255,"briefTitle":64256,"status":111,"phases":64257,"primaryCompletion":3386,"completion":3386,"start":8528,"enrollment":64258,"conditions":64259,"interventions":64260},"NCT06199934","Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data",[],19853610,[10628,9875],[64240],{"intervention":64262,"totalTrials":302,"cells":64263},"Rescriptor",{"EARLY_PHASE1":64264,"PHASE1":64266,"PHASE2":64268,"PHASE3":64270,"PHASE4":64272,"NA":64274},{"trials":64265,"activeCount":103},[],{"trials":64267,"activeCount":103},[],{"trials":64269,"activeCount":103},[],{"trials":64271,"activeCount":103},[],{"trials":64273,"activeCount":103},[],{"trials":64275,"activeCount":103},[64276],{"nctId":64277,"briefTitle":64278,"status":111,"phases":64279,"primaryCompletion":11290,"completion":11290,"start":2672,"enrollment":502,"conditions":64280,"interventions":64281},"NCT00823966","Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients",[],[57391],[64262],{"intervention":64283,"totalTrials":302,"cells":64284},"Doxazosin mesylate GITS",{"EARLY_PHASE1":64285,"PHASE1":64287,"PHASE2":64289,"PHASE3":64291,"PHASE4":64293,"NA":64295},{"trials":64286,"activeCount":103},[],{"trials":64288,"activeCount":103},[],{"trials":64290,"activeCount":103},[],{"trials":64292,"activeCount":103},[],{"trials":64294,"activeCount":103},[],{"trials":64296,"activeCount":103},[64297],{"nctId":64298,"briefTitle":64299,"status":111,"phases":64300,"primaryCompletion":3601,"completion":3601,"start":11014,"enrollment":64301,"conditions":64302,"interventions":64303},"NCT01003886","A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)",[],989,[30668],[64283],{"intervention":60030,"totalTrials":302,"cells":64305},{"EARLY_PHASE1":64306,"PHASE1":64308,"PHASE2":64310,"PHASE3":64312,"PHASE4":64314,"NA":64316},{"trials":64307,"activeCount":103},[],{"trials":64309,"activeCount":103},[],{"trials":64311,"activeCount":103},[],{"trials":64313,"activeCount":103},[],{"trials":64315,"activeCount":103},[],{"trials":64317,"activeCount":103},[64318],{"nctId":60021,"briefTitle":60022,"status":111,"phases":64319,"primaryCompletion":4367,"completion":4367,"start":60024,"enrollment":60025,"conditions":64320,"interventions":64321},[],[60027],[2435,60029,60030,60031,60032],{"intervention":60031,"totalTrials":302,"cells":64323},{"EARLY_PHASE1":64324,"PHASE1":64326,"PHASE2":64328,"PHASE3":64330,"PHASE4":64332,"NA":64334},{"trials":64325,"activeCount":103},[],{"trials":64327,"activeCount":103},[],{"trials":64329,"activeCount":103},[],{"trials":64331,"activeCount":103},[],{"trials":64333,"activeCount":103},[],{"trials":64335,"activeCount":103},[64336],{"nctId":60021,"briefTitle":60022,"status":111,"phases":64337,"primaryCompletion":4367,"completion":4367,"start":60024,"enrollment":60025,"conditions":64338,"interventions":64339},[],[60027],[2435,60029,60030,60031,60032],{"intervention":60032,"totalTrials":302,"cells":64341},{"EARLY_PHASE1":64342,"PHASE1":64344,"PHASE2":64346,"PHASE3":64348,"PHASE4":64350,"NA":64352},{"trials":64343,"activeCount":103},[],{"trials":64345,"activeCount":103},[],{"trials":64347,"activeCount":103},[],{"trials":64349,"activeCount":103},[],{"trials":64351,"activeCount":103},[],{"trials":64353,"activeCount":103},[64354],{"nctId":60021,"briefTitle":60022,"status":111,"phases":64355,"primaryCompletion":4367,"completion":4367,"start":60024,"enrollment":60025,"conditions":64356,"interventions":64357},[],[60027],[2435,60029,60030,60031,60032],{"intervention":58781,"totalTrials":302,"cells":64359},{"EARLY_PHASE1":64360,"PHASE1":64362,"PHASE2":64364,"PHASE3":64366,"PHASE4":64368,"NA":64370},{"trials":64361,"activeCount":103},[],{"trials":64363,"activeCount":103},[],{"trials":64365,"activeCount":103},[],{"trials":64367,"activeCount":103},[],{"trials":64369,"activeCount":103},[],{"trials":64371,"activeCount":103},[64372],{"nctId":58775,"briefTitle":58776,"status":111,"phases":64373,"primaryCompletion":569,"completion":569,"start":18026,"enrollment":58778,"conditions":64374,"interventions":64375},[],[22],[4517,58781],{"intervention":64377,"totalTrials":302,"cells":64378},"Access program - sildenafil citrate, Viagra, Revatio",{"EARLY_PHASE1":64379,"PHASE1":64381,"PHASE2":64383,"PHASE3":64385,"PHASE4":64387,"NA":64389},{"trials":64380,"activeCount":103},[],{"trials":64382,"activeCount":103},[],{"trials":64384,"activeCount":103},[],{"trials":64386,"activeCount":103},[],{"trials":64388,"activeCount":103},[],{"trials":64390,"activeCount":103},[64391],{"nctId":64392,"briefTitle":64393,"status":308,"phases":64394,"conditions":64395,"interventions":64396},"NCT01582438","An Open Label Access Study For Subjects Who Completed A1481156",[],[4942],[64377],{"intervention":10004,"totalTrials":302,"cells":64398},{"EARLY_PHASE1":64399,"PHASE1":64401,"PHASE2":64403,"PHASE3":64405,"PHASE4":64407,"NA":64409},{"trials":64400,"activeCount":103},[],{"trials":64402,"activeCount":103},[],{"trials":64404,"activeCount":103},[],{"trials":64406,"activeCount":103},[],{"trials":64408,"activeCount":103},[],{"trials":64410,"activeCount":103},[64411],{"nctId":9997,"briefTitle":9998,"status":111,"phases":64412,"primaryCompletion":10000,"completion":10000,"start":10000,"enrollment":10001,"conditions":64413,"interventions":64414},[],[1369],[10004,1460],{"intervention":64416,"totalTrials":302,"cells":64417},"Fragmin®",{"EARLY_PHASE1":64418,"PHASE1":64420,"PHASE2":64422,"PHASE3":64424,"PHASE4":64426,"NA":64428},{"trials":64419,"activeCount":103},[],{"trials":64421,"activeCount":103},[],{"trials":64423,"activeCount":103},[],{"trials":64425,"activeCount":103},[],{"trials":64427,"activeCount":103},[],{"trials":64429,"activeCount":103},[64430],{"nctId":64431,"briefTitle":64432,"status":111,"phases":64433,"primaryCompletion":4666,"completion":4666,"start":3642,"enrollment":64434,"conditions":64435,"interventions":64436},"NCT01046903","An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®",[],503,[9667],[64416],{"intervention":64438,"totalTrials":302,"cells":64439},"nirmatrelvir \u002F ritonavir",{"EARLY_PHASE1":64440,"PHASE1":64442,"PHASE2":64444,"PHASE3":64446,"PHASE4":64448,"NA":64450},{"trials":64441,"activeCount":103},[],{"trials":64443,"activeCount":103},[],{"trials":64445,"activeCount":103},[],{"trials":64447,"activeCount":103},[],{"trials":64449,"activeCount":103},[],{"trials":64451,"activeCount":103},[64452],{"nctId":64453,"briefTitle":64454,"status":111,"phases":64455,"primaryCompletion":7472,"completion":7472,"start":28465,"enrollment":64456,"conditions":64457,"interventions":64458},"NCT05263908","A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19",[],3346,[2593],[64438],{"intervention":62265,"totalTrials":302,"cells":64460},{"EARLY_PHASE1":64461,"PHASE1":64463,"PHASE2":64465,"PHASE3":64467,"PHASE4":64469,"NA":64471},{"trials":64462,"activeCount":103},[],{"trials":64464,"activeCount":103},[],{"trials":64466,"activeCount":103},[],{"trials":64468,"activeCount":103},[],{"trials":64470,"activeCount":103},[],{"trials":64472,"activeCount":103},[64473],{"nctId":62258,"briefTitle":62259,"status":111,"phases":64474,"primaryCompletion":3253,"completion":3253,"start":54609,"enrollment":62261,"conditions":64475,"interventions":64476},[],[62263],[62232,62265,62266],{"intervention":62266,"totalTrials":302,"cells":64478},{"EARLY_PHASE1":64479,"PHASE1":64481,"PHASE2":64483,"PHASE3":64485,"PHASE4":64487,"NA":64489},{"trials":64480,"activeCount":103},[],{"trials":64482,"activeCount":103},[],{"trials":64484,"activeCount":103},[],{"trials":64486,"activeCount":103},[],{"trials":64488,"activeCount":103},[],{"trials":64490,"activeCount":103},[64491],{"nctId":62258,"briefTitle":62259,"status":111,"phases":64492,"primaryCompletion":3253,"completion":3253,"start":54609,"enrollment":62261,"conditions":64493,"interventions":64494},[],[62263],[62232,62265,62266],{"intervention":64496,"totalTrials":302,"cells":64497},"Xalatan 0.005% eye drops",{"EARLY_PHASE1":64498,"PHASE1":64500,"PHASE2":64502,"PHASE3":64504,"PHASE4":64506,"NA":64508},{"trials":64499,"activeCount":103},[],{"trials":64501,"activeCount":103},[],{"trials":64503,"activeCount":103},[],{"trials":64505,"activeCount":103},[],{"trials":64507,"activeCount":103},[],{"trials":64509,"activeCount":103},[64510],{"nctId":64511,"briefTitle":64512,"status":111,"phases":64513,"primaryCompletion":4636,"completion":4636,"start":11417,"enrollment":64514,"conditions":64515,"interventions":64516},"NCT00950690","Efficacy and Tolerability of Xalatan in Patients",[],1289,[12881,12882],[64496],{"intervention":64518,"totalTrials":302,"cells":64519},"CP-75385-02 Cefoperazone\u002Fsulbactam",{"EARLY_PHASE1":64520,"PHASE1":64522,"PHASE2":64524,"PHASE3":64526,"PHASE4":64528,"NA":64530},{"trials":64521,"activeCount":103},[],{"trials":64523,"activeCount":103},[],{"trials":64525,"activeCount":103},[],{"trials":64527,"activeCount":103},[],{"trials":64529,"activeCount":103},[],{"trials":64531,"activeCount":103},[64532],{"nctId":64533,"briefTitle":64534,"status":649,"phases":64535,"start":3610,"enrollment":103,"conditions":64536,"interventions":64542},"NCT00463762","Cefoperazone\u002FSulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.",[],[64537,64538,64539,64540,64541],"Abscess, Intra-Abdominal","Cholecystitis","Wound Infections","Peritonitis","Appendicitis",[64518],{"intervention":64544,"totalTrials":302,"cells":64545},"Palbociclib in combination with AI",{"EARLY_PHASE1":64546,"PHASE1":64548,"PHASE2":64550,"PHASE3":64552,"PHASE4":64554,"NA":64556},{"trials":64547,"activeCount":103},[],{"trials":64549,"activeCount":103},[],{"trials":64551,"activeCount":103},[],{"trials":64553,"activeCount":103},[],{"trials":64555,"activeCount":103},[],{"trials":64557,"activeCount":103},[64558],{"nctId":64559,"briefTitle":64560,"status":111,"phases":64561,"primaryCompletion":64562,"completion":64562,"start":63333,"enrollment":20263,"conditions":64563,"interventions":64564},"NCT06307457","A Study of HR+\u002FHER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.",[],"2024-04-19",[31],[64544],{"intervention":64566,"totalTrials":302,"cells":64567},"dacomitinib hydrate",{"EARLY_PHASE1":64568,"PHASE1":64570,"PHASE2":64572,"PHASE3":64574,"PHASE4":64576,"NA":64578},{"trials":64569,"activeCount":103},[],{"trials":64571,"activeCount":103},[],{"trials":64573,"activeCount":103},[],{"trials":64575,"activeCount":103},[],{"trials":64577,"activeCount":103},[],{"trials":64579,"activeCount":103},[64580],{"nctId":64581,"briefTitle":64582,"status":111,"phases":64583,"primaryCompletion":64584,"completion":64584,"start":64585,"enrollment":35,"conditions":64586,"interventions":64588},"NCT04155541","Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)",[],"2025-04-25","2020-01-24",[64587],"EGFR Mutation-positive Inoperable or Reccrent NSCLC",[64566],{"intervention":64590,"totalTrials":302,"cells":64591},"Trumenba Vaccine",{"EARLY_PHASE1":64592,"PHASE1":64594,"PHASE2":64596,"PHASE3":64598,"PHASE4":64600,"NA":64602},{"trials":64593,"activeCount":103},[],{"trials":64595,"activeCount":103},[],{"trials":64597,"activeCount":103},[],{"trials":64599,"activeCount":103},[],{"trials":64601,"activeCount":103},[],{"trials":64603,"activeCount":103},[64604],{"nctId":64605,"briefTitle":64606,"status":111,"phases":64607,"primaryCompletion":64608,"completion":64608,"start":2077,"enrollment":64609,"conditions":64610,"interventions":64613},"NCT05873751","A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.",[],"2024-03-31",1307378,[64611,64612,18140],"Gonorrhea","Chlamydia",[64590,64614],"MenACWY Vaccine",{"intervention":64614,"totalTrials":302,"cells":64616},{"EARLY_PHASE1":64617,"PHASE1":64619,"PHASE2":64621,"PHASE3":64623,"PHASE4":64625,"NA":64627},{"trials":64618,"activeCount":103},[],{"trials":64620,"activeCount":103},[],{"trials":64622,"activeCount":103},[],{"trials":64624,"activeCount":103},[],{"trials":64626,"activeCount":103},[],{"trials":64628,"activeCount":103},[64629],{"nctId":64605,"briefTitle":64606,"status":111,"phases":64630,"primaryCompletion":64608,"completion":64608,"start":2077,"enrollment":64609,"conditions":64631,"interventions":64632},[],[64611,64612,18140],[64590,64614],{"intervention":64634,"totalTrials":302,"cells":64635},"sildenafil (Revatio) 20 mg TID",{"EARLY_PHASE1":64636,"PHASE1":64638,"PHASE2":64640,"PHASE3":64642,"PHASE4":64644,"NA":64646},{"trials":64637,"activeCount":103},[],{"trials":64639,"activeCount":103},[],{"trials":64641,"activeCount":103},[],{"trials":64643,"activeCount":103},[],{"trials":64645,"activeCount":103},[],{"trials":64647,"activeCount":103},[64648],{"nctId":64649,"briefTitle":64650,"status":308,"phases":64651,"conditions":64652,"interventions":64653},"NCT00866983","Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil",[],[4942],[64634],{"intervention":64655,"totalTrials":302,"cells":64656},"13-valent pneumococcal vaccine",{"EARLY_PHASE1":64657,"PHASE1":64659,"PHASE2":64661,"PHASE3":64663,"PHASE4":64665,"NA":64667},{"trials":64658,"activeCount":103},[],{"trials":64660,"activeCount":103},[],{"trials":64662,"activeCount":103},[],{"trials":64664,"activeCount":103},[],{"trials":64666,"activeCount":103},[],{"trials":64668,"activeCount":103},[64669],{"nctId":64670,"briefTitle":64671,"status":111,"phases":64672,"primaryCompletion":7387,"completion":7387,"start":9544,"enrollment":17766,"conditions":64673,"interventions":64674},"NCT01509105","Prevenar13 Post Market Surveillance",[],[16],[64655],{"intervention":60460,"totalTrials":302,"cells":64676},{"EARLY_PHASE1":64677,"PHASE1":64679,"PHASE2":64681,"PHASE3":64683,"PHASE4":64685,"NA":64687},{"trials":64678,"activeCount":103},[],{"trials":64680,"activeCount":103},[],{"trials":64682,"activeCount":103},[],{"trials":64684,"activeCount":103},[],{"trials":64686,"activeCount":103},[],{"trials":64688,"activeCount":103},[64689],{"nctId":60454,"briefTitle":60455,"status":168,"phases":64690,"primaryCompletion":4656,"completion":4656,"start":4206,"enrollment":1780,"conditions":64691,"interventions":64692},[],[60458],[17125,60460],{"intervention":64694,"totalTrials":302,"cells":64695},"Relugolix",{"EARLY_PHASE1":64696,"PHASE1":64698,"PHASE2":64700,"PHASE3":64702,"PHASE4":64704,"NA":64706},{"trials":64697,"activeCount":103},[],{"trials":64699,"activeCount":103},[],{"trials":64701,"activeCount":103},[],{"trials":64703,"activeCount":103},[],{"trials":64705,"activeCount":103},[],{"trials":64707,"activeCount":103},[64708],{"nctId":64709,"briefTitle":64710,"status":111,"phases":64711,"primaryCompletion":22919,"completion":22919,"start":334,"enrollment":64712,"conditions":64713,"interventions":64714},"NCT06462014","Description of Relugolix Use in Patients With Prostate Cancer Within the VHA",[],507,[1684],[64694],{"intervention":64716,"totalTrials":302,"cells":64717},"Vaccine Administration",{"EARLY_PHASE1":64718,"PHASE1":64720,"PHASE2":64722,"PHASE3":64724,"PHASE4":64726,"NA":64728},{"trials":64719,"activeCount":103},[],{"trials":64721,"activeCount":103},[],{"trials":64723,"activeCount":103},[],{"trials":64725,"activeCount":103},[],{"trials":64727,"activeCount":103},[],{"trials":64729,"activeCount":103},[64730],{"nctId":64731,"briefTitle":64732,"status":111,"phases":64733,"primaryCompletion":64734,"completion":64734,"start":64735,"enrollment":64736,"conditions":64737,"interventions":64739},"NCT05794191","A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV",[],"2024-08-15","2023-03-22",350399,[30750,9107,64738],"Infections, Pneumococcal",[64716],{"intervention":64741,"totalTrials":302,"cells":64742},"Avelumab first-line maintenance",{"EARLY_PHASE1":64743,"PHASE1":64745,"PHASE2":64747,"PHASE3":64749,"PHASE4":64751,"NA":64753},{"trials":64744,"activeCount":103},[],{"trials":64746,"activeCount":103},[],{"trials":64748,"activeCount":103},[],{"trials":64750,"activeCount":103},[],{"trials":64752,"activeCount":103},[],{"trials":64754,"activeCount":103},[64755],{"nctId":64756,"briefTitle":64757,"status":168,"phases":64758,"primaryCompletion":1497,"completion":1497,"start":1914,"enrollment":1210,"conditions":64759,"interventions":64762},"NCT05699135","A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer",[],[64760,5847,64761,907],"Urinary Bladder Neoplasms","Bladder Tumors",[64741],{"intervention":64764,"totalTrials":302,"cells":64765},"Observational",{"EARLY_PHASE1":64766,"PHASE1":64768,"PHASE2":64770,"PHASE3":64772,"PHASE4":64774,"NA":64776},{"trials":64767,"activeCount":103},[],{"trials":64769,"activeCount":103},[],{"trials":64771,"activeCount":103},[],{"trials":64773,"activeCount":103},[],{"trials":64775,"activeCount":103},[],{"trials":64777,"activeCount":103},[64778],{"nctId":64779,"briefTitle":64780,"status":111,"phases":64781,"primaryCompletion":7387,"completion":7387,"start":560,"enrollment":3029,"conditions":64782,"interventions":64784},"NCT01199016","Effect of Prevnar 13 on Ear Infections in Children",[],[64783],"Otitis Media",[64764],{"intervention":64786,"totalTrials":302,"cells":64787},"Pneumococcal 7-valent conjugate vaccine Prevnar",{"EARLY_PHASE1":64788,"PHASE1":64790,"PHASE2":64792,"PHASE3":64794,"PHASE4":64796,"NA":64798},{"trials":64789,"activeCount":103},[],{"trials":64791,"activeCount":103},[],{"trials":64793,"activeCount":103},[],{"trials":64795,"activeCount":103},[],{"trials":64797,"activeCount":103},[],{"trials":64799,"activeCount":103},[64800],{"nctId":64801,"briefTitle":64802,"status":111,"phases":64803,"primaryCompletion":2671,"completion":2671,"start":2642,"enrollment":16727,"conditions":64804,"interventions":64806},"NCT00227188","Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.",[],[64805],"Invasive Pneumococcal Disease",[64786],{"intervention":64808,"totalTrials":302,"cells":64809},"Tozinameran",{"EARLY_PHASE1":64810,"PHASE1":64812,"PHASE2":64814,"PHASE3":64816,"PHASE4":64818,"NA":64820},{"trials":64811,"activeCount":103},[],{"trials":64813,"activeCount":103},[],{"trials":64815,"activeCount":103},[],{"trials":64817,"activeCount":103},[],{"trials":64819,"activeCount":103},[],{"trials":64821,"activeCount":103},[64822],{"nctId":64823,"briefTitle":64824,"status":111,"phases":64825,"primaryCompletion":64826,"completion":64826,"start":1565,"enrollment":302,"conditions":64827,"interventions":64828},"NCT06743334","Secondary Databased Post-marketing Surveillance Study of BNT162b2",[],"2025-05-28",[2592,10628],[64808,64808,64808],{"intervention":64830,"totalTrials":302,"cells":64831},"tDMARDs",{"EARLY_PHASE1":64832,"PHASE1":64834,"PHASE2":64836,"PHASE3":64838,"PHASE4":64840,"NA":64842},{"trials":64833,"activeCount":103},[],{"trials":64835,"activeCount":103},[],{"trials":64837,"activeCount":103},[],{"trials":64839,"activeCount":103},[],{"trials":64841,"activeCount":103},[],{"trials":64843,"activeCount":103},[64844],{"nctId":64845,"briefTitle":64846,"status":111,"phases":64847,"primaryCompletion":4590,"completion":4590,"start":18026,"enrollment":2229,"conditions":64848,"interventions":64849},"NCT01438892","Impact Of RA Therapy Compliance On Patient-Reported Outcomes",[],[22],[64830,64850],"biodmards",{"intervention":64850,"totalTrials":302,"cells":64852},{"EARLY_PHASE1":64853,"PHASE1":64855,"PHASE2":64857,"PHASE3":64859,"PHASE4":64861,"NA":64863},{"trials":64854,"activeCount":103},[],{"trials":64856,"activeCount":103},[],{"trials":64858,"activeCount":103},[],{"trials":64860,"activeCount":103},[],{"trials":64862,"activeCount":103},[],{"trials":64864,"activeCount":103},[64865],{"nctId":64845,"briefTitle":64846,"status":111,"phases":64866,"primaryCompletion":4590,"completion":4590,"start":18026,"enrollment":2229,"conditions":64867,"interventions":64868},[],[22],[64830,64850],{"intervention":64870,"totalTrials":302,"cells":64871},"Selara",{"EARLY_PHASE1":64872,"PHASE1":64874,"PHASE2":64876,"PHASE3":64878,"PHASE4":64880,"NA":64882},{"trials":64873,"activeCount":103},[],{"trials":64875,"activeCount":103},[],{"trials":64877,"activeCount":103},[],{"trials":64879,"activeCount":103},[],{"trials":64881,"activeCount":103},[],{"trials":64883,"activeCount":103},[64884],{"nctId":64885,"briefTitle":64886,"status":111,"phases":64887,"primaryCompletion":2449,"completion":2449,"start":3839,"enrollment":64888,"conditions":64889,"interventions":64890},"NCT00749775","Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)",[],3338,[13280],[64870],{"intervention":64892,"totalTrials":302,"cells":64893},"Lortlatinib",{"EARLY_PHASE1":64894,"PHASE1":64896,"PHASE2":64898,"PHASE3":64900,"PHASE4":64902,"NA":64904},{"trials":64895,"activeCount":103},[],{"trials":64897,"activeCount":103},[],{"trials":64899,"activeCount":103},[],{"trials":64901,"activeCount":103},[],{"trials":64903,"activeCount":103},[],{"trials":64905,"activeCount":103},[64906],{"nctId":64907,"briefTitle":64908,"status":111,"phases":64909,"primaryCompletion":8394,"completion":8394,"start":64910,"enrollment":5425,"conditions":64911,"interventions":64913},"NCT04979988","Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients",[],"2021-08-02",[64912],"ALK-positive Non-small-cell Lung Cancer",[64892],{"intervention":64915,"totalTrials":302,"cells":64916},"Ritalin",{"EARLY_PHASE1":64917,"PHASE1":64919,"PHASE2":64921,"PHASE3":64923,"PHASE4":64925,"NA":64927},{"trials":64918,"activeCount":103},[],{"trials":64920,"activeCount":103},[],{"trials":64922,"activeCount":103},[],{"trials":64924,"activeCount":103},[],{"trials":64926,"activeCount":103},[],{"trials":64928,"activeCount":103},[64929],{"nctId":64930,"briefTitle":64931,"status":111,"phases":64932,"primaryCompletion":651,"completion":651,"start":9572,"enrollment":725,"conditions":64933,"interventions":64934},"NCT02265718","A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers",[],[16],[64915,64915],{"intervention":64936,"totalTrials":302,"cells":64937},"DMARDs or Biologics",{"EARLY_PHASE1":64938,"PHASE1":64940,"PHASE2":64942,"PHASE3":64944,"PHASE4":64946,"NA":64948},{"trials":64939,"activeCount":103},[],{"trials":64941,"activeCount":103},[],{"trials":64943,"activeCount":103},[],{"trials":64945,"activeCount":103},[],{"trials":64947,"activeCount":103},[],{"trials":64949,"activeCount":103},[64950],{"nctId":64951,"briefTitle":64952,"status":111,"phases":64953,"primaryCompletion":577,"completion":577,"start":4214,"enrollment":2020,"conditions":64954,"interventions":64955},"NCT00929357","Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment",[],[22],[64936],{"intervention":64957,"totalTrials":302,"cells":64958},"Etaneracept Smartclic",{"EARLY_PHASE1":64959,"PHASE1":64961,"PHASE2":64963,"PHASE3":64965,"PHASE4":64967,"NA":64969},{"trials":64960,"activeCount":103},[],{"trials":64962,"activeCount":103},[],{"trials":64964,"activeCount":103},[],{"trials":64966,"activeCount":103},[],{"trials":64968,"activeCount":103},[],{"trials":64970,"activeCount":103},[64971],{"nctId":64972,"briefTitle":64973,"status":168,"phases":64974,"primaryCompletion":3460,"completion":3460,"start":20164,"enrollment":2240,"conditions":64975,"interventions":64976},"NCT05891600","A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis",[],[22],[64957],{"intervention":64978,"totalTrials":302,"cells":64979},"Forteo",{"EARLY_PHASE1":64980,"PHASE1":64982,"PHASE2":64984,"PHASE3":64986,"PHASE4":64988,"NA":64990},{"trials":64981,"activeCount":103},[],{"trials":64983,"activeCount":103},[],{"trials":64985,"activeCount":103},[],{"trials":64987,"activeCount":103},[],{"trials":64989,"activeCount":103},[],{"trials":64991,"activeCount":103},[64992],{"nctId":64993,"briefTitle":64994,"status":111,"phases":64995,"completion":3314,"start":4615,"enrollment":2159,"conditions":64996,"interventions":64997},"NCT00365924","A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo",[95],[23074],[64978],{"intervention":9677,"totalTrials":302,"cells":64999},{"EARLY_PHASE1":65000,"PHASE1":65002,"PHASE2":65004,"PHASE3":65006,"PHASE4":65008,"NA":65010},{"trials":65001,"activeCount":103},[],{"trials":65003,"activeCount":103},[],{"trials":65005,"activeCount":103},[],{"trials":65007,"activeCount":103},[],{"trials":65009,"activeCount":103},[],{"trials":65011,"activeCount":103},[65012],{"nctId":9670,"briefTitle":9671,"status":111,"phases":65013,"primaryCompletion":7536,"completion":7536,"start":9673,"enrollment":9674,"conditions":65014,"interventions":65015},[],[9667],[9677,9578,9534,9599,9600,9610],{"intervention":65017,"totalTrials":302,"cells":65018},"Enbrel group",{"EARLY_PHASE1":65019,"PHASE1":65021,"PHASE2":65023,"PHASE3":65025,"PHASE4":65027,"NA":65029},{"trials":65020,"activeCount":103},[],{"trials":65022,"activeCount":103},[],{"trials":65024,"activeCount":103},[],{"trials":65026,"activeCount":103},[],{"trials":65028,"activeCount":103},[],{"trials":65030,"activeCount":103},[65031],{"nctId":65032,"briefTitle":65033,"status":649,"phases":65034,"primaryCompletion":13214,"completion":13214,"start":4680,"enrollment":103,"conditions":65035,"interventions":65037},"NCT01432249","Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis",[],[65036],"Pediatric Psoriasis",[65017],{"intervention":65039,"totalTrials":302,"cells":65040},"Oxycodone controlled-release test formulation",{"EARLY_PHASE1":65041,"PHASE1":65043,"PHASE2":65045,"PHASE3":65047,"PHASE4":65049,"NA":65051},{"trials":65042,"activeCount":103},[],{"trials":65044,"activeCount":103},[],{"trials":65046,"activeCount":103},[],{"trials":65048,"activeCount":103},[],{"trials":65050,"activeCount":103},[],{"trials":65052,"activeCount":103},[65053],{"nctId":65054,"briefTitle":65055,"status":111,"phases":65056,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":562,"conditions":65057,"interventions":65058},"NCT01677065","A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers",[],[16],[65039,65059],"Immediate-release reference drug",{"intervention":65059,"totalTrials":302,"cells":65061},{"EARLY_PHASE1":65062,"PHASE1":65064,"PHASE2":65066,"PHASE3":65068,"PHASE4":65070,"NA":65072},{"trials":65063,"activeCount":103},[],{"trials":65065,"activeCount":103},[],{"trials":65067,"activeCount":103},[],{"trials":65069,"activeCount":103},[],{"trials":65071,"activeCount":103},[],{"trials":65073,"activeCount":103},[65074],{"nctId":65054,"briefTitle":65055,"status":111,"phases":65075,"primaryCompletion":3353,"completion":3353,"start":1700,"enrollment":562,"conditions":65076,"interventions":65077},[],[16],[65039,65059],{"intervention":65079,"totalTrials":302,"cells":65080},"Inlyta",{"EARLY_PHASE1":65081,"PHASE1":65083,"PHASE2":65085,"PHASE3":65087,"PHASE4":65089,"NA":65091},{"trials":65082,"activeCount":103},[],{"trials":65084,"activeCount":103},[],{"trials":65086,"activeCount":103},[],{"trials":65088,"activeCount":103},[],{"trials":65090,"activeCount":103},[],{"trials":65092,"activeCount":103},[65093],{"nctId":65094,"briefTitle":65095,"status":649,"phases":65096,"primaryCompletion":65097,"completion":65097,"start":37042,"enrollment":103,"conditions":65098,"interventions":65099},"NCT04555603","Axitinib Therapy Management Study",[],"2021-02-22",[1859],[65079,65100,65101],"Bavencio","Keytruda",{"intervention":65100,"totalTrials":302,"cells":65103},{"EARLY_PHASE1":65104,"PHASE1":65106,"PHASE2":65108,"PHASE3":65110,"PHASE4":65112,"NA":65114},{"trials":65105,"activeCount":103},[],{"trials":65107,"activeCount":103},[],{"trials":65109,"activeCount":103},[],{"trials":65111,"activeCount":103},[],{"trials":65113,"activeCount":103},[],{"trials":65115,"activeCount":103},[65116],{"nctId":65094,"briefTitle":65095,"status":649,"phases":65117,"primaryCompletion":65097,"completion":65097,"start":37042,"enrollment":103,"conditions":65118,"interventions":65119},[],[1859],[65079,65100,65101],{"intervention":65101,"totalTrials":302,"cells":65121},{"EARLY_PHASE1":65122,"PHASE1":65124,"PHASE2":65126,"PHASE3":65128,"PHASE4":65130,"NA":65132},{"trials":65123,"activeCount":103},[],{"trials":65125,"activeCount":103},[],{"trials":65127,"activeCount":103},[],{"trials":65129,"activeCount":103},[],{"trials":65131,"activeCount":103},[],{"trials":65133,"activeCount":103},[65134],{"nctId":65094,"briefTitle":65095,"status":649,"phases":65135,"primaryCompletion":65097,"completion":65097,"start":37042,"enrollment":103,"conditions":65136,"interventions":65137},[],[1859],[65079,65100,65101],{"intervention":3290,"totalTrials":302,"cells":65139},{"EARLY_PHASE1":65140,"PHASE1":65142,"PHASE2":65144,"PHASE3":65146,"PHASE4":65148,"NA":65150},{"trials":65141,"activeCount":103},[],{"trials":65143,"activeCount":103},[],{"trials":65145,"activeCount":103},[],{"trials":65147,"activeCount":103},[],{"trials":65149,"activeCount":103},[],{"trials":65151,"activeCount":103},[65152],{"nctId":3281,"briefTitle":3282,"status":111,"phases":65153,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":3286,"conditions":65154,"interventions":65155},[],[1798],[1812,1832,3289,3290,3291,3292],{"intervention":3291,"totalTrials":302,"cells":65157},{"EARLY_PHASE1":65158,"PHASE1":65160,"PHASE2":65162,"PHASE3":65164,"PHASE4":65166,"NA":65168},{"trials":65159,"activeCount":103},[],{"trials":65161,"activeCount":103},[],{"trials":65163,"activeCount":103},[],{"trials":65165,"activeCount":103},[],{"trials":65167,"activeCount":103},[],{"trials":65169,"activeCount":103},[65170],{"nctId":3281,"briefTitle":3282,"status":111,"phases":65171,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":3286,"conditions":65172,"interventions":65173},[],[1798],[1812,1832,3289,3290,3291,3292],{"intervention":3292,"totalTrials":302,"cells":65175},{"EARLY_PHASE1":65176,"PHASE1":65178,"PHASE2":65180,"PHASE3":65182,"PHASE4":65184,"NA":65186},{"trials":65177,"activeCount":103},[],{"trials":65179,"activeCount":103},[],{"trials":65181,"activeCount":103},[],{"trials":65183,"activeCount":103},[],{"trials":65185,"activeCount":103},[],{"trials":65187,"activeCount":103},[65188],{"nctId":3281,"briefTitle":3282,"status":111,"phases":65189,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":3286,"conditions":65190,"interventions":65191},[],[1798],[1812,1832,3289,3290,3291,3292],{"intervention":65193,"totalTrials":302,"cells":65194},"Vizimpro",{"EARLY_PHASE1":65195,"PHASE1":65197,"PHASE2":65199,"PHASE3":65201,"PHASE4":65203,"NA":65205},{"trials":65196,"activeCount":103},[],{"trials":65198,"activeCount":103},[],{"trials":65200,"activeCount":103},[],{"trials":65202,"activeCount":103},[],{"trials":65204,"activeCount":103},[],{"trials":65206,"activeCount":103},[65207],{"nctId":65208,"briefTitle":65209,"status":111,"phases":65210,"primaryCompletion":65211,"completion":65211,"start":65212,"enrollment":27266,"conditions":65213,"interventions":65214},"NCT04721106","Korea Post Marketing Surveillance (PMS) Study of Vizimpro",[],"2026-01-19","2021-03-07",[946],[65193],{"intervention":65216,"totalTrials":302,"cells":65217},"ceftazidime avibactam group",{"EARLY_PHASE1":65218,"PHASE1":65220,"PHASE2":65222,"PHASE3":65224,"PHASE4":65226,"NA":65228},{"trials":65219,"activeCount":103},[],{"trials":65221,"activeCount":103},[],{"trials":65223,"activeCount":103},[],{"trials":65225,"activeCount":103},[],{"trials":65227,"activeCount":103},[],{"trials":65229,"activeCount":103},[65230],{"nctId":65231,"briefTitle":65232,"status":168,"phases":65233,"primaryCompletion":2441,"completion":2441,"start":65234,"enrollment":12763,"conditions":65235,"interventions":65237},"NCT05487586","Real-World Study of Ceftazidime Avibactam in China",[],"2022-10-20",[15674,60578,65236],"Complicated Intra Abdominal Infections",[65216],{"intervention":65239,"totalTrials":302,"cells":65240},"Epirubicin: Observational Study",{"EARLY_PHASE1":65241,"PHASE1":65243,"PHASE2":65245,"PHASE3":65247,"PHASE4":65249,"NA":65251},{"trials":65242,"activeCount":103},[],{"trials":65244,"activeCount":103},[],{"trials":65246,"activeCount":103},[],{"trials":65248,"activeCount":103},[],{"trials":65250,"activeCount":103},[],{"trials":65252,"activeCount":103},[65253],{"nctId":65254,"briefTitle":65255,"status":111,"phases":65256,"primaryCompletion":4846,"completion":4846,"start":65257,"enrollment":65258,"conditions":65259,"interventions":65261},"NCT01061359","Application Of Epirubicin Within A Neo-\u002FAdjuvant Chemotherapy In Patients With Primary Breast Cancer",[],"1999-01",1981,[65260],"Breast Neoplasm",[65239],{"intervention":1745,"totalTrials":302,"cells":65263},{"EARLY_PHASE1":65264,"PHASE1":65266,"PHASE2":65268,"PHASE3":65270,"PHASE4":65272,"NA":65274},{"trials":65265,"activeCount":103},[],{"trials":65267,"activeCount":103},[],{"trials":65269,"activeCount":103},[],{"trials":65271,"activeCount":103},[],{"trials":65273,"activeCount":103},[],{"trials":65275,"activeCount":103},[65276],{"nctId":1737,"briefTitle":1738,"status":111,"phases":65277,"primaryCompletion":1740,"completion":1740,"start":1741,"enrollment":1742,"conditions":65278,"interventions":65279},[],[25],[1745,1644],{"intervention":61763,"totalTrials":302,"cells":65281},{"EARLY_PHASE1":65282,"PHASE1":65284,"PHASE2":65286,"PHASE3":65288,"PHASE4":65290,"NA":65292},{"trials":65283,"activeCount":103},[],{"trials":65285,"activeCount":103},[],{"trials":65287,"activeCount":103},[],{"trials":65289,"activeCount":103},[],{"trials":65291,"activeCount":103},[],{"trials":65293,"activeCount":103},[65294],{"nctId":61758,"briefTitle":61759,"status":168,"phases":65295,"completion":11609,"start":2662,"enrollment":350,"conditions":65296,"interventions":65297},[95],[12968],[61763,6170],{"intervention":65299,"totalTrials":302,"cells":65300},"donezepil",{"EARLY_PHASE1":65301,"PHASE1":65303,"PHASE2":65305,"PHASE3":65307,"PHASE4":65309,"NA":65311},{"trials":65302,"activeCount":103},[],{"trials":65304,"activeCount":103},[],{"trials":65306,"activeCount":103},[],{"trials":65308,"activeCount":103},[],{"trials":65310,"activeCount":103},[],{"trials":65312,"activeCount":103},[65313],{"nctId":65314,"briefTitle":65315,"status":111,"phases":65316,"completion":11315,"start":13902,"enrollment":1796,"conditions":65317,"interventions":65318},"NCT00483028","A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI",[95],[17728],[65299],{"intervention":65320,"totalTrials":302,"cells":65321},"Isavuconazole",{"EARLY_PHASE1":65322,"PHASE1":65324,"PHASE2":65326,"PHASE3":65328,"PHASE4":65330,"NA":65332},{"trials":65323,"activeCount":103},[],{"trials":65325,"activeCount":103},[],{"trials":65327,"activeCount":103},[],{"trials":65329,"activeCount":103},[],{"trials":65331,"activeCount":103},[],{"trials":65333,"activeCount":103},[65334],{"nctId":65335,"briefTitle":65336,"status":111,"phases":65337,"primaryCompletion":65338,"completion":65338,"start":65339,"enrollment":16344,"conditions":65340,"interventions":65342},"NCT04550936","A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.",[],"2023-12-23","2021-03-10",[59706,65341],"Mucormycosis",[65320],{"intervention":65344,"totalTrials":302,"cells":65345},"Zinforo",{"EARLY_PHASE1":65346,"PHASE1":65348,"PHASE2":65350,"PHASE3":65352,"PHASE4":65354,"NA":65356},{"trials":65347,"activeCount":103},[],{"trials":65349,"activeCount":103},[],{"trials":65351,"activeCount":103},[],{"trials":65353,"activeCount":103},[],{"trials":65355,"activeCount":103},[],{"trials":65357,"activeCount":103},[65358],{"nctId":65359,"briefTitle":65360,"status":111,"phases":65361,"primaryCompletion":65362,"completion":65363,"start":65364,"enrollment":6018,"conditions":65365,"interventions":65367},"NCT04198571","Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries",[],"2021-07-23","2021-08-30","2020-05-17",[65366,19508],"Community Acquired Pneumonia",[65344],{"intervention":65369,"totalTrials":302,"cells":65370},"BZA 20 mg\u002FCE 0.45 mg",{"EARLY_PHASE1":65371,"PHASE1":65373,"PHASE2":65375,"PHASE3":65377,"PHASE4":65379,"NA":65381},{"trials":65372,"activeCount":103},[],{"trials":65374,"activeCount":103},[],{"trials":65376,"activeCount":103},[],{"trials":65378,"activeCount":103},[],{"trials":65380,"activeCount":103},[],{"trials":65382,"activeCount":103},[65383],{"nctId":65384,"briefTitle":65385,"status":111,"phases":65386,"primaryCompletion":4206,"completion":4206,"start":8251,"enrollment":64712,"conditions":65387,"interventions":65388},"NCT00774267","Study Evaluating Changes In Mammographic Breast Density",[],[23074],[65369,65389,65390],"BZA 20 mg\u002FCE 0.625 mg","Raloxifene 60 mg",{"intervention":65389,"totalTrials":302,"cells":65392},{"EARLY_PHASE1":65393,"PHASE1":65395,"PHASE2":65397,"PHASE3":65399,"PHASE4":65401,"NA":65403},{"trials":65394,"activeCount":103},[],{"trials":65396,"activeCount":103},[],{"trials":65398,"activeCount":103},[],{"trials":65400,"activeCount":103},[],{"trials":65402,"activeCount":103},[],{"trials":65404,"activeCount":103},[65405],{"nctId":65384,"briefTitle":65385,"status":111,"phases":65406,"primaryCompletion":4206,"completion":4206,"start":8251,"enrollment":64712,"conditions":65407,"interventions":65408},[],[23074],[65369,65389,65390],{"intervention":65390,"totalTrials":302,"cells":65410},{"EARLY_PHASE1":65411,"PHASE1":65413,"PHASE2":65415,"PHASE3":65417,"PHASE4":65419,"NA":65421},{"trials":65412,"activeCount":103},[],{"trials":65414,"activeCount":103},[],{"trials":65416,"activeCount":103},[],{"trials":65418,"activeCount":103},[],{"trials":65420,"activeCount":103},[],{"trials":65422,"activeCount":103},[65423],{"nctId":65384,"briefTitle":65385,"status":111,"phases":65424,"primaryCompletion":4206,"completion":4206,"start":8251,"enrollment":64712,"conditions":65425,"interventions":65426},[],[23074],[65369,65389,65390],{"intervention":65428,"totalTrials":302,"cells":65429},"Risperidone 2 mg",{"EARLY_PHASE1":65430,"PHASE1":65432,"PHASE2":65434,"PHASE3":65436,"PHASE4":65438,"NA":65440},{"trials":65431,"activeCount":103},[],{"trials":65433,"activeCount":103},[],{"trials":65435,"activeCount":103},[],{"trials":65437,"activeCount":103},[],{"trials":65439,"activeCount":103},[],{"trials":65441,"activeCount":103},[65442],{"nctId":65443,"briefTitle":65444,"status":111,"phases":65445,"completion":12004,"start":4702,"enrollment":2159,"conditions":65446,"interventions":65447},"NCT00174200","Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone",[95],[12632,12644],[65428],{"intervention":9691,"totalTrials":302,"cells":65449},{"EARLY_PHASE1":65450,"PHASE1":65452,"PHASE2":65454,"PHASE3":65456,"PHASE4":65458,"NA":65460},{"trials":65451,"activeCount":103},[],{"trials":65453,"activeCount":103},[],{"trials":65455,"activeCount":103},[],{"trials":65457,"activeCount":103},[],{"trials":65459,"activeCount":103},[],{"trials":65461,"activeCount":103},[65462],{"nctId":9679,"briefTitle":9680,"status":649,"phases":65463,"primaryCompletion":9682,"completion":9682,"start":9683,"enrollment":103,"conditions":65464,"interventions":65465},[],[9685,9686,9687],[9534,9689,9690,9691],{"intervention":65467,"totalTrials":302,"cells":65468},"Non-intervention",{"EARLY_PHASE1":65469,"PHASE1":65471,"PHASE2":65473,"PHASE3":65475,"PHASE4":65477,"NA":65479},{"trials":65470,"activeCount":103},[],{"trials":65472,"activeCount":103},[],{"trials":65474,"activeCount":103},[],{"trials":65476,"activeCount":103},[],{"trials":65478,"activeCount":103},[],{"trials":65480,"activeCount":103},[65481],{"nctId":65482,"briefTitle":65483,"status":111,"phases":65484,"primaryCompletion":12810,"completion":12810,"start":606,"enrollment":59151,"conditions":65485,"interventions":65486},"NCT01834222","Post Market Surveillance to Observe Safety of Prevenar13™ in Adults",[],[2526],[65467],{"intervention":65488,"totalTrials":302,"cells":65489},"Sitaxentan sodium",{"EARLY_PHASE1":65490,"PHASE1":65492,"PHASE2":65494,"PHASE3":65496,"PHASE4":65498,"NA":65500},{"trials":65491,"activeCount":103},[],{"trials":65493,"activeCount":103},[],{"trials":65495,"activeCount":103},[],{"trials":65497,"activeCount":103},[],{"trials":65499,"activeCount":103},[],{"trials":65501,"activeCount":103},[65502],{"nctId":65503,"briefTitle":65504,"status":111,"phases":65505,"primaryCompletion":65506,"completion":65506,"start":27964,"enrollment":1530,"conditions":65507,"interventions":65508},"NCT01445873","Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)",[],"2011-03-28",[4942],[65488],{"intervention":9700,"totalTrials":302,"cells":65510},{"EARLY_PHASE1":65511,"PHASE1":65513,"PHASE2":65515,"PHASE3":65517,"PHASE4":65519,"NA":65521},{"trials":65512,"activeCount":103},[],{"trials":65514,"activeCount":103},[],{"trials":65516,"activeCount":103},[],{"trials":65518,"activeCount":103},[],{"trials":65520,"activeCount":103},[],{"trials":65522,"activeCount":103},[65523],{"nctId":9693,"briefTitle":9694,"status":111,"phases":65524,"primaryCompletion":9696,"completion":9696,"start":5139,"enrollment":9697,"conditions":65525,"interventions":65526},[],[9555],[9700,9611,9640,9690,9689],{"intervention":60467,"totalTrials":302,"cells":65528},{"EARLY_PHASE1":65529,"PHASE1":65531,"PHASE2":65533,"PHASE3":65535,"PHASE4":65537,"NA":65539},{"trials":65530,"activeCount":103},[],{"trials":65532,"activeCount":103},[],{"trials":65534,"activeCount":103},[],{"trials":65536,"activeCount":103},[],{"trials":65538,"activeCount":103},[],{"trials":65540,"activeCount":103},[65541],{"nctId":60462,"briefTitle":60463,"status":111,"phases":65542,"primaryCompletion":524,"completion":524,"start":4206,"enrollment":3462,"conditions":65543,"interventions":65544},[],[19973],[17125,60467],{"intervention":65546,"totalTrials":302,"cells":65547},"dacomitnib",{"EARLY_PHASE1":65548,"PHASE1":65550,"PHASE2":65552,"PHASE3":65554,"PHASE4":65556,"NA":65558},{"trials":65549,"activeCount":103},[],{"trials":65551,"activeCount":103},[],{"trials":65553,"activeCount":103},[],{"trials":65555,"activeCount":103},[],{"trials":65557,"activeCount":103},[],{"trials":65559,"activeCount":103},[65560],{"nctId":65561,"briefTitle":65562,"status":649,"phases":65563,"primaryCompletion":2135,"completion":2135,"start":9696,"enrollment":103,"conditions":65564,"interventions":65565},"NCT06075615","A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.",[],[376],[65546],{"intervention":65567,"totalTrials":302,"cells":65568},"Tablet Methylprednisolone",{"EARLY_PHASE1":65569,"PHASE1":65571,"PHASE2":65573,"PHASE3":65575,"PHASE4":65577,"NA":65579},{"trials":65570,"activeCount":103},[],{"trials":65572,"activeCount":103},[],{"trials":65574,"activeCount":103},[],{"trials":65576,"activeCount":103},[],{"trials":65578,"activeCount":103},[],{"trials":65580,"activeCount":103},[65581],{"nctId":65582,"briefTitle":65583,"status":111,"phases":65584,"primaryCompletion":560,"completion":560,"start":4833,"enrollment":1519,"conditions":65585,"interventions":65587},"NCT00929981","A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients",[],[65586],"Dermatitis, Contact",[65567],{"intervention":4902,"totalTrials":302,"cells":65589},{"EARLY_PHASE1":65590,"PHASE1":65592,"PHASE2":65594,"PHASE3":65596,"PHASE4":65598,"NA":65600},{"trials":65591,"activeCount":103},[],{"trials":65593,"activeCount":103},[],{"trials":65595,"activeCount":103},[],{"trials":65597,"activeCount":103},[],{"trials":65599,"activeCount":103},[],{"trials":65601,"activeCount":103},[65602],{"nctId":4892,"briefTitle":4893,"status":111,"phases":65603,"primaryCompletion":4895,"completion":4895,"start":4896,"enrollment":4897,"conditions":65604,"interventions":65605},[],[4899],[3317,4901,4902],{"intervention":65607,"totalTrials":302,"cells":65608},"Pegaptanib",{"EARLY_PHASE1":65609,"PHASE1":65611,"PHASE2":65613,"PHASE3":65615,"PHASE4":65617,"NA":65619},{"trials":65610,"activeCount":103},[],{"trials":65612,"activeCount":103},[],{"trials":65614,"activeCount":103},[],{"trials":65616,"activeCount":103},[],{"trials":65618,"activeCount":103},[],{"trials":65620,"activeCount":103},[65621],{"nctId":65622,"briefTitle":65623,"status":111,"phases":65624,"primaryCompletion":4221,"completion":4221,"start":12773,"enrollment":65625,"conditions":65626,"interventions":65629},"NCT01245387","Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration",[],1001,[15014,65627,65628],"Age-related Macular Degeneration","Neovascular Macular Degeneration",[65607],{"intervention":65631,"totalTrials":302,"cells":65632},"Enco+bini",{"EARLY_PHASE1":65633,"PHASE1":65635,"PHASE2":65637,"PHASE3":65639,"PHASE4":65641,"NA":65643},{"trials":65634,"activeCount":103},[],{"trials":65636,"activeCount":103},[],{"trials":65638,"activeCount":103},[],{"trials":65640,"activeCount":103},[],{"trials":65642,"activeCount":103},[],{"trials":65644,"activeCount":103},[65645],{"nctId":65646,"briefTitle":65647,"status":111,"phases":65648,"primaryCompletion":3284,"completion":3284,"start":65649,"enrollment":58225,"conditions":65650,"interventions":65651},"NCT05954546","A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings",[],"2023-07-21",[3204],[65631],{"intervention":65653,"totalTrials":302,"cells":65654},"TRASTUZUMAB BS",{"EARLY_PHASE1":65655,"PHASE1":65657,"PHASE2":65659,"PHASE3":65661,"PHASE4":65663,"NA":65665},{"trials":65656,"activeCount":103},[],{"trials":65658,"activeCount":103},[],{"trials":65660,"activeCount":103},[],{"trials":65662,"activeCount":103},[],{"trials":65664,"activeCount":103},[],{"trials":65666,"activeCount":103},[65667],{"nctId":65668,"briefTitle":65669,"status":111,"phases":65670,"primaryCompletion":63920,"completion":63920,"start":1356,"enrollment":1487,"conditions":65671,"interventions":65672},"NCT04181333","Safety and Efficacy of Trastuzumab BS",[],[7780],[65653],{"intervention":62608,"totalTrials":302,"cells":65674},{"EARLY_PHASE1":65675,"PHASE1":65677,"PHASE2":65679,"PHASE3":65681,"PHASE4":65683,"NA":65685},{"trials":65676,"activeCount":103},[],{"trials":65678,"activeCount":103},[],{"trials":65680,"activeCount":103},[],{"trials":65682,"activeCount":103},[],{"trials":65684,"activeCount":103},[],{"trials":65686,"activeCount":103},[65687],{"nctId":62600,"briefTitle":62601,"status":111,"phases":65688,"primaryCompletion":62603,"completion":62603,"start":62604,"enrollment":62605,"conditions":65689,"interventions":65690},[],[30836,2592],[62608,37811],{"intervention":65692,"totalTrials":302,"cells":65693},"Patients who received Palbociclib as first line therapy in MBC setting",{"EARLY_PHASE1":65694,"PHASE1":65696,"PHASE2":65698,"PHASE3":65700,"PHASE4":65702,"NA":65704},{"trials":65695,"activeCount":103},[],{"trials":65697,"activeCount":103},[],{"trials":65699,"activeCount":103},[],{"trials":65701,"activeCount":103},[],{"trials":65703,"activeCount":103},[],{"trials":65705,"activeCount":103},[65706],{"nctId":65707,"briefTitle":65708,"status":111,"phases":65709,"primaryCompletion":7123,"completion":7123,"start":37366,"enrollment":65710,"conditions":65711,"interventions":65712},"NCT05132101","Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea",[],2758,[1369],[65692],{"intervention":65714,"totalTrials":302,"cells":65715},"Palbociclib plus hormonal treatment - first line treatment",{"EARLY_PHASE1":65716,"PHASE1":65718,"PHASE2":65720,"PHASE3":65722,"PHASE4":65724,"NA":65726},{"trials":65717,"activeCount":103},[],{"trials":65719,"activeCount":103},[],{"trials":65721,"activeCount":103},[],{"trials":65723,"activeCount":103},[],{"trials":65725,"activeCount":103},[],{"trials":65727,"activeCount":103},[65728],{"nctId":65729,"briefTitle":65730,"status":111,"phases":65731,"primaryCompletion":38102,"completion":38102,"start":65732,"enrollment":1210,"conditions":65733,"interventions":65736},"NCT05584644","A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer",[],"2021-05-24",[31,48276,25,65734,65735],"Breast Tumors","Cancer of Breast",[65714,65737],"Palbociclib plus hormonal treatment - second line treatment",{"intervention":65737,"totalTrials":302,"cells":65739},{"EARLY_PHASE1":65740,"PHASE1":65742,"PHASE2":65744,"PHASE3":65746,"PHASE4":65748,"NA":65750},{"trials":65741,"activeCount":103},[],{"trials":65743,"activeCount":103},[],{"trials":65745,"activeCount":103},[],{"trials":65747,"activeCount":103},[],{"trials":65749,"activeCount":103},[],{"trials":65751,"activeCount":103},[65752],{"nctId":65729,"briefTitle":65730,"status":111,"phases":65753,"primaryCompletion":38102,"completion":38102,"start":65732,"enrollment":1210,"conditions":65754,"interventions":65755},[],[31,48276,25,65734,65735],[65714,65737],{"intervention":65757,"totalTrials":302,"cells":65758},"palbociclib plus letrozole",{"EARLY_PHASE1":65759,"PHASE1":65761,"PHASE2":65763,"PHASE3":65765,"PHASE4":65767,"NA":65769},{"trials":65760,"activeCount":103},[],{"trials":65762,"activeCount":103},[],{"trials":65764,"activeCount":103},[],{"trials":65766,"activeCount":103},[],{"trials":65768,"activeCount":103},[],{"trials":65770,"activeCount":103},[65771],{"nctId":65772,"briefTitle":65773,"status":111,"phases":65774,"primaryCompletion":1468,"completion":1468,"start":65775,"enrollment":1578,"conditions":65776,"interventions":65777},"NCT04735367","Study to Evaluate Overall Survival in Japanese Patients With HR+\u002FHER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole",[],"2021-02-03",[31],[65757],{"intervention":57818,"totalTrials":302,"cells":65779},{"EARLY_PHASE1":65780,"PHASE1":65782,"PHASE2":65784,"PHASE3":65786,"PHASE4":65788,"NA":65790},{"trials":65781,"activeCount":103},[],{"trials":65783,"activeCount":103},[],{"trials":65785,"activeCount":103},[],{"trials":65787,"activeCount":103},[],{"trials":65789,"activeCount":103},[],{"trials":65791,"activeCount":103},[65792],{"nctId":57813,"briefTitle":57814,"status":111,"phases":65793,"primaryCompletion":586,"completion":586,"start":11291,"enrollment":597,"conditions":65794,"interventions":65795},[95],[34],[11452,57818],{"intervention":65797,"totalTrials":302,"cells":65798},"Aricept® Evess",{"EARLY_PHASE1":65799,"PHASE1":65801,"PHASE2":65803,"PHASE3":65805,"PHASE4":65807,"NA":65809},{"trials":65800,"activeCount":103},[],{"trials":65802,"activeCount":103},[],{"trials":65804,"activeCount":103},[],{"trials":65806,"activeCount":103},[],{"trials":65808,"activeCount":103},[],{"trials":65810,"activeCount":103},[65811],{"nctId":65812,"briefTitle":65813,"status":111,"phases":65814,"primaryCompletion":3642,"completion":3642,"start":11014,"enrollment":17686,"conditions":65815,"interventions":65817},"NCT00889603","Non-Interventional Study With Aricept® Evess",[],[17728,65816],"Vascular Dementia",[65797],{"intervention":65819,"totalTrials":302,"cells":65820},"Rituximab-Pfizer (PF-05280586) x 3 courses",{"EARLY_PHASE1":65821,"PHASE1":65823,"PHASE2":65825,"PHASE3":65827,"PHASE4":65829,"NA":65831},{"trials":65822,"activeCount":103},[],{"trials":65824,"activeCount":103},[],{"trials":65826,"activeCount":103},[],{"trials":65828,"activeCount":103},[],{"trials":65830,"activeCount":103},[],{"trials":65832,"activeCount":103},[65833],{"nctId":65834,"briefTitle":65835,"status":111,"phases":65836,"primaryCompletion":65837,"completion":65837,"start":65838,"enrollment":18338,"conditions":65839,"interventions":65840},"NCT01643928","Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)",[95],"2016-03-14","2012-08-16",[22],[65819,65841,65842],"Rituximab-EU+ Rituximab-Pfizer x 2 Courses","Rituximab-US + Rituximab-Pfizer x 2 Courses",{"intervention":65841,"totalTrials":302,"cells":65844},{"EARLY_PHASE1":65845,"PHASE1":65847,"PHASE2":65849,"PHASE3":65851,"PHASE4":65853,"NA":65855},{"trials":65846,"activeCount":103},[],{"trials":65848,"activeCount":103},[],{"trials":65850,"activeCount":103},[],{"trials":65852,"activeCount":103},[],{"trials":65854,"activeCount":103},[],{"trials":65856,"activeCount":103},[65857],{"nctId":65834,"briefTitle":65835,"status":111,"phases":65858,"primaryCompletion":65837,"completion":65837,"start":65838,"enrollment":18338,"conditions":65859,"interventions":65860},[95],[22],[65819,65841,65842],{"intervention":65842,"totalTrials":302,"cells":65862},{"EARLY_PHASE1":65863,"PHASE1":65865,"PHASE2":65867,"PHASE3":65869,"PHASE4":65871,"NA":65873},{"trials":65864,"activeCount":103},[],{"trials":65866,"activeCount":103},[],{"trials":65868,"activeCount":103},[],{"trials":65870,"activeCount":103},[],{"trials":65872,"activeCount":103},[],{"trials":65874,"activeCount":103},[65875],{"nctId":65834,"briefTitle":65835,"status":111,"phases":65876,"primaryCompletion":65837,"completion":65837,"start":65838,"enrollment":18338,"conditions":65877,"interventions":65878},[95],[22],[65819,65841,65842],{"intervention":65880,"totalTrials":302,"cells":65881},"Zyvox",{"EARLY_PHASE1":65882,"PHASE1":65884,"PHASE2":65886,"PHASE3":65888,"PHASE4":65890,"NA":65892},{"trials":65883,"activeCount":103},[],{"trials":65885,"activeCount":103},[],{"trials":65887,"activeCount":103},[],{"trials":65889,"activeCount":103},[],{"trials":65891,"activeCount":103},[],{"trials":65893,"activeCount":103},[65894],{"nctId":65895,"briefTitle":65896,"status":111,"phases":65897,"primaryCompletion":523,"completion":523,"start":12004,"enrollment":713,"conditions":65898,"interventions":65900},"NCT01224626","Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)",[],[65899],"Vancomycin Resistance Enterococcus Faecium",[65880],{"intervention":65902,"totalTrials":302,"cells":65903},"2-weeks placebo then gabapentin",{"EARLY_PHASE1":65904,"PHASE1":65906,"PHASE2":65908,"PHASE3":65910,"PHASE4":65912,"NA":65914},{"trials":65905,"activeCount":103},[],{"trials":65907,"activeCount":103},[],{"trials":65909,"activeCount":103},[],{"trials":65911,"activeCount":103},[],{"trials":65913,"activeCount":103},[],{"trials":65915,"activeCount":103},[65916],{"nctId":65917,"briefTitle":65918,"status":111,"phases":65919,"completion":3627,"start":13035,"enrollment":2218,"conditions":65920,"interventions":65921},"NCT00674687","A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing",[95],[57287,26924],[65902,65922],"1-week placebo then gabapentin",{"intervention":65922,"totalTrials":302,"cells":65924},{"EARLY_PHASE1":65925,"PHASE1":65927,"PHASE2":65929,"PHASE3":65931,"PHASE4":65933,"NA":65935},{"trials":65926,"activeCount":103},[],{"trials":65928,"activeCount":103},[],{"trials":65930,"activeCount":103},[],{"trials":65932,"activeCount":103},[],{"trials":65934,"activeCount":103},[],{"trials":65936,"activeCount":103},[65937],{"nctId":65917,"briefTitle":65918,"status":111,"phases":65938,"completion":3627,"start":13035,"enrollment":2218,"conditions":65939,"interventions":65940},[95],[57287,26924],[65902,65922],{"intervention":4570,"totalTrials":302,"cells":65942},{"EARLY_PHASE1":65943,"PHASE1":65945,"PHASE2":65947,"PHASE3":65949,"PHASE4":65951,"NA":65953},{"trials":65944,"activeCount":103},[],{"trials":65946,"activeCount":103},[],{"trials":65948,"activeCount":103},[],{"trials":65950,"activeCount":103},[],{"trials":65952,"activeCount":103},[],{"trials":65954,"activeCount":103},[65955],{"nctId":4563,"briefTitle":4564,"status":111,"phases":65956,"primaryCompletion":4566,"completion":4566,"start":77,"enrollment":4567,"conditions":65957,"interventions":65958},[],[22],[4404,4570,4571,4572],{"intervention":4571,"totalTrials":302,"cells":65960},{"EARLY_PHASE1":65961,"PHASE1":65963,"PHASE2":65965,"PHASE3":65967,"PHASE4":65969,"NA":65971},{"trials":65962,"activeCount":103},[],{"trials":65964,"activeCount":103},[],{"trials":65966,"activeCount":103},[],{"trials":65968,"activeCount":103},[],{"trials":65970,"activeCount":103},[],{"trials":65972,"activeCount":103},[65973],{"nctId":4563,"briefTitle":4564,"status":111,"phases":65974,"primaryCompletion":4566,"completion":4566,"start":77,"enrollment":4567,"conditions":65975,"interventions":65976},[],[22],[4404,4570,4571,4572],{"intervention":4572,"totalTrials":302,"cells":65978},{"EARLY_PHASE1":65979,"PHASE1":65981,"PHASE2":65983,"PHASE3":65985,"PHASE4":65987,"NA":65989},{"trials":65980,"activeCount":103},[],{"trials":65982,"activeCount":103},[],{"trials":65984,"activeCount":103},[],{"trials":65986,"activeCount":103},[],{"trials":65988,"activeCount":103},[],{"trials":65990,"activeCount":103},[65991],{"nctId":4563,"briefTitle":4564,"status":111,"phases":65992,"primaryCompletion":4566,"completion":4566,"start":77,"enrollment":4567,"conditions":65993,"interventions":65994},[],[22],[4404,4570,4571,4572]]